<SEC-DOCUMENT>0001447028-19-000071.txt : 20191106
<SEC-HEADER>0001447028-19-000071.hdr.sgml : 20191106
<ACCEPTANCE-DATETIME>20191106122745
ACCESSION NUMBER:		0001447028-19-000071
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		76
CONFORMED PERIOD OF REPORT:	20190930
FILED AS OF DATE:		20191106
DATE AS OF CHANGE:		20191106

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Arbutus Biopharma Corp
		CENTRAL INDEX KEY:			0001447028
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				980597776
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-34949
		FILM NUMBER:		191195651

	BUSINESS ADDRESS:	
		STREET 1:		100-8900 GLENLYON PARKWAY
		CITY:			BURNABY
		STATE:			A1
		ZIP:			V5J 5J8
		BUSINESS PHONE:		604-419-3200

	MAIL ADDRESS:	
		STREET 1:		100-8900 GLENLYON PARKWAY
		CITY:			BURNABY
		STATE:			A1
		ZIP:			V5J 5J8

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	TEKMIRA PHARMACEUTICALS Corp
		DATE OF NAME CHANGE:	20110607

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	TEKMIRA PHARMACEUTICALS CORP
		DATE OF NAME CHANGE:	20081003
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>arbutusq32019.htm
<DESCRIPTION>10-Q
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2019 Workiva -->
		<title>Document</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s2B05E6D285EB5D97965D9EAE106D7937"></a></div><div><div style="line-height:120%;padding-bottom:0px;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:10px;text-align:center;font-size:18pt;"><font style="font-family:inherit;font-size:18pt;font-weight:bold;">UNITED STATES</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:10px;text-align:center;font-size:18pt;"><font style="font-family:inherit;font-size:18pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:10px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Washington, D.C. 20549</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:10px;text-align:center;font-size:18pt;"><font style="font-family:inherit;font-size:18pt;font-weight:bold;">FORM 10-Q</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:10px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:10px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For the quarterly period ended </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">September&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#32;</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:10px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">OR</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:10px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[&#160;&#160; ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:10px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For the Transition Period from&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; to&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:10px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Commission File Number: </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">001-34949</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:10px;text-align:center;font-size:18pt;"><font style="font-family:inherit;font-size:18pt;font-weight:bold;text-decoration:underline;">ARBUTUS BIOPHARMA CORPORATION</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:10px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Exact Name of Registrant as Specified in Its Charter)</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:33%;"></td><td style="width:34%;"></td><td style="width:33%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">British Columbia, Canada</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">98-0597776</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(State or Other Jurisdiction of</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(I.R.S. Employer</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Incorporation or Organization)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Identification No.)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:10px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">701 Veterans Circle, Warminster, PA 18974</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:10px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Address of Principal Executive Offices and Zip Code)</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">267-469-0914</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:10px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Registrant&#8217;s Telephone Number, Including Area Code)</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Securities registered pursuant to Section 12(b) of the Act:</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:10px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.5078125%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:35%;"></td><td style="width:20%;"></td><td style="width:45%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Title of each class</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Trading Symbol(s)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Name of each exchange on which registered</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Common Shares, without par value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ABUS</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Nasdaq Stock Market LLC</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.   Yes [X]&#160;&#160;&#160;&#160;&#160;&#160; &#160;No [&#160; &#160;]</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).  Yes [X]&#160;&#160;&#160;&#160;&#160;&#160; &#160;No [&#160; &#160;]</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company.  See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221;  &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.:</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:92.578125%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:19%;"></td><td style="width:19%;"></td><td style="width:18%;"></td><td style="width:21%;"></td><td style="width:23%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Large accelerated filer [&#160;&#160; ]</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accelerated filer [X]</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-accelerated filer [&#160; &#160;]</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Smaller reporting company [X]</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Emerging growth company [&#160;&#160; ]</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160; [&#160; &#160;]</font></div><div><br></div><div><div style="line-height:120%;padding-bottom:0px;padding-top:8px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:0px;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Yes [&#160; &#160;]&#160;&#160;&#160;No [X]</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">October&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;">, the registrant had </font><font style="font-family:inherit;font-size:10pt;">56,850,172</font><font style="font-family:inherit;font-size:10pt;">&#160;common shares, without par value, outstanding. </font></div><div><br></div><div><div style="line-height:120%;padding-bottom:0px;padding-top:8px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></div><hr style="page-break-after:always"><div><a name="sDB1E41741A6F5318AD6ACE0E64AFCE99"></a></div><div><div style="line-height:120%;padding-bottom:0px;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:10px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ARBUTUS BIOPHARMA CORPORATION</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:10px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">TABLE OF CONTENTS </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:16%;"></td><td style="width:78%;"></td><td style="width:6%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Page</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sFD0188B204975758819885F16D82CFC8"><font style="font-family:inherit;font-size:10pt;">PART I. FINANCIAL INFORMATION</font></a></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sFD0188B204975758819885F16D82CFC8"> 1</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;text-decoration:none;" href="#sBC54D5B15D7C5947AEB447215A8B0F85"><font style="font-family:inherit;font-size:10pt;text-decoration:none;">&#160; &#160; &#160; &#160; &#160; &#160;ITEM 1.</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sBC54D5B15D7C5947AEB447215A8B0F85"><font style="font-family:inherit;font-size:10pt;">FINANCIAL STATEMENTS (UNAUDITED)</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sBC54D5B15D7C5947AEB447215A8B0F85"> 1</a></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160; &#160; &#160; &#160; </font><a style="font-family:inherit;font-size:10pt;text-decoration:none;" href="#sEBA38294291E56FE85B2BDF490B8030C"><font style="font-family:inherit;font-size:10pt;text-decoration:none;">&#160; &#160;ITEM 2.</font></a></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sEBA38294291E56FE85B2BDF490B8030C"><font style="font-family:inherit;font-size:10pt;">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</font></a></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sEBA38294291E56FE85B2BDF490B8030C"> 16</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160; &#160; &#160; &#160; &#160; &#160;</font><a style="font-family:inherit;font-size:10pt;text-decoration:none;" href="#s4161137050B85C7781FE1B7F9BF265C7"><font style="font-family:inherit;font-size:10pt;text-decoration:none;">ITEM 3.</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s4161137050B85C7781FE1B7F9BF265C7"><font style="font-family:inherit;font-size:10pt;">QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s4161137050B85C7781FE1B7F9BF265C7"> 28</a></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160; &#160; &#160; &#160; &#160; &#160;</font><a style="font-family:inherit;font-size:10pt;text-decoration:none;" href="#sE4776BF7DB5256BD82BDC2C36C357FE8"><font style="font-family:inherit;font-size:10pt;text-decoration:none;">ITEM 4.</font></a></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sE4776BF7DB5256BD82BDC2C36C357FE8"><font style="font-family:inherit;font-size:10pt;">CONTROLS AND PROCEDURES</font></a></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sE4776BF7DB5256BD82BDC2C36C357FE8"> 28</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s980E6CC5D0115F2C951EA7FAF7F2CFA8"><font style="font-family:inherit;font-size:10pt;">PART II. OTHER INFORMATION</font></a></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s980E6CC5D0115F2C951EA7FAF7F2CFA8"> 29</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160; &#160; &#160; &#160; &#160; &#160;</font><a style="font-family:inherit;font-size:10pt;text-decoration:none;" href="#s19A11E14437D55A1BE12945C7040C9C0"><font style="font-family:inherit;font-size:10pt;text-decoration:none;">ITEM 1.</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s19A11E14437D55A1BE12945C7040C9C0"><font style="font-family:inherit;font-size:10pt;">LEGAL PROCEEDINGS</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s19A11E14437D55A1BE12945C7040C9C0"> 29</a></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160; &#160; &#160; &#160; &#160;</font><a style="font-family:inherit;font-size:10pt;text-decoration:none;" href="#s38C2BFDFA08E555C9DD8A5E777A87DDD"><font style="font-family:inherit;font-size:10pt;text-decoration:none;">&#160;&#160;ITEM 1A.</font></a></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s38C2BFDFA08E555C9DD8A5E777A87DDD"><font style="font-family:inherit;font-size:10pt;">RISK FACTORS</font></a></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s38C2BFDFA08E555C9DD8A5E777A87DDD"> 29</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160; &#160; &#160; &#160; &#160; </font><a style="font-family:inherit;font-size:10pt;text-decoration:none;" href="#s4286BC1A506453A19BEDA12793C0B69A"><font style="font-family:inherit;font-size:10pt;text-decoration:none;">&#160;ITEM 2.</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s4286BC1A506453A19BEDA12793C0B69A"><font style="font-family:inherit;font-size:10pt;">UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s4286BC1A506453A19BEDA12793C0B69A"> 29</a></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160; &#160; &#160; &#160; &#160; &#160;</font><a style="font-family:inherit;font-size:10pt;text-decoration:none;" href="#s24227517A8F5521ABC8F93CEA9140C97"><font style="font-family:inherit;font-size:10pt;text-decoration:none;">ITEM 3.</font></a></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s24227517A8F5521ABC8F93CEA9140C97"><font style="font-family:inherit;font-size:10pt;">DEFAULTS UPON SENIOR SECURITIES</font></a></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s24227517A8F5521ABC8F93CEA9140C97"> 29</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160; &#160; &#160; &#160; &#160; &#160;</font><a style="font-family:inherit;font-size:10pt;text-decoration:none;" href="#s1F69C90C370A5886ACDF688F7A29F272"><font style="font-family:inherit;font-size:10pt;text-decoration:none;">ITEM 4.</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s1F69C90C370A5886ACDF688F7A29F272"><font style="font-family:inherit;font-size:10pt;">MINE SAFETY DISCLOSURES</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s1F69C90C370A5886ACDF688F7A29F272"> 29</a></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160; &#160; &#160; &#160; &#160; </font><a style="font-family:inherit;font-size:10pt;text-decoration:none;" href="#s2E696A04AEB1592592BA708C221A7E7A"><font style="font-family:inherit;font-size:10pt;text-decoration:none;">&#160;ITEM 5.</font></a></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s2E696A04AEB1592592BA708C221A7E7A"><font style="font-family:inherit;font-size:10pt;">OTHER INFORMATION</font></a></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s2E696A04AEB1592592BA708C221A7E7A"> 29</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160; &#160; &#160; &#160; &#160; </font><a style="font-family:inherit;font-size:10pt;text-decoration:none;" href="#s50708608BD5F5929955E62F059F6504B"><font style="font-family:inherit;font-size:10pt;text-decoration:none;">&#160;ITEM 6.</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s50708608BD5F5929955E62F059F6504B"><font style="font-family:inherit;font-size:10pt;">EXHIBITS</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s50708608BD5F5929955E62F059F6504B"> 29</a></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;padding-bottom:0px;padding-top:8px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3</font></div></div><hr style="page-break-after:always"><div><a name="sFD0188B204975758819885F16D82CFC8"></a></div><div><div style="line-height:120%;padding-bottom:0px;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PART I. FINANCIAL INFORMATION</font></div><div><a name="sBC54D5B15D7C5947AEB447215A8B0F85"></a></div><div style="line-height:120%;padding-bottom:0px;padding-top:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 1. FINANCIAL STATEMENTS (UNAUDITED)</font></div><div><a name="sFA0419E9BA315EECB22590E5F9E85688"></a></div><div style="line-height:120%;padding-bottom:0px;padding-top:8px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">ARBUTUS BIOPHARMA CORPORATION</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:16px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Condensed Consolidated Balance Sheets</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(Unaudited)</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(In thousands of U.S. Dollars, except share and per share amounts)</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:69%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September&#160;30, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Assets</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Current assets:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;Cash and cash equivalents (note 3)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">90,082</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">36,942</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;Short-term investments  (note 3)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">87,675</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;Accounts receivable</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,488</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,431</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;Prepaid expenses and other current assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,771</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,181</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total current assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">94,341</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">129,229</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Investment in Genevant (note 4)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">10,969</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">22,224</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Property and equipment, net accumulated depreciation $8,612 (December 31, 2018: $7,090) </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">9,150</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">10,145</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Right of use asset (note 5)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,817</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Intangible assets (note 6)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">43,836</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Goodwill (note 6)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">22,471</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Total assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:3px double #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">117,277</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:3px double #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">227,905</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Liabilities and stockholders' equity</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Current liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;Accounts payable and accrued liabilities (note 7)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">8,199</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">9,429</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Site consolidation accrual (note 8)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">203</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,331</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Liability-classified options (note 3)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">86</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">479</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Lease liability, current (note 5)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">329</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total current liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">8,817</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">11,239</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Liability related to sale of future royalties (note 9)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">18,675</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Deferred rent and inducements, non-current</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">645</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Contingent consideration (notes 3 and 10)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,005</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,126</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Lease liability, non-current (note 5)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,143</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Deferred tax liability (note 6)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">12,661</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Total liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">33,640</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">27,671</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Stockholders&#8217; equity:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Preferred shares (note 12)</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Authorized: 1,164,000 without par value</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Issued and outstanding: 1,164,000 (December 31, 2018: 1,164,000)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">134,405</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">126,136</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Common shares</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Authorized: unlimited number without par value</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Issued and outstanding: 56,850,172 (December 31, 2018: 55,518,800)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">884,623</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">879,405</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;Additional paid-in capital</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">55,385</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">48,084</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;Deficit</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(942,559</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(805,221</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;Accumulated other comprehensive loss</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(48,217</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(48,170</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total stockholders' equity</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">83,637</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">200,234</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Total liabilities and stockholders' equity</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:3px double #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">117,277</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:3px double #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">227,905</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">See accompanying notes to the condensed consolidated financial statements.</font></div><div><br></div><div><div style="line-height:120%;padding-bottom:0px;padding-top:8px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;1</font></div></div><hr style="page-break-after:always"><div><a name="sEE47AAB5DEAD50BABE4B8386F94479EE"></a></div><div><div style="line-height:120%;padding-bottom:0px;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:8px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">ARBUTUS BIOPHARMA CORPORATION</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:16px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Condensed Consolidated Statements of Operations</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(Unaudited)</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(In thousands of U.S. Dollars, except share and per share amounts)</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:53%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Revenue</font><font style="font-family:inherit;font-size:10pt;">&#160;(note 11)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,061</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,587</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,393</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,267</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Operating expenses</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,731</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,566</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">45,183</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">46,871</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">General and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,249</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,631</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,850</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,075</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Depreciation</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">507</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">497</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,521</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,677</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Site consolidation (note 8)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">182</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(492</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,710</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Impairment of intangible assets (note 6)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">43,836</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,811</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">43,836</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,811</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Impairment of goodwill (note 6)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,471</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,471</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Arbitration (note 10)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,486</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,486</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total operating expenses</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">94,462</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34,013</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">135,380</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">77,144</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Loss from operations</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(91,401</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(32,426</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(130,987</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(72,877</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Other income (loss)</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest income</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">503</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">756</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,709</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,319</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest expense (note 9)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,100</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,114</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(104</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Foreign exchange gain (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(25</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">145</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">43</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(740</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Gain on investment (note 4)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24,884</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Equity investment loss (note 4)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,512</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,838</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(11,497</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,838</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Change in fair value of contingent consideration (notes 3 and 10)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">376</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,608</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">121</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,263</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total other income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,758</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,671</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(10,738</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29,784</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Loss before income taxes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(95,159</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(28,755</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(141,725</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(43,093</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income tax benefit (note 6)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,656</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,282</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,656</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,282</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Net loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(82,503</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(24,473</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(129,069</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(38,811</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Items applicable to preferred shares:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrual of coupon on convertible preferred shares</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,792</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,567</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(8,269</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7,444</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Net loss attributable to common shareholders </font><font style="font-family:inherit;font-size:10pt;">(note 2)</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(85,295</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(27,040</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(137,338</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(46,255</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss attributable to common shareholders, per share</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic and diluted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.50</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.49</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2.43</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.84</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted average number of common shares</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic and diluted</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">56,850,172</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">55,421,504</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">56,469,358</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">55,241,284</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:10px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">See accompanying notes to the condensed consolidated financial statements.</font></div><div><br></div><div><div style="line-height:120%;padding-bottom:0px;padding-top:8px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;2</font></div></div><hr style="page-break-after:always"><div><a name="s97E9F3619E7E5B59BDCB08D369F026BF"></a></div><div><div style="line-height:120%;padding-bottom:0px;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:8px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">ARBUTUS BIOPHARMA CORPORATION</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:16px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Condensed Consolidated Statements of Comprehensive Income (Loss)</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(Unaudited)</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(In thousands of U.S. Dollars)</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:49%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Net loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(82,503</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(24,473</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(129,069</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(38,811</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other comprehensive income (loss):</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Share of other comprehensive income (loss) of equity method investment (note 4)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(12</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(47</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(12</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Comprehensive loss</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(82,476</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(24,485</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(129,116</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(38,823</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:8px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:8px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:8px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:8px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:8px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:8px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:8px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:8px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:8px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:8px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:8px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:8px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:8px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:8px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:8px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:8px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:8px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:8px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:8px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:8px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:8px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:8px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:8px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:8px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:8px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:10px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">See accompanying notes to the condensed consolidated financial statements.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:8px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;padding-bottom:0px;padding-top:8px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;3</font></div></div><hr style="page-break-after:always"><div><a name="s8B58236950CB5921AD787C6B441737B9"></a></div><div><div style="line-height:120%;padding-bottom:0px;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:8px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">ARBUTUS BIOPHARMA CORPORATION</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:16px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Condensed Consolidated Statement of Stockholders&#8217; Equity</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(Unaudited)</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(In thousands of U.S. Dollars, except share and per share amounts)</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="23"></td></tr><tr><td style="width:19%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Convertible Preferred Shares</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Common Shares</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Number of Shares</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Share Capital</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Number of Shares</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Share Capital</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Additional Paid-In Capital</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Deficit</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Accumulated Other Comprehensive Loss</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total Stockholders' Equity</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;Balance, December 31, 2018</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1,164,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">126,136</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">55,518,800</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">879,405</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">48,084</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(805,221</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(48,170</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">200,234</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;Accretion of accumulated dividends on Preferred Shares</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2,715</font></div></td><td style="vertical-align:bottom;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(2,715</font></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;Stock-based compensation</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-left:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1,665</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1,665</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;Certain fair value adjustments to liability-classified</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-left:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">47</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">47</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Issuance of common shares pursuant to our ATM</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-left:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">614,401</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2,248</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2,248</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;Issuance of common shares pursuant to exercise of options</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-left:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">122,603</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">490</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(202</font></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">288</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;Currency translation adjustment</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-left:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(22</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(22</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;Net loss</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-left:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(23,251</font></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(23,251</font></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Balance,  March 31, 2019</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1,164,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">128,851</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">56,255,804</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">882,143</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">49,594</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(831,187</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(48,192</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">181,209</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;Accretion of accumulated dividends on Preferred Shares</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2,762</font></div></td><td style="vertical-align:bottom;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(2,762</font></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;Stock-based compensation</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">3,915</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">3,915</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;Certain fair value adjustments to liability-classified</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">230</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">230</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Issuance of common shares pursuant to our ATM</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">593,689</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2,477</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2,477</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;Issuance of common shares pursuant to exercise of options</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">679</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(1</font></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;Currency translation adjustment</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(52</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(52</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;Net loss</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(23,315</font></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(23,315</font></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Balance,  June 30, 2019</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1,164,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">131,613</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">56,850,172</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">884,623</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">53,738</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(857,264</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(48,244</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">164,466</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;Accretion of accumulated dividends on Preferred Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2,792</font></div></td><td style="vertical-align:bottom;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(2,792</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;Stock-based compensation</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1,592</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1,592</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;Certain fair value adjustments to liability-classified</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">55</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">55</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;Currency translation adjustment</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">27</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">27</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;Net loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(82,503</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(82,503</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Balance,  September 30, 2019</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1,164,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">134,405</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">56,850,172</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">884,623</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">55,385</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(942,559</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(48,217</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">83,637</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:10px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:10px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">See accompanying notes to the condensed consolidated financial statements.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:10px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:10px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;padding-bottom:0px;padding-top:8px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;4</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:0px;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:8px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">ARBUTUS BIOPHARMA CORPORATION</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:16px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Condensed Consolidated Statement of Stockholders&#8217; Equity (continued)</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(Unaudited)</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(In thousands of U.S. Dollars, except share and per share amounts)</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:10px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="23"></td></tr><tr><td style="width:22%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Convertible Preferred Shares</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Common Shares</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Number of Shares</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Share Capital</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Number of Shares</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Share Capital</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Additional Paid-In Capital</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Deficit</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Accumulated Other Comprehensive Loss</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total Stockholders' Equity</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;Balance, December 31, 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">500,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">49,780</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">55,060,650</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">876,108</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">42,840</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(738,070</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(48,185</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">182,473</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Issuance of Preferred Shares, net of issuance costs of $135</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">664,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">66,265</font></div></td><td style="vertical-align:bottom;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">66,265</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Accretion of coupon on Preferred Shares</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2,336</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(2,336</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Stock-based compensation</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1,510</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1,510</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Certain fair value adjustments to liability stock option awards </font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(504</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(504</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Issuance of common shares pursuant to exercise of options</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">26,541</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">180</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(77</font></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">103</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;Net loss</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(17,429</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(17,429</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Balance,  March 31, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">1,164,000</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">118,381</font></div></td><td style="vertical-align:bottom;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">55,087,191</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">876,288</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">43,769</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(757,835</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(48,185</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">232,418</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Accretion of coupon on Preferred Shares</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2,541</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(2,541</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Stock-based compensation</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1,862</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1,862</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Certain fair value adjustments to liability stock option awards</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(34</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(34</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Issuance of common shares pursuant to exercise of options</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">238,059</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">1,903</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(1,168</font></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">735</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;Net income</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">3,091</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">3,091</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Balance,  June 30, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">1,164,000</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">120,922</font></div></td><td style="vertical-align:bottom;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">55,325,250</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">878,191</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">44,429</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(757,285</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(48,185</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">238,072</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Accretion of coupon on Preferred Shares</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2,567</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(2,567</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Stock-based compensation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1,658</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1,658</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Certain fair value adjustments to liability stock option awards</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(407</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(407</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Issuance of common shares pursuant to exercise of options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">147,069</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">614</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(180</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">434</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;Currency translation adjustment</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(12</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(12</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;Net loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(24,473</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(24,473</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Balance, September 30, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">1,164,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">123,489</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">55,472,319</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">878,805</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">45,500</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(784,325</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(48,197</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">215,272</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:10px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">See accompanying notes to the condensed consolidated financial statements.</font></div><div><br></div><div><div style="line-height:120%;padding-bottom:0px;padding-top:8px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;5</font></div></div><hr style="page-break-after:always"><div><a name="s1611E84CB3385B73B4D60381B2E86CA8"></a></div><div><div style="line-height:120%;padding-bottom:0px;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:8px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">ARBUTUS BIOPHARMA CORPORATION</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:16px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Condensed Consolidated Statements of Cash Flow</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(Unaudited)</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(In thousands of U.S. Dollars)</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:49%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">OPERATING ACTIVITIES</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Net loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(82,503</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(24,473</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(129,069</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(38,811</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Items not involving cash:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Deferred income tax benefit</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(12,661</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(4,282</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(12,661</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(4,282</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Depreciation</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">507</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">497</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1,521</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1,677</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Loss (gain) on sale of property and equipment</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(26</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(11</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(26</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Stock-based compensation expense</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1,516</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1,828</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">6,822</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">5,445</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Unrealized foreign exchange losses (gains)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">24</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(131</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(71</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">795</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Change in fair value of contingent consideration</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(376</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(5,608</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(121</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(6,263</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Impairment of intangible assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">43,836</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">14,811</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">43,836</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">14,811</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Impairment of goodwill</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">22,471</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">22,471</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Site consolidation non-cash portion</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">396</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Gain on investment </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(24,884</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Equity investment loss</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">3,512</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2,838</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">11,497</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2,838</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Non-cash royalty revenue</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(979</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(979</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Non-cash interest expense</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1,106</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1,106</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Net change in non-cash operating items:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;Accounts receivable</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(957</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">784</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(1,057</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(136</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;Prepaid expenses and other assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1,080</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">109</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1,839</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1,017</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;Accrued revenue</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">128</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;Accounts payable and accrued liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">538</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1,094</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(1,320</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(2,171</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;Deferred revenue</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(325</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(2,093</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Restructuring accrual</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(138</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(320</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(917</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">770</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Other liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(446</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(541</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:normal;">Net cash used in operating activities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(23,470</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(13,204</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(57,655</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(50,791</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">INVESTING ACTIVITIES</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Acquisition of short and long-term investments</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(48,025</font></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Disposition of short and long-term investments</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">16,410</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">24,590</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">87,675</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Proceeds from sale of property and equipment</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">25</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">11</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">25</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Acquisition of property and equipment</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(255</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(237</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(526</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(911</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:normal;">Net cash provided by (used) in investing activities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">16,155</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">24,378</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">87,160</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(48,911</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">FINANCING ACTIVITIES</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Proceeds from sale of future royalties, net</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">18,549</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">18,549</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Promissory note repayment</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(12,001</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Proceeds from sale of Series A Preferred Shares, net of issuance costs</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">66,265</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Issuance of common shares pursuant to the ATM</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">4,725</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Issuance of common shares pursuant to exercise of options</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">435</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">290</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1,273</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:normal;">Net cash provided by financing activities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">18,549</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">435</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">23,564</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">55,537</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Effect of foreign exchange rate changes on cash and cash equivalents</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(24</font></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">131</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">71</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(795</font></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:normal;">Increase in cash and cash equivalents</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">11,210</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">11,740</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">53,140</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(44,960</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Cash and cash equivalents, beginning of period</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">78,872</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">10,193</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">36,942</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">66,893</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:normal;">Cash and cash equivalents, end of period</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">90,082</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">21,933</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">90,082</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">21,933</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Supplemental cash flow information</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Non-cash transactions:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Preferred shares dividends accrued</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(2,792</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(2,567</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(8,269</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(7,444</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Investment in Genevant</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">24,665</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:10px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">See accompanying notes to the condensed consolidated financial statements.</font></div><div><br></div><div><div style="line-height:120%;padding-bottom:0px;padding-top:8px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;6</font></div></div><hr style="page-break-after:always"><div><a name="s91B07F54482D5F2EBCE46ADBDB973F50"></a></div><div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ARBUTUS BIOPHARMA CORPORATION</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Notes to Condensed Consolidated Financial Statements</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Tabular amounts in thousands of U.S. Dollars, except share and per share amounts)&#160;</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="sC99DDD5DD13B5C029D4A904696269B54"></a></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;font-weight:bold;">1.</font><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Nature of business and future operations</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Arbutus Biopharma Corporation (the &#8220;Company&#8221; or &#8220;Arbutus&#8221;) is a biopharmaceutical business dedicated to discovering, developing, and commercializing a cure for patients suffering from chronic hepatitis B infection, a disease of the liver caused by the hepatitis B virus (&#8220;HBV&#8221;). To pursue its strategy of developing a curative combination regimen, the Company has assembled a pipeline of multiple drug candidates with differing and complementary mechanisms of action targeting HBV.  These include  AB-729, the Company's subcutaneously-delivered RNA interference ("RNAi") therapeutic candidate currently in a Phase 1a/1b clinical trial, AB-452, the Company's lead oral HBV RNA destabilizer candidate currently in pre-clinical testing, next-generation oral capsid inhibitor compounds, and compounds that inhibit PD-L1. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The success of the Company is dependent on obtaining the necessary regulatory approvals to bring its products to market and achieving profitable operations. The Company's research and development activities and commercialization of its products are dependent on its ability to successfully complete these activities and to obtain adequate financing through a combination of financing activities and operations. It is not possible to predict either the outcome of the Company's existing or future research and development programs or the Company&#8217;s ability to continue to fund these programs in the future.</font></div><div><a name="s4E6BE996E7025B7192AE11E4BC5A1157"></a></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;font-weight:bold;">2.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160; </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Significant accounting policies</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Basis of presentation</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (&#8220;U.S. GAAP&#8221;) for interim financial statements and accordingly, do not include all disclosures required for annual financial statements. These statements should be read in conjunction with the Company&#8217;s audited consolidated financial statements and notes thereto for the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">&#32;included in the Company&#8217;s Annual Report on Form 10-K for the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">&#32;(the &#8220;2018 Form 10-K&#8221;). These unaudited condensed consolidated financial statements reflect, in the opinion of management, all adjustments and reclassifications necessary to fairly present the Company's financial position as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;">&#32;and the Company's results of operations and cash flows for the </font><font style="font-family:inherit;font-size:10pt;">three and nine months ended September 30, 2019 and 2018</font><font style="font-family:inherit;font-size:10pt;">. The results of operations for the </font><font style="font-family:inherit;font-size:10pt;">three and nine months ended September 30, 2019 and 2018</font><font style="font-family:inherit;font-size:10pt;">, respectively, are not necessarily indicative of the results for the full year. These unaudited condensed consolidated financial statements follow the same significant accounting policies as those described in the notes to the audited consolidated financial statements of the Company for the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">, except as described below under Recent Accounting Pronouncements.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Principles of consolidation</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These unaudited condensed consolidated financial statements include the accounts of the Company and its </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;">&#32;wholly-owned subsidiaries, Arbutus Biopharma Inc. ("Arbutus Inc.") and Arbutus Biopharma US Holdings, Inc. All intercompany transactions and balances have been eliminated in consolidation.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Income or loss per share</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company follows the two-class method when computing net loss attributable to common shareholders per share as the Company has issued Series A participating convertible preferred shares (the "Preferred Shares"), as further described in note 12, that meet the definition of participating securities. The Preferred Shares entitle the holders to participate in dividends but do not require the holders to participate in losses of the Company. Accordingly, if the Company reports a net loss attributable to holders of the Company's common shares, net losses are not allocated to holders of the Preferred Shares. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss attributable to common shareholders per share is calculated based on the weighted average number of common shares outstanding. The calculation of diluted net loss attributable to common shareholders per share does not differ from the calculation of basic net loss attributable to common shareholders per share, as the effect of the Company&#8217;s dilutive potential common shares </font></div><div><br></div><div><div style="line-height:120%;padding-bottom:0px;padding-top:8px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;7</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:0px;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">was anti-dilutive. During the </font><font style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2019 and 2018</font><font style="font-family:inherit;font-size:10pt;">, potential common shares of approximately </font><font style="font-family:inherit;font-size:10pt;">28.2 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">24.2 million</font><font style="font-family:inherit;font-size:10pt;">, respectively, consisting of the "if-converted" number of Preferred Shares and outstanding stock options, were excluded from the calculation of net loss per common share because their inclusion would be anti-dilutive. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table sets out the computation of basic and diluted net loss attributable to common shareholders per share:</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:41%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands, except share and per share amounts)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Numerator:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Allocation of distributable earnings</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Allocation of undistributable loss</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(85,295</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(27,040</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(137,338</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(46,255</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Allocation of loss attributed to common shareholders</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(85,295</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(27,040</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(137,338</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(46,255</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Denominator:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted average number of common shares - basic and diluted</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">56,850,172</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">55,421,504</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">56,469,358</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">55,241,284</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic and diluted net loss attributable to common shareholders per share</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.50</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.49</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2.43</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.84</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Equity method investment</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company accounts for its investment in associated companies in accordance with the Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC") 323, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Investments - Equity Method and Joint Ventures </font><font style="font-family:inherit;font-size:10pt;">("ASC</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#32;</font><font style="font-family:inherit;font-size:10pt;">323").  In accordance with ASC 323, associated companies are accounted for as equity method investments. Results of associated companies are presented on a one-line basis. Investments in, and advances to, associated companies are presented on a one-line basis in the caption &#8220;Investment in Genevant&#8221; in the Company's Condensed Consolidated Balance Sheets, net of allowance for losses, which represents the Company's best estimate of probable losses inherent in such assets.  The Company's proportionate share of any associated companies' net income or loss is presented on a one-line basis in the caption "Equity investment (loss)" in the Company's Condensed Consolidated Statement of Operations.  Transactions between the Company and any associated companies are eliminated on a basis proportional to the Company's ownership interest.  Financial results of Genevant Sciences Ltd. ("Genevant") are recorded on a one-quarter lag basis.    </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Revenue recognition </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company recognizes the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers under a five-step model: (i) identify contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when or as a performance obligation is satisfied. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company generates revenue primarily through collaboration agreements and license agreements. Such agreements may require the Company to deliver various rights and/or services, including intellectual property rights or licenses and research and development services. Under such agreements, the Company is generally eligible to receive non-refundable upfront payments, funding for research and development services, milestone payments, and royalties.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In contracts where the Company has more than one performance obligation to provide its customer with goods or services, each performance obligation is evaluated to determine whether it is distinct based on whether (i) the customer can benefit from the good or service either on its own or together with other resources that are readily available and (ii) the good or service is separately identifiable from other promises in the contract. The consideration under the contract is then allocated between the distinct performance obligations based on their respective relative stand-alone selling prices. The estimated stand-alone selling price of each deliverable reflects the Company's best estimate of what the selling price would be if the deliverable was regularly sold on </font></div><div><br></div><div><div style="line-height:120%;padding-bottom:0px;padding-top:8px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;8</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:0px;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">a stand-alone basis and is determined by reference to market rates for the good or service when sold to others or by using an adjusted market assessment approach if the selling price on a stand-alone basis is not available. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The consideration allocated to each distinct performance obligation is recognized as revenue when control is transferred to the customer for the related goods or services. Consideration associated with at-risk substantive performance milestones, including sales-based milestones, is recognized as revenue when it is probable that a significant reversal of the cumulative revenue recognized will not occur. Sales-based royalties received in connection with licenses of intellectual property are subject to a specific exception in the revenue standards, whereby the consideration is not included in the transaction price and recognized in revenue until the customer&#8217;s subsequent sales or usages occur.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Segment information</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company operates as a single segment. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Recent accounting pronouncements</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies that are adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on the Company's financial position or results of operations upon adoption.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company adopted Accounting Standard Update (&#8220;ASU&#8221;) No. 2016-02, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Leases</font><font style="font-family:inherit;font-size:10pt;">&#32;(Topic 842), as of January 1, 2019, using the modified retrospective approach with the effective date transition method (note 5). Accordingly, all periods prior to adoption are presented in accordance with legacy accounting and the Company recorded no retrospective adjustments to the comparative periods presented. In addition, the Company elected the package of practical expedients permitted under the transition guidance within ASC 842, which among other things, allowed the Company to carry forward its historical lease classification. In addition, the Company elected the short term exemption, which allows entities to not capitalize their leases with a term of 12 months or less. Adoption of the new standard resulted in the recording of operating lease right-of-use assets (&#8220;ROU assets&#8221;) and lease liabilities of approximately </font><font style="font-family:inherit;font-size:10pt;">$3.2 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$4.1 million</font><font style="font-family:inherit;font-size:10pt;">, respectively, as of January 1, 2019.  The standard did not materially impact the Company&#8217;s consolidated statements of operations and statements of cash flow.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In November 2018, the FASB issued targeted amendments to ASU No. 2018-18, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Collaborative Arrangements </font><font style="font-family:inherit;font-size:10pt;">(Topic 808), and ASU No. 2016-10, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers </font><font style="font-family:inherit;font-size:10pt;">(Topic 606), to clarify that certain transactions between parties to collaborative arrangements should be accounted for in accordance with FASB revenue guidance when the counterparty is a customer. This guidance also prohibits the presentation of collaborative arrangements as revenues from contracts with customers if the counterparty is not a customer. This guidance, which is required to be applied retrospectively&#160;and is effective for interim and annual periods beginning after December 15, 2019, with early adoption permitted, is not expected to have a material impact on the Company&#8217;s consolidated financial statements.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s7FF07924CB965E9797F89F41EE01C1FE"></a></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">3.&#160;&#160;&#160;&#160;Fair value of financial instruments</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company measures certain financial instruments and other items at fair value.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">To determine the fair value, the Company uses the fair value hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs market participants would use to value an asset or liability and are developed based on market data obtained from independent sources. Unobservable inputs are inputs based on assumptions about the factors market participants would use to value an asset or liability. The three levels of inputs that may be used to measure fair value are as follows:</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level 1 inputs are quoted market prices for identical instruments available in active markets.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level 2 inputs are inputs other than quoted prices included within Level 1 that are observable for the asset or liability either directly or indirectly. If the asset or liability has a contractual term, the input must be observable for substantially the full term. An example includes quoted market prices for similar assets or liabilities in active markets.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level 3 inputs are unobservable inputs for the asset or liability and will reflect management&#8217;s assumptions about market assumptions that would be used to price the asset or liability.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table presents information about the Company&#8217;s assets and liabilities that are measured at fair value on a recurring basis, and indicates the fair value hierarchy of the valuation techniques used to determine such fair value:</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:45%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Level 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Level 2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Level 3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">As of September 30, 2019</font></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Assets</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">90,082</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">90,082</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Liabilities</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Liability-classified options</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">86</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">86</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contingent consideration</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,005</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,005</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,091</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,091</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.8046875%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:45%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Level 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Level 2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Level 3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">As of December 31, 2018</font></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Assets</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36,942</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36,942</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Short-term investments</font></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">87,675</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">87,675</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">124,617</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">124,617</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Liabilities</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Liability-classified stock option awards</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">479</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">479</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contingent consideration</font></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,126</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,126</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,605</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,605</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company's liability-classified options are measured at fair value using the Black-Scholes valuation model. Assumptions about the Company's expected stock-price volatility are based on the historical volatility of the Company's publicly-traded stock. The risk-free interest rate used for each grant is equal to the zero coupon rate for instruments with a similar expected life. The assumptions around the expected life are based on the Company's historical data. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">To determine the fair value of the contingent consideration, the Company uses a probability-weighted assessment of the likelihood the milestones would be met and the estimated timing of such payments (see note 10). The potential contingent payments are then discounted to their present value using a probability-adjusted discount rate that reflects the early-stage nature of the development program, time to complete the program development, and overall biotech indices. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table presents the changes in fair value of the Company&#8217;s liability-classified stock option awards:</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:38%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Liability at beginning of the period</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Fair value of liability-classified options exercised in the period</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Increase (decrease) in fair value of liability</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Liability at end of the period</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nine months ended September 30, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,239</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,499</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,738</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nine months ended September 30, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">479</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(393</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">86</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table presents the changes in fair value of the Company&#8217;s contingent consideration: </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:38%;"></td><td style="width:1%;"></td><td style="width:18%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:18%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:18%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Liability at beginning of the period</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Increase (decrease) in fair value of liability</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Liability at end of the period</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nine months ended September 30, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,424</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6,263</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,161</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nine months ended September 30, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,126</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(121</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,005</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div><a name="sBF19B449DB5D5A4AAD489031511513CB"></a></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">4.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#32;Equity method investment</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In April 2018, the Company entered into an agreement with Roivant Sciences Ltd. (&#8220;Roivant&#8221;), its largest shareholder, to launch Genevant, a company focused on the discovery, development, and commercialization of a broad range of RNA-based therapeutics enabled by the Company's lipid nanoparticle ("LNP") and ligand conjugate delivery technologies. The Company licensed exclusive rights to its LNP and ligand conjugate delivery platforms to Genevant for RNA-based applications outside of HBV. Genevant plans to develop products in-house and pursue industry partnerships to build a diverse pipeline of therapeutics across multiple modalities, including RNAi, mRNA, and gene editing. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the terms of the agreement, Roivant contributed $</font><font style="font-family:inherit;font-size:10pt;">37.5</font><font style="font-family:inherit;font-size:10pt;">&#32;million in seed capital to Genevant.  The Company retained all rights to its LNP and conjugate delivery platforms for HBV, and is entitled to a tiered low single-digit royalty from Genevant on future sales of products enabled by the delivery platforms licensed to Genevant. The Company also retained the entirety of its royalty entitlement on the commercialization of Alnylam Pharmaceuticals Inc.'s ("Alnylam") ONPATTRO&#8482; (Patisiran/ALN-TTR02).  The Company recognized a non-cash gain of&#160;</font><font style="font-family:inherit;font-size:10pt;">$24.9 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in the second quarter of 2018 in connection with the equity interest received by Arbutus upon Genevant&#8217;s formation.  </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;">, the Company held an equity interest of approximately </font><font style="font-family:inherit;font-size:10pt;">40%</font><font style="font-family:inherit;font-size:10pt;">&#32;of the common equity of Genevant and accounts for its interest in Genevant using the equity method.  The carrying value of the Company's interest in Genevant as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;">&#32;was </font><font style="font-family:inherit;font-size:10pt;">$11.0 million</font><font style="font-family:inherit;font-size:10pt;">.  The basis difference between the Company&#8217;s carrying value in Genevant and the Company&#8217;s share of Genevant's net assets is attributed primarily to indefinite-lived in-process research and development ("IPR&amp;D") (the delivery technology transferred to Genevant).  For the </font><font style="font-family:inherit;font-size:10pt;">three and nine months ended September 30, 2019</font><font style="font-family:inherit;font-size:10pt;">, the Company recorded equity investment losses of </font><font style="font-family:inherit;font-size:10pt;">$3.5 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$11.5 million</font><font style="font-family:inherit;font-size:10pt;">, respectively, for its proportionate share of Genevant&#8217;s net loss, recorded on a one-quarter lag basis.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s35A8FCBF2600512C970F21341A566463"></a></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">5.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Leases</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;">&#32;operating leases for office and laboratory space.  The Company's corporate headquarters is located at 701 Veterans Circle, Warminster, Pennsylvania.  The lease expires on April 30, 2027, and the Company has the option of extending the lease for </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;">&#32;further </font><font style="font-family:inherit;font-size:10pt;">five</font><font style="font-family:inherit;font-size:10pt;">-year terms.  The Company also leases office space located at 626 Jacksonville Rd, Warminster, Pennsylvania under a lease that expires on December 31, 2021, and the Company has an option to extend the lease term to April 30, 2027.  In connection with the Company's site consolidation in 2018, the Company ceased using its office and laboratory space located in Burnaby, British Columbia, Canada on June 30, 2018. The Company subleased a portion of the Burnaby facility to various tenants, including Genevant, until the lease expired on July 31, 2019.  The Company recognized the remaining lease payments for the Burnaby facility, less sublease income under contract, in site consolidation expenses in 2018. The Company&#8217;s lease agreements do not contain any material residual value guarantees or material restrictive covenants.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company adopted ASU No. 2016-02, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Leases</font><font style="font-family:inherit;font-size:10pt;">&#32;(Topic 842) on January 1, 2019 using the modified retrospective basis applied at the effective date of the new standard and elected to utilize a package of practical expedients.  Leases with an initial term of 12 months or less are not recorded on the balance sheet. The Company determines if an arrangement is a lease at inception. Right-of-use assets represent the Company's right to use an underlying asset for the lease term and lease liabilities represent the Company's obligation to make lease payments arising from the lease. Operating lease right-of-use assets and lease liabilities are recognized based on the present value of lease payments over the lease term. The leases do not provide an implicit rate so, in determining the present value of lease payments, the Company utilized its incremental borrowing rate for the applicable lease, which was </font><font style="font-family:inherit;font-size:10pt;">9.0%</font><font style="font-family:inherit;font-size:10pt;">&#32;for the 701 Veterans Circle lease, </font><font style="font-family:inherit;font-size:10pt;">7.6%</font><font style="font-family:inherit;font-size:10pt;">&#32;for the 626 Jacksonville Rd. lease and </font><font style="font-family:inherit;font-size:10pt;">5.0%</font><font style="font-family:inherit;font-size:10pt;">&#32;for the Burnaby lease. The Company recognizes lease expense on a straight-line basis over the remaining lease term.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the </font><font style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2019</font><font style="font-family:inherit;font-size:10pt;">, the Company incurred total operating lease expenses of </font><font style="font-family:inherit;font-size:10pt;">$1.1 million</font><font style="font-family:inherit;font-size:10pt;">, which included lease expenses associated with fixed lease payments of </font><font style="font-family:inherit;font-size:10pt;">$0.9 million</font><font style="font-family:inherit;font-size:10pt;">, and variable payments associated with common area maintenance and similar expenses of </font><font style="font-family:inherit;font-size:10pt;">$0.2 million</font><font style="font-family:inherit;font-size:10pt;">. For the </font><font style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2018</font><font style="font-family:inherit;font-size:10pt;">, the straight-line fixed expense for leases was </font><font style="font-family:inherit;font-size:10pt;">$0.9 million</font><font style="font-family:inherit;font-size:10pt;">. Sublease income for the </font><font style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2019</font><font style="font-family:inherit;font-size:10pt;">&#32;was </font><font style="font-family:inherit;font-size:10pt;">$0.2 million</font><font style="font-family:inherit;font-size:10pt;">, versus </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;">&#32;for the </font><font style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2018</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;padding-bottom:0px;padding-top:8px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;9</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:0px;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted average remaining lease term and discount rate were as follows:</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:8px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:76%;"></td><td style="width:24%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">As of September 30, 2019</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted-average remaining lease term (years)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.3</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted average discount rate</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.9%</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company did not include options to extend its lease terms as part of its ROU asset and lease liabilities. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:20px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Supplemental cash flow information related to the Company's operating leases was as follows:</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:68%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash paid for amounts included in the measurement of lease liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">921</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Maturities of lease liabilities were as follows:</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:78%;"></td><td style="width:1%;"></td><td style="width:20%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">As of September 30, 2019</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">October through December 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">188</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2020</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">657</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2021</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">677</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2022</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">581</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2023</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">598</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Thereafter</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,039</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total Lease Payments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,740</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less: interest</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,268</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Present value of lease payments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,472</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s816857BCBC1859938CB13F657DC450EE"></a></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">6.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#32;Intangible assets and goodwill</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Acquired IPR&amp;D intangible assets relate to the Company's covalently closed circular DNA ("cccDNA") program.  During the </font><font style="font-family:inherit;font-size:10pt;">three months ended September 30, 2019</font><font style="font-family:inherit;font-size:10pt;">, the Company recorded a </font><font style="font-family:inherit;font-size:10pt;">$43.8 million</font><font style="font-family:inherit;font-size:10pt;">&#32;non-cash impairment expense to reduce the carrying value of its IPR&amp;D intangible assets to </font><font style="font-family:inherit;font-size:10pt;">zero</font><font style="font-family:inherit;font-size:10pt;">&#32;as of September 30, 2019.  The Company also recognized a corresponding income tax benefit of </font><font style="font-family:inherit;font-size:10pt;">$12.7 million</font><font style="font-family:inherit;font-size:10pt;">&#32;related to the decrease in its deferred tax liability related to the IPR&amp;D intangible assets.  The impairment was due to a decision to delay indefinitely the further development of the Company's cccDNA program while the Company focuses on its other development programs. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Goodwill represents the excess of purchase price over the value assigned to the net tangible and identifiable intangible assets in connection with the business combination that formed Arbutus.  In the third quarter of 2019, the Company assessed the changes in circumstances that occurred during the quarter to determine if it was more likely than not that the fair value of its single reporting unit was below its carrying amount.  Although the Company's annual impairment test is performed during the fourth quarter, the Company performs this qualitative assessment each interim reporting period.  Due to a sustained decrease in the Company's share price in recent months, the Company's market capitalization was reduced below the book value of its net assets and the Company concluded that the fair value of its single reporting unit was below its carrying amount by an amount in excess of the carrying value of the goodwill.  As a result, the Company recorded a </font><font style="font-family:inherit;font-size:10pt;">$22.5 million</font><font style="font-family:inherit;font-size:10pt;">&#32;non-cash impairment expense to reduce the carrying value of its goodwill asset to </font><font style="font-family:inherit;font-size:10pt;">zero</font><font style="font-family:inherit;font-size:10pt;">&#32;as of September 30, 2019.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;padding-bottom:0px;padding-top:8px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;10</font></div></div><hr style="page-break-after:always"><div><a name="s327210AAF6D5514EAE64FBE87DB0D9C4"></a></div><div><div style="line-height:120%;padding-bottom:0px;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">7.&#160;&#160;&#160;&#160;&#160; Accounts payable and accrued liabilities</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts payable and accrued liabilities are comprised of the following:</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:63%;"></td><td style="width:1%;"></td><td style="width:16%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:16%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">September&#160;30, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">December&#160;31, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Trade accounts payable</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,400</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,192</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development accruals</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,112</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,716</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Professional fee accruals</font></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,177</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">871</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Payroll accruals</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,509</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,341</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other accrued liabilities</font></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">309</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,199</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,429</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s08FC84D63AAE50E1805D74C09E24B94B"></a></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">8.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Site consolidation </font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In 2018, the Company substantially completed a site consolidation and organizational restructuring to align its HBV business in Warminster, PA, including a reduction of its global workforce and closure of its Burnaby facility. The Company estimates that the total expenses to complete the site consolidation will be approximately </font><font style="font-family:inherit;font-size:10pt;">$5.0</font><font style="font-family:inherit;font-size:10pt;">&#32;million, of which </font><font style="font-family:inherit;font-size:10pt;">$4.8 million</font><font style="font-family:inherit;font-size:10pt;">&#32;has been incurred as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;">.  Included in the site consolidation plan was the payment of one-time employee termination benefits, employee relocation costs, and site closure costs.  The Company ceased using its Burnaby facility as of June 30, 2018 and recognized the remaining committed cost, less sublease income under contract, in site consolidation expenses in 2018.  The lease for the Burnaby facility expired on July 31, 2019.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Site consolidation expenses were as follows: </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:41%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Employee severance and relocation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">231</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">198</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">429</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,399</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Facility and other expenses</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(49</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(690</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(396</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">311</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total site consolidation expense</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">182</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(492</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,710</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Site consolidation activity was as follows:</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:58%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Employee severance and relocation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Facility and other expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Site consolidation accrual as of December 31, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">697</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">634</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,331</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Additional accruals and other adjustments</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">429</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(396</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Payments</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(923</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(238</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,161</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Site consolidation accrual as of September 30, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">203</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">203</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="se3925930660e4e17b12872b56fe90d0c"></a></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">9.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Sale of future royalties </font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On July 2, 2019, the Company entered into a Purchase and Sale Agreement (the "Agreement") with the Ontario Municipal Employees Retirement System (or "OMERS"), pursuant to which the Company sold to OMERS part of its royalty interest on future global net sales of ONPATTRO&#8482; (Patisiran) ("ONPATTRO"), an RNA interference therapeutic currently being sold by Alnylam.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;padding-bottom:0px;padding-top:8px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;11</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:0px;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ONPATTRO utilizes Arbutus&#8217; LNP technology, which was licensed to Alnylam pursuant to the Cross-License Agreement, dated November 12, 2012, by and between the Company and Alnylam (the &#8220;LNP License Agreement&#8221;).&#160;Under the terms of the LNP License Agreement, the Company is entitled to tiered royalty payments on global net sales of ONPATTRO ranging from </font><font style="font-family:inherit;font-size:10pt;">1.00%</font><font style="font-family:inherit;font-size:10pt;">&#32;to </font><font style="font-family:inherit;font-size:10pt;">2.33%</font><font style="font-family:inherit;font-size:10pt;">&#32;after offsets, with the highest tier applicable to annual net sales above </font><font style="font-family:inherit;font-size:10pt;">$500 million</font><font style="font-family:inherit;font-size:10pt;">. This royalty interest was sold to OMERS, effective as of January 1, 2019, for </font><font style="font-family:inherit;font-size:10pt;">$20 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in gross proceeds before advisory fees. OMERS will retain this entitlement until it has received </font><font style="font-family:inherit;font-size:10pt;">$30 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in royalties, at which point </font><font style="font-family:inherit;font-size:10pt;">100%</font><font style="font-family:inherit;font-size:10pt;">&#32;of such royalty interest on future global net sales of ONPATTRO will revert to the Company. OMERS has assumed the risk of collecting up to </font><font style="font-family:inherit;font-size:10pt;">$30 million</font><font style="font-family:inherit;font-size:10pt;">&#32;of future royalty payments from Alnylam and Arbutus is not obligated to reimburse OMERS if they fail to collect any such future royalties.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The </font><font style="font-family:inherit;font-size:10pt;">$30 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in royalties to be paid to OMERS is accounted for as a liability, with the difference between the liability and the gross proceeds received accounted for as a discount. The discount, as well as </font><font style="font-family:inherit;font-size:10pt;">$1.5 million</font><font style="font-family:inherit;font-size:10pt;">&#32;of transaction costs, will be amortized as interest expense based on the projected balance of the liability as of the beginning of each period. Management estimated an effective annual interest rate of approximately </font><font style="font-family:inherit;font-size:10pt;">25%</font><font style="font-family:inherit;font-size:10pt;">. Over the course of the Agreement, the actual interest rate will be affected by the amount and timing of royalty revenue recognized and changes in the timing of forecasted royalty revenue. On a quarterly basis, the Company will reassess the expected timing of the royalty revenue, recalculate the amortization and effective interest rate and adjust the accounting prospectively as needed. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company will recognize non-cash royalty revenue related to the sales of ONPATTRO during the term of the Agreement. As royalties are remitted to OMERS from Alnylam, the balance of the recognized liability will be effectively repaid over the life of the Agreement. There are a number of factors that could materially affect the amount and timing of royalty payments from Alnylam, none of which are within the Company's control. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the </font><font style="font-family:inherit;font-size:10pt;">three and nine months ended September 30, 2019</font><font style="font-family:inherit;font-size:10pt;">, the Company recognized non-cash royalty revenue of </font><font style="font-family:inherit;font-size:10pt;">$1.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$1.1 million</font><font style="font-family:inherit;font-size:10pt;">&#32;of related non-cash interest expense. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The table below shows the activity related to the net liability from inception of the Agreement through </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:68%;"></td><td style="width:1%;"></td><td style="width:30%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Nine Months Ended September 30, 2019</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net liability related to sale of future royalties - beginning balance</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Initial recognition of liability</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Debt discount and issuance costs</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(11,451</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-cash royalty revenue</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(979</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-cash interest expense</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,106</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net liability related to sale of future royalties - ending balance</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,675</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition to the royalty from the Alnylam LNP License Agreement, the Company is also receiving a second, lower royalty interest on global net sales of ONPATTRO originating from a settlement agreement and subsequent license agreement with Acuitas Therapeutics, Inc. ("Acuitas"). The royalty from Acuitas has been retained by the Company and was not part of the royalty sale to OMERS.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="sFBA115D6A70759A9AF078F637107EF81"></a></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">10.&#160;&#160;&#160;&#160;&#160; Contingencies and commitments</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Arbitration with the University of British Columbia </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certain early work on LNP delivery systems and related inventions was undertaken by the Company and assigned to the University of British Columbia ("UBC"). These inventions were subsequently licensed back to the Company by UBC under a license agreement, initially entered into in 1998 and subsequently amended in 2001, 2006 and 2007. The Company has granted sublicenses under the UBC license to Alnylam. Alnylam has in turn sublicensed back to the Company under the licensed UBC patents for discovery, development and commercialization of siRNA products. Certain sublicenses were also granted to other parties.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;padding-bottom:0px;padding-top:8px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;12</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:0px;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On November 10, 2014, UBC filed a notice of arbitration against the Company and on January 16, 2015, filed a Statement of Claim, which alleged entitlement to </font><font style="font-family:inherit;font-size:10pt;">$3.5</font><font style="font-family:inherit;font-size:10pt;">&#32;million in allegedly unpaid royalties based on publicly available information, and an unspecified amount based on non-public information. UBC also sought interest and costs, including legal fees. The Company filed its Statement of Defense to UBC's Statement of Claims, as well as a Counterclaim involving a patent application that the Company alleged UBC wrongly licensed to a third party.  The proceedings were divided into </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;">&#32;phases, with the first hearing taking place in June 2017. In the first phase, the arbitrator determined which agreements are sublicense agreements within UBC's claim. Also in the first phase, UBC updated its alleged entitlement from </font><font style="font-family:inherit;font-size:10pt;">$3.5</font><font style="font-family:inherit;font-size:10pt;">&#32;million originally claimed to seek </font><font style="font-family:inherit;font-size:10pt;">$10.9</font><font style="font-family:inherit;font-size:10pt;">&#32;million in alleged unpaid royalties, plus interest arising from payments as early as 2008. The arbitrator also held in the first phase of the arbitration that the patent application that is the subject of the Counterclaim was not required to be licensed to Arbutus.&#160;The second phase of arbitration took place in April 2019. On&#160;August&#160;20, 2019, the arbitrator issued his decision for the second phase of the arbitration, awarding UBC </font><font style="font-family:inherit;font-size:10pt;">$5.9 million</font><font style="font-family:inherit;font-size:10pt;">, which includes interest of approximately </font><font style="font-family:inherit;font-size:10pt;">$2.6 million</font><font style="font-family:inherit;font-size:10pt;">. The Company paid the </font><font style="font-family:inherit;font-size:10pt;">$5.9 million</font><font style="font-family:inherit;font-size:10pt;">&#32;award to UBC in September 2019. The arbitrator also held that the third phase of the arbitration, which would address patent validity, should the Company choose to pursue a third phase, would not provide a defense to the award. An award for costs and attorneys&#8217; fees is still to be determined. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company recorded a charge of </font><font style="font-family:inherit;font-size:10pt;">$6.5 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in the third quarter of 2019, consisting of </font><font style="font-family:inherit;font-size:10pt;">$5.9 million</font><font style="font-family:inherit;font-size:10pt;">&#32;for the award (including interest) and </font><font style="font-family:inherit;font-size:10pt;">$0.6 million</font><font style="font-family:inherit;font-size:10pt;">&#32;for an estimate of a potential award for costs and attorney's fees. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">License Agreements between Enantigen and Blumberg and Drexel</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In October 2014, Arbutus Inc. acquired all of the outstanding shares of Enantigen Therapeutics, Inc. (&#8220;Enantigen&#8221;) pursuant to a stock purchase agreement. Through this transaction, Arbutus Inc. acquired a HBV surface antigen secretion inhibitor program and a capsid assembly inhibitor program. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the stock purchase agreement, Arbutus Inc. agreed to pay up to a total of </font><font style="font-family:inherit;font-size:10pt;">$21.0</font><font style="font-family:inherit;font-size:10pt;">&#32;million to Enantigen&#8217;s selling shareholders upon the achievement of specified development and regulatory milestones for (a) the first </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;">&#32;products that contain either a capsid compound or an HBV surface antigen compound that is covered by a patent acquired under this agreement, or (b) a capsid compound from an agreed upon list of compounds. The amount paid could be up to an additional </font><font style="font-family:inherit;font-size:10pt;">$102.5 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in sales performance milestones in connection with the sale of the first commercialized product by Arbutus Inc. for the treatment of HBV, regardless of whether such product is based upon assets acquired under this agreement, and a low single-digit royalty on net sales of such first commercialized HBV product, up to a maximum royalty payment of </font><font style="font-family:inherit;font-size:10pt;">$1.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;that, if paid, would be offset against Arbutus Inc.'s milestone payment obligations.  The contingent consideration for this acquisition is a financial liability and measured at its fair value at each reporting period, with any changes in fair value from the previous reporting period recorded in the statement of operations and comprehensive loss (see note 3).  The fair value of the contingent consideration was </font><font style="font-family:inherit;font-size:10pt;">$3.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the stock purchase agreement, Enantigen must also fulfill its obligations as they relate to the </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;">&#32;patent license agreements with The Baruch S. Blumberg Institute ("Blumberg") and Drexel University ("Drexel"). Pursuant to each patent license agreement, Enantigen is obligated to pay Blumberg and Drexel up to approximately </font><font style="font-family:inherit;font-size:10pt;">$0.5</font><font style="font-family:inherit;font-size:10pt;">&#32;million in development and regulatory milestones per licensed product, royalties in the low single-digits, and a percentage of revenue it receives from its sub-licensees.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Research Collaboration and Funding Agreement with Blumberg</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In November 2018, the Company entered into a new </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;">-year master services agreement with Blumberg that expires in November 2020.&#160; The new agreement replaces all rights and obligations of the prior research collaboration and funding agreements, as amended. Under the new agreement, Blumberg will perform specific research activities based upon statements of work and the Company will no longer provide a fixed amount of funding to Blumberg.&#160; As of September 30, 2019, the Company has executed statements of work with Blumberg for an aggregate cost of </font><font style="font-family:inherit;font-size:10pt;">$0.8</font><font style="font-family:inherit;font-size:10pt;">&#32;million under this new agreement.  Intellectual property that is generated during the research activities is the Company's exclusive property and all financial obligations for it to utilize the intellectual property are satisfied in the upfront cost of the research activities.  Under the terms of the new agreement, the Company retains all rights to any inventions arising from performance of the agreement and no license is granted to Blumberg, nor are milestones for said inventions due to Blumberg.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s1DA23736714C5CBCB859EE37BB55282C"></a></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;padding-bottom:0px;padding-top:8px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;13</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:0px;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">11.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160; </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Collaborations, contracts and licensing agreements</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue contracts are described in detail in the Overview section of Part I, Item 2, "Management's Discussion and Analysis of Financial Condition and Results of Operations" in the Company's 2018 Form 10-K. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In 2012, the Company entered into a license agreement with Alnylam that entitles Alnylam to develop and commercialize products with the Company's LNP technology. Alnylam's ONPATTRO program, which represents the first approved application of LNP technology, was approved by the U.S. Food and Drug Administration ("FDA") and the European Medicines Agency ("EMA") during the third quarter of 2018 and was launched immediately upon approval in the US. The Company is entitled to tiered low to mid single-digit royalty payments on global net sales of ONPATTRO and received its first royalty payment in the fourth quarter of 2018. In July 2019, the Company sold a portion of its royalty entitlement for Alnylam's ONPATTRO to OMERS.  See note 9 - Sale of future royalties for further details.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue for the </font><font style="font-family:inherit;font-size:10pt;">three and nine months ended September 30, 2019</font><font style="font-family:inherit;font-size:10pt;">&#32;consists primarily of a net </font><font style="font-family:inherit;font-size:10pt;">$1.5 million</font><font style="font-family:inherit;font-size:10pt;">&#32;development milestone earned under our license agreement with Gritstone, royalties on net global sales of Alnylam's ONPATTRO, a milestone and royalties on net sales of Spectrum Pharmaceuticals, Inc.'s ("Spectrum") Marqibo</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174; </sup></font><font style="font-family:inherit;font-size:10pt;">and services provided to Gritstone Oncology, Inc. ("Gritstone").  Revenue for the three and nine months ended September 30, 2018 consisted primarily of revenue earned under our license agreement with Gritstone, including a net </font><font style="font-family:inherit;font-size:10pt;">$1.3 million</font><font style="font-family:inherit;font-size:10pt;">&#32;development milestone payment, the earned portion of an upfront license fee and services provided to Gritstone.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s5A1DBF5DB8B45E96933E5AABE9F8617E"></a></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">12.         Stockholders' equity and stock-based compensation</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Open Market Sale Agreement</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In December&#160;2018, the Company entered into an Open Market Sale Agreement&#160;(&#8220;Sale Agreement&#8221;) with Jefferies LLC, under which it may issue and sell common shares, from time to time, for an aggregate sales price of up to </font><font style="font-family:inherit;font-size:10pt;">$50.0 million</font><font style="font-family:inherit;font-size:10pt;">. For the </font><font style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2019</font><font style="font-family:inherit;font-size:10pt;">, the Company issued </font><font style="font-family:inherit;font-size:10pt;">1,208,090</font><font style="font-family:inherit;font-size:10pt;">&#32;common shares pursuant to the Sale Agreement, resulting in gross proceeds of approximately </font><font style="font-family:inherit;font-size:10pt;">$5.2 million</font><font style="font-family:inherit;font-size:10pt;">. There were </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;">&#32;shares issued during the </font><font style="font-family:inherit;font-size:10pt;">three months ended September 30, 2019</font><font style="font-family:inherit;font-size:10pt;">&#32;under the Sale Agreement.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Series A participating convertible preferred shares </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In October 2017, the Company entered into a subscription agreement with Roivant for the sale of </font><font style="font-family:inherit;font-size:10pt;">1,164,000</font><font style="font-family:inherit;font-size:10pt;">&#32;Preferred Shares for gross proceeds of </font><font style="font-family:inherit;font-size:10pt;">$116.4</font><font style="font-family:inherit;font-size:10pt;">&#160;million. These Preferred Shares are non-voting and accrue an </font><font style="font-family:inherit;font-size:10pt;">8.75%</font><font style="font-family:inherit;font-size:10pt;">&#32;per annum coupon in the form of additional Preferred Shares, compounded annually, until October 16, 2021, at which time all the Preferred Shares will be subject to mandatory conversion into common shares (subject to limited exceptions in the event of certain fundamental corporate transactions relating to Arbutus&#8217; capital structure or assets, which would permit earlier conversion at Roivant&#8217;s option). The conversion price is </font><font style="font-family:inherit;font-size:10pt;">$7.13</font><font style="font-family:inherit;font-size:10pt;">&#160;per share, which will result in the Preferred Shares being converted into approximately </font><font style="font-family:inherit;font-size:10pt;">23</font><font style="font-family:inherit;font-size:10pt;">&#32;million common shares. After conversion of the Preferred Shares into common shares, based on the number of common shares outstanding </font><font style="font-family:inherit;font-size:10pt;">as of September 30, 2019</font><font style="font-family:inherit;font-size:10pt;">, Roivant would hold&#160;approximately </font><font style="font-family:inherit;font-size:10pt;">49%</font><font style="font-family:inherit;font-size:10pt;">&#32;of the Company's common shares. Roivant agreed to a </font><font style="font-family:inherit;font-size:10pt;">four</font><font style="font-family:inherit;font-size:10pt;">&#32;year lock-up period for this investment and its existing holdings in the Company. Roivant also agreed to a </font><font style="font-family:inherit;font-size:10pt;">four</font><font style="font-family:inherit;font-size:10pt;">&#32;year standstill whereby Roivant will not acquire greater than&#160;</font><font style="font-family:inherit;font-size:10pt;">49.99%</font><font style="font-family:inherit;font-size:10pt;">&#160;of the Company's common shares or securities convertible into common shares. The initial investment of&#160;</font><font style="font-family:inherit;font-size:10pt;">$50.0</font><font style="font-family:inherit;font-size:10pt;">&#160;million closed in October 2017, and the remaining amount of&#160;</font><font style="font-family:inherit;font-size:10pt;">$66.4</font><font style="font-family:inherit;font-size:10pt;">&#32;million closed in January 2018 following regulatory and shareholder approvals.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company records the Preferred Shares wholly as equity under ASC 480, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Distinguishing Liabilities From Equity,</font><font style="font-family:inherit;font-size:10pt;">&#32;with no bifurcation of conversion feature from the host contract, given that the Preferred Shares cannot be cash settled and the redemption features are within the Company's control, which include a fixed conversion ratio with predetermined timing and proceeds. The Company accrues for the </font><font style="font-family:inherit;font-size:10pt;">8.75%</font><font style="font-family:inherit;font-size:10pt;">&#32;per annum compounding coupon at each reporting period end date as an increase to preferred share capital, and an increase to deficit (see Condensed Consolidated Statement of Stockholders' Equity).</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;padding-bottom:0px;padding-top:8px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;14</font></div></div><hr style="page-break-after:always"><div><a name="s11370F249D405076B7B56F419FCCD280"></a></div><div><div style="line-height:120%;padding-bottom:0px;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">13.&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160; &#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Related Party Transactions</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Through the first quarter of 2019, the Company purchased certain research and development services from Genevant.  These services were billed at agreed hourly rates and were reflective of market rates for such services.&#160; The total cost of these services for the </font><font style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2019</font><font style="font-family:inherit;font-size:10pt;">&#32;was </font><font style="font-family:inherit;font-size:10pt;">$33 thousand</font><font style="font-family:inherit;font-size:10pt;">.  There were </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;">&#32;such costs incurred during the second and third quarter of 2019. The total cost of these services was </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$0.2 million</font><font style="font-family:inherit;font-size:10pt;">&#32;for the </font><font style="font-family:inherit;font-size:10pt;">three and nine months ended September 30, 2018</font><font style="font-family:inherit;font-size:10pt;">, respectively, and are included in the Condensed Consolidated Statements of Operations under research and development. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Conversely, Genevant purchased certain administrative and transitional services from the Company totaling </font><font style="font-family:inherit;font-size:10pt;">$40 thousand</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$284 thousand</font><font style="font-family:inherit;font-size:10pt;">&#32;for the </font><font style="font-family:inherit;font-size:10pt;">three and nine months ended September 30, 2019</font><font style="font-family:inherit;font-size:10pt;">, respectively. The total income from these services was </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$0.3 million</font><font style="font-family:inherit;font-size:10pt;">&#32;for the </font><font style="font-family:inherit;font-size:10pt;">three and nine months ended September 30, 2018</font><font style="font-family:inherit;font-size:10pt;">, which were netted against research and development expenses in the Condensed Consolidated Statements of Operations. In addition, Genevant had a sublease for </font><font style="font-family:inherit;font-size:10pt;">17,900</font><font style="font-family:inherit;font-size:10pt;">&#32;square feet in the Company's Burnaby facility. Sublease income from Genevant was </font><font style="font-family:inherit;font-size:10pt;">$21 thousand</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;">&#32;for the </font><font style="font-family:inherit;font-size:10pt;">three and nine months ended September 30, 2019</font><font style="font-family:inherit;font-size:10pt;">, respectively, and was netted against site consolidation costs and lease liability (see notes 7 and 8).  The Company&#8217;s Burnaby facility lease and the corresponding sublease to Genevant expired on July 31, 2019.</font></div><div><br></div><div><div style="line-height:120%;padding-bottom:0px;padding-top:8px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;15</font></div></div><hr style="page-break-after:always"><div><a name="sEBA38294291E56FE85B2BDF490B8030C"></a></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:24px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 2. MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:24px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">You should read the following discussion and analysis by our management of our financial position and results of operations in conjunction with our audited consolidated financial statements and related notes thereto included as part of our Annual Report on Form 10-K for the year ended </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#32;and our unaudited condensed consolidated financial statements for the </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">three and nine months ended September 30, 2019</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">. Our consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles and are presented in U.S. dollars.</font></div><div><a name="sACA490806ED25BA2AACE5744E2C2259C"></a></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</font><font style="font-family:inherit;font-size:12pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">This Quarterly Report on Form 10-Q (&#8220;Form 10-Q&#8221;) contains &#8220;forward-looking statements&#8221; or &#8220;forward-looking information&#8221; within the meaning of applicable U.S. and Canadian securities laws (we collectively refer to these items as &#8220;forward-looking statements&#8221;). Forward-looking statements are generally identifiable by use of the words &#8220;believes,&#8221; &#8220;may,&#8221; &#8220;plans,&#8221; &#8220;will,&#8221; &#8220;anticipates,&#8221; &#8220;intends,&#8221; &#8220;budgets,&#8221; &#8220;could,&#8221; &#8220;estimates,&#8221; &#8220;expects,&#8221; &#8220;forecasts,&#8221; &#8220;projects&#8221; and similar expressions that are not based on historical fact or that are predictions of or indicate future events and trends, and the negative of such expressions. Forward-looking statements in this Form 10-Q, including the documents incorporated by reference, include statements about, among other things:</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our strategy, future operations, pre-clinical research, pre-clinical studies, clinical trials, prospects and the plans of management;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the discovery, development and commercialization of a cure for chronic hepatitis B infection, a disease of the liver caused by the hepatitis B virus ("HBV");</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our beliefs and development path and strategy to achieve a cure for HBV;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">obtaining necessary regulatory approvals;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">obtaining adequate financing through a combination of financing activities and operations;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">using the results from our HBV studies to adaptively design additional clinical trials to test the efficacy of the combination therapy and the duration of the result in patients;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the expected timing of and amount for payments related to Enantigen Therapeutics, Inc.'s (&#8220;Enantigen&#8221;) transaction and its programs;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the potential of our drug candidates to improve upon the standard of care and contribute to a curative combination treatment regimen;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the potential benefits of the reversion of the OMERS royalty monetization transaction for our ONPATTRO&#8482; (Patisiran) royalty interest;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">developing a suite of products that intervene at different points in the viral life cycle, with the potential to reactivate the host immune system;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">using pre-clinical results to adaptively design clinical trials for additional cohorts of patients, testing the combination and the duration of therapy;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">selecting combination therapy regimens and treatment durations to conduct Phase 3 clinical trials intended to ultimately support regulatory filings for marketing approval;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">expanding our HBV drug candidate pipeline through internal development, acquisitions and in-licenses;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the potential of our assets, including our ownership stake in Genevant Sciences Ltd. (Genevant&#8221;) and the royalty entitlement on ONPATTRO, to provide significant non-dilutive capital;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our expectation to present results from the AB-506 Phase 1a/1b clinical trial along with further details regarding the two cases of acute hepatitis at the AASLD meeting in November 2019;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our expectation to select one of several oral next-generation capsid inhibitor lead compounds for IND-enabling studies in December of this year;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our expectation to make a decision regarding AB-452 clinical development in early 2020;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our expectation for AB-729 for preliminary safety and efficacy data from both healthy subjects and several single dose cohorts of subjects with CHB to be available in the first quarter of 2020. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">payments from the Gritstone Oncology, Inc. ("Gritstone") licensing agreement;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the belief that current legal proceedings will not have a material adverse effect on our consolidated results of operations, cash flows, or financial condition;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the expected return from strategic alliances, licensing agreements, and research collaborations;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">statements with respect to revenue and expense fluctuation and guidance;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the sufficiency of our cash and cash equivalents to extend into early 2021;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">obtaining funding to maintain and advance our business from a variety of sources including public or private equity or debt financing, collaborative arrangements with pharmaceutical companies and government grants and contracts; </font></div></td></tr></table><div><br></div><div><div style="line-height:120%;padding-bottom:0px;padding-top:8px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;16</font></div></div><hr style="page-break-after:always"><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">on-going arbitration; and </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the amount and timing of potential funding,</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">as well as other statements relating to our future operations, financial performance or financial condition, prospects or other future events. Forward-looking statements appear primarily in the sections of this Form 10-Q entitled &#8220;Part I, Item 1- Financial Statements (Unaudited),&#8221; and &#8220;Part I, Item 2-Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221;.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forward-looking statements are based upon current expectations and assumptions and are subject to a number of known and unknown risks, uncertainties and other factors that could cause actual results to differ materially and adversely from those expressed or implied by such statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed in this Form 10-Q and our Annual Report on Form 10-K for the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">&#32;(&#8220;Form 10-K&#8221;), and in particular the risks and uncertainties discussed under "Item 1A-Risk Factors" of this Form 10-Q and the Form 10-K. As a result, you should not place undue reliance on forward-looking statements.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Additionally, the forward-looking statements contained in this Form 10-Q represent our views only as of the date of this Form 10-Q (or any earlier date indicated in such statement). While we may update certain forward-looking statements from time to time, we specifically disclaim any obligation to do so, even if new information becomes available in the future. However, you are advised to consult any further disclosures we make on related subjects in the periodic and current reports that we file with the Securities and Exchange Commission.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The foregoing cautionary statements are intended to qualify all forward-looking statements wherever they may appear in this Form 10-Q. For all forward-looking statements, we claim protection of the safe harbor for the forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">This Form 10-Q also contains estimates, projections and other information concerning our industry, our business, and the markets for certain diseases, including data regarding the estimated size of those markets, and the incidence and prevalence of certain medical conditions. Information that is based on estimates, forecasts, projections, market research or similar methodologies is inherently subject to uncertainties and actual events or circumstances may differ materially from events and circumstances reflected in this information. Unless otherwise expressly stated, we obtained this industry, business, market and other data from reports, research surveys, studies and similar data prepared by market research firms and other third parties, industry, medical and general publications, government data and similar sources.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:0px;padding-top:8px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;17</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><a name="sD56F0D05255359938D5595F3DBFAE4B5"></a></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">OVERVIEW</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Arbutus Biopharma Corporation ("Arbutus", the "Company", "we", "us", and "our") is a publicly traded (Nasdaq Global Select Market: ABUS) therapeutic solutions company dedicated to discovering, developing, and commercializing a cure for patients suffering from chronic hepatitis B infection, a disease of the liver caused by the hepatitis B virus (&#8220;HBV&#8221;). HBV represents a significant, global unmet medical need. The World Health Organization estimates that approximately 257 million people worldwide suffer from HBV infection. With high morbidity and mortality, and a cure rate for HBV patients taking standard of care ("SOC") treatment regimens of less than 5%, our objective is to develop safe and effective therapies that can be combined and lead to higher cure rates with finite treatment durations. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">To pursue our strategy of developing a potential curative combination regimen for chronic HBV, we are developing a diverse product pipeline consisting of multiple drug candidates with potential complementary mechanisms of action, each of which has the potential to improve upon the SOC and contribute to a curative combination treatment regimen. Our clinical and pre-clinical pipeline includes agents that have the potential to form an effective proprietary combination therapy. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition to our drug pipeline focused on HBV, we have additional assets that have the potential to provide value to our company. The first is our royalty entitlement on ONPATTRO&#8482; (Patisiran), a drug developed by Alnylam Pharmaceuticals, Inc. ("Alnylam") that incorporates our lipid nanoparticle delivery ("LNP") technology and was approved by the U.S. Food and Drug Administration ("FDA") and the European Medicines Agency (&#8220;EMA&#8221;) during the third quarter of 2018 and launched immediately upon approval in the U.S.  In July 2019, we sold a portion of this royalty interest to an affiliate of the Ontario Municipal Employees Retirement System (&#8220;OMERS&#8221;), effective as of January 1, 2019, for $20 million in gross proceeds before advisory fees. OMERS will retain this entitlement until it has received $30 million in royalties, at which point 100% of such royalty interest on future global net sales of ONPATTRO will revert to us. OMERS has assumed the risk of collecting up to $30 million of future royalty payments from Alnylam and Arbutus is not obligated to reimburse OMERS if they fail to collect any such future royalties. If this royalty entitlement reverts to us, it has the potential to provide an active royalty stream or to be otherwise monetized again in full or in part.  In addition to this royalty from the Alnylam LNP license agreement, we are also receiving a second, lower royalty interest on global net sales of ONPATTRO originating from a settlement agreement and subsequent license agreement with Acuitas Therapeutics, Inc. (Acuitas). The royalty from Acuitas has been retained by us and was not part of the royalty sale to OMERS.  The second asset is our approximate 40% equity ownership interest in Genevant, a company to which we have licensed our LNP platform and conjugate delivery platform (the "Delivery Platforms") for all applications except HBV.  These additional assets have the potential to provide significant non-dilutive capital to fund development of our HBV pipeline.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Strategy</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our objective is to develop a cure for patients with chronic HBV infection.  We believe this can best be achieved by:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:66px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">developing a pipeline of proprietary therapeutic agents that target multiple elements of the HBV viral lifecycle, the most important of which we believe are HBV replication and hepatitis B surface antigen ("HBsAg") expression, and the host immune system; and </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:66px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">identifying an effective combination of complementary proprietary therapeutic agents administered for a finite treatment duration. </font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;padding-left:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our primary focus is to:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:66px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">progress our clinical and pre-clinical product candidates through Phase 1 and Phase 2 clinical trials;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:66px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">identify a safe and effective combination regimen to support a robust Phase 3 clinical registration program; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:66px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">obtain regulatory approval for such combination regimen; and </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:66px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">commercialize such combination regimen.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are currently conducting a Phase 1a/1b clinical trial and pre-clinical and investigational new drug ("IND")-enabling studies to evaluate proprietary HBV therapeutic agents alone, together with SOC therapies and in combination with each other. We expect to use the results from these clinical trials and other studies to adaptively design future clinical trials to test the safety, efficacy and duration of potential combination therapies.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;padding-bottom:0px;padding-top:8px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;18</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our HBV product pipeline consists of the following programs: </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><img src="hbvpipeline002.jpg" alt="hbvpipeline002.jpg" style="height:344px;width:684px;"></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We intend to expand our HBV pipeline through internal discovery and development and possibly acquisitions and in-licenses. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:174%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Agents for Combination Therapy</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current treatments for HBV include pegylated interferon-&#945; ("Peg-IFN&#945;") and nucleos(t)ide analogues ("NAs").  These treatments reduce viral load, but have low cure rates of less than 5%.  Peg-IFN&#945;, a synthetic version of a substance produced by the body to fight infection, is administered by injection and has numerous side effects including flu-like symptoms and depression. NAs are oral antiviral medications which when taken chronically reduce virus replication and eliminate HBV DNA in the blood.  However, liver inflammation and fibrosis still develop and virus replication resumes once NA therapy is stopped.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Given the biology of HBV, we believe combination therapies are the key to more effective HBV treatment and a potential cure. Additionally, we believe the development of an effective combination therapy can be accelerated when multiple components are controlled by a single company. Therefore, our R&amp;D pipeline includes multiple drug candidates that target various steps in the viral lifecycle. We believe each of these mechanisms, when combined with an approved NA, have the potential to improve upon the standard of care and contribute to a curative treatment regimen and a finite treatment duration. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We believe that our RNAi agent, AB-729, could be combined with a capsid inhibitor and approved NAs, in our first combination therapy for HBV patients.  In parallel, we are advancing our HBV RNA destabilizer program forward.  This program includes AB-452 and several follow-on compounds from distinct chemical scaffolds. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">HBsAg Reduction</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">RNAi Agents</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The development of RNAi drugs, which utilize the RNA interference pathway, allows for a novel approach to treating disease. There is one approved RNAi product, ONPATTRO, and there are a number of RNAi products currently advancing in human clinical trials. RNAi products are broadly applicable as they can eliminate the production of disease-causing or disease-associated proteins from cells, creating opportunities for therapeutic intervention that have not been achievable with conventional drugs. Our extensive experience in antiviral drug development has been applied to our RNAi program to develop therapeutics for chronic HBV infection.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our RNAi HBV candidates are designed to reduce HBsAg expression in patients chronically infected with HBV. Reducing HBsAg is thought to be a key prerequisite to enable a patient&#8217;s immune system to reawaken and respond against the virus. </font></div><div><br></div><div><div style="line-height:120%;padding-bottom:0px;padding-top:8px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;19</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">GalNAc RNAi (AB-729)</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Early in 2018, we nominated AB-729 for development.  AB-729 is a subcutaneously-delivered RNAi therapeutic targeted to hepatocytes using our novel covalently conjugated N-acetylgalactosamine ("GalNAc") delivery technology. This promising new agent acts on multiple HBV viral transcripts and was designed to inhibit viral replication and suppress all viral antigens.  AB-729 reduces HBsAg, is administered subcutaneously, and we anticipate will be dosed monthly.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We presented data from pre-clinical studies at the International Liver Congress of the European Association for the Study of the Liver (&#8220;EASL&#8221;) meeting in April 2018 in a presentation titled, &#8220;Durable Inhibition of Hepatitis B Virus Replication and Antigenemia Using Subcutaneously Administered siRNA Agent AB-729 in Preclinical Models&#8221;, which showed robust HBsAg knockdown and more durable in vivo activity than earlier-generation siRNA agents, including our LNP-based ARB-1467 product candidate, for the treatment of chronic HBV infection. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We successfully completed IND-enabling studies for AB-729 which we filed as part of a CTA. In July 2019, we initiated a single and multiple dose Phase 1a/1b clinical trial for AB-729 to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of AB-729 in healthy subjects and CHB subjects.  Preliminary safety data in single-dose cohorts of healthy subjects and safety and efficacy data in cohorts of subjects with CHB are expected in the first quarter of 2020. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our initial RNAi candidate, ARB-1467, demonstrated the ability to reduce HBsAg in patients but utilized a lipid nanoparticle delivery vehicle which required intravenous delivery and bi-weekly administration. We have discontinued development of ARB-1467 and are focused on AB-729.  </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">HBV Suppression</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Capsid Inhibitors (AB-506 &amp; AB-423)</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">HBV core protein assembles into a capsid structure, which is required for viral replication. The current SOC therapy (nucleoside analogues) significantly reduces HBV DNA levels in the serum, but HBV replication continues in the liver, thereby enabling HBV infection to persist. More effective therapy for patients requires new agents which will further block viral replication. We are developing capsid inhibitors (also known as core protein inhibitors) as oral therapeutics which, in combination with NAs, could sufficiently block HBV replication for the treatment of chronic HBV infection. By inhibiting assembly of functional viral capsids, the ability of HBV to replicate is impaired. Capsid inhibitor molecules also inhibit the uncoating step of the viral life cycle and thus reduce the formation of new covalently closed circular DNA ("cccDNA"), the viral reservoir which resides in the cell nucleus.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our capsid inhibitor discovery effort generated promising second generation compounds in 2017, which led to the nomination of AB-506 for IND/clinical trial authorization ("CTA")-enabling studies. AB-506 was an orally administered, highly selective capsid inhibitor that had shown improved potency and pharmacokinetics (&#8220;PK&#8221;) over our first generation capsid inhibitor, AB-423, in pre-clinical studies.  We presented AB-506 pre-clinical data at the American Association for the Study of Liver Disease ("AASLD") annual meeting in October 2017 in a presentation titled, "Antiviral Characterization of a Next Generation Chemical Series of HBV Capsid Inhibitors In Vitro and In Vivo," which showed potent inhibition of HBV replication and pre-genomic RNA encapsidation and an accelerated rate of capsid assembly leading to the production of non-functional viral capsids, which results in a disruption of viral replication.  Together, these factors indicated improved target engagement compared to first generation capsid inhibitors, including AB-423.</font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">&#32;</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We received regulatory approval of our CTA for AB-506 in the second quarter of 2018.  During the third quarter of 2018, we began a double-blind, randomized, placebo controlled, single and multiple dose Phase 1a/1b clinical trial for AB-506 evaluating the safety, tolerability and pharmacokinetics of AB-506, in healthy subjects and HBV-DNA positive subjects with chronic hepatitis B (CHB) infection. The healthy subject portion consisted of a single ascending dose part in which subjects were randomized 6:2 (active: placebo), n=21, to receive AB-506 doses ranging from 30-1000 mg, including investigation of food effect, and a multiple dose part in which subjects (randomized 10:2, n=12) received 400 mg of AB-506 once daily for 10 days. The third part of the trial enrolled HBV DNA+, HBeAg-positive or -negative CHB subjects (randomized 10:2; n=12 per cohort) at different doses of AB-506, with or without a nucleoside analogue, once daily for 28 days. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In July 2019, we announced preliminary results from a Phase 1a/1b clinical trial in healthy subjects and two cohorts of CHB subjects who received AB-506 monotherapy, which indicated that AB-506 was a potent oral capsid inhibitor in CHB subjects. No serious adverse events (&#8220;SAEs&#8221;) or clinically significant safety findings were observed in healthy subjects (N=33). Alanine aminotransferase (&#8220;ALT&#8221;) levels and other liver function tests remained normal throughout the 10 days of dosing in healthy subjects. </font></div><div><br></div><div><div style="line-height:120%;padding-bottom:0px;padding-top:8px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;20</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In two cohorts of CHB subjects, mean HBV DNA and HBV RNA decreases at Day 28 (end of treatment) ranged from -2.0 log (160mg dose) to -2.8 log (400mg dose) and -2.4 log (for both doses), respectively, comparable with other capsid inhibitors currently in development. No SAEs were observed in CHB subjects (N= 24). Four CHB subjects (two in each of the cohorts) experienced Grade 4 ALT flares which returned to baseline levels upon AB-506 discontinuation or completion of the 28-day treatment period. Aspartate aminotransferase values were also elevated to a lesser degree, however, none of the subjects met the criteria for drug induced liver injury as bilirubin values and liver synthetic function remained normal. All four ALT flares occurred after the subjects experienced a &gt;2 log decline in HBV DNA from baseline. We believe at least one of the ALT flare cases was immune-mediated and beneficial, as one subject in the 400 mg cohort who experienced a Grade 4 ALT flare also had notable declines in Hepatitis B surface antigen and Hepatitis B e-antigen of -1.4 log and -2.0 log, respectively, by Day 100 following AB-506 discontinuation.&#160; This subject was immediately put on nucleoside analogue therapy after AB-506 discontinuation per investigator&#8217;s decision. In addition, serum-based cytokine analysis of this subject showed an abrupt increase in IFN-gamma at the time of the flare, suggesting an immune-mediated response. For the other 3 subjects we continued to investigate the nature of the flares. Of these four subjects, two (one in each cohort) were asymptomatic, the other two (one in each cohort) had various mild to moderate adverse events at the time of their flares, one with mild heaviness in head, flatulence, discomfort and moderate fatigue, one with mild rash (knees, ankles, fingers and buttock). Two subjects in the 160 mg cohort experienced Grade 2 ALT flares. Both were asymptomatic and returned to baseline levels upon completing the 28-day treatment period.  </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">To further investigate the nature of the ALT flares, we initiated a healthy subjects study testing 28 days of dosing. Before completing the study, we observed two cases of acute hepatitis. Consequently, we immediately stopped the clinical trial and decided to discontinue all further development of AB-506.  We intend to present results from the AB-506 Phase 1a/1b clinical trial along with further details regarding the two cases of acute hepatitis at the AASLD meeting in November 2019.  As a result of our decision to discontinue further development of AB-506, we no longer expect to initiate a combination study of AB-506 and AB-729 in the second half of 2020.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have a number of oral next-generation capsid inhibitor compounds with chemical scaffolds different from AB-506 that we believe have the potential to contribute to the inhibition of HBV replication as part of a combination regimen. Our objective is to select one of several lead compounds for IND-enabling studies in December of this year.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">HBV RNA Destabilizer (AB-452) </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our HBV RNA destabilizer AB-452, an orally administered agent, has shown novel and broad activity in pre-clinical studies in destabilizing HBV RNA, which leads to RNA degradation and subsequent reduction in all viral antigens, including HBsAg. We presented these preclinical data at the AASLD annual meeting in October 2017 in a presentation titled, "Identification and Characterization of AB-452, a Potent Small Molecule HBV RNA destabilizer In Vitro and In Vivo," which showed that AB-452 has complementary effects when combined with two of Arbutus&#8217; proprietary HBV RNAi agents in vitro. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Additional data was presented at the EASL meeting in April 2018 in a presentation titled, &#8220;Preclinical antiviral drug combination studies utilizing novel orally bioavailable agents for chronic hepatitis B infection:  AB-506, a next generation HBV capsid inhibitor, and AB-452, an HBV RNA destabilizer,&#8221; which showed that in vivo combinations of AB-452, AB-506 and tenofovir, an NA, led to greater reductions in serum HBV DNA relative to monotherapy with the individual compounds, and an impact on HBsAg when AB-452 was included in the treatment regimen.  At the International HBV Meeting in October 2018, in a presentation titled &#8220;Mode of Action Studies on HBV RNA Destabilizer AB-452,&#8221; we presented data that showed that the HBV post-regulatory element is essential to AB-452 activity and that AB-452 induces HBV RNA shortening and RNA body degradation, further elucidating the mechanism of action of AB-452. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In October 2018, we announced the emergence of nonclinical safety findings in the AB-452 HBV RNA destabilizer program. Given the nature of these observations and the novel mechanism of action of this drug, additional studies were necessary to understand these findings and their implications before deciding whether to advance AB-452 into clinical trials. We have been evaluating AB-452 in a series of in vitro and in vivo studies to further characterize the compound, its mechanism of action, safety and pharmacokinetic profile. Following careful assessment of the nonclinical safety findings that led to pausing the entry of AB-452 into human clinical studies, we have concluded that the nonclinical safety study resulted in several confounding observations which included observations with no histological correlation, a lack of dose response regarding some key findings and an unexplained vehicle effect.  Because of these confounding observations, we have determined that repeating the 90-day preclinical safety study in two species is appropriate before making a go/no-go decision.  We expect that the results of this study will allow us to make that decision early in 2020. We remain committed to the development of oral HBV RNA destabilizers that have shown compelling anti-viral effects in multiple HBV pre-clinical models.  While we work to fully understand the nature of the AB-452 pre-clinical findings, we are also continuing to advance back-up compounds with chemical scaffolds different from AB-452 into the lead optimization stage. </font></div><div><br></div><div><div style="line-height:120%;padding-bottom:0px;padding-top:8px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;21</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Research Programs</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition to our clinical candidates, we have a number of research programs aimed at discovery and development of proprietary HBV candidates with different and complementary mechanisms of action. We have ongoing discovery efforts focused on checkpoint inhibition to identify novel, orally administered small molecule drug candidates to complement our pipeline of agents to form an effective combination therapy for the treatment of HBV.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Strategic Alliances and Licensing Agreements</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">ONPATTRO&#174; (Patisiran/ALN-TTR02)</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In 2012, we entered into a license agreement with Alnylam that entitles Alnylam to develop and commercialize products with our LNP technology. Alnylam's ONPATTRO&#8482; (Patisiran), which represents the first approved application of our LNP technology, was approved by the FDA and EMA during the third quarter of 2018 and was launched immediately upon approval in the US. Under the terms of this license agreement, we are entitled to tiered royalty payments on global net sales of ONPATTRO ranging from 1.00% - 2.33% after offsets, with the highest tier applicable to annual net sales above $500 million. This royalty interest was sold to OMERS, effective as of January 1, 2019, for $20 million in gross proceeds before advisory fees. OMERS will retain this entitlement until it has received $30 million in royalties, at which point 100% of this royalty entitlement on future global net sales of ONPATTRO will revert to us.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition to the royalty entitlement from the Alnylam LNP license agreement, we are also receiving a second, lower royalty entitlement on global net sales of ONPATTRO originating from a settlement agreement and subsequent license agreement with Acuitas Therapeutics. The royalty entitlement from Acuitas has been retained by us and was not part of the royalty entitlement sale to OMERS.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Genevant Sciences</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In April 2018, we entered into an agreement with Roivant Sciences Ltd. (&#8220;Roivant&#8221;), our largest shareholder, to launch Genevant, a company focused on the discovery, development, and commercialization of a broad range of RNA-based therapeutics enabled by our LNP and ligand conjugate delivery technologies. We have licensed exclusive rights to these delivery platforms to Genevant for RNA-based applications outside of HBV.  Genevant plans to develop products in-house and pursue industry partnerships to build a diverse pipeline of therapeutics across multiple modalities, including RNAi, mRNA, and gene editing. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the terms of the agreement, Roivant contributed $37.5 million in transaction-related seed capital to Genevant, consisting of an initial $22.5 million investment and a subsequent investment of $15 million at a pre-determined, stepped-up valuation.  We retain all rights to our delivery platforms for HBV, and are entitled to a tiered low single-digit royalty from Genevant on future sales of products enabled by the delivery platforms licensed to Genevant. We also retained the entirety of our royalty entitlement on the commercialization of Alnylam&#8217;s ONPATTRO.  As of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;">, we held an equity interest in Genevant of approximately </font><font style="font-family:inherit;font-size:10pt;">40%</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div><a name="s00526843DA7B5B1F9A819A348B37B5BE"></a></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CRITICAL ACCOUNTING POLICIES AND SIGNIFICANT JUDGEMENTS AND ESTIMATES</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">This management&#8217;s discussion and analysis of our financial condition and results of operations is based on our consolidated financial statements, which have been prepared in accordance with&#160;U.S. generally accepted accounting principles (&#8220;U.S. GAAP&#8221;). The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, and expenses. Our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.&#160;&#160;</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We believe there have been no significant changes in our critical accounting policies and estimates as discussed in &#8220;Item 7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; of our Annual Report on Form 10-K for the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div><a name="sA4A789A30BC65C06B8E4ACBB706B801A"></a></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">RECENT ACCOUNTING PRONOUNCEMENTS</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;padding-bottom:0px;padding-top:8px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;22</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:0px;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board or other standard setting bodies that are adopted by us as of the specified effective date. Unless otherwise discussed, we believe that the impact of recently issued standards that are not yet effective will not have a material impact on our financial position or results of operations upon adoption.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Please refer to note 2 to our condensed consolidated financial statements included in Part I, Item 1, "Financial Statements (Unaudited)" of this Quarterly Report on Form 10-Q for a description of recent accounting pronouncements applicable to our business.</font></div><div><a name="sE0BFEC2A6D3B5981BE765BAFCBEBDC21"></a></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">RESULTS OF OPERATIONS</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following summarizes the results of our operations for the periods shown:</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:47%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Nine Months Ended</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">September 30,</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands except  per share amounts)</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total revenue</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,061</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,587</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,393</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,267</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Operating expenses</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">94,462</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34,013</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">135,380</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">77,144</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss from operations</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(91,401</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(32,426</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(130,987</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(72,877</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(82,503</font></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(24,473</font></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(129,069</font></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(38,811</font></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss attributable to common shares</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(85,295</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(27,040</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(137,338</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(46,255</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic and diluted loss per common share</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.50</font></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.49</font></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2.43</font></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.84</font></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Revenue</font><font style="font-family:inherit;font-size:10pt;">&#32;</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue contracts are addressed in detail in the Overview section of Part I, Item 2, "Management's Discussion and Analysis of Financial Condition and Results of Operations" in our 2018 Form 10-K. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue </font><font style="font-family:inherit;font-size:10pt;">increased</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">$1.5 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">increased</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;">&#32;for the </font><font style="font-family:inherit;font-size:10pt;">three and nine months ended September 30, 2019</font><font style="font-family:inherit;font-size:10pt;">, respectively, as compared to the same periods in </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">.  Revenue for the </font><font style="font-family:inherit;font-size:10pt;">three and nine months ended September 30, 2019</font><font style="font-family:inherit;font-size:10pt;">&#32;consisted primarily of a net $1.5 million development milestone earned under our license agreement with Gritstone, royalties from sales of Alnylam's ONPATTRO</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">TM</sup></font><font style="font-family:inherit;font-size:10pt;">, a milestone and royalties from Spectrum Pharmaceuticals, Inc.'s Marqibo</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;and revenue from services provided to Gritstone. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the third quarter of 2018, Alnylam's ONPATTRO, which utilizes our LNP technology, was approved by the FDA and the EMA and was launched immediately upon approval in the US.  In July 2019, a portion of the ONPATTRO</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt"> </sup></font><font style="font-family:inherit;font-size:10pt;">royalty interest was sold to OMERS, effective as of January 1, 2019, for $20 million in gross proceeds before advisory fees. OMERS will retain this entitlement until it has received $30 million in royalty payments, at which point 100% of such royalty interest on future global net sales of ONPATTRO will revert to us. Revenue for the nine months ended September 30, 2019 included $1.0 million of non-cash revenue for ONPATTRO royalty payments remitted to OMERS.  </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue for the </font><font style="font-family:inherit;font-size:10pt;">three and nine months ended September 30, 2018</font><font style="font-family:inherit;font-size:10pt;">&#32;consisted primarily of revenue earned under our license agreement with Gritstone, including a net $1.3 million development milestone payment, the earned portion of a deferred upfront license fee and services provided to Gritstone.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:0px;padding-top:8px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;23</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Expenses</font><font style="font-family:inherit;font-size:10pt;">&#32;</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expenses are summarized in the following tables:</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.0234375%;border-collapse:collapse;text-align:left;"><tr><td colspan="14"></td></tr><tr><td style="width:45%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="13" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">% of Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">% of Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="13" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,731</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,566</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">49</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">General and administrative</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,249</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3</font></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,631</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8</font></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Depreciation</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">507</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">497</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Site consolidation (note 8)</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">182</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(492</font></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1</font></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Impairment of intangible assets (note 6)</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">43,836</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">46</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,811</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">44</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Impairment of goodwill (note 6)</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,471</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24</font></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Arbitration (note 10)</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,486</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total operating expenses</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">94,462</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100</font></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34,013</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100</font></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.0234375%;border-collapse:collapse;text-align:left;"><tr><td colspan="14"></td></tr><tr><td style="width:45%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="13" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">% of Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">% of Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="13" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">45,183</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">46,871</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">61</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">General and administrative</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,850</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12</font></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,075</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13</font></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Depreciation</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,521</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,677</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Site consolidation (note 8)</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,710</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Impairment of intangible assets (note 6)</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">43,836</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,811</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Impairment of goodwill (note 6)</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,471</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17</font></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Arbitration (note 10)</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,486</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total operating expenses</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">135,380</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100</font></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">77,144</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100</font></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Research and development </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development expenses consist primarily of clinical and pre-clinical trial expenses, personnel expenses, consulting and third party expenses, consumables and materials, as well as a portion of stock-based compensation and general overhead costs. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development expenses increased $1.2 million and </font><font style="font-family:inherit;font-size:10pt;">decreased</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">$1.7 million</font><font style="font-family:inherit;font-size:10pt;">&#32;for the three and </font><font style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2019</font><font style="font-family:inherit;font-size:10pt;">, respectively, as compared to the same periods in </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">. Research and development expenses during 2019 included: (i) patient enrollment in our Phase 1a/1b clinical trial for our capsid inhibitor AB-506; (ii) IND/CTA enabling pre-clinical studies and patient enrollment in our Phase 1a/1b clinical trial for our RNAi agent (AB-729); and (iii) in vitro and in vivo studies to further characterize our HBV RNA destabilizer (AB-452), including the compound itself, its mechanism of action and pharmacokinetic profile. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The increase in research and development expenses for the </font><font style="font-family:inherit;font-size:10pt;">three months ended September 30, 2019</font><font style="font-family:inherit;font-size:10pt;">&#32;as compared to the same period in </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">&#32;was due primarily to costs associated with our two Phase 1a/b clinical trials for AB-729 and AB-506.  In October 2019, we announced we had observed two cases of acute hepatitis in our healthy subjects study testing 28 days of dosing of AB-506.  Consequently, we immediately stopped the clinical trial and decided to discontinue all further development of AB-506. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The decrease in research and development expenses for the nine months ended September 30, 2019 as compared to the same period in </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">&#32;was due primarily to costs in 2018 associated with  AB-452, including drug product manufacturing, expenses in 2018 associated with the Phase 2 clinical trial for AB-1467, and IND/CTA-enabling work and CTA regulatory filings in 2018 for AB-506, AB-452 and AB-729. These decreases were partially offset by increased spending in 2019 for the two Phase 1a/1b clinical trials for AB-506 and AB-729. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;padding-bottom:0px;padding-top:8px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;24</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A significant portion of our research and development expenses are not tracked by project as they benefit multiple projects or our technology platform and because our most-advanced programs are not yet in late-stage clinical development.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">General and administrative</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">General and administrative expenses </font><font style="font-family:inherit;font-size:10pt;">increased</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">$0.6 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$5.8 million</font><font style="font-family:inherit;font-size:10pt;">&#32;for the </font><font style="font-family:inherit;font-size:10pt;">three and nine months ended September 30, 2019</font><font style="font-family:inherit;font-size:10pt;">, respectively, as compared to the same periods in </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">.  The </font><font style="font-family:inherit;font-size:10pt;">increase</font><font style="font-family:inherit;font-size:10pt;">&#32;for the three months ended September 30, 2019 compared to the same period in 2018 was due primarily to increased stock compensation expense and an increase in insurance premiums.  The </font><font style="font-family:inherit;font-size:10pt;">increase</font><font style="font-family:inherit;font-size:10pt;">&#32;for the nine months ended September 30, 2019 compared to the same period in 2018 was due primarily to our former President and Chief Executive Officer's departure from the company in June 2019.  In accordance with the terms of his legacy employment agreement, he received $2.3 million of cash severance (paid in July 2019) and we recognized $2.2 million of non-cash stock-based compensation expense for accelerated vesting of his stock options.  Additionally, general and administrative expenses increased for the nine months ended September 30, 2019 due to increased stock compensation expense and an increase in insurance premiums.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Site consolidation </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2018, we announced a site consolidation and organizational restructuring to better align our HBV business in Warminster, PA, by reducing our global workforce and closing our Burnaby, Canada facility. Most of the employee-related site consolidation expenses were expensed ratably over the period that employees provided services, which was substantially completed by June 30, 2018.  We expect total site consolidation expenses to be approximately $5.0 million, of which approximately $4.8 million has been incurred as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;">.  </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Impairment of intangible assets and goodwill</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In the third quarter of 2019, we recorded a $43.8 million non-cash impairment expense to reduce the carrying value of our in-process research and development ("IPR&amp;D") assets to zero as of September 30, 2019. We also recognized a corresponding income tax benefit of $12.7 million related to the decrease in our deferred tax liability associated with the IPR&amp;D intangible assets. The impairment was due to a decision to delay indefinitely the further development of our cccDNA program while we focus on our other development programs. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Also in the third quarter of 2019, we recorded a $22.5 million non-cash impairment expense to reduce the carrying value of our goodwill asset to zero as of September 30, 2019.  Due to a sustained decrease in our share price in recent months, our market capitalization was reduced below the book value of our net assets and we concluded that the fair value of our single reporting unit was below its carrying amount by an amount in excess of the carrying value of the goodwill asset. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Arbitration</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In the third quarter of 2019, the arbitrator in the arbitration proceedings between the University of British Columbia (&#8220;UBC&#8221;) and Arbutus issued his decision for the second phase of the arbitration, awarding UBC approximately $5.9 million, which includes interest of approximately $2.6 million. The arbitrator also held that the third phase of the arbitration, which would address patent validity, should Arbutus choose to pursue a third phase, would not provide a defense to the award. An award for costs and attorneys&#8217; fees is still to be determined. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company recorded expense of $6.5 million in the third quarter of 2019, consisting of $5.9 million for the award (including interest) and $0.6 million for an estimate of a potential award for costs and attorney's fees. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As previously disclosed, this arbitration concerned certain early work on lipid nanoparticle delivery systems and related inventions undertaken by Arbutus and assigned to UBC. These inventions were subsequently licensed back to us by UBC under a license agreement, initially entered into in 1998 and subsequently amended in 2001, 2006 and 2007. We have granted sublicenses under the UBC license to Alnylam Pharmaceuticals as well as other third parties. In the arbitration, UBC&#8217;s claim was for $10.9 million plus interest.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;padding-bottom:0px;padding-top:8px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;25</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Other income (loss)</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other income (loss) is summarized in the following table:</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:57%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td colspan="7" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Nine Months Ended</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td colspan="7" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">September 30,</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest income</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">503</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">756</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,709</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,319</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest expense (note 9)</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,100</font></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,114</font></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(104</font></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Foreign exchange gain (loss)</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(25</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">145</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">43</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(740</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Gain on investment (note 4)</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24,884</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Equity investment loss (note 4)</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,512</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,838</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(11,497</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,838</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Change in fair value of contingent consideration (notes 3 and 10)</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">376</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,608</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">121</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,263</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:normal;">Total other income (loss)</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,758</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,671</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(10,738</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29,784</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Interest income</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The </font><font style="font-family:inherit;font-size:10pt;">$0.3 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$0.6 million</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">decrease</font><font style="font-family:inherit;font-size:10pt;">&#32;in interest income for the </font><font style="font-family:inherit;font-size:10pt;">three and nine months ended September 30, 2019</font><font style="font-family:inherit;font-size:10pt;">, respectively, compared to the same periods in </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">&#32;was due primarily to a lower average balance of cash, cash equivalents and short-term investments. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Interest expense</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest expense in 2019 consisted primarily of non-cash amortization of the liability related to the sale of future royalties.  In July 2019, we sold a portion of our future royalties on sales of ONPATTRO&#8482; to OMERS.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Foreign exchange gains (losses)</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with our site consolidation to Warminster, PA, our Canadian dollar denominated expenses and cash balances have decreased significantly now that a majority of our business transactions are based in the United States.  We continue to incur expenses and hold some cash balances in Canadian dollars, and as such, will remain subject to risks associated with foreign currency fluctuations. In the future, we expect that the proportion of cash balances and expenses incurred in Canadian dollars, relative to U.S. dollars, will continue to decrease as a result of the site consolidation. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Gain on investment and equity investment losses</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In the second quarter of 2018, together with Roivant, we launched Genevant, a company focused on the discovery, development, and commercialization of a broad range of RNA-based therapeutics enabled by our LNP Delivery Technologies. We recognized a non-cash gain of&#160;$24.9 million in the second quarter of 2018 in connection with the equity interest received by Arbutus upon Genevant&#8217;s formation. We account for our </font><font style="font-family:inherit;font-size:10pt;">40%</font><font style="font-family:inherit;font-size:10pt;">&#32;ownership interest in Genevant using the equity method of accounting.  For the </font><font style="font-family:inherit;font-size:10pt;">three and nine months ended September 30, 2019</font><font style="font-family:inherit;font-size:10pt;">, we recorded </font><font style="font-family:inherit;font-size:10pt;">$3.5 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$11.5 million</font><font style="font-family:inherit;font-size:10pt;">, respectively, of equity investment </font><font style="font-family:inherit;font-size:10pt;">losses</font><font style="font-family:inherit;font-size:10pt;">, reflecting our proportionate share of Genevant's net results on a one-quarter lag basis.   </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Change in fair value of contingent consideration</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contingent consideration is a liability we assumed from our acquisition of Arbutus, Inc. in March 2015. In general, as time passes and assuming no changes to the assumptions related to the contingency, the fair value of the contingent consideration increases as the progress of our programs get closer to triggering contingent payments. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The change in the fair value of our contingent consideration liability </font><font style="font-family:inherit;font-size:10pt;">decreased</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">$5.2 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$6.1 million</font><font style="font-family:inherit;font-size:10pt;">&#32;for the </font><font style="font-family:inherit;font-size:10pt;">three and nine months ended September 30, 2019</font><font style="font-family:inherit;font-size:10pt;">, respectively, compared to the same periods in 2018.  During 2018, we recalibrated the estimated timing of future development milestones being achieved, resulting in a significant reduction of the estimated fair value of the liability. During the third quarter of 2019, we made some adjustments to the timing of future commercial milestones being achieved, resulting in a small </font><font style="font-family:inherit;font-size:10pt;">decrease</font><font style="font-family:inherit;font-size:10pt;">&#32;in the estimated fair value of the liability. </font></div><div><a name="s7E34FD7C2D2B57D0848EE56F204DD13E"></a></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;padding-bottom:0px;padding-top:8px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;26</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">LIQUIDITY AND CAPITAL RESOURCES</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes our cash flow activities for the periods indicated:</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:49%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td colspan="7" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(82,503</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(24,473</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(129,069</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(38,811</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Items not involving cash:</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">58,956</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,927</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">73,410</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(9,493</font></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net change in non-cash operating items:</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">77</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,342</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,996</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,487</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:normal;">Net cash used in operating activities</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(23,470</font></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(13,204</font></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(57,655</font></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(50,791</font></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:normal;">Net cash provided by (used) in investing activities</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,155</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24,378</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">87,160</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(48,911</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:normal;">Net cash provided by financing activities</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,549</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">435</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23,564</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">55,537</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Effect of foreign exchange rate changes on cash and cash equivalents</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(24</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">131</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">71</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(795</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:normal;">Increase in cash and cash equivalents</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,210</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,740</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">53,140</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(44,960</font></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents, beginning of period</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">78,872</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,193</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36,942</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">66,893</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:normal;">Cash and cash equivalents, end of period</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">90,082</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,933</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">90,082</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,933</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Since our incorporation, we have financed our operations through the sales of equity, debt, revenues from research and development collaborations and licenses with corporate partners, royalty monetization, interest income on funds available for investment, and government contracts, grants and tax credits.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For the </font><font style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2019</font><font style="font-family:inherit;font-size:10pt;">, operating activities used </font><font style="font-family:inherit;font-size:10pt;">$57.7 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in cash as compared to </font><font style="font-family:inherit;font-size:10pt;">$50.8 million</font><font style="font-family:inherit;font-size:10pt;">&#32;of cash used in the </font><font style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2018</font><font style="font-family:inherit;font-size:10pt;">. The </font><font style="font-family:inherit;font-size:10pt;">increase</font><font style="font-family:inherit;font-size:10pt;">&#32;in net cash used in operating activities is due primarily to payment of a $5.9 million arbitration award to UBC during the nine months ended September 30, 2019. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For the </font><font style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2019</font><font style="font-family:inherit;font-size:10pt;">, investing activities </font><font style="font-family:inherit;font-size:10pt;">increased</font><font style="font-family:inherit;font-size:10pt;">&#32;cash by </font><font style="font-family:inherit;font-size:10pt;">$87.2 million</font><font style="font-family:inherit;font-size:10pt;">&#32;as certain short-term investments matured.  For the </font><font style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2018</font><font style="font-family:inherit;font-size:10pt;">, investing activities included investment of the proceeds from the second tranche of the Series A participating convertible preferred shares (the "Preferred Shares") financing in short-term investments. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For the </font><font style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2019</font><font style="font-family:inherit;font-size:10pt;">, financing activities </font><font style="font-family:inherit;font-size:10pt;">increased</font><font style="font-family:inherit;font-size:10pt;">&#32;cash by </font><font style="font-family:inherit;font-size:10pt;">$23.6 million</font><font style="font-family:inherit;font-size:10pt;">&#32;due primarily to net proceeds from the sale a portion of our future royalties from sales of ONPATTRO.  For the </font><font style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2018</font><font style="font-family:inherit;font-size:10pt;">, financing activities included $66.3 million of net proceeds from the second tranche of the Preferred Shares financing, offset by repayment of a $12.0 million promissory note with a bank. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Sources of Liquidity</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;">, we had cash and cash equivalents of </font><font style="font-family:inherit;font-size:10pt;">$90.1 million</font><font style="font-family:inherit;font-size:10pt;">. We had no outstanding debt at </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In December&#160;2018, we entered into the Sale Agreement, under which we may issue and sell common shares, from time to time, for an aggregate sales price of up to $50.0 million.  For the </font><font style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2019</font><font style="font-family:inherit;font-size:10pt;">, we issued </font><font style="font-family:inherit;font-size:10pt;">1,208,090</font><font style="font-family:inherit;font-size:10pt;">&#32;common shares pursuant to the Sale Agreement, resulting in gross proceeds of approximately </font><font style="font-family:inherit;font-size:10pt;">$5.2 million</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition to our drug pipeline focused on HBV, we have additional assets that have the potential to provide value to our company. The first is our royalty entitlement on ONPATTRO, a drug developed by Alnylam that incorporates our LNP technology and was approved by the FDA and the EMA during the third quarter of 2018 and was launched immediately upon approval in the US.  In July 2019, we sold a portion of this royalty interest to OMERS, effective as of January 1, 2019, for $20 million in gross proceeds before advisory fees. OMERS will retain this entitlement until it has received $30 million in royalties, at which point 100% of such royalty interest on future global net sales of ONPATTRO will revert to us. OMERS has assumed the risk of collecting up to $30 million of future royalty payments from Alnylam and Arbutus is not obligated to reimburse OMERS if they fail to collect any such future royalties. If this royalty entitlement reverts to us, it has the potential to provide an active royalty stream or to be otherwise monetized again in full or in part.  In addition to the royalty from the Alnylam LNP license agreement, we are also receiving a second, lower royalty interest on global net sales of ONPATTRO originating from a settlement agreement and subsequent license agreement with Acuitas. The royalty from Acuitas has been retained by us and was not part of the royalty sale to OMERS. </font></div><div><br></div><div><div style="line-height:120%;padding-bottom:0px;padding-top:8px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;27</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The second asset is our approximate 40% equity ownership interest in Genevant, a company to which we have licensed our Delivery Platforms for all applications except HBV.  These additional assets have the potential to provide significant non-dilutive capital to fund development of our HBV pipeline.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In October 2017, we closed the sale of 500,000 Preferred Shares to Roivant for gross proceeds of&#160;$50.0 million. A second tranche of&#160;664,000 Preferred Shares for gross proceeds of $66.4 million&#160;closed in January 2018, following receipt of the approval of our shareholders. We are using these proceeds to develop and advance product candidates through clinical trials, as well as for working capital and general corporate purposes.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Cash requirements</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;">, we held an aggregate of </font><font style="font-family:inherit;font-size:10pt;">$90.1 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in cash and cash equivalents. In October 2019, we announced we had observed two cases of acute hepatitis in our healthy subjects study testing 28 days of dosing of AB-506.  Consequently, we immediately stopped the clinical trial and decided to discontinue all further development of AB-506.  As a result of discontinuing  development of AB-506 and the delay in a potential combination clinical trial beyond 2020, we believe that our cash and cash equivalents as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;">&#32;will be sufficient to fund our operations into early 2021. In the future, substantial additional funds will be required to continue with the active development of our pipeline products and technologies. In particular, our funding needs may vary depending on a number of factors including:</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:48px;padding-bottom:0px;padding-top:0px;text-align:justify;text-indent:12px;"><font style="padding-bottom:0px;padding-top:0px;text-align:justify;font-family:inherit;font-size:10pt;padding-right:36px;">&#8226;</font><font style="font-family:inherit;font-size:10pt;">the need for additional capital to fund future business development programs;</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:60px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">revenue earned from our legacy collaborative partnerships and licensing agreements, including potential royalty payments from Alnylam's ONPATTRO;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:60px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">revenue earned from ongoing collaborative partnerships, including milestone and royalty payments;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:60px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the extent to which we continue the development of our product candidates, add new product candidates to our pipeline, or form collaborative relationships to advance our products;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:60px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;padding-left:36px;"><div style="line-height:120%;text-align:justify;font-size:10pt;text-indent:-36px;"><font style="font-family:inherit;font-size:10pt;">delays in the development of our product candidates due to pre-clinical and clinical findings;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:60px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;padding-left:36px;"><div style="line-height:120%;text-align:justify;font-size:10pt;text-indent:-36px;"><font style="font-family:inherit;font-size:10pt;">our decisions to in-license or acquire additional products, product candidates or technology for development, in particular for our HBV therapeutics programs;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:60px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our ability to attract and retain corporate partners, and their effectiveness in carrying out the development and ultimate commercialization of our product candidates;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:60px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">whether batches of drugs that we manufacture fail to meet specifications resulting in delays and investigational and remanufacturing costs;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:60px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the decisions, and the timing of decisions, made by health regulatory agencies regarding our technology and products;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:60px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">competing technological and market developments; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:60px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">costs associated with prosecuting and enforcing our patent claims and other intellectual property rights, including litigation and arbitration arising in the course of our business activities.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;padding-left:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We intend to seek funding to maintain and advance our business from a variety of sources including public or private equity or debt financing, potential monetization transactions, collaborative arrangements with pharmaceutical companies and government grants and contracts. There can be no assurance that funding will be available at all or on acceptable terms to permit further development of our products.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If adequate funding is not available, we may be required to delay, reduce or eliminate one or more of our research or development programs or reduce expenses associated with our non-core activities. We may need to obtain funds through arrangements with collaborators or others that may require us to relinquish most or all of our rights to product candidates at an earlier stage of development or on less favorable terms than we would otherwise seek if we were better funded. Insufficient financing may also mean failing to prosecute our patents or relinquishing rights to some of our technologies that we would otherwise develop or commercialize.</font></div><div><a name="s9EE37A2705E454BB8F05BF5E0D9EA479"></a></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">OFF-BALANCE SHEET ARRANGEMENTS</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We do not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that is material to investors.</font></div><div><a name="s4161137050B85C7781FE1B7F9BF265C7"></a></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 3.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160; </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">There have been no material changes in our quantitative and qualitative disclosures about market risk from those disclosed in our Annual Report on Form 10-K for the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div><a name="sE4776BF7DB5256BD82BDC2C36C357FE8"></a></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 4.&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">&#32;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CONTROLS AND PROCEDURES</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Evaluation of Disclosure Controls and Procedures</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our management, with the participation of our principal executive officer and principal financial officer, evaluated the effectiveness of our disclosure controls and procedures as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;">. The term &#8220;disclosure controls and procedures&#8221;, as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC's rules and forms, and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosure, particularly during the period in which this Quarterly Report on Form 10-Q was being prepared. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their desired objectives, and our management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on the evaluation of our disclosure controls and procedures as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;">, our principal executive officer and principal financial officer concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Changes in Internal Control over Financial Reporting</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">There have been no changes in our internal control over financial reporting (as defined in Rules 13a&#8211;15(f) and 15d&#8211;15(f) under the Exchange Act) during the three months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;">&#32;that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</font></div><div><br></div><div><div style="line-height:120%;padding-bottom:0px;padding-top:8px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;28</font></div></div><hr style="page-break-after:always"><div><a name="s980E6CC5D0115F2C951EA7FAF7F2CFA8"></a></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:10px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PART II. OTHER INFORMATION</font></div><div><a name="s19A11E14437D55A1BE12945C7040C9C0"></a></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 1.&#160;&#160;&#160;&#160;&#160;&#160; LEGAL PROCEEDINGS</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For information regarding legal matters, please refer to note 10. Contingencies and Commitments to the condensed consolidated financial statements contained in Part I of this Quarterly Report on Form 10-Q, which is incorporated herein by reference.</font></div><div><a name="s38C2BFDFA08E555C9DD8A5E777A87DDD"></a></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 1A.&#160;&#160;&#160; RISK FACTORS</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">There have been no material changes in our risk factors from those disclosed in our Annual Report on Form 10-K for the fiscal year-ended December 31, 2018. </font></div><div><a name="s4286BC1A506453A19BEDA12793C0B69A"></a></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 2.&#160;&#160;&#160;&#160;&#160;&#160; UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">None.</font></div><div><a name="s24227517A8F5521ABC8F93CEA9140C97"></a></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 3.&#160;&#160;&#160;&#160;&#160;&#160; DEFAULTS UPON SENIOR SECURITIES</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">None.</font></div><div><a name="s1F69C90C370A5886ACDF688F7A29F272"></a></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 4.&#160;&#160;&#160;&#160;&#160;&#160; MINE SAFETY DISCLOSURES</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Not applicable.</font></div><div><a name="s2E696A04AEB1592592BA708C221A7E7A"></a></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 5.&#160;&#160;&#160;&#160;&#160;&#160; OTHER INFORMATION</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">None.  </font></div><div><a name="s50708608BD5F5929955E62F059F6504B"></a></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 6.&#160;&#160;&#160;&#160;&#160;&#160; EXHIBITS</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;padding-bottom:0px;padding-top:8px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;29</font></div></div><hr style="page-break-after:always"><div><a name="s3BD7D679DBDF5CF1AE1082CD15D2C56B"></a></div><div><div style="line-height:120%;padding-bottom:0px;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:10px;text-align:center;-sec-extract:summary;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EXHIBIT INDEX</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:91%;"></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Number</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Description</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1447028/000162828018003276/exhibit31_articlesandartic.htm"><font style="font-family:inherit;font-size:10pt;">Notice of Articles and Articles of Arbutus Biopharma Corporation, as amended. (incorporated herein by reference to Exhibit 3.1 to Arbutus Biopharma Corporation's Annual Report on Form 10-K for the year ended December 31, 2017, filed with the SEC on March 16, 2018).</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1447028/000162828018013909/exhibit31amendmenttoarticl.htm"><font style="font-family:inherit;font-size:10pt;">Amendment to Articles of Arbutus Biopharma Corporation (incorporated herein by reference to Exhibit 3.1 to the Arbutus Biopharma Corporation's Quarterly Report on Form 10-Q for the quarter ended September 30, 2018, filed with the SEC on November 7, 2018).</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1447028/000117184315000358/exh_21.htm"><font style="font-family:inherit;font-size:10pt;">Governance Agreement between the Company and Roivant Sciences Ltd., a Bermuda exempted company, dated January 11, 2015 (incorporated herein by reference to Exhibit 2.1 to the Registrant&#8217;s Current Report on Form 8-K/A filed with the SEC on January 26, 2015).</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.1*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="formofindemnificationagr.htm"><font style="font-family:inherit;font-size:10pt;">Form of Arbutus Biopharma Corporation Indemnity Agreement.</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.2&#8224;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1447028/000144702819000025/exhibit201redactedroyaltym.htm"><font style="font-family:inherit;font-size:10pt;">Purchase and Sale Agreement, dated July 2, 2019, by and between Arbutus Biopharma Corporation and OCM IP Healthcare Portfolio LP (incorporated by reference to Exhibit 10.6 to Arbutus Biopharma Corporation's Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2019, filed with the SEC on August 5, 2019).</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.3*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="boardagreementcheng.htm"><font style="font-family:inherit;font-size:10pt;">Offer Letter, dated August 8, 2019, by and between Arbutus Biopharma Corporation and Andrew Cheng. </font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31.1*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="exhibit311q32019.htm"><font style="font-family:inherit;font-size:10pt;">Certification of Principal Executive Officer pursuant to Rule 13a-14(a) or 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31.2*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="exhibit312q32019.htm"><font style="font-family:inherit;font-size:10pt;">Certification of Principal Financial Officer pursuant to Rule 13a-14(a) or 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32.1**</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="exhibit321q32019.htm"><font style="font-family:inherit;font-size:10pt;">Certification of Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32.2**</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="exhibit322q32019.htm"><font style="font-family:inherit;font-size:10pt;">Certification of Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">101</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following materials from Arbutus Biopharma Corporation's Quarterly Report on Form 10-Q for the quarter ended September 30, 2019, formatted in XBRL (eXtensible Business Reporting Language): (i) Condensed Consolidated Balance Sheets; (ii) Condensed Consolidated Statements of Operations; (iii) Condensed Consolidated Statements of Comprehensive Loss; (iv) Condensed Consolidated Statements of Stockholders' Equity; (v) Condensed Consolidated Statements of Cash Flows; and (vi) Notes to Condensed Consolidated Financial Statements    </font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*    Filed herewith.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">** Furnished herewith.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;padding-left:18px;text-indent:-18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8224;   Certain exhibits of this Exhibit have been omitted pursuant to Item 601(a)(5) of Regulation S-K. Arbutus Biopharma Corporation agrees to furnish a copy of this Exhibit to the Securities and Exchange Commission on a confidential basis upon request.</font></div><div><br></div><div><div style="line-height:120%;padding-bottom:0px;padding-top:8px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;30</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:0px;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;padding-left:18px;text-indent:-18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s14D63B12EB845DA09EAF9ECD1A71C542"></a></div><div style="line-height:120%;padding-bottom:0px;padding-top:10px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SIGNATURES</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:10px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;&#160;&#160;&#160;Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized on </font><font style="font-family:inherit;font-size:10pt;">November&#160;6, 2019</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:46%;"></td><td style="width:7%;"></td><td style="width:47%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ARBUTUS BIOPHARMA CORPORATION</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">By:</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ William H Collier</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">William H Collier</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">President and Chief Executive Officer</font></div></td></tr></table></div></div><div><br></div><div><div style="line-height:120%;padding-bottom:0px;padding-top:8px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;31</font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>formofindemnificationagr.htm
<DESCRIPTION>EXHIBIT 10.1
<TEXT>
<HTML>
<HEAD><!-- Document generated by Workiva Inc -->
<TITLE>formofindemnificationagr</TITLE>
</HEAD>
<BODY bgcolor="white">
<DIV align="center">
<DIV style="margin-left:1em;width:1055;"><!-- formofindemnificationagr001.jpg -->
<DIV style="padding-top:2em;">
<IMG src="formofindemnificationagr001.jpg" title="slide1" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">                                                                    Exhibit 10.1                                   INDEMNITY AGREEMENT                                                 THIS AGREEMENT, having an effective date of ____, _____ (&#8220;Effective Date&#8221;), is entered  into BY and BETWEEN:                 ARBUTUS  BIOPHARMA  CORPORATION,  a  company  duly              incorporated  under  the  laws  of  the  Province  of British  Columbia,  and              having an office at 701 Veterans Circle, Warminster, PA 18974                             (the &#8220;Indemnitor&#8221;)                 AND:                 __________________, with an address ______________________                             (the &#8220;Indemnitee&#8221;)                 WHEREAS:     (A)   the Indemnitor has requested the Indemnitee to act as a director or officer of the Indemnitor and        may ask the Indemnitee to act in a similar capacity with affiliates of the Indemnitor; and     (B)   the Indemnitee has agreed, subject to the granting of the indemnities and releases herein provided        for, to act as a director or officer of the Indemnitor and act in a similar capacity with affiliates of        the Indemnitor if requested;     NOW THEREFORE in consideration of these  premises, the mutual covenants and agreements  herein  contained and other good and valuable consideration, the receipt and sufficiency of which is acknowledged  by each of the parties hereto, the parties hereto covenant and agree as set forth below.     1.          INDEMNITY     1.1                                      Subject  to  &sect;1.2,  and  &sect;2.6(b)  below  the  Indemnitor  shall  indemnify  and  save  harmless the Indemnitee, and the Indemnitee&#8217;s successors, heirs and personal representatives (together with  the Indemnitee, the &#8220;Indemnified Parties&#8221;) against and from:           (a)               any  and all actions  and claims, whether current, threatened, pending or completed,        whether  civil,  criminal,  quasi-criminal  or  administrative,  of  every  nature  and  kind  whatsoever        which  may  be  brought  or  made by  any  person,  firm,  corporation  or  government,  or  by  any        governmental department, body, commission, board, bureau, agency or instrumentality against the        Indemnified Parties in connection with the Indemnitee&#8217;s execution of the duties of his office held        as a director or officer with the Indemnitor or any affiliate of the Indemnitor from time to time;                                       </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- formofindemnificationagr002.jpg -->
<DIV style="padding-top:2em;">
<IMG src="formofindemnificationagr002.jpg" title="slide2" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">                                        -2-        (b)               any and all costs, damages, charges, expenses (including legal fees and disbursements,        on a full indemnity basis), fines, liabilities (statutory or otherwise), losses and penalties which the        Indemnitee may sustain, incur or be liable for in consequence of his acting as a director or officer        of the Indemnitor or any affiliate of the Indemnitor from time to time, whether sustained or incurred        by reason of the Indemnitee&#8217;s negligence, default, breach of duty, breach of trust, failure to exercise        due diligence or otherwise in relation to the Indemnitor or any of its affiliates from time to time, or        any of their respective affairs;                 (c)               without in any way limiting the generality of the foregoing, any and all costs, damages,        charges,  expenses  (including  legal  fees  and  disbursements  on  a  full  indemnity  basis),  fines,        liabilities, losses and penalties which the Indemnified Parties may sustain, incur or be liable for as        a result of or arising by operation of statute and incurred by or imposed upon the Indemnified        Parties in relation to the affairs of the Company in the Indemnitee&#8217;s capacity as director or officer,        including but not limited to, all statutory obligations to creditors, employees, suppliers, contractors,        subcontractors and any government or agency or division of any government, whether federal,        provincial, state, regional or municipal whether existing at the date hereof or incurred hereafter;        and                 (d)               without in any way limiting the generality of the foregoing, the Indemnitor agrees that        should  any  payment  or  reimbursement  made  pursuant  to  this  Agreement,  including  without        limitation  the payment  of  insurance  premiums  or  any  payment  made  by  an  insurer  under  an        insurance policy, be deemed to constitute a taxable benefit or otherwise be or become subject to        any tax or levy upon the Indemnified Parties, then the Indemnitor shall pay such amount as may be        necessary to ensure that the amount received by or on behalf of the Indemnified Parties, after the        payment of or withholding for such tax, fully reimburses the Indemnified Parties for the actual cost,        expense or liability incurred by or on his or her behalf.           1.2                                      Notwithstanding the provisions of &sect;1.1, the Indemnitor shall not be obligated to  indemnify or save  harmless  the  Indemnified  Parties against and from any action, claim, cost, damage,  charge, expense, fine, liability, loss or penalty:           (a)               if in respect thereof the Indemnitee failed to act honestly and in good faith with a view        to the best interests of the Indemnitor or its affiliate as the case may be;                 (b)               in the case of a criminal or administrative action or proceeding, if the Indemnitee did        not have reasonable grounds for believing that his conduct was lawful;                 (c)               arising  out  of  any  act,  error  or  omission  of  the  Indemnitee  that  is  fraudulent  or        malicious and that is committed by the Indemnitee with actual fraudulent or malicious purpose or        intent; or                 (d)               for which he is entitled to indemnity pursuant to any valid and collectible policy of        insurance, to the extent of such insurance. Where partial indemnity is provided by such policy of        insurance, the obligation of the Indemnitor under &sect;1.1 shall continue in effect but be limited to that        portion of the liability for which indemnity is not provided by such policy.             </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- formofindemnificationagr003.jpg -->
<DIV style="padding-top:2em;">
<IMG src="formofindemnificationagr003.jpg" title="slide3" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">                                      -3-  1.3                                      The determination of any claim by judgment, order, settlement or conviction, or  upon a plea of &#8220;nolo contendere&#8221; or its equivalent, will not, of itself, create any presumption for the purposes  of this Agreement that the Indemnitee did not act honestly and in good faith with a view to the best interests  of the Indemnitor or with the care, diligence, and skill of a reasonably prudent person or, in the case of a  criminal or administrative action or proceeding, that he did not have reasonable grounds for believing that  his conduct was lawful (unless the judgment or order of a court specifically finds otherwise) or that the  Indemnitee had committed wilful neglect or gross default.     2.          DEFENSE     2.1                                      For the purposes of this section 2:           &#8220;Action&#8221; means any action, inquiry, investigation, suit or other proceeding before a court or other        tribunal in which a Claim is brought, made or advanced by or against the Indemnitee;                 &#8220;Claim&#8221;  means  any  allegation  of  charge,  claim,  cost,  damage,  expense,  fine,  liability,  loss  or        penalty contemplated by &sect;1.1;                 &#8220;Judgment&#8221; means an award of damages or other monetary compensation made in an Action or        any amounts the Indemnitee is ordered to pay by any court or other tribunal or any government,        governmental  department,  body,  commission,  board,  bureau,  agency  or  instrumentality  having        proper jurisdiction as a result of any Claim brought, made or advanced of or against the Indemnitee;        and                 &#8220;Settlement&#8221; means an agreement to compromise a Claim or an Action.           2.2                                      Upon the Indemnitee becoming aware of any pending or threatened Claim or  Action,  the  Indemnitee  must  provide  written  notice  of  it  to  the  Indemnitor  as  soon  as  is  reasonably  practicable.     2.3                                      The Indemnitor shall have full power and authority to conduct such investigation  of each Claim as is reasonably necessary in the circumstances and shall pay all costs of such investigation.     2.4                                      Subject to this subsection and &sect;2.6(b), the Indemnitor shall defend, on behalf of  the  Indemnitee, any  Claim or Action, even if the  basis for the  Claim or Action is groundless, false  or  fraudulent. If the Indemnitor has reasonable grounds for believing that any of the circumstances described  in &sect;1.2 apply to the Claim or Action, then the Indemnitor, upon giving the Indemnitee written notice of its  belief and the grounds therefore, may refuse to so defend the Claim or Action, but such refusal shall not  relieve the Indemnitor from any of its obligations of indemnity hereunder if it has determined that none of  the provisions of &sect;1.2 apply to the Claim or Action.                                 </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- formofindemnificationagr004.jpg -->
<DIV style="padding-top:2em;">
<IMG src="formofindemnificationagr004.jpg" title="slide4" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">                                        -4-  2.5                                      The Indemnitor shall consult with and pay reasonable heed to the Indemnitee  concerning the appointment of any defence counsel to be engaged by the Indemnitor in fulfillment of its  obligation to defend a Claim or Action, pursuant to &sect;2.4.     2.6                                      With  respect  to  a  Claim  or  Action  for  which  the  Indemnitor  is  obliged  to  indemnify the Indemnitee hereunder:           (a)               the Indemnitor may conduct negotiations towards a Settlement and, with the written        consent  of  the  Indemnitee  (which  the  Indemnitee  agrees  not  to  unreasonably  withhold),  the        Indemnitor may make such Settlement as it (in its sole judgment) deems appropriate or expedient        in the circumstances, provided, however, that the Indemnitee shall not be required, as part of any        proposed Settlement, to admit liability or agree to indemnify the Indemnitor in respect of, or make        contribution  to,  any  compensation  or  other  payment  for  which  provision  is  made  by  such        Settlement; and                 (b)               if the Indemnitee fails to give his consent to the terms of a proposed Settlement which        is  otherwise  acceptable  to  the  Indemnitor  and  the  claimant,  the  Indemnitor  may  require  the        Indemnitee to negotiate or defend the Claim or Action independently of the Indemnitor and in such        event any amount recovered by such claimant in excess of the amount for which Settlement could        have been made by the Indemnitor, shall not be recoverable under this Indemnity, it being further        agreed by the parties that the Indemnitor shall only be responsible for legal fees and costs up to the        time at which such Settlement could have been made.           2.7                                      The Indemnitor shall have the right to negotiate a Settlement in respect of any  Claim or Action which is founded upon any of the acts specified in &sect;1.2. In the event that the Indemnitor  negotiates  a  Settlement  in  respect  of  any  of  the  acts  specified  in  &sect;1.2,  the  Indemnitee  shall  pay  any  compensation  or  other  payment  for  which  provision  is  made  under the  Settlement  and  shall  not  seek  indemnity or contribution from the Indemnitor, within 60 days of the Indemnitor making demand therefor,  all fees, costs and expenses (including legal fees and disbursements on a full indemnity basis) which result  from the defence of the Claim or the Action in respect of which the Settlement was made, including the  cost of any investigation undertaken by the Indemnitor in connection therewith, to the date the Settlement  was made.     2.8                                      The  Indemnitor  shall  pay  any  Judgment  which  may  be  given  against  the  Indemnitee unless any of the circumstances set out in &sect;1.2 applies to the Action in respect of which the  Judgment is given or unless and to the extent the Indemnitee is otherwise entitled to indemnity under the  policy of insurance as contemplated by &sect;1.2(d) in either case, the Indemnitee shall pay to the Indemnitor,  within 60 days of the Indemnitor making demand therefore, all, fees, costs and expenses (including legal  fees and disbursements on a full indemnity basis) which result from the defence and appeal of the Action,  including the costs of any investigation undertaken by the Indemnitor in connection with the Action.     2.9                                      Upon  the  request  of the  Indemnitee  and  subject  to  the  restrictions  set  out in  the Business Corporations Act (British Columbia), the Indemnitor shall pay the expenses of the Indemnitee  incurred in relation to a Claim or an Action indemnified hereunder, provided the Indemnitee hereby gives  an undertaking to repay such expenses if it is finally determined that such payments are not indemnifiable  under this agreement or prohibited by the Business Corporations Act (British Columbia).       </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- formofindemnificationagr005.jpg -->
<DIV style="padding-top:2em;">
<IMG src="formofindemnificationagr005.jpg" title="slide5" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">                                      -5-    3.          GENERAL     3.1                                      Nothing herein contained shall in any way affect the Indemnitee&#8217;s right to resign  from his position as director or officer of the Indemnitor at any time.     3.2                                      The indemnity and release herein provided for shall survive the termination of  the Indemnitee&#8217;s position as director or officer of the Indemnitor, the termination of this Agreement, and  shall continue in full force and effect thereafter.     3.3                                      This Agreement supersedes all prior agreements between the parties with respect  to its subject matter. Notwithstanding the forgoing, nothing in this Agreement shall be deemed to diminish  or otherwise restrict an Indemnified Party&#8217;s right to indemnification under any provision of the Indemnitor&#8217;s  articles or under applicable corporate law.     3.4                                      Unless stated otherwise, all monies to be paid hereunder shall be paid within 10  days of becoming payable.     3.5                                      The Indemnitee acknowledges that he has been advised to obtain independent  legal advice with respect to entering into this Agreement, that he has obtained such independent legal advice  or has expressly waived such advice, and that he is entering into this Agreement with full knowledge of the  contents hereof, of his own free will and with full capacity and authority to do so.     3.6                                      If any provision of this Agreement is determined to be invalid or unenforceable  in whole or in part, such invalidity or unenforceability shall attach only to such provision or part thereof  and the remaining part of such provision and all other provisions hereof shall continue in full force and  effect. The parties hereto agree to negotiate in good faith to agree to a substitute provision which shall be  as close as possible to the intention of any invalid or unenforceable provision as may be valid or enforceable.  The invalidity or unenforceability of any provision in any particular jurisdiction shall not affect its validity  or enforceability in any other jurisdiction where it is valid or enforceable.     3.7                                      Each party hereto agrees to do all such things and take all such actions as may  be necessary or desirable to give full force and effect to the matters contemplated by this Agreement.     3.8                                      This Agreement shall enure to the benefit of and be binding upon the parties  hereto and their respective heirs, executors, administrators, legal representatives, successors and permitted  assigns.     3.9                                      Time shall be of the essence of this Agreement.     3.10                                  This Agreement and the application or interpretation hereof shall be governed  exclusively by its terms and by the laws of the Province of British Columbia and the laws of Canada  applicable therein and the parties hereto hereby irrevocably attorn to the jurisdiction of the courts of the  Province of British Columbia.                                              -6-  IN WITNESS WHEREOF parties hereto have duly executed this Agreement as of the date first written  above. </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- formofindemnificationagr006.jpg -->
<DIV style="padding-top:2em;">
<IMG src="formofindemnificationagr006.jpg" title="slide6" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">   ARBUTUS BIOPHARMA CORPORATION     Per: ___________________________________________           Authorized Signatory     Signed, Sealed and Delivered by __________ in the presence of:     ___________________________________________  Witness (Signature)     ___________________________________________  Name (please print)     ___________________________________________  Address     ___________________________________________  City, Province     ___________________________________________  Occupation                                                                                                                 </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- formofindemnificationagr007.jpg -->
<DIV style="padding-top:2em;">
<IMG src="formofindemnificationagr007.jpg" title="slide7" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">                               Schedule to Exhibit 10.1                                                                                                                             The following directors and executive officers are parties to an Indemnity Agreement with the Company,  each of which are substantially identical in all material respects to the representative Indemnity  Agreement filed herewith as Exhibit 10.1 except as to the name of the signatory and the effective date of  each signatory&#8217;s Indemnity Agreement. The name of each signatory to the Indemnity Agreement is set  forth below. The actual Indemnity Agreements are omitted pursuant to Instruction 2 to Item 601 of  Regulation S-K.                                        INDEMNITEE                                                                           William H. Collier                                  David C. Hastings                                 Michael McElhaugh                                 Gaston Picchio, PhD                                  Frank Torti, MD                                   James Meyers                                    Myrtle Potter                                   Andrew Cheng                                  </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
</DIV>
</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>3
<FILENAME>boardagreementcheng.htm
<DESCRIPTION>EXHIBIT 10.3
<TEXT>
<HTML>
<HEAD><!-- Document generated by Workiva Inc -->
<TITLE>boardagreementcheng</TITLE>
</HEAD>
<BODY bgcolor="white">
<DIV align="center">
<DIV style="margin-left:1em;width:1055;"><!-- boardagreementcheng001.jpg -->
<DIV style="padding-top:2em;">
<IMG src="boardagreementcheng001.jpg" title="slide1" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white"></FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
</DIV>
</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>exhibit311q32019.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2019 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s89B4B618DB8B5665848BE9535A7403E4"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit 31.1</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CERTIFICATION PURSUANT TO RULE 13a-14(a) OR 15d-14(a) OF THE SECURITIES </font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE </font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SARBANES-OXLEY ACT OF 2002 </font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">I, William Collier, certify that: </font></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;padding-bottom:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:90px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:60px;"><font style="font-family:inherit;font-size:10pt;">1.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">I have reviewed this Quarterly Report on Form 10-Q of Arbutus Biopharma Corporation;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;padding-bottom:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:90px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:60px;"><font style="font-family:inherit;font-size:10pt;">2.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;padding-bottom:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:90px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:60px;"><font style="font-family:inherit;font-size:10pt;">3.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;padding-bottom:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:90px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:60px;"><font style="font-family:inherit;font-size:10pt;">4.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;padding-bottom:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:126px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;padding-bottom:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:126px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;padding-bottom:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:126px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(c)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;padding-bottom:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:126px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(d)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an the annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;padding-bottom:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:90px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:60px;"><font style="font-family:inherit;font-size:10pt;">5.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;padding-bottom:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:126px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;padding-bottom:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:126px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div></td></tr></table><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date: </font><font style="font-family:inherit;font-size:10pt;">November&#160;6, 2019</font><font style="font-family:inherit;font-size:10pt;">&#32;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:93.5546875%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:51%;"></td><td style="width:49%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ William Collier</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Name: William Collier</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Title: President and Chief Executive Officer </font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>exhibit312q32019.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2019 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s0169AA2BC43F59F9B09812502085B6F3"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit 31.2</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CERTIFICATION PURSUANT TO RULE 13a-14(a) OR 15d-14(a) OF THE SECURITIES </font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE </font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SARBANES-OXLEY ACT OF 2002 </font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">I, David Hastings, certify that: </font></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;padding-bottom:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:90px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:60px;"><font style="font-family:inherit;font-size:10pt;">1.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">I have reviewed this Quarterly Report on Form 10-Q of Arbutus Biopharma Corporation;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;padding-bottom:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:90px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:60px;"><font style="font-family:inherit;font-size:10pt;">2.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;padding-bottom:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:90px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:60px;"><font style="font-family:inherit;font-size:10pt;">3.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;padding-bottom:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:90px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:60px;"><font style="font-family:inherit;font-size:10pt;">4.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;padding-bottom:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:126px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;padding-bottom:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:126px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;padding-bottom:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:126px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(c)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;padding-bottom:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:126px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(d)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an the annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;padding-bottom:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:90px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:60px;"><font style="font-family:inherit;font-size:10pt;">5.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;padding-bottom:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:126px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;padding-bottom:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:126px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:96px;"><font style="font-family:inherit;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div></td></tr></table><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date: </font><font style="font-family:inherit;font-size:10pt;">November&#160;6, 2019</font><font style="font-family:inherit;font-size:10pt;">&#32;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:93.5546875%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:51%;"></td><td style="width:49%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ David Hastings</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Name: David Hastings</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Title: Chief Financial Officer</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>6
<FILENAME>exhibit321q32019.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2019 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sB22BE626CB2B5679B45F085C6E4B4915"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit 32.1 </font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, </font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">AS ADOPTED PURSUANT TO SECTION 906 </font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">OF THE SARBANES-OXLEY ACT OF 2002 </font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with the Quarterly Report on Form 10-Q of Arbutus Biopharma Corporation (the &#8220;Company&#8221;) for the quarter ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;">, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I William Collier, President and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge: </font></div><table cellpadding="0" cellspacing="0" style="padding-top:20px;padding-bottom:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:120px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:90px;"><font style="font-family:inherit;font-size:10pt;">1.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;padding-bottom:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:120px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:90px;"><font style="font-family:inherit;font-size:10pt;">2.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The information contained in the Report fairly represents, in all material respects, the financial condition and results of the operations of the Company.</font></div></td></tr></table><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date: </font><font style="font-family:inherit;font-size:10pt;">November&#160;6, 2019</font><font style="font-family:inherit;font-size:10pt;">&#32;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:93.5546875%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:51%;"></td><td style="width:49%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ William Collier</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Name: William Collier</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Title: President and Chief Executive Officer </font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>7
<FILENAME>exhibit322q32019.htm
<DESCRIPTION>EXHIBIT 32.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2019 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sE5D1F3967E2F5CEF85E44F5297FDA12D"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit 32.2</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, </font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">AS ADOPTED PURSUANT TO SECTION 906 </font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">OF THE SARBANES-OXLEY ACT OF 2002 </font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with the Quarterly Report on Form 10-Q of Arbutus Biopharma Corporation (the &#8220;Company&#8221;) for the quarter ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;">, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I David Hastings, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge: </font></div><table cellpadding="0" cellspacing="0" style="padding-top:20px;padding-bottom:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:120px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:90px;"><font style="font-family:inherit;font-size:10pt;">1.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;padding-bottom:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:120px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:90px;"><font style="font-family:inherit;font-size:10pt;">2.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The information contained in the Report fairly represents, in all material respects, the financial condition and results of the operations of the Company.</font></div></td></tr></table><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date: </font><font style="font-family:inherit;font-size:10pt;">November&#160;6, 2019</font><font style="font-family:inherit;font-size:10pt;">&#32;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:93.5546875%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:51%;"></td><td style="width:49%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ David Hastings</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Name: David Hastings</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Title: Chief Financial Officer </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>8
<FILENAME>abus-20190930.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!--p:563236AFD8E85BE2903A4B79FAE60D64,x:19d943af09334e0ab5d52367cc4b0a72-->
<xbrli:xbrl xmlns:abus="http://arbutusbio.com/20190930" xmlns:acec="http://fasb.org/dis/acec/2018-01-31" xmlns:ap="http://fasb.org/dis/ap/2018-01-31" xmlns:aro="http://fasb.org/dis/aro/2018-01-31" xmlns:bc="http://fasb.org/dis/bc/2018-01-31" xmlns:bsoff="http://fasb.org/dis/bsoff/2018-01-31" xmlns:cc="http://fasb.org/dis/cc/2018-01-31" xmlns:cce="http://fasb.org/dis/cce/2018-01-31" xmlns:codification-part="http://fasb.org/codification-part/2018-01-31" xmlns:com="http://fasb.org/stm/com/2018-01-31" xmlns:con="http://fasb.org/dis/con/2018-01-31" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:country-all="http://xbrl.sec.gov/country-all/2017-01-31" xmlns:country-ent-all="http://xbrl.sec.gov/country-ent-all/2017-01-31" xmlns:country-ent-std="http://xbrl.sec.gov/country-ent-std/2017-01-31" xmlns:country-std="http://xbrl.sec.gov/country-std/2017-01-31" xmlns:crcgen="http://fasb.org/dis/crcgen/2018-01-31" xmlns:crcpb="http://fasb.org/dis/crcpb/2018-01-31" xmlns:crcrb="http://fasb.org/dis/crcrb/2018-01-31" xmlns:crcsbp="http://fasb.org/dis/crcsbp/2018-01-31" xmlns:ctbl="http://fasb.org/dis/ctbl/2018-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2017-01-31" xmlns:currency-all="http://xbrl.sec.gov/currency-all/2017-01-31" xmlns:currency-ent-all="http://xbrl.sec.gov/currency-ent-all/2017-01-31" xmlns:currency-ent-std="http://xbrl.sec.gov/currency-ent-std/2017-01-31" xmlns:currency-std="http://xbrl.sec.gov/currency-std/2017-01-31" xmlns:dccpoa="http://fasb.org/dis/dccpoa/2018-01-31" xmlns:debt="http://fasb.org/dis/debt/2018-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2018-01-31" xmlns:dei-all="http://xbrl.sec.gov/dei-all/2018-01-31" xmlns:dei-ent-all="http://xbrl.sec.gov/dei-ent-all/2018-01-31" xmlns:dei-ent-std="http://xbrl.sec.gov/dei-ent-std/2018-01-31" xmlns:dei-std="http://xbrl.sec.gov/dei-std/2018-01-31" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/deprecated" xmlns:deprecated1="http://www.xbrl.org/2009/role/deprecated" xmlns:diha="http://fasb.org/dis/diha/2018-01-31" xmlns:disops="http://fasb.org/dis/disops/2018-01-31" xmlns:dr="http://fasb.org/dis/dr/2018-01-31" xmlns:edco="http://fasb.org/dis/edco/2018-01-31" xmlns:ei="http://fasb.org/dis/ei/2018-01-31" xmlns:emjv="http://fasb.org/dis/emjv/2018-01-31" xmlns:eps="http://fasb.org/dis/eps/2018-01-31" xmlns:equity="http://fasb.org/dis/equity/2018-01-31" xmlns:ero="http://fasb.org/dis/ero/2018-01-31" xmlns:eui="http://fasb.org/dis/eui/2018-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2018-01-31" xmlns:exch-all="http://xbrl.sec.gov/exch-all/2018-01-31" xmlns:exch-ent-all="http://xbrl.sec.gov/exch-ent-all/2018-01-31" xmlns:exch-ent-std="http://xbrl.sec.gov/exch-ent-std/2018-01-31" xmlns:exch-std="http://xbrl.sec.gov/exch-std/2018-01-31" xmlns:fifvd="http://fasb.org/dis/fifvd/2018-01-31" xmlns:foct="http://fasb.org/dis/foct/2018-01-31" xmlns:fs-bd="http://fasb.org/dis/fs-bd/2018-01-31" xmlns:fs-bt="http://fasb.org/dis/fs-bt/2018-01-31" xmlns:fs-fhlb="http://fasb.org/dis/fs-fhlb/2018-01-31" xmlns:fs-ins="http://fasb.org/dis/fs-ins/2018-01-31" xmlns:fs-interest="http://fasb.org/dis/fs-interest/2018-01-31" xmlns:fs-mort="http://fasb.org/dis/fs-mort/2018-01-31" xmlns:guar="http://fasb.org/dis/guar/2018-01-31" xmlns:hco="http://fasb.org/dis/hco/2018-01-31" xmlns:iago="http://fasb.org/dis/iago/2018-01-31" xmlns:iaoi="http://fasb.org/dis/iaoi/2018-01-31" xmlns:ides="http://fasb.org/dis/ides/2018-01-31" xmlns:inctax="http://fasb.org/dis/inctax/2018-01-31" xmlns:inv="http://fasb.org/dis/inv/2018-01-31" xmlns:invco="http://fasb.org/dis/invco/2018-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:invest-all="http://xbrl.sec.gov/invest-all/2013-01-31" xmlns:invest-ent-all="http://xbrl.sec.gov/invest-ent-all/2013-01-31" xmlns:invest-ent-std="http://xbrl.sec.gov/invest-ent-std/2013-01-31" xmlns:invest-std="http://xbrl.sec.gov/invest-std/2013-01-31" xmlns:ir="http://fasb.org/dis/ir/2018-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:lea="http://fasb.org/dis/lea/2018-01-31" xmlns:leas="http://fasb.org/dis/leas/2018-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:naics-all="http://xbrl.sec.gov/naics-all/2017-01-31" xmlns:naics-ent-all="http://xbrl.sec.gov/naics-ent-all/2017-01-31" xmlns:naics-ent-std="http://xbrl.sec.gov/naics-ent-std/2017-01-31" xmlns:naics-std="http://xbrl.sec.gov/naics-std/2017-01-31" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:ni="http://fasb.org/dis/ni/2018-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:nt="http://fasb.org/dis/nt/2018-01-31" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:ocpfs="http://fasb.org/dis/ocpfs/2018-01-31" xmlns:oi="http://fasb.org/dis/oi/2018-01-31" xmlns:otherexp="http://fasb.org/dis/otherexp/2018-01-31" xmlns:othliab="http://fasb.org/dis/othliab/2018-01-31" xmlns:pay="http://fasb.org/dis/pay/2018-01-31" xmlns:ppe="http://fasb.org/dis/ppe/2018-01-31" xmlns:rcc="http://fasb.org/dis/rcc/2018-01-31" xmlns:rd="http://fasb.org/dis/rd/2018-01-31" xmlns:re="http://fasb.org/dis/re/2018-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:reference="http://www.xbrl.org/2009/role/reference" xmlns:regop="http://fasb.org/dis/regop/2018-01-31" xmlns:reorg="http://fasb.org/dis/reorg/2018-01-31" xmlns:rlnro="http://fasb.org/dis/rlnro/2018-01-31" xmlns:rpd="http://fasb.org/dis/rpd/2018-01-31" xmlns:ru="http://fasb.org/dis/ru/2018-01-31" xmlns:scf-dbo="http://fasb.org/stm/scf-dbo/2018-01-31" xmlns:scf-dir="http://fasb.org/stm/scf-dir/2018-01-31" xmlns:scf-indir="http://fasb.org/stm/scf-indir/2018-01-31" xmlns:scf-indira="http://fasb.org/stm/scf-indira/2018-01-31" xmlns:scf-inv="http://fasb.org/stm/scf-inv/2018-01-31" xmlns:scf-re="http://fasb.org/stm/scf-re/2018-01-31" xmlns:scf-sbo="http://fasb.org/stm/scf-sbo/2018-01-31" xmlns:scf-sd="http://fasb.org/stm/scf-sd/2018-01-31" xmlns:schedoi-fednote="http://fasb.org/dis/schedoi-fednote/2018-01-31" xmlns:schedoi-hold="http://fasb.org/dis/schedoi-hold/2018-01-31" xmlns:schedoi-iiaa="http://fasb.org/dis/schedoi-iiaa/2018-01-31" xmlns:schedoi-oocw="http://fasb.org/dis/schedoi-oocw/2018-01-31" xmlns:schedoi-otsh="http://fasb.org/dis/schedoi-otsh/2018-01-31" xmlns:schedoi-shorthold="http://fasb.org/dis/schedoi-shorthold/2018-01-31" xmlns:schedoi-sumhold="http://fasb.org/dis/schedoi-sumhold/2018-01-31" xmlns:se="http://fasb.org/dis/se/2018-01-31" xmlns:sec-cndfir="http://fasb.org/dis/sec-cndfir/2018-01-31" xmlns:sec-mort="http://fasb.org/dis/sec-mort/2018-01-31" xmlns:sec-re="http://fasb.org/dis/sec-re/2018-01-31" xmlns:sec-reins="http://fasb.org/dis/sec-reins/2018-01-31" xmlns:sec-sum="http://fasb.org/dis/sec-sum/2018-01-31" xmlns:sec-supins="http://fasb.org/dis/sec-supins/2018-01-31" xmlns:sec-suppc="http://fasb.org/dis/sec-suppc/2018-01-31" xmlns:sec-vq="http://fasb.org/dis/sec-vq/2018-01-31" xmlns:sfp-clreo="http://fasb.org/stm/sfp-clreo/2018-01-31" xmlns:sfp-cls="http://fasb.org/stm/sfp-cls/2018-01-31" xmlns:sfp-dbo="http://fasb.org/stm/sfp-dbo/2018-01-31" xmlns:sfp-ibo="http://fasb.org/stm/sfp-ibo/2018-01-31" xmlns:sfp-sbo="http://fasb.org/stm/sfp-sbo/2018-01-31" xmlns:sfp-ucreo="http://fasb.org/stm/sfp-ucreo/2018-01-31" xmlns:sheci="http://fasb.org/stm/sheci/2018-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:sic-all="http://xbrl.sec.gov/sic-all/2011-01-31" xmlns:sic-ent-all="http://xbrl.sec.gov/sic-ent-all/2011-01-31" xmlns:sic-ent-std="http://xbrl.sec.gov/sic-ent-std/2011-01-31" xmlns:sic-std="http://xbrl.sec.gov/sic-std/2011-01-31" xmlns:soc="http://fasb.org/stm/soc/2018-01-31" xmlns:soi="http://fasb.org/stm/soi/2018-01-31" xmlns:soi-egm="http://fasb.org/stm/soi-egm/2018-01-31" xmlns:soi-indira="http://fasb.org/stm/soi-indira/2018-01-31" xmlns:soi-ins="http://fasb.org/stm/soi-ins/2018-01-31" xmlns:soi-int="http://fasb.org/stm/soi-int/2018-01-31" xmlns:soi-re="http://fasb.org/stm/soi-re/2018-01-31" xmlns:soi-reit="http://fasb.org/stm/soi-reit/2018-01-31" xmlns:soi-sbi="http://fasb.org/stm/soi-sbi/2018-01-31" xmlns:spc="http://fasb.org/stm/spc/2018-01-31" xmlns:sr="http://fasb.org/dis/sr/2018-01-31" xmlns:srt="http://fasb.org/srt/2018-01-31" xmlns:srt-all="http://fasb.org/srt-all/2018-01-31" xmlns:srt-roles="http://fasb.org/srt-roles/2018-01-31" xmlns:srt-std="http://fasb.org/srt-std/2018-01-31" xmlns:srt-types="http://fasb.org/srt-types/2018-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:stpr-all="http://xbrl.sec.gov/stpr-all-all-all/2018-01-31" xmlns:stpr-ent-all="http://xbrl.sec.gov/stpr-ent-all-all-all/2018-01-31" xmlns:stpr-ent-std="http://xbrl.sec.gov/stpr-ent-std-std-std/2018-01-31" xmlns:stpr-std="http://xbrl.sec.gov/stpr-std-std-std/2018-01-31" xmlns:te="http://fasb.org/dis/te/2018-01-31" xmlns:tin-part="http://fasb.org/tin-part/2018-01-31" xmlns:ts="http://fasb.org/dis/ts/2018-01-31" xmlns:us-arcroles="http://fasb.org/us-arcroles/2018-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2018-01-31" xmlns:us-gaap-all="http://fasb.org/us-gaap-all/2018-01-31" xmlns:us-gaap-ent-std="http://fasb.org/us-gaap-ent-std/2018-01-31" xmlns:us-gaap-entryPoint-all="http://fasb.org/us-gaap-entryPoint-all/2018-01-31" xmlns:us-gaap-std="http://fasb.org/us-gaap-std/2018-01-31" xmlns:us-roles="http://fasb.org/us-roles/2018-01-31" xmlns:us-types="http://fasb.org/us-types/2018-01-31" xmlns:utreg="http://www.xbrl.org/2009/utr" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
	<link:schemaRef xlink:href="abus-20190930.xsd" xlink:type="simple" />
	<xbrli:context id="FD2019Q3YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2019Q4Oct31">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-10-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q3">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q3YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q3QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q3QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q3">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q2QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q1">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q2">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q1QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q2">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q2QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q1">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2019Q1">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-01-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q3QTD_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q3YTD_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q3QTD_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q3YTD_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q3_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_AwardTypeAxis_abus_EmployeeStockOptionLiabilityClassifiedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">abus:EmployeeStockOptionLiabilityClassifiedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q3_us-gaap_AwardTypeAxis_abus_EmployeeStockOptionLiabilityClassifiedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">abus:EmployeeStockOptionLiabilityClassifiedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q3YTD_us-gaap_AwardTypeAxis_abus_EmployeeStockOptionLiabilityClassifiedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">abus:EmployeeStockOptionLiabilityClassifiedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_AwardTypeAxis_abus_EmployeeStockOptionLiabilityClassifiedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">abus:EmployeeStockOptionLiabilityClassifiedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q3_us-gaap_AwardTypeAxis_abus_EmployeeStockOptionLiabilityClassifiedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">abus:EmployeeStockOptionLiabilityClassifiedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q3YTD_us-gaap_AwardTypeAxis_abus_EmployeeStockOptionLiabilityClassifiedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">abus:EmployeeStockOptionLiabilityClassifiedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q3QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_abus_GenevantSciencesCorporationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">abus:GenevantSciencesCorporationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q3_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_abus_GenevantSciencesCorporationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">abus:GenevantSciencesCorporationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q2Apr01-Apr30_dei_LegalEntityAxis_abus_RoivantSciencesLtdMember_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_abus_GenevantSciencesCorporationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">abus:RoivantSciencesLtdMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">abus:GenevantSciencesCorporationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-04-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q3YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_abus_GenevantSciencesCorporationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">abus:GenevantSciencesCorporationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q2QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_abus_GenevantSciencesCorporationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">abus:GenevantSciencesCorporationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q3_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_abus_GenevantSciencesCorporationMember_us-gaap_LeaseArrangementTypeAxis_abus_SubleaseBurnabyFacilityMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">abus:GenevantSciencesCorporationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">abus:SubleaseBurnabyFacilityMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q3_us-gaap_LeaseArrangementTypeAxis_abus_CorporateHeadquartersLocated701VeteransCircleWarminsterPennsylvaniaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">abus:CorporateHeadquartersLocated701VeteransCircleWarminsterPennsylvaniaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q3_us-gaap_LeaseArrangementTypeAxis_abus_OfficesLocatedat626JacksonvilleRd.WarminsterPennsylvaniaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">abus:OfficesLocatedat626JacksonvilleRd.WarminsterPennsylvaniaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q3QTD_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_abus_InProcessResearchandDevelopmentcccDNASterilizersMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">abus:InProcessResearchandDevelopmentcccDNASterilizersMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q3_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_abus_InProcessResearchandDevelopmentcccDNASterilizersMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">abus:InProcessResearchandDevelopmentcccDNASterilizersMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2019Q3Jan2018-Sep2019">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q3_us-gaap_RestructuringCostAndReserveAxis_us-gaap_FacilityClosingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:FacilityClosingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q3YTD_us-gaap_RestructuringCostAndReserveAxis_abus_EmployeeSeveranceandRelocationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">abus:EmployeeSeveranceandRelocationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q3QTD_us-gaap_RestructuringCostAndReserveAxis_us-gaap_FacilityClosingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:FacilityClosingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q3QTD_us-gaap_RestructuringCostAndReserveAxis_abus_EmployeeSeveranceandRelocationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">abus:EmployeeSeveranceandRelocationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q3YTD_us-gaap_RestructuringCostAndReserveAxis_us-gaap_FacilityClosingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:FacilityClosingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q3QTD_us-gaap_RestructuringCostAndReserveAxis_abus_EmployeeSeveranceandRelocationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">abus:EmployeeSeveranceandRelocationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q3YTD_us-gaap_RestructuringCostAndReserveAxis_us-gaap_FacilityClosingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:FacilityClosingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q3QTD_us-gaap_RestructuringCostAndReserveAxis_us-gaap_FacilityClosingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:FacilityClosingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q3YTD_us-gaap_RestructuringCostAndReserveAxis_abus_EmployeeSeveranceandRelocationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">abus:EmployeeSeveranceandRelocationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_RestructuringCostAndReserveAxis_us-gaap_FacilityClosingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:FacilityClosingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_RestructuringCostAndReserveAxis_abus_EmployeeSeveranceandRelocationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">abus:EmployeeSeveranceandRelocationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q3_us-gaap_RestructuringCostAndReserveAxis_abus_EmployeeSeveranceandRelocationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">abus:EmployeeSeveranceandRelocationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2019Q3Jul03-Sep30">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-03</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2019Q3Jul02">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-07-02</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2019Q3Jul02-Jul02_srt_CounterpartyNameAxis_abus_OMERSMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abus:OMERSMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-02</xbrli:startDate>
			<xbrli:endDate>2019-07-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q3QTD_srt_CounterpartyNameAxis_abus_OMERSMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abus:OMERSMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2019Q3Jul02-Jul02_srt_CounterpartyNameAxis_abus_OMERSMember_srt_RangeAxis_srt_MinimumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abus:OMERSMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-02</xbrli:startDate>
			<xbrli:endDate>2019-07-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2019Q1Jan01-Jan01_srt_CounterpartyNameAxis_abus_OMERSMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abus:OMERSMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-01-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2019Q3Jul02_srt_CounterpartyNameAxis_abus_OMERSMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abus:OMERSMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-07-02</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2019Q3Jul02-Jul02_srt_CounterpartyNameAxis_abus_OMERSMember_srt_RangeAxis_srt_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abus:OMERSMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-02</xbrli:startDate>
			<xbrli:endDate>2019-07-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q3QTD_srt_LitigationCaseAxis_abus_ArbitrationWithTheUniversityOfBritishColumbiaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:LitigationCaseAxis">abus:ArbitrationWithTheUniversityOfBritishColumbiaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2019Q3Aug20-Aug20_srt_LitigationCaseAxis_abus_ArbitrationWithTheUniversityOfBritishColumbiaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:LitigationCaseAxis">abus:ArbitrationWithTheUniversityOfBritishColumbiaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-08-20</xbrli:startDate>
			<xbrli:endDate>2019-08-20</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2014Q4Oct31_dei_LegalEntityAxis_abus_ArbutusInc.Member_srt_CounterpartyNameAxis_abus_BlumbergandDrexelMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">abus:ArbutusInc.Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abus:BlumbergandDrexelMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-10-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2015Q1Jan16_srt_LitigationCaseAxis_abus_ArbitrationWithTheUniversityOfBritishColumbiaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:LitigationCaseAxis">abus:ArbitrationWithTheUniversityOfBritishColumbiaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-16</xbrli:startDate>
			<xbrli:endDate>2015-01-16</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q2Jun2017_srt_LitigationCaseAxis_abus_ArbitrationWithTheUniversityOfBritishColumbiaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:LitigationCaseAxis">abus:ArbitrationWithTheUniversityOfBritishColumbiaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-06-01</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q4Nov01-Nov30_dei_LegalEntityAxis_abus_ArbutusInc.Member_srt_CounterpartyNameAxis_abus_BlumbergMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">abus:ArbutusInc.Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abus:BlumbergMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-11-01</xbrli:startDate>
			<xbrli:endDate>2018-11-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2014Q4Oct31_dei_LegalEntityAxis_abus_ArbutusInc.Member_us-gaap_BusinessAcquisitionAxis_abus_EnantigenMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">abus:ArbutusInc.Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">abus:EnantigenMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-10-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q4Nov30_dei_LegalEntityAxis_abus_ArbutusInc.Member_srt_CounterpartyNameAxis_abus_BlumbergMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">abus:ArbutusInc.Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abus:BlumbergMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-11-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q3_srt_CounterpartyNameAxis_abus_BlumbergandDrexelMember_us-gaap_BusinessAcquisitionAxis_abus_EnantigenMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abus:BlumbergandDrexelMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">abus:EnantigenMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q3_srt_LitigationCaseAxis_abus_ArbitrationWithTheUniversityOfBritishColumbiaMember_srt_RangeAxis_srt_MinimumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:LitigationCaseAxis">abus:ArbitrationWithTheUniversityOfBritishColumbiaMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q3QTD_srt_CounterpartyNameAxis_abus_GritstoneMember_srt_ProductOrServiceAxis_us-gaap_RoyaltyMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abus:GritstoneMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q3QTD_srt_CounterpartyNameAxis_abus_GritstoneMember_srt_ProductOrServiceAxis_us-gaap_LicenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abus:GritstoneMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q3YTD_srt_CounterpartyNameAxis_abus_GritstoneMember_srt_ProductOrServiceAxis_us-gaap_RoyaltyMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abus:GritstoneMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q3YTD_srt_CounterpartyNameAxis_abus_GritstoneMember_srt_ProductOrServiceAxis_us-gaap_LicenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abus:GritstoneMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q3Oct31_srt_CounterpartyNameAxis_abus_RoivantSciencesLtdMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abus:RoivantSciencesLtdMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-10-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q1Jan01-Jan31_srt_CounterpartyNameAxis_abus_RoivantSciencesLtdMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abus:RoivantSciencesLtdMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-01-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q3YTD_srt_CounterpartyNameAxis_abus_JefferiesLLCMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_abus_OpenMarketSaleAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abus:JefferiesLLCMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">abus:OpenMarketSaleAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_srt_CounterpartyNameAxis_abus_JefferiesLLCMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_abus_OpenMarketSaleAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abus:JefferiesLLCMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">abus:OpenMarketSaleAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q3QTD_srt_CounterpartyNameAxis_abus_JefferiesLLCMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_abus_OpenMarketSaleAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abus:JefferiesLLCMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">abus:OpenMarketSaleAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q4Oct01-Oct31_srt_CounterpartyNameAxis_abus_RoivantSciencesLtdMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abus:RoivantSciencesLtdMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-10-01</xbrli:startDate>
			<xbrli:endDate>2017-10-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q3YTD_srt_CounterpartyNameAxis_abus_RoivantSciencesLtdMember_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abus:RoivantSciencesLtdMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q3Oct31_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-10-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q4Oct01-Oct31_srt_CounterpartyNameAxis_abus_RoivantSciencesLtdMember_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abus:RoivantSciencesLtdMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-10-01</xbrli:startDate>
			<xbrli:endDate>2017-10-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q3Oct31_srt_CounterpartyNameAxis_abus_RoivantSciencesLtdMember_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abus:RoivantSciencesLtdMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-10-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q3YTD_srt_CounterpartyNameAxis_abus_GenevantSciencesCorporationMember_us-gaap_RelatedPartyTransactionAxis_abus_SubleaseBurnabyFacilityMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_EquityMethodInvesteeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abus:GenevantSciencesCorporationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abus:SubleaseBurnabyFacilityMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:EquityMethodInvesteeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q3YTD_srt_CounterpartyNameAxis_abus_GenevantSciencesCorporationMember_us-gaap_RelatedPartyTransactionAxis_abus_ResearchAndDevelopmentServicesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_EquityMethodInvesteeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abus:GenevantSciencesCorporationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abus:ResearchAndDevelopmentServicesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:EquityMethodInvesteeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q3QTD_srt_CounterpartyNameAxis_abus_GenevantSciencesCorporationMember_us-gaap_RelatedPartyTransactionAxis_abus_ResearchAndDevelopmentServicesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_EquityMethodInvesteeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abus:GenevantSciencesCorporationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abus:ResearchAndDevelopmentServicesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:EquityMethodInvesteeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q3YTD_srt_CounterpartyNameAxis_abus_GenevantSciencesCorporationMember_us-gaap_RelatedPartyTransactionAxis_abus_AdministrativeAndTransitionalServicesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_EquityMethodInvesteeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abus:GenevantSciencesCorporationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abus:AdministrativeAndTransitionalServicesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:EquityMethodInvesteeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q3QTD_srt_CounterpartyNameAxis_abus_GenevantSciencesCorporationMember_us-gaap_RelatedPartyTransactionAxis_abus_ResearchAndDevelopmentServicesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_EquityMethodInvesteeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abus:GenevantSciencesCorporationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abus:ResearchAndDevelopmentServicesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:EquityMethodInvesteeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q3_srt_CounterpartyNameAxis_abus_GenevantSciencesCorporationMember_us-gaap_RelatedPartyTransactionAxis_abus_SubleaseBurnabyFacilityMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_EquityMethodInvesteeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abus:GenevantSciencesCorporationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abus:SubleaseBurnabyFacilityMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:EquityMethodInvesteeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q3YTD_srt_CounterpartyNameAxis_abus_GenevantSciencesCorporationMember_us-gaap_RelatedPartyTransactionAxis_abus_AdministrativeAndTransitionalServicesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_EquityMethodInvesteeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abus:GenevantSciencesCorporationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abus:AdministrativeAndTransitionalServicesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:EquityMethodInvesteeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q3YTD_srt_CounterpartyNameAxis_abus_GenevantSciencesCorporationMember_us-gaap_RelatedPartyTransactionAxis_abus_ResearchAndDevelopmentServicesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_EquityMethodInvesteeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abus:GenevantSciencesCorporationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abus:ResearchAndDevelopmentServicesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:EquityMethodInvesteeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q3QTD_srt_CounterpartyNameAxis_abus_GenevantSciencesCorporationMember_us-gaap_RelatedPartyTransactionAxis_abus_SubleaseBurnabyFacilityMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_EquityMethodInvesteeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abus:GenevantSciencesCorporationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abus:SubleaseBurnabyFacilityMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:EquityMethodInvesteeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q3QTD_srt_CounterpartyNameAxis_abus_GenevantSciencesCorporationMember_us-gaap_RelatedPartyTransactionAxis_abus_AdministrativeAndTransitionalServicesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_EquityMethodInvesteeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abus:GenevantSciencesCorporationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abus:AdministrativeAndTransitionalServicesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:EquityMethodInvesteeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q3QTD_srt_CounterpartyNameAxis_abus_GenevantSciencesCorporationMember_us-gaap_RelatedPartyTransactionAxis_abus_AdministrativeAndTransitionalServicesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_EquityMethodInvesteeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abus:GenevantSciencesCorporationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abus:AdministrativeAndTransitionalServicesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:EquityMethodInvesteeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:unit id="usd">
		<xbrli:measure>iso4217:USD</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="patent">
		<xbrli:measure>abus:patent</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="subsidiary">
		<xbrli:measure>abus:subsidiary</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="usdPerShare">
		<xbrli:divide>
			<xbrli:unitNumerator>
				<xbrli:measure>iso4217:USD</xbrli:measure>
			</xbrli:unitNumerator>
			<xbrli:unitDenominator>
				<xbrli:measure>xbrli:shares</xbrli:measure>
			</xbrli:unitDenominator>
		</xbrli:divide>
	</xbrli:unit>
	<xbrli:unit id="shares">
		<xbrli:measure>xbrli:shares</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="Legal_proceedings">
		<xbrli:measure>abus:Legal_proceedings</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="product">
		<xbrli:measure>abus:product</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="lease">
		<xbrli:measure>abus:lease</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="number">
		<xbrli:measure>xbrli:pure</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="sqft">
		<xbrli:measure>utreg:sqft</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="renewal_option">
		<xbrli:measure>abus:renewal_option</xbrli:measure>
	</xbrli:unit>
	<abus:AccruedPayrollCurrent contextRef="FI2018Q4" decimals="-3" id="Fact-ED8A3B3DDEBF5EC9859DA1ADDB0C90DC" unitRef="usd">2341000</abus:AccruedPayrollCurrent>
	<abus:AccruedPayrollCurrent contextRef="FI2019Q3" decimals="-3" id="Fact-991F0B9D80345C518DAD65CB41590305" unitRef="usd">1509000</abus:AccruedPayrollCurrent>
	<abus:AccruedResearchAndDevelopment contextRef="FI2018Q4" decimals="-3" id="Fact-529800F060555617B67C97A9EC851440" unitRef="usd">2716000</abus:AccruedResearchAndDevelopment>
	<abus:AccruedResearchAndDevelopment contextRef="FI2019Q3" decimals="-3" id="Fact-21EAC38119E45FFAAB119D1C06EA2C72" unitRef="usd">4112000</abus:AccruedResearchAndDevelopment>
	<abus:AdjustmentstoAdditionalPaidinCapitalCertainFairValueAdjustmentstoLiabilityStockOptionAwards contextRef="FD2018Q1QTD" decimals="-3" id="Fact-6CB924220A4252B88A68E87794F2974F" unitRef="usd">-504000</abus:AdjustmentstoAdditionalPaidinCapitalCertainFairValueAdjustmentstoLiabilityStockOptionAwards>
	<abus:AdjustmentstoAdditionalPaidinCapitalCertainFairValueAdjustmentstoLiabilityStockOptionAwards contextRef="FD2018Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-F00971B2A6CB5B8481CA22C23FE43C04" unitRef="usd">-504000</abus:AdjustmentstoAdditionalPaidinCapitalCertainFairValueAdjustmentstoLiabilityStockOptionAwards>
	<abus:AdjustmentstoAdditionalPaidinCapitalCertainFairValueAdjustmentstoLiabilityStockOptionAwards contextRef="FD2018Q2QTD" decimals="-3" id="Fact-803CBC3A5BE05EDCA766F1FB11D755A8" unitRef="usd">-34000</abus:AdjustmentstoAdditionalPaidinCapitalCertainFairValueAdjustmentstoLiabilityStockOptionAwards>
	<abus:AdjustmentstoAdditionalPaidinCapitalCertainFairValueAdjustmentstoLiabilityStockOptionAwards contextRef="FD2018Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-1B1E592ECB1155A1AF688BD7285230F8" unitRef="usd">-34000</abus:AdjustmentstoAdditionalPaidinCapitalCertainFairValueAdjustmentstoLiabilityStockOptionAwards>
	<abus:AdjustmentstoAdditionalPaidinCapitalCertainFairValueAdjustmentstoLiabilityStockOptionAwards contextRef="FD2018Q3QTD" decimals="-3" id="Fact-2D4B38A920C8CCBB08F00708F56CA363" unitRef="usd">-407000</abus:AdjustmentstoAdditionalPaidinCapitalCertainFairValueAdjustmentstoLiabilityStockOptionAwards>
	<abus:AdjustmentstoAdditionalPaidinCapitalCertainFairValueAdjustmentstoLiabilityStockOptionAwards contextRef="FD2018Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-4A56A3406F73D490E02C0708F2D369E0" unitRef="usd">-407000</abus:AdjustmentstoAdditionalPaidinCapitalCertainFairValueAdjustmentstoLiabilityStockOptionAwards>
	<abus:AdjustmentstoAdditionalPaidinCapitalCertainFairValueAdjustmentstoLiabilityStockOptionAwards contextRef="FD2019Q1QTD" decimals="-3" id="Fact-7D97F1FF670C5B909D1D8B1DB36FD6F9" unitRef="usd">47000</abus:AdjustmentstoAdditionalPaidinCapitalCertainFairValueAdjustmentstoLiabilityStockOptionAwards>
	<abus:AdjustmentstoAdditionalPaidinCapitalCertainFairValueAdjustmentstoLiabilityStockOptionAwards contextRef="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-AA8796F8071150C184818D330009E92F" unitRef="usd">47000</abus:AdjustmentstoAdditionalPaidinCapitalCertainFairValueAdjustmentstoLiabilityStockOptionAwards>
	<abus:AdjustmentstoAdditionalPaidinCapitalCertainFairValueAdjustmentstoLiabilityStockOptionAwards contextRef="FD2019Q2QTD" decimals="-3" id="Fact-3194650569E451F6BADF078427F5498A" unitRef="usd">230000</abus:AdjustmentstoAdditionalPaidinCapitalCertainFairValueAdjustmentstoLiabilityStockOptionAwards>
	<abus:AdjustmentstoAdditionalPaidinCapitalCertainFairValueAdjustmentstoLiabilityStockOptionAwards contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-8F561B365D9559519E663ECE8CE5B28C" unitRef="usd">230000</abus:AdjustmentstoAdditionalPaidinCapitalCertainFairValueAdjustmentstoLiabilityStockOptionAwards>
	<abus:AdjustmentstoAdditionalPaidinCapitalCertainFairValueAdjustmentstoLiabilityStockOptionAwards contextRef="FD2019Q3QTD" decimals="-3" id="Fact-C0F600908F5130BB4FCC070B9767C4B0" unitRef="usd">55000</abus:AdjustmentstoAdditionalPaidinCapitalCertainFairValueAdjustmentstoLiabilityStockOptionAwards>
	<abus:AdjustmentstoAdditionalPaidinCapitalCertainFairValueAdjustmentstoLiabilityStockOptionAwards contextRef="FD2019Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-92A5AB1300BD7E89AFD2070B94CE279D" unitRef="usd">55000</abus:AdjustmentstoAdditionalPaidinCapitalCertainFairValueAdjustmentstoLiabilityStockOptionAwards>
	<abus:ContractualObligationAmountOfResearchFundingPerYear contextRef="I2018Q4Nov30_dei_LegalEntityAxis_abus_ArbutusInc.Member_srt_CounterpartyNameAxis_abus_BlumbergMember" decimals="-5" id="Fact-248F0CA62D3F52CC80B35D265C5D2E53" unitRef="usd">800000</abus:ContractualObligationAmountOfResearchFundingPerYear>
	<abus:ConvertiblePreferredStockSharesOfCommonStockIssueduponConversion contextRef="I2017Q3Oct31_srt_CounterpartyNameAxis_abus_RoivantSciencesLtdMember_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember" decimals="-6" id="Fact-5CB20F35E83F800882E73D1DABD16136" unitRef="shares">0</abus:ConvertiblePreferredStockSharesOfCommonStockIssueduponConversion>
	<abus:DistributableEarningsLossAvailabletoCommonShareholdersBasic contextRef="FD2018Q3QTD_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-6F17DED298A36CA4421A2214BEFE8B49" unitRef="usd">0</abus:DistributableEarningsLossAvailabletoCommonShareholdersBasic>
	<abus:DistributableEarningsLossAvailabletoCommonShareholdersBasic contextRef="FD2018Q3YTD_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-042524FD68F34033F2952213B27AC325" unitRef="usd">0</abus:DistributableEarningsLossAvailabletoCommonShareholdersBasic>
	<abus:DistributableEarningsLossAvailabletoCommonShareholdersBasic contextRef="FD2019Q3QTD_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-612806EDEEB3557FE5D106C8DCDA8E52" unitRef="usd">0</abus:DistributableEarningsLossAvailabletoCommonShareholdersBasic>
	<abus:DistributableEarningsLossAvailabletoCommonShareholdersBasic contextRef="FD2019Q3YTD_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-3254B55F0A4132CDD32C06C8DCDF8479" unitRef="usd">0</abus:DistributableEarningsLossAvailabletoCommonShareholdersBasic>
	<abus:EffectiveAnnualInterestRateOfRoyaltyLiability contextRef="D2019Q3Jul02-Jul02_srt_CounterpartyNameAxis_abus_OMERSMember" decimals="INF" id="Fact-BD820D6931FD11120D2D03222AEAFBEA" unitRef="number">0.25</abus:EffectiveAnnualInterestRateOfRoyaltyLiability>
	<abus:EmployeeStockOptionsLiabilityClassifiedOutstanding contextRef="FI2018Q4" decimals="-3" id="Fact-0ABC9CF84AE05871809D26D4FC7A0730" unitRef="usd">479000</abus:EmployeeStockOptionsLiabilityClassifiedOutstanding>
	<abus:EmployeeStockOptionsLiabilityClassifiedOutstanding contextRef="FI2019Q3" decimals="-3" id="Fact-2DEF69EED86D50058B2576E30DFBF3FC" unitRef="usd">86000</abus:EmployeeStockOptionsLiabilityClassifiedOutstanding>
	<abus:EmployeeStockOptionsLiabilityClassifiedOutstandingFairValueDisclosure contextRef="FI2017Q4_us-gaap_AwardTypeAxis_abus_EmployeeStockOptionLiabilityClassifiedMember" decimals="-3" id="Fact-7F50E46F6BC1B531EB5506CD483ABCC7" unitRef="usd">1239000</abus:EmployeeStockOptionsLiabilityClassifiedOutstandingFairValueDisclosure>
	<abus:EmployeeStockOptionsLiabilityClassifiedOutstandingFairValueDisclosure contextRef="FI2018Q3_us-gaap_AwardTypeAxis_abus_EmployeeStockOptionLiabilityClassifiedMember" decimals="-3" id="Fact-9EF1B4E3F890696AC3E1D4A519A5D392" unitRef="usd">2738000</abus:EmployeeStockOptionsLiabilityClassifiedOutstandingFairValueDisclosure>
	<abus:EmployeeStockOptionsLiabilityClassifiedOutstandingFairValueDisclosure contextRef="FI2018Q4_us-gaap_AwardTypeAxis_abus_EmployeeStockOptionLiabilityClassifiedMember" decimals="-3" id="Fact-B47D531746A3ED4BE3D206CD483242BA" unitRef="usd">479000</abus:EmployeeStockOptionsLiabilityClassifiedOutstandingFairValueDisclosure>
	<abus:EmployeeStockOptionsLiabilityClassifiedOutstandingFairValueDisclosure contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-5F2E8A826B3E087BF9A106CD5A4CF96E" unitRef="usd">0</abus:EmployeeStockOptionsLiabilityClassifiedOutstandingFairValueDisclosure>
	<abus:EmployeeStockOptionsLiabilityClassifiedOutstandingFairValueDisclosure contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-8A41BC7FE3619C2F463206CD5A48A9F0" unitRef="usd">0</abus:EmployeeStockOptionsLiabilityClassifiedOutstandingFairValueDisclosure>
	<abus:EmployeeStockOptionsLiabilityClassifiedOutstandingFairValueDisclosure contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-CEA314DA310B59B9A56BAA2AC2ECAA10" unitRef="usd">479000</abus:EmployeeStockOptionsLiabilityClassifiedOutstandingFairValueDisclosure>
	<abus:EmployeeStockOptionsLiabilityClassifiedOutstandingFairValueDisclosure contextRef="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-FF4A3E333AC89A3140C506CD5A60CE20" unitRef="usd">479000</abus:EmployeeStockOptionsLiabilityClassifiedOutstandingFairValueDisclosure>
	<abus:EmployeeStockOptionsLiabilityClassifiedOutstandingFairValueDisclosure contextRef="FI2019Q3_us-gaap_AwardTypeAxis_abus_EmployeeStockOptionLiabilityClassifiedMember" decimals="-3" id="Fact-FADC21B83D4D778DF34AD4A51B4101B5" unitRef="usd">86000</abus:EmployeeStockOptionsLiabilityClassifiedOutstandingFairValueDisclosure>
	<abus:EmployeeStockOptionsLiabilityClassifiedOutstandingFairValueDisclosure contextRef="FI2019Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-7410A5FE0263B1D3596FD4944F732B12" unitRef="usd">0</abus:EmployeeStockOptionsLiabilityClassifiedOutstandingFairValueDisclosure>
	<abus:EmployeeStockOptionsLiabilityClassifiedOutstandingFairValueDisclosure contextRef="FI2019Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-44138D91B3AFBD3A7CD6D494BF400D45" unitRef="usd">0</abus:EmployeeStockOptionsLiabilityClassifiedOutstandingFairValueDisclosure>
	<abus:EmployeeStockOptionsLiabilityClassifiedOutstandingFairValueDisclosure contextRef="FI2019Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-DDC50AC4D4065A9994E48E69A3819916" unitRef="usd">86000</abus:EmployeeStockOptionsLiabilityClassifiedOutstandingFairValueDisclosure>
	<abus:EmployeeStockOptionsLiabilityClassifiedOutstandingFairValueDisclosure contextRef="FI2019Q3_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-E66DE3CDF08695BF2169D4951F9C464D" unitRef="usd">86000</abus:EmployeeStockOptionsLiabilityClassifiedOutstandingFairValueDisclosure>
	<abus:EquityMethodInvestmentPropertyContribution contextRef="D2018Q2Apr01-Apr30_dei_LegalEntityAxis_abus_RoivantSciencesLtdMember_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_abus_GenevantSciencesCorporationMember" decimals="-5" id="Fact-557D64B9F8095AF69A8DB17C0548944D" unitRef="usd">37500000</abus:EquityMethodInvestmentPropertyContribution>
	<abus:FixedLeaseCost contextRef="FD2019Q3YTD" decimals="-5" id="Fact-407B7E6C69DCA8F6D096D4C329ED02AF" unitRef="usd">900000</abus:FixedLeaseCost>
	<abus:GrossProceedsFromRoyaltyInterestSold contextRef="D2019Q1Jan01-Jan01_srt_CounterpartyNameAxis_abus_OMERSMember" decimals="-6" id="Fact-4A83A9BA413DB00F4C7D40B18D830920" unitRef="usd">20000000</abus:GrossProceedsFromRoyaltyInterestSold>
	<abus:IncreaseDecreaseInFairValueOfContingentConsiderationLiability contextRef="FD2018Q3QTD" decimals="-3" id="Fact-9DDE4D54D0B452A88F3BADAF9DF1D874" unitRef="usd">-5608000</abus:IncreaseDecreaseInFairValueOfContingentConsiderationLiability>
	<abus:IncreaseDecreaseInFairValueOfContingentConsiderationLiability contextRef="FD2018Q3YTD" decimals="-3" id="Fact-587E27E71C3B50AEB6AA4E997A368EE9" unitRef="usd">-6263000</abus:IncreaseDecreaseInFairValueOfContingentConsiderationLiability>
	<abus:IncreaseDecreaseInFairValueOfContingentConsiderationLiability contextRef="FD2019Q3QTD" decimals="-3" id="Fact-30A449E244115D1F9BBC7C97CAF3A0D6" unitRef="usd">-376000</abus:IncreaseDecreaseInFairValueOfContingentConsiderationLiability>
	<abus:IncreaseDecreaseInFairValueOfContingentConsiderationLiability contextRef="FD2019Q3YTD" decimals="-3" id="Fact-61DE4E7D636C5C3699F6DAC32A1DAC3D" unitRef="usd">-121000</abus:IncreaseDecreaseInFairValueOfContingentConsiderationLiability>
	<abus:IncreaseDecreaseinFairValueofLiabilityClassifiedOptions contextRef="FD2018Q3YTD_us-gaap_AwardTypeAxis_abus_EmployeeStockOptionLiabilityClassifiedMember" decimals="-3" id="Fact-66E053B20F7F281BD6F406D04BBBFAF2" unitRef="usd">1499000</abus:IncreaseDecreaseinFairValueofLiabilityClassifiedOptions>
	<abus:IncreaseDecreaseinFairValueofLiabilityClassifiedOptions contextRef="FD2019Q3YTD_us-gaap_AwardTypeAxis_abus_EmployeeStockOptionLiabilityClassifiedMember" decimals="-3" id="Fact-280CDA523DCA149CC18906D04C76492A" unitRef="usd">-393000</abus:IncreaseDecreaseinFairValueofLiabilityClassifiedOptions>
	<abus:LesseeOperatingLeaseNumberOfRenewalOptions contextRef="FI2019Q3_us-gaap_LeaseArrangementTypeAxis_abus_CorporateHeadquartersLocated701VeteransCircleWarminsterPennsylvaniaMember" decimals="INF" id="Fact-6F1E0A91E58E5D9C8C6393AB40B3D30E" unitRef="renewal_option">2</abus:LesseeOperatingLeaseNumberOfRenewalOptions>
	<abus:LesseeOperatingLeaseNumberofLeases contextRef="FI2019Q3" decimals="INF" id="Fact-8DB6E680CC275D8EBEA186A83F6E1B42" unitRef="lease">2</abus:LesseeOperatingLeaseNumberofLeases>
	<abus:LiabilityFromSaleOfFutureRoyaltiesAdditions contextRef="D2019Q3Jul03-Sep30" decimals="-3" id="Fact-22245938C7184ECEA15903913DB3E608" unitRef="usd">30000000</abus:LiabilityFromSaleOfFutureRoyaltiesAdditions>
	<abus:LiabilityFromSaleOfFutureRoyaltiesDiscountsAndIssuanceCosts contextRef="D2019Q3Jul03-Sep30" decimals="-3" id="Fact-1A41714731C6AAA90A6E03950E076B8D" unitRef="usd">11451000</abus:LiabilityFromSaleOfFutureRoyaltiesDiscountsAndIssuanceCosts>
	<abus:LiabilityFromSaleOfFutureRoyaltiesNonCashExpense contextRef="D2019Q3Jul03-Sep30" decimals="-3" id="Fact-FE5F3201A4C5E2C3C64B039648705BAC" unitRef="usd">1106000</abus:LiabilityFromSaleOfFutureRoyaltiesNonCashExpense>
	<abus:LiabilityFromSaleOfFutureRoyaltiesNonCashRoyaltyIncome contextRef="D2019Q3Jul03-Sep30" decimals="-3" id="Fact-B9E56D1CD27A19DB692F0395DFC05909" unitRef="usd">979000</abus:LiabilityFromSaleOfFutureRoyaltiesNonCashRoyaltyIncome>
	<abus:LiabilityRelatedToSaleOfFutureRoyalties contextRef="FI2019Q3" decimals="-3" id="Fact-8C82C0EDD33DDA10C2900330CDAEE346" unitRef="usd">18675000</abus:LiabilityRelatedToSaleOfFutureRoyalties>
	<abus:LiabilityRelatedToSaleOfFutureRoyalties contextRef="I2019Q3Jul02" decimals="-3" id="Fact-9F6DE9DD1FFE30F7E4720330CD9E0CCD" unitRef="usd">0</abus:LiabilityRelatedToSaleOfFutureRoyalties>
	<abus:LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent contextRef="FI2018Q4" decimals="-3" id="Fact-16417B3437A962F03D2A03300B2AB2EA" unitRef="usd">0</abus:LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent>
	<abus:LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent contextRef="FI2019Q3" decimals="-3" id="Fact-C9716A4381A7FE3C50EA03300B2AB9CF" unitRef="usd">18675000</abus:LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent>
	<abus:LicenseAgreementMaximumDevelopmentAndRegulatoryMilestonePaymentsPerLicense contextRef="I2014Q4Oct31_dei_LegalEntityAxis_abus_ArbutusInc.Member_srt_CounterpartyNameAxis_abus_BlumbergandDrexelMember" decimals="-5" id="Fact-271116BF261E55149E64728E9F91EA15" unitRef="usd">102500000</abus:LicenseAgreementMaximumDevelopmentAndRegulatoryMilestonePaymentsPerLicense>
	<abus:LicenseAgreementMaximumDevelopmentAndRegulatoryMilestonePaymentsPerLicense contextRef="I2014Q4Oct31_dei_LegalEntityAxis_abus_ArbutusInc.Member_us-gaap_BusinessAcquisitionAxis_abus_EnantigenMember" decimals="-5" id="Fact-B48A55E5A28255AEBF081DEBA859FB18" unitRef="usd">500000</abus:LicenseAgreementMaximumDevelopmentAndRegulatoryMilestonePaymentsPerLicense>
	<abus:LicenseAgreementMaximumDevelopmentAndRegulatoryMilestonePaymentsPerRoyalty contextRef="I2014Q4Oct31_dei_LegalEntityAxis_abus_ArbutusInc.Member_srt_CounterpartyNameAxis_abus_BlumbergandDrexelMember" decimals="-5" id="Fact-494B89C91F4C5D2BA1F137EF8DE6A1E0" unitRef="usd">1000000</abus:LicenseAgreementMaximumDevelopmentAndRegulatoryMilestonePaymentsPerRoyalty>
	<abus:NetRentableAreaSublease contextRef="FI2019Q3_srt_CounterpartyNameAxis_abus_GenevantSciencesCorporationMember_us-gaap_RelatedPartyTransactionAxis_abus_SubleaseBurnabyFacilityMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_EquityMethodInvesteeMember" decimals="-2" id="Fact-539D230CA974598AAA34FC473E7B900C" unitRef="sqft">17900</abus:NetRentableAreaSublease>
	<abus:NonCashRoyaltyExpenseRelatedToSaleOfFutureRoyalties contextRef="FD2018Q3QTD" decimals="-3" id="Fact-783B4F68912FC46FD489039F14597FA9" unitRef="usd">0</abus:NonCashRoyaltyExpenseRelatedToSaleOfFutureRoyalties>
	<abus:NonCashRoyaltyExpenseRelatedToSaleOfFutureRoyalties contextRef="FD2018Q3YTD" decimals="-3" id="Fact-0F9C1081B1D20D32D86D039F2BCD897B" unitRef="usd">0</abus:NonCashRoyaltyExpenseRelatedToSaleOfFutureRoyalties>
	<abus:NonCashRoyaltyExpenseRelatedToSaleOfFutureRoyalties contextRef="FD2019Q3QTD" decimals="-3" id="Fact-C43A43B340681E9F9FBD039F08D36C6B" unitRef="usd">1106000</abus:NonCashRoyaltyExpenseRelatedToSaleOfFutureRoyalties>
	<abus:NonCashRoyaltyExpenseRelatedToSaleOfFutureRoyalties contextRef="FD2019Q3QTD_srt_CounterpartyNameAxis_abus_OMERSMember" decimals="-5" id="Fact-7B942256C02CD30755000313D318F35C" unitRef="usd">1100000</abus:NonCashRoyaltyExpenseRelatedToSaleOfFutureRoyalties>
	<abus:NonCashRoyaltyExpenseRelatedToSaleOfFutureRoyalties contextRef="FD2019Q3YTD" decimals="-3" id="Fact-4D28E0FE7B93139ADE43039F1F479D5D" unitRef="usd">1106000</abus:NonCashRoyaltyExpenseRelatedToSaleOfFutureRoyalties>
	<abus:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties contextRef="FD2018Q3QTD" decimals="-3" id="Fact-FB5D8544C6D31CEB29E5039E861DCE91" unitRef="usd">0</abus:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties>
	<abus:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties contextRef="FD2018Q3YTD" decimals="-3" id="Fact-8C52AC955542C8D2D0E4039EA1C3C295" unitRef="usd">0</abus:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties>
	<abus:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties contextRef="FD2019Q3QTD" decimals="-3" id="Fact-14835369AD99E95396B3039E7942CD01" unitRef="usd">979000</abus:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties>
	<abus:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties contextRef="FD2019Q3QTD_srt_CounterpartyNameAxis_abus_OMERSMember" decimals="-5" id="Fact-FC7909D923E5B4A28E9E0312CC3F4E1C" unitRef="usd">1000000</abus:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties>
	<abus:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties contextRef="FD2019Q3YTD" decimals="-3" id="Fact-ABF046CAA3037264001C039E90D6EDE3" unitRef="usd">979000</abus:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties>
	<abus:NoncontrollingInterestInvestmentCommitmentPeriod contextRef="D2017Q4Oct01-Oct31_srt_CounterpartyNameAxis_abus_RoivantSciencesLtdMember_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember" id="Fact-53B58A0E062F5BA2A1A988A6769C728C">P4Y</abus:NoncontrollingInterestInvestmentCommitmentPeriod>
	<abus:NoncontrollingInterestMaximumOwnershipPercentagebyNoncontrollingOwners contextRef="I2017Q3Oct31_srt_CounterpartyNameAxis_abus_RoivantSciencesLtdMember" decimals="4" id="Fact-70EC3B33DFD150D88F6E5FC93EB20B25" unitRef="number">0.4999</abus:NoncontrollingInterestMaximumOwnershipPercentagebyNoncontrollingOwners>
	<abus:NoncontrollingInterestOwnershipPercentageByNoncontrollingOwnersAfterConversion contextRef="I2017Q3Oct31_srt_CounterpartyNameAxis_abus_RoivantSciencesLtdMember" decimals="2" id="Fact-31FBBA673E442E42CB39D4D29C22B2D3" unitRef="number">0.49</abus:NoncontrollingInterestOwnershipPercentageByNoncontrollingOwnersAfterConversion>
	<abus:NumberOfProductsCoveredByPatentAcquiredUnderAgreement contextRef="I2014Q4Oct31_dei_LegalEntityAxis_abus_ArbutusInc.Member_us-gaap_BusinessAcquisitionAxis_abus_EnantigenMember" decimals="INF" id="Fact-5F94DD684BB553E4A279600F1544C3C7" unitRef="product">2</abus:NumberOfProductsCoveredByPatentAcquiredUnderAgreement>
	<abus:NumberofPatentLicenses contextRef="I2014Q4Oct31_dei_LegalEntityAxis_abus_ArbutusInc.Member_srt_CounterpartyNameAxis_abus_BlumbergandDrexelMember" decimals="INF" id="Fact-04E6E94E851E5B468A6D28352917AAF6" unitRef="patent">3</abus:NumberofPatentLicenses>
	<abus:Numberoflegalproceedings contextRef="D2017Q2Jun2017_srt_LitigationCaseAxis_abus_ArbitrationWithTheUniversityOfBritishColumbiaMember" decimals="INF" id="Fact-778E330DCA095CCD86BD62245BCFB237" unitRef="Legal_proceedings">3</abus:Numberoflegalproceedings>
	<abus:ProceedsFromSaleOfFutureRoyaltiesNet contextRef="FD2018Q3QTD" decimals="-3" id="Fact-1C4E61CA6F36380DD0FF03A1596CFB6D" unitRef="usd">0</abus:ProceedsFromSaleOfFutureRoyaltiesNet>
	<abus:ProceedsFromSaleOfFutureRoyaltiesNet contextRef="FD2018Q3YTD" decimals="-3" id="Fact-331D2C19FD0F34BEF92703A16FDCBC2E" unitRef="usd">0</abus:ProceedsFromSaleOfFutureRoyaltiesNet>
	<abus:ProceedsFromSaleOfFutureRoyaltiesNet contextRef="FD2019Q3QTD" decimals="-3" id="Fact-AC67EA07820A388BC9B1039FC318F687" unitRef="usd">18549000</abus:ProceedsFromSaleOfFutureRoyaltiesNet>
	<abus:ProceedsFromSaleOfFutureRoyaltiesNet contextRef="FD2019Q3YTD" decimals="-3" id="Fact-9071798E93763B92766D03A165A872A5" unitRef="usd">18549000</abus:ProceedsFromSaleOfFutureRoyaltiesNet>
	<abus:ResearchFundingPeriod contextRef="D2018Q4Nov01-Nov30_dei_LegalEntityAxis_abus_ArbutusInc.Member_srt_CounterpartyNameAxis_abus_BlumbergMember" id="Fact-DCBC14F8C03A523CA9BF511B52C00954">P2Y</abus:ResearchFundingPeriod>
	<abus:RoyaltyGuaranteesCommitmentsPercentage contextRef="D2019Q3Jul02-Jul02_srt_CounterpartyNameAxis_abus_OMERSMember" decimals="INF" id="Fact-108391980D523772C69340B1E2E0D3B9" unitRef="number">1</abus:RoyaltyGuaranteesCommitmentsPercentage>
	<abus:RoyaltyInterestSoldMaximumRoyaltiesForBuyer contextRef="D2019Q3Jul02-Jul02_srt_CounterpartyNameAxis_abus_OMERSMember" decimals="-6" id="Fact-714959EECE2454BE321940B1CC8EFE54" unitRef="usd">30000000</abus:RoyaltyInterestSoldMaximumRoyaltiesForBuyer>
	<abus:RoyaltyInterestSoldPercentageOfSalesAnnualRevenueThresholdOfHighestTier contextRef="D2019Q3Jul02-Jul02_srt_CounterpartyNameAxis_abus_OMERSMember" decimals="-6" id="Fact-B4DCB048E6AF25F38F4140B1761E777D" unitRef="usd">500000000</abus:RoyaltyInterestSoldPercentageOfSalesAnnualRevenueThresholdOfHighestTier>
	<abus:RoyaltyPayable contextRef="I2019Q3Jul02_srt_CounterpartyNameAxis_abus_OMERSMember" decimals="-6" id="Fact-1C47CA384B459A0E47F937FDBDB8E3C1" unitRef="usd">30000000</abus:RoyaltyPayable>
	<abus:RoyaltyPercentageofInterestSold contextRef="D2019Q3Jul02-Jul02_srt_CounterpartyNameAxis_abus_OMERSMember_srt_RangeAxis_srt_MaximumMember" decimals="INF" id="Fact-199718598D583009F3A440B14A38D326" unitRef="number">0.0233</abus:RoyaltyPercentageofInterestSold>
	<abus:RoyaltyPercentageofInterestSold contextRef="D2019Q3Jul02-Jul02_srt_CounterpartyNameAxis_abus_OMERSMember_srt_RangeAxis_srt_MinimumMember" decimals="INF" id="Fact-E8CD73FD5C426114BBA840B133C60B5C" unitRef="number">0.01</abus:RoyaltyPercentageofInterestSold>
	<abus:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisesinPeriodFairValue contextRef="FD2018Q3YTD_us-gaap_AwardTypeAxis_abus_EmployeeStockOptionLiabilityClassifiedMember" decimals="-3" id="Fact-8D95A13DCED6AD32E20F06CD483E86FD" unitRef="usd">0</abus:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisesinPeriodFairValue>
	<abus:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisesinPeriodFairValue contextRef="FD2019Q3YTD_us-gaap_AwardTypeAxis_abus_EmployeeStockOptionLiabilityClassifiedMember" decimals="-3" id="Fact-87EA1706088DB9BC8B1906CD4837253D" unitRef="usd">0</abus:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisesinPeriodFairValue>
	<abus:StrightlineFixedLeaseCost contextRef="FD2019Q3YTD" decimals="-5" id="Fact-098E39A26C7558F740D3D4C724B8BDF1" unitRef="usd">900000</abus:StrightlineFixedLeaseCost>
	<abus:TransactionCostsRelatedToSaleOfFutureRoyalties contextRef="D2019Q3Jul02-Jul02_srt_CounterpartyNameAxis_abus_OMERSMember" decimals="-5" id="Fact-B93FADA73F45149D89060320656AC7AE" unitRef="usd">1500000</abus:TransactionCostsRelatedToSaleOfFutureRoyalties>
	<abus:WhollyOwnedSubsidiariesIncludedinFinancialStatements contextRef="FI2019Q3" decimals="INF" id="Fact-02FF225FEE3B5391A76FFFB90014EDBB" unitRef="subsidiary">2</abus:WhollyOwnedSubsidiariesIncludedinFinancialStatements>
	<dei:AmendmentFlag contextRef="FD2019Q3YTD" id="Fact-6E3D20420129579BA41E055B2562CA62">false</dei:AmendmentFlag>
	<dei:CurrentFiscalYearEndDate contextRef="FD2019Q3YTD" id="Fact-B8F01FE968A65DCE975AAB24FA469D77">--12-31</dei:CurrentFiscalYearEndDate>
	<dei:DocumentFiscalPeriodFocus contextRef="FD2019Q3YTD" id="Fact-9A0CA4AA40865267BBCCDB2704451037">Q3</dei:DocumentFiscalPeriodFocus>
	<dei:DocumentFiscalYearFocus contextRef="FD2019Q3YTD" id="Fact-334159ADAF695E5587A6D8252637C70A">2019</dei:DocumentFiscalYearFocus>
	<dei:DocumentPeriodEndDate contextRef="FD2019Q3YTD" id="Fact-2C1B0BF68B8E5D61B102CBD61108B2B6">2019-09-30</dei:DocumentPeriodEndDate>
	<dei:DocumentType contextRef="FD2019Q3YTD" id="Fact-E0CA02196E4051C995D3AA29A78A2CAD">10-Q</dei:DocumentType>
	<dei:EntityCentralIndexKey contextRef="FD2019Q3YTD" id="Fact-FEE87CFCF77652F5AE793451C666EE9D">0001447028</dei:EntityCentralIndexKey>
	<dei:EntityCommonStockSharesOutstanding contextRef="I2019Q4Oct31" decimals="0" id="Fact-47B416ADFDB8B34841B222E36BB0758C" unitRef="shares">56850172</dei:EntityCommonStockSharesOutstanding>
	<dei:EntityCurrentReportingStatus contextRef="FD2019Q3YTD" id="Fact-632F5A6A7099564DB0B64BDB20D425A6">Yes</dei:EntityCurrentReportingStatus>
	<dei:EntityEmergingGrowthCompany contextRef="FD2019Q3YTD" id="Fact-D5C9214F3735517EBA7EE6C92DCE1B72">false</dei:EntityEmergingGrowthCompany>
	<dei:EntityFilerCategory contextRef="FD2019Q3YTD" id="Fact-08DE80CCF85A578891758E0D0BB5E626">Accelerated Filer</dei:EntityFilerCategory>
	<dei:EntityRegistrantName contextRef="FD2019Q3YTD" id="Fact-6590F33AD7D95335B66A044B041BEFA0">Arbutus Biopharma Corp</dei:EntityRegistrantName>
	<dei:EntityShellCompany contextRef="FD2019Q3YTD" id="Fact-B53A50D88BDC5CE69AEC508BD3F2501B">false</dei:EntityShellCompany>
	<dei:EntitySmallBusiness contextRef="FD2019Q3YTD" id="Fact-F1B4F5A2BA0F5E1B8C6F32C9F31C5A17">true</dei:EntitySmallBusiness>
	<us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="FI2018Q4" decimals="-3" id="Fact-625A5C60EDDE5CA3B157E401A57D4045" unitRef="usd">9429000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
	<us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="FI2019Q3" decimals="-3" id="Fact-0327C7E260005D32BFF3D1FE925776E4" unitRef="usd">8199000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
	<us-gaap:AccountsPayableTradeCurrent contextRef="FI2018Q4" decimals="-3" id="Fact-FE7A3E114E975235AE969E8F40704471" unitRef="usd">3192000</us-gaap:AccountsPayableTradeCurrent>
	<us-gaap:AccountsPayableTradeCurrent contextRef="FI2019Q3" decimals="-3" id="Fact-069E0F2CFF4E57D4A95938B9F1D711B6" unitRef="usd">1400000</us-gaap:AccountsPayableTradeCurrent>
	<us-gaap:AccountsReceivableNetCurrent contextRef="FI2018Q4" decimals="-3" id="Fact-30086A801CA252A197A9AE3F7036B814" unitRef="usd">1431000</us-gaap:AccountsReceivableNetCurrent>
	<us-gaap:AccountsReceivableNetCurrent contextRef="FI2019Q3" decimals="-3" id="Fact-6F6BF29FE41D58F88353A18593034EBA" unitRef="usd">2488000</us-gaap:AccountsReceivableNetCurrent>
	<us-gaap:AccruedProfessionalFeesCurrent contextRef="FI2018Q4" decimals="-3" id="Fact-A6BB855F08AE5EC896E76BBBCAECDD2E" unitRef="usd">871000</us-gaap:AccruedProfessionalFeesCurrent>
	<us-gaap:AccruedProfessionalFeesCurrent contextRef="FI2019Q3" decimals="-3" id="Fact-5BC2FFA5882750EFB57A0E7C93584A7B" unitRef="usd">1177000</us-gaap:AccruedProfessionalFeesCurrent>
	<us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="FI2018Q4" decimals="-3" id="Fact-85903AF676DC52F5A3884EA01232A94A" unitRef="usd">7090000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
	<us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="FI2019Q3" decimals="-3" id="Fact-24075385017A5AD2A0B9A745C21CF2AB" unitRef="usd">8612000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2018Q4" decimals="-3" id="Fact-483B6917F003595B8AF10478BC1AAD9A" unitRef="usd">-48170000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2019Q3" decimals="-3" id="Fact-F4DC09DAE5FE52E0ABD2803BFB86967B" unitRef="usd">-48217000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AdditionalPaidInCapital contextRef="FI2018Q4" decimals="-3" id="Fact-C513FC09582B5EB19D94D627F43B5094" unitRef="usd">48084000</us-gaap:AdditionalPaidInCapital>
	<us-gaap:AdditionalPaidInCapital contextRef="FI2019Q3" decimals="-3" id="Fact-C12A713373685BB8BF67C8C404D0AB87" unitRef="usd">55385000</us-gaap:AdditionalPaidInCapital>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="FD2018Q1QTD" decimals="-3" id="Fact-EA8987261797511482D4398F7A873DE8" unitRef="usd">1510000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="FD2018Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-247B9B061E335B8690D7BB491DAF0068" unitRef="usd">1510000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="FD2018Q2QTD" decimals="-3" id="Fact-97E13D379E2F5D5AB7D8E235A850C26B" unitRef="usd">1862000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="FD2018Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-0A58F8E8CF31590D83A0F3D636D33933" unitRef="usd">1862000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="FD2018Q3QTD" decimals="-3" id="Fact-FAD049D2E030FACF51710708EF3E1049" unitRef="usd">1658000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="FD2018Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-8A1A9AC4D94C964376000708ECA3D175" unitRef="usd">1658000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="FD2019Q1QTD" decimals="-3" id="Fact-96754B5CD44955C5B337C2B17E5E72B4" unitRef="usd">1665000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-77D86362231A5EE9BFF70124233FBDE4" unitRef="usd">1665000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="FD2019Q2QTD" decimals="-3" id="Fact-5CE10818C5625345BF69622FD5B12E11" unitRef="usd">3915000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-D5D790CB3A4A5690BD6C46A9B79A361B" unitRef="usd">3915000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="FD2019Q3QTD" decimals="-3" id="Fact-32D3A911E0C41127B8F3070B91380156" unitRef="usd">1592000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="FD2019Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-7EA10483FD429FE04815070B8E982C0F" unitRef="usd">1592000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts contextRef="FD2018Q1QTD" decimals="-3" id="Fact-D756549A7A775A809D2CB662806D173A" unitRef="usd">135000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2018Q3YTD" decimals="-5" id="Fact-918A6EC152F9942236C6CFA06E3E3E0D" unitRef="shares">24200000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2019Q3YTD" decimals="-5" id="Fact-A532428708A2D86CF130CFB214FC7EA8" unitRef="shares">28200000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AssetImpairmentCharges contextRef="FD2018Q3QTD" decimals="-3" id="Fact-009CAC43BC7852BCB7C28BD6E90ABD57" unitRef="usd">14811000</us-gaap:AssetImpairmentCharges>
	<us-gaap:AssetImpairmentCharges contextRef="FD2018Q3YTD" decimals="-3" id="Fact-7066013D9F6759E8899CA332FB0C7E6E" unitRef="usd">14811000</us-gaap:AssetImpairmentCharges>
	<us-gaap:AssetImpairmentCharges contextRef="FD2019Q3QTD" decimals="-3" id="Fact-4213857889E45867B49FCA9A55D6A479" unitRef="usd">43836000</us-gaap:AssetImpairmentCharges>
	<us-gaap:AssetImpairmentCharges contextRef="FD2019Q3YTD" decimals="-3" id="Fact-44BC3148696C561DACE352DFBE889A35" unitRef="usd">43836000</us-gaap:AssetImpairmentCharges>
	<us-gaap:Assets contextRef="FI2018Q4" decimals="-3" id="Fact-3C19287CCCD352B9A4ABEC43314A70AF" unitRef="usd">227905000</us-gaap:Assets>
	<us-gaap:Assets contextRef="FI2019Q3" decimals="-3" id="Fact-EFFA35D0599256998E68CFFDE7B3622F" unitRef="usd">117277000</us-gaap:Assets>
	<us-gaap:AssetsCurrent contextRef="FI2018Q4" decimals="-3" id="Fact-D3D416F18D1D5B51B8A7764B7EF018BE" unitRef="usd">129229000</us-gaap:AssetsCurrent>
	<us-gaap:AssetsCurrent contextRef="FI2019Q3" decimals="-3" id="Fact-90E8E013EF085EE3BD68FE4C19E54839" unitRef="usd">94341000</us-gaap:AssetsCurrent>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-69C892DB8588858DBC1806CD5A547CA3" unitRef="usd">124617000</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-0AC5274BA5EE8A7FDA4C06CD5A3FFF2F" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-A5B06ED74EC0334FC77706CD5A63AED3" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-D991ADD295F488B2EC1F06CD5A809267" unitRef="usd">124617000</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1 contextRef="FD2018Q3QTD" decimals="-3" id="Fact-FAA2B550A07E59C68ACEF97C475BF25E" unitRef="usd">-5608000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
	<us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1 contextRef="FD2018Q3YTD" decimals="-3" id="Fact-AB3F924D0FD65D3DB4F0A402EE81966E" unitRef="usd">-6263000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
	<us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1 contextRef="FD2019Q3QTD" decimals="-3" id="Fact-E1C2F0530F7A5BA58FCCBBC091719CCF" unitRef="usd">-376000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
	<us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1 contextRef="FD2019Q3YTD" decimals="-3" id="Fact-13ABF1D4E55551FC87472DABBB4D7422" unitRef="usd">-121000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
	<us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh contextRef="I2014Q4Oct31_dei_LegalEntityAxis_abus_ArbutusInc.Member_us-gaap_BusinessAcquisitionAxis_abus_EnantigenMember" decimals="INF" id="Fact-B353CA215DAE536EB7E409A009BBB1F3" unitRef="usd">21000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh>
	<us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent contextRef="FI2017Q4" decimals="-3" id="Fact-28AC2B480C7B9A3BC67606CD3A1B168C" unitRef="usd">10424000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
	<us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent contextRef="FI2018Q3" decimals="-3" id="Fact-6EF74F8C8F2C78F5A46C06CD3A1EE645" unitRef="usd">4161000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
	<us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent contextRef="FI2018Q4" decimals="-3" id="Fact-DBFB6EB798795E8EB145E3D89F104223" unitRef="usd">3126000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
	<us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-B20894E6D5C752D4CDAA06CD5A6CA6BF" unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
	<us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-516E3CEF0271944E7FA306CD5A501489" unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
	<us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-1E798B2DDA645716943B3D2DFEB7C898" unitRef="usd">3126000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
	<us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent contextRef="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-E15CA3E87D17F715460506CD5A59119F" unitRef="usd">3126000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
	<us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent contextRef="FI2019Q3" decimals="-3" id="Fact-87EC726EC466525E999AE46B3A0C3531" unitRef="usd">3005000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
	<us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent contextRef="FI2019Q3_srt_CounterpartyNameAxis_abus_BlumbergandDrexelMember_us-gaap_BusinessAcquisitionAxis_abus_EnantigenMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-382211EBD9E47BEA63D7C5ABDE7FDCF5" unitRef="usd">3000000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
	<us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent contextRef="FI2019Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-5D925DCB6DCFB678B968D4947FD2DF47" unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
	<us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent contextRef="FI2019Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-156EB6E2FD3868DC4C68D494C147C7E5" unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
	<us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent contextRef="FI2019Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-F77CC11BFB6F5D86A8CB292FA59E4EE9" unitRef="usd">3005000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
	<us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent contextRef="FI2019Q3_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-449C4601DA306DE6F158D4952108DE81" unitRef="usd">3005000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2018Q4" decimals="-3" id="Fact-A1528028440A5B598C6D51EA3690E6A4" unitRef="usd">36942000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2019Q3" decimals="-3" id="Fact-85D21036915557AC997C9C3702BD61A3" unitRef="usd">90082000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-B29B8A97CAB05B67941F4852DFE7DCAE" unitRef="usd">36942000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-36B61A039C93949AE0D606CD5A78B045" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-0FD91C240BF50C7C932906CD5A743E8B" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-DFDC5B0F87A3FEE512B606CD5A8327E1" unitRef="usd">36942000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2019Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-698B3F0C5EB559908F26BD65A04540C4" unitRef="usd">90082000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2019Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-9D49D6F591523385706BD491EB99F9F2" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2019Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-F7C76A494E1032BA3EF5D49221E40C16" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2019Q3_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-2395C224DAC9343AA4CED492BB074182" unitRef="usd">90082000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="FI2017Q4" decimals="-3" id="Fact-8BDD3C1B188159F6B245962E101051FE" unitRef="usd">66893000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
	<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="FI2018Q2" decimals="-3" id="Fact-5F375252D8A2581CA2B5674C3EDC099D" unitRef="usd">10193000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
	<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="FI2018Q3" decimals="-3" id="Fact-ADC0B06FBC9351C78F37AC619B317A6D" unitRef="usd">21933000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
	<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="FI2018Q4" decimals="-3" id="Fact-0295E0970555583A89D13438258787FE" unitRef="usd">36942000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
	<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="FI2019Q2" decimals="-3" id="Fact-37B50D1B96F154C9AEE0063C9910B62A" unitRef="usd">78872000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
	<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="FI2019Q3" decimals="-3" id="Fact-C511BBF85205518DA81E3AA3B77682C8" unitRef="usd">90082000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
	<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="FD2018Q3QTD" decimals="-3" id="Fact-A2DF097A1CBC50E2B538E6C8798DBEB8" unitRef="usd">11740000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
	<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="FD2018Q3YTD" decimals="-3" id="Fact-03067DB682B2596298AA3A886C2A587B" unitRef="usd">-44960000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
	<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="FD2019Q3QTD" decimals="-3" id="Fact-F9534527856C579882F58596C0CA7C4D" unitRef="usd">11210000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
	<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="FD2019Q3YTD" decimals="-3" id="Fact-14A53650A6F550E8A1F939B77A5058D2" unitRef="usd">53140000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
	<us-gaap:CommonStockNoParValue contextRef="FI2018Q4" id="Fact-9194195B1BE75D85B5CC2112FDB03835" unitRef="usdPerShare" xsi:nil="true" />
	<us-gaap:CommonStockNoParValue contextRef="FI2019Q3" id="Fact-4311044A2BED5C30A554D07BFA761C79" unitRef="usdPerShare" xsi:nil="true" />
	<us-gaap:CommonStockSharesIssued contextRef="FI2018Q4" decimals="INF" id="Fact-9A3D32726647519FAC5F919E907AD096" unitRef="shares">55518800</us-gaap:CommonStockSharesIssued>
	<us-gaap:CommonStockSharesIssued contextRef="FI2019Q3" decimals="INF" id="Fact-8BA68D4DF81F5E0482471907FAE48282" unitRef="shares">56850172</us-gaap:CommonStockSharesIssued>
	<us-gaap:CommonStockSharesOutstanding contextRef="FI2018Q4" decimals="INF" id="Fact-B9D00B78CB00552A943D350C5092B5DE" unitRef="shares">55518800</us-gaap:CommonStockSharesOutstanding>
	<us-gaap:CommonStockSharesOutstanding contextRef="FI2019Q3" decimals="INF" id="Fact-60E721FE083356C690AF66DBE4B3F215" unitRef="shares">56850172</us-gaap:CommonStockSharesOutstanding>
	<us-gaap:CommonStockSharesSubscriptions contextRef="FI2018Q4_srt_CounterpartyNameAxis_abus_JefferiesLLCMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_abus_OpenMarketSaleAgreementMember" decimals="INF" id="Fact-52FA096A582F5F0BADC0F25493071DB8" unitRef="usd">50000000.0</us-gaap:CommonStockSharesSubscriptions>
	<us-gaap:CommonStockValue contextRef="FI2018Q4" decimals="-3" id="Fact-8B948B0C25BB53D3B8E24C942034B0BA" unitRef="usd">879405000</us-gaap:CommonStockValue>
	<us-gaap:CommonStockValue contextRef="FI2019Q3" decimals="-3" id="Fact-D7FDB2FA0C8B533E950F4D39BE52C006" unitRef="usd">884623000</us-gaap:CommonStockValue>
	<us-gaap:ComprehensiveIncomeNetOfTax contextRef="FD2018Q3QTD" decimals="-3" id="Fact-0F8F69296F1F58B7B36FD7AD73960D8F" unitRef="usd">-24485000</us-gaap:ComprehensiveIncomeNetOfTax>
	<us-gaap:ComprehensiveIncomeNetOfTax contextRef="FD2018Q3YTD" decimals="-3" id="Fact-6B649A18607653A0A9100981A319C7A6" unitRef="usd">-38823000</us-gaap:ComprehensiveIncomeNetOfTax>
	<us-gaap:ComprehensiveIncomeNetOfTax contextRef="FD2019Q3QTD" decimals="-3" id="Fact-CAE3D409F1D054C7BF6262BD92BD5E96" unitRef="usd">-82476000</us-gaap:ComprehensiveIncomeNetOfTax>
	<us-gaap:ComprehensiveIncomeNetOfTax contextRef="FD2019Q3YTD" decimals="-3" id="Fact-44FCD25B60D35303839EF0DDA76B0FC5" unitRef="usd">-129116000</us-gaap:ComprehensiveIncomeNetOfTax>
	<us-gaap:ContributionOfProperty contextRef="FD2018Q3QTD" decimals="-3" id="Fact-9269570D68B6AE0BC73203A7EB7E9042" unitRef="usd">0</us-gaap:ContributionOfProperty>
	<us-gaap:ContributionOfProperty contextRef="FD2018Q3YTD" decimals="-3" id="Fact-592E0EC8616A992E55B803A803B713E3" unitRef="usd">24665000</us-gaap:ContributionOfProperty>
	<us-gaap:ContributionOfProperty contextRef="FD2019Q3QTD" decimals="-3" id="Fact-27F385DA22EC3EA8A73D03A7D29AE040" unitRef="usd">0</us-gaap:ContributionOfProperty>
	<us-gaap:ContributionOfProperty contextRef="FD2019Q3YTD" decimals="-3" id="Fact-A0A60F75A107F61E841203A7F8DA4B0C" unitRef="usd">0</us-gaap:ContributionOfProperty>
	<us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="FD2018Q3QTD" decimals="-3" id="Fact-6ADC2FFA9B5DAB9218A303A37785F337" unitRef="usd">-4282000</us-gaap:DeferredIncomeTaxExpenseBenefit>
	<us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="FD2018Q3YTD" decimals="-3" id="Fact-2687C8A4F5939FC1D9FB03A38E80D8CC" unitRef="usd">-4282000</us-gaap:DeferredIncomeTaxExpenseBenefit>
	<us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="FD2019Q3QTD" decimals="-3" id="Fact-285D9D00978BC62A7DF203A36B40AC80" unitRef="usd">-12661000</us-gaap:DeferredIncomeTaxExpenseBenefit>
	<us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="FD2019Q3YTD" decimals="-3" id="Fact-1ADE4D4497D9F714167B03A382C959CB" unitRef="usd">-12661000</us-gaap:DeferredIncomeTaxExpenseBenefit>
	<us-gaap:DeferredIncomeTaxLiabilitiesNet contextRef="FI2018Q4" decimals="-3" id="Fact-C60DF68B92605E4EA11E4A8F325EA136" unitRef="usd">12661000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
	<us-gaap:DeferredIncomeTaxLiabilitiesNet contextRef="FI2019Q3" decimals="-3" id="Fact-FEA0523DC94B5F69A402170D1A3A5C19" unitRef="usd">0</us-gaap:DeferredIncomeTaxLiabilitiesNet>
	<us-gaap:DeferredRentCreditNoncurrent contextRef="FI2018Q4" decimals="-3" id="Fact-4080361F081651AFB208EA82AB32CD72" unitRef="usd">645000</us-gaap:DeferredRentCreditNoncurrent>
	<us-gaap:DeferredRentCreditNoncurrent contextRef="FI2019Q3" decimals="-3" id="Fact-399311288E4C5BD4BEAFB53A8EB4965D" unitRef="usd">0</us-gaap:DeferredRentCreditNoncurrent>
	<us-gaap:Depreciation contextRef="FD2018Q3QTD" decimals="-3" id="Fact-8DE4ABC2632058EB8E7ED3F73098E6E2" unitRef="usd">497000</us-gaap:Depreciation>
	<us-gaap:Depreciation contextRef="FD2018Q3YTD" decimals="-3" id="Fact-1A689D0E81975483940470C6F2EDB0A1" unitRef="usd">1677000</us-gaap:Depreciation>
	<us-gaap:Depreciation contextRef="FD2019Q3QTD" decimals="-3" id="Fact-065A34979383552A85A4CE28AAE1B42B" unitRef="usd">507000</us-gaap:Depreciation>
	<us-gaap:Depreciation contextRef="FD2019Q3YTD" decimals="-3" id="Fact-E3BA3519B4765A3B96A5E4EEF8FFBC56" unitRef="usd">1521000</us-gaap:Depreciation>
	<us-gaap:DepreciationDepletionAndAmortization contextRef="FD2018Q3QTD" decimals="-3" id="Fact-E693755FF15C5584B79CF98A8DD7E6F9" unitRef="usd">497000</us-gaap:DepreciationDepletionAndAmortization>
	<us-gaap:DepreciationDepletionAndAmortization contextRef="FD2018Q3YTD" decimals="-3" id="Fact-8369B58F80155357BB210EFB1EABA392" unitRef="usd">1677000</us-gaap:DepreciationDepletionAndAmortization>
	<us-gaap:DepreciationDepletionAndAmortization contextRef="FD2019Q3QTD" decimals="-3" id="Fact-389AF37F38A25643BD6CA57F89D82B21" unitRef="usd">507000</us-gaap:DepreciationDepletionAndAmortization>
	<us-gaap:DepreciationDepletionAndAmortization contextRef="FD2019Q3YTD" decimals="-3" id="Fact-55AA64977AEF559186F65CAB8A0D2AB3" unitRef="usd">1521000</us-gaap:DepreciationDepletionAndAmortization>
	<us-gaap:DividendsPreferredStockCash contextRef="FD2018Q3QTD" decimals="-3" id="Fact-A1BE75E00F37C5EF1CE9224C8E67DEB4" unitRef="usd">2567000</us-gaap:DividendsPreferredStockCash>
	<us-gaap:DividendsPreferredStockCash contextRef="FD2018Q3YTD" decimals="-3" id="Fact-E57A48B97E37F25C6B51224C8E51DF3A" unitRef="usd">7444000</us-gaap:DividendsPreferredStockCash>
	<us-gaap:DividendsPreferredStockCash contextRef="FD2019Q3QTD" decimals="-3" id="Fact-5C6B332058B6794FFF11224C8E43CDC1" unitRef="usd">2792000</us-gaap:DividendsPreferredStockCash>
	<us-gaap:DividendsPreferredStockCash contextRef="FD2019Q3YTD" decimals="-3" id="Fact-D2951B510A6DDC6A3DFF224C8E59F437" unitRef="usd">8269000</us-gaap:DividendsPreferredStockCash>
	<us-gaap:EarningsPerShareBasicAndDiluted contextRef="FD2018Q3QTD" decimals="2" id="Fact-80E92CCA061E5F36A63377CA55869854" unitRef="usdPerShare">-0.49</us-gaap:EarningsPerShareBasicAndDiluted>
	<us-gaap:EarningsPerShareBasicAndDiluted contextRef="FD2018Q3QTD_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember" decimals="2" id="Fact-F7CB777CA4ABA8D5796822141498CCEE" unitRef="usdPerShare">-0.49</us-gaap:EarningsPerShareBasicAndDiluted>
	<us-gaap:EarningsPerShareBasicAndDiluted contextRef="FD2018Q3YTD" decimals="2" id="Fact-B7D9DCC6D4E35C1C85CD893D4239FEC5" unitRef="usdPerShare">-0.84</us-gaap:EarningsPerShareBasicAndDiluted>
	<us-gaap:EarningsPerShareBasicAndDiluted contextRef="FD2018Q3YTD_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember" decimals="2" id="Fact-957356374DAB744CCD872213B27FBA52" unitRef="usdPerShare">-0.84</us-gaap:EarningsPerShareBasicAndDiluted>
	<us-gaap:EarningsPerShareBasicAndDiluted contextRef="FD2019Q3QTD" decimals="2" id="Fact-3FDB454CA33DF4FA0271039AB405868A" unitRef="usdPerShare">-1.50</us-gaap:EarningsPerShareBasicAndDiluted>
	<us-gaap:EarningsPerShareBasicAndDiluted contextRef="FD2019Q3QTD_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember" decimals="2" id="Fact-9762DDB28D950D0A9BFE06C70D1F1DF3" unitRef="usdPerShare">-1.50</us-gaap:EarningsPerShareBasicAndDiluted>
	<us-gaap:EarningsPerShareBasicAndDiluted contextRef="FD2019Q3YTD" decimals="2" id="Fact-34553D0FC61135C82232039AB415F950" unitRef="usdPerShare">-2.43</us-gaap:EarningsPerShareBasicAndDiluted>
	<us-gaap:EarningsPerShareBasicAndDiluted contextRef="FD2019Q3YTD_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember" decimals="2" id="Fact-0EEC3E009C9FB204450E06C70D0ED209" unitRef="usdPerShare">-2.43</us-gaap:EarningsPerShareBasicAndDiluted>
	<us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="FD2018Q3QTD" decimals="-3" id="Fact-D79E77FA3F035C74ADE5DD62DB8950A8" unitRef="usd">131000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
	<us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="FD2018Q3YTD" decimals="-3" id="Fact-36B8CE3937C450779D8F5A1C26FBCC3C" unitRef="usd">-795000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
	<us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="FD2019Q3QTD" decimals="-3" id="Fact-42DDC27782BC5F2D9F825D472BCAEE66" unitRef="usd">-24000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
	<us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="FD2019Q3YTD" decimals="-3" id="Fact-EC006D28224D5EDD94A0E43E2495174A" unitRef="usd">71000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
	<us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="FI2019Q3_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_abus_GenevantSciencesCorporationMember" decimals="2" id="Fact-79B9B39CC43AB4E4A198D4A8EA968E85" unitRef="number">0.40</us-gaap:EquityMethodInvestmentOwnershipPercentage>
	<us-gaap:EquityMethodInvestments contextRef="FI2018Q4" decimals="-3" id="Fact-937A8E4D712051FA9E57643C7FA035CA" unitRef="usd">22224000</us-gaap:EquityMethodInvestments>
	<us-gaap:EquityMethodInvestments contextRef="FI2019Q3" decimals="-3" id="Fact-13F41EC110155CFBAB95EF54A76DD83D" unitRef="usd">10969000</us-gaap:EquityMethodInvestments>
	<us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="FD2018Q3QTD" decimals="-3" id="Fact-1671CF6686735326BB9A472D9300910A" unitRef="usd">145000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
	<us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="FD2018Q3YTD" decimals="-3" id="Fact-B6DD62FFAE58525D9A3F19B12E7F1B28" unitRef="usd">-740000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
	<us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="FD2019Q3QTD" decimals="-3" id="Fact-CAE82D1E567F51FF8EFEF06ACA7B2421" unitRef="usd">-25000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
	<us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="FD2019Q3YTD" decimals="-3" id="Fact-03F49B880DB455009C6A7C5C9D49EBDF" unitRef="usd">43000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
	<us-gaap:ForeignCurrencyTransactionGainLossUnrealized contextRef="FD2018Q3QTD" decimals="-3" id="Fact-42218DE7E0E75020B91841D7A903E1B0" unitRef="usd">131000</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
	<us-gaap:ForeignCurrencyTransactionGainLossUnrealized contextRef="FD2018Q3YTD" decimals="-3" id="Fact-E5478951221D5DCAB6EF78BEBB92CE5C" unitRef="usd">-795000</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
	<us-gaap:ForeignCurrencyTransactionGainLossUnrealized contextRef="FD2019Q3QTD" decimals="-3" id="Fact-AB5237561F32514F83718B637ADDE00D" unitRef="usd">-24000</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
	<us-gaap:ForeignCurrencyTransactionGainLossUnrealized contextRef="FD2019Q3YTD" decimals="-3" id="Fact-492EF38758C15FF7BB464721D9F50767" unitRef="usd">71000</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
	<us-gaap:GainLossOnInvestments contextRef="FD2018Q3QTD" decimals="-3" id="Fact-E7DBE7CDCC6B5FA6A67F3D3F15BCEC73" unitRef="usd">0</us-gaap:GainLossOnInvestments>
	<us-gaap:GainLossOnInvestments contextRef="FD2018Q3YTD" decimals="-3" id="Fact-38B353B43C5959EC8D66252399185196" unitRef="usd">24884000</us-gaap:GainLossOnInvestments>
	<us-gaap:GainLossOnInvestments contextRef="FD2019Q3QTD" decimals="-3" id="Fact-DF07AFB7460B5B508D7B0C64D210096E" unitRef="usd">0</us-gaap:GainLossOnInvestments>
	<us-gaap:GainLossOnInvestments contextRef="FD2019Q3YTD" decimals="-3" id="Fact-A6D32D928A2F5CDDBB83B581EF34E5A7" unitRef="usd">0</us-gaap:GainLossOnInvestments>
	<us-gaap:GainLossOnSaleOfEquityInvestments contextRef="FD2018Q3QTD" decimals="-3" id="Fact-9786E57E654350ECB42FC4D95161221A" unitRef="usd">-2838000</us-gaap:GainLossOnSaleOfEquityInvestments>
	<us-gaap:GainLossOnSaleOfEquityInvestments contextRef="FD2018Q3YTD" decimals="-3" id="Fact-315233F099335C22A9498D58DA277EC9" unitRef="usd">-2838000</us-gaap:GainLossOnSaleOfEquityInvestments>
	<us-gaap:GainLossOnSaleOfEquityInvestments contextRef="FD2019Q3QTD" decimals="-3" id="Fact-6FED6C7F74485FE7A8A92655E12FAFBB" unitRef="usd">-3512000</us-gaap:GainLossOnSaleOfEquityInvestments>
	<us-gaap:GainLossOnSaleOfEquityInvestments contextRef="FD2019Q3YTD" decimals="-3" id="Fact-7CEB3537C7EF5AB8A39B6631CEBB5385" unitRef="usd">-11497000</us-gaap:GainLossOnSaleOfEquityInvestments>
	<us-gaap:GainLossOnSaleOfPropertyPlantEquipment contextRef="FD2018Q3QTD" decimals="-3" id="Fact-DFA4649C17145573A3AEA1A2B3B44397" unitRef="usd">26000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
	<us-gaap:GainLossOnSaleOfPropertyPlantEquipment contextRef="FD2018Q3YTD" decimals="-3" id="Fact-5774EC425D7D53749205E2F81F7FED44" unitRef="usd">26000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
	<us-gaap:GainLossOnSaleOfPropertyPlantEquipment contextRef="FD2019Q3QTD" decimals="-3" id="Fact-C1DACEA7BB60583CB40BEFBEDD72E2B3" unitRef="usd">0</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
	<us-gaap:GainLossOnSaleOfPropertyPlantEquipment contextRef="FD2019Q3YTD" decimals="-3" id="Fact-06BDC5EC63F15A748767E38EF2029617" unitRef="usd">11000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
	<us-gaap:GeneralAndAdministrativeExpense contextRef="FD2018Q3QTD" decimals="-3" id="Fact-2EBD8DACB52A53AE88121C58F22A9A7C" unitRef="usd">2631000</us-gaap:GeneralAndAdministrativeExpense>
	<us-gaap:GeneralAndAdministrativeExpense contextRef="FD2018Q3YTD" decimals="-3" id="Fact-69E83A135490539BB99E7EF0533F865F" unitRef="usd">10075000</us-gaap:GeneralAndAdministrativeExpense>
	<us-gaap:GeneralAndAdministrativeExpense contextRef="FD2019Q3QTD" decimals="-3" id="Fact-A6BBBB6D9BAA5190A23B7F19C3D821B6" unitRef="usd">3249000</us-gaap:GeneralAndAdministrativeExpense>
	<us-gaap:GeneralAndAdministrativeExpense contextRef="FD2019Q3YTD" decimals="-3" id="Fact-4F335586A240548B87BBD90786B4FE45" unitRef="usd">15850000</us-gaap:GeneralAndAdministrativeExpense>
	<us-gaap:Goodwill contextRef="FI2018Q4" decimals="-3" id="Fact-88EE9E4965355179B829B05ABE644780" unitRef="usd">22471000</us-gaap:Goodwill>
	<us-gaap:Goodwill contextRef="FI2019Q3" decimals="-3" id="Fact-A20D47118B2658E48BACA3F952446059" unitRef="usd">0</us-gaap:Goodwill>
	<us-gaap:Goodwill contextRef="FI2019Q3" decimals="INF" id="Fact-24429959AFABA007124222A5201BC3E4" unitRef="usd">0</us-gaap:Goodwill>
	<us-gaap:GoodwillImpairmentLoss contextRef="FD2018Q3QTD" decimals="-3" id="Fact-EC7CD8676740FFC46694222FD015FBDF" unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
	<us-gaap:GoodwillImpairmentLoss contextRef="FD2018Q3YTD" decimals="-3" id="Fact-B7DA33458976AAD4E0E8222FD012427F" unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
	<us-gaap:GoodwillImpairmentLoss contextRef="FD2019Q3QTD" decimals="-3" id="Fact-8216E62C2CDE2B0A2AE5222FD019AB38" unitRef="usd">22471000</us-gaap:GoodwillImpairmentLoss>
	<us-gaap:GoodwillImpairmentLoss contextRef="FD2019Q3YTD" decimals="-5" id="Fact-A4C545B59171B1B4F47722A569EC3883" unitRef="usd">22500000</us-gaap:GoodwillImpairmentLoss>
	<us-gaap:GoodwillImpairmentLoss contextRef="FD2019Q3YTD" decimals="-3" id="Fact-6BD2D61DCFFD0D47057C222FD01CC2BB" unitRef="usd">22471000</us-gaap:GoodwillImpairmentLoss>
	<us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill contextRef="FD2018Q3QTD" decimals="-3" id="Fact-B5610DA7C591F7AE1F6BD9A2CAAF2A87" unitRef="usd">14811000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
	<us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill contextRef="FD2018Q3YTD" decimals="-3" id="Fact-0B27431FDC590096E969D9A2E2EA41AE" unitRef="usd">14811000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
	<us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill contextRef="FD2019Q3QTD" decimals="-3" id="Fact-84600D129668E41BA746D9A2FCBC94A9" unitRef="usd">43836000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
	<us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill contextRef="FD2019Q3QTD_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_abus_InProcessResearchandDevelopmentcccDNASterilizersMember" decimals="-5" id="Fact-1B4047B1300EEBEEF827BB59D4A38A89" unitRef="usd">43800000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
	<us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill contextRef="FD2019Q3YTD" decimals="-3" id="Fact-84E1244B5E8412661023D9A30EB13B36" unitRef="usd">43836000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
	<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="FD2018Q3QTD" decimals="-3" id="Fact-DD1D4F4252065588B627DFCB57E870D9" unitRef="usd">-28755000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
	<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="FD2018Q3YTD" decimals="-3" id="Fact-781BD2880EF150E88BB81BD1FB953787" unitRef="usd">-43093000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
	<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="FD2019Q3QTD" decimals="-3" id="Fact-3CB2DBB03E775AF4913167DBFBD9BFEF" unitRef="usd">-95159000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
	<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="FD2019Q3YTD" decimals="-3" id="Fact-5D71BC1109AB5E63BB37712D6EDCB7C6" unitRef="usd">-141725000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
	<us-gaap:IncomeLossFromEquityMethodInvestments contextRef="FD2018Q2QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_abus_GenevantSciencesCorporationMember" decimals="-5" id="Fact-0629663D062C55899F077870FE9439F5" unitRef="usd">24900000</us-gaap:IncomeLossFromEquityMethodInvestments>
	<us-gaap:IncomeLossFromEquityMethodInvestments contextRef="FD2018Q3QTD" decimals="-3" id="Fact-4CF31B72BEBD5C2484585C5E843678D1" unitRef="usd">-2838000</us-gaap:IncomeLossFromEquityMethodInvestments>
	<us-gaap:IncomeLossFromEquityMethodInvestments contextRef="FD2018Q3YTD" decimals="-3" id="Fact-EF9D799CBCA750299F1F12BEFB42094A" unitRef="usd">-2838000</us-gaap:IncomeLossFromEquityMethodInvestments>
	<us-gaap:IncomeLossFromEquityMethodInvestments contextRef="FD2019Q3QTD" decimals="-3" id="Fact-360FE44512DC50759EA880E419A6055B" unitRef="usd">-3512000</us-gaap:IncomeLossFromEquityMethodInvestments>
	<us-gaap:IncomeLossFromEquityMethodInvestments contextRef="FD2019Q3QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_abus_GenevantSciencesCorporationMember" decimals="-5" id="Fact-CA5F4C80F7CB5C40D1CF259087206A94" unitRef="usd">-3500000</us-gaap:IncomeLossFromEquityMethodInvestments>
	<us-gaap:IncomeLossFromEquityMethodInvestments contextRef="FD2019Q3YTD" decimals="-3" id="Fact-632FF7810B8B5C3A80EEB5FBCD5B06C9" unitRef="usd">-11497000</us-gaap:IncomeLossFromEquityMethodInvestments>
	<us-gaap:IncomeLossFromEquityMethodInvestments contextRef="FD2019Q3YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_abus_GenevantSciencesCorporationMember" decimals="-5" id="Fact-4D430819BEB448425E732590A09F3DF2" unitRef="usd">-11500000</us-gaap:IncomeLossFromEquityMethodInvestments>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2018Q3QTD" decimals="-3" id="Fact-55980A224D0D8C4611FFD89AC7344926" unitRef="usd">-4282000</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2018Q3YTD" decimals="-3" id="Fact-B79D8B4B0C93C43F4A55D89ACA73211D" unitRef="usd">-4282000</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2019Q3QTD" decimals="-3" id="Fact-A9EFCF9532F16311ED6FD89AC5A4CBF9" unitRef="usd">-12656000</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2019Q3YTD" decimals="-3" id="Fact-74E08EBFD791807C7E6CD89AC8D4A4A4" unitRef="usd">-12656000</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability contextRef="FD2019Q3QTD_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_abus_InProcessResearchandDevelopmentcccDNASterilizersMember" decimals="-5" id="Fact-1C5A693CA507E0F5A31EBB59F0269C05" unitRef="usd">-12700000</us-gaap:IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability>
	<us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="FD2018Q3QTD" decimals="-3" id="Fact-69995F9402575153B6B50667EFF90BB0" unitRef="usd">1094000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
	<us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="FD2018Q3YTD" decimals="-3" id="Fact-06CF972FEC7B563D98D47B310A059CB5" unitRef="usd">-2171000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
	<us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="FD2019Q3QTD" decimals="-3" id="Fact-428662ED1EFE505F8E313C764AF4AD92" unitRef="usd">538000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
	<us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="FD2019Q3YTD" decimals="-3" id="Fact-CC9C5425770F57CAB9950C3F90ECFE12" unitRef="usd">-1320000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
	<us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="FD2018Q3QTD" decimals="-3" id="Fact-3106D878CD3B5B3090CD2BA938A5428C" unitRef="usd">-784000</us-gaap:IncreaseDecreaseInAccountsReceivable>
	<us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="FD2018Q3YTD" decimals="-3" id="Fact-D7AC2366F56E5EE092BEA75D674C6ADF" unitRef="usd">136000</us-gaap:IncreaseDecreaseInAccountsReceivable>
	<us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="FD2019Q3QTD" decimals="-3" id="Fact-F3F21CB7D80E5671AC3B88A6FABDA300" unitRef="usd">957000</us-gaap:IncreaseDecreaseInAccountsReceivable>
	<us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="FD2019Q3YTD" decimals="-3" id="Fact-0C9BE0DF04825DB8931075C6CDA3D20C" unitRef="usd">1057000</us-gaap:IncreaseDecreaseInAccountsReceivable>
	<us-gaap:IncreaseDecreaseInContractWithCustomerAsset contextRef="FD2018Q3QTD" decimals="-3" id="Fact-C6DDD682BAE453E595952E3B9A930551" unitRef="usd">0</us-gaap:IncreaseDecreaseInContractWithCustomerAsset>
	<us-gaap:IncreaseDecreaseInContractWithCustomerAsset contextRef="FD2018Q3YTD" decimals="-3" id="Fact-D4F4487A994D51DCB1418E0BCAC8AF3A" unitRef="usd">-128000</us-gaap:IncreaseDecreaseInContractWithCustomerAsset>
	<us-gaap:IncreaseDecreaseInContractWithCustomerAsset contextRef="FD2019Q3QTD" decimals="-3" id="Fact-7E259E0903865949BCAD28F425B15081" unitRef="usd">0</us-gaap:IncreaseDecreaseInContractWithCustomerAsset>
	<us-gaap:IncreaseDecreaseInContractWithCustomerAsset contextRef="FD2019Q3YTD" decimals="-3" id="Fact-F8AC9C68EF715E5C98F466B7530BE204" unitRef="usd">0</us-gaap:IncreaseDecreaseInContractWithCustomerAsset>
	<us-gaap:IncreaseDecreaseInContractWithCustomerLiability contextRef="FD2018Q3QTD" decimals="-3" id="Fact-1889DFE69BD45DFD87CB26568DFE4E4F" unitRef="usd">-325000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
	<us-gaap:IncreaseDecreaseInContractWithCustomerLiability contextRef="FD2018Q3YTD" decimals="-3" id="Fact-7EBC076915A35C9B9C0C07A45E604344" unitRef="usd">-2093000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
	<us-gaap:IncreaseDecreaseInContractWithCustomerLiability contextRef="FD2019Q3QTD" decimals="-3" id="Fact-ADABF00190BF5952A55387BECCC610C8" unitRef="usd">0</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
	<us-gaap:IncreaseDecreaseInContractWithCustomerLiability contextRef="FD2019Q3YTD" decimals="-3" id="Fact-59380448A2AD583DAB85A28A2C3BAE7C" unitRef="usd">0</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
	<us-gaap:IncreaseDecreaseInOtherOperatingLiabilities contextRef="FD2018Q3QTD" decimals="-3" id="Fact-84A2EC3AAED63E44B21F039DDC7B05BB" unitRef="usd">0</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
	<us-gaap:IncreaseDecreaseInOtherOperatingLiabilities contextRef="FD2018Q3YTD" decimals="-3" id="Fact-374A71743BE9566CB578E3D1A84791E6" unitRef="usd">-2000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
	<us-gaap:IncreaseDecreaseInOtherOperatingLiabilities contextRef="FD2019Q3QTD" decimals="-3" id="Fact-E0F4407588F25312AFA92E3749410C00" unitRef="usd">-446000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
	<us-gaap:IncreaseDecreaseInOtherOperatingLiabilities contextRef="FD2019Q3YTD" decimals="-3" id="Fact-99AF088905B95AC4B04A13982AC571E4" unitRef="usd">-541000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
	<us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="FD2018Q3QTD" decimals="-3" id="Fact-ED502D07E14F52B9A997F9DDCD6372E6" unitRef="usd">-109000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
	<us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="FD2018Q3YTD" decimals="-3" id="Fact-12017F31976C5913ACEB0A3CF2387696" unitRef="usd">-1017000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
	<us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="FD2019Q3QTD" decimals="-3" id="Fact-088A291ED62A5D8EBFF35293C39E9BAA" unitRef="usd">-1080000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
	<us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="FD2019Q3YTD" decimals="-3" id="Fact-7D076BF4C887503AAC47FF2B5F312BF1" unitRef="usd">-1839000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
	<us-gaap:IncreaseDecreaseInRestructuringReserve contextRef="FD2018Q3QTD" decimals="-3" id="Fact-1354CA90EF47559EA10E121AA820BA67" unitRef="usd">-320000</us-gaap:IncreaseDecreaseInRestructuringReserve>
	<us-gaap:IncreaseDecreaseInRestructuringReserve contextRef="FD2018Q3YTD" decimals="-3" id="Fact-126BEA97C6EE5F7CB16A91B8AD6E58DD" unitRef="usd">770000</us-gaap:IncreaseDecreaseInRestructuringReserve>
	<us-gaap:IncreaseDecreaseInRestructuringReserve contextRef="FD2019Q3QTD" decimals="-3" id="Fact-0B64E2F909CD5B54BA9A7BB16B0B4497" unitRef="usd">-138000</us-gaap:IncreaseDecreaseInRestructuringReserve>
	<us-gaap:IncreaseDecreaseInRestructuringReserve contextRef="FD2019Q3YTD" decimals="-3" id="Fact-8C5787BE444B54E4B3B1FA1EAAB1595C" unitRef="usd">-917000</us-gaap:IncreaseDecreaseInRestructuringReserve>
	<us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="FI2018Q4" decimals="-3" id="Fact-8D6A6D3315F2513DA297C60D9A77B94D" unitRef="usd">43836000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
	<us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="FI2019Q3" decimals="-3" id="Fact-536D90AAE5F350E9883A150EE8C9C60D" unitRef="usd">0</us-gaap:IntangibleAssetsNetExcludingGoodwill>
	<us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="FI2019Q3_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_abus_InProcessResearchandDevelopmentcccDNASterilizersMember" decimals="INF" id="Fact-49C17FE5BD1794A9D89E22A4E67E79A5" unitRef="usd">0</us-gaap:IntangibleAssetsNetExcludingGoodwill>
	<us-gaap:InterestExpense contextRef="FD2018Q3QTD" decimals="-3" id="Fact-F06A62ECB05E557E8CF4584E80BD9FD8" unitRef="usd">0</us-gaap:InterestExpense>
	<us-gaap:InterestExpense contextRef="FD2018Q3YTD" decimals="-3" id="Fact-AB36113D6B695BC1B17B6825D33DAC53" unitRef="usd">104000</us-gaap:InterestExpense>
	<us-gaap:InterestExpense contextRef="FD2019Q3QTD" decimals="-3" id="Fact-716C0D2858B952C6B14A355CD4F78246" unitRef="usd">1100000</us-gaap:InterestExpense>
	<us-gaap:InterestExpense contextRef="FD2019Q3YTD" decimals="-3" id="Fact-064C47E7916A500784837E05574AC2EC" unitRef="usd">1114000</us-gaap:InterestExpense>
	<us-gaap:InvestmentIncomeInterest contextRef="FD2018Q3QTD" decimals="-3" id="Fact-BFAEBE91AA0C57BBB6D4810662C79F1E" unitRef="usd">756000</us-gaap:InvestmentIncomeInterest>
	<us-gaap:InvestmentIncomeInterest contextRef="FD2018Q3YTD" decimals="-3" id="Fact-3CD313BE4E205958B156980F04B4642C" unitRef="usd">2319000</us-gaap:InvestmentIncomeInterest>
	<us-gaap:InvestmentIncomeInterest contextRef="FD2019Q3QTD" decimals="-3" id="Fact-F561423549225265BCEF9F0C85A2B4E3" unitRef="usd">503000</us-gaap:InvestmentIncomeInterest>
	<us-gaap:InvestmentIncomeInterest contextRef="FD2019Q3YTD" decimals="-3" id="Fact-32156D446B675D6A8ADFA86B12263B54" unitRef="usd">1709000</us-gaap:InvestmentIncomeInterest>
	<us-gaap:InvestmentsFairValueDisclosure contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-EDB6EC0942B257F8BD2239C1C18DD553" unitRef="usd">87675000</us-gaap:InvestmentsFairValueDisclosure>
	<us-gaap:InvestmentsFairValueDisclosure contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-E7417A6D43E8CB26E66106CD5A70499E" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
	<us-gaap:InvestmentsFairValueDisclosure contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-8F3B739879418C18CD2706CD5A3937C2" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
	<us-gaap:InvestmentsFairValueDisclosure contextRef="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-E1D0D98AF2229AEC4F6506CD5A5C4A11" unitRef="usd">87675000</us-gaap:InvestmentsFairValueDisclosure>
	<us-gaap:LesseeOperatingLeaseDiscountRate contextRef="FI2019Q3_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_abus_GenevantSciencesCorporationMember_us-gaap_LeaseArrangementTypeAxis_abus_SubleaseBurnabyFacilityMember" decimals="3" id="Fact-A932DC5285DB5761AD1ABE90FD678627" unitRef="number">0.050</us-gaap:LesseeOperatingLeaseDiscountRate>
	<us-gaap:LesseeOperatingLeaseDiscountRate contextRef="FI2019Q3_us-gaap_LeaseArrangementTypeAxis_abus_CorporateHeadquartersLocated701VeteransCircleWarminsterPennsylvaniaMember" decimals="3" id="Fact-1990A230A105539EA2C64C2B85EF381A" unitRef="number">0.090</us-gaap:LesseeOperatingLeaseDiscountRate>
	<us-gaap:LesseeOperatingLeaseDiscountRate contextRef="FI2019Q3_us-gaap_LeaseArrangementTypeAxis_abus_OfficesLocatedat626JacksonvilleRd.WarminsterPennsylvaniaMember" decimals="3" id="Fact-78675569DA7452679DB37767E376EA36" unitRef="number">0.076</us-gaap:LesseeOperatingLeaseDiscountRate>
	<us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="FI2019Q3" decimals="-3" id="Fact-BA06EC89F991E6FAFF3406D423CC0142" unitRef="usd">4740000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
	<us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive contextRef="FI2019Q3" decimals="-3" id="Fact-03D2D5348D6DBDCD9E0A06D423BE928B" unitRef="usd">2039000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
	<us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive contextRef="FI2019Q3" decimals="-3" id="Fact-074EFBA5C8AA8AC6177306D423F4A0D3" unitRef="usd">598000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
	<us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour contextRef="FI2019Q3" decimals="-3" id="Fact-94A58E4E1FFBF07D887E06D42405FB1D" unitRef="usd">581000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
	<us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree contextRef="FI2019Q3" decimals="-3" id="Fact-E79B1A7572819540582E06D423FDEBC4" unitRef="usd">677000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
	<us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo contextRef="FI2019Q3" decimals="-3" id="Fact-7B2C6FDDD163E56F941F06D423E6C1DF" unitRef="usd">657000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
	<us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear contextRef="FI2019Q3" decimals="-3" id="Fact-4923037EB40F35453CE006D423D52773" unitRef="usd">188000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
	<us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount contextRef="FI2019Q3" decimals="-3" id="Fact-B0DEFFC232E9DB3E7E5006D42413B4D0" unitRef="usd">1268000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
	<us-gaap:LessorOperatingLeaseRenewalTerm contextRef="FI2019Q3_us-gaap_LeaseArrangementTypeAxis_abus_CorporateHeadquartersLocated701VeteransCircleWarminsterPennsylvaniaMember" id="Fact-52906EA2C76E54238D0B1BC1BA74C30A">P5Y</us-gaap:LessorOperatingLeaseRenewalTerm>
	<us-gaap:Liabilities contextRef="FI2018Q4" decimals="-3" id="Fact-DE8F570A178C5FC89B1780358AE6512A" unitRef="usd">27671000</us-gaap:Liabilities>
	<us-gaap:Liabilities contextRef="FI2019Q3" decimals="-3" id="Fact-319766B005D95CF89256809CD4D83A20" unitRef="usd">33640000</us-gaap:Liabilities>
	<us-gaap:LiabilitiesAndStockholdersEquity contextRef="FI2018Q4" decimals="-3" id="Fact-AC958AB0B0945CBCB5B8D9AE93C2ABBC" unitRef="usd">227905000</us-gaap:LiabilitiesAndStockholdersEquity>
	<us-gaap:LiabilitiesAndStockholdersEquity contextRef="FI2019Q3" decimals="-3" id="Fact-F22ED52BF4435997B94A29090657C44F" unitRef="usd">117277000</us-gaap:LiabilitiesAndStockholdersEquity>
	<us-gaap:LiabilitiesCurrent contextRef="FI2018Q4" decimals="-3" id="Fact-47B753FD3AF358D3A344FA937E5CED02" unitRef="usd">11239000</us-gaap:LiabilitiesCurrent>
	<us-gaap:LiabilitiesCurrent contextRef="FI2019Q3" decimals="-3" id="Fact-C410FAAB5A545F09BA2E59CF4A06E7CB" unitRef="usd">8817000</us-gaap:LiabilitiesCurrent>
	<us-gaap:LiabilitiesFairValueDisclosure contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-670B8422A401CA812BAC06CD5A67BA6B" unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
	<us-gaap:LiabilitiesFairValueDisclosure contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-91F8DC76F6CAF28A60B906CD5A7CEEF6" unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
	<us-gaap:LiabilitiesFairValueDisclosure contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-0ED194E5F31FB7EAF08206CD5A32CD54" unitRef="usd">3605000</us-gaap:LiabilitiesFairValueDisclosure>
	<us-gaap:LiabilitiesFairValueDisclosure contextRef="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-67E32B9E791EB75FC21606CD5A44FEDF" unitRef="usd">3605000</us-gaap:LiabilitiesFairValueDisclosure>
	<us-gaap:LiabilitiesFairValueDisclosure contextRef="FI2019Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-1F9FE84B7A7DF6C4DEE1D4949EDE0ED2" unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
	<us-gaap:LiabilitiesFairValueDisclosure contextRef="FI2019Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-01D7A68D934816B610D1D495524BD32F" unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
	<us-gaap:LiabilitiesFairValueDisclosure contextRef="FI2019Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-5AF3B6131E1087F07CE6D495550919CE" unitRef="usd">3091000</us-gaap:LiabilitiesFairValueDisclosure>
	<us-gaap:LiabilitiesFairValueDisclosure contextRef="FI2019Q3_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-03B103E2ABCD49319E7DD495575022AC" unitRef="usd">3091000</us-gaap:LiabilitiesFairValueDisclosure>
	<us-gaap:LitigationSettlementAmountAwardedToOtherParty contextRef="D2019Q3Aug20-Aug20_srt_LitigationCaseAxis_abus_ArbitrationWithTheUniversityOfBritishColumbiaMember" decimals="-5" id="Fact-FE1C8297D1E553061A8922BB2A7FEC10" unitRef="usd">5900000</us-gaap:LitigationSettlementAmountAwardedToOtherParty>
	<us-gaap:LitigationSettlementAmountAwardedToOtherParty contextRef="FD2019Q3QTD_srt_LitigationCaseAxis_abus_ArbitrationWithTheUniversityOfBritishColumbiaMember" decimals="-5" id="Fact-8E5D76E650A34F3EC57B22BEB6B4B264" unitRef="usd">5900000</us-gaap:LitigationSettlementAmountAwardedToOtherParty>
	<us-gaap:LitigationSettlementInterest contextRef="D2019Q3Aug20-Aug20_srt_LitigationCaseAxis_abus_ArbitrationWithTheUniversityOfBritishColumbiaMember" decimals="-5" id="Fact-D6ED4A7898577F10CD7F22BC239813A7" unitRef="usd">2600000</us-gaap:LitigationSettlementInterest>
	<us-gaap:LossContingencyDamagesSoughtValue contextRef="D2015Q1Jan16_srt_LitigationCaseAxis_abus_ArbitrationWithTheUniversityOfBritishColumbiaMember" decimals="-5" id="Fact-9678C7BEB37154AD9F75603FDDA11A19" unitRef="usd">3500000</us-gaap:LossContingencyDamagesSoughtValue>
	<us-gaap:LossContingencyDamagesSoughtValue contextRef="D2017Q2Jun2017_srt_LitigationCaseAxis_abus_ArbitrationWithTheUniversityOfBritishColumbiaMember" decimals="-5" id="Fact-9F48F2A11F4056E393BF03718084A340" unitRef="usd">10900000</us-gaap:LossContingencyDamagesSoughtValue>
	<us-gaap:LossContingencyEstimateOfPossibleLoss contextRef="FI2019Q3_srt_LitigationCaseAxis_abus_ArbitrationWithTheUniversityOfBritishColumbiaMember_srt_RangeAxis_srt_MinimumMember" decimals="-5" id="Fact-AF6321C6C433F8BC021B22C10D442823" unitRef="usd">600000</us-gaap:LossContingencyEstimateOfPossibleLoss>
	<us-gaap:LossContingencyLossInPeriod contextRef="FD2018Q3QTD" decimals="-3" id="Fact-D1427C73C59A0E1D46252235B604DB75" unitRef="usd">0</us-gaap:LossContingencyLossInPeriod>
	<us-gaap:LossContingencyLossInPeriod contextRef="FD2018Q3YTD" decimals="-3" id="Fact-488140C1D60942C4A2CB2235B618BF28" unitRef="usd">0</us-gaap:LossContingencyLossInPeriod>
	<us-gaap:LossContingencyLossInPeriod contextRef="FD2019Q3QTD" decimals="-3" id="Fact-72B8D14116EE2423814C2235B621C0CC" unitRef="usd">6486000</us-gaap:LossContingencyLossInPeriod>
	<us-gaap:LossContingencyLossInPeriod contextRef="FD2019Q3QTD_srt_LitigationCaseAxis_abus_ArbitrationWithTheUniversityOfBritishColumbiaMember" decimals="-5" id="Fact-426787E2BE9F9860C18D22C00C58E3A0" unitRef="usd">6500000</us-gaap:LossContingencyLossInPeriod>
	<us-gaap:LossContingencyLossInPeriod contextRef="FD2019Q3YTD" decimals="-3" id="Fact-A63892B7607E5FE6F2A42235B62EFCA4" unitRef="usd">6486000</us-gaap:LossContingencyLossInPeriod>
	<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="FD2018Q3QTD" decimals="-3" id="Fact-AAE1AD17BB6958F58B264CB04D91DE16" unitRef="usd">435000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
	<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="FD2018Q3YTD" decimals="-3" id="Fact-EAEC7604628B5D1491C728AAF74A6F8B" unitRef="usd">55537000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
	<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="FD2019Q3QTD" decimals="-3" id="Fact-191FBC52E35B562CAC4F30CBAEC950E0" unitRef="usd">18549000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
	<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="FD2019Q3YTD" decimals="-3" id="Fact-3FFD757A508850D4AEE62D2EF1550136" unitRef="usd">23564000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
	<us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="FD2018Q3QTD" decimals="-3" id="Fact-C4E48291F4A1582E8B6A4DE5C0232F05" unitRef="usd">24378000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
	<us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="FD2018Q3YTD" decimals="-3" id="Fact-A20B65C438AF5B2792F8128FF0F5131A" unitRef="usd">-48911000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
	<us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="FD2019Q3QTD" decimals="-3" id="Fact-84CB50B867575FDB8644655D362FB774" unitRef="usd">16155000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
	<us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="FD2019Q3YTD" decimals="-3" id="Fact-6260EF5B8CC455D8A80C2F9EECAE0702" unitRef="usd">87160000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
	<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="FD2018Q3QTD" decimals="-3" id="Fact-A92FE9C230CD59F981EC3A56E4321790" unitRef="usd">-13204000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
	<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="FD2018Q3YTD" decimals="-3" id="Fact-F03F2F0F88CE532B8AF3222D9E4C1225" unitRef="usd">-50791000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
	<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="FD2019Q3QTD" decimals="-3" id="Fact-3E5DFE55C111560B9CD459C3C71E4229" unitRef="usd">-23470000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
	<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="FD2019Q3YTD" decimals="-3" id="Fact-9AA2C2827CAE5FECB1196581571AD4AC" unitRef="usd">-57655000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
	<us-gaap:NetIncomeLoss contextRef="FD2018Q1QTD" decimals="-3" id="Fact-ECF07137CDA15B68ABEAFFFD67D3067D" unitRef="usd">-17429000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2018Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-A6427ED7B45D5FE4B4DD20D190B84955" unitRef="usd">-17429000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2018Q2QTD" decimals="-3" id="Fact-4AF79BE1DB025A008C9105390693A328" unitRef="usd">3091000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2018Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-C4D8249B967454268723BF9B48639F3C" unitRef="usd">3091000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2018Q3QTD" decimals="-3" id="Fact-65E133D5E07557E3990DB329E7B080BC" unitRef="usd">-24473000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2018Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-23EADADD85505A2AFDD907099FCED5D5" unitRef="usd">-24473000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2018Q3YTD" decimals="-3" id="Fact-AED6659D38CF58098DC69E6947BEB487" unitRef="usd">-38811000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2019Q1QTD" decimals="-3" id="Fact-EB913FE296315D6581E22B148812706E" unitRef="usd">-23251000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-EB162940CDF9554FB7A958588DC20329" unitRef="usd">-23251000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2019Q2QTD" decimals="-3" id="Fact-2D714722FE0650CAB7F5344F0DA208BE" unitRef="usd">-23315000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-37D8055F92F35ED8A390F7FB4FF217DC" unitRef="usd">-23315000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2019Q3QTD" decimals="-3" id="Fact-8A150FF399695DA08252E23779EFB034" unitRef="usd">-82503000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2019Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-8430F9918A1807221840070BEED026D5" unitRef="usd">-82503000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2019Q3YTD" decimals="-3" id="Fact-F5644AA195AB5475ACEEC3FF3676F905" unitRef="usd">-129069000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="FD2018Q3QTD" decimals="-3" id="Fact-4CB99A61BBE02D78555406C1B61293B5" unitRef="usd">-27040000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
	<us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="FD2018Q3QTD_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-2B8BA333A73C246A3CEA2213EEA1DC17" unitRef="usd">-27040000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
	<us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="FD2018Q3YTD" decimals="-3" id="Fact-FC35AADEC93954888C06B1C2E1A7925C" unitRef="usd">-46255000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
	<us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="FD2018Q3YTD_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-E836E3C675E48CEFB7E42213B202FB33" unitRef="usd">-46255000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
	<us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="FD2019Q3QTD" decimals="-3" id="Fact-181D0E33FE7450F299719856CC32E89D" unitRef="usd">-85295000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
	<us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="FD2019Q3QTD_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-1C7A2256E4DACA50A1FE06C70D0AE418" unitRef="usd">-85295000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
	<us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="FD2019Q3YTD" decimals="-3" id="Fact-9E514F390DD15CF5AC12CF414B2E9E61" unitRef="usd">-137338000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
	<us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="FD2019Q3YTD_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-21F9E17CA10890155F5E06C70CFC8EEA" unitRef="usd">-137338000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
	<us-gaap:NonoperatingIncomeExpense contextRef="FD2018Q3QTD" decimals="-3" id="Fact-2431FB493D3E598095241A333A414D11" unitRef="usd">3671000</us-gaap:NonoperatingIncomeExpense>
	<us-gaap:NonoperatingIncomeExpense contextRef="FD2018Q3YTD" decimals="-3" id="Fact-714F759F6DF359B8A0F8945F93C5BB72" unitRef="usd">29784000</us-gaap:NonoperatingIncomeExpense>
	<us-gaap:NonoperatingIncomeExpense contextRef="FD2019Q3QTD" decimals="-3" id="Fact-6E88A691C0E0522B8B1760DF18EF76D4" unitRef="usd">-3758000</us-gaap:NonoperatingIncomeExpense>
	<us-gaap:NonoperatingIncomeExpense contextRef="FD2019Q3YTD" decimals="-3" id="Fact-ADA8CC2D6523502B9CD517BE029B18F1" unitRef="usd">-10738000</us-gaap:NonoperatingIncomeExpense>
	<us-gaap:OperatingExpenses contextRef="FD2018Q3QTD" decimals="-3" id="Fact-9D8F4AB0E1865A1F8934D0580CBDE5F7" unitRef="usd">34013000</us-gaap:OperatingExpenses>
	<us-gaap:OperatingExpenses contextRef="FD2018Q3YTD" decimals="-3" id="Fact-69AC797A86CD5062BE32BC19D1DC5975" unitRef="usd">77144000</us-gaap:OperatingExpenses>
	<us-gaap:OperatingExpenses contextRef="FD2019Q3QTD" decimals="-3" id="Fact-6D40DE4E1D285AFD8707A458C7F743A3" unitRef="usd">94462000</us-gaap:OperatingExpenses>
	<us-gaap:OperatingExpenses contextRef="FD2019Q3YTD" decimals="-3" id="Fact-FBC2843C0AEE564FB10B8AE0EF10370B" unitRef="usd">135380000</us-gaap:OperatingExpenses>
	<us-gaap:OperatingIncomeLoss contextRef="FD2018Q3QTD" decimals="-3" id="Fact-95A7FB66B63056AF96520AC79218E63F" unitRef="usd">-32426000</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingIncomeLoss contextRef="FD2018Q3YTD" decimals="-3" id="Fact-A1FC8910D6A25E399EEA734D298E97DC" unitRef="usd">-72877000</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingIncomeLoss contextRef="FD2019Q3QTD" decimals="-3" id="Fact-B0A49C3166C55AEBB337A6B84718A473" unitRef="usd">-91401000</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingIncomeLoss contextRef="FD2019Q3YTD" decimals="-3" id="Fact-841B2ABDA5125B3E8D9C88682DF062E0" unitRef="usd">-130987000</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingLeaseExpense contextRef="FD2019Q3YTD" decimals="-5" id="Fact-DC56A4880B833D458898D4C470970534" unitRef="usd">1100000</us-gaap:OperatingLeaseExpense>
	<us-gaap:OperatingLeaseLiability contextRef="FI2019Q3" decimals="-3" id="Fact-3E294DC3C26C9EC993B506D423DECA07" unitRef="usd">3472000</us-gaap:OperatingLeaseLiability>
	<us-gaap:OperatingLeaseLiabilityCurrent contextRef="FI2018Q4" decimals="-3" id="Fact-3FE790F2FFA955AAA5E2629D461F605E" unitRef="usd">0</us-gaap:OperatingLeaseLiabilityCurrent>
	<us-gaap:OperatingLeaseLiabilityCurrent contextRef="FI2019Q3" decimals="-3" id="Fact-69699C153C95593D9847FD1E1F4223CA" unitRef="usd">329000</us-gaap:OperatingLeaseLiabilityCurrent>
	<us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="FI2018Q4" decimals="-3" id="Fact-976D8C38331B5AC28ED6FC15564DA652" unitRef="usd">0</us-gaap:OperatingLeaseLiabilityNoncurrent>
	<us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="FI2019Q3" decimals="-3" id="Fact-4E8F43BCFDE55E14BBF76D47A582BADF" unitRef="usd">3143000</us-gaap:OperatingLeaseLiabilityNoncurrent>
	<us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="I2019Q1" decimals="-5" id="Fact-F687385391D85D7093CD4FD76515BF37" unitRef="usd">4100000</us-gaap:OperatingLeaseLiabilityNoncurrent>
	<us-gaap:OperatingLeasePayments contextRef="FD2018Q3YTD" decimals="-3" id="Fact-CBDE4E20A40C06095CF506D41766038E" unitRef="usd">0</us-gaap:OperatingLeasePayments>
	<us-gaap:OperatingLeasePayments contextRef="FD2019Q3YTD" decimals="-3" id="Fact-DC4D740AC9537C18526006D41762E9DF" unitRef="usd">921000</us-gaap:OperatingLeasePayments>
	<us-gaap:OperatingLeaseRightOfUseAsset contextRef="FI2018Q4" decimals="-3" id="Fact-63AC5ED4DE34571CA57F723DEFE7EA42" unitRef="usd">0</us-gaap:OperatingLeaseRightOfUseAsset>
	<us-gaap:OperatingLeaseRightOfUseAsset contextRef="FI2019Q3" decimals="-3" id="Fact-9CC9D83C26385BF0B6D302BCE49F2F50" unitRef="usd">2817000</us-gaap:OperatingLeaseRightOfUseAsset>
	<us-gaap:OperatingLeaseRightOfUseAsset contextRef="I2019Q1" decimals="-5" id="Fact-406F2790CFC35D38A1323C6474225DCE" unitRef="usd">3200000</us-gaap:OperatingLeaseRightOfUseAsset>
	<us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="FI2019Q3" decimals="3" id="Fact-C4D859798A8699316EDC06D4128DF7E8" unitRef="number">0.089</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
	<us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="FI2019Q3" id="Fact-C48CCB23A3BD1E61642B06D412825775">P7Y3M18D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
	<us-gaap:OtherAccruedLiabilitiesCurrent contextRef="FI2018Q4" decimals="-3" id="Fact-A2CD489386F45918AD34657B0E6412D8" unitRef="usd">309000</us-gaap:OtherAccruedLiabilitiesCurrent>
	<us-gaap:OtherAccruedLiabilitiesCurrent contextRef="FI2019Q3" decimals="-3" id="Fact-0BDC40E3263D517898DD241B721B9511" unitRef="usd">1000</us-gaap:OtherAccruedLiabilitiesCurrent>
	<us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent contextRef="FD2018Q3QTD" decimals="-3" id="Fact-584A540E927B54DC976A2A7F5103C67F" unitRef="usd">-12000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
	<us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent contextRef="FD2018Q3YTD" decimals="-3" id="Fact-F9EF72399DF15CF499F8DA27D9DA7A88" unitRef="usd">-12000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
	<us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent contextRef="FD2019Q3QTD" decimals="-3" id="Fact-AA3BCF3F2821555B9BCA347BE43097DA" unitRef="usd">27000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
	<us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent contextRef="FD2019Q3YTD" decimals="-3" id="Fact-FF992C689BA6551EAADD7BF03E132FC3" unitRef="usd">-47000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="FD2018Q3QTD" decimals="-3" id="Fact-18AE1C8AEB1C9420F3E60709031AA5DF" unitRef="usd">-12000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="FD2018Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-3" id="Fact-33862E03FA4300A81582070ACF42CDFF" unitRef="usd">-12000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="FD2019Q1QTD" decimals="-3" id="Fact-CA4EFD0801585971AE50B54A5AE3ECD2" unitRef="usd">-22000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-3" id="Fact-521F54ACD95B54FC96E219FD184F1267" unitRef="usd">-22000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="FD2019Q2QTD" decimals="-3" id="Fact-2127EC3DEDF45066B3BF95238DB6951D" unitRef="usd">-52000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-3" id="Fact-B7DAB9C8901954D2A43A7A27DED5A499" unitRef="usd">-52000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="FD2019Q3QTD" decimals="-3" id="Fact-B7279258C4A5BEFAAF52070BEA98ADE9" unitRef="usd">27000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="FD2019Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-3" id="Fact-7B6B08B9F2CD6D105EB7070BE94AE8E5" unitRef="usd">27000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:PaymentsForLegalSettlements contextRef="D2019Q3Aug20-Aug20_srt_LitigationCaseAxis_abus_ArbitrationWithTheUniversityOfBritishColumbiaMember" decimals="-5" id="Fact-0DB4C9EEA22D8D01248822BD2EBC8EF0" unitRef="usd">5900000</us-gaap:PaymentsForLegalSettlements>
	<us-gaap:PaymentsForProceedsFromInvestments contextRef="FD2018Q3QTD" decimals="-3" id="Fact-A350385D21BF58FC8AA37AE83F5DBE87" unitRef="usd">0</us-gaap:PaymentsForProceedsFromInvestments>
	<us-gaap:PaymentsForProceedsFromInvestments contextRef="FD2018Q3YTD" decimals="-3" id="Fact-ECC53EE456DB598FB9AF5F2E8B6EC1B4" unitRef="usd">48025000</us-gaap:PaymentsForProceedsFromInvestments>
	<us-gaap:PaymentsForProceedsFromInvestments contextRef="FD2019Q3QTD" decimals="-3" id="Fact-8FB6785616565C2A84A273EF47F952BC" unitRef="usd">0</us-gaap:PaymentsForProceedsFromInvestments>
	<us-gaap:PaymentsForProceedsFromInvestments contextRef="FD2019Q3YTD" decimals="-3" id="Fact-2ACCDD5849DB5681BF969030B54835E4" unitRef="usd">0</us-gaap:PaymentsForProceedsFromInvestments>
	<us-gaap:PaymentsForRestructuring contextRef="FD2019Q3YTD" decimals="-3" id="Fact-9BABC6F4D00AAAB2E69506F074B33B3E" unitRef="usd">1161000</us-gaap:PaymentsForRestructuring>
	<us-gaap:PaymentsForRestructuring contextRef="FD2019Q3YTD_us-gaap_RestructuringCostAndReserveAxis_abus_EmployeeSeveranceandRelocationMember" decimals="-3" id="Fact-86DCDDC43E62543C4E1B06F074A4B4C5" unitRef="usd">923000</us-gaap:PaymentsForRestructuring>
	<us-gaap:PaymentsForRestructuring contextRef="FD2019Q3YTD_us-gaap_RestructuringCostAndReserveAxis_us-gaap_FacilityClosingMember" decimals="-3" id="Fact-319A7A8ACA6A9FC3AB8906F074945DB6" unitRef="usd">238000</us-gaap:PaymentsForRestructuring>
	<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="FD2018Q3QTD" decimals="-3" id="Fact-1FCE934B1C6850A5BF31184168BDF30B" unitRef="usd">237000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
	<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="FD2018Q3YTD" decimals="-3" id="Fact-916F58FB617D50D683527652BCA4355A" unitRef="usd">911000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
	<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="FD2019Q3QTD" decimals="-3" id="Fact-020D7E2584C6547D8D2912AFEC61244B" unitRef="usd">255000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
	<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="FD2019Q3YTD" decimals="-3" id="Fact-8BB464A3E9DB52C5B9455164B0E844DC" unitRef="usd">526000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
	<us-gaap:PreferredStockAccretionOfRedemptionDiscount contextRef="FD2018Q1QTD" decimals="-3" id="Fact-58811CD8F50E5981A7C6196A7AB4F2F5" unitRef="usd">0</us-gaap:PreferredStockAccretionOfRedemptionDiscount>
	<us-gaap:PreferredStockAccretionOfRedemptionDiscount contextRef="FD2018Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="-3" id="Fact-0C6AA2A5DF2957E19C60AE8E1B284085" unitRef="usd">-2336000</us-gaap:PreferredStockAccretionOfRedemptionDiscount>
	<us-gaap:PreferredStockAccretionOfRedemptionDiscount contextRef="FD2018Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-88641E5F1A175647B69DD714A385B2C2" unitRef="usd">2336000</us-gaap:PreferredStockAccretionOfRedemptionDiscount>
	<us-gaap:PreferredStockAccretionOfRedemptionDiscount contextRef="FD2018Q2QTD" decimals="-3" id="Fact-FAD2084F84235EC08F5B563512F24500" unitRef="usd">0</us-gaap:PreferredStockAccretionOfRedemptionDiscount>
	<us-gaap:PreferredStockAccretionOfRedemptionDiscount contextRef="FD2018Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="-3" id="Fact-6DCE3F0B54A053ED924176D8D46949F8" unitRef="usd">-2541000</us-gaap:PreferredStockAccretionOfRedemptionDiscount>
	<us-gaap:PreferredStockAccretionOfRedemptionDiscount contextRef="FD2018Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-62D68A0E9CFC5DEE99FD21F01F71A028" unitRef="usd">2541000</us-gaap:PreferredStockAccretionOfRedemptionDiscount>
	<us-gaap:PreferredStockAccretionOfRedemptionDiscount contextRef="FD2018Q3QTD" decimals="-3" id="Fact-E699E06F817E3300FFFF0708E90F975E" unitRef="usd">0</us-gaap:PreferredStockAccretionOfRedemptionDiscount>
	<us-gaap:PreferredStockAccretionOfRedemptionDiscount contextRef="FD2018Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="-3" id="Fact-B67C981AEFB5F8AF1DBA0708E3DD09C8" unitRef="usd">-2567000</us-gaap:PreferredStockAccretionOfRedemptionDiscount>
	<us-gaap:PreferredStockAccretionOfRedemptionDiscount contextRef="FD2018Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-AE81BD74A973B3EF411A0708E71BE1F7" unitRef="usd">2567000</us-gaap:PreferredStockAccretionOfRedemptionDiscount>
	<us-gaap:PreferredStockAccretionOfRedemptionDiscount contextRef="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="-3" id="Fact-85A8AE1FCF5955A98A41D3FE83C3A946" unitRef="usd">-2715000</us-gaap:PreferredStockAccretionOfRedemptionDiscount>
	<us-gaap:PreferredStockAccretionOfRedemptionDiscount contextRef="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-E381FC2D3B38548DA3A72AD3EC552660" unitRef="usd">2715000</us-gaap:PreferredStockAccretionOfRedemptionDiscount>
	<us-gaap:PreferredStockAccretionOfRedemptionDiscount contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="-3" id="Fact-49C2CD5BF0D35B27BA9C7AB0A7134580" unitRef="usd">-2762000</us-gaap:PreferredStockAccretionOfRedemptionDiscount>
	<us-gaap:PreferredStockAccretionOfRedemptionDiscount contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-7FF5C742570E5D729F63154FE1A89E2A" unitRef="usd">2762000</us-gaap:PreferredStockAccretionOfRedemptionDiscount>
	<us-gaap:PreferredStockAccretionOfRedemptionDiscount contextRef="FD2019Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="-3" id="Fact-69EF2714349BA1EA77AE070B5BB3DDA7" unitRef="usd">-2792000</us-gaap:PreferredStockAccretionOfRedemptionDiscount>
	<us-gaap:PreferredStockAccretionOfRedemptionDiscount contextRef="FD2019Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-C2BF26836477ED13F6AE070B5EEF1DAA" unitRef="usd">2792000</us-gaap:PreferredStockAccretionOfRedemptionDiscount>
	<us-gaap:PreferredStockDividendRatePercentage contextRef="D2017Q4Oct01-Oct31_srt_CounterpartyNameAxis_abus_RoivantSciencesLtdMember_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember" decimals="INF" id="Fact-CA0707ABB78670E596B73CFF3ECD447E" unitRef="number">0.0875</us-gaap:PreferredStockDividendRatePercentage>
	<us-gaap:PreferredStockDividendRatePercentage contextRef="FD2019Q3YTD_srt_CounterpartyNameAxis_abus_RoivantSciencesLtdMember_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember" decimals="INF" id="Fact-8D7E54F2B6505A0FBB33526E321E2E8D" unitRef="number">0.0875</us-gaap:PreferredStockDividendRatePercentage>
	<us-gaap:PreferredStockDividendsAndOtherAdjustments contextRef="FD2018Q3QTD" decimals="-3" id="Fact-BBD881E882655B87AEEB035E908BC3AD" unitRef="usd">2567000</us-gaap:PreferredStockDividendsAndOtherAdjustments>
	<us-gaap:PreferredStockDividendsAndOtherAdjustments contextRef="FD2018Q3YTD" decimals="-3" id="Fact-B037A7541CBB5242AA600F7819950152" unitRef="usd">7444000</us-gaap:PreferredStockDividendsAndOtherAdjustments>
	<us-gaap:PreferredStockDividendsAndOtherAdjustments contextRef="FD2019Q3QTD" decimals="-3" id="Fact-37877A15F9565B4DA4922A054999E1BE" unitRef="usd">2792000</us-gaap:PreferredStockDividendsAndOtherAdjustments>
	<us-gaap:PreferredStockDividendsAndOtherAdjustments contextRef="FD2019Q3YTD" decimals="-3" id="Fact-07919F88D23E5C97BCE5414B7049EEAF" unitRef="usd">8269000</us-gaap:PreferredStockDividendsAndOtherAdjustments>
	<us-gaap:PreferredStockIncludingAdditionalPaidInCapitalNetOfDiscount contextRef="FI2018Q4" decimals="-3" id="Fact-42F773BC986F5CE089D5E738B33A5972" unitRef="usd">126136000</us-gaap:PreferredStockIncludingAdditionalPaidInCapitalNetOfDiscount>
	<us-gaap:PreferredStockIncludingAdditionalPaidInCapitalNetOfDiscount contextRef="FI2019Q3" decimals="-3" id="Fact-7D2962C36C0557A9A95130D6AC12F5B7" unitRef="usd">134405000</us-gaap:PreferredStockIncludingAdditionalPaidInCapitalNetOfDiscount>
	<us-gaap:PreferredStockNoParValue contextRef="FI2018Q4" id="Fact-017879811A9D50EFA69EF0B92DF55799" unitRef="usdPerShare" xsi:nil="true" />
	<us-gaap:PreferredStockNoParValue contextRef="FI2019Q3" id="Fact-16F5B45E94BB5885A6C32C42F44F0555" unitRef="usdPerShare" xsi:nil="true" />
	<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="I2017Q3Oct31_srt_CounterpartyNameAxis_abus_RoivantSciencesLtdMember_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember" decimals="INF" id="Fact-6EA1A67F55BBFA0937163D004719B0BF" unitRef="usdPerShare">7.13</us-gaap:PreferredStockParOrStatedValuePerShare>
	<us-gaap:PreferredStockSharesAuthorized contextRef="FI2018Q4" decimals="INF" id="Fact-016CEE0A569C57F58FC4F26B1E52CCD4" unitRef="shares">1164000</us-gaap:PreferredStockSharesAuthorized>
	<us-gaap:PreferredStockSharesAuthorized contextRef="FI2019Q3" decimals="INF" id="Fact-D9A3654642FF56B7A73E6901C541E628" unitRef="shares">1164000</us-gaap:PreferredStockSharesAuthorized>
	<us-gaap:PreferredStockSharesIssued contextRef="FI2018Q4" decimals="INF" id="Fact-50B202D8DEB159AAA03D7F6CA3FADC18" unitRef="shares">1164000</us-gaap:PreferredStockSharesIssued>
	<us-gaap:PreferredStockSharesIssued contextRef="FI2019Q3" decimals="INF" id="Fact-4D41A48269E85C78AEB15627C2796E27" unitRef="shares">1164000</us-gaap:PreferredStockSharesIssued>
	<us-gaap:PreferredStockSharesOutstanding contextRef="FI2018Q4" decimals="INF" id="Fact-1E5013337C2A59F79B74449BB657832D" unitRef="shares">1164000</us-gaap:PreferredStockSharesOutstanding>
	<us-gaap:PreferredStockSharesOutstanding contextRef="FI2019Q3" decimals="INF" id="Fact-0244BB47A67B540BBB9A2126262E21FF" unitRef="shares">1164000</us-gaap:PreferredStockSharesOutstanding>
	<us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="FI2018Q4" decimals="-3" id="Fact-F3D68E9BEA9955EB9B107EE3F7FE6523" unitRef="usd">3181000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
	<us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="FI2019Q3" decimals="-3" id="Fact-6A27D773F6B557DBB3CC8031F5CBF709" unitRef="usd">1771000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
	<us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="FD2018Q3QTD" decimals="-3" id="Fact-FA6036222F05555C8F22F271392213F6" unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
	<us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="FD2018Q3YTD" decimals="-3" id="Fact-813F6FD88B96580DA3556D1C31ABCA76" unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
	<us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="FD2019Q3QTD" decimals="-3" id="Fact-7BE664D6DDCA536B9824AA67D38652B3" unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
	<us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="FD2019Q3YTD" decimals="-3" id="Fact-D0F53E81DC4A556B869B43F2AB2D0827" unitRef="usd">4725000</us-gaap:ProceedsFromIssuanceOfCommonStock>
	<us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="FD2019Q3YTD_srt_CounterpartyNameAxis_abus_JefferiesLLCMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_abus_OpenMarketSaleAgreementMember" decimals="-5" id="Fact-FA76B9721B2C1C1D9F6BD4CEE61164DE" unitRef="usd">5200000</us-gaap:ProceedsFromIssuanceOfCommonStock>
	<us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock contextRef="D2017Q4Oct01-Oct31_srt_CounterpartyNameAxis_abus_RoivantSciencesLtdMember" decimals="-5" id="Fact-A48BC82D36D65036B1467E37A64C2210" unitRef="usd">50000000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
	<us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock contextRef="D2018Q1Jan01-Jan31_srt_CounterpartyNameAxis_abus_RoivantSciencesLtdMember" decimals="-5" id="Fact-9D2E0DF87C105524B825F25953BF815D" unitRef="usd">66400000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
	<us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock contextRef="FD2018Q3QTD" decimals="-3" id="Fact-B7A7ED0228255D1FA63D77FA24588DC9" unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
	<us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock contextRef="FD2018Q3YTD" decimals="-3" id="Fact-779E5C5D02635B1EB5F83EACB53BD9DC" unitRef="usd">66265000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
	<us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock contextRef="FD2019Q3QTD" decimals="-3" id="Fact-14E69C87B41B50219547D80BCF75EEB3" unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
	<us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock contextRef="FD2019Q3YTD" decimals="-3" id="Fact-C1BB87EB40AC5C42AE4ECBBC596DF88C" unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
	<us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment contextRef="FD2018Q3QTD" decimals="-3" id="Fact-4EE9B7555A2C5D8ABAE06386B0799DE7" unitRef="usd">25000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
	<us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment contextRef="FD2018Q3YTD" decimals="-3" id="Fact-8CC61C7A06A55A27B8C193F83847DB0E" unitRef="usd">25000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
	<us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment contextRef="FD2019Q3QTD" decimals="-3" id="Fact-24B23C2847AB57F397AD65850E45CA85" unitRef="usd">0</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
	<us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment contextRef="FD2019Q3YTD" decimals="-3" id="Fact-F45F1A6494445D28B050BD7001E3B3E3" unitRef="usd">11000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
	<us-gaap:ProceedsFromSaleOfRestrictedInvestments contextRef="FD2018Q3QTD" decimals="-3" id="Fact-423270B938DC5B49A1E8D7C0D429E8A7" unitRef="usd">24590000</us-gaap:ProceedsFromSaleOfRestrictedInvestments>
	<us-gaap:ProceedsFromSaleOfRestrictedInvestments contextRef="FD2018Q3YTD" decimals="-3" id="Fact-B20FB2A1C9E65EAB937712B34F73F4F2" unitRef="usd">0</us-gaap:ProceedsFromSaleOfRestrictedInvestments>
	<us-gaap:ProceedsFromSaleOfRestrictedInvestments contextRef="FD2019Q3QTD" decimals="-3" id="Fact-6F664E7BA29559BAA7CE8FECF7354C83" unitRef="usd">16410000</us-gaap:ProceedsFromSaleOfRestrictedInvestments>
	<us-gaap:ProceedsFromSaleOfRestrictedInvestments contextRef="FD2019Q3YTD" decimals="-3" id="Fact-0E946C3CDBF1570C86FA360CC849300F" unitRef="usd">87675000</us-gaap:ProceedsFromSaleOfRestrictedInvestments>
	<us-gaap:ProceedsFromStockOptionsExercised contextRef="FD2018Q3QTD" decimals="-3" id="Fact-C3BE99D092A750B6B4A7658D1DCBD5C4" unitRef="usd">435000</us-gaap:ProceedsFromStockOptionsExercised>
	<us-gaap:ProceedsFromStockOptionsExercised contextRef="FD2018Q3YTD" decimals="-3" id="Fact-89AB43D8F4CE5ECAA9F059C165738167" unitRef="usd">1273000</us-gaap:ProceedsFromStockOptionsExercised>
	<us-gaap:ProceedsFromStockOptionsExercised contextRef="FD2019Q3QTD" decimals="-3" id="Fact-CEC80E69555C57599F13BC991F7D0A4C" unitRef="usd">0</us-gaap:ProceedsFromStockOptionsExercised>
	<us-gaap:ProceedsFromStockOptionsExercised contextRef="FD2019Q3YTD" decimals="-3" id="Fact-6F86B7F6CE5D599FBD0DE790B91C6A74" unitRef="usd">290000</us-gaap:ProceedsFromStockOptionsExercised>
	<us-gaap:PropertyPlantAndEquipmentNet contextRef="FI2018Q4" decimals="-3" id="Fact-1C0C41357690500D8AD83AE925265F34" unitRef="usd">10145000</us-gaap:PropertyPlantAndEquipmentNet>
	<us-gaap:PropertyPlantAndEquipmentNet contextRef="FI2019Q3" decimals="-3" id="Fact-521ED8225FED5B0B98C6D999BE38DA48" unitRef="usd">9150000</us-gaap:PropertyPlantAndEquipmentNet>
	<us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty contextRef="FD2018Q3QTD_srt_CounterpartyNameAxis_abus_GenevantSciencesCorporationMember_us-gaap_RelatedPartyTransactionAxis_abus_ResearchAndDevelopmentServicesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_EquityMethodInvesteeMember" decimals="-5" id="Fact-3DCFC3D3286451BA81F55F3CAE0E3383" unitRef="usd">100000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
	<us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty contextRef="FD2018Q3YTD_srt_CounterpartyNameAxis_abus_GenevantSciencesCorporationMember_us-gaap_RelatedPartyTransactionAxis_abus_ResearchAndDevelopmentServicesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_EquityMethodInvesteeMember" decimals="-5" id="Fact-EC76E36DD3A9519FAE417DF49BD7E151" unitRef="usd">200000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
	<us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty contextRef="FD2019Q3QTD_srt_CounterpartyNameAxis_abus_GenevantSciencesCorporationMember_us-gaap_RelatedPartyTransactionAxis_abus_ResearchAndDevelopmentServicesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_EquityMethodInvesteeMember" decimals="INF" id="Fact-6CBCF750781C513A8E14A68BA98987A0" unitRef="usd">0</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
	<us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty contextRef="FD2019Q3YTD_srt_CounterpartyNameAxis_abus_GenevantSciencesCorporationMember_us-gaap_RelatedPartyTransactionAxis_abus_ResearchAndDevelopmentServicesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_EquityMethodInvesteeMember" decimals="-3" id="Fact-79CF057C01875D24B10A6DF9CC25AF95" unitRef="usd">33000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
	<us-gaap:RepaymentsOfNotesPayable contextRef="FD2018Q3QTD" decimals="-3" id="Fact-C150052474F8570DABF2A8C59BF49B69" unitRef="usd">0</us-gaap:RepaymentsOfNotesPayable>
	<us-gaap:RepaymentsOfNotesPayable contextRef="FD2018Q3YTD" decimals="-3" id="Fact-6D8FFDE0F83F58BBBE0744EDA680EBC3" unitRef="usd">12001000</us-gaap:RepaymentsOfNotesPayable>
	<us-gaap:RepaymentsOfNotesPayable contextRef="FD2019Q3QTD" decimals="-3" id="Fact-29805C24AB565F7ABA8613ACA5C3ADE9" unitRef="usd">0</us-gaap:RepaymentsOfNotesPayable>
	<us-gaap:RepaymentsOfNotesPayable contextRef="FD2019Q3YTD" decimals="-3" id="Fact-C5429C79AAA85433A72A47ACC6E8CF95" unitRef="usd">0</us-gaap:RepaymentsOfNotesPayable>
	<us-gaap:ResearchAndDevelopmentExpense contextRef="FD2018Q3QTD" decimals="-3" id="Fact-D6A3EDD0DD9456D7BC49CBC08EAB3C5A" unitRef="usd">16566000</us-gaap:ResearchAndDevelopmentExpense>
	<us-gaap:ResearchAndDevelopmentExpense contextRef="FD2018Q3YTD" decimals="-3" id="Fact-B39191790F3B5289B28E5407E9DDD882" unitRef="usd">46871000</us-gaap:ResearchAndDevelopmentExpense>
	<us-gaap:ResearchAndDevelopmentExpense contextRef="FD2019Q3QTD" decimals="-3" id="Fact-F74DDF9E075559688E2AEBB63CD696D8" unitRef="usd">17731000</us-gaap:ResearchAndDevelopmentExpense>
	<us-gaap:ResearchAndDevelopmentExpense contextRef="FD2019Q3YTD" decimals="-3" id="Fact-7FDC32FE81FF5D57BA8FF85FAEFC068C" unitRef="usd">45183000</us-gaap:ResearchAndDevelopmentExpense>
	<us-gaap:RestructuringAndRelatedCostExpectedCost1 contextRef="FI2019Q3_us-gaap_RestructuringCostAndReserveAxis_us-gaap_FacilityClosingMember" decimals="-5" id="Fact-8D1644D87E985AE387EB34CB9D9ECA71" unitRef="usd">5000000</us-gaap:RestructuringAndRelatedCostExpectedCost1>
	<us-gaap:RestructuringCharges contextRef="D2019Q3Jan2018-Sep2019" decimals="-5" id="Fact-2B10658D32BF5CBE8A6587C97A05C168" unitRef="usd">4800000</us-gaap:RestructuringCharges>
	<us-gaap:RestructuringCharges contextRef="FD2018Q3QTD" decimals="-3" id="Fact-54BCB75E51BD54348FFAB6939741A441" unitRef="usd">-492000</us-gaap:RestructuringCharges>
	<us-gaap:RestructuringCharges contextRef="FD2018Q3QTD_us-gaap_RestructuringCostAndReserveAxis_abus_EmployeeSeveranceandRelocationMember" decimals="-3" id="Fact-199D6D071F337021B6D006F07DC85821" unitRef="usd">198000</us-gaap:RestructuringCharges>
	<us-gaap:RestructuringCharges contextRef="FD2018Q3QTD_us-gaap_RestructuringCostAndReserveAxis_us-gaap_FacilityClosingMember" decimals="-3" id="Fact-1EACFC92ED2F73B3D59B06F07DB2202C" unitRef="usd">-690000</us-gaap:RestructuringCharges>
	<us-gaap:RestructuringCharges contextRef="FD2018Q3YTD" decimals="-3" id="Fact-20E98F4AE56A5E87B6883BF07D4A59AA" unitRef="usd">3710000</us-gaap:RestructuringCharges>
	<us-gaap:RestructuringCharges contextRef="FD2018Q3YTD_us-gaap_RestructuringCostAndReserveAxis_abus_EmployeeSeveranceandRelocationMember" decimals="-3" id="Fact-B406B212D4425B652288221C211D5CCA" unitRef="usd">3399000</us-gaap:RestructuringCharges>
	<us-gaap:RestructuringCharges contextRef="FD2018Q3YTD_us-gaap_RestructuringCostAndReserveAxis_us-gaap_FacilityClosingMember" decimals="-3" id="Fact-5C8EE67FFF0C34A3AE79221C2108E2DC" unitRef="usd">311000</us-gaap:RestructuringCharges>
	<us-gaap:RestructuringCharges contextRef="FD2019Q3QTD" decimals="-3" id="Fact-AE947CCAFA705B138D007DE23FC67327" unitRef="usd">182000</us-gaap:RestructuringCharges>
	<us-gaap:RestructuringCharges contextRef="FD2019Q3QTD_us-gaap_RestructuringCostAndReserveAxis_abus_EmployeeSeveranceandRelocationMember" decimals="-3" id="Fact-E6041395F74B50ED0D0C06F07DC819A6" unitRef="usd">231000</us-gaap:RestructuringCharges>
	<us-gaap:RestructuringCharges contextRef="FD2019Q3QTD_us-gaap_RestructuringCostAndReserveAxis_us-gaap_FacilityClosingMember" decimals="-3" id="Fact-0F40851267BBD523A1D806F07DB9F340" unitRef="usd">-49000</us-gaap:RestructuringCharges>
	<us-gaap:RestructuringCharges contextRef="FD2019Q3YTD" decimals="-3" id="Fact-7E76ECB5F45B57928DC7D26A29FE626E" unitRef="usd">33000</us-gaap:RestructuringCharges>
	<us-gaap:RestructuringCharges contextRef="FD2019Q3YTD_us-gaap_RestructuringCostAndReserveAxis_abus_EmployeeSeveranceandRelocationMember" decimals="-3" id="Fact-F8E27AD183A06729CBCF221C20E4009B" unitRef="usd">429000</us-gaap:RestructuringCharges>
	<us-gaap:RestructuringCharges contextRef="FD2019Q3YTD_us-gaap_RestructuringCostAndReserveAxis_us-gaap_FacilityClosingMember" decimals="-3" id="Fact-3864AD5333B0D7427740221C20D4ACF9" unitRef="usd">-396000</us-gaap:RestructuringCharges>
	<us-gaap:RestructuringCosts contextRef="FD2018Q3QTD" decimals="-3" id="Fact-A2286E788DD65EB7B4C8A5EFE1819858" unitRef="usd">0</us-gaap:RestructuringCosts>
	<us-gaap:RestructuringCosts contextRef="FD2018Q3YTD" decimals="-3" id="Fact-ABB4A85CAB49501D97C58903CF6D7B24" unitRef="usd">396000</us-gaap:RestructuringCosts>
	<us-gaap:RestructuringCosts contextRef="FD2019Q3QTD" decimals="-3" id="Fact-5D5FA83F7B7E5474905293DFBEFF056F" unitRef="usd">0</us-gaap:RestructuringCosts>
	<us-gaap:RestructuringCosts contextRef="FD2019Q3YTD" decimals="-3" id="Fact-94E66D4C487C5AF79FFA819BFAC46D01" unitRef="usd">0</us-gaap:RestructuringCosts>
	<us-gaap:RestructuringReserve contextRef="FI2018Q4" decimals="-3" id="Fact-31D66FBA9E4217FFD11206F074851E1A" unitRef="usd">1331000</us-gaap:RestructuringReserve>
	<us-gaap:RestructuringReserve contextRef="FI2018Q4_us-gaap_RestructuringCostAndReserveAxis_abus_EmployeeSeveranceandRelocationMember" decimals="-3" id="Fact-D4DCB44C988C2DD0184606F0749462FD" unitRef="usd">697000</us-gaap:RestructuringReserve>
	<us-gaap:RestructuringReserve contextRef="FI2018Q4_us-gaap_RestructuringCostAndReserveAxis_us-gaap_FacilityClosingMember" decimals="-3" id="Fact-B408F32C6E8FBAC29F7506F074A4E8EF" unitRef="usd">634000</us-gaap:RestructuringReserve>
	<us-gaap:RestructuringReserve contextRef="FI2019Q3" decimals="-3" id="Fact-1CE2C44B7A6F2A9BEFE006F074B3ABB2" unitRef="usd">203000</us-gaap:RestructuringReserve>
	<us-gaap:RestructuringReserve contextRef="FI2019Q3_us-gaap_RestructuringCostAndReserveAxis_abus_EmployeeSeveranceandRelocationMember" decimals="-3" id="Fact-724C66996291A535CF8806F074A49096" unitRef="usd">203000</us-gaap:RestructuringReserve>
	<us-gaap:RestructuringReserve contextRef="FI2019Q3_us-gaap_RestructuringCostAndReserveAxis_us-gaap_FacilityClosingMember" decimals="-3" id="Fact-5A5F3C8AA2351ADF5D8506F074A45903" unitRef="usd">0</us-gaap:RestructuringReserve>
	<us-gaap:RestructuringReserveCurrent contextRef="FI2018Q4" decimals="-3" id="Fact-F380D1DD41D35307829BC3A930EAF77D" unitRef="usd">1331000</us-gaap:RestructuringReserveCurrent>
	<us-gaap:RestructuringReserveCurrent contextRef="FI2019Q3" decimals="-3" id="Fact-2232AAB21378513FAF8D677DC0A4A52A" unitRef="usd">203000</us-gaap:RestructuringReserveCurrent>
	<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="FI2018Q4" decimals="-3" id="Fact-1B7D5D02462051BA87863CDFBEDD3714" unitRef="usd">-805221000</us-gaap:RetainedEarningsAccumulatedDeficit>
	<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="FI2019Q3" decimals="-3" id="Fact-BA5C447E72EA5AD2937F412A27C82BC9" unitRef="usd">-942559000</us-gaap:RetainedEarningsAccumulatedDeficit>
	<us-gaap:RevenueFromRelatedParties contextRef="FD2018Q3QTD_srt_CounterpartyNameAxis_abus_GenevantSciencesCorporationMember_us-gaap_RelatedPartyTransactionAxis_abus_AdministrativeAndTransitionalServicesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_EquityMethodInvesteeMember" decimals="-5" id="Fact-80FB901FE524559AB976D0A4A6BAA093" unitRef="usd">100000</us-gaap:RevenueFromRelatedParties>
	<us-gaap:RevenueFromRelatedParties contextRef="FD2018Q3YTD_srt_CounterpartyNameAxis_abus_GenevantSciencesCorporationMember_us-gaap_RelatedPartyTransactionAxis_abus_AdministrativeAndTransitionalServicesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_EquityMethodInvesteeMember" decimals="-5" id="Fact-B83F048914C451B6828548A0D35CA8BA" unitRef="usd">300000</us-gaap:RevenueFromRelatedParties>
	<us-gaap:RevenueFromRelatedParties contextRef="FD2019Q3QTD_srt_CounterpartyNameAxis_abus_GenevantSciencesCorporationMember_us-gaap_RelatedPartyTransactionAxis_abus_AdministrativeAndTransitionalServicesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_EquityMethodInvesteeMember" decimals="-5" id="Fact-D8A4BC7149A050EE84ACC4325BDE95C1" unitRef="usd">0</us-gaap:RevenueFromRelatedParties>
	<us-gaap:RevenueFromRelatedParties contextRef="FD2019Q3QTD_srt_CounterpartyNameAxis_abus_GenevantSciencesCorporationMember_us-gaap_RelatedPartyTransactionAxis_abus_SubleaseBurnabyFacilityMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_EquityMethodInvesteeMember" decimals="-3" id="Fact-1981E63D343150609B620B1136E40039" unitRef="usd">21000</us-gaap:RevenueFromRelatedParties>
	<us-gaap:RevenueFromRelatedParties contextRef="FD2019Q3YTD_srt_CounterpartyNameAxis_abus_GenevantSciencesCorporationMember_us-gaap_RelatedPartyTransactionAxis_abus_AdministrativeAndTransitionalServicesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_EquityMethodInvesteeMember" decimals="-3" id="Fact-88A9F8F666945F318C1AFAB7888CC74D" unitRef="usd">284000</us-gaap:RevenueFromRelatedParties>
	<us-gaap:RevenueFromRelatedParties contextRef="FD2019Q3YTD_srt_CounterpartyNameAxis_abus_GenevantSciencesCorporationMember_us-gaap_RelatedPartyTransactionAxis_abus_SubleaseBurnabyFacilityMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_EquityMethodInvesteeMember" decimals="-5" id="Fact-172CA3CB3E8E5ABBBFBF02CB0F128DFB" unitRef="usd">100000</us-gaap:RevenueFromRelatedParties>
	<us-gaap:Revenues contextRef="FD2018Q3QTD" decimals="-3" id="Fact-4482F0A3F95D5723ABB127E2BBB7AC01" unitRef="usd">1587000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2018Q3QTD_srt_CounterpartyNameAxis_abus_GritstoneMember_srt_ProductOrServiceAxis_us-gaap_LicenseMember" decimals="-5" id="Fact-CD19A73AE513FAD4106122D4E7199CB7" unitRef="usd">1300000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2018Q3YTD" decimals="-3" id="Fact-484849028A885A808AF5359D69C5D290" unitRef="usd">4267000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2018Q3YTD_srt_CounterpartyNameAxis_abus_GritstoneMember_srt_ProductOrServiceAxis_us-gaap_LicenseMember" decimals="-5" id="Fact-0BB52029F0952A72B12422D283CC1A37" unitRef="usd">1300000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2019Q3QTD" decimals="-3" id="Fact-0054AA77B35D58F695C5A1143217160A" unitRef="usd">3061000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2019Q3QTD_srt_CounterpartyNameAxis_abus_GritstoneMember_srt_ProductOrServiceAxis_us-gaap_RoyaltyMember" decimals="-5" id="Fact-D9D16BB937ABC7C6404F22CD783AEC8D" unitRef="usd">1500000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2019Q3YTD" decimals="-3" id="Fact-61B4B32E30FC5489ACC0E942AA96E72A" unitRef="usd">4393000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2019Q3YTD_srt_CounterpartyNameAxis_abus_GritstoneMember_srt_ProductOrServiceAxis_us-gaap_RoyaltyMember" decimals="-5" id="Fact-8B33F90337449106D98122D269EABAC0" unitRef="usd">1500000</us-gaap:Revenues>
	<us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction contextRef="FD2019Q3QTD_srt_CounterpartyNameAxis_abus_JefferiesLLCMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_abus_OpenMarketSaleAgreementMember" decimals="INF" id="Fact-638EBCC38A664E24B671D4CEA31FA2D9" unitRef="shares">0</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
	<us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction contextRef="FD2019Q3YTD_srt_CounterpartyNameAxis_abus_JefferiesLLCMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_abus_OpenMarketSaleAgreementMember" decimals="INF" id="Fact-E4C3680D8AB05ACF06A6D4CED16A59FF" unitRef="shares">1208090</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
	<us-gaap:ShareBasedCompensation contextRef="FD2018Q3QTD" decimals="-3" id="Fact-6FC83D90CD8E54569919FB683DF85B23" unitRef="usd">1828000</us-gaap:ShareBasedCompensation>
	<us-gaap:ShareBasedCompensation contextRef="FD2018Q3YTD" decimals="-3" id="Fact-0C308E1434AE5D47B67FA78011F854C7" unitRef="usd">5445000</us-gaap:ShareBasedCompensation>
	<us-gaap:ShareBasedCompensation contextRef="FD2019Q3QTD" decimals="-3" id="Fact-7EA0832D2EE35BA7AFA2C16A8E648873" unitRef="usd">1516000</us-gaap:ShareBasedCompensation>
	<us-gaap:ShareBasedCompensation contextRef="FD2019Q3YTD" decimals="-3" id="Fact-A51FBE9C4AF85D00A26A2EE31A6A35A5" unitRef="usd">6822000</us-gaap:ShareBasedCompensation>
	<us-gaap:SharesIssued contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-8761739AD8E85A09966407304BC89508" unitRef="shares">55060650</us-gaap:SharesIssued>
	<us-gaap:SharesIssued contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="INF" id="Fact-AA8B8CFDC8C059CEB92EC457ED868646" unitRef="shares">500000</us-gaap:SharesIssued>
	<us-gaap:SharesIssued contextRef="FI2018Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-61EAA32A77A7547492A1A97D57B9176F" unitRef="shares">55087191</us-gaap:SharesIssued>
	<us-gaap:SharesIssued contextRef="FI2018Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="INF" id="Fact-609841FE99A1558597F9ACA2A2BB9C7D" unitRef="shares">1164000</us-gaap:SharesIssued>
	<us-gaap:SharesIssued contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-09705824174C5FB0AC05F6D6CEDB8912" unitRef="shares">55325250</us-gaap:SharesIssued>
	<us-gaap:SharesIssued contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="INF" id="Fact-4B3A1295AA5557C18E3031B9CF9BF3D9" unitRef="shares">1164000</us-gaap:SharesIssued>
	<us-gaap:SharesIssued contextRef="FI2018Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-CEAEAF1A036DBECB03530709465D70D0" unitRef="shares">55472319</us-gaap:SharesIssued>
	<us-gaap:SharesIssued contextRef="FI2018Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="INF" id="Fact-0CD5E11A00A3428013D9070943B06C6A" unitRef="shares">1164000</us-gaap:SharesIssued>
	<us-gaap:SharesIssued contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-775CF808424E51CCAAC06F11A83BA79C" unitRef="shares">55518800</us-gaap:SharesIssued>
	<us-gaap:SharesIssued contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="INF" id="Fact-3C195DE6E39150759E91A8E809C63EB2" unitRef="shares">1164000</us-gaap:SharesIssued>
	<us-gaap:SharesIssued contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-958C4224139B5020AA6147734F425C62" unitRef="shares">56255804</us-gaap:SharesIssued>
	<us-gaap:SharesIssued contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="INF" id="Fact-A53FE088DA7D52D3834ACE12A0F1B957" unitRef="shares">1164000</us-gaap:SharesIssued>
	<us-gaap:SharesIssued contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-E9F6AD7E6B395B77B86966D1D4980292" unitRef="shares">56850172</us-gaap:SharesIssued>
	<us-gaap:SharesIssued contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="INF" id="Fact-37662BDE6614529CA56CA1B21C3EED55" unitRef="shares">1164000</us-gaap:SharesIssued>
	<us-gaap:SharesIssued contextRef="FI2019Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-601BB2FF21C3C79A1CCD070810787F81" unitRef="shares">56850172</us-gaap:SharesIssued>
	<us-gaap:SharesIssued contextRef="FI2019Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="INF" id="Fact-CFC9DD13AD0FB5CEE6AF07080DDB2E37" unitRef="shares">1164000</us-gaap:SharesIssued>
	<us-gaap:SharesIssued contextRef="I2017Q3Oct31_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredStockMember" decimals="INF" id="Fact-CF15DDC8205054BF9BA681D45D4ABF18" unitRef="shares">1164000</us-gaap:SharesIssued>
	<us-gaap:ShortTermInvestments contextRef="FI2018Q4" decimals="-3" id="Fact-F4A1CE12A54B5C77A65BDCFB49588288" unitRef="usd">87675000</us-gaap:ShortTermInvestments>
	<us-gaap:ShortTermInvestments contextRef="FI2019Q3" decimals="-3" id="Fact-29131C9F16125C77BBE017CA5D36B548" unitRef="usd">0</us-gaap:ShortTermInvestments>
	<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="FD2018Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="INF" id="Fact-ED3651E1DD7258E8B6136046D1424A82" unitRef="shares">664000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
	<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-5019FB850BF2562FB40461B0FAFC5588" unitRef="shares">614401</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
	<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-AAE263053CAC505E92542904D9ADE26E" unitRef="shares">593689</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
	<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="FD2018Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-6192CA5E56DF5F62AA7B7732B8FC1875" unitRef="shares">26541</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="FD2018Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-BD65BED571755E969003A5E36BEB3D6E" unitRef="shares">238059</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="FD2018Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-97A489DC7E2EB2C24F900708F7B5279D" unitRef="shares">147069</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-0AA6E7F2BDF25D449E60E4E269CAB1FF" unitRef="shares">122603</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-C924A3B14CFE532A8269F90C4F36ABD6" unitRef="shares">679</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="D2017Q4Oct01-Oct31_srt_CounterpartyNameAxis_abus_RoivantSciencesLtdMember_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember" decimals="-5" id="Fact-4C2E0D3AC9CC5DEC9047340A23265071" unitRef="usd">116400000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
	<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="FD2018Q1QTD" decimals="-3" id="Fact-4327283F1B10590789990C51F33BCAA2" unitRef="usd">66265000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
	<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="FD2018Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="-3" id="Fact-2020B32EBA105711A4BC2E6DDCD0DC4E" unitRef="usd">66265000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
	<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="FD2019Q1QTD" decimals="-3" id="Fact-E44CCF8A5EC2501D920536A0B2D788DC" unitRef="usd">2248000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
	<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-DB3320D5DF47566EAA07A4FEA3B50F35" unitRef="usd">2248000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
	<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="FD2019Q2QTD" decimals="-3" id="Fact-8E998CC4869155FC937C569C9163F8C3" unitRef="usd">2477000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
	<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-9E849274D9B7520982BB936CE7FB14F2" unitRef="usd">2477000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
	<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="FD2018Q1QTD" decimals="-3" id="Fact-7E65117A84005DFFABDB3EA80EEC165C" unitRef="usd">103000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="FD2018Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-F8605C0F323D54F8B840001A84FAD6D6" unitRef="usd">-77000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="FD2018Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-597953DC05585829BFCAA0D86BD9BA3D" unitRef="usd">180000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="FD2018Q2QTD" decimals="-3" id="Fact-4AB5C5292C3C5910995F907B32D4CC39" unitRef="usd">735000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="FD2018Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-A9F54186AA3B564288969CE97011B327" unitRef="usd">-1168000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="FD2018Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-46A21AB81BF05695ACB7E21098B344D8" unitRef="usd">1903000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="FD2018Q3QTD" decimals="-3" id="Fact-81A551C760FB65AC80BE0708FCE9D432" unitRef="usd">434000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="FD2018Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-D16E3720131E945D39160708FA600426" unitRef="usd">-180000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="FD2018Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-BFD53DD1B6AD7D21148C0708F9104FA7" unitRef="usd">614000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="FD2019Q1QTD" decimals="-3" id="Fact-5D0154098CA95239BF97D51A59E21543" unitRef="usd">288000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-382A67C237255CD08B73335658D0397C" unitRef="usd">-202000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-2D668FA47B6B5D95BD281976EF705054" unitRef="usd">490000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="FD2019Q2QTD" decimals="-3" id="Fact-8079B35AEC765C8D87622CDDE49877F2" unitRef="usd">2000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-7F2EFD7706DE56D284613670155D1A39" unitRef="usd">-1000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-64A32962F5805AAF87B3B9A8AA5E1DC5" unitRef="usd">3000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
	<us-gaap:StockholdersEquity contextRef="FI2017Q4" decimals="-3" id="Fact-14C00BCA08CE56E99F96316B18A4E89F" unitRef="usd">182473000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-3" id="Fact-9E155DDBA6BC5F25B78D3B7199AA46E5" unitRef="usd">-48185000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-641AB88516EB56F1871A331A48BCDBA5" unitRef="usd">42840000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-D1A32D3DC0F9557BB44810F06CC436F1" unitRef="usd">876108000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="-3" id="Fact-6CBE7312495B5741977E99354F8CC2EB" unitRef="usd">49780000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-B8554F9FF6BB5384A0F12DAE2241B650" unitRef="usd">-738070000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2018Q1" decimals="-3" id="Fact-73A59A0A91E05AA29F42310ADFF8C83F" unitRef="usd">232418000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2018Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-3" id="Fact-6997697218E351BCBC65DBDDCA3693BB" unitRef="usd">-48185000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2018Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-BBF67E5F0F185CEA9CF7C948F6AD8A06" unitRef="usd">43769000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2018Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-4AC8A339703B55AAB885CFFC754BB29F" unitRef="usd">876288000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2018Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="-3" id="Fact-C5473ECC5D9A5A6AB8DC11E3824BBEB8" unitRef="usd">118381000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2018Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-47798409E5A1594C84E17BE8797F8804" unitRef="usd">-757835000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2018Q2" decimals="-3" id="Fact-0BE09AF46DBB54CD8E2AE09E8E6F4A07" unitRef="usd">238072000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-3" id="Fact-5E1D8BA5CCE6516E942D36077FF479C3" unitRef="usd">-48185000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-32BF97F42F885B95AE2A980D8976CD39" unitRef="usd">44429000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-E11C3D005C445B30B861D084F0BE904D" unitRef="usd">878191000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="-3" id="Fact-0D7FEEF315015F798A59BCC695E11E0E" unitRef="usd">120922000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-3F66A4F8510354BB95AB2B4DC59D7B3E" unitRef="usd">-757285000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2018Q3" decimals="-3" id="Fact-88258CB98FF2743CE3BC07094CCF1887" unitRef="usd">215272000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2018Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-3" id="Fact-CB6131F9973D77DAFDBA07094B8F255F" unitRef="usd">-48197000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2018Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-B675020C83FF644CFFAB070948F35353" unitRef="usd">45500000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2018Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-B1FF764F8A598596C5DD070947971A5F" unitRef="usd">878805000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2018Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="-3" id="Fact-21CDA1CAD43B59D3DB98070945010EA7" unitRef="usd">123489000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2018Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-0CFF1099B65D98F9F96707094A32BD5E" unitRef="usd">-784325000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2018Q4" decimals="-3" id="Fact-A4FD9D5A455D511EB2C01DCC61152B36" unitRef="usd">200234000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-3" id="Fact-6F89B4226B9E575295D10C507FB4CC44" unitRef="usd">-48170000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-68E32797113354AEAE9A739BFD7DD277" unitRef="usd">48084000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-DD4275F64A8D5C70AD8689205E7388E0" unitRef="usd">879405000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="-3" id="Fact-EFF76440803157268F5E029FA924DF5D" unitRef="usd">126136000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-485FB6AD357F5BDD8DF62859DF948D61" unitRef="usd">-805221000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2019Q1" decimals="-3" id="Fact-3BC0A34536B75B12AEAE633D2F047262" unitRef="usd">181209000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-3" id="Fact-E59B05C5DCD75220AE44E29B269A08EA" unitRef="usd">-48192000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-0BD57A3461955C9490B83D773F8F3A24" unitRef="usd">49594000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-2C62BA6564C45631BE5E1ACF71FCD586" unitRef="usd">882143000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="-3" id="Fact-304B4A397F2C51199A3E070E3121AA03" unitRef="usd">128851000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-B79C898DA30C5D15B529FF5B8087512D" unitRef="usd">-831187000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2019Q2" decimals="-3" id="Fact-691BDF448A455ED28476E40CC735471E" unitRef="usd">164466000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-3" id="Fact-553540EE34975D358CB6DF0F5715CC44" unitRef="usd">-48244000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-402FD650CC845C74A5C95B87854BFD92" unitRef="usd">53738000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-F78F8F4092135FC3ABA586753E2D4F10" unitRef="usd">884623000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="-3" id="Fact-FA0A05F624635F82B1519F16BEBC2586" unitRef="usd">131613000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-FF5A0716C4D85BD3ABCD78851B12B170" unitRef="usd">-857264000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2019Q3" decimals="-3" id="Fact-01509FDCA1AB5CD1A1711BD99F7B4C25" unitRef="usd">83637000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2019Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-3" id="Fact-3BC1FB85A70701BE9300070815ADD7CF" unitRef="usd">-48217000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2019Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-5BA177FE97017056D22007081310AAA9" unitRef="usd">55385000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2019Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-C558AD86D901107EA7AC070811C102B0" unitRef="usd">884623000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2019Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="-3" id="Fact-74AE1A8D61BE4A937B7807080F275C4E" unitRef="usd">134405000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2019Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-FE695E801F40D2CC04CB0708145C7423" unitRef="usd">-942559000</us-gaap:StockholdersEquity>
	<us-gaap:SubleaseIncome contextRef="FD2018Q3YTD" decimals="-5" id="Fact-2EC617633749E9CF385DD4C847B37A9A" unitRef="usd">100000</us-gaap:SubleaseIncome>
	<us-gaap:SubleaseIncome contextRef="FD2019Q3YTD" decimals="-5" id="Fact-DDD26FBC649A3A02BD3DD4C796EC015E" unitRef="usd">200000</us-gaap:SubleaseIncome>
	<us-gaap:UndistributedEarningsLossAvailableToCommonShareholdersBasic contextRef="FD2018Q3QTD_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-F023D45F1E9858EDA22D225474D2575E" unitRef="usd">-27040000</us-gaap:UndistributedEarningsLossAvailableToCommonShareholdersBasic>
	<us-gaap:UndistributedEarningsLossAvailableToCommonShareholdersBasic contextRef="FD2018Q3YTD_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-F8EA06B1A85565247840225474DAED7D" unitRef="usd">-46255000</us-gaap:UndistributedEarningsLossAvailableToCommonShareholdersBasic>
	<us-gaap:UndistributedEarningsLossAvailableToCommonShareholdersBasic contextRef="FD2019Q3QTD_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-82A3578BAD1C373BF93906C70D136AB5" unitRef="usd">-85295000</us-gaap:UndistributedEarningsLossAvailableToCommonShareholdersBasic>
	<us-gaap:UndistributedEarningsLossAvailableToCommonShareholdersBasic contextRef="FD2019Q3YTD_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-C8EA75483E350DCB59C306C70D23C64A" unitRef="usd">-137338000</us-gaap:UndistributedEarningsLossAvailableToCommonShareholdersBasic>
	<us-gaap:VariableLeaseCost contextRef="FD2019Q3YTD" decimals="-5" id="Fact-4A9599CB44B8267D569ED4C511632092" unitRef="usd">200000</us-gaap:VariableLeaseCost>
	<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="FD2018Q3QTD" decimals="0" id="Fact-C4A8841860FC5A7BBF4D58B1AF5EADF2" unitRef="shares">55421504</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
	<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="FD2018Q3QTD_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember" decimals="0" id="Fact-D186A5789A9F077D5885225474D65B91" unitRef="shares">55421504</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
	<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="FD2018Q3YTD" decimals="0" id="Fact-D53531D1F76C5439819DEE524F2E5685" unitRef="shares">55241284</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
	<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="FD2018Q3YTD_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember" decimals="0" id="Fact-6C1C9C43BA1C2A82DBFF225474DD1E3B" unitRef="shares">55241284</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
	<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="FD2019Q3QTD" decimals="0" id="Fact-5138D2E7A8F15C4D813441C716216C5F" unitRef="shares">56850172</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
	<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="FD2019Q3QTD_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember" decimals="0" id="Fact-6EEF7A5BC5421921DEAF06C70D1BF6CA" unitRef="shares">56850172</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
	<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="FD2019Q3YTD" decimals="0" id="Fact-FB4F83E4FD6054C1BCB24336903F6712" unitRef="shares">56469358</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
	<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="FD2019Q3YTD_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember" decimals="0" id="Fact-BDE33991B9979AB9822B06C70D05E9DD" unitRef="shares">56469358</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
	<abus:ChangesInFairValueofLiabilityOptionTableTextBlock contextRef="FD2019Q3YTD" id="Fact-E641097582F95944B291A60A0C0F41AE">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following table presents the changes in fair value of the Company&amp;#8217;s liability-classified stock option awards:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:38%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Liability at beginning of the period&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Fair value of liability-classified options exercised in the period&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Increase (decrease) in fair value of liability&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Liability at end of the period&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;(in thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Nine months ended September 30, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,239&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,499&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,738&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Nine months ended September 30, 2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;479&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(393&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;86&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</abus:ChangesInFairValueofLiabilityOptionTableTextBlock>
	<abus:LiabilitiesRelatedToSaleOfFutureRoyaltiesRollForwardTableTextBlock contextRef="FD2019Q3YTD" id="Fact-826334E215F8567D619602EEB2C9E043">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The table below shows the activity related to the net liability from inception of the Agreement through &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:68%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:30%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Nine Months Ended September 30, 2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;(in thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Net liability related to sale of future royalties - beginning balance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Initial recognition of liability&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;30,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Debt discount and issuance costs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(11,451&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Non-cash royalty revenue&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(979&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Non-cash interest expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,106&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Net liability related to sale of future royalties - ending balance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;18,675&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</abus:LiabilitiesRelatedToSaleOfFutureRoyaltiesRollForwardTableTextBlock>
	<abus:LiabilitiesRelatedToSaleOfFutureRoyaltiesTextBlock contextRef="FD2019Q3YTD" id="Fact-E0F80574D52778B2B07302DB25851BA7">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Sale of future royalties &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:16px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;On July 2, 2019, the Company entered into a Purchase and Sale Agreement (the "Agreement") with the Ontario Municipal Employees Retirement System (or "OMERS"), pursuant to which the Company sold to OMERS part of its royalty interest on future global net sales of ONPATTRO&amp;#8482; (Patisiran) ("ONPATTRO"), an RNA interference therapeutic currently being sold by Alnylam.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;ONPATTRO utilizes Arbutus&amp;#8217; LNP technology, which was licensed to Alnylam pursuant to the Cross-License Agreement, dated November 12, 2012, by and between the Company and Alnylam (the &amp;#8220;LNP License Agreement&amp;#8221;).&amp;#160;Under the terms of the LNP License Agreement, the Company is entitled to tiered royalty payments on global net sales of ONPATTRO ranging from &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.00%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2.33%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; after offsets, with the highest tier applicable to annual net sales above &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$500 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. This royalty interest was sold to OMERS, effective as of January 1, 2019, for &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$20 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; in gross proceeds before advisory fees. OMERS will retain this entitlement until it has received &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$30 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; in royalties, at which point &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;100%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of such royalty interest on future global net sales of ONPATTRO will revert to the Company. OMERS has assumed the risk of collecting up to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$30 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of future royalty payments from Alnylam and Arbutus is not obligated to reimburse OMERS if they fail to collect any such future royalties.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$30 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; in royalties to be paid to OMERS is accounted for as a liability, with the difference between the liability and the gross proceeds received accounted for as a discount. The discount, as well as &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.5 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of transaction costs, will be amortized as interest expense based on the projected balance of the liability as of the beginning of each period. Management estimated an effective annual interest rate of approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;25%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. Over the course of the Agreement, the actual interest rate will be affected by the amount and timing of royalty revenue recognized and changes in the timing of forecasted royalty revenue. On a quarterly basis, the Company will reassess the expected timing of the royalty revenue, recalculate the amortization and effective interest rate and adjust the accounting prospectively as needed. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company will recognize non-cash royalty revenue related to the sales of ONPATTRO during the term of the Agreement. As royalties are remitted to OMERS from Alnylam, the balance of the recognized liability will be effectively repaid over the life of the Agreement. There are a number of factors that could materially affect the amount and timing of royalty payments from Alnylam, none of which are within the Company's control. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;During the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;three and nine months ended September 30, 2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, the Company recognized non-cash royalty revenue of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.1 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of related non-cash interest expense. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The table below shows the activity related to the net liability from inception of the Agreement through &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:68%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:30%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Nine Months Ended September 30, 2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;(in thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Net liability related to sale of future royalties - beginning balance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Initial recognition of liability&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;30,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Debt discount and issuance costs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(11,451&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Non-cash royalty revenue&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(979&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Non-cash interest expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,106&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Net liability related to sale of future royalties - ending balance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;18,675&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In addition to the royalty from the Alnylam LNP License Agreement, the Company is also receiving a second, lower royalty interest on global net sales of ONPATTRO originating from a settlement agreement and subsequent license agreement with Acuitas Therapeutics, Inc. ("Acuitas"). The royalty from Acuitas has been retained by the Company and was not part of the royalty sale to OMERS.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</abus:LiabilitiesRelatedToSaleOfFutureRoyaltiesTextBlock>
	<us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock contextRef="FD2019Q3YTD" id="Fact-DCC903C5C34E552AA1391BAF19234837">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Accounts payable and accrued liabilities&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accounts payable and accrued liabilities are comprised of the following:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:63%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:16%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:16%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;September&amp;#160;30, 2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;(in thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Trade accounts payable&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,400&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,192&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Research and development accruals&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,112&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,716&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Professional fee accruals&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,177&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;871&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Payroll accruals&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,509&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,341&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Other accrued liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;309&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8,199&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9,429&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
	<us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="FD2019Q3YTD" id="Fact-235298A9126D5A939DB4B9CAE2D3585B">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Basis of presentation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;These unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (&amp;#8220;U.S. GAAP&amp;#8221;) for interim financial statements and accordingly, do not include all disclosures required for annual financial statements. These statements should be read in conjunction with the Company&amp;#8217;s audited consolidated financial statements and notes thereto for the year ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; included in the Company&amp;#8217;s Annual Report on Form 10-K for the year ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; (the &amp;#8220;2018 Form 10-K&amp;#8221;). These unaudited condensed consolidated financial statements reflect, in the opinion of management, all adjustments and reclassifications necessary to fairly present the Company's financial position as of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and the Company's results of operations and cash flows for the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;three and nine months ended September 30, 2019 and 2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. The results of operations for the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;three and nine months ended September 30, 2019 and 2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively, are not necessarily indicative of the results for the full year. These unaudited condensed consolidated financial statements follow the same significant accounting policies as those described in the notes to the audited consolidated financial statements of the Company for the year ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, except as described below under Recent Accounting Pronouncements.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
	<us-gaap:CollaborativeArrangementDisclosureTextBlock contextRef="FD2019Q3YTD" id="Fact-D901725F0E995624BBF95090A1AD51CC">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Collaborations, contracts and licensing agreements&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Revenue contracts are described in detail in the Overview section of Part I, Item 2, "Management's Discussion and Analysis of Financial Condition and Results of Operations" in the Company's 2018 Form 10-K. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In 2012, the Company entered into a license agreement with Alnylam that entitles Alnylam to develop and commercialize products with the Company's LNP technology. Alnylam's ONPATTRO program, which represents the first approved application of LNP technology, was approved by the U.S. Food and Drug Administration ("FDA") and the European Medicines Agency ("EMA") during the third quarter of 2018 and was launched immediately upon approval in the US. The Company is entitled to tiered low to mid single-digit royalty payments on global net sales of ONPATTRO and received its first royalty payment in the fourth quarter of 2018. In July 2019, the Company sold a portion of its royalty entitlement for Alnylam's ONPATTRO to OMERS.  See note 9 - Sale of future royalties for further details.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Revenue for the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;three and nine months ended September 30, 2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; consists primarily of a net &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.5 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; development milestone earned under our license agreement with Gritstone, royalties on net global sales of Alnylam's ONPATTRO, a milestone and royalties on net sales of Spectrum Pharmaceuticals, Inc.'s ("Spectrum") Marqibo&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&amp;#174; &lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;and services provided to Gritstone Oncology, Inc. ("Gritstone").  Revenue for the three and nine months ended September 30, 2018 consisted primarily of revenue earned under our license agreement with Gritstone, including a net &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.3 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; development milestone payment, the earned portion of an upfront license fee and services provided to Gritstone.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
	<us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="FD2019Q3YTD" id="Fact-A58AC47CE5BA56BB9B0887704D829820">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Contingencies and commitments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Arbitration with the University of British Columbia &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Certain early work on LNP delivery systems and related inventions was undertaken by the Company and assigned to the University of British Columbia ("UBC"). These inventions were subsequently licensed back to the Company by UBC under a license agreement, initially entered into in 1998 and subsequently amended in 2001, 2006 and 2007. The Company has granted sublicenses under the UBC license to Alnylam. Alnylam has in turn sublicensed back to the Company under the licensed UBC patents for discovery, development and commercialization of siRNA products. Certain sublicenses were also granted to other parties.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;On November 10, 2014, UBC filed a notice of arbitration against the Company and on January 16, 2015, filed a Statement of Claim, which alleged entitlement to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$3.5&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; million in allegedly unpaid royalties based on publicly available information, and an unspecified amount based on non-public information. UBC also sought interest and costs, including legal fees. The Company filed its Statement of Defense to UBC's Statement of Claims, as well as a Counterclaim involving a patent application that the Company alleged UBC wrongly licensed to a third party.  The proceedings were divided into &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;three&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; phases, with the first hearing taking place in June 2017. In the first phase, the arbitrator determined which agreements are sublicense agreements within UBC's claim. Also in the first phase, UBC updated its alleged entitlement from &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$3.5&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; million originally claimed to seek &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$10.9&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; million in alleged unpaid royalties, plus interest arising from payments as early as 2008. The arbitrator also held in the first phase of the arbitration that the patent application that is the subject of the Counterclaim was not required to be licensed to Arbutus.&amp;#160;The second phase of arbitration took place in April 2019. On&amp;#160;August&amp;#160;20, 2019, the arbitrator issued his decision for the second phase of the arbitration, awarding UBC &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$5.9 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, which includes interest of approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$2.6 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. The Company paid the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$5.9 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; award to UBC in September 2019. The arbitrator also held that the third phase of the arbitration, which would address patent validity, should the Company choose to pursue a third phase, would not provide a defense to the award. An award for costs and attorneys&amp;#8217; fees is still to be determined. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:8px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company recorded a charge of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$6.5 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; in the third quarter of 2019, consisting of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$5.9 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; for the award (including interest) and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.6 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; for an estimate of a potential award for costs and attorney's fees. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;License Agreements between Enantigen and Blumberg and Drexel&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In October 2014, Arbutus Inc. acquired all of the outstanding shares of Enantigen Therapeutics, Inc. (&amp;#8220;Enantigen&amp;#8221;) pursuant to a stock purchase agreement. Through this transaction, Arbutus Inc. acquired a HBV surface antigen secretion inhibitor program and a capsid assembly inhibitor program. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Under the stock purchase agreement, Arbutus Inc. agreed to pay up to a total of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$21.0&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; million to Enantigen&amp;#8217;s selling shareholders upon the achievement of specified development and regulatory milestones for (a) the first &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;two&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; products that contain either a capsid compound or an HBV surface antigen compound that is covered by a patent acquired under this agreement, or (b) a capsid compound from an agreed upon list of compounds. The amount paid could be up to an additional &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$102.5 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; in sales performance milestones in connection with the sale of the first commercialized product by Arbutus Inc. for the treatment of HBV, regardless of whether such product is based upon assets acquired under this agreement, and a low single-digit royalty on net sales of such first commercialized HBV product, up to a maximum royalty payment of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; that, if paid, would be offset against Arbutus Inc.'s milestone payment obligations.  The contingent consideration for this acquisition is a financial liability and measured at its fair value at each reporting period, with any changes in fair value from the previous reporting period recorded in the statement of operations and comprehensive loss (see note 3).  The fair value of the contingent consideration was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$3.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; as of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Under the stock purchase agreement, Enantigen must also fulfill its obligations as they relate to the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;three&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; patent license agreements with The Baruch S. Blumberg Institute ("Blumberg") and Drexel University ("Drexel"). Pursuant to each patent license agreement, Enantigen is obligated to pay Blumberg and Drexel up to approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.5&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; million in development and regulatory milestones per licensed product, royalties in the low single-digits, and a percentage of revenue it receives from its sub-licensees.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Research Collaboration and Funding Agreement with Blumberg&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In November 2018, the Company entered into a new &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;two&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;-year master services agreement with Blumberg that expires in November 2020.&amp;#160; The new agreement replaces all rights and obligations of the prior research collaboration and funding agreements, as amended. Under the new agreement, Blumberg will perform specific research activities based upon statements of work and the Company will no longer provide a fixed amount of funding to Blumberg.&amp;#160; As of September 30, 2019, the Company has executed statements of work with Blumberg for an aggregate cost of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.8&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; million under this new agreement.  Intellectual property that is generated during the research activities is the Company's exclusive property and all financial obligations for it to utilize the intellectual property are satisfied in the upfront cost of the research activities.  Under the terms of the new agreement, the Company retains all rights to any inventions arising from performance of the agreement and no license is granted to Blumberg, nor are milestones for said inventions due to Blumberg.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
	<us-gaap:ConsolidationPolicyTextBlock contextRef="FD2019Q3YTD" id="Fact-FCC49AF2417C52148F9249025BFB8B87">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Principles of consolidation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;These unaudited condensed consolidated financial statements include the accounts of the Company and its &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;two&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; wholly-owned subsidiaries, Arbutus Biopharma Inc. ("Arbutus Inc.") and Arbutus Biopharma US Holdings, Inc. All intercompany transactions and balances have been eliminated in consolidation.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
	<us-gaap:EarningsPerSharePolicyTextBlock contextRef="FD2019Q3YTD" id="Fact-C801A1AF9FA15D078B5BFBE899641C2E">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Income or loss per share&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company follows the two-class method when computing net loss attributable to common shareholders per share as the Company has issued Series A participating convertible preferred shares (the "Preferred Shares"), as further described in note 12, that meet the definition of participating securities. The Preferred Shares entitle the holders to participate in dividends but do not require the holders to participate in losses of the Company. Accordingly, if the Company reports a net loss attributable to holders of the Company's common shares, net losses are not allocated to holders of the Preferred Shares. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:8px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Net loss attributable to common shareholders per share is calculated based on the weighted average number of common shares outstanding. The calculation of diluted net loss attributable to common shareholders per share does not differ from the calculation of basic net loss attributable to common shareholders per share, as the effect of the Company&amp;#8217;s dilutive potential common shares was anti-dilutive. During the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;nine months ended September 30, 2019 and 2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, potential common shares of approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;28.2 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;24.2 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively, consisting of the "if-converted" number of Preferred Shares and outstanding stock options, were excluded from the calculation of net loss per common share because their inclusion would be anti-dilutive.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
	<us-gaap:EquityMethodInvestmentsDisclosureTextBlock contextRef="FD2019Q3YTD" id="Fact-2B50354B768355C9A1C2F713014752B0">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt; Equity method investment&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In April 2018, the Company entered into an agreement with Roivant Sciences Ltd. (&amp;#8220;Roivant&amp;#8221;), its largest shareholder, to launch Genevant, a company focused on the discovery, development, and commercialization of a broad range of RNA-based therapeutics enabled by the Company's lipid nanoparticle ("LNP") and ligand conjugate delivery technologies. The Company licensed exclusive rights to its LNP and ligand conjugate delivery platforms to Genevant for RNA-based applications outside of HBV. Genevant plans to develop products in-house and pursue industry partnerships to build a diverse pipeline of therapeutics across multiple modalities, including RNAi, mRNA, and gene editing. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Under the terms of the agreement, Roivant contributed $&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;37.5&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; million in seed capital to Genevant.  The Company retained all rights to its LNP and conjugate delivery platforms for HBV, and is entitled to a tiered low single-digit royalty from Genevant on future sales of products enabled by the delivery platforms licensed to Genevant. The Company also retained the entirety of its royalty entitlement on the commercialization of Alnylam Pharmaceuticals Inc.'s ("Alnylam") ONPATTRO&amp;#8482; (Patisiran/ALN-TTR02).  The Company recognized a non-cash gain of&amp;#160;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$24.9 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; in the second quarter of 2018 in connection with the equity interest received by Arbutus upon Genevant&amp;#8217;s formation.  &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;As of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, the Company held an equity interest of approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;40%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of the common equity of Genevant and accounts for its interest in Genevant using the equity method.  The carrying value of the Company's interest in Genevant as of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$11.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.  The basis difference between the Company&amp;#8217;s carrying value in Genevant and the Company&amp;#8217;s share of Genevant's net assets is attributed primarily to indefinite-lived in-process research and development ("IPR&amp;amp;D") (the delivery technology transferred to Genevant).  For the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;three and nine months ended September 30, 2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, the Company recorded equity investment losses of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$3.5 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$11.5 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively, for its proportionate share of Genevant&amp;#8217;s net loss, recorded on a one-quarter lag basis.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:EquityMethodInvestmentsDisclosureTextBlock>
	<us-gaap:EquityMethodInvestmentsPolicy contextRef="FD2019Q3YTD" id="Fact-CABB6F890A455AFAAADA2F79FB90FC98">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Equity method investment&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company accounts for its investment in associated companies in accordance with the Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC") 323, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Investments - Equity Method and Joint Ventures &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;("ASC&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt; &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;323").  In accordance with ASC 323, associated companies are accounted for as equity method investments. Results of associated companies are presented on a one-line basis. Investments in, and advances to, associated companies are presented on a one-line basis in the caption &amp;#8220;Investment in Genevant&amp;#8221; in the Company's Condensed Consolidated Balance Sheets, net of allowance for losses, which represents the Company's best estimate of probable losses inherent in such assets.  The Company's proportionate share of any associated companies' net income or loss is presented on a one-line basis in the caption "Equity investment (loss)" in the Company's Condensed Consolidated Statement of Operations.  Transactions between the Company and any associated companies are eliminated on a basis proportional to the Company's ownership interest.  Financial results of Genevant Sciences Ltd. ("Genevant") are recorded on a one-quarter lag basis. &lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:EquityMethodInvestmentsPolicy>
	<us-gaap:FairValueDisclosuresTextBlock contextRef="FD2019Q3YTD" id="Fact-48795912D51A5002BA50CB5E111781FF">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Fair value of financial instruments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company measures certain financial instruments and other items at fair value.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;To determine the fair value, the Company uses the fair value hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs market participants would use to value an asset or liability and are developed based on market data obtained from independent sources. Unobservable inputs are inputs based on assumptions about the factors market participants would use to value an asset or liability. The three levels of inputs that may be used to measure fair value are as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:72px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:36px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Level 1 inputs are quoted market prices for identical instruments available in active markets.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:72px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:36px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Level 2 inputs are inputs other than quoted prices included within Level 1 that are observable for the asset or liability either directly or indirectly. If the asset or liability has a contractual term, the input must be observable for substantially the full term. An example includes quoted market prices for similar assets or liabilities in active markets.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:72px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:36px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Level 3 inputs are unobservable inputs for the asset or liability and will reflect management&amp;#8217;s assumptions about market assumptions that would be used to price the asset or liability.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following table presents information about the Company&amp;#8217;s assets and liabilities that are measured at fair value on a recurring basis, and indicates the fair value hierarchy of the valuation techniques used to determine such fair value:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Level 1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Level 2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Level 3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;As of September 30, 2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;(in thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Cash and cash equivalents&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;90,082&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;90,082&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Liability-classified options&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;86&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;86&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Contingent consideration&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,005&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,005&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,091&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,091&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.8046875%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Level 1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Level 2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Level 3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;As of December 31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;(in thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Cash and cash equivalents&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;36,942&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;36,942&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Short-term investments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;87,675&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;87,675&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;124,617&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;124,617&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Liability-classified stock option awards&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;479&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;479&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Contingent consideration&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,126&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,126&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,605&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,605&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company's liability-classified options are measured at fair value using the Black-Scholes valuation model. Assumptions about the Company's expected stock-price volatility are based on the historical volatility of the Company's publicly-traded stock. The risk-free interest rate used for each grant is equal to the zero coupon rate for instruments with a similar expected life. The assumptions around the expected life are based on the Company's historical data. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;To determine the fair value of the contingent consideration, the Company uses a probability-weighted assessment of the likelihood the milestones would be met and the estimated timing of such payments (see note 10). The potential contingent payments are then discounted to their present value using a probability-adjusted discount rate that reflects the early-stage nature of the development program, time to complete the program development, and overall biotech indices. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following table presents the changes in fair value of the Company&amp;#8217;s liability-classified stock option awards:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:38%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Liability at beginning of the period&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Fair value of liability-classified options exercised in the period&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Increase (decrease) in fair value of liability&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Liability at end of the period&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;(in thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Nine months ended September 30, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,239&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,499&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,738&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Nine months ended September 30, 2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;479&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(393&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;86&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following table presents the changes in fair value of the Company&amp;#8217;s contingent consideration: &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:38%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:18%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:18%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:18%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Liability at beginning of the period&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Increase (decrease) in fair value of liability&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Liability at end of the period&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;(in thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Nine months ended September 30, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;10,424&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(6,263&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,161&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Nine months ended September 30, 2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,126&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(121&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,005&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
	<us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="FD2019Q3YTD" id="Fact-1914F64D574957D281D68F5F7B360AB9">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Fair value of financial instruments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company measures certain financial instruments and other items at fair value.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;To determine the fair value, the Company uses the fair value hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs market participants would use to value an asset or liability and are developed based on market data obtained from independent sources. Unobservable inputs are inputs based on assumptions about the factors market participants would use to value an asset or liability. The three levels of inputs that may be used to measure fair value are as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:72px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:36px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Level 1 inputs are quoted market prices for identical instruments available in active markets.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:72px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:36px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Level 2 inputs are inputs other than quoted prices included within Level 1 that are observable for the asset or liability either directly or indirectly. If the asset or liability has a contractual term, the input must be observable for substantially the full term. An example includes quoted market prices for similar assets or liabilities in active markets.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:72px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:36px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Level 3 inputs are unobservable inputs for the asset or liability and will reflect management&amp;#8217;s assumptions about market assumptions that would be used to price the asset or liability.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
	<us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock contextRef="FD2019Q3YTD" id="Fact-0E4463AC8DB5509C8A58E96C9FA34F5A">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt; Intangible assets and goodwill&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Acquired IPR&amp;amp;D intangible assets relate to the Company's covalently closed circular DNA ("cccDNA") program.  During the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;three months ended September 30, 2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, the Company recorded a &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$43.8 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; non-cash impairment expense to reduce the carrying value of its IPR&amp;amp;D intangible assets to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;zero&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; as of September 30, 2019.  The Company also recognized a corresponding income tax benefit of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$12.7 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; related to the decrease in its deferred tax liability related to the IPR&amp;amp;D intangible assets.  The impairment was due to a decision to delay indefinitely the further development of the Company's cccDNA program while the Company focuses on its other development programs. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Goodwill represents the excess of purchase price over the value assigned to the net tangible and identifiable intangible assets in connection with the business combination that formed Arbutus.  In the third quarter of 2019, the Company assessed the changes in circumstances that occurred during the quarter to determine if it was more likely than not that the fair value of its single reporting unit was below its carrying amount.  Although the Company's annual impairment test is performed during the fourth quarter, the Company performs this qualitative assessment each interim reporting period.  Due to a sustained decrease in the Company's share price in recent months, the Company's market capitalization was reduced below the book value of its net assets and the Company concluded that the fair value of its single reporting unit was below its carrying amount by an amount in excess of the carrying value of the goodwill.  As a result, the Company recorded a &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$22.5 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; non-cash impairment expense to reduce the carrying value of its goodwill asset to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;zero&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; as of September 30, 2019.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
	<us-gaap:LeaseCostTableTextBlock contextRef="FD2019Q3YTD" id="Fact-49692CC41CBF5F7CAAE974D520874026">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:8px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Weighted average remaining lease term and discount rate were as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:8px;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="2" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:76%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:24%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;As of September 30, 2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Weighted-average remaining lease term (years)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Weighted average discount rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8.9%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company did not include options to extend its lease terms as part of its ROU asset and lease liabilities. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:20px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Supplemental cash flow information related to the Company's operating leases was as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:68%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Nine Months Ended September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;(in thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Cash paid for amounts included in the measurement of lease liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;921&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
	<us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="FD2019Q3YTD" id="Fact-43F8B3768EB45CD883C217CC48D739F9">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Maturities of lease liabilities were as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:78%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:20%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;As of September 30, 2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;(in thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;October through December 2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;188&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;657&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2021&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;677&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2022&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;581&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2023&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;598&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Thereafter&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,039&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total Lease Payments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,740&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Less: interest&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1,268&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Present value of lease payments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,472&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
	<us-gaap:LesseeOperatingLeasesTextBlock contextRef="FD2019Q3YTD" id="Fact-53F9152432145AA9BF9AB462452541F2">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Leases&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company has &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;two&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; operating leases for office and laboratory space.  The Company's corporate headquarters is located at 701 Veterans Circle, Warminster, Pennsylvania.  The lease expires on April 30, 2027, and the Company has the option of extending the lease for &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;two&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; further &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;five&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;-year terms.  The Company also leases office space located at 626 Jacksonville Rd, Warminster, Pennsylvania under a lease that expires on December 31, 2021, and the Company has an option to extend the lease term to April 30, 2027.  In connection with the Company's site consolidation in 2018, the Company ceased using its office and laboratory space located in Burnaby, British Columbia, Canada on June 30, 2018. The Company subleased a portion of the Burnaby facility to various tenants, including Genevant, until the lease expired on July 31, 2019.  The Company recognized the remaining lease payments for the Burnaby facility, less sublease income under contract, in site consolidation expenses in 2018. The Company&amp;#8217;s lease agreements do not contain any material residual value guarantees or material restrictive covenants.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company adopted ASU No. 2016-02, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Leases&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; (Topic 842) on January 1, 2019 using the modified retrospective basis applied at the effective date of the new standard and elected to utilize a package of practical expedients.  Leases with an initial term of 12 months or less are not recorded on the balance sheet. The Company determines if an arrangement is a lease at inception. Right-of-use assets represent the Company's right to use an underlying asset for the lease term and lease liabilities represent the Company's obligation to make lease payments arising from the lease. Operating lease right-of-use assets and lease liabilities are recognized based on the present value of lease payments over the lease term. The leases do not provide an implicit rate so, in determining the present value of lease payments, the Company utilized its incremental borrowing rate for the applicable lease, which was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9.0%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; for the 701 Veterans Circle lease, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7.6%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; for the 626 Jacksonville Rd. lease and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5.0%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; for the Burnaby lease. The Company recognizes lease expense on a straight-line basis over the remaining lease term.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;During the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;nine months ended September 30, 2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, the Company incurred total operating lease expenses of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.1 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, which included lease expenses associated with fixed lease payments of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.9 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, and variable payments associated with common area maintenance and similar expenses of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.2 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. For the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;nine months ended September 30, 2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, the straight-line fixed expense for leases was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.9 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. Sublease income for the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;nine months ended September 30, 2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.2 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, versus &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.1 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; for the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;nine months ended September 30, 2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:8px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Weighted average remaining lease term and discount rate were as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:8px;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="2" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:76%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:24%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;As of September 30, 2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Weighted-average remaining lease term (years)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Weighted average discount rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8.9%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company did not include options to extend its lease terms as part of its ROU asset and lease liabilities. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:20px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Supplemental cash flow information related to the Company's operating leases was as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:68%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Nine Months Ended September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;(in thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Cash paid for amounts included in the measurement of lease liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;921&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Maturities of lease liabilities were as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:78%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:20%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;As of September 30, 2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;(in thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;October through December 2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;188&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;657&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2021&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;677&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2022&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;581&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2023&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;598&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Thereafter&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,039&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total Lease Payments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,740&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Less: interest&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1,268&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Present value of lease payments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,472&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
	<us-gaap:NatureOfOperations contextRef="FD2019Q3YTD" id="Fact-751EE6AA793B5D779E6EFDA8E5AC7340">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Nature of business and future operations&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Arbutus Biopharma Corporation (the &amp;#8220;Company&amp;#8221; or &amp;#8220;Arbutus&amp;#8221;) is a biopharmaceutical business dedicated to discovering, developing, and commercializing a cure for patients suffering from chronic hepatitis B infection, a disease of the liver caused by the hepatitis B virus (&amp;#8220;HBV&amp;#8221;). To pursue its strategy of developing a curative combination regimen, the Company has assembled a pipeline of multiple drug candidates with differing and complementary mechanisms of action targeting HBV.  These include  AB-729, the Company's subcutaneously-delivered RNA interference ("RNAi") therapeutic candidate currently in a Phase 1a/1b clinical trial, AB-452, the Company's lead oral HBV RNA destabilizer candidate currently in pre-clinical testing, next-generation oral capsid inhibitor compounds, and compounds that inhibit PD-L1. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The success of the Company is dependent on obtaining the necessary regulatory approvals to bring its products to market and achieving profitable operations. The Company's research and development activities and commercialization of its products are dependent on its ability to successfully complete these activities and to obtain adequate financing through a combination of financing activities and operations. It is not possible to predict either the outcome of the Company's existing or future research and development programs or the Company&amp;#8217;s ability to continue to fund these programs in the future.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:NatureOfOperations>
	<us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="FD2019Q3YTD" id="Fact-9017E64D9BAE5554A21428A486337F0A">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Recent accounting pronouncements&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies that are adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on the Company's financial position or results of operations upon adoption.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company adopted Accounting Standard Update (&amp;#8220;ASU&amp;#8221;) No. 2016-02, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Leases&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; (Topic 842), as of January 1, 2019, using the modified retrospective approach with the effective date transition method (note 5). Accordingly, all periods prior to adoption are presented in accordance with legacy accounting and the Company recorded no retrospective adjustments to the comparative periods presented. In addition, the Company elected the package of practical expedients permitted under the transition guidance within ASC 842, which among other things, allowed the Company to carry forward its historical lease classification. In addition, the Company elected the short term exemption, which allows entities to not capitalize their leases with a term of 12 months or less. Adoption of the new standard resulted in the recording of operating lease right-of-use assets (&amp;#8220;ROU assets&amp;#8221;) and lease liabilities of approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$3.2 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$4.1 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively, as of January 1, 2019.  The standard did not materially impact the Company&amp;#8217;s consolidated statements of operations and statements of cash flow.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In November 2018, the FASB issued targeted amendments to ASU No. 2018-18, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Collaborative Arrangements &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(Topic 808), and ASU No. 2016-10, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Revenue from Contracts with Customers &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(Topic 606), to clarify that certain transactions between parties to collaborative arrangements should be accounted for in accordance with FASB revenue guidance when the counterparty is a customer. This guidance also prohibits the presentation of collaborative arrangements as revenues from contracts with customers if the counterparty is not a customer. This guidance, which is required to be applied retrospectively&amp;#160;and is effective for interim and annual periods beginning after December 15, 2019, with early adoption permitted, is not expected to have a material impact on the Company&amp;#8217;s consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
	<us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="FD2019Q3YTD" id="Fact-DF4BAAE12CB6584C848D382F9BFBA995">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Related Party Transactions&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Through the first quarter of 2019, the Company purchased certain research and development services from Genevant.  These services were billed at agreed hourly rates and were reflective of market rates for such services.&amp;#160; The total cost of these services for the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;nine months ended September 30, 2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$33 thousand&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.  There were &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;no&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; such costs incurred during the second and third quarter of 2019. The total cost of these services was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.1 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.2 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; for the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;three and nine months ended September 30, 2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively, and are included in the Condensed Consolidated Statements of Operations under research and development. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Conversely, Genevant purchased certain administrative and transitional services from the Company totaling &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$40 thousand&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$284 thousand&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; for the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;three and nine months ended September 30, 2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively. The total income from these services was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.1 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.3 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; for the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;three and nine months ended September 30, 2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, which were netted against research and development expenses in the Condensed Consolidated Statements of Operations. In addition, Genevant had a sublease for &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;17,900&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; square feet in the Company's Burnaby facility. Sublease income from Genevant was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$21 thousand&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.1 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; for the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;three and nine months ended September 30, 2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively, and was netted against site consolidation costs and lease liability (see notes 7 and 8).  The Company&amp;#8217;s Burnaby facility lease and the corresponding sublease to Genevant expired on July 31, 2019.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
	<us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock contextRef="FD2019Q3YTD" id="Fact-3096B9904CA15806B0F17BBD8CA4CEB5">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Site consolidation &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In 2018, the Company substantially completed a site consolidation and organizational restructuring to align its HBV business in Warminster, PA, including a reduction of its global workforce and closure of its Burnaby facility. The Company estimates that the total expenses to complete the site consolidation will be approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$5.0&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; million, of which &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$4.8 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; has been incurred as of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.  Included in the site consolidation plan was the payment of one-time employee termination benefits, employee relocation costs, and site closure costs.  The Company ceased using its Burnaby facility as of June 30, 2018 and recognized the remaining committed cost, less sublease income under contract, in site consolidation expenses in 2018.  The lease for the Burnaby facility expired on July 31, 2019.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Site consolidation expenses were as follows: &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:41%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Three Months Ended September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Nine Months Ended September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;(in thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Employee severance and relocation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;231&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;198&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;429&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,399&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Facility and other expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(49&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(690&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(396&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;311&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total site consolidation expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;182&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(492&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;33&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,710&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Site consolidation activity was as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:58%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Employee severance and relocation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Facility and other expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;(in thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Site consolidation accrual as of December 31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;697&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;634&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,331&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Additional accruals and other adjustments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;429&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(396&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;33&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Payments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(923&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(238&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1,161&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Site consolidation accrual as of September 30, 2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;203&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;203&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock>
	<us-gaap:RevenueFromContractWithCustomerPolicyTextBlock contextRef="FD2019Q3YTD" id="Fact-FAEDCC07D9AC5202B923A3927A69D40F">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Revenue recognition &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company recognizes the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers under a five-step model: (i) identify contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when or as a performance obligation is satisfied. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company generates revenue primarily through collaboration agreements and license agreements. Such agreements may require the Company to deliver various rights and/or services, including intellectual property rights or licenses and research and development services. Under such agreements, the Company is generally eligible to receive non-refundable upfront payments, funding for research and development services, milestone payments, and royalties.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In contracts where the Company has more than one performance obligation to provide its customer with goods or services, each performance obligation is evaluated to determine whether it is distinct based on whether (i) the customer can benefit from the good or service either on its own or together with other resources that are readily available and (ii) the good or service is separately identifiable from other promises in the contract. The consideration under the contract is then allocated between the distinct performance obligations based on their respective relative stand-alone selling prices. The estimated stand-alone selling price of each deliverable reflects the Company's best estimate of what the selling price would be if the deliverable was regularly sold on a stand-alone basis and is determined by reference to market rates for the good or service when sold to others or by using an adjusted market assessment approach if the selling price on a stand-alone basis is not available. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The consideration allocated to each distinct performance obligation is recognized as revenue when control is transferred to the customer for the related goods or services. Consideration associated with at-risk substantive performance milestones, including sales-based milestones, is recognized as revenue when it is probable that a significant reversal of the cumulative revenue recognized will not occur. Sales-based royalties received in connection with licenses of intellectual property are subject to a specific exception in the revenue standards, whereby the consideration is not included in the transaction price and recognized in revenue until the customer&amp;#8217;s subsequent sales or usages occur.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
	<us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock contextRef="FD2019Q3YTD" id="Fact-DA860A8A4BDA5924A265C9A1884E407F">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accounts payable and accrued liabilities are comprised of the following:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:63%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:16%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:16%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;September&amp;#160;30, 2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;(in thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Trade accounts payable&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,400&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,192&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Research and development accruals&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,112&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,716&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Professional fee accruals&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,177&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;871&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Payroll accruals&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,509&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,341&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Other accrued liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;309&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8,199&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9,429&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
	<us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock contextRef="FD2019Q3YTD" id="Fact-866609BCB5B05FE99DAFAF3CFE51B031">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following table presents the changes in fair value of the Company&amp;#8217;s contingent consideration: &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:38%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:18%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:18%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:18%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Liability at beginning of the period&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Increase (decrease) in fair value of liability&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Liability at end of the period&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;(in thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Nine months ended September 30, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;10,424&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(6,263&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,161&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Nine months ended September 30, 2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,126&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(121&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,005&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock>
	<us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="FD2019Q3YTD" id="Fact-3635AD473B40595CA1A895B81DF67D6C">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following table sets out the computation of basic and diluted net loss attributable to common shareholders per share:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:41%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Three Months Ended September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Nine Months Ended September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;(in thousands, except share and per share amounts)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Numerator:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Allocation of distributable earnings&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Allocation of undistributable loss&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(85,295&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(27,040&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(137,338&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(46,255&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Allocation of loss attributed to common shareholders&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(85,295&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(27,040&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(137,338&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(46,255&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Denominator:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Weighted average number of common shares - basic and diluted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;56,850,172&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;55,421,504&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;56,469,358&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;55,241,284&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Basic and diluted net loss attributable to common shareholders per share&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1.50&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(0.49&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(2.43&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(0.84&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
	<us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="FD2019Q3YTD" id="Fact-05A8964E20A75CBC99E0612BD62CA9B7">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following table presents information about the Company&amp;#8217;s assets and liabilities that are measured at fair value on a recurring basis, and indicates the fair value hierarchy of the valuation techniques used to determine such fair value:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Level 1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Level 2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Level 3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;As of September 30, 2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;(in thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Cash and cash equivalents&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;90,082&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;90,082&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Liability-classified options&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;86&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;86&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Contingent consideration&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,005&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,005&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,091&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,091&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
	<us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock contextRef="FD2019Q3YTD" id="Fact-38D9D40A9D0E59619184171C26F1DDD3">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Site consolidation expenses were as follows: &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:41%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Three Months Ended September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Nine Months Ended September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;(in thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Employee severance and relocation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;231&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;198&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;429&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,399&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Facility and other expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(49&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(690&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(396&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;311&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total site consolidation expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;182&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(492&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;33&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,710&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Site consolidation activity was as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:58%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Employee severance and relocation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Facility and other expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;(in thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Site consolidation accrual as of December 31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;697&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;634&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,331&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Additional accruals and other adjustments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;429&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(396&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;33&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Payments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(923&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(238&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1,161&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Site consolidation accrual as of September 30, 2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;203&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;203&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock>
	<us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="FD2019Q3YTD" id="Fact-DC5B08C13C0FBC6D4B7D2258334B2F67">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Segment information&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company operates as a single segment. &lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
	<us-gaap:SignificantAccountingPoliciesTextBlock contextRef="FD2019Q3YTD" id="Fact-8F7C0403FC9254A2A79AE1DF7766414C">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Significant accounting policies&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Basis of presentation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;These unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (&amp;#8220;U.S. GAAP&amp;#8221;) for interim financial statements and accordingly, do not include all disclosures required for annual financial statements. These statements should be read in conjunction with the Company&amp;#8217;s audited consolidated financial statements and notes thereto for the year ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; included in the Company&amp;#8217;s Annual Report on Form 10-K for the year ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; (the &amp;#8220;2018 Form 10-K&amp;#8221;). These unaudited condensed consolidated financial statements reflect, in the opinion of management, all adjustments and reclassifications necessary to fairly present the Company's financial position as of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and the Company's results of operations and cash flows for the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;three and nine months ended September 30, 2019 and 2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. The results of operations for the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;three and nine months ended September 30, 2019 and 2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively, are not necessarily indicative of the results for the full year. These unaudited condensed consolidated financial statements follow the same significant accounting policies as those described in the notes to the audited consolidated financial statements of the Company for the year ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, except as described below under Recent Accounting Pronouncements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Principles of consolidation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;These unaudited condensed consolidated financial statements include the accounts of the Company and its &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;two&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; wholly-owned subsidiaries, Arbutus Biopharma Inc. ("Arbutus Inc.") and Arbutus Biopharma US Holdings, Inc. All intercompany transactions and balances have been eliminated in consolidation.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Income or loss per share&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company follows the two-class method when computing net loss attributable to common shareholders per share as the Company has issued Series A participating convertible preferred shares (the "Preferred Shares"), as further described in note 12, that meet the definition of participating securities. The Preferred Shares entitle the holders to participate in dividends but do not require the holders to participate in losses of the Company. Accordingly, if the Company reports a net loss attributable to holders of the Company's common shares, net losses are not allocated to holders of the Preferred Shares. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:8px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Net loss attributable to common shareholders per share is calculated based on the weighted average number of common shares outstanding. The calculation of diluted net loss attributable to common shareholders per share does not differ from the calculation of basic net loss attributable to common shareholders per share, as the effect of the Company&amp;#8217;s dilutive potential common shares was anti-dilutive. During the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;nine months ended September 30, 2019 and 2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, potential common shares of approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;28.2 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;24.2 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively, consisting of the "if-converted" number of Preferred Shares and outstanding stock options, were excluded from the calculation of net loss per common share because their inclusion would be anti-dilutive. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following table sets out the computation of basic and diluted net loss attributable to common shareholders per share:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:41%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Three Months Ended September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Nine Months Ended September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;(in thousands, except share and per share amounts)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Numerator:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Allocation of distributable earnings&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Allocation of undistributable loss&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(85,295&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(27,040&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(137,338&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(46,255&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Allocation of loss attributed to common shareholders&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(85,295&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(27,040&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(137,338&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(46,255&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Denominator:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Weighted average number of common shares - basic and diluted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;56,850,172&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;55,421,504&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;56,469,358&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;55,241,284&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Basic and diluted net loss attributable to common shareholders per share&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1.50&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(0.49&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(2.43&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(0.84&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Equity method investment&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company accounts for its investment in associated companies in accordance with the Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC") 323, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Investments - Equity Method and Joint Ventures &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;("ASC&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt; &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;323").  In accordance with ASC 323, associated companies are accounted for as equity method investments. Results of associated companies are presented on a one-line basis. Investments in, and advances to, associated companies are presented on a one-line basis in the caption &amp;#8220;Investment in Genevant&amp;#8221; in the Company's Condensed Consolidated Balance Sheets, net of allowance for losses, which represents the Company's best estimate of probable losses inherent in such assets.  The Company's proportionate share of any associated companies' net income or loss is presented on a one-line basis in the caption "Equity investment (loss)" in the Company's Condensed Consolidated Statement of Operations.  Transactions between the Company and any associated companies are eliminated on a basis proportional to the Company's ownership interest.  Financial results of Genevant Sciences Ltd. ("Genevant") are recorded on a one-quarter lag basis.    &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Revenue recognition &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company recognizes the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers under a five-step model: (i) identify contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when or as a performance obligation is satisfied. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company generates revenue primarily through collaboration agreements and license agreements. Such agreements may require the Company to deliver various rights and/or services, including intellectual property rights or licenses and research and development services. Under such agreements, the Company is generally eligible to receive non-refundable upfront payments, funding for research and development services, milestone payments, and royalties.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In contracts where the Company has more than one performance obligation to provide its customer with goods or services, each performance obligation is evaluated to determine whether it is distinct based on whether (i) the customer can benefit from the good or service either on its own or together with other resources that are readily available and (ii) the good or service is separately identifiable from other promises in the contract. The consideration under the contract is then allocated between the distinct performance obligations based on their respective relative stand-alone selling prices. The estimated stand-alone selling price of each deliverable reflects the Company's best estimate of what the selling price would be if the deliverable was regularly sold on a stand-alone basis and is determined by reference to market rates for the good or service when sold to others or by using an adjusted market assessment approach if the selling price on a stand-alone basis is not available. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The consideration allocated to each distinct performance obligation is recognized as revenue when control is transferred to the customer for the related goods or services. Consideration associated with at-risk substantive performance milestones, including sales-based milestones, is recognized as revenue when it is probable that a significant reversal of the cumulative revenue recognized will not occur. Sales-based royalties received in connection with licenses of intellectual property are subject to a specific exception in the revenue standards, whereby the consideration is not included in the transaction price and recognized in revenue until the customer&amp;#8217;s subsequent sales or usages occur.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Segment information&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company operates as a single segment. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Recent accounting pronouncements&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies that are adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on the Company's financial position or results of operations upon adoption.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company adopted Accounting Standard Update (&amp;#8220;ASU&amp;#8221;) No. 2016-02, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Leases&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; (Topic 842), as of January 1, 2019, using the modified retrospective approach with the effective date transition method (note 5). Accordingly, all periods prior to adoption are presented in accordance with legacy accounting and the Company recorded no retrospective adjustments to the comparative periods presented. In addition, the Company elected the package of practical expedients permitted under the transition guidance within ASC 842, which among other things, allowed the Company to carry forward its historical lease classification. In addition, the Company elected the short term exemption, which allows entities to not capitalize their leases with a term of 12 months or less. Adoption of the new standard resulted in the recording of operating lease right-of-use assets (&amp;#8220;ROU assets&amp;#8221;) and lease liabilities of approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$3.2 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$4.1 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively, as of January 1, 2019.  The standard did not materially impact the Company&amp;#8217;s consolidated statements of operations and statements of cash flow.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In November 2018, the FASB issued targeted amendments to ASU No. 2018-18, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Collaborative Arrangements &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(Topic 808), and ASU No. 2016-10, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Revenue from Contracts with Customers &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(Topic 606), to clarify that certain transactions between parties to collaborative arrangements should be accounted for in accordance with FASB revenue guidance when the counterparty is a customer. This guidance also prohibits the presentation of collaborative arrangements as revenues from contracts with customers if the counterparty is not a customer. This guidance, which is required to be applied retrospectively&amp;#160;and is effective for interim and annual periods beginning after December 15, 2019, with early adoption permitted, is not expected to have a material impact on the Company&amp;#8217;s consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
	<us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="FD2019Q3YTD" id="Fact-ADC9DE8B51CF52269F780A0A167AD7E3">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;  Stockholders' equity and stock-based compensation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:8px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Open Market Sale Agreement&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In December&amp;#160;2018, the Company entered into an Open Market Sale Agreement&amp;#160;(&amp;#8220;Sale Agreement&amp;#8221;) with Jefferies LLC, under which it may issue and sell common shares, from time to time, for an aggregate sales price of up to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$50.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. For the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;nine months ended September 30, 2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, the Company issued &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,208,090&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; common shares pursuant to the Sale Agreement, resulting in gross proceeds of approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$5.2 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. There were &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;no&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares issued during the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;three months ended September 30, 2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; under the Sale Agreement.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Series A participating convertible preferred shares &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In October 2017, the Company entered into a subscription agreement with Roivant for the sale of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,164,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; Preferred Shares for gross proceeds of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$116.4&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;million. These Preferred Shares are non-voting and accrue an &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8.75%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per annum coupon in the form of additional Preferred Shares, compounded annually, until October 16, 2021, at which time all the Preferred Shares will be subject to mandatory conversion into common shares (subject to limited exceptions in the event of certain fundamental corporate transactions relating to Arbutus&amp;#8217; capital structure or assets, which would permit earlier conversion at Roivant&amp;#8217;s option). The conversion price is &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$7.13&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;per share, which will result in the Preferred Shares being converted into approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;23&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; million common shares. After conversion of the Preferred Shares into common shares, based on the number of common shares outstanding &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;as of September 30, 2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, Roivant would hold&amp;#160;approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;49%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of the Company's common shares. Roivant agreed to a &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;four&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; year lock-up period for this investment and its existing holdings in the Company. Roivant also agreed to a &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;four&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; year standstill whereby Roivant will not acquire greater than&amp;#160;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;49.99%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;of the Company's common shares or securities convertible into common shares. The initial investment of&amp;#160;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$50.0&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;million closed in October 2017, and the remaining amount of&amp;#160;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$66.4&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; million closed in January 2018 following regulatory and shareholder approvals.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company records the Preferred Shares wholly as equity under ASC 480, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Distinguishing Liabilities From Equity,&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; with no bifurcation of conversion feature from the host contract, given that the Preferred Shares cannot be cash settled and the redemption features are within the Company's control, which include a fixed conversion ratio with predetermined timing and proceeds. The Company accrues for the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8.75%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per annum compounding coupon at each reporting period end date as an increase to preferred share capital, and an increase to deficit (see Condensed Consolidated Statement of Stockholders' Equity).&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
	<link:footnoteLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
	</link:footnoteLink>
</xbrli:xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>9
<FILENAME>abus-20190930.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<xsd:schema attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://arbutusbio.com/20190930" xmlns:abus="http://arbutusbio.com/20190930" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <xsd:import namespace="http://fasb.org/srt/2018-01-31" schemaLocation="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-gaap/2018-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-roles/2018-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2018/elts/us-roles-2018-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-types/2018-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2018/elts/us-types-2018-01-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/country/2017-01-31" schemaLocation="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/currency/2017-01-31" schemaLocation="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2018-01-31" schemaLocation="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/exch/2018-01-31" schemaLocation="https://xbrl.sec.gov/exch/2018/exch-2018-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/invest/2013-01-31" schemaLocation="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/naics/2017-01-31" schemaLocation="http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/sic/2011-01-31" schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/stpr/2018-01-31" schemaLocation="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="abus-20190930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="abus-20190930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="abus-20190930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="abus-20190930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple" />
      <link:roleType id="AccountsPayableAndAccruedLiabilities" roleURI="http://arbutusbio.com/role/AccountsPayableAndAccruedLiabilities">
        <link:definition>2107100 - Disclosure - Accounts Payable and Accrued Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccountsPayableAndAccruedLiabilitiesDetails" roleURI="http://arbutusbio.com/role/AccountsPayableAndAccruedLiabilitiesDetails">
        <link:definition>2407402 - Disclosure - Accounts Payable and Accrued Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccountsPayableAndAccruedLiabilitiesTables" roleURI="http://arbutusbio.com/role/AccountsPayableAndAccruedLiabilitiesTables">
        <link:definition>2307301 - Disclosure - Accounts Payable and Accrued Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationsContractsAndLicensingAgreements" roleURI="http://arbutusbio.com/role/CollaborationsContractsAndLicensingAgreements">
        <link:definition>2111100 - Disclosure - Collaborations, Contracts and Licensing Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationsContractsAndLicensingAgreementsDetails" roleURI="http://arbutusbio.com/role/CollaborationsContractsAndLicensingAgreementsDetails">
        <link:definition>2411401 - Disclosure - Collaborations, Contracts and Licensing Agreements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheets" roleURI="http://arbutusbio.com/role/CondensedConsolidatedBalanceSheets">
        <link:definition>1001000 - Statement - Condensed Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsParenthetical" roleURI="http://arbutusbio.com/role/CondensedConsolidatedBalanceSheetsParenthetical">
        <link:definition>1001501 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementOfStockholdersEquity" roleURI="http://arbutusbio.com/role/CondensedConsolidatedStatementOfStockholdersEquity">
        <link:definition>1004000 - Statement - Condensed Consolidated Statement of Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementOfStockholdersEquityParenthetical" roleURI="http://arbutusbio.com/role/CondensedConsolidatedStatementOfStockholdersEquityParenthetical">
        <link:definition>1004501 - Statement - Condensed Consolidated Statement of Stockholders' Equity (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsOfCashFlow" roleURI="http://arbutusbio.com/role/CondensedConsolidatedStatementsOfCashFlow">
        <link:definition>1005000 - Statement - Condensed Consolidated Statements of Cash Flow</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsOfComprehensiveIncomeLossCondensedConsolidatedStatementsOfComprehensiveIncomeLoss" roleURI="http://arbutusbio.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLossCondensedConsolidatedStatementsOfComprehensiveIncomeLoss">
        <link:definition>1003000 - Statement - Condensed Consolidated Statements of Comprehensive Income (Loss) Condensed Consolidated Statements of Comprehensive Income (Loss)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsOfOperations" roleURI="http://arbutusbio.com/role/CondensedConsolidatedStatementsOfOperations">
        <link:definition>1002000 - Statement - Condensed Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ContingenciesAndCommitments" roleURI="http://arbutusbio.com/role/ContingenciesAndCommitments">
        <link:definition>2110100 - Disclosure - Contingencies and Commitments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ContingenciesAndCommitmentsDetails" roleURI="http://arbutusbio.com/role/ContingenciesAndCommitmentsDetails">
        <link:definition>2410401 - Disclosure - Contingencies and Commitments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DocumentAndEntityInformation" roleURI="http://arbutusbio.com/role/DocumentAndEntityInformation">
        <link:definition>0001000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityMethodInvestment" roleURI="http://arbutusbio.com/role/EquityMethodInvestment">
        <link:definition>2104100 - Disclosure - Equity Method Investment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityMethodInvestmentDetails" roleURI="http://arbutusbio.com/role/EquityMethodInvestmentDetails">
        <link:definition>2404401 - Disclosure - Equity Method Investment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueOfFinancialInstruments" roleURI="http://arbutusbio.com/role/FairValueOfFinancialInstruments">
        <link:definition>2103100 - Disclosure - Fair Value of Financial Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueOfFinancialInstrumentsAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" roleURI="http://arbutusbio.com/role/FairValueOfFinancialInstrumentsAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails">
        <link:definition>2403402 - Disclosure - Fair Value of Financial Instruments - Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueOfFinancialInstrumentsChangesInFairValueOfContingentConsiderationDetails" roleURI="http://arbutusbio.com/role/FairValueOfFinancialInstrumentsChangesInFairValueOfContingentConsiderationDetails">
        <link:definition>2403404 - Disclosure - Fair Value of Financial Instruments - Changes in Fair Value of Contingent Consideration (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueOfFinancialInstrumentsChangesInFairValueOfLiabilitiesClassifiedAsStockOptionDetails" roleURI="http://arbutusbio.com/role/FairValueOfFinancialInstrumentsChangesInFairValueOfLiabilitiesClassifiedAsStockOptionDetails">
        <link:definition>2403403 - Disclosure - Fair Value of Financial Instruments - Changes in Fair Value of Liabilities-Classified as Stock Option (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueOfFinancialInstrumentsTables" roleURI="http://arbutusbio.com/role/FairValueOfFinancialInstrumentsTables">
        <link:definition>2303301 - Disclosure - Fair Value of Financial Instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsAndGoodwill" roleURI="http://arbutusbio.com/role/IntangibleAssetsAndGoodwill">
        <link:definition>2106100 - Disclosure - Intangible Assets and Goodwill</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsAndGoodwillDetails" roleURI="http://arbutusbio.com/role/IntangibleAssetsAndGoodwillDetails">
        <link:definition>2406401 - Disclosure - Intangible Assets and Goodwill (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://arbutusbio.com/role/Leases">
        <link:definition>2105100 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesMaturitiesOfLeaseLiabilitiesDetails" roleURI="http://arbutusbio.com/role/LeasesMaturitiesOfLeaseLiabilitiesDetails">
        <link:definition>2405405 - Disclosure - Leases - Maturities of Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesMaturitiesOfLeaseLiabilitiesDetailsCalc2" roleURI="http://arbutusbio.com/role/LeasesMaturitiesOfLeaseLiabilitiesDetailsCalc2">
        <link:definition>2405405 - Disclosure - Leases - Maturities of Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesNarrativeDetails" roleURI="http://arbutusbio.com/role/LeasesNarrativeDetails">
        <link:definition>2405402 - Disclosure - Leases - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesSupplementalCashFlowInformationDetails" roleURI="http://arbutusbio.com/role/LeasesSupplementalCashFlowInformationDetails">
        <link:definition>2405404 - Disclosure - Leases - Supplemental Cash Flow Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://arbutusbio.com/role/LeasesTables">
        <link:definition>2305301 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesWeightedAverageRemainingLeaseTermAndDiscountRateDetails" roleURI="http://arbutusbio.com/role/LeasesWeightedAverageRemainingLeaseTermAndDiscountRateDetails">
        <link:definition>2405403 - Disclosure - Leases - Weighted Average Remaining Lease Term and Discount Rate (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NatureOfBusinessAndFutureOperations" roleURI="http://arbutusbio.com/role/NatureOfBusinessAndFutureOperations">
        <link:definition>2101100 - Disclosure - Nature of Business and Future Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransaction" roleURI="http://arbutusbio.com/role/RelatedPartyTransaction">
        <link:definition>2113100 - Disclosure - Related Party Transaction</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactionDetails" roleURI="http://arbutusbio.com/role/RelatedPartyTransactionDetails">
        <link:definition>2413401 - Disclosure - Related Party Transaction (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SaleOfFutureRoyalties" roleURI="http://arbutusbio.com/role/SaleOfFutureRoyalties">
        <link:definition>2109100 - Disclosure - Sale of Future Royalties</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SaleOfFutureRoyaltiesLiabilityActivityDetails" roleURI="http://arbutusbio.com/role/SaleOfFutureRoyaltiesLiabilityActivityDetails">
        <link:definition>2409403 - Disclosure - Sale of Future Royalties - Liability Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SaleOfFutureRoyaltiesNarrativeDetails" roleURI="http://arbutusbio.com/role/SaleOfFutureRoyaltiesNarrativeDetails">
        <link:definition>2409402 - Disclosure - Sale of Future Royalties - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SaleOfFutureRoyaltiesTables" roleURI="http://arbutusbio.com/role/SaleOfFutureRoyaltiesTables">
        <link:definition>2309301 - Disclosure - Sale of Future Royalties (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantAccountingPolicies" roleURI="http://arbutusbio.com/role/SignificantAccountingPolicies">
        <link:definition>2102100 - Disclosure - Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantAccountingPoliciesNarrativeDetails" roleURI="http://arbutusbio.com/role/SignificantAccountingPoliciesNarrativeDetails">
        <link:definition>2402403 - Disclosure - Significant Accounting Policies - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantAccountingPoliciesPolicies" roleURI="http://arbutusbio.com/role/SignificantAccountingPoliciesPolicies">
        <link:definition>2202201 - Disclosure - Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantAccountingPoliciesScheduleOfComputationOfBasicAndDilutedIncomeLossDetails" roleURI="http://arbutusbio.com/role/SignificantAccountingPoliciesScheduleOfComputationOfBasicAndDilutedIncomeLossDetails">
        <link:definition>2402404 - Disclosure - Significant Accounting Policies - Schedule of Computation of Basic and Diluted Income (Loss) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantAccountingPoliciesTables" roleURI="http://arbutusbio.com/role/SignificantAccountingPoliciesTables">
        <link:definition>2302302 - Disclosure - Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SiteConsolidation" roleURI="http://arbutusbio.com/role/SiteConsolidation">
        <link:definition>2108100 - Disclosure - Site Consolidation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SiteConsolidationConsolidationExpensesDetails" roleURI="http://arbutusbio.com/role/SiteConsolidationConsolidationExpensesDetails">
        <link:definition>2408403 - Disclosure - Site Consolidation - Consolidation Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SiteConsolidationNarrativeDetails" roleURI="http://arbutusbio.com/role/SiteConsolidationNarrativeDetails">
        <link:definition>2408402 - Disclosure - Site Consolidation - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SiteConsolidationReserveActivityDetails" roleURI="http://arbutusbio.com/role/SiteConsolidationReserveActivityDetails">
        <link:definition>2408404 - Disclosure - Site Consolidation - Reserve Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SiteConsolidationTables" roleURI="http://arbutusbio.com/role/SiteConsolidationTables">
        <link:definition>2308301 - Disclosure - Site Consolidation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityAndStockBasedCompensation" roleURI="http://arbutusbio.com/role/StockholdersEquityAndStockBasedCompensation">
        <link:definition>2112100 - Disclosure - Stockholders' Equity and Stock-based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityAndStockBasedCompensationDetails" roleURI="http://arbutusbio.com/role/StockholdersEquityAndStockBasedCompensationDetails">
        <link:definition>2412401 - Disclosure - Stockholders' Equity and Stock-based Compensation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="abus_AccruedPayrollCurrent" name="AccruedPayrollCurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="abus_AccruedResearchAndDevelopment" name="AccruedResearchAndDevelopment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="abus_AdjustmentstoAdditionalPaidinCapitalCertainFairValueAdjustmentstoLiabilityStockOptionAwards" name="AdjustmentstoAdditionalPaidinCapitalCertainFairValueAdjustmentstoLiabilityStockOptionAwards" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="abus_AdministrativeAndTransitionalServicesMember" name="AdministrativeAndTransitionalServicesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="abus_ArbitrationWithTheUniversityOfBritishColumbiaMember" name="ArbitrationWithTheUniversityOfBritishColumbiaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="abus_ArbutusInc.Member" name="ArbutusInc.Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="abus_BlumbergMember" name="BlumbergMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="abus_BlumbergandDrexelMember" name="BlumbergandDrexelMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="abus_ChangesInFairValueofLiabilityOptionTableTextBlock" name="ChangesInFairValueofLiabilityOptionTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="abus_ContingenciesandCommitmentsLineItems" name="ContingenciesandCommitmentsLineItems" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="abus_ContingenciesandCommitmentsTable" name="ContingenciesandCommitmentsTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="abus_ContractualObligationAmountOfResearchFundingPerYear" name="ContractualObligationAmountOfResearchFundingPerYear" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="abus_ConvertiblePreferredStockSharesOfCommonStockIssueduponConversion" name="ConvertiblePreferredStockSharesOfCommonStockIssueduponConversion" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="abus_CorporateHeadquartersLocated701VeteransCircleWarminsterPennsylvaniaMember" name="CorporateHeadquartersLocated701VeteransCircleWarminsterPennsylvaniaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="abus_DistributableEarningsLossAvailabletoCommonShareholdersBasic" name="DistributableEarningsLossAvailabletoCommonShareholdersBasic" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="abus_DocumentAndEntityInformationAbstract" name="DocumentAndEntityInformationAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="abus_EffectiveAnnualInterestRateOfRoyaltyLiability" name="EffectiveAnnualInterestRateOfRoyaltyLiability" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="abus_EmployeeSeveranceandRelocationMember" name="EmployeeSeveranceandRelocationMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="abus_EmployeeStockOptionLiabilityClassifiedMember" name="EmployeeStockOptionLiabilityClassifiedMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="abus_EmployeeStockOptionsLiabilityClassifiedOutstanding" name="EmployeeStockOptionsLiabilityClassifiedOutstanding" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="abus_EmployeeStockOptionsLiabilityClassifiedOutstandingFairValueDisclosure" name="EmployeeStockOptionsLiabilityClassifiedOutstandingFairValueDisclosure" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="abus_EnantigenMember" name="EnantigenMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="abus_EquityMethodInvestmentPropertyContribution" name="EquityMethodInvestmentPropertyContribution" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="abus_FairValueLiabilitiesMeasuredonRecurringBasisRollForward" name="FairValueLiabilitiesMeasuredonRecurringBasisRollForward" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="abus_FixedLeaseCost" name="FixedLeaseCost" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="abus_GenevantSciencesCorporationMember" name="GenevantSciencesCorporationMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="abus_GritstoneMember" name="GritstoneMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="abus_GrossProceedsFromRoyaltyInterestSold" name="GrossProceedsFromRoyaltyInterestSold" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="abus_InProcessResearchandDevelopmentcccDNASterilizersMember" name="InProcessResearchandDevelopmentcccDNASterilizersMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="abus_IncreaseDecreaseInFairValueOfContingentConsiderationLiability" name="IncreaseDecreaseInFairValueOfContingentConsiderationLiability" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="abus_IncreaseDecreaseinFairValueofLiabilityClassifiedOptions" name="IncreaseDecreaseinFairValueofLiabilityClassifiedOptions" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="abus_JefferiesLLCMember" name="JefferiesLLCMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="abus_LesseeOperatingLeaseNumberOfRenewalOptions" name="LesseeOperatingLeaseNumberOfRenewalOptions" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="instant" />
  <xsd:element id="abus_LesseeOperatingLeaseNumberofLeases" name="LesseeOperatingLeaseNumberofLeases" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="instant" />
  <xsd:element id="abus_LiabilitiesRelatedToSaleOfFutureRoyaltiesRollForwardTableTextBlock" name="LiabilitiesRelatedToSaleOfFutureRoyaltiesRollForwardTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="abus_LiabilitiesRelatedToSaleOfFutureRoyaltiesTextBlock" name="LiabilitiesRelatedToSaleOfFutureRoyaltiesTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="abus_LiabilityFromSaleOfFutureRoyaltiesAdditions" name="LiabilityFromSaleOfFutureRoyaltiesAdditions" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="abus_LiabilityFromSaleOfFutureRoyaltiesDiscountsAndIssuanceCosts" name="LiabilityFromSaleOfFutureRoyaltiesDiscountsAndIssuanceCosts" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="abus_LiabilityFromSaleOfFutureRoyaltiesNonCashExpense" name="LiabilityFromSaleOfFutureRoyaltiesNonCashExpense" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="abus_LiabilityFromSaleOfFutureRoyaltiesNonCashRoyaltyIncome" name="LiabilityFromSaleOfFutureRoyaltiesNonCashRoyaltyIncome" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="abus_LiabilityRelatedToSaleOfFutureRoyalties" name="LiabilityRelatedToSaleOfFutureRoyalties" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="abus_LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent" name="LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="abus_LiabilityRelatedToSaleOfFutureRoyaltiesRollForward" name="LiabilityRelatedToSaleOfFutureRoyaltiesRollForward" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="abus_LicenseAgreementMaximumDevelopmentAndRegulatoryMilestonePaymentsPerLicense" name="LicenseAgreementMaximumDevelopmentAndRegulatoryMilestonePaymentsPerLicense" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="abus_LicenseAgreementMaximumDevelopmentAndRegulatoryMilestonePaymentsPerRoyalty" name="LicenseAgreementMaximumDevelopmentAndRegulatoryMilestonePaymentsPerRoyalty" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="abus_NetRentableAreaSublease" name="NetRentableAreaSublease" nillable="true" substitutionGroup="xbrli:item" type="num:areaItemType" xbrli:periodType="instant" />
  <xsd:element id="abus_NonCashRoyaltyExpenseRelatedToSaleOfFutureRoyalties" name="NonCashRoyaltyExpenseRelatedToSaleOfFutureRoyalties" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="abus_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" name="NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="abus_NoncontrollingInterestInvestmentCommitmentPeriod" name="NoncontrollingInterestInvestmentCommitmentPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="abus_NoncontrollingInterestMaximumOwnershipPercentagebyNoncontrollingOwners" name="NoncontrollingInterestMaximumOwnershipPercentagebyNoncontrollingOwners" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element id="abus_NoncontrollingInterestOwnershipPercentageByNoncontrollingOwnersAfterConversion" name="NoncontrollingInterestOwnershipPercentageByNoncontrollingOwnersAfterConversion" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element id="abus_NumberOfProductsCoveredByPatentAcquiredUnderAgreement" name="NumberOfProductsCoveredByPatentAcquiredUnderAgreement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="instant" />
  <xsd:element id="abus_NumberofPatentLicenses" name="NumberofPatentLicenses" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="instant" />
  <xsd:element id="abus_Numberoflegalproceedings" name="Numberoflegalproceedings" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="abus_OMERSMember" name="OMERSMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="abus_OfficesLocatedat626JacksonvilleRd.WarminsterPennsylvaniaMember" name="OfficesLocatedat626JacksonvilleRd.WarminsterPennsylvaniaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="abus_OpenMarketSaleAgreementMember" name="OpenMarketSaleAgreementMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="abus_OtherLiabilitiesDisclosureLineItems" name="OtherLiabilitiesDisclosureLineItems" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="abus_ProceedsFromSaleOfFutureRoyaltiesNet" name="ProceedsFromSaleOfFutureRoyaltiesNet" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="abus_ResearchAndDevelopmentServicesMember" name="ResearchAndDevelopmentServicesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="abus_ResearchFundingPeriod" name="ResearchFundingPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="abus_RoivantSciencesLtdMember" name="RoivantSciencesLtdMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="abus_RoyaltyGuaranteesCommitmentsPercentage" name="RoyaltyGuaranteesCommitmentsPercentage" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="abus_RoyaltyInterestSoldMaximumRoyaltiesForBuyer" name="RoyaltyInterestSoldMaximumRoyaltiesForBuyer" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="abus_RoyaltyInterestSoldPercentageOfSalesAnnualRevenueThresholdOfHighestTier" name="RoyaltyInterestSoldPercentageOfSalesAnnualRevenueThresholdOfHighestTier" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="abus_RoyaltyPayable" name="RoyaltyPayable" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="abus_RoyaltyPercentageofInterestSold" name="RoyaltyPercentageofInterestSold" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="abus_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisesinPeriodFairValue" name="SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisesinPeriodFairValue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="abus_StrightlineFixedLeaseCost" name="StrightlineFixedLeaseCost" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="abus_SubleaseBurnabyFacilityMember" name="SubleaseBurnabyFacilityMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="abus_TransactionCostsRelatedToSaleOfFutureRoyalties" name="TransactionCostsRelatedToSaleOfFutureRoyalties" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="abus_WeightedAverageNumberOfCommonSharesAbstract" name="WeightedAverageNumberOfCommonSharesAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="abus_WhollyOwnedSubsidiariesIncludedinFinancialStatements" name="WhollyOwnedSubsidiariesIncludedinFinancialStatements" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="instant" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>10
<FILENAME>abus-20190930_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://arbutusbio.com/role/AccountsPayableAndAccruedLiabilities" xlink:href="abus-20190930.xsd#AccountsPayableAndAccruedLiabilities" xlink:type="simple" />
  <link:roleRef roleURI="http://arbutusbio.com/role/AccountsPayableAndAccruedLiabilitiesDetails" xlink:href="abus-20190930.xsd#AccountsPayableAndAccruedLiabilitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://arbutusbio.com/role/AccountsPayableAndAccruedLiabilitiesTables" xlink:href="abus-20190930.xsd#AccountsPayableAndAccruedLiabilitiesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://arbutusbio.com/role/CollaborationsContractsAndLicensingAgreements" xlink:href="abus-20190930.xsd#CollaborationsContractsAndLicensingAgreements" xlink:type="simple" />
  <link:roleRef roleURI="http://arbutusbio.com/role/CollaborationsContractsAndLicensingAgreementsDetails" xlink:href="abus-20190930.xsd#CollaborationsContractsAndLicensingAgreementsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://arbutusbio.com/role/CondensedConsolidatedBalanceSheets" xlink:href="abus-20190930.xsd#CondensedConsolidatedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://arbutusbio.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:href="abus-20190930.xsd#CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://arbutusbio.com/role/CondensedConsolidatedStatementOfStockholdersEquity" xlink:href="abus-20190930.xsd#CondensedConsolidatedStatementOfStockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://arbutusbio.com/role/CondensedConsolidatedStatementOfStockholdersEquityParenthetical" xlink:href="abus-20190930.xsd#CondensedConsolidatedStatementOfStockholdersEquityParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://arbutusbio.com/role/CondensedConsolidatedStatementsOfCashFlow" xlink:href="abus-20190930.xsd#CondensedConsolidatedStatementsOfCashFlow" xlink:type="simple" />
  <link:roleRef roleURI="http://arbutusbio.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLossCondensedConsolidatedStatementsOfComprehensiveIncomeLoss" xlink:href="abus-20190930.xsd#CondensedConsolidatedStatementsOfComprehensiveIncomeLossCondensedConsolidatedStatementsOfComprehensiveIncomeLoss" xlink:type="simple" />
  <link:roleRef roleURI="http://arbutusbio.com/role/CondensedConsolidatedStatementsOfOperations" xlink:href="abus-20190930.xsd#CondensedConsolidatedStatementsOfOperations" xlink:type="simple" />
  <link:roleRef roleURI="http://arbutusbio.com/role/ContingenciesAndCommitments" xlink:href="abus-20190930.xsd#ContingenciesAndCommitments" xlink:type="simple" />
  <link:roleRef roleURI="http://arbutusbio.com/role/ContingenciesAndCommitmentsDetails" xlink:href="abus-20190930.xsd#ContingenciesAndCommitmentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://arbutusbio.com/role/DocumentAndEntityInformation" xlink:href="abus-20190930.xsd#DocumentAndEntityInformation" xlink:type="simple" />
  <link:roleRef roleURI="http://arbutusbio.com/role/EquityMethodInvestment" xlink:href="abus-20190930.xsd#EquityMethodInvestment" xlink:type="simple" />
  <link:roleRef roleURI="http://arbutusbio.com/role/EquityMethodInvestmentDetails" xlink:href="abus-20190930.xsd#EquityMethodInvestmentDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://arbutusbio.com/role/FairValueOfFinancialInstruments" xlink:href="abus-20190930.xsd#FairValueOfFinancialInstruments" xlink:type="simple" />
  <link:roleRef roleURI="http://arbutusbio.com/role/FairValueOfFinancialInstrumentsAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:href="abus-20190930.xsd#FairValueOfFinancialInstrumentsAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://arbutusbio.com/role/FairValueOfFinancialInstrumentsChangesInFairValueOfContingentConsiderationDetails" xlink:href="abus-20190930.xsd#FairValueOfFinancialInstrumentsChangesInFairValueOfContingentConsiderationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://arbutusbio.com/role/FairValueOfFinancialInstrumentsChangesInFairValueOfLiabilitiesClassifiedAsStockOptionDetails" xlink:href="abus-20190930.xsd#FairValueOfFinancialInstrumentsChangesInFairValueOfLiabilitiesClassifiedAsStockOptionDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://arbutusbio.com/role/FairValueOfFinancialInstrumentsTables" xlink:href="abus-20190930.xsd#FairValueOfFinancialInstrumentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://arbutusbio.com/role/IntangibleAssetsAndGoodwill" xlink:href="abus-20190930.xsd#IntangibleAssetsAndGoodwill" xlink:type="simple" />
  <link:roleRef roleURI="http://arbutusbio.com/role/IntangibleAssetsAndGoodwillDetails" xlink:href="abus-20190930.xsd#IntangibleAssetsAndGoodwillDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://arbutusbio.com/role/Leases" xlink:href="abus-20190930.xsd#Leases" xlink:type="simple" />
  <link:roleRef roleURI="http://arbutusbio.com/role/LeasesMaturitiesOfLeaseLiabilitiesDetails" xlink:href="abus-20190930.xsd#LeasesMaturitiesOfLeaseLiabilitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://arbutusbio.com/role/LeasesMaturitiesOfLeaseLiabilitiesDetailsCalc2" xlink:href="abus-20190930.xsd#LeasesMaturitiesOfLeaseLiabilitiesDetailsCalc2" xlink:type="simple" />
  <link:roleRef roleURI="http://arbutusbio.com/role/LeasesNarrativeDetails" xlink:href="abus-20190930.xsd#LeasesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://arbutusbio.com/role/LeasesSupplementalCashFlowInformationDetails" xlink:href="abus-20190930.xsd#LeasesSupplementalCashFlowInformationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://arbutusbio.com/role/LeasesTables" xlink:href="abus-20190930.xsd#LeasesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://arbutusbio.com/role/LeasesWeightedAverageRemainingLeaseTermAndDiscountRateDetails" xlink:href="abus-20190930.xsd#LeasesWeightedAverageRemainingLeaseTermAndDiscountRateDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://arbutusbio.com/role/NatureOfBusinessAndFutureOperations" xlink:href="abus-20190930.xsd#NatureOfBusinessAndFutureOperations" xlink:type="simple" />
  <link:roleRef roleURI="http://arbutusbio.com/role/RelatedPartyTransaction" xlink:href="abus-20190930.xsd#RelatedPartyTransaction" xlink:type="simple" />
  <link:roleRef roleURI="http://arbutusbio.com/role/RelatedPartyTransactionDetails" xlink:href="abus-20190930.xsd#RelatedPartyTransactionDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://arbutusbio.com/role/SaleOfFutureRoyalties" xlink:href="abus-20190930.xsd#SaleOfFutureRoyalties" xlink:type="simple" />
  <link:roleRef roleURI="http://arbutusbio.com/role/SaleOfFutureRoyaltiesLiabilityActivityDetails" xlink:href="abus-20190930.xsd#SaleOfFutureRoyaltiesLiabilityActivityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://arbutusbio.com/role/SaleOfFutureRoyaltiesNarrativeDetails" xlink:href="abus-20190930.xsd#SaleOfFutureRoyaltiesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://arbutusbio.com/role/SaleOfFutureRoyaltiesTables" xlink:href="abus-20190930.xsd#SaleOfFutureRoyaltiesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://arbutusbio.com/role/SignificantAccountingPolicies" xlink:href="abus-20190930.xsd#SignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://arbutusbio.com/role/SignificantAccountingPoliciesNarrativeDetails" xlink:href="abus-20190930.xsd#SignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://arbutusbio.com/role/SignificantAccountingPoliciesPolicies" xlink:href="abus-20190930.xsd#SignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://arbutusbio.com/role/SignificantAccountingPoliciesScheduleOfComputationOfBasicAndDilutedIncomeLossDetails" xlink:href="abus-20190930.xsd#SignificantAccountingPoliciesScheduleOfComputationOfBasicAndDilutedIncomeLossDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://arbutusbio.com/role/SignificantAccountingPoliciesTables" xlink:href="abus-20190930.xsd#SignificantAccountingPoliciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://arbutusbio.com/role/SiteConsolidation" xlink:href="abus-20190930.xsd#SiteConsolidation" xlink:type="simple" />
  <link:roleRef roleURI="http://arbutusbio.com/role/SiteConsolidationConsolidationExpensesDetails" xlink:href="abus-20190930.xsd#SiteConsolidationConsolidationExpensesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://arbutusbio.com/role/SiteConsolidationNarrativeDetails" xlink:href="abus-20190930.xsd#SiteConsolidationNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://arbutusbio.com/role/SiteConsolidationReserveActivityDetails" xlink:href="abus-20190930.xsd#SiteConsolidationReserveActivityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://arbutusbio.com/role/SiteConsolidationTables" xlink:href="abus-20190930.xsd#SiteConsolidationTables" xlink:type="simple" />
  <link:roleRef roleURI="http://arbutusbio.com/role/StockholdersEquityAndStockBasedCompensation" xlink:href="abus-20190930.xsd#StockholdersEquityAndStockBasedCompensation" xlink:type="simple" />
  <link:roleRef roleURI="http://arbutusbio.com/role/StockholdersEquityAndStockBasedCompensationDetails" xlink:href="abus-20190930.xsd#StockholdersEquityAndStockBasedCompensationDetails" xlink:type="simple" />
  <link:calculationLink xlink:role="http://arbutusbio.com/role/AccountsPayableAndAccruedLiabilities" xlink:type="extended" />
  <link:calculationLink xlink:role="http://arbutusbio.com/role/AccountsPayableAndAccruedLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_0B5CAF3596065D4191C03021940B0973" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="loc_us-gaap_AccountsPayableTradeCurrent_C9287247E6605A1C8BF50152302755B8" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_0B5CAF3596065D4191C03021940B0973" xlink:to="loc_us-gaap_AccountsPayableTradeCurrent_C9287247E6605A1C8BF50152302755B8" xlink:type="arc" />
    <link:loc xlink:href="abus-20190930.xsd#abus_AccruedResearchAndDevelopment" xlink:label="loc_abus_AccruedResearchAndDevelopment_0377B7C716F75FE6B52EA3B9F3A055D0" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_0B5CAF3596065D4191C03021940B0973" xlink:to="loc_abus_AccruedResearchAndDevelopment_0377B7C716F75FE6B52EA3B9F3A055D0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_8DFEB078C95B5B8495897BB147B92E56" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_0B5CAF3596065D4191C03021940B0973" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_8DFEB078C95B5B8495897BB147B92E56" xlink:type="arc" />
    <link:loc xlink:href="abus-20190930.xsd#abus_AccruedPayrollCurrent" xlink:label="loc_abus_AccruedPayrollCurrent_E94CE7DB563651AEA5B57AF434649F00" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_0B5CAF3596065D4191C03021940B0973" xlink:to="loc_abus_AccruedPayrollCurrent_E94CE7DB563651AEA5B57AF434649F00" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_70BE368964FE5B86B77A6877C2AB4B38" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_0B5CAF3596065D4191C03021940B0973" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_70BE368964FE5B86B77A6877C2AB4B38" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://arbutusbio.com/role/AccountsPayableAndAccruedLiabilitiesTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://arbutusbio.com/role/CollaborationsContractsAndLicensingAgreements" xlink:type="extended" />
  <link:calculationLink xlink:role="http://arbutusbio.com/role/CollaborationsContractsAndLicensingAgreementsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://arbutusbio.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_96dd7052-744e-d270-4e77-67944ec39152" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_d79dcc1c-93de-0ecd-2bd5-7c1f224c9b98" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_96dd7052-744e-d270-4e77-67944ec39152" xlink:to="loc_us-gaap_AssetsCurrent_d79dcc1c-93de-0ecd-2bd5-7c1f224c9b98" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_32f41ea9-05c6-e713-464b-586a571d1c1f" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d79dcc1c-93de-0ecd-2bd5-7c1f224c9b98" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_32f41ea9-05c6-e713-464b-586a571d1c1f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShortTermInvestments" xlink:label="loc_us-gaap_ShortTermInvestments_4f46bf2c-e8aa-a88a-d064-0418c3eb39b0" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d79dcc1c-93de-0ecd-2bd5-7c1f224c9b98" xlink:to="loc_us-gaap_ShortTermInvestments_4f46bf2c-e8aa-a88a-d064-0418c3eb39b0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_928a1618-af56-709a-989c-a303706b8ca2" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d79dcc1c-93de-0ecd-2bd5-7c1f224c9b98" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_928a1618-af56-709a-989c-a303706b8ca2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_ce9014ac-0ac4-6ed2-b53f-a0edc046d6b4" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d79dcc1c-93de-0ecd-2bd5-7c1f224c9b98" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_ce9014ac-0ac4-6ed2-b53f-a0edc046d6b4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityMethodInvestments" xlink:label="loc_us-gaap_EquityMethodInvestments_0682cfaa-83e6-dea4-d697-0d84430cc679" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_96dd7052-744e-d270-4e77-67944ec39152" xlink:to="loc_us-gaap_EquityMethodInvestments_0682cfaa-83e6-dea4-d697-0d84430cc679" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_f37ad080-c77a-efc5-c936-389b16abc420" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_96dd7052-744e-d270-4e77-67944ec39152" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_f37ad080-c77a-efc5-c936-389b16abc420" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_52f5671e-53e6-6055-795e-6bd414fd86c2" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_96dd7052-744e-d270-4e77-67944ec39152" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_52f5671e-53e6-6055-795e-6bd414fd86c2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_af012273-e8ee-655c-daa2-86b96989d377" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_96dd7052-744e-d270-4e77-67944ec39152" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_af012273-e8ee-655c-daa2-86b96989d377" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_831ad0b9-9dba-3997-20e6-e99a19aa28db" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_96dd7052-744e-d270-4e77-67944ec39152" xlink:to="loc_us-gaap_Goodwill_831ad0b9-9dba-3997-20e6-e99a19aa28db" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_63817d40-f759-fa9c-45a5-8bbbb36ed5c9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_066608da-f041-4af6-3da0-95354b640e11" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_63817d40-f759-fa9c-45a5-8bbbb36ed5c9" xlink:to="loc_us-gaap_Liabilities_066608da-f041-4af6-3da0-95354b640e11" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_2dcbbde2-9146-a0ba-7f6c-c71b481e0841" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_066608da-f041-4af6-3da0-95354b640e11" xlink:to="loc_us-gaap_LiabilitiesCurrent_2dcbbde2-9146-a0ba-7f6c-c71b481e0841" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_47ecca60-0dc8-25b2-6295-72031a21e0cb" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_2dcbbde2-9146-a0ba-7f6c-c71b481e0841" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_47ecca60-0dc8-25b2-6295-72031a21e0cb" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestructuringReserveCurrent" xlink:label="loc_us-gaap_RestructuringReserveCurrent_a96bd12b-bf0d-8f9b-e78d-e34cf5aa9942" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_2dcbbde2-9146-a0ba-7f6c-c71b481e0841" xlink:to="loc_us-gaap_RestructuringReserveCurrent_a96bd12b-bf0d-8f9b-e78d-e34cf5aa9942" xlink:type="arc" />
    <link:loc xlink:href="abus-20190930.xsd#abus_EmployeeStockOptionsLiabilityClassifiedOutstanding" xlink:label="loc_abus_EmployeeStockOptionsLiabilityClassifiedOutstanding_e9953fdd-2ce7-8df2-121c-60cf7076b3da" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_2dcbbde2-9146-a0ba-7f6c-c71b481e0841" xlink:to="loc_abus_EmployeeStockOptionsLiabilityClassifiedOutstanding_e9953fdd-2ce7-8df2-121c-60cf7076b3da" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_09c9f846-159b-1776-fceb-d1cad0eb94ab" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_2dcbbde2-9146-a0ba-7f6c-c71b481e0841" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_09c9f846-159b-1776-fceb-d1cad0eb94ab" xlink:type="arc" />
    <link:loc xlink:href="abus-20190930.xsd#abus_LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent" xlink:label="loc_abus_LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent_5FE3D03B659A77E0CF3E0330032B0C28" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_066608da-f041-4af6-3da0-95354b640e11" xlink:to="loc_abus_LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent_5FE3D03B659A77E0CF3E0330032B0C28" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="loc_us-gaap_DeferredRentCreditNoncurrent_2c8b0baf-771b-c301-80d6-9e2df7367293" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_066608da-f041-4af6-3da0-95354b640e11" xlink:to="loc_us-gaap_DeferredRentCreditNoncurrent_2c8b0baf-771b-c301-80d6-9e2df7367293" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_1c24f6a3-e8ba-9221-ee1e-4678b4a6cab8" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_066608da-f041-4af6-3da0-95354b640e11" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_1c24f6a3-e8ba-9221-ee1e-4678b4a6cab8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_7e28dff2-da63-21d2-137e-ce9d56cb1b6e" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_066608da-f041-4af6-3da0-95354b640e11" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_7e28dff2-da63-21d2-137e-ce9d56cb1b6e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_d3ba3006-9df7-8186-2eb2-dc5094562cfe" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_066608da-f041-4af6-3da0-95354b640e11" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_d3ba3006-9df7-8186-2eb2-dc5094562cfe" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_6765f135-8c69-bebc-a116-d59a52a5b2f2" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_63817d40-f759-fa9c-45a5-8bbbb36ed5c9" xlink:to="loc_us-gaap_StockholdersEquity_6765f135-8c69-bebc-a116-d59a52a5b2f2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_aefe3f0c-abe4-5b83-9a64-da77d8e253dd" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_6765f135-8c69-bebc-a116-d59a52a5b2f2" xlink:to="loc_us-gaap_CommonStockValue_aefe3f0c-abe4-5b83-9a64-da77d8e253dd" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_6dca832a-861c-478d-b1a0-396533beb40d" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_6765f135-8c69-bebc-a116-d59a52a5b2f2" xlink:to="loc_us-gaap_AdditionalPaidInCapital_6dca832a-861c-478d-b1a0-396533beb40d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_a59bc5ae-63a0-c9bc-32f7-e2bd9f32bd26" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_6765f135-8c69-bebc-a116-d59a52a5b2f2" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_a59bc5ae-63a0-c9bc-32f7-e2bd9f32bd26" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_798442bf-12e1-d944-3fa1-8b797b67482e" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_6765f135-8c69-bebc-a116-d59a52a5b2f2" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_798442bf-12e1-d944-3fa1-8b797b67482e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockIncludingAdditionalPaidInCapitalNetOfDiscount" xlink:label="loc_us-gaap_PreferredStockIncludingAdditionalPaidInCapitalNetOfDiscount_b52af1df-5c4e-b608-5f14-6be14c7f0793" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_6765f135-8c69-bebc-a116-d59a52a5b2f2" xlink:to="loc_us-gaap_PreferredStockIncludingAdditionalPaidInCapitalNetOfDiscount_b52af1df-5c4e-b608-5f14-6be14c7f0793" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://arbutusbio.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended" />
  <link:calculationLink xlink:role="http://arbutusbio.com/role/CondensedConsolidatedStatementOfStockholdersEquity" xlink:type="extended" />
  <link:calculationLink xlink:role="http://arbutusbio.com/role/CondensedConsolidatedStatementOfStockholdersEquityParenthetical" xlink:type="extended" />
  <link:calculationLink xlink:role="http://arbutusbio.com/role/CondensedConsolidatedStatementsOfCashFlow" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_9743d583-dfae-6ae9-f133-a1e331df792c" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_9743d583-dfae-6ae9-f133-a1e331df792c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_a10eea14-f4db-3125-d183-77bb54500e95" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_NetIncomeLoss_a10eea14-f4db-3125-d183-77bb54500e95" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_e8a9abf2-38d3-77d1-fb6b-693fef632294" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_e8a9abf2-38d3-77d1-fb6b-693fef632294" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_b11c1cb0-596b-4c3d-0283-76cef67837c7" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_b11c1cb0-596b-4c3d-0283-76cef67837c7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_ef1b7738-192b-a4ca-6396-5577f303c271" xlink:type="locator" />
    <link:calculationArc order="4" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_ef1b7738-192b-a4ca-6396-5577f303c271" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_90cbc3ab-f555-6407-b3b4-b2bfa84c9f18" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_ShareBasedCompensation_90cbc3ab-f555-6407-b3b4-b2bfa84c9f18" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_82e8758d-2519-6da2-6cfb-eda5d7152782" xlink:type="locator" />
    <link:calculationArc order="6" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_82e8758d-2519-6da2-6cfb-eda5d7152782" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_9dbcf839-4ba1-0e2b-8942-4c8a9981ac5b" xlink:type="locator" />
    <link:calculationArc order="7" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_9dbcf839-4ba1-0e2b-8942-4c8a9981ac5b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="loc_us-gaap_AssetImpairmentCharges_45c69f9e-da88-288e-46e4-172c1cc97df8" xlink:type="locator" />
    <link:calculationArc order="8" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_AssetImpairmentCharges_45c69f9e-da88-288e-46e4-172c1cc97df8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_0d30eb77-a66f-56df-77a0-7c7ad008c84e" xlink:type="locator" />
    <link:calculationArc order="9" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_0d30eb77-a66f-56df-77a0-7c7ad008c84e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestructuringCosts" xlink:label="loc_us-gaap_RestructuringCosts_67ea87a8-7d37-4887-3b63-625eddafca56" xlink:type="locator" />
    <link:calculationArc order="10" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_RestructuringCosts_67ea87a8-7d37-4887-3b63-625eddafca56" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GainLossOnInvestments" xlink:label="loc_us-gaap_GainLossOnInvestments_7b996bea-e1a6-f08b-4e6b-a307dfbe0ae3" xlink:type="locator" />
    <link:calculationArc order="11" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_GainLossOnInvestments_7b996bea-e1a6-f08b-4e6b-a307dfbe0ae3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GainLossOnSaleOfEquityInvestments" xlink:label="loc_us-gaap_GainLossOnSaleOfEquityInvestments_87411b28-fab2-062e-4fdd-e3bdeaaa2b27" xlink:type="locator" />
    <link:calculationArc order="12" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_GainLossOnSaleOfEquityInvestments_87411b28-fab2-062e-4fdd-e3bdeaaa2b27" xlink:type="arc" />
    <link:loc xlink:href="abus-20190930.xsd#abus_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" xlink:label="loc_abus_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties_1DC263D2B78B60EE09BD0312C306DBAA" xlink:type="locator" />
    <link:calculationArc order="13" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_abus_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties_1DC263D2B78B60EE09BD0312C306DBAA" xlink:type="arc" />
    <link:loc xlink:href="abus-20190930.xsd#abus_NonCashRoyaltyExpenseRelatedToSaleOfFutureRoyalties" xlink:label="loc_abus_NonCashRoyaltyExpenseRelatedToSaleOfFutureRoyalties_BFE9B007B8F33C65D7F70313CA411CAC" xlink:type="locator" />
    <link:calculationArc order="14" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_abus_NonCashRoyaltyExpenseRelatedToSaleOfFutureRoyalties_BFE9B007B8F33C65D7F70313CA411CAC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_5f96c19e-85fe-99f6-cec0-c2c9d7470ed4" xlink:type="locator" />
    <link:calculationArc order="15" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_5f96c19e-85fe-99f6-cec0-c2c9d7470ed4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_0e4168a9-901d-abb5-15c0-3622e9e2c070" xlink:type="locator" />
    <link:calculationArc order="16" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_0e4168a9-901d-abb5-15c0-3622e9e2c070" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerAsset" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerAsset_335f837a-5be7-880a-50f9-2dc4be725c2b" xlink:type="locator" />
    <link:calculationArc order="17" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerAsset_335f837a-5be7-880a-50f9-2dc4be725c2b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_91c354d1-d18f-051e-80cb-f13c01058b9d" xlink:type="locator" />
    <link:calculationArc order="18" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_91c354d1-d18f-051e-80cb-f13c01058b9d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_7d3f88de-7d0f-fe63-f176-2a8af9ecbcbd" xlink:type="locator" />
    <link:calculationArc order="19" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_7d3f88de-7d0f-fe63-f176-2a8af9ecbcbd" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInRestructuringReserve" xlink:label="loc_us-gaap_IncreaseDecreaseInRestructuringReserve_798a67c3-e24b-7389-5bdb-7a364e9fdbda" xlink:type="locator" />
    <link:calculationArc order="20" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_IncreaseDecreaseInRestructuringReserve_798a67c3-e24b-7389-5bdb-7a364e9fdbda" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_a039d388-4db8-a076-4618-28899f6ce801" xlink:type="locator" />
    <link:calculationArc order="21" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_a039d388-4db8-a076-4618-28899f6ce801" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_28655e34-499f-b7bf-c54f-5de0990d0c65" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_9743d583-dfae-6ae9-f133-a1e331df792c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_28655e34-499f-b7bf-c54f-5de0990d0c65" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsForProceedsFromInvestments" xlink:label="loc_us-gaap_PaymentsForProceedsFromInvestments_7195f44f-7ebf-9a11-2e1c-81aa8617d2d4" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_28655e34-499f-b7bf-c54f-5de0990d0c65" xlink:to="loc_us-gaap_PaymentsForProceedsFromInvestments_7195f44f-7ebf-9a11-2e1c-81aa8617d2d4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromSaleOfRestrictedInvestments" xlink:label="loc_us-gaap_ProceedsFromSaleOfRestrictedInvestments_1880f4b5-a1fc-d439-2f25-edf870e93934" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_28655e34-499f-b7bf-c54f-5de0990d0c65" xlink:to="loc_us-gaap_ProceedsFromSaleOfRestrictedInvestments_1880f4b5-a1fc-d439-2f25-edf870e93934" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_2e493320-ebb4-7df2-c1f0-2dc8298386c7" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_28655e34-499f-b7bf-c54f-5de0990d0c65" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_2e493320-ebb4-7df2-c1f0-2dc8298386c7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_6d89f221-3ede-36b2-fcad-4a4ce1606f6a" xlink:type="locator" />
    <link:calculationArc order="4" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_28655e34-499f-b7bf-c54f-5de0990d0c65" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_6d89f221-3ede-36b2-fcad-4a4ce1606f6a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d8917e24-06dd-060d-a290-e426c7895e54" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_9743d583-dfae-6ae9-f133-a1e331df792c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d8917e24-06dd-060d-a290-e426c7895e54" xlink:type="arc" />
    <link:loc xlink:href="abus-20190930.xsd#abus_ProceedsFromSaleOfFutureRoyaltiesNet" xlink:label="loc_abus_ProceedsFromSaleOfFutureRoyaltiesNet_2ACE7C21CDDF6016140603A0EC2FA14D" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d8917e24-06dd-060d-a290-e426c7895e54" xlink:to="loc_abus_ProceedsFromSaleOfFutureRoyaltiesNet_2ACE7C21CDDF6016140603A0EC2FA14D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable_0875b2e3-27c1-eb02-1003-25cd8f923808" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d8917e24-06dd-060d-a290-e426c7895e54" xlink:to="loc_us-gaap_RepaymentsOfNotesPayable_0875b2e3-27c1-eb02-1003-25cd8f923808" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_7c2a31aa-de85-3d78-fe3c-7d70dce934c1" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d8917e24-06dd-060d-a290-e426c7895e54" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_7c2a31aa-de85-3d78-fe3c-7d70dce934c1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_6ec8bc8e-bcd9-36ad-d8ae-2c2fa1dfd920" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d8917e24-06dd-060d-a290-e426c7895e54" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_6ec8bc8e-bcd9-36ad-d8ae-2c2fa1dfd920" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_706d3cc5-3df5-1e1a-5067-c02728407eb6" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d8917e24-06dd-060d-a290-e426c7895e54" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_706d3cc5-3df5-1e1a-5067-c02728407eb6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_714a30d1-878f-1497-8ad1-4b1e113da228" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_9743d583-dfae-6ae9-f133-a1e331df792c" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_714a30d1-878f-1497-8ad1-4b1e113da228" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://arbutusbio.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLossCondensedConsolidatedStatementsOfComprehensiveIncomeLoss" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_cf605d39-9067-2f07-a6b5-7dfa6481009e" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_a10eea14-f4db-3125-d183-77bb54500e95" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_cf605d39-9067-2f07-a6b5-7dfa6481009e" xlink:to="loc_us-gaap_NetIncomeLoss_a10eea14-f4db-3125-d183-77bb54500e95" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_29b707e4-876d-47bd-8655-71c027f42964" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_cf605d39-9067-2f07-a6b5-7dfa6481009e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_29b707e4-876d-47bd-8655-71c027f42964" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://arbutusbio.com/role/CondensedConsolidatedStatementsOfOperations" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_4d7615b5-9ab5-8e33-2d33-f406eee209fc" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_a10eea14-f4db-3125-d183-77bb54500e95" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_4d7615b5-9ab5-8e33-2d33-f406eee209fc" xlink:to="loc_us-gaap_NetIncomeLoss_a10eea14-f4db-3125-d183-77bb54500e95" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_4d8b6d19-6a54-06aa-2077-c10380bd20d1" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_a10eea14-f4db-3125-d183-77bb54500e95" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_4d8b6d19-6a54-06aa-2077-c10380bd20d1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_c5398800-6e68-ed86-a47c-16106e0730c2" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_4d8b6d19-6a54-06aa-2077-c10380bd20d1" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_c5398800-6e68-ed86-a47c-16106e0730c2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest_5fcda05e-5b0d-7f20-111d-115dec47eebc" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_c5398800-6e68-ed86-a47c-16106e0730c2" xlink:to="loc_us-gaap_InvestmentIncomeInterest_5fcda05e-5b0d-7f20-111d-115dec47eebc" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_a56b34b7-57ab-a07c-7f03-8366849a14f0" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_c5398800-6e68-ed86-a47c-16106e0730c2" xlink:to="loc_us-gaap_InterestExpense_a56b34b7-57ab-a07c-7f03-8366849a14f0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_743ecb1a-adc1-2b63-ff24-350f33c715bd" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_c5398800-6e68-ed86-a47c-16106e0730c2" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_743ecb1a-adc1-2b63-ff24-350f33c715bd" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GainLossOnInvestments" xlink:label="loc_us-gaap_GainLossOnInvestments_7b996bea-e1a6-f08b-4e6b-a307dfbe0ae3" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_c5398800-6e68-ed86-a47c-16106e0730c2" xlink:to="loc_us-gaap_GainLossOnInvestments_7b996bea-e1a6-f08b-4e6b-a307dfbe0ae3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_d01a4d5f-b660-27b4-db84-9a80227862fc" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_c5398800-6e68-ed86-a47c-16106e0730c2" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_d01a4d5f-b660-27b4-db84-9a80227862fc" xlink:type="arc" />
    <link:loc xlink:href="abus-20190930.xsd#abus_IncreaseDecreaseInFairValueOfContingentConsiderationLiability" xlink:label="loc_abus_IncreaseDecreaseInFairValueOfContingentConsiderationLiability_ff85cfdf-8805-3a5a-a398-60cf70a0b37f" xlink:type="locator" />
    <link:calculationArc order="6" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_c5398800-6e68-ed86-a47c-16106e0730c2" xlink:to="loc_abus_IncreaseDecreaseInFairValueOfContingentConsiderationLiability_ff85cfdf-8805-3a5a-a398-60cf70a0b37f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_5c890570-5904-7978-36d8-35b96dcf45ab" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_4d8b6d19-6a54-06aa-2077-c10380bd20d1" xlink:to="loc_us-gaap_OperatingIncomeLoss_5c890570-5904-7978-36d8-35b96dcf45ab" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_435f940b-a471-4122-5132-a245458f6913" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_5c890570-5904-7978-36d8-35b96dcf45ab" xlink:to="loc_us-gaap_Revenues_435f940b-a471-4122-5132-a245458f6913" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_a2f4cf19-54a3-c9c5-9b4d-23b76125e270" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_5c890570-5904-7978-36d8-35b96dcf45ab" xlink:to="loc_us-gaap_OperatingExpenses_a2f4cf19-54a3-c9c5-9b4d-23b76125e270" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_11c9d7e5-c56e-e78a-ae7b-17989a817204" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_a2f4cf19-54a3-c9c5-9b4d-23b76125e270" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_11c9d7e5-c56e-e78a-ae7b-17989a817204" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_a698662c-5d68-9b87-98fe-02485cda58f8" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_a2f4cf19-54a3-c9c5-9b4d-23b76125e270" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_a698662c-5d68-9b87-98fe-02485cda58f8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_38b416a4-4707-fba3-1084-9b8a37fd745a" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_a2f4cf19-54a3-c9c5-9b4d-23b76125e270" xlink:to="loc_us-gaap_Depreciation_38b416a4-4707-fba3-1084-9b8a37fd745a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="loc_us-gaap_RestructuringCharges_e04ca6ce-4142-8baf-2785-53947ccd390b" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_a2f4cf19-54a3-c9c5-9b4d-23b76125e270" xlink:to="loc_us-gaap_RestructuringCharges_e04ca6ce-4142-8baf-2785-53947ccd390b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_3033a3a4-4909-893b-2ce2-fe08fce76ef4" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_a2f4cf19-54a3-c9c5-9b4d-23b76125e270" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_3033a3a4-4909-893b-2ce2-fe08fce76ef4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_0d30eb77-a66f-56df-77a0-7c7ad008c84e" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_a2f4cf19-54a3-c9c5-9b4d-23b76125e270" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_0d30eb77-a66f-56df-77a0-7c7ad008c84e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LossContingencyLossInPeriod" xlink:label="loc_us-gaap_LossContingencyLossInPeriod_79cb97fb-4e93-4a0f-392d-ff8859a63194" xlink:type="locator" />
    <link:calculationArc order="7" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_a2f4cf19-54a3-c9c5-9b4d-23b76125e270" xlink:to="loc_us-gaap_LossContingencyLossInPeriod_79cb97fb-4e93-4a0f-392d-ff8859a63194" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_97bbae57-7f84-4da9-acab-610e56204929" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_a10eea14-f4db-3125-d183-77bb54500e95" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_97bbae57-7f84-4da9-acab-610e56204929" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockDividendsAndOtherAdjustments" xlink:label="loc_us-gaap_PreferredStockDividendsAndOtherAdjustments_1462a445-26c1-c50b-6d1d-6a030076b285" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_4d7615b5-9ab5-8e33-2d33-f406eee209fc" xlink:to="loc_us-gaap_PreferredStockDividendsAndOtherAdjustments_1462a445-26c1-c50b-6d1d-6a030076b285" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://arbutusbio.com/role/ContingenciesAndCommitments" xlink:type="extended" />
  <link:calculationLink xlink:role="http://arbutusbio.com/role/ContingenciesAndCommitmentsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://arbutusbio.com/role/DocumentAndEntityInformation" xlink:type="extended" />
  <link:calculationLink xlink:role="http://arbutusbio.com/role/EquityMethodInvestment" xlink:type="extended" />
  <link:calculationLink xlink:role="http://arbutusbio.com/role/EquityMethodInvestmentDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://arbutusbio.com/role/FairValueOfFinancialInstruments" xlink:type="extended" />
  <link:calculationLink xlink:role="http://arbutusbio.com/role/FairValueOfFinancialInstrumentsAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_4f2d2e40-e149-3246-b591-f2ca332c7df6" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_67a1f3e7-c91e-d9a1-0253-362c8d727f2d" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_4f2d2e40-e149-3246-b591-f2ca332c7df6" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_67a1f3e7-c91e-d9a1-0253-362c8d727f2d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_a786ac72-7b36-d915-a262-d97f0559057f" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_4f2d2e40-e149-3246-b591-f2ca332c7df6" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_a786ac72-7b36-d915-a262-d97f0559057f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_6bae24fb-c89c-2c1d-91e1-c77efe1775f1" xlink:type="locator" />
    <link:loc xlink:href="abus-20190930.xsd#abus_EmployeeStockOptionsLiabilityClassifiedOutstandingFairValueDisclosure" xlink:label="loc_abus_EmployeeStockOptionsLiabilityClassifiedOutstandingFairValueDisclosure_bba97f10-6573-2b0b-631f-60cf70a3438c" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_6bae24fb-c89c-2c1d-91e1-c77efe1775f1" xlink:to="loc_abus_EmployeeStockOptionsLiabilityClassifiedOutstandingFairValueDisclosure_bba97f10-6573-2b0b-631f-60cf70a3438c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_1c24f6a3-e8ba-9221-ee1e-4678b4a6cab8" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_6bae24fb-c89c-2c1d-91e1-c77efe1775f1" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_1c24f6a3-e8ba-9221-ee1e-4678b4a6cab8" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://arbutusbio.com/role/FairValueOfFinancialInstrumentsChangesInFairValueOfContingentConsiderationDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://arbutusbio.com/role/FairValueOfFinancialInstrumentsChangesInFairValueOfLiabilitiesClassifiedAsStockOptionDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://arbutusbio.com/role/FairValueOfFinancialInstrumentsTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://arbutusbio.com/role/IntangibleAssetsAndGoodwill" xlink:type="extended" />
  <link:calculationLink xlink:role="http://arbutusbio.com/role/IntangibleAssetsAndGoodwillDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://arbutusbio.com/role/Leases" xlink:type="extended" />
  <link:calculationLink xlink:role="http://arbutusbio.com/role/LeasesMaturitiesOfLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4d26bd18-43c4-5981-04d4-83d0e9328a1d" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_dba432e7-eec4-e0dc-718d-f46fe263fe47" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4d26bd18-43c4-5981-04d4-83d0e9328a1d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_dba432e7-eec4-e0dc-718d-f46fe263fe47" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_41784c6f-4555-af92-3354-8f8701c77f60" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4d26bd18-43c4-5981-04d4-83d0e9328a1d" xlink:to="loc_us-gaap_OperatingLeaseLiability_41784c6f-4555-af92-3354-8f8701c77f60" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://arbutusbio.com/role/LeasesMaturitiesOfLeaseLiabilitiesDetailsCalc2" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_ED26553B258309FAE4CE2226E6A0A7DF_4d26bd18-43c4-5981-04d4-83d0e9328a1d" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_ED26553B258309FAE4CE2226E6A0A7DF_d0e3c4ab-df94-52c6-3761-ce2ed0f2f507" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_ED26553B258309FAE4CE2226E6A0A7DF_4d26bd18-43c4-5981-04d4-83d0e9328a1d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_ED26553B258309FAE4CE2226E6A0A7DF_d0e3c4ab-df94-52c6-3761-ce2ed0f2f507" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_ED26553B258309FAE4CE2226E6A0A7DF_e0f20176-305e-e29f-ab09-584aea596901" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_ED26553B258309FAE4CE2226E6A0A7DF_4d26bd18-43c4-5981-04d4-83d0e9328a1d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_ED26553B258309FAE4CE2226E6A0A7DF_e0f20176-305e-e29f-ab09-584aea596901" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_ED26553B258309FAE4CE2226E6A0A7DF_8e35e675-3955-0e95-1b9c-d08dd410962e" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_ED26553B258309FAE4CE2226E6A0A7DF_4d26bd18-43c4-5981-04d4-83d0e9328a1d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_ED26553B258309FAE4CE2226E6A0A7DF_8e35e675-3955-0e95-1b9c-d08dd410962e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_ED26553B258309FAE4CE2226E6A0A7DF_852d78fc-d4b9-e5fb-fd5a-9da7d3d49669" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_ED26553B258309FAE4CE2226E6A0A7DF_4d26bd18-43c4-5981-04d4-83d0e9328a1d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_ED26553B258309FAE4CE2226E6A0A7DF_852d78fc-d4b9-e5fb-fd5a-9da7d3d49669" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_ED26553B258309FAE4CE2226E6A0A7DF_7a6864a2-d55e-24e7-17f1-75d5cad038ee" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_ED26553B258309FAE4CE2226E6A0A7DF_4d26bd18-43c4-5981-04d4-83d0e9328a1d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_ED26553B258309FAE4CE2226E6A0A7DF_7a6864a2-d55e-24e7-17f1-75d5cad038ee" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_ED26553B258309FAE4CE2226E6A0A7DF_a8c7556a-9f4c-b4fb-2e42-b21cf84287a7" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_ED26553B258309FAE4CE2226E6A0A7DF_4d26bd18-43c4-5981-04d4-83d0e9328a1d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_ED26553B258309FAE4CE2226E6A0A7DF_a8c7556a-9f4c-b4fb-2e42-b21cf84287a7" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://arbutusbio.com/role/LeasesNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://arbutusbio.com/role/LeasesSupplementalCashFlowInformationDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://arbutusbio.com/role/LeasesTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://arbutusbio.com/role/LeasesWeightedAverageRemainingLeaseTermAndDiscountRateDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://arbutusbio.com/role/NatureOfBusinessAndFutureOperations" xlink:type="extended" />
  <link:calculationLink xlink:role="http://arbutusbio.com/role/RelatedPartyTransaction" xlink:type="extended" />
  <link:calculationLink xlink:role="http://arbutusbio.com/role/RelatedPartyTransactionDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://arbutusbio.com/role/SaleOfFutureRoyalties" xlink:type="extended" />
  <link:calculationLink xlink:role="http://arbutusbio.com/role/SaleOfFutureRoyaltiesLiabilityActivityDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://arbutusbio.com/role/SaleOfFutureRoyaltiesNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://arbutusbio.com/role/SaleOfFutureRoyaltiesTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://arbutusbio.com/role/SignificantAccountingPolicies" xlink:type="extended" />
  <link:calculationLink xlink:role="http://arbutusbio.com/role/SignificantAccountingPoliciesNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://arbutusbio.com/role/SignificantAccountingPoliciesPolicies" xlink:type="extended" />
  <link:calculationLink xlink:role="http://arbutusbio.com/role/SignificantAccountingPoliciesScheduleOfComputationOfBasicAndDilutedIncomeLossDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://arbutusbio.com/role/SignificantAccountingPoliciesTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://arbutusbio.com/role/SiteConsolidation" xlink:type="extended" />
  <link:calculationLink xlink:role="http://arbutusbio.com/role/SiteConsolidationConsolidationExpensesDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://arbutusbio.com/role/SiteConsolidationNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://arbutusbio.com/role/SiteConsolidationReserveActivityDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://arbutusbio.com/role/SiteConsolidationTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://arbutusbio.com/role/StockholdersEquityAndStockBasedCompensation" xlink:type="extended" />
  <link:calculationLink xlink:role="http://arbutusbio.com/role/StockholdersEquityAndStockBasedCompensationDetails" xlink:type="extended" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>11
<FILENAME>abus-20190930_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://arbutusbio.com/role/AccountsPayableAndAccruedLiabilities" xlink:href="abus-20190930.xsd#AccountsPayableAndAccruedLiabilities" xlink:type="simple" />
  <link:roleRef roleURI="http://arbutusbio.com/role/AccountsPayableAndAccruedLiabilitiesDetails" xlink:href="abus-20190930.xsd#AccountsPayableAndAccruedLiabilitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://arbutusbio.com/role/AccountsPayableAndAccruedLiabilitiesTables" xlink:href="abus-20190930.xsd#AccountsPayableAndAccruedLiabilitiesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://arbutusbio.com/role/CollaborationsContractsAndLicensingAgreements" xlink:href="abus-20190930.xsd#CollaborationsContractsAndLicensingAgreements" xlink:type="simple" />
  <link:roleRef roleURI="http://arbutusbio.com/role/CollaborationsContractsAndLicensingAgreementsDetails" xlink:href="abus-20190930.xsd#CollaborationsContractsAndLicensingAgreementsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://arbutusbio.com/role/CondensedConsolidatedBalanceSheets" xlink:href="abus-20190930.xsd#CondensedConsolidatedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://arbutusbio.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:href="abus-20190930.xsd#CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://arbutusbio.com/role/CondensedConsolidatedStatementOfStockholdersEquity" xlink:href="abus-20190930.xsd#CondensedConsolidatedStatementOfStockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://arbutusbio.com/role/CondensedConsolidatedStatementOfStockholdersEquityParenthetical" xlink:href="abus-20190930.xsd#CondensedConsolidatedStatementOfStockholdersEquityParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://arbutusbio.com/role/CondensedConsolidatedStatementsOfCashFlow" xlink:href="abus-20190930.xsd#CondensedConsolidatedStatementsOfCashFlow" xlink:type="simple" />
  <link:roleRef roleURI="http://arbutusbio.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLossCondensedConsolidatedStatementsOfComprehensiveIncomeLoss" xlink:href="abus-20190930.xsd#CondensedConsolidatedStatementsOfComprehensiveIncomeLossCondensedConsolidatedStatementsOfComprehensiveIncomeLoss" xlink:type="simple" />
  <link:roleRef roleURI="http://arbutusbio.com/role/CondensedConsolidatedStatementsOfOperations" xlink:href="abus-20190930.xsd#CondensedConsolidatedStatementsOfOperations" xlink:type="simple" />
  <link:roleRef roleURI="http://arbutusbio.com/role/ContingenciesAndCommitments" xlink:href="abus-20190930.xsd#ContingenciesAndCommitments" xlink:type="simple" />
  <link:roleRef roleURI="http://arbutusbio.com/role/ContingenciesAndCommitmentsDetails" xlink:href="abus-20190930.xsd#ContingenciesAndCommitmentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://arbutusbio.com/role/DocumentAndEntityInformation" xlink:href="abus-20190930.xsd#DocumentAndEntityInformation" xlink:type="simple" />
  <link:roleRef roleURI="http://arbutusbio.com/role/EquityMethodInvestment" xlink:href="abus-20190930.xsd#EquityMethodInvestment" xlink:type="simple" />
  <link:roleRef roleURI="http://arbutusbio.com/role/EquityMethodInvestmentDetails" xlink:href="abus-20190930.xsd#EquityMethodInvestmentDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://arbutusbio.com/role/FairValueOfFinancialInstruments" xlink:href="abus-20190930.xsd#FairValueOfFinancialInstruments" xlink:type="simple" />
  <link:roleRef roleURI="http://arbutusbio.com/role/FairValueOfFinancialInstrumentsAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:href="abus-20190930.xsd#FairValueOfFinancialInstrumentsAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://arbutusbio.com/role/FairValueOfFinancialInstrumentsChangesInFairValueOfContingentConsiderationDetails" xlink:href="abus-20190930.xsd#FairValueOfFinancialInstrumentsChangesInFairValueOfContingentConsiderationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://arbutusbio.com/role/FairValueOfFinancialInstrumentsChangesInFairValueOfLiabilitiesClassifiedAsStockOptionDetails" xlink:href="abus-20190930.xsd#FairValueOfFinancialInstrumentsChangesInFairValueOfLiabilitiesClassifiedAsStockOptionDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://arbutusbio.com/role/FairValueOfFinancialInstrumentsTables" xlink:href="abus-20190930.xsd#FairValueOfFinancialInstrumentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://arbutusbio.com/role/IntangibleAssetsAndGoodwill" xlink:href="abus-20190930.xsd#IntangibleAssetsAndGoodwill" xlink:type="simple" />
  <link:roleRef roleURI="http://arbutusbio.com/role/IntangibleAssetsAndGoodwillDetails" xlink:href="abus-20190930.xsd#IntangibleAssetsAndGoodwillDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://arbutusbio.com/role/Leases" xlink:href="abus-20190930.xsd#Leases" xlink:type="simple" />
  <link:roleRef roleURI="http://arbutusbio.com/role/LeasesMaturitiesOfLeaseLiabilitiesDetails" xlink:href="abus-20190930.xsd#LeasesMaturitiesOfLeaseLiabilitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://arbutusbio.com/role/LeasesNarrativeDetails" xlink:href="abus-20190930.xsd#LeasesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://arbutusbio.com/role/LeasesSupplementalCashFlowInformationDetails" xlink:href="abus-20190930.xsd#LeasesSupplementalCashFlowInformationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://arbutusbio.com/role/LeasesTables" xlink:href="abus-20190930.xsd#LeasesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://arbutusbio.com/role/LeasesWeightedAverageRemainingLeaseTermAndDiscountRateDetails" xlink:href="abus-20190930.xsd#LeasesWeightedAverageRemainingLeaseTermAndDiscountRateDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://arbutusbio.com/role/NatureOfBusinessAndFutureOperations" xlink:href="abus-20190930.xsd#NatureOfBusinessAndFutureOperations" xlink:type="simple" />
  <link:roleRef roleURI="http://arbutusbio.com/role/RelatedPartyTransaction" xlink:href="abus-20190930.xsd#RelatedPartyTransaction" xlink:type="simple" />
  <link:roleRef roleURI="http://arbutusbio.com/role/RelatedPartyTransactionDetails" xlink:href="abus-20190930.xsd#RelatedPartyTransactionDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://arbutusbio.com/role/SaleOfFutureRoyalties" xlink:href="abus-20190930.xsd#SaleOfFutureRoyalties" xlink:type="simple" />
  <link:roleRef roleURI="http://arbutusbio.com/role/SaleOfFutureRoyaltiesLiabilityActivityDetails" xlink:href="abus-20190930.xsd#SaleOfFutureRoyaltiesLiabilityActivityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://arbutusbio.com/role/SaleOfFutureRoyaltiesNarrativeDetails" xlink:href="abus-20190930.xsd#SaleOfFutureRoyaltiesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://arbutusbio.com/role/SaleOfFutureRoyaltiesTables" xlink:href="abus-20190930.xsd#SaleOfFutureRoyaltiesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://arbutusbio.com/role/SignificantAccountingPolicies" xlink:href="abus-20190930.xsd#SignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://arbutusbio.com/role/SignificantAccountingPoliciesNarrativeDetails" xlink:href="abus-20190930.xsd#SignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://arbutusbio.com/role/SignificantAccountingPoliciesPolicies" xlink:href="abus-20190930.xsd#SignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://arbutusbio.com/role/SignificantAccountingPoliciesScheduleOfComputationOfBasicAndDilutedIncomeLossDetails" xlink:href="abus-20190930.xsd#SignificantAccountingPoliciesScheduleOfComputationOfBasicAndDilutedIncomeLossDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://arbutusbio.com/role/SignificantAccountingPoliciesTables" xlink:href="abus-20190930.xsd#SignificantAccountingPoliciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://arbutusbio.com/role/SiteConsolidation" xlink:href="abus-20190930.xsd#SiteConsolidation" xlink:type="simple" />
  <link:roleRef roleURI="http://arbutusbio.com/role/SiteConsolidationConsolidationExpensesDetails" xlink:href="abus-20190930.xsd#SiteConsolidationConsolidationExpensesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://arbutusbio.com/role/SiteConsolidationNarrativeDetails" xlink:href="abus-20190930.xsd#SiteConsolidationNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://arbutusbio.com/role/SiteConsolidationReserveActivityDetails" xlink:href="abus-20190930.xsd#SiteConsolidationReserveActivityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://arbutusbio.com/role/SiteConsolidationTables" xlink:href="abus-20190930.xsd#SiteConsolidationTables" xlink:type="simple" />
  <link:roleRef roleURI="http://arbutusbio.com/role/StockholdersEquityAndStockBasedCompensation" xlink:href="abus-20190930.xsd#StockholdersEquityAndStockBasedCompensation" xlink:type="simple" />
  <link:roleRef roleURI="http://arbutusbio.com/role/StockholdersEquityAndStockBasedCompensationDetails" xlink:href="abus-20190930.xsd#StockholdersEquityAndStockBasedCompensationDetails" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple" />
  <link:definitionLink xlink:role="http://arbutusbio.com/role/AccountsPayableAndAccruedLiabilities" xlink:type="extended" />
  <link:definitionLink xlink:role="http://arbutusbio.com/role/AccountsPayableAndAccruedLiabilitiesDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://arbutusbio.com/role/AccountsPayableAndAccruedLiabilitiesTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://arbutusbio.com/role/CollaborationsContractsAndLicensingAgreements" xlink:type="extended" />
  <link:definitionLink xlink:role="http://arbutusbio.com/role/CollaborationsContractsAndLicensingAgreementsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_3456F50925F320BC753022A5BCB95442" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_6E713B7867C6C308D4B422A5BCB6555F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_3456F50925F320BC753022A5BCB95442" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_6E713B7867C6C308D4B422A5BCB6555F" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_1F7E2172D911C5D9196822A5BCB86085" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_6E713B7867C6C308D4B422A5BCB6555F" xlink:to="loc_srt_ProductOrServiceAxis_1F7E2172D911C5D9196822A5BCB86085" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_036BB1B44DE71349C06722A5BCB86A0D_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_1F7E2172D911C5D9196822A5BCB86085" xlink:to="loc_srt_ProductsAndServicesDomain_036BB1B44DE71349C06722A5BCB86A0D_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_036BB1B44DE71349C06722A5BCB86A0D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_1F7E2172D911C5D9196822A5BCB86085" xlink:to="loc_srt_ProductsAndServicesDomain_036BB1B44DE71349C06722A5BCB86A0D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RoyaltyMember" xlink:label="loc_us-gaap_RoyaltyMember_17C7EC99BAC5C8A7244822D204428E4F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_036BB1B44DE71349C06722A5BCB86A0D" xlink:to="loc_us-gaap_RoyaltyMember_17C7EC99BAC5C8A7244822D204428E4F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LicenseMember" xlink:label="loc_us-gaap_LicenseMember_B1B833069F729F20821822D39FE2A387" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_036BB1B44DE71349C06722A5BCB86A0D" xlink:to="loc_us-gaap_LicenseMember_B1B833069F729F20821822D39FE2A387" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_E5ADC51A6C902DB557BB22A5BCB8E759" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_6E713B7867C6C308D4B422A5BCB6555F" xlink:to="loc_srt_CounterpartyNameAxis_E5ADC51A6C902DB557BB22A5BCB8E759" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9919ECC628EE9357E79522A5BCB86F3C_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_E5ADC51A6C902DB557BB22A5BCB8E759" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9919ECC628EE9357E79522A5BCB86F3C_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9919ECC628EE9357E79522A5BCB86F3C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_E5ADC51A6C902DB557BB22A5BCB8E759" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9919ECC628EE9357E79522A5BCB86F3C" xlink:type="arc" />
    <link:loc xlink:href="abus-20190930.xsd#abus_GritstoneMember" xlink:label="loc_abus_GritstoneMember_A851292A3F049A92FC3F22A5BCB9E62D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9919ECC628EE9357E79522A5BCB86F3C" xlink:to="loc_abus_GritstoneMember_A851292A3F049A92FC3F22A5BCB9E62D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_D59D1B732FDE9F262C9322A5BCBA5796" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_3456F50925F320BC753022A5BCB95442" xlink:to="loc_us-gaap_Revenues_D59D1B732FDE9F262C9322A5BCBA5796" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://arbutusbio.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended" />
  <link:definitionLink xlink:role="http://arbutusbio.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended" />
  <link:definitionLink xlink:role="http://arbutusbio.com/role/CondensedConsolidatedStatementOfStockholdersEquity" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_22757A62F5EEEEDE50E6223D3FEE6BEF" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_DE147DD10B3EB30DE186223D3FEC4526" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_22757A62F5EEEEDE50E6223D3FEE6BEF" xlink:to="loc_us-gaap_StatementTable_DE147DD10B3EB30DE186223D3FEC4526" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_99119CD9887D57349810223D3FEC6481" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_DE147DD10B3EB30DE186223D3FEC4526" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_99119CD9887D57349810223D3FEC6481" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_F02FA9F6CA06E5F84AC3223D3FEC50B1_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_99119CD9887D57349810223D3FEC6481" xlink:to="loc_us-gaap_EquityComponentDomain_F02FA9F6CA06E5F84AC3223D3FEC50B1_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_F02FA9F6CA06E5F84AC3223D3FEC50B1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_99119CD9887D57349810223D3FEC6481" xlink:to="loc_us-gaap_EquityComponentDomain_F02FA9F6CA06E5F84AC3223D3FEC50B1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaap_PreferredStockMember_E4BC93CBA8EAD16C98DA223D3FED170B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_F02FA9F6CA06E5F84AC3223D3FEC50B1" xlink:to="loc_us-gaap_PreferredStockMember_E4BC93CBA8EAD16C98DA223D3FED170B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_E562DFD1CD58BB1AF611223D3FEDE63A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_F02FA9F6CA06E5F84AC3223D3FEC50B1" xlink:to="loc_us-gaap_CommonStockMember_E562DFD1CD58BB1AF611223D3FEDE63A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_12734BBC94AE583A291A223D3FEDF47C" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_F02FA9F6CA06E5F84AC3223D3FEC50B1" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_12734BBC94AE583A291A223D3FEDF47C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_E6DD5D260965F5ED1019223D3FED0CEB" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_F02FA9F6CA06E5F84AC3223D3FEC50B1" xlink:to="loc_us-gaap_RetainedEarningsMember_E6DD5D260965F5ED1019223D3FED0CEB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_4A369AFFE4641DEC2A17223D3FED52CF" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_F02FA9F6CA06E5F84AC3223D3FEC50B1" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_4A369AFFE4641DEC2A17223D3FED52CF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_E40794393CACB28EE723223D3FEEB452" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_22757A62F5EEEEDE50E6223D3FEE6BEF" xlink:to="loc_us-gaap_SharesIssued_E40794393CACB28EE723223D3FEEB452" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_6CCA7B441BE0B8BD8AF5223D3FEE8897" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_22757A62F5EEEEDE50E6223D3FEE6BEF" xlink:to="loc_us-gaap_StockholdersEquity_6CCA7B441BE0B8BD8AF5223D3FEE8897" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockAccretionOfRedemptionDiscount" xlink:label="loc_us-gaap_PreferredStockAccretionOfRedemptionDiscount_F3D041E7CBB1CA87D80D223D3FEE092C" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_22757A62F5EEEEDE50E6223D3FEE6BEF" xlink:to="loc_us-gaap_PreferredStockAccretionOfRedemptionDiscount_F3D041E7CBB1CA87D80D223D3FEE092C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_EE2FDA69188072FC37C5223D3FEE6C3C" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_22757A62F5EEEEDE50E6223D3FEE6BEF" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_EE2FDA69188072FC37C5223D3FEE6C3C" xlink:type="arc" />
    <link:loc xlink:href="abus-20190930.xsd#abus_AdjustmentstoAdditionalPaidinCapitalCertainFairValueAdjustmentstoLiabilityStockOptionAwards" xlink:label="loc_abus_AdjustmentstoAdditionalPaidinCapitalCertainFairValueAdjustmentstoLiabilityStockOptionAwards_D9A3C6488D85EC5B85A6223D3FEE626D" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_22757A62F5EEEEDE50E6223D3FEE6BEF" xlink:to="loc_abus_AdjustmentstoAdditionalPaidinCapitalCertainFairValueAdjustmentstoLiabilityStockOptionAwards_D9A3C6488D85EC5B85A6223D3FEE626D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_C13E2E1DD2F089FDC129223D3FEF385D" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_22757A62F5EEEEDE50E6223D3FEE6BEF" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_C13E2E1DD2F089FDC129223D3FEF385D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_72003B93A40A7ADB93FD223D3FEF1540" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_22757A62F5EEEEDE50E6223D3FEE6BEF" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_72003B93A40A7ADB93FD223D3FEF1540" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_80CBF4191D66874E035B223D3FEF849B" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_22757A62F5EEEEDE50E6223D3FEE6BEF" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_80CBF4191D66874E035B223D3FEF849B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_84CC7861F543A29E5934223D3FEF331B" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_22757A62F5EEEEDE50E6223D3FEE6BEF" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_84CC7861F543A29E5934223D3FEF331B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_FF336CA66BC711A1FDAE223D3FEF5559" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_22757A62F5EEEEDE50E6223D3FEE6BEF" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_FF336CA66BC711A1FDAE223D3FEF5559" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_2707DD543F0E59C404CE223D3FEF44D4" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_22757A62F5EEEEDE50E6223D3FEE6BEF" xlink:to="loc_us-gaap_NetIncomeLoss_2707DD543F0E59C404CE223D3FEF44D4" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://arbutusbio.com/role/CondensedConsolidatedStatementOfStockholdersEquityParenthetical" xlink:type="extended" />
  <link:definitionLink xlink:role="http://arbutusbio.com/role/CondensedConsolidatedStatementsOfCashFlow" xlink:type="extended" />
  <link:definitionLink xlink:role="http://arbutusbio.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLossCondensedConsolidatedStatementsOfComprehensiveIncomeLoss" xlink:type="extended" />
  <link:definitionLink xlink:role="http://arbutusbio.com/role/CondensedConsolidatedStatementsOfOperations" xlink:type="extended" />
  <link:definitionLink xlink:role="http://arbutusbio.com/role/ContingenciesAndCommitments" xlink:type="extended" />
  <link:definitionLink xlink:role="http://arbutusbio.com/role/ContingenciesAndCommitmentsDetails" xlink:type="extended">
    <link:loc xlink:href="abus-20190930.xsd#abus_ContingenciesandCommitmentsLineItems" xlink:label="loc_abus_ContingenciesandCommitmentsLineItems_1D7800D87E3399DFC45B22A5BCC7D316" xlink:type="locator" />
    <link:loc xlink:href="abus-20190930.xsd#abus_ContingenciesandCommitmentsTable" xlink:label="loc_abus_ContingenciesandCommitmentsTable_469E5A584B3DF7581FE522A5BCC21207" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_abus_ContingenciesandCommitmentsLineItems_1D7800D87E3399DFC45B22A5BCC7D316" xlink:to="loc_abus_ContingenciesandCommitmentsTable_469E5A584B3DF7581FE522A5BCC21207" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_LitigationCaseAxis" xlink:label="loc_srt_LitigationCaseAxis_515521503F6AEAA157C522A5BCC62DE0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_abus_ContingenciesandCommitmentsTable_469E5A584B3DF7581FE522A5BCC21207" xlink:to="loc_srt_LitigationCaseAxis_515521503F6AEAA157C522A5BCC62DE0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_LitigationCaseTypeDomain" xlink:label="loc_srt_LitigationCaseTypeDomain_27BA4CDA31657FF57E9422A5BCC635A2_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_515521503F6AEAA157C522A5BCC62DE0" xlink:to="loc_srt_LitigationCaseTypeDomain_27BA4CDA31657FF57E9422A5BCC635A2_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_LitigationCaseTypeDomain" xlink:label="loc_srt_LitigationCaseTypeDomain_27BA4CDA31657FF57E9422A5BCC635A2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_515521503F6AEAA157C522A5BCC62DE0" xlink:to="loc_srt_LitigationCaseTypeDomain_27BA4CDA31657FF57E9422A5BCC635A2" xlink:type="arc" />
    <link:loc xlink:href="abus-20190930.xsd#abus_ArbitrationWithTheUniversityOfBritishColumbiaMember" xlink:label="loc_abus_ArbitrationWithTheUniversityOfBritishColumbiaMember_B03736938A46211554E622A5BCC6E401" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_27BA4CDA31657FF57E9422A5BCC635A2" xlink:to="loc_abus_ArbitrationWithTheUniversityOfBritishColumbiaMember_B03736938A46211554E622A5BCC6E401" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_31C53FAFB565AA9D198B22C271212EEF" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_abus_ContingenciesandCommitmentsTable_469E5A584B3DF7581FE522A5BCC21207" xlink:to="loc_srt_RangeAxis_31C53FAFB565AA9D198B22C271212EEF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_A736C55138CE5167C73222C2713322FD_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_31C53FAFB565AA9D198B22C271212EEF" xlink:to="loc_srt_RangeMember_A736C55138CE5167C73222C2713322FD_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_A736C55138CE5167C73222C2713322FD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_31C53FAFB565AA9D198B22C271212EEF" xlink:to="loc_srt_RangeMember_A736C55138CE5167C73222C2713322FD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_84042D52F3E196FD615522C29C29A5EA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_A736C55138CE5167C73222C2713322FD" xlink:to="loc_srt_MinimumMember_84042D52F3E196FD615522C29C29A5EA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_16756E48676478890BDD22C2BB5BD0C5" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_A736C55138CE5167C73222C2713322FD" xlink:to="loc_srt_MaximumMember_16756E48676478890BDD22C2BB5BD0C5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_6B776F92D1E13F2918B322A5BCC3D463" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_abus_ContingenciesandCommitmentsTable_469E5A584B3DF7581FE522A5BCC21207" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_6B776F92D1E13F2918B322A5BCC3D463" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_16937745751FE70A77F522A5BCC38450_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_6B776F92D1E13F2918B322A5BCC3D463" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_16937745751FE70A77F522A5BCC38450_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_16937745751FE70A77F522A5BCC38450" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_6B776F92D1E13F2918B322A5BCC3D463" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_16937745751FE70A77F522A5BCC38450" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_1F9C3A6EE4FC8CB6AB4422A5BCC3ACE7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_16937745751FE70A77F522A5BCC38450" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_1F9C3A6EE4FC8CB6AB4422A5BCC3ACE7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_2BA3FA104FF58F6297D822A5BCC3990F" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_abus_ContingenciesandCommitmentsTable_469E5A584B3DF7581FE522A5BCC21207" xlink:to="loc_srt_CounterpartyNameAxis_2BA3FA104FF58F6297D822A5BCC3990F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_A451F1FD0618596E5DB422A5BCC3236E_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_2BA3FA104FF58F6297D822A5BCC3990F" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_A451F1FD0618596E5DB422A5BCC3236E_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_A451F1FD0618596E5DB422A5BCC3236E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_2BA3FA104FF58F6297D822A5BCC3990F" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_A451F1FD0618596E5DB422A5BCC3236E" xlink:type="arc" />
    <link:loc xlink:href="abus-20190930.xsd#abus_BlumbergandDrexelMember" xlink:label="loc_abus_BlumbergandDrexelMember_4FAB4DB332A4ADF5597322A5BCC4BF78" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_A451F1FD0618596E5DB422A5BCC3236E" xlink:to="loc_abus_BlumbergandDrexelMember_4FAB4DB332A4ADF5597322A5BCC4BF78" xlink:type="arc" />
    <link:loc xlink:href="abus-20190930.xsd#abus_BlumbergMember" xlink:label="loc_abus_BlumbergMember_C1FF69089AE9B9E3B4E622A5BCC4DA00" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_A451F1FD0618596E5DB422A5BCC3236E" xlink:to="loc_abus_BlumbergMember_C1FF69089AE9B9E3B4E622A5BCC4DA00" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_EE94B0C5AF088B1229DA22A5BCC56FC1" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_abus_ContingenciesandCommitmentsTable_469E5A584B3DF7581FE522A5BCC21207" xlink:to="loc_dei_LegalEntityAxis_EE94B0C5AF088B1229DA22A5BCC56FC1" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_7A0C2397C3342E16075022A5BCC5BF63_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_EE94B0C5AF088B1229DA22A5BCC56FC1" xlink:to="loc_dei_EntityDomain_7A0C2397C3342E16075022A5BCC5BF63_default" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_7A0C2397C3342E16075022A5BCC5BF63" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_EE94B0C5AF088B1229DA22A5BCC56FC1" xlink:to="loc_dei_EntityDomain_7A0C2397C3342E16075022A5BCC5BF63" xlink:type="arc" />
    <link:loc xlink:href="abus-20190930.xsd#abus_ArbutusInc.Member" xlink:label="loc_abus_ArbutusInc.Member_F8D75BDCA0AA6F978C3022A5BCC5FE67" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_7A0C2397C3342E16075022A5BCC5BF63" xlink:to="loc_abus_ArbutusInc.Member_F8D75BDCA0AA6F978C3022A5BCC5FE67" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_7536FC64FDD229A5D1A422A5BCC6B669" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_abus_ContingenciesandCommitmentsTable_469E5A584B3DF7581FE522A5BCC21207" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_7536FC64FDD229A5D1A422A5BCC6B669" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_DA8E4A58ED75A580B3FB22A5BCC65437_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_7536FC64FDD229A5D1A422A5BCC6B669" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_DA8E4A58ED75A580B3FB22A5BCC65437_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_DA8E4A58ED75A580B3FB22A5BCC65437" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_7536FC64FDD229A5D1A422A5BCC6B669" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_DA8E4A58ED75A580B3FB22A5BCC65437" xlink:type="arc" />
    <link:loc xlink:href="abus-20190930.xsd#abus_EnantigenMember" xlink:label="loc_abus_EnantigenMember_C886B96468F34BE2145E22A5BCC73395" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_DA8E4A58ED75A580B3FB22A5BCC65437" xlink:to="loc_abus_EnantigenMember_C886B96468F34BE2145E22A5BCC73395" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LossContingencyDamagesSoughtValue" xlink:label="loc_us-gaap_LossContingencyDamagesSoughtValue_75601D1BBC9B42FC033322A5BCC78D8F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abus_ContingenciesandCommitmentsLineItems_1D7800D87E3399DFC45B22A5BCC7D316" xlink:to="loc_us-gaap_LossContingencyDamagesSoughtValue_75601D1BBC9B42FC033322A5BCC78D8F" xlink:type="arc" />
    <link:loc xlink:href="abus-20190930.xsd#abus_Numberoflegalproceedings" xlink:label="loc_abus_Numberoflegalproceedings_DAD6BBFED2AD096A544C22A5BCC77AFB" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abus_ContingenciesandCommitmentsLineItems_1D7800D87E3399DFC45B22A5BCC7D316" xlink:to="loc_abus_Numberoflegalproceedings_DAD6BBFED2AD096A544C22A5BCC77AFB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_DAA29A13D17D75F5861222BB2A36145A" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abus_ContingenciesandCommitmentsLineItems_1D7800D87E3399DFC45B22A5BCC7D316" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_DAA29A13D17D75F5861222BB2A36145A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LitigationSettlementInterest" xlink:label="loc_us-gaap_LitigationSettlementInterest_E078D8E941C5180F0BB822BC234E05B7" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abus_ContingenciesandCommitmentsLineItems_1D7800D87E3399DFC45B22A5BCC7D316" xlink:to="loc_us-gaap_LitigationSettlementInterest_E078D8E941C5180F0BB822BC234E05B7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LossContingencyLossInPeriod" xlink:label="loc_us-gaap_LossContingencyLossInPeriod_2930139CC65D8CF397B022C4AADC80E9" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abus_ContingenciesandCommitmentsLineItems_1D7800D87E3399DFC45B22A5BCC7D316" xlink:to="loc_us-gaap_LossContingencyLossInPeriod_2930139CC65D8CF397B022C4AADC80E9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsForLegalSettlements" xlink:label="loc_us-gaap_PaymentsForLegalSettlements_ABEC9B16DBD66753ABF722BD2E72366D" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abus_ContingenciesandCommitmentsLineItems_1D7800D87E3399DFC45B22A5BCC7D316" xlink:to="loc_us-gaap_PaymentsForLegalSettlements_ABEC9B16DBD66753ABF722BD2E72366D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:label="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_A2405E7AC47DB7354A4522C253757E9C" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abus_ContingenciesandCommitmentsLineItems_1D7800D87E3399DFC45B22A5BCC7D316" xlink:to="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_A2405E7AC47DB7354A4522C253757E9C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_CCF3FD6D5E2ACCF9B22B22A5BCC83FC3" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abus_ContingenciesandCommitmentsLineItems_1D7800D87E3399DFC45B22A5BCC7D316" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_CCF3FD6D5E2ACCF9B22B22A5BCC83FC3" xlink:type="arc" />
    <link:loc xlink:href="abus-20190930.xsd#abus_NumberOfProductsCoveredByPatentAcquiredUnderAgreement" xlink:label="loc_abus_NumberOfProductsCoveredByPatentAcquiredUnderAgreement_8ECD01BCE34600CEDF9E22A5BCC87F9D" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abus_ContingenciesandCommitmentsLineItems_1D7800D87E3399DFC45B22A5BCC7D316" xlink:to="loc_abus_NumberOfProductsCoveredByPatentAcquiredUnderAgreement_8ECD01BCE34600CEDF9E22A5BCC87F9D" xlink:type="arc" />
    <link:loc xlink:href="abus-20190930.xsd#abus_LicenseAgreementMaximumDevelopmentAndRegulatoryMilestonePaymentsPerLicense" xlink:label="loc_abus_LicenseAgreementMaximumDevelopmentAndRegulatoryMilestonePaymentsPerLicense_39292316DAFDE26DC8F022A5BCC893C8" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abus_ContingenciesandCommitmentsLineItems_1D7800D87E3399DFC45B22A5BCC7D316" xlink:to="loc_abus_LicenseAgreementMaximumDevelopmentAndRegulatoryMilestonePaymentsPerLicense_39292316DAFDE26DC8F022A5BCC893C8" xlink:type="arc" />
    <link:loc xlink:href="abus-20190930.xsd#abus_LicenseAgreementMaximumDevelopmentAndRegulatoryMilestonePaymentsPerRoyalty" xlink:label="loc_abus_LicenseAgreementMaximumDevelopmentAndRegulatoryMilestonePaymentsPerRoyalty_2D21ED2AD0F2E46DEEF822A5BCC8B75A" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abus_ContingenciesandCommitmentsLineItems_1D7800D87E3399DFC45B22A5BCC7D316" xlink:to="loc_abus_LicenseAgreementMaximumDevelopmentAndRegulatoryMilestonePaymentsPerRoyalty_2D21ED2AD0F2E46DEEF822A5BCC8B75A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_A581717BF0C47642B23122A5BCC82297" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abus_ContingenciesandCommitmentsLineItems_1D7800D87E3399DFC45B22A5BCC7D316" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_A581717BF0C47642B23122A5BCC82297" xlink:type="arc" />
    <link:loc xlink:href="abus-20190930.xsd#abus_NumberofPatentLicenses" xlink:label="loc_abus_NumberofPatentLicenses_CE78E8FB16505F59C32222A5BCC8F95A" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abus_ContingenciesandCommitmentsLineItems_1D7800D87E3399DFC45B22A5BCC7D316" xlink:to="loc_abus_NumberofPatentLicenses_CE78E8FB16505F59C32222A5BCC8F95A" xlink:type="arc" />
    <link:loc xlink:href="abus-20190930.xsd#abus_ResearchFundingPeriod" xlink:label="loc_abus_ResearchFundingPeriod_67FC3B8D5C9C268A1E6C22A5BCC8E30A" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abus_ContingenciesandCommitmentsLineItems_1D7800D87E3399DFC45B22A5BCC7D316" xlink:to="loc_abus_ResearchFundingPeriod_67FC3B8D5C9C268A1E6C22A5BCC8E30A" xlink:type="arc" />
    <link:loc xlink:href="abus-20190930.xsd#abus_ContractualObligationAmountOfResearchFundingPerYear" xlink:label="loc_abus_ContractualObligationAmountOfResearchFundingPerYear_1F79143E209E0E9D0A0C22A5BCC991F8" xlink:type="locator" />
    <link:definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abus_ContingenciesandCommitmentsLineItems_1D7800D87E3399DFC45B22A5BCC7D316" xlink:to="loc_abus_ContractualObligationAmountOfResearchFundingPerYear_1F79143E209E0E9D0A0C22A5BCC991F8" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://arbutusbio.com/role/DocumentAndEntityInformation" xlink:type="extended" />
  <link:definitionLink xlink:role="http://arbutusbio.com/role/EquityMethodInvestment" xlink:type="extended" />
  <link:definitionLink xlink:role="http://arbutusbio.com/role/EquityMethodInvestmentDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_EED131FDDFD02FE0FDF52271CB7F56F9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_81EB6EB7ABBE49F83E3C2271CB7DD7E6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_EED131FDDFD02FE0FDF52271CB7F56F9" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_81EB6EB7ABBE49F83E3C2271CB7DD7E6" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_E2109013831DC0A7C0E52271CB7EF6AE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_81EB6EB7ABBE49F83E3C2271CB7DD7E6" xlink:to="loc_dei_LegalEntityAxis_E2109013831DC0A7C0E52271CB7EF6AE" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_AE7E7B25717EB7494CCD2271CB7EAAE8_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_E2109013831DC0A7C0E52271CB7EF6AE" xlink:to="loc_dei_EntityDomain_AE7E7B25717EB7494CCD2271CB7EAAE8_default" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_AE7E7B25717EB7494CCD2271CB7EAAE8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_E2109013831DC0A7C0E52271CB7EF6AE" xlink:to="loc_dei_EntityDomain_AE7E7B25717EB7494CCD2271CB7EAAE8" xlink:type="arc" />
    <link:loc xlink:href="abus-20190930.xsd#abus_RoivantSciencesLtdMember" xlink:label="loc_abus_RoivantSciencesLtdMember_0AE556DF6FAD8B136BF32271CB7E1B5E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_AE7E7B25717EB7494CCD2271CB7EAAE8" xlink:to="loc_abus_RoivantSciencesLtdMember_0AE556DF6FAD8B136BF32271CB7E1B5E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_B172BF96AD15F665E4C42271CB7F4D8B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_81EB6EB7ABBE49F83E3C2271CB7DD7E6" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_B172BF96AD15F665E4C42271CB7F4D8B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_49D586A9A25B71705F0E2271CB7F6831_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_B172BF96AD15F665E4C42271CB7F4D8B" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_49D586A9A25B71705F0E2271CB7F6831_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_49D586A9A25B71705F0E2271CB7F6831" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_B172BF96AD15F665E4C42271CB7F4D8B" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_49D586A9A25B71705F0E2271CB7F6831" xlink:type="arc" />
    <link:loc xlink:href="abus-20190930.xsd#abus_GenevantSciencesCorporationMember" xlink:label="loc_abus_GenevantSciencesCorporationMember_A5ECAC950E898206400B2271CB7F4A90" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_49D586A9A25B71705F0E2271CB7F6831" xlink:to="loc_abus_GenevantSciencesCorporationMember_A5ECAC950E898206400B2271CB7F4A90" xlink:type="arc" />
    <link:loc xlink:href="abus-20190930.xsd#abus_EquityMethodInvestmentPropertyContribution" xlink:label="loc_abus_EquityMethodInvestmentPropertyContribution_B00D4BE0434BD4ABA5D02271CB7FC432" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_EED131FDDFD02FE0FDF52271CB7F56F9" xlink:to="loc_abus_EquityMethodInvestmentPropertyContribution_B00D4BE0434BD4ABA5D02271CB7FC432" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_39EC85C9CD8A57FBC4EB2271CB80F50E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_EED131FDDFD02FE0FDF52271CB7F56F9" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_39EC85C9CD8A57FBC4EB2271CB80F50E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_C2593CB560C861F6B0332271CB80636E" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_EED131FDDFD02FE0FDF52271CB7F56F9" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_C2593CB560C861F6B0332271CB80636E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityMethodInvestments" xlink:label="loc_us-gaap_EquityMethodInvestments_0BBB32FB76790F125F732271CB805057" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_EED131FDDFD02FE0FDF52271CB7F56F9" xlink:to="loc_us-gaap_EquityMethodInvestments_0BBB32FB76790F125F732271CB805057" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://arbutusbio.com/role/FairValueOfFinancialInstruments" xlink:type="extended" />
  <link:definitionLink xlink:role="http://arbutusbio.com/role/FairValueOfFinancialInstrumentsAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_E2C2BC36E8365D10AED4220D83A0551B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8A43FC9B80B0D819FD64220D839D3BE2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_E2C2BC36E8365D10AED4220D83A0551B" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8A43FC9B80B0D819FD64220D839D3BE2" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_E2C273BD9995AC14DF5A220D839E70F3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8A43FC9B80B0D819FD64220D839D3BE2" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_E2C273BD9995AC14DF5A220D839E70F3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_428F1C303BD6AE330AD6220D839ED75D_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_E2C273BD9995AC14DF5A220D839E70F3" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_428F1C303BD6AE330AD6220D839ED75D_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_428F1C303BD6AE330AD6220D839ED75D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_E2C273BD9995AC14DF5A220D839E70F3" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_428F1C303BD6AE330AD6220D839ED75D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_7E8A1F25761DD8714ED6220D839EB928" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_428F1C303BD6AE330AD6220D839ED75D" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_7E8A1F25761DD8714ED6220D839EB928" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_42DFCA41E85973D29E27220D839F6205" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8A43FC9B80B0D819FD64220D839D3BE2" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_42DFCA41E85973D29E27220D839F6205" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_FA1261375F7DF15D47B6220D839FBA4D_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_42DFCA41E85973D29E27220D839F6205" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_FA1261375F7DF15D47B6220D839FBA4D_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_FA1261375F7DF15D47B6220D839FBA4D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_42DFCA41E85973D29E27220D839F6205" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_FA1261375F7DF15D47B6220D839FBA4D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_F77DB0154B64598B0F6E220D839FF0F6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_FA1261375F7DF15D47B6220D839FBA4D" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_F77DB0154B64598B0F6E220D839FF0F6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_031CDA948E138B9DE33F220D839F4B9E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_FA1261375F7DF15D47B6220D839FBA4D" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_031CDA948E138B9DE33F220D839F4B9E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_31C71F9F9A5DE0D652B5220D83A06B56" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_FA1261375F7DF15D47B6220D839FBA4D" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_31C71F9F9A5DE0D652B5220D83A06B56" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_03D1484311141D01ED52220D83A0E76E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_E2C2BC36E8365D10AED4220D83A0551B" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_03D1484311141D01ED52220D83A0E76E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_043AE5F8989205022D6D220D83A07BB3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_03D1484311141D01ED52220D83A0E76E" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_043AE5F8989205022D6D220D83A07BB3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_DFC98B7C07BD8E9AF32E220D83A5EA4E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_03D1484311141D01ED52220D83A0E76E" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_DFC98B7C07BD8E9AF32E220D83A5EA4E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_DE18C872DB1EC84609C9220D83A6C52A" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_03D1484311141D01ED52220D83A0E76E" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_DE18C872DB1EC84609C9220D83A6C52A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_B4B97EA55AF95781ADF8220D83A65C65" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_E2C2BC36E8365D10AED4220D83A0551B" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_B4B97EA55AF95781ADF8220D83A65C65" xlink:type="arc" />
    <link:loc xlink:href="abus-20190930.xsd#abus_EmployeeStockOptionsLiabilityClassifiedOutstandingFairValueDisclosure" xlink:label="loc_abus_EmployeeStockOptionsLiabilityClassifiedOutstandingFairValueDisclosure_81FF0186D127FE0FEB4C220D83A6CF94" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_B4B97EA55AF95781ADF8220D83A65C65" xlink:to="loc_abus_EmployeeStockOptionsLiabilityClassifiedOutstandingFairValueDisclosure_81FF0186D127FE0FEB4C220D83A6CF94" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_31EC4FA0DA922DE6C084220D83A6FEED" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_B4B97EA55AF95781ADF8220D83A65C65" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_31EC4FA0DA922DE6C084220D83A6FEED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_F7A4BADCAE5DA522C4CC220D83A6D6DC" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_B4B97EA55AF95781ADF8220D83A65C65" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_F7A4BADCAE5DA522C4CC220D83A6D6DC" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://arbutusbio.com/role/FairValueOfFinancialInstrumentsChangesInFairValueOfContingentConsiderationDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://arbutusbio.com/role/FairValueOfFinancialInstrumentsChangesInFairValueOfLiabilitiesClassifiedAsStockOptionDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_6184525B369BE39609322271CBB0672C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_58760FA0C1263A9890942271CBAF382C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_6184525B369BE39609322271CBB0672C" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_58760FA0C1263A9890942271CBAF382C" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_DEA75AA343EC5AC72A802271CBAF4E5D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_58760FA0C1263A9890942271CBAF382C" xlink:to="loc_us-gaap_AwardTypeAxis_DEA75AA343EC5AC72A802271CBAF4E5D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_C132ADE50E7992D45BA72271CBB084EC_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_DEA75AA343EC5AC72A802271CBAF4E5D" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_C132ADE50E7992D45BA72271CBB084EC_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_C132ADE50E7992D45BA72271CBB084EC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_DEA75AA343EC5AC72A802271CBAF4E5D" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_C132ADE50E7992D45BA72271CBB084EC" xlink:type="arc" />
    <link:loc xlink:href="abus-20190930.xsd#abus_EmployeeStockOptionLiabilityClassifiedMember" xlink:label="loc_abus_EmployeeStockOptionLiabilityClassifiedMember_AF352824FE49E959E6FF2271CBB0D8E2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_C132ADE50E7992D45BA72271CBB084EC" xlink:to="loc_abus_EmployeeStockOptionLiabilityClassifiedMember_AF352824FE49E959E6FF2271CBB0D8E2" xlink:type="arc" />
    <link:loc xlink:href="abus-20190930.xsd#abus_FairValueLiabilitiesMeasuredonRecurringBasisRollForward" xlink:label="loc_abus_FairValueLiabilitiesMeasuredonRecurringBasisRollForward_AE61A533BBDC446119EF2271CBB15E64" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_6184525B369BE39609322271CBB0672C" xlink:to="loc_abus_FairValueLiabilitiesMeasuredonRecurringBasisRollForward_AE61A533BBDC446119EF2271CBB15E64" xlink:type="arc" />
    <link:loc xlink:href="abus-20190930.xsd#abus_EmployeeStockOptionsLiabilityClassifiedOutstandingFairValueDisclosure" xlink:label="loc_abus_EmployeeStockOptionsLiabilityClassifiedOutstandingFairValueDisclosure_27D6EEFE9D2CB9A9B3F32271CBB16437" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abus_FairValueLiabilitiesMeasuredonRecurringBasisRollForward_AE61A533BBDC446119EF2271CBB15E64" xlink:to="loc_abus_EmployeeStockOptionsLiabilityClassifiedOutstandingFairValueDisclosure_27D6EEFE9D2CB9A9B3F32271CBB16437" xlink:type="arc" />
    <link:loc xlink:href="abus-20190930.xsd#abus_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisesinPeriodFairValue" xlink:label="loc_abus_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisesinPeriodFairValue_BAD1BF3A80C80730ADFA2271CBB11A6C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abus_FairValueLiabilitiesMeasuredonRecurringBasisRollForward_AE61A533BBDC446119EF2271CBB15E64" xlink:to="loc_abus_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisesinPeriodFairValue_BAD1BF3A80C80730ADFA2271CBB11A6C" xlink:type="arc" />
    <link:loc xlink:href="abus-20190930.xsd#abus_IncreaseDecreaseinFairValueofLiabilityClassifiedOptions" xlink:label="loc_abus_IncreaseDecreaseinFairValueofLiabilityClassifiedOptions_D681C7BF3C824F4FB3652271CBB1E353" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abus_FairValueLiabilitiesMeasuredonRecurringBasisRollForward_AE61A533BBDC446119EF2271CBB15E64" xlink:to="loc_abus_IncreaseDecreaseinFairValueofLiabilityClassifiedOptions_D681C7BF3C824F4FB3652271CBB1E353" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://arbutusbio.com/role/FairValueOfFinancialInstrumentsTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://arbutusbio.com/role/IntangibleAssetsAndGoodwill" xlink:type="extended" />
  <link:definitionLink xlink:role="http://arbutusbio.com/role/IntangibleAssetsAndGoodwillDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_954B774A89927BA3F86F22A3049A1084" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_8C4CA432DB4D06C8AA5522A3049AE799" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_954B774A89927BA3F86F22A3049A1084" xlink:to="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_8C4CA432DB4D06C8AA5522A3049AE799" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_A8B4845D9822919F568622A3049A5F55" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_8C4CA432DB4D06C8AA5522A3049AE799" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_A8B4845D9822919F568622A3049A5F55" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_8921C8A192D43C89ED0C22A3049A8532_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_A8B4845D9822919F568622A3049A5F55" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_8921C8A192D43C89ED0C22A3049A8532_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_8921C8A192D43C89ED0C22A3049A8532" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_A8B4845D9822919F568622A3049A5F55" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_8921C8A192D43C89ED0C22A3049A8532" xlink:type="arc" />
    <link:loc xlink:href="abus-20190930.xsd#abus_InProcessResearchandDevelopmentcccDNASterilizersMember" xlink:label="loc_abus_InProcessResearchandDevelopmentcccDNASterilizersMember_446EBA45B9DF2DE358E922A3049AC7A8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_8921C8A192D43C89ED0C22A3049A8532" xlink:to="loc_abus_InProcessResearchandDevelopmentcccDNASterilizersMember_446EBA45B9DF2DE358E922A3049AC7A8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_6AC913BBD64C27A6C2B122A3049A401B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_954B774A89927BA3F86F22A3049A1084" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_6AC913BBD64C27A6C2B122A3049A401B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_5D28BAA53B6A1B374DA422A5A4C6CFF8" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_954B774A89927BA3F86F22A3049A1084" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_5D28BAA53B6A1B374DA422A5A4C6CFF8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability_E924F5EFFD3B5450BAB022A3049A20E1" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_954B774A89927BA3F86F22A3049A1084" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability_E924F5EFFD3B5450BAB022A3049A20E1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_C4101617BDFF9E5D6DE722A5A51894E0" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_954B774A89927BA3F86F22A3049A1084" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_C4101617BDFF9E5D6DE722A5A51894E0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_5F12B7AFFBA3BBF66F0822A5A54D07B9" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_954B774A89927BA3F86F22A3049A1084" xlink:to="loc_us-gaap_Goodwill_5F12B7AFFBA3BBF66F0822A5A54D07B9" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://arbutusbio.com/role/Leases" xlink:type="extended" />
  <link:definitionLink xlink:role="http://arbutusbio.com/role/LeasesMaturitiesOfLeaseLiabilitiesDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://arbutusbio.com/role/LeasesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_6860ED463086CB7FCCAF06BB94948E4A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_00A2485C994411A23E6D06BB9494414F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6860ED463086CB7FCCAF06BB94948E4A" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_00A2485C994411A23E6D06BB9494414F" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseArrangementTypeAxis" xlink:label="loc_us-gaap_LeaseArrangementTypeAxis_FBC866BFD92E55B5EF8506BB94940D8C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_00A2485C994411A23E6D06BB9494414F" xlink:to="loc_us-gaap_LeaseArrangementTypeAxis_FBC866BFD92E55B5EF8506BB94940D8C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:label="loc_us-gaap_LeaseArrangementTypeDomain_CAFE7F1C49C47F684F3A06BB94944505_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LeaseArrangementTypeAxis_FBC866BFD92E55B5EF8506BB94940D8C" xlink:to="loc_us-gaap_LeaseArrangementTypeDomain_CAFE7F1C49C47F684F3A06BB94944505_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:label="loc_us-gaap_LeaseArrangementTypeDomain_CAFE7F1C49C47F684F3A06BB94944505" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LeaseArrangementTypeAxis_FBC866BFD92E55B5EF8506BB94940D8C" xlink:to="loc_us-gaap_LeaseArrangementTypeDomain_CAFE7F1C49C47F684F3A06BB94944505" xlink:type="arc" />
    <link:loc xlink:href="abus-20190930.xsd#abus_CorporateHeadquartersLocated701VeteransCircleWarminsterPennsylvaniaMember" xlink:label="loc_abus_CorporateHeadquartersLocated701VeteransCircleWarminsterPennsylvaniaMember_F490152DAF8D4C5068F606BB94947250" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LeaseArrangementTypeDomain_CAFE7F1C49C47F684F3A06BB94944505" xlink:to="loc_abus_CorporateHeadquartersLocated701VeteransCircleWarminsterPennsylvaniaMember_F490152DAF8D4C5068F606BB94947250" xlink:type="arc" />
    <link:loc xlink:href="abus-20190930.xsd#abus_OfficesLocatedat626JacksonvilleRd.WarminsterPennsylvaniaMember" xlink:label="loc_abus_OfficesLocatedat626JacksonvilleRd.WarminsterPennsylvaniaMember_C0FD2C731CA6C173C79806BB949471B2" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LeaseArrangementTypeDomain_CAFE7F1C49C47F684F3A06BB94944505" xlink:to="loc_abus_OfficesLocatedat626JacksonvilleRd.WarminsterPennsylvaniaMember_C0FD2C731CA6C173C79806BB949471B2" xlink:type="arc" />
    <link:loc xlink:href="abus-20190930.xsd#abus_SubleaseBurnabyFacilityMember" xlink:label="loc_abus_SubleaseBurnabyFacilityMember_ECD67A58DE9F4D449A4C06BB9494600D" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LeaseArrangementTypeDomain_CAFE7F1C49C47F684F3A06BB94944505" xlink:to="loc_abus_SubleaseBurnabyFacilityMember_ECD67A58DE9F4D449A4C06BB9494600D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_3B20AF102D82D3DEA75306BB94948472" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_00A2485C994411A23E6D06BB9494414F" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_3B20AF102D82D3DEA75306BB94948472" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_B75698FC8FC0E5AF68D206BB94945583_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_3B20AF102D82D3DEA75306BB94948472" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_B75698FC8FC0E5AF68D206BB94945583_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_B75698FC8FC0E5AF68D206BB94945583" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_3B20AF102D82D3DEA75306BB94948472" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_B75698FC8FC0E5AF68D206BB94945583" xlink:type="arc" />
    <link:loc xlink:href="abus-20190930.xsd#abus_GenevantSciencesCorporationMember" xlink:label="loc_abus_GenevantSciencesCorporationMember_A42222D239D898AD348A06BB94941A6E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_B75698FC8FC0E5AF68D206BB94945583" xlink:to="loc_abus_GenevantSciencesCorporationMember_A42222D239D898AD348A06BB94941A6E" xlink:type="arc" />
    <link:loc xlink:href="abus-20190930.xsd#abus_LesseeOperatingLeaseNumberofLeases" xlink:label="loc_abus_LesseeOperatingLeaseNumberofLeases_670FA3B50FEE7A50B5E706BB94947CE0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6860ED463086CB7FCCAF06BB94948E4A" xlink:to="loc_abus_LesseeOperatingLeaseNumberofLeases_670FA3B50FEE7A50B5E706BB94947CE0" xlink:type="arc" />
    <link:loc xlink:href="abus-20190930.xsd#abus_LesseeOperatingLeaseNumberOfRenewalOptions" xlink:label="loc_abus_LesseeOperatingLeaseNumberOfRenewalOptions_A4C933B28E1D0A6C663B06BB9494C71A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6860ED463086CB7FCCAF06BB94948E4A" xlink:to="loc_abus_LesseeOperatingLeaseNumberOfRenewalOptions_A4C933B28E1D0A6C663B06BB9494C71A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LessorOperatingLeaseRenewalTerm" xlink:label="loc_us-gaap_LessorOperatingLeaseRenewalTerm_727B87B30001A33FFD9506BB94940683" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6860ED463086CB7FCCAF06BB94948E4A" xlink:to="loc_us-gaap_LessorOperatingLeaseRenewalTerm_727B87B30001A33FFD9506BB94940683" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseDiscountRate" xlink:label="loc_us-gaap_LesseeOperatingLeaseDiscountRate_45AE6F8147EE7446A7FA06BB9494DBB9" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6860ED463086CB7FCCAF06BB94948E4A" xlink:to="loc_us-gaap_LesseeOperatingLeaseDiscountRate_45AE6F8147EE7446A7FA06BB9494DBB9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseExpense" xlink:label="loc_us-gaap_OperatingLeaseExpense_FFD10BA008B9E91D981A06BB9494ED58" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6860ED463086CB7FCCAF06BB94948E4A" xlink:to="loc_us-gaap_OperatingLeaseExpense_FFD10BA008B9E91D981A06BB9494ED58" xlink:type="arc" />
    <link:loc xlink:href="abus-20190930.xsd#abus_FixedLeaseCost" xlink:label="loc_abus_FixedLeaseCost_DA7CEA2CA93B0E03AFDF06BB94948C62" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6860ED463086CB7FCCAF06BB94948E4A" xlink:to="loc_abus_FixedLeaseCost_DA7CEA2CA93B0E03AFDF06BB94948C62" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_VariableLeaseCost" xlink:label="loc_us-gaap_VariableLeaseCost_7EBDA04837E6CC99796906BB9494F83C" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6860ED463086CB7FCCAF06BB94948E4A" xlink:to="loc_us-gaap_VariableLeaseCost_7EBDA04837E6CC99796906BB9494F83C" xlink:type="arc" />
    <link:loc xlink:href="abus-20190930.xsd#abus_StrightlineFixedLeaseCost" xlink:label="loc_abus_StrightlineFixedLeaseCost_87C9CD7962F887FFDE3B06BB9494F41A" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6860ED463086CB7FCCAF06BB94948E4A" xlink:to="loc_abus_StrightlineFixedLeaseCost_87C9CD7962F887FFDE3B06BB9494F41A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubleaseIncome" xlink:label="loc_us-gaap_SubleaseIncome_31A0EA7F74F62086C39406BB9494E938" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6860ED463086CB7FCCAF06BB94948E4A" xlink:to="loc_us-gaap_SubleaseIncome_31A0EA7F74F62086C39406BB9494E938" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://arbutusbio.com/role/LeasesSupplementalCashFlowInformationDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://arbutusbio.com/role/LeasesTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://arbutusbio.com/role/LeasesWeightedAverageRemainingLeaseTermAndDiscountRateDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://arbutusbio.com/role/NatureOfBusinessAndFutureOperations" xlink:type="extended" />
  <link:definitionLink xlink:role="http://arbutusbio.com/role/RelatedPartyTransaction" xlink:type="extended" />
  <link:definitionLink xlink:role="http://arbutusbio.com/role/RelatedPartyTransactionDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_202C5004BCE7D51EBD4E25AE3BD66834" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_C1A44E62DEAE562F44B525AE3BD31EC0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_202C5004BCE7D51EBD4E25AE3BD66834" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_C1A44E62DEAE562F44B525AE3BD31EC0" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_DC7AFD7AB16E30E00C0725AE3BD3A506" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_C1A44E62DEAE562F44B525AE3BD31EC0" xlink:to="loc_srt_CounterpartyNameAxis_DC7AFD7AB16E30E00C0725AE3BD3A506" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1E41B19EF33B3D87616525AE3BD4FACC_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_DC7AFD7AB16E30E00C0725AE3BD3A506" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1E41B19EF33B3D87616525AE3BD4FACC_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1E41B19EF33B3D87616525AE3BD4FACC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_DC7AFD7AB16E30E00C0725AE3BD3A506" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1E41B19EF33B3D87616525AE3BD4FACC" xlink:type="arc" />
    <link:loc xlink:href="abus-20190930.xsd#abus_GenevantSciencesCorporationMember" xlink:label="loc_abus_GenevantSciencesCorporationMember_512CD5E98B9A026B12D225AE3BD49D9C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1E41B19EF33B3D87616525AE3BD4FACC" xlink:to="loc_abus_GenevantSciencesCorporationMember_512CD5E98B9A026B12D225AE3BD49D9C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_FB8A2A7D3D1D800E729425AE3BD493BB" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_C1A44E62DEAE562F44B525AE3BD31EC0" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_FB8A2A7D3D1D800E729425AE3BD493BB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_45D7782822C03CCD955825AE3BD4B7CF_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_FB8A2A7D3D1D800E729425AE3BD493BB" xlink:to="loc_us-gaap_RelatedPartyDomain_45D7782822C03CCD955825AE3BD4B7CF_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_45D7782822C03CCD955825AE3BD4B7CF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_FB8A2A7D3D1D800E729425AE3BD493BB" xlink:to="loc_us-gaap_RelatedPartyDomain_45D7782822C03CCD955825AE3BD4B7CF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityMethodInvesteeMember" xlink:label="loc_us-gaap_EquityMethodInvesteeMember_311E4ADD0D90DC33B2DD25AE3BD5733C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_45D7782822C03CCD955825AE3BD4B7CF" xlink:to="loc_us-gaap_EquityMethodInvesteeMember_311E4ADD0D90DC33B2DD25AE3BD5733C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_ACAFBBF02AC3851CCB5525AE3BD5FBAD" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_C1A44E62DEAE562F44B525AE3BD31EC0" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_ACAFBBF02AC3851CCB5525AE3BD5FBAD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_BBE91D3C5777F2286B7A25AE3BD5C1E7_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_ACAFBBF02AC3851CCB5525AE3BD5FBAD" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_BBE91D3C5777F2286B7A25AE3BD5C1E7_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_BBE91D3C5777F2286B7A25AE3BD5C1E7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_ACAFBBF02AC3851CCB5525AE3BD5FBAD" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_BBE91D3C5777F2286B7A25AE3BD5C1E7" xlink:type="arc" />
    <link:loc xlink:href="abus-20190930.xsd#abus_ResearchAndDevelopmentServicesMember" xlink:label="loc_abus_ResearchAndDevelopmentServicesMember_DF97D9586FB249DE13E225AE3BD6EA6B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_BBE91D3C5777F2286B7A25AE3BD5C1E7" xlink:to="loc_abus_ResearchAndDevelopmentServicesMember_DF97D9586FB249DE13E225AE3BD6EA6B" xlink:type="arc" />
    <link:loc xlink:href="abus-20190930.xsd#abus_AdministrativeAndTransitionalServicesMember" xlink:label="loc_abus_AdministrativeAndTransitionalServicesMember_A04120C725DCA5C6D77A25AE3BD65544" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_BBE91D3C5777F2286B7A25AE3BD5C1E7" xlink:to="loc_abus_AdministrativeAndTransitionalServicesMember_A04120C725DCA5C6D77A25AE3BD65544" xlink:type="arc" />
    <link:loc xlink:href="abus-20190930.xsd#abus_SubleaseBurnabyFacilityMember" xlink:label="loc_abus_SubleaseBurnabyFacilityMember_D5AD0AC5B2EC57D83ECD25AE3BD65122" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_BBE91D3C5777F2286B7A25AE3BD5C1E7" xlink:to="loc_abus_SubleaseBurnabyFacilityMember_D5AD0AC5B2EC57D83ECD25AE3BD65122" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:label="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_13998BFE435DEF59479C25AE3BD79125" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_202C5004BCE7D51EBD4E25AE3BD66834" xlink:to="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_13998BFE435DEF59479C25AE3BD79125" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromRelatedParties" xlink:label="loc_us-gaap_RevenueFromRelatedParties_709345E1E845BCFEC4C825AE3BD7F38B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_202C5004BCE7D51EBD4E25AE3BD66834" xlink:to="loc_us-gaap_RevenueFromRelatedParties_709345E1E845BCFEC4C825AE3BD7F38B" xlink:type="arc" />
    <link:loc xlink:href="abus-20190930.xsd#abus_NetRentableAreaSublease" xlink:label="loc_abus_NetRentableAreaSublease_42381E083C94BFBB40A725AE3BD7A523" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_202C5004BCE7D51EBD4E25AE3BD66834" xlink:to="loc_abus_NetRentableAreaSublease_42381E083C94BFBB40A725AE3BD7A523" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://arbutusbio.com/role/SaleOfFutureRoyalties" xlink:type="extended" />
  <link:definitionLink xlink:role="http://arbutusbio.com/role/SaleOfFutureRoyaltiesLiabilityActivityDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://arbutusbio.com/role/SaleOfFutureRoyaltiesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="abus-20190930.xsd#abus_OtherLiabilitiesDisclosureLineItems" xlink:label="loc_abus_OtherLiabilitiesDisclosureLineItems_54A6764CA633B079610537F6E139EBB8" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AirlineProductsAndServicesTable" xlink:label="loc_us-gaap_AirlineProductsAndServicesTable_EF103123BF7F0FE76C9C37F6E1368F8A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_abus_OtherLiabilitiesDisclosureLineItems_54A6764CA633B079610537F6E139EBB8" xlink:to="loc_us-gaap_AirlineProductsAndServicesTable_EF103123BF7F0FE76C9C37F6E1368F8A" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_EAEE2AF0984EC8B9757B37F6E1372394" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AirlineProductsAndServicesTable_EF103123BF7F0FE76C9C37F6E1368F8A" xlink:to="loc_srt_CounterpartyNameAxis_EAEE2AF0984EC8B9757B37F6E1372394" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_26103288836D7187435F37F6E1374012_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_EAEE2AF0984EC8B9757B37F6E1372394" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_26103288836D7187435F37F6E1374012_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_26103288836D7187435F37F6E1374012" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_EAEE2AF0984EC8B9757B37F6E1372394" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_26103288836D7187435F37F6E1374012" xlink:type="arc" />
    <link:loc xlink:href="abus-20190930.xsd#abus_OMERSMember" xlink:label="loc_abus_OMERSMember_774F15CE50361F5E72C437F6E1371F44" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_26103288836D7187435F37F6E1374012" xlink:to="loc_abus_OMERSMember_774F15CE50361F5E72C437F6E1371F44" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_0990859F55F7A79DF59637F6E1388988" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AirlineProductsAndServicesTable_EF103123BF7F0FE76C9C37F6E1368F8A" xlink:to="loc_srt_RangeAxis_0990859F55F7A79DF59637F6E1388988" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_0AB4243930815FFA59D837F6E1382AC3_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_0990859F55F7A79DF59637F6E1388988" xlink:to="loc_srt_RangeMember_0AB4243930815FFA59D837F6E1382AC3_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_0AB4243930815FFA59D837F6E1382AC3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_0990859F55F7A79DF59637F6E1388988" xlink:to="loc_srt_RangeMember_0AB4243930815FFA59D837F6E1382AC3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_42CF3AB6B8ECD83A15D537F6E1384B29" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_0AB4243930815FFA59D837F6E1382AC3" xlink:to="loc_srt_MinimumMember_42CF3AB6B8ECD83A15D537F6E1384B29" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_6C88CFC9F48D505B6ED437F6E1387C2D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_0AB4243930815FFA59D837F6E1382AC3" xlink:to="loc_srt_MaximumMember_6C88CFC9F48D505B6ED437F6E1387C2D" xlink:type="arc" />
    <link:loc xlink:href="abus-20190930.xsd#abus_RoyaltyPercentageofInterestSold" xlink:label="loc_abus_RoyaltyPercentageofInterestSold_C77E87CC76B339BE49E437F6E13933E6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abus_OtherLiabilitiesDisclosureLineItems_54A6764CA633B079610537F6E139EBB8" xlink:to="loc_abus_RoyaltyPercentageofInterestSold_C77E87CC76B339BE49E437F6E13933E6" xlink:type="arc" />
    <link:loc xlink:href="abus-20190930.xsd#abus_RoyaltyInterestSoldPercentageOfSalesAnnualRevenueThresholdOfHighestTier" xlink:label="loc_abus_RoyaltyInterestSoldPercentageOfSalesAnnualRevenueThresholdOfHighestTier_3933366E059E7174410637F6E13919CD" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abus_OtherLiabilitiesDisclosureLineItems_54A6764CA633B079610537F6E139EBB8" xlink:to="loc_abus_RoyaltyInterestSoldPercentageOfSalesAnnualRevenueThresholdOfHighestTier_3933366E059E7174410637F6E13919CD" xlink:type="arc" />
    <link:loc xlink:href="abus-20190930.xsd#abus_GrossProceedsFromRoyaltyInterestSold" xlink:label="loc_abus_GrossProceedsFromRoyaltyInterestSold_B1E7E56A22C3761B6A4E37F6E1397C2E" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abus_OtherLiabilitiesDisclosureLineItems_54A6764CA633B079610537F6E139EBB8" xlink:to="loc_abus_GrossProceedsFromRoyaltyInterestSold_B1E7E56A22C3761B6A4E37F6E1397C2E" xlink:type="arc" />
    <link:loc xlink:href="abus-20190930.xsd#abus_RoyaltyInterestSoldMaximumRoyaltiesForBuyer" xlink:label="loc_abus_RoyaltyInterestSoldMaximumRoyaltiesForBuyer_9E1A830204AD21DD9FBE37F6E1394994" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abus_OtherLiabilitiesDisclosureLineItems_54A6764CA633B079610537F6E139EBB8" xlink:to="loc_abus_RoyaltyInterestSoldMaximumRoyaltiesForBuyer_9E1A830204AD21DD9FBE37F6E1394994" xlink:type="arc" />
    <link:loc xlink:href="abus-20190930.xsd#abus_RoyaltyGuaranteesCommitmentsPercentage" xlink:label="loc_abus_RoyaltyGuaranteesCommitmentsPercentage_DCA5FAC4D0F01F81FB7737F6E13AB660" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abus_OtherLiabilitiesDisclosureLineItems_54A6764CA633B079610537F6E139EBB8" xlink:to="loc_abus_RoyaltyGuaranteesCommitmentsPercentage_DCA5FAC4D0F01F81FB7737F6E13AB660" xlink:type="arc" />
    <link:loc xlink:href="abus-20190930.xsd#abus_RoyaltyPayable" xlink:label="loc_abus_RoyaltyPayable_48867B464149732419C837F6E13A42C0" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abus_OtherLiabilitiesDisclosureLineItems_54A6764CA633B079610537F6E139EBB8" xlink:to="loc_abus_RoyaltyPayable_48867B464149732419C837F6E13A42C0" xlink:type="arc" />
    <link:loc xlink:href="abus-20190930.xsd#abus_TransactionCostsRelatedToSaleOfFutureRoyalties" xlink:label="loc_abus_TransactionCostsRelatedToSaleOfFutureRoyalties_4EFF4865FA617B0B7B9037F6E13AE346" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abus_OtherLiabilitiesDisclosureLineItems_54A6764CA633B079610537F6E139EBB8" xlink:to="loc_abus_TransactionCostsRelatedToSaleOfFutureRoyalties_4EFF4865FA617B0B7B9037F6E13AE346" xlink:type="arc" />
    <link:loc xlink:href="abus-20190930.xsd#abus_EffectiveAnnualInterestRateOfRoyaltyLiability" xlink:label="loc_abus_EffectiveAnnualInterestRateOfRoyaltyLiability_5609BE2E7EB93777C4AD37F6E13ABB6F" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abus_OtherLiabilitiesDisclosureLineItems_54A6764CA633B079610537F6E139EBB8" xlink:to="loc_abus_EffectiveAnnualInterestRateOfRoyaltyLiability_5609BE2E7EB93777C4AD37F6E13ABB6F" xlink:type="arc" />
    <link:loc xlink:href="abus-20190930.xsd#abus_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" xlink:label="loc_abus_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties_53B56B98F40D6F50FB5E37F6E13A3BB2" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abus_OtherLiabilitiesDisclosureLineItems_54A6764CA633B079610537F6E139EBB8" xlink:to="loc_abus_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties_53B56B98F40D6F50FB5E37F6E13A3BB2" xlink:type="arc" />
    <link:loc xlink:href="abus-20190930.xsd#abus_NonCashRoyaltyExpenseRelatedToSaleOfFutureRoyalties" xlink:label="loc_abus_NonCashRoyaltyExpenseRelatedToSaleOfFutureRoyalties_6E61EB4AC6800F9F595B37F6E13A0E92" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abus_OtherLiabilitiesDisclosureLineItems_54A6764CA633B079610537F6E139EBB8" xlink:to="loc_abus_NonCashRoyaltyExpenseRelatedToSaleOfFutureRoyalties_6E61EB4AC6800F9F595B37F6E13A0E92" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://arbutusbio.com/role/SaleOfFutureRoyaltiesTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://arbutusbio.com/role/SignificantAccountingPolicies" xlink:type="extended" />
  <link:definitionLink xlink:role="http://arbutusbio.com/role/SignificantAccountingPoliciesNarrativeDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://arbutusbio.com/role/SignificantAccountingPoliciesPolicies" xlink:type="extended" />
  <link:definitionLink xlink:role="http://arbutusbio.com/role/SignificantAccountingPoliciesScheduleOfComputationOfBasicAndDilutedIncomeLossDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasicLineItems" xlink:label="loc_us-gaap_EarningsPerShareBasicLineItems_458CEA408BE31A8F3FAB2216DDD4049F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_2AAC4A8158D85ACB9A972216DDD33788" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_458CEA408BE31A8F3FAB2216DDD4049F" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_2AAC4A8158D85ACB9A972216DDD33788" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_9F9D9F0E6D517404969F2216DDD39050" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_2AAC4A8158D85ACB9A972216DDD33788" xlink:to="loc_us-gaap_StatementClassOfStockAxis_9F9D9F0E6D517404969F2216DDD39050" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_358F592153C7E08A12D52216DDD3A483_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_9F9D9F0E6D517404969F2216DDD39050" xlink:to="loc_us-gaap_ClassOfStockDomain_358F592153C7E08A12D52216DDD3A483_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_358F592153C7E08A12D52216DDD3A483" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_9F9D9F0E6D517404969F2216DDD39050" xlink:to="loc_us-gaap_ClassOfStockDomain_358F592153C7E08A12D52216DDD3A483" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_BD15C47E71A72D3924452216DDD40017" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_358F592153C7E08A12D52216DDD3A483" xlink:to="loc_us-gaap_CommonStockMember_BD15C47E71A72D3924452216DDD40017" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasicAbstract" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract_65A638B917648CA4032D2216DDD42B1D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_458CEA408BE31A8F3FAB2216DDD4049F" xlink:to="loc_us-gaap_EarningsPerShareBasicAbstract_65A638B917648CA4032D2216DDD42B1D" xlink:type="arc" />
    <link:loc xlink:href="abus-20190930.xsd#abus_DistributableEarningsLossAvailabletoCommonShareholdersBasic" xlink:label="loc_abus_DistributableEarningsLossAvailabletoCommonShareholdersBasic_DCB013AEBCF33AE3CC952216DDD468E6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_65A638B917648CA4032D2216DDD42B1D" xlink:to="loc_abus_DistributableEarningsLossAvailabletoCommonShareholdersBasic_DCB013AEBCF33AE3CC952216DDD468E6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UndistributedEarningsLossAvailableToCommonShareholdersBasic" xlink:label="loc_us-gaap_UndistributedEarningsLossAvailableToCommonShareholdersBasic_B35054FB83447F79D8332216DDD585F8" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_65A638B917648CA4032D2216DDD42B1D" xlink:to="loc_us-gaap_UndistributedEarningsLossAvailableToCommonShareholdersBasic_B35054FB83447F79D8332216DDD585F8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_EC859D890440EACDF6272216DDD58A4F" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_65A638B917648CA4032D2216DDD42B1D" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_EC859D890440EACDF6272216DDD58A4F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareDilutedAbstract" xlink:label="loc_us-gaap_EarningsPerShareDilutedAbstract_1DC9C8E27A38DEF1B8522216DDD54100" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_458CEA408BE31A8F3FAB2216DDD4049F" xlink:to="loc_us-gaap_EarningsPerShareDilutedAbstract_1DC9C8E27A38DEF1B8522216DDD54100" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_9026D562B1C21E17CD5A2216DDD5C241" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_1DC9C8E27A38DEF1B8522216DDD54100" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_9026D562B1C21E17CD5A2216DDD5C241" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_FB13E61C2E104E5913302216DDD62BAA" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_1DC9C8E27A38DEF1B8522216DDD54100" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_FB13E61C2E104E5913302216DDD62BAA" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://arbutusbio.com/role/SignificantAccountingPoliciesTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://arbutusbio.com/role/SiteConsolidation" xlink:type="extended" />
  <link:definitionLink xlink:role="http://arbutusbio.com/role/SiteConsolidationConsolidationExpensesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_31B5A10A3597536D9A1539F37B30AA61" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_8D7F440F7C8D50538C4DE4544B608363" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_31B5A10A3597536D9A1539F37B30AA61" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_8D7F440F7C8D50538C4DE4544B608363" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_3DAC6CAEA6415996833114877E5B9BA1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_8D7F440F7C8D50538C4DE4544B608363" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_3DAC6CAEA6415996833114877E5B9BA1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_CE88AA7A901CB7AC2A6A378B6D1D340C_4255EDDFE78950DAA8318D818A72A356" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_3DAC6CAEA6415996833114877E5B9BA1" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_CE88AA7A901CB7AC2A6A378B6D1D340C_4255EDDFE78950DAA8318D818A72A356" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_B51CEC86C3FD5FEFAA68BA5C74E5D8D6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_3DAC6CAEA6415996833114877E5B9BA1" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_B51CEC86C3FD5FEFAA68BA5C74E5D8D6" xlink:type="arc" />
    <link:loc xlink:href="abus-20190930.xsd#abus_EmployeeSeveranceandRelocationMember" xlink:label="loc_abus_EmployeeSeveranceandRelocationMember_352D08CFEB355492BF7CCCD40E63EE59" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_B51CEC86C3FD5FEFAA68BA5C74E5D8D6" xlink:to="loc_abus_EmployeeSeveranceandRelocationMember_352D08CFEB355492BF7CCCD40E63EE59" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FacilityClosingMember" xlink:label="loc_us-gaap_FacilityClosingMember_AC1E0C478286589DBA54BB024EB9A1C3" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_B51CEC86C3FD5FEFAA68BA5C74E5D8D6" xlink:to="loc_us-gaap_FacilityClosingMember_AC1E0C478286589DBA54BB024EB9A1C3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="loc_us-gaap_RestructuringCharges_CFC8AEAAF37157E686158A55FD02C164" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_31B5A10A3597536D9A1539F37B30AA61" xlink:to="loc_us-gaap_RestructuringCharges_CFC8AEAAF37157E686158A55FD02C164" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://arbutusbio.com/role/SiteConsolidationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_A4F0CC379B1254A7AFBE22A5BCEBC7F7" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_CC3DA4B64637EA9EA4B522A5BCEAAE5A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_A4F0CC379B1254A7AFBE22A5BCEBC7F7" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_CC3DA4B64637EA9EA4B522A5BCEAAE5A" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_66059EC09F10BEA800E222A5BCEBA2C8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_CC3DA4B64637EA9EA4B522A5BCEAAE5A" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_66059EC09F10BEA800E222A5BCEBA2C8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_28BCE298146416E8370422A5BCEB06BC_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_66059EC09F10BEA800E222A5BCEBA2C8" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_28BCE298146416E8370422A5BCEB06BC_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_28BCE298146416E8370422A5BCEB06BC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_66059EC09F10BEA800E222A5BCEBA2C8" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_28BCE298146416E8370422A5BCEB06BC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FacilityClosingMember" xlink:label="loc_us-gaap_FacilityClosingMember_629A4AAAC4CE2213294622A5BCEB54BD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_28BCE298146416E8370422A5BCEB06BC" xlink:to="loc_us-gaap_FacilityClosingMember_629A4AAAC4CE2213294622A5BCEB54BD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_C1EA52DB73086059074322A5BCEC7A15" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_A4F0CC379B1254A7AFBE22A5BCEBC7F7" xlink:to="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_C1EA52DB73086059074322A5BCEC7A15" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="loc_us-gaap_RestructuringCharges_65C5F73E5CE0C9FBE78722A5BCEC3186" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_A4F0CC379B1254A7AFBE22A5BCEBC7F7" xlink:to="loc_us-gaap_RestructuringCharges_65C5F73E5CE0C9FBE78722A5BCEC3186" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://arbutusbio.com/role/SiteConsolidationReserveActivityDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_661AD269842770DC7B272216DD096BBF" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_AD33F6BE6A13ECF51BFC2216DD085AE5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_661AD269842770DC7B272216DD096BBF" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_AD33F6BE6A13ECF51BFC2216DD085AE5" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_B9E2701F7683E204BA642216DD0835BB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_AD33F6BE6A13ECF51BFC2216DD085AE5" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_B9E2701F7683E204BA642216DD0835BB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_4E891DAF85F92B5C97172216DD088C07_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_B9E2701F7683E204BA642216DD0835BB" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_4E891DAF85F92B5C97172216DD088C07_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_4E891DAF85F92B5C97172216DD088C07" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_B9E2701F7683E204BA642216DD0835BB" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_4E891DAF85F92B5C97172216DD088C07" xlink:type="arc" />
    <link:loc xlink:href="abus-20190930.xsd#abus_EmployeeSeveranceandRelocationMember" xlink:label="loc_abus_EmployeeSeveranceandRelocationMember_E2F6F77696C7D96576022216DD097FCA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_4E891DAF85F92B5C97172216DD088C07" xlink:to="loc_abus_EmployeeSeveranceandRelocationMember_E2F6F77696C7D96576022216DD097FCA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FacilityClosingMember" xlink:label="loc_us-gaap_FacilityClosingMember_3E1F782070DA9D4EC5962216DD0913D9" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_4E891DAF85F92B5C97172216DD088C07" xlink:to="loc_us-gaap_FacilityClosingMember_3E1F782070DA9D4EC5962216DD0913D9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestructuringReserveRollForward" xlink:label="loc_us-gaap_RestructuringReserveRollForward_1DD424A5652DB334CB502216DD093FE2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_661AD269842770DC7B272216DD096BBF" xlink:to="loc_us-gaap_RestructuringReserveRollForward_1DD424A5652DB334CB502216DD093FE2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestructuringReserve" xlink:label="loc_us-gaap_RestructuringReserve_ACD12751F2221D080CCA2216DD092B23" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_1DD424A5652DB334CB502216DD093FE2" xlink:to="loc_us-gaap_RestructuringReserve_ACD12751F2221D080CCA2216DD092B23" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="loc_us-gaap_RestructuringCharges_A64F22DA2FD659B549FF2216DD0A27A5" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_1DD424A5652DB334CB502216DD093FE2" xlink:to="loc_us-gaap_RestructuringCharges_A64F22DA2FD659B549FF2216DD0A27A5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsForRestructuring" xlink:label="loc_us-gaap_PaymentsForRestructuring_84BD410F4882427842952216DD0A533F" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_1DD424A5652DB334CB502216DD093FE2" xlink:to="loc_us-gaap_PaymentsForRestructuring_84BD410F4882427842952216DD0A533F" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://arbutusbio.com/role/SiteConsolidationTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://arbutusbio.com/role/StockholdersEquityAndStockBasedCompensation" xlink:type="extended" />
  <link:definitionLink xlink:role="http://arbutusbio.com/role/StockholdersEquityAndStockBasedCompensationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_410F348477E32F4AE2BC3D14B947B034" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_A8845820659274ABB6183D14B943389A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_410F348477E32F4AE2BC3D14B947B034" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_A8845820659274ABB6183D14B943389A" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_18708BE4970E514B53E93D14B944AE93" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_A8845820659274ABB6183D14B943389A" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_18708BE4970E514B53E93D14B944AE93" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_28AAEDF6459C9B8574833D14B9446F5C_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_18708BE4970E514B53E93D14B944AE93" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_28AAEDF6459C9B8574833D14B9446F5C_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_28AAEDF6459C9B8574833D14B9446F5C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_18708BE4970E514B53E93D14B944AE93" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_28AAEDF6459C9B8574833D14B9446F5C" xlink:type="arc" />
    <link:loc xlink:href="abus-20190930.xsd#abus_OpenMarketSaleAgreementMember" xlink:label="loc_abus_OpenMarketSaleAgreementMember_8963535DCDB0B8F6442F3D14B944D829" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_28AAEDF6459C9B8574833D14B9446F5C" xlink:to="loc_abus_OpenMarketSaleAgreementMember_8963535DCDB0B8F6442F3D14B944D829" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_86CCD784173026C3C19C3D14B94536EB" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_A8845820659274ABB6183D14B943389A" xlink:to="loc_srt_CounterpartyNameAxis_86CCD784173026C3C19C3D14B94536EB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_848784F256B8D45B678A3D14B9455775_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_86CCD784173026C3C19C3D14B94536EB" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_848784F256B8D45B678A3D14B9455775_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_848784F256B8D45B678A3D14B9455775" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_86CCD784173026C3C19C3D14B94536EB" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_848784F256B8D45B678A3D14B9455775" xlink:type="arc" />
    <link:loc xlink:href="abus-20190930.xsd#abus_JefferiesLLCMember" xlink:label="loc_abus_JefferiesLLCMember_4AE484D027B8ED762CF13D14B945E3B2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_848784F256B8D45B678A3D14B9455775" xlink:to="loc_abus_JefferiesLLCMember_4AE484D027B8ED762CF13D14B945E3B2" xlink:type="arc" />
    <link:loc xlink:href="abus-20190930.xsd#abus_RoivantSciencesLtdMember" xlink:label="loc_abus_RoivantSciencesLtdMember_419D259FB5738D3811763D14B946A203" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_848784F256B8D45B678A3D14B9455775" xlink:to="loc_abus_RoivantSciencesLtdMember_419D259FB5738D3811763D14B946A203" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_BDEA20B6D42F6EFD5AE53D14B946A298" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_A8845820659274ABB6183D14B943389A" xlink:to="loc_us-gaap_StatementClassOfStockAxis_BDEA20B6D42F6EFD5AE53D14B946A298" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_B3D56FB8EBD3EB99CA5C3D14B946D94F_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_BDEA20B6D42F6EFD5AE53D14B946A298" xlink:to="loc_us-gaap_ClassOfStockDomain_B3D56FB8EBD3EB99CA5C3D14B946D94F_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_B3D56FB8EBD3EB99CA5C3D14B946D94F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_BDEA20B6D42F6EFD5AE53D14B946A298" xlink:to="loc_us-gaap_ClassOfStockDomain_B3D56FB8EBD3EB99CA5C3D14B946D94F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_A1A39D20DCCB19B0ED093D14B946C269" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_B3D56FB8EBD3EB99CA5C3D14B946D94F" xlink:to="loc_us-gaap_CommonStockMember_A1A39D20DCCB19B0ED093D14B946C269" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaap_PreferredStockMember_ABE845B80F1AE7D79D1E3D14B9467B8D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_B3D56FB8EBD3EB99CA5C3D14B946D94F" xlink:to="loc_us-gaap_PreferredStockMember_ABE845B80F1AE7D79D1E3D14B9467B8D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_0E2236A1E040ED9FA3233D14B9475D95" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_B3D56FB8EBD3EB99CA5C3D14B946D94F" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_0E2236A1E040ED9FA3233D14B9475D95" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesSubscriptions" xlink:label="loc_us-gaap_CommonStockSharesSubscriptions_4125854ABF870B53CFED3D14B947BFC1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_410F348477E32F4AE2BC3D14B947B034" xlink:to="loc_us-gaap_CommonStockSharesSubscriptions_4125854ABF870B53CFED3D14B947BFC1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_ABF8D90C7C72F5EFD8103D14B9475D73" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_410F348477E32F4AE2BC3D14B947B034" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_ABF8D90C7C72F5EFD8103D14B9475D73" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_DC8D10FA3ECFB5068B663D14B947119E" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_410F348477E32F4AE2BC3D14B947B034" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_DC8D10FA3ECFB5068B663D14B947119E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_00CA4CF54AF40A4788243D14B9482AEC" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_410F348477E32F4AE2BC3D14B947B034" xlink:to="loc_us-gaap_SharesIssued_00CA4CF54AF40A4788243D14B9482AEC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_71FCB455B4B2C77250813D14B9488EFF" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_410F348477E32F4AE2BC3D14B947B034" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_71FCB455B4B2C77250813D14B9488EFF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="loc_us-gaap_PreferredStockDividendRatePercentage_51982025683795A74D303D14B948A3A6" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_410F348477E32F4AE2BC3D14B947B034" xlink:to="loc_us-gaap_PreferredStockDividendRatePercentage_51982025683795A74D303D14B948A3A6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_EA7D596498526AAE9CCB3D14B94D28BF" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_410F348477E32F4AE2BC3D14B947B034" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_EA7D596498526AAE9CCB3D14B94D28BF" xlink:type="arc" />
    <link:loc xlink:href="abus-20190930.xsd#abus_ConvertiblePreferredStockSharesOfCommonStockIssueduponConversion" xlink:label="loc_abus_ConvertiblePreferredStockSharesOfCommonStockIssueduponConversion_F5A7F7311C15AF8136513D14B94D94BB" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_410F348477E32F4AE2BC3D14B947B034" xlink:to="loc_abus_ConvertiblePreferredStockSharesOfCommonStockIssueduponConversion_F5A7F7311C15AF8136513D14B94D94BB" xlink:type="arc" />
    <link:loc xlink:href="abus-20190930.xsd#abus_NoncontrollingInterestOwnershipPercentageByNoncontrollingOwnersAfterConversion" xlink:label="loc_abus_NoncontrollingInterestOwnershipPercentageByNoncontrollingOwnersAfterConversion_6C08D8097235311768DA3D14B94EECCD" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_410F348477E32F4AE2BC3D14B947B034" xlink:to="loc_abus_NoncontrollingInterestOwnershipPercentageByNoncontrollingOwnersAfterConversion_6C08D8097235311768DA3D14B94EECCD" xlink:type="arc" />
    <link:loc xlink:href="abus-20190930.xsd#abus_NoncontrollingInterestInvestmentCommitmentPeriod" xlink:label="loc_abus_NoncontrollingInterestInvestmentCommitmentPeriod_E12F193A303E916DCDFC3D14B94EB8E8" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_410F348477E32F4AE2BC3D14B947B034" xlink:to="loc_abus_NoncontrollingInterestInvestmentCommitmentPeriod_E12F193A303E916DCDFC3D14B94EB8E8" xlink:type="arc" />
    <link:loc xlink:href="abus-20190930.xsd#abus_NoncontrollingInterestMaximumOwnershipPercentagebyNoncontrollingOwners" xlink:label="loc_abus_NoncontrollingInterestMaximumOwnershipPercentagebyNoncontrollingOwners_F8A3893E28DE56097A8E3D14B94E2F34" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_410F348477E32F4AE2BC3D14B947B034" xlink:to="loc_abus_NoncontrollingInterestMaximumOwnershipPercentagebyNoncontrollingOwners_F8A3893E28DE56097A8E3D14B94E2F34" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_55F747BA31A1F87954773D14B94E88F4" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_410F348477E32F4AE2BC3D14B947B034" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_55F747BA31A1F87954773D14B94E88F4" xlink:type="arc" />
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>12
<FILENAME>abus-20190930_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_CB00B0CF18A23D13830537DF0C9056C5_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract_E34C0002288B51A28990C888AE977923" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_E34C0002288B51A28990C888AE977923" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_E34C0002288B51A28990C888AE977923" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract_E34C0002288B51A28990C888AE977923" xlink:type="arc" />
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_EB61F0D28E45C721AA1837DF0C90DC57_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_D19C7457983A5F67A854B08B4A0EBD08" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related party transactions</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_EB61F0D28E45C721AA1837DF0C90DC57_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_D19C7457983A5F67A854B08B4A0EBD08" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_D19C7457983A5F67A854B08B4A0EBD08" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_D19C7457983A5F67A854B08B4A0EBD08" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_D19C7457983A5F67A854B08B4A0EBD08" xlink:type="arc" />
    <link:label id="lab_us-gaap_LeasesAbstract_9234D381C0E8C4A3F27302DE05FCC740_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract_9234D381C0E8C4A3F27302DE05FCC740" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_9234D381C0E8C4A3F27302DE05FCC740" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract_9234D381C0E8C4A3F27302DE05FCC740" xlink:to="lab_us-gaap_LeasesAbstract_9234D381C0E8C4A3F27302DE05FCC740" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_B20AB7A35FED02E7794C02DE05FCD790_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock_B20AB7A35FED02E7794C02DE05FCD790" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_B20AB7A35FED02E7794C02DE05FCD790_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock_B20AB7A35FED02E7794C02DE05FCD790" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_B20AB7A35FED02E7794C02DE05FCD790" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock_B20AB7A35FED02E7794C02DE05FCD790" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock_B20AB7A35FED02E7794C02DE05FCD790" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_C1A44E62DEAE562F44B525AE3BD31EC0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_C1A44E62DEAE562F44B525AE3BD31EC0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_C1A44E62DEAE562F44B525AE3BD31EC0_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_C1A44E62DEAE562F44B525AE3BD31EC0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_C1A44E62DEAE562F44B525AE3BD31EC0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_C1A44E62DEAE562F44B525AE3BD31EC0" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_C1A44E62DEAE562F44B525AE3BD31EC0" xlink:type="arc" />
    <link:label id="lab_srt_CounterpartyNameAxis_DC7AFD7AB16E30E00C0725AE3BD3A506_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis_DC7AFD7AB16E30E00C0725AE3BD3A506" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_DC7AFD7AB16E30E00C0725AE3BD3A506_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis_DC7AFD7AB16E30E00C0725AE3BD3A506" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_DC7AFD7AB16E30E00C0725AE3BD3A506" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis_DC7AFD7AB16E30E00C0725AE3BD3A506" xlink:to="lab_srt_CounterpartyNameAxis_DC7AFD7AB16E30E00C0725AE3BD3A506" xlink:type="arc" />
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_1E41B19EF33B3D87616525AE3BD4FACC_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain_1E41B19EF33B3D87616525AE3BD4FACC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_1E41B19EF33B3D87616525AE3BD4FACC_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain_1E41B19EF33B3D87616525AE3BD4FACC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1E41B19EF33B3D87616525AE3BD4FACC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1E41B19EF33B3D87616525AE3BD4FACC" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain_1E41B19EF33B3D87616525AE3BD4FACC" xlink:type="arc" />
    <link:label id="lab_abus_GenevantSciencesCorporationMember_512CD5E98B9A026B12D225AE3BD49D9C_terseLabel_en-US" xlink:label="lab_abus_GenevantSciencesCorporationMember_512CD5E98B9A026B12D225AE3BD49D9C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Genevant Sciences Corporation</link:label>
    <link:label id="lab_abus_GenevantSciencesCorporationMember_512CD5E98B9A026B12D225AE3BD49D9C_label_en-US" xlink:label="lab_abus_GenevantSciencesCorporationMember_512CD5E98B9A026B12D225AE3BD49D9C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Genevant Sciences Corporation [Member]</link:label>
    <link:label id="lab_abus_GenevantSciencesCorporationMember_512CD5E98B9A026B12D225AE3BD49D9C_documentation_en-US" xlink:label="lab_abus_GenevantSciencesCorporationMember_512CD5E98B9A026B12D225AE3BD49D9C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Genevant Sciences Corporation [Member]</link:label>
    <link:loc xlink:href="abus-20190930.xsd#abus_GenevantSciencesCorporationMember" xlink:label="loc_abus_GenevantSciencesCorporationMember_512CD5E98B9A026B12D225AE3BD49D9C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_GenevantSciencesCorporationMember_512CD5E98B9A026B12D225AE3BD49D9C" xlink:to="lab_abus_GenevantSciencesCorporationMember_512CD5E98B9A026B12D225AE3BD49D9C" xlink:type="arc" />
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_FB8A2A7D3D1D800E729425AE3BD493BB_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_FB8A2A7D3D1D800E729425AE3BD493BB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_FB8A2A7D3D1D800E729425AE3BD493BB_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_FB8A2A7D3D1D800E729425AE3BD493BB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_FB8A2A7D3D1D800E729425AE3BD493BB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_FB8A2A7D3D1D800E729425AE3BD493BB" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_FB8A2A7D3D1D800E729425AE3BD493BB" xlink:type="arc" />
    <link:label id="lab_us-gaap_RelatedPartyDomain_45D7782822C03CCD955825AE3BD4B7CF_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain_45D7782822C03CCD955825AE3BD4B7CF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_45D7782822C03CCD955825AE3BD4B7CF_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain_45D7782822C03CCD955825AE3BD4B7CF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_45D7782822C03CCD955825AE3BD4B7CF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain_45D7782822C03CCD955825AE3BD4B7CF" xlink:to="lab_us-gaap_RelatedPartyDomain_45D7782822C03CCD955825AE3BD4B7CF" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityMethodInvesteeMember_311E4ADD0D90DC33B2DD25AE3BD5733C_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvesteeMember_311E4ADD0D90DC33B2DD25AE3BD5733C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Method Investee</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvesteeMember_311E4ADD0D90DC33B2DD25AE3BD5733C_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvesteeMember_311E4ADD0D90DC33B2DD25AE3BD5733C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investee [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityMethodInvesteeMember" xlink:label="loc_us-gaap_EquityMethodInvesteeMember_311E4ADD0D90DC33B2DD25AE3BD5733C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvesteeMember_311E4ADD0D90DC33B2DD25AE3BD5733C" xlink:to="lab_us-gaap_EquityMethodInvesteeMember_311E4ADD0D90DC33B2DD25AE3BD5733C" xlink:type="arc" />
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_ACAFBBF02AC3851CCB5525AE3BD5FBAD_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis_ACAFBBF02AC3851CCB5525AE3BD5FBAD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_ACAFBBF02AC3851CCB5525AE3BD5FBAD_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis_ACAFBBF02AC3851CCB5525AE3BD5FBAD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_ACAFBBF02AC3851CCB5525AE3BD5FBAD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_ACAFBBF02AC3851CCB5525AE3BD5FBAD" xlink:to="lab_us-gaap_RelatedPartyTransactionAxis_ACAFBBF02AC3851CCB5525AE3BD5FBAD" xlink:type="arc" />
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_BBE91D3C5777F2286B7A25AE3BD5C1E7_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain_BBE91D3C5777F2286B7A25AE3BD5C1E7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_BBE91D3C5777F2286B7A25AE3BD5C1E7_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain_BBE91D3C5777F2286B7A25AE3BD5C1E7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_BBE91D3C5777F2286B7A25AE3BD5C1E7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_BBE91D3C5777F2286B7A25AE3BD5C1E7" xlink:to="lab_us-gaap_RelatedPartyTransactionDomain_BBE91D3C5777F2286B7A25AE3BD5C1E7" xlink:type="arc" />
    <link:label id="lab_abus_ResearchAndDevelopmentServicesMember_DF97D9586FB249DE13E225AE3BD6EA6B_terseLabel_en-US" xlink:label="lab_abus_ResearchAndDevelopmentServicesMember_DF97D9586FB249DE13E225AE3BD6EA6B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development services</link:label>
    <link:label id="lab_abus_ResearchAndDevelopmentServicesMember_DF97D9586FB249DE13E225AE3BD6EA6B_label_en-US" xlink:label="lab_abus_ResearchAndDevelopmentServicesMember_DF97D9586FB249DE13E225AE3BD6EA6B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research And Development Services [Member]</link:label>
    <link:label id="lab_abus_ResearchAndDevelopmentServicesMember_DF97D9586FB249DE13E225AE3BD6EA6B_documentation_en-US" xlink:label="lab_abus_ResearchAndDevelopmentServicesMember_DF97D9586FB249DE13E225AE3BD6EA6B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research And Development Services [Member]</link:label>
    <link:loc xlink:href="abus-20190930.xsd#abus_ResearchAndDevelopmentServicesMember" xlink:label="loc_abus_ResearchAndDevelopmentServicesMember_DF97D9586FB249DE13E225AE3BD6EA6B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_ResearchAndDevelopmentServicesMember_DF97D9586FB249DE13E225AE3BD6EA6B" xlink:to="lab_abus_ResearchAndDevelopmentServicesMember_DF97D9586FB249DE13E225AE3BD6EA6B" xlink:type="arc" />
    <link:label id="lab_abus_AdministrativeAndTransitionalServicesMember_A04120C725DCA5C6D77A25AE3BD65544_terseLabel_en-US" xlink:label="lab_abus_AdministrativeAndTransitionalServicesMember_A04120C725DCA5C6D77A25AE3BD65544" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Administrative And Transitional Services</link:label>
    <link:label id="lab_abus_AdministrativeAndTransitionalServicesMember_A04120C725DCA5C6D77A25AE3BD65544_label_en-US" xlink:label="lab_abus_AdministrativeAndTransitionalServicesMember_A04120C725DCA5C6D77A25AE3BD65544" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Administrative And Transitional Services [Member]</link:label>
    <link:label id="lab_abus_AdministrativeAndTransitionalServicesMember_A04120C725DCA5C6D77A25AE3BD65544_documentation_en-US" xlink:label="lab_abus_AdministrativeAndTransitionalServicesMember_A04120C725DCA5C6D77A25AE3BD65544" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Administrative And Transitional Services [Member]</link:label>
    <link:loc xlink:href="abus-20190930.xsd#abus_AdministrativeAndTransitionalServicesMember" xlink:label="loc_abus_AdministrativeAndTransitionalServicesMember_A04120C725DCA5C6D77A25AE3BD65544" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_AdministrativeAndTransitionalServicesMember_A04120C725DCA5C6D77A25AE3BD65544" xlink:to="lab_abus_AdministrativeAndTransitionalServicesMember_A04120C725DCA5C6D77A25AE3BD65544" xlink:type="arc" />
    <link:label id="lab_abus_SubleaseBurnabyFacilityMember_D5AD0AC5B2EC57D83ECD25AE3BD65122_terseLabel_en-US" xlink:label="lab_abus_SubleaseBurnabyFacilityMember_D5AD0AC5B2EC57D83ECD25AE3BD65122" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sublease, Burnaby Facility</link:label>
    <link:label id="lab_abus_SubleaseBurnabyFacilityMember_D5AD0AC5B2EC57D83ECD25AE3BD65122_label_en-US" xlink:label="lab_abus_SubleaseBurnabyFacilityMember_D5AD0AC5B2EC57D83ECD25AE3BD65122" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sublease, Burnaby Facility [Member]</link:label>
    <link:label id="lab_abus_SubleaseBurnabyFacilityMember_D5AD0AC5B2EC57D83ECD25AE3BD65122_documentation_en-US" xlink:label="lab_abus_SubleaseBurnabyFacilityMember_D5AD0AC5B2EC57D83ECD25AE3BD65122" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sublease, Burnaby Facility [Member]</link:label>
    <link:loc xlink:href="abus-20190930.xsd#abus_SubleaseBurnabyFacilityMember" xlink:label="loc_abus_SubleaseBurnabyFacilityMember_D5AD0AC5B2EC57D83ECD25AE3BD65122" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_SubleaseBurnabyFacilityMember_D5AD0AC5B2EC57D83ECD25AE3BD65122" xlink:to="lab_abus_SubleaseBurnabyFacilityMember_D5AD0AC5B2EC57D83ECD25AE3BD65122" xlink:type="arc" />
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_202C5004BCE7D51EBD4E25AE3BD66834_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems_202C5004BCE7D51EBD4E25AE3BD66834" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_202C5004BCE7D51EBD4E25AE3BD66834_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems_202C5004BCE7D51EBD4E25AE3BD66834" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_202C5004BCE7D51EBD4E25AE3BD66834" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_202C5004BCE7D51EBD4E25AE3BD66834" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems_202C5004BCE7D51EBD4E25AE3BD66834" xlink:type="arc" />
    <link:label id="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_13998BFE435DEF59479C25AE3BD79125_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_13998BFE435DEF59479C25AE3BD79125" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expenses from transactions with related party</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_13998BFE435DEF59479C25AE3BD79125_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_13998BFE435DEF59479C25AE3BD79125" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction, Expenses from Transactions with Related Party</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:label="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_13998BFE435DEF59479C25AE3BD79125" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_13998BFE435DEF59479C25AE3BD79125" xlink:to="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_13998BFE435DEF59479C25AE3BD79125" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueFromRelatedParties_709345E1E845BCFEC4C825AE3BD7F38B_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromRelatedParties_709345E1E845BCFEC4C825AE3BD7F38B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income from related party</link:label>
    <link:label id="lab_us-gaap_RevenueFromRelatedParties_709345E1E845BCFEC4C825AE3BD7F38B_label_en-US" xlink:label="lab_us-gaap_RevenueFromRelatedParties_709345E1E845BCFEC4C825AE3BD7F38B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Related Parties</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromRelatedParties" xlink:label="loc_us-gaap_RevenueFromRelatedParties_709345E1E845BCFEC4C825AE3BD7F38B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromRelatedParties_709345E1E845BCFEC4C825AE3BD7F38B" xlink:to="lab_us-gaap_RevenueFromRelatedParties_709345E1E845BCFEC4C825AE3BD7F38B" xlink:type="arc" />
    <link:label id="lab_abus_NetRentableAreaSublease_42381E083C94BFBB40A725AE3BD7A523_terseLabel_en-US" xlink:label="lab_abus_NetRentableAreaSublease_42381E083C94BFBB40A725AE3BD7A523" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Area of sublease facility</link:label>
    <link:label id="lab_abus_NetRentableAreaSublease_42381E083C94BFBB40A725AE3BD7A523_label_en-US" xlink:label="lab_abus_NetRentableAreaSublease_42381E083C94BFBB40A725AE3BD7A523" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Rentable Area, Sublease</link:label>
    <link:label id="lab_abus_NetRentableAreaSublease_42381E083C94BFBB40A725AE3BD7A523_documentation_en-US" xlink:label="lab_abus_NetRentableAreaSublease_42381E083C94BFBB40A725AE3BD7A523" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Net Rentable Area, Sublease</link:label>
    <link:loc xlink:href="abus-20190930.xsd#abus_NetRentableAreaSublease" xlink:label="loc_abus_NetRentableAreaSublease_42381E083C94BFBB40A725AE3BD7A523" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_NetRentableAreaSublease_42381E083C94BFBB40A725AE3BD7A523" xlink:to="lab_abus_NetRentableAreaSublease_42381E083C94BFBB40A725AE3BD7A523" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_DCB755D6A3F82EE2445902DE06223BD7_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_DCB755D6A3F82EE2445902DE06223BD7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_DCB755D6A3F82EE2445902DE06223BD7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_DCB755D6A3F82EE2445902DE06223BD7" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_DCB755D6A3F82EE2445902DE06223BD7" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_B80F453D12A0A4DB277502DE0622F462_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_B80F453D12A0A4DB277502DE0622F462" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets and goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_B80F453D12A0A4DB277502DE0622F462_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_B80F453D12A0A4DB277502DE0622F462" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_B80F453D12A0A4DB277502DE0622F462" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_B80F453D12A0A4DB277502DE0622F462" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_B80F453D12A0A4DB277502DE0622F462" xlink:type="arc" />
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_D09E258C4CC1DBD366EA7EED036A6678_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock_D87FF64440205F3F86452916CC1E01A2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Lease Terms, Discount Rate and Supplemental Cash Flow Information</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_D09E258C4CC1DBD366EA7EED036A6678_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock_D87FF64440205F3F86452916CC1E01A2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_D87FF64440205F3F86452916CC1E01A2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock_D87FF64440205F3F86452916CC1E01A2" xlink:to="lab_us-gaap_LeaseCostTableTextBlock_D87FF64440205F3F86452916CC1E01A2" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_3883032530BFA49C83F67EED036A506E_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_3290DC90F8D85D0B9D958C548DBC3D8E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Maturities of Lease Liabilities</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_3883032530BFA49C83F67EED036A506E_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_3290DC90F8D85D0B9D958C548DBC3D8E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_3290DC90F8D85D0B9D958C548DBC3D8E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_3290DC90F8D85D0B9D958C548DBC3D8E" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_3290DC90F8D85D0B9D958C548DBC3D8E" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_3A671A77B6727742DB4B223D3FA3FFC2_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract_3A671A77B6727742DB4B223D3FA3FFC2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_3A671A77B6727742DB4B223D3FA3FFC2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3A671A77B6727742DB4B223D3FA3FFC2" xlink:to="lab_us-gaap_AccountingPoliciesAbstract_3A671A77B6727742DB4B223D3FA3FFC2" xlink:type="arc" />
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_2CE57B845A1352BD06D1223D3FA3F874_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_2CE57B845A1352BD06D1223D3FA3F874" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basis of presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_2CE57B845A1352BD06D1223D3FA3F874_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_2CE57B845A1352BD06D1223D3FA3F874" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_2CE57B845A1352BD06D1223D3FA3F874" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_2CE57B845A1352BD06D1223D3FA3F874" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_2CE57B845A1352BD06D1223D3FA3F874" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_F885462D5149424DD04A223D3FA4A8C4_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock_F885462D5149424DD04A223D3FA4A8C4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Principles of consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_F885462D5149424DD04A223D3FA4A8C4_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock_F885462D5149424DD04A223D3FA4A8C4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_F885462D5149424DD04A223D3FA4A8C4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock_F885462D5149424DD04A223D3FA4A8C4" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock_F885462D5149424DD04A223D3FA4A8C4" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_7557A2BD2B23DCD52A12223D3FA49AB0_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock_7557A2BD2B23DCD52A12223D3FA49AB0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income or loss per share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_7557A2BD2B23DCD52A12223D3FA49AB0_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock_7557A2BD2B23DCD52A12223D3FA49AB0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_7557A2BD2B23DCD52A12223D3FA49AB0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock_7557A2BD2B23DCD52A12223D3FA49AB0" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock_7557A2BD2B23DCD52A12223D3FA49AB0" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityMethodInvestmentsPolicy_B5BE6FC302CCF0BB72C6223D3FA47D57_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsPolicy_B5BE6FC302CCF0BB72C6223D3FA47D57" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity method investment</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsPolicy_B5BE6FC302CCF0BB72C6223D3FA47D57_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsPolicy_B5BE6FC302CCF0BB72C6223D3FA47D57" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investments [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityMethodInvestmentsPolicy" xlink:label="loc_us-gaap_EquityMethodInvestmentsPolicy_B5BE6FC302CCF0BB72C6223D3FA47D57" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsPolicy_B5BE6FC302CCF0BB72C6223D3FA47D57" xlink:to="lab_us-gaap_EquityMethodInvestmentsPolicy_B5BE6FC302CCF0BB72C6223D3FA47D57" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_FCB5C2AED75868A1A6E3223D3FA4130C_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_FCB5C2AED75868A1A6E3223D3FA4130C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue recognition</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_FCB5C2AED75868A1A6E3223D3FA4130C_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_FCB5C2AED75868A1A6E3223D3FA4130C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_FCB5C2AED75868A1A6E3223D3FA4130C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_FCB5C2AED75868A1A6E3223D3FA4130C" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_FCB5C2AED75868A1A6E3223D3FA4130C" xlink:type="arc" />
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_218B350CCCD77855281C2258333C4683_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_218B350CCCD77855281C2258333C4683" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment information</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_218B350CCCD77855281C2258333C4683_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_218B350CCCD77855281C2258333C4683" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_218B350CCCD77855281C2258333C4683" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_218B350CCCD77855281C2258333C4683" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_218B350CCCD77855281C2258333C4683" xlink:type="arc" />
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_1FC20068F7385AFDA4C5223D3FA474A6_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_1FC20068F7385AFDA4C5223D3FA474A6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recent accounting pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_1FC20068F7385AFDA4C5223D3FA474A6_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_1FC20068F7385AFDA4C5223D3FA474A6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_1FC20068F7385AFDA4C5223D3FA474A6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_1FC20068F7385AFDA4C5223D3FA474A6" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_1FC20068F7385AFDA4C5223D3FA474A6" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_122AA0DD9762F38E6699223D3FA45924_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_122AA0DD9762F38E6699223D3FA45924" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value of financial instruments</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_122AA0DD9762F38E6699223D3FA45924_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_122AA0DD9762F38E6699223D3FA45924" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_122AA0DD9762F38E6699223D3FA45924" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_122AA0DD9762F38E6699223D3FA45924" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_122AA0DD9762F38E6699223D3FA45924" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract_4D15D7623DC4E5446804378B6D236C97_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract_4DE878FE633D518485A0C880E5986159" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring and Related Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_4DE878FE633D518485A0C880E5986159" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_4DE878FE633D518485A0C880E5986159" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract_4DE878FE633D518485A0C880E5986159" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_710EE8B9ACCA11CFE39F378B6D236129_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_CD04F14423D25C17B1F69F8AE5E89FD6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of expenses and reserve recorded for site consolidation</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_710EE8B9ACCA11CFE39F378B6D236129_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_CD04F14423D25C17B1F69F8AE5E89FD6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring and Related Costs [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_CD04F14423D25C17B1F69F8AE5E89FD6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_CD04F14423D25C17B1F69F8AE5E89FD6" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_CD04F14423D25C17B1F69F8AE5E89FD6" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherLiabilitiesDisclosureAbstract_B3A40610212A88D9F83D02ED1D80012D_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesDisclosureAbstract_B3A40610212A88D9F83D02ED1D80012D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_B3A40610212A88D9F83D02ED1D80012D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_B3A40610212A88D9F83D02ED1D80012D" xlink:to="lab_us-gaap_OtherLiabilitiesDisclosureAbstract_B3A40610212A88D9F83D02ED1D80012D" xlink:type="arc" />
    <link:label id="lab_abus_LiabilitiesRelatedToSaleOfFutureRoyaltiesTextBlock_BBDEC3478E30698D130502ED1D809747_terseLabel_en-US" xlink:label="lab_abus_LiabilitiesRelatedToSaleOfFutureRoyaltiesTextBlock_BBDEC3478E30698D130502ED1D809747" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of future royalties</link:label>
    <link:label id="lab_abus_LiabilitiesRelatedToSaleOfFutureRoyaltiesTextBlock_BBDEC3478E30698D130502ED1D809747_label_en-US" xlink:label="lab_abus_LiabilitiesRelatedToSaleOfFutureRoyaltiesTextBlock_BBDEC3478E30698D130502ED1D809747" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities Related To Sale Of Future Royalties [Text Block]</link:label>
    <link:label id="lab_abus_LiabilitiesRelatedToSaleOfFutureRoyaltiesTextBlock_BBDEC3478E30698D130502ED1D809747_documentation_en-US" xlink:label="lab_abus_LiabilitiesRelatedToSaleOfFutureRoyaltiesTextBlock_BBDEC3478E30698D130502ED1D809747" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Liabilities Related To Sale Of Future Royalties</link:label>
    <link:loc xlink:href="abus-20190930.xsd#abus_LiabilitiesRelatedToSaleOfFutureRoyaltiesTextBlock" xlink:label="loc_abus_LiabilitiesRelatedToSaleOfFutureRoyaltiesTextBlock_BBDEC3478E30698D130502ED1D809747" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_LiabilitiesRelatedToSaleOfFutureRoyaltiesTextBlock_BBDEC3478E30698D130502ED1D809747" xlink:to="lab_abus_LiabilitiesRelatedToSaleOfFutureRoyaltiesTextBlock_BBDEC3478E30698D130502ED1D809747" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_304307865FB5E806E8A206BB94828579_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_304307865FB5E806E8A206BB94828579" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average remaining lease term (years)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_304307865FB5E806E8A206BB94828579_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_304307865FB5E806E8A206BB94828579" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_304307865FB5E806E8A206BB94828579" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_304307865FB5E806E8A206BB94828579" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_304307865FB5E806E8A206BB94828579" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_1638AC13171D10DA3A0606BB9482DC9E_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_1638AC13171D10DA3A0606BB9482DC9E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average discount rate</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_1638AC13171D10DA3A0606BB9482DC9E_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_1638AC13171D10DA3A0606BB9482DC9E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_1638AC13171D10DA3A0606BB9482DC9E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_1638AC13171D10DA3A0606BB9482DC9E" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_1638AC13171D10DA3A0606BB9482DC9E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_2AAC4A8158D85ACB9A972216DDD33788_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_2AAC4A8158D85ACB9A972216DDD33788" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_2AAC4A8158D85ACB9A972216DDD33788_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_2AAC4A8158D85ACB9A972216DDD33788" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_2AAC4A8158D85ACB9A972216DDD33788" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_2AAC4A8158D85ACB9A972216DDD33788" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_2AAC4A8158D85ACB9A972216DDD33788" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_9F9D9F0E6D517404969F2216DDD39050_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis_9F9D9F0E6D517404969F2216DDD39050" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_9F9D9F0E6D517404969F2216DDD39050_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis_9F9D9F0E6D517404969F2216DDD39050" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_9F9D9F0E6D517404969F2216DDD39050" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis_9F9D9F0E6D517404969F2216DDD39050" xlink:to="lab_us-gaap_StatementClassOfStockAxis_9F9D9F0E6D517404969F2216DDD39050" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfStockDomain_358F592153C7E08A12D52216DDD3A483_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain_358F592153C7E08A12D52216DDD3A483" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_358F592153C7E08A12D52216DDD3A483_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain_358F592153C7E08A12D52216DDD3A483" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_358F592153C7E08A12D52216DDD3A483" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain_358F592153C7E08A12D52216DDD3A483" xlink:to="lab_us-gaap_ClassOfStockDomain_358F592153C7E08A12D52216DDD3A483" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockMember_BD15C47E71A72D3924452216DDD40017_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember_BD15C47E71A72D3924452216DDD40017" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Shares</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_BD15C47E71A72D3924452216DDD40017_label_en-US" xlink:label="lab_us-gaap_CommonStockMember_BD15C47E71A72D3924452216DDD40017" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_BD15C47E71A72D3924452216DDD40017" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember_BD15C47E71A72D3924452216DDD40017" xlink:to="lab_us-gaap_CommonStockMember_BD15C47E71A72D3924452216DDD40017" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareBasicLineItems_458CEA408BE31A8F3FAB2216DDD4049F_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicLineItems_458CEA408BE31A8F3FAB2216DDD4049F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicLineItems_458CEA408BE31A8F3FAB2216DDD4049F_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicLineItems_458CEA408BE31A8F3FAB2216DDD4049F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasicLineItems" xlink:label="loc_us-gaap_EarningsPerShareBasicLineItems_458CEA408BE31A8F3FAB2216DDD4049F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_458CEA408BE31A8F3FAB2216DDD4049F" xlink:to="lab_us-gaap_EarningsPerShareBasicLineItems_458CEA408BE31A8F3FAB2216DDD4049F" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareBasicAbstract_65A638B917648CA4032D2216DDD42B1D_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAbstract_65A638B917648CA4032D2216DDD42B1D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Numerator:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAbstract_65A638B917648CA4032D2216DDD42B1D_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAbstract_65A638B917648CA4032D2216DDD42B1D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasicAbstract" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract_65A638B917648CA4032D2216DDD42B1D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_65A638B917648CA4032D2216DDD42B1D" xlink:to="lab_us-gaap_EarningsPerShareBasicAbstract_65A638B917648CA4032D2216DDD42B1D" xlink:type="arc" />
    <link:label id="lab_abus_DistributableEarningsLossAvailabletoCommonShareholdersBasic_DCB013AEBCF33AE3CC952216DDD468E6_terseLabel_en-US" xlink:label="lab_abus_DistributableEarningsLossAvailabletoCommonShareholdersBasic_DCB013AEBCF33AE3CC952216DDD468E6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Allocation of distributable earnings</link:label>
    <link:label id="lab_abus_DistributableEarningsLossAvailabletoCommonShareholdersBasic_DCB013AEBCF33AE3CC952216DDD468E6_label_en-US" xlink:label="lab_abus_DistributableEarningsLossAvailabletoCommonShareholdersBasic_DCB013AEBCF33AE3CC952216DDD468E6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Distributable Earnings (Loss) Available to Common Shareholders, Basic</link:label>
    <link:label id="lab_abus_DistributableEarningsLossAvailabletoCommonShareholdersBasic_DCB013AEBCF33AE3CC952216DDD468E6_documentation_en-US" xlink:label="lab_abus_DistributableEarningsLossAvailabletoCommonShareholdersBasic_DCB013AEBCF33AE3CC952216DDD468E6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Distributable Earnings (Loss) Available to Common Shareholders, Basic</link:label>
    <link:loc xlink:href="abus-20190930.xsd#abus_DistributableEarningsLossAvailabletoCommonShareholdersBasic" xlink:label="loc_abus_DistributableEarningsLossAvailabletoCommonShareholdersBasic_DCB013AEBCF33AE3CC952216DDD468E6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_DistributableEarningsLossAvailabletoCommonShareholdersBasic_DCB013AEBCF33AE3CC952216DDD468E6" xlink:to="lab_abus_DistributableEarningsLossAvailabletoCommonShareholdersBasic_DCB013AEBCF33AE3CC952216DDD468E6" xlink:type="arc" />
    <link:label id="lab_us-gaap_UndistributedEarningsLossAvailableToCommonShareholdersBasic_B35054FB83447F79D8332216DDD585F8_terseLabel_en-US" xlink:label="lab_us-gaap_UndistributedEarningsLossAvailableToCommonShareholdersBasic_B35054FB83447F79D8332216DDD585F8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Allocation of undistributable loss</link:label>
    <link:label id="lab_us-gaap_UndistributedEarningsLossAvailableToCommonShareholdersBasic_B35054FB83447F79D8332216DDD585F8_label_en-US" xlink:label="lab_us-gaap_UndistributedEarningsLossAvailableToCommonShareholdersBasic_B35054FB83447F79D8332216DDD585F8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Undistributed Earnings (Loss) Available to Common Shareholders, Basic</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UndistributedEarningsLossAvailableToCommonShareholdersBasic" xlink:label="loc_us-gaap_UndistributedEarningsLossAvailableToCommonShareholdersBasic_B35054FB83447F79D8332216DDD585F8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UndistributedEarningsLossAvailableToCommonShareholdersBasic_B35054FB83447F79D8332216DDD585F8" xlink:to="lab_us-gaap_UndistributedEarningsLossAvailableToCommonShareholdersBasic_B35054FB83447F79D8332216DDD585F8" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_EC859D890440EACDF6272216DDD58A4F_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_EC859D890440EACDF6272216DDD58A4F" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss attributable to common shareholders (note 2)</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_EC859D890440EACDF6272216DDD58A4F_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_EC859D890440EACDF6272216DDD58A4F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_EC859D890440EACDF6272216DDD58A4F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_EC859D890440EACDF6272216DDD58A4F" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_EC859D890440EACDF6272216DDD58A4F" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareDilutedAbstract_1DC9C8E27A38DEF1B8522216DDD54100_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDilutedAbstract_1DC9C8E27A38DEF1B8522216DDD54100" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Denominator:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDilutedAbstract_1DC9C8E27A38DEF1B8522216DDD54100_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDilutedAbstract_1DC9C8E27A38DEF1B8522216DDD54100" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Diluted [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareDilutedAbstract" xlink:label="loc_us-gaap_EarningsPerShareDilutedAbstract_1DC9C8E27A38DEF1B8522216DDD54100" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_1DC9C8E27A38DEF1B8522216DDD54100" xlink:to="lab_us-gaap_EarningsPerShareDilutedAbstract_1DC9C8E27A38DEF1B8522216DDD54100" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_9026D562B1C21E17CD5A2216DDD5C241_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_9026D562B1C21E17CD5A2216DDD5C241" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average number of common shares - basic and diluted</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_9026D562B1C21E17CD5A2216DDD5C241_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_9026D562B1C21E17CD5A2216DDD5C241" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic and Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_9026D562B1C21E17CD5A2216DDD5C241" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_9026D562B1C21E17CD5A2216DDD5C241" xlink:to="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_9026D562B1C21E17CD5A2216DDD5C241" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_FB13E61C2E104E5913302216DDD62BAA_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted_FB13E61C2E104E5913302216DDD62BAA" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Basic and diluted net loss attributable to common shareholders per share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_FB13E61C2E104E5913302216DDD62BAA_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted_FB13E61C2E104E5913302216DDD62BAA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic and Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_FB13E61C2E104E5913302216DDD62BAA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDiluted_FB13E61C2E104E5913302216DDD62BAA" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDiluted_FB13E61C2E104E5913302216DDD62BAA" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasePayments_7B9AEA21C3664692A5E5538D8C9671E4_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments_8B2AB2EDC9D95CA7B24A40449AEEC1A0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash paid for amounts included in the measurement of lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_7B9AEA21C3664692A5E5538D8C9671E4_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments_8B2AB2EDC9D95CA7B24A40449AEEC1A0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaap_OperatingLeasePayments_8B2AB2EDC9D95CA7B24A40449AEEC1A0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments_8B2AB2EDC9D95CA7B24A40449AEEC1A0" xlink:to="lab_us-gaap_OperatingLeasePayments_8B2AB2EDC9D95CA7B24A40449AEEC1A0" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_73B03F085F96B52AFAC9378B6D1D1F27_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_8D7F440F7C8D50538C4DE4544B608363" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_73B03F085F96B52AFAC9378B6D1D1F27_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_8D7F440F7C8D50538C4DE4544B608363" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_8D7F440F7C8D50538C4DE4544B608363" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_8D7F440F7C8D50538C4DE4544B608363" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_8D7F440F7C8D50538C4DE4544B608363" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_4243CE8DCDE91D62D687378B6D1D8E5B_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis_3DAC6CAEA6415996833114877E5B9BA1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_4243CE8DCDE91D62D687378B6D1D8E5B_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis_3DAC6CAEA6415996833114877E5B9BA1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_3DAC6CAEA6415996833114877E5B9BA1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_3DAC6CAEA6415996833114877E5B9BA1" xlink:to="lab_us-gaap_RestructuringCostAndReserveAxis_3DAC6CAEA6415996833114877E5B9BA1" xlink:type="arc" />
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_CE88AA7A901CB7AC2A6A378B6D1D340C_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain_B51CEC86C3FD5FEFAA68BA5C74E5D8D6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_CE88AA7A901CB7AC2A6A378B6D1D340C_label_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain_B51CEC86C3FD5FEFAA68BA5C74E5D8D6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_B51CEC86C3FD5FEFAA68BA5C74E5D8D6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_B51CEC86C3FD5FEFAA68BA5C74E5D8D6" xlink:to="lab_us-gaap_TypeOfRestructuringDomain_B51CEC86C3FD5FEFAA68BA5C74E5D8D6" xlink:type="arc" />
    <link:label id="lab_abus_EmployeeSeveranceandRelocationMember_DB4025766E1AAA33C9A237BF7B5636A8_terseLabel_en-US" xlink:label="lab_abus_EmployeeSeveranceandRelocationMember_352D08CFEB355492BF7CCCD40E63EE59" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee severance and relocation</link:label>
    <link:label id="lab_abus_EmployeeSeveranceandRelocationMember_DB4025766E1AAA33C9A237BF7B5636A8_label_en-US" xlink:label="lab_abus_EmployeeSeveranceandRelocationMember_352D08CFEB355492BF7CCCD40E63EE59" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Severance and Relocation [Member]</link:label>
    <link:label id="lab_abus_EmployeeSeveranceandRelocationMember_DB4025766E1AAA33C9A237BF7B5636A8_documentation_en-US" xlink:label="lab_abus_EmployeeSeveranceandRelocationMember_352D08CFEB355492BF7CCCD40E63EE59" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Employee Severance and Relocation</link:label>
    <link:loc xlink:href="abus-20190930.xsd#abus_EmployeeSeveranceandRelocationMember" xlink:label="loc_abus_EmployeeSeveranceandRelocationMember_352D08CFEB355492BF7CCCD40E63EE59" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_EmployeeSeveranceandRelocationMember_352D08CFEB355492BF7CCCD40E63EE59" xlink:to="lab_abus_EmployeeSeveranceandRelocationMember_352D08CFEB355492BF7CCCD40E63EE59" xlink:type="arc" />
    <link:label id="lab_us-gaap_FacilityClosingMember_CB8C0C5DC624E2BD5749378B6D1E7EA3_terseLabel_en-US" xlink:label="lab_us-gaap_FacilityClosingMember_AC1E0C478286589DBA54BB024EB9A1C3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Facility and other expenses</link:label>
    <link:label id="lab_us-gaap_FacilityClosingMember_CB8C0C5DC624E2BD5749378B6D1E7EA3_label_en-US" xlink:label="lab_us-gaap_FacilityClosingMember_AC1E0C478286589DBA54BB024EB9A1C3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Facility Closing [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FacilityClosingMember" xlink:label="loc_us-gaap_FacilityClosingMember_AC1E0C478286589DBA54BB024EB9A1C3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FacilityClosingMember_AC1E0C478286589DBA54BB024EB9A1C3" xlink:to="lab_us-gaap_FacilityClosingMember_AC1E0C478286589DBA54BB024EB9A1C3" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_DB823533958A7ED8526C378B6D1E4CDB_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems_31B5A10A3597536D9A1539F37B30AA61" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_DB823533958A7ED8526C378B6D1E4CDB_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems_31B5A10A3597536D9A1539F37B30AA61" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_31B5A10A3597536D9A1539F37B30AA61" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_31B5A10A3597536D9A1539F37B30AA61" xlink:to="lab_us-gaap_RestructuringCostAndReserveLineItems_31B5A10A3597536D9A1539F37B30AA61" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestructuringCharges_BD20FB8DD67E982917AB378B6D1FFA31_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges_CFC8AEAAF37157E686158A55FD02C164" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total site consolidation expense</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_BD20FB8DD67E982917AB378B6D1FFA31_label_en-US" xlink:label="lab_us-gaap_RestructuringCharges_CFC8AEAAF37157E686158A55FD02C164" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Charges</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="loc_us-gaap_RestructuringCharges_CFC8AEAAF37157E686158A55FD02C164" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCharges_CFC8AEAAF37157E686158A55FD02C164" xlink:to="lab_us-gaap_RestructuringCharges_CFC8AEAAF37157E686158A55FD02C164" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_782756FBB86B439ECEAE32CAFADFC403_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract_A6DE3FF6E3755C3DBA50EDD7BE5DB54F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_A6DE3FF6E3755C3DBA50EDD7BE5DB54F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_A6DE3FF6E3755C3DBA50EDD7BE5DB54F" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract_A6DE3FF6E3755C3DBA50EDD7BE5DB54F" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_CC00D60DD664DDABC3AE32E22952CDA2_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1EB73740B70D50009247C81E342EC193" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated of property, plant, and equipment</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_CC00D60DD664DDABC3AE32E22952CDA2_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1EB73740B70D50009247C81E342EC193" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1EB73740B70D50009247C81E342EC193" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1EB73740B70D50009247C81E342EC193" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1EB73740B70D50009247C81E342EC193" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockNoParValue_9032E5A9F195B9ECB58C32E485CBB43D_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockNoParValue_070B6A688D6A5227AA9AA824FF890378" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, no par value (in USD per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockNoParValue_9032E5A9F195B9ECB58C32E485CBB43D_label_en-US" xlink:label="lab_us-gaap_PreferredStockNoParValue_070B6A688D6A5227AA9AA824FF890378" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, No Par Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockNoParValue" xlink:label="loc_us-gaap_PreferredStockNoParValue_070B6A688D6A5227AA9AA824FF890378" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockNoParValue_070B6A688D6A5227AA9AA824FF890378" xlink:to="lab_us-gaap_PreferredStockNoParValue_070B6A688D6A5227AA9AA824FF890378" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_F1DEFD89E3E0923510D132CAFADFEF61_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized_4D3D1FB035A15124A238C5F600A8C05B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_F1DEFD89E3E0923510D132CAFADFEF61_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized_4D3D1FB035A15124A238C5F600A8C05B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_4D3D1FB035A15124A238C5F600A8C05B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized_4D3D1FB035A15124A238C5F600A8C05B" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized_4D3D1FB035A15124A238C5F600A8C05B" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_7D68979BF3EAE840A58232CAFADF7C05_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued_43F0F180169C5287BCC8563F93E3B857" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_7D68979BF3EAE840A58232CAFADF7C05_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued_43F0F180169C5287BCC8563F93E3B857" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_43F0F180169C5287BCC8563F93E3B857" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued_43F0F180169C5287BCC8563F93E3B857" xlink:to="lab_us-gaap_PreferredStockSharesIssued_43F0F180169C5287BCC8563F93E3B857" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_E40821C0F921579E879532CAFADF5C77_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding_4BFAD12728B956A09B4C7D0B142CD8DF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_E40821C0F921579E879532CAFADF5C77_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding_4BFAD12728B956A09B4C7D0B142CD8DF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_4BFAD12728B956A09B4C7D0B142CD8DF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding_4BFAD12728B956A09B4C7D0B142CD8DF" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding_4BFAD12728B956A09B4C7D0B142CD8DF" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockNoParValue_25471E9F8A930B878DEF32CAFADF4186_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockNoParValue_8641E353780255AA9DCE6ECB11B12D84" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common shares, no par value (in USD per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockNoParValue_25471E9F8A930B878DEF32CAFADF4186_label_en-US" xlink:label="lab_us-gaap_CommonStockNoParValue_8641E353780255AA9DCE6ECB11B12D84" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, No Par Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockNoParValue" xlink:label="loc_us-gaap_CommonStockNoParValue_8641E353780255AA9DCE6ECB11B12D84" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockNoParValue_8641E353780255AA9DCE6ECB11B12D84" xlink:to="lab_us-gaap_CommonStockNoParValue_8641E353780255AA9DCE6ECB11B12D84" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesIssued_5BBABFEE74B14EA68B2C32CAFADF9367_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued_0EEC22A007245265885BE4EDBC78A7A1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common shares, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_5BBABFEE74B14EA68B2C32CAFADF9367_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued_0EEC22A007245265885BE4EDBC78A7A1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_0EEC22A007245265885BE4EDBC78A7A1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued_0EEC22A007245265885BE4EDBC78A7A1" xlink:to="lab_us-gaap_CommonStockSharesIssued_0EEC22A007245265885BE4EDBC78A7A1" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_138781A6C21A7D574B7032CAFADF061D_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_FD0CAE23CC5A5182BFBB6A9541182CC1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common shares, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_138781A6C21A7D574B7032CAFADF061D_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_FD0CAE23CC5A5182BFBB6A9541182CC1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_FD0CAE23CC5A5182BFBB6A9541182CC1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding_FD0CAE23CC5A5182BFBB6A9541182CC1" xlink:to="lab_us-gaap_CommonStockSharesOutstanding_FD0CAE23CC5A5182BFBB6A9541182CC1" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_2529102E3BD0F0615A0E223D3FC961B7_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract_2529102E3BD0F0615A0E223D3FC961B7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_2529102E3BD0F0615A0E223D3FC961B7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_2529102E3BD0F0615A0E223D3FC961B7" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract_2529102E3BD0F0615A0E223D3FC961B7" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_7A0DAC2E0795747CF600223D3FC96AE3_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_7A0DAC2E0795747CF600223D3FC96AE3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">OPERATING ACTIVITIES</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_7A0DAC2E0795747CF600223D3FC96AE3_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_7A0DAC2E0795747CF600223D3FC96AE3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_7A0DAC2E0795747CF600223D3FC96AE3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_7A0DAC2E0795747CF600223D3FC96AE3" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_7A0DAC2E0795747CF600223D3FC96AE3" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLoss_369FB5E98668D7FBF8C4223D3FCA44AD_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_369FB5E98668D7FBF8C4223D3FCA44AD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_369FB5E98668D7FBF8C4223D3FCA44AD_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_369FB5E98668D7FBF8C4223D3FCA44AD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_369FB5E98668D7FBF8C4223D3FCA44AD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_369FB5E98668D7FBF8C4223D3FCA44AD" xlink:to="lab_us-gaap_NetIncomeLoss_369FB5E98668D7FBF8C4223D3FCA44AD" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_EC37C24388968F783A41223D3FCA7CE3_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_EC37C24388968F783A41223D3FCA7CE3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Items not involving cash:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_EC37C24388968F783A41223D3FCA7CE3_label_en-US" xlink:label="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_EC37C24388968F783A41223D3FCA7CE3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_EC37C24388968F783A41223D3FCA7CE3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_EC37C24388968F783A41223D3FCA7CE3" xlink:to="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_EC37C24388968F783A41223D3FCA7CE3" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_599140F4D338E47D09F0223D3FCA8E5A_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_599140F4D338E47D09F0223D3FCA8E5A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred income tax benefit</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_599140F4D338E47D09F0223D3FCA8E5A_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_599140F4D338E47D09F0223D3FCA8E5A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_599140F4D338E47D09F0223D3FCA8E5A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_599140F4D338E47D09F0223D3FCA8E5A" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_599140F4D338E47D09F0223D3FCA8E5A" xlink:type="arc" />
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_8D2A2F99781477E135CD223D3FCA2063_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization_8D2A2F99781477E135CD223D3FCA2063" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_8D2A2F99781477E135CD223D3FCA2063_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization_8D2A2F99781477E135CD223D3FCA2063" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_8D2A2F99781477E135CD223D3FCA2063" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization_8D2A2F99781477E135CD223D3FCA2063" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization_8D2A2F99781477E135CD223D3FCA2063" xlink:type="arc" />
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_6800A2AA5ADE8F244F73223D3FCB3524_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_6800A2AA5ADE8F244F73223D3FCB3524" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Loss (gain) on sale of property and equipment</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_6800A2AA5ADE8F244F73223D3FCB3524_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_6800A2AA5ADE8F244F73223D3FCB3524" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_6800A2AA5ADE8F244F73223D3FCB3524" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_6800A2AA5ADE8F244F73223D3FCB3524" xlink:to="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_6800A2AA5ADE8F244F73223D3FCB3524" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensation_0F3F7E08C94AAA158763223D3FCB7D69_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation_0F3F7E08C94AAA158763223D3FCB7D69" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_0F3F7E08C94AAA158763223D3FCB7D69_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation_0F3F7E08C94AAA158763223D3FCB7D69" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_0F3F7E08C94AAA158763223D3FCB7D69" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation_0F3F7E08C94AAA158763223D3FCB7D69" xlink:to="lab_us-gaap_ShareBasedCompensation_0F3F7E08C94AAA158763223D3FCB7D69" xlink:type="arc" />
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_572AF24EDFAF31997E43223D3FCB9E69_negatedLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_572AF24EDFAF31997E43223D3FCB9E69" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Unrealized foreign exchange losses (gains)</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_572AF24EDFAF31997E43223D3FCB9E69_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_572AF24EDFAF31997E43223D3FCB9E69" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Currency Transaction Gain (Loss), Unrealized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_572AF24EDFAF31997E43223D3FCB9E69" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_572AF24EDFAF31997E43223D3FCB9E69" xlink:to="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_572AF24EDFAF31997E43223D3FCB9E69" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_3320B49448B715F63EDE223D3FCBC5FF_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_3320B49448B715F63EDE223D3FCBC5FF" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Change in fair value of contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_3320B49448B715F63EDE223D3FCBC5FF_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_3320B49448B715F63EDE223D3FCBC5FF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_3320B49448B715F63EDE223D3FCBC5FF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_3320B49448B715F63EDE223D3FCBC5FF" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_3320B49448B715F63EDE223D3FCBC5FF" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetImpairmentCharges_C90C3F3AC20670445DC3223D3FCBD599_terseLabel_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges_C90C3F3AC20670445DC3223D3FCBD599" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment of intangible assets</link:label>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_C90C3F3AC20670445DC3223D3FCBD599_label_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges_C90C3F3AC20670445DC3223D3FCBD599" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Impairment Charges</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="loc_us-gaap_AssetImpairmentCharges_C90C3F3AC20670445DC3223D3FCBD599" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetImpairmentCharges_C90C3F3AC20670445DC3223D3FCBD599" xlink:to="lab_us-gaap_AssetImpairmentCharges_C90C3F3AC20670445DC3223D3FCBD599" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_05D842872D1C00C861FA223F55B156D0_verboseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss_05D842872D1C00C861FA223F55B156D0" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Impairment of goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_05D842872D1C00C861FA223F55B156D0_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss_05D842872D1C00C861FA223F55B156D0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill, Impairment Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_05D842872D1C00C861FA223F55B156D0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairmentLoss_05D842872D1C00C861FA223F55B156D0" xlink:to="lab_us-gaap_GoodwillImpairmentLoss_05D842872D1C00C861FA223F55B156D0" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestructuringCosts_95BF919AB0882C304ABC223D3FCB80C7_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCosts_95BF919AB0882C304ABC223D3FCB80C7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Site consolidation non-cash portion</link:label>
    <link:label id="lab_us-gaap_RestructuringCosts_95BF919AB0882C304ABC223D3FCB80C7_label_en-US" xlink:label="lab_us-gaap_RestructuringCosts_95BF919AB0882C304ABC223D3FCB80C7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Costs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestructuringCosts" xlink:label="loc_us-gaap_RestructuringCosts_95BF919AB0882C304ABC223D3FCB80C7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCosts_95BF919AB0882C304ABC223D3FCB80C7" xlink:to="lab_us-gaap_RestructuringCosts_95BF919AB0882C304ABC223D3FCB80C7" xlink:type="arc" />
    <link:label id="lab_us-gaap_GainLossOnInvestments_284C5BB57451C88E97C5223D3FCB8155_negatedLabel_en-US" xlink:label="lab_us-gaap_GainLossOnInvestments_284C5BB57451C88E97C5223D3FCB8155" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Gain on investment</link:label>
    <link:label id="lab_us-gaap_GainLossOnInvestments_284C5BB57451C88E97C5223D3FCB8155_label_en-US" xlink:label="lab_us-gaap_GainLossOnInvestments_284C5BB57451C88E97C5223D3FCB8155" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GainLossOnInvestments" xlink:label="loc_us-gaap_GainLossOnInvestments_284C5BB57451C88E97C5223D3FCB8155" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnInvestments_284C5BB57451C88E97C5223D3FCB8155" xlink:to="lab_us-gaap_GainLossOnInvestments_284C5BB57451C88E97C5223D3FCB8155" xlink:type="arc" />
    <link:label id="lab_us-gaap_GainLossOnSaleOfEquityInvestments_B92CD49AA714AA7C0BDA223D3FCCBA41_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfEquityInvestments_B92CD49AA714AA7C0BDA223D3FCCBA41" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Equity investment loss</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfEquityInvestments_B92CD49AA714AA7C0BDA223D3FCCBA41_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfEquityInvestments_B92CD49AA714AA7C0BDA223D3FCCBA41" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Sale of Equity Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GainLossOnSaleOfEquityInvestments" xlink:label="loc_us-gaap_GainLossOnSaleOfEquityInvestments_B92CD49AA714AA7C0BDA223D3FCCBA41" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfEquityInvestments_B92CD49AA714AA7C0BDA223D3FCCBA41" xlink:to="lab_us-gaap_GainLossOnSaleOfEquityInvestments_B92CD49AA714AA7C0BDA223D3FCCBA41" xlink:type="arc" />
    <link:label id="lab_abus_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties_622E902EC4EF41F953E9223D3FCCD22A_negatedTerseLabel_en-US" xlink:label="lab_abus_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties_622E902EC4EF41F953E9223D3FCCD22A" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Non-cash royalty revenue</link:label>
    <link:label id="lab_abus_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties_622E902EC4EF41F953E9223D3FCCD22A_label_en-US" xlink:label="lab_abus_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties_622E902EC4EF41F953E9223D3FCCD22A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non Cash Royalty Revenue Related To Sale Of Future Royalties</link:label>
    <link:label id="lab_abus_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties_622E902EC4EF41F953E9223D3FCCD22A_documentation_en-US" xlink:label="lab_abus_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties_622E902EC4EF41F953E9223D3FCCD22A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Non Cash Royalty Revenue Related To Sale Of Future Royalties</link:label>
    <link:loc xlink:href="abus-20190930.xsd#abus_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" xlink:label="loc_abus_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties_622E902EC4EF41F953E9223D3FCCD22A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties_622E902EC4EF41F953E9223D3FCCD22A" xlink:to="lab_abus_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties_622E902EC4EF41F953E9223D3FCCD22A" xlink:type="arc" />
    <link:label id="lab_abus_NonCashRoyaltyExpenseRelatedToSaleOfFutureRoyalties_FBFF8277F3BA157C360B223D3FCCB9D4_terseLabel_en-US" xlink:label="lab_abus_NonCashRoyaltyExpenseRelatedToSaleOfFutureRoyalties_FBFF8277F3BA157C360B223D3FCCB9D4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-cash interest expense</link:label>
    <link:label id="lab_abus_NonCashRoyaltyExpenseRelatedToSaleOfFutureRoyalties_FBFF8277F3BA157C360B223D3FCCB9D4_label_en-US" xlink:label="lab_abus_NonCashRoyaltyExpenseRelatedToSaleOfFutureRoyalties_FBFF8277F3BA157C360B223D3FCCB9D4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non Cash Royalty Expense Related To Sale Of Future Royalties</link:label>
    <link:label id="lab_abus_NonCashRoyaltyExpenseRelatedToSaleOfFutureRoyalties_FBFF8277F3BA157C360B223D3FCCB9D4_documentation_en-US" xlink:label="lab_abus_NonCashRoyaltyExpenseRelatedToSaleOfFutureRoyalties_FBFF8277F3BA157C360B223D3FCCB9D4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Non Cash Royalty Expense Related To Sale Of Future Royalties</link:label>
    <link:loc xlink:href="abus-20190930.xsd#abus_NonCashRoyaltyExpenseRelatedToSaleOfFutureRoyalties" xlink:label="loc_abus_NonCashRoyaltyExpenseRelatedToSaleOfFutureRoyalties_FBFF8277F3BA157C360B223D3FCCB9D4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_NonCashRoyaltyExpenseRelatedToSaleOfFutureRoyalties_FBFF8277F3BA157C360B223D3FCCB9D4" xlink:to="lab_abus_NonCashRoyaltyExpenseRelatedToSaleOfFutureRoyalties_FBFF8277F3BA157C360B223D3FCCB9D4" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_0A2DAA79E9F4E9323786223D3FCCBB8A_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_0A2DAA79E9F4E9323786223D3FCCBB8A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net change in non-cash operating items:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_0A2DAA79E9F4E9323786223D3FCCBB8A_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_0A2DAA79E9F4E9323786223D3FCCBB8A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_0A2DAA79E9F4E9323786223D3FCCBB8A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_0A2DAA79E9F4E9323786223D3FCCBB8A" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_0A2DAA79E9F4E9323786223D3FCCBB8A" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_419A36702AE775B02C30223D3FCC628E_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_419A36702AE775B02C30223D3FCC628E" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_419A36702AE775B02C30223D3FCC628E_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_419A36702AE775B02C30223D3FCC628E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_419A36702AE775B02C30223D3FCC628E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_419A36702AE775B02C30223D3FCC628E" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_419A36702AE775B02C30223D3FCC628E" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_19BCF75276A3B28532D1223D3FCD9FCD_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_19BCF75276A3B28532D1223D3FCD9FCD" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_19BCF75276A3B28532D1223D3FCD9FCD_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_19BCF75276A3B28532D1223D3FCD9FCD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_19BCF75276A3B28532D1223D3FCD9FCD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_19BCF75276A3B28532D1223D3FCD9FCD" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_19BCF75276A3B28532D1223D3FCD9FCD" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerAsset_053FAE8D41C0BB7A9A61223D3FCDDEA9_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerAsset_053FAE8D41C0BB7A9A61223D3FCDDEA9" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accrued revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerAsset_053FAE8D41C0BB7A9A61223D3FCDDEA9_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerAsset_053FAE8D41C0BB7A9A61223D3FCDDEA9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Asset</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerAsset" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerAsset_053FAE8D41C0BB7A9A61223D3FCDDEA9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerAsset_053FAE8D41C0BB7A9A61223D3FCDDEA9" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerAsset_053FAE8D41C0BB7A9A61223D3FCDDEA9" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_41113DA1BE53555F26F7223D3FCDE0B8_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_41113DA1BE53555F26F7223D3FCDE0B8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable and accrued liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_41113DA1BE53555F26F7223D3FCDE0B8_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_41113DA1BE53555F26F7223D3FCDE0B8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_41113DA1BE53555F26F7223D3FCDE0B8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_41113DA1BE53555F26F7223D3FCDE0B8" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_41113DA1BE53555F26F7223D3FCDE0B8" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_DC2C55F2195E3BA5A3AF223D3FCDD386_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_DC2C55F2195E3BA5A3AF223D3FCDD386" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_DC2C55F2195E3BA5A3AF223D3FCDD386_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_DC2C55F2195E3BA5A3AF223D3FCDD386" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_DC2C55F2195E3BA5A3AF223D3FCDD386" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_DC2C55F2195E3BA5A3AF223D3FCDD386" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_DC2C55F2195E3BA5A3AF223D3FCDD386" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInRestructuringReserve_F6BD378BEC12D345424C223D3FCD186A_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInRestructuringReserve_F6BD378BEC12D345424C223D3FCD186A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring accrual</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInRestructuringReserve_F6BD378BEC12D345424C223D3FCD186A_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInRestructuringReserve_F6BD378BEC12D345424C223D3FCD186A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Restructuring Reserve</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInRestructuringReserve" xlink:label="loc_us-gaap_IncreaseDecreaseInRestructuringReserve_F6BD378BEC12D345424C223D3FCD186A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInRestructuringReserve_F6BD378BEC12D345424C223D3FCD186A" xlink:to="lab_us-gaap_IncreaseDecreaseInRestructuringReserve_F6BD378BEC12D345424C223D3FCD186A" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_6A83CFD64C447B30D219223D3FCD6D69_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_6A83CFD64C447B30D219223D3FCD6D69" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_6A83CFD64C447B30D219223D3FCD6D69_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_6A83CFD64C447B30D219223D3FCD6D69" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Operating Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_6A83CFD64C447B30D219223D3FCD6D69" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_6A83CFD64C447B30D219223D3FCD6D69" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_6A83CFD64C447B30D219223D3FCD6D69" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_70A805E4934A78562BAE223D3FCDF89E_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_70A805E4934A78562BAE223D3FCDF89E" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_70A805E4934A78562BAE223D3FCDF89E_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_70A805E4934A78562BAE223D3FCDF89E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_70A805E4934A78562BAE223D3FCDF89E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_70A805E4934A78562BAE223D3FCDF89E" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_70A805E4934A78562BAE223D3FCDF89E" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_F0EFAD81E48C29B9CEB1223D3FD352D4_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_F0EFAD81E48C29B9CEB1223D3FD352D4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">INVESTING ACTIVITIES</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_F0EFAD81E48C29B9CEB1223D3FD352D4_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_F0EFAD81E48C29B9CEB1223D3FD352D4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_F0EFAD81E48C29B9CEB1223D3FD352D4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_F0EFAD81E48C29B9CEB1223D3FD352D4" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_F0EFAD81E48C29B9CEB1223D3FD352D4" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsForProceedsFromInvestments_EDA100C763C1E17B17FF223D3FD3DDF7_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromInvestments_EDA100C763C1E17B17FF223D3FD3DDF7" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Acquisition of short and long-term investments</link:label>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromInvestments_EDA100C763C1E17B17FF223D3FD3DDF7_label_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromInvestments_EDA100C763C1E17B17FF223D3FD3DDF7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments for (Proceeds from) Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsForProceedsFromInvestments" xlink:label="loc_us-gaap_PaymentsForProceedsFromInvestments_EDA100C763C1E17B17FF223D3FD3DDF7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForProceedsFromInvestments_EDA100C763C1E17B17FF223D3FD3DDF7" xlink:to="lab_us-gaap_PaymentsForProceedsFromInvestments_EDA100C763C1E17B17FF223D3FD3DDF7" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromSaleOfRestrictedInvestments_1C531D5A60B184ABF553223D3FD3EAF2_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfRestrictedInvestments_1C531D5A60B184ABF553223D3FD3EAF2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disposition of short and long-term investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfRestrictedInvestments_1C531D5A60B184ABF553223D3FD3EAF2_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfRestrictedInvestments_1C531D5A60B184ABF553223D3FD3EAF2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale of Restricted Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromSaleOfRestrictedInvestments" xlink:label="loc_us-gaap_ProceedsFromSaleOfRestrictedInvestments_1C531D5A60B184ABF553223D3FD3EAF2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfRestrictedInvestments_1C531D5A60B184ABF553223D3FD3EAF2" xlink:to="lab_us-gaap_ProceedsFromSaleOfRestrictedInvestments_1C531D5A60B184ABF553223D3FD3EAF2" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_0A111951DCC417837D2C223D3FD33613_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_0A111951DCC417837D2C223D3FD33613" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from sale of property and equipment</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_0A111951DCC417837D2C223D3FD33613_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_0A111951DCC417837D2C223D3FD33613" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale of Property, Plant, and Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_0A111951DCC417837D2C223D3FD33613" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_0A111951DCC417837D2C223D3FD33613" xlink:to="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_0A111951DCC417837D2C223D3FD33613" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_EC87D9761B88C1ADA8E3223D3FD48135_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_EC87D9761B88C1ADA8E3223D3FD48135" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Acquisition of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_EC87D9761B88C1ADA8E3223D3FD48135_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_EC87D9761B88C1ADA8E3223D3FD48135" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_EC87D9761B88C1ADA8E3223D3FD48135" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_EC87D9761B88C1ADA8E3223D3FD48135" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_EC87D9761B88C1ADA8E3223D3FD48135" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_5A9045F8A305011975ED223D3FD4B07F_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_5A9045F8A305011975ED223D3FD4B07F" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by (used) in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_5A9045F8A305011975ED223D3FD4B07F_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_5A9045F8A305011975ED223D3FD4B07F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_5A9045F8A305011975ED223D3FD4B07F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_5A9045F8A305011975ED223D3FD4B07F" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_5A9045F8A305011975ED223D3FD4B07F" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_B0CC6CDE15652D801072223D3FD4D7B4_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_B0CC6CDE15652D801072223D3FD4D7B4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">FINANCING ACTIVITIES</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_B0CC6CDE15652D801072223D3FD4D7B4_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_B0CC6CDE15652D801072223D3FD4D7B4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_B0CC6CDE15652D801072223D3FD4D7B4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_B0CC6CDE15652D801072223D3FD4D7B4" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_B0CC6CDE15652D801072223D3FD4D7B4" xlink:type="arc" />
    <link:label id="lab_abus_ProceedsFromSaleOfFutureRoyaltiesNet_161E3CD2F9AA070AFC9B223D3FD4DCE9_terseLabel_en-US" xlink:label="lab_abus_ProceedsFromSaleOfFutureRoyaltiesNet_161E3CD2F9AA070AFC9B223D3FD4DCE9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from sale of future royalties, net</link:label>
    <link:label id="lab_abus_ProceedsFromSaleOfFutureRoyaltiesNet_161E3CD2F9AA070AFC9B223D3FD4DCE9_label_en-US" xlink:label="lab_abus_ProceedsFromSaleOfFutureRoyaltiesNet_161E3CD2F9AA070AFC9B223D3FD4DCE9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds From Sale Of Future Royalties, Net</link:label>
    <link:label id="lab_abus_ProceedsFromSaleOfFutureRoyaltiesNet_161E3CD2F9AA070AFC9B223D3FD4DCE9_documentation_en-US" xlink:label="lab_abus_ProceedsFromSaleOfFutureRoyaltiesNet_161E3CD2F9AA070AFC9B223D3FD4DCE9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Proceeds From Sale Of Future Royalties, Net</link:label>
    <link:loc xlink:href="abus-20190930.xsd#abus_ProceedsFromSaleOfFutureRoyaltiesNet" xlink:label="loc_abus_ProceedsFromSaleOfFutureRoyaltiesNet_161E3CD2F9AA070AFC9B223D3FD4DCE9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_ProceedsFromSaleOfFutureRoyaltiesNet_161E3CD2F9AA070AFC9B223D3FD4DCE9" xlink:to="lab_abus_ProceedsFromSaleOfFutureRoyaltiesNet_161E3CD2F9AA070AFC9B223D3FD4DCE9" xlink:type="arc" />
    <link:label id="lab_us-gaap_RepaymentsOfNotesPayable_AA2AF24420F216B5AEED223D3FD4814A_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfNotesPayable_AA2AF24420F216B5AEED223D3FD4814A" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Promissory note repayment</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfNotesPayable_AA2AF24420F216B5AEED223D3FD4814A_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfNotesPayable_AA2AF24420F216B5AEED223D3FD4814A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repayments of Notes Payable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable_AA2AF24420F216B5AEED223D3FD4814A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfNotesPayable_AA2AF24420F216B5AEED223D3FD4814A" xlink:to="lab_us-gaap_RepaymentsOfNotesPayable_AA2AF24420F216B5AEED223D3FD4814A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_4A42AF46CA8A81A99D6E223D3FD42B10_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_4A42AF46CA8A81A99D6E223D3FD42B10" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from sale of Series A Preferred Shares, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_4A42AF46CA8A81A99D6E223D3FD42B10_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_4A42AF46CA8A81A99D6E223D3FD42B10" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Convertible Preferred Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_4A42AF46CA8A81A99D6E223D3FD42B10" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_4A42AF46CA8A81A99D6E223D3FD42B10" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_4A42AF46CA8A81A99D6E223D3FD42B10" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_F32B796859F662F22F0E223D3FD5677A_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_F32B796859F662F22F0E223D3FD5677A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common shares pursuant to the ATM</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_F32B796859F662F22F0E223D3FD5677A_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_F32B796859F662F22F0E223D3FD5677A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_F32B796859F662F22F0E223D3FD5677A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_F32B796859F662F22F0E223D3FD5677A" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_F32B796859F662F22F0E223D3FD5677A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_92A339767F3C70D1F5A2223D3FD53B3F_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised_92A339767F3C70D1F5A2223D3FD53B3F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common shares pursuant to exercise of options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_92A339767F3C70D1F5A2223D3FD53B3F_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised_92A339767F3C70D1F5A2223D3FD53B3F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_92A339767F3C70D1F5A2223D3FD53B3F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised_92A339767F3C70D1F5A2223D3FD53B3F" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised_92A339767F3C70D1F5A2223D3FD53B3F" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_651C1C6D6E08E1DD868A223D3FD54367_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_651C1C6D6E08E1DD868A223D3FD54367" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_651C1C6D6E08E1DD868A223D3FD54367_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_651C1C6D6E08E1DD868A223D3FD54367" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_651C1C6D6E08E1DD868A223D3FD54367" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_651C1C6D6E08E1DD868A223D3FD54367" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_651C1C6D6E08E1DD868A223D3FD54367" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_D8DFE6EFD28394CE15CF223D3FD57651_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_D8DFE6EFD28394CE15CF223D3FD57651" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of foreign exchange rate changes on cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_D8DFE6EFD28394CE15CF223D3FD57651_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_D8DFE6EFD28394CE15CF223D3FD57651" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_D8DFE6EFD28394CE15CF223D3FD57651" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_D8DFE6EFD28394CE15CF223D3FD57651" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_D8DFE6EFD28394CE15CF223D3FD57651" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_BC4E290BA10C6A71DCBD223D3FD5F06F_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_BC4E290BA10C6A71DCBD223D3FD5F06F" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Increase in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_BC4E290BA10C6A71DCBD223D3FD5F06F_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_BC4E290BA10C6A71DCBD223D3FD5F06F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_BC4E290BA10C6A71DCBD223D3FD5F06F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_BC4E290BA10C6A71DCBD223D3FD5F06F" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_BC4E290BA10C6A71DCBD223D3FD5F06F" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8A4360EF863A6431EC15223D3FD69FE2_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8A4360EF863A6431EC15223D3FD69FE2" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents, beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8A4360EF863A6431EC15223D3FD69FE2_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8A4360EF863A6431EC15223D3FD69FE2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8A4360EF863A6431EC15223D3FD69FE2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8A4360EF863A6431EC15223D3FD69FE2" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8A4360EF863A6431EC15223D3FD69FE2" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_96C4D3525F421C417296223D3FD6042D_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_96C4D3525F421C417296223D3FD6042D" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents, end of period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_96C4D3525F421C417296223D3FD6042D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_96C4D3525F421C417296223D3FD6042D" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_96C4D3525F421C417296223D3FD6042D" xlink:type="arc" />
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_B25D1182B7494D1DFD77223D3FD69203_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract_B25D1182B7494D1DFD77223D3FD69203" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplemental cash flow information</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_B25D1182B7494D1DFD77223D3FD69203_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract_B25D1182B7494D1DFD77223D3FD69203" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_B25D1182B7494D1DFD77223D3FD69203" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_B25D1182B7494D1DFD77223D3FD69203" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract_B25D1182B7494D1DFD77223D3FD69203" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_90AA322E4288A741D8A7223D3FD6D541_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_90AA322E4288A741D8A7223D3FD6D541" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-cash transactions:</link:label>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_90AA322E4288A741D8A7223D3FD6D541_label_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_90AA322E4288A741D8A7223D3FD6D541" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_90AA322E4288A741D8A7223D3FD6D541" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_90AA322E4288A741D8A7223D3FD6D541" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_90AA322E4288A741D8A7223D3FD6D541" xlink:type="arc" />
    <link:label id="lab_us-gaap_DividendsPreferredStockCash_D20D51231768DDC8EBA3223D3FD6350D_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DividendsPreferredStockCash_D20D51231768DDC8EBA3223D3FD6350D" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Preferred shares dividends accrued</link:label>
    <link:label id="lab_us-gaap_DividendsPreferredStockCash_D20D51231768DDC8EBA3223D3FD6350D_label_en-US" xlink:label="lab_us-gaap_DividendsPreferredStockCash_D20D51231768DDC8EBA3223D3FD6350D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividends, Preferred Stock, Cash</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DividendsPreferredStockCash" xlink:label="loc_us-gaap_DividendsPreferredStockCash_D20D51231768DDC8EBA3223D3FD6350D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsPreferredStockCash_D20D51231768DDC8EBA3223D3FD6350D" xlink:to="lab_us-gaap_DividendsPreferredStockCash_D20D51231768DDC8EBA3223D3FD6350D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContributionOfProperty_B767972D27DC621FA5C9223D3FD6FA95_terseLabel_en-US" xlink:label="lab_us-gaap_ContributionOfProperty_B767972D27DC621FA5C9223D3FD6FA95" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment in Genevant</link:label>
    <link:label id="lab_us-gaap_ContributionOfProperty_B767972D27DC621FA5C9223D3FD6FA95_label_en-US" xlink:label="lab_us-gaap_ContributionOfProperty_B767972D27DC621FA5C9223D3FD6FA95" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contribution of Property</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContributionOfProperty" xlink:label="loc_us-gaap_ContributionOfProperty_B767972D27DC621FA5C9223D3FD6FA95" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContributionOfProperty_B767972D27DC621FA5C9223D3FD6FA95" xlink:to="lab_us-gaap_ContributionOfProperty_B767972D27DC621FA5C9223D3FD6FA95" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_7E3E530AC746C6C49BBE2216DD339FD3_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_7E3E530AC746C6C49BBE2216DD339FD3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">October through December 2019</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_7E3E530AC746C6C49BBE2216DD339FD3_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_7E3E530AC746C6C49BBE2216DD339FD3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Remainder of Fiscal Year</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_7E3E530AC746C6C49BBE2216DD339FD3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_7E3E530AC746C6C49BBE2216DD339FD3" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_7E3E530AC746C6C49BBE2216DD339FD3" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_97892AB0EBAC4CF483222216DD33DAAE_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_97892AB0EBAC4CF483222216DD33DAAE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2020</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_97892AB0EBAC4CF483222216DD33DAAE_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_97892AB0EBAC4CF483222216DD33DAAE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Two</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_97892AB0EBAC4CF483222216DD33DAAE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_97892AB0EBAC4CF483222216DD33DAAE" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_97892AB0EBAC4CF483222216DD33DAAE" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_3B73E90BB944EB84C58C2216DD336696_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_3B73E90BB944EB84C58C2216DD336696" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_3B73E90BB944EB84C58C2216DD336696_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_3B73E90BB944EB84C58C2216DD336696" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Three</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_3B73E90BB944EB84C58C2216DD336696" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_3B73E90BB944EB84C58C2216DD336696" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_3B73E90BB944EB84C58C2216DD336696" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_3963D5CC19F74C7E3B9B2216DD330B45_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_3963D5CC19F74C7E3B9B2216DD330B45" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_3963D5CC19F74C7E3B9B2216DD330B45_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_3963D5CC19F74C7E3B9B2216DD330B45" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Four</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_3963D5CC19F74C7E3B9B2216DD330B45" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_3963D5CC19F74C7E3B9B2216DD330B45" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_3963D5CC19F74C7E3B9B2216DD330B45" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_E1AC9991CFDBD02778782216DD343EEB_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_E1AC9991CFDBD02778782216DD343EEB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_E1AC9991CFDBD02778782216DD343EEB_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_E1AC9991CFDBD02778782216DD343EEB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Five</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_E1AC9991CFDBD02778782216DD343EEB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_E1AC9991CFDBD02778782216DD343EEB" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_E1AC9991CFDBD02778782216DD343EEB" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_D8262822B4D4E0AC9A142216DD34A7A2_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_D8262822B4D4E0AC9A142216DD34A7A2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_D8262822B4D4E0AC9A142216DD34A7A2_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_D8262822B4D4E0AC9A142216DD34A7A2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due after Year Five</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_D8262822B4D4E0AC9A142216DD34A7A2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_D8262822B4D4E0AC9A142216DD34A7A2" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_D8262822B4D4E0AC9A142216DD34A7A2" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_DE6EA0BD6D7C6A2EF94F2216DD342F24_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_DE6EA0BD6D7C6A2EF94F2216DD342F24" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total Lease Payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_DE6EA0BD6D7C6A2EF94F2216DD342F24_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_DE6EA0BD6D7C6A2EF94F2216DD342F24" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_DE6EA0BD6D7C6A2EF94F2216DD342F24" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_DE6EA0BD6D7C6A2EF94F2216DD342F24" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_DE6EA0BD6D7C6A2EF94F2216DD342F24" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_A54BC6A914D9C80341D22216DD342E61_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_A54BC6A914D9C80341D22216DD342E61" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Less: interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_A54BC6A914D9C80341D22216DD342E61_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_A54BC6A914D9C80341D22216DD342E61" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_A54BC6A914D9C80341D22216DD342E61" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_A54BC6A914D9C80341D22216DD342E61" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_A54BC6A914D9C80341D22216DD342E61" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseLiability_85D0154124B5013F1B1C2216DD34842A_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability_85D0154124B5013F1B1C2216DD34842A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Present value of lease payments</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_85D0154124B5013F1B1C2216DD34842A_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability_85D0154124B5013F1B1C2216DD34842A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_85D0154124B5013F1B1C2216DD34842A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability_85D0154124B5013F1B1C2216DD34842A" xlink:to="lab_us-gaap_OperatingLeaseLiability_85D0154124B5013F1B1C2216DD34842A" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_BA325A706D13F3AA09B606E23AC837B2_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract_BA325A706D13F3AA09B606E23AC837B2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_BA325A706D13F3AA09B606E23AC837B2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_BA325A706D13F3AA09B606E23AC837B2" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract_BA325A706D13F3AA09B606E23AC837B2" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_84A3CDCA66B89F19E65D06E23AC824FD_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_84A3CDCA66B89F19E65D06E23AC824FD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance costs on preferred stock issued</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_84A3CDCA66B89F19E65D06E23AC824FD_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_84A3CDCA66B89F19E65D06E23AC824FD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_84A3CDCA66B89F19E65D06E23AC824FD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_84A3CDCA66B89F19E65D06E23AC824FD" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_84A3CDCA66B89F19E65D06E23AC824FD" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityNoteAbstract_794487BDEDFBF75BB71E02DE05E1D660_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract_794487BDEDFBF75BB71E02DE05E1D660" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_794487BDEDFBF75BB71E02DE05E1D660" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_794487BDEDFBF75BB71E02DE05E1D660" xlink:to="lab_us-gaap_StockholdersEquityNoteAbstract_794487BDEDFBF75BB71E02DE05E1D660" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_7A2A86722D5CBDC40C6702DE05E2FCDA_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_7A2A86722D5CBDC40C6702DE05E2FCDA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders' equity and stock-based compensation</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_7A2A86722D5CBDC40C6702DE05E2FCDA_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_7A2A86722D5CBDC40C6702DE05E2FCDA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_7A2A86722D5CBDC40C6702DE05E2FCDA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_7A2A86722D5CBDC40C6702DE05E2FCDA" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_7A2A86722D5CBDC40C6702DE05E2FCDA" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementTable_DE147DD10B3EB30DE186223D3FEC4526_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable_DE147DD10B3EB30DE186223D3FEC4526" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_DE147DD10B3EB30DE186223D3FEC4526_label_en-US" xlink:label="lab_us-gaap_StatementTable_DE147DD10B3EB30DE186223D3FEC4526" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_DE147DD10B3EB30DE186223D3FEC4526" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable_DE147DD10B3EB30DE186223D3FEC4526" xlink:to="lab_us-gaap_StatementTable_DE147DD10B3EB30DE186223D3FEC4526" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_99119CD9887D57349810223D3FEC6481_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis_99119CD9887D57349810223D3FEC6481" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_99119CD9887D57349810223D3FEC6481_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis_99119CD9887D57349810223D3FEC6481" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_99119CD9887D57349810223D3FEC6481" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_99119CD9887D57349810223D3FEC6481" xlink:to="lab_us-gaap_StatementEquityComponentsAxis_99119CD9887D57349810223D3FEC6481" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityComponentDomain_F02FA9F6CA06E5F84AC3223D3FEC50B1_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain_F02FA9F6CA06E5F84AC3223D3FEC50B1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_F02FA9F6CA06E5F84AC3223D3FEC50B1_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain_F02FA9F6CA06E5F84AC3223D3FEC50B1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_F02FA9F6CA06E5F84AC3223D3FEC50B1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain_F02FA9F6CA06E5F84AC3223D3FEC50B1" xlink:to="lab_us-gaap_EquityComponentDomain_F02FA9F6CA06E5F84AC3223D3FEC50B1" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockMember_E4BC93CBA8EAD16C98DA223D3FED170B_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockMember_E4BC93CBA8EAD16C98DA223D3FED170B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Convertible Preferred Shares</link:label>
    <link:label id="lab_us-gaap_PreferredStockMember_E4BC93CBA8EAD16C98DA223D3FED170B_label_en-US" xlink:label="lab_us-gaap_PreferredStockMember_E4BC93CBA8EAD16C98DA223D3FED170B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaap_PreferredStockMember_E4BC93CBA8EAD16C98DA223D3FED170B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockMember_E4BC93CBA8EAD16C98DA223D3FED170B" xlink:to="lab_us-gaap_PreferredStockMember_E4BC93CBA8EAD16C98DA223D3FED170B" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_12734BBC94AE583A291A223D3FEDF47C_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember_12734BBC94AE583A291A223D3FEDF47C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_12734BBC94AE583A291A223D3FEDF47C_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember_12734BBC94AE583A291A223D3FEDF47C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_12734BBC94AE583A291A223D3FEDF47C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember_12734BBC94AE583A291A223D3FEDF47C" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember_12734BBC94AE583A291A223D3FEDF47C" xlink:type="arc" />
    <link:label id="lab_us-gaap_RetainedEarningsMember_E6DD5D260965F5ED1019223D3FED0CEB_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember_E6DD5D260965F5ED1019223D3FED0CEB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_E6DD5D260965F5ED1019223D3FED0CEB_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember_E6DD5D260965F5ED1019223D3FED0CEB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_E6DD5D260965F5ED1019223D3FED0CEB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember_E6DD5D260965F5ED1019223D3FED0CEB" xlink:to="lab_us-gaap_RetainedEarningsMember_E6DD5D260965F5ED1019223D3FED0CEB" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_4A369AFFE4641DEC2A17223D3FED52CF_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_4A369AFFE4641DEC2A17223D3FED52CF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_4A369AFFE4641DEC2A17223D3FED52CF_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_4A369AFFE4641DEC2A17223D3FED52CF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_4A369AFFE4641DEC2A17223D3FED52CF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_4A369AFFE4641DEC2A17223D3FED52CF" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_4A369AFFE4641DEC2A17223D3FED52CF" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementLineItems_22757A62F5EEEEDE50E6223D3FEE6BEF_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems_22757A62F5EEEEDE50E6223D3FEE6BEF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_22757A62F5EEEEDE50E6223D3FEE6BEF_label_en-US" xlink:label="lab_us-gaap_StatementLineItems_22757A62F5EEEEDE50E6223D3FEE6BEF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_22757A62F5EEEEDE50E6223D3FEE6BEF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems_22757A62F5EEEEDE50E6223D3FEE6BEF" xlink:to="lab_us-gaap_StatementLineItems_22757A62F5EEEEDE50E6223D3FEE6BEF" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharesIssued_E40794393CACB28EE723223D3FEEB452_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesIssued_E40794393CACB28EE723223D3FEEB452" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesIssued_E40794393CACB28EE723223D3FEEB452_label_en-US" xlink:label="lab_us-gaap_SharesIssued_E40794393CACB28EE723223D3FEEB452" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_E40794393CACB28EE723223D3FEEB452" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssued_E40794393CACB28EE723223D3FEEB452" xlink:to="lab_us-gaap_SharesIssued_E40794393CACB28EE723223D3FEEB452" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquity_6CCA7B441BE0B8BD8AF5223D3FEE8897_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity_6CCA7B441BE0B8BD8AF5223D3FEE8897" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_6CCA7B441BE0B8BD8AF5223D3FEE8897_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity_6CCA7B441BE0B8BD8AF5223D3FEE8897" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_6CCA7B441BE0B8BD8AF5223D3FEE8897" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_6CCA7B441BE0B8BD8AF5223D3FEE8897" xlink:to="lab_us-gaap_StockholdersEquity_6CCA7B441BE0B8BD8AF5223D3FEE8897" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockAccretionOfRedemptionDiscount_F3D041E7CBB1CA87D80D223D3FEE092C_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockAccretionOfRedemptionDiscount_F3D041E7CBB1CA87D80D223D3FEE092C" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Accretion of accumulated dividends on Preferred Shares</link:label>
    <link:label id="lab_us-gaap_PreferredStockAccretionOfRedemptionDiscount_F3D041E7CBB1CA87D80D223D3FEE092C_label_en-US" xlink:label="lab_us-gaap_PreferredStockAccretionOfRedemptionDiscount_F3D041E7CBB1CA87D80D223D3FEE092C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Accretion of Redemption Discount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockAccretionOfRedemptionDiscount" xlink:label="loc_us-gaap_PreferredStockAccretionOfRedemptionDiscount_F3D041E7CBB1CA87D80D223D3FEE092C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockAccretionOfRedemptionDiscount_F3D041E7CBB1CA87D80D223D3FEE092C" xlink:to="lab_us-gaap_PreferredStockAccretionOfRedemptionDiscount_F3D041E7CBB1CA87D80D223D3FEE092C" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_EE2FDA69188072FC37C5223D3FEE6C3C_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_EE2FDA69188072FC37C5223D3FEE6C3C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_EE2FDA69188072FC37C5223D3FEE6C3C_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_EE2FDA69188072FC37C5223D3FEE6C3C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_EE2FDA69188072FC37C5223D3FEE6C3C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_EE2FDA69188072FC37C5223D3FEE6C3C" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_EE2FDA69188072FC37C5223D3FEE6C3C" xlink:type="arc" />
    <link:label id="lab_abus_AdjustmentstoAdditionalPaidinCapitalCertainFairValueAdjustmentstoLiabilityStockOptionAwards_D9A3C6488D85EC5B85A6223D3FEE626D_terseLabel_en-US" xlink:label="lab_abus_AdjustmentstoAdditionalPaidinCapitalCertainFairValueAdjustmentstoLiabilityStockOptionAwards_D9A3C6488D85EC5B85A6223D3FEE626D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Certain fair value adjustments to liability-classified</link:label>
    <link:label id="lab_abus_AdjustmentstoAdditionalPaidinCapitalCertainFairValueAdjustmentstoLiabilityStockOptionAwards_D9A3C6488D85EC5B85A6223D3FEE626D_label_en-US" xlink:label="lab_abus_AdjustmentstoAdditionalPaidinCapitalCertainFairValueAdjustmentstoLiabilityStockOptionAwards_D9A3C6488D85EC5B85A6223D3FEE626D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Additional Paid in Capital, Certain Fair Value Adjustments to Liability Stock Option Awards</link:label>
    <link:label id="lab_abus_AdjustmentstoAdditionalPaidinCapitalCertainFairValueAdjustmentstoLiabilityStockOptionAwards_D9A3C6488D85EC5B85A6223D3FEE626D_documentation_en-US" xlink:label="lab_abus_AdjustmentstoAdditionalPaidinCapitalCertainFairValueAdjustmentstoLiabilityStockOptionAwards_D9A3C6488D85EC5B85A6223D3FEE626D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Adjustments to Additional Paid in Capital, Certain Fair Value Adjustments to Liability Stock Option Awards</link:label>
    <link:loc xlink:href="abus-20190930.xsd#abus_AdjustmentstoAdditionalPaidinCapitalCertainFairValueAdjustmentstoLiabilityStockOptionAwards" xlink:label="loc_abus_AdjustmentstoAdditionalPaidinCapitalCertainFairValueAdjustmentstoLiabilityStockOptionAwards_D9A3C6488D85EC5B85A6223D3FEE626D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_AdjustmentstoAdditionalPaidinCapitalCertainFairValueAdjustmentstoLiabilityStockOptionAwards_D9A3C6488D85EC5B85A6223D3FEE626D" xlink:to="lab_abus_AdjustmentstoAdditionalPaidinCapitalCertainFairValueAdjustmentstoLiabilityStockOptionAwards_D9A3C6488D85EC5B85A6223D3FEE626D" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_C13E2E1DD2F089FDC129223D3FEF385D_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_C13E2E1DD2F089FDC129223D3FEF385D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common shares pursuant to the Sale Agreement (shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_C13E2E1DD2F089FDC129223D3FEF385D_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_C13E2E1DD2F089FDC129223D3FEF385D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_C13E2E1DD2F089FDC129223D3FEF385D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_C13E2E1DD2F089FDC129223D3FEF385D" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_C13E2E1DD2F089FDC129223D3FEF385D" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_72003B93A40A7ADB93FD223D3FEF1540_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_72003B93A40A7ADB93FD223D3FEF1540" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common shares pursuant to the Sale Agreement</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_72003B93A40A7ADB93FD223D3FEF1540_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_72003B93A40A7ADB93FD223D3FEF1540" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_72003B93A40A7ADB93FD223D3FEF1540" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_72003B93A40A7ADB93FD223D3FEF1540" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_72003B93A40A7ADB93FD223D3FEF1540" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_80CBF4191D66874E035B223D3FEF849B_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_80CBF4191D66874E035B223D3FEF849B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common shares pursuant to exercise of options (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_80CBF4191D66874E035B223D3FEF849B_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_80CBF4191D66874E035B223D3FEF849B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_80CBF4191D66874E035B223D3FEF849B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_80CBF4191D66874E035B223D3FEF849B" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_80CBF4191D66874E035B223D3FEF849B" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_84CC7861F543A29E5934223D3FEF331B_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_84CC7861F543A29E5934223D3FEF331B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common shares pursuant to exercise of options</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_84CC7861F543A29E5934223D3FEF331B_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_84CC7861F543A29E5934223D3FEF331B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_84CC7861F543A29E5934223D3FEF331B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_84CC7861F543A29E5934223D3FEF331B" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_84CC7861F543A29E5934223D3FEF331B" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_FF336CA66BC711A1FDAE223D3FEF5559_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_FF336CA66BC711A1FDAE223D3FEF5559" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Currency translation adjustment</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_FF336CA66BC711A1FDAE223D3FEF5559_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_FF336CA66BC711A1FDAE223D3FEF5559" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_FF336CA66BC711A1FDAE223D3FEF5559" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_FF336CA66BC711A1FDAE223D3FEF5559" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_FF336CA66BC711A1FDAE223D3FEF5559" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLoss_2707DD543F0E59C404CE223D3FEF44D4_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_2707DD543F0E59C404CE223D3FEF44D4" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_2707DD543F0E59C404CE223D3FEF44D4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_2707DD543F0E59C404CE223D3FEF44D4" xlink:to="lab_us-gaap_NetIncomeLoss_2707DD543F0E59C404CE223D3FEF44D4" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharesIssued_D2EC89ABB09852D2723D223D3FF0D658_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesIssued_D2EC89ABB09852D2723D223D3FF0D658" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_D2EC89ABB09852D2723D223D3FF0D658" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssued_D2EC89ABB09852D2723D223D3FF0D658" xlink:to="lab_us-gaap_SharesIssued_D2EC89ABB09852D2723D223D3FF0D658" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquity_19F218C9DFDD1EA178F9223D3FF0D191_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity_19F218C9DFDD1EA178F9223D3FF0D191" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_19F218C9DFDD1EA178F9223D3FF0D191" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_19F218C9DFDD1EA178F9223D3FF0D191" xlink:to="lab_us-gaap_StockholdersEquity_19F218C9DFDD1EA178F9223D3FF0D191" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_2BF35F9DCAC58E76C2303258A65EB4B2_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract_2DE2669B043A5CEB90ECA6AA035BCBFF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_2DE2669B043A5CEB90ECA6AA035BCBFF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_2DE2669B043A5CEB90ECA6AA035BCBFF" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract_2DE2669B043A5CEB90ECA6AA035BCBFF" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_0654414AF0519D2A2E7F3258A65EB035_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_3DB68E3B86A2534DAC4E0166248FDC18" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets and liabilities measured at fair value on a recurring basis</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_0654414AF0519D2A2E7F3258A65EB035_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_3DB68E3B86A2534DAC4E0166248FDC18" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_3DB68E3B86A2534DAC4E0166248FDC18" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_3DB68E3B86A2534DAC4E0166248FDC18" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_3DB68E3B86A2534DAC4E0166248FDC18" xlink:type="arc" />
    <link:label id="lab_abus_ChangesInFairValueofLiabilityOptionTableTextBlock_3A03D04ADF4E9A314A1C3258A65E54C4_terseLabel_en-US" xlink:label="lab_abus_ChangesInFairValueofLiabilityOptionTableTextBlock_D1F70F33421C5B8DBE871534B6C675C8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in fair value of liability option</link:label>
    <link:label id="lab_abus_ChangesInFairValueofLiabilityOptionTableTextBlock_3A03D04ADF4E9A314A1C3258A65E54C4_label_en-US" xlink:label="lab_abus_ChangesInFairValueofLiabilityOptionTableTextBlock_D1F70F33421C5B8DBE871534B6C675C8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Changes In Fair Value of Liability Option [Table Text Block]</link:label>
    <link:label id="lab_abus_ChangesInFairValueofLiabilityOptionTableTextBlock_3A03D04ADF4E9A314A1C3258A65E54C4_documentation_en-US" xlink:label="lab_abus_ChangesInFairValueofLiabilityOptionTableTextBlock_D1F70F33421C5B8DBE871534B6C675C8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Changes In Fair Value of Liability Option [Table Text Block]</link:label>
    <link:loc xlink:href="abus-20190930.xsd#abus_ChangesInFairValueofLiabilityOptionTableTextBlock" xlink:label="loc_abus_ChangesInFairValueofLiabilityOptionTableTextBlock_D1F70F33421C5B8DBE871534B6C675C8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_ChangesInFairValueofLiabilityOptionTableTextBlock_D1F70F33421C5B8DBE871534B6C675C8" xlink:to="lab_abus_ChangesInFairValueofLiabilityOptionTableTextBlock_D1F70F33421C5B8DBE871534B6C675C8" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_A1B813E85DA7C0A9A0FC3258A65FCDBA_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_5924CE6B224A5EC9B9DE0CB0487B5598" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of changes in fair value of contingent consideration</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_A1B813E85DA7C0A9A0FC3258A65FCDBA_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_5924CE6B224A5EC9B9DE0CB0487B5598" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_5924CE6B224A5EC9B9DE0CB0487B5598" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_5924CE6B224A5EC9B9DE0CB0487B5598" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_5924CE6B224A5EC9B9DE0CB0487B5598" xlink:type="arc" />
    <link:label id="lab_abus_WhollyOwnedSubsidiariesIncludedinFinancialStatements_00F15E7C9FCD61B4A5C406BB94D7DE71_terseLabel_en-US" xlink:label="lab_abus_WhollyOwnedSubsidiariesIncludedinFinancialStatements_00F15E7C9FCD61B4A5C406BB94D7DE71" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Wholly-owed subsidiaries</link:label>
    <link:label id="lab_abus_WhollyOwnedSubsidiariesIncludedinFinancialStatements_00F15E7C9FCD61B4A5C406BB94D7DE71_label_en-US" xlink:label="lab_abus_WhollyOwnedSubsidiariesIncludedinFinancialStatements_00F15E7C9FCD61B4A5C406BB94D7DE71" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Wholly Owned Subsidiaries Included in Financial Statements</link:label>
    <link:label id="lab_abus_WhollyOwnedSubsidiariesIncludedinFinancialStatements_00F15E7C9FCD61B4A5C406BB94D7DE71_documentation_en-US" xlink:label="lab_abus_WhollyOwnedSubsidiariesIncludedinFinancialStatements_00F15E7C9FCD61B4A5C406BB94D7DE71" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the number of wholly owned subsidiaries included in the reporting of the financial statements.</link:label>
    <link:loc xlink:href="abus-20190930.xsd#abus_WhollyOwnedSubsidiariesIncludedinFinancialStatements" xlink:label="loc_abus_WhollyOwnedSubsidiariesIncludedinFinancialStatements_00F15E7C9FCD61B4A5C406BB94D7DE71" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_WhollyOwnedSubsidiariesIncludedinFinancialStatements_00F15E7C9FCD61B4A5C406BB94D7DE71" xlink:to="lab_abus_WhollyOwnedSubsidiariesIncludedinFinancialStatements_00F15E7C9FCD61B4A5C406BB94D7DE71" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_16E81968537F7C584F9606BB94D73DDD_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_16E81968537F7C584F9606BB94D73DDD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Anti-dilutive common shares excluded from calculation of loss per common share (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_16E81968537F7C584F9606BB94D73DDD_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_16E81968537F7C584F9606BB94D73DDD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_16E81968537F7C584F9606BB94D73DDD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_16E81968537F7C584F9606BB94D73DDD" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_16E81968537F7C584F9606BB94D73DDD" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_C194A904B1C87CF7A59506BB94D74898_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset_C194A904B1C87CF7A59506BB94D74898" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">ROU assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_C194A904B1C87CF7A59506BB94D74898_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset_C194A904B1C87CF7A59506BB94D74898" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_C194A904B1C87CF7A59506BB94D74898" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset_C194A904B1C87CF7A59506BB94D74898" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset_C194A904B1C87CF7A59506BB94D74898" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_DAB995D74C840D35B6B606BB94D7EDB8_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_DAB995D74C840D35B6B606BB94D7EDB8" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_DAB995D74C840D35B6B606BB94D7EDB8_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_DAB995D74C840D35B6B606BB94D7EDB8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_DAB995D74C840D35B6B606BB94D7EDB8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_DAB995D74C840D35B6B606BB94D7EDB8" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_DAB995D74C840D35B6B606BB94D7EDB8" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_0380249E50FE9340C4850E27CBB12BAE_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract_DC8D1E21D8175F99AEB1D691790A7306" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_DC8D1E21D8175F99AEB1D691790A7306" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_DC8D1E21D8175F99AEB1D691790A7306" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract_DC8D1E21D8175F99AEB1D691790A7306" xlink:type="arc" />
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_E27A965C89C509AA67290E27CBB1E9D8_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_2AA2485121535E70A6864694CD5952E7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborations, contracts and licensing agreements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_E27A965C89C509AA67290E27CBB1E9D8_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_2AA2485121535E70A6864694CD5952E7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_2AA2485121535E70A6864694CD5952E7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_2AA2485121535E70A6864694CD5952E7" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_2AA2485121535E70A6864694CD5952E7" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_C91B6327A416FD7FECAA3788BD3357A9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_8C478FEDD50D5ADAB839A5B1CF23CF29" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of basic and diluted net income (loss) per common share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_C91B6327A416FD7FECAA3788BD3357A9_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_8C478FEDD50D5ADAB839A5B1CF23CF29" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_8C478FEDD50D5ADAB839A5B1CF23CF29" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_8C478FEDD50D5ADAB839A5B1CF23CF29" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_8C478FEDD50D5ADAB839A5B1CF23CF29" xlink:type="arc" />
    <link:label id="lab_us-gaap_AirlineProductsAndServicesTable_EF103123BF7F0FE76C9C37F6E1368F8A_terseLabel_en-US" xlink:label="lab_us-gaap_AirlineProductsAndServicesTable_EF103123BF7F0FE76C9C37F6E1368F8A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Products and Services [Table]</link:label>
    <link:label id="lab_us-gaap_AirlineProductsAndServicesTable_EF103123BF7F0FE76C9C37F6E1368F8A_label_en-US" xlink:label="lab_us-gaap_AirlineProductsAndServicesTable_EF103123BF7F0FE76C9C37F6E1368F8A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Products and Services [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AirlineProductsAndServicesTable" xlink:label="loc_us-gaap_AirlineProductsAndServicesTable_EF103123BF7F0FE76C9C37F6E1368F8A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AirlineProductsAndServicesTable_EF103123BF7F0FE76C9C37F6E1368F8A" xlink:to="lab_us-gaap_AirlineProductsAndServicesTable_EF103123BF7F0FE76C9C37F6E1368F8A" xlink:type="arc" />
    <link:label id="lab_abus_OMERSMember_774F15CE50361F5E72C437F6E1371F44_terseLabel_en-US" xlink:label="lab_abus_OMERSMember_774F15CE50361F5E72C437F6E1371F44" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">OMERS</link:label>
    <link:label id="lab_abus_OMERSMember_774F15CE50361F5E72C437F6E1371F44_label_en-US" xlink:label="lab_abus_OMERSMember_774F15CE50361F5E72C437F6E1371F44" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">OMERS [Member]</link:label>
    <link:label id="lab_abus_OMERSMember_774F15CE50361F5E72C437F6E1371F44_documentation_en-US" xlink:label="lab_abus_OMERSMember_774F15CE50361F5E72C437F6E1371F44" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">OMERS</link:label>
    <link:loc xlink:href="abus-20190930.xsd#abus_OMERSMember" xlink:label="loc_abus_OMERSMember_774F15CE50361F5E72C437F6E1371F44" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_OMERSMember_774F15CE50361F5E72C437F6E1371F44" xlink:to="lab_abus_OMERSMember_774F15CE50361F5E72C437F6E1371F44" xlink:type="arc" />
    <link:label id="lab_srt_RangeAxis_0990859F55F7A79DF59637F6E1388988_terseLabel_en-US" xlink:label="lab_srt_RangeAxis_0990859F55F7A79DF59637F6E1388988" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Range [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_0990859F55F7A79DF59637F6E1388988_label_en-US" xlink:label="lab_srt_RangeAxis_0990859F55F7A79DF59637F6E1388988" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_0990859F55F7A79DF59637F6E1388988" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis_0990859F55F7A79DF59637F6E1388988" xlink:to="lab_srt_RangeAxis_0990859F55F7A79DF59637F6E1388988" xlink:type="arc" />
    <link:label id="lab_srt_RangeMember_0AB4243930815FFA59D837F6E1382AC3_terseLabel_en-US" xlink:label="lab_srt_RangeMember_0AB4243930815FFA59D837F6E1382AC3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Range [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_0AB4243930815FFA59D837F6E1382AC3_label_en-US" xlink:label="lab_srt_RangeMember_0AB4243930815FFA59D837F6E1382AC3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_0AB4243930815FFA59D837F6E1382AC3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember_0AB4243930815FFA59D837F6E1382AC3" xlink:to="lab_srt_RangeMember_0AB4243930815FFA59D837F6E1382AC3" xlink:type="arc" />
    <link:label id="lab_srt_MinimumMember_42CF3AB6B8ECD83A15D537F6E1384B29_terseLabel_en-US" xlink:label="lab_srt_MinimumMember_42CF3AB6B8ECD83A15D537F6E1384B29" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_42CF3AB6B8ECD83A15D537F6E1384B29_label_en-US" xlink:label="lab_srt_MinimumMember_42CF3AB6B8ECD83A15D537F6E1384B29" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_42CF3AB6B8ECD83A15D537F6E1384B29" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember_42CF3AB6B8ECD83A15D537F6E1384B29" xlink:to="lab_srt_MinimumMember_42CF3AB6B8ECD83A15D537F6E1384B29" xlink:type="arc" />
    <link:label id="lab_srt_MaximumMember_6C88CFC9F48D505B6ED437F6E1387C2D_terseLabel_en-US" xlink:label="lab_srt_MaximumMember_6C88CFC9F48D505B6ED437F6E1387C2D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_6C88CFC9F48D505B6ED437F6E1387C2D_label_en-US" xlink:label="lab_srt_MaximumMember_6C88CFC9F48D505B6ED437F6E1387C2D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_6C88CFC9F48D505B6ED437F6E1387C2D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember_6C88CFC9F48D505B6ED437F6E1387C2D" xlink:to="lab_srt_MaximumMember_6C88CFC9F48D505B6ED437F6E1387C2D" xlink:type="arc" />
    <link:label id="lab_abus_OtherLiabilitiesDisclosureLineItems_54A6764CA633B079610537F6E139EBB8_terseLabel_en-US" xlink:label="lab_abus_OtherLiabilitiesDisclosureLineItems_54A6764CA633B079610537F6E139EBB8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Liabilities Disclosure [Line Items]</link:label>
    <link:label id="lab_abus_OtherLiabilitiesDisclosureLineItems_54A6764CA633B079610537F6E139EBB8_label_en-US" xlink:label="lab_abus_OtherLiabilitiesDisclosureLineItems_54A6764CA633B079610537F6E139EBB8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities Disclosure [Line Items]</link:label>
    <link:label id="lab_abus_OtherLiabilitiesDisclosureLineItems_54A6764CA633B079610537F6E139EBB8_documentation_en-US" xlink:label="lab_abus_OtherLiabilitiesDisclosureLineItems_54A6764CA633B079610537F6E139EBB8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Liabilities Disclosure [Line Items]</link:label>
    <link:loc xlink:href="abus-20190930.xsd#abus_OtherLiabilitiesDisclosureLineItems" xlink:label="loc_abus_OtherLiabilitiesDisclosureLineItems_54A6764CA633B079610537F6E139EBB8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_OtherLiabilitiesDisclosureLineItems_54A6764CA633B079610537F6E139EBB8" xlink:to="lab_abus_OtherLiabilitiesDisclosureLineItems_54A6764CA633B079610537F6E139EBB8" xlink:type="arc" />
    <link:label id="lab_abus_RoyaltyPercentageofInterestSold_C77E87CC76B339BE49E437F6E13933E6_verboseLabel_en-US" xlink:label="lab_abus_RoyaltyPercentageofInterestSold_C77E87CC76B339BE49E437F6E13933E6" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Royalty interest sold percentage</link:label>
    <link:label id="lab_abus_RoyaltyPercentageofInterestSold_C77E87CC76B339BE49E437F6E13933E6_label_en-US" xlink:label="lab_abus_RoyaltyPercentageofInterestSold_C77E87CC76B339BE49E437F6E13933E6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty, Percentage of Interest Sold</link:label>
    <link:label id="lab_abus_RoyaltyPercentageofInterestSold_C77E87CC76B339BE49E437F6E13933E6_documentation_en-US" xlink:label="lab_abus_RoyaltyPercentageofInterestSold_C77E87CC76B339BE49E437F6E13933E6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Royalty, Percentage of Interest Sold</link:label>
    <link:loc xlink:href="abus-20190930.xsd#abus_RoyaltyPercentageofInterestSold" xlink:label="loc_abus_RoyaltyPercentageofInterestSold_C77E87CC76B339BE49E437F6E13933E6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_RoyaltyPercentageofInterestSold_C77E87CC76B339BE49E437F6E13933E6" xlink:to="lab_abus_RoyaltyPercentageofInterestSold_C77E87CC76B339BE49E437F6E13933E6" xlink:type="arc" />
    <link:label id="lab_abus_RoyaltyInterestSoldPercentageOfSalesAnnualRevenueThresholdOfHighestTier_3933366E059E7174410637F6E13919CD_terseLabel_en-US" xlink:label="lab_abus_RoyaltyInterestSoldPercentageOfSalesAnnualRevenueThresholdOfHighestTier_3933366E059E7174410637F6E13919CD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Annual royalty revenue</link:label>
    <link:label id="lab_abus_RoyaltyInterestSoldPercentageOfSalesAnnualRevenueThresholdOfHighestTier_3933366E059E7174410637F6E13919CD_label_en-US" xlink:label="lab_abus_RoyaltyInterestSoldPercentageOfSalesAnnualRevenueThresholdOfHighestTier_3933366E059E7174410637F6E13919CD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty Interest Sold, Percentage Of Sales, Annual Revenue Threshold Of Highest Tier</link:label>
    <link:label id="lab_abus_RoyaltyInterestSoldPercentageOfSalesAnnualRevenueThresholdOfHighestTier_3933366E059E7174410637F6E13919CD_documentation_en-US" xlink:label="lab_abus_RoyaltyInterestSoldPercentageOfSalesAnnualRevenueThresholdOfHighestTier_3933366E059E7174410637F6E13919CD" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Royalty Interest Sold, Percentage Of Sales, Annual Revenue Threshold Of Highest Tier</link:label>
    <link:loc xlink:href="abus-20190930.xsd#abus_RoyaltyInterestSoldPercentageOfSalesAnnualRevenueThresholdOfHighestTier" xlink:label="loc_abus_RoyaltyInterestSoldPercentageOfSalesAnnualRevenueThresholdOfHighestTier_3933366E059E7174410637F6E13919CD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_RoyaltyInterestSoldPercentageOfSalesAnnualRevenueThresholdOfHighestTier_3933366E059E7174410637F6E13919CD" xlink:to="lab_abus_RoyaltyInterestSoldPercentageOfSalesAnnualRevenueThresholdOfHighestTier_3933366E059E7174410637F6E13919CD" xlink:type="arc" />
    <link:label id="lab_abus_GrossProceedsFromRoyaltyInterestSold_B1E7E56A22C3761B6A4E37F6E1397C2E_terseLabel_en-US" xlink:label="lab_abus_GrossProceedsFromRoyaltyInterestSold_B1E7E56A22C3761B6A4E37F6E1397C2E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross proceeds from sale of royalty interest. before advisory fees</link:label>
    <link:label id="lab_abus_GrossProceedsFromRoyaltyInterestSold_B1E7E56A22C3761B6A4E37F6E1397C2E_label_en-US" xlink:label="lab_abus_GrossProceedsFromRoyaltyInterestSold_B1E7E56A22C3761B6A4E37F6E1397C2E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gross Proceeds From Royalty Interest Sold</link:label>
    <link:label id="lab_abus_GrossProceedsFromRoyaltyInterestSold_B1E7E56A22C3761B6A4E37F6E1397C2E_documentation_en-US" xlink:label="lab_abus_GrossProceedsFromRoyaltyInterestSold_B1E7E56A22C3761B6A4E37F6E1397C2E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Gross Proceeds From Royalty Interest Sold</link:label>
    <link:loc xlink:href="abus-20190930.xsd#abus_GrossProceedsFromRoyaltyInterestSold" xlink:label="loc_abus_GrossProceedsFromRoyaltyInterestSold_B1E7E56A22C3761B6A4E37F6E1397C2E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_GrossProceedsFromRoyaltyInterestSold_B1E7E56A22C3761B6A4E37F6E1397C2E" xlink:to="lab_abus_GrossProceedsFromRoyaltyInterestSold_B1E7E56A22C3761B6A4E37F6E1397C2E" xlink:type="arc" />
    <link:label id="lab_abus_RoyaltyInterestSoldMaximumRoyaltiesForBuyer_9E1A830204AD21DD9FBE37F6E1394994_terseLabel_en-US" xlink:label="lab_abus_RoyaltyInterestSoldMaximumRoyaltiesForBuyer_9E1A830204AD21DD9FBE37F6E1394994" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entitlement of royalties to be received</link:label>
    <link:label id="lab_abus_RoyaltyInterestSoldMaximumRoyaltiesForBuyer_9E1A830204AD21DD9FBE37F6E1394994_label_en-US" xlink:label="lab_abus_RoyaltyInterestSoldMaximumRoyaltiesForBuyer_9E1A830204AD21DD9FBE37F6E1394994" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty Interest Sold, Maximum Royalties For Buyer</link:label>
    <link:label id="lab_abus_RoyaltyInterestSoldMaximumRoyaltiesForBuyer_9E1A830204AD21DD9FBE37F6E1394994_documentation_en-US" xlink:label="lab_abus_RoyaltyInterestSoldMaximumRoyaltiesForBuyer_9E1A830204AD21DD9FBE37F6E1394994" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Royalty Interest Sold, Maximum Royalties For Buyer</link:label>
    <link:loc xlink:href="abus-20190930.xsd#abus_RoyaltyInterestSoldMaximumRoyaltiesForBuyer" xlink:label="loc_abus_RoyaltyInterestSoldMaximumRoyaltiesForBuyer_9E1A830204AD21DD9FBE37F6E1394994" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_RoyaltyInterestSoldMaximumRoyaltiesForBuyer_9E1A830204AD21DD9FBE37F6E1394994" xlink:to="lab_abus_RoyaltyInterestSoldMaximumRoyaltiesForBuyer_9E1A830204AD21DD9FBE37F6E1394994" xlink:type="arc" />
    <link:label id="lab_abus_RoyaltyGuaranteesCommitmentsPercentage_DCA5FAC4D0F01F81FB7737F6E13AB660_verboseLabel_en-US" xlink:label="lab_abus_RoyaltyGuaranteesCommitmentsPercentage_DCA5FAC4D0F01F81FB7737F6E13AB660" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Royalty guarantees commitments percentage</link:label>
    <link:label id="lab_abus_RoyaltyGuaranteesCommitmentsPercentage_DCA5FAC4D0F01F81FB7737F6E13AB660_label_en-US" xlink:label="lab_abus_RoyaltyGuaranteesCommitmentsPercentage_DCA5FAC4D0F01F81FB7737F6E13AB660" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty Guarantees Commitments Percentage</link:label>
    <link:label id="lab_abus_RoyaltyGuaranteesCommitmentsPercentage_DCA5FAC4D0F01F81FB7737F6E13AB660_documentation_en-US" xlink:label="lab_abus_RoyaltyGuaranteesCommitmentsPercentage_DCA5FAC4D0F01F81FB7737F6E13AB660" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the royalty guarantees commitments percentage.</link:label>
    <link:loc xlink:href="abus-20190930.xsd#abus_RoyaltyGuaranteesCommitmentsPercentage" xlink:label="loc_abus_RoyaltyGuaranteesCommitmentsPercentage_DCA5FAC4D0F01F81FB7737F6E13AB660" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_RoyaltyGuaranteesCommitmentsPercentage_DCA5FAC4D0F01F81FB7737F6E13AB660" xlink:to="lab_abus_RoyaltyGuaranteesCommitmentsPercentage_DCA5FAC4D0F01F81FB7737F6E13AB660" xlink:type="arc" />
    <link:label id="lab_abus_RoyaltyPayable_48867B464149732419C837F6E13A42C0_terseLabel_en-US" xlink:label="lab_abus_RoyaltyPayable_48867B464149732419C837F6E13A42C0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Future royalty payments</link:label>
    <link:label id="lab_abus_RoyaltyPayable_48867B464149732419C837F6E13A42C0_label_en-US" xlink:label="lab_abus_RoyaltyPayable_48867B464149732419C837F6E13A42C0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty Payable</link:label>
    <link:label id="lab_abus_RoyaltyPayable_48867B464149732419C837F6E13A42C0_documentation_en-US" xlink:label="lab_abus_RoyaltyPayable_48867B464149732419C837F6E13A42C0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the royalty payable.</link:label>
    <link:loc xlink:href="abus-20190930.xsd#abus_RoyaltyPayable" xlink:label="loc_abus_RoyaltyPayable_48867B464149732419C837F6E13A42C0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_RoyaltyPayable_48867B464149732419C837F6E13A42C0" xlink:to="lab_abus_RoyaltyPayable_48867B464149732419C837F6E13A42C0" xlink:type="arc" />
    <link:label id="lab_abus_TransactionCostsRelatedToSaleOfFutureRoyalties_4EFF4865FA617B0B7B9037F6E13AE346_terseLabel_en-US" xlink:label="lab_abus_TransactionCostsRelatedToSaleOfFutureRoyalties_4EFF4865FA617B0B7B9037F6E13AE346" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Transaction costs on sale of royalties</link:label>
    <link:label id="lab_abus_TransactionCostsRelatedToSaleOfFutureRoyalties_4EFF4865FA617B0B7B9037F6E13AE346_label_en-US" xlink:label="lab_abus_TransactionCostsRelatedToSaleOfFutureRoyalties_4EFF4865FA617B0B7B9037F6E13AE346" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Transaction Costs Related To Sale Of Future Royalties</link:label>
    <link:label id="lab_abus_TransactionCostsRelatedToSaleOfFutureRoyalties_4EFF4865FA617B0B7B9037F6E13AE346_documentation_en-US" xlink:label="lab_abus_TransactionCostsRelatedToSaleOfFutureRoyalties_4EFF4865FA617B0B7B9037F6E13AE346" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Transaction Costs Related To Sale Of Future Royalties</link:label>
    <link:loc xlink:href="abus-20190930.xsd#abus_TransactionCostsRelatedToSaleOfFutureRoyalties" xlink:label="loc_abus_TransactionCostsRelatedToSaleOfFutureRoyalties_4EFF4865FA617B0B7B9037F6E13AE346" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_TransactionCostsRelatedToSaleOfFutureRoyalties_4EFF4865FA617B0B7B9037F6E13AE346" xlink:to="lab_abus_TransactionCostsRelatedToSaleOfFutureRoyalties_4EFF4865FA617B0B7B9037F6E13AE346" xlink:type="arc" />
    <link:label id="lab_abus_EffectiveAnnualInterestRateOfRoyaltyLiability_5609BE2E7EB93777C4AD37F6E13ABB6F_terseLabel_en-US" xlink:label="lab_abus_EffectiveAnnualInterestRateOfRoyaltyLiability_5609BE2E7EB93777C4AD37F6E13ABB6F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effective annual interest rate on royalty liability</link:label>
    <link:label id="lab_abus_EffectiveAnnualInterestRateOfRoyaltyLiability_5609BE2E7EB93777C4AD37F6E13ABB6F_label_en-US" xlink:label="lab_abus_EffectiveAnnualInterestRateOfRoyaltyLiability_5609BE2E7EB93777C4AD37F6E13ABB6F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Annual Interest Rate Of Royalty Liability</link:label>
    <link:label id="lab_abus_EffectiveAnnualInterestRateOfRoyaltyLiability_5609BE2E7EB93777C4AD37F6E13ABB6F_documentation_en-US" xlink:label="lab_abus_EffectiveAnnualInterestRateOfRoyaltyLiability_5609BE2E7EB93777C4AD37F6E13ABB6F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Effective Annual Interest Rate Of Royalty Liability</link:label>
    <link:loc xlink:href="abus-20190930.xsd#abus_EffectiveAnnualInterestRateOfRoyaltyLiability" xlink:label="loc_abus_EffectiveAnnualInterestRateOfRoyaltyLiability_5609BE2E7EB93777C4AD37F6E13ABB6F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_EffectiveAnnualInterestRateOfRoyaltyLiability_5609BE2E7EB93777C4AD37F6E13ABB6F" xlink:to="lab_abus_EffectiveAnnualInterestRateOfRoyaltyLiability_5609BE2E7EB93777C4AD37F6E13ABB6F" xlink:type="arc" />
    <link:label id="lab_abus_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties_53B56B98F40D6F50FB5E37F6E13A3BB2_verboseLabel_en-US" xlink:label="lab_abus_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties_53B56B98F40D6F50FB5E37F6E13A3BB2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Non-cash royalty revenue</link:label>
    <link:loc xlink:href="abus-20190930.xsd#abus_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" xlink:label="loc_abus_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties_53B56B98F40D6F50FB5E37F6E13A3BB2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties_53B56B98F40D6F50FB5E37F6E13A3BB2" xlink:to="lab_abus_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties_53B56B98F40D6F50FB5E37F6E13A3BB2" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_00A2485C994411A23E6D06BB9494414F_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable_00A2485C994411A23E6D06BB9494414F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_00A2485C994411A23E6D06BB9494414F_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable_00A2485C994411A23E6D06BB9494414F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_00A2485C994411A23E6D06BB9494414F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_00A2485C994411A23E6D06BB9494414F" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable_00A2485C994411A23E6D06BB9494414F" xlink:type="arc" />
    <link:label id="lab_us-gaap_LeaseArrangementTypeAxis_FBC866BFD92E55B5EF8506BB94940D8C_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseArrangementTypeAxis_FBC866BFD92E55B5EF8506BB94940D8C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease Arrangement, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LeaseArrangementTypeAxis_FBC866BFD92E55B5EF8506BB94940D8C_label_en-US" xlink:label="lab_us-gaap_LeaseArrangementTypeAxis_FBC866BFD92E55B5EF8506BB94940D8C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease Arrangement, Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseArrangementTypeAxis" xlink:label="loc_us-gaap_LeaseArrangementTypeAxis_FBC866BFD92E55B5EF8506BB94940D8C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseArrangementTypeAxis_FBC866BFD92E55B5EF8506BB94940D8C" xlink:to="lab_us-gaap_LeaseArrangementTypeAxis_FBC866BFD92E55B5EF8506BB94940D8C" xlink:type="arc" />
    <link:label id="lab_us-gaap_LeaseArrangementTypeDomain_CAFE7F1C49C47F684F3A06BB94944505_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseArrangementTypeDomain_CAFE7F1C49C47F684F3A06BB94944505" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease Arrangement, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LeaseArrangementTypeDomain_CAFE7F1C49C47F684F3A06BB94944505_label_en-US" xlink:label="lab_us-gaap_LeaseArrangementTypeDomain_CAFE7F1C49C47F684F3A06BB94944505" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease Arrangement, Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:label="loc_us-gaap_LeaseArrangementTypeDomain_CAFE7F1C49C47F684F3A06BB94944505" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseArrangementTypeDomain_CAFE7F1C49C47F684F3A06BB94944505" xlink:to="lab_us-gaap_LeaseArrangementTypeDomain_CAFE7F1C49C47F684F3A06BB94944505" xlink:type="arc" />
    <link:label id="lab_abus_CorporateHeadquartersLocated701VeteransCircleWarminsterPennsylvaniaMember_F490152DAF8D4C5068F606BB94947250_terseLabel_en-US" xlink:label="lab_abus_CorporateHeadquartersLocated701VeteransCircleWarminsterPennsylvaniaMember_F490152DAF8D4C5068F606BB94947250" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Corporate Headquarters Located 701 Veterans Circle, Warminster, Pennsylvania</link:label>
    <link:label id="lab_abus_CorporateHeadquartersLocated701VeteransCircleWarminsterPennsylvaniaMember_F490152DAF8D4C5068F606BB94947250_label_en-US" xlink:label="lab_abus_CorporateHeadquartersLocated701VeteransCircleWarminsterPennsylvaniaMember_F490152DAF8D4C5068F606BB94947250" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Corporate Headquarters Located 701 Veterans Circle, Warminster, Pennsylvania [Member]</link:label>
    <link:label id="lab_abus_CorporateHeadquartersLocated701VeteransCircleWarminsterPennsylvaniaMember_F490152DAF8D4C5068F606BB94947250_documentation_en-US" xlink:label="lab_abus_CorporateHeadquartersLocated701VeteransCircleWarminsterPennsylvaniaMember_F490152DAF8D4C5068F606BB94947250" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Corporate Headquarters Located 701 Veterans Circle, Warminster, Pennsylvania</link:label>
    <link:loc xlink:href="abus-20190930.xsd#abus_CorporateHeadquartersLocated701VeteransCircleWarminsterPennsylvaniaMember" xlink:label="loc_abus_CorporateHeadquartersLocated701VeteransCircleWarminsterPennsylvaniaMember_F490152DAF8D4C5068F606BB94947250" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_CorporateHeadquartersLocated701VeteransCircleWarminsterPennsylvaniaMember_F490152DAF8D4C5068F606BB94947250" xlink:to="lab_abus_CorporateHeadquartersLocated701VeteransCircleWarminsterPennsylvaniaMember_F490152DAF8D4C5068F606BB94947250" xlink:type="arc" />
    <link:label id="lab_abus_OfficesLocatedat626JacksonvilleRd.WarminsterPennsylvaniaMember_C0FD2C731CA6C173C79806BB949471B2_terseLabel_en-US" xlink:label="lab_abus_OfficesLocatedat626JacksonvilleRd.WarminsterPennsylvaniaMember_C0FD2C731CA6C173C79806BB949471B2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Offices Located at 626 Jacksonville Rd., Warminster, Pennsylvania [Member]</link:label>
    <link:label id="lab_abus_OfficesLocatedat626JacksonvilleRd.WarminsterPennsylvaniaMember_C0FD2C731CA6C173C79806BB949471B2_label_en-US" xlink:label="lab_abus_OfficesLocatedat626JacksonvilleRd.WarminsterPennsylvaniaMember_C0FD2C731CA6C173C79806BB949471B2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Offices Located at 626 Jacksonville Rd., Warminster, Pennsylvania [Member]</link:label>
    <link:label id="lab_abus_OfficesLocatedat626JacksonvilleRd.WarminsterPennsylvaniaMember_C0FD2C731CA6C173C79806BB949471B2_documentation_en-US" xlink:label="lab_abus_OfficesLocatedat626JacksonvilleRd.WarminsterPennsylvaniaMember_C0FD2C731CA6C173C79806BB949471B2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Offices Located at 626 Jacksonville Rd., Warminster, Pennsylvania</link:label>
    <link:loc xlink:href="abus-20190930.xsd#abus_OfficesLocatedat626JacksonvilleRd.WarminsterPennsylvaniaMember" xlink:label="loc_abus_OfficesLocatedat626JacksonvilleRd.WarminsterPennsylvaniaMember_C0FD2C731CA6C173C79806BB949471B2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_OfficesLocatedat626JacksonvilleRd.WarminsterPennsylvaniaMember_C0FD2C731CA6C173C79806BB949471B2" xlink:to="lab_abus_OfficesLocatedat626JacksonvilleRd.WarminsterPennsylvaniaMember_C0FD2C731CA6C173C79806BB949471B2" xlink:type="arc" />
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_3B20AF102D82D3DEA75306BB94948472_terseLabel_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_3B20AF102D82D3DEA75306BB94948472" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_3B20AF102D82D3DEA75306BB94948472_label_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_3B20AF102D82D3DEA75306BB94948472" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_3B20AF102D82D3DEA75306BB94948472" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_3B20AF102D82D3DEA75306BB94948472" xlink:to="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_3B20AF102D82D3DEA75306BB94948472" xlink:type="arc" />
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_B75698FC8FC0E5AF68D206BB94945583_terseLabel_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain_B75698FC8FC0E5AF68D206BB94945583" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_B75698FC8FC0E5AF68D206BB94945583_label_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain_B75698FC8FC0E5AF68D206BB94945583" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_B75698FC8FC0E5AF68D206BB94945583" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_B75698FC8FC0E5AF68D206BB94945583" xlink:to="lab_srt_EquityMethodInvesteeNameDomain_B75698FC8FC0E5AF68D206BB94945583" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_6860ED463086CB7FCCAF06BB94948E4A_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems_6860ED463086CB7FCCAF06BB94948E4A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_6860ED463086CB7FCCAF06BB94948E4A_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems_6860ED463086CB7FCCAF06BB94948E4A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_6860ED463086CB7FCCAF06BB94948E4A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6860ED463086CB7FCCAF06BB94948E4A" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems_6860ED463086CB7FCCAF06BB94948E4A" xlink:type="arc" />
    <link:label id="lab_abus_LesseeOperatingLeaseNumberofLeases_670FA3B50FEE7A50B5E706BB94947CE0_terseLabel_en-US" xlink:label="lab_abus_LesseeOperatingLeaseNumberofLeases_670FA3B50FEE7A50B5E706BB94947CE0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of leases</link:label>
    <link:label id="lab_abus_LesseeOperatingLeaseNumberofLeases_670FA3B50FEE7A50B5E706BB94947CE0_label_en-US" xlink:label="lab_abus_LesseeOperatingLeaseNumberofLeases_670FA3B50FEE7A50B5E706BB94947CE0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Number of Leases</link:label>
    <link:label id="lab_abus_LesseeOperatingLeaseNumberofLeases_670FA3B50FEE7A50B5E706BB94947CE0_documentation_en-US" xlink:label="lab_abus_LesseeOperatingLeaseNumberofLeases_670FA3B50FEE7A50B5E706BB94947CE0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Number of Leases</link:label>
    <link:loc xlink:href="abus-20190930.xsd#abus_LesseeOperatingLeaseNumberofLeases" xlink:label="loc_abus_LesseeOperatingLeaseNumberofLeases_670FA3B50FEE7A50B5E706BB94947CE0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_LesseeOperatingLeaseNumberofLeases_670FA3B50FEE7A50B5E706BB94947CE0" xlink:to="lab_abus_LesseeOperatingLeaseNumberofLeases_670FA3B50FEE7A50B5E706BB94947CE0" xlink:type="arc" />
    <link:label id="lab_abus_LesseeOperatingLeaseNumberOfRenewalOptions_A4C933B28E1D0A6C663B06BB9494C71A_terseLabel_en-US" xlink:label="lab_abus_LesseeOperatingLeaseNumberOfRenewalOptions_A4C933B28E1D0A6C663B06BB9494C71A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of renewal options</link:label>
    <link:label id="lab_abus_LesseeOperatingLeaseNumberOfRenewalOptions_A4C933B28E1D0A6C663B06BB9494C71A_label_en-US" xlink:label="lab_abus_LesseeOperatingLeaseNumberOfRenewalOptions_A4C933B28E1D0A6C663B06BB9494C71A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Number Of Renewal Options</link:label>
    <link:label id="lab_abus_LesseeOperatingLeaseNumberOfRenewalOptions_A4C933B28E1D0A6C663B06BB9494C71A_documentation_en-US" xlink:label="lab_abus_LesseeOperatingLeaseNumberOfRenewalOptions_A4C933B28E1D0A6C663B06BB9494C71A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Number Of Renewal Options</link:label>
    <link:loc xlink:href="abus-20190930.xsd#abus_LesseeOperatingLeaseNumberOfRenewalOptions" xlink:label="loc_abus_LesseeOperatingLeaseNumberOfRenewalOptions_A4C933B28E1D0A6C663B06BB9494C71A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_LesseeOperatingLeaseNumberOfRenewalOptions_A4C933B28E1D0A6C663B06BB9494C71A" xlink:to="lab_abus_LesseeOperatingLeaseNumberOfRenewalOptions_A4C933B28E1D0A6C663B06BB9494C71A" xlink:type="arc" />
    <link:label id="lab_us-gaap_LessorOperatingLeaseRenewalTerm_727B87B30001A33FFD9506BB94940683_terseLabel_en-US" xlink:label="lab_us-gaap_LessorOperatingLeaseRenewalTerm_727B87B30001A33FFD9506BB94940683" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease renewal term</link:label>
    <link:label id="lab_us-gaap_LessorOperatingLeaseRenewalTerm_727B87B30001A33FFD9506BB94940683_label_en-US" xlink:label="lab_us-gaap_LessorOperatingLeaseRenewalTerm_727B87B30001A33FFD9506BB94940683" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessor, Operating Lease, Renewal Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LessorOperatingLeaseRenewalTerm" xlink:label="loc_us-gaap_LessorOperatingLeaseRenewalTerm_727B87B30001A33FFD9506BB94940683" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LessorOperatingLeaseRenewalTerm_727B87B30001A33FFD9506BB94940683" xlink:to="lab_us-gaap_LessorOperatingLeaseRenewalTerm_727B87B30001A33FFD9506BB94940683" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseDiscountRate_45AE6F8147EE7446A7FA06BB9494DBB9_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseDiscountRate_45AE6F8147EE7446A7FA06BB9494DBB9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Incremental borrowing rate</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseDiscountRate_45AE6F8147EE7446A7FA06BB9494DBB9_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseDiscountRate_45AE6F8147EE7446A7FA06BB9494DBB9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Discount Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseDiscountRate" xlink:label="loc_us-gaap_LesseeOperatingLeaseDiscountRate_45AE6F8147EE7446A7FA06BB9494DBB9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseDiscountRate_45AE6F8147EE7446A7FA06BB9494DBB9" xlink:to="lab_us-gaap_LesseeOperatingLeaseDiscountRate_45AE6F8147EE7446A7FA06BB9494DBB9" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseExpense_FFD10BA008B9E91D981A06BB9494ED58_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense_FFD10BA008B9E91D981A06BB9494ED58" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total operating lease expense</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseExpense_FFD10BA008B9E91D981A06BB9494ED58_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense_FFD10BA008B9E91D981A06BB9494ED58" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseExpense" xlink:label="loc_us-gaap_OperatingLeaseExpense_FFD10BA008B9E91D981A06BB9494ED58" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseExpense_FFD10BA008B9E91D981A06BB9494ED58" xlink:to="lab_us-gaap_OperatingLeaseExpense_FFD10BA008B9E91D981A06BB9494ED58" xlink:type="arc" />
    <link:label id="lab_abus_FixedLeaseCost_DA7CEA2CA93B0E03AFDF06BB94948C62_terseLabel_en-US" xlink:label="lab_abus_FixedLeaseCost_DA7CEA2CA93B0E03AFDF06BB94948C62" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fixed lease payments</link:label>
    <link:label id="lab_abus_FixedLeaseCost_DA7CEA2CA93B0E03AFDF06BB94948C62_label_en-US" xlink:label="lab_abus_FixedLeaseCost_DA7CEA2CA93B0E03AFDF06BB94948C62" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fixed Lease, Cost</link:label>
    <link:label id="lab_abus_FixedLeaseCost_DA7CEA2CA93B0E03AFDF06BB94948C62_documentation_en-US" xlink:label="lab_abus_FixedLeaseCost_DA7CEA2CA93B0E03AFDF06BB94948C62" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fixed Lease, Cost</link:label>
    <link:loc xlink:href="abus-20190930.xsd#abus_FixedLeaseCost" xlink:label="loc_abus_FixedLeaseCost_DA7CEA2CA93B0E03AFDF06BB94948C62" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_FixedLeaseCost_DA7CEA2CA93B0E03AFDF06BB94948C62" xlink:to="lab_abus_FixedLeaseCost_DA7CEA2CA93B0E03AFDF06BB94948C62" xlink:type="arc" />
    <link:label id="lab_us-gaap_VariableLeaseCost_7EBDA04837E6CC99796906BB9494F83C_terseLabel_en-US" xlink:label="lab_us-gaap_VariableLeaseCost_7EBDA04837E6CC99796906BB9494F83C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable lease costs</link:label>
    <link:label id="lab_us-gaap_VariableLeaseCost_7EBDA04837E6CC99796906BB9494F83C_label_en-US" xlink:label="lab_us-gaap_VariableLeaseCost_7EBDA04837E6CC99796906BB9494F83C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Lease, Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_VariableLeaseCost" xlink:label="loc_us-gaap_VariableLeaseCost_7EBDA04837E6CC99796906BB9494F83C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableLeaseCost_7EBDA04837E6CC99796906BB9494F83C" xlink:to="lab_us-gaap_VariableLeaseCost_7EBDA04837E6CC99796906BB9494F83C" xlink:type="arc" />
    <link:label id="lab_abus_StrightlineFixedLeaseCost_87C9CD7962F887FFDE3B06BB9494F41A_terseLabel_en-US" xlink:label="lab_abus_StrightlineFixedLeaseCost_87C9CD7962F887FFDE3B06BB9494F41A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Straight-line fixed expenses leases</link:label>
    <link:label id="lab_abus_StrightlineFixedLeaseCost_87C9CD7962F887FFDE3B06BB9494F41A_label_en-US" xlink:label="lab_abus_StrightlineFixedLeaseCost_87C9CD7962F887FFDE3B06BB9494F41A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stright-line Fixed Lease, Cost</link:label>
    <link:label id="lab_abus_StrightlineFixedLeaseCost_87C9CD7962F887FFDE3B06BB9494F41A_documentation_en-US" xlink:label="lab_abus_StrightlineFixedLeaseCost_87C9CD7962F887FFDE3B06BB9494F41A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stright-line Fixed Lease, Cost</link:label>
    <link:loc xlink:href="abus-20190930.xsd#abus_StrightlineFixedLeaseCost" xlink:label="loc_abus_StrightlineFixedLeaseCost_87C9CD7962F887FFDE3B06BB9494F41A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_StrightlineFixedLeaseCost_87C9CD7962F887FFDE3B06BB9494F41A" xlink:to="lab_abus_StrightlineFixedLeaseCost_87C9CD7962F887FFDE3B06BB9494F41A" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubleaseIncome_31A0EA7F74F62086C39406BB9494E938_terseLabel_en-US" xlink:label="lab_us-gaap_SubleaseIncome_31A0EA7F74F62086C39406BB9494E938" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sublease income</link:label>
    <link:label id="lab_us-gaap_SubleaseIncome_31A0EA7F74F62086C39406BB9494E938_label_en-US" xlink:label="lab_us-gaap_SubleaseIncome_31A0EA7F74F62086C39406BB9494E938" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sublease Income</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubleaseIncome" xlink:label="loc_us-gaap_SubleaseIncome_31A0EA7F74F62086C39406BB9494E938" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubleaseIncome_31A0EA7F74F62086C39406BB9494E938" xlink:to="lab_us-gaap_SubleaseIncome_31A0EA7F74F62086C39406BB9494E938" xlink:type="arc" />
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_8D989095B5EB99F65C8B02DE0617A275_label_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract_8D989095B5EB99F65C8B02DE0617A275" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_8D989095B5EB99F65C8B02DE0617A275" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_8D989095B5EB99F65C8B02DE0617A275" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract_8D989095B5EB99F65C8B02DE0617A275" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_BBFDEA4FA2396798E07002DE061738AF_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_BBFDEA4FA2396798E07002DE061738AF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable and accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_BBFDEA4FA2396798E07002DE061738AF_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_BBFDEA4FA2396798E07002DE061738AF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_BBFDEA4FA2396798E07002DE061738AF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_BBFDEA4FA2396798E07002DE061738AF" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_BBFDEA4FA2396798E07002DE061738AF" xlink:type="arc" />
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_D3187851C97DF37BA4BC60CF9559902D_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0E1D91A3FEDA5B1AA8F307EE9D762D80" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0E1D91A3FEDA5B1AA8F307EE9D762D80" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0E1D91A3FEDA5B1AA8F307EE9D762D80" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0E1D91A3FEDA5B1AA8F307EE9D762D80" xlink:type="arc" />
    <link:label id="lab_us-gaap_NatureOfOperations_B5FDE4529281A996F3B460CF955A32D1_terseLabel_en-US" xlink:label="lab_us-gaap_NatureOfOperations_56503DCA353C575F9145A98AC3B081B8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Nature of business and future operations</link:label>
    <link:label id="lab_us-gaap_NatureOfOperations_B5FDE4529281A996F3B460CF955A32D1_label_en-US" xlink:label="lab_us-gaap_NatureOfOperations_56503DCA353C575F9145A98AC3B081B8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nature of Operations [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NatureOfOperations" xlink:label="loc_us-gaap_NatureOfOperations_56503DCA353C575F9145A98AC3B081B8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NatureOfOperations_56503DCA353C575F9145A98AC3B081B8" xlink:to="lab_us-gaap_NatureOfOperations_56503DCA353C575F9145A98AC3B081B8" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_7E3EDD3CBB114627294E0E27CBE27008_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_AFCE06CE1379555E8B7F6CA5DD8107EE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investments and Joint Ventures [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_AFCE06CE1379555E8B7F6CA5DD8107EE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_AFCE06CE1379555E8B7F6CA5DD8107EE" xlink:to="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_AFCE06CE1379555E8B7F6CA5DD8107EE" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock_9434D8DFBE5C8D102F260E27CBE236C1_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock_7E0D51BA71FC5D66ABA3F87781A42CED" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity method investment</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock_9434D8DFBE5C8D102F260E27CBE236C1_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock_7E0D51BA71FC5D66ABA3F87781A42CED" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investments and Joint Ventures Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:label="loc_us-gaap_EquityMethodInvestmentsDisclosureTextBlock_7E0D51BA71FC5D66ABA3F87781A42CED" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsDisclosureTextBlock_7E0D51BA71FC5D66ABA3F87781A42CED" xlink:to="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock_7E0D51BA71FC5D66ABA3F87781A42CED" xlink:type="arc" />
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_E20BF1880B2BC91357673787E58C4863_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock_B552AD8232415AB6BC6395812AEE5A71" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Significant accounting policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_E20BF1880B2BC91357673787E58C4863_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock_B552AD8232415AB6BC6395812AEE5A71" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_B552AD8232415AB6BC6395812AEE5A71" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock_B552AD8232415AB6BC6395812AEE5A71" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock_B552AD8232415AB6BC6395812AEE5A71" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_8C4CA432DB4D06C8AA5522A3049AE799_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_8C4CA432DB4D06C8AA5522A3049AE799" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Indefinite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_8C4CA432DB4D06C8AA5522A3049AE799_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_8C4CA432DB4D06C8AA5522A3049AE799" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Indefinite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_8C4CA432DB4D06C8AA5522A3049AE799" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_8C4CA432DB4D06C8AA5522A3049AE799" xlink:to="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_8C4CA432DB4D06C8AA5522A3049AE799" xlink:type="arc" />
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_A8B4845D9822919F568622A3049A5F55_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_A8B4845D9822919F568622A3049A5F55" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_A8B4845D9822919F568622A3049A5F55_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_A8B4845D9822919F568622A3049A5F55" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_A8B4845D9822919F568622A3049A5F55" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_A8B4845D9822919F568622A3049A5F55" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_A8B4845D9822919F568622A3049A5F55" xlink:type="arc" />
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_8921C8A192D43C89ED0C22A3049A8532_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_8921C8A192D43C89ED0C22A3049A8532" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_8921C8A192D43C89ED0C22A3049A8532_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_8921C8A192D43C89ED0C22A3049A8532" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_8921C8A192D43C89ED0C22A3049A8532" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_8921C8A192D43C89ED0C22A3049A8532" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_8921C8A192D43C89ED0C22A3049A8532" xlink:type="arc" />
    <link:label id="lab_abus_InProcessResearchandDevelopmentcccDNASterilizersMember_446EBA45B9DF2DE358E922A3049AC7A8_verboseLabel_en-US" xlink:label="lab_abus_InProcessResearchandDevelopmentcccDNASterilizersMember_446EBA45B9DF2DE358E922A3049AC7A8" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">IPR&amp;D &#8211; cccDNA</link:label>
    <link:label id="lab_abus_InProcessResearchandDevelopmentcccDNASterilizersMember_446EBA45B9DF2DE358E922A3049AC7A8_label_en-US" xlink:label="lab_abus_InProcessResearchandDevelopmentcccDNASterilizersMember_446EBA45B9DF2DE358E922A3049AC7A8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">In Process Research and Development, cccDNA Sterilizers [Member]</link:label>
    <link:label id="lab_abus_InProcessResearchandDevelopmentcccDNASterilizersMember_446EBA45B9DF2DE358E922A3049AC7A8_documentation_en-US" xlink:label="lab_abus_InProcessResearchandDevelopmentcccDNASterilizersMember_446EBA45B9DF2DE358E922A3049AC7A8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">In Process Research and Development, cccDNA Sterilizers [Member]</link:label>
    <link:loc xlink:href="abus-20190930.xsd#abus_InProcessResearchandDevelopmentcccDNASterilizersMember" xlink:label="loc_abus_InProcessResearchandDevelopmentcccDNASterilizersMember_446EBA45B9DF2DE358E922A3049AC7A8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_InProcessResearchandDevelopmentcccDNASterilizersMember_446EBA45B9DF2DE358E922A3049AC7A8" xlink:to="lab_abus_InProcessResearchandDevelopmentcccDNASterilizersMember_446EBA45B9DF2DE358E922A3049AC7A8" xlink:type="arc" />
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_954B774A89927BA3F86F22A3049A1084_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_954B774A89927BA3F86F22A3049A1084" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Indefinite-lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_954B774A89927BA3F86F22A3049A1084_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_954B774A89927BA3F86F22A3049A1084" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indefinite-lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_954B774A89927BA3F86F22A3049A1084" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_954B774A89927BA3F86F22A3049A1084" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_954B774A89927BA3F86F22A3049A1084" xlink:type="arc" />
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_6AC913BBD64C27A6C2B122A3049A401B_verboseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_6AC913BBD64C27A6C2B122A3049A401B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Impairment of intangible assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_6AC913BBD64C27A6C2B122A3049A401B_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_6AC913BBD64C27A6C2B122A3049A401B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment of Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_6AC913BBD64C27A6C2B122A3049A401B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_6AC913BBD64C27A6C2B122A3049A401B" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_6AC913BBD64C27A6C2B122A3049A401B" xlink:type="arc" />
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_5D28BAA53B6A1B374DA422A5A4C6CFF8_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_5D28BAA53B6A1B374DA422A5A4C6CFF8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_5D28BAA53B6A1B374DA422A5A4C6CFF8_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_5D28BAA53B6A1B374DA422A5A4C6CFF8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_5D28BAA53B6A1B374DA422A5A4C6CFF8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_5D28BAA53B6A1B374DA422A5A4C6CFF8" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_5D28BAA53B6A1B374DA422A5A4C6CFF8" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability_E924F5EFFD3B5450BAB022A3049A20E1_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability_E924F5EFFD3B5450BAB022A3049A20E1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Tax benefit related to decrease in deferred tax liability for indefinite delay of further development) Liability</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability_E924F5EFFD3B5450BAB022A3049A20E1_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability_E924F5EFFD3B5450BAB022A3049A20E1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit), Continuing Operations, Adjustment of Deferred Tax (Asset) Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability_E924F5EFFD3B5450BAB022A3049A20E1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability_E924F5EFFD3B5450BAB022A3049A20E1" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability_E924F5EFFD3B5450BAB022A3049A20E1" xlink:type="arc" />
    <link:label id="lab_us-gaap_Goodwill_5F12B7AFFBA3BBF66F0822A5A54D07B9_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill_5F12B7AFFBA3BBF66F0822A5A54D07B9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_5F12B7AFFBA3BBF66F0822A5A54D07B9_label_en-US" xlink:label="lab_us-gaap_Goodwill_5F12B7AFFBA3BBF66F0822A5A54D07B9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_5F12B7AFFBA3BBF66F0822A5A54D07B9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill_5F12B7AFFBA3BBF66F0822A5A54D07B9" xlink:to="lab_us-gaap_Goodwill_5F12B7AFFBA3BBF66F0822A5A54D07B9" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_A8845820659274ABB6183D14B943389A_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable_A8845820659274ABB6183D14B943389A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_A8845820659274ABB6183D14B943389A_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable_A8845820659274ABB6183D14B943389A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_A8845820659274ABB6183D14B943389A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_A8845820659274ABB6183D14B943389A" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable_A8845820659274ABB6183D14B943389A" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_18708BE4970E514B53E93D14B944AE93_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis_18708BE4970E514B53E93D14B944AE93" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_18708BE4970E514B53E93D14B944AE93_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis_18708BE4970E514B53E93D14B944AE93" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_18708BE4970E514B53E93D14B944AE93" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_18708BE4970E514B53E93D14B944AE93" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis_18708BE4970E514B53E93D14B944AE93" xlink:type="arc" />
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_28AAEDF6459C9B8574833D14B9446F5C_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain_28AAEDF6459C9B8574833D14B9446F5C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_28AAEDF6459C9B8574833D14B9446F5C_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain_28AAEDF6459C9B8574833D14B9446F5C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_28AAEDF6459C9B8574833D14B9446F5C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_28AAEDF6459C9B8574833D14B9446F5C" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain_28AAEDF6459C9B8574833D14B9446F5C" xlink:type="arc" />
    <link:label id="lab_abus_OpenMarketSaleAgreementMember_8963535DCDB0B8F6442F3D14B944D829_terseLabel_en-US" xlink:label="lab_abus_OpenMarketSaleAgreementMember_8963535DCDB0B8F6442F3D14B944D829" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Open Market Sale Agreement</link:label>
    <link:label id="lab_abus_OpenMarketSaleAgreementMember_8963535DCDB0B8F6442F3D14B944D829_label_en-US" xlink:label="lab_abus_OpenMarketSaleAgreementMember_8963535DCDB0B8F6442F3D14B944D829" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Open Market Sale Agreement [Member]</link:label>
    <link:label id="lab_abus_OpenMarketSaleAgreementMember_8963535DCDB0B8F6442F3D14B944D829_documentation_en-US" xlink:label="lab_abus_OpenMarketSaleAgreementMember_8963535DCDB0B8F6442F3D14B944D829" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Open Market Sale Agreement</link:label>
    <link:loc xlink:href="abus-20190930.xsd#abus_OpenMarketSaleAgreementMember" xlink:label="loc_abus_OpenMarketSaleAgreementMember_8963535DCDB0B8F6442F3D14B944D829" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_OpenMarketSaleAgreementMember_8963535DCDB0B8F6442F3D14B944D829" xlink:to="lab_abus_OpenMarketSaleAgreementMember_8963535DCDB0B8F6442F3D14B944D829" xlink:type="arc" />
    <link:label id="lab_abus_JefferiesLLCMember_4AE484D027B8ED762CF13D14B945E3B2_terseLabel_en-US" xlink:label="lab_abus_JefferiesLLCMember_4AE484D027B8ED762CF13D14B945E3B2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Jefferies LLC</link:label>
    <link:label id="lab_abus_JefferiesLLCMember_4AE484D027B8ED762CF13D14B945E3B2_label_en-US" xlink:label="lab_abus_JefferiesLLCMember_4AE484D027B8ED762CF13D14B945E3B2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Jefferies LLC [Member]</link:label>
    <link:label id="lab_abus_JefferiesLLCMember_4AE484D027B8ED762CF13D14B945E3B2_documentation_en-US" xlink:label="lab_abus_JefferiesLLCMember_4AE484D027B8ED762CF13D14B945E3B2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Jefferies LLC</link:label>
    <link:loc xlink:href="abus-20190930.xsd#abus_JefferiesLLCMember" xlink:label="loc_abus_JefferiesLLCMember_4AE484D027B8ED762CF13D14B945E3B2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_JefferiesLLCMember_4AE484D027B8ED762CF13D14B945E3B2" xlink:to="lab_abus_JefferiesLLCMember_4AE484D027B8ED762CF13D14B945E3B2" xlink:type="arc" />
    <link:label id="lab_abus_RoivantSciencesLtdMember_419D259FB5738D3811763D14B946A203_terseLabel_en-US" xlink:label="lab_abus_RoivantSciencesLtdMember_419D259FB5738D3811763D14B946A203" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Roivant Sciences Ltd</link:label>
    <link:label id="lab_abus_RoivantSciencesLtdMember_419D259FB5738D3811763D14B946A203_label_en-US" xlink:label="lab_abus_RoivantSciencesLtdMember_419D259FB5738D3811763D14B946A203" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Roivant Sciences Ltd [Member]</link:label>
    <link:label id="lab_abus_RoivantSciencesLtdMember_419D259FB5738D3811763D14B946A203_documentation_en-US" xlink:label="lab_abus_RoivantSciencesLtdMember_419D259FB5738D3811763D14B946A203" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Roivant Sciences Ltd [Member]</link:label>
    <link:loc xlink:href="abus-20190930.xsd#abus_RoivantSciencesLtdMember" xlink:label="loc_abus_RoivantSciencesLtdMember_419D259FB5738D3811763D14B946A203" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_RoivantSciencesLtdMember_419D259FB5738D3811763D14B946A203" xlink:to="lab_abus_RoivantSciencesLtdMember_419D259FB5738D3811763D14B946A203" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockMember_ABE845B80F1AE7D79D1E3D14B9467B8D_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockMember_ABE845B80F1AE7D79D1E3D14B9467B8D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred Shares</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaap_PreferredStockMember_ABE845B80F1AE7D79D1E3D14B9467B8D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockMember_ABE845B80F1AE7D79D1E3D14B9467B8D" xlink:to="lab_us-gaap_PreferredStockMember_ABE845B80F1AE7D79D1E3D14B9467B8D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConvertiblePreferredStockMember_0E2236A1E040ED9FA3233D14B9475D95_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockMember_0E2236A1E040ED9FA3233D14B9475D95" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible Preferred Stock</link:label>
    <link:label id="lab_us-gaap_ConvertiblePreferredStockMember_0E2236A1E040ED9FA3233D14B9475D95_label_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockMember_0E2236A1E040ED9FA3233D14B9475D95" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Preferred Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_0E2236A1E040ED9FA3233D14B9475D95" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertiblePreferredStockMember_0E2236A1E040ED9FA3233D14B9475D95" xlink:to="lab_us-gaap_ConvertiblePreferredStockMember_0E2236A1E040ED9FA3233D14B9475D95" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfStockLineItems_410F348477E32F4AE2BC3D14B947B034_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems_410F348477E32F4AE2BC3D14B947B034" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_410F348477E32F4AE2BC3D14B947B034_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems_410F348477E32F4AE2BC3D14B947B034" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_410F348477E32F4AE2BC3D14B947B034" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems_410F348477E32F4AE2BC3D14B947B034" xlink:to="lab_us-gaap_ClassOfStockLineItems_410F348477E32F4AE2BC3D14B947B034" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesSubscriptions_4125854ABF870B53CFED3D14B947BFC1_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesSubscriptions_4125854ABF870B53CFED3D14B947BFC1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate sale price of common shares under agreement</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesSubscriptions_4125854ABF870B53CFED3D14B947BFC1_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesSubscriptions_4125854ABF870B53CFED3D14B947BFC1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Value, Subscriptions</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesSubscriptions" xlink:label="loc_us-gaap_CommonStockSharesSubscriptions_4125854ABF870B53CFED3D14B947BFC1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesSubscriptions_4125854ABF870B53CFED3D14B947BFC1" xlink:to="lab_us-gaap_CommonStockSharesSubscriptions_4125854ABF870B53CFED3D14B947BFC1" xlink:type="arc" />
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_ABF8D90C7C72F5EFD8103D14B9475D73_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_ABF8D90C7C72F5EFD8103D14B9475D73" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares issued under agreement (in sales)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_ABF8D90C7C72F5EFD8103D14B9475D73_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_ABF8D90C7C72F5EFD8103D14B9475D73" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_ABF8D90C7C72F5EFD8103D14B9475D73" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_ABF8D90C7C72F5EFD8103D14B9475D73" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_ABF8D90C7C72F5EFD8103D14B9475D73" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_DC8D10FA3ECFB5068B663D14B947119E_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_DC8D10FA3ECFB5068B663D14B947119E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of shares under the agreement</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_DC8D10FA3ECFB5068B663D14B947119E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_DC8D10FA3ECFB5068B663D14B947119E" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_DC8D10FA3ECFB5068B663D14B947119E" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharesIssued_00CA4CF54AF40A4788243D14B9482AEC_terseLabel_en-US" xlink:label="lab_us-gaap_SharesIssued_00CA4CF54AF40A4788243D14B9482AEC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares issued (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_00CA4CF54AF40A4788243D14B9482AEC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssued_00CA4CF54AF40A4788243D14B9482AEC" xlink:to="lab_us-gaap_SharesIssued_00CA4CF54AF40A4788243D14B9482AEC" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_71FCB455B4B2C77250813D14B9488EFF_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_71FCB455B4B2C77250813D14B9488EFF" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common shares pursuant to the agreement</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_71FCB455B4B2C77250813D14B9488EFF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_71FCB455B4B2C77250813D14B9488EFF" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_71FCB455B4B2C77250813D14B9488EFF" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockDividendRatePercentage_51982025683795A74D303D14B948A3A6_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockDividendRatePercentage_51982025683795A74D303D14B948A3A6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock dividend rate as a percent</link:label>
    <link:label id="lab_us-gaap_PreferredStockDividendRatePercentage_51982025683795A74D303D14B948A3A6_label_en-US" xlink:label="lab_us-gaap_PreferredStockDividendRatePercentage_51982025683795A74D303D14B948A3A6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Dividend Rate, Percentage</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="loc_us-gaap_PreferredStockDividendRatePercentage_51982025683795A74D303D14B948A3A6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockDividendRatePercentage_51982025683795A74D303D14B948A3A6" xlink:to="lab_us-gaap_PreferredStockDividendRatePercentage_51982025683795A74D303D14B948A3A6" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_EA7D596498526AAE9CCB3D14B94D28BF_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare_EA7D596498526AAE9CCB3D14B94D28BF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stated value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_EA7D596498526AAE9CCB3D14B94D28BF_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare_EA7D596498526AAE9CCB3D14B94D28BF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_EA7D596498526AAE9CCB3D14B94D28BF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare_EA7D596498526AAE9CCB3D14B94D28BF" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare_EA7D596498526AAE9CCB3D14B94D28BF" xlink:type="arc" />
    <link:label id="lab_abus_ConvertiblePreferredStockSharesOfCommonStockIssueduponConversion_F5A7F7311C15AF8136513D14B94D94BB_terseLabel_en-US" xlink:label="lab_abus_ConvertiblePreferredStockSharesOfCommonStockIssueduponConversion_F5A7F7311C15AF8136513D14B94D94BB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of common shares to be issued upon conversion of convertible preferred stock</link:label>
    <link:label id="lab_abus_ConvertiblePreferredStockSharesOfCommonStockIssueduponConversion_F5A7F7311C15AF8136513D14B94D94BB_label_en-US" xlink:label="lab_abus_ConvertiblePreferredStockSharesOfCommonStockIssueduponConversion_F5A7F7311C15AF8136513D14B94D94BB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Preferred Stock, Shares Of Common Stock Issued upon Conversion</link:label>
    <link:label id="lab_abus_ConvertiblePreferredStockSharesOfCommonStockIssueduponConversion_F5A7F7311C15AF8136513D14B94D94BB_documentation_en-US" xlink:label="lab_abus_ConvertiblePreferredStockSharesOfCommonStockIssueduponConversion_F5A7F7311C15AF8136513D14B94D94BB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Convertible Preferred Stock, Shares Of Common Stock Issued upon Conversion</link:label>
    <link:loc xlink:href="abus-20190930.xsd#abus_ConvertiblePreferredStockSharesOfCommonStockIssueduponConversion" xlink:label="loc_abus_ConvertiblePreferredStockSharesOfCommonStockIssueduponConversion_F5A7F7311C15AF8136513D14B94D94BB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_ConvertiblePreferredStockSharesOfCommonStockIssueduponConversion_F5A7F7311C15AF8136513D14B94D94BB" xlink:to="lab_abus_ConvertiblePreferredStockSharesOfCommonStockIssueduponConversion_F5A7F7311C15AF8136513D14B94D94BB" xlink:type="arc" />
    <link:label id="lab_abus_NoncontrollingInterestOwnershipPercentageByNoncontrollingOwnersAfterConversion_6C08D8097235311768DA3D14B94EECCD_terseLabel_en-US" xlink:label="lab_abus_NoncontrollingInterestOwnershipPercentageByNoncontrollingOwnersAfterConversion_6C08D8097235311768DA3D14B94EECCD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ownership percentage by noncontrolling owners after conversion</link:label>
    <link:label id="lab_abus_NoncontrollingInterestOwnershipPercentageByNoncontrollingOwnersAfterConversion_6C08D8097235311768DA3D14B94EECCD_label_en-US" xlink:label="lab_abus_NoncontrollingInterestOwnershipPercentageByNoncontrollingOwnersAfterConversion_6C08D8097235311768DA3D14B94EECCD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncontrolling Interest, Ownership Percentage By Noncontrolling Owners After Conversion</link:label>
    <link:label id="lab_abus_NoncontrollingInterestOwnershipPercentageByNoncontrollingOwnersAfterConversion_6C08D8097235311768DA3D14B94EECCD_documentation_en-US" xlink:label="lab_abus_NoncontrollingInterestOwnershipPercentageByNoncontrollingOwnersAfterConversion_6C08D8097235311768DA3D14B94EECCD" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Noncontrolling Interest, Ownership Percentage By Noncontrolling Owners After Conversion</link:label>
    <link:loc xlink:href="abus-20190930.xsd#abus_NoncontrollingInterestOwnershipPercentageByNoncontrollingOwnersAfterConversion" xlink:label="loc_abus_NoncontrollingInterestOwnershipPercentageByNoncontrollingOwnersAfterConversion_6C08D8097235311768DA3D14B94EECCD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_NoncontrollingInterestOwnershipPercentageByNoncontrollingOwnersAfterConversion_6C08D8097235311768DA3D14B94EECCD" xlink:to="lab_abus_NoncontrollingInterestOwnershipPercentageByNoncontrollingOwnersAfterConversion_6C08D8097235311768DA3D14B94EECCD" xlink:type="arc" />
    <link:label id="lab_abus_NoncontrollingInterestInvestmentCommitmentPeriod_E12F193A303E916DCDFC3D14B94EB8E8_terseLabel_en-US" xlink:label="lab_abus_NoncontrollingInterestInvestmentCommitmentPeriod_E12F193A303E916DCDFC3D14B94EB8E8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment commitment period</link:label>
    <link:label id="lab_abus_NoncontrollingInterestInvestmentCommitmentPeriod_E12F193A303E916DCDFC3D14B94EB8E8_label_en-US" xlink:label="lab_abus_NoncontrollingInterestInvestmentCommitmentPeriod_E12F193A303E916DCDFC3D14B94EB8E8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncontrolling Interest, Investment Commitment Period</link:label>
    <link:label id="lab_abus_NoncontrollingInterestInvestmentCommitmentPeriod_E12F193A303E916DCDFC3D14B94EB8E8_documentation_en-US" xlink:label="lab_abus_NoncontrollingInterestInvestmentCommitmentPeriod_E12F193A303E916DCDFC3D14B94EB8E8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Noncontrolling Interest, Investment Commitment Period</link:label>
    <link:loc xlink:href="abus-20190930.xsd#abus_NoncontrollingInterestInvestmentCommitmentPeriod" xlink:label="loc_abus_NoncontrollingInterestInvestmentCommitmentPeriod_E12F193A303E916DCDFC3D14B94EB8E8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_NoncontrollingInterestInvestmentCommitmentPeriod_E12F193A303E916DCDFC3D14B94EB8E8" xlink:to="lab_abus_NoncontrollingInterestInvestmentCommitmentPeriod_E12F193A303E916DCDFC3D14B94EB8E8" xlink:type="arc" />
    <link:label id="lab_abus_NoncontrollingInterestMaximumOwnershipPercentagebyNoncontrollingOwners_F8A3893E28DE56097A8E3D14B94E2F34_terseLabel_en-US" xlink:label="lab_abus_NoncontrollingInterestMaximumOwnershipPercentagebyNoncontrollingOwners_F8A3893E28DE56097A8E3D14B94E2F34" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum ownership percentage by noncontrolling owners</link:label>
    <link:label id="lab_abus_NoncontrollingInterestMaximumOwnershipPercentagebyNoncontrollingOwners_F8A3893E28DE56097A8E3D14B94E2F34_label_en-US" xlink:label="lab_abus_NoncontrollingInterestMaximumOwnershipPercentagebyNoncontrollingOwners_F8A3893E28DE56097A8E3D14B94E2F34" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncontrolling Interest, Maximum Ownership Percentage by Noncontrolling Owners</link:label>
    <link:label id="lab_abus_NoncontrollingInterestMaximumOwnershipPercentagebyNoncontrollingOwners_F8A3893E28DE56097A8E3D14B94E2F34_documentation_en-US" xlink:label="lab_abus_NoncontrollingInterestMaximumOwnershipPercentagebyNoncontrollingOwners_F8A3893E28DE56097A8E3D14B94E2F34" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Noncontrolling Interest, Maximum Ownership Percentage by Noncontrolling Owners</link:label>
    <link:loc xlink:href="abus-20190930.xsd#abus_NoncontrollingInterestMaximumOwnershipPercentagebyNoncontrollingOwners" xlink:label="loc_abus_NoncontrollingInterestMaximumOwnershipPercentagebyNoncontrollingOwners_F8A3893E28DE56097A8E3D14B94E2F34" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_NoncontrollingInterestMaximumOwnershipPercentagebyNoncontrollingOwners_F8A3893E28DE56097A8E3D14B94E2F34" xlink:to="lab_abus_NoncontrollingInterestMaximumOwnershipPercentagebyNoncontrollingOwners_F8A3893E28DE56097A8E3D14B94E2F34" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_55F747BA31A1F87954773D14B94E88F4_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_55F747BA31A1F87954773D14B94E88F4" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from sale of stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_55F747BA31A1F87954773D14B94E88F4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_55F747BA31A1F87954773D14B94E88F4" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_55F747BA31A1F87954773D14B94E88F4" xlink:type="arc" />
    <link:label id="lab_abus_DocumentAndEntityInformationAbstract_1BFD9D3B5F29449DF1E522A5BD894A0E_label_en-US" xlink:label="lab_abus_DocumentAndEntityInformationAbstract_1BFD9D3B5F29449DF1E522A5BD894A0E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document and Entity Information [Abstract]</link:label>
    <link:label id="lab_abus_DocumentAndEntityInformationAbstract_1BFD9D3B5F29449DF1E522A5BD894A0E_documentation_en-US" xlink:label="lab_abus_DocumentAndEntityInformationAbstract_1BFD9D3B5F29449DF1E522A5BD894A0E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Document and Entity Information [Abstract]</link:label>
    <link:loc xlink:href="abus-20190930.xsd#abus_DocumentAndEntityInformationAbstract" xlink:label="loc_abus_DocumentAndEntityInformationAbstract_1BFD9D3B5F29449DF1E522A5BD894A0E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_DocumentAndEntityInformationAbstract_1BFD9D3B5F29449DF1E522A5BD894A0E" xlink:to="lab_abus_DocumentAndEntityInformationAbstract_1BFD9D3B5F29449DF1E522A5BD894A0E" xlink:type="arc" />
    <link:label id="lab_dei_DocumentType_3FC49B5DDF578D0DAF5322A5BD8978CD_terseLabel_en-US" xlink:label="lab_dei_DocumentType_3FC49B5DDF578D0DAF5322A5BD8978CD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_3FC49B5DDF578D0DAF5322A5BD8978CD_label_en-US" xlink:label="lab_dei_DocumentType_3FC49B5DDF578D0DAF5322A5BD8978CD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_3FC49B5DDF578D0DAF5322A5BD8978CD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType_3FC49B5DDF578D0DAF5322A5BD8978CD" xlink:to="lab_dei_DocumentType_3FC49B5DDF578D0DAF5322A5BD8978CD" xlink:type="arc" />
    <link:label id="lab_dei_AmendmentFlag_1E42C1FD031AE31444A922A5BD897987_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag_1E42C1FD031AE31444A922A5BD897987" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_1E42C1FD031AE31444A922A5BD897987_label_en-US" xlink:label="lab_dei_AmendmentFlag_1E42C1FD031AE31444A922A5BD897987" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_1E42C1FD031AE31444A922A5BD897987" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag_1E42C1FD031AE31444A922A5BD897987" xlink:to="lab_dei_AmendmentFlag_1E42C1FD031AE31444A922A5BD897987" xlink:type="arc" />
    <link:label id="lab_dei_DocumentPeriodEndDate_DAF34774C1EC6598632822A5BD895CA8_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate_DAF34774C1EC6598632822A5BD895CA8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_DAF34774C1EC6598632822A5BD895CA8_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate_DAF34774C1EC6598632822A5BD895CA8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_DAF34774C1EC6598632822A5BD895CA8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate_DAF34774C1EC6598632822A5BD895CA8" xlink:to="lab_dei_DocumentPeriodEndDate_DAF34774C1EC6598632822A5BD895CA8" xlink:type="arc" />
    <link:label id="lab_dei_EntityRegistrantName_0E7F7FB317BBDD23BC5F22A5BD898E96_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName_0E7F7FB317BBDD23BC5F22A5BD898E96" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_0E7F7FB317BBDD23BC5F22A5BD898E96_label_en-US" xlink:label="lab_dei_EntityRegistrantName_0E7F7FB317BBDD23BC5F22A5BD898E96" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_0E7F7FB317BBDD23BC5F22A5BD898E96" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName_0E7F7FB317BBDD23BC5F22A5BD898E96" xlink:to="lab_dei_EntityRegistrantName_0E7F7FB317BBDD23BC5F22A5BD898E96" xlink:type="arc" />
    <link:label id="lab_dei_EntityCentralIndexKey_97B8DD9973D406A9EB0022A5BD895D90_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey_97B8DD9973D406A9EB0022A5BD895D90" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_97B8DD9973D406A9EB0022A5BD895D90_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey_97B8DD9973D406A9EB0022A5BD895D90" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_97B8DD9973D406A9EB0022A5BD895D90" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey_97B8DD9973D406A9EB0022A5BD895D90" xlink:to="lab_dei_EntityCentralIndexKey_97B8DD9973D406A9EB0022A5BD895D90" xlink:type="arc" />
    <link:label id="lab_dei_CurrentFiscalYearEndDate_8FC41143DBAA8F70CEE722A5BD8A9BAE_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate_8FC41143DBAA8F70CEE722A5BD8A9BAE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_8FC41143DBAA8F70CEE722A5BD8A9BAE_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate_8FC41143DBAA8F70CEE722A5BD8A9BAE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_8FC41143DBAA8F70CEE722A5BD8A9BAE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate_8FC41143DBAA8F70CEE722A5BD8A9BAE" xlink:to="lab_dei_CurrentFiscalYearEndDate_8FC41143DBAA8F70CEE722A5BD8A9BAE" xlink:type="arc" />
    <link:label id="lab_dei_EntityFilerCategory_DB6B07204553FD6E8A3622A5BD8A410D_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory_DB6B07204553FD6E8A3622A5BD8A410D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_DB6B07204553FD6E8A3622A5BD8A410D_label_en-US" xlink:label="lab_dei_EntityFilerCategory_DB6B07204553FD6E8A3622A5BD8A410D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_DB6B07204553FD6E8A3622A5BD8A410D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory_DB6B07204553FD6E8A3622A5BD8A410D" xlink:to="lab_dei_EntityFilerCategory_DB6B07204553FD6E8A3622A5BD8A410D" xlink:type="arc" />
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_EA0EB168274B8B61EB8B22A5BD8ADF69_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding_EA0EB168274B8B61EB8B22A5BD8ADF69" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_EA0EB168274B8B61EB8B22A5BD8ADF69_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding_EA0EB168274B8B61EB8B22A5BD8ADF69" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_EA0EB168274B8B61EB8B22A5BD8ADF69" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding_EA0EB168274B8B61EB8B22A5BD8ADF69" xlink:to="lab_dei_EntityCommonStockSharesOutstanding_EA0EB168274B8B61EB8B22A5BD8ADF69" xlink:type="arc" />
    <link:label id="lab_dei_EntityCurrentReportingStatus_BB0A6CD651735B56157222A5BD8A12B3_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus_BB0A6CD651735B56157222A5BD8A12B3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_BB0A6CD651735B56157222A5BD8A12B3_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus_BB0A6CD651735B56157222A5BD8A12B3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_BB0A6CD651735B56157222A5BD8A12B3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus_BB0A6CD651735B56157222A5BD8A12B3" xlink:to="lab_dei_EntityCurrentReportingStatus_BB0A6CD651735B56157222A5BD8A12B3" xlink:type="arc" />
    <link:label id="lab_dei_DocumentFiscalYearFocus_5A0F3B67DF6CD37F105722A5BD8ADB30_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus_5A0F3B67DF6CD37F105722A5BD8ADB30" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_5A0F3B67DF6CD37F105722A5BD8ADB30_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus_5A0F3B67DF6CD37F105722A5BD8ADB30" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_5A0F3B67DF6CD37F105722A5BD8ADB30" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus_5A0F3B67DF6CD37F105722A5BD8ADB30" xlink:to="lab_dei_DocumentFiscalYearFocus_5A0F3B67DF6CD37F105722A5BD8ADB30" xlink:type="arc" />
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_4C63198D869B56AF505822A5BD8AEFB4_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus_4C63198D869B56AF505822A5BD8AEFB4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_4C63198D869B56AF505822A5BD8AEFB4_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus_4C63198D869B56AF505822A5BD8AEFB4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_4C63198D869B56AF505822A5BD8AEFB4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus_4C63198D869B56AF505822A5BD8AEFB4" xlink:to="lab_dei_DocumentFiscalPeriodFocus_4C63198D869B56AF505822A5BD8AEFB4" xlink:type="arc" />
    <link:label id="lab_dei_EntityEmergingGrowthCompany_121DF1C247286925B48D22A5BD8AD620_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany_121DF1C247286925B48D22A5BD8AD620" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_121DF1C247286925B48D22A5BD8AD620_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany_121DF1C247286925B48D22A5BD8AD620" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_121DF1C247286925B48D22A5BD8AD620" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany_121DF1C247286925B48D22A5BD8AD620" xlink:to="lab_dei_EntityEmergingGrowthCompany_121DF1C247286925B48D22A5BD8AD620" xlink:type="arc" />
    <link:label id="lab_dei_EntityShellCompany_6FFA953B9473FCBD805522A5BD8B77F6_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany_6FFA953B9473FCBD805522A5BD8B77F6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_6FFA953B9473FCBD805522A5BD8B77F6_label_en-US" xlink:label="lab_dei_EntityShellCompany_6FFA953B9473FCBD805522A5BD8B77F6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityShellCompany" xlink:label="loc_dei_EntityShellCompany_6FFA953B9473FCBD805522A5BD8B77F6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany_6FFA953B9473FCBD805522A5BD8B77F6" xlink:to="lab_dei_EntityShellCompany_6FFA953B9473FCBD805522A5BD8B77F6" xlink:type="arc" />
    <link:label id="lab_dei_EntitySmallBusiness_90BCEA8BD3DF49B8392422A5BD8B1B01_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness_90BCEA8BD3DF49B8392422A5BD8B1B01" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_90BCEA8BD3DF49B8392422A5BD8B1B01_label_en-US" xlink:label="lab_dei_EntitySmallBusiness_90BCEA8BD3DF49B8392422A5BD8B1B01" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness_90BCEA8BD3DF49B8392422A5BD8B1B01" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness_90BCEA8BD3DF49B8392422A5BD8B1B01" xlink:to="lab_dei_EntitySmallBusiness_90BCEA8BD3DF49B8392422A5BD8B1B01" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_81EB6EB7ABBE49F83E3C2271CB7DD7E6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_81EB6EB7ABBE49F83E3C2271CB7DD7E6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Equity Method Investments [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_81EB6EB7ABBE49F83E3C2271CB7DD7E6_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_81EB6EB7ABBE49F83E3C2271CB7DD7E6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Equity Method Investments [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_81EB6EB7ABBE49F83E3C2271CB7DD7E6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_81EB6EB7ABBE49F83E3C2271CB7DD7E6" xlink:to="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_81EB6EB7ABBE49F83E3C2271CB7DD7E6" xlink:type="arc" />
    <link:label id="lab_dei_LegalEntityAxis_E2109013831DC0A7C0E52271CB7EF6AE_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis_E2109013831DC0A7C0E52271CB7EF6AE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:label id="lab_dei_LegalEntityAxis_E2109013831DC0A7C0E52271CB7EF6AE_label_en-US" xlink:label="lab_dei_LegalEntityAxis_E2109013831DC0A7C0E52271CB7EF6AE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_E2109013831DC0A7C0E52271CB7EF6AE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis_E2109013831DC0A7C0E52271CB7EF6AE" xlink:to="lab_dei_LegalEntityAxis_E2109013831DC0A7C0E52271CB7EF6AE" xlink:type="arc" />
    <link:label id="lab_dei_EntityDomain_AE7E7B25717EB7494CCD2271CB7EAAE8_terseLabel_en-US" xlink:label="lab_dei_EntityDomain_AE7E7B25717EB7494CCD2271CB7EAAE8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
    <link:label id="lab_dei_EntityDomain_AE7E7B25717EB7494CCD2271CB7EAAE8_label_en-US" xlink:label="lab_dei_EntityDomain_AE7E7B25717EB7494CCD2271CB7EAAE8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_AE7E7B25717EB7494CCD2271CB7EAAE8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain_AE7E7B25717EB7494CCD2271CB7EAAE8" xlink:to="lab_dei_EntityDomain_AE7E7B25717EB7494CCD2271CB7EAAE8" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_EED131FDDFD02FE0FDF52271CB7F56F9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_EED131FDDFD02FE0FDF52271CB7F56F9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Equity Method Investments [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_EED131FDDFD02FE0FDF52271CB7F56F9_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_EED131FDDFD02FE0FDF52271CB7F56F9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Equity Method Investments [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_EED131FDDFD02FE0FDF52271CB7F56F9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_EED131FDDFD02FE0FDF52271CB7F56F9" xlink:to="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_EED131FDDFD02FE0FDF52271CB7F56F9" xlink:type="arc" />
    <link:label id="lab_abus_EquityMethodInvestmentPropertyContribution_B00D4BE0434BD4ABA5D02271CB7FC432_verboseLabel_en-US" xlink:label="lab_abus_EquityMethodInvestmentPropertyContribution_B00D4BE0434BD4ABA5D02271CB7FC432" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Property contribution to investment in Genevant</link:label>
    <link:label id="lab_abus_EquityMethodInvestmentPropertyContribution_B00D4BE0434BD4ABA5D02271CB7FC432_label_en-US" xlink:label="lab_abus_EquityMethodInvestmentPropertyContribution_B00D4BE0434BD4ABA5D02271CB7FC432" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investment, Property Contribution</link:label>
    <link:label id="lab_abus_EquityMethodInvestmentPropertyContribution_B00D4BE0434BD4ABA5D02271CB7FC432_documentation_en-US" xlink:label="lab_abus_EquityMethodInvestmentPropertyContribution_B00D4BE0434BD4ABA5D02271CB7FC432" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Equity Method Investment, Property Contribution</link:label>
    <link:loc xlink:href="abus-20190930.xsd#abus_EquityMethodInvestmentPropertyContribution" xlink:label="loc_abus_EquityMethodInvestmentPropertyContribution_B00D4BE0434BD4ABA5D02271CB7FC432" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_EquityMethodInvestmentPropertyContribution_B00D4BE0434BD4ABA5D02271CB7FC432" xlink:to="lab_abus_EquityMethodInvestmentPropertyContribution_B00D4BE0434BD4ABA5D02271CB7FC432" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_39EC85C9CD8A57FBC4EB2271CB80F50E_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments_39EC85C9CD8A57FBC4EB2271CB80F50E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Gains (losses) on equity method investments</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_39EC85C9CD8A57FBC4EB2271CB80F50E_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments_39EC85C9CD8A57FBC4EB2271CB80F50E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Equity Method Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_39EC85C9CD8A57FBC4EB2271CB80F50E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromEquityMethodInvestments_39EC85C9CD8A57FBC4EB2271CB80F50E" xlink:to="lab_us-gaap_IncomeLossFromEquityMethodInvestments_39EC85C9CD8A57FBC4EB2271CB80F50E" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_C2593CB560C861F6B0332271CB80636E_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_C2593CB560C861F6B0332271CB80636E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ownership interest in equity method investment</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_C2593CB560C861F6B0332271CB80636E_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_C2593CB560C861F6B0332271CB80636E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investment, Ownership Percentage</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_C2593CB560C861F6B0332271CB80636E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_C2593CB560C861F6B0332271CB80636E" xlink:to="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_C2593CB560C861F6B0332271CB80636E" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityMethodInvestments_0BBB32FB76790F125F732271CB805057_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments_0BBB32FB76790F125F732271CB805057" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment in Genevant</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestments_0BBB32FB76790F125F732271CB805057_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments_0BBB32FB76790F125F732271CB805057" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityMethodInvestments" xlink:label="loc_us-gaap_EquityMethodInvestments_0BBB32FB76790F125F732271CB805057" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestments_0BBB32FB76790F125F732271CB805057" xlink:to="lab_us-gaap_EquityMethodInvestments_0BBB32FB76790F125F732271CB805057" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_78729C6BDEB6F3EAF12B02DE05BE5BEC_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_78729C6BDEB6F3EAF12B02DE05BE5BEC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_78729C6BDEB6F3EAF12B02DE05BE5BEC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_78729C6BDEB6F3EAF12B02DE05BE5BEC" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_78729C6BDEB6F3EAF12B02DE05BE5BEC" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_230A10A911D27B3C486302DE05BEA62A_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_230A10A911D27B3C486302DE05BEA62A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingencies and commitments</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_230A10A911D27B3C486302DE05BEA62A_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_230A10A911D27B3C486302DE05BEA62A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_230A10A911D27B3C486302DE05BEA62A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_230A10A911D27B3C486302DE05BEA62A" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_230A10A911D27B3C486302DE05BEA62A" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8A43FC9B80B0D819FD64220D839D3BE2_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8A43FC9B80B0D819FD64220D839D3BE2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8A43FC9B80B0D819FD64220D839D3BE2_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8A43FC9B80B0D819FD64220D839D3BE2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8A43FC9B80B0D819FD64220D839D3BE2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8A43FC9B80B0D819FD64220D839D3BE2" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8A43FC9B80B0D819FD64220D839D3BE2" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_E2C273BD9995AC14DF5A220D839E70F3_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis_E2C273BD9995AC14DF5A220D839E70F3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_E2C273BD9995AC14DF5A220D839E70F3_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis_E2C273BD9995AC14DF5A220D839E70F3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_E2C273BD9995AC14DF5A220D839E70F3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_E2C273BD9995AC14DF5A220D839E70F3" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis_E2C273BD9995AC14DF5A220D839E70F3" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_428F1C303BD6AE330AD6220D839ED75D_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain_428F1C303BD6AE330AD6220D839ED75D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_428F1C303BD6AE330AD6220D839ED75D_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain_428F1C303BD6AE330AD6220D839ED75D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement Frequency [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_428F1C303BD6AE330AD6220D839ED75D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_428F1C303BD6AE330AD6220D839ED75D" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain_428F1C303BD6AE330AD6220D839ED75D" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_7E8A1F25761DD8714ED6220D839EB928_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember_7E8A1F25761DD8714ED6220D839EB928" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_7E8A1F25761DD8714ED6220D839EB928_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember_7E8A1F25761DD8714ED6220D839EB928" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurements, Recurring [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_7E8A1F25761DD8714ED6220D839EB928" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember_7E8A1F25761DD8714ED6220D839EB928" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember_7E8A1F25761DD8714ED6220D839EB928" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_42DFCA41E85973D29E27220D839F6205_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_42DFCA41E85973D29E27220D839F6205" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_42DFCA41E85973D29E27220D839F6205_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_42DFCA41E85973D29E27220D839F6205" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_42DFCA41E85973D29E27220D839F6205" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_42DFCA41E85973D29E27220D839F6205" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_42DFCA41E85973D29E27220D839F6205" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_FA1261375F7DF15D47B6220D839FBA4D_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_FA1261375F7DF15D47B6220D839FBA4D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_FA1261375F7DF15D47B6220D839FBA4D_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_FA1261375F7DF15D47B6220D839FBA4D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_FA1261375F7DF15D47B6220D839FBA4D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_FA1261375F7DF15D47B6220D839FBA4D" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_FA1261375F7DF15D47B6220D839FBA4D" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_F77DB0154B64598B0F6E220D839FF0F6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member_F77DB0154B64598B0F6E220D839FF0F6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_F77DB0154B64598B0F6E220D839FF0F6_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member_F77DB0154B64598B0F6E220D839FF0F6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_F77DB0154B64598B0F6E220D839FF0F6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member_F77DB0154B64598B0F6E220D839FF0F6" xlink:to="lab_us-gaap_FairValueInputsLevel1Member_F77DB0154B64598B0F6E220D839FF0F6" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_031CDA948E138B9DE33F220D839F4B9E_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member_031CDA948E138B9DE33F220D839F4B9E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_031CDA948E138B9DE33F220D839F4B9E_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member_031CDA948E138B9DE33F220D839F4B9E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_031CDA948E138B9DE33F220D839F4B9E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member_031CDA948E138B9DE33F220D839F4B9E" xlink:to="lab_us-gaap_FairValueInputsLevel2Member_031CDA948E138B9DE33F220D839F4B9E" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_31C71F9F9A5DE0D652B5220D83A06B56_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member_31C71F9F9A5DE0D652B5220D83A06B56" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_31C71F9F9A5DE0D652B5220D83A06B56_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member_31C71F9F9A5DE0D652B5220D83A06B56" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_31C71F9F9A5DE0D652B5220D83A06B56" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member_31C71F9F9A5DE0D652B5220D83A06B56" xlink:to="lab_us-gaap_FairValueInputsLevel3Member_31C71F9F9A5DE0D652B5220D83A06B56" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_E2C2BC36E8365D10AED4220D83A0551B_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_E2C2BC36E8365D10AED4220D83A0551B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_E2C2BC36E8365D10AED4220D83A0551B_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_E2C2BC36E8365D10AED4220D83A0551B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_E2C2BC36E8365D10AED4220D83A0551B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_E2C2BC36E8365D10AED4220D83A0551B" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_E2C2BC36E8365D10AED4220D83A0551B" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_03D1484311141D01ED52220D83A0E76E_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract_03D1484311141D01ED52220D83A0E76E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_03D1484311141D01ED52220D83A0E76E_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract_03D1484311141D01ED52220D83A0E76E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_03D1484311141D01ED52220D83A0E76E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_03D1484311141D01ED52220D83A0E76E" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract_03D1484311141D01ED52220D83A0E76E" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_043AE5F8989205022D6D220D83A07BB3_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_043AE5F8989205022D6D220D83A07BB3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_043AE5F8989205022D6D220D83A07BB3_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_043AE5F8989205022D6D220D83A07BB3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_043AE5F8989205022D6D220D83A07BB3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_043AE5F8989205022D6D220D83A07BB3" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_043AE5F8989205022D6D220D83A07BB3" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_DFC98B7C07BD8E9AF32E220D83A5EA4E_verboseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure_DFC98B7C07BD8E9AF32E220D83A5EA4E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_DFC98B7C07BD8E9AF32E220D83A5EA4E_label_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure_DFC98B7C07BD8E9AF32E220D83A5EA4E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_DFC98B7C07BD8E9AF32E220D83A5EA4E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsFairValueDisclosure_DFC98B7C07BD8E9AF32E220D83A5EA4E" xlink:to="lab_us-gaap_InvestmentsFairValueDisclosure_DFC98B7C07BD8E9AF32E220D83A5EA4E" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_DE18C872DB1EC84609C9220D83A6C52A_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure_DE18C872DB1EC84609C9220D83A6C52A" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total Assets</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_DE18C872DB1EC84609C9220D83A6C52A_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure_DE18C872DB1EC84609C9220D83A6C52A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_DE18C872DB1EC84609C9220D83A6C52A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_DE18C872DB1EC84609C9220D83A6C52A" xlink:to="lab_us-gaap_AssetsFairValueDisclosure_DE18C872DB1EC84609C9220D83A6C52A" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_B4B97EA55AF95781ADF8220D83A65C65_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_B4B97EA55AF95781ADF8220D83A65C65" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_B4B97EA55AF95781ADF8220D83A65C65_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_B4B97EA55AF95781ADF8220D83A65C65" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_B4B97EA55AF95781ADF8220D83A65C65" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_B4B97EA55AF95781ADF8220D83A65C65" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_B4B97EA55AF95781ADF8220D83A65C65" xlink:type="arc" />
    <link:label id="lab_abus_EmployeeStockOptionsLiabilityClassifiedOutstandingFairValueDisclosure_81FF0186D127FE0FEB4C220D83A6CF94_netLabel_en-US" xlink:label="lab_abus_EmployeeStockOptionsLiabilityClassifiedOutstandingFairValueDisclosure_81FF0186D127FE0FEB4C220D83A6CF94" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xml:lang="en-US">Liability-classified options</link:label>
    <link:label id="lab_abus_EmployeeStockOptionsLiabilityClassifiedOutstandingFairValueDisclosure_81FF0186D127FE0FEB4C220D83A6CF94_label_en-US" xlink:label="lab_abus_EmployeeStockOptionsLiabilityClassifiedOutstandingFairValueDisclosure_81FF0186D127FE0FEB4C220D83A6CF94" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock Options, Liability Classified, Outstanding, Fair Value Disclosure</link:label>
    <link:label id="lab_abus_EmployeeStockOptionsLiabilityClassifiedOutstandingFairValueDisclosure_81FF0186D127FE0FEB4C220D83A6CF94_documentation_en-US" xlink:label="lab_abus_EmployeeStockOptionsLiabilityClassifiedOutstandingFairValueDisclosure_81FF0186D127FE0FEB4C220D83A6CF94" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Employee Stock Options, Liability Classified, Outstanding, Fair Value Disclosure</link:label>
    <link:loc xlink:href="abus-20190930.xsd#abus_EmployeeStockOptionsLiabilityClassifiedOutstandingFairValueDisclosure" xlink:label="loc_abus_EmployeeStockOptionsLiabilityClassifiedOutstandingFairValueDisclosure_81FF0186D127FE0FEB4C220D83A6CF94" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_EmployeeStockOptionsLiabilityClassifiedOutstandingFairValueDisclosure_81FF0186D127FE0FEB4C220D83A6CF94" xlink:to="lab_abus_EmployeeStockOptionsLiabilityClassifiedOutstandingFairValueDisclosure_81FF0186D127FE0FEB4C220D83A6CF94" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_31EC4FA0DA922DE6C084220D83A6FEED_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_31EC4FA0DA922DE6C084220D83A6FEED" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration (notes 3 and 10)</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_31EC4FA0DA922DE6C084220D83A6FEED_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_31EC4FA0DA922DE6C084220D83A6FEED" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_31EC4FA0DA922DE6C084220D83A6FEED" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_31EC4FA0DA922DE6C084220D83A6FEED" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_31EC4FA0DA922DE6C084220D83A6FEED" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_F7A4BADCAE5DA522C4CC220D83A6D6DC_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure_F7A4BADCAE5DA522C4CC220D83A6D6DC" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total Liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_F7A4BADCAE5DA522C4CC220D83A6D6DC_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure_F7A4BADCAE5DA522C4CC220D83A6D6DC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial and Nonfinancial Liabilities, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_F7A4BADCAE5DA522C4CC220D83A6D6DC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_F7A4BADCAE5DA522C4CC220D83A6D6DC" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosure_F7A4BADCAE5DA522C4CC220D83A6D6DC" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestructuringReserveRollForward_1DD424A5652DB334CB502216DD093FE2_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserveRollForward_1DD424A5652DB334CB502216DD093FE2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring Reserve [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_RestructuringReserveRollForward_1DD424A5652DB334CB502216DD093FE2_label_en-US" xlink:label="lab_us-gaap_RestructuringReserveRollForward_1DD424A5652DB334CB502216DD093FE2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Reserve [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestructuringReserveRollForward" xlink:label="loc_us-gaap_RestructuringReserveRollForward_1DD424A5652DB334CB502216DD093FE2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserveRollForward_1DD424A5652DB334CB502216DD093FE2" xlink:to="lab_us-gaap_RestructuringReserveRollForward_1DD424A5652DB334CB502216DD093FE2" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestructuringReserve_ACD12751F2221D080CCA2216DD092B23_periodStartLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserve_ACD12751F2221D080CCA2216DD092B23" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Site consolidation accrual as of December 31, 2018</link:label>
    <link:label id="lab_us-gaap_RestructuringReserve_ACD12751F2221D080CCA2216DD092B23_label_en-US" xlink:label="lab_us-gaap_RestructuringReserve_ACD12751F2221D080CCA2216DD092B23" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Reserve</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestructuringReserve" xlink:label="loc_us-gaap_RestructuringReserve_ACD12751F2221D080CCA2216DD092B23" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserve_ACD12751F2221D080CCA2216DD092B23" xlink:to="lab_us-gaap_RestructuringReserve_ACD12751F2221D080CCA2216DD092B23" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestructuringCharges_A64F22DA2FD659B549FF2216DD0A27A5_netLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges_A64F22DA2FD659B549FF2216DD0A27A5" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xml:lang="en-US">Additional accruals and other adjustments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="loc_us-gaap_RestructuringCharges_A64F22DA2FD659B549FF2216DD0A27A5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCharges_A64F22DA2FD659B549FF2216DD0A27A5" xlink:to="lab_us-gaap_RestructuringCharges_A64F22DA2FD659B549FF2216DD0A27A5" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsForRestructuring_84BD410F4882427842952216DD0A533F_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRestructuring_84BD410F4882427842952216DD0A533F" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Payments</link:label>
    <link:label id="lab_us-gaap_PaymentsForRestructuring_84BD410F4882427842952216DD0A533F_label_en-US" xlink:label="lab_us-gaap_PaymentsForRestructuring_84BD410F4882427842952216DD0A533F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments for Restructuring</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsForRestructuring" xlink:label="loc_us-gaap_PaymentsForRestructuring_84BD410F4882427842952216DD0A533F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRestructuring_84BD410F4882427842952216DD0A533F" xlink:to="lab_us-gaap_PaymentsForRestructuring_84BD410F4882427842952216DD0A533F" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestructuringReserve_B76A788F544BA2CDDC1B2216DD0A5934_periodEndLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserve_B76A788F544BA2CDDC1B2216DD0A5934" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Site consolidation accrual as of September 30, 2019</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestructuringReserve" xlink:label="loc_us-gaap_RestructuringReserve_B76A788F544BA2CDDC1B2216DD0A5934" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserve_B76A788F544BA2CDDC1B2216DD0A5934" xlink:to="lab_us-gaap_RestructuringReserve_B76A788F544BA2CDDC1B2216DD0A5934" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsAbstract_BDA20EAE8C44047394C23D1724FECB0F_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract_BDA20EAE8C44047394C23D1724FECB0F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_BDA20EAE8C44047394C23D1724FECB0F_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract_BDA20EAE8C44047394C23D1724FECB0F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_BDA20EAE8C44047394C23D1724FECB0F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract_BDA20EAE8C44047394C23D1724FECB0F" xlink:to="lab_us-gaap_AssetsAbstract_BDA20EAE8C44047394C23D1724FECB0F" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_8808EFE57F75D9909EE23D1724FEF1DC_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract_8808EFE57F75D9909EE23D1724FEF1DC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_8808EFE57F75D9909EE23D1724FEF1DC_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract_8808EFE57F75D9909EE23D1724FEF1DC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_8808EFE57F75D9909EE23D1724FEF1DC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract_8808EFE57F75D9909EE23D1724FEF1DC" xlink:to="lab_us-gaap_AssetsCurrentAbstract_8808EFE57F75D9909EE23D1724FEF1DC" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_C0CE3A9EFA5DFAE9A7EA3D1724FE96DD_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_C0CE3A9EFA5DFAE9A7EA3D1724FE96DD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_C0CE3A9EFA5DFAE9A7EA3D1724FE96DD_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_C0CE3A9EFA5DFAE9A7EA3D1724FE96DD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_C0CE3A9EFA5DFAE9A7EA3D1724FE96DD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_C0CE3A9EFA5DFAE9A7EA3D1724FE96DD" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_C0CE3A9EFA5DFAE9A7EA3D1724FE96DD" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShortTermInvestments_974710C0B8829515DFEE3D1724FE0775_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestments_974710C0B8829515DFEE3D1724FE0775" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestments_974710C0B8829515DFEE3D1724FE0775_label_en-US" xlink:label="lab_us-gaap_ShortTermInvestments_974710C0B8829515DFEE3D1724FE0775" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short-term Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShortTermInvestments" xlink:label="loc_us-gaap_ShortTermInvestments_974710C0B8829515DFEE3D1724FE0775" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestments_974710C0B8829515DFEE3D1724FE0775" xlink:to="lab_us-gaap_ShortTermInvestments_974710C0B8829515DFEE3D1724FE0775" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_0A2EED5604DC36E296903D1724FE8500_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent_0A2EED5604DC36E296903D1724FE8500" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_0A2EED5604DC36E296903D1724FE8500_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent_0A2EED5604DC36E296903D1724FE8500" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, Net, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_0A2EED5604DC36E296903D1724FE8500" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent_0A2EED5604DC36E296903D1724FE8500" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent_0A2EED5604DC36E296903D1724FE8500" xlink:type="arc" />
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_6B1F4A47952DBEC9421E3D1725001BF0_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_6B1F4A47952DBEC9421E3D1725001BF0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_6B1F4A47952DBEC9421E3D1725001BF0_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_6B1F4A47952DBEC9421E3D1725001BF0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_6B1F4A47952DBEC9421E3D1725001BF0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_6B1F4A47952DBEC9421E3D1725001BF0" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_6B1F4A47952DBEC9421E3D1725001BF0" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsCurrent_1033BCC2718C324941D43D172500491C_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent_1033BCC2718C324941D43D172500491C" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_1033BCC2718C324941D43D172500491C_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent_1033BCC2718C324941D43D172500491C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_1033BCC2718C324941D43D172500491C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent_1033BCC2718C324941D43D172500491C" xlink:to="lab_us-gaap_AssetsCurrent_1033BCC2718C324941D43D172500491C" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_5C9FA29D37FA766E70CB3D17250044C4_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_5C9FA29D37FA766E70CB3D17250044C4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, net accumulated depreciation $8,612 (December 31, 2018: $7,090)</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_5C9FA29D37FA766E70CB3D17250044C4_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_5C9FA29D37FA766E70CB3D17250044C4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_5C9FA29D37FA766E70CB3D17250044C4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_5C9FA29D37FA766E70CB3D17250044C4" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet_5C9FA29D37FA766E70CB3D17250044C4" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_A29306E534F7E6C79AC73D172500A058_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset_A29306E534F7E6C79AC73D172500A058" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Right of use asset (note 5)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_A29306E534F7E6C79AC73D172500A058" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset_A29306E534F7E6C79AC73D172500A058" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset_A29306E534F7E6C79AC73D172500A058" xlink:type="arc" />
    <link:label id="lab_us-gaap_Assets_033150184195B8DF58AA3D172501BC20_totalLabel_en-US" xlink:label="lab_us-gaap_Assets_033150184195B8DF58AA3D172501BC20" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_033150184195B8DF58AA3D172501BC20_label_en-US" xlink:label="lab_us-gaap_Assets_033150184195B8DF58AA3D172501BC20" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_033150184195B8DF58AA3D172501BC20" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets_033150184195B8DF58AA3D172501BC20" xlink:to="lab_us-gaap_Assets_033150184195B8DF58AA3D172501BC20" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_E918D187B60205B932033D1725011668_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_E918D187B60205B932033D1725011668" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liabilities and stockholders' equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_E918D187B60205B932033D1725011668_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_E918D187B60205B932033D1725011668" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_E918D187B60205B932033D1725011668" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_E918D187B60205B932033D1725011668" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_E918D187B60205B932033D1725011668" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_B75352631CA9B086C95C3D1725017610_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract_B75352631CA9B086C95C3D1725017610" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_B75352631CA9B086C95C3D1725017610_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract_B75352631CA9B086C95C3D1725017610" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_B75352631CA9B086C95C3D1725017610" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_B75352631CA9B086C95C3D1725017610" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract_B75352631CA9B086C95C3D1725017610" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_37EDDF392332AB56F0323D1725012D28_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_37EDDF392332AB56F0323D1725012D28" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable and accrued liabilities (note 7)</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_37EDDF392332AB56F0323D1725012D28_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_37EDDF392332AB56F0323D1725012D28" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable and Accrued Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_37EDDF392332AB56F0323D1725012D28" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_37EDDF392332AB56F0323D1725012D28" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_37EDDF392332AB56F0323D1725012D28" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestructuringReserveCurrent_BE7A1D9DA8BD259045093D1725023AEF_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserveCurrent_BE7A1D9DA8BD259045093D1725023AEF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Site consolidation accrual (note 8)</link:label>
    <link:label id="lab_us-gaap_RestructuringReserveCurrent_BE7A1D9DA8BD259045093D1725023AEF_label_en-US" xlink:label="lab_us-gaap_RestructuringReserveCurrent_BE7A1D9DA8BD259045093D1725023AEF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Reserve, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestructuringReserveCurrent" xlink:label="loc_us-gaap_RestructuringReserveCurrent_BE7A1D9DA8BD259045093D1725023AEF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserveCurrent_BE7A1D9DA8BD259045093D1725023AEF" xlink:to="lab_us-gaap_RestructuringReserveCurrent_BE7A1D9DA8BD259045093D1725023AEF" xlink:type="arc" />
    <link:label id="lab_abus_EmployeeStockOptionsLiabilityClassifiedOutstanding_2B77B34F3A4BF8B24C433D1725024FCC_terseLabel_en-US" xlink:label="lab_abus_EmployeeStockOptionsLiabilityClassifiedOutstanding_2B77B34F3A4BF8B24C433D1725024FCC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liability-classified options (note 3)</link:label>
    <link:label id="lab_abus_EmployeeStockOptionsLiabilityClassifiedOutstanding_2B77B34F3A4BF8B24C433D1725024FCC_label_en-US" xlink:label="lab_abus_EmployeeStockOptionsLiabilityClassifiedOutstanding_2B77B34F3A4BF8B24C433D1725024FCC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock Options, Liability Classified, Outstanding</link:label>
    <link:label id="lab_abus_EmployeeStockOptionsLiabilityClassifiedOutstanding_2B77B34F3A4BF8B24C433D1725024FCC_documentation_en-US" xlink:label="lab_abus_EmployeeStockOptionsLiabilityClassifiedOutstanding_2B77B34F3A4BF8B24C433D1725024FCC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Employee Stock Options, Liability Classified, Outstanding</link:label>
    <link:loc xlink:href="abus-20190930.xsd#abus_EmployeeStockOptionsLiabilityClassifiedOutstanding" xlink:label="loc_abus_EmployeeStockOptionsLiabilityClassifiedOutstanding_2B77B34F3A4BF8B24C433D1725024FCC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_EmployeeStockOptionsLiabilityClassifiedOutstanding_2B77B34F3A4BF8B24C433D1725024FCC" xlink:to="lab_abus_EmployeeStockOptionsLiabilityClassifiedOutstanding_2B77B34F3A4BF8B24C433D1725024FCC" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_D50DC1E05F0071B44ED13D1725022BAB_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent_D50DC1E05F0071B44ED13D1725022BAB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease liability, current (note 5)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_D50DC1E05F0071B44ED13D1725022BAB_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent_D50DC1E05F0071B44ED13D1725022BAB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_D50DC1E05F0071B44ED13D1725022BAB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent_D50DC1E05F0071B44ED13D1725022BAB" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent_D50DC1E05F0071B44ED13D1725022BAB" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesCurrent_F8034C3447883A82411B3D172502210C_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent_F8034C3447883A82411B3D172502210C" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_F8034C3447883A82411B3D172502210C_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent_F8034C3447883A82411B3D172502210C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_F8034C3447883A82411B3D172502210C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent_F8034C3447883A82411B3D172502210C" xlink:to="lab_us-gaap_LiabilitiesCurrent_F8034C3447883A82411B3D172502210C" xlink:type="arc" />
    <link:label id="lab_abus_LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent_484B0A39748478CB617E3D1725021C6F_terseLabel_en-US" xlink:label="lab_abus_LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent_484B0A39748478CB617E3D1725021C6F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liability related to sale of future royalties (note 9)</link:label>
    <link:label id="lab_abus_LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent_484B0A39748478CB617E3D1725021C6F_label_en-US" xlink:label="lab_abus_LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent_484B0A39748478CB617E3D1725021C6F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liability Related To Sale Of Future Royalties, Noncurrent</link:label>
    <link:label id="lab_abus_LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent_484B0A39748478CB617E3D1725021C6F_documentation_en-US" xlink:label="lab_abus_LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent_484B0A39748478CB617E3D1725021C6F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Liability Related To Sale Of Future Royalties, Noncurrent</link:label>
    <link:loc xlink:href="abus-20190930.xsd#abus_LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent" xlink:label="loc_abus_LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent_484B0A39748478CB617E3D1725021C6F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent_484B0A39748478CB617E3D1725021C6F" xlink:to="lab_abus_LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent_484B0A39748478CB617E3D1725021C6F" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredRentCreditNoncurrent_9990FB8E4F8E3261E0E73D17250228FB_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredRentCreditNoncurrent_9990FB8E4F8E3261E0E73D17250228FB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred rent and inducements, non-current</link:label>
    <link:label id="lab_us-gaap_DeferredRentCreditNoncurrent_9990FB8E4F8E3261E0E73D17250228FB_label_en-US" xlink:label="lab_us-gaap_DeferredRentCreditNoncurrent_9990FB8E4F8E3261E0E73D17250228FB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Rent Credit, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="loc_us-gaap_DeferredRentCreditNoncurrent_9990FB8E4F8E3261E0E73D17250228FB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRentCreditNoncurrent_9990FB8E4F8E3261E0E73D17250228FB" xlink:to="lab_us-gaap_DeferredRentCreditNoncurrent_9990FB8E4F8E3261E0E73D17250228FB" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_48336F1E367558F329FA3D1725036359_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_48336F1E367558F329FA3D1725036359" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease liability, non-current (note 5)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_48336F1E367558F329FA3D1725036359" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_48336F1E367558F329FA3D1725036359" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_48336F1E367558F329FA3D1725036359" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_31298D8AA4AE919D03C13D172503D6EB_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_31298D8AA4AE919D03C13D172503D6EB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax liability (note 6)</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_31298D8AA4AE919D03C13D172503D6EB_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_31298D8AA4AE919D03C13D172503D6EB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Liabilities, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_31298D8AA4AE919D03C13D172503D6EB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_31298D8AA4AE919D03C13D172503D6EB" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_31298D8AA4AE919D03C13D172503D6EB" xlink:type="arc" />
    <link:label id="lab_us-gaap_Liabilities_CF18F089B502274DAD2D3D17250324CC_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities_CF18F089B502274DAD2D3D17250324CC" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_CF18F089B502274DAD2D3D17250324CC_label_en-US" xlink:label="lab_us-gaap_Liabilities_CF18F089B502274DAD2D3D17250324CC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_CF18F089B502274DAD2D3D17250324CC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities_CF18F089B502274DAD2D3D17250324CC" xlink:to="lab_us-gaap_Liabilities_CF18F089B502274DAD2D3D17250324CC" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_E42B2FBACC1ED9504E9A3D172503B925_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract_E42B2FBACC1ED9504E9A3D172503B925" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_E42B2FBACC1ED9504E9A3D172503B925_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract_E42B2FBACC1ED9504E9A3D172503B925" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_E42B2FBACC1ED9504E9A3D172503B925" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract_E42B2FBACC1ED9504E9A3D172503B925" xlink:to="lab_us-gaap_StockholdersEquityAbstract_E42B2FBACC1ED9504E9A3D172503B925" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockIncludingAdditionalPaidInCapitalNetOfDiscount_EC0F16856F882ACEDEB23D1725033C9E_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockIncludingAdditionalPaidInCapitalNetOfDiscount_EC0F16856F882ACEDEB23D1725033C9E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred shares, Authorized - 1,164,000 with no par value, Issued and outstanding: 1,164,000 (December 31, 2018 - 1,164,000)</link:label>
    <link:label id="lab_us-gaap_PreferredStockIncludingAdditionalPaidInCapitalNetOfDiscount_EC0F16856F882ACEDEB23D1725033C9E_label_en-US" xlink:label="lab_us-gaap_PreferredStockIncludingAdditionalPaidInCapitalNetOfDiscount_EC0F16856F882ACEDEB23D1725033C9E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Including Additional Paid in Capital, Net of Discount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockIncludingAdditionalPaidInCapitalNetOfDiscount" xlink:label="loc_us-gaap_PreferredStockIncludingAdditionalPaidInCapitalNetOfDiscount_EC0F16856F882ACEDEB23D1725033C9E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockIncludingAdditionalPaidInCapitalNetOfDiscount_EC0F16856F882ACEDEB23D1725033C9E" xlink:to="lab_us-gaap_PreferredStockIncludingAdditionalPaidInCapitalNetOfDiscount_EC0F16856F882ACEDEB23D1725033C9E" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockValue_E3620A696A3B04A2EA7A3D1725044D16_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue_E3620A696A3B04A2EA7A3D1725044D16" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common shares, Authorized - unlimited number with no par value, Issued and outstanding: 56,850,172 (December 31, 2018 - 55,518,800)</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_E3620A696A3B04A2EA7A3D1725044D16_label_en-US" xlink:label="lab_us-gaap_CommonStockValue_E3620A696A3B04A2EA7A3D1725044D16" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_E3620A696A3B04A2EA7A3D1725044D16" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue_E3620A696A3B04A2EA7A3D1725044D16" xlink:to="lab_us-gaap_CommonStockValue_E3620A696A3B04A2EA7A3D1725044D16" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_1D40A512AB843FDE76C03D1725040914_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital_1D40A512AB843FDE76C03D1725040914" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_1D40A512AB843FDE76C03D1725040914_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital_1D40A512AB843FDE76C03D1725040914" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_1D40A512AB843FDE76C03D1725040914" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital_1D40A512AB843FDE76C03D1725040914" xlink:to="lab_us-gaap_AdditionalPaidInCapital_1D40A512AB843FDE76C03D1725040914" xlink:type="arc" />
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_D8931ACD837EB782E5DD3D1725041880_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_D8931ACD837EB782E5DD3D1725041880" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_D8931ACD837EB782E5DD3D1725041880_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_D8931ACD837EB782E5DD3D1725041880" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_D8931ACD837EB782E5DD3D1725041880" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit_D8931ACD837EB782E5DD3D1725041880" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit_D8931ACD837EB782E5DD3D1725041880" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_EB9B465DB5FCB6B765973D1725041B67_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_EB9B465DB5FCB6B765973D1725041B67" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_EB9B465DB5FCB6B765973D1725041B67_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_EB9B465DB5FCB6B765973D1725041B67" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_EB9B465DB5FCB6B765973D1725041B67" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_EB9B465DB5FCB6B765973D1725041B67" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_EB9B465DB5FCB6B765973D1725041B67" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquity_103EC90C4209A620F6CB3D172504EAD6_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity_103EC90C4209A620F6CB3D172504EAD6" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total stockholders' equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_103EC90C4209A620F6CB3D172504EAD6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_103EC90C4209A620F6CB3D172504EAD6" xlink:to="lab_us-gaap_StockholdersEquity_103EC90C4209A620F6CB3D172504EAD6" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_E55DCE8428C735F572B93D1725046591_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_E55DCE8428C735F572B93D1725046591" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities and stockholders' equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_E55DCE8428C735F572B93D1725046591_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_E55DCE8428C735F572B93D1725046591" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_E55DCE8428C735F572B93D1725046591" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_E55DCE8428C735F572B93D1725046591" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity_E55DCE8428C735F572B93D1725046591" xlink:type="arc" />
    <link:label id="lab_abus_FairValueLiabilitiesMeasuredonRecurringBasisRollForward_8405EC0AB2CA9754B57C25AE3C726AAC_terseLabel_en-US" xlink:label="lab_abus_FairValueLiabilitiesMeasuredonRecurringBasisRollForward_8405EC0AB2CA9754B57C25AE3C726AAC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis [Roll Forward]</link:label>
    <link:label id="lab_abus_FairValueLiabilitiesMeasuredonRecurringBasisRollForward_8405EC0AB2CA9754B57C25AE3C726AAC_label_en-US" xlink:label="lab_abus_FairValueLiabilitiesMeasuredonRecurringBasisRollForward_8405EC0AB2CA9754B57C25AE3C726AAC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis [Roll Forward]</link:label>
    <link:label id="lab_abus_FairValueLiabilitiesMeasuredonRecurringBasisRollForward_8405EC0AB2CA9754B57C25AE3C726AAC_documentation_en-US" xlink:label="lab_abus_FairValueLiabilitiesMeasuredonRecurringBasisRollForward_8405EC0AB2CA9754B57C25AE3C726AAC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis [Roll Forward]</link:label>
    <link:loc xlink:href="abus-20190930.xsd#abus_FairValueLiabilitiesMeasuredonRecurringBasisRollForward" xlink:label="loc_abus_FairValueLiabilitiesMeasuredonRecurringBasisRollForward_8405EC0AB2CA9754B57C25AE3C726AAC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_FairValueLiabilitiesMeasuredonRecurringBasisRollForward_8405EC0AB2CA9754B57C25AE3C726AAC" xlink:to="lab_abus_FairValueLiabilitiesMeasuredonRecurringBasisRollForward_8405EC0AB2CA9754B57C25AE3C726AAC" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_3442DA15CD3F057FB2F125AE3C72FA68_periodStartLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_3442DA15CD3F057FB2F125AE3C72FA68" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Liability at beginning of the period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_3442DA15CD3F057FB2F125AE3C72FA68" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_3442DA15CD3F057FB2F125AE3C72FA68" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_3442DA15CD3F057FB2F125AE3C72FA68" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_F1386400DB05BA10F4D325AE3C735FCD_netLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_F1386400DB05BA10F4D325AE3C735FCD" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xml:lang="en-US">Increase (decrease) in fair value of liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_F1386400DB05BA10F4D325AE3C735FCD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_F1386400DB05BA10F4D325AE3C735FCD" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_F1386400DB05BA10F4D325AE3C735FCD" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_68AA631C9258C767FFA925AE3C73E147_periodEndLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_68AA631C9258C767FFA925AE3C73E147" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Liability at end of the period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_68AA631C9258C767FFA925AE3C73E147" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_68AA631C9258C767FFA925AE3C73E147" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_68AA631C9258C767FFA925AE3C73E147" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_6E713B7867C6C308D4B422A5BCB6555F_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_6E713B7867C6C308D4B422A5BCB6555F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_6E713B7867C6C308D4B422A5BCB6555F_label_en-US" xlink:label="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_6E713B7867C6C308D4B422A5BCB6555F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_6E713B7867C6C308D4B422A5BCB6555F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_6E713B7867C6C308D4B422A5BCB6555F" xlink:to="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_6E713B7867C6C308D4B422A5BCB6555F" xlink:type="arc" />
    <link:label id="lab_srt_ProductOrServiceAxis_1F7E2172D911C5D9196822A5BCB86085_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis_1F7E2172D911C5D9196822A5BCB86085" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_1F7E2172D911C5D9196822A5BCB86085_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis_1F7E2172D911C5D9196822A5BCB86085" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_1F7E2172D911C5D9196822A5BCB86085" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis_1F7E2172D911C5D9196822A5BCB86085" xlink:to="lab_srt_ProductOrServiceAxis_1F7E2172D911C5D9196822A5BCB86085" xlink:type="arc" />
    <link:label id="lab_srt_ProductsAndServicesDomain_036BB1B44DE71349C06722A5BCB86A0D_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain_036BB1B44DE71349C06722A5BCB86A0D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_036BB1B44DE71349C06722A5BCB86A0D_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain_036BB1B44DE71349C06722A5BCB86A0D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_036BB1B44DE71349C06722A5BCB86A0D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain_036BB1B44DE71349C06722A5BCB86A0D" xlink:to="lab_srt_ProductsAndServicesDomain_036BB1B44DE71349C06722A5BCB86A0D" xlink:type="arc" />
    <link:label id="lab_us-gaap_RoyaltyMember_17C7EC99BAC5C8A7244822D204428E4F_terseLabel_en-US" xlink:label="lab_us-gaap_RoyaltyMember_17C7EC99BAC5C8A7244822D204428E4F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalties</link:label>
    <link:label id="lab_us-gaap_RoyaltyMember_17C7EC99BAC5C8A7244822D204428E4F_label_en-US" xlink:label="lab_us-gaap_RoyaltyMember_17C7EC99BAC5C8A7244822D204428E4F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RoyaltyMember" xlink:label="loc_us-gaap_RoyaltyMember_17C7EC99BAC5C8A7244822D204428E4F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyMember_17C7EC99BAC5C8A7244822D204428E4F" xlink:to="lab_us-gaap_RoyaltyMember_17C7EC99BAC5C8A7244822D204428E4F" xlink:type="arc" />
    <link:label id="lab_us-gaap_LicenseMember_B1B833069F729F20821822D39FE2A387_terseLabel_en-US" xlink:label="lab_us-gaap_LicenseMember_B1B833069F729F20821822D39FE2A387" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License</link:label>
    <link:label id="lab_us-gaap_LicenseMember_B1B833069F729F20821822D39FE2A387_label_en-US" xlink:label="lab_us-gaap_LicenseMember_B1B833069F729F20821822D39FE2A387" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LicenseMember" xlink:label="loc_us-gaap_LicenseMember_B1B833069F729F20821822D39FE2A387" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicenseMember_B1B833069F729F20821822D39FE2A387" xlink:to="lab_us-gaap_LicenseMember_B1B833069F729F20821822D39FE2A387" xlink:type="arc" />
    <link:label id="lab_abus_GritstoneMember_A851292A3F049A92FC3F22A5BCB9E62D_terseLabel_en-US" xlink:label="lab_abus_GritstoneMember_A851292A3F049A92FC3F22A5BCB9E62D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gritstone</link:label>
    <link:label id="lab_abus_GritstoneMember_A851292A3F049A92FC3F22A5BCB9E62D_label_en-US" xlink:label="lab_abus_GritstoneMember_A851292A3F049A92FC3F22A5BCB9E62D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gritstone [Member]</link:label>
    <link:label id="lab_abus_GritstoneMember_A851292A3F049A92FC3F22A5BCB9E62D_documentation_en-US" xlink:label="lab_abus_GritstoneMember_A851292A3F049A92FC3F22A5BCB9E62D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Gritstone [Member]</link:label>
    <link:loc xlink:href="abus-20190930.xsd#abus_GritstoneMember" xlink:label="loc_abus_GritstoneMember_A851292A3F049A92FC3F22A5BCB9E62D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_GritstoneMember_A851292A3F049A92FC3F22A5BCB9E62D" xlink:to="lab_abus_GritstoneMember_A851292A3F049A92FC3F22A5BCB9E62D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_3456F50925F320BC753022A5BCB95442_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_3456F50925F320BC753022A5BCB95442" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others [Line Items]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_3456F50925F320BC753022A5BCB95442_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_3456F50925F320BC753022A5BCB95442" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_3456F50925F320BC753022A5BCB95442" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_3456F50925F320BC753022A5BCB95442" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_3456F50925F320BC753022A5BCB95442" xlink:type="arc" />
    <link:label id="lab_us-gaap_Revenues_D59D1B732FDE9F262C9322A5BCBA5796_terseLabel_en-US" xlink:label="lab_us-gaap_Revenues_D59D1B732FDE9F262C9322A5BCBA5796" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_Revenues_D59D1B732FDE9F262C9322A5BCBA5796_label_en-US" xlink:label="lab_us-gaap_Revenues_D59D1B732FDE9F262C9322A5BCBA5796" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_D59D1B732FDE9F262C9322A5BCBA5796" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues_D59D1B732FDE9F262C9322A5BCBA5796" xlink:to="lab_us-gaap_Revenues_D59D1B732FDE9F262C9322A5BCBA5796" xlink:type="arc" />
    <link:label id="lab_abus_ContingenciesandCommitmentsTable_469E5A584B3DF7581FE522A5BCC21207_terseLabel_en-US" xlink:label="lab_abus_ContingenciesandCommitmentsTable_469E5A584B3DF7581FE522A5BCC21207" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingencies and Commitments [Table]</link:label>
    <link:label id="lab_abus_ContingenciesandCommitmentsTable_469E5A584B3DF7581FE522A5BCC21207_label_en-US" xlink:label="lab_abus_ContingenciesandCommitmentsTable_469E5A584B3DF7581FE522A5BCC21207" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingencies and Commitments [Table]</link:label>
    <link:label id="lab_abus_ContingenciesandCommitmentsTable_469E5A584B3DF7581FE522A5BCC21207_documentation_en-US" xlink:label="lab_abus_ContingenciesandCommitmentsTable_469E5A584B3DF7581FE522A5BCC21207" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" />
    <link:loc xlink:href="abus-20190930.xsd#abus_ContingenciesandCommitmentsTable" xlink:label="loc_abus_ContingenciesandCommitmentsTable_469E5A584B3DF7581FE522A5BCC21207" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_ContingenciesandCommitmentsTable_469E5A584B3DF7581FE522A5BCC21207" xlink:to="lab_abus_ContingenciesandCommitmentsTable_469E5A584B3DF7581FE522A5BCC21207" xlink:type="arc" />
    <link:label id="lab_srt_LitigationCaseAxis_515521503F6AEAA157C522A5BCC62DE0_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseAxis_515521503F6AEAA157C522A5BCC62DE0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:label id="lab_srt_LitigationCaseAxis_515521503F6AEAA157C522A5BCC62DE0_label_en-US" xlink:label="lab_srt_LitigationCaseAxis_515521503F6AEAA157C522A5BCC62DE0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_LitigationCaseAxis" xlink:label="loc_srt_LitigationCaseAxis_515521503F6AEAA157C522A5BCC62DE0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseAxis_515521503F6AEAA157C522A5BCC62DE0" xlink:to="lab_srt_LitigationCaseAxis_515521503F6AEAA157C522A5BCC62DE0" xlink:type="arc" />
    <link:label id="lab_srt_LitigationCaseTypeDomain_27BA4CDA31657FF57E9422A5BCC635A2_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain_27BA4CDA31657FF57E9422A5BCC635A2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:label id="lab_srt_LitigationCaseTypeDomain_27BA4CDA31657FF57E9422A5BCC635A2_label_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain_27BA4CDA31657FF57E9422A5BCC635A2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_LitigationCaseTypeDomain" xlink:label="loc_srt_LitigationCaseTypeDomain_27BA4CDA31657FF57E9422A5BCC635A2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseTypeDomain_27BA4CDA31657FF57E9422A5BCC635A2" xlink:to="lab_srt_LitigationCaseTypeDomain_27BA4CDA31657FF57E9422A5BCC635A2" xlink:type="arc" />
    <link:label id="lab_abus_ArbitrationWithTheUniversityOfBritishColumbiaMember_B03736938A46211554E622A5BCC6E401_terseLabel_en-US" xlink:label="lab_abus_ArbitrationWithTheUniversityOfBritishColumbiaMember_B03736938A46211554E622A5BCC6E401" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Arbitration with the University of British Columbia</link:label>
    <link:label id="lab_abus_ArbitrationWithTheUniversityOfBritishColumbiaMember_B03736938A46211554E622A5BCC6E401_label_en-US" xlink:label="lab_abus_ArbitrationWithTheUniversityOfBritishColumbiaMember_B03736938A46211554E622A5BCC6E401" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Arbitration With The University Of British Columbia [Member]</link:label>
    <link:label id="lab_abus_ArbitrationWithTheUniversityOfBritishColumbiaMember_B03736938A46211554E622A5BCC6E401_documentation_en-US" xlink:label="lab_abus_ArbitrationWithTheUniversityOfBritishColumbiaMember_B03736938A46211554E622A5BCC6E401" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information related to arbitration with the University of British Columbia.</link:label>
    <link:loc xlink:href="abus-20190930.xsd#abus_ArbitrationWithTheUniversityOfBritishColumbiaMember" xlink:label="loc_abus_ArbitrationWithTheUniversityOfBritishColumbiaMember_B03736938A46211554E622A5BCC6E401" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_ArbitrationWithTheUniversityOfBritishColumbiaMember_B03736938A46211554E622A5BCC6E401" xlink:to="lab_abus_ArbitrationWithTheUniversityOfBritishColumbiaMember_B03736938A46211554E622A5BCC6E401" xlink:type="arc" />
    <link:label id="lab_abus_BlumbergandDrexelMember_4FAB4DB332A4ADF5597322A5BCC4BF78_terseLabel_en-US" xlink:label="lab_abus_BlumbergandDrexelMember_4FAB4DB332A4ADF5597322A5BCC4BF78" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Blumberg and Drexel</link:label>
    <link:label id="lab_abus_BlumbergandDrexelMember_4FAB4DB332A4ADF5597322A5BCC4BF78_label_en-US" xlink:label="lab_abus_BlumbergandDrexelMember_4FAB4DB332A4ADF5597322A5BCC4BF78" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Blumberg and Drexel [Member]</link:label>
    <link:label id="lab_abus_BlumbergandDrexelMember_4FAB4DB332A4ADF5597322A5BCC4BF78_documentation_en-US" xlink:label="lab_abus_BlumbergandDrexelMember_4FAB4DB332A4ADF5597322A5BCC4BF78" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Blumberg and Drexel [Member]</link:label>
    <link:loc xlink:href="abus-20190930.xsd#abus_BlumbergandDrexelMember" xlink:label="loc_abus_BlumbergandDrexelMember_4FAB4DB332A4ADF5597322A5BCC4BF78" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_BlumbergandDrexelMember_4FAB4DB332A4ADF5597322A5BCC4BF78" xlink:to="lab_abus_BlumbergandDrexelMember_4FAB4DB332A4ADF5597322A5BCC4BF78" xlink:type="arc" />
    <link:label id="lab_abus_BlumbergMember_C1FF69089AE9B9E3B4E622A5BCC4DA00_terseLabel_en-US" xlink:label="lab_abus_BlumbergMember_C1FF69089AE9B9E3B4E622A5BCC4DA00" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Blumberg</link:label>
    <link:label id="lab_abus_BlumbergMember_C1FF69089AE9B9E3B4E622A5BCC4DA00_label_en-US" xlink:label="lab_abus_BlumbergMember_C1FF69089AE9B9E3B4E622A5BCC4DA00" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Blumberg [Member]</link:label>
    <link:label id="lab_abus_BlumbergMember_C1FF69089AE9B9E3B4E622A5BCC4DA00_documentation_en-US" xlink:label="lab_abus_BlumbergMember_C1FF69089AE9B9E3B4E622A5BCC4DA00" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Blumberg</link:label>
    <link:loc xlink:href="abus-20190930.xsd#abus_BlumbergMember" xlink:label="loc_abus_BlumbergMember_C1FF69089AE9B9E3B4E622A5BCC4DA00" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_BlumbergMember_C1FF69089AE9B9E3B4E622A5BCC4DA00" xlink:to="lab_abus_BlumbergMember_C1FF69089AE9B9E3B4E622A5BCC4DA00" xlink:type="arc" />
    <link:label id="lab_abus_ArbutusInc.Member_F8D75BDCA0AA6F978C3022A5BCC5FE67_terseLabel_en-US" xlink:label="lab_abus_ArbutusInc.Member_F8D75BDCA0AA6F978C3022A5BCC5FE67" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Arbutus Inc.</link:label>
    <link:label id="lab_abus_ArbutusInc.Member_F8D75BDCA0AA6F978C3022A5BCC5FE67_label_en-US" xlink:label="lab_abus_ArbutusInc.Member_F8D75BDCA0AA6F978C3022A5BCC5FE67" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Arbutus Inc. [Member]</link:label>
    <link:label id="lab_abus_ArbutusInc.Member_F8D75BDCA0AA6F978C3022A5BCC5FE67_documentation_en-US" xlink:label="lab_abus_ArbutusInc.Member_F8D75BDCA0AA6F978C3022A5BCC5FE67" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Arbutus Inc. [Member]</link:label>
    <link:loc xlink:href="abus-20190930.xsd#abus_ArbutusInc.Member" xlink:label="loc_abus_ArbutusInc.Member_F8D75BDCA0AA6F978C3022A5BCC5FE67" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_ArbutusInc.Member_F8D75BDCA0AA6F978C3022A5BCC5FE67" xlink:to="lab_abus_ArbutusInc.Member_F8D75BDCA0AA6F978C3022A5BCC5FE67" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_7536FC64FDD229A5D1A422A5BCC6B669_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis_7536FC64FDD229A5D1A422A5BCC6B669" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_7536FC64FDD229A5D1A422A5BCC6B669_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis_7536FC64FDD229A5D1A422A5BCC6B669" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_7536FC64FDD229A5D1A422A5BCC6B669" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_7536FC64FDD229A5D1A422A5BCC6B669" xlink:to="lab_us-gaap_BusinessAcquisitionAxis_7536FC64FDD229A5D1A422A5BCC6B669" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_DA8E4A58ED75A580B3FB22A5BCC65437_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain_DA8E4A58ED75A580B3FB22A5BCC65437" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_DA8E4A58ED75A580B3FB22A5BCC65437_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain_DA8E4A58ED75A580B3FB22A5BCC65437" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_DA8E4A58ED75A580B3FB22A5BCC65437" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_DA8E4A58ED75A580B3FB22A5BCC65437" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain_DA8E4A58ED75A580B3FB22A5BCC65437" xlink:type="arc" />
    <link:label id="lab_abus_EnantigenMember_C886B96468F34BE2145E22A5BCC73395_terseLabel_en-US" xlink:label="lab_abus_EnantigenMember_C886B96468F34BE2145E22A5BCC73395" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Enantigen</link:label>
    <link:label id="lab_abus_EnantigenMember_C886B96468F34BE2145E22A5BCC73395_label_en-US" xlink:label="lab_abus_EnantigenMember_C886B96468F34BE2145E22A5BCC73395" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Enantigen [Member]</link:label>
    <link:label id="lab_abus_EnantigenMember_C886B96468F34BE2145E22A5BCC73395_documentation_en-US" xlink:label="lab_abus_EnantigenMember_C886B96468F34BE2145E22A5BCC73395" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Enantigen</link:label>
    <link:loc xlink:href="abus-20190930.xsd#abus_EnantigenMember" xlink:label="loc_abus_EnantigenMember_C886B96468F34BE2145E22A5BCC73395" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_EnantigenMember_C886B96468F34BE2145E22A5BCC73395" xlink:to="lab_abus_EnantigenMember_C886B96468F34BE2145E22A5BCC73395" xlink:type="arc" />
    <link:label id="lab_abus_ContingenciesandCommitmentsLineItems_1D7800D87E3399DFC45B22A5BCC7D316_terseLabel_en-US" xlink:label="lab_abus_ContingenciesandCommitmentsLineItems_1D7800D87E3399DFC45B22A5BCC7D316" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingencies and Commitments [Line Items]</link:label>
    <link:label id="lab_abus_ContingenciesandCommitmentsLineItems_1D7800D87E3399DFC45B22A5BCC7D316_label_en-US" xlink:label="lab_abus_ContingenciesandCommitmentsLineItems_1D7800D87E3399DFC45B22A5BCC7D316" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingencies and Commitments [Line Items]</link:label>
    <link:label id="lab_abus_ContingenciesandCommitmentsLineItems_1D7800D87E3399DFC45B22A5BCC7D316_documentation_en-US" xlink:label="lab_abus_ContingenciesandCommitmentsLineItems_1D7800D87E3399DFC45B22A5BCC7D316" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" />
    <link:loc xlink:href="abus-20190930.xsd#abus_ContingenciesandCommitmentsLineItems" xlink:label="loc_abus_ContingenciesandCommitmentsLineItems_1D7800D87E3399DFC45B22A5BCC7D316" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_ContingenciesandCommitmentsLineItems_1D7800D87E3399DFC45B22A5BCC7D316" xlink:to="lab_abus_ContingenciesandCommitmentsLineItems_1D7800D87E3399DFC45B22A5BCC7D316" xlink:type="arc" />
    <link:label id="lab_us-gaap_LossContingencyDamagesSoughtValue_75601D1BBC9B42FC033322A5BCC78D8F_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyDamagesSoughtValue_75601D1BBC9B42FC033322A5BCC78D8F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss contingency, damages sought for allegedly unpaid royalties</link:label>
    <link:label id="lab_us-gaap_LossContingencyDamagesSoughtValue_75601D1BBC9B42FC033322A5BCC78D8F_label_en-US" xlink:label="lab_us-gaap_LossContingencyDamagesSoughtValue_75601D1BBC9B42FC033322A5BCC78D8F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency, Damages Sought, Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LossContingencyDamagesSoughtValue" xlink:label="loc_us-gaap_LossContingencyDamagesSoughtValue_75601D1BBC9B42FC033322A5BCC78D8F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyDamagesSoughtValue_75601D1BBC9B42FC033322A5BCC78D8F" xlink:to="lab_us-gaap_LossContingencyDamagesSoughtValue_75601D1BBC9B42FC033322A5BCC78D8F" xlink:type="arc" />
    <link:label id="lab_abus_Numberoflegalproceedings_DAD6BBFED2AD096A544C22A5BCC77AFB_terseLabel_en-US" xlink:label="lab_abus_Numberoflegalproceedings_DAD6BBFED2AD096A544C22A5BCC77AFB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of legal proceedings</link:label>
    <link:label id="lab_abus_Numberoflegalproceedings_DAD6BBFED2AD096A544C22A5BCC77AFB_label_en-US" xlink:label="lab_abus_Numberoflegalproceedings_DAD6BBFED2AD096A544C22A5BCC77AFB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of legal proceedings</link:label>
    <link:label id="lab_abus_Numberoflegalproceedings_DAD6BBFED2AD096A544C22A5BCC77AFB_documentation_en-US" xlink:label="lab_abus_Numberoflegalproceedings_DAD6BBFED2AD096A544C22A5BCC77AFB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of legal proceedings</link:label>
    <link:loc xlink:href="abus-20190930.xsd#abus_Numberoflegalproceedings" xlink:label="loc_abus_Numberoflegalproceedings_DAD6BBFED2AD096A544C22A5BCC77AFB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_Numberoflegalproceedings_DAD6BBFED2AD096A544C22A5BCC77AFB" xlink:to="lab_abus_Numberoflegalproceedings_DAD6BBFED2AD096A544C22A5BCC77AFB" xlink:type="arc" />
    <link:label id="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty_DAA29A13D17D75F5861222BB2A36145A_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty_DAA29A13D17D75F5861222BB2A36145A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Arbitration settlement, amount awarded to other party</link:label>
    <link:label id="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty_DAA29A13D17D75F5861222BB2A36145A_label_en-US" xlink:label="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty_DAA29A13D17D75F5861222BB2A36145A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Settlement, Amount Awarded to Other Party</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_DAA29A13D17D75F5861222BB2A36145A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_DAA29A13D17D75F5861222BB2A36145A" xlink:to="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty_DAA29A13D17D75F5861222BB2A36145A" xlink:type="arc" />
    <link:label id="lab_us-gaap_LitigationSettlementInterest_E078D8E941C5180F0BB822BC234E05B7_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationSettlementInterest_E078D8E941C5180F0BB822BC234E05B7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Arbitration settlement interest</link:label>
    <link:label id="lab_us-gaap_LitigationSettlementInterest_E078D8E941C5180F0BB822BC234E05B7_label_en-US" xlink:label="lab_us-gaap_LitigationSettlementInterest_E078D8E941C5180F0BB822BC234E05B7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Settlement Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LitigationSettlementInterest" xlink:label="loc_us-gaap_LitigationSettlementInterest_E078D8E941C5180F0BB822BC234E05B7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationSettlementInterest_E078D8E941C5180F0BB822BC234E05B7" xlink:to="lab_us-gaap_LitigationSettlementInterest_E078D8E941C5180F0BB822BC234E05B7" xlink:type="arc" />
    <link:label id="lab_us-gaap_LossContingencyLossInPeriod_2930139CC65D8CF397B022C4AADC80E9_verboseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyLossInPeriod_2930139CC65D8CF397B022C4AADC80E9" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Arbitration settlement charges</link:label>
    <link:label id="lab_us-gaap_LossContingencyLossInPeriod_2930139CC65D8CF397B022C4AADC80E9_label_en-US" xlink:label="lab_us-gaap_LossContingencyLossInPeriod_2930139CC65D8CF397B022C4AADC80E9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency, Loss in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LossContingencyLossInPeriod" xlink:label="loc_us-gaap_LossContingencyLossInPeriod_2930139CC65D8CF397B022C4AADC80E9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyLossInPeriod_2930139CC65D8CF397B022C4AADC80E9" xlink:to="lab_us-gaap_LossContingencyLossInPeriod_2930139CC65D8CF397B022C4AADC80E9" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsForLegalSettlements_ABEC9B16DBD66753ABF722BD2E72366D_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForLegalSettlements_ABEC9B16DBD66753ABF722BD2E72366D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Arbitration settlement payment</link:label>
    <link:label id="lab_us-gaap_PaymentsForLegalSettlements_ABEC9B16DBD66753ABF722BD2E72366D_label_en-US" xlink:label="lab_us-gaap_PaymentsForLegalSettlements_ABEC9B16DBD66753ABF722BD2E72366D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments for Legal Settlements</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsForLegalSettlements" xlink:label="loc_us-gaap_PaymentsForLegalSettlements_ABEC9B16DBD66753ABF722BD2E72366D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForLegalSettlements_ABEC9B16DBD66753ABF722BD2E72366D" xlink:to="lab_us-gaap_PaymentsForLegalSettlements_ABEC9B16DBD66753ABF722BD2E72366D" xlink:type="arc" />
    <link:label id="lab_us-gaap_LossContingencyEstimateOfPossibleLoss_A2405E7AC47DB7354A4522C253757E9C_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyEstimateOfPossibleLoss_A2405E7AC47DB7354A4522C253757E9C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimate of potential arbitration award for costs and attorney's fees</link:label>
    <link:label id="lab_us-gaap_LossContingencyEstimateOfPossibleLoss_A2405E7AC47DB7354A4522C253757E9C_label_en-US" xlink:label="lab_us-gaap_LossContingencyEstimateOfPossibleLoss_A2405E7AC47DB7354A4522C253757E9C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency, Estimate of Possible Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:label="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_A2405E7AC47DB7354A4522C253757E9C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_A2405E7AC47DB7354A4522C253757E9C" xlink:to="lab_us-gaap_LossContingencyEstimateOfPossibleLoss_A2405E7AC47DB7354A4522C253757E9C" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_CCF3FD6D5E2ACCF9B22B22A5BCC83FC3_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_CCF3FD6D5E2ACCF9B22B22A5BCC83FC3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Business combination, high end of payment upon achievement of certain triggering events</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_CCF3FD6D5E2ACCF9B22B22A5BCC83FC3_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_CCF3FD6D5E2ACCF9B22B22A5BCC83FC3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_CCF3FD6D5E2ACCF9B22B22A5BCC83FC3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_CCF3FD6D5E2ACCF9B22B22A5BCC83FC3" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_CCF3FD6D5E2ACCF9B22B22A5BCC83FC3" xlink:type="arc" />
    <link:label id="lab_abus_NumberOfProductsCoveredByPatentAcquiredUnderAgreement_8ECD01BCE34600CEDF9E22A5BCC87F9D_terseLabel_en-US" xlink:label="lab_abus_NumberOfProductsCoveredByPatentAcquiredUnderAgreement_8ECD01BCE34600CEDF9E22A5BCC87F9D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of products covered by patent acquired under the agreement</link:label>
    <link:label id="lab_abus_NumberOfProductsCoveredByPatentAcquiredUnderAgreement_8ECD01BCE34600CEDF9E22A5BCC87F9D_label_en-US" xlink:label="lab_abus_NumberOfProductsCoveredByPatentAcquiredUnderAgreement_8ECD01BCE34600CEDF9E22A5BCC87F9D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Products Covered By Patent Acquired Under Agreement</link:label>
    <link:label id="lab_abus_NumberOfProductsCoveredByPatentAcquiredUnderAgreement_8ECD01BCE34600CEDF9E22A5BCC87F9D_documentation_en-US" xlink:label="lab_abus_NumberOfProductsCoveredByPatentAcquiredUnderAgreement_8ECD01BCE34600CEDF9E22A5BCC87F9D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Products Covered By Patent Acquired Under Agreement</link:label>
    <link:loc xlink:href="abus-20190930.xsd#abus_NumberOfProductsCoveredByPatentAcquiredUnderAgreement" xlink:label="loc_abus_NumberOfProductsCoveredByPatentAcquiredUnderAgreement_8ECD01BCE34600CEDF9E22A5BCC87F9D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_NumberOfProductsCoveredByPatentAcquiredUnderAgreement_8ECD01BCE34600CEDF9E22A5BCC87F9D" xlink:to="lab_abus_NumberOfProductsCoveredByPatentAcquiredUnderAgreement_8ECD01BCE34600CEDF9E22A5BCC87F9D" xlink:type="arc" />
    <link:label id="lab_abus_LicenseAgreementMaximumDevelopmentAndRegulatoryMilestonePaymentsPerLicense_39292316DAFDE26DC8F022A5BCC893C8_verboseLabel_en-US" xlink:label="lab_abus_LicenseAgreementMaximumDevelopmentAndRegulatoryMilestonePaymentsPerLicense_39292316DAFDE26DC8F022A5BCC893C8" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Development and regulatory milestones payment per licensed compound series, maximum</link:label>
    <link:label id="lab_abus_LicenseAgreementMaximumDevelopmentAndRegulatoryMilestonePaymentsPerLicense_39292316DAFDE26DC8F022A5BCC893C8_label_en-US" xlink:label="lab_abus_LicenseAgreementMaximumDevelopmentAndRegulatoryMilestonePaymentsPerLicense_39292316DAFDE26DC8F022A5BCC893C8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License Agreement Maximum Development And Regulatory Milestone Payments Per License</link:label>
    <link:label id="lab_abus_LicenseAgreementMaximumDevelopmentAndRegulatoryMilestonePaymentsPerLicense_39292316DAFDE26DC8F022A5BCC893C8_documentation_en-US" xlink:label="lab_abus_LicenseAgreementMaximumDevelopmentAndRegulatoryMilestonePaymentsPerLicense_39292316DAFDE26DC8F022A5BCC893C8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">License Agreement, Maximum Development and Regulatory Milestone Payments Per License</link:label>
    <link:loc xlink:href="abus-20190930.xsd#abus_LicenseAgreementMaximumDevelopmentAndRegulatoryMilestonePaymentsPerLicense" xlink:label="loc_abus_LicenseAgreementMaximumDevelopmentAndRegulatoryMilestonePaymentsPerLicense_39292316DAFDE26DC8F022A5BCC893C8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_LicenseAgreementMaximumDevelopmentAndRegulatoryMilestonePaymentsPerLicense_39292316DAFDE26DC8F022A5BCC893C8" xlink:to="lab_abus_LicenseAgreementMaximumDevelopmentAndRegulatoryMilestonePaymentsPerLicense_39292316DAFDE26DC8F022A5BCC893C8" xlink:type="arc" />
    <link:label id="lab_abus_LicenseAgreementMaximumDevelopmentAndRegulatoryMilestonePaymentsPerRoyalty_2D21ED2AD0F2E46DEEF822A5BCC8B75A_terseLabel_en-US" xlink:label="lab_abus_LicenseAgreementMaximumDevelopmentAndRegulatoryMilestonePaymentsPerRoyalty_2D21ED2AD0F2E46DEEF822A5BCC8B75A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Development and regulatory milestones payment per royalty, maximum</link:label>
    <link:label id="lab_abus_LicenseAgreementMaximumDevelopmentAndRegulatoryMilestonePaymentsPerRoyalty_2D21ED2AD0F2E46DEEF822A5BCC8B75A_label_en-US" xlink:label="lab_abus_LicenseAgreementMaximumDevelopmentAndRegulatoryMilestonePaymentsPerRoyalty_2D21ED2AD0F2E46DEEF822A5BCC8B75A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License Agreement Maximum Development And Regulatory Milestone Payments Per Royalty</link:label>
    <link:label id="lab_abus_LicenseAgreementMaximumDevelopmentAndRegulatoryMilestonePaymentsPerRoyalty_2D21ED2AD0F2E46DEEF822A5BCC8B75A_documentation_en-US" xlink:label="lab_abus_LicenseAgreementMaximumDevelopmentAndRegulatoryMilestonePaymentsPerRoyalty_2D21ED2AD0F2E46DEEF822A5BCC8B75A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">License Agreement Maximum Development And Regulatory Royalty Payment per Royalty</link:label>
    <link:loc xlink:href="abus-20190930.xsd#abus_LicenseAgreementMaximumDevelopmentAndRegulatoryMilestonePaymentsPerRoyalty" xlink:label="loc_abus_LicenseAgreementMaximumDevelopmentAndRegulatoryMilestonePaymentsPerRoyalty_2D21ED2AD0F2E46DEEF822A5BCC8B75A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_LicenseAgreementMaximumDevelopmentAndRegulatoryMilestonePaymentsPerRoyalty_2D21ED2AD0F2E46DEEF822A5BCC8B75A" xlink:to="lab_abus_LicenseAgreementMaximumDevelopmentAndRegulatoryMilestonePaymentsPerRoyalty_2D21ED2AD0F2E46DEEF822A5BCC8B75A" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_A581717BF0C47642B23122A5BCC82297_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_A581717BF0C47642B23122A5BCC82297" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value of contingent consideration</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_A581717BF0C47642B23122A5BCC82297" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_A581717BF0C47642B23122A5BCC82297" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_A581717BF0C47642B23122A5BCC82297" xlink:type="arc" />
    <link:label id="lab_abus_NumberofPatentLicenses_CE78E8FB16505F59C32222A5BCC8F95A_terseLabel_en-US" xlink:label="lab_abus_NumberofPatentLicenses_CE78E8FB16505F59C32222A5BCC8F95A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of patent license agreements</link:label>
    <link:label id="lab_abus_NumberofPatentLicenses_CE78E8FB16505F59C32222A5BCC8F95A_label_en-US" xlink:label="lab_abus_NumberofPatentLicenses_CE78E8FB16505F59C32222A5BCC8F95A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Patent Licenses</link:label>
    <link:label id="lab_abus_NumberofPatentLicenses_CE78E8FB16505F59C32222A5BCC8F95A_documentation_en-US" xlink:label="lab_abus_NumberofPatentLicenses_CE78E8FB16505F59C32222A5BCC8F95A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of Patent Licenses</link:label>
    <link:loc xlink:href="abus-20190930.xsd#abus_NumberofPatentLicenses" xlink:label="loc_abus_NumberofPatentLicenses_CE78E8FB16505F59C32222A5BCC8F95A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_NumberofPatentLicenses_CE78E8FB16505F59C32222A5BCC8F95A" xlink:to="lab_abus_NumberofPatentLicenses_CE78E8FB16505F59C32222A5BCC8F95A" xlink:type="arc" />
    <link:label id="lab_abus_ResearchFundingPeriod_67FC3B8D5C9C268A1E6C22A5BCC8E30A_verboseLabel_en-US" xlink:label="lab_abus_ResearchFundingPeriod_67FC3B8D5C9C268A1E6C22A5BCC8E30A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Research funding period</link:label>
    <link:label id="lab_abus_ResearchFundingPeriod_67FC3B8D5C9C268A1E6C22A5BCC8E30A_label_en-US" xlink:label="lab_abus_ResearchFundingPeriod_67FC3B8D5C9C268A1E6C22A5BCC8E30A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research Funding Period</link:label>
    <link:label id="lab_abus_ResearchFundingPeriod_67FC3B8D5C9C268A1E6C22A5BCC8E30A_documentation_en-US" xlink:label="lab_abus_ResearchFundingPeriod_67FC3B8D5C9C268A1E6C22A5BCC8E30A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research Funding Period</link:label>
    <link:loc xlink:href="abus-20190930.xsd#abus_ResearchFundingPeriod" xlink:label="loc_abus_ResearchFundingPeriod_67FC3B8D5C9C268A1E6C22A5BCC8E30A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_ResearchFundingPeriod_67FC3B8D5C9C268A1E6C22A5BCC8E30A" xlink:to="lab_abus_ResearchFundingPeriod_67FC3B8D5C9C268A1E6C22A5BCC8E30A" xlink:type="arc" />
    <link:label id="lab_abus_ContractualObligationAmountOfResearchFundingPerYear_1F79143E209E0E9D0A0C22A5BCC991F8_verboseLabel_en-US" xlink:label="lab_abus_ContractualObligationAmountOfResearchFundingPerYear_1F79143E209E0E9D0A0C22A5BCC991F8" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Research funding per year under research collaboration and funding agreement</link:label>
    <link:label id="lab_abus_ContractualObligationAmountOfResearchFundingPerYear_1F79143E209E0E9D0A0C22A5BCC991F8_label_en-US" xlink:label="lab_abus_ContractualObligationAmountOfResearchFundingPerYear_1F79143E209E0E9D0A0C22A5BCC991F8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contractual Obligation Amount Of Research Funding Per Year</link:label>
    <link:label id="lab_abus_ContractualObligationAmountOfResearchFundingPerYear_1F79143E209E0E9D0A0C22A5BCC991F8_documentation_en-US" xlink:label="lab_abus_ContractualObligationAmountOfResearchFundingPerYear_1F79143E209E0E9D0A0C22A5BCC991F8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contractual Obligation, Amount of Research Funding Per Year</link:label>
    <link:loc xlink:href="abus-20190930.xsd#abus_ContractualObligationAmountOfResearchFundingPerYear" xlink:label="loc_abus_ContractualObligationAmountOfResearchFundingPerYear_1F79143E209E0E9D0A0C22A5BCC991F8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_ContractualObligationAmountOfResearchFundingPerYear_1F79143E209E0E9D0A0C22A5BCC991F8" xlink:to="lab_abus_ContractualObligationAmountOfResearchFundingPerYear_1F79143E209E0E9D0A0C22A5BCC991F8" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsPayableTradeCurrent_47350D0A6980A6E02C8537DF0CE42F39_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableTradeCurrent_0CA628B9898F5E28B4C3A98D331D140A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trade accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableTradeCurrent_47350D0A6980A6E02C8537DF0CE42F39_label_en-US" xlink:label="lab_us-gaap_AccountsPayableTradeCurrent_0CA628B9898F5E28B4C3A98D331D140A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Trade, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="loc_us-gaap_AccountsPayableTradeCurrent_0CA628B9898F5E28B4C3A98D331D140A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableTradeCurrent_0CA628B9898F5E28B4C3A98D331D140A" xlink:to="lab_us-gaap_AccountsPayableTradeCurrent_0CA628B9898F5E28B4C3A98D331D140A" xlink:type="arc" />
    <link:label id="lab_abus_AccruedResearchAndDevelopment_F3C4C38CFCB649A6D72737DF0CE5A7FC_terseLabel_en-US" xlink:label="lab_abus_AccruedResearchAndDevelopment_EFF9523E1CF5575C9F9C4107B885E4A4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development accruals</link:label>
    <link:label id="lab_abus_AccruedResearchAndDevelopment_F3C4C38CFCB649A6D72737DF0CE5A7FC_label_en-US" xlink:label="lab_abus_AccruedResearchAndDevelopment_EFF9523E1CF5575C9F9C4107B885E4A4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Research And Development</link:label>
    <link:label id="lab_abus_AccruedResearchAndDevelopment_F3C4C38CFCB649A6D72737DF0CE5A7FC_documentation_en-US" xlink:label="lab_abus_AccruedResearchAndDevelopment_EFF9523E1CF5575C9F9C4107B885E4A4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research and development accruals</link:label>
    <link:loc xlink:href="abus-20190930.xsd#abus_AccruedResearchAndDevelopment" xlink:label="loc_abus_AccruedResearchAndDevelopment_EFF9523E1CF5575C9F9C4107B885E4A4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_AccruedResearchAndDevelopment_EFF9523E1CF5575C9F9C4107B885E4A4" xlink:to="lab_abus_AccruedResearchAndDevelopment_EFF9523E1CF5575C9F9C4107B885E4A4" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_48C00DD393089D0DC21437DF0CE5CBC5_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent_00ED3492128256EB8FFBE18906929D95" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Professional fee accruals</link:label>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_48C00DD393089D0DC21437DF0CE5CBC5_label_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent_00ED3492128256EB8FFBE18906929D95" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Professional Fees, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_00ED3492128256EB8FFBE18906929D95" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrent_00ED3492128256EB8FFBE18906929D95" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrent_00ED3492128256EB8FFBE18906929D95" xlink:type="arc" />
    <link:label id="lab_abus_AccruedPayrollCurrent_307F912E03758431ADA937DF0CE59AF8_terseLabel_en-US" xlink:label="lab_abus_AccruedPayrollCurrent_FDAC86D3B9265CA1B5F844061734F34F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payroll accruals</link:label>
    <link:label id="lab_abus_AccruedPayrollCurrent_307F912E03758431ADA937DF0CE59AF8_label_en-US" xlink:label="lab_abus_AccruedPayrollCurrent_FDAC86D3B9265CA1B5F844061734F34F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Payroll Current</link:label>
    <link:label id="lab_abus_AccruedPayrollCurrent_307F912E03758431ADA937DF0CE59AF8_documentation_en-US" xlink:label="lab_abus_AccruedPayrollCurrent_FDAC86D3B9265CA1B5F844061734F34F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued Payroll Current</link:label>
    <link:loc xlink:href="abus-20190930.xsd#abus_AccruedPayrollCurrent" xlink:label="loc_abus_AccruedPayrollCurrent_FDAC86D3B9265CA1B5F844061734F34F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_AccruedPayrollCurrent_FDAC86D3B9265CA1B5F844061734F34F" xlink:to="lab_abus_AccruedPayrollCurrent_FDAC86D3B9265CA1B5F844061734F34F" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_25F06E3A83BC98D8A67B37DF0CE55777_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent_CF02DD40698C5C3CBE726B11AA99737B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other accrued liabilities</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_25F06E3A83BC98D8A67B37DF0CE55777_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent_CF02DD40698C5C3CBE726B11AA99737B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_CF02DD40698C5C3CBE726B11AA99737B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent_CF02DD40698C5C3CBE726B11AA99737B" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent_CF02DD40698C5C3CBE726B11AA99737B" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_2FC2E21D0E3188185A3437DF0CE64A6B_totalLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_5E3B7DEFF3C05F3C8D43DCC662E2886A" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Accounts payable and accrued liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_5E3B7DEFF3C05F3C8D43DCC662E2886A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_5E3B7DEFF3C05F3C8D43DCC662E2886A" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_5E3B7DEFF3C05F3C8D43DCC662E2886A" xlink:type="arc" />
    <link:label id="lab_abus_LiabilitiesRelatedToSaleOfFutureRoyaltiesRollForwardTableTextBlock_3A4FDE242D06B9300A2822B97A6FF551_terseLabel_en-US" xlink:label="lab_abus_LiabilitiesRelatedToSaleOfFutureRoyaltiesRollForwardTableTextBlock_3A4FDE242D06B9300A2822B97A6FF551" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of activity related to the net liability from inception of the Agreement</link:label>
    <link:label id="lab_abus_LiabilitiesRelatedToSaleOfFutureRoyaltiesRollForwardTableTextBlock_3A4FDE242D06B9300A2822B97A6FF551_label_en-US" xlink:label="lab_abus_LiabilitiesRelatedToSaleOfFutureRoyaltiesRollForwardTableTextBlock_3A4FDE242D06B9300A2822B97A6FF551" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities Related To Sale Of Future Royalties Roll Forward [Table Text Block]</link:label>
    <link:label id="lab_abus_LiabilitiesRelatedToSaleOfFutureRoyaltiesRollForwardTableTextBlock_3A4FDE242D06B9300A2822B97A6FF551_documentation_en-US" xlink:label="lab_abus_LiabilitiesRelatedToSaleOfFutureRoyaltiesRollForwardTableTextBlock_3A4FDE242D06B9300A2822B97A6FF551" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Liabilities Related To Sale Of Future Royalties Roll Forward</link:label>
    <link:loc xlink:href="abus-20190930.xsd#abus_LiabilitiesRelatedToSaleOfFutureRoyaltiesRollForwardTableTextBlock" xlink:label="loc_abus_LiabilitiesRelatedToSaleOfFutureRoyaltiesRollForwardTableTextBlock_3A4FDE242D06B9300A2822B97A6FF551" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_LiabilitiesRelatedToSaleOfFutureRoyaltiesRollForwardTableTextBlock_3A4FDE242D06B9300A2822B97A6FF551" xlink:to="lab_abus_LiabilitiesRelatedToSaleOfFutureRoyaltiesRollForwardTableTextBlock_3A4FDE242D06B9300A2822B97A6FF551" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementAbstract_E0834E0D5E9805A5645041B4C440862A_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract_E0834E0D5E9805A5645041B4C440862A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_E0834E0D5E9805A5645041B4C440862A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract_E0834E0D5E9805A5645041B4C440862A" xlink:to="lab_us-gaap_IncomeStatementAbstract_E0834E0D5E9805A5645041B4C440862A" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenuesAbstract_A15F86861B9D1AD7E60441B4C440F52D_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract_A15F86861B9D1AD7E60441B4C440F52D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_A15F86861B9D1AD7E60441B4C440F52D_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract_A15F86861B9D1AD7E60441B4C440F52D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaap_RevenuesAbstract_A15F86861B9D1AD7E60441B4C440F52D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract_A15F86861B9D1AD7E60441B4C440F52D" xlink:to="lab_us-gaap_RevenuesAbstract_A15F86861B9D1AD7E60441B4C440F52D" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_C55E72F572DD755DF23C41B4C441B821_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract_C55E72F572DD755DF23C41B4C441B821" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_C55E72F572DD755DF23C41B4C441B821_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract_C55E72F572DD755DF23C41B4C441B821" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_C55E72F572DD755DF23C41B4C441B821" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract_C55E72F572DD755DF23C41B4C441B821" xlink:to="lab_us-gaap_OperatingExpensesAbstract_C55E72F572DD755DF23C41B4C441B821" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_DEAE03F50F7EDB15D3B441B4C4419293_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense_DEAE03F50F7EDB15D3B441B4C4419293" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_DEAE03F50F7EDB15D3B441B4C4419293_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense_DEAE03F50F7EDB15D3B441B4C4419293" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_DEAE03F50F7EDB15D3B441B4C4419293" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense_DEAE03F50F7EDB15D3B441B4C4419293" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense_DEAE03F50F7EDB15D3B441B4C4419293" xlink:type="arc" />
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_AFBA6E83562861110EB241B4C441D7BD_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense_AFBA6E83562861110EB241B4C441D7BD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_AFBA6E83562861110EB241B4C441D7BD_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense_AFBA6E83562861110EB241B4C441D7BD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_AFBA6E83562861110EB241B4C441D7BD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense_AFBA6E83562861110EB241B4C441D7BD" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense_AFBA6E83562861110EB241B4C441D7BD" xlink:type="arc" />
    <link:label id="lab_us-gaap_Depreciation_664A01BD474377D2BC4041B4C4414AF4_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation_664A01BD474377D2BC4041B4C4414AF4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation</link:label>
    <link:label id="lab_us-gaap_Depreciation_664A01BD474377D2BC4041B4C4414AF4_label_en-US" xlink:label="lab_us-gaap_Depreciation_664A01BD474377D2BC4041B4C4414AF4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_664A01BD474377D2BC4041B4C4414AF4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation_664A01BD474377D2BC4041B4C4414AF4" xlink:to="lab_us-gaap_Depreciation_664A01BD474377D2BC4041B4C4414AF4" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestructuringCharges_3075CD0D4B20A34A270041B4C441224F_verboseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges_3075CD0D4B20A34A270041B4C441224F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Site consolidation (note 8)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="loc_us-gaap_RestructuringCharges_3075CD0D4B20A34A270041B4C441224F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCharges_3075CD0D4B20A34A270041B4C441224F" xlink:to="lab_us-gaap_RestructuringCharges_3075CD0D4B20A34A270041B4C441224F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_32F18A9519510BE5987641B4C441E99B_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_32F18A9519510BE5987641B4C441E99B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment of intangible assets (note 6)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_32F18A9519510BE5987641B4C441E99B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_32F18A9519510BE5987641B4C441E99B" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_32F18A9519510BE5987641B4C441E99B" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_534B2A79E965631B78C341B4C4429BF2_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss_534B2A79E965631B78C341B4C4429BF2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment of goodwill (note 6)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_534B2A79E965631B78C341B4C4429BF2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairmentLoss_534B2A79E965631B78C341B4C4429BF2" xlink:to="lab_us-gaap_GoodwillImpairmentLoss_534B2A79E965631B78C341B4C4429BF2" xlink:type="arc" />
    <link:label id="lab_us-gaap_LossContingencyLossInPeriod_AD523730E9D49A33DD7A41B4C4427C58_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyLossInPeriod_AD523730E9D49A33DD7A41B4C4427C58" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Arbitration (note 10)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LossContingencyLossInPeriod" xlink:label="loc_us-gaap_LossContingencyLossInPeriod_AD523730E9D49A33DD7A41B4C4427C58" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyLossInPeriod_AD523730E9D49A33DD7A41B4C4427C58" xlink:to="lab_us-gaap_LossContingencyLossInPeriod_AD523730E9D49A33DD7A41B4C4427C58" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingExpenses_CA78E175C69A42EB1FBB41B4C4428E90_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses_CA78E175C69A42EB1FBB41B4C4428E90" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_CA78E175C69A42EB1FBB41B4C4428E90_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses_CA78E175C69A42EB1FBB41B4C4428E90" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_CA78E175C69A42EB1FBB41B4C4428E90" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses_CA78E175C69A42EB1FBB41B4C4428E90" xlink:to="lab_us-gaap_OperatingExpenses_CA78E175C69A42EB1FBB41B4C4428E90" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingIncomeLoss_364F3FBEDAC723AC511641B4C442B539_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss_364F3FBEDAC723AC511641B4C442B539" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_364F3FBEDAC723AC511641B4C442B539_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss_364F3FBEDAC723AC511641B4C442B539" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_364F3FBEDAC723AC511641B4C442B539" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss_364F3FBEDAC723AC511641B4C442B539" xlink:to="lab_us-gaap_OperatingIncomeLoss_364F3FBEDAC723AC511641B4C442B539" xlink:type="arc" />
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_E52FB86E2BF977C90CAE41B4C442F75C_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract_E52FB86E2BF977C90CAE41B4C442F75C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other income (loss)</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_E52FB86E2BF977C90CAE41B4C442F75C_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract_E52FB86E2BF977C90CAE41B4C442F75C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_E52FB86E2BF977C90CAE41B4C442F75C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_E52FB86E2BF977C90CAE41B4C442F75C" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract_E52FB86E2BF977C90CAE41B4C442F75C" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_360FCC5D1867E3AF7EAE41B4C4429BD6_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest_360FCC5D1867E3AF7EAE41B4C4429BD6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_360FCC5D1867E3AF7EAE41B4C4429BD6_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest_360FCC5D1867E3AF7EAE41B4C4429BD6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest_360FCC5D1867E3AF7EAE41B4C4429BD6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest_360FCC5D1867E3AF7EAE41B4C4429BD6" xlink:to="lab_us-gaap_InvestmentIncomeInterest_360FCC5D1867E3AF7EAE41B4C4429BD6" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestExpense_292A2FA53CA3EBDC0BF941B4C4438AB0_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense_292A2FA53CA3EBDC0BF941B4C4438AB0" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Interest expense (note 9)</link:label>
    <link:label id="lab_us-gaap_InterestExpense_292A2FA53CA3EBDC0BF941B4C4438AB0_label_en-US" xlink:label="lab_us-gaap_InterestExpense_292A2FA53CA3EBDC0BF941B4C4438AB0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_292A2FA53CA3EBDC0BF941B4C4438AB0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense_292A2FA53CA3EBDC0BF941B4C4438AB0" xlink:to="lab_us-gaap_InterestExpense_292A2FA53CA3EBDC0BF941B4C4438AB0" xlink:type="arc" />
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_051DD1899C3538DC5B2E41B4C4433489_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_051DD1899C3538DC5B2E41B4C4433489" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign exchange gain (loss)</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_051DD1899C3538DC5B2E41B4C4433489_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_051DD1899C3538DC5B2E41B4C4433489" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Currency Transaction Gain (Loss), before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_051DD1899C3538DC5B2E41B4C4433489" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_051DD1899C3538DC5B2E41B4C4433489" xlink:to="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_051DD1899C3538DC5B2E41B4C4433489" xlink:type="arc" />
    <link:label id="lab_us-gaap_GainLossOnInvestments_638CF3D89050696C3F1541B4C443C1E4_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnInvestments_638CF3D89050696C3F1541B4C443C1E4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gain on investment (note 4)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GainLossOnInvestments" xlink:label="loc_us-gaap_GainLossOnInvestments_638CF3D89050696C3F1541B4C443C1E4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnInvestments_638CF3D89050696C3F1541B4C443C1E4" xlink:to="lab_us-gaap_GainLossOnInvestments_638CF3D89050696C3F1541B4C443C1E4" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_53755EDE5A754110796941B4C44365A0_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments_53755EDE5A754110796941B4C44365A0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity investment loss (note 4)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_53755EDE5A754110796941B4C44365A0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromEquityMethodInvestments_53755EDE5A754110796941B4C44365A0" xlink:to="lab_us-gaap_IncomeLossFromEquityMethodInvestments_53755EDE5A754110796941B4C44365A0" xlink:type="arc" />
    <link:label id="lab_abus_IncreaseDecreaseInFairValueOfContingentConsiderationLiability_3A7ADA0229627068752641B4C4437DDC_negatedTerseLabel_en-US" xlink:label="lab_abus_IncreaseDecreaseInFairValueOfContingentConsiderationLiability_3A7ADA0229627068752641B4C4437DDC" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Change in fair value of contingent consideration (notes 3 and 10)</link:label>
    <link:label id="lab_abus_IncreaseDecreaseInFairValueOfContingentConsiderationLiability_3A7ADA0229627068752641B4C4437DDC_label_en-US" xlink:label="lab_abus_IncreaseDecreaseInFairValueOfContingentConsiderationLiability_3A7ADA0229627068752641B4C4437DDC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Fair Value Of Contingent Consideration Liability</link:label>
    <link:label id="lab_abus_IncreaseDecreaseInFairValueOfContingentConsiderationLiability_3A7ADA0229627068752641B4C4437DDC_documentation_en-US" xlink:label="lab_abus_IncreaseDecreaseInFairValueOfContingentConsiderationLiability_3A7ADA0229627068752641B4C4437DDC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Fair Value Of Contingent Consideration Liability</link:label>
    <link:loc xlink:href="abus-20190930.xsd#abus_IncreaseDecreaseInFairValueOfContingentConsiderationLiability" xlink:label="loc_abus_IncreaseDecreaseInFairValueOfContingentConsiderationLiability_3A7ADA0229627068752641B4C4437DDC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_IncreaseDecreaseInFairValueOfContingentConsiderationLiability_3A7ADA0229627068752641B4C4437DDC" xlink:to="lab_abus_IncreaseDecreaseInFairValueOfContingentConsiderationLiability_3A7ADA0229627068752641B4C4437DDC" xlink:type="arc" />
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_CA6D4E98F7FD80615BCB41B4C44310FE_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense_CA6D4E98F7FD80615BCB41B4C44310FE" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total other income (loss)</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_CA6D4E98F7FD80615BCB41B4C44310FE_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense_CA6D4E98F7FD80615BCB41B4C44310FE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_CA6D4E98F7FD80615BCB41B4C44310FE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_CA6D4E98F7FD80615BCB41B4C44310FE" xlink:to="lab_us-gaap_NonoperatingIncomeExpense_CA6D4E98F7FD80615BCB41B4C44310FE" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_383E67F91BAA8513595641B4C444C453_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_383E67F91BAA8513595641B4C444C453" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_383E67F91BAA8513595641B4C444C453_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_383E67F91BAA8513595641B4C444C453" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_383E67F91BAA8513595641B4C444C453" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_383E67F91BAA8513595641B4C444C453" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_383E67F91BAA8513595641B4C444C453" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_8A3C048B483BBF019D7941B4C444625F_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_8A3C048B483BBF019D7941B4C444625F" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Income tax benefit (note 6)</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_8A3C048B483BBF019D7941B4C444625F_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_8A3C048B483BBF019D7941B4C444625F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_8A3C048B483BBF019D7941B4C444625F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_8A3C048B483BBF019D7941B4C444625F" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit_8A3C048B483BBF019D7941B4C444625F" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLoss_D2EEF148CBD49B8B715541B4C444B3EA_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_D2EEF148CBD49B8B715541B4C444B3EA" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_D2EEF148CBD49B8B715541B4C444B3EA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_D2EEF148CBD49B8B715541B4C444B3EA" xlink:to="lab_us-gaap_NetIncomeLoss_D2EEF148CBD49B8B715541B4C444B3EA" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockDividendsAndOtherAdjustmentsAbstract_33E30B3FA88E844521F941B4C444BA38_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockDividendsAndOtherAdjustmentsAbstract_33E30B3FA88E844521F941B4C444BA38" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Items applicable to preferred shares:</link:label>
    <link:label id="lab_us-gaap_PreferredStockDividendsAndOtherAdjustmentsAbstract_33E30B3FA88E844521F941B4C444BA38_label_en-US" xlink:label="lab_us-gaap_PreferredStockDividendsAndOtherAdjustmentsAbstract_33E30B3FA88E844521F941B4C444BA38" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock Dividends and Other Adjustments [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockDividendsAndOtherAdjustmentsAbstract" xlink:label="loc_us-gaap_PreferredStockDividendsAndOtherAdjustmentsAbstract_33E30B3FA88E844521F941B4C444BA38" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockDividendsAndOtherAdjustmentsAbstract_33E30B3FA88E844521F941B4C444BA38" xlink:to="lab_us-gaap_PreferredStockDividendsAndOtherAdjustmentsAbstract_33E30B3FA88E844521F941B4C444BA38" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockDividendsAndOtherAdjustments_9D320D8FA204EF67CA7941B4C44447AB_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockDividendsAndOtherAdjustments_9D320D8FA204EF67CA7941B4C44447AB" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Accrual of coupon on convertible preferred shares</link:label>
    <link:label id="lab_us-gaap_PreferredStockDividendsAndOtherAdjustments_9D320D8FA204EF67CA7941B4C44447AB_label_en-US" xlink:label="lab_us-gaap_PreferredStockDividendsAndOtherAdjustments_9D320D8FA204EF67CA7941B4C44447AB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock Dividends and Other Adjustments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockDividendsAndOtherAdjustments" xlink:label="loc_us-gaap_PreferredStockDividendsAndOtherAdjustments_9D320D8FA204EF67CA7941B4C44447AB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockDividendsAndOtherAdjustments_9D320D8FA204EF67CA7941B4C44447AB" xlink:to="lab_us-gaap_PreferredStockDividendsAndOtherAdjustments_9D320D8FA204EF67CA7941B4C44447AB" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_64E1BECCECF24E4EB3AA41B4C4457E1F_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract_64E1BECCECF24E4EB3AA41B4C4457E1F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss attributable to common shareholders, per share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_64E1BECCECF24E4EB3AA41B4C4457E1F_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract_64E1BECCECF24E4EB3AA41B4C4457E1F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_64E1BECCECF24E4EB3AA41B4C4457E1F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract_64E1BECCECF24E4EB3AA41B4C4457E1F" xlink:to="lab_us-gaap_EarningsPerShareAbstract_64E1BECCECF24E4EB3AA41B4C4457E1F" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_F4D5F131712EC554406C41B4C4456281_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted_F4D5F131712EC554406C41B4C4456281" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basic and dilutive (in USD per share)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_F4D5F131712EC554406C41B4C4456281" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDiluted_F4D5F131712EC554406C41B4C4456281" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDiluted_F4D5F131712EC554406C41B4C4456281" xlink:type="arc" />
    <link:label id="lab_abus_WeightedAverageNumberOfCommonSharesAbstract_235DE84DA950E5C1527D41B4C44595C2_terseLabel_en-US" xlink:label="lab_abus_WeightedAverageNumberOfCommonSharesAbstract_235DE84DA950E5C1527D41B4C44595C2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average number of common shares</link:label>
    <link:label id="lab_abus_WeightedAverageNumberOfCommonSharesAbstract_235DE84DA950E5C1527D41B4C44595C2_label_en-US" xlink:label="lab_abus_WeightedAverageNumberOfCommonSharesAbstract_235DE84DA950E5C1527D41B4C44595C2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number Of Common Shares [Abstract]</link:label>
    <link:label id="lab_abus_WeightedAverageNumberOfCommonSharesAbstract_235DE84DA950E5C1527D41B4C44595C2_documentation_en-US" xlink:label="lab_abus_WeightedAverageNumberOfCommonSharesAbstract_235DE84DA950E5C1527D41B4C44595C2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Weighted average number of common shares</link:label>
    <link:loc xlink:href="abus-20190930.xsd#abus_WeightedAverageNumberOfCommonSharesAbstract" xlink:label="loc_abus_WeightedAverageNumberOfCommonSharesAbstract_235DE84DA950E5C1527D41B4C44595C2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_WeightedAverageNumberOfCommonSharesAbstract_235DE84DA950E5C1527D41B4C44595C2" xlink:to="lab_abus_WeightedAverageNumberOfCommonSharesAbstract_235DE84DA950E5C1527D41B4C44595C2" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_514D3790F6D16AC3916141B4C445622B_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_514D3790F6D16AC3916141B4C445622B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Basic and diluted (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_514D3790F6D16AC3916141B4C445622B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_514D3790F6D16AC3916141B4C445622B" xlink:to="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_514D3790F6D16AC3916141B4C445622B" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_31FA093526E23A04352C3258A661CBE3_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock_BD6E25C2E3145B0683E9C88337B23F18" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value of financial instruments</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_31FA093526E23A04352C3258A661CBE3_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock_BD6E25C2E3145B0683E9C88337B23F18" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_BD6E25C2E3145B0683E9C88337B23F18" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock_BD6E25C2E3145B0683E9C88337B23F18" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock_BD6E25C2E3145B0683E9C88337B23F18" xlink:type="arc" />
    <link:label id="lab_abus_LiabilityRelatedToSaleOfFutureRoyaltiesRollForward_7E5DB8DCB2B38967D65922A5BCCFA45C_terseLabel_en-US" xlink:label="lab_abus_LiabilityRelatedToSaleOfFutureRoyaltiesRollForward_7E5DB8DCB2B38967D65922A5BCCFA45C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liability Related To Sale Of Future Royalties [Roll Forward]</link:label>
    <link:label id="lab_abus_LiabilityRelatedToSaleOfFutureRoyaltiesRollForward_7E5DB8DCB2B38967D65922A5BCCFA45C_label_en-US" xlink:label="lab_abus_LiabilityRelatedToSaleOfFutureRoyaltiesRollForward_7E5DB8DCB2B38967D65922A5BCCFA45C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liability Related To Sale Of Future Royalties [Roll Forward]</link:label>
    <link:label id="lab_abus_LiabilityRelatedToSaleOfFutureRoyaltiesRollForward_7E5DB8DCB2B38967D65922A5BCCFA45C_documentation_en-US" xlink:label="lab_abus_LiabilityRelatedToSaleOfFutureRoyaltiesRollForward_7E5DB8DCB2B38967D65922A5BCCFA45C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Liability Related To Sale Of Future Royalties [Roll Forward]</link:label>
    <link:loc xlink:href="abus-20190930.xsd#abus_LiabilityRelatedToSaleOfFutureRoyaltiesRollForward" xlink:label="loc_abus_LiabilityRelatedToSaleOfFutureRoyaltiesRollForward_7E5DB8DCB2B38967D65922A5BCCFA45C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_LiabilityRelatedToSaleOfFutureRoyaltiesRollForward_7E5DB8DCB2B38967D65922A5BCCFA45C" xlink:to="lab_abus_LiabilityRelatedToSaleOfFutureRoyaltiesRollForward_7E5DB8DCB2B38967D65922A5BCCFA45C" xlink:type="arc" />
    <link:label id="lab_abus_LiabilityRelatedToSaleOfFutureRoyalties_E497CB9A0A2412CAF07E22A5BCCF4597_periodStartLabel_en-US" xlink:label="lab_abus_LiabilityRelatedToSaleOfFutureRoyalties_E497CB9A0A2412CAF07E22A5BCCF4597" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Net liability related to sale of future royalties - beginning balance</link:label>
    <link:label id="lab_abus_LiabilityRelatedToSaleOfFutureRoyalties_E497CB9A0A2412CAF07E22A5BCCF4597_label_en-US" xlink:label="lab_abus_LiabilityRelatedToSaleOfFutureRoyalties_E497CB9A0A2412CAF07E22A5BCCF4597" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liability Related To Sale Of Future Royalties</link:label>
    <link:label id="lab_abus_LiabilityRelatedToSaleOfFutureRoyalties_E497CB9A0A2412CAF07E22A5BCCF4597_documentation_en-US" xlink:label="lab_abus_LiabilityRelatedToSaleOfFutureRoyalties_E497CB9A0A2412CAF07E22A5BCCF4597" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Liability Related To Sale Of Future Royalties</link:label>
    <link:loc xlink:href="abus-20190930.xsd#abus_LiabilityRelatedToSaleOfFutureRoyalties" xlink:label="loc_abus_LiabilityRelatedToSaleOfFutureRoyalties_E497CB9A0A2412CAF07E22A5BCCF4597" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_LiabilityRelatedToSaleOfFutureRoyalties_E497CB9A0A2412CAF07E22A5BCCF4597" xlink:to="lab_abus_LiabilityRelatedToSaleOfFutureRoyalties_E497CB9A0A2412CAF07E22A5BCCF4597" xlink:type="arc" />
    <link:label id="lab_abus_LiabilityFromSaleOfFutureRoyaltiesAdditions_59BECD2FA509DF43815322A5BCD07D41_terseLabel_en-US" xlink:label="lab_abus_LiabilityFromSaleOfFutureRoyaltiesAdditions_59BECD2FA509DF43815322A5BCD07D41" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Initial recognition of liability</link:label>
    <link:label id="lab_abus_LiabilityFromSaleOfFutureRoyaltiesAdditions_59BECD2FA509DF43815322A5BCD07D41_label_en-US" xlink:label="lab_abus_LiabilityFromSaleOfFutureRoyaltiesAdditions_59BECD2FA509DF43815322A5BCD07D41" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liability From Sale Of Future Royalties, Additions</link:label>
    <link:label id="lab_abus_LiabilityFromSaleOfFutureRoyaltiesAdditions_59BECD2FA509DF43815322A5BCD07D41_documentation_en-US" xlink:label="lab_abus_LiabilityFromSaleOfFutureRoyaltiesAdditions_59BECD2FA509DF43815322A5BCD07D41" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Liability From Sale Of Future Royalties, Additions</link:label>
    <link:loc xlink:href="abus-20190930.xsd#abus_LiabilityFromSaleOfFutureRoyaltiesAdditions" xlink:label="loc_abus_LiabilityFromSaleOfFutureRoyaltiesAdditions_59BECD2FA509DF43815322A5BCD07D41" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_LiabilityFromSaleOfFutureRoyaltiesAdditions_59BECD2FA509DF43815322A5BCD07D41" xlink:to="lab_abus_LiabilityFromSaleOfFutureRoyaltiesAdditions_59BECD2FA509DF43815322A5BCD07D41" xlink:type="arc" />
    <link:label id="lab_abus_LiabilityFromSaleOfFutureRoyaltiesDiscountsAndIssuanceCosts_5C1B7165F67B219CF5B922A5BCD05994_negatedTerseLabel_en-US" xlink:label="lab_abus_LiabilityFromSaleOfFutureRoyaltiesDiscountsAndIssuanceCosts_5C1B7165F67B219CF5B922A5BCD05994" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Debt discount and issuance costs</link:label>
    <link:label id="lab_abus_LiabilityFromSaleOfFutureRoyaltiesDiscountsAndIssuanceCosts_5C1B7165F67B219CF5B922A5BCD05994_label_en-US" xlink:label="lab_abus_LiabilityFromSaleOfFutureRoyaltiesDiscountsAndIssuanceCosts_5C1B7165F67B219CF5B922A5BCD05994" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liability From Sale Of Future Royalties, Discounts And Issuance Costs</link:label>
    <link:label id="lab_abus_LiabilityFromSaleOfFutureRoyaltiesDiscountsAndIssuanceCosts_5C1B7165F67B219CF5B922A5BCD05994_documentation_en-US" xlink:label="lab_abus_LiabilityFromSaleOfFutureRoyaltiesDiscountsAndIssuanceCosts_5C1B7165F67B219CF5B922A5BCD05994" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Liability From Sale Of Future Royalties, Discounts And Issuance Costs</link:label>
    <link:loc xlink:href="abus-20190930.xsd#abus_LiabilityFromSaleOfFutureRoyaltiesDiscountsAndIssuanceCosts" xlink:label="loc_abus_LiabilityFromSaleOfFutureRoyaltiesDiscountsAndIssuanceCosts_5C1B7165F67B219CF5B922A5BCD05994" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_LiabilityFromSaleOfFutureRoyaltiesDiscountsAndIssuanceCosts_5C1B7165F67B219CF5B922A5BCD05994" xlink:to="lab_abus_LiabilityFromSaleOfFutureRoyaltiesDiscountsAndIssuanceCosts_5C1B7165F67B219CF5B922A5BCD05994" xlink:type="arc" />
    <link:label id="lab_abus_LiabilityFromSaleOfFutureRoyaltiesNonCashRoyaltyIncome_63434F75EE7359FB18B322A5BCD0B273_negatedTerseLabel_en-US" xlink:label="lab_abus_LiabilityFromSaleOfFutureRoyaltiesNonCashRoyaltyIncome_63434F75EE7359FB18B322A5BCD0B273" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Non-cash royalty revenue</link:label>
    <link:label id="lab_abus_LiabilityFromSaleOfFutureRoyaltiesNonCashRoyaltyIncome_63434F75EE7359FB18B322A5BCD0B273_label_en-US" xlink:label="lab_abus_LiabilityFromSaleOfFutureRoyaltiesNonCashRoyaltyIncome_63434F75EE7359FB18B322A5BCD0B273" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liability From Sale Of Future Royalties, Non Cash Royalty Income</link:label>
    <link:label id="lab_abus_LiabilityFromSaleOfFutureRoyaltiesNonCashRoyaltyIncome_63434F75EE7359FB18B322A5BCD0B273_documentation_en-US" xlink:label="lab_abus_LiabilityFromSaleOfFutureRoyaltiesNonCashRoyaltyIncome_63434F75EE7359FB18B322A5BCD0B273" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Liability From Sale Of Future Royalties, Non Cash Royalty Income</link:label>
    <link:loc xlink:href="abus-20190930.xsd#abus_LiabilityFromSaleOfFutureRoyaltiesNonCashRoyaltyIncome" xlink:label="loc_abus_LiabilityFromSaleOfFutureRoyaltiesNonCashRoyaltyIncome_63434F75EE7359FB18B322A5BCD0B273" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_LiabilityFromSaleOfFutureRoyaltiesNonCashRoyaltyIncome_63434F75EE7359FB18B322A5BCD0B273" xlink:to="lab_abus_LiabilityFromSaleOfFutureRoyaltiesNonCashRoyaltyIncome_63434F75EE7359FB18B322A5BCD0B273" xlink:type="arc" />
    <link:label id="lab_abus_LiabilityFromSaleOfFutureRoyaltiesNonCashExpense_71F92C32FC6B369F623A22A5BCD0184E_terseLabel_en-US" xlink:label="lab_abus_LiabilityFromSaleOfFutureRoyaltiesNonCashExpense_71F92C32FC6B369F623A22A5BCD0184E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-cash interest expense</link:label>
    <link:label id="lab_abus_LiabilityFromSaleOfFutureRoyaltiesNonCashExpense_71F92C32FC6B369F623A22A5BCD0184E_label_en-US" xlink:label="lab_abus_LiabilityFromSaleOfFutureRoyaltiesNonCashExpense_71F92C32FC6B369F623A22A5BCD0184E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liability From Sale Of Future Royalties, Non Cash Expense</link:label>
    <link:label id="lab_abus_LiabilityFromSaleOfFutureRoyaltiesNonCashExpense_71F92C32FC6B369F623A22A5BCD0184E_documentation_en-US" xlink:label="lab_abus_LiabilityFromSaleOfFutureRoyaltiesNonCashExpense_71F92C32FC6B369F623A22A5BCD0184E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Liability From Sale Of Future Royalties, Non Cash Expense</link:label>
    <link:loc xlink:href="abus-20190930.xsd#abus_LiabilityFromSaleOfFutureRoyaltiesNonCashExpense" xlink:label="loc_abus_LiabilityFromSaleOfFutureRoyaltiesNonCashExpense_71F92C32FC6B369F623A22A5BCD0184E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_LiabilityFromSaleOfFutureRoyaltiesNonCashExpense_71F92C32FC6B369F623A22A5BCD0184E" xlink:to="lab_abus_LiabilityFromSaleOfFutureRoyaltiesNonCashExpense_71F92C32FC6B369F623A22A5BCD0184E" xlink:type="arc" />
    <link:label id="lab_abus_LiabilityRelatedToSaleOfFutureRoyalties_10004952148457823C1822A5BCD0775F_periodEndLabel_en-US" xlink:label="lab_abus_LiabilityRelatedToSaleOfFutureRoyalties_10004952148457823C1822A5BCD0775F" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Net liability related to sale of future royalties - ending balance</link:label>
    <link:loc xlink:href="abus-20190930.xsd#abus_LiabilityRelatedToSaleOfFutureRoyalties" xlink:label="loc_abus_LiabilityRelatedToSaleOfFutureRoyalties_10004952148457823C1822A5BCD0775F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_LiabilityRelatedToSaleOfFutureRoyalties_10004952148457823C1822A5BCD0775F" xlink:to="lab_abus_LiabilityRelatedToSaleOfFutureRoyalties_10004952148457823C1822A5BCD0775F" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_831FB750BA0E5166FF72223D3FFA8F1B_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_831FB750BA0E5166FF72223D3FFA8F1B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_831FB750BA0E5166FF72223D3FFA8F1B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_831FB750BA0E5166FF72223D3FFA8F1B" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_831FB750BA0E5166FF72223D3FFA8F1B" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_5E9DE277470939102DB3223D3FFA28DC_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_5E9DE277470939102DB3223D3FFA28DC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income (loss):</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_5E9DE277470939102DB3223D3FFA28DC_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_5E9DE277470939102DB3223D3FFA28DC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_5E9DE277470939102DB3223D3FFA28DC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_5E9DE277470939102DB3223D3FFA28DC" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_5E9DE277470939102DB3223D3FFA28DC" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_E1A6380C51B485CB9FBC223D3FFA9DD7_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_E1A6380C51B485CB9FBC223D3FFA9DD7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share of other comprehensive income (loss) of equity method investment (note 4)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_E1A6380C51B485CB9FBC223D3FFA9DD7_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_E1A6380C51B485CB9FBC223D3FFA9DD7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_E1A6380C51B485CB9FBC223D3FFA9DD7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_E1A6380C51B485CB9FBC223D3FFA9DD7" xlink:to="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_E1A6380C51B485CB9FBC223D3FFA9DD7" xlink:type="arc" />
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_9F19D7213D89F08F65F6223D3FFB13C7_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax_9F19D7213D89F08F65F6223D3FFB13C7" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_9F19D7213D89F08F65F6223D3FFB13C7_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax_9F19D7213D89F08F65F6223D3FFB13C7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_9F19D7213D89F08F65F6223D3FFB13C7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_9F19D7213D89F08F65F6223D3FFB13C7" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax_9F19D7213D89F08F65F6223D3FFB13C7" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_6B647D9408083361ECA602DE060E081C_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_6B647D9408083361ECA602DE060E081C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Site consolidation</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_6B647D9408083361ECA602DE060E081C_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_6B647D9408083361ECA602DE060E081C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring and Related Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_6B647D9408083361ECA602DE060E081C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_6B647D9408083361ECA602DE060E081C" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_6B647D9408083361ECA602DE060E081C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_E6E97C1B1643A678D0B360CF9574055D_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_C53E2C3151A457F58BC362F92B11A746" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of accounts payable and accrued liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_E6E97C1B1643A678D0B360CF9574055D_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_C53E2C3151A457F58BC362F92B11A746" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_C53E2C3151A457F58BC362F92B11A746" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_C53E2C3151A457F58BC362F92B11A746" xlink:to="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_C53E2C3151A457F58BC362F92B11A746" xlink:type="arc" />
    <link:label id="lab_us-gaap_AwardTypeAxis_DEA75AA343EC5AC72A802271CBAF4E5D_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis_DEA75AA343EC5AC72A802271CBAF4E5D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_DEA75AA343EC5AC72A802271CBAF4E5D_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis_DEA75AA343EC5AC72A802271CBAF4E5D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_DEA75AA343EC5AC72A802271CBAF4E5D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis_DEA75AA343EC5AC72A802271CBAF4E5D" xlink:to="lab_us-gaap_AwardTypeAxis_DEA75AA343EC5AC72A802271CBAF4E5D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_C132ADE50E7992D45BA72271CBB084EC_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_C132ADE50E7992D45BA72271CBB084EC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Award [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_C132ADE50E7992D45BA72271CBB084EC_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_C132ADE50E7992D45BA72271CBB084EC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Award [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_C132ADE50E7992D45BA72271CBB084EC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_C132ADE50E7992D45BA72271CBB084EC" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_C132ADE50E7992D45BA72271CBB084EC" xlink:type="arc" />
    <link:label id="lab_abus_EmployeeStockOptionLiabilityClassifiedMember_AF352824FE49E959E6FF2271CBB0D8E2_terseLabel_en-US" xlink:label="lab_abus_EmployeeStockOptionLiabilityClassifiedMember_AF352824FE49E959E6FF2271CBB0D8E2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liability classified stock options</link:label>
    <link:label id="lab_abus_EmployeeStockOptionLiabilityClassifiedMember_AF352824FE49E959E6FF2271CBB0D8E2_label_en-US" xlink:label="lab_abus_EmployeeStockOptionLiabilityClassifiedMember_AF352824FE49E959E6FF2271CBB0D8E2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock Option, Liability Classified [Member]</link:label>
    <link:label id="lab_abus_EmployeeStockOptionLiabilityClassifiedMember_AF352824FE49E959E6FF2271CBB0D8E2_documentation_en-US" xlink:label="lab_abus_EmployeeStockOptionLiabilityClassifiedMember_AF352824FE49E959E6FF2271CBB0D8E2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Employee Stock Option, Liability Classified [Member]</link:label>
    <link:loc xlink:href="abus-20190930.xsd#abus_EmployeeStockOptionLiabilityClassifiedMember" xlink:label="loc_abus_EmployeeStockOptionLiabilityClassifiedMember_AF352824FE49E959E6FF2271CBB0D8E2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_EmployeeStockOptionLiabilityClassifiedMember_AF352824FE49E959E6FF2271CBB0D8E2" xlink:to="lab_abus_EmployeeStockOptionLiabilityClassifiedMember_AF352824FE49E959E6FF2271CBB0D8E2" xlink:type="arc" />
    <link:label id="lab_abus_EmployeeStockOptionsLiabilityClassifiedOutstandingFairValueDisclosure_27D6EEFE9D2CB9A9B3F32271CBB16437_periodStartLabel_en-US" xlink:label="lab_abus_EmployeeStockOptionsLiabilityClassifiedOutstandingFairValueDisclosure_27D6EEFE9D2CB9A9B3F32271CBB16437" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Liability at beginning of the period</link:label>
    <link:loc xlink:href="abus-20190930.xsd#abus_EmployeeStockOptionsLiabilityClassifiedOutstandingFairValueDisclosure" xlink:label="loc_abus_EmployeeStockOptionsLiabilityClassifiedOutstandingFairValueDisclosure_27D6EEFE9D2CB9A9B3F32271CBB16437" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_EmployeeStockOptionsLiabilityClassifiedOutstandingFairValueDisclosure_27D6EEFE9D2CB9A9B3F32271CBB16437" xlink:to="lab_abus_EmployeeStockOptionsLiabilityClassifiedOutstandingFairValueDisclosure_27D6EEFE9D2CB9A9B3F32271CBB16437" xlink:type="arc" />
    <link:label id="lab_abus_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisesinPeriodFairValue_BAD1BF3A80C80730ADFA2271CBB11A6C_negatedTerseLabel_en-US" xlink:label="lab_abus_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisesinPeriodFairValue_BAD1BF3A80C80730ADFA2271CBB11A6C" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Fair value of liability-classified options exercised in the period</link:label>
    <link:label id="lab_abus_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisesinPeriodFairValue_BAD1BF3A80C80730ADFA2271CBB11A6C_label_en-US" xlink:label="lab_abus_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisesinPeriodFairValue_BAD1BF3A80C80730ADFA2271CBB11A6C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Fair Value</link:label>
    <link:label id="lab_abus_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisesinPeriodFairValue_BAD1BF3A80C80730ADFA2271CBB11A6C_documentation_en-US" xlink:label="lab_abus_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisesinPeriodFairValue_BAD1BF3A80C80730ADFA2271CBB11A6C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Fair Value</link:label>
    <link:loc xlink:href="abus-20190930.xsd#abus_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisesinPeriodFairValue" xlink:label="loc_abus_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisesinPeriodFairValue_BAD1BF3A80C80730ADFA2271CBB11A6C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisesinPeriodFairValue_BAD1BF3A80C80730ADFA2271CBB11A6C" xlink:to="lab_abus_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisesinPeriodFairValue_BAD1BF3A80C80730ADFA2271CBB11A6C" xlink:type="arc" />
    <link:label id="lab_abus_IncreaseDecreaseinFairValueofLiabilityClassifiedOptions_D681C7BF3C824F4FB3652271CBB1E353_terseLabel_en-US" xlink:label="lab_abus_IncreaseDecreaseinFairValueofLiabilityClassifiedOptions_D681C7BF3C824F4FB3652271CBB1E353" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase (decrease) in fair value of liability</link:label>
    <link:label id="lab_abus_IncreaseDecreaseinFairValueofLiabilityClassifiedOptions_D681C7BF3C824F4FB3652271CBB1E353_label_en-US" xlink:label="lab_abus_IncreaseDecreaseinFairValueofLiabilityClassifiedOptions_D681C7BF3C824F4FB3652271CBB1E353" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Fair Value of Liability Classified Options</link:label>
    <link:label id="lab_abus_IncreaseDecreaseinFairValueofLiabilityClassifiedOptions_D681C7BF3C824F4FB3652271CBB1E353_documentation_en-US" xlink:label="lab_abus_IncreaseDecreaseinFairValueofLiabilityClassifiedOptions_D681C7BF3C824F4FB3652271CBB1E353" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Fair Value of Liability Classified Options</link:label>
    <link:loc xlink:href="abus-20190930.xsd#abus_IncreaseDecreaseinFairValueofLiabilityClassifiedOptions" xlink:label="loc_abus_IncreaseDecreaseinFairValueofLiabilityClassifiedOptions_D681C7BF3C824F4FB3652271CBB1E353" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_IncreaseDecreaseinFairValueofLiabilityClassifiedOptions_D681C7BF3C824F4FB3652271CBB1E353" xlink:to="lab_abus_IncreaseDecreaseinFairValueofLiabilityClassifiedOptions_D681C7BF3C824F4FB3652271CBB1E353" xlink:type="arc" />
    <link:label id="lab_abus_EmployeeStockOptionsLiabilityClassifiedOutstandingFairValueDisclosure_BFCB9D515EA4AA0594B32271CBB14515_periodEndLabel_en-US" xlink:label="lab_abus_EmployeeStockOptionsLiabilityClassifiedOutstandingFairValueDisclosure_BFCB9D515EA4AA0594B32271CBB14515" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Liability at end of the period</link:label>
    <link:loc xlink:href="abus-20190930.xsd#abus_EmployeeStockOptionsLiabilityClassifiedOutstandingFairValueDisclosure" xlink:label="loc_abus_EmployeeStockOptionsLiabilityClassifiedOutstandingFairValueDisclosure_BFCB9D515EA4AA0594B32271CBB14515" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_EmployeeStockOptionsLiabilityClassifiedOutstandingFairValueDisclosure_BFCB9D515EA4AA0594B32271CBB14515" xlink:to="lab_abus_EmployeeStockOptionsLiabilityClassifiedOutstandingFairValueDisclosure_BFCB9D515EA4AA0594B32271CBB14515" xlink:type="arc" />
    <link:label id="lab_us-gaap_FacilityClosingMember_629A4AAAC4CE2213294622A5BCEB54BD_verboseLabel_en-US" xlink:label="lab_us-gaap_FacilityClosingMember_629A4AAAC4CE2213294622A5BCEB54BD" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Facility closing</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FacilityClosingMember" xlink:label="loc_us-gaap_FacilityClosingMember_629A4AAAC4CE2213294622A5BCEB54BD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FacilityClosingMember_629A4AAAC4CE2213294622A5BCEB54BD" xlink:to="lab_us-gaap_FacilityClosingMember_629A4AAAC4CE2213294622A5BCEB54BD" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1_C1EA52DB73086059074322A5BCEC7A15_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1_C1EA52DB73086059074322A5BCEC7A15" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected total cost of site consolidation</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1_C1EA52DB73086059074322A5BCEC7A15_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1_C1EA52DB73086059074322A5BCEC7A15" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring and Related Cost, Expected Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_C1EA52DB73086059074322A5BCEC7A15" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_C1EA52DB73086059074322A5BCEC7A15" xlink:to="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1_C1EA52DB73086059074322A5BCEC7A15" xlink:type="arc" />
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>13
<FILENAME>abus-20190930_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://arbutusbio.com/role/AccountsPayableAndAccruedLiabilities" xlink:href="abus-20190930.xsd#AccountsPayableAndAccruedLiabilities" xlink:type="simple" />
  <link:roleRef roleURI="http://arbutusbio.com/role/AccountsPayableAndAccruedLiabilitiesDetails" xlink:href="abus-20190930.xsd#AccountsPayableAndAccruedLiabilitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://arbutusbio.com/role/AccountsPayableAndAccruedLiabilitiesTables" xlink:href="abus-20190930.xsd#AccountsPayableAndAccruedLiabilitiesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://arbutusbio.com/role/CollaborationsContractsAndLicensingAgreements" xlink:href="abus-20190930.xsd#CollaborationsContractsAndLicensingAgreements" xlink:type="simple" />
  <link:roleRef roleURI="http://arbutusbio.com/role/CollaborationsContractsAndLicensingAgreementsDetails" xlink:href="abus-20190930.xsd#CollaborationsContractsAndLicensingAgreementsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://arbutusbio.com/role/CondensedConsolidatedBalanceSheets" xlink:href="abus-20190930.xsd#CondensedConsolidatedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://arbutusbio.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:href="abus-20190930.xsd#CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://arbutusbio.com/role/CondensedConsolidatedStatementOfStockholdersEquity" xlink:href="abus-20190930.xsd#CondensedConsolidatedStatementOfStockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://arbutusbio.com/role/CondensedConsolidatedStatementOfStockholdersEquityParenthetical" xlink:href="abus-20190930.xsd#CondensedConsolidatedStatementOfStockholdersEquityParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://arbutusbio.com/role/CondensedConsolidatedStatementsOfCashFlow" xlink:href="abus-20190930.xsd#CondensedConsolidatedStatementsOfCashFlow" xlink:type="simple" />
  <link:roleRef roleURI="http://arbutusbio.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLossCondensedConsolidatedStatementsOfComprehensiveIncomeLoss" xlink:href="abus-20190930.xsd#CondensedConsolidatedStatementsOfComprehensiveIncomeLossCondensedConsolidatedStatementsOfComprehensiveIncomeLoss" xlink:type="simple" />
  <link:roleRef roleURI="http://arbutusbio.com/role/CondensedConsolidatedStatementsOfOperations" xlink:href="abus-20190930.xsd#CondensedConsolidatedStatementsOfOperations" xlink:type="simple" />
  <link:roleRef roleURI="http://arbutusbio.com/role/ContingenciesAndCommitments" xlink:href="abus-20190930.xsd#ContingenciesAndCommitments" xlink:type="simple" />
  <link:roleRef roleURI="http://arbutusbio.com/role/ContingenciesAndCommitmentsDetails" xlink:href="abus-20190930.xsd#ContingenciesAndCommitmentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://arbutusbio.com/role/DocumentAndEntityInformation" xlink:href="abus-20190930.xsd#DocumentAndEntityInformation" xlink:type="simple" />
  <link:roleRef roleURI="http://arbutusbio.com/role/EquityMethodInvestment" xlink:href="abus-20190930.xsd#EquityMethodInvestment" xlink:type="simple" />
  <link:roleRef roleURI="http://arbutusbio.com/role/EquityMethodInvestmentDetails" xlink:href="abus-20190930.xsd#EquityMethodInvestmentDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://arbutusbio.com/role/FairValueOfFinancialInstruments" xlink:href="abus-20190930.xsd#FairValueOfFinancialInstruments" xlink:type="simple" />
  <link:roleRef roleURI="http://arbutusbio.com/role/FairValueOfFinancialInstrumentsAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:href="abus-20190930.xsd#FairValueOfFinancialInstrumentsAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://arbutusbio.com/role/FairValueOfFinancialInstrumentsChangesInFairValueOfContingentConsiderationDetails" xlink:href="abus-20190930.xsd#FairValueOfFinancialInstrumentsChangesInFairValueOfContingentConsiderationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://arbutusbio.com/role/FairValueOfFinancialInstrumentsChangesInFairValueOfLiabilitiesClassifiedAsStockOptionDetails" xlink:href="abus-20190930.xsd#FairValueOfFinancialInstrumentsChangesInFairValueOfLiabilitiesClassifiedAsStockOptionDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://arbutusbio.com/role/FairValueOfFinancialInstrumentsTables" xlink:href="abus-20190930.xsd#FairValueOfFinancialInstrumentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://arbutusbio.com/role/IntangibleAssetsAndGoodwill" xlink:href="abus-20190930.xsd#IntangibleAssetsAndGoodwill" xlink:type="simple" />
  <link:roleRef roleURI="http://arbutusbio.com/role/IntangibleAssetsAndGoodwillDetails" xlink:href="abus-20190930.xsd#IntangibleAssetsAndGoodwillDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://arbutusbio.com/role/Leases" xlink:href="abus-20190930.xsd#Leases" xlink:type="simple" />
  <link:roleRef roleURI="http://arbutusbio.com/role/LeasesMaturitiesOfLeaseLiabilitiesDetails" xlink:href="abus-20190930.xsd#LeasesMaturitiesOfLeaseLiabilitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://arbutusbio.com/role/LeasesNarrativeDetails" xlink:href="abus-20190930.xsd#LeasesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://arbutusbio.com/role/LeasesSupplementalCashFlowInformationDetails" xlink:href="abus-20190930.xsd#LeasesSupplementalCashFlowInformationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://arbutusbio.com/role/LeasesTables" xlink:href="abus-20190930.xsd#LeasesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://arbutusbio.com/role/LeasesWeightedAverageRemainingLeaseTermAndDiscountRateDetails" xlink:href="abus-20190930.xsd#LeasesWeightedAverageRemainingLeaseTermAndDiscountRateDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://arbutusbio.com/role/NatureOfBusinessAndFutureOperations" xlink:href="abus-20190930.xsd#NatureOfBusinessAndFutureOperations" xlink:type="simple" />
  <link:roleRef roleURI="http://arbutusbio.com/role/RelatedPartyTransaction" xlink:href="abus-20190930.xsd#RelatedPartyTransaction" xlink:type="simple" />
  <link:roleRef roleURI="http://arbutusbio.com/role/RelatedPartyTransactionDetails" xlink:href="abus-20190930.xsd#RelatedPartyTransactionDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://arbutusbio.com/role/SaleOfFutureRoyalties" xlink:href="abus-20190930.xsd#SaleOfFutureRoyalties" xlink:type="simple" />
  <link:roleRef roleURI="http://arbutusbio.com/role/SaleOfFutureRoyaltiesLiabilityActivityDetails" xlink:href="abus-20190930.xsd#SaleOfFutureRoyaltiesLiabilityActivityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://arbutusbio.com/role/SaleOfFutureRoyaltiesNarrativeDetails" xlink:href="abus-20190930.xsd#SaleOfFutureRoyaltiesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://arbutusbio.com/role/SaleOfFutureRoyaltiesTables" xlink:href="abus-20190930.xsd#SaleOfFutureRoyaltiesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://arbutusbio.com/role/SignificantAccountingPolicies" xlink:href="abus-20190930.xsd#SignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://arbutusbio.com/role/SignificantAccountingPoliciesNarrativeDetails" xlink:href="abus-20190930.xsd#SignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://arbutusbio.com/role/SignificantAccountingPoliciesPolicies" xlink:href="abus-20190930.xsd#SignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://arbutusbio.com/role/SignificantAccountingPoliciesScheduleOfComputationOfBasicAndDilutedIncomeLossDetails" xlink:href="abus-20190930.xsd#SignificantAccountingPoliciesScheduleOfComputationOfBasicAndDilutedIncomeLossDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://arbutusbio.com/role/SignificantAccountingPoliciesTables" xlink:href="abus-20190930.xsd#SignificantAccountingPoliciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://arbutusbio.com/role/SiteConsolidation" xlink:href="abus-20190930.xsd#SiteConsolidation" xlink:type="simple" />
  <link:roleRef roleURI="http://arbutusbio.com/role/SiteConsolidationConsolidationExpensesDetails" xlink:href="abus-20190930.xsd#SiteConsolidationConsolidationExpensesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://arbutusbio.com/role/SiteConsolidationNarrativeDetails" xlink:href="abus-20190930.xsd#SiteConsolidationNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://arbutusbio.com/role/SiteConsolidationReserveActivityDetails" xlink:href="abus-20190930.xsd#SiteConsolidationReserveActivityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://arbutusbio.com/role/SiteConsolidationTables" xlink:href="abus-20190930.xsd#SiteConsolidationTables" xlink:type="simple" />
  <link:roleRef roleURI="http://arbutusbio.com/role/StockholdersEquityAndStockBasedCompensation" xlink:href="abus-20190930.xsd#StockholdersEquityAndStockBasedCompensation" xlink:type="simple" />
  <link:roleRef roleURI="http://arbutusbio.com/role/StockholdersEquityAndStockBasedCompensationDetails" xlink:href="abus-20190930.xsd#StockholdersEquityAndStockBasedCompensationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:presentationLink xlink:role="http://arbutusbio.com/role/AccountsPayableAndAccruedLiabilities" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_8D989095B5EB99F65C8B02DE0617A275" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_BBFDEA4FA2396798E07002DE061738AF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_8D989095B5EB99F65C8B02DE0617A275" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_BBFDEA4FA2396798E07002DE061738AF" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://arbutusbio.com/role/AccountsPayableAndAccruedLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_31915EA9F1645D109BD172CC586DAE16" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="loc_us-gaap_AccountsPayableTradeCurrent_0CA628B9898F5E28B4C3A98D331D140A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_31915EA9F1645D109BD172CC586DAE16" xlink:to="loc_us-gaap_AccountsPayableTradeCurrent_0CA628B9898F5E28B4C3A98D331D140A" xlink:type="arc" />
    <link:loc xlink:href="abus-20190930.xsd#abus_AccruedResearchAndDevelopment" xlink:label="loc_abus_AccruedResearchAndDevelopment_EFF9523E1CF5575C9F9C4107B885E4A4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_31915EA9F1645D109BD172CC586DAE16" xlink:to="loc_abus_AccruedResearchAndDevelopment_EFF9523E1CF5575C9F9C4107B885E4A4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_00ED3492128256EB8FFBE18906929D95" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_31915EA9F1645D109BD172CC586DAE16" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_00ED3492128256EB8FFBE18906929D95" xlink:type="arc" />
    <link:loc xlink:href="abus-20190930.xsd#abus_AccruedPayrollCurrent" xlink:label="loc_abus_AccruedPayrollCurrent_FDAC86D3B9265CA1B5F844061734F34F" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_31915EA9F1645D109BD172CC586DAE16" xlink:to="loc_abus_AccruedPayrollCurrent_FDAC86D3B9265CA1B5F844061734F34F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_CF02DD40698C5C3CBE726B11AA99737B" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_31915EA9F1645D109BD172CC586DAE16" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_CF02DD40698C5C3CBE726B11AA99737B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_5E3B7DEFF3C05F3C8D43DCC662E2886A" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_31915EA9F1645D109BD172CC586DAE16" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_5E3B7DEFF3C05F3C8D43DCC662E2886A" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://arbutusbio.com/role/AccountsPayableAndAccruedLiabilitiesTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_F7C084CEC966563C93C183DF421A2880" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_C53E2C3151A457F58BC362F92B11A746" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_F7C084CEC966563C93C183DF421A2880" xlink:to="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_C53E2C3151A457F58BC362F92B11A746" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://arbutusbio.com/role/CollaborationsContractsAndLicensingAgreements" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_DC8D1E21D8175F99AEB1D691790A7306" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_2AA2485121535E70A6864694CD5952E7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_DC8D1E21D8175F99AEB1D691790A7306" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_2AA2485121535E70A6864694CD5952E7" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://arbutusbio.com/role/CollaborationsContractsAndLicensingAgreementsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_85EE2AA500F087509A2022A5BCB6AFF8" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_6E713B7867C6C308D4B422A5BCB6555F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_85EE2AA500F087509A2022A5BCB6AFF8" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_6E713B7867C6C308D4B422A5BCB6555F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_1F7E2172D911C5D9196822A5BCB86085" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_6E713B7867C6C308D4B422A5BCB6555F" xlink:to="loc_srt_ProductOrServiceAxis_1F7E2172D911C5D9196822A5BCB86085" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_036BB1B44DE71349C06722A5BCB86A0D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_1F7E2172D911C5D9196822A5BCB86085" xlink:to="loc_srt_ProductsAndServicesDomain_036BB1B44DE71349C06722A5BCB86A0D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RoyaltyMember" xlink:label="loc_us-gaap_RoyaltyMember_17C7EC99BAC5C8A7244822D204428E4F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_036BB1B44DE71349C06722A5BCB86A0D" xlink:to="loc_us-gaap_RoyaltyMember_17C7EC99BAC5C8A7244822D204428E4F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LicenseMember" xlink:label="loc_us-gaap_LicenseMember_B1B833069F729F20821822D39FE2A387" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_036BB1B44DE71349C06722A5BCB86A0D" xlink:to="loc_us-gaap_LicenseMember_B1B833069F729F20821822D39FE2A387" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_E5ADC51A6C902DB557BB22A5BCB8E759" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_6E713B7867C6C308D4B422A5BCB6555F" xlink:to="loc_srt_CounterpartyNameAxis_E5ADC51A6C902DB557BB22A5BCB8E759" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9919ECC628EE9357E79522A5BCB86F3C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_E5ADC51A6C902DB557BB22A5BCB8E759" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9919ECC628EE9357E79522A5BCB86F3C" xlink:type="arc" />
    <link:loc xlink:href="abus-20190930.xsd#abus_GritstoneMember" xlink:label="loc_abus_GritstoneMember_A851292A3F049A92FC3F22A5BCB9E62D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9919ECC628EE9357E79522A5BCB86F3C" xlink:to="loc_abus_GritstoneMember_A851292A3F049A92FC3F22A5BCB9E62D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_3456F50925F320BC753022A5BCB95442" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_6E713B7867C6C308D4B422A5BCB6555F" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_3456F50925F320BC753022A5BCB95442" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_D59D1B732FDE9F262C9322A5BCBA5796" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_3456F50925F320BC753022A5BCB95442" xlink:to="loc_us-gaap_Revenues_D59D1B732FDE9F262C9322A5BCBA5796" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://arbutusbio.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_23E54EADBEAD3E96C5EA3D1724FEE3B1" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_BDA20EAE8C44047394C23D1724FECB0F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_23E54EADBEAD3E96C5EA3D1724FEE3B1" xlink:to="loc_us-gaap_AssetsAbstract_BDA20EAE8C44047394C23D1724FECB0F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_8808EFE57F75D9909EE23D1724FEF1DC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_BDA20EAE8C44047394C23D1724FECB0F" xlink:to="loc_us-gaap_AssetsCurrentAbstract_8808EFE57F75D9909EE23D1724FEF1DC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_C0CE3A9EFA5DFAE9A7EA3D1724FE96DD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_8808EFE57F75D9909EE23D1724FEF1DC" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_C0CE3A9EFA5DFAE9A7EA3D1724FE96DD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShortTermInvestments" xlink:label="loc_us-gaap_ShortTermInvestments_974710C0B8829515DFEE3D1724FE0775" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_8808EFE57F75D9909EE23D1724FEF1DC" xlink:to="loc_us-gaap_ShortTermInvestments_974710C0B8829515DFEE3D1724FE0775" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_0A2EED5604DC36E296903D1724FE8500" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_8808EFE57F75D9909EE23D1724FEF1DC" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_0A2EED5604DC36E296903D1724FE8500" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_6B1F4A47952DBEC9421E3D1725001BF0" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_8808EFE57F75D9909EE23D1724FEF1DC" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_6B1F4A47952DBEC9421E3D1725001BF0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_1033BCC2718C324941D43D172500491C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_BDA20EAE8C44047394C23D1724FECB0F" xlink:to="loc_us-gaap_AssetsCurrent_1033BCC2718C324941D43D172500491C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityMethodInvestments" xlink:label="loc_us-gaap_EquityMethodInvestments_3F6095C6991D7BA17A623D172500FDDF" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_BDA20EAE8C44047394C23D1724FECB0F" xlink:to="loc_us-gaap_EquityMethodInvestments_3F6095C6991D7BA17A623D172500FDDF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_5C9FA29D37FA766E70CB3D17250044C4" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_BDA20EAE8C44047394C23D1724FECB0F" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_5C9FA29D37FA766E70CB3D17250044C4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_A29306E534F7E6C79AC73D172500A058" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_BDA20EAE8C44047394C23D1724FECB0F" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_A29306E534F7E6C79AC73D172500A058" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_8984253CF5C3C93596373D172500218F" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_BDA20EAE8C44047394C23D1724FECB0F" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_8984253CF5C3C93596373D172500218F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_E21861B4C3FDD71B40503D172501BA22" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_BDA20EAE8C44047394C23D1724FECB0F" xlink:to="loc_us-gaap_Goodwill_E21861B4C3FDD71B40503D172501BA22" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_033150184195B8DF58AA3D172501BC20" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_23E54EADBEAD3E96C5EA3D1724FEE3B1" xlink:to="loc_us-gaap_Assets_033150184195B8DF58AA3D172501BC20" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_E918D187B60205B932033D1725011668" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_23E54EADBEAD3E96C5EA3D1724FEE3B1" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_E918D187B60205B932033D1725011668" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_B75352631CA9B086C95C3D1725017610" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_E918D187B60205B932033D1725011668" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_B75352631CA9B086C95C3D1725017610" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_37EDDF392332AB56F0323D1725012D28" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_B75352631CA9B086C95C3D1725017610" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_37EDDF392332AB56F0323D1725012D28" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestructuringReserveCurrent" xlink:label="loc_us-gaap_RestructuringReserveCurrent_BE7A1D9DA8BD259045093D1725023AEF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_B75352631CA9B086C95C3D1725017610" xlink:to="loc_us-gaap_RestructuringReserveCurrent_BE7A1D9DA8BD259045093D1725023AEF" xlink:type="arc" />
    <link:loc xlink:href="abus-20190930.xsd#abus_EmployeeStockOptionsLiabilityClassifiedOutstanding" xlink:label="loc_abus_EmployeeStockOptionsLiabilityClassifiedOutstanding_2B77B34F3A4BF8B24C433D1725024FCC" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_B75352631CA9B086C95C3D1725017610" xlink:to="loc_abus_EmployeeStockOptionsLiabilityClassifiedOutstanding_2B77B34F3A4BF8B24C433D1725024FCC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_D50DC1E05F0071B44ED13D1725022BAB" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_B75352631CA9B086C95C3D1725017610" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_D50DC1E05F0071B44ED13D1725022BAB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_F8034C3447883A82411B3D172502210C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_E918D187B60205B932033D1725011668" xlink:to="loc_us-gaap_LiabilitiesCurrent_F8034C3447883A82411B3D172502210C" xlink:type="arc" />
    <link:loc xlink:href="abus-20190930.xsd#abus_LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent" xlink:label="loc_abus_LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent_484B0A39748478CB617E3D1725021C6F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_E918D187B60205B932033D1725011668" xlink:to="loc_abus_LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent_484B0A39748478CB617E3D1725021C6F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="loc_us-gaap_DeferredRentCreditNoncurrent_9990FB8E4F8E3261E0E73D17250228FB" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_E918D187B60205B932033D1725011668" xlink:to="loc_us-gaap_DeferredRentCreditNoncurrent_9990FB8E4F8E3261E0E73D17250228FB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_804130262CC1FAA7AE5B3D1725035082" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_E918D187B60205B932033D1725011668" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_804130262CC1FAA7AE5B3D1725035082" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_48336F1E367558F329FA3D1725036359" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_E918D187B60205B932033D1725011668" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_48336F1E367558F329FA3D1725036359" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_31298D8AA4AE919D03C13D172503D6EB" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_E918D187B60205B932033D1725011668" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_31298D8AA4AE919D03C13D172503D6EB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_CF18F089B502274DAD2D3D17250324CC" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_23E54EADBEAD3E96C5EA3D1724FEE3B1" xlink:to="loc_us-gaap_Liabilities_CF18F089B502274DAD2D3D17250324CC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_E42B2FBACC1ED9504E9A3D172503B925" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_23E54EADBEAD3E96C5EA3D1724FEE3B1" xlink:to="loc_us-gaap_StockholdersEquityAbstract_E42B2FBACC1ED9504E9A3D172503B925" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockIncludingAdditionalPaidInCapitalNetOfDiscount" xlink:label="loc_us-gaap_PreferredStockIncludingAdditionalPaidInCapitalNetOfDiscount_EC0F16856F882ACEDEB23D1725033C9E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_E42B2FBACC1ED9504E9A3D172503B925" xlink:to="loc_us-gaap_PreferredStockIncludingAdditionalPaidInCapitalNetOfDiscount_EC0F16856F882ACEDEB23D1725033C9E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_E3620A696A3B04A2EA7A3D1725044D16" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_E42B2FBACC1ED9504E9A3D172503B925" xlink:to="loc_us-gaap_CommonStockValue_E3620A696A3B04A2EA7A3D1725044D16" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_1D40A512AB843FDE76C03D1725040914" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_E42B2FBACC1ED9504E9A3D172503B925" xlink:to="loc_us-gaap_AdditionalPaidInCapital_1D40A512AB843FDE76C03D1725040914" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_D8931ACD837EB782E5DD3D1725041880" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_E42B2FBACC1ED9504E9A3D172503B925" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_D8931ACD837EB782E5DD3D1725041880" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_EB9B465DB5FCB6B765973D1725041B67" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_E42B2FBACC1ED9504E9A3D172503B925" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_EB9B465DB5FCB6B765973D1725041B67" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_103EC90C4209A620F6CB3D172504EAD6" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_E42B2FBACC1ED9504E9A3D172503B925" xlink:to="loc_us-gaap_StockholdersEquity_103EC90C4209A620F6CB3D172504EAD6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_E55DCE8428C735F572B93D1725046591" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_23E54EADBEAD3E96C5EA3D1724FEE3B1" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_E55DCE8428C735F572B93D1725046591" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://arbutusbio.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_A6DE3FF6E3755C3DBA50EDD7BE5DB54F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1EB73740B70D50009247C81E342EC193" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_A6DE3FF6E3755C3DBA50EDD7BE5DB54F" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1EB73740B70D50009247C81E342EC193" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockNoParValue" xlink:label="loc_us-gaap_PreferredStockNoParValue_070B6A688D6A5227AA9AA824FF890378" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_A6DE3FF6E3755C3DBA50EDD7BE5DB54F" xlink:to="loc_us-gaap_PreferredStockNoParValue_070B6A688D6A5227AA9AA824FF890378" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_4D3D1FB035A15124A238C5F600A8C05B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_A6DE3FF6E3755C3DBA50EDD7BE5DB54F" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_4D3D1FB035A15124A238C5F600A8C05B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_43F0F180169C5287BCC8563F93E3B857" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_A6DE3FF6E3755C3DBA50EDD7BE5DB54F" xlink:to="loc_us-gaap_PreferredStockSharesIssued_43F0F180169C5287BCC8563F93E3B857" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_4BFAD12728B956A09B4C7D0B142CD8DF" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_A6DE3FF6E3755C3DBA50EDD7BE5DB54F" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_4BFAD12728B956A09B4C7D0B142CD8DF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockNoParValue" xlink:label="loc_us-gaap_CommonStockNoParValue_8641E353780255AA9DCE6ECB11B12D84" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_A6DE3FF6E3755C3DBA50EDD7BE5DB54F" xlink:to="loc_us-gaap_CommonStockNoParValue_8641E353780255AA9DCE6ECB11B12D84" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_0EEC22A007245265885BE4EDBC78A7A1" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_A6DE3FF6E3755C3DBA50EDD7BE5DB54F" xlink:to="loc_us-gaap_CommonStockSharesIssued_0EEC22A007245265885BE4EDBC78A7A1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_FD0CAE23CC5A5182BFBB6A9541182CC1" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_A6DE3FF6E3755C3DBA50EDD7BE5DB54F" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_FD0CAE23CC5A5182BFBB6A9541182CC1" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://arbutusbio.com/role/CondensedConsolidatedStatementOfStockholdersEquity" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_3E9879EB73BBB856BE5A223D3FECE434" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_DE147DD10B3EB30DE186223D3FEC4526" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_3E9879EB73BBB856BE5A223D3FECE434" xlink:to="loc_us-gaap_StatementTable_DE147DD10B3EB30DE186223D3FEC4526" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_99119CD9887D57349810223D3FEC6481" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_DE147DD10B3EB30DE186223D3FEC4526" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_99119CD9887D57349810223D3FEC6481" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_F02FA9F6CA06E5F84AC3223D3FEC50B1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_99119CD9887D57349810223D3FEC6481" xlink:to="loc_us-gaap_EquityComponentDomain_F02FA9F6CA06E5F84AC3223D3FEC50B1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaap_PreferredStockMember_E4BC93CBA8EAD16C98DA223D3FED170B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_F02FA9F6CA06E5F84AC3223D3FEC50B1" xlink:to="loc_us-gaap_PreferredStockMember_E4BC93CBA8EAD16C98DA223D3FED170B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_E562DFD1CD58BB1AF611223D3FEDE63A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_F02FA9F6CA06E5F84AC3223D3FEC50B1" xlink:to="loc_us-gaap_CommonStockMember_E562DFD1CD58BB1AF611223D3FEDE63A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_12734BBC94AE583A291A223D3FEDF47C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_F02FA9F6CA06E5F84AC3223D3FEC50B1" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_12734BBC94AE583A291A223D3FEDF47C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_E6DD5D260965F5ED1019223D3FED0CEB" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_F02FA9F6CA06E5F84AC3223D3FEC50B1" xlink:to="loc_us-gaap_RetainedEarningsMember_E6DD5D260965F5ED1019223D3FED0CEB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_4A369AFFE4641DEC2A17223D3FED52CF" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_F02FA9F6CA06E5F84AC3223D3FEC50B1" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_4A369AFFE4641DEC2A17223D3FED52CF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_22757A62F5EEEEDE50E6223D3FEE6BEF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_DE147DD10B3EB30DE186223D3FEC4526" xlink:to="loc_us-gaap_StatementLineItems_22757A62F5EEEEDE50E6223D3FEE6BEF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_E40794393CACB28EE723223D3FEEB452" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_22757A62F5EEEEDE50E6223D3FEE6BEF" xlink:to="loc_us-gaap_SharesIssued_E40794393CACB28EE723223D3FEEB452" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_6CCA7B441BE0B8BD8AF5223D3FEE8897" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_22757A62F5EEEEDE50E6223D3FEE6BEF" xlink:to="loc_us-gaap_StockholdersEquity_6CCA7B441BE0B8BD8AF5223D3FEE8897" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockAccretionOfRedemptionDiscount" xlink:label="loc_us-gaap_PreferredStockAccretionOfRedemptionDiscount_F3D041E7CBB1CA87D80D223D3FEE092C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_22757A62F5EEEEDE50E6223D3FEE6BEF" xlink:to="loc_us-gaap_PreferredStockAccretionOfRedemptionDiscount_F3D041E7CBB1CA87D80D223D3FEE092C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_EE2FDA69188072FC37C5223D3FEE6C3C" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_22757A62F5EEEEDE50E6223D3FEE6BEF" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_EE2FDA69188072FC37C5223D3FEE6C3C" xlink:type="arc" />
    <link:loc xlink:href="abus-20190930.xsd#abus_AdjustmentstoAdditionalPaidinCapitalCertainFairValueAdjustmentstoLiabilityStockOptionAwards" xlink:label="loc_abus_AdjustmentstoAdditionalPaidinCapitalCertainFairValueAdjustmentstoLiabilityStockOptionAwards_D9A3C6488D85EC5B85A6223D3FEE626D" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_22757A62F5EEEEDE50E6223D3FEE6BEF" xlink:to="loc_abus_AdjustmentstoAdditionalPaidinCapitalCertainFairValueAdjustmentstoLiabilityStockOptionAwards_D9A3C6488D85EC5B85A6223D3FEE626D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_C13E2E1DD2F089FDC129223D3FEF385D" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_22757A62F5EEEEDE50E6223D3FEE6BEF" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_C13E2E1DD2F089FDC129223D3FEF385D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_72003B93A40A7ADB93FD223D3FEF1540" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_22757A62F5EEEEDE50E6223D3FEE6BEF" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_72003B93A40A7ADB93FD223D3FEF1540" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_80CBF4191D66874E035B223D3FEF849B" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_22757A62F5EEEEDE50E6223D3FEE6BEF" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_80CBF4191D66874E035B223D3FEF849B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_84CC7861F543A29E5934223D3FEF331B" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_22757A62F5EEEEDE50E6223D3FEE6BEF" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_84CC7861F543A29E5934223D3FEF331B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_FF336CA66BC711A1FDAE223D3FEF5559" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_22757A62F5EEEEDE50E6223D3FEE6BEF" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_FF336CA66BC711A1FDAE223D3FEF5559" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_2707DD543F0E59C404CE223D3FEF44D4" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_22757A62F5EEEEDE50E6223D3FEE6BEF" xlink:to="loc_us-gaap_NetIncomeLoss_2707DD543F0E59C404CE223D3FEF44D4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_D2EC89ABB09852D2723D223D3FF0D658" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_22757A62F5EEEEDE50E6223D3FEE6BEF" xlink:to="loc_us-gaap_SharesIssued_D2EC89ABB09852D2723D223D3FF0D658" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_19F218C9DFDD1EA178F9223D3FF0D191" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_22757A62F5EEEEDE50E6223D3FEE6BEF" xlink:to="loc_us-gaap_StockholdersEquity_19F218C9DFDD1EA178F9223D3FF0D191" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://arbutusbio.com/role/CondensedConsolidatedStatementOfStockholdersEquityParenthetical" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_BA325A706D13F3AA09B606E23AC837B2" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_84A3CDCA66B89F19E65D06E23AC824FD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_BA325A706D13F3AA09B606E23AC837B2" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_84A3CDCA66B89F19E65D06E23AC824FD" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://arbutusbio.com/role/CondensedConsolidatedStatementsOfCashFlow" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_2529102E3BD0F0615A0E223D3FC961B7" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_7A0DAC2E0795747CF600223D3FC96AE3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_2529102E3BD0F0615A0E223D3FC961B7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_7A0DAC2E0795747CF600223D3FC96AE3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_369FB5E98668D7FBF8C4223D3FCA44AD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_7A0DAC2E0795747CF600223D3FC96AE3" xlink:to="loc_us-gaap_NetIncomeLoss_369FB5E98668D7FBF8C4223D3FCA44AD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_EC37C24388968F783A41223D3FCA7CE3" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_7A0DAC2E0795747CF600223D3FC96AE3" xlink:to="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_EC37C24388968F783A41223D3FCA7CE3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_599140F4D338E47D09F0223D3FCA8E5A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_EC37C24388968F783A41223D3FCA7CE3" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_599140F4D338E47D09F0223D3FCA8E5A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_8D2A2F99781477E135CD223D3FCA2063" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_EC37C24388968F783A41223D3FCA7CE3" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_8D2A2F99781477E135CD223D3FCA2063" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_6800A2AA5ADE8F244F73223D3FCB3524" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_EC37C24388968F783A41223D3FCA7CE3" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_6800A2AA5ADE8F244F73223D3FCB3524" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_0F3F7E08C94AAA158763223D3FCB7D69" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_EC37C24388968F783A41223D3FCA7CE3" xlink:to="loc_us-gaap_ShareBasedCompensation_0F3F7E08C94AAA158763223D3FCB7D69" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_572AF24EDFAF31997E43223D3FCB9E69" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_EC37C24388968F783A41223D3FCA7CE3" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_572AF24EDFAF31997E43223D3FCB9E69" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_3320B49448B715F63EDE223D3FCBC5FF" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_EC37C24388968F783A41223D3FCA7CE3" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_3320B49448B715F63EDE223D3FCBC5FF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="loc_us-gaap_AssetImpairmentCharges_C90C3F3AC20670445DC3223D3FCBD599" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_EC37C24388968F783A41223D3FCA7CE3" xlink:to="loc_us-gaap_AssetImpairmentCharges_C90C3F3AC20670445DC3223D3FCBD599" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_05D842872D1C00C861FA223F55B156D0" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_EC37C24388968F783A41223D3FCA7CE3" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_05D842872D1C00C861FA223F55B156D0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestructuringCosts" xlink:label="loc_us-gaap_RestructuringCosts_95BF919AB0882C304ABC223D3FCB80C7" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_EC37C24388968F783A41223D3FCA7CE3" xlink:to="loc_us-gaap_RestructuringCosts_95BF919AB0882C304ABC223D3FCB80C7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GainLossOnInvestments" xlink:label="loc_us-gaap_GainLossOnInvestments_284C5BB57451C88E97C5223D3FCB8155" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_EC37C24388968F783A41223D3FCA7CE3" xlink:to="loc_us-gaap_GainLossOnInvestments_284C5BB57451C88E97C5223D3FCB8155" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GainLossOnSaleOfEquityInvestments" xlink:label="loc_us-gaap_GainLossOnSaleOfEquityInvestments_B92CD49AA714AA7C0BDA223D3FCCBA41" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_EC37C24388968F783A41223D3FCA7CE3" xlink:to="loc_us-gaap_GainLossOnSaleOfEquityInvestments_B92CD49AA714AA7C0BDA223D3FCCBA41" xlink:type="arc" />
    <link:loc xlink:href="abus-20190930.xsd#abus_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" xlink:label="loc_abus_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties_622E902EC4EF41F953E9223D3FCCD22A" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_EC37C24388968F783A41223D3FCA7CE3" xlink:to="loc_abus_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties_622E902EC4EF41F953E9223D3FCCD22A" xlink:type="arc" />
    <link:loc xlink:href="abus-20190930.xsd#abus_NonCashRoyaltyExpenseRelatedToSaleOfFutureRoyalties" xlink:label="loc_abus_NonCashRoyaltyExpenseRelatedToSaleOfFutureRoyalties_FBFF8277F3BA157C360B223D3FCCB9D4" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_EC37C24388968F783A41223D3FCA7CE3" xlink:to="loc_abus_NonCashRoyaltyExpenseRelatedToSaleOfFutureRoyalties_FBFF8277F3BA157C360B223D3FCCB9D4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_0A2DAA79E9F4E9323786223D3FCCBB8A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_7A0DAC2E0795747CF600223D3FC96AE3" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_0A2DAA79E9F4E9323786223D3FCCBB8A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_419A36702AE775B02C30223D3FCC628E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_0A2DAA79E9F4E9323786223D3FCCBB8A" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_419A36702AE775B02C30223D3FCC628E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_19BCF75276A3B28532D1223D3FCD9FCD" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_0A2DAA79E9F4E9323786223D3FCCBB8A" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_19BCF75276A3B28532D1223D3FCD9FCD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerAsset" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerAsset_053FAE8D41C0BB7A9A61223D3FCDDEA9" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_0A2DAA79E9F4E9323786223D3FCCBB8A" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerAsset_053FAE8D41C0BB7A9A61223D3FCDDEA9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_41113DA1BE53555F26F7223D3FCDE0B8" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_0A2DAA79E9F4E9323786223D3FCCBB8A" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_41113DA1BE53555F26F7223D3FCDE0B8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_DC2C55F2195E3BA5A3AF223D3FCDD386" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_0A2DAA79E9F4E9323786223D3FCCBB8A" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_DC2C55F2195E3BA5A3AF223D3FCDD386" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInRestructuringReserve" xlink:label="loc_us-gaap_IncreaseDecreaseInRestructuringReserve_F6BD378BEC12D345424C223D3FCD186A" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_0A2DAA79E9F4E9323786223D3FCCBB8A" xlink:to="loc_us-gaap_IncreaseDecreaseInRestructuringReserve_F6BD378BEC12D345424C223D3FCD186A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_6A83CFD64C447B30D219223D3FCD6D69" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_0A2DAA79E9F4E9323786223D3FCCBB8A" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_6A83CFD64C447B30D219223D3FCD6D69" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_70A805E4934A78562BAE223D3FCDF89E" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_7A0DAC2E0795747CF600223D3FC96AE3" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_70A805E4934A78562BAE223D3FCDF89E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_F0EFAD81E48C29B9CEB1223D3FD352D4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_2529102E3BD0F0615A0E223D3FC961B7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_F0EFAD81E48C29B9CEB1223D3FD352D4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsForProceedsFromInvestments" xlink:label="loc_us-gaap_PaymentsForProceedsFromInvestments_EDA100C763C1E17B17FF223D3FD3DDF7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_F0EFAD81E48C29B9CEB1223D3FD352D4" xlink:to="loc_us-gaap_PaymentsForProceedsFromInvestments_EDA100C763C1E17B17FF223D3FD3DDF7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromSaleOfRestrictedInvestments" xlink:label="loc_us-gaap_ProceedsFromSaleOfRestrictedInvestments_1C531D5A60B184ABF553223D3FD3EAF2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_F0EFAD81E48C29B9CEB1223D3FD352D4" xlink:to="loc_us-gaap_ProceedsFromSaleOfRestrictedInvestments_1C531D5A60B184ABF553223D3FD3EAF2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_0A111951DCC417837D2C223D3FD33613" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_F0EFAD81E48C29B9CEB1223D3FD352D4" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_0A111951DCC417837D2C223D3FD33613" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_EC87D9761B88C1ADA8E3223D3FD48135" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_F0EFAD81E48C29B9CEB1223D3FD352D4" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_EC87D9761B88C1ADA8E3223D3FD48135" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_5A9045F8A305011975ED223D3FD4B07F" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_F0EFAD81E48C29B9CEB1223D3FD352D4" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_5A9045F8A305011975ED223D3FD4B07F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_B0CC6CDE15652D801072223D3FD4D7B4" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_2529102E3BD0F0615A0E223D3FC961B7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_B0CC6CDE15652D801072223D3FD4D7B4" xlink:type="arc" />
    <link:loc xlink:href="abus-20190930.xsd#abus_ProceedsFromSaleOfFutureRoyaltiesNet" xlink:label="loc_abus_ProceedsFromSaleOfFutureRoyaltiesNet_161E3CD2F9AA070AFC9B223D3FD4DCE9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_B0CC6CDE15652D801072223D3FD4D7B4" xlink:to="loc_abus_ProceedsFromSaleOfFutureRoyaltiesNet_161E3CD2F9AA070AFC9B223D3FD4DCE9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable_AA2AF24420F216B5AEED223D3FD4814A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_B0CC6CDE15652D801072223D3FD4D7B4" xlink:to="loc_us-gaap_RepaymentsOfNotesPayable_AA2AF24420F216B5AEED223D3FD4814A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_4A42AF46CA8A81A99D6E223D3FD42B10" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_B0CC6CDE15652D801072223D3FD4D7B4" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_4A42AF46CA8A81A99D6E223D3FD42B10" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_F32B796859F662F22F0E223D3FD5677A" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_B0CC6CDE15652D801072223D3FD4D7B4" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_F32B796859F662F22F0E223D3FD5677A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_92A339767F3C70D1F5A2223D3FD53B3F" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_B0CC6CDE15652D801072223D3FD4D7B4" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_92A339767F3C70D1F5A2223D3FD53B3F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_651C1C6D6E08E1DD868A223D3FD54367" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_B0CC6CDE15652D801072223D3FD4D7B4" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_651C1C6D6E08E1DD868A223D3FD54367" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_D8DFE6EFD28394CE15CF223D3FD57651" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_2529102E3BD0F0615A0E223D3FC961B7" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_D8DFE6EFD28394CE15CF223D3FD57651" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_BC4E290BA10C6A71DCBD223D3FD5F06F" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_2529102E3BD0F0615A0E223D3FC961B7" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_BC4E290BA10C6A71DCBD223D3FD5F06F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8A4360EF863A6431EC15223D3FD69FE2" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_2529102E3BD0F0615A0E223D3FC961B7" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8A4360EF863A6431EC15223D3FD69FE2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_96C4D3525F421C417296223D3FD6042D" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_2529102E3BD0F0615A0E223D3FC961B7" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_96C4D3525F421C417296223D3FD6042D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_B25D1182B7494D1DFD77223D3FD69203" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_2529102E3BD0F0615A0E223D3FC961B7" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_B25D1182B7494D1DFD77223D3FD69203" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_90AA322E4288A741D8A7223D3FD6D541" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_B25D1182B7494D1DFD77223D3FD69203" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_90AA322E4288A741D8A7223D3FD6D541" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DividendsPreferredStockCash" xlink:label="loc_us-gaap_DividendsPreferredStockCash_D20D51231768DDC8EBA3223D3FD6350D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_90AA322E4288A741D8A7223D3FD6D541" xlink:to="loc_us-gaap_DividendsPreferredStockCash_D20D51231768DDC8EBA3223D3FD6350D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContributionOfProperty" xlink:label="loc_us-gaap_ContributionOfProperty_B767972D27DC621FA5C9223D3FD6FA95" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_90AA322E4288A741D8A7223D3FD6D541" xlink:to="loc_us-gaap_ContributionOfProperty_B767972D27DC621FA5C9223D3FD6FA95" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://arbutusbio.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLossCondensedConsolidatedStatementsOfComprehensiveIncomeLoss" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_831FB750BA0E5166FF72223D3FFA8F1B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_E8DD0BC8592A966A144A223D3FFAB4C6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_831FB750BA0E5166FF72223D3FFA8F1B" xlink:to="loc_us-gaap_NetIncomeLoss_E8DD0BC8592A966A144A223D3FFAB4C6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_5E9DE277470939102DB3223D3FFA28DC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_831FB750BA0E5166FF72223D3FFA8F1B" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_5E9DE277470939102DB3223D3FFA28DC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_E1A6380C51B485CB9FBC223D3FFA9DD7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_5E9DE277470939102DB3223D3FFA28DC" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_E1A6380C51B485CB9FBC223D3FFA9DD7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_9F19D7213D89F08F65F6223D3FFB13C7" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_831FB750BA0E5166FF72223D3FFA8F1B" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_9F19D7213D89F08F65F6223D3FFB13C7" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://arbutusbio.com/role/CondensedConsolidatedStatementsOfOperations" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_E0834E0D5E9805A5645041B4C440862A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaap_RevenuesAbstract_A15F86861B9D1AD7E60441B4C440F52D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_E0834E0D5E9805A5645041B4C440862A" xlink:to="loc_us-gaap_RevenuesAbstract_A15F86861B9D1AD7E60441B4C440F52D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_A3D8FFD9BC2B82B5326D41B4C440751A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_A15F86861B9D1AD7E60441B4C440F52D" xlink:to="loc_us-gaap_Revenues_A3D8FFD9BC2B82B5326D41B4C440751A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_C55E72F572DD755DF23C41B4C441B821" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_E0834E0D5E9805A5645041B4C440862A" xlink:to="loc_us-gaap_OperatingExpensesAbstract_C55E72F572DD755DF23C41B4C441B821" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_DEAE03F50F7EDB15D3B441B4C4419293" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_C55E72F572DD755DF23C41B4C441B821" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_DEAE03F50F7EDB15D3B441B4C4419293" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_AFBA6E83562861110EB241B4C441D7BD" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_C55E72F572DD755DF23C41B4C441B821" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_AFBA6E83562861110EB241B4C441D7BD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_664A01BD474377D2BC4041B4C4414AF4" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_C55E72F572DD755DF23C41B4C441B821" xlink:to="loc_us-gaap_Depreciation_664A01BD474377D2BC4041B4C4414AF4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="loc_us-gaap_RestructuringCharges_3075CD0D4B20A34A270041B4C441224F" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_C55E72F572DD755DF23C41B4C441B821" xlink:to="loc_us-gaap_RestructuringCharges_3075CD0D4B20A34A270041B4C441224F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_32F18A9519510BE5987641B4C441E99B" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_C55E72F572DD755DF23C41B4C441B821" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_32F18A9519510BE5987641B4C441E99B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_534B2A79E965631B78C341B4C4429BF2" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_C55E72F572DD755DF23C41B4C441B821" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_534B2A79E965631B78C341B4C4429BF2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LossContingencyLossInPeriod" xlink:label="loc_us-gaap_LossContingencyLossInPeriod_AD523730E9D49A33DD7A41B4C4427C58" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_C55E72F572DD755DF23C41B4C441B821" xlink:to="loc_us-gaap_LossContingencyLossInPeriod_AD523730E9D49A33DD7A41B4C4427C58" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_CA78E175C69A42EB1FBB41B4C4428E90" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_C55E72F572DD755DF23C41B4C441B821" xlink:to="loc_us-gaap_OperatingExpenses_CA78E175C69A42EB1FBB41B4C4428E90" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_364F3FBEDAC723AC511641B4C442B539" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_E0834E0D5E9805A5645041B4C440862A" xlink:to="loc_us-gaap_OperatingIncomeLoss_364F3FBEDAC723AC511641B4C442B539" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_E52FB86E2BF977C90CAE41B4C442F75C" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_E0834E0D5E9805A5645041B4C440862A" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_E52FB86E2BF977C90CAE41B4C442F75C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest_360FCC5D1867E3AF7EAE41B4C4429BD6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_E52FB86E2BF977C90CAE41B4C442F75C" xlink:to="loc_us-gaap_InvestmentIncomeInterest_360FCC5D1867E3AF7EAE41B4C4429BD6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_292A2FA53CA3EBDC0BF941B4C4438AB0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_E52FB86E2BF977C90CAE41B4C442F75C" xlink:to="loc_us-gaap_InterestExpense_292A2FA53CA3EBDC0BF941B4C4438AB0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_051DD1899C3538DC5B2E41B4C4433489" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_E52FB86E2BF977C90CAE41B4C442F75C" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_051DD1899C3538DC5B2E41B4C4433489" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GainLossOnInvestments" xlink:label="loc_us-gaap_GainLossOnInvestments_638CF3D89050696C3F1541B4C443C1E4" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_E52FB86E2BF977C90CAE41B4C442F75C" xlink:to="loc_us-gaap_GainLossOnInvestments_638CF3D89050696C3F1541B4C443C1E4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_53755EDE5A754110796941B4C44365A0" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_E52FB86E2BF977C90CAE41B4C442F75C" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_53755EDE5A754110796941B4C44365A0" xlink:type="arc" />
    <link:loc xlink:href="abus-20190930.xsd#abus_IncreaseDecreaseInFairValueOfContingentConsiderationLiability" xlink:label="loc_abus_IncreaseDecreaseInFairValueOfContingentConsiderationLiability_3A7ADA0229627068752641B4C4437DDC" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_E52FB86E2BF977C90CAE41B4C442F75C" xlink:to="loc_abus_IncreaseDecreaseInFairValueOfContingentConsiderationLiability_3A7ADA0229627068752641B4C4437DDC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_CA6D4E98F7FD80615BCB41B4C44310FE" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_E52FB86E2BF977C90CAE41B4C442F75C" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_CA6D4E98F7FD80615BCB41B4C44310FE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_383E67F91BAA8513595641B4C444C453" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_E52FB86E2BF977C90CAE41B4C442F75C" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_383E67F91BAA8513595641B4C444C453" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_8A3C048B483BBF019D7941B4C444625F" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_E52FB86E2BF977C90CAE41B4C442F75C" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_8A3C048B483BBF019D7941B4C444625F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_D2EEF148CBD49B8B715541B4C444B3EA" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_E0834E0D5E9805A5645041B4C440862A" xlink:to="loc_us-gaap_NetIncomeLoss_D2EEF148CBD49B8B715541B4C444B3EA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockDividendsAndOtherAdjustmentsAbstract" xlink:label="loc_us-gaap_PreferredStockDividendsAndOtherAdjustmentsAbstract_33E30B3FA88E844521F941B4C444BA38" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_E0834E0D5E9805A5645041B4C440862A" xlink:to="loc_us-gaap_PreferredStockDividendsAndOtherAdjustmentsAbstract_33E30B3FA88E844521F941B4C444BA38" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockDividendsAndOtherAdjustments" xlink:label="loc_us-gaap_PreferredStockDividendsAndOtherAdjustments_9D320D8FA204EF67CA7941B4C44447AB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PreferredStockDividendsAndOtherAdjustmentsAbstract_33E30B3FA88E844521F941B4C444BA38" xlink:to="loc_us-gaap_PreferredStockDividendsAndOtherAdjustments_9D320D8FA204EF67CA7941B4C44447AB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_668CFAD2E4430E46D72641B4C445127D" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_E0834E0D5E9805A5645041B4C440862A" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_668CFAD2E4430E46D72641B4C445127D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_64E1BECCECF24E4EB3AA41B4C4457E1F" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_E0834E0D5E9805A5645041B4C440862A" xlink:to="loc_us-gaap_EarningsPerShareAbstract_64E1BECCECF24E4EB3AA41B4C4457E1F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_F4D5F131712EC554406C41B4C4456281" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_64E1BECCECF24E4EB3AA41B4C4457E1F" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_F4D5F131712EC554406C41B4C4456281" xlink:type="arc" />
    <link:loc xlink:href="abus-20190930.xsd#abus_WeightedAverageNumberOfCommonSharesAbstract" xlink:label="loc_abus_WeightedAverageNumberOfCommonSharesAbstract_235DE84DA950E5C1527D41B4C44595C2" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_E0834E0D5E9805A5645041B4C440862A" xlink:to="loc_abus_WeightedAverageNumberOfCommonSharesAbstract_235DE84DA950E5C1527D41B4C44595C2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_514D3790F6D16AC3916141B4C445622B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abus_WeightedAverageNumberOfCommonSharesAbstract_235DE84DA950E5C1527D41B4C44595C2" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_514D3790F6D16AC3916141B4C445622B" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://arbutusbio.com/role/ContingenciesAndCommitments" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_78729C6BDEB6F3EAF12B02DE05BE5BEC" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_230A10A911D27B3C486302DE05BEA62A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_78729C6BDEB6F3EAF12B02DE05BE5BEC" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_230A10A911D27B3C486302DE05BEA62A" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://arbutusbio.com/role/ContingenciesAndCommitmentsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_5103ED9B4740D6AE08F422A5BCC15E8D" xlink:type="locator" />
    <link:loc xlink:href="abus-20190930.xsd#abus_ContingenciesandCommitmentsTable" xlink:label="loc_abus_ContingenciesandCommitmentsTable_469E5A584B3DF7581FE522A5BCC21207" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_5103ED9B4740D6AE08F422A5BCC15E8D" xlink:to="loc_abus_ContingenciesandCommitmentsTable_469E5A584B3DF7581FE522A5BCC21207" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_LitigationCaseAxis" xlink:label="loc_srt_LitigationCaseAxis_515521503F6AEAA157C522A5BCC62DE0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abus_ContingenciesandCommitmentsTable_469E5A584B3DF7581FE522A5BCC21207" xlink:to="loc_srt_LitigationCaseAxis_515521503F6AEAA157C522A5BCC62DE0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_LitigationCaseTypeDomain" xlink:label="loc_srt_LitigationCaseTypeDomain_27BA4CDA31657FF57E9422A5BCC635A2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_515521503F6AEAA157C522A5BCC62DE0" xlink:to="loc_srt_LitigationCaseTypeDomain_27BA4CDA31657FF57E9422A5BCC635A2" xlink:type="arc" />
    <link:loc xlink:href="abus-20190930.xsd#abus_ArbitrationWithTheUniversityOfBritishColumbiaMember" xlink:label="loc_abus_ArbitrationWithTheUniversityOfBritishColumbiaMember_B03736938A46211554E622A5BCC6E401" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_27BA4CDA31657FF57E9422A5BCC635A2" xlink:to="loc_abus_ArbitrationWithTheUniversityOfBritishColumbiaMember_B03736938A46211554E622A5BCC6E401" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_31C53FAFB565AA9D198B22C271212EEF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abus_ContingenciesandCommitmentsTable_469E5A584B3DF7581FE522A5BCC21207" xlink:to="loc_srt_RangeAxis_31C53FAFB565AA9D198B22C271212EEF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_A736C55138CE5167C73222C2713322FD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_31C53FAFB565AA9D198B22C271212EEF" xlink:to="loc_srt_RangeMember_A736C55138CE5167C73222C2713322FD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_84042D52F3E196FD615522C29C29A5EA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_A736C55138CE5167C73222C2713322FD" xlink:to="loc_srt_MinimumMember_84042D52F3E196FD615522C29C29A5EA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_16756E48676478890BDD22C2BB5BD0C5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_A736C55138CE5167C73222C2713322FD" xlink:to="loc_srt_MaximumMember_16756E48676478890BDD22C2BB5BD0C5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_6B776F92D1E13F2918B322A5BCC3D463" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abus_ContingenciesandCommitmentsTable_469E5A584B3DF7581FE522A5BCC21207" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_6B776F92D1E13F2918B322A5BCC3D463" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_16937745751FE70A77F522A5BCC38450" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_6B776F92D1E13F2918B322A5BCC3D463" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_16937745751FE70A77F522A5BCC38450" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_1F9C3A6EE4FC8CB6AB4422A5BCC3ACE7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_16937745751FE70A77F522A5BCC38450" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_1F9C3A6EE4FC8CB6AB4422A5BCC3ACE7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_2BA3FA104FF58F6297D822A5BCC3990F" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abus_ContingenciesandCommitmentsTable_469E5A584B3DF7581FE522A5BCC21207" xlink:to="loc_srt_CounterpartyNameAxis_2BA3FA104FF58F6297D822A5BCC3990F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_A451F1FD0618596E5DB422A5BCC3236E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_2BA3FA104FF58F6297D822A5BCC3990F" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_A451F1FD0618596E5DB422A5BCC3236E" xlink:type="arc" />
    <link:loc xlink:href="abus-20190930.xsd#abus_BlumbergandDrexelMember" xlink:label="loc_abus_BlumbergandDrexelMember_4FAB4DB332A4ADF5597322A5BCC4BF78" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_A451F1FD0618596E5DB422A5BCC3236E" xlink:to="loc_abus_BlumbergandDrexelMember_4FAB4DB332A4ADF5597322A5BCC4BF78" xlink:type="arc" />
    <link:loc xlink:href="abus-20190930.xsd#abus_BlumbergMember" xlink:label="loc_abus_BlumbergMember_C1FF69089AE9B9E3B4E622A5BCC4DA00" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_A451F1FD0618596E5DB422A5BCC3236E" xlink:to="loc_abus_BlumbergMember_C1FF69089AE9B9E3B4E622A5BCC4DA00" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_EE94B0C5AF088B1229DA22A5BCC56FC1" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abus_ContingenciesandCommitmentsTable_469E5A584B3DF7581FE522A5BCC21207" xlink:to="loc_dei_LegalEntityAxis_EE94B0C5AF088B1229DA22A5BCC56FC1" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_7A0C2397C3342E16075022A5BCC5BF63" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_EE94B0C5AF088B1229DA22A5BCC56FC1" xlink:to="loc_dei_EntityDomain_7A0C2397C3342E16075022A5BCC5BF63" xlink:type="arc" />
    <link:loc xlink:href="abus-20190930.xsd#abus_ArbutusInc.Member" xlink:label="loc_abus_ArbutusInc.Member_F8D75BDCA0AA6F978C3022A5BCC5FE67" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_7A0C2397C3342E16075022A5BCC5BF63" xlink:to="loc_abus_ArbutusInc.Member_F8D75BDCA0AA6F978C3022A5BCC5FE67" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_7536FC64FDD229A5D1A422A5BCC6B669" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abus_ContingenciesandCommitmentsTable_469E5A584B3DF7581FE522A5BCC21207" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_7536FC64FDD229A5D1A422A5BCC6B669" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_DA8E4A58ED75A580B3FB22A5BCC65437" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_7536FC64FDD229A5D1A422A5BCC6B669" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_DA8E4A58ED75A580B3FB22A5BCC65437" xlink:type="arc" />
    <link:loc xlink:href="abus-20190930.xsd#abus_EnantigenMember" xlink:label="loc_abus_EnantigenMember_C886B96468F34BE2145E22A5BCC73395" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_DA8E4A58ED75A580B3FB22A5BCC65437" xlink:to="loc_abus_EnantigenMember_C886B96468F34BE2145E22A5BCC73395" xlink:type="arc" />
    <link:loc xlink:href="abus-20190930.xsd#abus_ContingenciesandCommitmentsLineItems" xlink:label="loc_abus_ContingenciesandCommitmentsLineItems_1D7800D87E3399DFC45B22A5BCC7D316" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abus_ContingenciesandCommitmentsTable_469E5A584B3DF7581FE522A5BCC21207" xlink:to="loc_abus_ContingenciesandCommitmentsLineItems_1D7800D87E3399DFC45B22A5BCC7D316" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LossContingencyDamagesSoughtValue" xlink:label="loc_us-gaap_LossContingencyDamagesSoughtValue_75601D1BBC9B42FC033322A5BCC78D8F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abus_ContingenciesandCommitmentsLineItems_1D7800D87E3399DFC45B22A5BCC7D316" xlink:to="loc_us-gaap_LossContingencyDamagesSoughtValue_75601D1BBC9B42FC033322A5BCC78D8F" xlink:type="arc" />
    <link:loc xlink:href="abus-20190930.xsd#abus_Numberoflegalproceedings" xlink:label="loc_abus_Numberoflegalproceedings_DAD6BBFED2AD096A544C22A5BCC77AFB" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abus_ContingenciesandCommitmentsLineItems_1D7800D87E3399DFC45B22A5BCC7D316" xlink:to="loc_abus_Numberoflegalproceedings_DAD6BBFED2AD096A544C22A5BCC77AFB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_DAA29A13D17D75F5861222BB2A36145A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abus_ContingenciesandCommitmentsLineItems_1D7800D87E3399DFC45B22A5BCC7D316" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_DAA29A13D17D75F5861222BB2A36145A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LitigationSettlementInterest" xlink:label="loc_us-gaap_LitigationSettlementInterest_E078D8E941C5180F0BB822BC234E05B7" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abus_ContingenciesandCommitmentsLineItems_1D7800D87E3399DFC45B22A5BCC7D316" xlink:to="loc_us-gaap_LitigationSettlementInterest_E078D8E941C5180F0BB822BC234E05B7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LossContingencyLossInPeriod" xlink:label="loc_us-gaap_LossContingencyLossInPeriod_2930139CC65D8CF397B022C4AADC80E9" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abus_ContingenciesandCommitmentsLineItems_1D7800D87E3399DFC45B22A5BCC7D316" xlink:to="loc_us-gaap_LossContingencyLossInPeriod_2930139CC65D8CF397B022C4AADC80E9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsForLegalSettlements" xlink:label="loc_us-gaap_PaymentsForLegalSettlements_ABEC9B16DBD66753ABF722BD2E72366D" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abus_ContingenciesandCommitmentsLineItems_1D7800D87E3399DFC45B22A5BCC7D316" xlink:to="loc_us-gaap_PaymentsForLegalSettlements_ABEC9B16DBD66753ABF722BD2E72366D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:label="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_A2405E7AC47DB7354A4522C253757E9C" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abus_ContingenciesandCommitmentsLineItems_1D7800D87E3399DFC45B22A5BCC7D316" xlink:to="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_A2405E7AC47DB7354A4522C253757E9C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_CCF3FD6D5E2ACCF9B22B22A5BCC83FC3" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abus_ContingenciesandCommitmentsLineItems_1D7800D87E3399DFC45B22A5BCC7D316" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_CCF3FD6D5E2ACCF9B22B22A5BCC83FC3" xlink:type="arc" />
    <link:loc xlink:href="abus-20190930.xsd#abus_NumberOfProductsCoveredByPatentAcquiredUnderAgreement" xlink:label="loc_abus_NumberOfProductsCoveredByPatentAcquiredUnderAgreement_8ECD01BCE34600CEDF9E22A5BCC87F9D" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abus_ContingenciesandCommitmentsLineItems_1D7800D87E3399DFC45B22A5BCC7D316" xlink:to="loc_abus_NumberOfProductsCoveredByPatentAcquiredUnderAgreement_8ECD01BCE34600CEDF9E22A5BCC87F9D" xlink:type="arc" />
    <link:loc xlink:href="abus-20190930.xsd#abus_LicenseAgreementMaximumDevelopmentAndRegulatoryMilestonePaymentsPerLicense" xlink:label="loc_abus_LicenseAgreementMaximumDevelopmentAndRegulatoryMilestonePaymentsPerLicense_39292316DAFDE26DC8F022A5BCC893C8" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abus_ContingenciesandCommitmentsLineItems_1D7800D87E3399DFC45B22A5BCC7D316" xlink:to="loc_abus_LicenseAgreementMaximumDevelopmentAndRegulatoryMilestonePaymentsPerLicense_39292316DAFDE26DC8F022A5BCC893C8" xlink:type="arc" />
    <link:loc xlink:href="abus-20190930.xsd#abus_LicenseAgreementMaximumDevelopmentAndRegulatoryMilestonePaymentsPerRoyalty" xlink:label="loc_abus_LicenseAgreementMaximumDevelopmentAndRegulatoryMilestonePaymentsPerRoyalty_2D21ED2AD0F2E46DEEF822A5BCC8B75A" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abus_ContingenciesandCommitmentsLineItems_1D7800D87E3399DFC45B22A5BCC7D316" xlink:to="loc_abus_LicenseAgreementMaximumDevelopmentAndRegulatoryMilestonePaymentsPerRoyalty_2D21ED2AD0F2E46DEEF822A5BCC8B75A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_A581717BF0C47642B23122A5BCC82297" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abus_ContingenciesandCommitmentsLineItems_1D7800D87E3399DFC45B22A5BCC7D316" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_A581717BF0C47642B23122A5BCC82297" xlink:type="arc" />
    <link:loc xlink:href="abus-20190930.xsd#abus_NumberofPatentLicenses" xlink:label="loc_abus_NumberofPatentLicenses_CE78E8FB16505F59C32222A5BCC8F95A" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abus_ContingenciesandCommitmentsLineItems_1D7800D87E3399DFC45B22A5BCC7D316" xlink:to="loc_abus_NumberofPatentLicenses_CE78E8FB16505F59C32222A5BCC8F95A" xlink:type="arc" />
    <link:loc xlink:href="abus-20190930.xsd#abus_ResearchFundingPeriod" xlink:label="loc_abus_ResearchFundingPeriod_67FC3B8D5C9C268A1E6C22A5BCC8E30A" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abus_ContingenciesandCommitmentsLineItems_1D7800D87E3399DFC45B22A5BCC7D316" xlink:to="loc_abus_ResearchFundingPeriod_67FC3B8D5C9C268A1E6C22A5BCC8E30A" xlink:type="arc" />
    <link:loc xlink:href="abus-20190930.xsd#abus_ContractualObligationAmountOfResearchFundingPerYear" xlink:label="loc_abus_ContractualObligationAmountOfResearchFundingPerYear_1F79143E209E0E9D0A0C22A5BCC991F8" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abus_ContingenciesandCommitmentsLineItems_1D7800D87E3399DFC45B22A5BCC7D316" xlink:to="loc_abus_ContractualObligationAmountOfResearchFundingPerYear_1F79143E209E0E9D0A0C22A5BCC991F8" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://arbutusbio.com/role/DocumentAndEntityInformation" xlink:type="extended">
    <link:loc xlink:href="abus-20190930.xsd#abus_DocumentAndEntityInformationAbstract" xlink:label="loc_abus_DocumentAndEntityInformationAbstract_1BFD9D3B5F29449DF1E522A5BD894A0E" xlink:type="locator" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_3FC49B5DDF578D0DAF5322A5BD8978CD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abus_DocumentAndEntityInformationAbstract_1BFD9D3B5F29449DF1E522A5BD894A0E" xlink:to="loc_dei_DocumentType_3FC49B5DDF578D0DAF5322A5BD8978CD" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_1E42C1FD031AE31444A922A5BD897987" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abus_DocumentAndEntityInformationAbstract_1BFD9D3B5F29449DF1E522A5BD894A0E" xlink:to="loc_dei_AmendmentFlag_1E42C1FD031AE31444A922A5BD897987" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_DAF34774C1EC6598632822A5BD895CA8" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abus_DocumentAndEntityInformationAbstract_1BFD9D3B5F29449DF1E522A5BD894A0E" xlink:to="loc_dei_DocumentPeriodEndDate_DAF34774C1EC6598632822A5BD895CA8" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_0E7F7FB317BBDD23BC5F22A5BD898E96" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abus_DocumentAndEntityInformationAbstract_1BFD9D3B5F29449DF1E522A5BD894A0E" xlink:to="loc_dei_EntityRegistrantName_0E7F7FB317BBDD23BC5F22A5BD898E96" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_97B8DD9973D406A9EB0022A5BD895D90" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abus_DocumentAndEntityInformationAbstract_1BFD9D3B5F29449DF1E522A5BD894A0E" xlink:to="loc_dei_EntityCentralIndexKey_97B8DD9973D406A9EB0022A5BD895D90" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_8FC41143DBAA8F70CEE722A5BD8A9BAE" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abus_DocumentAndEntityInformationAbstract_1BFD9D3B5F29449DF1E522A5BD894A0E" xlink:to="loc_dei_CurrentFiscalYearEndDate_8FC41143DBAA8F70CEE722A5BD8A9BAE" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_DB6B07204553FD6E8A3622A5BD8A410D" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abus_DocumentAndEntityInformationAbstract_1BFD9D3B5F29449DF1E522A5BD894A0E" xlink:to="loc_dei_EntityFilerCategory_DB6B07204553FD6E8A3622A5BD8A410D" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_EA0EB168274B8B61EB8B22A5BD8ADF69" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abus_DocumentAndEntityInformationAbstract_1BFD9D3B5F29449DF1E522A5BD894A0E" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_EA0EB168274B8B61EB8B22A5BD8ADF69" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_BB0A6CD651735B56157222A5BD8A12B3" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abus_DocumentAndEntityInformationAbstract_1BFD9D3B5F29449DF1E522A5BD894A0E" xlink:to="loc_dei_EntityCurrentReportingStatus_BB0A6CD651735B56157222A5BD8A12B3" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_5A0F3B67DF6CD37F105722A5BD8ADB30" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abus_DocumentAndEntityInformationAbstract_1BFD9D3B5F29449DF1E522A5BD894A0E" xlink:to="loc_dei_DocumentFiscalYearFocus_5A0F3B67DF6CD37F105722A5BD8ADB30" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_4C63198D869B56AF505822A5BD8AEFB4" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abus_DocumentAndEntityInformationAbstract_1BFD9D3B5F29449DF1E522A5BD894A0E" xlink:to="loc_dei_DocumentFiscalPeriodFocus_4C63198D869B56AF505822A5BD8AEFB4" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_121DF1C247286925B48D22A5BD8AD620" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abus_DocumentAndEntityInformationAbstract_1BFD9D3B5F29449DF1E522A5BD894A0E" xlink:to="loc_dei_EntityEmergingGrowthCompany_121DF1C247286925B48D22A5BD8AD620" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityShellCompany" xlink:label="loc_dei_EntityShellCompany_6FFA953B9473FCBD805522A5BD8B77F6" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abus_DocumentAndEntityInformationAbstract_1BFD9D3B5F29449DF1E522A5BD894A0E" xlink:to="loc_dei_EntityShellCompany_6FFA953B9473FCBD805522A5BD8B77F6" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness_90BCEA8BD3DF49B8392422A5BD8B1B01" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abus_DocumentAndEntityInformationAbstract_1BFD9D3B5F29449DF1E522A5BD894A0E" xlink:to="loc_dei_EntitySmallBusiness_90BCEA8BD3DF49B8392422A5BD8B1B01" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://arbutusbio.com/role/EquityMethodInvestment" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_AFCE06CE1379555E8B7F6CA5DD8107EE" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:label="loc_us-gaap_EquityMethodInvestmentsDisclosureTextBlock_7E0D51BA71FC5D66ABA3F87781A42CED" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_AFCE06CE1379555E8B7F6CA5DD8107EE" xlink:to="loc_us-gaap_EquityMethodInvestmentsDisclosureTextBlock_7E0D51BA71FC5D66ABA3F87781A42CED" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://arbutusbio.com/role/EquityMethodInvestmentDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_09CBF8915E8A1FA886652271CB7DDE72" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_81EB6EB7ABBE49F83E3C2271CB7DD7E6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_09CBF8915E8A1FA886652271CB7DDE72" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_81EB6EB7ABBE49F83E3C2271CB7DD7E6" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_E2109013831DC0A7C0E52271CB7EF6AE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_81EB6EB7ABBE49F83E3C2271CB7DD7E6" xlink:to="loc_dei_LegalEntityAxis_E2109013831DC0A7C0E52271CB7EF6AE" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_AE7E7B25717EB7494CCD2271CB7EAAE8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_E2109013831DC0A7C0E52271CB7EF6AE" xlink:to="loc_dei_EntityDomain_AE7E7B25717EB7494CCD2271CB7EAAE8" xlink:type="arc" />
    <link:loc xlink:href="abus-20190930.xsd#abus_RoivantSciencesLtdMember" xlink:label="loc_abus_RoivantSciencesLtdMember_0AE556DF6FAD8B136BF32271CB7E1B5E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_AE7E7B25717EB7494CCD2271CB7EAAE8" xlink:to="loc_abus_RoivantSciencesLtdMember_0AE556DF6FAD8B136BF32271CB7E1B5E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_B172BF96AD15F665E4C42271CB7F4D8B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_81EB6EB7ABBE49F83E3C2271CB7DD7E6" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_B172BF96AD15F665E4C42271CB7F4D8B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_49D586A9A25B71705F0E2271CB7F6831" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_B172BF96AD15F665E4C42271CB7F4D8B" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_49D586A9A25B71705F0E2271CB7F6831" xlink:type="arc" />
    <link:loc xlink:href="abus-20190930.xsd#abus_GenevantSciencesCorporationMember" xlink:label="loc_abus_GenevantSciencesCorporationMember_A5ECAC950E898206400B2271CB7F4A90" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_49D586A9A25B71705F0E2271CB7F6831" xlink:to="loc_abus_GenevantSciencesCorporationMember_A5ECAC950E898206400B2271CB7F4A90" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_EED131FDDFD02FE0FDF52271CB7F56F9" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_81EB6EB7ABBE49F83E3C2271CB7DD7E6" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_EED131FDDFD02FE0FDF52271CB7F56F9" xlink:type="arc" />
    <link:loc xlink:href="abus-20190930.xsd#abus_EquityMethodInvestmentPropertyContribution" xlink:label="loc_abus_EquityMethodInvestmentPropertyContribution_B00D4BE0434BD4ABA5D02271CB7FC432" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_EED131FDDFD02FE0FDF52271CB7F56F9" xlink:to="loc_abus_EquityMethodInvestmentPropertyContribution_B00D4BE0434BD4ABA5D02271CB7FC432" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_39EC85C9CD8A57FBC4EB2271CB80F50E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_EED131FDDFD02FE0FDF52271CB7F56F9" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_39EC85C9CD8A57FBC4EB2271CB80F50E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_C2593CB560C861F6B0332271CB80636E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_EED131FDDFD02FE0FDF52271CB7F56F9" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_C2593CB560C861F6B0332271CB80636E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityMethodInvestments" xlink:label="loc_us-gaap_EquityMethodInvestments_0BBB32FB76790F125F732271CB805057" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_EED131FDDFD02FE0FDF52271CB7F56F9" xlink:to="loc_us-gaap_EquityMethodInvestments_0BBB32FB76790F125F732271CB805057" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://arbutusbio.com/role/FairValueOfFinancialInstruments" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_8F4A59303A71505CA86369B537749C19" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_BD6E25C2E3145B0683E9C88337B23F18" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_8F4A59303A71505CA86369B537749C19" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_BD6E25C2E3145B0683E9C88337B23F18" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://arbutusbio.com/role/FairValueOfFinancialInstrumentsAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_4F3280D3006EE6F55F04220D839D4719" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8A43FC9B80B0D819FD64220D839D3BE2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_4F3280D3006EE6F55F04220D839D4719" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8A43FC9B80B0D819FD64220D839D3BE2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_E2C273BD9995AC14DF5A220D839E70F3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8A43FC9B80B0D819FD64220D839D3BE2" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_E2C273BD9995AC14DF5A220D839E70F3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_428F1C303BD6AE330AD6220D839ED75D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_E2C273BD9995AC14DF5A220D839E70F3" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_428F1C303BD6AE330AD6220D839ED75D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_7E8A1F25761DD8714ED6220D839EB928" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_428F1C303BD6AE330AD6220D839ED75D" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_7E8A1F25761DD8714ED6220D839EB928" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_42DFCA41E85973D29E27220D839F6205" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8A43FC9B80B0D819FD64220D839D3BE2" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_42DFCA41E85973D29E27220D839F6205" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_FA1261375F7DF15D47B6220D839FBA4D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_42DFCA41E85973D29E27220D839F6205" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_FA1261375F7DF15D47B6220D839FBA4D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_F77DB0154B64598B0F6E220D839FF0F6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_FA1261375F7DF15D47B6220D839FBA4D" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_F77DB0154B64598B0F6E220D839FF0F6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_031CDA948E138B9DE33F220D839F4B9E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_FA1261375F7DF15D47B6220D839FBA4D" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_031CDA948E138B9DE33F220D839F4B9E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_31C71F9F9A5DE0D652B5220D83A06B56" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_FA1261375F7DF15D47B6220D839FBA4D" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_31C71F9F9A5DE0D652B5220D83A06B56" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_E2C2BC36E8365D10AED4220D83A0551B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8A43FC9B80B0D819FD64220D839D3BE2" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_E2C2BC36E8365D10AED4220D83A0551B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_03D1484311141D01ED52220D83A0E76E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_E2C2BC36E8365D10AED4220D83A0551B" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_03D1484311141D01ED52220D83A0E76E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_043AE5F8989205022D6D220D83A07BB3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_03D1484311141D01ED52220D83A0E76E" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_043AE5F8989205022D6D220D83A07BB3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_DFC98B7C07BD8E9AF32E220D83A5EA4E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_03D1484311141D01ED52220D83A0E76E" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_DFC98B7C07BD8E9AF32E220D83A5EA4E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_DE18C872DB1EC84609C9220D83A6C52A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_03D1484311141D01ED52220D83A0E76E" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_DE18C872DB1EC84609C9220D83A6C52A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_B4B97EA55AF95781ADF8220D83A65C65" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_E2C2BC36E8365D10AED4220D83A0551B" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_B4B97EA55AF95781ADF8220D83A65C65" xlink:type="arc" />
    <link:loc xlink:href="abus-20190930.xsd#abus_EmployeeStockOptionsLiabilityClassifiedOutstandingFairValueDisclosure" xlink:label="loc_abus_EmployeeStockOptionsLiabilityClassifiedOutstandingFairValueDisclosure_81FF0186D127FE0FEB4C220D83A6CF94" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/netLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_B4B97EA55AF95781ADF8220D83A65C65" xlink:to="loc_abus_EmployeeStockOptionsLiabilityClassifiedOutstandingFairValueDisclosure_81FF0186D127FE0FEB4C220D83A6CF94" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_31EC4FA0DA922DE6C084220D83A6FEED" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_B4B97EA55AF95781ADF8220D83A65C65" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_31EC4FA0DA922DE6C084220D83A6FEED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_F7A4BADCAE5DA522C4CC220D83A6D6DC" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_B4B97EA55AF95781ADF8220D83A65C65" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_F7A4BADCAE5DA522C4CC220D83A6D6DC" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://arbutusbio.com/role/FairValueOfFinancialInstrumentsChangesInFairValueOfContingentConsiderationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_F1C02C752258B08B92F525AE3C726676" xlink:type="locator" />
    <link:loc xlink:href="abus-20190930.xsd#abus_FairValueLiabilitiesMeasuredonRecurringBasisRollForward" xlink:label="loc_abus_FairValueLiabilitiesMeasuredonRecurringBasisRollForward_8405EC0AB2CA9754B57C25AE3C726AAC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_F1C02C752258B08B92F525AE3C726676" xlink:to="loc_abus_FairValueLiabilitiesMeasuredonRecurringBasisRollForward_8405EC0AB2CA9754B57C25AE3C726AAC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_3442DA15CD3F057FB2F125AE3C72FA68" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abus_FairValueLiabilitiesMeasuredonRecurringBasisRollForward_8405EC0AB2CA9754B57C25AE3C726AAC" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_3442DA15CD3F057FB2F125AE3C72FA68" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_F1386400DB05BA10F4D325AE3C735FCD" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/netLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abus_FairValueLiabilitiesMeasuredonRecurringBasisRollForward_8405EC0AB2CA9754B57C25AE3C726AAC" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_F1386400DB05BA10F4D325AE3C735FCD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_68AA631C9258C767FFA925AE3C73E147" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abus_FairValueLiabilitiesMeasuredonRecurringBasisRollForward_8405EC0AB2CA9754B57C25AE3C726AAC" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_68AA631C9258C767FFA925AE3C73E147" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://arbutusbio.com/role/FairValueOfFinancialInstrumentsChangesInFairValueOfLiabilitiesClassifiedAsStockOptionDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_52D34055336F0778D4882271CBAFC966" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_58760FA0C1263A9890942271CBAF382C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_52D34055336F0778D4882271CBAFC966" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_58760FA0C1263A9890942271CBAF382C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_DEA75AA343EC5AC72A802271CBAF4E5D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_58760FA0C1263A9890942271CBAF382C" xlink:to="loc_us-gaap_AwardTypeAxis_DEA75AA343EC5AC72A802271CBAF4E5D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_C132ADE50E7992D45BA72271CBB084EC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_DEA75AA343EC5AC72A802271CBAF4E5D" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_C132ADE50E7992D45BA72271CBB084EC" xlink:type="arc" />
    <link:loc xlink:href="abus-20190930.xsd#abus_EmployeeStockOptionLiabilityClassifiedMember" xlink:label="loc_abus_EmployeeStockOptionLiabilityClassifiedMember_AF352824FE49E959E6FF2271CBB0D8E2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_C132ADE50E7992D45BA72271CBB084EC" xlink:to="loc_abus_EmployeeStockOptionLiabilityClassifiedMember_AF352824FE49E959E6FF2271CBB0D8E2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_6184525B369BE39609322271CBB0672C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_58760FA0C1263A9890942271CBAF382C" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_6184525B369BE39609322271CBB0672C" xlink:type="arc" />
    <link:loc xlink:href="abus-20190930.xsd#abus_FairValueLiabilitiesMeasuredonRecurringBasisRollForward" xlink:label="loc_abus_FairValueLiabilitiesMeasuredonRecurringBasisRollForward_AE61A533BBDC446119EF2271CBB15E64" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_6184525B369BE39609322271CBB0672C" xlink:to="loc_abus_FairValueLiabilitiesMeasuredonRecurringBasisRollForward_AE61A533BBDC446119EF2271CBB15E64" xlink:type="arc" />
    <link:loc xlink:href="abus-20190930.xsd#abus_EmployeeStockOptionsLiabilityClassifiedOutstandingFairValueDisclosure" xlink:label="loc_abus_EmployeeStockOptionsLiabilityClassifiedOutstandingFairValueDisclosure_27D6EEFE9D2CB9A9B3F32271CBB16437" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abus_FairValueLiabilitiesMeasuredonRecurringBasisRollForward_AE61A533BBDC446119EF2271CBB15E64" xlink:to="loc_abus_EmployeeStockOptionsLiabilityClassifiedOutstandingFairValueDisclosure_27D6EEFE9D2CB9A9B3F32271CBB16437" xlink:type="arc" />
    <link:loc xlink:href="abus-20190930.xsd#abus_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisesinPeriodFairValue" xlink:label="loc_abus_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisesinPeriodFairValue_BAD1BF3A80C80730ADFA2271CBB11A6C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abus_FairValueLiabilitiesMeasuredonRecurringBasisRollForward_AE61A533BBDC446119EF2271CBB15E64" xlink:to="loc_abus_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisesinPeriodFairValue_BAD1BF3A80C80730ADFA2271CBB11A6C" xlink:type="arc" />
    <link:loc xlink:href="abus-20190930.xsd#abus_IncreaseDecreaseinFairValueofLiabilityClassifiedOptions" xlink:label="loc_abus_IncreaseDecreaseinFairValueofLiabilityClassifiedOptions_D681C7BF3C824F4FB3652271CBB1E353" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abus_FairValueLiabilitiesMeasuredonRecurringBasisRollForward_AE61A533BBDC446119EF2271CBB15E64" xlink:to="loc_abus_IncreaseDecreaseinFairValueofLiabilityClassifiedOptions_D681C7BF3C824F4FB3652271CBB1E353" xlink:type="arc" />
    <link:loc xlink:href="abus-20190930.xsd#abus_EmployeeStockOptionsLiabilityClassifiedOutstandingFairValueDisclosure" xlink:label="loc_abus_EmployeeStockOptionsLiabilityClassifiedOutstandingFairValueDisclosure_BFCB9D515EA4AA0594B32271CBB14515" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abus_FairValueLiabilitiesMeasuredonRecurringBasisRollForward_AE61A533BBDC446119EF2271CBB15E64" xlink:to="loc_abus_EmployeeStockOptionsLiabilityClassifiedOutstandingFairValueDisclosure_BFCB9D515EA4AA0594B32271CBB14515" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://arbutusbio.com/role/FairValueOfFinancialInstrumentsTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_2DE2669B043A5CEB90ECA6AA035BCBFF" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_3DB68E3B86A2534DAC4E0166248FDC18" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_2DE2669B043A5CEB90ECA6AA035BCBFF" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_3DB68E3B86A2534DAC4E0166248FDC18" xlink:type="arc" />
    <link:loc xlink:href="abus-20190930.xsd#abus_ChangesInFairValueofLiabilityOptionTableTextBlock" xlink:label="loc_abus_ChangesInFairValueofLiabilityOptionTableTextBlock_D1F70F33421C5B8DBE871534B6C675C8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_2DE2669B043A5CEB90ECA6AA035BCBFF" xlink:to="loc_abus_ChangesInFairValueofLiabilityOptionTableTextBlock_D1F70F33421C5B8DBE871534B6C675C8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_5924CE6B224A5EC9B9DE0CB0487B5598" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_2DE2669B043A5CEB90ECA6AA035BCBFF" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_5924CE6B224A5EC9B9DE0CB0487B5598" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://arbutusbio.com/role/IntangibleAssetsAndGoodwill" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_DCB755D6A3F82EE2445902DE06223BD7" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_B80F453D12A0A4DB277502DE0622F462" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_DCB755D6A3F82EE2445902DE06223BD7" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_B80F453D12A0A4DB277502DE0622F462" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://arbutusbio.com/role/IntangibleAssetsAndGoodwillDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_C147E98B3769330E8BA322A3049AD78D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_8C4CA432DB4D06C8AA5522A3049AE799" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_C147E98B3769330E8BA322A3049AD78D" xlink:to="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_8C4CA432DB4D06C8AA5522A3049AE799" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_A8B4845D9822919F568622A3049A5F55" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_8C4CA432DB4D06C8AA5522A3049AE799" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_A8B4845D9822919F568622A3049A5F55" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_8921C8A192D43C89ED0C22A3049A8532" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_A8B4845D9822919F568622A3049A5F55" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_8921C8A192D43C89ED0C22A3049A8532" xlink:type="arc" />
    <link:loc xlink:href="abus-20190930.xsd#abus_InProcessResearchandDevelopmentcccDNASterilizersMember" xlink:label="loc_abus_InProcessResearchandDevelopmentcccDNASterilizersMember_446EBA45B9DF2DE358E922A3049AC7A8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_8921C8A192D43C89ED0C22A3049A8532" xlink:to="loc_abus_InProcessResearchandDevelopmentcccDNASterilizersMember_446EBA45B9DF2DE358E922A3049AC7A8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_954B774A89927BA3F86F22A3049A1084" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_8C4CA432DB4D06C8AA5522A3049AE799" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_954B774A89927BA3F86F22A3049A1084" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_6AC913BBD64C27A6C2B122A3049A401B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_954B774A89927BA3F86F22A3049A1084" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_6AC913BBD64C27A6C2B122A3049A401B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_5D28BAA53B6A1B374DA422A5A4C6CFF8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_954B774A89927BA3F86F22A3049A1084" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_5D28BAA53B6A1B374DA422A5A4C6CFF8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability_E924F5EFFD3B5450BAB022A3049A20E1" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_954B774A89927BA3F86F22A3049A1084" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability_E924F5EFFD3B5450BAB022A3049A20E1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_C4101617BDFF9E5D6DE722A5A51894E0" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_954B774A89927BA3F86F22A3049A1084" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_C4101617BDFF9E5D6DE722A5A51894E0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_5F12B7AFFBA3BBF66F0822A5A54D07B9" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_954B774A89927BA3F86F22A3049A1084" xlink:to="loc_us-gaap_Goodwill_5F12B7AFFBA3BBF66F0822A5A54D07B9" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://arbutusbio.com/role/Leases" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_9234D381C0E8C4A3F27302DE05FCC740" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_B20AB7A35FED02E7794C02DE05FCD790" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_9234D381C0E8C4A3F27302DE05FCC740" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_B20AB7A35FED02E7794C02DE05FCD790" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://arbutusbio.com/role/LeasesMaturitiesOfLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_60B9AAAB88923BBEE4E92216DD332D55" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_7E3E530AC746C6C49BBE2216DD339FD3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_60B9AAAB88923BBEE4E92216DD332D55" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_7E3E530AC746C6C49BBE2216DD339FD3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_97892AB0EBAC4CF483222216DD33DAAE" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_60B9AAAB88923BBEE4E92216DD332D55" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_97892AB0EBAC4CF483222216DD33DAAE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_3B73E90BB944EB84C58C2216DD336696" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_60B9AAAB88923BBEE4E92216DD332D55" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_3B73E90BB944EB84C58C2216DD336696" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_3963D5CC19F74C7E3B9B2216DD330B45" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_60B9AAAB88923BBEE4E92216DD332D55" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_3963D5CC19F74C7E3B9B2216DD330B45" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_E1AC9991CFDBD02778782216DD343EEB" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_60B9AAAB88923BBEE4E92216DD332D55" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_E1AC9991CFDBD02778782216DD343EEB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_D8262822B4D4E0AC9A142216DD34A7A2" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_60B9AAAB88923BBEE4E92216DD332D55" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_D8262822B4D4E0AC9A142216DD34A7A2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_DE6EA0BD6D7C6A2EF94F2216DD342F24" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_60B9AAAB88923BBEE4E92216DD332D55" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_DE6EA0BD6D7C6A2EF94F2216DD342F24" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_A54BC6A914D9C80341D22216DD342E61" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_60B9AAAB88923BBEE4E92216DD332D55" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_A54BC6A914D9C80341D22216DD342E61" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_85D0154124B5013F1B1C2216DD34842A" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_60B9AAAB88923BBEE4E92216DD332D55" xlink:to="loc_us-gaap_OperatingLeaseLiability_85D0154124B5013F1B1C2216DD34842A" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://arbutusbio.com/role/LeasesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_C9DB1AE382A6A428903906BB9494F4E4" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_00A2485C994411A23E6D06BB9494414F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_C9DB1AE382A6A428903906BB9494F4E4" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_00A2485C994411A23E6D06BB9494414F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseArrangementTypeAxis" xlink:label="loc_us-gaap_LeaseArrangementTypeAxis_FBC866BFD92E55B5EF8506BB94940D8C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_00A2485C994411A23E6D06BB9494414F" xlink:to="loc_us-gaap_LeaseArrangementTypeAxis_FBC866BFD92E55B5EF8506BB94940D8C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:label="loc_us-gaap_LeaseArrangementTypeDomain_CAFE7F1C49C47F684F3A06BB94944505" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseArrangementTypeAxis_FBC866BFD92E55B5EF8506BB94940D8C" xlink:to="loc_us-gaap_LeaseArrangementTypeDomain_CAFE7F1C49C47F684F3A06BB94944505" xlink:type="arc" />
    <link:loc xlink:href="abus-20190930.xsd#abus_CorporateHeadquartersLocated701VeteransCircleWarminsterPennsylvaniaMember" xlink:label="loc_abus_CorporateHeadquartersLocated701VeteransCircleWarminsterPennsylvaniaMember_F490152DAF8D4C5068F606BB94947250" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseArrangementTypeDomain_CAFE7F1C49C47F684F3A06BB94944505" xlink:to="loc_abus_CorporateHeadquartersLocated701VeteransCircleWarminsterPennsylvaniaMember_F490152DAF8D4C5068F606BB94947250" xlink:type="arc" />
    <link:loc xlink:href="abus-20190930.xsd#abus_OfficesLocatedat626JacksonvilleRd.WarminsterPennsylvaniaMember" xlink:label="loc_abus_OfficesLocatedat626JacksonvilleRd.WarminsterPennsylvaniaMember_C0FD2C731CA6C173C79806BB949471B2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseArrangementTypeDomain_CAFE7F1C49C47F684F3A06BB94944505" xlink:to="loc_abus_OfficesLocatedat626JacksonvilleRd.WarminsterPennsylvaniaMember_C0FD2C731CA6C173C79806BB949471B2" xlink:type="arc" />
    <link:loc xlink:href="abus-20190930.xsd#abus_SubleaseBurnabyFacilityMember" xlink:label="loc_abus_SubleaseBurnabyFacilityMember_ECD67A58DE9F4D449A4C06BB9494600D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseArrangementTypeDomain_CAFE7F1C49C47F684F3A06BB94944505" xlink:to="loc_abus_SubleaseBurnabyFacilityMember_ECD67A58DE9F4D449A4C06BB9494600D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_3B20AF102D82D3DEA75306BB94948472" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_00A2485C994411A23E6D06BB9494414F" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_3B20AF102D82D3DEA75306BB94948472" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_B75698FC8FC0E5AF68D206BB94945583" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_3B20AF102D82D3DEA75306BB94948472" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_B75698FC8FC0E5AF68D206BB94945583" xlink:type="arc" />
    <link:loc xlink:href="abus-20190930.xsd#abus_GenevantSciencesCorporationMember" xlink:label="loc_abus_GenevantSciencesCorporationMember_A42222D239D898AD348A06BB94941A6E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_B75698FC8FC0E5AF68D206BB94945583" xlink:to="loc_abus_GenevantSciencesCorporationMember_A42222D239D898AD348A06BB94941A6E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_6860ED463086CB7FCCAF06BB94948E4A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_00A2485C994411A23E6D06BB9494414F" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_6860ED463086CB7FCCAF06BB94948E4A" xlink:type="arc" />
    <link:loc xlink:href="abus-20190930.xsd#abus_LesseeOperatingLeaseNumberofLeases" xlink:label="loc_abus_LesseeOperatingLeaseNumberofLeases_670FA3B50FEE7A50B5E706BB94947CE0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6860ED463086CB7FCCAF06BB94948E4A" xlink:to="loc_abus_LesseeOperatingLeaseNumberofLeases_670FA3B50FEE7A50B5E706BB94947CE0" xlink:type="arc" />
    <link:loc xlink:href="abus-20190930.xsd#abus_LesseeOperatingLeaseNumberOfRenewalOptions" xlink:label="loc_abus_LesseeOperatingLeaseNumberOfRenewalOptions_A4C933B28E1D0A6C663B06BB9494C71A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6860ED463086CB7FCCAF06BB94948E4A" xlink:to="loc_abus_LesseeOperatingLeaseNumberOfRenewalOptions_A4C933B28E1D0A6C663B06BB9494C71A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LessorOperatingLeaseRenewalTerm" xlink:label="loc_us-gaap_LessorOperatingLeaseRenewalTerm_727B87B30001A33FFD9506BB94940683" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6860ED463086CB7FCCAF06BB94948E4A" xlink:to="loc_us-gaap_LessorOperatingLeaseRenewalTerm_727B87B30001A33FFD9506BB94940683" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseDiscountRate" xlink:label="loc_us-gaap_LesseeOperatingLeaseDiscountRate_45AE6F8147EE7446A7FA06BB9494DBB9" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6860ED463086CB7FCCAF06BB94948E4A" xlink:to="loc_us-gaap_LesseeOperatingLeaseDiscountRate_45AE6F8147EE7446A7FA06BB9494DBB9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseExpense" xlink:label="loc_us-gaap_OperatingLeaseExpense_FFD10BA008B9E91D981A06BB9494ED58" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6860ED463086CB7FCCAF06BB94948E4A" xlink:to="loc_us-gaap_OperatingLeaseExpense_FFD10BA008B9E91D981A06BB9494ED58" xlink:type="arc" />
    <link:loc xlink:href="abus-20190930.xsd#abus_FixedLeaseCost" xlink:label="loc_abus_FixedLeaseCost_DA7CEA2CA93B0E03AFDF06BB94948C62" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6860ED463086CB7FCCAF06BB94948E4A" xlink:to="loc_abus_FixedLeaseCost_DA7CEA2CA93B0E03AFDF06BB94948C62" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_VariableLeaseCost" xlink:label="loc_us-gaap_VariableLeaseCost_7EBDA04837E6CC99796906BB9494F83C" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6860ED463086CB7FCCAF06BB94948E4A" xlink:to="loc_us-gaap_VariableLeaseCost_7EBDA04837E6CC99796906BB9494F83C" xlink:type="arc" />
    <link:loc xlink:href="abus-20190930.xsd#abus_StrightlineFixedLeaseCost" xlink:label="loc_abus_StrightlineFixedLeaseCost_87C9CD7962F887FFDE3B06BB9494F41A" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6860ED463086CB7FCCAF06BB94948E4A" xlink:to="loc_abus_StrightlineFixedLeaseCost_87C9CD7962F887FFDE3B06BB9494F41A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubleaseIncome" xlink:label="loc_us-gaap_SubleaseIncome_31A0EA7F74F62086C39406BB9494E938" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6860ED463086CB7FCCAF06BB94948E4A" xlink:to="loc_us-gaap_SubleaseIncome_31A0EA7F74F62086C39406BB9494E938" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://arbutusbio.com/role/LeasesSupplementalCashFlowInformationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_A52F5D21669C54DCA1281BBE03D3E7EC" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaap_OperatingLeasePayments_8B2AB2EDC9D95CA7B24A40449AEEC1A0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_A52F5D21669C54DCA1281BBE03D3E7EC" xlink:to="loc_us-gaap_OperatingLeasePayments_8B2AB2EDC9D95CA7B24A40449AEEC1A0" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://arbutusbio.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_0F18A937393B516E94ADA6687D1B50BC" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_D87FF64440205F3F86452916CC1E01A2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_0F18A937393B516E94ADA6687D1B50BC" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_D87FF64440205F3F86452916CC1E01A2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_3290DC90F8D85D0B9D958C548DBC3D8E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_0F18A937393B516E94ADA6687D1B50BC" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_3290DC90F8D85D0B9D958C548DBC3D8E" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://arbutusbio.com/role/LeasesWeightedAverageRemainingLeaseTermAndDiscountRateDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_A0C25632AA5E4D39A94106BB9482E113" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_304307865FB5E806E8A206BB94828579" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_A0C25632AA5E4D39A94106BB9482E113" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_304307865FB5E806E8A206BB94828579" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_1638AC13171D10DA3A0606BB9482DC9E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_A0C25632AA5E4D39A94106BB9482E113" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_1638AC13171D10DA3A0606BB9482DC9E" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://arbutusbio.com/role/NatureOfBusinessAndFutureOperations" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0E1D91A3FEDA5B1AA8F307EE9D762D80" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NatureOfOperations" xlink:label="loc_us-gaap_NatureOfOperations_56503DCA353C575F9145A98AC3B081B8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0E1D91A3FEDA5B1AA8F307EE9D762D80" xlink:to="loc_us-gaap_NatureOfOperations_56503DCA353C575F9145A98AC3B081B8" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://arbutusbio.com/role/RelatedPartyTransaction" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_E34C0002288B51A28990C888AE977923" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_D19C7457983A5F67A854B08B4A0EBD08" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_E34C0002288B51A28990C888AE977923" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_D19C7457983A5F67A854B08B4A0EBD08" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://arbutusbio.com/role/RelatedPartyTransactionDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_7F77F40F69825AC072DF25AE3BD3DF20" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_C1A44E62DEAE562F44B525AE3BD31EC0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_7F77F40F69825AC072DF25AE3BD3DF20" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_C1A44E62DEAE562F44B525AE3BD31EC0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_DC7AFD7AB16E30E00C0725AE3BD3A506" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_C1A44E62DEAE562F44B525AE3BD31EC0" xlink:to="loc_srt_CounterpartyNameAxis_DC7AFD7AB16E30E00C0725AE3BD3A506" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1E41B19EF33B3D87616525AE3BD4FACC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_DC7AFD7AB16E30E00C0725AE3BD3A506" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1E41B19EF33B3D87616525AE3BD4FACC" xlink:type="arc" />
    <link:loc xlink:href="abus-20190930.xsd#abus_GenevantSciencesCorporationMember" xlink:label="loc_abus_GenevantSciencesCorporationMember_512CD5E98B9A026B12D225AE3BD49D9C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1E41B19EF33B3D87616525AE3BD4FACC" xlink:to="loc_abus_GenevantSciencesCorporationMember_512CD5E98B9A026B12D225AE3BD49D9C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_FB8A2A7D3D1D800E729425AE3BD493BB" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_C1A44E62DEAE562F44B525AE3BD31EC0" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_FB8A2A7D3D1D800E729425AE3BD493BB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_45D7782822C03CCD955825AE3BD4B7CF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_FB8A2A7D3D1D800E729425AE3BD493BB" xlink:to="loc_us-gaap_RelatedPartyDomain_45D7782822C03CCD955825AE3BD4B7CF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityMethodInvesteeMember" xlink:label="loc_us-gaap_EquityMethodInvesteeMember_311E4ADD0D90DC33B2DD25AE3BD5733C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_45D7782822C03CCD955825AE3BD4B7CF" xlink:to="loc_us-gaap_EquityMethodInvesteeMember_311E4ADD0D90DC33B2DD25AE3BD5733C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_ACAFBBF02AC3851CCB5525AE3BD5FBAD" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_C1A44E62DEAE562F44B525AE3BD31EC0" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_ACAFBBF02AC3851CCB5525AE3BD5FBAD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_BBE91D3C5777F2286B7A25AE3BD5C1E7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_ACAFBBF02AC3851CCB5525AE3BD5FBAD" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_BBE91D3C5777F2286B7A25AE3BD5C1E7" xlink:type="arc" />
    <link:loc xlink:href="abus-20190930.xsd#abus_ResearchAndDevelopmentServicesMember" xlink:label="loc_abus_ResearchAndDevelopmentServicesMember_DF97D9586FB249DE13E225AE3BD6EA6B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_BBE91D3C5777F2286B7A25AE3BD5C1E7" xlink:to="loc_abus_ResearchAndDevelopmentServicesMember_DF97D9586FB249DE13E225AE3BD6EA6B" xlink:type="arc" />
    <link:loc xlink:href="abus-20190930.xsd#abus_AdministrativeAndTransitionalServicesMember" xlink:label="loc_abus_AdministrativeAndTransitionalServicesMember_A04120C725DCA5C6D77A25AE3BD65544" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_BBE91D3C5777F2286B7A25AE3BD5C1E7" xlink:to="loc_abus_AdministrativeAndTransitionalServicesMember_A04120C725DCA5C6D77A25AE3BD65544" xlink:type="arc" />
    <link:loc xlink:href="abus-20190930.xsd#abus_SubleaseBurnabyFacilityMember" xlink:label="loc_abus_SubleaseBurnabyFacilityMember_D5AD0AC5B2EC57D83ECD25AE3BD65122" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_BBE91D3C5777F2286B7A25AE3BD5C1E7" xlink:to="loc_abus_SubleaseBurnabyFacilityMember_D5AD0AC5B2EC57D83ECD25AE3BD65122" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_202C5004BCE7D51EBD4E25AE3BD66834" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_C1A44E62DEAE562F44B525AE3BD31EC0" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_202C5004BCE7D51EBD4E25AE3BD66834" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:label="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_13998BFE435DEF59479C25AE3BD79125" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_202C5004BCE7D51EBD4E25AE3BD66834" xlink:to="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_13998BFE435DEF59479C25AE3BD79125" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromRelatedParties" xlink:label="loc_us-gaap_RevenueFromRelatedParties_709345E1E845BCFEC4C825AE3BD7F38B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_202C5004BCE7D51EBD4E25AE3BD66834" xlink:to="loc_us-gaap_RevenueFromRelatedParties_709345E1E845BCFEC4C825AE3BD7F38B" xlink:type="arc" />
    <link:loc xlink:href="abus-20190930.xsd#abus_NetRentableAreaSublease" xlink:label="loc_abus_NetRentableAreaSublease_42381E083C94BFBB40A725AE3BD7A523" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_202C5004BCE7D51EBD4E25AE3BD66834" xlink:to="loc_abus_NetRentableAreaSublease_42381E083C94BFBB40A725AE3BD7A523" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://arbutusbio.com/role/SaleOfFutureRoyalties" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_B3A40610212A88D9F83D02ED1D80012D" xlink:type="locator" />
    <link:loc xlink:href="abus-20190930.xsd#abus_LiabilitiesRelatedToSaleOfFutureRoyaltiesTextBlock" xlink:label="loc_abus_LiabilitiesRelatedToSaleOfFutureRoyaltiesTextBlock_BBDEC3478E30698D130502ED1D809747" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_B3A40610212A88D9F83D02ED1D80012D" xlink:to="loc_abus_LiabilitiesRelatedToSaleOfFutureRoyaltiesTextBlock_BBDEC3478E30698D130502ED1D809747" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://arbutusbio.com/role/SaleOfFutureRoyaltiesLiabilityActivityDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_2B411B33020DFED8DB9A22A5BCCF4B8A" xlink:type="locator" />
    <link:loc xlink:href="abus-20190930.xsd#abus_LiabilityRelatedToSaleOfFutureRoyaltiesRollForward" xlink:label="loc_abus_LiabilityRelatedToSaleOfFutureRoyaltiesRollForward_7E5DB8DCB2B38967D65922A5BCCFA45C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_2B411B33020DFED8DB9A22A5BCCF4B8A" xlink:to="loc_abus_LiabilityRelatedToSaleOfFutureRoyaltiesRollForward_7E5DB8DCB2B38967D65922A5BCCFA45C" xlink:type="arc" />
    <link:loc xlink:href="abus-20190930.xsd#abus_LiabilityRelatedToSaleOfFutureRoyalties" xlink:label="loc_abus_LiabilityRelatedToSaleOfFutureRoyalties_E497CB9A0A2412CAF07E22A5BCCF4597" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abus_LiabilityRelatedToSaleOfFutureRoyaltiesRollForward_7E5DB8DCB2B38967D65922A5BCCFA45C" xlink:to="loc_abus_LiabilityRelatedToSaleOfFutureRoyalties_E497CB9A0A2412CAF07E22A5BCCF4597" xlink:type="arc" />
    <link:loc xlink:href="abus-20190930.xsd#abus_LiabilityFromSaleOfFutureRoyaltiesAdditions" xlink:label="loc_abus_LiabilityFromSaleOfFutureRoyaltiesAdditions_59BECD2FA509DF43815322A5BCD07D41" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abus_LiabilityRelatedToSaleOfFutureRoyaltiesRollForward_7E5DB8DCB2B38967D65922A5BCCFA45C" xlink:to="loc_abus_LiabilityFromSaleOfFutureRoyaltiesAdditions_59BECD2FA509DF43815322A5BCD07D41" xlink:type="arc" />
    <link:loc xlink:href="abus-20190930.xsd#abus_LiabilityFromSaleOfFutureRoyaltiesDiscountsAndIssuanceCosts" xlink:label="loc_abus_LiabilityFromSaleOfFutureRoyaltiesDiscountsAndIssuanceCosts_5C1B7165F67B219CF5B922A5BCD05994" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abus_LiabilityRelatedToSaleOfFutureRoyaltiesRollForward_7E5DB8DCB2B38967D65922A5BCCFA45C" xlink:to="loc_abus_LiabilityFromSaleOfFutureRoyaltiesDiscountsAndIssuanceCosts_5C1B7165F67B219CF5B922A5BCD05994" xlink:type="arc" />
    <link:loc xlink:href="abus-20190930.xsd#abus_LiabilityFromSaleOfFutureRoyaltiesNonCashRoyaltyIncome" xlink:label="loc_abus_LiabilityFromSaleOfFutureRoyaltiesNonCashRoyaltyIncome_63434F75EE7359FB18B322A5BCD0B273" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abus_LiabilityRelatedToSaleOfFutureRoyaltiesRollForward_7E5DB8DCB2B38967D65922A5BCCFA45C" xlink:to="loc_abus_LiabilityFromSaleOfFutureRoyaltiesNonCashRoyaltyIncome_63434F75EE7359FB18B322A5BCD0B273" xlink:type="arc" />
    <link:loc xlink:href="abus-20190930.xsd#abus_LiabilityFromSaleOfFutureRoyaltiesNonCashExpense" xlink:label="loc_abus_LiabilityFromSaleOfFutureRoyaltiesNonCashExpense_71F92C32FC6B369F623A22A5BCD0184E" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abus_LiabilityRelatedToSaleOfFutureRoyaltiesRollForward_7E5DB8DCB2B38967D65922A5BCCFA45C" xlink:to="loc_abus_LiabilityFromSaleOfFutureRoyaltiesNonCashExpense_71F92C32FC6B369F623A22A5BCD0184E" xlink:type="arc" />
    <link:loc xlink:href="abus-20190930.xsd#abus_LiabilityRelatedToSaleOfFutureRoyalties" xlink:label="loc_abus_LiabilityRelatedToSaleOfFutureRoyalties_10004952148457823C1822A5BCD0775F" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abus_LiabilityRelatedToSaleOfFutureRoyaltiesRollForward_7E5DB8DCB2B38967D65922A5BCCFA45C" xlink:to="loc_abus_LiabilityRelatedToSaleOfFutureRoyalties_10004952148457823C1822A5BCD0775F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://arbutusbio.com/role/SaleOfFutureRoyaltiesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_6D9AFAF669C9D79C0B1037F6E1367D54" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AirlineProductsAndServicesTable" xlink:label="loc_us-gaap_AirlineProductsAndServicesTable_EF103123BF7F0FE76C9C37F6E1368F8A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_6D9AFAF669C9D79C0B1037F6E1367D54" xlink:to="loc_us-gaap_AirlineProductsAndServicesTable_EF103123BF7F0FE76C9C37F6E1368F8A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_EAEE2AF0984EC8B9757B37F6E1372394" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AirlineProductsAndServicesTable_EF103123BF7F0FE76C9C37F6E1368F8A" xlink:to="loc_srt_CounterpartyNameAxis_EAEE2AF0984EC8B9757B37F6E1372394" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_26103288836D7187435F37F6E1374012" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_EAEE2AF0984EC8B9757B37F6E1372394" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_26103288836D7187435F37F6E1374012" xlink:type="arc" />
    <link:loc xlink:href="abus-20190930.xsd#abus_OMERSMember" xlink:label="loc_abus_OMERSMember_774F15CE50361F5E72C437F6E1371F44" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_26103288836D7187435F37F6E1374012" xlink:to="loc_abus_OMERSMember_774F15CE50361F5E72C437F6E1371F44" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_0990859F55F7A79DF59637F6E1388988" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AirlineProductsAndServicesTable_EF103123BF7F0FE76C9C37F6E1368F8A" xlink:to="loc_srt_RangeAxis_0990859F55F7A79DF59637F6E1388988" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_0AB4243930815FFA59D837F6E1382AC3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_0990859F55F7A79DF59637F6E1388988" xlink:to="loc_srt_RangeMember_0AB4243930815FFA59D837F6E1382AC3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_42CF3AB6B8ECD83A15D537F6E1384B29" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_0AB4243930815FFA59D837F6E1382AC3" xlink:to="loc_srt_MinimumMember_42CF3AB6B8ECD83A15D537F6E1384B29" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_6C88CFC9F48D505B6ED437F6E1387C2D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_0AB4243930815FFA59D837F6E1382AC3" xlink:to="loc_srt_MaximumMember_6C88CFC9F48D505B6ED437F6E1387C2D" xlink:type="arc" />
    <link:loc xlink:href="abus-20190930.xsd#abus_OtherLiabilitiesDisclosureLineItems" xlink:label="loc_abus_OtherLiabilitiesDisclosureLineItems_54A6764CA633B079610537F6E139EBB8" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AirlineProductsAndServicesTable_EF103123BF7F0FE76C9C37F6E1368F8A" xlink:to="loc_abus_OtherLiabilitiesDisclosureLineItems_54A6764CA633B079610537F6E139EBB8" xlink:type="arc" />
    <link:loc xlink:href="abus-20190930.xsd#abus_RoyaltyPercentageofInterestSold" xlink:label="loc_abus_RoyaltyPercentageofInterestSold_C77E87CC76B339BE49E437F6E13933E6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abus_OtherLiabilitiesDisclosureLineItems_54A6764CA633B079610537F6E139EBB8" xlink:to="loc_abus_RoyaltyPercentageofInterestSold_C77E87CC76B339BE49E437F6E13933E6" xlink:type="arc" />
    <link:loc xlink:href="abus-20190930.xsd#abus_RoyaltyInterestSoldPercentageOfSalesAnnualRevenueThresholdOfHighestTier" xlink:label="loc_abus_RoyaltyInterestSoldPercentageOfSalesAnnualRevenueThresholdOfHighestTier_3933366E059E7174410637F6E13919CD" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abus_OtherLiabilitiesDisclosureLineItems_54A6764CA633B079610537F6E139EBB8" xlink:to="loc_abus_RoyaltyInterestSoldPercentageOfSalesAnnualRevenueThresholdOfHighestTier_3933366E059E7174410637F6E13919CD" xlink:type="arc" />
    <link:loc xlink:href="abus-20190930.xsd#abus_GrossProceedsFromRoyaltyInterestSold" xlink:label="loc_abus_GrossProceedsFromRoyaltyInterestSold_B1E7E56A22C3761B6A4E37F6E1397C2E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abus_OtherLiabilitiesDisclosureLineItems_54A6764CA633B079610537F6E139EBB8" xlink:to="loc_abus_GrossProceedsFromRoyaltyInterestSold_B1E7E56A22C3761B6A4E37F6E1397C2E" xlink:type="arc" />
    <link:loc xlink:href="abus-20190930.xsd#abus_RoyaltyInterestSoldMaximumRoyaltiesForBuyer" xlink:label="loc_abus_RoyaltyInterestSoldMaximumRoyaltiesForBuyer_9E1A830204AD21DD9FBE37F6E1394994" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abus_OtherLiabilitiesDisclosureLineItems_54A6764CA633B079610537F6E139EBB8" xlink:to="loc_abus_RoyaltyInterestSoldMaximumRoyaltiesForBuyer_9E1A830204AD21DD9FBE37F6E1394994" xlink:type="arc" />
    <link:loc xlink:href="abus-20190930.xsd#abus_RoyaltyGuaranteesCommitmentsPercentage" xlink:label="loc_abus_RoyaltyGuaranteesCommitmentsPercentage_DCA5FAC4D0F01F81FB7737F6E13AB660" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abus_OtherLiabilitiesDisclosureLineItems_54A6764CA633B079610537F6E139EBB8" xlink:to="loc_abus_RoyaltyGuaranteesCommitmentsPercentage_DCA5FAC4D0F01F81FB7737F6E13AB660" xlink:type="arc" />
    <link:loc xlink:href="abus-20190930.xsd#abus_RoyaltyPayable" xlink:label="loc_abus_RoyaltyPayable_48867B464149732419C837F6E13A42C0" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abus_OtherLiabilitiesDisclosureLineItems_54A6764CA633B079610537F6E139EBB8" xlink:to="loc_abus_RoyaltyPayable_48867B464149732419C837F6E13A42C0" xlink:type="arc" />
    <link:loc xlink:href="abus-20190930.xsd#abus_TransactionCostsRelatedToSaleOfFutureRoyalties" xlink:label="loc_abus_TransactionCostsRelatedToSaleOfFutureRoyalties_4EFF4865FA617B0B7B9037F6E13AE346" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abus_OtherLiabilitiesDisclosureLineItems_54A6764CA633B079610537F6E139EBB8" xlink:to="loc_abus_TransactionCostsRelatedToSaleOfFutureRoyalties_4EFF4865FA617B0B7B9037F6E13AE346" xlink:type="arc" />
    <link:loc xlink:href="abus-20190930.xsd#abus_EffectiveAnnualInterestRateOfRoyaltyLiability" xlink:label="loc_abus_EffectiveAnnualInterestRateOfRoyaltyLiability_5609BE2E7EB93777C4AD37F6E13ABB6F" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abus_OtherLiabilitiesDisclosureLineItems_54A6764CA633B079610537F6E139EBB8" xlink:to="loc_abus_EffectiveAnnualInterestRateOfRoyaltyLiability_5609BE2E7EB93777C4AD37F6E13ABB6F" xlink:type="arc" />
    <link:loc xlink:href="abus-20190930.xsd#abus_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" xlink:label="loc_abus_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties_53B56B98F40D6F50FB5E37F6E13A3BB2" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abus_OtherLiabilitiesDisclosureLineItems_54A6764CA633B079610537F6E139EBB8" xlink:to="loc_abus_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties_53B56B98F40D6F50FB5E37F6E13A3BB2" xlink:type="arc" />
    <link:loc xlink:href="abus-20190930.xsd#abus_NonCashRoyaltyExpenseRelatedToSaleOfFutureRoyalties" xlink:label="loc_abus_NonCashRoyaltyExpenseRelatedToSaleOfFutureRoyalties_6E61EB4AC6800F9F595B37F6E13A0E92" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abus_OtherLiabilitiesDisclosureLineItems_54A6764CA633B079610537F6E139EBB8" xlink:to="loc_abus_NonCashRoyaltyExpenseRelatedToSaleOfFutureRoyalties_6E61EB4AC6800F9F595B37F6E13A0E92" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://arbutusbio.com/role/SaleOfFutureRoyaltiesTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_78C1F0BFCA9EBBDEF16B22B97A65C0B7" xlink:type="locator" />
    <link:loc xlink:href="abus-20190930.xsd#abus_LiabilitiesRelatedToSaleOfFutureRoyaltiesRollForwardTableTextBlock" xlink:label="loc_abus_LiabilitiesRelatedToSaleOfFutureRoyaltiesRollForwardTableTextBlock_95E3DC8D7BFB471AC6B922A5BCDC5D10" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_78C1F0BFCA9EBBDEF16B22B97A65C0B7" xlink:to="loc_abus_LiabilitiesRelatedToSaleOfFutureRoyaltiesRollForwardTableTextBlock_95E3DC8D7BFB471AC6B922A5BCDC5D10" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://arbutusbio.com/role/SignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_4253A7DF047F5773A35CE3134B580057" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_B552AD8232415AB6BC6395812AEE5A71" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4253A7DF047F5773A35CE3134B580057" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_B552AD8232415AB6BC6395812AEE5A71" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://arbutusbio.com/role/SignificantAccountingPoliciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_847196B7CCB51B07382A06BB94D7B042" xlink:type="locator" />
    <link:loc xlink:href="abus-20190930.xsd#abus_WhollyOwnedSubsidiariesIncludedinFinancialStatements" xlink:label="loc_abus_WhollyOwnedSubsidiariesIncludedinFinancialStatements_00F15E7C9FCD61B4A5C406BB94D7DE71" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_847196B7CCB51B07382A06BB94D7B042" xlink:to="loc_abus_WhollyOwnedSubsidiariesIncludedinFinancialStatements_00F15E7C9FCD61B4A5C406BB94D7DE71" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_16E81968537F7C584F9606BB94D73DDD" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_847196B7CCB51B07382A06BB94D7B042" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_16E81968537F7C584F9606BB94D73DDD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_C194A904B1C87CF7A59506BB94D74898" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_847196B7CCB51B07382A06BB94D7B042" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_C194A904B1C87CF7A59506BB94D74898" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_DAB995D74C840D35B6B606BB94D7EDB8" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_847196B7CCB51B07382A06BB94D7B042" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_DAB995D74C840D35B6B606BB94D7EDB8" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://arbutusbio.com/role/SignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_3A671A77B6727742DB4B223D3FA3FFC2" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_2CE57B845A1352BD06D1223D3FA3F874" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3A671A77B6727742DB4B223D3FA3FFC2" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_2CE57B845A1352BD06D1223D3FA3F874" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_F885462D5149424DD04A223D3FA4A8C4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3A671A77B6727742DB4B223D3FA3FFC2" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_F885462D5149424DD04A223D3FA4A8C4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_7557A2BD2B23DCD52A12223D3FA49AB0" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3A671A77B6727742DB4B223D3FA3FFC2" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_7557A2BD2B23DCD52A12223D3FA49AB0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityMethodInvestmentsPolicy" xlink:label="loc_us-gaap_EquityMethodInvestmentsPolicy_B5BE6FC302CCF0BB72C6223D3FA47D57" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3A671A77B6727742DB4B223D3FA3FFC2" xlink:to="loc_us-gaap_EquityMethodInvestmentsPolicy_B5BE6FC302CCF0BB72C6223D3FA47D57" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_FCB5C2AED75868A1A6E3223D3FA4130C" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3A671A77B6727742DB4B223D3FA3FFC2" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_FCB5C2AED75868A1A6E3223D3FA4130C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_218B350CCCD77855281C2258333C4683" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3A671A77B6727742DB4B223D3FA3FFC2" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_218B350CCCD77855281C2258333C4683" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_1FC20068F7385AFDA4C5223D3FA474A6" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3A671A77B6727742DB4B223D3FA3FFC2" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_1FC20068F7385AFDA4C5223D3FA474A6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_122AA0DD9762F38E6699223D3FA45924" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3A671A77B6727742DB4B223D3FA3FFC2" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_122AA0DD9762F38E6699223D3FA45924" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://arbutusbio.com/role/SignificantAccountingPoliciesScheduleOfComputationOfBasicAndDilutedIncomeLossDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_D3C1ECD1F1A779A08F892216DDD3B005" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_2AAC4A8158D85ACB9A972216DDD33788" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_D3C1ECD1F1A779A08F892216DDD3B005" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_2AAC4A8158D85ACB9A972216DDD33788" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_9F9D9F0E6D517404969F2216DDD39050" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_2AAC4A8158D85ACB9A972216DDD33788" xlink:to="loc_us-gaap_StatementClassOfStockAxis_9F9D9F0E6D517404969F2216DDD39050" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_358F592153C7E08A12D52216DDD3A483" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_9F9D9F0E6D517404969F2216DDD39050" xlink:to="loc_us-gaap_ClassOfStockDomain_358F592153C7E08A12D52216DDD3A483" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_BD15C47E71A72D3924452216DDD40017" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_358F592153C7E08A12D52216DDD3A483" xlink:to="loc_us-gaap_CommonStockMember_BD15C47E71A72D3924452216DDD40017" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasicLineItems" xlink:label="loc_us-gaap_EarningsPerShareBasicLineItems_458CEA408BE31A8F3FAB2216DDD4049F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_2AAC4A8158D85ACB9A972216DDD33788" xlink:to="loc_us-gaap_EarningsPerShareBasicLineItems_458CEA408BE31A8F3FAB2216DDD4049F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasicAbstract" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract_65A638B917648CA4032D2216DDD42B1D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_458CEA408BE31A8F3FAB2216DDD4049F" xlink:to="loc_us-gaap_EarningsPerShareBasicAbstract_65A638B917648CA4032D2216DDD42B1D" xlink:type="arc" />
    <link:loc xlink:href="abus-20190930.xsd#abus_DistributableEarningsLossAvailabletoCommonShareholdersBasic" xlink:label="loc_abus_DistributableEarningsLossAvailabletoCommonShareholdersBasic_DCB013AEBCF33AE3CC952216DDD468E6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_65A638B917648CA4032D2216DDD42B1D" xlink:to="loc_abus_DistributableEarningsLossAvailabletoCommonShareholdersBasic_DCB013AEBCF33AE3CC952216DDD468E6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UndistributedEarningsLossAvailableToCommonShareholdersBasic" xlink:label="loc_us-gaap_UndistributedEarningsLossAvailableToCommonShareholdersBasic_B35054FB83447F79D8332216DDD585F8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_65A638B917648CA4032D2216DDD42B1D" xlink:to="loc_us-gaap_UndistributedEarningsLossAvailableToCommonShareholdersBasic_B35054FB83447F79D8332216DDD585F8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_EC859D890440EACDF6272216DDD58A4F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_65A638B917648CA4032D2216DDD42B1D" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_EC859D890440EACDF6272216DDD58A4F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareDilutedAbstract" xlink:label="loc_us-gaap_EarningsPerShareDilutedAbstract_1DC9C8E27A38DEF1B8522216DDD54100" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_458CEA408BE31A8F3FAB2216DDD4049F" xlink:to="loc_us-gaap_EarningsPerShareDilutedAbstract_1DC9C8E27A38DEF1B8522216DDD54100" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_9026D562B1C21E17CD5A2216DDD5C241" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_1DC9C8E27A38DEF1B8522216DDD54100" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_9026D562B1C21E17CD5A2216DDD5C241" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_FB13E61C2E104E5913302216DDD62BAA" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_1DC9C8E27A38DEF1B8522216DDD54100" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_FB13E61C2E104E5913302216DDD62BAA" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://arbutusbio.com/role/SignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_3F23F5E5E5645DFAACB06EC24D64BB75" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_8C478FEDD50D5ADAB839A5B1CF23CF29" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3F23F5E5E5645DFAACB06EC24D64BB75" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_8C478FEDD50D5ADAB839A5B1CF23CF29" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://arbutusbio.com/role/SiteConsolidation" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_232BA65A4CCBD8D6C29F02DE060ED039" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_6B647D9408083361ECA602DE060E081C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_232BA65A4CCBD8D6C29F02DE060ED039" xlink:to="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_6B647D9408083361ECA602DE060E081C" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://arbutusbio.com/role/SiteConsolidationConsolidationExpensesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_0FC97208931250C8B8406D010BD972B9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_8D7F440F7C8D50538C4DE4544B608363" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_0FC97208931250C8B8406D010BD972B9" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_8D7F440F7C8D50538C4DE4544B608363" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_3DAC6CAEA6415996833114877E5B9BA1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_8D7F440F7C8D50538C4DE4544B608363" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_3DAC6CAEA6415996833114877E5B9BA1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_B51CEC86C3FD5FEFAA68BA5C74E5D8D6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_3DAC6CAEA6415996833114877E5B9BA1" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_B51CEC86C3FD5FEFAA68BA5C74E5D8D6" xlink:type="arc" />
    <link:loc xlink:href="abus-20190930.xsd#abus_EmployeeSeveranceandRelocationMember" xlink:label="loc_abus_EmployeeSeveranceandRelocationMember_352D08CFEB355492BF7CCCD40E63EE59" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_B51CEC86C3FD5FEFAA68BA5C74E5D8D6" xlink:to="loc_abus_EmployeeSeveranceandRelocationMember_352D08CFEB355492BF7CCCD40E63EE59" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FacilityClosingMember" xlink:label="loc_us-gaap_FacilityClosingMember_AC1E0C478286589DBA54BB024EB9A1C3" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_B51CEC86C3FD5FEFAA68BA5C74E5D8D6" xlink:to="loc_us-gaap_FacilityClosingMember_AC1E0C478286589DBA54BB024EB9A1C3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_31B5A10A3597536D9A1539F37B30AA61" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_8D7F440F7C8D50538C4DE4544B608363" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_31B5A10A3597536D9A1539F37B30AA61" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="loc_us-gaap_RestructuringCharges_CFC8AEAAF37157E686158A55FD02C164" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_31B5A10A3597536D9A1539F37B30AA61" xlink:to="loc_us-gaap_RestructuringCharges_CFC8AEAAF37157E686158A55FD02C164" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://arbutusbio.com/role/SiteConsolidationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_48AD55D9D1C31AF656EA22A5BCEA4B16" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_CC3DA4B64637EA9EA4B522A5BCEAAE5A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_48AD55D9D1C31AF656EA22A5BCEA4B16" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_CC3DA4B64637EA9EA4B522A5BCEAAE5A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_66059EC09F10BEA800E222A5BCEBA2C8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_CC3DA4B64637EA9EA4B522A5BCEAAE5A" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_66059EC09F10BEA800E222A5BCEBA2C8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_28BCE298146416E8370422A5BCEB06BC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_66059EC09F10BEA800E222A5BCEBA2C8" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_28BCE298146416E8370422A5BCEB06BC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FacilityClosingMember" xlink:label="loc_us-gaap_FacilityClosingMember_629A4AAAC4CE2213294622A5BCEB54BD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_28BCE298146416E8370422A5BCEB06BC" xlink:to="loc_us-gaap_FacilityClosingMember_629A4AAAC4CE2213294622A5BCEB54BD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_A4F0CC379B1254A7AFBE22A5BCEBC7F7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_CC3DA4B64637EA9EA4B522A5BCEAAE5A" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_A4F0CC379B1254A7AFBE22A5BCEBC7F7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_C1EA52DB73086059074322A5BCEC7A15" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_A4F0CC379B1254A7AFBE22A5BCEBC7F7" xlink:to="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_C1EA52DB73086059074322A5BCEC7A15" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="loc_us-gaap_RestructuringCharges_65C5F73E5CE0C9FBE78722A5BCEC3186" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_A4F0CC379B1254A7AFBE22A5BCEBC7F7" xlink:to="loc_us-gaap_RestructuringCharges_65C5F73E5CE0C9FBE78722A5BCEC3186" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://arbutusbio.com/role/SiteConsolidationReserveActivityDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_9FC181AECA45E74D3C262216DD08AC09" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_AD33F6BE6A13ECF51BFC2216DD085AE5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_9FC181AECA45E74D3C262216DD08AC09" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_AD33F6BE6A13ECF51BFC2216DD085AE5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_B9E2701F7683E204BA642216DD0835BB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_AD33F6BE6A13ECF51BFC2216DD085AE5" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_B9E2701F7683E204BA642216DD0835BB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_4E891DAF85F92B5C97172216DD088C07" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_B9E2701F7683E204BA642216DD0835BB" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_4E891DAF85F92B5C97172216DD088C07" xlink:type="arc" />
    <link:loc xlink:href="abus-20190930.xsd#abus_EmployeeSeveranceandRelocationMember" xlink:label="loc_abus_EmployeeSeveranceandRelocationMember_E2F6F77696C7D96576022216DD097FCA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_4E891DAF85F92B5C97172216DD088C07" xlink:to="loc_abus_EmployeeSeveranceandRelocationMember_E2F6F77696C7D96576022216DD097FCA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FacilityClosingMember" xlink:label="loc_us-gaap_FacilityClosingMember_3E1F782070DA9D4EC5962216DD0913D9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_4E891DAF85F92B5C97172216DD088C07" xlink:to="loc_us-gaap_FacilityClosingMember_3E1F782070DA9D4EC5962216DD0913D9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_661AD269842770DC7B272216DD096BBF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_AD33F6BE6A13ECF51BFC2216DD085AE5" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_661AD269842770DC7B272216DD096BBF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestructuringReserveRollForward" xlink:label="loc_us-gaap_RestructuringReserveRollForward_1DD424A5652DB334CB502216DD093FE2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_661AD269842770DC7B272216DD096BBF" xlink:to="loc_us-gaap_RestructuringReserveRollForward_1DD424A5652DB334CB502216DD093FE2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestructuringReserve" xlink:label="loc_us-gaap_RestructuringReserve_ACD12751F2221D080CCA2216DD092B23" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_1DD424A5652DB334CB502216DD093FE2" xlink:to="loc_us-gaap_RestructuringReserve_ACD12751F2221D080CCA2216DD092B23" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="loc_us-gaap_RestructuringCharges_A64F22DA2FD659B549FF2216DD0A27A5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/netLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_1DD424A5652DB334CB502216DD093FE2" xlink:to="loc_us-gaap_RestructuringCharges_A64F22DA2FD659B549FF2216DD0A27A5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsForRestructuring" xlink:label="loc_us-gaap_PaymentsForRestructuring_84BD410F4882427842952216DD0A533F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_1DD424A5652DB334CB502216DD093FE2" xlink:to="loc_us-gaap_PaymentsForRestructuring_84BD410F4882427842952216DD0A533F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestructuringReserve" xlink:label="loc_us-gaap_RestructuringReserve_B76A788F544BA2CDDC1B2216DD0A5934" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_1DD424A5652DB334CB502216DD093FE2" xlink:to="loc_us-gaap_RestructuringReserve_B76A788F544BA2CDDC1B2216DD0A5934" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://arbutusbio.com/role/SiteConsolidationTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_4DE878FE633D518485A0C880E5986159" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_CD04F14423D25C17B1F69F8AE5E89FD6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_4DE878FE633D518485A0C880E5986159" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_CD04F14423D25C17B1F69F8AE5E89FD6" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://arbutusbio.com/role/StockholdersEquityAndStockBasedCompensation" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_794487BDEDFBF75BB71E02DE05E1D660" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_7A2A86722D5CBDC40C6702DE05E2FCDA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_794487BDEDFBF75BB71E02DE05E1D660" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_7A2A86722D5CBDC40C6702DE05E2FCDA" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://arbutusbio.com/role/StockholdersEquityAndStockBasedCompensationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_8F13A7347F2243E62C943D14B9417F34" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_A8845820659274ABB6183D14B943389A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_8F13A7347F2243E62C943D14B9417F34" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_A8845820659274ABB6183D14B943389A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_18708BE4970E514B53E93D14B944AE93" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_A8845820659274ABB6183D14B943389A" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_18708BE4970E514B53E93D14B944AE93" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_28AAEDF6459C9B8574833D14B9446F5C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_18708BE4970E514B53E93D14B944AE93" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_28AAEDF6459C9B8574833D14B9446F5C" xlink:type="arc" />
    <link:loc xlink:href="abus-20190930.xsd#abus_OpenMarketSaleAgreementMember" xlink:label="loc_abus_OpenMarketSaleAgreementMember_8963535DCDB0B8F6442F3D14B944D829" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_28AAEDF6459C9B8574833D14B9446F5C" xlink:to="loc_abus_OpenMarketSaleAgreementMember_8963535DCDB0B8F6442F3D14B944D829" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_86CCD784173026C3C19C3D14B94536EB" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_A8845820659274ABB6183D14B943389A" xlink:to="loc_srt_CounterpartyNameAxis_86CCD784173026C3C19C3D14B94536EB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_848784F256B8D45B678A3D14B9455775" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_86CCD784173026C3C19C3D14B94536EB" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_848784F256B8D45B678A3D14B9455775" xlink:type="arc" />
    <link:loc xlink:href="abus-20190930.xsd#abus_JefferiesLLCMember" xlink:label="loc_abus_JefferiesLLCMember_4AE484D027B8ED762CF13D14B945E3B2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_848784F256B8D45B678A3D14B9455775" xlink:to="loc_abus_JefferiesLLCMember_4AE484D027B8ED762CF13D14B945E3B2" xlink:type="arc" />
    <link:loc xlink:href="abus-20190930.xsd#abus_RoivantSciencesLtdMember" xlink:label="loc_abus_RoivantSciencesLtdMember_419D259FB5738D3811763D14B946A203" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_848784F256B8D45B678A3D14B9455775" xlink:to="loc_abus_RoivantSciencesLtdMember_419D259FB5738D3811763D14B946A203" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_BDEA20B6D42F6EFD5AE53D14B946A298" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_A8845820659274ABB6183D14B943389A" xlink:to="loc_us-gaap_StatementClassOfStockAxis_BDEA20B6D42F6EFD5AE53D14B946A298" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_B3D56FB8EBD3EB99CA5C3D14B946D94F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_BDEA20B6D42F6EFD5AE53D14B946A298" xlink:to="loc_us-gaap_ClassOfStockDomain_B3D56FB8EBD3EB99CA5C3D14B946D94F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_A1A39D20DCCB19B0ED093D14B946C269" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_B3D56FB8EBD3EB99CA5C3D14B946D94F" xlink:to="loc_us-gaap_CommonStockMember_A1A39D20DCCB19B0ED093D14B946C269" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaap_PreferredStockMember_ABE845B80F1AE7D79D1E3D14B9467B8D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_B3D56FB8EBD3EB99CA5C3D14B946D94F" xlink:to="loc_us-gaap_PreferredStockMember_ABE845B80F1AE7D79D1E3D14B9467B8D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_0E2236A1E040ED9FA3233D14B9475D95" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_B3D56FB8EBD3EB99CA5C3D14B946D94F" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_0E2236A1E040ED9FA3233D14B9475D95" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_410F348477E32F4AE2BC3D14B947B034" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_A8845820659274ABB6183D14B943389A" xlink:to="loc_us-gaap_ClassOfStockLineItems_410F348477E32F4AE2BC3D14B947B034" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesSubscriptions" xlink:label="loc_us-gaap_CommonStockSharesSubscriptions_4125854ABF870B53CFED3D14B947BFC1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_410F348477E32F4AE2BC3D14B947B034" xlink:to="loc_us-gaap_CommonStockSharesSubscriptions_4125854ABF870B53CFED3D14B947BFC1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_ABF8D90C7C72F5EFD8103D14B9475D73" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_410F348477E32F4AE2BC3D14B947B034" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_ABF8D90C7C72F5EFD8103D14B9475D73" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_DC8D10FA3ECFB5068B663D14B947119E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_410F348477E32F4AE2BC3D14B947B034" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_DC8D10FA3ECFB5068B663D14B947119E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_00CA4CF54AF40A4788243D14B9482AEC" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_410F348477E32F4AE2BC3D14B947B034" xlink:to="loc_us-gaap_SharesIssued_00CA4CF54AF40A4788243D14B9482AEC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_71FCB455B4B2C77250813D14B9488EFF" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_410F348477E32F4AE2BC3D14B947B034" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_71FCB455B4B2C77250813D14B9488EFF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="loc_us-gaap_PreferredStockDividendRatePercentage_51982025683795A74D303D14B948A3A6" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_410F348477E32F4AE2BC3D14B947B034" xlink:to="loc_us-gaap_PreferredStockDividendRatePercentage_51982025683795A74D303D14B948A3A6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_EA7D596498526AAE9CCB3D14B94D28BF" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_410F348477E32F4AE2BC3D14B947B034" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_EA7D596498526AAE9CCB3D14B94D28BF" xlink:type="arc" />
    <link:loc xlink:href="abus-20190930.xsd#abus_ConvertiblePreferredStockSharesOfCommonStockIssueduponConversion" xlink:label="loc_abus_ConvertiblePreferredStockSharesOfCommonStockIssueduponConversion_F5A7F7311C15AF8136513D14B94D94BB" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_410F348477E32F4AE2BC3D14B947B034" xlink:to="loc_abus_ConvertiblePreferredStockSharesOfCommonStockIssueduponConversion_F5A7F7311C15AF8136513D14B94D94BB" xlink:type="arc" />
    <link:loc xlink:href="abus-20190930.xsd#abus_NoncontrollingInterestOwnershipPercentageByNoncontrollingOwnersAfterConversion" xlink:label="loc_abus_NoncontrollingInterestOwnershipPercentageByNoncontrollingOwnersAfterConversion_6C08D8097235311768DA3D14B94EECCD" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_410F348477E32F4AE2BC3D14B947B034" xlink:to="loc_abus_NoncontrollingInterestOwnershipPercentageByNoncontrollingOwnersAfterConversion_6C08D8097235311768DA3D14B94EECCD" xlink:type="arc" />
    <link:loc xlink:href="abus-20190930.xsd#abus_NoncontrollingInterestInvestmentCommitmentPeriod" xlink:label="loc_abus_NoncontrollingInterestInvestmentCommitmentPeriod_E12F193A303E916DCDFC3D14B94EB8E8" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_410F348477E32F4AE2BC3D14B947B034" xlink:to="loc_abus_NoncontrollingInterestInvestmentCommitmentPeriod_E12F193A303E916DCDFC3D14B94EB8E8" xlink:type="arc" />
    <link:loc xlink:href="abus-20190930.xsd#abus_NoncontrollingInterestMaximumOwnershipPercentagebyNoncontrollingOwners" xlink:label="loc_abus_NoncontrollingInterestMaximumOwnershipPercentagebyNoncontrollingOwners_F8A3893E28DE56097A8E3D14B94E2F34" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_410F348477E32F4AE2BC3D14B947B034" xlink:to="loc_abus_NoncontrollingInterestMaximumOwnershipPercentagebyNoncontrollingOwners_F8A3893E28DE56097A8E3D14B94E2F34" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_55F747BA31A1F87954773D14B94E88F4" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_410F348477E32F4AE2BC3D14B947B034" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_55F747BA31A1F87954773D14B94E88F4" xlink:type="arc" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>boardagreementcheng001.jpg
<TEXT>
begin 644 boardagreementcheng001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  H'!P@'!@H(" @+"@H+#A@0#@T-
M#AT5%A$8(Q\E)"(?(B$F*S<O)BDT*2$B,$$Q-#D[/CX^)2Y$24,\2#<]/CO_
MVP!# 0H+"PX-#AP0$!P[*"(H.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[
M.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SO_P  1" 55!!\# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH *2EHH 2EHHH **** "BBB@
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M*** "BBB@ HI"0*6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M>GZE(T=G<I*Z@$@9Z4W6^= O,,/]0W)/'2N0\#IYUU?1*S1EK<#>O49/4>]
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ J"YLK:[ %Q!%-CIYB!L?G4]% %1M+L'<.]E;LP
M+1*2 .@Z4];"T1%1;:$*K;U41C ;U'O[U8HH RM7T"UU73I+0!+<N<B5(QE3
MD$G\<<U4\/\ A2'0[J:Z-V]S/*@3<45 %';"\5T%% %:73[.>3S);6&1_P"\
MT8)_.G?8K; 'V>+"YP-@XSU_.IZ* *T^GV=S;BWGMH98AT1XP5'X4-86CGYK
M:(_)Y?*#[G]WZ>U6:* *?]E:?M9?L5OM< ,/*7YL<#/'.*?_ &?:?91:_9HO
M(7I%L&T?ATJS10! UG;O.)VAC:4*4#E!N"GMGTK*U'PO9WKVBQQPP6\-P)Y8
M4A $Q (&<>F36Y10!3;2=.D2-'L;=DB!"*T2D(#UQQQ36T;3&.6T^U)P%R85
MZ#H.G:KU% %.32M/ED:26RMW=\;F:%23CIDX]A^5/@T^TMG>2WMH8GD^\R1A
M2WUQUJS10!533;*.X:X2T@69B29%C 8YZ\]:L@8%+10 44W>NX+N&3T%.H *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MIK.J EF"@=2: '44E+0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 444E "T444 %%%% !1124 +13?,3=MW#=C.,\XIU !1110 4444
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M?Z4 7_.CW >8N3VS2-,&B+Q.C>ASQ6<D4;0+E47_ $C.-H]>E(PP+\1 DDC
M"]\8_I0!I^:H^\Z@]^:<75>I S5&55,LQ(&?)'/OS0V3$GS L(QN!'#?X4 7
M!*AD,88%AU%.WK@G<,#J<]*H%5%Q,BD)+(H(QUQW_P ^]).J26DS!FR4.=W0
M4 :-5[RX>VC#JJMR =S8ZTZ$1PQHJ@ $#&!UJ+4ANM&Z\E>G7J* 'Q7,C3&&
M6,(V-PP<@BGBX!N/)QSC.:8(T@5I<L[!<%CR2*JSK+;VGVD,)&5@^-O^>U &
MG13(W$D8=>C#(I] !1110 56OA_HYP,X(./QJS5>\ -NP.,' Y^M $R]!3J:
MHP *=0 4444 %5[J=X?+$:!R[;>6QBK%5KQ1B-SGY'SQ0 ]Y)%:,! P8X;GI
MQ3_-0G&]<GMFF"57*JN>1GI5/:B)N"A6,_<8[T 6'NUA,C3O&L:D $'D9]:E
M,\:A=TBKNZ9/6LZ<$F\(!/*$8'TS23>6;QFG,ODR( F%./<'B@#1N9Q#$2&0
M-@[0QP":='(6MUD8?,5!(%9\C+%).LH=E\L$$@D8 J[ <6:$CH@R* (H;N65
M(I!$NR3KAN5'O4T=S')OPP C;:Q/'-4#Y9>.:TWHSN-R8(&,\DCZ4R1Q##./
M)Y$P)RI( S][M0!I27,42!V==I. <TYID4J"Z@MT!/6LAIBZ.L<,FT72G.P@
M%<]>G3@U.Z)]IE2:.5A*RLK+G'8#GM0!H><@D"%U#'H,\FB9VCB9U ) ) -4
M/,VW8,09P9<.K*?E[9!JY<?\>\G'\![>U ##=E;1)V49;'R@]S[TW[:4CD,B
MX:/ XZ'/3!JJYE&B1A4*MA58%>@[\4ZVA$B3P_-]F8YC8'!_ T 61=2AGC>(
M&15W*%/WA1%<3M.$D@V#!.=V:9:VTPN7EF?>%&U">N/P%+"CRRSSJ5!;Y8R1
MT ]?QH E6Y+W;0!" JYW$&K%40+D7XW;"I3D\C S^I_*KU !1110 4E+2'I0
M!0!_XG;#&<VXQ[?-_P#7J_53 &J9YR8L'ICKQ5N@!:*** "BBB@!AEC7.9%&
MWKD]*1IHE.&D0'&>6%9.H6,LMZZ0[0EVO[TLN0,=^O7M4=E82W>FRF[C(E*B
M),C!PG0\^_.: -OS$R1N&0,D9[4PW,*AF,T>%^\=PXK!@ANI+A)9D(-ROEME
M""%'KSU/-2:A8R'4MD0'E7T?ERD@D+CG/'M0!N),DF-KJV1D8/4>M#SQQLJO
M(JLW"@G!-9=A-]GL3<7",BIB-0 22H.!]>:I:I/&TUVC90J5("QEB_ .<]N.
MW%(#;FO8D1]DL32*#A-PR3C.*CL=2BNX8B9(Q,\8<Q!P2!]*SK1;:\N;^9(U
MD( V-LY'R]L^]06D=NPL(X(MMU&096"%2%YSGIG/3GUI@=#]HBVJ?-3#G"G<
M.?I4=M?VUTKM%*I5'V$].:P8;@K:6ELX;SXKD;PD9( W'^?%2!1_9ETC0MD7
M.2NWG&X<_P _6@#>$\9W_O%^0X;G[OUJM-J(7[.\#1RQ2R;6<.,"L^1K662_
M,IDCCD,>6P1T[U$SI-9C[2D9A6X!,D:%59<$YQ].M &S<76VU:6"2$D=&=OE
M_$U)]H1$C$TD:NX'?@GVK&:U@$-^\4 6!PNW:AY(ZD#C\Z6?8D]RER'=)8E\
ML%<Y..@XZYH W:8LT;G"R*QQG .:S?,D%C]A&Y;OR"PR"1Z=?6JT?ESZ>R6D
M3K<QP&/=L88QC(^OI0!LK<PN6VRHVW[V&'%*+F$G F3.,_>%8L7DR7%L]O'L
M$<3"8;"NWCH?QS45K' T>F+(B'>'R"@.: .ACD25=T;JZ^H.:?6;HYC$$J1;
M=JS.,+T'-:5 !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MZ48'I2T4 )M'I1M7&,#%+10 FT>E&T>E+10 FT9SBC ]*6B@!-H]*,#TI:*
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M^8,@ @#H.3^59B^,W*F_DLMFDBX-O]IWDN".-Q7'"YXZT =7135;<,@Y!IU
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !24M)0 M%%%
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M 4444 %%%% !1110 E+110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M!21G% $EWJ%GIZ![RZAMU8X#2N%!/XU*DJ2('1@RL,@@Y!K#\5V$,^FSW/\
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M,]B>N>U '=4M9>A/J\EHTFK&V+NP:/R,X"D#@Y]\UJ4 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M/M=MYZV_VB+SG7<L>\;B/4#TH-W;"18S<1!V;:%WC).,X^N* ..GT5+V73=
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M)*F T4GM22^(M8M(HKF]T$Q6\DBJ2MP&= QP"PQ_6KFO^([?P^ELTZES<2A
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** (YW:.!W1#(RJ2$! +>W-<K%X\CFM);Q=*NS;0.%F<%#Y?U
M&<]ZZR3_ %;?2O&;<ZDOAZ\:)BUA]L"WB1K\Q&,YW<X'X=<4 >OVM];W=G%>
M12@PRJ&5CQP:L9'K7FFM75M=7.@6MJ\,6DR6Y\L3L?+WX(P_8XXZ]S6QI=G8
MK_81O-?>:ZBW+ (Y#LN,,>Q'/IGVH [2BBB@ HHHH 0]*SK36[.]U.ZT^)SY
M]IC>#C!SZ4_6=272]+GNV4L47Y%'5F/"@?4XKS>)KSPIXGT^\O;62!;E=D[,
MXD\PD_,W!XYP<4 >K9'K1N'K7EVH6\5]XXUR*YE=8H[5Y%(D*@$(N#Z=ZBAD
MEUF?PL+^9R9O,CD?<5+JIX&??I[YH ]6R/6J>IZ@--L9+KR)[G9C]W A=V^@
M%>8I>W@L/[+6ZD73Y-6-ONW,2(^/EW9^[S1J;RQV'B*PBW&RL[J-H!N/[MBV
M"!W.1F@#U:&82PI)AEWJ&VL,$9]145YJ-I8^2+B8(9Y!'&.I9CVKS#4;8/J4
MT/VB98TT9;AA'*0'=4&W.>M2W,<%Y+X3DU"5G%S&RS-)*0,*1CG/'4\]Z /4
M@PQUI=P]:\G\0V\9UKQ J74Z1PVZ3(J3-M=ODQGGD<G\ZL:3+=Z?JZRPW5Q-
M)<Z*;EA)(7#2;20![#L.U 'J&X9QFC</6O,/";75W/;W9U:(>:LL<\37#--.
M0"1P>F!C!'853T2:X270+W[;=/-<WCQ2L\[L-H*_+@GIS0!ZG%?V\UY+:1RA
MIH55G4?PYSCGUXZ4VYU&UM+FWMYI@DER^R)>['&?RXZUQG@ZWMO^$KUJ1G(D
MBN&2,&4Y;);.>?FZ=Q4?B6%'^)&EH[.!)&I)$A7D%N <\=!TH ]!R/6@GBO*
MEU*^_LR]U>2ZF34(M25$0.<'CF/;TQ_A7HNIZF-,T.2_G4!HX@VS.,L>BC\>
M* %M-8L[S4;JPAEW3VF/,'U]/6KQ(]:\KTZ6X\.>)K"]O+2>V6\7RYC.X)=C
MC<P]!DCK6G>:6^M^/=1TYK^YM[<0K)B&4C#87G'3N: .KTOQ!%J>J7^GK;RP
MRV+!7WD8;).",?2M?</6O)KVU7^T?$LGGW"/9!'1HY]F2#CYAU/_ .NF75]J
M,FIVCW,\J-/I)+?.0'/EN0?3/"GZT >J7M_;6$2R7,RQJ[K&N>[$X J<$8YK
MR4QB[\,: ;F1Y";]H6+.>%+=.OZ]JN:TD5KKVO0PL5C73@R+O/7Y.10!Z?D>
MM0WMQ]DLIKG8TGE(7*KC)Q]:\NUG[3_9.DW4S/<V26"K*D;D-"QR!)P?;]"*
M]$FN$N_#$LZ;MDMHQ!=2IY7N#TH S4\=:6;..]:*[2UDD\H3-&-H;WYR*Z19
M$=0RL"I&0:\81;F'P7%/)>JUD+[#61&TRG )^;J?I6UJ-R=4N-8DNE>);+3T
MDM(RQ7R20I[=3DXH ].R/6C(]:\HU6]FOHK5KJX>XD.F;S SF-86'23.>6..
MF.<]:DOWGU"#PI,T[Q7$V8FE4X.%=0/7GGK[T >GSSI!!)*W(C4L0.N!5'0]
M=M?$%DUW9K*L:N4_>KM). ?7WKBK[2TMM<30Y[JY:Q@LI9X/-F(+R')SD8SC
M^E;'PT+GPI\TJR8F;:H/W!@<'\<G\: .OW#UK"U?Q;IVD7OV-UN+BXV;VCMH
M_,9![\UPMYJ%\]OJ6L27DL.HVFH+'%$2?W:\_)C.,'_V6KMG!]I^*BM/YD3E
M%E9!(00WE@E>#TSVZ4 =?K/B>VT*UM[JZ@N&AGP%9 N02,X()!IMIXLLI]27
M3;B&YL;I_N)<Q[=_T()!_.L/XIG&D6*CO<YS_P !/^-9_C/??^+=%M[([YU1
M20AR4.\'.1TQ@F@#NK'5$O[FZ@2*>-K63RV,D>T-[J>XJ_N'K7E]Q<W0L/%2
M&[O#]FN(_)/VAB4'F-T.>!_]:C6(+S1_#]CJ2ZG>RG4%A$SR7+#RQMW87'(S
MCKZ#OF@#U#(]:ANKRWLK=KBYF6*)<99NG/ KS34]2OM.M/LTFI+)83W:,WV:
M=Y'@C/)3S#CJ.GT/:E\2Z6+'0HD_M?[?&+X-$H<_NE8$[2=QSV()_"@#U#</
M6C(]:\UOXU_M?5;0W,JVNF:<SVJ^>V,D [B<Y)R35=KB^UJ#PND]W<V\D[R1
MM,LA#.H(PU 'J61ZTM>6^(-/.B742-<3WNGVD2I*5G(F@)8D-Z#.1VP0,5Z?
M$ZR0HZG*LH()]* 'T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !24M% !1110 4E+10 R2-)
MHFCD4.C##*PR"*J1:+IEO')'!IUK&DHVR*D*@./0@#FKU% &<=!T@P+ =+L_
M)1BRQ^0NT$]P,5+_ &58!X7%E;[K<8A/EC,8_P!GCBKE% "444M "4M)2T 4
M]0TNRU6%8KZW2>-6W!6['UIESHNFWNS[790W&Q-B^:N[ _'Z5?HH Y,^"(9/
M$<NH3_9IK)XQ&+5H?N@  <_A4^K^%!J>K:;<*+=+2Q4KY#)D.#U''3 QBNEH
MH SET/2UT\Z>+"W%J3DP[!M)]2/7BD/A_238_8?[/@^S;MYBV_*6]2.]:.*6
M@#*/AG16+%M+MB63RV)C&2N ,?3 ''M3I?#NCS0102Z9:R10Y\M'B4A,]<>E
M:=% &7+X;T:>1Y)=+M7:3[Y,8^;Z^O04^WT#2+6=9[?3;6*5%VJZ1 $#&,9]
M,5HTE &?!H.DVLCR6^F6D3R*59DA520>HX%,7PWHR^4%TNT41-OC B "-QR/
M0\#\JU** *<6E6$-Z]['90)<R?>F6,!V^IZTEYI-AJ$J2WEE;W#Q_<:6,,5^
MF:NT4 9QT+3#??;?L4/G[MV_;_%_>QTS[]:L7=A:W\/DWEM%<1YSLE0,N?7!
MJS10!0N=%TR\$8NM/MIQ$-L8DB#;1[9Z5)'IEE%=F[CM(%N"NTRA!O(Z8SUQ
MP*MT4 9%QX7T6ZN3<SZ; \S-N9\<L<YY]?QJ>]T33=2>)KVQM[@Q?<\R,-MK
M0HH RF\-:.]G]C?3;8VX8N$V< GJ1Z4EUX9T6^E$MUIEM*X0(&9.0HZ#\*UJ
M* ,9O">AL(P=-A(B3RT'. N2<8SR,DGFM.>UAN;5[66,-$Z[63L1Z5-10!DI
MX7T-)1(-*M-PZ?NA@>X'0'@5+>:%IFH7"3W=E#,Z#:"ZYXSG!]?QK1HH S+O
MPYH]].)[K3;::0)L#,@Z=A_GI2#P[I(^SXL(?]%_U Q_J^<\?C6I10!1O]'T
M_5"AOK.&X,>=GF+G&>M/L=,L],B,5C:Q6Z$Y*QJ%!-6Z* ,Z;0=*GN_M<NGV
M[S[@Y<H,EAT)]32G0]-.I?VB;*+[7D'SL?-Z=:T** *=_I-AJ807UI%<A/NB
M5=P'X4RQT33--=I+*PM[=W^\T<8!-7Z* ,Q?#NCK'-&--MPD[!I5V<2$'()]
M>:GGTFPNK 6$]I%);* HB9?E '3'I5RB@#,@\/:3;Z>;"/3K?[*S;FB9 P8^
MISU/UIPT#2%M#:#2[,6Y;>8O)7:6]<8ZUHT4 9<_AS1KCRA+IEJPB7:@\H !
M?[OT]NE3SZ187#0-+9PL;;!A.T9CQ_=].@Z5=HH SKC0=+NKU;R:QA>X!!\P
MKR<<C/KT[UH#@4M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%1S
M2&*%Y C.5&=JXR?89K!B\7P2V(OQI]\+/<0T^Q2$QP20&S@>N* .BHJ*&XAN
M($GAE62*0!D=3D,#W%/+ =Z '44FX>M9NMZW#H5D+NXAEEC+A,1 $@GIU(H
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%)0 M%)10 M%%% !1110 4444 %%%% !1110
M4444 %%%% !1124 +1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MM+VWO[2.[MI1)#*-R,.XJ;(KF?"QF7P#:LLGERK Y5P VWDXZUFVGB35IXM
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MJZDENMHFN"R^8RJ<A?NX _"KUQXAT:TD,=QJ=M$P4/AY .#T-*VO:4L,4O\
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MY4+[\]CVJQIVKV6K)(UG-YAB;:ZLC(RGW! - &9<>"]/N&D<W%VCO<"YWI(
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MSM5L[:.W1W98Q@%SDXJ>D!#*".01D4M !1110 4444 %%%)0 M%%% !1110
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M]MG<I%<:NL\%N(6+)$#R2 ...U>E<*N3@ #DU';W%O=P":WE2:)NCH00?QH
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MK^&<5L<52UG[(VD7*WMP;:W9"'E5MI4>H- '%:5H-W+-J.G"96M]+$L=FO\
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MDU"\@O=1MM*ALH)+&(3W+M 56X8C@<'C"XYYYKHM=T2'7K$6=Q+)'$'#GRR
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MXU:]N6F 5Y7<9V#^$#& #W]:S]<\-)9:1JLFEK.TEY&%-I'CRR> "%QP>^:
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MZ=<>0-6%VD4,2QG!C;G?UY&W)]JTD\(6EM:6<45Q<M]@F,\(++DL3D@\=/\
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MVQVUU.LK[L_>XZ#':@#J**0=*6@ HHHH **** "BBB@ HHHH **** "BBB@
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M%JG^FS)"5V@( 58D#)/3\:OZ'IEQ!KTFE/\ -8:7*;B EB3EQ\B_\!^8_B*
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M7&CW4A7S&VHBJ69SZ!1DFJJ>)M(FM'N8;Q9(T;8=JL6W8SM"XR3["L7QK/\
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M?'UH Z34=8L-*:,7DXC,IPJ@$DXZG [#N>U"ZWICNJ+>(6:#[0HYYC_O#VK
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MI>Z@D$D,/V01F"%X2QNMPY Y[$]JW=2O[RS\,R7IDMX;I(0[-*"(U;C.1UH
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M06\EA;*\C>6'620@$@<_=[?C52V\4:UK%QI:64T%JM_%*"'AW[)(^ISNY!H
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MP:S7\1Z+'*8I-4M8W5RC*\H!5AU!STZ57\.MK203P:PJDQO^YE+*7=#G[P'
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M'IWH [FSM8+&VCMK>,1Q1KM51V%3;A7 OK^M:*4EN;M+];ZP:ZC5T">2RKG
MQU'-!N_%%II,]V]\#%)9F9'D:-G#CGY !]TC\10!WX(-!KA=+UG7TN!;/>1W
M<ESI8NX1)&$P_0#([>N:;'XFU,Z==M-J/V6Y@2(/%=VNUXV+88J%'S \ ?Y-
M '=[A6?++IDNM0V\KHU_%&9(XV)RJ]"P'3\>M<%J6KZO>:;J=K-<W,(M+B';
MYD:I(4<]&QQQP>*V]6UB_P!#UI$:472+IKRDM"NYG!]1SCU% '9BBN'&LZS;
M0Z1=M>^?%JJ[9 T:@Q.5R"F!T]CG]:;I/B'6FM=(O[F_AGBOKDV\D/D@;>2
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MS7?$.I2VM]' ILIIF25&>,)&N<#:>&+<?CFI_#VJZE/K/V/4;F2.<1,TEK-
M%_B^5HV'5<>IH ZZBBB@!*6BB@ IDB;T*GH1CBGT4 9VE:)9:,KK:1D&0Y=W
M<NS8Z9)[>U:-%% !1110 4444 %%%% !1110 4444 %%%% !1110!'/"ES;R
M02C*2J48>H(P:PK7P;86DMBZ7-Z_V%BT*R3;E!(QT(XX],5M7MU'8V4UU*2(
MX4+MCT K TV37-8TA=4345@>92\-ND*E ,G 8GDG'H10!,W@W3VT\V9GNO\
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M.C\2:=-+;11R2%KR%IH<1GYE7K^/M533=<M8-(AFEO[N]-Q.T<)>#$CMW4*
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M<E20>1[&I;3PEIEE/%-"9]\,;11EIF;:IZCFFZEXNT_3+R:TEBNY)H4$C+%
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MS)Y7F'RPYS\^WINYZU8L= L["Y$\;SR,B[(Q-*SB)>,A<],X'Y5IT4 %%%%
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MM_#>K:;%I-VEI%/+:W,L\MO&X5@'&  3P<4:=H.LP66E6\MAM-MJ+7$K"52
MI/;GGK^E=[10!B>*VCC\*ZCY@4J82N&.!D\#GMR:Y/2)5^V?99F:ZOKJS>TA
MD$\3K&JKP"$).,_Q&O170.I5@&4]0>]5K32[&P)-I9P09ZF.,+G\J .0TG1M
M:M]2T66?3]D>G6KP.XF0EBP."!GI3;#0]<L(]+O!9H]Q82S^9;F51YBR$G*D
M' QGH:[NEH X+^Q/$2S7,J6JHEWJ'GRQQ7(#F/'0-QCGKCK4%AX:UNSGLP=.
M79;:F]UE)U(*, ,#/.>.]>B44 >?S^&];DOKS48(%BF745N[>-I%Q(H&"."<
M'ZU<U71]>U>.WOKBVLC+!,6%@[Y0H5VD%L8+'U[5VE% &1X<L)K&RD$UC:63
M22;Q#;<A1@#D]S7-ZEH.LWD/B$1V84ZC+"T.Z5<;4X)Z\< 5W=% '-Z3I]]#
MXFOKZ>W,<$\$4:$NI.5&#G!JO=Z3J9UK6[R&V#QWMFL,.7 RV,<\\#FNLHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH ***0G% "T444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MZ.&CB?RE52BD*&&",#).,CUJOIVH:Y!8P6$FA.MQ$B1^:9D\D@#&[(.>W3%
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M0XQE3QP>:S;^VU1;C2-431$W6\\K2VD#KD;Q@,3P"<\FLV'1=;,Z&YTMU/\
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M#KV<,2-*+8QJD*A5R1C@$\#\: .:T/6)X1;WMW-JEQ/?1X2T*JRR-G<6CYX
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MI:** "DI:* $-%%% !12TE !12TE "TE+24 +1110 4E+10 E+110 4E+10
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MJS24 9E_X=TS4H[:.XA)%J,1%'*E1C&,@YQBJUMX.T:SGBFMH98FAD,B;)G
M!/7C/L!6[10!DMX:TM[N[N986E>\79,)'+*P[<9QQBDM?"^DV<,\,5ME;A/+
MD+NSDI_=!)) YZ5K=Z6@#G8O OA^(DK:R9,;1DF=SE3P1UJ_I7A[3M&+M9PL
MKR *SNY=L#H,D\#VK3HH RM0\,Z1JEZEY>6:2S)@!CD9 Z ^OXT7WAK2M1N3
M<7-MND90K[6*AP.@8#K^-:M% &7/X=TZXGDG>-P\L'V=MLC >7_=P#@"H_\
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MT5EWOB+3;"\%I+)(T^ Q2*)I"H)QD[0<58T[5;/5;<W%E,)8PQ4G!&".HP:
M+=+2=:6@ HI*,\4 +15.RU6UOK87$3D(7,8WC:2P.,<U.L\3R/&K@NF-R@\K
MGIF@"6BDHH 6BBB@ HHHH ***2@!:*** "BBDH 6BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@!#TK@#JEIH'B#4+K3]2TRZCO)"TT
M$MR(GB<9[\C&2>*[\TWRDY^1>?:@#S_5];M]4MK"^_M;3(M0LKCS4MTN-RE3
MCY2V.O'7&*S]2ELM174+[[=9+=WKQA8%N"51$P22V.I(KU#RD_N+^5'EK_=7
M\J /-M1U&VO-0U2Z%S:HMWIYM4_?G[W')XX'7IZ5'9:M;I>V[M<6FVWTLV>/
M..2V,YZ<#./>O3?+7^Z/RH\M>RC\J /,;'4].L)/#XEU*QSIJRK,3,0#N./E
MRN3@<\XJK)J6EM8.YO\ 3VN$U4WD<;3G:RGJ,[>OX5ZJ]K#)C?$CD=-R@TPV
M%H>3;0GO_JQ0!YO-?6-_%K"2ZQI<<.H%)3(DK%ED4#"A"H)&X=?2G76LVNK^
M'WM;W4=*M9(V1K;R$D*NRG^(XZ'VKT26WL[>)YY(852,%V8H. !R?TK'T_Q9
MHM]*8HD>*/?LCD>$JCG;NX/;CUQ0!0T7Q-:1R//J-U90%U"1Q6L+E< DY+%0
M3UZ=.*I/KFEV7B.35M+UC3I4OU"S0W,[1X*]"" <=.XKH;+Q5I5]?+:*)HFD
M_P!0TT119QZH3UI?[<T07K6^8P1-Y+2^7\GF]=N[IF@#E-?\2V^I6$EO+K&E
MK(9D=(XYG9$"G/WPIW$_@!52^U&">?4YTUO2[9M4\HH([TL4VXR&VKP",\UZ
M+>W%CIEG)=W02*&/EFVY_053MM<TN>WN9I(_LIM!NGCN$"O&,9!(&>HH \^:
M^TLV^L0)JNDV_P!OCCCCCA>0HFW'?9SW.>^:U-)\2Z3;Z^E]<ZMIZQBR6U.R
M1V(9<'/*# //>NNLM<TJ\:5=OD/%'YS+/'Y9\L]'&>U-T_Q!I>IW8M8HY$>1
M/,A,L6T3I_>3U% '!Z?JFGR^%HM,O;^QM8/MADD+3,TI4/NX0#OZYIUIJNE:
M?>R1P:OI+61G\U))+:0W$:[MVP$J1U[G/K7ID-C:P*1#;Q1@G)"(!DU+Y,?_
M #S7\J /.M&UW3K30;G3/[4TF2>2=I%$[2")U9@65BR#!QD=ZKJ--A1VM_$.
ME1&*]2YM+<WI>- /O*3C(SGL*]-\F/\ YYK^5'DQ_P!Q?RH \YU2YT[4HM4G
M.N:1'<:B(XPAN_DC1"#G.W))(Z8 K6T"^M+KQ=<7::GITOVFW2)(H+C>^5YS
MC:.PKL?*C_N+^5 C13D*!]!0 ^BBB@ HHHH **** "BBB@ IK'"DTZDH \^M
M=5M]!U&[?2+^SN;*[D\PPS^:AC?OM(0@C_"G:CK,>HQV-X-5L5U*QF,@C6*7
MRF4C!4G&?QQ7>[%]!2[!V _*@#RZ^-OJ5MJ$W]H6GVJ_NHG:-5D\M%CZ?-LR
M2>.PJ?4+B._;6V2ZM4&HI$D1/F\%,#G]WW'I7I(10. !^%+M H \TCFC_?!K
MFUQ)I L 1YQ.\#[W^KZ5'::OIMG<: USK%AG25D2;YY,G<"!C*=N.M>G[133
M!&>L:G\* /*HM4TR*RL@FLZ89[*_>Z"[I=KJ3G!.S(/;I3BNEWPU3_BHM*C6
MYN1<PNTA4B09^5D<<K\QYSZ>]>I^3'_SS7\JBN&M;2W>XN/+CBC4LSL  !0!
MYUJ.HZ;>6<4=SJ>A03VTJ2V\5HK20L1D$2$#@$D\=O?-:VC>,-%L$ECOM2TN
M*1G^5+")A$!TSNQR36SIWB33-1NTM5MIH7E+>298=HE  )(_ ]ZMV6JZ??WE
MW:P1L)+,@2[XBN,YZ9^E '&ZE<:1J*:J#KFDQ2W%PEQ:2BZRT;JJKSQQ]T],
M]:='<:):W6C_ &;6M+:WL8I(Y=]UAI"_WR !UZGKSFNIM?$>D7=S#%"6(N'9
M(93"0DC+U ;&#5S4;ZQTJV$]UA59PBJJY9V/0 #J: .%T74K+2;F&Q;5-#DM
M;=B\=X& E9><(>.#R!G/3UJ.WGL8-/TN+^V=*+V%X\[?OV^9220!\N>_Z5V0
M\1Z1_9\][(_E);R>5(DD>'#_ -W'<GM3HM?TF2"ZG=A!]DP)TF3:Z=QD'USQ
MZT </=RZ=-+J,RZYI@EGO8KN%%D8CY,_*3MXSZ\U+?W>FZ^+R^O-5LK.[>)(
M[9(Y#(%V,6RQQSD\<#I7<:;JUCJ<TD$2/'/$JN\4T11P&&0<'M6CY2?W5_*@
M#SJ?58]1T.YLKF^T>W>=551;*Y'!W%B0OL./<UV^C:G:ZG9J]M*DAC 639G"
MMCID@9J]Y:_W1^5*% Z "@!U%%% !1110 4444 %%%% !1110 4444 %%%%
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MW ?.?YUJQ>&-)@EMI8K8HUJ,0XD;Y0>O>I=,T+3=(\TV%LL/G'+X).?;GH*
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M_P!8N<#;@\Y-5;[QQ;Q:?>2V]E<_:;4HK13(!@O]TG!/'ZUD1>'/$-O;7?\
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M<D8P<GK@UTME+?R3W N[6.&-'Q R2;BZ^I&.* +M%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 0
MW;3+9S-;J&F",8P>A;''ZUPWA.^U74;YS<:N5N8I_P#2;.? +)M&=JXR,'TX
M]:[>_2Y>QF6R=8[DH?*9QD!NV:Y:TT'5;S7X=2U"UM[0VTS2%XY-[3Y50!G
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M@;>.U '3CI2T@Z4M !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M8ID*.I/3(/\ .M'-<MXLU)+" -8ND=Q-/%!=7$9 :*,DXRW;O@\XR:Q]9O\
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MC;CG/X5Q&CE-"UTV2*MUIE]<".W).YXV"!@>>JX;&?:@#:C\=:7+-#&MM?\
M[^01QN;8A6)Z8/2MR]OHK"SENI@Q2-<D(,D^P'<UC7 -_P"+[2V0XATR$SN
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M];BU.2> PR6US;$"6"4C<N1D'@D$5P&I1O+K5_JA+2V$.JP"3'W3@88]><'
M_&NITAEN/'>L3Q!FCCABB+XXW8S@'Z4 =31110 4444 %%%% !1110 4444
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M7T1;BWG&FP"2V79$=OW1]._XTZR\-:-IUQ+/::?%%),NUR!U'<8Z >PK4HH
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M#*I4$S.2 >W7I6K9V%MI]LEM:Q>5"GW4!.!0!Q&JO+8>,-2O!)-/Y&G>=Y)
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MOM$:YC<J2"<$<>U9%SI)_P"$D70A=.EM]F:>+[5(TF]R?F8'<"".WXT =^6
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MG@CUKSJ6PM;66SBAC)%[H\CW(9R=[!<JS9/.#T-=3X.L[,>$[58X8\3P@S@
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MRY$+DC[P 8X/WBN3GOS4=Y8:7'HMY);ZB+MY=/#M''&BHNTJ%8A>C#)'KP:
M/0[R_E@>V6WM#<B64(Y5P/+7^\<]:M^8N[;D9],UP-[I&GZ?9>&GM+:.)IKR
M&1V7.68J,G/OQ567RYO#VLWER0-9@OOEE^[(AW (!Z<$\"@#O-7U(Z7ILUVD
M/GF%2YC#A20.O6K5K*T]K%,R;&D0,5SG&1TS7G5R;&9?$AUJ2W>^C4+!]H8!
ME&S("@].<=.IKM])U*SEM[:SCN8WN%MD<QJV2%P.: -!Y%C&68 >YQ0957&6
M STYKF-82*Y\9V-IJ4(FLI+9S$D@RGFY.<@\'Y?YUREM9PSZKI=O.AFLO[3G
MCMUE&,Q@#CZ9[>U 'J/G)LW[EV_WL\4 *XX((]:\PF2*-KJU>8VNDPZRRRA$
M#)&I7*_*01C.>V,]J[3PG::?96UU%IEY)=0&<G>P&P-@9"[0!CZ4 ;H4"G44
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% $5P)#;R")59RI"AFP"?<X
M-8?A[PO;:;ID$5Y;P27<2LIE0DYSGD9Z9![5M7DS6UI+,L3RF-2VQ,9;Z9(K
MB%\1W-U/H6ISI=0"9I4:"(Y2?"MC:N[GG YQUH Z]-$TR+3Y-/2TC6UD^_$,
MX:F7/A[2+SROM.GP3>2FQ-ZYPOI[UD:CXAL[_2HI@VH6I6]2&18@JR1N&QM?
MG&#G\JG_ .$QLUOY[-K*^46S[9I_)!CCXSEB#P/PH T+SP]I&H2Q275A%*T(
MVH2,8'IQU'L:NRVT%Q;M;S1))"Z[6C894CTQ7(2ZW)?^*]&:"._M[:??CS/E
MCG&TX( /OW /2M_4M>@TJ^L;2:WG<WLGEI(@!56XZY.>_I0 ^S\/Z58)(EO:
M*HD4HVXECM_NY).![=*LV6G6>FP>196Z019SL08 K)E\86,(N-\$X:*X-NBG
M8//<==A+8P.^2*8OC739+>!H(KB:>XD:)+:,*9-RXR.NWC([T 7;KPUH]Y-<
M2W%DCO<[?-R2-VTY'?U ^O>IO[%T[[6UU]F4RO'Y;$DX*8 VD=,<5D#Q>TFK
M6=M'IESY5Q"969M@9,-M)(+< <YZ^U7-,\3VVJW8A@M;D1.C/%<,H\N0*<'!
M!)'X@4 6M+T'3-%60:=:K!YARV"3G\^WM3=1\/Z3JT\<]]91SR1\*S9''H<=
M1[&F:GX@@TVX6U6VN+NY9#)Y-NH+!!U8Y(']:IR^,].7[%Y%O=W0O=WE&&+/
MS+U4Y(P?Y=Z +UUX=TF\F66>R1G50F5)7*C^$@'D>QXJ1]$TR21Y&LX][Q>2
M6'!"8QM'H/84:3J]OK-@EY;!U5B59)!AD8=0?<51_P"$NT\7ZVQ281O-Y"7(
M4&)I,XV\'.<@CD8X/- %J/P[I,26BK:#_0B3 6=B4SUY)YZ]ZB_X171A;PP?
M96$4$AEC43/A6/?K4$'C"PEU"*T>&X@6<,8)Y5 27;UQSD=#U Z5$?$]GJ@-
MFL-];K=1.T%SLVB0*#DJ0<CIW H OIX:TA8KJ+[(&2\;=,&=FW'GGD\'GJ*#
MX:TDZ?)8&U)@E8-(#(Q+D=,MG)_.N>\&>)D_LZPT^\CO6FG9U2ZD0F-VW'Y=
MQ.2<5TVI:S:Z5+;1W0D'VJ01QLJ$C<>@)[4 +;Z+86M\;V&%A<-&(BYD9LJ,
M8')]JBN_#6CWUZ;RYLEDF;;N)=L-CIE<X/XBH[KQ-8VTLT*I-/-%*L(CB4$N
M[#(49('3KZ56'C33)(5,,<\MPTQ@^RHH,@<=0>=OXYQ[T 7_ /A'])-U<W)L
M8VFNAME9LG</Z?A1:>'M)L8Y$M[-0)4\M]S%R4_NY8GCVK/?QMI:PVDJ1W,O
MVLLL:QQ9;<IP5QZYXK3.L6B:.NJREHK<Q"3YQA@".F/7VH JIX2T&*UFM8]/
M5(I_]8JNPW>V<YQ[=*FM?#^EV=ZEY!;E9XX_+5S*Q^7TY-0#Q+:O<36A@N8;
ME(3,D4D>#*N.J\\_3@UD>$OMFH11Z[->719T=9H#S'*=S8*Y/&!QB@#?O] T
MG5)O.O;..:384W$D$J>QP>:@/A+0BZO_ &>N5"C =MI"_=R,X.,=ZY75?$5Y
MJ7AR:^43V;PWXB78^ 5W ;3@\G_(KID\6:<+6[FF6X@^QLBR)+$5<EA\N![T
M :6H:79ZI;?9[V'S8MP;;N(Y'3H:AU'0=+U>-$O[..<1_=W9R/Q'--TK7+?5
M3/$L<D%Q;,%F@EQN3/0\$C!^M4[_ ,76=A>/ ]M<O%#(L<UPJC9&S=!UR?P%
M %:[\+B^U^.:XM83IL-MY"1K*RL.<YP ..V,UKSZ%IEW;0036:>7;',(7*F/
M'H1@BL^Y\96-M/-$UK>-]FE$=PZQ96+/0D^E)>^,[&QN[NWEM+UC9X,K)$"H
M![YSTY'YT 7SX>TDFUQ:!?LAS!M=EV'UX/7W[U))HFFRZA_:$EG&UR5VF0YY
M&,=.G0FLC^T;=O$DDT<FHR/'8^:ENH'E3(<'<H)Y;G'.*M1>*[":RLKF..9O
MMLACCCPH<$$Y)&> ,9H L67AO1M.\[[)IT,?G@B3C.X>G/;VIMIX7T6QN8KF
MVL$CFBSL<,V5SQZU23QOILLT<<,%S()E=H655Q)LSD ;LY.#C(%,C\=:?-:&
MYCLKXK\H3,0 =BVW:#G&<CUH V;[2+#4C&;RW65HCE&R05^A'-0OX<TB00!K
M) +88A"L1L]Q@]??K55O%4 2#;87K2SB3$6P KLSNW$G Z>M5G\<V AM9([*
M^F%U&SQB*(,?ER&7&>HQ0!M6.E66FB06<'E"5B[@,2"QZGDTZVTVTM)Y9H(M
MDDQS(VXG<?Q/M65;>+K.XCO6>TN[8V,*S2K.JJ=K D8^;KQ6G)J=O#I9U&?=
M#"(Q(VX<J,=..] #9]&TVYA>&:SB=))?.8$=7_O?7BH%\,Z(JNJ:="HD96;:
M,98=#]1ZU7C\3VTTJVYM;F*>2#SX(Y%4&=<=%YZ^QQ6-X3^VZR(]1N;S5(I(
MI'+@R+Y$OS'Y0O/3&.@H Z1_#VCR6B6KZ= T*,752F<,>ISUS[U%_P (KH/V
M<6_]E6YB#[PNS@-Z_6N;UGQ-<W]CKEG':7=HUA@I<(P&",<,0>,\XQGBM31_
M&%E-;K!>1W%K)!9K.TERH42*!@L.2?S% &C_ ,(MH0MGMAI=OY+OYA3;QNQC
M(]/PJ#PUHUQH_P!N258%BGG,D2PDX5<8 Q@=A1I7BVPU74O[/CBFAF,7FH)-
MF'7VVL?R-/US6(;<G3D2ZFNI8F?9: ;T4?Q9)&/YT 6;K0-*O;AI[BRBDD?
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M =/2UB>'M:N]:C\^73'M+=T5XI&D5M^>O Z5MT %%%% !1110 4444 %%%%
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MA&68_C@ >I- &%/H&N/+9ZHMS9?VI;._R;"L)1AC;Z\>M7O#VE7^G3ZE->M
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MOY+B^C%]>2)*#%&5BC9.GRDDFNK-Y;AF7SX\J S#>. >Y]JD,BC'S#+=.>M
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M).\CT;WZXK*T.)M3N?#Z:D[2>?:3!AO8&1%;Y=WKQFO0KBQM+M EQ;Q3*IR
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M9M/M+JVO&_M&>TE2:(29\UMI+&0=@#T/%4?"$UG((?[8C)E@LR]B5/!C!.[
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M8Z4 <#/I$ES9ZY:V#>;%I]TD]E\^0K;=SH,=L'&*DU&1]6\):OKDJN/M(C6
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M0DC.W!XZGFI]9MK&RN=:M+'8L#::DQC5MP\P,.>O7!_6O26L+-L[K6%MW7*
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M_OD\-ZO<6;2WAN&1-L@'G+C/3@+S_*NRTC2)=/\ #T6E32K(8XC'YB#&0?\
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MUT.M:)<ZAJ&GZA9W,<,]DSX\Q"ZD,,'@$<UF/X.O6M&B6^A#G4OM^[RCC/\
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MN/"T"ZH!*SVH\_S<$-\O.:X?3XM,M/#WA_5?+MXW34%%Q< #(7+XW'J.WZ4
M>AW6JV5E"LMQ<(J,XC!'.6)P!Q4_VF+;DRIC."=PZUY2#I=S8:I<$V[HNL*P
M;J!$S=1VP14MX^D6;^)X"UM%%=0QM91 ##C;D%1]: /4FGB0X:1!TZL!UH2>
M)Y#&LB%QU4,,C\*\UT+3+'5-;<-%#<O'ID+H&8[?-P.N#Z]?K1X8M+674[2X
MFU*6+5H[AA-:I;J)"226WGJ5QW/3- 'I;S)&0'=5+' R<9I@O(#LQ/$?,.$P
MX^8^WK7+^,[>QNM3T*"\$962Z(.Y@"5QT_/%<@\%A!X<U;4(_+2>VU79:NI
M,2[Q]WTX!_*@#UA[J".18I)HTD?[J,P!/T'>L_7M831=-FN5\IYD0ND,DFTO
MCKCUK@[V2S=-?^VN#JXN ]B7;#D?\L_+QSTQ1JSVJ+KD6O$?VA]GC^R&<98@
M+SL/^]GI0!W5OJ]W->6Z-:1K:RVHF:8S#*GTV]<#U]ZQY?%VJ3>;-IEA97%M
M'*T>Y[L(PQQN8'  )Z50M;G3KGQ=I11D?S-*(G<GY77&,<_0YK'G@T=_ 6I7
M$:6IN%NF"NJJ6"F3Y1D=L XH ].:[AC,23S11RR?=1G +'T'K0;NV^T?9_M$
M7GXSY6\;ORZUP$4NFQ:IJ,7B*&26YG=)+'J6D0#Y1&1T/'J*SM:O+'^V))4E
MCLI8=44-O!>4XQEV8G(3T4"@#T&77X)K?45TQH[J[L@1Y.X ,V,XSZ=LU=6_
MC2TAFO'BMFD495Y!@,1T![UY\1I2:3XLA>*!94ED:(% "@P-N#CCYL8%-M)[
M ZC;MX@:$V+Z1&+5I/F4D*-V"> V0?TH ]):XC0X>1%)&0"V.!UI2[&(M$%<
MD97)P#Z<UY=H]M;3:MI<.M!0C:=(0EPV"5WG9G_@///I77> KDW'A.(F42".
M21%(.<*&.!^6* +OA_7QJ]BLMQY,%PSNHA63)(4XR,\FM07,1C$@E0H<88,,
M<G'6O,].MK1[6P2S51K<>I?.$&)5CW'.['(7'K6I=:-/!XAFT.!%^P:K*MTY
MP/D53EU^A.W\Z .SU#4K;3+0W5U*(X@0-Q]2<"LZ+Q#OUZ[L95@CM;>!)?M!
ME^]NZ=L?K57QM:0#PX))%C6*UGB?YD!"KO /T&":YZ\;P_>ZWJLLSVLENFFJ
MULLC8"D!ONJ<8[?GGO0!W\UU;6R*\\\42N<*SN%#'VSUI]Q))';220QB615)
M5"<;CCIGM7E43P7,FGC6]0GALYM-6.&6-%<;LD,O*M@_3GI7HFENMEX>@>XD
ME6..+[UVP#X[;CP,XQ0!BP^-KH:7#JUYI(BT^5MC2QS[F0[B,E<#C@UT[WUK
M"(S+<11&;B,.X4M],]:\L0Z;=>#8DBU.634DE+Q6(E,@)WG \OD=.:W+J:&+
M5KZ/Q(L*&XT^,6SR B-&VG>BD\9+'/'/% ';W.H6ED$-U<PP;SA?,<+D^V:<
M]Y;QMM>>)3Z%@/3_ !%>7W32K:06FHQ"._.E'][+&TCNN6Q&HYPPXRW\JMZ#
M!I&M:[:1W9M[@G2HUVEOF,B\'/?('0^E '9>(-;FTN*(6BP2S/,BLDDF"JLP
M7=CJ>2/SK6DFCAA,LSK&BC+,QP!^)KS22XL8K!XM10-K4>II(_F(3*%WCD8'
M(V\>G-=5XTN(X_#P:2!9HI)HP=Y(1 3]YL$9 ]* -Q+^TE@6>.YA>)CA9%<%
M3]#3X[B*96:*5'5202K9P1U%>22RZ>5U".6YAN%;4+>1)$C\M".0Y4#IU_$<
MUJ:J(K>^URQTA0+54@>XMX!QMS^\./IC.* .UM]8N)O$,VG-!%Y"0B5)D<L2
M,XP1C YSW[4^^UR&WFELH'CDODMVF6)FP,#L2.F:Y[0[S2)?&KKHP@^SR6 W
M&!2!N#<9&,9Q3=5?3K/QA?27R1(TE@# Y3)W_,"<]CCN: .CT+6H]6TVVE>2
M);J6$2O"C<J#WQUQ5V.]MIIWMX[B)Y8^717!9?J*\UT^."WF\.2V2HEQ<6DX
MD9."S[<+D_7BKG@NTLY+JR\V6_&IVBNKH8=B("<MN;;SDGN<\T =?K6NC2FM
MX(;=KN\NFVPP(<$^I)[ 5#:ZMK":K#9:GI]O$DX8I-!*74E1G&"!S_A6?XCC
MDL/$>F:^Z.]G;*T<Y09*;@0#CTYJ:^\10:MI]U;:#*US.;=V$L:';'P>YQR>
M@% &]%?VL\C1PW4,CI]Y4<$CZTT:E8OP+RW)*[L"4=.YZ]*X#2UL;I_#PTR-
M5N88V34%50 (@,.)!ZD],^M4+>PT]K31I!;1#S-5=)6*8/EYP ?]G!''O0!Z
M;_:%B(U<WD&QVVJQD&&/H.>34B7UK)"TR7,+1+]YU<%1]37F%^E@FDW\?EQ*
ML6M@J@3&R,XS@8Z$#M3[O3EE367\/ G20L!9+<;@QR&8J#U( .10!Z6NH6;1
M&5;J!HPP4N) 1D]!GUH2^M9(Y)$N862(D.RR A".N3VKRZ\M],G\-7<FF3WE
MR9[F#>\L 1,\\JJ@<@#G%7+^WT]]6U*V@>6&SFMK<;[1 5W[A\Q4<$=S[ T
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MZQ5MPLX <YR(QG-6:* &/%'*A21%=3U5AD&H_L5KY)A^S1>43DIL&T_A4]%
M%<V%F0@-K"1']P>6/E^GI4K1I( '0, 01D9YI]% $;00M()6B0R+T8J,C\:1
M;>%)&D6%%=OO,% )_&I:* ((;*UMY9)8;>..24Y=D4 L?>I617&& (/8TZB@
M!OEIDG:,D8)QU%1?8K4+M^S18SG&P8S4]% $:PQ*Y=8U#GJP')HDMX92#)$C
ME>A90<5)10!&]O#*5,D2.5^[N4''TIS(CJ5905/4'H:=10!$MO H8+"@#_>
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MYH L4E1K<0NRJLJ,7&Y0&'(]165K&LW&F:KIMN(X3;WDIC=V8AEXSD<8QTH
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MC.TXX858OK""_M6M9U)A?&Y5)&X9S@X[5%JFGRWUB+:VO9K$A@?,AQNP.W-
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M_9V:Z:^G1EH=-6XM0DN3(H& &X !^E6YO!DUP;J2;4P9[FW%NTJVX7Y<Y8D
MX+'UHE\&/.W[W4?E^P"Q(6(@[.N<[NN: ((O$+ZW!J^GW,%LP@LR^^)BZ,2I
MR.>#@]QD<5F:+$J:AX0("EOLDV3QG&#_ (UM6_@ZY@>:1=9??-:BV?\ <+MV
M@8& .F!^M2VOA.6UGTJ5=0#?V8C1J##_ *Q3USSP<4 6=>UN[TJZL+:SM(KE
M[R1D >39@@9'.#5!/%]TT MVL8QJ37AM!&'/E[@ 2<]<8K4U?1)=3O+&YCO!
M ;*3S%'E!MQ]^>E4#X/9XI=^I/YYN_M<,R1 &%SUP,G(Z<&@#-USQ1JL6EZA
M JPVM]92QK(Z$LI1S\K+G^M;^HZG>:9X:?472$W$,0=TR2I/H#UJE/X.6\L[
M^.[OGEN;YT9[CRE&W9C: OIQZUJ2:1]JT1]+O;A[@21&-Y2 I.>^!_GB@#)F
M\3WUM>1QRV49673VNPB,2X*CE?0_6JL/C6<:5+?SQ6<B_NUB:WE+ .V?E<$9
M&.I_(5./"&H&YBNF\0S&>& P1N(%&Q2,<>_?-(_@<7!O)KK4&:ZN?+*S11B/
MRV0Y#8!Y/K^- %WPYXAEUB6Z@GMV1[<C$JQLL<BGH1NP<]:I7GBR[%QJ3Z?:
MP36VE8%P9'96;UV\=L'K6MHVE7ECODU#4Y;^=P%W,-BJH]%'?U-4+SPDTMY?
M/:7QM;?4EQ=PB(-N/]Y3_"3D]CUH K0^*]5U+5/LNEZ=;2QF&.?S'G/RHWX<
MGV'H>:UM;UB6P:TM+6))+R]DV1"1L(,<DGOC'I3;#P__ &=JKWD-S^[>%(/)
M,?15&!SGK3];T,ZL+>6&Z:UNK1_,@E"A@&]U/44 <4;G['H/B&74=/M9W_M
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M%QK%MJ=L]TT5G)J;R/'Y1!E3<#PWH>.E7[OP0]Q+,8]6DBCEN1<[/)5B&!!
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MNKFQU%K1;^,)=($#9P,94_PMCO3O^$;$=]IL]M<B*+3D*10F,$'(PQ)SG)%
M&K965O86L=M:QB*&,85%Z"K%%% !1110 4444 %%%% !1110 4444 %)2T4
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MG7$;:KI#@^5$(IT:!4.R $-\A8]2>IR>_2I---G#:^&)D_=RM<2^:\8 ;=G
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M6[2@!_I7G<-HEH^B&YM1]CEU*:2/S%R!$<;1@\X_BJ&6VV26[+;,+.YU@RP
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M+2M.C^SW$)6>Z4W$=L6DC!P0JC! W9 SCM0!VMUXMTFVFLXQ=)+]L/[MHR"
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M\>Y4<G /3KZ<4 7&DL[9XT=X8FD.V,$A2Q]!4RJ@^ZH&?05YE/<:E/::#=7
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M:\MTGMI(YH7'RNA!4_0U* !V %<3I/BJXNK73].TJRM8+J:"2<QD$1Q@,<*
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M'3&0>E 'H6!Z"FL >/6N/L?&.J:A/%+;:.TEE*[+N$;@HHZ,7(VGH<@=*O\
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MHW&<9SUJ;Q%]N.OZ'';78A6263Y3'N!(0]>1D8R,?C0!JP7FF>(K"9;2Y\^
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %)2T4 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 E+110 4444 %%%% !1110 44E% "T444 )2TE+0 44G>B@!:**
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M,I?V<V+6._=;I/*!(0O]X']/Q]JZ_0]0NM3-W=EU:Q:7;:'9AF4#EL]P3G%
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M('?WJR/$MO\ V[+I313!HE!,NP[<^_' ]SQ4UGXBTR^NEMX+K=)(I:/<A42
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MZU8B\2Z5-I\M\MUB&%]CED(8-Z;2,DGMQ5K3]5M-320VTC$Q-LD5T*,A]""
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MXJTB.T@NOM+.DZ,Z".-G;:.IV@9 'O0!EZ]X4 TV]N+1[JZO'M!:HC%<%,C
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M!A&SMN5>2"3ZXXS63%I&HQ:-I]D^D7D=]:QR!+JV=04D).%)S@H<C/->CTM
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MSC\>]3UQUB-3T2_T[1X-1BO%/^NA,1S$G/(;L/3-=C0 4444 %%%-9@H))
M&3F@!U%4IM6T^W4M+>P( ,\R#I57_A)=,8@12R3;N1Y4+OG\A0!KT5C)XDA:
M8I_9^I! 2/-^R.5X^G/Z5HV=Y!?VL=U;/OBD&5;!'\Z +%%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M"RCT^RAM(<^7$H49ZGW-206\5O$(X8U1!T %2T %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M/WH&Q?HO05:T^XGNK.*>XMS;.XSY1;<5';/O5K(H 14"#"@ >@IU)D4;AZT
M+129%+0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M"!DX!QUJ.P\5:/J=U':VERSRR@E 874,!UP2 * $CN]2D18K32A;1@</<N
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 1ONUP_AF
MVU2=+H6\UNEH-4D\^)H\LZY&0#G&/;%=O(@EC9&) 88.TD'\QTJGIVCV6E(Z
M64;1)(=S+YC,"?7DGF@#DO,O9KS69WUZYM+?29OW:@+MP5S@@=1G@"JMOJ>J
M11:HGVR]@6/3A=1><X=RQ_B[[0?[HZ9[5V<6@:;#]IVP%A=_Z\22,XD]R&)%
M5/\ A#-!  %D5&SRSB>097T/S<_C0!RQU'41"L-QJ4UU'>Z+)<2)(J_*V#]W
M:!5_P5J,NH^7:S7,UN;.WC$=L!@2+@?.3WSZ>E;Y\*:.=G^C/^[B\E,32#;'
M_='S=*?#X:TJWN+:XBMV62U39"WFN=B\\=>1SWH EUE$;1KXE06^S2#..<;3
MQ7.:/<?8/APE]#"%FM[>1HRPR0V3\PX[]:ZRYM(KNVDMY@QCD&U@&*Y'ID<U
M!;:/96E@;&&(_9B"#$[LXP>WS$\4 <D+W4+670W35Y[A-4A992=IP^W.Y>.,
M$_I6-?+J6I>"[?4[S6;J8O<K'Y "A1\^,G R3QWKO;7PSI=IM\N*0B-62,/*
M["-6&"%R>*'\,Z6VBOI"P%+1CD*')*G.<@DD@YH SH+J\MO'$6G-?22VIL/,
MVR!<E@V,D@>U=,<,A/!XK$F\)Z6(F:&V_?>08%WROMVD'@C/OGIUYJSHFER:
M?H%OIUQ+O>.,JSQDCOV/6@#S[3=3N/"8MK](2UK?V\@*'.#*K';Z\G@?C6EX
M1AEM/'%U'=',[V(DF8CJ[%6.?SQ^%=?'X<TJ.UBMA;;XH9?-C61V;:WJ,G].
ME,?PSIDE[/>M'*9[A#'*WG-\RD8VXSC% &=K>W_A-/#S K@B?GU^456U943X
MA:2;1]L\L;_: IQN0#C..O0]?05LGPOI;"UQ'*GV-=MN4G=3&.^,'O4MCX>T
MS3GFDMK?;)/D22,Q9F'IDDF@#14Y7(IU5-,TVVTFPCLK12L,>=H)R>3D\_C5
MN@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M>@R--9LQ%^UTS1 '."J9QD^F..M:OB^QN;^733#ITE[';3^;*@*@%<8QR10
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MA2\,L?SD-@+@#.<DCIZT ;M%9NEZ[:ZK-/!&DT,]OCS(IDVL >AK2H ****
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MQ6"!]JX^9CD_X?A7;U52*B[(F$G)79YS;^&M=M/+N[;3PDMI?-/';F=2)$;
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M3FT;3]23=<Z@+I+ZXA9P@E/'R\]"  !^-==?:/I^I3PSWEG%/) <QLZY*U<
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MJ7?)K/VTCS8_ECX_VNOM6_X>M-0L+_58KBS*03W<EQ%/O4[@V,#:.?SKHJ*
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M=M-'(R3(<ERQ'?Z#\:=INC:YIL&E7B::99[$2QR6S3*I<.2=RMDCC/0UW]%
M&#X4LKZQL+F.^M_(>2ZDE5=X?Y6.1R*PM7T36)[?4K6WTS<DNHI<QR"9?G7C
M/RGIC'XYKNZ* ."U7PYJFJ:CK#I9O"EPL30M*Z%)&3JI .<&MGPS87,,LMQ<
M:#8:22BH$MPI=SU)++_#TP*Z2B@#EWT_4=%\0W.I:;9_;;:^"^?") CHX_B!
M;@CVIFK6>NZS8K.UI%;RVUPDT%J9<F3;U#,. 3V_G75T4 <+JFA:OJHU6_.G
M^1-=6:VL5MYB%B=P)8G..WK4D&G:I#K,=Z=)G*#3%ML!XR0X'0?-P/>NVI*
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M2Y2)],CME"RQ_?5<?WOUKNJ* .)TO1M5M[GPX9M/(6PBD2=O,3Y2<@'KS_\
M7J)-%UNTF%Y!IHDEAU66Y$1F51(CJ5R#SC'O7=T4 </?>&=5NCK-H+>(1W\J
MW4<YE^4,,?(5QGMUI3X<O=0TB=#HMAI5RH78(L'SBIS\V.BG'0Y]>U=O10!S
M&G0:A864UU;^'+.TN6"J+:)E5GP>69QQCG('Z\UTJDD D8-.HH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBDH 1B!U-<K-=WOBF\FL;"9K;3HFV2W*?>D/HI[5<\47<SK!H]FVVYOFVE
M@<;(Q]X_Y]ZU=/L8-.LXK6W7:D:X^ON:T7NJ[W>QF_>=C,/A31X=,EMULHS\
MA_>,,OGUSUS4OA2\FO?#UK-<'=)M*EO7!(S^E7]0<QZ?<..JQ,?TJGX:M/L.
M@6D!SGRPQSZGG^M%[P=][A:T[(U:YOQEF=-,L.JW5Z@<>JCDUTE<MXFNDA\1
MZ2T@^6WCGG/'HO'\J*2O+0*KM$L:"&F\0:U=D':95A4]OE&#70YK"\(V[0Z%
M%+(,2W+-,^?5C_ABK.O:W%H6FO=2 ,V=L:9QN:B:<IV7H*#4879J4M5[2=Y[
M6*62/RV= Q3.=N1TJ>LS46BBB@ HHHH **** $/2N%BN$3XD"?.?.9X<YZ$#
M&/S4UW+\+7 _97DT>?6X0&GM;S[2I'\2CEA_X\:WHVUOZ&%:^ECO\TM06EQ'
M=VL=Q$VZ.50ZGV-35@;AFC-0W5Q':V\MQ*<1Q(78^@ R:BT[4;;5;-+RTDWP
MR9P<$=.#P:-;7%?6PFKZ@NFZ5<W9P3$A*@]V[#\\50\,::;+2Q/,,W5V?.F8
M]23SC\*J^+O])_LW3,G%W=KN]U7DUT:@*N ,8K1Z0MW(WGZ'/^,3Y.F070&6
MM[F-U_.NA7[M<YXS;S=-M[)?]9=7"(HKI%Z4/X(_,(_&_D(_ SZ5YSIH%UK=
MAJ;@F6]OY&!]$48'^?:N[UBY-II-U.!DQPNP_ 5R&B0C[1X9M\Y*023D9Z;L
MD5K1TBW_ %LS*MK)+^MSNQ2TE+7,=(4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 444E "T444 %%%% !1110 4444 %--
M.J.9_+A=_P"ZI- F<[H:_P!I>(M3U-^1"_V:'V ZUTHKG_!"$>&HI6.7F=Y&
M/J=Q']*Z#%74^*W8BG\-P-4[;5+.ZO;BRAEW3VV/,3!&W-7"?>N/\+2+>^+-
M>O4/RADC4CH<9Y_041C=-]ARE9I=SL.U<)XXCEN/$6F6L/#SQF//L6&:[DG
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M[G?<33E[P>)M9_LG33Y0W7=P?+MT'4L>_P"%8.H:<= T;19S]^UNU>X?_?\
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M1JNAZE=,<W_F>=(W3<_*_GD5Z#)*D49=V"JHR6/  IU[)I+:PZ-];]P>58R
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M]LEOYFIQI6G@ "PM@!T'E+Q^E%X>8>^5QXCTO(W7/E@]#*C(/S( J[#>6UP
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M%+::^DM;HGH 0I4G\?Y4 =?+%=12)&^N['?A0T48)/MQS3VBN;=P;G6B%;.
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MD0]%&>/K72T4<UE9(7+K=F?]GU#O?1\?].__ ->L*7P-#-<M))?R^4\OFM;
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M8>H>$],OG9R)("[[W\IL!CW)'2MVBFFX[$N*>XQ%"(JC. ,<FGT44B@HHHH
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M!)$]C'Y<$<9 15],8]ZBN_"\%Y8+9S7U\\:S^?N:4,V[L,D'@=A6[10!D?\
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M1110 4444 %)2TAH 6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH *2EI* %HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MTM(: %HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***2@!:*** "BBB@
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M*R#XJT('']IP9]FI#XKT-1DZC$._6@#8HK&7Q=H+=-2BZXYR*=_PE6A%MO\
M:<&?]Z@#7HK(/BK0E.#J< ^K4?\ "5:$1D:G;D<=&H UZ*RCXFT08SJ=OS_M
MT?\ "3:)D_\ $SMN/]L4 :M%97_"3:)@'^T[?!Y'SBE'B316'RZE;G/^WUH
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MSSH_[Z_G1YL?]X?G0 ^BF"6,G&\?G2&>(=9%'XT 244SS4_O#\Z/,3^\/SH
M?13/-3^\/SH\U/[P_.@!]%,$J'^(?G1YJ?WA^= #Z*9YB^HI/.C_ +X_.@"2
MBH_.C_O"CSXB,^8N/K0!)148FC/1U_.E\Z/.-XX]Z 'T4SS$_O"CS4_O#\Z
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MFYMI.?KS4><C'&?44$;4],"@1)YF" &QCWI SE1\S9'09IF"#C^E)Z=/7Z4
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M8$],&HF)^\QSZG/-)D$@_+@G'(&,47 G$K!2-S]SWI@?IEC^)IF\XQP !]*
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M^U!48Z'\: '9P<$9].*3N,$]Z3J?FQQ[TA!![4 *&&1GZ#-*&Y^4YIA7/)R
M.M."^F2?2@"5>&SGYL4[ V@$\]?7I3!G/W2I[4I1@YQZ<9[T  /RG/:DQDY
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MOQUI!G/7&,]: #&>#^0[4@SQ\N*7##CH.A^M'&0,8 ]* $4@<C)&/84HPSX
MQ]:3G/0\TO 7..2.H/6DP$8%1C!]J,#JZ9'I[4$[N%[<CO\ A1P<\8QU_6F
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M$\KDY';UH )PN,>X- AN#CD$?C2$8.,89>H]Z> WKGM29/"XR#R.>!0  [N
MO';)Z4Y?O<=?3-1C=GK@TY2V.HX'>@8]@,$#(ST)-)R&) &">F:%D#9R2/?_
M #FD(&[(;(]*!(=\V,+QV)ZXI@ .0,\GGFI!A<#:=W&??GM30O3 R/7IS0 A
M4A0,]>QIH4+T /?K2L>>IP>>!WI5VDD8&*$ *".IS_GM0H*Y&#]11M4 \?GV
MI0H; QUH :1QU(S2Y&"N<#MD4=!]P9[BCC?RGL?3K[T 21J",=^,8[5Z=X8!
M'A^T)QRG;ZUY@CKGGK[BO4O#C;M!LR.GEX_4T S4I&.%)P3CL*6BF(0'-%%!
MZ4 >=_$$-_;=N?X3;_\ LQKDVP?8^E=AX_/G:K;+#M9XXF#8< @Y!Q7(.K9'
MRD<$ D$#/UH CX7.["G-&T 8 R<5(L;9XC)Z\#)INUMNT@@XZ8P:0QAQNSQD
M&G%!T&WVH 8,,*0:4@DG*MG&: (B/3G)Z8IP;I@#_&G;6#?Q9Z8QG/%!5B.5
M8^N!0!&$.">/6E)(&=HSQSQ4A0\C')]J;MQR,CCH10 !<9[YZ>U 4 8XY/?O
M3MN .,X_2@@$XP<8H -F1P ,\4A5<D''3KFE.WDG/UI"J[L<'% (854KQS^-
M(%/IP/0=:D&S&>V.N:,#GYCCTH&1@?+]W(]*?L495<%B>U.*]QQ[8I T?S9(
M_P XH$)M.X9 Z]CFDVDMG;UYQSQ3BRAQS^5'RY&#]<"@!I'.*4#@<#\:7<,$
M[OTHRF,@\=: &D'G&?;M04Y'(]\D<<4K,N.OYBE)4=#]<>U Q NXKG;GZ?\
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M/(X SZD4_=#]X,N/][%,8QA0WF* 21RP_E0 %06P2<CTH$>,Y!S2J8R,^8I
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E** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>formofindemnificationagr001.jpg
<TEXT>
begin 644 formofindemnificationagr001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  H'!P@'!@H(" @+"@H+#A@0#@T-
M#AT5%A$8(Q\E)"(?(B$F*S<O)BDT*2$B,$$Q-#D[/CX^)2Y$24,\2#<]/CO_
MVP!# 0H+"PX-#AP0$!P[*"(H.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[
M.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SO_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MGCJ'P]?:RFM0W-H\Y8P)'+;%2 -VS *G/<=?UH>'I/$6OZ:]_+XW>R)N9HQ
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MK[P'J\EU!;)',_\ 8P;<P !.3R>:]+HH Y"Z2?4?%/A#4;?3;J"UBCN_,66
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M^SK/=RM*^GS'[K L3A6Z$GD>O:I-.\/+K7CKQ8[:KJMEY5S -MC=M"&S"/O
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MFIV_Q,M-$U?=)<:7ILT4=T?^7F$NAC?ZX&#[BO3 BARX4!CP3CDT;%W[]HW
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MG=Q&57JW\/(Z8]JNVVJW-AJ]SI]UJ^F>'+BSLK1+BYN(1)<7S"(9*EF (4Y
MP&.:[;PUX=B\/:-;6#2)=26[2E9S$%.'D9\#DX^]CKVK5>WAED222&-W3[K,
MH)7Z'M0!Y%\&D23Q/K<KAFECBV!I(PC@&:0D%<?*3@9%7(H?[-TNZ\16Z8.A
M>)KMW51_R[-)LE4#_=(/_ :]26*-&9DC56;[Q P3]:Q?$F@7>O6J6$&HK96$
MQ(OHTA#/.A(RH;(VYP03@]: *W@2WE;1)-9ND*W6M3M>N#U5&XC7\$"_K734
MU$2*-8T4*B@!5 X ':G4 87C:TN[[P5J]K8JSW$MHZHJ]6XY ^HR/QKC]<\0
M>'-4L/"%KID\$TT>K612&/!>V4, 0X_@ZA<'&37IM1"V@5V=8(PS,&8A!DD=
MS[T >5+KNFZ?\+]>T2YNT34T>]B-F3^]RSN0=O7;@YSTQFMWP9;0WNK^*+6X
M0/#/!8QR*?XE-HH(_(UW!MX&E,IAC,C+M+%1DCTSZ4V>%S;3K:,D$[H0DI3<
M%;&%)'&<<<4 >=^$UO-2UZPT*^#,GA!9!*[#B60DI ?PBRWXUZ76/X=T*31H
M;J2[O/MM_?3&:ZN?+"!VP% "\X4*  ,UL4 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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ML5HF4'!.3R1TKF;SP[J5QKFJOJGAQM<>>X+6%S/=J+:&(@;4:,MD;3G.%.:
M+FF_$ZWU+P5?^(DTUUDM)Q"MGYN7D9BNS!V_Q;QV/0]:TV\:VWE:1-%:M+'J
M-E)?2%7Y@B2,,3C'S')"XXYKD?#/@37=.OM#2YM4BLE$<VHCS58B: RB+&#R
M"'0\?W1G%;/A'PKK&CW>KR3K"A@B>ST<R$.ODF1Y 6 .<9901P<)0!H:+XLU
M75?L%TWA\#3=0_U=Q;78G:'(R#*H4;??!.#P:Z+4;^WTO3KC4+M]D%M$TLC8
MSA0,FO/;'PQJ1UG3+JS\,?\ "/7L-PCZA=V]V@MYHQ]]5C5CG=VRHQGK7<^(
M=)&N^'K_ $KS/+-W T:N?X21P?SQ0!S[>-M5M;.VU34?#?V73+MD6.;[8&DB
MW\(9$V_*"2,X)QFJ7P\MKB[UG7=8U#3D2[.H7$'VG[6964!P/)"X VK@8;OZ
M"G7]IXG\1Z%:^&KW0Q8)OA%[?&Y1HRD;*Q,8!W$L5'! QGFM[PEIEYI<.K+>
M1>6;G5KJXB^8'=&[Y4\'C([=: +?B6YN[/PUJ-S8H'N(K9V3,FS'')S@\@9/
MOC%<$-7UA;3X?W<ME)<74B,$B6ZW&Y!M@%=V(&,YW'.<<]:]&U6U>^TB]LXR
M ]Q;R1J3TRRD#^=<=I&CZ[)_PAGVS26M/[$$D%SNGC?Y1;^6KC:>A;MU'>@"
MT_CZ73S?6FLZ.UOJ5MY(AMK><2BZ,I*H$; P<@@Y'%7[+Q+J":U:Z5KNCII\
MM\CM:R0W0G1RHRR$[5*L!ST(.#S7/>,?!6I:_P"(;R]AM898D@M7@29P$G>.
M1RT;=P"K8SC'-6-!\.[?$=G>0>"[30X+57:66:1))7<C $>QB !DY)ZCM0!K
M_$5VC^'^LNC%6%L<%3@CD5P^KQ^ ;/PY+<:%JQ36A"#:?8M1EDE:;'RKMW'.
M3P>*] \:Z;=ZOX-U33[&+S;FX@*1IN"[CD=SP*T;'3[:U@AVVL,<JH 2J '.
M.>10!R7A[QUJE_I[WFH:']FLM.66/4;UKD?+)$#NVQXRP.!]"V.<58'C;4[>
MTM=5U+PZ;32+ID"W'VL-)"'("-)'M^4$D9P21FETSPO=R^#]=T6^7[,^HW5X
MT;;@V%D8E&X/N#CK5"^LO%'B'P[;^%[S0Q9*3$EY?FY1HC'&RDF-0=Q+;>A
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M 5R=[JC>-_%VA+_9(N---O-)]FFNS$0ZLJN74#[R'( R<]<BNAMX-=\+:MK
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MKZ>AFC$,:K(!)*@4_+D8*[N,')P>.*]+U34(-)TNZU&Y.(;6)I7QUPHS@>]
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M444 ,CBCA39%&L:Y+848&2<D_B233Z** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 55DL(FU"._0F.X5/+9EZ2)G.UO7!Y'<9
M/8D&U10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !56*QB2_DO
MG)DN'7RPQ_@3.=J^G/)]3] !:HH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MOW/7=CGZ5F0>)++5]?T1XCJ,0GDO8K=4D"P3B+"L[K_$,CY?3F@#K:*\PO\
MQ/KMSH/C8R17EF;)R+>82HIM\*F$!1LYY+9]^O:NGL?&7F:A86=[HU_8Q:B"
MMG<S[-LK!=V" Q9"0,@,,T =1169KFO6VA0P&6&>YGNI1#;V]N@:25\$X&2
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MW9<?VSKH]QJ<O^- '045@'PC;D8_MC7/_!G+_C0/"-N !_;&N''<ZG+_ (T
M;]%<^OA"W7/_ !.=<.3GG4Y?\:!X0MPQ/]LZYSV_M.7_ !H Z"BN?/A"W+ _
MVSKG';^TY?\ &AO"%NV/^)SK@P<\:G+_ (T =!16 WA"W92/[8UP9[C4Y?\
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MH Z"BL#_ (1&W_Z#&N?^#.7_ !K9M+86=K';K++*(Q@/-(7<_5CR: )J***
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !61#
MI;Z?XCNM1MTWPZDB"X4'E)$!"N/4%< _[H]3C7HH P)?!>C2V5U9%+@6UU<?
M:)(A<OM#[M_RC/RC=\V!CFK;>'K"357U.82S7$EM]ED\QR4>+D[2O0\DG\:U
M** ,31/".D^'Y-UB+G:H(BCFN7D2 'J$5B0OX<UMT44 4M3TBSUB.WCO8RZV
MUPES'ABN)$.5/'\J6YTJSN]2LM1FC+7%AYGD,&("[UVMQWX]:N44 9[:'ISW
M][>R6XDEOX%@N Y)5T7.!M/'\1K*MO &@VUQ:SA;N4V,BR6BS7DDBV^.@0$X
M Z<>PKI:* .>O_ ^BZA>7%RZW<!O/^/J.VNY(H[GM\ZJ0#Q^=7+'PWI6FVMY
M:V=J(8+W_6QJQ ^X$P/0;0!Q6K10!E-X<TQM-T[3C"WV?3)(I+9=YRK1?<R>
M^/>K%GI%G837LMO&5>_E\Z<EB=S;0N?;@#I5VB@#'L?"VDZ<VFM;0,ITN*2&
MUS(QV*^-P.3ST'6I+;P]I]GK=WJ]NLJ7%XNV=1*WEN>/FV9QNPH&<?SK4HH
MYJ/X?^'XYD(AN3;1R^<EBUU(;97SG(BSMZ\XZ>U(?A_X?,I_<W'V4R^<;#[5
M)]E+YSGRL[>O.,8]JZ:B@ K)L-,;^W+O6[I=L\\26\*9R8X5).#[LS$G\!VK
M6HH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MK@?*V-V.N#TH G^(4-[+86!CM[VZTU+H'4K>Q)$TD6TX P02N<9 YK&\/?\
M"+G6HKGP;J#6L\,<GVO1W,B&Z&W@;)#PP./F&?>M=X_&7]B:'J$42G4K)2M_
MITDZA;L$;2=XR W&X=N3GTJI>VNO^)-8TR_N/#(TL:3*;GS9+J-YIR%($*[<
MX5B1DDXH [.QGGN;&">YM6M)I$#/ S!C&>ZDC@XJQ5>QGGN;&">ZM3:3R(&D
M@9PYC/=<C@X]JL4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1139)$BC:21@B("S,3@ #J: '45EZ+K!U315U>:(6U
MO+NEAW'GR?X7;TROS8[ UF^#O&2^*UNPUBUE+ 4DC1WW&6%QE).@QG!X[8ZT
M =-167+K!MO$D&DW$01+N!I+68'[[I]]".Q (8>HW>E:E !1110 445EZQK]
MIHLVGPW&2U_<BW3# !203N.>V%_,B@#4HK%M/$D$VM:OI]P(K9--DAC$TDP
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MHJ'[5;"Y^S?:(O/QGRMXW8^G6H-8O_[*T6^U+RO-^QVTD_E[MN_:I;&>V<4
M7:*HZ7J2:CH]AJ#JL!O+>.81E\XW*&QGC.,U9@N8+I"]O/',H."T;A@#Z<4
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MZP88;Z'O0!)13(9HKB(2PRI+&W1D8$'\14<U[:6TB1SW4,3O]U7D"EOH#UH
MGHJ"6\M8!F6YAC^;9\\@'S>GUIT]S!;*&N)XXE8X!D<*"?3F@"6BLG0-<_MP
M:D?L_D_8=0EL_O[M^S'S=!C.>GZUK4 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5SGQ"DFC^'^MM!
MG?\ 9'!Q_=/#?IFNCJ&[M8;ZSGM+A-\,\;1R*>ZL,$?D: .0\;W,D7@RST+2
M%#76L>796R!MO[LKESGL-@(SVS63//K'A_Q5HFLWVB6^EZ?L729S!>><-C?Z
MHD;5VA6'7GK76Z#H1MK+3QJL,<][I*O;VMUG),?W0WL2@4'W!K4U'3;+5[&2
MQU"W2XMI,;XWZ'!!'Z@4 <]XYRESX8EBXF&N0*I'7:RN''TVYKJZQ+K2)[_Q
M38WDX L=,B9X%W9,D[C;N(]%7./=_:MN@ HHHH *XSQ]IUA>:EX8-Y9V\^_5
M5B;SHE;*&-R5.1T) X]A79U1U;1M-UVS^QZI9QW4 8.$D'1AT(]#R?SH Y'3
M?#NCZOX_\6R:EIUO>>6]K'&L\8=4!MUS@'@'ISUXKD/#T=_JEYH&G-:6.HP6
MVFSM;6^IS,L3,MS(A( 5MS*BJ ".!S7L-KIMG97%Q<6UNL<MSL\YQG+[5"KG
MZ  51N/"6@76G0Z?-I<+6]NS/"O(,;,26*L#D9)/0T 8G@*TN+"_UVT=].B@
M2XC9+&PF>1+1ROSK\RK@'@X'3)Z4NB?\E#\:_P#7&Q_]%/73:7I.GZ+9BTTV
MTCM8=Q8K&.I/4D]2?<TZ+3;."]NKV*W5;B\""XD'60*"%S] 30!Y*F@Z9;?
MZ#6H[.+^TXXX[A+W;^^5A* ,/U  XQTQ6[IFDZ-K%GXMOM?@AEO8K^X22:8
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M.-#$TDEO=2@, S)L4*=N[\5'!S7II\*Z VFRZ:=)MOL<LGFM"$PN_ &X>AP
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MFTR%3R Q/&><"N;O+K4+V;6[74KG7(;WSYH[/3-.MC'%-'T1C($YW=2Q<=Z
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M M\2+2YGMBD-P0,_*Q]1R,@9[5YCX[MIM4TZTDTR?Q%K@4R"6:YMW6-&:-@
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M;N\NEM(6#2VD; 1W&"" _&2 1T!%;%%% !1110 4444 %%%% !1110 4444
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M **H6&L6NHWVH6< D$FGRK%-N7 W%0PQZ\$5?H **** "BBB@ HHHH ****
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MR""&<,1L(B38,#'&03FL=OAOITFDOH\NJZM)I9!$=F;A0D7.1@A=QP>0&)'
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M^'(]<M[?Q/)K4R^?'<)-&+(\Y">69,>7CCE<]Z[7QK?7D'A6TN8I);.>2\M
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M?:01J!O)[V_DU*-$N9;F8%F*$E6! &TCC&.!@<5#=_#C3]30+JVK:MJ1C7;
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MLM*M&N]0NX;6!/O23.%4?B:X7P!>:4/%.K16,36,-Q9V+65K<G$IC"/T!))
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MZD,2L>/^6G QGC --U'Q-H6DO(FH:M:6SQ%0Z22@,"PR..O(!K(\=?Z_PO\
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MN;DJ@&[874;2.%'.?2N8\"32_P!@ZY:VTRKJ-SH48M(]P$DC*)@=@ZDCVZ4
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MVN[#*@J&W*&[$CFLCQ1XYFNO".K7>E:9J(L1')%#JL3JHW@[=R@-OV[N-P%
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MPJW10!'%#% I6&)(U+%B$4 $GDGCN:@;2M.:^%\UA;&['2X,*^9_WUC-6Z*
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M9)9Y40$!G#,VWDG SG'7M6;%HVI#PCXXM39RB:_O;U[9,<RJ\:A2/J17>T4
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M1^8EE;[=RJ."SL2%5<\9)ZU%IWBTS:O%I&L:3<Z/?3J6MUF=)(YP.2%=206
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M6WJ 1AF))W=>*H>&]-T_Q5KFIVFIZE+KEEI,-O!9%YCM<,I+2':1N;(*[O\
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MG/(LCZO;J[&=G^TY#'>P)(+=\^Y]: /2**IZM=166CWEU/<-;Q0P.[S(,M&
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M92D%M$L4:DDX51@#)Z\"N2UKXCZ9:V5A<:;.)_M&HQVTZM;REHDW#S,KC(8
M\ \GL#BE_P"$ZMK+Q9JMGJ-R_P!EC@MI;.*.V=Y#O5BYVJI;'W<Y''XT ;^M
M>'-+\0)$-0MR[P-NAFC=HY(CZJZD$5#H_A+2-%NWO;>*6:\==C75U.\TNWT#
M,3@?2DE\8:!%I-KJG]H+);7AVVYB1G>4]PJ %B1CD8X[U6?X@^%H[=)I-4";
MV=!&T,@D#+C*E-NX-\PX(R<\9H U[#2;+3;B\GM8BDE]-YTY+$[GP!GGIP!T
MJO-X:TJ?4KO4'MV%Q?6QM;EED91+'TY .,XXSUJW;:C:76FQZE'+BUDB\T22
M H F,Y(;!''K6+;_ ! \,W,\$$>HL'N9%BMR]M*@G9F"C82N&&2.1Q0!#'\.
M/#T,:Q1?VBD: *JKJ4X"@= !OKHK*SBT^RBM("YBA7:OF.7;'NQR3^-8]UXZ
M\-V=Y+:S:C@PR>5-*L,C11/_ '6D"[5/U/%2:IXQT+2+LVMW>,9E022)!!),
M8T/1FV*=H^M $I\+Z0=&72/L[?8TG\\)YC9W^9YF<YS]XYJW<Z59W>I66HS1
MEKFQ\SR&W$;=XPW'0\#O5&]\7Z%8V]I/)?"5;U=]NMO&TS2J.I"H"<#UQ5/P
M?XB?Q%/K4JW"7%I;WOE6K(N/DV*>>^<D]>: -^\L[?4+.6SNX4FMYD*21N,A
M@>U8MGX'T*TD+M!/=_N6@1;RX>=8HV&&1 Y(4$<?2B_\=>'=.N9X+B]D)MFV
M3R16TLD<+>C.JE0?QX[U'/\ $/PM 9<ZF9!"Q64PP22"/'=BJD!??H>U $NG
M^"-$TV\@NHH[F9K7/V5+FZDF2V[?(K$A:LCPOI"^&3X<%NW]FE"GE>8V<$[C
M\V<]?>F:AXOT+36MUGO2[7,7G1);Q/,S1_W\("0ON>*J^#-?EU_3]2O))TGA
MBU*XBMWC7@PJWR8QUX[]Z '7G@;0[VZGG9+J(77-U#!=R117'&/G16 /'7UJ
M[9^&M'L-,NM,M[&,65W(\DT!R48O]X8/0>PZ4Y?$>D-X?.OB]7^S0AD,^UL8
M!P>,9SD8QC.:K:CXQT32[C[-<7$S3B,2O%!;2RM&AZ%PJG;^.* (+/P)H5G=
MVMV([J::S;-LUQ=R2^2,$;5#,<+@]/IZ"FI\/_#R3JPMY_LZ2^<MD;F0VROG
M.X19V]>V,>U1>'?%2ZWK^N>3>1W&EVL%K+;.B] ZN7]SRO0],5KMXBTE-!37
M6NP-.D5&6?RVY#,%7C&>21VH 9'X9TB/PX?#WV0-II1D,+N3P6+'G.>ISG/%
M4&^'^@3>4;R.[OGA8&-[N\EE9 .-HRW"G/([]ZFU'QOX?TNZFMKF\D+VW_'P
M8;:258>_SLJD+^)K$TOXC::+S6%U+4/,A@NS]F,%N\@6WV(0[%%.%R3\Q_I0
M!OZ?X1TC3#8&WCF)TUI&M?-G=_+WKM8#)Z8X [5'J7@O1M3OIKR5+F&2Y 6Y
M%M=20K< # #A2 W'%1VNO2WGCK^S[>XCETU]'CO(B@!W,TK+N#=QM I]QXY\
M.6M[):2ZAAHI/*EE$+F&-_[K2 ; ?J>* +]IH.F6%\EY:6JPRQVJV:!"0JQ*
MQ8*%Z=2>>M2Z?I5GI9NS:1E#>7#7,V6)W2, ">>G0<4:GJUAHU@]]J-REO;I
M@%VR<D]  .23Z#FL^U\9:!=6MW<"_P#(6R4-<+<QO"\:GH2K@'![<<T 6=9\
M/:=KH@:\219K9BT%Q!*T4L1/!VNI!&?2JMOX-T.VMDA2V=BMVEXTLDSO)),A
MRK,Y.6QZ'BF6WCGP[=+<%;YXS;V[7+K/;R1,8E&2ZAE!88';-%IXY\.7M_!9
M6^H;I+EML#F&18Y6_NJY7:3[ T =!65<^'--NM;CUEXY5O$B,)>.9E#ISPR@
MX;&X]:HGQWX=>?[/'J)4NYACG-O)Y+2<C:)-NPG(['FI;+Q#96GA&UUG4]7B
MG@:-2;P0F,3$]-J8SD^@&: +#^&-)?PVOAYK=O[.1501>8V<*P8?-G/4#O57
M4?!&B:E>SW4B7,+W8 NEMKJ2%+@=/G52 W%9MKXXM;_QDMI;WH33HM-EN+E9
MX3"\3JZ\MO (&TGVJ_%X_P##,P=O[0:-5A><-+;RQB2-1EF3<HWX'/RYH ;-
M\/\ P]([^5!<6D,JJDUO:74D,4P P R*0#P,43_#_P .S/)LMY[6&8!9[:UN
MI(89@!@;D4@'@8J6'QSX;GM+N[CU(?9[,J)93$X4EB0H4D?/D@CY<]*QO$/Q
M/TFPTJ9M/ED.H*T>VWN;.9#M9PI;!4< $\^N!WQ0!VL$$5M!'!!&L442A$1!
M@*H&  /2N&\)_#NS@\/6D>MVDZW(D>2XM#=L8)'\QBC,BL48[=O]:Z.SU>.]
M\1K#!J(:&33DN$LFMF1P"Y'F%B!C.,;3R,9J"7QWX:AO'MI-1QLE\EYA"YA1
M^FTR[=@/XT :MOI=I:ZE>:C#&5N+T1B=MQ.[8"%XZ#@GI6/<> ?#]S<2R/!<
M+#<2>;/:1W4BV\KYSN:,':>?:I+_ ,<^'=.N;BVN+YS-:MMGCBMY)#'P#EMJ
MG"X(YZ?E6U:7=O?V<5W:3+-!,@>.1#D,#T- &</"^D#0KC0Q;$6%RSM)$'89
M+MN;!SD<^E2ZAH&G:H]J]W"7-HLBQ8<C:'0HW0\_*2*RO$GB^/0?$6BZ:ZGR
M[YY#.P@D<J@1MNW:#DE@,]<#MWK/T[X@V-I<ZU!KEZ0]GJ<T48BMG?RH%"[2
M^Q3@9+<GK@^E &]=>%-(O-)LM,D@D2'3PHM'BF9)(=HV@JX.X''OS50^ ?#[
M0,KP7$EPTHE-Z]U(;G>!@'S<[A@<8SCVJWJ'BW1--6V\Z\,C7<?FP);Q/,\D
M?]\*@)V^_2KEEK&G:CI8U.SNDFM-I;S%SP!UR.H(QTZT 8__  K_ ,/^4VZ&
MX:Y:43&^-U(;G>!@'S<[NAQC./:DA\$V-EJMA?61D$D$[S7,\]Q)++<9C* ,
M6)R.0>>F.!R:FL_'?AJ_CN);?4U:&VA$\LS1NL:H<?Q$ 9Y QUSQC-.L_&OA
MZ],P2_\ ),,1G874+P'RQU<;P,K[B@#>K M?!6AV:QI!;RB.&\%[%&9W*12C
M=@J">!\[<=.:=I_C3P_J<YA@OBCB(S+]HA>$/&.KJ7 # >HJG-X\T"ZL[E+3
M5OLTIMI9(+B:UD"-M4DNFY0),8S@9SB@#9N-#TZ[U(ZA<6XEG:U:T;>25:)B
M"RE>AR16;8^!M#T^[M[B..YE%H=UK#/=22Q6Y]41B0/Z5+/XKTC2;+3O[3U(
M-->P!X62!R;C 7)50"<DL/EZ\^U9?B#X@Z?9>%;C5M*E$\T4Z6_E2P2 QN6
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M]+@B69XBI&$8D YQ@C(/2J4/BS0[C0CKD-^KZ>)/+\Y4;[VX(!MQG.X@=.]
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M57T[5]$3SK338I6FSJ]S;B7[,0H^52>%+\C)[#O79  = !2 I(" 58 X(ZT
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M$  \8)K@_&=Y]JU..X76YM<C6TYNA;JD0VW$+,J;%&["C)Y.*]U(R,&@  8
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M"=QKG? \,OA6PT'Q+>RM=6&HV_V.:251G3R7/EE3V0GAO<@U[!@9S@9/>EH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %<C\3)6@\*),D33-'?VK"->KD2J<#W-==7/>-=*U'5]!2WTH1&[2[@F
M3S6PHV2!LG\J *%QXJU_3+I;/4]$M5N;NWEEL!;W1D622-=QB<E1AL=",@U<
M?Q?'-I.@W=A )Y=;EC2*(OC8"-TC'C^  Y]ZK1V.N:[XFTS4M5TZ/3+721(Z
M1BX$S3RNNW/ X4 GKR<]*RO!NC,GC75<2K+INB2RPZ>%^[&\Y$DBCW7A?QH
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M&Y8;+B"6.-3R00K H",^E '4:%XDN;S6;C1-5MK>"_AA%PC6L_FQ31$[202
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M],U'5_#-Q9Z7)MN'9"4\PQ^:@8%DW#E=PR,T <]KGC[6?"S!-9TK3V>>"62
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M!]J]%_X0;PGYGF'P[II;.23;*<G\JTKS2=.U"P%A>6,$]H,8@>,%!CIQTXH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M9,?,J@KP5/ X/6NOU73_  OIO]H>)]:,6H)?(BQ^>BR_+MPL<(QSNZX'4G-
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MLJWB7HBD$:1EBI4Q[LEMPX.X#&?I0!V]1RSPP!3-*D8=PB[V W,>@&>I/I7
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M:?=7-B$<7.GR;H9D;."!D[6!!!&3VKJ* "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***H:UK-GH&G
M/?WYD6!&528XRYR2 .G3DCD\4 4],T:YL?$>O:F\D31ZDT#0J"<KLC"'=QZ^
MF:T-+_M+^S8?[7^R_;L'SOLF[RLY.-N[GICK5NB@#$\)Z+<:#HK65U)$\AN9
MI<Q$D8>1F'4#G!K;HHH **H:MK-GHL,,MZ9 L\R0(4C+?.Q &2.!R>IJ_0 4
M444 %%(S*HRQ &<9)JC#K-G/K4^CH9/M5O$LT@:,J-K$@$$]>AZ4 7Z**0G
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M;'RYO,$/G;_+/EXSC&[IN]NN* .(M_AU<QV'B.TDNH66^0Q:9@G_ $9!(\J
M\=I'SQG@"NG\+:/-H7A^"RNI4FNR7EN94Z22NQ9SV[G\JV** ,#Q=HM]K-C9
M'3)+=;NPOHKR-;DL(W*9^4E02.OI2Z+HU[9>(]9U:[>#&I);;4B9CM:.,JV<
M@<9/'MZ5O44 >>VO@+5-,:UU"U;3;F^A>Y26"Y#&&:&24R*-VW*L">N#U-=+
MX;TO4[*2\NM4>R22Y9?+M;*,".!0.FXJ&8GJ2?PK<8A5+'. ,\#)JEI&L6FN
M6/VRR9VA\QX\NA0[E8J>#R.0>M %#5M#N;_Q7H&K121+#IAN/.5B=S>9'M&W
MC'7KDBG:+HMQIVNZ[?S21-'J5Q'+$$)RH6,*=W'7([9K;HH X#1?!>O>&8["
M\TR:PGOHK>2UNX)G=8I4,K2(RL%R&&['(YJ,> M;EDN-3N;S3I-5_M+[= "C
M- P,81HF!&0,# (R> :]#HH X&?PCXBU36--U"[.D6$-C>0S?8[120RJ268R
M% 2W( 7@8Z\UT:Z+<#QU)KWF1?9FTQ;0)D[]XE9\XQC&".];=% '%Z5X,U"Q
M\0V.HRSVS16UYJ,[JK-N*W!4H!QU&.?TS1JO@S4+[Q1/JD<]LL,M[I]P%9FW
M;;<L7'3&3N&/UQ7:50N]9L[+5K'3)C(+F_+B ",E3M4L<MT' Z=: ,C4?#^H
M3^,TU: VDEC<:?\ 8+R*9F5PF]FW)@$$_-C!Q62?"WBH^&_^$2-YIW]E[/L_
MV[+_ &C[/_=\O&W=MXSNQCM7>44 8'A7P]+X>&JQLT9BN[]IX A)VQE$4 Y
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M=A Q X!( Z5L7NH:WJU_K=GHT[V\^FND4./+VLYC5\R!@3M);'&. 3UZ7/\
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M28MR[3@@ DXXY)ZT ;->8VMUJFDZ#JFKV>HM%';^(IE:U$2%9E>Z",&)!/\
M%QM(Q[UW7A_39]*TA;.>[N;AE=RKW,OFR*I)(#-W('^'051;P58-H]SI1N[T
MV]S=?:Y/G7<9-X?.=O\ > /X4 4KO4-=UBYUJ#19VMY].G$$ _=[&;RU?,@8
M%L$L1QC@9ZU8MM0U6;QD=.FNU2&31TN1'&BLL4I?:2&QEAQQFI[SP;I]WJYU
M07>H6UQ*BI<FUN3$+H*,#S O?'&1BK8\/VR:U_:T4\\,_P!E%HJH5V)&#D
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M^TOB_P C6W@71E2:V"V\9S^X\S:V0<KGCU]_7?A\(Z=;HULCW'V!KC[1]@+
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MW<7]K1[+E(Y<*?EV%@,<$J,9_KS0GA>U2?29A=W9;2$,=L"R8VE0I#?+S\H
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M< "NXH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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ML+;<@VJWDKE1Z#B@:5IPMI+86%J()?OQ>2NU_J,8-6Z* ((+&TM@PM[6&$.
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M6[SJ01*T2EACISC-6:* "J)TU9M7CU&X(=[=&2W0#B/=C<WNQP![#CN<WJ*
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M7=I,LT$RAXY%/# ]"*FH **** "BHXIXIU9H94D"L58HP.&'4?45)0 4444
M%%5[Z_M=,LY+R]G2"WB +R.<!<G'\S5B@ HHHH **** "BHKFYAL[66ZN9%B
MAA1I)';HJ@9)/T J&SU6PU"66.SNHYGA5&D5#G:'7<I/U'- %NBBB@ HHHH
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MQ]G.^/\ >^8RD[N<] >* +6H:AK.J^+9M!TF^338;*U2>YN?(65V9R0J*&X
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ME>&FU1] MFUE]]Z=^]C$(RPWG:2O\)V[>.U:M !1110 4444 %%%% !1110
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MR$V,\:LQ"Q2FWC9F"@XR3CKZ4 >G4FX;MN1GKBH[F:.WM99Y7,<<2,[.!G:
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M=2Z?DS2>;+")I!#(_7<T8;83]1S6M:Z9965W=W5M (YKQE>=@Q.\JH4<$X'
M XJKIGB;1M8N([?3[Y9Y)+872!58!HBQ7<"1C[P((Z@]:M6>IV>H37<-K-YK
MV<ODSX4@(^ =N2,$X(Z9H LLJNA1U#*PP01D$5S?_"N_"QMVMGTYY;<YVP27
M,K1Q9Z[%+80^XP:U]7UK3M!M%N]4NEMH&D6,2,"1N/3.!Q]3Q5;2O%.D:S<R
M6MI<2+/&GFF*>!X7*?WP' )7W% %.Y^'_AB\EG>?3BRW!+2Q"XD$3,1@OL#;
M=W^UC/?K6M:Z-I]E+=RVUOL>]V^>=['?M4(.IX^4 <5EP^/?#4]RL*:@<2,4
MCF:"00RL.JK(5VL>.QY[4VV^('A>[AGGAU/,%O")I)C#($"D@  E>6RP&T<Y
M.,4 :/\ PCFD_P!DVNE?9!]CLV1X(O,;Y"ARISG)P?4TT^&M'.CR:0;,?8I)
M?.:+S&Y??YF<YS]X9Z_I52+QSX=DCN7DOVM?LL8EE2Z@D@<(3@,%=02"<#C/
M) I;;QMX?NDNF%Y)$UI;M<RQSV\D3B)1DN%906&!V!H T-1T33M6DADOK;SF
M@618SO9=HD0H_0CJI(J"\\+Z/?Z7::;/:9M[(*+;9(Z/#M&T;7!W#CWY[U5M
M/'/AR]OX+*"_+/<MM@=H)%CE;^ZKE=I/L#704 <Z? /AIH%B;3V9EF\_SS<2
M^<7QC)DW;CQQC.*U;71]/LXKR*"V58[Z9YKA6)82.XPQ(.>N.G2LKQWXB?PQ
MX3O-0@S]I"[8/W3.H<]"<#  Y.3@=N]5M*U&X$FA17'B1[IKTW!V3:<87NMJ
M] -H\O:03R!N% $H^'GA?R/L[Z?)+"/]7'+=2NL/.?D!;Y/^ X]*M6W@S0+0
MCR+ H%NUO%3SI"J3#=AE7=@?>;@<<]*:_C7P^FK-I7VYFO$E,+QI!(VQ@ ?F
M(7 '(YZ'GG@U7C^(OA25H=NJ@13_ ')WAD6+.,[2Y4*&QV)S0!KZGHNFZR;4
MZC:K<?9)UN(-Q(V2+T/!Y^AXINL:#IFO01Q:C;>;Y+[XG5V1XV]592"/P-0:
M1XJT?7;N:TL+EVN(4$C12P/$Q0G 8!P,K[BMB@#FF\#Z5#]B%C"(3!?I>RS2
M.\DLC*#C+,22><<Y !..:Z6L_5]<T[0K9)]1N/*61Q'&H4N\C'HJJH)8_050
M'C?PZ=.DOFU#RXXI1"\<D3K*)#T3RR-V3V&.: #4/!'A_4[V6[N;)O,N,>>(
MYY(TGQTWJK -^(K2M]'T^TOVOK>U6*=H$MRR$@"-<[5"] !D]!6;'XW\/26-
MU>-?F&.S9%N%FA>.2(NP5=R$!@"2.<8J%?B'X8:*.0:A)B9W2$?99=TK+MR$
M&W+??3&.N>.] '2USUWX$\.7MY-<SV!S</YD\23R)%,WJ\88*Q^HY[U:M/%6
MBWNFW6H1WRQP69(N?/5HFA([,K $?ESVJM:>./#UZTBI>21M'"UQMGMI(B\:
MC)9 RC<,<\9H T&T+2WUB#5S9Q_;K:$P13#(*(?X0.G<]NYJOJWA71]:NTN[
MRV<7*)Y8G@G>%RG]TLA!(]C5:V\=^&KNVNKJ+4A]GM$5Y9FB=4PQP,$CYCGC
M R<\5C^(OB?I.G:-=26#R_VBB PV]U931[@3C=@J/EQGGIT'<4 =)I?AG1M$
MF$VFV"6SB 091F^X&+ 8)QG))SU.>363;Z1?:IX[77=3TR.SATR&2WLCYJR/
M.6;_ %AQ]T;<X!Y^8U?M-9BOO$<$5OJ1\F;3VG6QDM'1SB0+YI9@",?=VGGG
M-1WGCKP[87DMK/?L#;OY<\J02/%"WH\@4JI^IX[T =!56'3;.#4KG48H=MU=
M(B32;C\RIG:,9P,;CTK)OO'/A[3[N>TFO7>XM\&6*"WDE95*A@WRJ?EVL#GI
MSZUL6%_:ZI8PWUC.L]M.N^.1.C"@#)N/!/A^X"$V<D4D<TDR2P7$D<BM(<OA
ME8'!/;.*@D^'GA60-G2MK,RLSI/(KEEW8;<&SGYFR<Y.><UK:OK>G:%:K<ZE
M<B%'<1H I9I&/154 EC[ 5G)XY\.-937;ZCY*6\J13+-"\;Q,YPNY2,@'U(Q
M[T 27W@S0-1U-]1NK$M/*%$VV9U28+TWJ"%?'N#5C3?#>D:1-%-868A>&V^R
MQGS&;;%N+;>2?XB3GK4FC:W8:_9&\TZ1Y(0Y3+Q/&<C'9@#CD<T_5M8L-#L3
M>ZE<""$,$!(+%F/1549))] * ,[4O!6@:K>RWEU9N)IP%G,-Q)$)P.@<(P#?
MC6U;V\-I;QV]O$D4,2A$C0855'  %8MCXU\/W\\UO%?^7-;P-<31SQ/"T4:D
M LV\#;]X=?6H[7QYX<NY-D=[(I,32Q^9:RH)D49)CRHW\<X7)H EN?!>@75_
M/>RV;E[E@T\:SR+%,WJ\8;:WXCGO5C1/#.C^'!,-)LQ;"?;Y@$C-G;G'WB<8
MR>E/F\0:5!HD6M278^P3+&T<JHS;]Y 7"@9R21QC-4]1\:Z!I5[+:75X_FP
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MA^]5V@\(>;\[=)6<E;<_A%DUZ761X>T(Z)!<-/>/?7MY,9KJZ= AD;  PHX
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MTZ'6XE@N8L7$2@7:@2A?*4@-CCC)X[52M[=5_9ZG018+6\S$8Y)\YCFO4Z*
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M5"2K,_7 ./EZ?** '^$](?0_#5G8S'=<!/,N'/5I7.YS_P!]$UL444 %%%%
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M[6<$%3@?B*J^$X_$6@^+=?AMM"TV9FBMWFLK*1;=82V\H%)&&P,ACP2<$9H
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MI)]SBN6_L7Q1JWA[3?"^I:=;6UK!Y N[U+D/YD<15@JIC(8E0#G@<XS0!?\
M^$KUW45OK[0]%MKK3;&5XMTUR4ENBG#&,!2 ,@@9/--M/&U[XCN"GA73K>ZC
M@MXI[B6\G,0!D&Y8EVJWS8ZGH*BM+#Q5X<M+[1]+TVVO;>:>62SO'NA&(!(Q
M;$BD9.TD_=SGVJMH'A?6_ 4CQZ19Q:Q;WD$(F#3B%HID7:6Y!RC?F* (? 'B
M&:W:VTZZLC!'JEY?.CL_S1S+*6,9'3[I/.>H-=?HVMMK%_JL<< 6UL+G[-'-
MNR97"@R<=@"<?@:XK4=)U'0OAW+=:B\$>KV.J-J-N4;<KR&4D*.YW!B,>]=#
M"EUX)^'T/E0)=WL"HTR/)M\V61QOY[DLQP._ H W=9U:WT/1KO5+O=Y-K$9&
M"]3CH![D\?C7/_\ "4Z]IL$6HZ[H44&FRQM([VD[2R6H"EOWBE0.0,9!X-;/
MB?11XB\-W^D&3RC=0E%<C(5NH)]L@5S]]9^+_$VG+HM_:6^DV[Q,E[=QSK-Y
MX*%<1KC*@D@Y.",8H 4^,=<L].MM=U31+>WT:Y9-QCN2T]NCD!7==H!'(R <
MC-56\?ZU_8ESKZ:%;_V987#Q7!:Z/FN%DVEHUVXP!@\D<Y'O2W>D^*]<\/0>
M%M0TZUM8!Y4=WJ"70=9(T(/R)C<&;:.O YIS>%=5/PRU30O*C^W7,L[1KY@P
M0\I9>?H: +9\7:Q9:E;0ZKH]O;P:A;S36ABN2[J8TWE)!M !*^F0/>J(\>ZZ
MFEZ7K4WAV$Z?J;QPPQQW>9_,<?(2"H7:6XZYP0?:M7Q+H5_J>I:-/;(K)9Q7
M2RDN!@R0%%^OS&JLOAK4F\(^%=-$:?:-+NK*6Y&\858L;\'O0!G^(?$]W%8:
MMI/B;0K21HK6&[2.WNG,<L9F5,%MH(*M@^];FO\ BBZL-?M="T^&Q%U<6[7'
MFW]R88L!MNU< EF/IV%9?C7PKJNMZG>SV,4;I-I4=LA:0+F07*R$?]\@\UI>
M*],O[^\ASH5CKVF&(J]K,RI+%)G[ZNPQ@C@C(- &?%XVUV[U5]&BT:PL=2MX
M@\L5_?;1+EB!Y.U27!"YR<8S5GP[KL$NI>(;V]T=M)N+:&WEO2\I=C^Z8\CH
M-H!QCJ*YZS\':O9VDMIJ7A:PUFPF=I+6U-V/-TX$G]V)'&2N,=#P<]:T?!G@
M?5-,L->L-:E5H]3@CA5TE,A5=CJ5R>?E#!03UQ0!:/C36X-'B\27>A01Z%+M
M<[;DM<QQ,1B0IMVD8(. <@&D_P"$SU^]AU>ZTK0[26UT>ZFAE>:[*M.(S_RS
M 4\[<'DXYQS5:?1_%NH>%(_!]Q86L,0C2VEU1;D%6A7 RL>-VXJ,8/&>]:NB
M>'KW3M"\0V3QJK7U[=RVP#@Y1QA,^E '0:5J$>K:19ZE"I6.[@295;J R@X/
MYUR6OW&I6_Q-TT:59Q7-S+I4R#SI"D<8\Q"68@$XXQ@#J15_PK-J&FG3_#-U
M:QJ+/1X7DE27<5D'R%2!VX.#WP?2DUNQUV'QE9ZYI5E#>00V$EO-$\PC9]SJ
M<*3QG@'GC@CO0!5?Q[<6L-Q8W>DC^W8;R.S6SBFS'*\BED<.1PA4$DD9&*L'
MQ5J^EW_]G:YH\9N9[>2>R_LZ5I5N"@RT>&4$-@@^E9,WA#7;RYG\3.EM#K1O
MX;J&S,NZ,11(R"-G ^\0['(&,XH\0:!XJ\7R?:S#'H<EC:S)9H+D2/)+( K$
MLHPJ[00._.: )M7\<Z[X;BAN-:TG3UBN5<1PV]ZS2Q.$9U#@J,CY<$CI_.6+
MQMK*Z+;ZG=:%$@U-X8]+@6YR\SR D;^,*,#=GGBN<USP)JFIZ1;P:3X1T_2'
MADW2L;E'FF)1E^^!]T;L\G)XXXKK=0\-ZC-X4T&.U\H:GHIMYTCD;Y)'1-K(
M6'0$$\^N* ,^&XUB7XH:5%K-C;V\L>G7!22UF,D<@+)TW*"",<C'<5WM<5Y/
MB6[\56_B"]TNWL;:RL+B-(7NU=MYVG+,. #MQ[8R>M=-H=_+JNAV.H3P>1)=
M0)*T0.=NX9QF@#SOP9XBUS1?AOI^I'1H)-'LXSYK?:"+ADWG=(J;<8&3P3DX
MKM]$\1C63JY2%533[DPHRMGS1L5PW3C[U<EI^A>,4\"1>#IM.M8A+$8)-0%T
M"L43$[@4QDM@D#''0YK1M-'\0^'K[5K+2M.M[JRU&02074ER$^SGRU0[UQEL
M;<_+U]NP!%9^/M:UB73[72-"@EN;S35OV\VY*)$OF,A!.W)^Z,?7VJY+XOU2
M[OK^+1;#3Y8=-E,$S7=[Y332J,ND8VGITRV 34'@OPMJFB:A837L2*D&B)9N
M5D#8E$S.1],$<U2F\'W&FZIJK1^$=)U^._N7NH+BY,:O"S\E'W*25#9(QV-
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MS791YA$3GRP%/.T \GJ<#.*4>.;W5-1^QZ%9V)9;2"ZVW]V8GG$J;PL:A3G
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M1="U2VM([NVUBTG$ME.98W1A(,<@%2".AKJ8KI3XO\006.GPC4(K*W;SY)F
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M7\)Z+/8WM[>S:%IFBQS!4@MK2-#( .I=U !R<8 Z5U% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M-TSQ;:7,^IQZA-:V/V/47LXC+.%\W:JG/..?FZ"MNYN8;2UDN9G5(HU+,S$
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M?$%YK<887%Y$D;CL-O<>Y 4'_<%5M'\1IJ4^L>=Y,$&FW7DB;S/E==BMN)/
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M74MS'"6VO*%!Y))' '&2>N:U*** "BBB@ HHHH **** "BBB@ HHHH ****
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M4K>V@A^ "RQ0QH\OEF1E4 N1<@#)[UZ;I^DZ?I2NNGV<-J'V[A$@7.T;5_(
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
?!1110 4444 %%%% !1110 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>formofindemnificationagr002.jpg
<TEXT>
begin 644 formofindemnificationagr002.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  H'!P@'!@H(" @+"@H+#A@0#@T-
M#AT5%A$8(Q\E)"(?(B$F*S<O)BDT*2$B,$$Q-#D[/CX^)2Y$24,\2#<]/CO_
MVP!# 0H+"PX-#AP0$!P[*"(H.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[
M.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SO_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KG/%=Y+)=Z3X?MY7BDU:=A
M+(C%66"-=\F".A/"Y_VJZ.N5\1J;7QOX7U)^("]Q9LW97D0%/S*$?B* ,Z+Q
M#J5GXZ\26%KIM]JWEBV=(8Y56.!/*&<%V !)/0=<'TJQJ_B2*;P[8^,=.DF2
M&RG NH'RI,3.(Y4=?[RG#?\  ?0U&EWJ.@^-?$-X^@W]Y97WV<PS6D8<EDB
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M\ET18=PRJY<C+$<X%2>%M3OKJWDT[58774=.CACN93C;*[("67';.:RDDO\
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M0WTJ6=PI)VLQ$@"#!Y&/YT =2/B-'<6=Y?Z?H.H7UCI\LB75S$T85 A.2H+
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MMI;:[&5\AK6T(@"@,&5U+9?<&()R".,5WE8]GXBBU32=/U/3+.XNK:^F$8(
M4QIE@9&!_A&WZ\B@#(D\.^+;B\75)/%$<-[$5$5I! PLRH!R'0OEB<]<\8&/
M:[X>\-W.FZMJ&LZC<6TE]?JB.EI 8HD5,XX))8G/))KHJ* .-A\'ZQ9'5;*Q
MU:TAL-4N)9Y)6M2URGF?>4-NVGV)!Q5CP+X/F\'V=U!-?)=F=HR&6,IM"1A/
M4^E=510!P^E^!=2\/0:?/HVJ6RW]M;-:S_:+=FAN(S(SKP&!#*6/.:V?"WAZ
MZT$:D][J OI]0NS<O((O+ )501C)X^7CVQ6_10!YSX?L/$-U=>*!I.KVUI!-
MK-Q&XFMC(\1POSQD,.<'H<C@&M=/!,^BRV%UX8OHK6XL[,6<B7<1DCN(P=P+
M;2"&W$G(]<5UV .@I: .3TCPEJ=KXH3Q!JFMF^N#!+&\0C*QQ[BI C&3M4;?
MJ2<U5U/P%=7'B"?7;/4+=;K[:EU#%<0%XN(A&0P!!)XR".E;.I>)OL6L3Z5!
MIMQ>7,5BMXJ1$9<&39M&>_>MV@#@KWP!JVJ^*K#Q#J.MP/-;/$6ABMBJ!8Y
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M2[1]8CU9HR;N.!H%?<<!&(8C'3J!0!YNME<ZYXBUN.?P_)J\.GW L[6,ZCY
MM8U08*KG.6SG=U_*D\#Z6?%EUJ=OXJN#J;:4([>WC%WO5%()WED.&?H"W7*F
MNXU/P?I&JW[WT@N;>YE01S26EU) 9E'0/M(W>G-13>!- =8!;6\U@8(?(5K&
MYD@+1YSM8J1N&2>N3S0!R&@Z7IEGXWNI[&Y;5I++1O-BN9)"[/*)94P2#R0
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M3R3OX=)VQC+.JW<3,!ZG:&X]Z .UTSQEH.KWL=G:7C^=,I:$2P21"8#J4+J
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MIU]#5/5@?^%H>'SCC[#=_P#LE1^&H4\SQDY0;I-3E5B1]X"%,#]3^= &M?\
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M:B_X2K3M4BT^?3-86%'U%;61)+9B\C;6)A*D H3C.2.WO7'>!H5;7O#Q9/\
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M\PP2!6;:6^4[<-PIP1U_$5PWC76+#6M9UF73+A+N&/PS,AFB.Y&;SXR0&Z'
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MQ4-P2!C\.:S=3N)=5\<+H5S974EA_9S28CE11N:0+YN0X. !Q_$,G H [&D
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M&.T' 'I5N#QA87.FZ1J$=O=?9]7F$$#%5RCG=C>-W'W3TS0!O  #   ]!0
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M$UBTM3=16 N$FB1U63$BJ 5W$ XV\\C\:Z&B@#F[+PVDUOKSZNBJ-<D)EA#
M^7&(PBC/3=@9)'0GC.,TO@BTNX= BNM1N!=75RJ_O@,;HE&V,\^JC>?=S5J]
M@T'Q-=SZ1?01WLFF21S20R(<1LRDH?0Y&>.?>M@    8 Z 4 <\;"_'Q#_M0
M6C&R.F_93+O7A_,WYVYSC''U[=ZS-/TG7M)O[W3DTBQN[*XNI9[?4))5!@61
MBQ5T()8@DXQP>.1V[6B@#@-8T/Q)J)OA-8174L>IQ7-G.]R ! LBL$1<?*P
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MSPOYBMD"-4P0#D'Y<_C70T4 >=V?A[Q'!H?AW23I<6-%U))'F-TN)HU$@W*
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M;F+)ORQ/?)<_3% '&P:IXD;P#:^,I]?G-S%-&AM$C18)4$PB.X8R6/)SGC/
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MN?J*CO-5T[3W1+V_M;5G^Z)IE0M],GFN0\-6-S8^/[Q99=(MY)+!3<6.FK(
M2'^21LC:#@L.N2".*J3B+5=<\0W%CHVD-';RB"^OM9E+\J@R%C ^5 /]H T
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M7)C)&"0>V1Q4]% &,GA#PY'J1U%-$LENRQ;S1",[O7V/OUJXNCZ:MI:VBV,
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M;@<@X-%_I]EJEH]I?VL5U;O]Z.5 RG\#5FB@"AI6A:5H<+Q:5I\%FDAR_E(
M6/N>IJ"Z\+:!?:E_:-UI%I-=\9E>($MCH3ZX]ZUJ* *.GZ+I>E/(^GV$%JTH
MPYB0+N&2>WNQ/XFGII>GQVL]JME (+EG>:+8-LA;[Q8=\]ZMT4 8<7@KPQ#
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M8HQ613@'&?N(HZ=:V=4T;4W\8:9KFG/:%(87MKJ.X9E/ELRL63 .6&T\' H
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MU9LDLV.=H )XYKG+31-;T#75UFWLM)M7U*YM[2:QLDD:,0Y8O)D!1Y@!SDC
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M///;IQQ0!W,,$5M D$$2111J%1$4*J@=  .@JGHVM6VN6LUQ:I*B0W$ENPE
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MUE4OP'CW81""%QMH ]9HHKSW1])_X2S2]2US4M3OX;TW5PENT-W)$MDL;%5
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MQN!)*GO7K]W96E_$(KRUAN8P<A)HPXS]#4<^EZ=<P1P7%A;2PQ?<CDA5E3Z
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M<>U=;XELTM_#'@V.QB2*6/4+1("H VDQM_,XSZUVZ:/I<=O]G33;18=V[RQ
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M++O0-+'R?E.2,C'>O1+JRM+Z+RKRVAN(\YV31AQGZ&G):V\;(R01*T:[$*H
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M/7([YJM'I%K%JW]I(NV06PMD0 !40-GC SZ?D,8YR 8>N?\ )1O"O_7"^_\
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MG$GRJX+$, &.23P6'2O:KBVM[R%H+J".>)NJ2H&4_@:B_LO3_*6'[!;>6JE
MGDK@*>HQCI[4 <GX/U.XG\5:I9W?]EWUPMM%))JFF@@2#)"I(,D;P,D8/2NV
MJ"UL[6QB\FSMH;>/.=D,809^@J>@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ K(UK6KG39[6TL=*GU&[NMVQ$8)&@49)=SPO7CN:UZX[QE9ZE<ZSISM:
MZC>Z(L<@N+;3I_*D,O&TMAE++C/ /6@#6\/^(GUBZO["[TZ33[_3F03P-(L@
MPXRK*PZ@@&J^O>*KC2M:M]'L=&GU.\N;=IHTCE6,85@#DMP!@]?7 [UE^!=$
MN])\0:]<R:,VEV=ZMNUM&THD.%#AMQ!/S<@GD]>IQ6O-IUTWQ"M=2$)-I'I<
ML+2Y& YE0@>O0&@""7Q;?37UQ9Z1X?FU"2R5?MA%PD:QN5#>6I/WV /.,#WJ
MC9_$-]:6XE\/Z!<ZA%9JIN=TR12(Q&2BH<EF'([<C S67>>%UT[Q#J\][X9O
M-:@U"X-S;3V=QM*,P&Z-UWK@ C(;G@UGQ^%9+6!H[_P-+%>%=]I=:%=E6C9N
M2LCM(#D'OR/2@#OM \31:_;7\\=G/;"RF\IDG&UR=BORO\)^;&/45@:-X@FU
MOQ?::C;Q2K%<^'6N$M&EXW>< /;/;-4/"]KXN\,V>H:;J&DSZG>ZBXG2]CE3
MR@[1JK"0D@C:5Y(!SSBKG@KP_JNF:GI$M[9M"EOH'V64E@=LOG!MO!].: -'
MX>:KJNKZ'--JD+AA=3!)GE#[_P!XX*X'0+@#W[5J^(/$$>AI:QI:RWM[>R^3
M:VL1 :1L9))/ 4 9)[5G>!;;4--L+S2[_3Y;<V]W,\<S,I2=9)'8%<'/ (SD
M#K3O%>GZ@=3T77M.M#>RZ3+)YEJK!6DCD3:Q4GC<." <9YH YSQIXUU2'PWJ
MVG-I4^F:JEL)<K<JP$);:9$<=2"0I'!&X&NS\-:>NF:'#;K9261R2T,ER9V4
MYZER3G. ?QKA_%FBZ]XPCU'48M&N+-(M.-K:6UPR":=VD1F8@,0H 7')KTZ@
M#"UGQ(]AJL&CZ=ITFI:E-$9_)618UCB!QO9ST!/ X.:QY_B,MNT=H^B7?]JF
MZ^R26 ==R2%"R$-T*MC[W'<]JLZO;:CI/C-/$=IILVI6L]B+.XAMROFQ%7+*
MX#$!@<D$9]ZPHO#VN7_C:V\3W.G-;)<7Z,;=G4O!#'"Z*SX.,L7Z#.* ._TV
MXNKK3XI[VR-C<.#OMS()#&<]-PX/K63J'B'4TU.XL=)\/3Z@;55,TKS+!'EA
MD*A;[YQUQP/6N@KS[4]+U"X\3ZD=8T75-9MY&3^S4M[L1VR)MY#KO7!W9R2#
MGM0!8TCXDOXAN_LVC>';NZ= C3EIDC$*DE6SGJ0P(P.N":L6/B?3](\)ZAJP
MANWBAU":'RY)@[O(9=F 3@!2Q[]!63\)O#.L>'9M875K#[+YOE+$0P*MAYB=
MN#TPR]?6K]EH^K6O@O5+1M'M[V:;49Y?L5T1MGB:7=P<X!*\C/0XH -4\2W)
MN]-LM:\/W]BTE_;&"6WN0\3$R!0&=1ZG)0]1FM/4/%ES!XBFT'3M$FU"\BMT
MN,B98TVDD'+-TP0/7.?8UQ#^%M3DU[1Y= T35=+T>VOK>6[M+VY5D)613N1-
M[8V@-DYYZ 5W5GIMW'\0M2U)X"+6:P@BCER,,RLY(]>XH I1>/TNK2U2STBX
MEU:YN);?^SRZJ8WB_P!86?H%''/?(XJ_H/BB35]8OM)NM*FT^[L(XWE6217!
MWYQM(ZC !S[].*Y*TT;5M#\2MK4=DMQ.VIWY%CYZ)+/;R%")(\G!P0,@]CVK
M6\+7=]??$/Q#/>V)LF%I:JL#2*[(OSD;BI(W'DX!. 10!)XTU.ZTSQ3X5>U@
MN+HO-<K]EA?;YQ,6%!R<8!.<GH 33Y_'YTY+I-5T>:SNK)H6N(O.5P()&V^<
MK#[P!ZCC%2^+;;51X@\/:IINFO?II\D[3QHZJP5H]O&XCGDX'MVJM;Z+<^)]
M<U35-6TZ73[.YTW^S8;><J970L69V"DA>2 !GMF@#H+G6T@\16.BQPM--=0R
M3NRM@0QK@;CZY8@"K&JZI:Z+I5SJ5ZY2WMHR[D#)P.P]STKD/AG;7UU!=:UJ
MC+)<;4TZ!P<AHH,J6!_VGW'\*Z'QAHLOB+PIJ&E0.J33QCRRW3<K!@#[$J!0
M!D7'CNZTR"&[UGPY<Z?9W((@F:='._:2J.HY0MC'?GK26WC^:33K+6+K0+FU
MT:[*+]L:9"8RY #,G4)N.-WT..:R?&#Z[XL\.C3I?#]SIBVY^TWT]P\9C C!
M;;'M8ELD=<#%068UKQ/\.])\,KH<]NMQ;6RRW[.GD+ NUMRX.XL0 -N!@DT
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MV',A#.5&&'"YS@FNC\,Q:M<>+M;UB_TN33[>[@MDMEE92Y";\[MI.#SG'N*
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M25U+E4#@[MI.#R#CW%3^,;/4&GT;5=/LGOFTR]\V6WC8!WC9&4E<D D9Z9H
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MQQ'R;</\VP=2 >3R>3ZGGK5VN>EU=W\76EC'86Y,^G2W$%V[?.,,@V$8X!W
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M((?(/GHN[=Y>_=C;GOC...*Z*RNX[[3[>]0%8YXEE4-U 89Y_.I\C&<C'7-
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M&_ W;>F?:N3A\%31:!)X8:\C?16FW("A\Y8M^\Q9S@\Y&[T/3O76Y&,YX]:
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M]O%Y!$ZKNW",ONQM!]LD<<"MF;6;:'7;;1F60W-S"\ZD#Y0J$ Y/KEA5_(!
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M$5E8S88R.SGR5+?=5NI&1PQQ7/\ C_28K"6!#X<L]$6:TF8P07(E+E2FUF4
M*I&Y@""2<FO0- \!6TK:K-J^C0V=M?\ DK#9+.9'C$>3O:0'.\LQ.0>/4UL/
M\/\ PQ-S<:<US)M9#+/<2R2,K#!!8MDC'09XZC!H IV5G;:=\3H[.SA6"WBT
M'"1H,*H^T=JY[2=#TO6_A]>>)=7RVL2+<3RWQD(EMI$9MH4Y^0+M' X_.N^T
M[P[I>E3Q3VENRRPV_P!F1WF=R(MV_;\Q.?F.<GG\*I77@7PY>7LMU-IY)GD\
MR:)9I%BE?^\T8;:Q^HY[T <9X-T>T\8:IJUYXCMOMCM:V#&*0D('>V4L^T<;
MCQSU':J&D:=>:OI>C2>39^(?L=O<1MI%[=;'V"X=5E7.02 H3+>E>KVNEV5E
M>W5Y;0".>\*&=@3\VQ=J\9P,#CC%94O@?P]);V\*V3P_92YADAN)(Y$WL68;
MU8-@DDX)Q0!@6*Z9J/PRURP2RNHHK(7,4MG>N)#;RH-X16'55)4BL^RTNQN/
M^$*T&:%8]*N].:\FMU)5+J<1H<-CKC);'>O0+#1--TS3&TVSM$CM7W;XSEM^
M[[Q8G)8GN36>/!'AY=(CTH6#?989?-B!GD+Q/ZH^[<OX$4 96@VT&A_$/4-$
MTH>7IK:='=/;*Q*03%RORC^'<N#CVJEI>A:7XJOO$UYXAB%Q/;ZC+:Q&1R/L
ML**NPI_=)R6R.M=?H^@:9H*2KI]OY;3MNFE=VDDE/8L[$D_B:JZGX-T'5[V2
M\O+-C-,H68Q3R1"91T#A6 ;\<T <=X2T/1];\6ZS>RSRZO'8FR:RGGD/+"!#
MYAQ@%CM7DCM[FL33;"_UOPC/KMQHEJ]_-YLS:U-JIBEMG5FP0-GR!,8VYQ@>
M]>M6&C:=IEQ<7%C:I ]T(Q+L)P0BA$ '0 * .,5F7/@3PW=WDMS-IY)GD\V:
M)9Y%AE?KN:,-M8_4<T <-I6CZ=K_ ,--5\2:S()]9=+II;T2'="R;@JJ0>%P
M!\HX(;WK2\ VT%]/K-K=1K-!+I.EJ\;<A@;<Y%=1>>!?#=_=S7-QIV3<',T:
M3.D<I[%D5@I/OC-:&FZ%IFD2RRV%L(7EBBB<[V;*1+M0<D]!Q[]Z /,M'LK<
M>!_!NG*OV:RUF\ U!HV*>>0K%48C^\5 ]\5%\2+"U\,-)9: @M(;_3W>ZMHB
M0BE)(]DFWL<DC/>O18O!7AV#2KC2DTU?L5Q)YK0M([*K>JY/R?\  <4R/P-X
M=2TNK9K%IEO%5)WFN)))'4$$+O9BP (' /:@#GO$/@RRL8--L=%BLY&>Y:>;
M3;VY91J9"8))Y)9?O>G<U?\  <EI!=:MID6E7.CW4#QRS:>\RRPQ;U.#$1Q@
M[22/6NBUC0M-UZWCAU&W\T1/YD;*[(\;>JLI!!^AK*'@G3K2]T^?3HS";>Z^
MT3RO-))+-\A4 LQ);DCJ> #CK0!F_$:6[EGT'2H8!<6U_>,MQ ;@P+/M0LL;
M. < GMCG&*XO7-&N+;Q5HNGFRMM#LKV]@\[3K34?,9SEE\Q5 4H"I921[=Z]
M>U72-/UNQ-EJ5LMQ 6#;6)!5AT((Y!]P<UF6W@;P[:S1W"V+27$<R3K/-<22
M2;TR%^9F)P,GCI[4 <S#X0T,?$:ZT=;(+I;:7'=-8AF$+3>8R;RN<$A1^N>M
M8?AC2K'4_%5GI.H$RV5G'?Q0V\CDK(J7("HW]X <X/\ ='I7JXTRS75FU40_
MZ8\ MVEW'F,,6 QG'4GG&:Y6[\ V-SXN@N/L.W3EM9V9TN&5UN'E5]RD-N!/
MS=..<4 <S>1II_B"31;(D:99>)-,:WBW$K"[AC(B^@R <=LUT;:99^)OB'K%
MIKL2W=OIUM;_ &.UE)\O#AB\FWH3D 9[5T$'A/0[:R@LXK +%;W2WB?O&+&8
M'(=FSEC]2:=J_AC2-<N(KF]MW^T1*42>&9X9 IZKN0@D>QH \\L&;1-8.IV\
MSR:=HNM/IA9W+;+:4+\I8\D1R%<?6EU6ZO;GPU=Z_ 6'_"1ZS#;@B4Q?Z&K%
M$&_^ -@Y/^W75>(M G3PR/"_AW1H!9WJM%+,TH5;4$C+E3\SL<D^N1S6\=#T
MU]"31)K5)K!85A\EQD%5  _D.: /)/%MIJ/AS[(UAI=IX;2]86MQ%;:KDW2%
ME&<;!@CNXR0&-6?$7A^^LEMXK"STOPA]J5H)7_M?Y;I<#Y2-H).<?,.<$UZ%
M;>!?#EMYO_$O^T&:(PL;J9YR(S_"-[':/IBF0^ ?#,(D#::;@/$80+F>2;8A
M_A7>QVCZ8H Y_P -0P:)XNM+.[\-G0;R\MY(XC97(DM;O8 S%EZA@.A(SR>:
MZCQE"UQX2U&!-2CTQI8MBW4K[%0D@ $]@?N_C6=>_#[2&TN\@L876ZG@,$=Q
M<74LIA4D?=+,2 ,9P,9Q@UT=S86M[I[V%W"MQ;RQ^7)'(,AA[T >->*(8- L
MDMKWPV=!N[HQ1126%T)+6[VS1,V\=00 2">>O)KKOB1(HUG18]^&-IJ1VYYQ
M]E;FMV+P#X:C217T]K@/$8<75Q)-L0]57>QV].V*KW7@'18-.N6T^Q9K\6TT
M=O+-<2.REHV0+N=CQAB,=!G- '+7&C:;HOP\T;Q%I@_XG*_9'CNU<F2X=V0-
M&3GYE(+#;V ]J@TGP_HTGPKO==F/_$R@6ZFBO/,(DMW1WV*AS\HR!P.NX^M=
MAX<\":1IEEI<\]AB^M8(R4:=WCCFV@,RIG8&SGD#WJAX6^'6G6^B6XUO3MUZ
MLTDDT?VAC%(?-9D+(&V,0I7J#^E %30;BXN]0\67-TNVXFT>PDE&,8<P2$_K
M6==RWD_A'P'I,=N+JVOXE^T6[7!@6<I$"L;/@\$Y.,<XQ7I T;3UNKZZ%O\
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M71E8D$DD'+9(!.[.:9>>!O#M_>RW=Q8$M<.'GC2>1(IF]7C#!6/U'/>@#B/
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MN;J.:WBE?J6*VZ \]^<_G73^)+B6U\-:E/#9+?21VTA6V==RR_*?E([CV[T
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MF"!X89?$6I2(CH5(4V^1D'I]* /3;76M.O;2ZNX+D-#9R217#,K+Y;)]\$$
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ML((;:2">#ZU3\0&SUSQ!HL\6NWGB+[->6ZO.+:%+>-7E7*,R*N2<9QSC!Z4
M>NZ/K-EKMB+VP>1X2Q7,D31G(]F -<KK7B:ZE^(-GX<L]2FT^%(?,F9+!I3*
MY=0$R5("X/+C@=,YKN*Y1@?^%N1M@X_L%AG_ +;K0!=U'QKH&E7LMI=7C^9
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MO0!ZQ15+2-6LM=TR'4M.F,UK-NV.49<X8J>& (Y!J[0 4444 %%%% !1110
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M&>H&<XK-\.^+=0TW0_$.LZM#'/$NIR)#'%<,[M*Q15B7<H 09&#]>!B@#T?
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M(& .N?3) '3^";ZZM'TFY\37<VC.^6MGB4RLF[/EF8G.WMTSCC-=8JJH"*
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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ML\!N!"\<D8(5@2,%2#SWXJKI>B^(8M>N]:UR6"5IM),)\HC$3>:[B,< D*K
M;CU.:[6D90ZE6&588(/>@#R[0+7Q-K_PTT_P^MA;Q6=W;HC:E]H!VPYR1Y>,
M[\?+Z=\U?E\)W\>OZC-<>';+7//D!L;N]N 8[6/: $,; D!2"?E'-=Y9V=MI
M]I%:6D*0P0KMCC08"CT%3T <'\+_  EJWA2#4H]52)3.\?EF-PP8*""?;J*Z
M7Q5I#ZYX9OM/A(6>2/= Q.-LJD,A_P"^@*UZ* /-=0\!ZW>:!I:(\4>I2SW
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MTK3;:]MYIY9;.[>Z$?D"1BV)%(R=I)^[U]JE\">#[GPE>ZC'(RR6\MO:1Q2
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MKPGI]]>PSI<20(9'E55\T[02ZA3C:2>.GT%;M !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !7*>(5-OX[\+7[\0$W-H6/17= 4_/8175U2U;2K?6+!K2Y
M+J-RR))&</&ZD%64]B" : .72XG\*^+M;N+K3+^[MM6:*>WFL[=IOF5 AC8+
M]T\9!/&#UK#D@O8?A!J-G>6,EI?:A>R116LBX.^6X^4#U'.<CL*],^T0BX%L
M9D\\IO\ +W#>5SC=CKC/>J]YI5O?WUE=W!=C8NTD461LWD8#$8Y(!./3)]L
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M44SQ%:ZKXCE\3W=KHM_'%<:5 EJ)H"CS;)2QPIY!Z_*><8XY%>K44 9Z7?\
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MX[NH+BTD33-)EN+BPD92$D>XVG"GOM_>#CINKG]1AUG6/"E_!J4'B:ZU^1)
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M@)W!E9B2>,8^8=ZYFU\!:II;6NH6<FG3W\#W*20W(8PS0R2F0#=C*L#WP>]
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MED!\_P U,Y /8 _C4-]X5\0>)=5L+GQ!+IL5M;17$,EO9L[%EEB*%@S <\C
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M->6V6GS77PKNO%%QJ6HC5;<3RV\BWCX@V2L H4':1P<Y!Z_2N@\':?;-X_\
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M*:-)(W&&1U!!'N#7EUW8:I!J.M:!HUS<36=I>VDPL7U!HY)HWC8R1)*QR,D
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M'M^A:@#KJ*@O9TMK&XN)9A D43.TI&1& ,EL>W6O)+^9[30[37=,M?$'GK/
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MK6GZUIFK/*FGWL5R8E1W\IL@!QE3GW%4+GQMX:L[<3W&L6\<;!BI.?FVOL;
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M;.YNWN(Y['>;>6WF,;1EL9(([_*/UI^D>)]%UV62'3-0CGEC4,T>"K;?[V&
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M!+Z]GC6"(I#Y:PP@D[0,G)).2?8>E:<>G01:I/J0W&>>)(B21A54D@#\6/\
MD4 <IXXNK"R\4^$KG4RBVL5U.6=Q\J'ROE8^@#8.>W7M7+>-3_;^J:UJ&@R"
MYT^"QMH[^:W7S$E99]YQCARJ<GGIQ7KCQ1R8\R-7QD#<,]>#1##%;QB.&)(D
M'144 #\!0!YS#/#JWBGP^5\70:Q/#(TT*6%B@\M-A#>8P?Y%(.,'OCBMCQ9+
M#I_C+PUJNI,L>FP?:(VFDXCAF=5V%CT&<, 3TKJX;6WMV=H+>*(N<L40+N/O
MCK3Y(XYHVCE171A@JPR#^% 'C?BJ>UUC7/$-UHTBRVD8L'O)H8_-21$D;>P
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MNXNBUF5& T@VR!CD#(7 P3[5J)X<U8?"33-&-DWV^&6 R0;ERH6<,><XZ<T
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M=@,I\]5$8(Z!>,]F&?6NMU?Q)+9:M%H^F:8^I:C)"9VC$JQ)%'G&YG/3)X
M/0URD^B:V=%UW1AI,Q:76Q>P3!T*2QM<(_'.00H)(-7?%/AK?XO77)]$FUJQ
MFM!;RPVTNR:%U8D, 64,"#C&?>@"Q!\09K[4SHMCH,SZS"&:ZM)[A(A"%QT?
MG=G<",#IZ5TNC:E)JNG+<S6%S82[F22WN%PRLIP<'HP]"."*\Y7PN!.]QJ'P
M]5M/G8F);.X+7T!& I=C(!R,\*>,#-=!X,N-8TNXCT+5K:Z*W(GNK1[BY$LD
M$*LJK$Y&<D;@<YXW =J )_%&KZO8^,/#=I86SRV]Q),9$6=4$Q$3?*<_W?O>
M_P!:S=-\0ZQ9:EXG2ST6YU5+;4G=V-RL:QIY:?*F[.3P3@ #D<\UL>*[;4%U
MOP_J]CI\M^FGSS>=%"RA]LD10$;B <$T_0=,O+0^)3/ 4^V:C)+!DCYT,2 '
M\P>M $*^.!J+6</A_2Y=3N+FT6\9&E6%8(VX&]CGYB<C ST]*J6_Q&>_U8Z+
M8^'[J75(XV,UL\J((65L,&;IC&"&&<[AQ7-:9X*N=*6PO-6\.7&JQ2:=%!/!
M;S 36TJ$]MZAE(([\$5K^"_#6H:=XVN-5DT&/2;.XL'1$27S&!\U2HD)8_.5
M&3CC&.] '6>&_$']OVMRTEG)975G<-;7-O(P;8X /##@C!'-<-=Z[KEWX/\
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MGU%&;3T%Q&QF*X+!^T>%.3DGC/?BN0\0^$I]9TV2/1?!$MB\<9+R7MQF0OD
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MLW;2YTZ*Z^RV<>T<^6,2/G&3ER0.?X:R;NTO'^,%I(FIRQQ_V4[^6(D(V"5
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M&SN.>%(P/>K?A?5_%7CBQN=6BU$:-]ED^SQV0ME=7E5%+F0L-V"6Q@$$#WH
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M?">WGA\ :=)+>/-'*A:.)D51"-S9 (&3D\\YH [2J>JZM8:)8/?:E<K;VZ$
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MD[/NE\<=,>U4M<U'5?!OBS4-1NKT:I+#H0%K)+$$;+7** X0 '#-G@#(XZT
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M05^U[?[&F27_ %>?-VQE,=?EZY[U#K_BB\TK6[+2-.T5M3N;N%Y@!<K#M52
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M'H][ITEW=:EJTNHW=VRECM\N*, 8"I'DA?<YR>]:]%% !1110 4444 %%%%
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M"VKRX7:R%5((VY;;CKGTQ4[>']1?Q6UE#8Z+Y$ \\>&9=2,B%BN&=1M 7C!
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@C.X#DD\KZ"@#J;G7M.M;"SO9)\PWTD4=L44L9&D^X !Z]:GU+4K/1]/EO\
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MW*9KFZF #2M@ <#@    #I6M110 4444 %%%% !1110 4444 %%%% !1110
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MCED,NIF,R*<838FP8_"L34? C:G%I0F\0ZGYVEEFBF)1F=R?OMN4@L!P#VH
MD\+65_=ZQJ/BC4;9K)]02.*WM&^_'"F<&3_;).<=AQ74UCZ+HMYI4TKW.O7^
MIAU "703">XVJ*V* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MXW*_S=/O#'!]S6%;Z9)K&MZ EI-XCNETZ[6>1M5@,4=K&JGY,E%WN3M&?F.
M>>M=YXBT"/Q#9P0M=SVDMK<)<P3P8W1R+G!P00>">* .5LM"N-5\;^*XQK6H
M64,4EJ +20([O]G3YF;!)P.W3DYK#L?%FL:R-(TV\GU9D2QDGNI-)B_?3N)W
MB7)'W5PF21U)KTG3-$CTW4=0OA<2S3:@8FE+XQE(P@(P.X&3[UC1> ;:SMK'
M^S=3O+&]L1*D=W'L+.DCERCJ059<GCCB@!W@F\U:9M2M+^+43:V\B&RN-1A\
MN:1&'*M_>*D'GT(KE]/_ +=7X91^+Y/$E])J,%N;E8WD!@9%)^1DQ\V0.O7)
M]J[S0M BT1;F0W=Q>W=Y)YES=7!&Z1@, 8    X  XKCO!_@6XNO!6FV6JZC
MJ<-FZ^9<:3*JH"P8G:25WA3@$KF@"QHLFHZ[XCUB_GUC4(++39X98+*!PJMF
M)'97XY7VXZFJULNMW_@23QF?$5[#J)MY+V.!''V5%7+",QXY&T8)/.>:[;3=
M$M]+U#4KR&1V;49EED5L80J@4 >V!6&WP^A^S2:7%K6H0Z)*Y9]-0ILP3DH'
MV[PA/\(/K0!CV?C&]T_1M<>[=Y+E[>*_TU'.25N% 2,>H67*_2M71Y-3LO&M
MEHUYJ$URL>@"6;>V0\WF@,_UZCZ5IZGX/TS4]7TG4I \;Z5Q%''@(X&"JL/1
M64$>]7#HD!\2_P!NF1S-]B^Q^7QLV[]^?7.: /.UU35=-D1_$6K:YI&J"X.^
M>6+S=.F!8X1=O"@C R<$'G-:-OK>KWG@WPC9QZA+#=ZVZQW%[P9%0*S-M)XW
M$# /:M9OA]&]E_9,FN:@^B[]XT]O+(X;<%\S;O*@]L_C5UO!=@WABPT/[1<H
M-.*O:W2,%EB=<X8'&,\D=,<T <CXRO=6\%K-9V>M7US#?Z?/)$US+OEMI8BI
MW*^,X(;&#WK3O(M8T#4?#]ZNNWEY+J=R+:Z@N&!@8O&S JH'R ,O;M6A<> (
M=2BO&UC5[S4+NZMC:BXD5$\F,D$A%50H)(&3@FM?5O#UKK"Z<MP\@73[A9U5
M<8<A67#>V&/2@#A-+U/4+'4-/7Q!JNNZ5JC7*K<&\B$MA<Y/*(5^5<\8/&/>
MNF\1W-]?^*M+\.6U]-86]Q!+<W,UN0LKJA "*Q^[RV21SBFQ> D6*WL;C7-0
MN=)M95DAL)/+VC:<JK.%W,H/0$]A6KKOAV+6I;2Z2[GL;^R9FM[NWV[DW##*
M0P(93QD$=J /./&\=[9KJ7AV?6+Z[MH8[2]MWDD!=0]PL;([8^8 C<N>1[UZ
MO:VYLK)(!+-<F)<;YGW._P!3ZUSDG@&TN;*^2^U&[N[S4'A:>\DVA\1N&554
M *JY'0#O75T >4:->:A9^'KS7;;['J6GO-)<ZMH4BX:R?<6;9NSR,9*MP<9&
M,UK_ !#TS2[[PNWB-83+<R?9!!+(2?+1IHS\JGA20>2.:R_%=O\ VR\^SPU?
M6OB5+@1QF&!GMKR(.,>:^ C1E<9W<C&*]!UW1(-?T9],GD>&)WC;,6,C8ZN
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M_;:##.(YIKFXNI3-<W4Y!DF?IDX   '  &!6K0 4444 %%%% !1110 4444
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M9M\6(O[7\HQ_V5_Q+Q/C9O\ ,/F;<\;\;??%<@;/3[_XEI:6T,4NB'6 8XT
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M)8T&7(VL>0.<'!J-?B#80I%/J6F:EIEG/$TL-U=1+Y;J%W?PL2I(Z @9^O%
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M= "1Q6A10!%;6UO9P+!:P1P0KG;'$@51DY. /<T?9;<79NQ!']H*",S;!O*
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M2;]R[4C4\L>I.!C ZUM^,[34)[[P_+IMJTTEM>._"DJG[EPI8]AD@?C75T4
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MC87MUXCT.:VTPZA'#;WRR1MQ&VZ$!4=L$*&/'-<-K&@:AJFCII7A:S\1VGG
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M-(70X=%$+_8X9_/1/,.0_F&3.>OWCFB]\7:#IT%M-=:BB+=IYD*A69W7^]M
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MT.H,ES<WT4PF%U<W+R2$A2H!)/0!CQTI]WK-W#X[T_1DV?9;FREF?*_-N5E
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M'QM)]@: -&TTJTL;Z]O8$*S7[J\Y+$ABJA1@=N *R6\#:(+*SMH%N;5K'?\
M9Y[>X>.5 [%F&\')!)/!JS%XNT"?6%T>+4XGOV=XQ H);<A(8'CC&T]?0U<U
M76-.T2U%UJ5W';1%@BE^K,>@ ')/L* ,F/P%X=CTZXL%M)/*N)UN&8SN764
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MK0O/(YCCP&VNP_A5\;6/L#0!"G@;1!:7,$L=Q</=O&\]Q<7#R32%&#("Y.<
M@<#BM2\T>RO]0L[ZYBWS6/F>3D\#>NULCH<CUJC!XS\.7.HKI\.K0/<-(8U
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MCD5?HH RI_#6DW&J:;J4EJ#<:6C):L&(" C&,=^.F>E3P:196^H7U\D9\[4
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M/[K,":]5F@AN$V3Q)*N<[74,,_C3MB';E%^7[O'3Z4 5-91I-#OT12S-;2
M=2=IKSK2[FQU.P^'*0RQ7*V\GER@$-LE2WS@^A!P?RKU*HUMX4^Y#&OS%N%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MJ*/4;.74IM.2<&Z@C622+!RJMG!].<&N6^)UO//HNG>3>R6V-3M@0B*V29
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M$\<NW(5L;E(8 D=<8[4S0/!J:%J_]HC4)KJ1K/[/*9E^:1S*TC.3GC)?&,<
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MN(!.,8'-=5YL>UFWKM7.XYX&/6N?MO$]S?\ C"ZT6QLH'M; (+FZ>YPV73<
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MGHJJL&3M 4@CWZ@&@#A=-TO1=6T;Q/J>OQ0R:A%>W*S7$N/,M53/EA&/* *
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MQ6\&G6L3V\ML(62%5,8: %MI XR3DXZUU<FDV$VJ0:I):HU[;H8XIB/F13U
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M8Y)929#%+%,6B=NK#* C.?TK2\7W&O2^*+G3M"O)(YVT,RQQ";8I;[0@)&>
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M@3VX.:W-4\/G1?%'A1X]6U"[C>^99([VX,VY_*?YP6^[WR!QR.*UW^'VG7K
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MQ)H5D^R[UFP@;S#'B2Y13O'5>3U&1D>]4CXNT[_A,E\.>?;^8;03^89UR7+
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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ML[NP55 ZDD]!0!)1573M3L=6M1=:==PW<!8J)(7#+D=1D5:H **** "BBB@
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MBZA:,-_<8CY6_ X/X5R-[\.+B^\-:5ITFI*+RWN9);VY"G]^DQ8S ?[V1^5
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MT+X@7F@:?))_9LFFI>?9WD9UMY?,*87). PYQ[4 =(VKVJ:['HI+_:Y+9KD
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MVQ0H$0$DX4# Y/->3FW.C1_VKKEI>3HEUYP\2Z7?B7<IDXW1D\+C"D $8Z4
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M=FY$6HX-M;M<R"2"1"8E&2Z[E&X?[N: (Y-)C\+6%]-H6DW&H/>R[FLOM/R
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M:Q1R/9R73/!'.!RXCW%=V<G(XSS6KJ7@S2-3OIKU_M=O+<J%N?LEU)"+@ 8
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M>$8K6Y^+']I0WESJ(FMIV%Y-;I%',Z^6A:,+U&#@G R<]:]:9592K $'J"*
M !@# % '!:=#$-.^(#"-<O=W 8XZCR%/]3^=5_APBMK;RLH,@\/Z8 QZX,9S
M_(?E7HU% 'E'AD!?&&BJ!@+J6M  =AN2GZD&O=,\>Z#;%FU.2\^UK:J"'D@
MAR1ZY (_&O5*3 SG'/K0!YSXFU[2/%%EHVG^'IENKM;Z&<)$IW6D:<NSC^#
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M4IM7DU/1]>?3I)XEBGC>W$\;;<[6"DC:PR>>A]*O>']%M_#NAVNDVKN\5LI
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M;"X2XMY+9MLB=#@$'\B"*\VAUG2;[X/6GAJQP^KW$$<,5BJD2>:6#>9CLO\
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MG?\ P%==10!Y3X3X\;:>!T%WJX ]/WJ4:HLEYIGC[0;1F.J2W?VI+90?,D@
MBW%1WR 1^->K4F!G..?6@#Q7Q:Z>)_#\&GZ=XEN=?NC^]@L+>QB1H=JG)?:
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M=I655VD *02 .O'->GUP5IX2U8_#"PTADC@U6QF%S''(X*%TF+JI*Y&"/YT
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "JS:?:-J2:DT(-W'$85ER<A"02/S JS10 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 5G66@:5I^IW6IVMFD=Y>']
M_-DEFYSCD\#/.!@5HT4 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %9VG:!I6E7EW>6-FD5Q>OON)<EF<Y)ZDG R3P.*T:* "BBB@ HHH
MH **** *UYI]IJ'D?:X1+]FF6>+)/R2+T;\,FK-%% !1110 4444 %%%% !1
M110!#=6T-[:36MPF^&=&CD7)&5(P1D<CBH=+TFPT2P2PTVV2WMX\E47)Y/))
M)Y)]S5RB@ HHHH **** "JUQIUI=7EK>3P*\]FS- Y)S&67:<?4'%6:* "BB
MB@ HHHH SFT#2GUQ-;>S1M01/+2=B25'3@9P#@XSC-:-%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
J1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>formofindemnificationagr003.jpg
<TEXT>
begin 644 formofindemnificationagr003.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  H'!P@'!@H(" @+"@H+#A@0#@T-
M#AT5%A$8(Q\E)"(?(B$F*S<O)BDT*2$B,$$Q-#D[/CX^)2Y$24,\2#<]/CO_
MVP!# 0H+"PX-#AP0$!P[*"(H.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[
M.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SO_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M) /. ,DXKJZ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ KSKQSX;M+ 6%W;7>I1RWVKP0S8OYMI21SN &[ _#I7HM<UXVTV\U.T
MTE+*!IF@U:VGD (^5%;+-SZ4 8GBNQA\(:7IDVG2:C('UJU,D9NI)7D )^0;
MF[],=#6JGCC[%=W-MXATJ72&ALVO$9IDF62-2 V"O\0)'%6?&.G7>HQZ*+2
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M3/)B\[S_ "T\TKLW[1NVYSC/IFN9U7Q7=Z5>+]HM((X3?QVJPM+^^DC<JHF
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M6W>=Y1:,;<$ D'D@]?3) .VHKE+GQ%K\NLZQI>E:19S2::D4BM-=,HE#ACC
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M*P/H5P?QJW0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0-R?F]\8[8[UHZ)X<@TGPV=$9O-@?S0RC(55D9B47DD* V!]*V"0O4@?6EH
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M41>B7R&PV)3+MQN]6(SGI78@@YP0<=:HZUK%KH6C7>JW6]H+1"[B, L?8>]
M&0OAB]LY=8CT^]BCM-8=I94DC+-!*R[79.><X!P>A]>E21>%FL-8TJ\TRZ2"
M"PL38-#)$7+1;D88.1AOD')!Z]*NKKB-XG30Q VYK#[9YN[C&\)MQ^.<UJT
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MG7?AS5H/$MQK&AZK!:B_1$O(;BW,JDH,*Z888;;Q@\5TI8+C) SQS02 ,DX
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M:X7RD.<N<]0/0<\U:)"C)('UH XK37OI/B#XHCLKBT$OV>S5_,!.UMC_ #
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MEE8Z[ON)X(1*8-UNH$NT@@@'J<'&:Z3PN]OJ?C9M0M]=O=<-O8F)[S[/%'
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M7'?%8NGZEI_AWP+IMW?/]GM8;.W4D(6VY55'"@GJ16KJW_('O?\ KWD_]!-
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M+?A6,\L:QLQ8D!5)( ';EB?>K&,]:X\^*O$-]?:Q;:/HMI*-)N#&\EQ<LGG
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MG,72Y!<)M&X AMS*.>QSVK&\9^*]4M_"M[;:W96$46I6LL4+V5V9C#)L)"2
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M4L,^G /6@#@/#7A/Q=X6\5ZCK$>E:?/!<AP;:WN!&N&8,!'D<;<8P<9%:O\
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M!?/=;?*64<ADQDL.<8X/'2O0** .0\'>'-1T;4I)[Q$5&TJQMAM<'YXD(?\
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M+&TBU:">U_LY;Q;F*0,&)D9,<<8^6I-1\5Z/8Z1?ZA%J%I<_887D:..X0DD
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M+"W^PD%3;>6/+P3DC;TZ\U6U'PMH&KW*7.HZ/9W4R  22PAC@= ?4>QK6HH
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M0:-9"]W;_/\ )7=N_O?7WZTEWX4\/7^H?VA=Z+93W603+)"I)(Z$^OXUKT4
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M:T]F8X"BZ0DGTZT :5%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MK5]X@\.K?ZC%'#<FXFC:./HFV1E SWQCKWKH* "BBB@ HHHH **** "BBB@
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MK+3M$ABC^T!VGOIXC)';JN, *",L2>.>QH W**Y+3?%<UA>:QI_B:YM%;2C
M3>PHR)(LOW<J2=K9&.O<5UM !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MN:(AHIIC<@@9'#$)D$]LXKV!XTE0I(BNC#!5AD&F);P1Q"%(8UC7HBJ !^%
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M!"\GF-$C/MV[BH)QZ9]* //[V6&PG\":KJ1":9;VS)),_P#JX97A01LWIT8
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MFWQ.(Q)SG@@C/';U- '6T5S'A_Q1+KM[Y22VJM$TBW5DRLEQ:D'"Y!/S ^H
M'(K4UF^N[%;;[.L"1RR[9KFX8;(%VD@[<@L2P"@ ]Z -.BN*_P"$UU)M!M;Z
M*RMGG;5QILP9G13^]\O<H(R,^AZ>]7(==UZ2YUW3?LME)J.G11SVXCW^7,KA
MB$.3D-E",].1Q0!U-%<]I?B&76+;1)K,PM]OA:>Y!0_NU4 ,!SP0Y"X/N>V*
MOZU?75C# ]LD 5Y@DT\[@) F"=Q&1NY 4 'JU &E17(V7C*:XTU=\$1OGU9M
M+C(#+&S#)\PJ>0-@)VYZC&><U%XIU'Q+8^&]3=_LUNT-Q!'#=1*<3Q2.JMA=
MQ*,"V,DG/;'4 '6O>6T=W%:/<1K<3*S1Q%@&<+C) [XR/SJ:N>N=7NK/Q9IF
MFW4-HZ7%I/*URH(92FW( .< [AW/2L^7QE>1>&[?Q48(#I$LJ[X0&\Z.%GV+
M)NS@GD$KCH>O'(!V-%<;?^)]>CN/$D=I::?C0T24&5W/FH8_,(XQ@X[]![]N
MJL+M;_3K:\52BW$22A3U 8 X_6@!US>6UDB/=7$<"NZQJ9&"AF8X"C/<FIJP
MO%6JSZ3;6$L5K!.L^H00/YQ/R!W W*.Y'UXJA>>(=>.KZ[I]C:Z>/[+MXIXW
MF=SO#!S@@8Y^3\/>@#K**YNS\33:PVEVVGQQPW%]IRZA(TP+K#&V !@$;B22
M.HX4GVK/A\8:F8('FM[7<=>.DRA V" =N]23Z@\'U]N0#L998X(7FFD6..-2
MSNQP% Y))]*2&:*Y@CG@D62*50Z.AR&4C((/<8KG+CQ#?)-XFMA;6TQTB!)8
M@Q*B4,C,0W7IC''7VJL_B76&?P]::?96 ?6-/>=3*S!(G5$;&!_#\X]3].M
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M&>]<GJFF_P#".:-H7A^[URWMXK>629;ZYL,VYQG:C@O@-ER0=P^[Z@5Z."&
M*D$'H167I^N+J&OZOI(MRC:6809"V1)YB;NG;'2@"CX1FNVAGA>XT^[LDVM;
MW-A;&&-R2V\8R0<<'<#CYCW%3SZ%>)XBN-9T^_BA>ZMD@ECFMS(!L+%64AE_
MO'@YK;W+NVY&X\XSS4-W<K:6LLQPQCC9]N<%L#- '-3^!S;P:8^A:H^G7NFJ
MZ+.\0E$ZR'=()%R,Y;YN,8-6=3\-7^HZ?90-K"_:+>]CO))Y+;<)'1@P4*&
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M//FV[!H7DGDD:/ ( 4LQP,,>.E 'G,6@:?:?!>V\11PD:O!''/%>[CYB$2@
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MFG.LEJ-S?NV52JGKS@$CG-2QZ99Q:I-J:0@7<T2Q22;C\R*20,9QW- ',VI
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M./<6VCZDDU:K.T#25T+0;/2T<.+:()N P">^!SQFM&@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M53J$I7[%-"ODI,DCLC)(K9Q@JQY&.?J.M2ZIJ,.DZ=-?3I(\<(!*Q+N9B3@
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MB-9K>2-BP#*02C%3^!'(H EHKC?!NLI9^ ?#QN#+<W5[&(X8U.9)7^9CR3V
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M,#Q7H5WJT5E>Z7-%#JFF3^?:M,#L?(PR-CG# XXK,O$\9^(TBT^:QCT"V\Q6
MNKN&_P#,E=5(.V/: 5SCJ3TKLJ* .630-474O%T\,RVS:M'$ME.&Y1E@V;CZ
M8:N4;P/JDNB6EI;>%M-L;RVEADN+U[A9);DHP+;6QD9P6.X^V*]4I&8*I8]
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M2HZ$@X( !Y%86N:?K5KXHM/$&C6L5]BU:SN;2281$H6W*ZL>,@YSGM^G444
M<Q?V&LW>L>';Z6UC;[%/--<B*48C#QLBJN<%L;N3QG!^E9KZ/XD@CUAK*WV&
M\U=+O8+A4::WVHKH&!^1CMZ^AZUW-% 'GE]X6UN33?%%I;:7:PKJS0O;)%<
M*A54!!X&/NG)]3WZUK^+C=7,VB)9V2R:DEPUPD/VE8IHU5"&*L0RD990<@@@
M_B.LJAJFB:9K*QC4;**X,))C9AAD)Z[6'(_"@#D'TO4-2TJ]L+?2CIFKPW<6
MI@W4Z3QW,F_^)DZ9V%<8&!C%;4%UKT.E76H2Z%96=Q%%^[M!=K^\/=FDV@*
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MZE;<S6(A0NB8!#[MVW!SQSDGM5I_&^EG1M.U&VBNKIM4)6TM(8P9I&&=PP2
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M2++X.T:\U>Z:6]O8"^$B+R2D9+$(@S@#'0<<5IOXIT*.&RF;4X!'?@FV;/\
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ML(+.+)2",(">IP.I]SU-4TT:WEUHZNU[=7!X\JW>;=!"P!4LJ]FQD'KU-:E
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MP/E54++N8_7C%=#7,>(O#=]?^(-/UO3S8S2V<4D1M[]&,>&(.]2,X88QTZ4
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MUOXDNM:O9K=GNK*"!TA#8$B;BQ&?X26X[UEW7@J\N/!^JZ(E[%'-?:BUW',
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M(Q)R,(PR"<C&17*C3IO&OC&[M;_5K._A.C/#++IJGR;9FD4H Q)R^5+=>PH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M19,,3A@RC)&.#5>^TW^ROAW#XP@U6];6DMXKQ[I[IV69FVDH4SMV'=@ #TH
M]'OKM+"PN+R169+>)I6"]2%!)Q^5,TN_BU72;/4H5=(KR!)T5\;@K*& .._-
M>=VNFKXH\(:WXCU&]O(M09KH1E;ET6T1-RB/8#MQ@<@CG)I- UD^$+6RN;V:
M1M/U#PY!=0J[DA9H(E#(H[;E*GZB@#T^BL7PC97EEX9LUU&626]F4SW#2,21
M(YW%>>@&<8]JVJ "BO.=#TF/Q+X7F\3:GK%W9ZC++-(MV+ID2Q5)& 4)D+M
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M:65) K2%<#J2-M6/A9J6H77BK5+.\NKB1+2W,4<<TYE*!9W !/\ $0.,^PH
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M.&;;O,85G*K_ 'FV@[1[G%9-IX[LM2\1:II-M=6X2VMEDMYP&82-M8N21QM
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MUN-6AS)&)08P9 $/1B5!P#ZF@"Q8:9/:Z_JNH/,S17HA$<1D+!2BD%L'A<Y
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MZ!I>L6UK"\(FEF-N9C*S,H6->0 "ISNZ5UNI:I8Z/9->:C=1VT"D O(<#)Z
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M=?">W6*)YD2"TDGBC&6>)2A< =_E!/X5VC6\#R^:T,;2;=N\J"<>F?2I
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MC\Z IS\P#90* 02>V>M>K1VT$,CR10QH[_>95 +?4]Z06L"N\B0QI)(,-(J
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !56;3+"XU"WU":TADN[8,L,S("R!A@@'W%6J* ..
M\1:7X5L[?2] N;9].AN[EWL[BT(A%O.!G._/RL<D#@YKG/&UWXG\"Z1MM?$<
MFJPWJR0)#<QK]IA^1CYBNO+;0.21QQ7I6I:98ZQ9/9:C:175N_WHY5R,^OL?
M>LW2?!GAS0[AKC3M)@AF92GF'+L%/4 L3@?2@#SC4?#;IX:TN==-\,V2%XO*
MO%N7>2ZW=4;]U^\WC/!)JQ-I>G#X$6$HL+4,S6TK/Y*Y+F9%9B<=2ORD^G%=
M_9>"_#>GWRWMII$$<T9+1D9*QD]2JDX7\ *D@\)Z!;:5=:5#I<"6-VQ>:WP=
MC'CG&>.@Z8QB@#'U:W@M/'_@^WMH8X(8X+Y4CC4*JC9'P . *YBSTR]U_4O$
MUQ=Z/HFHNFH30/)J5RZ26\2_<"@1ML7;R&!&<D]J]'@T+2[9K%H;15.G(T=J
M<DF)6 # 9/< =?2JNI^#_#^L7AO+_2XIIV4*[Y93(!T#8(W#ZYH \U\">'[#
M5]$\2SZS]FUB>(>7'<DF10!",,A8 AL!<M@'Y15V#2;&T\'^#-:BMU&IS:A9
M&6\/,T@<X8,_4C!Q@\8KTFUT73+&.YCM+**!+K'G*@P&PH4<=OE '%-.AZ8;
M"TL#9I]FLG1[>/)Q&R?=(^E 'G=MIM[K^O>)YKK1]$U-XKY[?.IW#J\$*@;
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M=""I^4G'0D$\#L,5Z>Z"1&0D@,,':Q!_ CD5DKX4T1+"WL%LRMM:R^=#$)I
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M&SL+:P1UMX]ID;?(S,69VQC+,223@ <GH!5/5O#.BZ[/#/J>GQ7$L&1&YR&
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MD>U=M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M'3?N'/; % '<HZ2('C=75N0RG(-.KR[PWX@\0Z#\.])U5["P;1X$CCD0R/\
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M^%BZA;Z9#K]VFC_V;(59[.&Z+7D43$ ,1T9AD$K@?6@#T&21(D+R.J*.K,<
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M)2^&=5OB)$DM'L[2WA;/SL8E8,6';);-:OBC2[K6O#.H:;8W7V6XN82D<N2
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MAITV_P _4&D6'"Y&47<V3VXH S?$^BWU]<Z9JNDO"-0TJ9GCCG)$<J.NUT)
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MIW"(;8P  >P+$XZ5K_\ "O\ 3@MO)%J&HQ7T-RUR;]95\Z1V7:VXE2,%<#
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M[")K6X=YA,3*H,"$JK'[H[#'0=*BUG5]6\,7VJZ#8ZAJ%S%-<6,=O)))YUQ
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M:B_X5WI_D#3SJ>IG1Q)O_LLS+Y/7.W.W?LS_  [J ..A_MH?#&U\6CQ%J?\
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MVU!H)-2O;"UU^ZBNH+*Z\NX\H(FQ4)(.T$G*@CK5&P2UU7QYHD,>M:X[12W
M:TOG>*XLP(@P4DG)W'//<<9.*[*+X=:7:Q+]BOM1MKI+J2ZCNUF#2H[JJN,L
MI#*VT$A@>>]'_"O+#[9'J1U34_[52;S6U#S4\U_EV["-NW;MXP * .MK@-)T
MF]\17'B*:Z\0ZI!]FU.>"S6"Z9%@VX.2!][KT.1@=.:[^N!TCP;<7ESXADN-
M0U73$O-4FWQ0.$6XA(7!^921G)&Y<9% &5H][JOC?4]&ANM8O["*?0S<W LI
MC$9)%FV;ACIGKQ].E;&DZ?=>++G6;B[UO5+5;*_EL;2.TNFB$0BP-[8^^Q/)
MW9KI+/PSIVGZM;ZA:*\1MK#[!%"I'EK%N#=,9SD=<U2O?!D$]_=W=EJVI:7]
MN.;N*SE54E.,;L,IVL1U*XH Y?PKXLOK>>#4-=O7EM-0L9LN3\@FM68.5'1=
M\8W$#J5-6=.N]9C?PA/>WMR)=7O;BYN(3*VT(\3.D>/[JC;QV-=!J7@70]3\
M/6>@O#)!963J\*POAAC(()(.0P8Y]<FM*^T2UO\ 4--O9&D1],D:2%8R I+(
M4((QTP>V* .8L;6\\6:SKUQ-K.H62Z?>FRLX;2<QK'L52791PY);^+(QQ7&>
M%]3O;FQTK1&769;&TL7F=-'8(\LC3R %FW*=@ Z ]3S7I5_X.M[O4[B^MM2U
M#3FO5"WD=I*JK<8& 3E25;'&5P:JP_#[3K&UL4TR_P!0L+BPB>&*ZAD7S&C9
MRY1P5*L,DD9'% #O!$^K-#J%KJ4-^(()Q]CEU +Y[1D9VL03DJ<C/4@BDU_5
M)= \6:=?W%S(-,N;6>":,L?+21%\U6QTW%5<9^E:VA>'[30()D@DGGFN93-<
M7-P^Z29SQDG '3@   4SQ-X:L/%>D'3-0:98C(L@:%@K@CT)!Z@D'V)H \^T
MW7M?.@7>C7E_.-7U.ZM&M)=YWPQW*AB%/4! DO3IBN@T>PO-6\::W)<:UJ26
MVEWL0MK6*Y*H?W:,P<?Q*>..G)]:WI_"FF7'B>R\0LL@N[& P1*I CVG(!(Q
MG(#-CGO5K3]&M]-OM1O(7E:349A-*'((5@H7Y<#IA1US0!YO=^?K/PGT"[O;
MZ\DG.H1*T@G8,^;@KDGN0!P>U:TM@FE?$B[NUN[^8V7A]+@+)=.WF%7==K>H
M.W./[Q)ZFN@/@G3?^$1B\-">[6VA8/%.'43(P?>&!QC(/M4A\*0'6++53J-\
M;JVM1:RL77%U&"3B0;>>23QCK0!P%K?^(+KP_!K=I'XHGUJ95N%?*_8GR<[/
M+WXV8XSC/>I+2/5KGX83^+)/$.K)J-N)I8%%R?+01RL-K)T?.TYW9ZXZ"NL_
MX5Y8>1]@_M/4SI'F;_[+,R^3USMSMW[,_P .ZM"'PCI\'A"7PNDMQ]BE25"Y
M9?, D9F.#MQU8XXH V+64S6D,K  NBL<>XKB_L5WK_CW7["?6=2M[&SAM62"
MUN6B^=T;G(Y'W3P."3SG%=M#$L$*1*25C4*,]< 51M-%MK/6]1U:-Y3/J*Q+
M*K$;5$88+M&,_P 1SDF@#S_0=0U?Q#>:;X;N]7O(X8$NY+BYAD\N:Y$4WEHI
M<<CCDXY-9_BJWN(->B\.RZKJ%S:0WUC/;O)<L9(A)(592W5B-H*D\C)KNF\!
MZ<L$(MKR^M;JWN)IX;R*11*AE8LZ_=P5)/0@]*;)\/\ 39K&YBGO;^6\NIHY
MY-1:4>?OC.4(.W: O8 8YH @M-0N;#Q7XB@-Q<7%OI^F6TD44LA;D+)D\]SM
M&3WK.TO3M0N?"EEXJF\37T6HRQI>2%YB;8J>3%Y60H&#M'?/.:ZO3_#UO8:E
M<:A]HN+FXNK>&WF:<J0XC! ;@#D[CGM["LJ/X?Z>BQVIU'47TJ*42II;RJ8
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MS"'EWR)O!7D ["2!@'(]*ZA?A[I]JDMOI6IZEI5G.H6>UM)E$;X4+GYE)4D
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MD<AQT)QR*ETOP+JUMX_'BB_U2VN2X8R)'$4PQC"849/R@ =3GB@#3\&?\?\
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M8SOY$\L+&XM48DE5P=K8R<$XK9\*Z!+X>LKRVFN?M)N+Z:Y60_>P[9&[W]:
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M&E;^"--P&!R223U%;&M^#?[6\6Z?K"W(CMXMIO+?'_'P8R6B_)B<Y[8J34]
MU2/Q$VO:#<VB3SP+!=6]XC&.4*258%>0PR1W!% '&P?$V]OM0_LZ;6--TR&
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !117,?$&\NK7PXD=K</:_:[R"VEN(SAHHW<!F![''&?>
M@#IF8(I9C@ 9)K$\+^(I?$UDU^NESV=D^#:RS2(3.N2,[025Z=_6N5\2>'M,
M\/W^CP:8DL<6ISM:W=K]H<K<1["V\Y.=RE0<CGGFMGX8V%M9^ M,E@CV/<P+
M)*=Q.YNF>3Q^% '6T5YMJXO-=\?:O97&BRZQ::;# L%L+X6Z(77<SD9&XD\
M]MM9&DQ3ZAJ-UI.I:9J&NS:<S)#8C48VAM(BV5\R3<-TGWEYR0%H ]@K,N-;
MAMO$-EHK1.9;R&699!C:H3;D'_OJO+O!$#>(O$]_X>UEYFTW2O.:WL#=,Z@^
M;MP7!!<(.!GUK3D\/Z9-X[TK1$U2XO;.!+S?!]H;="/W9$!8'=M&0<$Y[=*
M/4:P=8\4QZ=J4>DV.GW.JZF\?F_9K?:/+3.-SNQ 4$]*S?!L"Z7XE\3:+:M(
M+"SEMWMX7D+B+S(]S $Y(&1G%)X<*P_$;Q9#<$"YF^RRQ;NKPB/;Q[!L@^]
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MF%^'GAV% +.WGLI%E:5)K6Y>*1"P 8!@<X(4<=*NZ=X2T72KFVN;.V9)K99
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M70H+1/[/6-H_)?Y@RMDG.>N<FLN+X>^'D*B>&YO8HD:.&"\NI)HX588(16)
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M\A?YVZXST'MTJY110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M]ZQ[?Q9K.IZ*^NP:AK::B^Z6VL8-*>2SV@G;&6$9+9 Y;=P3[4 >LLP1"S'
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MLSE54%@0 ,$GCGI0!UE%>5SZOXJBU&71AKQ,W]NQ6*W/DID0M 6SMQC=T/\
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M0>-8+J/P]-!;9BUMF&6E , $9?D ')XZ9'6NB@N(+J/S+>:.9,XW1L&&?J*
M.7G\#SZHTLVN:Y+J$XM)K:V86ZQ)!YJ%&?:/O-@XSG'M6C>^&8KW2-)TYKET
M73)[>97"@ES%C /IG%:T%U;W.[[/<13;#AO+<-M/OBG33PVT1EGE2*,=7=@H
M'XF@!+J 75I-;EMHEC9"1VR,5@-X1:/0-)T^RU:XM+G254072*#NPNTAD/#
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MLH9I+F$03&1=P>,$D*0>,9)JMI/A70M#N&N--TV*"9EV&3EF"_W023@>PXH
MR-5_Y*IH'_7A=?\ LE8^C>&](UB?QE<:E80W<G]I3PH9D#>6!&I^7/W3D]1@
M\#TKO9-.LY=0AU"2!6NH$9(I3U56Z@?7 I+?3;.T^T_9[=8_M<IEGQ_RT<@
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MED'5PN=H/TR?SH \FT[3+W6M#UK4+W2]"N)7NK@75[?73K<6Q5B .(SL"@#
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M+=K?3K2.UA9S(8XQA=QZG';H*MT %%%% !1110 4444 %%%% !1110 4444
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M(!D]L\XKF-0TZ\D\832"RG:(^*+*8-Y1*[%MF!;..@/&?6@#<U;QOI\^CZK
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MRZ/X;U+4X$1Y;2UDF17SM)520#CMQ0!I45P<WB?Q?:R:/++9:4\>MD1P0J9
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M@F5AN5U.3CN",G!!YKGK36;_ $#7O&VK:C);S6MDT3-'&C!V/E+Y:J22 ,$
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M*[VPXW @Y_"NGU#6_$,_BZYT#1X]/C6&SCN3<W2NVW<S KM4C.<#'3&#UXH
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MY(]L />1OE3]2/PS7)>"_L?A7Q1%H%OJ$%U!JEBDVZ*8./M<:XEZ'^)<-^%
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MC:-=S0W#L',TBHN[Y1G (&,D]<]L4 =I5:'4;&YNI;6"\MY;B'_6Q)*K.GU
M.1^-><S_ !*U*/1!KBZAX;\N0!AIHG+W,2,< G#_ #,,@E<#H1G-1>&;Z]\-
M?"W4/$D<&G2W&^5XW$+!Y#]H=6\QMV6'IC& .] 'JE%8/B/7KG1K_2((+=9E
MOKAXY%();"QLXV\]25 YKF]$\;:]K$,%Y9_V+J+29\W28)3%=6_!P"SM@D$
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M&U*.+=/+&O;RV3:&(&"<GJ<5WM4-0UBUTR[L+:X$A?4)_(AVKD;MI;GT& :
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M23QQ6AT^:U8Y.]79D96 Q@@%<]16]<:O;6VLV>DR"3[1>QR21$#Y<)C=D_\
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M:>U7: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M3QSQ $?,R @!N.1@G/2L1OAOITFE/H\FJZL^ED$1V1N%"19.1@A=QP>0&)'
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MUK<JQ&\;/,(48)V[5!'%>@ZGH%CJ]]9W5XK.;-9E6/(V.LB;&##'(Q]*R8/
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M-"\Q;:,EQ,<-GU&!S[4 >M455MK^TN;F>SBN(Y+FU">?&K9:/<,KD=LCFK5
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M^F1Q5JB@".:WAN(O*FACECX.QU!''(X-#PQ2/'))$CO&<HS*"5.,9'IQ4E%
M%2YTK3KV=)[NPM;B6/[DDL*LR_0D<5/%!##O\J)(_,8N^U0-S'J3ZGCK4E%
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MC'W7&*M44 0VMI;6, @M+>*WB'2.) BC\!22V5I-<)<2VL,DT8*I(\8+*#U
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M-&TL*2&-MR%E!*GU'H:DHH :Z)(C1R*'1@0RL,@CT-03:=8W%HMG-96\MLN
M(7B4H,=/E(Q5FB@"J^FV$EJEH]C;M;QD%(6B4HI'3 Q@5-%!%#O\J)(_,8N^
MU0-S'J3ZGWJ2B@"K;:7I]G.\]K86T$LGWY(H55F^I YI_P!BM!:?9/LL/V?&
M/)\L;,=?N]*GHH C2WACFDFCAC227'F.J@,^.!D]\5)110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
L !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>formofindemnificationagr004.jpg
<TEXT>
begin 644 formofindemnificationagr004.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  H'!P@'!@H(" @+"@H+#A@0#@T-
M#AT5%A$8(Q\E)"(?(B$F*S<O)BDT*2$B,$$Q-#D[/CX^)2Y$24,\2#<]/CO_
MVP!# 0H+"PX-#AP0$!P[*"(H.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[
M.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SO_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M^U:""55U*0(J2.=P49X]O2O1:YGQQI]WJ%GI"6=N\S0ZO:S2!!G:BMEF/L*
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MKK%O&)(M.7S'M&C+!592W.489(XR#0!HM\1;';:1QZ;?R7ES<2VILPBB6*9
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MX977@$@[&&W&1D5)XSN_$-M9:YX?O]7BO(FTAKY)Q:K&^U7"-&0#C!R"#U%
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MF\DL(V# 'DDC(XS4MAX+DL?">MZ$=1:=M4DN&%Q*I++YJXRW/S$=2>,UU=%
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M.AT*#Q)'%I4)54FCMRMX(@>(PX;:..-V,XJQ#X-DA^'<WA3[:I>2.5/M'EG
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M7SI;-;F06\CYSN,0.T\^V* .0\(:+;>,;/6[_71-+*\ZE(_-=5@=H(V9E (
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M9P<$;=HXSG!_V>G-=30 45Y7=7<YUB?XBJ[&SL]16Q !R&LAF.1QZ_O&+?\
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M,\*RV\C7(=Y,]<J ,#N#W&.*?XXGMK7P7JD]Y9B]@2 F2W:0H)!D<;AR/PH
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M2.GWQ&FT[MON1D]*AL?'-[KD=G%HFBI<7DUFEW<+-=;(K96SM4OM)9C@\8%
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M'K7I-% '(WN@ZC-I/A"WC@!DTR[MI+H;U^14B96/7G!(Z5>M]+O$^(%YJS1
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M9'S*S$#:1Q@$'O5KP-I.HZ-HT\%^'B62Z>2VM7G\YK6$XVQE^^,$]3UKI**
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M3.NH7$[G6O+19]I4,MVGS\*#D]^WH!71:S?ZKX(U:SGEUJ[U:"[M;N2>&Y5
M \4)E!3:HV@[2,<]:TY/ @>RU;3_ .UIOL6I78NUA,2_N)/-$C8;J02N,'I6
MKK'ARVUO4M.N[IR4L?/!AQE95EC,; ^G!H X"'Q'KL6F6FL077B*_P!2<QRS
MV1TEQ:2(Q&Y$(CXP#PVXYQ[UU'Q"_P!7X;_[&&S_ /0C2P^![I+>WTV7Q)?2
MZ/;.ICM-B*Y53E4:4?,5&!QQP.M;.NZ%'KJZ>))VB^PW\-ZNT9W&,DA3['-
M&#J)U?5/B'-HL.LW.GZ>FF1W#BV">87,C+PS XSWX["L73]<U[4-0@\*-J\J
M2+J5Y!-J*(HF:&%48 <;0Q\P G':NYCT2-/%$VN^<QDELTM3%C@!6+9S_P "
MK(D\"0^9-=6NI3VU^=1EO[>Z1%)A:155DVGAE(49!H X_5[_ %3P?XDUHQW\
MM]=36MG!:W$L0DD0/(XRRJ!O8?-CCGCK4/B3Q-K^@Z<9M&OO$%TD@VW#ZIIK
M1B%LC#JWEJ "?E*G^]78GX>PW<NHSZMJUU>W&HQ1H\H58S$T;%D:/'W<<<<]
M.<Y-1:I\/[O7[;R=;\3W=V(UVP!(4B53D$LP7[YP,<\#/2@"M?6WB'3O%.CZ
M4GBB\E368Y_M3O%'F(QA6)A&W"YR1SG .>36==ZMXBL+B;0;;6Y9)8=>M;2.
M\GC1I/*FA+D,, -@\].<5W=]HD=]K^EZNTS(^FK,%C X?S% .3[8K.N?!<%S
MK,NI&\D5I-1M[\H%& T4>P+]#UH Y?Q+J.N>$Y]4L8-=N[R-]'>\ADN@ADAE
M615."% P0W3%:GB:QEN?B-X4==1NX-\5U\L13"[44G&5/WLX/L!C'6M3Q)X,
M@\1W4T\MY)"9=/>Q(50<!G5MWU^6K6M^'7U6_P!,U"VU&2QN]-9S'(L:N&5P
M ZD-Z@#GM0!PR^)M3UI+_44U#7[69)Y4L(+'3&EM@J$JN\^6=Y)'//%0Z9XK
MUCQ)#<WM]=Z_I4\+^3#;:;IC2Q1NH&XR'8VX[L_+D8 KKY?!5U$][#I/B&ZT
MZPOY&DFMDB1]K/\ ?,;GE,_C@GC%,B\"S:7Y\7A_Q!=Z7:W.#-#Y:S9?:%+J
MS<JQ Y///- %36=1OM5^#5]>ZG:/:7LE@_GQ/&4(8$@G:>0#C(]C52^GUCPC
M!H.K3:Y=7R7<R6]W:2(@BPT3,/+ 4%<;/4Y[UU5UX8MI_!\GAJ.>9+=[<P>:
M[;WP>K$GJ>].U7P[!JT&E0RS,JZ;=1W(&T'S-BLNT^QW4 >>P>)]>N=#CUV"
M[U^;59 )DLH]*=K)U)R(P1'DC;QOW>]6](US78? =UXWOM6N)VBCG6&P>-5C
M&)"BE^,DAO<<<5OIX#N(K(:1%XCOH]$#Y%FJ*'5,Y\L3?>"Y_''&:TM.\)6-
MEX3?PW,S7-I()0Y8;21([,>G3&[@^U '!ZCX@U[2M*6^L;[Q'?7A0B\CN]*9
M(%!4Y=#Y8V;3R.2,#FNEU#6M1A\ ^'=0CNF6ZNY+ 328&7$A7?V[Y-3_ /"#
MW-U%;V6K>([V_P!-MO\ 5VQ18R^!@"1UY< 'VSWS4*_#ZX>RL=/NO$EY<6.F
MS126D!A1=OEL"H9@,O@# Z=<XZ4 9,4GB'4?#FOZV?$MW;2:9<WGV2&%(]A6
M)F($F5);ICJ, #K5O0KW6?'$]W=#6;C2H;..!(8[14^:5HE=F?<#N&6P%XX%
M=%:^%H;70-4T@7+LFI27#M(5&4\[.<#OC-4(O!$VGR*^C:[<:<TEM%!=;84<
M3>6@17 ;[CX'4>W% '#:!KU_!I^E>'S<W]O'MN[J\FTNU,TSG[2Z!5PK;5R"
M2<>@[U;@UGQ3J'BZQ\-0ZGJMK83&8I?W=CY,\L80,5PR@%E((W ?QYKJ;3X>
MQZ79V TO5[FTOK#S5CN]BN7CD<N4=3PPR?S&:GL/!'V;Q#:Z_=ZO=7U_"93(
M\BA5?>@0!5'"  =NN>: ->PTR\M+N.6;5[B[B2U6$Q2HHW.#S*2!U/3'2M.J
M:V=P-9>]-_*;=H!&+3:-BMG._/7..*N4 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M<_XHU"=)=-T6RF:&ZU:X,?FH<-'"@WRL#V.T8'NP- '045@ZEXLM-/U&338+
M'4-2NH(U>:.R@\PPJ?N[B2!DX.!G-9X\413:AHFLV5Q*^E:M(UA)%("IBF^8
MH=IZ'*LA]<KZ4 ==1110 4444 %%%% !1110 45'-)Y,$DNQY-BEMB#+-@=
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MED@*,02QSTXSQDXY(% '5T5S]YXRTZWN(K:SM[W5)Y8%N/+L(?,*1-]UF)(
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M.A7<WQ!.E&SD?1K^XCU2:0*?+5TC9&0GIDL(VKO[>WAM+:*VMXUBAA0)&BC
M50, "I: /,/#.DZLVE:X^I6LRRZ9ICZ/9AD.953>2RCN&_=@$==M7=0BN;/P
M-X)N'LKIQIL]E+=1QPLTD:K RL2H&>"1D5Z%10!RWAR&3_A,O%%XT$L<5RUH
MT3O&5#@0#.,]<'@^AI_P]MI[3P?!#<0R0R"XN3LD4J0#.Y'!]00:Z+SX?M'V
M?S4\[9O\O<-VW.,XZXSWI);B"W3?--'$NX+N=@!D]!SWH \]U1;B.X\?:>;&
M[,NH6OFVK+ S)*!;A2 P&,[N,=:TM>L;F3PYX2AAMY2T&HV#2*B$F-5')([
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MQCD62%U<G;(@4L%(.1QUJ#P;I3K\2I-7CT[58[:XLI0MWJ+%GG(:,!B"HV9
M. >2!FO34GADFDA25&EBP9$# LF>F1VSBI* .9\-6TT/B;Q3))!)''->1-&S
M*0''DH"0>_.:Z:BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MVC)W'Z5O>&=%GT2+4TN)(W^V:G<7:>63PDC9 .1U]: -B42&)Q"5$FT["XR
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M3 .ZRC<Q*S*1P"'Q\N: *-[\3KC1KA+&;4-!U>6\ %K=65P$AA?< 1,-S;5
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MU34EU"6_2#,O(;<@;=D8X'S #D\"KWA31;C0=)DL[F2.1WNIY@8R2,/(6 Y
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M?5NU=GXG\.W>I:AIVKZ8;0WNG[U\F\4F*>-P-RD@$@C ((!H Y:7XH3VM_\
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MTO8&$A()::((I& > 1S_ %I+[PQ>77A'1M'2:$3:>]HTCDG:WE%=V.,\XXH
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M,C@X(Y.T@@@C)KJ:PO#NF:K:37EWJLEFCW!416ME&!' H']\J&8GJ<\>E;M
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !6=J.MVVF:CIMC,DK2:E*T41
M0 JI52QW9/ P.V:T:Y+Q9_R-OA#_ *_IO_1+4 =;17!Q:0/$7CSQ-:ZC?7QL
M[06ODVT-T\2JS19+?*1Z<#IR>*Q?#$]YXHOM-T#5M0O)+.TL[B9]L[1O=,ER
MT2[W4@G:H!Z]2,T >BV.M6VH:KJ6FQ)*LVFO&DS. %8N@<;>>>#WQ6C7C5Z]
M[H>NZQHNGW%]<B]U>T@>2.<"X,7D%O+61B,-@!<DYP/6D\1#7=*N+2'3+;5]
M$L+N>%)5NM028I)YJX>/]XS<Y(8=#QF@#V:BO/9?#D4'CR#1(=2U-=-N]/>Y
MNH#?2DS.CA0=Y;<,[N=I&<5CV_VZ;4K+04U:_CMH?$5W9JXN&\PP+"'V%NI^
M\0#U';D"@#T_4[_^S;"2[^R7-WL*CR;6/?(V6 X&1G&<GV!I'U6TCUB'26D/
MVN:%IU3:?N*0"<].K"O,O$XG\-2>(-*TR^O4M/L=G=1H]R[F%S<A&VLQ+ $#
MGFNBU#2K6?XO:=,YGW_V;)-\MPZC<DB < XQZCH>X- ';T5YMI6FOXB\&7/B
MJ^U6_AU243S12Q7;HEIL9@J! =N!MYR#G)J+P*EQXOU>\U?5;Z]!MC9S0V\5
MPT<:R- C,=H/()'3I@GUH ].HKE?B$]RNBV*6EW-:23:G;1>;"VUE#. ?YUC
M'PY#'\0!H$>H:FNEW&F&\GMS?2GS)%D" [RVX9W9(!&<"@#T.BO*+6\0Q?V%
M=WNLWR6FKWD$-A9NQFN8DQMWR[E(5=W=N>/2J=I>ZCH?BVXNP-0LM,TNXMO.
ML+N\\_RH;@,C,3N;HP1@,G'- 'L=%<SX8GGU;6M;UEII#:&?[%9QECLV19#N
M!T^9RW/^R*S]8LFUGXEP:7/>7<=A_8[3RP07#Q"5A-M&2I![]B.@H [:BO*8
MM)DG\)>*;N;5]4>70KF\BTYA>2+Y"Q#<N<'YCDXRV>  ,59,\/B*\E:2#7-=
MN!! #'93_9;>S<Q@D;O,4%B3DG!QP* .]MM9M[K7+W2$243V4<4DC,!L(DW8
MP<Y_A.>*T*\%T#Q)KB6]Y=>;<%)K:VBU#5 1)):PK+*F\#^)L8^;G&":[;Q)
M)-'K&A^&["'4;[3#:27,D=I>!);K! &Z5G4D<Y.&R<B@#T2BN.\%#5;75=3L
M9[.\M=-"QR6L-]=)/+"QR&7(=CM/!&3ZU@:[!?6^IZO>ZM;ZQ=6_G,UIJ>DW
MQ/V% !\IA##&W!))!SF@#U"BO/\ PUJLE[\/O$M^FH2W*BXOV@N68@[ "5(_
MN\8('&*I^$K5O&,DD>LWEZ\.G6%C'!#'=21?,\"NTK%2"S$G@F@#O(M:MI?$
M%QHBI*+BWMTN&8@;"K$@ '.<_*>U:%>8:3H$.J>.KFQO-=N=4@M=+B1YH+@Q
MF<B60 .T;9)7H>>2,FNF\ S7!TW4[*:YFN%T[5;BTA>9R[^6I&T%CR<9Q0!+
M?^,HK?4[C3M/TC4M6FM,"Y-G&I2(D9VEF8 MCG S5[P]JVF:Y9S7^G0F%VF*
M74<D7ERI*H *R#^\  /IBN>32KV;5M4U3P7XAAB+W3)?65W;EX3<* &YX93T
MSC.:YB;7M4U7Q:?#5WH<D<UMYD^I6^C7*P_;7PFQBY93MPP)&<],]. #U*\U
M2TL+FSMKB0K+?2F*!0I.Y@I8_3@&JE[XFTZRAUB1C)*=&B$EVD:<C*;P!G )
MVX/7O7F#Z3=S>.=)L=0M=3M=.:[ MHKG4M\L.8I"R@I(2!D @DYZC.*TM1TJ
MUMYOB3/&9]\=LH7=<2,/GMPS9!.#STST' P.* /3[:X2[M8;F,$),BNH;J 1
MGFI:\Z\17U\[^%=$@@O9[6ZM&FN(;*=89)PB+A=Y9<#YLD Y-84D&MKXXTG1
M0=6TG1[N4D03:@LDJ'RWWJK*[,$( ZG@YQ@T >Q45YWIOAJ&[\6Z]H,NH:G_
M &591P2P6POI1L>13D[]VXXV9 )(R3Q7/Z1K&K:__8VF7D&IZI;0Z:\\L5I=
MB&2=A.\2M(Y=2P 0=#U.30![)5/4M4M-)ABEO)"BS3QP)A2<N[!5''N:\MT^
MWUJ[\>6F@7\VJ6.DE)WCMY+\-.8]L9,;.CDX#="3G:<9IFMZ9''J=]HC7-[+
M96.LZ=]F22[D)B6;&]0V[)''&>1VYYH ]AHJM)Y.GZ8W[[R8;:$_O9"7V*J]
M23R< 9YZUY+J-Q):^'H->TR'Q"]PDT+G6;RZ\N.<-(H_U)D.48'  4<8[4 >
MQU4N[[[+=6D'V2YF^U2%/,ACW)#@$Y<Y^4<8SZD5YC";G16AO?$0UF&X6Z#M
MKUG>&XM9E+\!X]V$0@A<;>*[+Q1<3P^)O"L<4TB)+>R+(JL0''DL<$=^: -N
MWU2TNM3O-.AD+7%DL9G7:0%W@E>>_ I-7U6#1M-DOK@.ZIA4C09>1V("HH[D
MD@#ZURWAW2K6+XE^*+E3/YD?V9ES<2%<R(Q;*DX//0'[O;%6_%#&?QAX2L'Y
M@DNI[AAZO'"2GZDG\* -^"_,VHRV365U&8HDD,SI^Z;=GY5;/)&.?J*N5S&G
MW$[?$K6+=II#"EA;,L98[5)9\D#H#Q7"V]E<Q_"&'Q:=6U)]8MXA-%.;R3:H
M$FT)LSM((ZY&3D\T >LW]W]AL)[O[//<^2A?R;=-\CX[*.YJ&76+2"]T^RF+
MQW.HAS!$R'/RKN;/88&/SJAXWFEM_!&M302/%*EG(RNC%64[3R".E<YK6FV]
M_P",_!4EPTY>6VG#%+B1,[(U8=",<DY]1P<@4 >@45Y5JT5Y8W>IW^M1:R\?
MVIY+;6M*O3(EK$#PIA# *% PV5/>NO\ %ZW^I>&(#HMQO::6)RB7'V=KJ+J8
MT?\ A+#^M '350UO5[?0=&NM5NDD>"U3>ZQ %B/;) _6O+Y=2-OJUIX=LY-=
MT&35;F&*XL[N9GV1_-N>"4LQRQ 7(/X5)\1K0>%K4V&FW-T;+5K&Y6>UGN'F
M5&C56$BER2">AYP<B@#UE6#H&'0C-17=E:W\!@O+:&YA)R8YHPZG\#7#>*[R
M]N_%6F:$EI?W=D+!KN:WL;A8'G;<% 9BRG:.N >I%:'@C^U;>_U6QNK6\MM/
MC,;V<5[=)/+%D'>A(=CMR 1D]S0!OZ,]M]GG@M-+DTZ&VN'A$;0")7Q_&@'!
M4]CWK1KS6ZO[P> ?'$XNYQ+!JETL3B0[HU!7 4]@/:M?QGJ-Q8+X:E@ED#&^
M!9%<CS0(7.#CJ,@4 =%KVM6WA[1+G5KM)7@M5#.L0!8@D#@$@=_6M&O(-;T8
M7OP@F\27.J7LFI75LMQ/*URYC?<P_=^7G:%&<# X(%=%INF_\)5<Z_J6H:E>
MP3V>HS6EH8+IXEM%CP P4$ D_>.X'/% '>T5Y%X*MI_$U[8VNJ:E?R6O]AQS
M21)=R)YLGGR %BI!Z>_/&>E*;"Y_X5[JVM2ZQJ<E_I-Q/'8RF[<>4D4F "H.
M&SCDL">W:@#URBO+([F_\3:SK$]WI6M7T=K<_9K9;"_6W2WVJ#N \Q26).<D
M$=*C\$Z=J7BC5-8M_%-]?,;-+=1!%>E 6*L Y,38+;5!QG&2<C- 'I<^JVEO
MJEKIDDA%U=H[Q(%/*IC<<]!U'YTS3]6AU"YO;54>*XL9O*EC?&<$95AZJP.0
M?J.HKS+PY:?VGXD\,2ZA<W=S/&E_&96N9 SB&4!,X([=?[W?-=C(QMOBO (_
MNWFCOYRCN8Y1M8_]]L/QH ZNL^+6K:7Q!<:(J2BXM[=+AF(&PJQ( !SG/RGM
M6%XL::_\2^'_  ^US-;V5\9Y;GR9#&THC4$)N'(!+9..PKC/$ N?"?B'68-(
MN[IFN+2SAB9IM\ENLDS JKN?K@L>-PYXH ]@HKQSQ+<:[X8M([O1=/UG25F_
MT>Y:^U".<2;\ .H,K$2 GJ,#GFD\4QZUHFBR76DZ=KFF9B=+N2^U-)5F4H?G
M \UB) 0"-H'>@#V2BO-;[1)+/4/#'D:QJBS:NYBU"7[8Y,Z^7O. 3A.1@;0,
M \57O;#5+74M<T#1+NYDM8)[*=;.2_9))8W63S(DE8Y7=M4]>Q]: /4J*XGP
M3=6D6LWVG)'K&G3^0DITS47,BH 2#)$Y9LJ20#SUJIK/V75_$VI0"WUS7)(-
MD:PV4YMK>R;;DC?YBAF.<D\XZ4 >@T5X[\,+2?QE'JTFO:MJ-RMM(D442WLB
M;"%QO)4C)PHYZ9R>]6O#[WGB;Q!IVFZEJMY);6]K=QR&.X:,WBQ3A%+%2#G&
M,D<G:?4T >L45Y/JTM_9WMYX9L]5O8[:#6M/CMY_/9I84G#;H]YY(&,C.>HK
M;GT=/^$KT_PBM[?II4=E+?2+]KDWW#^8%"%\[MHR3@&@#O:*\CU1;RT\=6OA
M"UUF_CTYKN&16^TL9(5>.7?%O)S@[1C)R,\5>\2^;X7N=8TK2[R[6TN-!FNQ
M$]P\C6\J,%#JS$L <],]10!W5['866IVVH?V0UQ>W,BVOVF"W5GB4@G+MU"#
M&"?<5J5Y[<:8^AVWAF:+4;^:XU'5K8W;RW+L)"8I">,X )/0<<#TIVM_9=6\
M4:A;"WUS6Y+=8XQ;V4YMH+-BN>7\Q0S'.>^.E ':+JMHVLOI"R$W:0"X9-IP
M$+%0<].2#^57*\9^'Q>?7)M7NY+NZO+727E!DNG8NR3RH W.&^50,=,\]>:E
MM#KM[X8BUVWT_6WUF91<)J1U&-;<DG.WRS*%$>.,%<T >PT5RGC34+Z/0M,@
MMYGL9=5O[>TFFB;YH%D/S%6]>, ^]<SXXMV\%PQC1;Z^CCU&TNXIH)+J27E8
M6=95+$E6!')'K0!ZC17/^#]&33M*BO&O+NZNKZ"*2XDN)V<%]N254\+UZ#L!
MZ5R^K7%YK7CG6+&?3-5U&RTQ(4A@L+U;=59TWEW_ 'B%CS@=0,&@#TBBO&[G
M6O$?A6T74GN9C=R2W%D+.\F$[&!5W).PC+ -'G#>H'/K6_<:1NUOPGHRZY>S
MVEQ:7,MS,ETP:]XC;.X'."3V/"Y H ]%J.&WAMD*00I$I8L510H+$Y)X[DDD
MUY;K^J:CX7GUG0-(NKM[=S9^0QF+R6GG.5=5=SQD+QD\$U4\02:WX?CMI-(M
M-8T2*Z<6MW+?7Z3JP<@"11YC$.">H ZT >GZGKEMI=]I]G-%-)+J$CQQ>6H(
M!5"YSDCL.V>:LZ=>?VAI\%Y]FN+7SEW>3<ILD3V9>QK@==\.VN@^)_#4EE=W
MA5Y;@/%/=/+N80/^\&XG!]<8!R*J2ZQJG_"NO"-M!)>32ZK(D5P\$P6>1 K,
M55V(PS8QG/K0!ZE4<\T=O!)/*VV.)2[MZ #)->.ZZFN:=JNEVFFP:OH>GWUY
M#%*ESJ"3,KF0 /'^\=N03D=.E;NMZ/#H^NOI=K=7YLM2TBZDGAEO)7S)'M(<
M$MD$YP<'!% 'H&GW\&J:=;W]JQ:"YB66,D8)5AD<?2K-<W\/;.&S\":1Y/F?
MOK2*5]\K/\Q1<XW$X'L.!Z5TE !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !5"_T>UU&_L+V??YNGR-+#M; W%2ISZ\&K]9UW>3PZYIUHEQ9I%<),9(I2
M?.D*A<>7CC R=V?44 /M-(M;+5;_ %.+?Y^H>7YV6R/D7:N!VXK);P+I(M;:
M*WEO+6:UEEDANH)MDJ>8Q9QG&"I)Z$&K5[XQ\-Z=*8KS6K.&19#&R/*,JPZ@
MCMC/>M5[F!+1KMID%NJ>89=WR[<9W9],<T <['\/]"2TO+=ENI?MDJ3R2R7#
M&42H.)%?J&SDY]_3BFGX>Z1-,MS?7.H7]TC1E+BZN-[H$8,%7C &0,\9/K68
MOQ(CO?#*:K8M:"4:E';3QLY<11-,4#$Y&"5&X'I73Z7XGT+6II8=,U6UNI(1
MN=8Y 2!Z^X]^E $[Z1:OKD6LG?\ :HK=K=?F^78S!CQZY450B\(:7#J2WZ>=
MYRWTE\,OQYLB!&XQTP.E36'BOP_JE^;&QUBTN+D9Q''*"6QUQZ_A5Z_U&RTN
MS>\O[J*UMX_O22N%4?B: ,O5_"&EZW<W5Q>>=ONH([>38^!LCD\Q<<==U6-1
M\.VFI:O8ZJ\US!=V)(1[>4IO4D$HX_B4D#BJC^*++4(;.;1-7TV1)+Z.WF,S
MG)!SE% Y$AQQGCK5R]\3:'IMV+2]U2V@N"ZIY3R -N8948]Z ,RY\ Z3<2W(
M%QJ$%I=R&2YL8+HI!*Q^]E>HSW (S6MIFA6.D7=Y<V<9C-X8S(F?E78@10H[
M# %0W7BSP_9:D--N=8M(KLD+Y32@$$] ?0GT-78=1LKB*XEAN8W2UD:.=E;(
MC9?O ^A% $>JZ1:ZQ#!%=;]L%Q'<)L;'SHVY?PS2'2+4Z^NMG?\ :UM3:CYO
MEV%@QX]<@54N?&/ANSA$UQK5G&A1'!,HY5P2I ZD$ G\*5O%_AQ;JVM3K=EY
MUT%,*B8'>&^[^?;UH I2^ ]*>Y:[@GO;2[-U+<BYMY]KAI<;UZ$%3M'!!K*U
MWPQ!I.G:E'I.EZAJE[KMN;69Y)MZ[L';)*S'(QN/(] ,#BNBO?%WAW3K\V%Y
MK-G!<@@-&\H!4GH#V!^M4O#7CC3/$%OJ<_VJUB2PN)%)\X$>2IPLI)Q@-@F@
M#6T'28M"T*RTN$[EM850M_>;^)OQ.3^-*=(M3KXUOY_M8M3:CYOEV%@W3UR*
MHVWC;PQ=B8P:Y9OY">9)^\QA?[W/4>XJ>S\4:#J&I/IMGJUI/>)G,*2 L<=<
M>N.^* $3PUI\>F:KIZ^;Y.K2327/S\YE&'P>W'2J"^ ],BFD:VO-2M8IU5;B
M"WNBD<VU0N6QR"0 "01FKX\6>'VU7^RAK%H;W?Y?DB49W?W?3=[=:23Q9X>A
MU3^RY-9LTO-VSR3*,AO[I[ ^W6@"MH7@C1/#T=W%912-#>1^5)%,V]=F7.T#
M'3]XU-;P/I1TNQL4FO8SII;['<QSD30 ]5#_ -W'&#G@#TJV?%OAY=4_LPZS
M9B\W^7Y7FC._^[GIN]NM;% &5HGAVRT)KF6![BXNKM@UQ=7,IDEEP,*"?0#H
M!@50O/ VFW=U=RI>:C:17[%[NVMKHI%.Q&&)'8D=<$9JY?\ BWP]I<SPWVL6
ML$L;['1Y!N4X!Y';@@Y]Q4E_XET/3(4FO=5M8(Y(O-1FD&'3(&X>HRPZ>M &
M0WPZT,>?%!)?6UE<\S6$%RR6[G &2OX#C.#CD5/)X&TW_1VL[O4-/EAM4M3+
M9W!C:6-!A0_&"0.^,^]7+_Q9X?TM8&OM8M8/M""2+=(,LAZ-CT]^E7;;5=/O
M+CR+:]@FE,2SA8W#9C;@,,=0<=: *.C^%-)T&Z^T:="T1^S+;[=^1M5BV>>2
M26))[YJWI>D6ND?:_LN__3+I[J7>V?G?&<>W%5-0UI!/;PV&H:>KKJ$=M<K.
MQSRI)C7'_+0\$ \=:EU3Q+HFBW$=OJ>J6UI+*,HDL@!QTS[#W/% %#4/!&G7
MNIRZE;7FHZ7=7&//?3[HQ";'0L.03[XJ,?#_ $-+6&.#[7;W,,K3+?Q7#"Y+
ML,,QD.2<@#(/'M3=#\9VLWA=-9UR\M+-7N9H58-M5MLC*N 223@9XK2/BK0%
MTD:L=8M/L);8)O-&"W]WZ^W6@#,?X>:-)$2UQJ'VTSK<'4/M1^TEPI4?/Z $
MC &.:M7O@S3;Z_U&[>:\0ZG;^1=QQS8CE&W:&*_W@O -,T'Q3'KWB/4[2SGM
MKBPMK>"2&:$Y+%]^X$YQQM'&!CFN@F<QPR.,9521GZ4 96I^&-.U2RL[>4SQ
M/88-K<P2E)82!C(8>HX(Z&J5GX$TBTU6#5FDO+K489#)]JN9][O\I4 \8V@$
MX Q5;PQX_P!)U72],&HZI80ZK>1JS6Z/MPQZ#!)P3Q@$YK7U+Q7H&CW:VFHZ
MO:6L[ 'RY) " >A/H/K0!8MM(M;76+W58M_VB^2-)LM\N(P0N!V^\:R!X"TB
M.RL8+66\M); .(+JWGV3*KL692<8()/0BMN+5=/G-SY5Y"_V0 S[7!\L%=P)
M] 5Y^E,76=,>RMKU;Z%K:[=8X)0XVR,QPH4]R30!F:7X)TC2=3BU.#[3)>Q^
M9ON)IB[S%\!BY/7A1CH!3M1\&:5JDFH2SFX674'@DDDBEVM&\7W&0CH15BX\
M6>'K34_[,N-9LXKO<%,32@$,>@/8'V-6XM6T^?3&U.*\A>R569IPPV +G<2?
M;!S]* 'K8Q'3183L]S%Y/DN9FW-(N,'<>Y(ZFN;?X<:1-IRZ=<7NJ7%G$!]G
M@ENR4@QTVC';H-V<"M?4/%.A:5#!-?ZK;6Z7*!X=[\NN,[@.N/>F7/C#PY9Q
MI)/K=DB2*C(WG A@V=I&.H.T_D: ,]/A]I"!8/M&H'3UE\T::;D_9@=VX#;U
MQNYVYQ[5MWVD6NHWUA>3[_-T^5I8=K8&XJ5.?7@FKU<Y?>,K"Q\9V?AR6:!'
MN(BS,TF&#DJ$3'JVXG\* +R^';2/Q(^O137,5S-&(YHTE(BFV@A2R]R >*J^
M+--N+FWLM2L(C+>Z3<K<QQKUE7!61![E"<>X%9^C?$#2I;=EUO5+"SNS=S0I
M%OV_*DC*I.2<9 ZG K8U7Q5H.B3K!J6K6UM*R[A&[_-CU('0>] $]OI-I'K%
MQK,8D%S=PQQ/N/&U<D<=C\QJF/".ECPC_P (O^^_L_R_+^_\^-V[KCUJII_C
MK2=3\72:%:WEK*OV=9(98Y@WG.=Q*C'HJY_&IO%OBVT\*IIQN7A!O;Q(3YLF
MW9'D;Y/<*"/S% &MJFG6^KZ7<Z;=;O(NHVBDV'!VD8.#5'4_#%CJG]G,\UU;
MS::<V\UO,4=01@@GN"  :RU\=Z?:^(=6M=4O[.UL;:.U>UE+8:7S49F[\C@=
M!QGFMNX\1:+::7'JD^J6J64V/*G,HVR9[+ZGV% &7<^ M+N9;H"ZU&"TO9#)
M<V4-T4@E9OO97J-W?!&:U-5T'3]8TQ-/N(V2*)D>%H6*/"R_=9".A%3Z;JNG
MZS:"[TV\ANX"<;XG# 'T/H?:LS2]<N;SQ=K^DS+$MOIB6S1,H(8^8C,VXYP>
MG& * *S?#_1KA9FU"6^U"YE146ZNK@M+$%.Y=C#&S#<\?C2/X TFXANEO[F_
MOYKJ#[.;BZN-\D<><E4XPN2/3-74\9^&9;N"T37+)I[@+Y2"8?-GI^)[#O2Z
MKXKT32;A[*YU6TAO=FY(9) #G'&?3/OUH ?K'AJQUHVTLKW%M=6>?L]U:RF.
M6,$8(![@]P012:9H=EX:M;VXMENKNXG_ 'MQ-*_FSW!4<#)QVX X%4-+\:6"
M^$]*U?7KZTLIK^ /MSM#'OM4DG _&KTWB_PY;VR7,NMV2Q/&)4?S@0RDD9'K
MR"/P- &5X5T1[O0-:BUG3Y(8=8U"YG^S3$!Q%)@ -@\' ['BK%KX#TRWN;*X
MEO-2O)-/D#VINKHN(@ 1M QC'//?@<\5:D\:^&(DMG?7K%5NQF$^</F&<9]A
MD$<]P:EU'Q7X?TB22+4-7M;>2-@KH\@W D!AQUZ$'\: ,FZ^&VAW=K-9//J"
M:?*Q<6*71$$;$YRJ]N<G'0'M61KFF.=9U0R>&]8DDNCA#IEULMKY=H"^<-PV
MD=#QR/6NN35UN-7LTM;^PDLKBT>8*')EDP5PR$<%,$Y]R*H>&/&VF^(QJ;1W
M-LBV%S(@Q*#F%>DI/8'DT -\'>$(O#MA8RSDG4([!+28JV4P&+X'_ F/-73X
M5TTZ!>Z(?.^R7SR/+\_S9D;<V#CCDT_3O%>@:O)+'I^KVEP\*EW5)1D*.K?3
MWZ4NF>*=!UF[:UTW5K6ZG4$F..0$D>H]1[B@"G>>"M/N;R2[M[S4-.EG14N#
M97)C$X48&X8/..,C!JSH/A72?#4EP^E0- MRL:NF[*@("!CWY))[DU;U36M,
MT2W6?4[Z&TC=MJF5L;CZ =2?I6!?^.M/@U31&MM1L7TF^%S]HNB_"&- 0 <X
M!R<$$9Z4 6AX'TI#8M!->6\EA/+-#+%.5;]XVYU/JI/:GZ9I]Q<>+=2UV[B:
M)5B6QLU88)C4[G?'^TYX]E![U<L_$VAW^FS:C:ZK:R6D'$TWF@+'_O9Z?C6%
MK7Q!TM=%GN=!U*RO+J&6%3$23\KRJA.W()X;KTSB@#>UO0;+7H(DNC-%+;R>
M9!<02%)86Z95A[<8Z&LR+P#HB_;C<_:;Y]1A6*Z>ZG+M(%.0<]B.,8QC Q5H
MZS<CQVNA;(OLQTPW>[!W[Q*$QG.,8/I6K>7MMI]LUS>3I!"I :1S@ D@#GW)
M _&@#GA\/M&F;.IS7VKA8FBB6_N3((E88.WI@X_BZ^]1S?#G2+N+RM0O-3U!
M%B:*%;JZ+B ,,$IQUQQDY-:^G>*-!U>]DLM.U:UNKB,$M'%("<#J1ZCW%,B\
M6^'9]4_LR+6;-[S=L$0E&2W]T=B?;K0!-<:%9W,^F32>9NTMR]OAN^PISZ\&
MJ>I>#=)U6[N[NX$ZW%R86\V.4HT3Q;MC(1]TC<?SJ+PKXQL/%,VHQVTT!:TN
M7C18Y-Q>(8"R?0G-,U7Q;#HOB^+3M0N+:UT]M.:Y,LI(;S!(JA0<\\$\8S0!
M>TCPS::1>RWWVF[O;V:,1-<WDWF.$!R%'  &>>!UJM<^#+"?4KJ]CO-0M/MI
M!NH+:Y,<<Y QD@<@D<$J16C%K^CS:2=7CU.U:P49:Y\T;%^I['VI-)\0:1KJ
M2-I6HP7?E$!Q&^2N>F1U% '%Z#\-K?3M=UY+>74],LWDB%M):W10RH8P74]<
M@,2!QD=C5RZ\$0MXJTJ*RBN;'3K#398X;BTF*-%(9%(Y[D@MG.<Y.:Z75/$N
MB:))Y>IZI;6C[5;;*X!PQ(!Q]5;\C3+_ ,6>']+O5LK[6+2WN& /ER2@$9Z9
M],^] %:'P5I$-I#!_I$C1WR7[SR2EI9ID.0SL>OTXJUK7ARRUQ[>::2XM[JU
M),%U:RF.6//! /H>X.12WWBC0=,O8[*]U:TM[B4 K&\H!P>A/H#[U/9ZSIFH
M2I%9WT,[R0^>JH^28]Q7=],@B@#D-:\ VYGTF.UCO+@R:D)[^]><F<XC<*Y?
M@C:2,8Z>E;<?@G2Q:ZA%<37EY-J,/D3W5S-OE,?]T'&%'/85:NM91KZT@L;^
MPQ]M-M<I*QWDA"Q1,?Q]#SVS4D_B;0[;44TZ?5+:.[DE$*P&0;RY (7'K\R_
MF* 'WFAV=]'IT<WF8TV=+B#:V/G52HSZC#&J%UX-L+C4[F_CO-0LVO<?:HK6
MY,:3D#&2!R#CC*D59D\6>'HM4_LN36;-;S?L\DRC(;^[Z9]NM9WB7QQI.D6.
MI16VJ63:K:6\CI;.^<NJDA2 1SQTSF@!VE^ =&T6_MKS3I+RW:W5D$:3G8Z,
MS/L8=U#,2*8?AYHQ!M_.OQIQD\PZ8+D_9B<YQLZXSSMSCVKHK&=KFPMYW #2
MQ*[ =,D U%J>KZ=HMK]IU.]AM(2VT-*X&X^@]3["@!-5TBQUK39-.OX?,MY,
M< E2I!R"".001P16,/ 6ER"<WUUJ&HRS6SVRS7EQYC0QN,,$XP"1WQGWJVOC
M+PT^G-J"ZW9FV5_++^:.'[+CKGVQ5_3-6T[6K7[5IEY#=P[MI>)LX/H?0^QH
M GMK=+2UAMHL^7"BHN3DX P*R-4\*66IZC_:4=U>Z?>F/RGGL9_+:1!T#<$'
M'8XS3KCQCX;M+G[-<:W9QR^88RK2@%6#;2#Z<@CGTJQJWB+1M#6,ZIJ5O:^;
MS&)'^9QW('4B@"AHO@C1-"NY;JUADDEDB\HF=_,PI.6Z]V/))Z_3BL*^\!QK
MK^@6MF;Z/3;*.[99XY]KVK-L**K=<<-@'/&1TKHY/&?AF*T2Z?7+(0NF]7\T
M$,N[;Q^/%5-!\;:;K_B+4]*M;BW?[(4\AHY=QG!4%V ] 3M_"@">'P7HR:9?
M6%Q'+>C42&NYKF4O+,1]TENVWC&,8[56_P"%?:-.V=3FOM7 B:*(7]R9!"K#
M!V],''\77WK>U'4['2+-KS4;N*U@4X,DKA1GL/K[5S?B'X@Z1I_A&[UG2]0L
M[R2/]W"GF<-*>BD=>F3CC@4 6(/ >FQWUK>SWNI7L]GN%N]U=&3RU92I4#'3
M!^O YXJT_A'29/#=MH#QRFUM-I@<2$21,OW65AR&'K4_AN[N+[1(;JXU"TU!
MI22+BS0K&PSC R3T((S3-2\7>'M'N_LFHZQ:V\^ 3&\G*YZ9]/QH SA\/M(>
M\AOKRYU"_O()8Y(KBZN-[IL;<%'& N>3QSZUL7FAV5_JD&HW"NTT$$D"C=A2
MDF-P(_ 56O/&7AJP&;K6[*/D#_6@GE0PZ=L,#GT(J]::MIU_,8;2]@GD$:RE
M8W#?(WW6X['UH @T#0K?P[IHT^TN+J:!&S&+F7S#&N  JGLHQP*TZ@MKVUO&
MG6VG24V\ABE"'.QP 2I]^1^=3T %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %<KKG_)1O"O\ UPOO_08JZJF-#$\J2M&C21Y".5!*YZX/;- '#^&[.VDM
MO'$DD$;M+JES%(64'<@C4@'V^8_G6UX );P#H9))_P!"C'/TK=2"&,2!(D42
ML6<!0-Y/4GU-+'%'#&L42+&BC"JHP /84 >2B2SO/AQ;Z<TD4LD7B!8[FWW
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M9JR\,4A0R1(YC;<A90=I]1Z&@#S?1]4\,6_PQL-/O(X[BZ0I&^GIC[2;O?\
MW,AMV_G/I6#IYQ\.+C3]1\2Z9:+^\CN[&73_ #+L3%CG_EJ"SYP0<>GI7L(T
MZQ%Y]M%G;BZ(QY_E+O\ ^^L9H?3;"2\6\>RMVN5Z3&)2X_X%C- 'D4-TNA>$
MV6TUC3]:T^&?][H^IV_E7?G>9\P7!+;BV2 P/'K7KEAJ-IJ=N9[.=)D5S&Q4
MYVL."I]P:#IE@UX+TV-L;H=)S$N__OK&:;IFF0:5!)% 6/FS/,[-C)9VR>@
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M7\.%X;O0+J#4+72K$QWJ64][;^9&DIN&.W!9=K%,8)/8BKVG26-M\4X]6O\
M5[:^M2SQR7<-MY-I'=[!CYMS*7*Y!.>M>M26%G+;&VDM('@8DF)HP5))R3CI
MUI/[.L?L7V+[%;_9<8\CREV?]\XQ0!Q.AZSH5MXX\7:I%=V\=DD-IY]RK#RR
M_P X)R.#S@9]<UW5R<VDI'_/,_RJE?Z!IU_I4^FFW2""XC$4@AC524!^[TZ=
M1[9XP>:T< C&./2@#REK2W@_9ZA:.%%;RHIMP49WF9?F^OO6QX=U'1=*E\50
M:_<VMO=OJ4\EPMTP#2P''ED _>7;P ,_K7<_9+8VWV4V\7D 8\K8-F/ITIES
MIUC>2I+=65O/)']QY8E8K]"1Q0!XS8PW^CZ%96GES1-XKL?L,88'<K"?:A/I
M^XE_\=KH?#MJQ\7P^$O+9;3PY>7%Z%(XV. ;<9]1YK_]\UZ5)!#*R-)$CM&=
MR%E!*GU'I0L$*3/,L2++( '<* S =,GO0!XWIC/%X#U"PU7Q+I=D=\ZZA9SZ
M?YER92QR?]8"['@J0/3TJW!9W5BB_#TO-)'K$MO=+,Z%&^SLNZYR,G:=T9&,
M_P#+2O5)--L)KM;N6RMWN$^[,T2EU^C8S4IAB:99C$AE4%5<J-P!Z@&@#SFX
M-U8_$O6C_;6G:.9;:W^R-?6H</"J881L74 !\Y'T/:L[X::=82>.=7G2:+4(
MC;;H91:>3& TS[O+4EODR#@@UZG=V%G?HJ7MI!<JIRJS1AP#^-/CMH(GWQP1
MHVT)N5 #M'0?0>E $=MJ%I=SW$%O<)++:N$F13DQL1G!_"N9U:ZM[/XH:*US
M/'"LVGW$49D8*'<O'A1GJ3Z5T=GID%E>7MW&6,M[())"<<84* , <<=^>3S4
MTUK;W+1M/;Q2F)MT9= VQO49Z&@#SS2[*V/PL\5.8(RTTFHO(2HRS*7VG\,#
M'TJIHNM,S7ODWVCZ$(;>V2[GO8S+<7.(5PP4NHVX.!US7IXMH%A>%8(Q$^=R
M!!M;/7([YJ)],T^2>.X>QMFFA $<AA4L@'0 XR* /+/A%>6T.IQP33I'+/IH
M6&.0A&D*W,^0J^P[#I77_$.6.WLM#N)I%CAAURT>61SA44,<DGL/>NE&GV2R
MI*MG )(R2CB)<J3U(..,U+/!#<PM#<1)-$WWDD4,I^H- '(Z!':W/Q+\3WBK
M'*1:V0BE&&^1D<G!]#A?RKA=+%Q::UI4HU"TTRSBN-0AM)[NW\R&*7SS\N-R
MA25Z'/8BO9XK:"!BT,$<9954E$ R!P!QV':F/86<ENUM):0/ Y+-$T8*L2<D
MD=.M '(^"45_$NOW::S!J32>2EPUI:>5!Y@!Y#;V#-@X./;-2:)_R4/QK_UQ
ML?\ T4]=;;VT%I"L-M!'!$OW4C0*H_ 4JP0I+)*L2+)+@.X4 OCID]\4 >5?
M9+>']G>-HX45O)2;<%YW^</FSZ^]:>EWVC:=8>+[/7Y;>.[DO[AYXIR \\3#
M]UM!Y8%<  =Z] ^QVWV7[+]FB^SXQY6P;,?3I39K"RN+B.XGM()9HON2/&&9
M/H3R* /'O"C7EKJ.F3-K-CI1ET.!;.:^MO,5U!/F*A+J%.<$CJ015WP#9V;_
M !2OKF*\BU%39S2I-%:^3$LAE56,0W-D=?F!QRU>I3:;87%LMK/8V\L"?=B>
M)61?H","I([2VA96BMXHV1/+4J@!"]=H]O:@#S>UL;1/ ?Q *V\8)OM0SA1_
M",K^1Z>E:'@2VAE\4^(+F2-7E-KIZ;V&3M-LI(_'O]!7<BUMQ')&((]DQ)D7
M8,.3U)'?-+';P0LS10QQL^ Q50"V!@9^@H \N\  )K>@QJ,)'9ZDJ@= !=#
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M2:':PQZ=!=N)GAO]1W&.#  8* 1ER#W(Z5TL&E6T&JSZD@/G30I"1@!51,D
M8'^UWST%37=E:7\0BO+6&YC!SLFC#C/K@T >+K+:W'Q%O;B7Q3!!J"M#]EU.
M.T46K2>7(&5@6(Z?*#NSD&N^\#:E+>:GKEO<1:;+/!+$9=0TT'RKIBIZYS\Z
M@#.#WKIY-,T^6,QR6-LZ% A5HE(*CH,8Z#TJ6WM;>SA$-K!'!$O1(D"J/P%
M'G&CZKX:LM'\90:A/:I,^J7IN896 >4%F"@ \MZ#'?-5M%O[^SNM/L))=+TC
M4;;18//O]4#-(R')"(NY1A<<DGK7<:-X7MM.-U)=1V]W-+J$]Y%(T(W1>8^[
M )[CU%:EUIUC?,C7=G;W#1G*&6)7*_3(XH \?^'$5KJ'Q(OGE:*]6/[9)'+Y
M(16)>(;U7^$$,<>QKN?#=Q;Q?$+Q99M-&D\DML\<)8!F40*"0.X%=2EG:Q7#
M7$=M"DSC#2*@#-]3U[#\J4VML;H71MXOM 7:)=@W@>F>N* .3\8/!:^+_"U]
MJ;*FF0RSJ\DG^KCF*#RBV>!T;!/0UR7CVXM=0O\ Q'=:3)'-;)H\4=[- 08V
MF^T(4!(X+!=WX<5ZW-#%<0M#/$DL;C#(ZAE/U!J*/3K&*T-I'96Z6QZPK$H0
M_P# <8H LUYC-K)F?Q,(+W1]#MTNY8;B*:$S75TP&W=M+@8;HH ->G56;3K%
MKP7K65N;H<"<Q+O'_ L9H \R^"MM;S6^KSO$DDC1VL19@#\GDCY?I[55TBZ'
MA3PQX>\6JC-!%%=6%VJ]2ADD:+\G7'_ J]:M[.UM PMK:* ,<L(T"Y^N*P]:
M\.76KW5G9B>UM]"A=)I[5(?GF=7+!<YP$)VD\9X/K0!-X-TJ;2?#-M%=\WMQ
MNN;MCU,TAW-GZ$X_"MRBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MA55CB&7D=CA54=R2:Y*<>*+GQ'HOB&\T1S!;SW,:VD+(9H(I$159_FP3E22
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M>Z->VAMFB!SD1,1EF';)(/M7I% !17G$VN>++C2?$>LV^JVUO#HE[=1Q6YM
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MIL$NS&&V]B01Q70T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MEM>F22*3:61)!M'!(P2N<$U,_C;Q!;II5W/X=@-KK)6.S2.[_>K(R[D\S*X
M..<$X'KTH [FDKAK[Q[J>B0:K%JVD0&]T[[.X2UG+)-'*^S(+*"".>".:=JO
MB?5;(RZ=XBT2T$%_87,D*V]VSY\N,LT4AVC!*]UH [>EKSW6;_4UTKP2VBV]
MO!;W,T&V![EU'^I)6-B%.4 [G)RHX[C4N/%NIW6J7UIHMEI\J::XBGDO+PQ>
M;+@$I& IZ9 R<#- '745PEA\0KOQ&S+X>L+1?L\:FZ;4KHQ!9#G,2[5.XC'W
MNE;FF^(9M>\+2ZCIUM''>)OB>WGEPL<J'#*64'/3(('/% &ZLB,S*KJ2OW@#
MTI20!DG%><^ %NM%^'L6J6NA175_?;-OV>4F2Y)8X>9BORX+,3UP*C\6>+[J
MPMY='\3:/IUXMQ&LL:6=ZY4E98QM?Y0RD;@P/?&/7 !Z5D9QWI:Y4_\ )6D_
M[ +?^CQ5/3?&NKZN6O-/TJSN;)+DPO;)>?Z8BA]A=DVX'KM)Z=Z .VHKC?']
MWK%M=>'4TT0[9=5C5A).\?F-M<A6VJ?DXR3Z@<'M;N?$6L7>N7>D:!IUI/)I
MZ(;N>[G:.,.PW"--JDDXYSP!0!T]%8V@>(HM:TB6]F@-G+:2R07<#MN\F1/O
M#(ZCOGT-<W=^.]>@\-2^*8O#]N^D%=T*&Z(N-F<+(R[<8/' .0#GF@#O,@]Z
M6N*@UY=/L/%>IZ=HZ&:PN]\Z"9LW&(T+/ST(7L./E]ZV+OQ+&NHZ+:6,:W']
MJAIO,+8$<"IN+_JH'UH W:0D#K7"_P#"?ZA+IDOB"VTRS?18BS;6O-MU)$IP
M9 FW Z$A2<D"K/Q%O$D\$17MLIG1KJTEC"=9!YJ$8SZT =CTZTM<#X@\4:E8
M6MWIWB;0K-H+W3[B:%+:[9@XC7+Q.=H(.#U%:.J>*7TF'0K"QMK2.;4X28FO
M;@Q00JJJ<%L$L?F  H ZVBLO1-0U"[LYGU;3UL9X9"A*2^9'*H (=&P#M.>X
M!XK!M/%VOZA8IKECX?CGT:23;&BSL;N2/=M\P)MQCOMSG% '945QB^,-<OK&
MZUK2-$M[C1[9Y IDN2D]RJ$AG1=I &0< G)Q3;7QKJNOZC=VGAO2[6>.WA@G
M%Q=W#1J5EC#JN I.[J/08Y- ':T5P5O\1+K5#IUK86-E:WMW!)+(-1NS'&C)
M(8S&I"DNVY2>W'-6%\::S=7HTB#1[6TU.&,R7?VZ[VPQ#<0NUE4EMV,C@8%
M':T5P-E\0]2U76O[!T_18#J2))YXENOW4+HP!.X*2R$,""!G)Q[UGZSXI\0W
M\NF6B6=M:7EGK\=K<QB[<)*VPN@R$YC8<G/(*C@]@#TZBL#QI<:A;>!]6N+,
MHES'92,6\UDV80[F5@,Y'4=.<<BLNV\1ZO;V&B:/;V%K<ZQ>6GG8-PPABA4
M>8[;=Q)R!@#KGGU .SHK!T#7[J_U"]TC5;)+/4K$([K%)YD<L;9VNA(!QD$$
M$<5SRW>LR^,/&%O.(#9Q6,8 ^T.3&I24H54KC)_B&1CL30!WW7I2UYQX=\2Z
MWHW@[P_=W6CVPT=H[:U,@N29U#802%=NW:3CC.<$5H/XYU*Y@O-4TS3K&;2[
M.1U_?7FRXN A(9HUVD 9!P"<G% ';T5Q7C[6+BX^&,^JZ+(%CN88Y/-,C1NL
M3D<K@'GD#''!//8VK_Q1JL&I6^AV]GIYU4V_VBZ::[9;>!=Q"@-MW,3CI@4
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M0 4444 %%%% !1110 4444 %<KXG0V?BOPUK3?ZB*:6SF;^[YR@(3[;U4?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M'=@3S12LX'F)P,_+GY3QG'TK5F^']OJ+R76LZM>W^H%56"[PD36NUMP,850
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M?5K6#R&OD2,F="<E70C:1GD<#!J[H/A^#0H[EEN)KN[O)?-NKJ<@O*V,#H
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ML;N>XBF4(2?..70@C&.U:VE6NH0:IJTUW/*]M-,IM4D<'8H0;L = 3G@\\4
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MK\V,'W- 'H9UG2A<26QU*T$\0)DB,Z[D ZDC.16+X.\37GBA+F^:.QBL [+
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MSWKC-.LM%O/#'BRYUV*W>^6\NOM<DP!DBQGR\$\@!=NW'X5I?\T*_P"Y?_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MXXU6VMKZ,1FS8<':51LJ>#CCI5FZ\?:3:!]]O>N5U)]-"QQ!F>95W< ')!X
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M4(FMYHYHFSAXV#*<'!Y'N*DH X_Q!87<VE^$XX;69VMM3M'F5(R3$JJP8MZ
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M<4Z;6*&./!_3MWSZ5UE%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M-"QV".+*LX'3YGW<^PK&32;1?B5XAN0)O,CTV.5?](DQN<2!LKNP1CH",#J
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MDEB23R>O2N5LVU?Q%IE[K+Z7K4U]+--]FO+?4XX8K0*Q556,R#@8YW+SS]:
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M0MC&!@X&#ZU:\.6&JZMXZN=$UVYU*+3[>R9X;5K_ #(R>;\JR/$Y)(+,.N2
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MC7<]ZLUU>7LZA)+J\F,DA0=%!Z 9YP!4]OHEG;:IJ6HQA_/U,1BXRW!"*57
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M%PNE0M"ER4+J7+#*KM&,^PY]33(?&7ARXU(:=%J]N]RTGEJH)VL_]T-C:3[
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MFC>.3YR7?>#N8L>2QR>:+OPYIE]H$6B7,3/:0QHD?SD.FP#:P8<AA@<UJT4
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MD[/N+##,<\DG'7-=+10!1UC2;77-+ETZ]#F"8J6V-@_*P8<_4"H=;\/6.O+
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MP Q1AT! ''(KHJ* ,G1?#EEH<MQ<0R7%S=W1'GW5U*9)9 .@SV ] !6M110
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M8X(8XD)R510HS^% 'F_C>^L?$]]I\'AR>'4+N*TO'EDM&$@CB:!EVL1TW,0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M,C&>&+9/XT >C)X@TF2QL;U+U#;ZA*L5K)@XE=LX X]CU]*TJ\LT_P#Y)_\
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MAV+7VI7*V]NI"EV!.2>@ ')/L*Q-=U#5+SQ59^&M+O?[/WVKWES=+&KN$#!
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MGGOK/56M]1_M.6_MKCR PB\Q%1XV4GYE(7U!Z>E=:SJI 9@"W !/6@LJD L
M6X )ZT <;)\/I=1N-1NM8UJ2ZN+^"*/?# (OL[QN61H^3@ XX.>_//#M0\&:
MWKEI);:SXI:6/[/)%&MM:^2K,R[=\@#G?C^[P,UO>'-:7Q#H5OJJ0&!9RX\L
MMN(VNR]?^ YK4H Q;SPZ+NZT.?[5L_LB0OCR\^;F,ICKQUSWK.U/P0-2U^75
M?[0,?F7-G/Y?DYQ]G+'&=W\6[KCC'>NI9E7&Y@,G R>II68*I9B !U)H YOQ
M1X/'B6X\TWQMO]!GM,>5O_UFWYNHZ;>G?-2:QX9N+_\ L>>QU,65YI+$Q2M
M)5<%-C KD=1[\5T (8 @@@]"*175\[6#8.#@]Z .8E\*ZI:7U_+H.O#3K?49
M3-/#):";9*1AGC.X8)QG!R,U)X;\%VOAC4&GL[AVA-G';"-U^;*LS%RV>2Q<
MGH*Z1F"J68@ =230K*RAE8%3T(/% %/5]/\ [5TJXL1=3VAF3:)[=RKQGJ""
M/?\ /I7(:W\/-2\3I -<\11S/9\VSP6 CP<KEG^<YR 1@8 SFNZ5E==RL&![
M@YIU &#XC\+Q>([BQ>:Y:&.U$X=%7)D$D31G!S\I ;.<&L2Y\ ZM?>'(=!NO
M$J"SM!&+<0V 0G81M\SYSNP!T&WGFNXZ5G:YK5OH>@7>L2J9HK6(R%8R,MZ
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M?NX[]:Z2\OK>QL;F\F?]U:QM++MY(502>/H*+*^AOM-M]03*0W$*3+YF 0K
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MNVMI+=XXQNM98-VUP2<-G=TP.,UT$-S<OJ5S;R631V\2(T=R7!$I.=P"]1C
MZ]<U8WJ&"EAN/(&>: .!\3>';YM/.I>)-;O;Z.SVF!-+M?*\A]P_?E-S;RN
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MG^'-1N(='M4LXK[P]J N(XLA9"B J2.Y&3SUK0NK>+5=2\&Z-J(WZ;-I[SM
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MI]S:V=M-;!X;&6.6W7<PV/']P]><>]9MUX%\-7E[)=SZ8K/-)YDJ"5UBE?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 51U?5['0M.?4-1F\FV1E5I""0"S!1GVR15ZN4^)4+7'@N>)8S
M)NN;;*@9R/.3/Z4 7=.\9Z/J6HBPC>Y@F>,RQ"ZMGA$T8ZLA8#(J*V\>:#=7
M,,22W"PW$GE07<EK(EO,_3:LA&TGTYY[5D?$+3KK4]6T:ULU/G2VNHQ(PZ*S
M6Y R>V3BN3GB@U7PC;^'AJ^OW&H21QP'1S;QIY#KC[Q\H812,YST'6@#O)?B
M/X;A1YY)[D6H8HEW]DD\B5@<%4?&&/7ZXXJUJ/C71M,O9[20W4[VH!NFM;62
M9;8$9^=E!"\<UP>N:[;1?"5?#TFG7<6I6L$%O/;O:N%A*,H,A?&W!(R"#R6%
M;NC:W9>#[G7K#6TGAN)]2GNX"L#O]KCDP5V$ @G^'';% &C%XVCNO'<&CVRR
M3V$VGB=)HK9V#NS##;P,;-IZ],D@G/%6]*\1V5KX,MM9U#63>PL"/MAMO*:9
MBY  C49SGC '.*X[P7;W'AOQ#H<>KP2VK7>D20Q*8V(61KHR+&2!P0K#KTI]
MC=WVE?"3P^T,(B/VI5GN)+7SC9)YCDRA".HX^F: -3Q+\3;33M)G%G;WL&IC
MRS'!>6$J$HSJI?! XP3CWP.^*Z&]\7:98I:B1+Q[B\0R0VD5I(\Y4=28P,J!
M[XKRCQEYE_>13VNH:IK<8M23=2VX6,E9HG98PJ*#A5)/7Z\5TVKW$/\ PF:^
M(7UG4=.TK4=.2.WO[6 %0RL28WWHQ7.<C@9YH ZG_A/=!>.(VLEU>32[O]%M
MK6229-IPV] ,K@D#G%:^DZO8ZYIZ7VGS>;"Q*Y*E65@<%2#R"#V->46UOI,&
MLSZP^I>)-+>\9O(UR5%"7.W:-I18Q\IP"-P&=M=_X#O=2OM#GEU'$F+N1;>Y
M^S>0;J+C$I3L2<_E0!?UCQ+I^BSPVLXN)[N=2\=M:6[S2LHZMM4' ]S4NBZ[
M8:_:/<V$CL(I#%*DD;1O$XZJRL 0>17+>*M5N+3QA#;3ZB=#LFLLK?Q6:RR3
MOO.8@[*P4 8.,9.:7X;!UN/$6\WK;]0$B/?)MED4QKAR,#KC/0?2@"YXVUR[
MTZ^T?3H=2BTB#49)%FU*5%81;5!"#=\H+9ZGTHL9-:T*\%Q?ZW'J_A]K=Y);
MV81QM:LN".5QO5AGMD$?G-XMU7^S;FU35-)2^\/SHRW<@MS.8'XVEEY^0\\X
M/->;^(](T_6 \?P[M;TV[1F34T@21()%4JRJ%<8,F1P /ZT =UK'Q+TNTT:Z
MN+6.\2Z^S/+9+<V,J)<$+D%<@94<$],#GI4;^/I%O?#$(M+LQZE&[71-A+N.
M$.-@Q_>&3@'Y<'H<URGB9+;Q+I'V2PUGQ!KMRD4LXMVMXT%NRQM_K/W2G)SM
MV@Y.:W9=8LC+X&UK=+]@M?.@GE\A_P!VY@V $8R/F&.E '1^'-<EFL]=N]5N
MU$-AJES$LCA5$<*$8!P!T&>3S3!\0_#XC:6:2[MHS$TT4EQ9R1K.BC),98?-
MQS@<US=UI-_J?@+QE96D,C7$NLW$B1@8:15D1B!ZY"D#UK \7/9Z[X>-M:ZU
MX@UF>-'G^RO;QQBU*HW,G[H8Z[< Y.>* /0A\1/#GFHCW%Q&DJEK>:2TD6.Y
MQU$;;?G/L,Y[9JS;>-M#GL;Z\DN);1=.*BZCNX'BDBW?=RA&>>V.M9&K6I-Q
MX&1824AN%R O"8@;'TYQ7/>,],OKSQ/K$]K'=&.U?3;F7[,@:1D0R;B@((9E
MR#C!Z4 =B?B!H$44SW<EU8F)%D*7EK)"S(6"AE##YAEATZ=Z3_A/]%=WBC%Z
M)C"\UNLEE*OVI5&28\K\_KQVYKSCQI'::[8(]EJVMZ^UHN\R20HD5N&9%*MB
M-22<_='3&3TKO_%UO)+XF\+B*,MMFN1D#A<P,!]* +_@GQ!+XE\+VNHW$;I<
M.O[W,+1J6Z_)GJO/49^M6=<O?L=SI*?VDUE]HOEBV" 2?:,JQ\O/\&<9W>WO
M67\-+N*;P/86J^8L]C&(+B.2-D:-QU!! ]>U.\9QN^H>%RB,P768RV!G \N3
MDT 6M0\::1IVHSZ:_P!KN+VW"M);VMK),X4C.["@\8QS6GI6JV6MZ;#J.G3B
M>VG&4< C/.",'D$$$8K T*%E^(OBN9HR T=D%<CK\CYP:?\ #R)H?#4B.C(1
M?W6 1CCSGQ0!?USQ7I7AV:""_DE$URK-#%%"TC2;2 0 !R?F''U]*@N_&FD6
MCPQ!;RXGE@6X,%M9R2R11MT9U RGT/-5M5@,GQ*\/RF,LL5G=G=CA2?+'7Z9
MKF[Y/[%\;Z[/JFNZGHT-^T4MM/;0J\<ZJ@4J28VPRD'CC@T =2_C[0"J&TEN
M=0#1"9OL5K)-Y2$D9?:/EZ'@\\'BH8_B1X;N%D:RGNKY81NE-K:22>6N =S8
M' P?T/H:X32K?3=)GN+M=4\1>&KN\)GCNKJ)9$O06;[T:IMR#R%X.'JW\//%
MUMI4>MR>(();6\GN@X*6;J)L1J @4#AL8.W_ &Z ._O?%VC6=M9S+/)=F_7?
M:Q6D3323+C)(503@=R:@/CO0/L4=PEQ-))+,T"6B6[FX,BC+)Y6-P(!&<CN/
M6O/--T>_\.W6DW^KWFH:+:S:=)$)K6)7^S.UP\HC?*-M!5E[#E<=JL:.UMI7
MCL^+9CJEUI5Q&]LVIWD YDPF) J("$(4KN(YQ0!TM[\1[3^U])M;".ZD2>XD
MBO8S8RF6+:C$)MQD-G!(P>.>G-=Q7FFJ:_:7/B/2?$"Z9);Z3;:@RMJ(@;-S
MFW90Q4+NV@D*"<YKTN@#"U/QAI.EW\EB_P!JN;B% \Z6EJ\WD*>A?:#M]?6N
M;UOQ>^J>(]&TS1=3O;>RNXGF>ZL[(RF7[H4*2I&T$G<>W0XJ;3M7L_"&O^(8
M=<\V!KZ]^UVT_DNZSQE% 12H/*D$8]ZRO!^G7MIXFT66ZLY;43P:A.L+K@PI
M)*K*I]#CG'O0!ZA6#J7C+2M-O9K,I>W4UL UP+.TDF$ (R-Y48''..N*WJ\W
MNM8G/B'6;6^U6\T?R[C%O8Z=8J9KU=HQ)YA1BQ;IQC&.: .@_P"%B>'9"4M)
M[F^D"+)Y=I:R2ML90V[ '  (SGH>.M:&E^*]&UFXMX+"[\UKFV-U$=C /&&V
M'DCJ&X(ZBN"^"=I+;G5S/;O%(([9/G0@Y'F9'/O3($ET/PC8>*%@?S-%U6Z,
ML>,%K>25E< ?BK#Z4 >F6>JVFH7=[;6TA=[&013G:0H<J&P#T) (SCI2ZGJE
MEHVGRW^H7"P6T0RSMD^P  Y))["LOP5ILVF^&;<W@_TZ\9KN[/<RR'<P/TR%
M_"JGC^VGETO3KR*WDN8M-U."\N(8EW,\2D[L+WQD''M0 R]^(.FQZ;?-#%?1
M7T%LTT5M<6,J.XQPP4C)7.,D=!R<5/X!N[W4/#4-_?ZA>7D]R%=OM-L( A*@
MD(-HRG/#<YKFO%6HV_BZ]M)-"66YBTZSO);FY$+*J!X&58\D#+,3T]J[7PJK
M)X1T964JRV$ ((P0?+6@"CXV\2S>&=-M9H(GDDN+N*(E8&D 0L WW?XL'CU/
MK6:_C86?C&[M+DWDMLUA;SVMG#9,\VYMQ8E0NX8&,[NGUJW\1@R^&X+@([QV
MNH6T\NQ"Q5%D!8X'/ J/17CO/B+J>HP*6@GTNU:*4H1N4ESW'TXH T#XUT'^
MR+?4TNGEBNI#%!%'"[322#J@C W9&.>*N:-X@T_75F%HTJRVS!9[>>)HI8B1
MD;E8 C(Z'H:\M^PW-KKIU>>XO["P@UK4XWNK2(.UN7==K$%6^5L$9 KKO!D5
MO=>)-1U6UOM5U&/[/'!]NNT1(YL$G" (I.W)Y]Z .HU?6K'0K1;F_E9%>01Q
MJB%WD<]%55!))]!62OC_ $!8[DW4MS8RVP5GM[NUDBE(8X7:A&6R>.,U7\>:
MC=Z?'I9A=;6"2ZQ/J)M1.;,;3A@I! )/&XC S7GVH[W^(NE:TDVJZU86,:33
M7<]OC<H<AC&JHN54NIX!_B/:@#M?$/Q(M+/1YWL(;N/48Y(@;>ZL95=$=P-Y
M4@<8S@]-V!W .S=^--*M)(X3%J$T[PB=H(+&5Y(8ST+J%RG0\'FN5\8Z]:^(
M=(OVTC3'O(+6.W>74DA8$8N$8Q*"N6PH+'!P,4[7+_2)M?.JP:OJ>@37%I&T
M&H11%X+U>>&C*GYE]#@\T =_IVHVFK:?#?V$ZSVTZ[HY%Z$?CT^E9FJ>+]+T
MJ^DLI%N[B>%!).MI:R3>0AZ%RH.WH3ZTWP5=:C>>%;2?5(%AN&W\"'RMZ[CM
M;9_"6&#CWKF?$LEA9>*[VX_M;4_#=\\496YCB\ZWO@!QE-I!9?NXX- &S'\2
M?#5Q'+)9SW5Y'!S,]M:22")< [FPO Y_0^AK1O\ Q9I%A!9R^?)=-?KOM8K2
M)II)EQG<JJ"<8/6O/OAUXNM-)TS6O[=MI;>^FOFDV1V;CSCL0>6J@<-_L]MP
MJOI^C7_AJ?1+O6+[4-'MVTIH#<6L:O\ 9Y#,TGEOE&VC:RC..JXH ] /CS0/
MLD4T<\\LLLK0I:1V[M<&11EE,6-P(!&<C'(]:C@\4V.K:SI26.K20>9)<12V
M,EH0\CH@)5RPS&5SGWS7$Z)+:Z1X\E\5W!U2ZTJZ@>U.J7D ^:4;,/M1 0A"
ME0Q')'6ME-136_B%H.H66E/!9B>[5+PQE3=_Z.!O(*@@ _*"<YQ0!9T7Q#?:
MYXXU5#?:A;65@0D-J; K&P\O+&1F7(;<<@9&0!U%;=AXBL;/P=9ZQJ.K?:H7
MC7_2S;^6T[$X&(UYR?[H%4]!CD77_&+,C /=1E21][]PO2N5FT^\;X:^#[I?
MMD4>G31S7)MHPTL2[6'F!2#G:2#T/&: .S7Q[H"PW#W4UQ8R6RAWM[NV>*4J
M3A2J$9;)XXS5&U\7G5/'&GZ9:-<V\+6D\ES:W5J8I P*;&PPSC!;&.#^%<;J
M@AOO$.E:S8WFL^(X-&F2>ZN)($$<4989"A8U+L#AL#. #740:S9:]\2]*N=,
M22:WAT^X1KKR65&8E#M!(&2/_9J .PU6;[-H][/]I-KY5O(_GB/?Y6%)W;?X
ML=<=\5EOXITS2-%TFXU+4&E^WPIY4XMR#<-LW9V*#@MV7U.!5OQ.K/X4U=5!
M9C8S  #))V&N3:V=[?X=*T+$1;"X*GY"+8]?3F@#J=%\3:=KLUQ;VWVB&YM<
M>=;W4#0R(#T.U@#@T_Q+?W.E^&=1O[)8VN+>W>2,2$!=P'&:RX8G'Q4NY=C!
M&T6(;L<$^<_&?6M'Q1HLFOZ%+8PSK!-O26)W7<F]&#*&'=21S0!B>#KS4M2>
MVO[;Q*FM:=+"1=I/&D<MO-Q@*$48'4%6Z=032/XDUR7Q_I6G-8M8:5<?:5'G
M;3)<F-?O8YVKDC'<]361!)<W/Q TI9M)_L3707>^FCD'V>_MPN"%_OG)4\C*
M@<]!70Z[&[?$+PHZHQ1$O=S <#,:8S0!KZ_+JT6CRG0X(YK]BJ1>80%3) +G
M)&<#)QWQ6 MWKF@>*]'TR]UK^V(=5$JNDEM'$\)1-V]=@'R]B#G&1S5SQ!XU
MM-'TK4[F"WGN;BPD6'R1$P#R,,C!QR,<DCT]:P_!^L:#+J_VN\U2;4?$-\NQ
MI38SQQQ*/F\J/<@"J,=SDGDT >@UR_BGQ7)H&M:+9)!-)'>S,)S':O*=@5B
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M8(RG(SR>"<-2:K;VVK^*-$O;/4-7UM+>_M8Y+RXB18%5I@3'Q&I8\9]!0!Z
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M9!+=C4+6)T+PRSV$J+,H&24)7GCGZ5N7>LV%DED\TV1?S)#;[%+>8S D=.V
M3GH!7F6I/#K=_P"'XSKFHZ_"^H(MR6M!%;1*RLN,*@PQSC!)P,YK4\%VU]>>
M(8=.U!6,?A"*2U1V_P"6LCL51A](5'_?5 'I%<W>^/-$L9KA7^VS16CF.YN8
M+.22&!AU#.!CCOZ5TE>1WNIW6H:+K5K=ZE?6=\QN8TT+3[%5_O %FV$LK##,
MV0,$T =I-\1/#L?GF.:ZNEMF(N&MK22580/XF*C 7W[\UK:9X@TS6+F>"PN?
M.>!(I&PI *2+N1@3U!'I7#_"ZW=/ NLF2%E>2=OO*06'V>+U]\UF,VH>&_#/
MAO7-.@<W-[I8TJ1 ,$2L,P-CV?(_&@#U'2]5M-8M6NK&0R0K*\6\J0&*,5;&
M>HR#S5RJ&A:5%H>A66EP\I:PK'N_O$#EOQ.3^-7Z "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***R
M?$VNCP]HS7HMS<S-(D,$ ;:99'8*JY[<GKZ"@#6IKHLB,C#*L,$>U<?J'BGQ
M!X9MIKKQ!I5M/;^3OCETZ1B!+N"K$VX?Q%AAAZ'BI'\1^(=&NK ^(;"P6UU"
M86Z/9RNS6\K E%<,,,"1C([T */ TLL,.GWWB&_O-)@D5ULI53+;3N57D W,
MH(''M76UYW%X]\2?\(W8>)I=%LCIUTZ1&".=O/)9MH89&T#=V/./TFUGQQKW
MAIKR+5].L'E6R^UVWV65V4@2*C(VX Y^?((XXH [ZBN3;Q+K>D7VG_\ "16-
ME;V6I/Y2/;RLS6TFTLJR9&&R 1D=Q63_ ,+%U!M+/B!8-*_LL$M]D-W_ *88
M@<;\?=SCG;Z=Z /0J*\]M_'7B._\+W'B:STK3VTZT:0R*\SB2=$8Y9.,+\OK
MGD'VJS+XWU*^UB\LM'BTM&M$C9+>_N#'/=[D#_(!P!R!GGGTH [FD9@JEF("
M@9)/05QU]XD\3)%/<KIVEZ5# @(CU2ZP\S;06"E?E !.T')R17->'/$>I:V/
M%^L75M:R6+Z?'*]JTCG ^SL50>Q&=W3DG% 'JRL&4,I!!&01WI:Y%O$<]KI/
MAS3]'T^!K_5K96@AD<K#;QK&K,6/)( ( '4U0U7QYJWAY+RSU33+:34K=89H
M1;2,8KF)Y1&2,\JP)Q@^HH [VBN6M=>UZU\36.DZY8V*)J<<K6\EG*[&-D 8
MJ^X#/!ZC'TK?U348-)TNZU&Y)$-K$TKX'.%&>/>@"U17%/XK\1:?IMKKVKZ7
M8Q:1<-'YB0S,T]LDA 5FR-K8R,@8QFK/AGQ#K_B&]EF;3[*#2X+F:V=S*QF=
MD8@,HQC'0')SG- '6452UG5(-$T>[U2ZW&&UB:1@O4X'0>YZ5S$WBCQ-IEG:
MZIJ^EZ?%87;HA6*9S+:&0X0OD889(!QTSQF@#LG=(QEV503C)..:=7CLEUK+
M>!+N>\6&Y9/$*F)8Y&+NXN.5);H,@!?;K77W'B_5?#VHB#Q/:62036<UU#+8
MR,Q'E %D(8#)P1@C'TH [.BO/9_B'J>G:=#K&H0Z0;*?;FWMKLO<6^[[I<=&
MY(#8QC/>MWP=K6O>(+&'5-0L;.TL;JW5X%CD9I=W<L",!3R1@YQC- '2T5@^
M+M?NO#VFVUQ9V:WDUQ>16RPLVW<7..#V.:J0^(=9T_6XM*UVQM6DO+>2:S>P
M=B':, M&0^/FP<@]#[4 =317GVK^-?$VC6<%Y=66C!KEUC73Q=,;F)GX7=V;
M!(S@5K#QFUSX;T._L;='O-8GC@2%B<1MSYN>^$"O^0H ZNBN"G\:>(S8ZUJ=
MII5@;'1;N>&;S9G$DZQ,<E !@';CD]\\<5;7Q?J]G?:9/J]A:6^E:JKF(QRL
MTT&(S(/,XP<J.W0^O< [*LW2]&BTN\U*YCE=VU&Y^T.&QA3M5<#V^6N/'Q$U
M!=+7Q!)!I0TIB&-H+O-XL1.-^/NYQSM].]$7CKQ)<>%G\4Q:3IYTVW9_,C,[
M^;*BN59DXP,8[YS@^U 'H5%<1X1NM7NO''B9KA[=K420<!W+*#$"@4'@#!R?
M<G%;_BU[V+PIJ<E@8A.MK(<R$@ ;3DC'?&<>] &G#<P7&[R)HY=AVML8-M/H
M<5+7GGA^];PE\/\ 1C;Z58MJ&JF"*UBMLH)F>,$/*Q&<X#%CSZ5;U7QEK?AE
M9X=;L;%IWLYKFREM9',<C1KN:-@W(..<]Z .XHK&\-WNMZC:M>:O:6EK%.J2
M6L<$C.ZJ1G$F0!NZ=.*75]:FTK6=&MFA0VFHS/;R2DG,<FPL@'UVL/RH V*:
M'0N4#*7 R5SR!7&6OQ"25O$K3VRQ0Z.C2VS;O^/E%9T)_P"^XROXBLZSN_$<
MOCV\-C962WT^D6DEP;F1Q% ?F)4  ECDX[=#]* /1"Z*ZH6 9L[03R<=:Q]=
M\/'7YK:.XU">/3XV#SV2*NVX*L&7<Q&<9'('6N?TOQ-_;/B+0TO=*@CU!)-0
MMI760MY#Q; VP]PV1U':K9\2>(=4GU*;P_IME-9Z;.]N?M,K"2ZD3[X3 PO/
M )SDT =:KHS,JLI*G# 'I]:=7F^A7OB2?Q%XF?1M-M(V>XAEE&H2,I5C"G[L
M!0>1W.<#CK79^&=;7Q'X=LM76$P?:8\M&3G8P)!&>_(- &K17*WNOZ]-XMNO
M#^D65D?L]M'<-<W3L%7<6&TA>23@8Z=#6=+X]U,V]G;V^DP'59-1DTVX@>4[
M(Y50L&#8R4^Z>F<9[T =W17(OX@\1R:E#H-K9Z:=6CMOM-],TC_9H06(55XW
M,3C/.,5!I_CB];Q';Z+JFGPVLWGO:7+1R%E678)(BI/\+KNQGD$4 =F[I&NY
MV55]6.!3JX7Q'XE%S8ZVLFFP7>GZ=>VMJID9OWLQ=-_3^X67\15[Q!XKN['Q
M+!H5DVFVTLEM]H^T:E,R(_S%0B =6XR>>E '5!T+E REEY*YY%.KC/#FMR3^
M(-9DU71X=,N[:S@DN9$E\S>O[S!R.-N!D< \\U#_ ,)AXB&@CQ2=(L_[%*^=
MY'G-]J$&?]9TVYQ\VWT[T =S17#P^+?$>K'5Y-$T_3GMM,G9!)<2N#< *& 4
M <'!ZGCD>]=1H.JIKF@V.JQQF);N!9=A.=N1R,]\4 7@Z%R@92R\E<\BG5S5
MI?PIXUUZ-;!!+;6=O(\T>3),"'PN.G&./K6=X=\8:UKWV.\@MM*N;.Y<":WM
M;LFYLU.?F<-@''<#!YXS0!T>CZ)%H\NHR12O(=0O&NW#8^5F51@>WRUIU3U>
M];3=%OK]$#M:V\DRJW0E5)P?RKCF\:>)H+/1]2GT6Q:UUITAMH8[AA*DDB%D
M+DC 4XR<9('J: .]HKD(/$^O6UYJNEW^DV]UJ-I:I=6T=A(=LZLQ7!W_ '2"
M.3Z?KEZQ\0M6\+W$":O;Z5>_:@R1PZ=<L98Y,?*K!NH)XS^G:@#T%G16568
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M^R1_;1"+G;^\$))3/MGG% $]%<EKOBN]M/$ZZ#8MIEM+]F$XFU.9D67+$!$
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MVNGI.IABN3*[,Z8W9V@8X&!]:["J6G:K::K]J^RLS?9+E[:7*D8D7&1[]>M
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MWVFT8$X5'=&W)MP.<'BO4:R$\2V,OB-]!@CNIKJ$#SY(X&,4!*[@'?H"1TH
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MJZGDL8HI$BEDRCLT.X;ACD*>!Z"NH@\%64&O)JZW,YE2^FO0AV[=TD0C(Z=
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M#VVYJU!X+MY9;JXUJ^N-9N+JV-HSW 1 D1ZJJH  2>2>O I-/\&BVO[*YO\
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M;U(FPN"H)&,_,<<\<BL"X\0:E9>,[6W6#6-1BL;M);.UO@/M1:2"0%2>NTD
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MX379]WPO%W!!H6F:=,4DM+=&>>[+>8#_ *PD8?J2>3@&@#UIO$>A)-# VLV
MEGXB0W*9?G' SSR"/J*EO-:TK3KB*VOM2M+6:;_5QS3JC/\ 0$\UYI8Z1I[_
M  3U>Z>SA:>07<K2L@+;DE<*<]>-HK2\*'29KKQ(_B3[*UV[HTAN\<VODIL(
MW?P_>Z=Z .L\(ZU-XB\,VFJW$2123F3*1YVC:[+W_P!VK1U[1QJ/]FG5K(7N
M<?9C<)YF?3;G-<Y\.=X^%EE]ASO\JX\C/7/F2;?Z5Q%G;O-\,U-SJ7A^V@/,
MLKVLK7D=QNY)(?)EW>WX8H ]?_M73?[/_M#^T+7['_S\><OE]<?>SCKQ]:@N
M?$6AV3[+K6+"!O,,>V2Y13O&"5Y/7D<>XKS"R-JOBN&[F\Y_"GV\#?PL!U':
M 9-I&1'NS[;_ &KH/#X\.#6O&;:H;/SOMS>>+C;_ *CRUQU[9W4 =O?:G8:9
M;"YO[VWM("<"2>544GZDU'_;>D_9H[G^U+/R)59HY?M";7"_>(.<$#OZ5Y+H
M*ZJ]_P"&%GEL8@-(E-C_ &M&SH3Y[8VX8?/Y7E?A4FGZ7;W/Q+L8+FZTZ]@:
M]FDEM;*W=;:*98,G&XD$DA"<$X(YH ]4AU[1I]/?4(=6LI+.,X>X6X0QH?=L
MX%+#KVCW-A)?P:K926D7^LG2X4QI]6S@5YKXCT[3AXYU&V%[#I+-+83V[/;[
MX'N )0!(O3!&>3CD"LK69[L>.=/L+^VT""?S4EN;N(N]G,VUQ")4R-K AL9/
M<=J /7HM?T:>P?4(M6LGLXSA[A;A#&A]"V<"IM/U/3]5@,^G7UO>1 X+P2JX
M!],@UY+K>FQ3^,;<WGB+1;*_'E,L5I8R&WDE!;RS-EBN<;P,D'D5U_A"[D3Q
M7JNGWVGZ;'J/V>*::[TR1C%*N6"AE/W7'/U% &S_ &Y<7.L:G:6:P"#3+?\
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M6XB3,X7DJN'(#8YVL0:M6OC>TN-2L[2;3=1M(M0)%G=W$06*<@9X^;*Y'(W
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M0;6$PP:+I\<95E*K;( 0V-PZ=#@9]<"KAL[5IH)FMH3);@B%R@W1 C!"GMD
M=*YO7/$5_8>.M$TJ"RNY;6YCF:7RDC(D(V@$$L#A,DMTZC&:R]+\:7%A/XB2
MXT_5=46RU2?<\"!EMX0%P,LPSC#':N?UH ZC6])GNK2=]):UM;^4IOEE@5UG
M53_JY.,E2"1ZC/%9&A^%+R#7H-5O[?2K%+.*2.VM-+C(3=)C>[$@9.% QC\:
ML2>.+*66.'2;"^UB1K=+EQ9QKB*-QE=Q=E )'(7K6QH^KVFNZ;'?V3,8G)!5
MUVNC X96!Z$$$$4 66M;=KI+IH(C<(I1)2@WJIZ@'J <#BJ=WX=T2_O5O;S2
M+&XNEQB:6W5GXZ<D9XKD?&VKZT^LR0Z#<2(-!M!J%VB'B<EQMA;ZHLAQ[BNM
MDU_38?#PU^6X":?Y N/-(S\A&1P._(X]: .>U7PWX@N[Z[:,:'=+,S?9KV\M
MS]ILT8?=7:N&V\X)(]ZU[;P=H4>F:?976FVE\=/@2&*6Y@5VPH]QW/.*PM<^
M(;V6C7+#1-5L+N:SEEL&N(8\.50MDC><;1\Q4\X!X)XJYINMF]N?"YO#J=K=
M7EM,PA;8(YBJ(6:0 GURN/4YQ0!T5OI6FV=U)=VNGVL%Q*,2310JKN/<@9/0
M5-/:V]TJ+<01S"-Q(@D0-M8'(89Z$'H:P+SQI;P7UW:V6DZEJ@L#MNY;.)62
M)L9*_,P+,!U"YJ)_'^F275O:Z99WVJ3W5FMY"MI&I#1EF7DLPVD%><XZ@<GB
M@#>U#2]/U:W^SZC8V]Y$#D)/$' /K@]ZB;0='?31IC:59&Q4Y%L8%\L'UVXQ
MFF:!KUKXBT]KNUCFA,4K0S0SIMDBD7[RL.>>G?O5.SU.W3Q!XA3[1?2-8QP/
M+#(5,48,98>4,YY YSCG% %QO#6A-IPTYM&L#9JVX0?9TV!O7&,9]ZMV5C9Z
M;;+:V-K#:P+]V*&,(H_ 5S%O\1M/N+>ROO[*U2+3;QTC2^DA41*[< -\V<9X
MSC&>A/6NCU;4H='TF[U.X5VAM(6E=8P"Q"C)QD@9_&@"NOAG0%N9KE=$T\33
MAEED^S)EPWW@3CG/?UJU#IFGV]BUA#8VT5HX96MTB41L&^\"H&.<G/K6#%X\
ML&TR34I=.U*"VWQI:F2 ;KTOG:(E!RQ..^."#4<WQ"L;*3[+J.E:G97\FW[/
M9R1*9+G<VT",JQ4G)&<D8H W+O0-&O\ R/MFDV5Q]F $/FP*WE@= N1P/:K=
MO:V]G#Y-K!'!&"6V1(%7).2<#U))KE)_B1965_%IU]HNKVVH3-MCMC C,^02
MNTJQ!R1CKP>N!S5ZW\::=Y6H'4H;G2IM-C$UQ!=J-PC/1E*DA@2,<'KQ0!H3
M^'=#NKU[VXT>QFN9%*O+);HS,",$$D<\<?2K45C9P>;Y-K#'Y^/-V1@>9@8&
M['7CCGM7.CQ_86YC?5].U'1[>9&>&XO8E"284L1\K$JV 2%(!/UXJO>?$)(;
M'S6T/5K4W43&QDFA0+.P4D#[_P IQSAL9 /?B@#=@\+>'K4R&#0M.B\W&_9:
MH-V"",\>H!^HJ>QT32=,GEGL-,M+66;_ %DD,*HS_4@<UG^"=6N];\):??7T
M,Z7#PIO>95'G':"74*2-ISQT/L*75/%4-AJG]E6NGWNJ7RQ"62&S13Y2'H69
MF &><#.30!:_X1K0?M$UQ_8NG^=<?ZUS;)F3G/)QSSS5Z"UM[8RFW@BA,TAD
MD\M N]SC+''4\#GVKSK7_&C:W?Z)8:2=:MK>YFF6\^R1*EP'C4YBYZ,IY8>A
M'6O0Y9/L5@\A66?R(BVU<%Y-H[9QDG% %2W\.Z'9WYO[;1[&&[8DF>.W17R>
MO(&>:2'PWH5M=O=P:-817$@(>5+9 S ]><=^_K6?<>.M'MM.T2_<S&+6Y(X[
M?"C*;\<OSP 2 <9Y/>LOQYXJ%EI6J6UE+<P7.FM:23W$?"JLDH^4$'))4'(Q
MT/O0!UQTZQ-O!;FSMS#;,K01^4NV(K]TJ,8!';'2GM9VKW!N6MHFF:/RC(4!
M8IG.W/7&>W2N<'C.WGG?3[S3=5TN2>VEEMGGB53*J+EMF&.& YPV*DC\3V.F
M>%=&NR;Z^>_AB6TB*A[FY8H#R <;L<L<X'K0!H6_A?P_:"86^AZ?$+A2LH2U
M0"13V/'(]JORVEM,(1+;12"!P\0= ?+8# *^A )Y'K7!^(O'04Z<@@U'3;NV
MU:W2[LW0>;)$Z2$!0A(<,5QP>HKI='\4PZIJLNE3Z=?:;?1PB<0W:*#)%G&Y
M2K$=>#0!=.@Z.5NE.E616](-T/LZ8G(Y!?CYNIZ^M2:=I&FZ/"T6F6%M9QL<
MLL$2H&/J<#FL#Q?XBO\ 1=7T*WL[.[GCNKHB80)&3*H1CL&YA@Y /;@=>U9]
MIXMNK'Q)XEM#8:IJWV:Z1ECM4#""/RE/5F Y.["C)/- '5W^@:-JLZ7&H:59
M7<L?"23P*[#VR15I+2VCN3<I;Q+.4$9E" ,4'(7/7 STK ;QSITL%@=,M;O4
MY]0@^T0V]L@WK&#@L^X@*,\<GKP*TM#UVUUZVEE@CF@E@E,4]O<)MDA<<X8<
M]B#D$@YH O06MO:^9]G@BA\V0R2>6@7>YZL<=2?6J1\.:&;]]0.CV)NWSNG-
MNF]L]<G&:X[4-4%_XSU+2]9\4W7A^*V\L6,$$B0>>I7)D,C*=W.1@=,5IVFN
M7_ANV6QUB636KFYN&73#:*K3740 .6'"C;GEL@8Q0!T[:=8O8?V>UG;M9[ G
MV<Q*8]HZ#;C&/:B^TZRU2V-KJ%I!=P$Y,<\8=<^N#7#ZS\0YQJ>F6%EI>IPW
M0OD2]M'BC\PH48JH);!W8R"#C"GD="VY\6:M<2^.+8VU];)I]DS6LA6-?LY$
M!;)*L3EC\PZ\8Z=* .SCT'1HH1#'I-BD855V"W0#"G<HQCL22/0\U;^RVXNS
M=^1%]I,?EF;8-Y3.=N[KC))Q6 OB:'2O#VBO<I<WM]?P1B&W@7?+.^P%CR0,
M#J22 *J2_$?2[69+2\T[4[>_:80_8FA5I=S*2I&&(8-M(!!//7% '53VMO<F
M(SP1RF%Q)&9$#;'&0&&>AY//O0EK;Q7$MS'!$D\X42RJ@#2!?N[CU.,G&>F:
MYB/Q_%+<3V*:!K#:G;X:2Q$*;PA&0^[=MQVZYSVJ5?'FFW-GI\NG6E[?W&H1
MM)%:01KYJJIVL7W$*H##')Z],T ;,^AZ3=6365QIEI+;,YD,+P*4+DY+8QC.
M2>?>B+1-)@MY;:+3+..&9 DD:P*%=1P 1CD#WKGC\2-+^U0V*Z?J;:C,TD?V
M$0+YJ.@4E6&[ R&# YVX!.:H:]\0)O[(<Z=I^H6U_;W\%O=02Q1[X@S*>[8^
M=<A2,_AUH ZRT\.:'8Q^7::/8P)YBR[8[=%&]3E6Z=0>A[5=^RV_VO[7Y$7V
MD1^7YVP;]F<[=W7&><5']K;^S?MC6LZMY/FFW(7S <9V8!QN[=<9[UB7'CO1
MK;2M&U*3S_)UJ6.. !1E"W=^> #P<9Y]: -I-+T^.=9TL+995D>59%A4,'88
M9LXZD<$]31/I>GW,CR3V%M*\@4.TD*L6VG*Y)'.#R/2LS4?%^F:7<ZC#<+.?
M[.ABEF=$W#,A(2,<Y+G'3&.1S6==?$2QTM]NMZ3J>E>9&TD!N(T;SL8RJ[&;
MYN1P<4 =)<Z;87MQ!<75E;SS6S;H))8E9HCZJ2,@\#I6/H>AZE'KUYKVN26;
MWTT*VL*V@;9%"I+8RW))8Y/T%3:9XG%_J8TVZTC4=-N'B,L0NT7;(H(!PR,P
MR,C@X-&N>*K70M0LM/DL[R[NK]9&MXK6,,7*;<CDC'#9R>, Y(H U[FVM[R!
MH+J".>%L;HY4#*<'(R#[BJUEHFDZ;<RW-CIEI:S3?ZR2&%49^_) YKG5^(MK
M)!<M#H6L2SV)(O;=(%WVP'.6);!R,D;22<5;D\;6DLD46DZ=?:O));)=%;5%
M CC<94L790"><#KQ0!H1^%_#T4DTD>AZ<K7 (E(M4^<'J#QR#3AX9T%;XWXT
M6P%T3DS"V3?GUSCK6+!\1-.OO)BTS3=2O[QU=Y;.*)1);A6*GS-S  Y! &3F
ML[P]XWB2QU2[NOMUW)/K<MO8V8C)G.$0^6%)&W;\V<D <T =G+I6G3Z<-.EL
M+9[( *+9H5,8 Z#;C%9&H^$[2:QMM)T^TM+'3&N5FO8H8PAE5#N"@ 8.6"Y)
M[ ^M6M&\20:M=W%A)9W6GW]LJO):W2@-L/1U*DAER",@]:T;YUCL+B1F=56)
MB6C^\  >1[T 3U5&F:>L-Q +&V$5VS/<((EVS,WWBPQ\Q/?/6N?3Q;IVC>%-
M#OISJ-W%J(CB@9D$D\C,A9=X!Y8XQQGDBG1^/=-B-\FJVE[I$MC +F2.[C7+
MQD[0R[2P/S8&/4XH Z!K"S>*")K2!H[9E:!#&"(BHPI4?PD#@8Z4VZTS3[YF
M:[L;:X9HS$QEB5R4)!*G(Z9 ./45Q?B?QRX\.7\)L-4T6]FLI);*2Y14,FT9
M.TJQVL!S@X-=.NN06UYH^ESK,]SJ<#O&X *CRU4MN.<\[AC - %V_P!,L-4M
MOLVH64%W!G/ESQAUSZX--M](TRT6W6VTZUA%KN\CRX57RMW#;<#C/?'6LO4/
M&FEZ9<ZG;W"7'F:;Y 94C#&9IL[$C .68[3UQ7+Z]XNGEUN&&XAUG1HHM+O)
MKF'"K(0%4JZ$,5+##8YX/7% 'H:VMNES)<I!&L\JA7E" ,X'0$]2!D_G1':V
M\5Q+<1P1)-/M\V14 :3;PNX]3C/&:P;WQ99:+:Z/'+#?W<FI18MA'&'DD(4'
M#<CDY^G7) YJ)/'VF)::A)?VE[87&G-&LMI/$#*QD_U80*2&W'@8/UQ0!K3^
M'=$N=0&H7&D6,MXI!$[VZ%\CH=Q&:)?#NAS:B-1ET>Q>\!W?:&MT+Y['=C.?
M>LVS\:07&N6FBW>D:GI][>*[Q+<QIM*JNXG<K$=L8Z@]0*B\=:_?Z#!I)L+>
MXE-UJ4$4IA5&RA89C^8CYFZ#\>10!KR>'-#EO);R31K![F92LLK6R%G!&""<
M<Y'!JW!96ML9#;VT,)E(,GEQA=YQC)QUX 'X5Q<?BJ\M/'&LVGV#4[_-K:R0
M64*J?(RK%R<L%4Y*CKR>F:TU\>Z9<6-C-8VM[>7-^7$5C%$!,I0X?>"0%"G@
MDGZ9H W['3;'2X6@T^RM[2)G+LD$012QZG '7@59K*T/Q!;:XMPD<%Q:W5HX
MCN;6Y0+)$2,C(!(((Y!!(-:M !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %<U\1+:>\\!ZK;VL$D\S
MQJ%CB0LS?.O0#DUTM% ',Z]97,_C;PK<Q6\DD-L]T9I%0E8]T.%R>V3P*IS2
M7'AGQOJFISZ;>W=CJT$&V:S@:8Q/$&4JRKD@$$$'&*[*B@#S/1]&U63QMIVO
M7.FSVT5YJ-Y<>6Z<P1F (ADQPK-CI72Z)97,/C3Q7<RV\B0W+6ODR,A"R;8<
M':>^#Q73TU75U#(P93T(.0: .=^'MI<V'@/2;6\@DMYXX2'BE4JRG<>H/2N1
MO+'4G\)^*=%&DWYN7UG[5$1;L4FC:Y1@48<-\H)([5ZE5+4=9TS2!$=2U"VM
M/.;;'YTH3>?09ZT <SX\T6]UO4M&M[6*3:R7L4DRJ2L/F6SHI8CH,D5RT.CF
MYT*TT.?1O%,U_B.">UGO9TLUVD MOR4V#&0!GL,5ZY10!S?CC3;R_P!%MY;&
M W,^GWL%Z+<'!F$;9*CW(S^5<UXC^V^-M7T^"QTC4;2W%G>PO=7EJT01Y82H
M4@\XSU/0YXS7I-% 'DL.D_:](LM&ET?Q5-??NHKBVN;V=+./:1E]^2A48RH&
M>@XK03P]J>H?!VVL(K69;V"<S_9F)B=PMPS;03@J2O(/TKT:::*V@DGGE2**
M)2\DCL%5% R22>@ [TL<D<T22Q.LD;J&5U.0P/0@]Q0!XYXJT<Z]H[P:9HWB
MJ\EBC:5CJD\X6!@, *CY\QSG&%[=Z[?Q?I=UJ$/AR"W@E(CU!#*T:$^2GE.I
M8^@!(KKZ* . T/5]8T7PS9>'8?#MX^L6H6W!>!OLI ;'F&4<;=O/KGC%<_8Z
M)+HV@S:%>Z=XIN;^(R11Q6EU,MG=*S':=RG8BD'YL^_%>OT4 <QKOAV>_P#A
MO-X?M$$,_P!A2&*,R;@&4#"[CU^[C)K(U>_O?%UAI^C6VA:E9S_:H);M[FV,
M<=LL;!FPYX8\8&W.?:NW:]M%E@B:ZA$ESGR$,@S+@9.T=\#GBIZ .8\ VUQ:
MZ'=1W,$D+MJ-TX61"I*F5B#SV(IGCA;F-]"U""QNKR.QU)99H[6(R2!/+=<A
M1R>2*ZJFEU#*I8!FZ GDT <UX9M+B'Q-XGNIK:6**ZNH7A>1"OF*(5!QGK@Y
M%<#H?AR]T@6%_JEGKT=M-9O _P#9K2I- ZSR, Z)ABI5@0<'FO7[:[MKR+S;
M6XBGCW%=\3AAD'!&1W!XJ:@#E? VG_9X]1O?[/O[,7EP"K:A</)/,JK@.X;E
M?3!.< 52CN)O!7B;5Y+JPNY])U:874=S:P--Y,NT!U=5R0#@$'%=O10!YMXH
MOM?\6:%K(L-*NH])$$201S6S+/<R^:I+*O4(%'<<UJ>*Y=3'B>WAG?6HM#-H
M2'TB)F=KC=]UR@+*-N,8P,]Z[6B@#R7PEHNIVWQ+%W)I&I6UGON'66[W2':T
M404M(2<L=IXR<'CM6[!I=^O@KQM;&RG$UW>:@\$?EG=*&7Y2H[Y[8ZUW4TT5
MO!)//(D44:EWD=@JJH&223T %$<D<T22Q.LD;J&5U.0P/0@]Q0!R&I:?>/%X
M+6.TE;[)=1M.%0_N@(6&6]!GCFK_ (YTR\U/P^IL(?M%Q9W4-VL&<>=Y;ABO
MU(S71TT.K,RJP)4X8 ]/K0!Y_P"(9[SQG-I\-AH^I6T5B\EU<2WEJT)!$3*L
M:@\L26YQQ75>$+>6T\':-;3Q-#-%8PK)&ZX96"#((['-:D\\-K!)<7$R0PQ*
M6>21@JJ!U))X IR.LB*Z,&5AE6!R"/6@#E?$@N;7QGX<U-;"[NK:);F"5K:$
MR&(R! I8#D+P>>U-T"PNX--\5I+:RQO<ZG=20AD(,BLBA2/4''%==10!XWX=
MT"YT%1)K%IXDCBO+.V>-M*>92CK&$:.1(SD$$<$C&#UKT'P58G3?#SN^GW-B
MUQ/)<-#<3M/,=Q^\Y/.X@9(YY/K6_--%;023SRI%%$I>21V"JB@9))/0 =Z6
M.2.:))8G62-U#*ZG(8'H0>XH X/P]X1N]6M[S7-4O]7TR]U:X>66UAF\K9&"
M5C5@5/(4#\ZIQ^'=8_X077?""6TTATZY5].DF&%N8=ZRJF[H3P5/H2.E>ET4
M <-K>N:IXET>[TO2?#]_&;BPN%N7OK=H?+)B8*B$\,Q8@<9&.:;IJW=_JO@R
MZ&F7UO'96MS#<"XMVC,3>7&HSGH"0<'O7:/>VD;P(]U"K7!*PJT@!E.,X7U.
M!GBIZ .%TR]NO!]UK5E=:+J5W]JU":]M)K.V:59A)@[21]U@>#NP.]5O 7AW
M4]#UV'^T+5D/]C .ZC*)(]S+(8PW3(##(%>AU#)=VT-S#;2W$4<]QN\F)G :
M3:,MM'4X'7'2@# \&6=S:2>(3<V\D/GZU/+%O4KO0JF&&>H.#S[55MK"\7Q+
MXSF-K*([JWMU@<H<2D0L"%/?!..*Z^B@#S^ZTJ_;X.Z;IRV,YO(X[/=;B,[U
M*RQELKUX )-=-XRMYKOP9K-M;1/--+92I'&BY9B5.  .IK4ANK>Y>5(+B*5H
M'V2JCAC&V,[6QT.".#ZU-0!PWBS0[R]\+:!)!;W4C:7-!--;VLACG*!"K;""
M"'&<@>QKG=1TFTU.[AN5\,>)=7LK1<RRZA=3K+%N(!\F-SN9AC)QCH*];HH
M\::ZU#2_'.@S6L/B'4-'BDD,<6I1'SA(8G#^6' =@J<X]1@9K6\1:+J?CB;6
M-1LK"ZM8ETV.TMDNT,#W+K.LS84X*CY0H)QR:[S5+/37OM-U&_N%@DLIS]G+
MR!%9Y%*;>>I.[@>M:.]=X3<-Q&=N><4 >0Z_H,GBC2QINF:9XGENV!D8ZQ=3
M+#;LJG'WR5=B?E&/4G(KKIO$.IZW;1:;I_AV^MYI8V6\:]MVBCMUV$$*QX9B
M< 8R,<FNRHH YSP#)*?!NGVMQ97=G/90I;2QW4)C)95&2N>J^AK/DEN/#'C;
M5]2N--OKNRU>* I-9V[3&)XU*E&5<D9R"#C%=;-=VUO+#%/<1123MLB5W ,C
M8SA0>IP">*FH \RTC2-5_P"$TTK6;K3I[9+[4[ZZ,3)DP1M;A$\S'"LVWI[X
MKTVBB@#RI?"&IWC:YI$MI+'::5:SII$A4@.\LGG*5/?;L5>.E6)=)U?4/A[?
M7UWITXU75]2AN9;;RR9(T69%52.N B9_$UZ;10!Q_C.PO+O7M#EMK6::.&*^
M$C1H6"%K<A<XZ9/ ]ZSAI^HZ=I'@?5_[.N;@Z-:^7=VL49,R"2 (6"=25(Y'
M7DUZ#10!P&K7NK>)-4TB6WT2ZATRTU>VD62>!DE<A9-[E#RJ#*C) Y-;4MG<
MGXGV]Z+>0VRZ/)$9MIV!S,A"YZ9P"<5TM(S!5+,0% R23P* .5\;+<PW>@:E
M#8W5Y%8WYDG2TB,D@4QNN0HY/)%3>&;2X@\0>)IYK>2*.YO8WB=T*B11"@R,
M]1G(K?\ M=M]J6U^T1?:'0R+%O&]D! + =<9(Y]ZFH \:T3PY?:3%I.H:I9:
M[';2:<;:7^S6E2:WD69V =$PQ4AL]#S7=>![ 6XU*^&GZA:+>3KL?4;AY)YU
M5<!V#<IZ $YP!75T4 <1JFL+!J%]IWB_P_)?6)E+V-S#8&XB,1 PK8!*N#GZ
MUQUMX9NK?Q!_;UMI.N6GASS'C@M+662.Z@#*N9%13N",P/R]<<XKV&XO;2T@
MDN+FZA@AB($DDD@54)Q@$G@=1^8J>@#R*?3)DUNR\1V>A:_/;65]"&FNY)9K
MJ:,))DB)_F"J6'YGBMG4(+X:CXZMQI=\_P#;&G![25+=F1RMML*9'1MW&WK7
MHE% 'G.NZ'>>3X4U-[;4W@L+,P7<>G2/'<Q;D3# *0QP5PP'-9L&BRW?C?1]
M6L]'ULVT%TJ&]U.:5Y&78Y/R/RB D8)QR:]8HH YK3K.YC^(NM7CV\BV\ME;
M)'*5.UB"^0#W(R*X'2O#E]IDMAJ>I66N1VKV]Q;2#36ECG@;[3(ZEE3#%&5N
MV>@->NR7=M#<0V\MQ%'-<;A#&S@-)@9.T=3@<G%.DGAA21Y9418EWR,S !%]
M3Z#@_E0!YGX<T2<?$.SUF+1]5@M9([A?M.HS22RR85 K.&Y3/S  G) [5+XD
MTK4VU3Q/>0Z;=3I]JTR>,11$F98^7V?WB/05Z1#-%<0I-#(DL4BAD=&!5E/(
M((ZBGT 0VEP+NTAN5BEB$J!Q',A1UR,X93R#[5YB/!^I7L^N:--:2I8Z9;7*
MZ3(5(5WG<2KM/?;M"\=,UZEO7?LW#<!G;GG'K3J /.+>/Q/%X'U#6H[2YM]9
MU6]6:XCCBS<0P K'A%/5@BY Q_%6)KNES7NIZ7=66@>(->M(A.MT-5DE7S T
M9 "JV"N.3D* 3M /I[ [K&A=V"JHR6)P *C^UVWVS[']HB^T^7YOD[QOV9QN
MV]<9XS0!PGAB*]@\3VD>C'Q NC>5)]LAUB-@D1Q^[6(N-V<]0"1BMO5K.YE^
M(/A^[2WD>W@MKM9)0I*H6";03VS@UTU% '(Z;87<=[XR=[651=3Y@)0CS1Y"
MCY?7G(^M<KH\>L6]O9V&N1^([:RATZV6S@TN)UWOL_>"1D&Y6#< $@8KUBH;
M:[MKV$3VEQ%<1$E0\3AER#@C(]""* /*/ =KJ?@W6=6U#4M U,6NI2LJB*%[
MB2%E=B <9+*0_P!\9!(ZTAT35;FY&OW.DZM;PQ:W=RR6UHS1W0BFBB"R+M()
MP5P0I/4CUKUPNJE0S %CA03U.,\?@#3J /.M*N+72-:FUT:1XADMA%'9+=ZA
M-(\K&20<".4Y" XRW')X!KN]31I-*NT12SM X50,DG:>*DN+:"Z5%N(DD6-U
MD4.,@,IR#]0>:1KVT6:"%KJ$2W()@0R#=* ,DJ.^!SQ0!PR:5?\ _"-> H&L
M9_,L[JW:Y0QG,(6)@2P[8..M0^._#^J:QXFEFL+.281Z0C(2,)+(ETDGE[NF
M2JG KT:B@#S[Q7K>J^)/#U[IVD>'=15)+.7[2UW:O$RG;\J1@_?8GKC(Q5W7
MTN]/UCPMK7]GW=U;6$4\-RMM$9)(_,C0*=@Y(RISCI74ZCJFGZ1;_:-2OK>S
MBS@//($!/H,]Z-.U73M7@,^FWUO>1 X+P2!P#Z''0T >:WEAK.J^(-3\0PZ)
M>I%;7NG7L%O-'LDN8XEE5PH/\7S9VGGIW.*F\63:AXHOC+8:#JB6\6CWT0DG
MM&C9Y'1<(%(SV&/4DXSBO3F944NS!549))P *3>@95W+EN5&>OTH Y"33[MM
M;\$2_9)2EG#,)VV'$)-N%&[TYXYK'\3Z'JESXPO=3M+*286;Z?=1(1M%R8FD
MW(K'@MALX]<5Z':W=M>P">TN(KB$D@21.&4D'!&1Z$$?A5?6-'M-<TY[&]5S
M&S*X:-RKHRG*LK#H01F@#CKC69=8^(_A<_V3>V4,:7A#7D7EL[>6,@+G.!QS
MT.>.E:_CZWN9-+TZYMK2>[^PZK;74L5NF^0QH^6VJ.2?:KNE^%;33=1_M*6\
MOM1O!&8DFO9O,,:$Y(4  #.!DXS6W0!RN@07#^-]>U)[2XAM[NULC"\T13.%
M?<.>XR,CM7$VWAR_L=7&L7UEK2V;37D$@TUI(YX@TY='VH0S(P],] :]@I.E
M '(^"=/6.^U344T_4[>.X,<<<^IW$CSW"J#R4?E "2!D\^@KKZ:K*Z!T8,K#
M((.013J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH *Q?%FN3:!HOVFUA2>[GFCMK:-SA3([!5W8[#K
M^%;59/B70QX@T=K-;@VTZ2)-;SA=WE2HP93CN,C\C0!S^KZSXJ\(V,U]J)L]
M8MC%A&AB^SM%.S*J(06.Y26ZCD8IUYJ_BCPQ+I]QJ\UEJ=O?SK;/%;0&%X)7
M!V!26.Y2PQS@\@T:EX3U_P 40O#X@U:WMH4A*PQ::'"M+D%9'W'G:5!"_7FI
M)_#?B+79[%/$&HV26UA*+A/L",))I5!",Q;A<$YP,\T <]:^+==US3C]FU_1
MA>3(RW6ERVS12V@P<[=SY=EQR,5U7PX2Z3P%I/VJ>.;=;(T6R/9L3:,*>3DC
MGGCZ5DWO@G7=<BL[+6[S3)8K.5'_ +0B@87<H3H,GA2>Y!-=#X0TK4M#\/P:
M5J4UK.;0"*"2W5EW1@ #<#_%UZ<4 9D>J>(_$6IZJNB7=E86FF7!M5-Q;F5K
MB90"V<,-J@D#C)Z_2N:TV_U+Q5X\T6_EDM(&6SG#V[VQD$1CD5)5!W<EB"0V
M. <8-=2V@^(-)U/49O#MYIXMM2F-Q)%>HY,$I #,I7[P. <''/>F:#X(;0=5
MTVYCO!.EI9SQ3,ZX>:620.7] ,@\?2@#HM6N+JTTJZN+*&.:YCC+1I+($0M_
MM,>@]:\\OO'FI:1<0JOB/1=;:=)!)!9PX^SN(V92&#G<N5P<X/\ 3N/%>AMX
MD\,WND)<?9VN4 63&0"&#8(]#C!]B:Y?6/!?B+7;.SAGN-(L8[-R4M[.%Q&V
MY&0L2>F > !Z\]* $7Q#XKMM)T77[R?3VM-2EMXY+..W8-$LN '#EN6Y!(P!
MV]ZLKXRU$>#)9FB@.OI?'3/)"G8;G?M'&<XVD/UZ5HWWA>XNO"FCZ.MQ$LNG
MO:,[D':WDE<X^N.*P].L;+6_BI<ZEIMVEUIUI$EQ-Y1#1_;"K1C!'!(CY/H<
M4 =;XDN'LO".JW)2*=X+":3;*FY'*QDX9>X..1Z5@W^O:Q#!X4M-)CLXY=8C
M*OYD9V1 0A\JH(X'/'?&,BNDUW3WU;P_J.FQ.J/>6DL"NW12R%03^=9G_"-W
M'VOPO-Y\>-$1UE&#^\S#Y?R_CSS0!S]YXL\1Z!?7MIJ,MG>1Z<]M//<10&,M
M:R,4?Y=QPRG!ZG@&MC5O%DNGZWJ"QHCZ?H^FF[O"!EFD;/EQ@]LA2?Q%69O#
M N_$&K7MTZ/::EIZ6;1#.X %LG\FJGH'@@V7A2_TC5[O[;<:D&2YN$&"5V"-
M,9]%4?CF@#F9/B5>V%A;ZM+K>B:D9BOFZ1:@K+$&Z!'W'<P)&<CUHC\5ZWKF
MBR&V\0:+)<3V[_:].>V:*:T&PEMH9\N1C!X]ZZ"/PYXM>SMM*FUFQM[2WVJ;
MVT@874JKT!#952>,D9JK?>"-<U];*VUR[TMDLW5_M]O PNIMHP 2>%SU;!.?
M:@"OX7N[RSM? =G<BSN1>6\A23[-AX$6W!558D\]B1C(["M6+5?$NO7^JRZ+
M/8VUIIET]K'%<0,[74B8WY8,-BY. 0#ZTS1_"6KVLGALW]W9.-!\Z)?(5QYD
M31"-,Y_BSDGM65<ZA%H>JZ_#IWB;3]+AEN&FN[>_B/G0R,H+20_,-X;@C@\_
ME0 ^T\7ZSJ&A:7?7>KZ/H,-S;-))=7(#-)('9=B1EQP  2>>M9'A[7=:\3?$
M#3IVU"Q;[(+JW\R&V;9-&AB+,,OP6##![8Z&KG@SP?KEAIVEZO:II[3S:>D3
MPZE&Y:WPS,"A'3(897CGO6AI7@37='\0)K$>J65U,UY/+.98F7?',(]^T _*
MP*''4<CTH EL_%<]CX$DU*&PM?M<FH26EM!$GEQM(TY12V/S)[\^M2ZCK7B3
MPK-:G5[NQU"VO]\2O#;F%H)]C,HQN.Y3M([&IXO!$C>#I=#FO5CN/MCW<%S$
MN?*?S3(AP>N. ?QIEWX8\0>()[=_$%YIZQ62NT$5FCXDF*%0[EN@&20!Z]:
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MYQ5_Q%_R4CP;]+[_ -%+5O3],\32ZM;76KWUA#;VJM^XT^-A]H8C&7+= .H
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M8F164C=VPO/O5%/#'B/3+2\T?1=2L(]+NI)&C>>)S-:"0DLJ@'#8))&<=>]
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %175M%>6LUK.@>&=&CD4
M_P 2D8(_(U+10!@/X)T"30K'1'LRUC83":",N>'!)R3U/WCGZU/JWABPU>_A
MU"22ZMKR&,Q+<6EPT+F,G.TE3R,\UL44 <J/AQX<CN6NK6*ZM+IF#?:;>[D2
M4'&"=V<G=WSG)YK:T?1+'0K:2&R1_P![(99I99&DDE<]69F))/%:%% &-_PB
MFD?\(T/#ODO_ &>#G9YASGS/,^]U^]4FK^&M*UV>.74K;SS'#+"%+$#9( &&
M!]!SVK5HH YD> -#?[.;HWMZUJZO;F[NY)?*VD$!03@#@9XY'!IJ_#OP^IB4
MI>/#;RK+;6[W<C16[!MWR*3@<C\LCO7444 <Y>^!-$O;JYF87<,=XV^ZM[>[
MDCAN&[ET4X)/?UK4T[1;+2I[B6S1H_M&P,F\E%"+M4*O11CL*OT4 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %9OB#3[S5=(EL;&_:PDF*AIT'SJF1N"GL2,C/;-:58OBR778M F'ANU
M%QJ,A"1Y=%$8/5_F(!('0>N* .=BL+/1?B%I>G>''G7]S*^JP>>\D8CV_NV?
M<3ARV,=R,]JL?$2X6 Z*+Z:4:1)=E+V"WD*RS94[  I#, W)"\X[<4>$H=4T
M?;9'PC<6RSL7NK^?4(99)7P3N?!RQ)X]LT[4K77KF_T+Q.-$#75DDT=QIGVE
M&=!)@;D?A2PV^V0<4 1?#VXBGO\ 74TV6;^QHIXUM(+AV,D+;3YGRL=R*3C
M;WKMZY?0-/U.X\4ZCXBO['^S4N;>.VBM3(KR,%).]]I(SS@#)XKJ* "BBB@
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MA]NV$)O:3H<X&..Y(YK;KSWX>Z1/'K6H/<2":UT0OI>GMG/R>878GW ,:?\
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MWH.HJK2+:S7$S1!]OF!(';;GWQZ5U^I1W<VF745A.(+MX7$$K*"$?!VD@@Y
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M@21A/Y1(+C"=#PW0^@]:Z73[BXNK&*>[LWLIW&7MW=7*'TRI(/X5B^.--O\
M4M$A_LVW%S<6M[!<B#>$,@1P2 3P#CUH PUU/6X/B)JD5CI(N[F33K5WB>[\
MN* C?GY\')R<#"\X[5=M_'TFH0VEMI^C/+K%Q)-')923A%M_*;:Y>3!XSC&!
MSFKNCZ?J(\8ZCK%U9FVAO+&V55:16*NNXNIP3TW 9Z'M7(2^!+^/5'U>[T&+
M5HS?7GF6+3(&:*23?'(A)QD<\$@X- '<Z#X@DU2ZO=.OK$V&HV)3SH/-$BE6
M!*NK #(.#V!!%;=<IX-T1]/NK^\/A^TT2&?8D$$9#3%1G)D96*\D\ =.]=70
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !5;4=1M-)L)K^^F$%M -TDA!(4=.U6:Y7XF_\DYUK_K@/
M_0A0!U*L'4,IR",@TM<?XAOM977?#6D:5?BR348KCSY/)60@(B,"-PZ\D#MS
MR#BL:[\1^(=&U&^\-_VDMY=27EG;V5]/ H:(3ARQ95 #;1&<<<YY]* ._EU&
MS@U"WT^6<+=72N\,>#EPN-Q].,BK5>8>(I=3\)>*M.U*_P!3?5HK;3;V6#SH
MD1]X5,J2@ *D[<<9'/6JT_C/5['2X=3@UR^U*\<*;FP;1WCB4,.?+?RQC9G.
M68@XH ]8HKS :KXOB\+:#XA.OI+<:E+! UJ]J@AQ+\H;@!MV<,>0.H  JUJ^
MK^(/#=UK5@^MO?%-$?4+>>6WC5H9%?:0 HP1R#@@]* /1:H6NMZ9>:9!J4-[
M$;2Y8+#*QVAR6V@#..2>,5R<EWXDT>;P]J-YK?VR/5;N*VN;,VZ+''YB$@H0
M-WRD=R<UBWUUJ>O?#?PIJ$^I/'<3:E;B1XX8P&8S85L;< KC( X/<&@#U6BO
M/M:\37*>)Y-!DUR\T^#3[6(S7-KIYN)KF5QGG;&RH,#/09)...F-8^.=4U/4
MKC2[[6[JP@L!C[9::3(TUYN)V,4,;>6-HY&!D].* /6J*YKP1K=[K.FW0OB\
MLEI<M"ER]LT'VF/ *OL8#!YP1C&12Z%JU]>2>)1<3[Q8W\D-O\BC8@C1@.!S
MR3US0!TE5;C4;.UOK2RFG"7%X7$$9!R^T;F_(<\UY[X?UKQ/XEO],L?[<:TC
MGT..]N)H[>(R&0RNORY7 R ,\8^7@#.:9IFI:C?>,]!MM3N1=3Z;JNHV?V@(
M$,JK;J0Q X!^;''I0!Z?17FUYXMN-0US5H?[?O='AT^X:UMX[72VN?,90-SR
M-Y;#&3C:".!67;>-M=O8I+C7-6N_#3;0MFPTW-K*P&"SLR%AE@>.,#% 'KM%
M>5R>*]86>=M5\2_V-<^8/L)^Q!M.N8\#:WF[22&Y.=PQFO1M1NIH=#N+JWFM
M(YEMRZ2SN1 IQD,S#^'O]* +U%>1ZKXSU'2K6UN].\5W.KR3,8IP^G!+=248
MAHW\L#((&!DY'6M==1\466@Z#XDN==^T?;I;5;BR^S1K%Y<I X(&X,-P.<XS
MVQQ0!Z+17 GQ5J]IX6U.RFG$OB&UO_[-@<QJ#(\C#R9-H&/N-GICY37<QAH+
M51-*96C0;Y" "Y Y.!QS[4 2UES>(])@UR/1'N_^)A* PA2-F(!Z;B 0O3N1
M7(VM]XIU7PC+XPAUP6S&.2Y@T[[/&T'E+DA&8C<20OW@1@FF>!#=:GXSUK5S
MJ<YBGM[*=H6BCPZR0ED4D+D;,X&,9[YH ] N+B"TMY+BYF2&&)2SR2,%50.Y
M)Z5#_:=D=2331.OVN2 W"QX.3&" 6STZD5SWQ/BEE^'NK>7</#LBW.%53YB_
MW3D' ]QSQ6--IVJR>/M*L[?6Y(Y_[#D\Z\,$9D*><IPHQM!SM&<= >_- 'HM
M%>7W?C+6=),V@7.IE[I=4-J-2%GYCK!Y0D+>4@(9QG'3'<CBMGPMXANYO$K:
M5_:%YJUC);&5+JZT]K=X9 0"A)10P(.0<9XQ0!V]59=1LX=1@T^2<+=7*.\4
M>#EE7&X^G&16!K5]JE_XOM_#6FWYTZ,61O;FYCC5Y&7?L5%W @<Y).#TJG:7
M7B/3O&>EZ/JFH0WEO-'=.DJQ*KRHH387^4;6!+#Y>#Q0!VM%>?VFKZ^[^(M<
MN=8(T[0KRZ1+%+=/WZQKN 9\9'4 8YX.>M7=/MO%\FFV&M?V]'/)<*LUS92P
M(D"1L,D1D*6W*#P23DCF@#LZ*X*7Q+JZ_!R'Q +O&I-#$QG\M.2TJJ?EQMZ$
M]JADOO$^HP^*;R#Q UG%HUU,MM$EM&V_8@?:Y(Y7D#CGDY)XH ]#I"<#)Z5Y
M^NK>);2#PUKMQJJSIK5Q%#+IP@18HQ+&67:V-V1@9))S^E9,'B+6+H16M_XK
MGTC69G*3V%[8)'%M)((A8H<GIM)8YH ]2M[F"\MTN+:9)H7&4DC8,K#U!'6I
M:\RT*ZO=(^&.AR-XDAT^&X*[YYXU,D4>#^[A4+\[9'5LD GKQ6;<^,_$$'B"
MVT72=<GO(KN>W$5U?Z>(G4.SHPP47<N0#D =,9ZT >OT5YSK7B/7/!%_?0W.
MI-K$3:6UU!]HA1&CF$BH!\@&5.\''M6CJ/\ PE'A73'UNXUQ=5BM[>22]M9X
M4C7(4E3$47(^; PQ/!ZYH [6BO)Y?&.MVFF0:E9:Q>:MJ,FTS:9)H\D<!W=D
M?RP1MSU+'.*TO#/B2\N=7T^WN_$TRWTO%[I6IV(MSG;_ ,L2%'(/;)R* /1J
M*YKQOJ&K:=IEM+I@N%C:Y5;R>UMQ/+##@Y94.0><#.#@=JXMO'5R+VWTJS\6
M&[M;IV9KT:>7N[5$7YD:)4P2S$8;;P <T >J3W,%MY?GS1Q>:XC3>P&YCT4>
MI/I4M>,ZKJNJZIXAT?2TUR_N+1-2@>WO9=.$#JY#@A@\8#,N,C P0QR#CCV%
MY/LUJTDK%_*0LS8Y; Y- $M5;K3K.]N+6XN8!)+9R&2!B3\C$$9_(FN&AOO%
M5YX-D\9)K8B?R7O(]-^SH8/)7)V%L;R2H^]D<FMGP;X@NM?&KW,TA,,=PGV9
M"H!C1H4?;D#GECR: .E-U;B[%H9H_M#1F01;AN* @%L>F2!GWJKKDFFQ:)=M
MJ[A+#RB+AB6&%/!Y7G\J\X\%W&KZWXRTC5;W69GFGT(S2 0Q ,HG"E.%X!(W
M9ZY[XXKN/'&H76E>"]4OK*01W$$!:-R@;!R.Q!!_&@#2TK3;#2=-ALM-MT@M
M8Q\B+GOSGGDDYZFKE<?K5[KEQXJT;1].U/[#!>64LMQ((4=AM*8*[AP><>G)
MXZ59\)WVIG5=<T74[W[>VESQ"*Y:-49TDC#@,% &1G&<<T :NK^(-*T)83J5
MV(6G)$2*C.[XZX502<=^*L:=J5EJ]C'?:?<)<6\H^21#P>Q^ASVKCO$?]H7G
MQ!M8]&FM;74M.L&FC%WDI>([8,8 Y &S)8<@D<5<T=+#Q-H]_I3V5SH=Q%=G
M^TK2"38Q=OF/SKU5P<Y&,B@#4>R\.^+9+>_9(M0_LZ=UB?<VQ9 1NXSAL$#K
MD>E6-7\1Z/H)B74[Z.W>;/EI@L[8ZD*H)Q[XK#^&EO%::!?6T"".*'5;I(T'
M15$A 'Y5I:Q)H?AVZE\37^5NGA6U4@EGD&25CC7N23T'X]* -/3M2LM6LDO=
M/NH[FWD^[)&V0?4?7VJU7->"-+O;&PO[V_@%I-JM[)>?9 ?]0&  4_[6!D^Y
MK/\ $VKRP:^]G-XI_LN%85:&VL+;[1<R,<Y9QL;:O0 #KSS0!VM%>5>!]<\6
M>-+_ %2TGU^2TM].VH98K.-)7?+@$AE.W.W+#&<@ 8YJU:>(O$^KZUI^@QZH
MEK+%<7MK?W,=NA,ODF,K(@8$*Q#@>@)/' % '3>(O#_A1Y6U36K54:9DADD$
MDB"4DA5#A" W4#D&MB"[TZVODT2!HXIXK82I;(N L0.T$<8 SQBO.O$NH:C
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M,LK1)=Q&,NHR5ST.._-9^F>&KJUUFTU:_P!4%Y<V]@]DQ6W$0D!D#AL!CC
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M2G#2>8-H/N:>9X54.94"E=P)88QZ_2@#&T[P[<:3HVH65EJ9BN+NYGN([GR
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M.2\TZQ8-#"EN(I'(&%\QPQW8![ 9/6M7PMHEUX=T2/2[C41?I;_+ _D",I&
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M9Q4J;?)VX)R1USUJ_L79L*@KC&#TQ0!YMKNC:'HG@W2-6T*""+4DGM?L=U"
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MOX@CCO8[;1$:S@N0'1LRNKOM/!("JN>PQ7INCZ#I>@020:59I:QR,&95).2
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MT>WW)&(AY8,8*#@*0I ( [&@#.T2XU*V^%7GK>Q7]]!83&&X@9G60J&\O!8
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MN/ OA>[N9[B?1K=WN"3)U"ECU;;G 8^H&:EU+P=X>UB[-W?Z7%+.RA7?+*7
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M3;X-1M7E0QG,8"ORP[8..M '11>/-&Q>B]2\TV2Q@%Q+%>V[1N8R<!E'.1G
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MH-.UM+C<-5MW/DWMNJDO&.^XC^%NG)!['H]>@FD\>>%)DB=HXC>>8ZJ2J9B
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M &<3#[).UM)YR;3O7&3[CD<]ZY#5&DMO%/BNWDMKDMJFDH+1TA9DD*12[AN
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M65Z/@??VTUG(EY)#>9A$9W%C))C ZGMC\* .HO\ QE86=]-9P6FH:C-;*K7
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M':7-A/K?B5(-2WZ3?VU[$]^I$UQ;^7LEY('5<G'&, 8'2@#U6SU>UOM2OK"
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MHECPTFX$_P!S<0?]GI0!Z117/WWB4IK6FV&GQ+=)<VLEY,RY)6%0-I4=RS$
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MB[3<,M_#P OM75S^*]9T'5;>'Q+:V"6EW;SS(]D[LT)B3S&5MV-WR@X(QR*
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M_I>D6MY9W,<TVM6LA6:X"G)P@08+=\D@9.*[^""&V@2"WB2**-0J1HH55 Z
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M9Y[?YSM"NJ@;CC@_*?6KGB?PY-K.G:+;'9Y5E=I+= DY,8C=6VX')^:NHHH
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M P!V- '&>%+[5/%]U8Z1J6K7J06=C)-*]O,89+EQ</$I9EYP%0=#R3S6_P"
MK22QU?Q1:R7<EVT>H*!-*<NP\I<;CW(& 3WQ5M/ .GVUO:+87]_97-GYHCNX
M9%\PK(Y=D;*E67<<@$<5H>'_  S9^'/MAM9[J=[V433/<R!V9\ $YP.N,GW/
M8<4 85M:W/BOQ'KIN=6U"SATVX6UM(;.X,00[ QD8#[Y);C=D8XQ6)\-;F\C
MU'2+![N1X?[,O9'0,0CR"](W[>F<$\^]=CJ'A&WO-4FU&UU+4--FND5+K['*
MJBX & 6RIP0.-PP<4FA>"M+\/7%K-8R7)-I;2VT:R."-DDOFG/&<AN![>O6@
M#C+BYU'2KF:X\17?B"PN5NRZ:I;R&>P$>_Y5:-3A5VX&",YYSVJOHNF7>E_"
M2W\26VN7\=[:6QN(D$Y^SA0Q_=F+[I!'4GG)ZUV+_#ZP:*6R74]232I9#(^F
M+*HA.6W%1\NX*3S@-45K\-M-M;"#2_[3U272HF#FPEG4Q2,#GYL*#@GDJ"!G
MM0 [PEJ=U?Q>(Y[B:4B._;RED<GR5\F-MHST )-<KX;34_$^H:397?B#58+=
MO#T5U+]GNF1Y)?.=0Q;GMU]<#TKM+OP39W&I7=W%J.HVD5^0;RUMY@L4Y QD
M\9&1P=I&:FT3PAIV@W5O<VDMP[V]@M@HE92#&KEP3@#YLL>>GM0!QNM/J>GZ
MCJD^M3>(;>,7#/9:GILIEMK:$8V^9$I[?Q;@<U0T[5-9\0:#+K87Q1)J,YD>
MTFLG1;2+:Q"+Y9<!EX&[<I/6NWNO EI/+>K!JVIV=GJ#M)=65O*HBD9OO]5+
M+N[X(S43?#O3DAFLK/4M3L=,N"3-I]O.!"V>H&5+*#W (S0!R&FC6]7\%>(O
M$&I:SJEKJ&GSW+P6\-TRI R#>5('WAG*X.0 .*TK^?4/#T'A_P 1?VM?WEQ?
M _;()9R89<P/)A8^BX*\8_6NLM/!VEV/A_4M#MO.CL]2:8R*&&8Q(,$)QP .
MF<_C5BY\-V-U#I4,K2E-*=7A&1\Y5"F&XY&">F* /.+6]\07/A^WUJTA\43Z
MU*J7 E:1/L4F2#L\OS,!,' ^4'O3K:/59?A;+XLD\0:L-2MQ++"/M3>6@25E
MVLG1\XY+9Z^@KKA\.].\@6!U+4VT@2;QI9F4P=<[?N[MN?X=V*OQ^$-.C\'R
M>%UEN/L4B.A?<OF8=RQYQCJ3VH Y+3=.O6\0>-KC2KVX34?)@-OYMRQCWR0;
MN03@X/"Y^Z/:I?#5Y]C\1:?:WT_B+3+R9'CEMM4=KB"\?;GY),E001GC&>F*
MZ.X\$:9<W][<RSW9BU"W6"[M?,'E3!5VJQ&,A@.A!%%CX-AMK^TN[S5]2U,V
M.3:QWDJE8B1C=\J@LV"1ELT 5-=>ZU?QM9>'!?7-E9"Q>]G-K*8Y)R'"!-XY
M &<G'6N5UJ[UC3/$L'A2TUV_^SOJ5H8[AI2TT<<J2AXRQ^\/E!&[...N*] U
MOPY;:U/;7?VFYLKVTW>1=VKA74-U4Y!!4X'!%48/ FF1R17$MS>7%XE]'?27
M<T@,DTB*RJ&XQM 8X  H IZ5!/H?Q#.CQ:E?75C=:6UUY=Y<-,4D655RK-R
M0W3UH\7W4+:Y9V$NH:LX,#2G3-(1A-)R )'D4C:@Y&,C)[UT3:-;-XBCUPO+
M]ICM6M0N1LV%@Q.,9SD#O5/5?"\6I:O%J\&HWNG7T<'V=I;5D_>1[MVU@ZL.
M#D@X[T 9'P]OKR:36["Z:^,=E>*L":A())XT9 VUF!.?S/6LC0=._LRW\<W5
MO?7YEMI;B.,R73MTA5@YR>7S_%UKL=!\,67AV>^FM)KJ5K]UDF-Q+O)<#!;.
M,Y/4\_3 XJ:RT"RLCJ>WS)5U29IKA)"",LH4@8 XP* .9U'4KV/X=>&[M;R=
M;BX?3A)*)"'DW%-V3U.<G/K6+=?\DNUW_L/-_P"EJ5TL?PYL%@M;:;5]6N+6
MQE26TMY)U*0%&!4#"\CC'S9P#QCK5^3P=ITF@W6C&6Y^SW=V;MV#KO#F42X!
MQC&X>G2@#?KS'^U=6D^$=C=Q:G<I?2ZCY?VHR%GQ]K90"3U&,#!XP,5Z=7/I
MX,TU/#<&@B6Y^RV]P+A6WKO+>:9<$XQC<?3I0!ROB6XOO >IPS:?JFH7B7>G
M7CR17MPTR^9$JLK@'IRW(&!@4S6] FLM'\/ZB^N:A=SRZE9-<K<7!DCF+.IR
MJGA,'IMQQQS7<ZGX>L-7U&SO;P.YM(IXEBR-CK*H5PPQSP/45C+\/+'_ $..
M;5]6GMM/GCFL[:2=2D)0@J/NY8<8^8G )QZT <C::EJ^OZ7=:R(O%'V^664V
MDEE(BVL 5BJ+L+@,./FW+D\TW31KFJ^!M?\ $6I:UJEMJ6GW%RT,$-TRQP,G
MS%"HX89RN#D   5VEQX"LI6NXK?5=3LK&]=GN;&WF41.6^]C*EE#=PI'6K5I
MX,TJP\.ZCH-L9H[+4&F9U##,8D&"$XX '3.?QH YN2._TC4/#.I?VSJ%Q-JK
M&.]CEG)A?="SY5.B8(XQBLB%-5A^%MKXO;Q!JDFJ1)'*-UTQB9?,"[&3HV5Z
MD\D]Z]$N_#EG>#2Q)),/[*</!M8?,0A3YN.>#VQ5<^#]./@Y?"OFW/V)8Q&'
MW+YF V[KC'4>E '*WCSZGX$\=+=7ER_V:^O1%^^8;51 0G7[O^STYJ[#Y_AN
MX\*72WUW)IUW$+&Y2>X:0*\@WQ-R?[P*Y[ @5T47A?3XM.U>P)FD@UB:::Y#
M,,@R !@I &!@<=:Y[Q/H\\'A"+PC9PZIJLUWM2"\F 9;;:ZD,\@ V[1R.,G&
M* -7P;=7.K1:CKDT\KV]_=L+*-G)1((_D4@=MQ#,?7(K$MM".L_$3Q5YFI7U
MK!&+0>79W!A+,8>&++SQV'3DUV^G6,&F:;;6%LNV&VB6)![*,#^58EYX+M[C
M6KS6+75M3T^\O@BS-:RJ 550H&&4CMG/4'H: .2@UN>]M+73-2UC5+B6TO+N
MV:WTR-OM%^L3;5D9U(VJ!UZ9/>LR&Y\1RZ]?:?%'XAGT6PD1YK'[:!?*)(\K
M\X;+*""=H;/(S7>GP'IL"V#:7=WNF3V,;Q)<6[J7D5SN8/O5@V6YZ=:JCX:Z
M;%JKZO;:KJT&IR8W7:W"LY."#G<I!SQD8QP, 8H Q/".LM<>.H=.M]8U6XMX
M[6X:2SU%62:W;='M1P3\Q )PQR<'&:KW5QJ6EW,]QXANO$%A<+=EX]4MI#/8
M"+?\JM$IPJ[<#!&<\Y[5V&D>!].TC73KBW5[=:B\;I-/<2*QEW;>3A1T"@ #
M  [5!)\/K!XI;-=3U*/2II#))IJ2J(3EMQ4?+N"D\X#=Z #2Y/L_Q+UJVB8&
M&\L;>[;'0."T>?Q55_(5!XAUN;PQXHDO;BXD:PNM*F>.%G)19X?FX'0%E;MU
MVU?\-V$S:MJ^NW,#P->R+!;1.NUD@B!520>FXEFQZ$5;\1^&-.\46UM!J/F;
M;:X6=#&P!) (VG(/RD$@B@#A-*U/7!I,'A.^U&Y;69-5ACDG\UO-%NR+.Y#9
MSP R_I4^E:#)J2^+[O\ M?4K0PZM<^0EI<&)4<*IWD#[QZ#!R,#WKM/^$7T[
M_A+?^$FQ)]N^S?9\;ALQG[V,9W8XSGIVJ2PT"TTZ'4HH7F*ZG<R7,V]@2&<
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MHUF0[5"@!5 R>![UO6'A"VM-3@U"ZU'4-2EM%9+47DJLL (P2,*,DCC+9.*
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M&?I7)Z ME:>*K2/4A%%I%OJ>IQ6BRX$,<X<;1SP#MW;<]\XH ]5LM5T[4O\
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MH **** "BBB@ HHHH **** "BBB@ HHHH **** "HKFUM[R$PW4$4\1()25
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M#:P+]Z6:0(H_$\4 6**@L[ZTU&V6YL;J&Z@;[LL,@=3^(XJ>@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***@BO+6>XGMX;B*2
M:W($T:."T9(R P[9'/- $]%0B\MFO&LQ<1&Y1!(T(<;PI. Q'7&1UJ:@ HHH
MH ***:70.J%@&;. 3R<=: '45#:W=M>P^?:7$<\18KOB<,N0<$9'H01^%34
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MSV^TRQ*X+1[AE=PZC.#C-34 %%%0W%W;6:H]S<1PJ[K&AD<*&9C@*,]R>@H
MFHJ.>>*V@DN)Y4BAB4O)([ *B@9))/0 4L4L<T22Q.LD;J&5U.0P/0@^E #Z
M**:[K&-SL%&0,DXY)P/UH =1130ZER@8%E )7/(ST_D: '4444 %%02WUI L
M;374,:RRB&,LX =R<!1ZG(/%3T %%%% !1110 44UG52H9@"QPH)ZGK@?D:5
MF5%+,0JJ,DGH!0 M%16US!>6T=S:S1SPRKN22-@RL/4$=:>[I&A=V"J.I8X
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MC3.U%SR>222>I-;M !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M^GSPL+14.-H3'S C'4YSD\#O2T+P#J>@>)$UVUN]/$ERT@O;9(&2)(W9"1"
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M]O=7MEOX[BWFM+:-9#:1&)MW()R2Q/+<'@"@#LH5D6"-9I%DE"@.ZKM#'')
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M,6]),,3SNX)[YJMJ6D6VB_#N#Q;97EP=:CA@NC>M<.QN'<KE6!."K;B,8]*
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M=\^E_P!J6%['/--<NR!TC4I(Q8G!!.=U 'H]9GB'7(/#NDOJ$\4D^'2..&(
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M-4KW5K6POK"RF+^=J$C1PA5R,JI8Y/88%<EH^M-XT\0Z-/"S);:?8?;+I%)
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M_LW39+594L7OUN&BDW8+* 255A^&5KMZ "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *J:IIEIK.F3Z
M=?Q>;;7"[9$R1D?4=.:MUE>)+UM/T=[A=0CL")8E\^2(R 9=1C:/7.,]LYH
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MRC->7#SNL?\ <!8G"^W?O56W\ Z#;SQ.L5RUO!)YL-G)=2-;Q/G.Y8R=HY_
M5-!XW\.SVMW<C4"BV2>9<)+!)')&G][8RAB/<"G6/C/P]J.IIIUKJ(>XEW>4
M#$ZK+CKL<@*^/8F@"_INDV>DQ3Q6<91+B=[B0%BV7<Y8\^_:L0_#OP\UK)9/
M'=O8ONVV37DA@C)SRJ9P#DDCT/(J7QAXJ3PO'II(R;R]CA;,3OMC+#>1M'4
M\#OV!Q5G4?%^AZ4\,=W>,)9XO.2*."2239_>*JI*CW(% $;>#=&:ZN;CRYU:
M\M/LEPJW#A9DV;!N&<%@O&>M6+[PSI6HZ5;:;<0/Y-GL^S.DC))"5&%*N#D'
M'?-7=/U"SU6QBOK"X2XMIAE)(SD&LB]\=>&]/NIK>XU AK=]DSI;R/'$WHSJ
MI53]3Q0 D7@?0TAE22*>XEFECEEN+BX>261HR"F7)S@$=.E:&HZ%INK75O<W
MUN)GMXY8T#$[=LBA7!'0Y [T:SK=KHN@76LRGS+>WA,HV'[_ * 'W) _&N>B
MM?'E[IRZF-:LK2ZD3S4TW[$&B7C(1I"=V>Q([T :6G^"='TZ[M[A#>3_ &3_
M (]8KF[DECM^,?(K$@<<>U:5EH]E87]]?6\9%QJ#J]Q(S$EBHPHYZ #L*PM%
M\0:M?^*XM/O[7[$K:-'=R6K %HYC*R'YAVP!BK,WCWPS;W+0R:E@))Y33""0
MPJ^<8,H78.?>@"YJGAG2-9O8[R_M!-*D#V_+$!HWZJP[CN/0\BJ=KX&T2V=V
MD2ZO,P/;H+RZDF$43##(FX_*"...<4[3_$-G;^&SJNIZQ#/ MP\;72PM&H/F
ME%7&,\'"YZ<9J-/B!X7D,BC5,-&H8(T$@:0$X!0%<N,_W<T :NC:1;:%IT>G
MV;3&"/[@FE:0J/0$\X'85F6.CRV.O:S;&$OI>KC[3N4X\N4@)(I[_, K _[W
MM6GH^MZ=K]D;S3+D3PAS&QVE2K#JI5@"#[$53U7QAH.BWC6=]>E9T0/)'%#)
M*8U]7V*=H^N* ,Y/AIX;6!;8I?O;*-OD-J$QC(]-N[&/:MM-"TV*^L[R*V$<
MEC UO;A"0J1G&0%Z?PBJ.H>./#6F)"]UJL8%Q")XO+1I/,0G *[0<]#T]*V9
M+NWALVO)I5BMTC\QI'.T*N,Y.>G% %>'1[&WO[^^2+]]J(07)+$APB[5XZ#B
ML^P\&:-IL-I#!'.8[&X-Q;+)<.XB8KMP,G[N.W2H8_B!X8E8K_:+1_NGE5I;
M:6-9$52S%2R@-@ GC-2VOCGPW>W\%E;ZD'EN#MA)B<1R-_=5RNTGVSGM0 E_
MX*TC4+VXNF-Y;M=X^U1VMW)$EQQCYU4@'CBKFE^'=+T6QN;'3[;R+>ZD:22-
M6.,LH4X]!A1P*TZX?PUXQU#4O$_EWGEC2M5$QTE@N"?);:P)[[A\WX4 =?IN
MG6VDZ;;Z?9H4M[:,1QJ6)(4=.36#-\._#\LDWEK>6T%PQ::TMKR2*"0GKE%.
M.?;%:NL>(]*T(PIJ%T4DGSY44<;2R/CKA$!) ]<5@S?$32W\0:-8V%PMQ:WZ
MRF658)"R%<!%Z<'<3G/3'.,T :]]X2T:]M;. 6[6OV 8M)+21H9( 1@A64@X
M/<=Z9;>#=$M8H42WD9X;M;WSI)F>228 @,[$Y;@G@\5)I.K1-IU_>7>JP7$-
MK=3J\WE^4L*HWW#GKMZ%N]1Z=XT\/ZK<BVM;\F5D,D:RPR1>:H&24W*-XQSQ
MF@!VJ^$M+U?45U"8W4%SY?E/):W3PF6/.=K;2,BC3?"&B:1<P7%A:&%[;S?*
M <[4\P@N ,],@?2J\/Q \+7$UO%%JJM]I95CD\F01EFZ*7V[0WL2#5[Q->MI
MWA^ZNUU"/3S&%Q<R1&58\L!RHY.<X_&@"6+0["#^T?+B8?VFY>Y^<_,2H4X]
M.!VK*/@#0@R26XO+2:.".W6:VNY(W$2# 7(/3'7UP*T-5\3:-HEPEOJ-Z(9I
M(S)'&(V9G ('RA0<G)' Y_*HH?&'A^?1IM834HQ9V[F.9W5D:-_[I4C<&Y'&
M,F@!]IX7T>P?3GM+3R?[,21+8*YPHDQOSS\Q.!R>:J2^!M$ENKF5ENA#=R&6
MXM$NI%MY7/5FC!P<]^QJA#XXM;_QA;6=G>J+ 6,TUTLT31/&RE<%@X!48)/H
M:O1>/_"\P<C4]JI$\P:2"1!(BC+%"5&_ &?ES0!#H_AL6?B))E@>'3](M/L>
MG([[BQ<AI'SUQ@*HSZ'VK5\/:2^C:8UK))O9IY9>&+!0SE@H)Y. 0*H+\0/"
MK3&+^UXU.UF5VC=4D"]=K$;6/L"34D'C?PY/97%XNI!(;65(IS+$\;1,YPNY
M6 (!]<8H 2?P3HEP=3\R*?R]5.ZZB$[B-FR#N"YP&)49(K4O=*M-0NK.YN8R
M\EC(98#N(VL5*G([\$]:QF\;:'J%K?Q:?JRPW,-I).KS6T@"J%/[P!E&]1U^
M7.:R_%GBZ?2]+T*WM-3$=SJ3Q>9>K9/(!$5)9U3&,D@87K@]* --?A_X?65<
M17/V59?.6P-U(;8/G.?*SMZ\XZ>U;-_I%GJ5Q97%U&7DL9O/@(8C:^",\=>"
M:HZ5>ROK,MC+JZ7C0V4#M%]F,;@G.9">GS8^Z.F*C_X3CPV+_P"Q?VFN_P W
MR?,\I_*\S^[YN-F?;- &G;Z59VVJW>IQ1D7-ZL:S-N)#! 0O'0?>-9DW@K1)
M;2.!8IH6AN)+B*>&=TEBD<Y<JX.1G/3I65XJ^(>E:?HVIC3=20ZA;(RQL86:
M+S1_#OQL+>V<UNZWJ%Q8^#M0U.!@+F#3Y)T8C(#K&6''U% %2'P)X>BL[VU-
MF\L=^4:Y::9W>1ESA]Q.0V23D'-1CX?Z$Q9[I;N]E8(!-=W<DKHJL'"J2>!N
M4'CKWI-$\=:'J2V%HVHJU]<Q*/\ 5.L<DFT%E5\;2<YX!JQ<^./#=I?26<VI
M*KQ2>5(XB<Q1O_=:0#8I]B: -.72K2;5[?57C)NK>)XHWW' 5B"1CIV%4_\
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M#ZXK4H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ KE/B7_ ,B9+_U]6O\ Z/2NKHH Y*2-'^,$+,H+
M)H+E2>Q\\#^1-<G-LL/&5QJUTA_LNP\0R/=$*2L1>V4)(P'0!CU[9KUFDZT
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M '#^#=5NKOQ1>6IU.SU^VCLU;^UX+98W5M_$+,ORMP2W']:[JFJJHNU5"CT
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MD9)""521=HVD@'H6YXKSWQCX?EA\)W$T7@6STA[=-]S=O.D@XXQ$%8G))'+
M8&:[:YMO$/B>^TB'4-(&F6^G727D\YN$D$TB [5C"G.TDY);' H =J'C/6K'
M3[C66\,,NE6S-N:>Z\JX9 V"XB*\#N 3DBK%MXZMYO!E[XAELVBDLGDAEM!)
MN/FJVU4#8_BRN#C^*N.N/!FM7OAR\L;SPS]MUZ19-VK7=ZCQN<D@Q@L2I(P
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M=;V#7)N'W ;-\6U>,Y.3Z4 8MSXJ%]=VEAK&C-!J%GK=O;M'%>$HC/&S)(&
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M$D D5&9-Z9VEN,@XX)'&:SM2\.>)=1-_K36CQ27]Y;>?I<-V$D>TB5@4,@(
M9BV2 <8&,T 7]2^(6H^']2ALM=T"*#S=LAFM[WS$2(N$9CE <J67CH1GGBMW
M5?$PT[5_[.BM/M#QV$M].WF;1&B<*.AR6;(]L$\UR$'@E[OQ DH\,1:1I-Q8
M7%K.#,CS;F P[X)S[8+$8).*L>"-/U#4O"&JZK>%9[_4K<VD+ \/'%&8T()_
MO-N;_@5 %H?$+4DL=,U2?PQ(NGZHR16Y2[5IC(XR@V8 VL1@'/3!('2K$OCV
M;2I;^VU_1S9W5K;QW$,5O<"?[0KOL4 X7#;L#]:)O#^IMX3\(V*VP^T:9<V+
MW2;U_=B-<.<YP<'TSGM5'QKX+U'Q)X@N;B"*(PC3(DB:5AL>9)S)L8=<%>,X
MQS0!8UKQ_J7ABT^T:_X=2V$L;&V,-Z)%9P,^6YVC:<9P0"#BK)\8ZM#=V*W?
MAT06^J%DLI#> L9-A9%D4+\FX#L6Q7):YX)O=8TR6WTKP'9Z3*(6+R3SQN[O
MV6(JV!S_ !-CCM7<>(=)O;Z7PXUM#O%CJ,<UQ\P&Q!&X)Y//)'2@#F_#GC/4
M]/\  UE>:E:"YN+R_DMK:26\P)7:60G>Q7Y%7:0.N<# '2NQT35-3O9KFVU3
M2#8RP!2LD<WFPS*V>5? Y&.01W%<G8:-X@L_"']AW'ANTOHK2\<O#<2QLM["
M\COF/GY&&Y?O8_"K_@O0;S2]8OKF+3I]&TF6%$BTZ:Z$Q\W)+2 !F"#&!@&@
M#0U#7]>6[O$TOPW]HM[(X>:[N?L_G'&2(P5.X#.-QP,UEZ'\0[SQ/?\ D:-X
M>::&+R&N)Y;I4$22*#TQR1\W ZA??%4;OPWJ5QK>JOJGAS^W)+BX9K"ZN+M?
MLT$1 VHT9;(VG.<*<U/\+/#&L>&X]275K06YF$"QXE1]VQ"I/RDX_&@"Z?&^
MH36-QK5AX?-UH=LSYN?M0665$)#R)'MP0,'JP)Q6MKWB>WT7PHWB**%KRW A
M=%1MI=9'501QZ-G'?I7"6_@6?2=.ETA?!-GJ=TC.MMJ<DZ")E))5I5)# J#R
M #G'!KK_ !/H5W=^ AHVGP1//&+55CBQ&F(Y8R=NX\ !3@$]J (QXQO;#58+
M3Q#HRZ;!=02S03I="; C7>ZN HVD+D\$BJY\=:E!I<.O7GAPP:',5(G^U S1
MQL0%D>/;PIR.C$@&K7C#PY=>(-4TI(UQ:K%>17,H89C$L#1@X)R>3VK'NM/\
M5:MX2B\(3Z*EL3'';3ZE]I1H?*0C+HH.XL0O0@8SUH T?A_J>L:BVN'4X %C
MU2=%?[3YNP@@>6!M'RJ,8/?T%:(NK;_A8KVGV9_M0TA9/M'G';L\XC;LZ9SS
MNZ]JK^$-/U+1[[6K*ZL"EK/J$UW;W0F5ED5R,+MSN!'N*L#2[P?$5]7\K_0C
MI"VPDW#_ %@F+8QG/0]<8H Q?^%@ZI)HUQKD'ADOIMG)(EQ(;P!R$8JS(NWY
M@ ,\D=QVS5__ (3"^OKR[&@Z&=1L[ A;B<W(B9GVABD:D'<0".I'/%5+7P]J
MD?POU/17M@+^X2\$<7F+\WF.Y3G..0P[U%H]CXC\)&^M++11J,-_*+J*47"(
M()610ZR G.T%<Y7/% %/P9XFO(_"VAZ1I=A_:6I2VCW,GG3^4D4?F,H9FP22
M3P !VJ]%\1+VYUW_ (1Z#PXYUA%?SH'N@$B*[2"7V\H5;((&>@QSFL"Q\!7U
MA!I5[J7AR+62EB;:ZL_.021.)&970DA6!#8(S6IX4\*:CI_C4:P^@V>D63VL
ML:PV[AG3+)M$A!.6.&/R\#IF@"VGCS69K#4)X/"VZ32'=-05[U552G)$9VG>
M=O/('4=:M+XUOM1U)[#0M#%XPM(+M99KH1)LD4D _*2#TP!G//3')9:%J4.D
M^+X)+?$FIW=S):C>O[Q7B55/7C)!ZXIO@O0=3TC4)9;ZW$2-I5A;@[U;]Y$C
M!QP>Q(YZ'M0 S3O$]IKVM^'9I--F@O)1?1E6N.+9X]@D4@##YXP>,8]ZQ_#L
M=Q?>(?%&LZOI"--:O+$)1?,QA B7]THV@8().[WZ5=T'PQK%EX@TN[N+0)#;
MW>IR2-YBG:LS*8S@'G.#].^*U=+T74+:/Q6)8-IU&[EDMOG4[U,2J#UXY!ZX
MH +#6Y;;P=H<NCZ)<73WL,2P6_FDK"I3.9)2#@ #J1DGM7,^)_%^J+K.D:3>
MZ*8M3M]3@GCAM;H2)<HR2J!N(7;\P&<CWJ_>>'M;7PIX7LFLIKJ"PC5-3TZ"
MZ$3S8CP/FW $*W)&>:PKGP;XAA\7Z?K.B^%;6QM;=HY!;_:8P?DWY\P@_?;?
MC(W8XR>* -SQ7XFOF\/:[HVK:<--O_[->YMVAN/-CE0$ X;"D,"1QCWK>O?$
M4VG_ -EZ5IUC_:&IWD'F+$TOEI'&H&YW;!P,D 8!R:Y[Q#H7B#Q9_:%]+I)L
M3%IDMI96LD\;22R2$%F)4E5&% '/O5KQ/X3EO-1TG5CHT6LI:VAM;FQ>14;!
MP0Z$D+D$'@GD&@#H-!\02ZI=7NG7]B;#4K$IYT(E$BLK E71L#(.#V!!%;=<
MIX,T-].N;^\/A^ST2*?8D$$9#S;1G)D925Y)X Z5U= !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%<]XXU&[TOPT]U93&&87-N@< 'AID5ASZ@D4 =#17(^,M9U#2]9TB&RN3$D]
MO?/(H4'<8X-R'D=CS6*NJ>*;/POHOBFYUWS_ +4]MY]E]FC6)HY2J\$#<&^8
M'.<9[8XH ]"NKF&RM)KNX?9#!&TDC8)VJ!DG YZ"BTNH;ZS@O+9]\%Q&LD;X
M(W*PR#@\C@UYY*=<\4>#M9\0+KDUJCI=);6*1IY/DIN0J^5W%FVGYLC&?PJA
MIWBN:9+723K-YI%KIVF68W6>G-<O/(\*MDG8X50"!C )YYH ]8J&[O+:PM9+
MJ[G2"",9>21L 5YEX?U_Q;XK\0SZ0NLMIT5G;!VN!8!6N")&57"2#*AEVD@]
M"O&,FNC^*<#S> +TK<RP^6\3'9M_>#S%&#D'CG/&.0.V00#I?[3L_P"UQI/G
M?Z:8/M'E;3_J]VW=G&.O&,YI;K4K2RNK2UN)=DUZYC@7:3O8*6(R!@< ]<5Q
M5YI5_-\2+2P@UN[@*Z&?/NPL9GD7SN@.W:"3CG;T%0:9K^MP^(;/1;G4GN5@
MUJ:T>9D4--$+?S%#8&,@GJ,9Q0!Z-17G'B#Q%JEEK^HPZAKEUH$,;*--D%BL
MEK,-HYDD*L<[L@C(Q75ZMJ-W!X.:_@U'38+@VZ-]LE<_9E)QEP><CD[1W.*
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MM** //\ Q1I6GZ_XAT/PY96\X.F2!KHK$RQ1VH4'RRQ&&W%8Q@$]#FO0***
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M;SF9F>2,YZ EL9'/RBNFHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
2*** "BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>formofindemnificationagr005.jpg
<TEXT>
begin 644 formofindemnificationagr005.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  H'!P@'!@H(" @+"@H+#A@0#@T-
M#AT5%A$8(Q\E)"(?(B$F*S<O)BDT*2$B,$$Q-#D[/CX^)2Y$24,\2#<]/CO_
MVP!# 0H+"PX-#AP0$!P[*"(H.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[
M.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SO_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M.875O"R!HG=4X^9@.H/Y4 =U161HNL7NJ22K=Z%>:8(P"K7+(0^>PVL>E:]
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MLI;*^@2XMYEVR1N,AA0!QMW;W.C_ !*TBZN[XZG_ &F)[>&.5 K68 WDQA<
MC@ DC/3FNTN+6WNO+%Q!',(G$B>8@;:PZ,,]#R>:R]+\(Z)H]RUU:6KF<Q^4
M)9YY)F5/[JEV.T>PJ_I>EV6BZ;#IVGP^1:P B./<6V@DGJ23U)H Y_X;_P#(
MJO\ ]?\ =?\ HYZZNJFG:99Z3:FUL8?)A,CR;=Q;YF)9CR3U)-6Z "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KC-<\.-KFKZA<
MV4PM-7L##+8W0_@;:<JWJK="*[.J=OI5I:W]Q?0K*)[G'FEIW8-CI\I) _ 4
M <59^,9Y[7Q%JWV)H-4TO2XUN;1P?W<R&<X]UZ$'T-6[BZO=,3POJ-K?W-V-
M3N(K:[220NLRR1EO, Z(5(S\N!C-=8--LEO+F\%M'YUW&L<[8_UBKG:"._WC
M56P\-Z7IK0FV@<"VS]G1YG=8,\'8K$A>"1QT!(Z4 >>W=LD/PV\:L))W*ZA=
M1CS)G?@2C'4GGWZUU=N;RQ^(/]G'4KN>"\TM[AEF8,$D615#(,87ACP..!6A
M<>#]"NH;^&:R8Q:C)YER@GD57;(). W&2 3C&<#.:L_V!IW]IQ:GLG-W%"8$
ME-S*<(>HQNP>0#SW - '$1ZCJS^&-'D_MB[$TGB(VDDNY2TD?GNN#QZ*..GM
M5R6\UK3?^$RL=.OIKF6PMX;BS:[D#M&SHQ;D]AMR >*Z$>#="%G%:"VF$,%S
M]JC47<PVRY)W@[LYR2?J:J^(?#,<ECJEQIMC]HOM11([E)KJ0":,$949)56V
M[@IQP30!%I:WUQXKBFM+G4AHXL \BW.X SEL ?O!G[N<@8 ('K3?$L#77C?P
MS"L\D&Z*]!>(@-C8G0]OKU]*;H&@/;ZG!=6VGZKI,<1/FQW>IF=905("A!(X
MZD')P1CWKH+K1+"\U2UU.>*1KNS#""03.H0-][Y0<'.!G([4 <7::[J%MIT>
MG/=R3!O$,VF"XN)BKF)0[*ID )W$@+G&>>QY#_$*:_HGAO6)/[9:/;<6TEHD
M<YED@1Y%1E9V 9E)R1WZC/%=*_@_09-.O-/ELC+;7TQGG22>1]TA.2X)8E3G
MN,4?\(=H9T=]):UD:UD=7D!N9=TC*006?=N.,#&3Q@4 95Y]JL-?L- 2_N;F
M._2XN2UU>&)W92@$:NBY  9FP,?7'%5+PZYI-IHL%UK+32_V[';OY3Y+0ME@
MDC$ L0,<\9'6NFU?PWI.NV<%KJ5LTZV[!H7\UQ(A'<.#NS^//>FR>%]'EM+.
MT:U<0V4PG@"SR*5D'\9(;+'D\G/4T <KJ)U*>\\:J-;U")=,ACFM5BD"[&\@
MOV'3/;OWSQCHKG6[JV^'[Z\J+)=)IGVK;C@OY>[IZ9JR_AC29)=1E:";?JBA
M+LBZE'FC& ,;N...,<<5=M=/M;/3H].AC/V6./RUCD8R?)TP2Q)(QQS0!SX\
M[3]/AU^WUB>[0Z>\CVTCEUNY-F]67G"'AN%&"#[5EOJ.H6OAOPWXBM[^>XN;
MZ:V6[B:0M'.)L!E5.B%2>-N.G.:Z71O">BZ!([Z;9F(L" &E=P@)R0H8D*">
MPQ3K/PSI-@\9MK9E2&0RPPF5VBB<YR40G:O4]!QDXQF@#B]1N-530O%VH+KE
M^LVD7[FU <!0%CC;:P Y7DC'3\:UX(HQ\3+^YDGEC"Z/!,29GV*=\F>,XV\=
M.G>ME_".B26U_;O;2F+4G\R[3[5+B5NY/S<=!T]!4S>&]):]BO'MF>>*#[.'
M>9VW1Y)"L"</@DGYLT <MI.HWRZ]X;"7]W<6^IVMP99YFP+HJJLLBQ$D1CGC
M&.#R*J3:CJR^#-4G75[L7%KX@:V28L-QC^TK'M/'3!Z#%=7:>"] LGM'@LG#
M6))MBUQ*QB!&"HRQ^7_9Z>U.;P?H;6$U@UK,;>>X^U2)]KF^:7.[=G=G.>?K
M0!SVI:IJ/AC5/$20WMS>I#HRZA$MRV_RY=TBG' POR@D#CCC%74_M3395UM+
M])M/-E([V[7CSFY<(75TRH"G .0O&#TXK='A_3/[2DU%H'>YE@^SR-)/(ZO'
MS\I4MM(Y/;N:@T;PEHF@.[Z;9F(L"H#2O($4G)"AB0H/H,4 <C>"2_T7P7K4
MU]//<7FIVDLP\PF,EU9B G1=IX&,'CG-=3XKEU2&UM9-,@:Z"3[KFUBG\J6:
M+:V0C9'()5L9&<8SS3(_ OAZ(1HEI*L4-P+B&$74HCBD&3E%W87DD\ 5JWVE
MVNHM TXE#VSEXGBE:-E;!'52,\$C!XH X=KJ'6)/"36=]>X;4KI&>X&)X3Y<
MN8VW9^91\N>>@-3VNH7-O8:QI\^LW0%MK26MO(W[V>5&$;>2K9!R=S*&)X!S
MGBNF/A?1S+:3?9G$EG*\T+K/("'?.]CAOF)R<DYZU%-X.T*XCNDEM)6%W.MQ
M*3<RY\U>C@[LJPP.5QTH YN>ZO&T#Q]I]R\IBL[:3R$FE,K1J]KO*ESR>3ZG
M&<9-6C_R'_ ?_7I<?^B$K<_X1#0MM\OV-L:C&([H^?)F50,<G=G)'4]3WS4P
M\-Z6+C3[CR9?-TU"EJQN9/W:D8(^]SD8'.>E &=XUN;NTMM)EM+N:WW:M:Q2
M+&0!(C2 %3QG&/2LJ\34+S7/%EM_;5_#%9VL$UNL,@3RV*2'@@=,J.._?-=9
MJFC6.LQPQW\3R+!*LT865X]KJ<JWRD=#4#>&M*:ZOKHPS>=J$8BN6%U*/,4#
M &-V!@$],=3ZT 1:3J<ESX(LM5N[E()9=-CN)9V7Y4)C#%B/0<G%<_H][?#Q
M+I5J+R]>VU#2I)'DN),M*ZE,3*AR(\[B=OOR!BNMMM(L+31QI$4!-BL1A$,C
MLX\O&-N6).,<8]*H6O@W0K*2UE@M)!)9HT<#M<RLR*<?+DMG P, \#MB@#C]
M,OM53PYX:UJ36;V:XN-6%I*DD@,<D;S.A!7')P 0>W;BM:ZU"[T'Q!JFFSW,
M\XU. 2:3YDK8$A.QH@>V&96R.0I/I6TG@W0DTZVT]+:9;6UG^T0QB[F^23.0
MP._/7GZFFQVU]JNO17&HZ4EI;Z7+(;1VF61YV(VAQC[HVEN#SDCTH O3Z;*^
MA-IT=]<)-Y.Q;K>?,#XX?/KGG'3MTKA;?Q-<HOAW4;BXN%BM6^QZVC3G9'*2
M8E9L_P#3123[$9[5Z56;)X?TF:TOK22RC:#4)3+<IVD<XY/_ 'R/RH PY)91
M'I:R7]X)-2N99ULD=A)-&58J@?</+5 5)YZC'?%9MM+KFI> ;JXM[RY.HZ9?
M3B,),<SI%*1Y3-P6RHP#US@^M=AJFA:=K$EM)>PNTEHY>"2.5XG0D8.&0@X(
MX(Z&J+V!\-6K+X;T);EKJY+S1BZ\M8]V27^;.!G^%?7@4 )H6HQ>(+U]7LKB
M5M/$$<<2[SM9R-[$CID!E7ZAAVK$\8:A=0QZ_-8ZC<O/IUFDJ)"QB2S8!FRQ
MS^\+#!VD$ #G&<UU>B:7'HVD6]A&$'EJ2Y1=JER2S$#L"Q)Q56^\):'J5W=7
M5W9&22]B$5P!,ZK*H&!N4$ D#H<9'8T 8>JVZWGCKPI-)).K3VEVS;)G4 A8
MNF#QUYQU[U#!C3?%WC+4(O/EDL[.WG2,SN0Y\N4X(SR..!V[5TH\,Z2+NRNA
M!*)K!#';,+F7Y%/7C=@YP,DYSWJ6WT+3K75;K4X8I!=7843N9Y&$@ P 5+;>
M 3CCO0!S-G+K"VNG>(HM0CDMGM&DN(6NWE%X3'N78I4!&!'1>V1VJYH,<^IZ
M7HFNG7)PUU &NX]Y,=PSK]Q5SB,JW0J,\8.>M:&D^#]"T.[:YTZQ\EV)*KYK
MLD>>NQ22JY]@/2ETOPCH6C7KW>GV/DR,S,%\URD9;J40G:N>>@'7% &;\.K9
M(?#TSB29RU]=*?,F9^D[CN3SZGJ>]9*VJ1Q?$%Q).Q7S  \[L.;53T)QWX]!
MP.*[/3M%T_29+A[& Q&YD,L@\QF&XG)(!)"Y)S@8%5[CPOH]U/?SRVK%]1C\
MNZVSR*)!C;T#  [>,CG'% '-:4]YIFJ>$E34+J:+4M/D$\$C@QC9$C+M7'RD
M=/?OFG:'/K6N:=HWB&'48K<2S*UV&NW>.1&.UHA%M"JP) !!SD<YS72+X9TE
M)M.F6&;?IBE+0_:9?W:D8(^]SP .<\<5%9^#]!L-5DU.UL!'<2.9"!(_EASU
M8)G:&]P* ,SXH?\ (E2_]?5M_P"CDI;Z.\O?B VF?VK>P6<FDF4Q02!-K>:%
MR#C(X[]??'%;NL:'I^OV@M-2A>: ,&V+,\8)!R"=I&<$4W_A']._M0:ILG^V
M"#[.)?M4N?+Z[<;L=>?7//6@#D-%U^_OK/PIIEW>2[M1:[%Q<!MLDH@)"KN'
M()X)(Y^4^M5A>R^'KOQ1Y%P_[S6+. SSRG,:2)&"2Y!Z X#'.."<UUI\%Z#_
M &7#IHM)%M[>8SP8N9=\+DY+(^[<O))X/>GIX1T-(;^)K(RIJ0 NA-,\GFX
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M]YPDKH"??"C-=!5'2='L=#LA9:=$\5N&9@C2O)@DY."Q)&22?J35Z@ HHHH
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MC1VO6:^\U8C%'!(VUF"E<D+@ [EYZ<^QK1U35K#1;%[[4;E;>W0@%VR<D]
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M%)?2N&G?RX8HHVDDE;T55!)H T:*S-&\0Z=KPG%E)();9@L\$T312Q$\C<C
M$9K3H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBN7OOB%HFFSM#=Q:E&5F\D,=/EVN^< *=N#GMCK0!U%%8$'C/2IXHI62]@6
M:ZCM$^T6DD1:1\[0 P'''7M6_0 4455O-0@L9;6*;S-UW+Y4>U"PW8)YQT&
M>30!:HHHH **I6FK6E[J%]80.S3V#(LZE2 I90PP>_!J[0 4444 %%5=0U&#
M3($GN/,V/*D0V(6.YC@<#MD]:4ZA:#4ETTSK]K>$SB'OY8(4M],D"@"S1110
M 4444 %%1SS);6\D\IPD2%V(&< #)J+3K^WU73K?4+1BUO<QK+&Q&"5(R.*
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %5=0MK&\MA#J$<,D)=2%FQM+ @KU[YQBK59^N:+:>(-*ETZ]W
MB.0A@\;;7C8'*LI[$$9H Y:Y;4;;XF:5<:ZD!MYDGM],:T8_(Q&X^:&&22JC
M&. 1T[UT>N2Z+I@CU[5C'&U@K"*9LDKO !"CN3@#'6J=EX3=-5@U/5=9N]5N
M;1&2U,RHBP[A@L%0#+$<9-5-2\"R:G'I7G>(M1\[2RS1S$1LSN3]]@RD$@<
MXXH D\+65]=ZQJ/BC4+9K)M02.*VM'^_'"F<-)_M,3G'8<5U-8^BZ-?:7-*]
MWK][J:NH"I<K& A]1M45L4 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MX.N/#(N9C;SK,K2G&\>8S,>V.-QJ3Q+9R?\ ""ZM96R/-)_9DT4:*NYG/E$
M #J30!S%S_:_A_1-(\12:[>WD\TUNMY;RL##*LI (1<?*1N&"/3G-0VMYJT5
MEXD\47&L7LPT>]OH[6P# 0,J%MH<8R<$C'(P%%:VB>#':QT=M3U6_NK:Q2*:
M"PG"*L4@48W$*&;:>@8\8[UMV'ARSLK'4K)RUQ!J5S//,DF,?O3EEX[<XH Y
M+4H]8\.>%;?Q2WB&^O+I/)DN[>9U,$RR,H954#Y,;N"/2AM?U:#PU=: ;R1M
M?34_[,AN&^^5<[TE/TB).?5:V(O :[+6SO=<U"]TJR=7@L9MFW*_=#L%#.H[
M GL*T)/"=A)XPC\3EI!=1P>5Y8(V%N0'(_O!6*_0T 8C:]>Z5J'C5VFDN8M(
ML[>2VBD.0#Y+,?S(!-8^NZ/J4?A;2-5N=?O;N6XO+.2ZAF93$Q:13\B@?)@D
M8QVSFNYB\.V::GK%[(6F&L)''/"^-NU$*8'U!.:Q&^'HEM[6RG\0:E-86,T<
MMI;-Y>(]C @%@NYP ,#)X!^E ',PZYJ^NV]]JB3>)8[GSY5L4T^V#6L:HQ50
MPQ\Y)'S9^@Q5W0QKWC'P[J.MW^L7FFWD;2016<!"PQ%%PP="#NRV<YZ#IBN@
MG\#G?>1:?KVH:=87\C27-I"(RNYOO;&92R9[X/>F#X?V]LD]KI>KWVFZ==J!
M<V4)5E<[0I(9@64D#D@\T 6? D?F_#O1H][)OL47<APRY7J/>N2TBYN/"O@7
MQ/K-M=W-Q/#?W,<:7#AD#>=M#D8'.3D^N*]#T72XM$T6STN&1Y([2)8E=\98
M#N<52MO"MA#HVH:3-ON;;49YIIE?@_O&)(&/3/'>@#G]4MM5\(1:;JH\07^H
M-)>0V][!=.K1S"1MI*+@;""<C'IS4GPW@U/4=&M?$.IZY?74MPDB"V9QY*J'
M(!QC);Y3SGOCM5^W\%'[19'4]<O]3MM.D$EI;7 0*KK]UG*J"Y';-:WA[18?
M#NAV^DV\KRQ6^[:\F-QRQ;G'UH P_'$FL17&G/;)JCZ4/,^VC2<?:<X&S'?;
MUSMYKD-(+>(/'5I:VGBF_F2*SN!)(T7DW<,>]"(F+#.<X.[ )''O7HFM^'SJ
MMW:W]KJ-SIU]:!ECG@"L"K8RK*P(8<#Z50T;P-:Z3XC?Q ]_=7FHSQ-'<2S;
M1YN2O.%  P$  % '-R:M>:<=4T.\\37<<-GJ<444_E>=>31O$'\I-H)+9/WL
M'BL2_P!3NU\8Z3I GUE[![VRND36%Q*KB?:2N?FVD'H>XKO;_P !VUWJ\^L0
M:C=6FH/<K<Q31A6\IA'Y9&T@@@KUS5>7X=076OVFN7NLW]U>V[QLSR; K['#
MJ H4!1D=!ZGO0!8LO^2I:K_V"K;_ -#DJSXU.LKH:'15N&<7$?VD6I43F#^/
MR]W&[I^M7X=&AA\17.M"5S-<6\=NR'&T!"Q!'O\ -2:[HD6NV<<+W,]K+!,L
M\%Q P#Q2+T/(((Y(((P<T >>Z?X@E7Q=I&GV6O:LT4]UB?3=5A*W$0\MSRQ^
M\I(''.".M7O'FO:MINJ:S'87TD(@T>WFB4'A9&N=I;\5X^E:US\/5O[M-3OM
M>OYM8A*?9KX+&A@"Y. @7:0=QSD'-$_P[@O3?2WVL7UU<W]ND$\SA!PL@<;5
M  7H!@#]: (KVWU+PC/I.H2Z[?ZC:R7ODZA]J<%0)0%5@  %57QQVW50UK7-
M5ET?Q1K=I?30VUO=0V5B$. -DB+*X]<LQ7/HM=OK.E6^N:/=:9=;A%=1E&9>
MJ^C#W!P1]*S9/!]D_@U/#"S3);JJ RC!=B'#ECVR6&3]30!%J.HW.C^-[$W%
MRPTO4K9X=K'Y(IT^<'VW)N'_  &N3N/$NM2:7IL@GOU'B/4)I8_LL>^:"T09
M5(U/1F4 Y[9)KN?%'ANU\5:,VF7<LL*EU=)82 Z,.XSZ@D?0FDU;PQ9:IIUG
M:))+9/I[*]G/;D!X"HP,9!!&."#P10!A>%;S58_$DMEY6N2Z3);>8LNK0X>&
M8,!M#]U(.<'H12-IY;XS&;[==C_B3B;8)!M_UNW9C'W>^/6MO2/#;6&IRZK?
M:I=:G?R1"$2S!46./.=JH@ &3U/6GWGAU;CQ-:Z_#?3VUQ##]GDC0*4GBW;M
MIR,CGN* /.=(M-3T_P"$X\1VFOWT,]F)98+9&40!5F;*LF/FSR<D]_:KRZ]J
M'B#4-6GDE\20):W3VMHFDP!HDV8!9S_&Q/.#QCZUV$?@ZTC\$R>%1<S&V>-T
M,W&_#.6/;'4U!+X+>*YN9=(UV^TI+W!NHH%C97; !==RG8Q Y(H GT>;4]9\
M#1OJ\<]AJ$MNZ3[5\N16!(W $<9QG\:X33-1OM&^'WA>QLKK42VL2?O'@42R
MPQJI++$N."<>^.37J&F:5:Z1I,&F6JL+>"/8H9LDCN2>Y/)KGX/ %M#H4.DG
M5;YELYQ-I\X*"6T(Z!2!\PY.<@YS0!QNIZIXEM=6T[3=+NM?MM/O[N&(W.J0
M?O(7)((5B/F!4YP>ZUT$NG:FGC&Q\-1^)-5^QG39;B:5I5,TA$H &_;Q]X#(
M&<#'>M$^ ENM4M=5U76KW4+ZTGCDCD=4155"3M"* !DGD]>*VVT6%O$T>NF5
M_.CLVM!'QM*EPV?7.10!P,46N7'ASQ+=2>)]25_#\]S%9E&4%_*7>#*<?.3D
M#TP/>MCP[KNH:E>^())[ABL>G64\2#[L3/ S-M],G'Y5N1>%K:+2]<L!<2E-
M:FGEE8XS&94"D+] .,TW2O"=KI3WS17$S_;;6"V?=CY5BC* CW(.30!Q:2Z[
M:^ -,\7R>(K^:]!MVD@9E\B2-Y%3:4QUPV2V<YS^#M;U265=9NK;7M>N[NU>
M4PG2X"MI;;!D(Y(VMC'S$D_A78R>$;27P;!X8-S,+>%85$HQO/ENKCMCDJ*H
M_P#"!*MI=Z9%KE_%I%T\CO8QB,8WDEE#[=VW)/&?QH X?0KF_A\)^+?$$>J7
M@O3!%)GS!MWO#&Y;&.HS@>U=KJ]UJ&I>(-&\/6]_-8PW%F]W=3P$"60+M 16
M(^7ELDCFF0?#>VMM/OM/CU>\%I?VB6\T15,%D14$@.,@[4'MR:V-7\,Q:F;&
M>&]N+&^T\$6]W!M+*" &4A@0RG X([4 <1K^J:]H.JR>&[36[F7?-9S6MU/A
MY8EDE,;(YQ\XR,\]N*Z"UCOM \=V&F_VQ?7]IJ5I,[I>N'*21E<,I &,ANG2
MK \!VLC-<7FHW5W?R7<%S+=R;0S>4V40*  J^P'>MBYT6&Z\06.LM*XELHI8
MD08VL'VY)_[YH R?%EY?2:QH?A^RO)+$:I),9[F+'F+'$FXJI/0G(Y[5P_Q#
MBOM+M=0T*36;^[LI; 7L0GD#2(ZRHA5FQED(;//0BO2M>\/P:[';L;B:TNK.
M7S;:Z@(#Q-C!Z@@@C@@C!K'N?A_;ZC:ZA_:FJW=]>W\*P/=NJ*8XU8,$15 5
M1D GCF@#IK&U-E9QVQN9[DH#^]N&W.W.>3@58HHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J&ZN
MH+*UDNKF01PQ*6=VZ 5-7*?$N"*;P->&5<^7)"R\XP?-09_(F@#5;6V7Q9'H
M1M"!)9O=+<;Q@[75=NW'^UUSVK6KB[W3;.Y^(=A8DN+<:/< I'*REAYT?!(.
M<9]^U8^F:M.FB>'+&[O@EI/?7EL\UR6=7\MW$4;G<"00,<GG:.M 'IE8M]X@
M:S\36&A_8B[WZ221S"0!5" %MPQG/(QC--\,Z>=+CO;3^U?MR"Y+H@4@6P8
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MUX06V+A\I&9HAL)SEAAVX.:UY(8[3Q]XAO;> /=Q:5#-$I8_/)F4 8SSG %
M'<45YT)I5\(^&/$&GW,LFIW-Q:K._F$_:C(<2HXZ$ EL?W=O&,5H>&=-BNO$
M6NW%Q<WDC6&JG[.&NY"J PID$9Y'S=#D#MB@#M:H7NJQ6L%\80+B>RA$TD*M
M@X() R>!G::N12QSQ++#(LD;#*NC @_0BN%MK.UA\2>.9 @5Q%$5)8]6MR3W
MY[T =?HNH_VQH=CJ8B\G[9;QS^7NW;-R@XSQG&:O5YOH-N+#_A +F"><27UK
MY5P&F8JZ?9BP7;G  *C&!4NC[]>T^UUB378[._MK\_: J,90WF%3;L-^-I&
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M-YYD[.LFQ(V4X)P",GH!UQ5+2KK&N>%+BVN)3;:BMT'GFG)FNT$9<-(HX&"
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MMTBEQN)YPH)]<5?L-.MI;JUU.S\0*UO=VCHT-MY@-R-N0Y;S"0R_WNO.">:
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M>N!Z5J5ROPS 'P^TL!BP"R#).<_O&KJJ "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MM<[]Q7RACIW/6NPUW5_^$@C\+6MI=2VVGZ[*7GDAD*.46,OY>X<C)X..>"*
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M:XS*4+K\[;<@GC/4 UUE[X5TS3_'_A:VB-XR>5=OF2]E8Y78R\[NF2>._?-
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MMX=2M;2]CCCES<*65$:0)D@>IRH]ZJZQXPMM)\6Z5H<C1@7J2-*[!LIC 0#
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MM8WFK013H0'4Y(CSTW,!A?Q(J.[\<^&+&9HKG6;='20QN.3L(.#NP.!GN>*
M+$?A?2DTB]TEX#-9WTLDL\<C9W,[;C@]N>GI68_PZT2Y4+J4VH:FB1M'"E[=
MM(( >"4Z8/OR>*TK?Q;H%WJXTFWU6"6\)(6-22&(Z@-T)'< TQ_&?AR/4SIS
M:O;BY$GE$9.T/_=+8VAO;.: &Z;X2LM/U&+4)+R_U"Y@1D@>^N3+Y(;[VT=
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M?PX@E^PR1R1$%_FVN26Y_P"!&EU3Q5H6BW:6NHZE#;SNN_8<DJO]YL#Y1[G
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M8Q@ *I/11C@?6M.JFF:I8ZS8I?:==1W-O)G;)&<C(ZCV/M5N@ HHHH ****
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ML=LNT@$MN8@#(4 XSGIQ7M/DQ&7S3&GF8V[]HSCTS4:65K$C)';0HC'+*L8
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MGPV$,L5RD,4B/M(8)(EJ#@^A! JAX^MIY/$NLF#*PI#I\]YLB\S,2ROEBO\
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M: Z)XW8Q*3-JE\LA(^\ HP#[<G\S7=B- 5(105&%..@]J B*& 10&.2 .IH
M\K\":I8>'KD76OW,=HM]H]B;&XG.$:-(L.@8\9W<[>^16Q\.]7TNWTZ^"L+6
M._UVY2SB9"I/0A<8XX[=JWM3T76GU$W6D:Q#;Q/&J-:W=L9HD*YPZ ,NT\\]
MC2Z3X2M=.LK6&:YENIH;M[V29@%\Z=\Y8@=!EN /0=: *'Q(BCGT/3X94#QR
M:M:*RD9!!D (K&^)-G=76N6T&GH3=3:-?(H0?,XPGR_J<#WKT5D5P RA@#D9
M&>:"BE@Y4%AT..10!YMKNLZ'K/@S2-)T">";47GM19VT)!EMF1E+%E'*;5#
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MW;O* MCTSZ5(  , 8 [4 >:PZIIJW_@O6KF[A?2H;![;[26!BM[DH@^8]%)
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M10 4444 %%%% !1110 4444 %%%% !1110 57O[^VTVS>[NY/+B3 )P222<
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MM-*D@U6XEN"EPXMY9P/.:'^ R8_BZ^^,9YS6W0 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MB>6=+Z?RX[0(^QMQ )8[P0 !SC/%,M_'NIWNJ_\ ".6FE6KZZC,93]I)M4B
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MCZ5Z!8V%GIEHEG86T5M;Q_=BB0*H_ 4MK96MD)1:P)")I6FD"#&YV.68^Y-
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MXPHX]Z[.BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *S]=U&XTK2)KNTL)M0N
M%PL5O"#EV) &3V SDGL :T*S];UJT\/Z:VH7PD^SHZ*[(N=@9@-Q]AGDT 9-
MAKVL6_B*VT37[2R62]@>:WELI&904QN5@P![C!Z&K'BG6[[21IUMI=M!<WVH
M77D1I.Y5 -C,S$@$\;?UKGI8K72_B3I5SI>H/?3:JDPNXY9A/Y4(&\.K')C7
M=@8!P?3BM#Q&?">N:EH(U68W$4[3?8Y8YO\ 1I&V@,K,#R2.@SSR/:@#9T27
MQ#)YW]NVVGP@;?)^QS/)GKG=N48[8Q[UK5P_A."UT[QQK.EZ$^=&BMHG>)'+
MQP7))RJ\G&5P2!WKN* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ KB/$>O>--"DAD^RZ%);W5\EI;_O)MXWMA"W&/KC-=O7(?$7
M_CQT/_L.6?\ Z'0 Z\UWQ'H=M92:U#I6Z[U."T!M7D*K&Y(9CN Y&..U=!I^
MLZ7JQD&G:E:7AB.)/L\RR;/K@\5SGQ'MH;VPT.UN(Q)#-KEJDB-T922"#]17
M.?$:U>PU>8Z+;K;SS:!<J_V=-I9%>//3T7=0!Z)9Z[H^H7;VEEJME<W$?WXH
M;A7=?7(!S53Q9K<WA_11?01)*_VB&+:^<8=PI/'UKAFM28_#3IJGAV"-;N$V
M#:=:2^<_J@PQ^4C(;(QZUTWQ+_Y%(?\ 7]:_^CEH Z*\U73M.S]NO[:UVIYA
M\Z94PN0,\GID@9]Z:FL:7)IIU)-1M6L@,FY$R^6/^!9Q7.:E86M]\5=-^U0)
M,(-)FE174$!O-1<X/LQKD)X+6U\:RVUS''%H:>(5>>,@")9&M@8RPZ %_7C-
M '>V7BN#4?%JZ78SVMU8G33=_:89 _S"385R#C&*T+?Q'H=V9Q;ZS83&W4O-
MY=RC>6HZEL'@#UKR_P =BT7Q#K_]@^4LYT%?MGV8=!]HCWYV]_+SGVJ'QQ;-
M_P (W;.=3\.P[89#9C2[6022Q^4VY 0S80KU)&.G- 'K">(-%ENI;6/5[%YX
M5+R1+<(611U)&> *6VUW1[RU-U;:K936ZN(S+'<*RAB<!<@XR21Q[UPNIZ#I
M2VG@.$6$ 5KJ)7Q&/G!A+$-ZY(!.>M9OC.QMDU;Q'9Q0I%!<+I9D2,;029RI
M/'?% 'HK>(=.N[6^_LK5=.N;FUA=ROVE2J$ X+X/RKGJ:I:IXPM=$314OYK0
M2ZFZJ[K<!8XP4+,X)ZKD8!]QS7,_$&PL]/U33C96L-MOTK4XF\E FY%M\A3C
ML#TJ755METKP!-="(1B>!7>7& #;MP2>V: .UOM=T?3)8XK_ %6SM))>8TGG
M5"P]@3S2W^N:3I7E_P!HZI9VGF_ZOSYU3?\ 3)YKSJQCO9?$/BOSKCP^DGVU
MA*NK0,[_ &?:/+P=X'E[?;KFL;P'!=&YU*.'4=$N"L<:Q2:K:RDO:[?E\L,P
M(CZC\/I0![4CK(BNC!D895E.01ZBL^X\1Z':WPL;C6;"&Z) \B2Y17R>@P3F
MLCX=1)#X2C2&^CO+<3R^3)#$Z1JF\_*H;DJ#D \\5PFHW27WP\U6_M+71--T
MNY,[*EP7GO)9-QZDD;7+=/O8&/2@#U6ZU[1[*]2RN]5LK>ZDQMAEN%5VSTP"
M<U1TCQ%]LFUS[:8+:#2[UH!*6VC8$5MS$G ^]7$>"3X>?X?:I+XE^SR7+22M
MJ1F(\TC^'!//W<;<=^E94,<HN=1U>6-KCPQ9ZNDEW82*WFE3$F)'R<L$^0E3
MG/)/2@#UJYUW2+.+S;G5;*%/+67=)<*HV-PK<GH<'![XIYU?3!IW]I'4;461
M&?M/G+Y>/][.*Y4VEAJ?Q<2YDBANHTT".2 D!EYF?##MT/7T-<M8065OXRBM
MKY(H]&B\07P2.0 0K-Y,1C!!X'5]H]: /4;;7-)O8HI;75+.>.:3RXVCG5@[
MXSM&#R<=NM6%N[9[I[5+B)KB-0SQ!P74'H2.H!KRSQ5:P/XNU.\T%(S_ &5I
M\.H7 M\;/M$4VY<XXW&+S!]#5>XUJ73+V;QY;[Y$UM[RS@X/(55%MQVRT+?]
M]4 >B)XB6?Q;;:3:M!/:SV,MQY\;[OF214P"#CN<^XJ]<Z]H]G?)8W6JV4%T
M^-L$EPJN<]/E)S7):-I2Z'XUT'2UP3;>'Y$8C^)O-CW'\3D_C7-:9!<S^'->
M_M"[\/1;KJY_M'[?;N]PC;C@DAQVQMP/3'- 'INJ>(=,TPR6\VHV<=[Y3/%;
M23JKN0"1A<Y.:IZ7XLL)/#>EZIK%]9:?)J$"2!)9A&"2 2%W'GK7#>#DT+_A
M ==&NS07%V&E^U2W2XE=-@\IL-\P!7:5]SQS2_#QM-CO'.O-;*[:/9?83=[0
M/(\L^9MW<??SG\* /2Y-8TN*SDO)-2M$MHF*23-.H1&'8G. ?:F?\)!HO]G?
MVE_:]C]BSM^T_:$\O/INSC/M7CFD['U33AILFGQ:4=7U V9OHV>WW_+Y>0".
M=N=N3^M7[G34D\>"3_A(M$MM51E*VL-C(;1YMK??)8J'*YZ'/ XS0!ZY97]G
MJ5L+FPNX;J!C@20R!U/XBL/_ (3*RDUG6M*ADMS/IENLB9G!,S[7+*%'/R[1
MGZ]JI>![O?JFNV,^G6-M?6\L3W4^G2,UO.S*<$ _=8!>1[U3 M(O&7C1&$*3
M/I]NT8. S?NY=Q'?TS0!OZ!XLTW5K#31-J%C'J5Y:QS-9K.N\%D#8"DY[U<N
M?$>AV5Z+*ZUFP@NB0/)DN45^>G!.:X"YTNPLOA-X=NK>TACN%DL)Q*J .'9T
M+-GKDY-4-0NDOO NN7]I:Z)IVF7#7)*W1>>\EERPR<D;7+=.N,B@#T/0/%=A
MX@O]2M+:6 O8W!B4).KF50JGS !_#EL?A2Z]X@.C:MHULPA6"_FD2:65L>6J
MQE\YZ=N]<U\*&MOLVJJ#%]H-RC8&-^PP1<^N,_K5_P :V=O?^)O"5M=PI-"U
M]*S(XR#MB9AD=^0* .FL-7TW58'GT_4+:[B0X9X)E=5/N0>*98:YI&J320Z?
MJEG=R1??2"=7*_4 UYGX]@>RU;Q)%ID:VZ3:1:R7(B7 *_:"KL0O7Y,@^V:T
M?LTG]O>&I&U/P]"RW -H-*M)!)+%M.Y,AF 0KW(P"!S0!UVO>(#HNK:-;,(5
MM[^:1)I96V^6JQE\YZ=N]7[/6=+U&UDNK'4K2Y@BSYDL,RNJ8]2#@5S7C6SM
M[_Q-X2MKN%)H6OI2R.,@XB9AD=^0*YWQ<^FZ/XHUJ.33(Y[:\TVT#VXD,$<D
MAG959V7H!QGU''>@#T&T\2:%?F46>LV%P85+2>5<HVQ1U)P>![U+IVM:5J^_
M^S=3M+WR_O\ V>=9-OUP>*\@\>01RZUHEIKVI:-IZNLH9M+MV8PKLRGF9/S(
M6"\8 QN_#KM$N;BS\;V-IJEIH]U=W-G*(-0TMF0B)<$B2/H >,'IGI0!OZEX
MGBTKQ5!IEY);6UD]C)<R7$S[-I5U4#).,'=6M#J>GW%A_:$-];R6>"WVA)5,
M>!U.[.*Y'7$TM_BOHO\ :GDD#3IC;B;&TR[UQUXSC=BN/U\#^V=4&F-:1Z"=
M;LQ,TBEK3S?+;?O"D#;O\O=SC.,T >M66MZ3J4$MQ8ZG9W4,/^LDAG5U3ZD'
MBH[;Q%H=Y#+-;:Q8310D"5X[E&5,G R0>,FO)/'4%RFK6+W&HZ(LC>6MY%86
MTHC>V,B?-/AB-@8#N"<G%)\1;67[+"]QJ>B)<?9V"Q:5;2*TT)9.'.Y@%!VD
M9QR.* /8+36])O[N2SL]3L[BYB_UD,4ZLZ>N0#D5;EFB@B>::1(XT&6=V "C
MU)/2N.UO2[#3/%G@\V-I#;%+B:$>4@7Y/(;Y>.HXJY\0+NTMO#T4=W8I>K<W
MD,,<4TQBBWELJ9&'\ (R0<@T :]EXAT34A*;'5[&Z$*[I?)N$?8/4X/ ]ZQ[
MOQQIJZUI-M9:AI]S97C3BYN%N%80^7'O'(.!^->:^/S,GB?1(M3FTG:>+Z+2
MXV79;;XR1(Q.6& >,# !]:Z_7[/P[??$#PQ:6T=HSW-O=QS+;[?F@,# 9QVY
M./QH [Z:\M;>%9IKF**)RJJ[N K$] ">N>U4].U&22WOI[Z>Q6.VNI4#P3;E
M2-3QO)^ZX'WAVKA/#\ESK&J:-X7O-SGPQ)))>L1P[1G9;'\0=_\ P&D$%C=>
M"?%4&HWQL8'\0W ^T>49%1O/4KN7NN0 <\8H [ZSU[1]1AEFLM5LKF. 9E>&
MX5Q&/4D'BEL]=T?48I9;'5;.YC@&97AG5Q&/4D'C\:\@\937MOJ.G6>I0:$\
MD[Q^;J%EO$9M5D7*SQ@_<+%#G.."!4WC6#;JFDR:E?:-L+H+N+2K>1#)9^8F
MXR'<PV# QG'?% 'HC>+[.Y\0Z/I^E7=G?6]^9UFEAF$GEF- P'RG'.>]6O%/
MB6V\+Z;'=W'EL99XX41Y0F=S $\]E!R?I7.Z@NB#XG>%CIPM1<F"YW_9]O\
MJ_+^3..W7'XU=^)BQ?\ "+Q23*FV._M26<#"CS5SR>@H Z"[US2+"UAN[S5+
M.WMYP#%++.JK(",@J2<'@YXJW!/#=0)/;S)-%(,I)&P96'J".M<5:#37^)NH
MG4OLS#^SK?\ LOS=I3R?F\S9GC[V.G;VJQ\/C#YOB$:?M_LD:H_V/9_J_NKO
MV=MN[.,<=: .CU'6M*TC9_:6I6EEYGW/M$ZQ[OID\UEWOBRWL/$MM8SW%I%I
MTVGO=F[DE"@$.JC#9Q@[JR=,73F^(7B;^V?LYNMD'V87.W_CV\OG9N[;MV['
M?K7(>$UTE_'MJ+KR?[-62_\ ['$N/+*^:NW;GC'^LQ0!Z-KGC/2M(TBUU**Z
MM;J&ZN(X8V2X4*0S ,V><A0<G^E:-YK^C:?!#/>ZM96T4ZAHGEN%42 \Y4D\
MCZ5Y?K*67V_7I;-81I,>M:=AE \I9<CSL=A_!N]ZZ*\NH[OQI?Q:19:/'-9V
M<(FO=2D9U,3 LHBC!QM /)! .: .KM=4-YK'E6US83V+VBS1M%.&E9BY&<#C
M9@<'UR*4^)-"$\,!UK3_ #9_]4GVE,R<XX&>>017F7PF='\:ZIY<L4D:VL@1
MH5VQE?M+D;5R=J\Y SWJ2STC3_\ A15_=&SA:XD2XF:4H-V]96"G/7@** /6
M)&*Q.R[<A21N.!^-9^GZJIT:SO-3N[".2=1EX9P86;!.$8]> 3^!J8,SZ'O8
MDLUMDD]SMKSA+6"^^'O@"VN8UDADU.V#HPR&&R7@CN* /1[#6=+U6.233M2M
M+M(CB1H)E<)]<'BL:^\9V/\ :&E6VDWEC?B\OOLTYBF#F(;&;/RG@_+WKCOB
M':"TUS4QI\'DK-H*M<BW7:6C%U&'.!UPA8?2K_BQ=#&J^%&T(6?VWSV^R_9M
MO,7E-CIVW;<9]_>@#N?[>T?^TO[-_M6R^VYQ]F^T+YF?3;G.:9'XBT.:[BM(
MM9L'N)@&BB6Y0LX/3 SS7D]G;M-\,T-QJ7A^VMSS+*UK*UY'<;N22'R9=WM^
M&*LV \/CX%#R?LYO3'\FS'G?:]_RX_BW9QCV]J /4]0UO2=)>--2U.SLVE^X
MMQ.L9;Z9/--N_$&BV*LUWJ]C;A=H)EN$7&X97J>XY'M7G>G1ZK+XI\1?;)]"
M2]!C$JZK SMY/EC&W# ;.N??K4/PGTG3I]:UYY'M]32&.!+>8P,$6-O,RJA^
M=OR@#V4=J /3;G6-+L[%+ZZU&U@M),;)Y)E5&STPQ.#69I7B>'4-6UN%I;46
M.F^08[I9!M=7C#EBV<8'K7 >#$M$\0Z1#J8C%A%#?QZ>LV/+6<7)R!GC.SI5
M+6ELQK.L)I#6<>E'7;(7)==UL#Y;9WA2/D\SKSC- 'K=MX@T6]@:>UU>QGB1
MPC/'<(RAB< $@]2>@[U!-XKT)+&]NH-6L;@6,9>58KE"5QT!YXR<#ZFO+/'%
M@T^IV:7FH:.9Y?*CFM]+MI$,L)FC +G<P !Z9QU-=/XUTVRM/$>D+:V<$(ET
MW48W6.,*&58E*@@=0#R/2@#L?#NMP>(="M-4@:/]_$KO''('\IRH)0D=QG%:
M=<]X":W;P+HOV9HB!90B3RR/O[%SG'?UKH: "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *9)&DT;12
MHKHX*LK#(8'L13ZYSQY>7-AX7>XM)Y()1=6R[XVP<&9 1^()% &IIVA:1I!D
M.FZ79V9E^^8(%3=]<"EDT72IM-&FR:9:/9+]VV,"^6O?A<8'6J>L>)8-*OH-
M.BLKO4;^=#*MK:*I8(#@NQ8@*N>.3R:SA\0=.F,=M:V&H7&IO(\;::L2B>(K
M@L7RP55Y'.<'/&: .BL=.LM+MA;:?:06D .1'!&$7/K@59KDXOB)I4D5X6LM
M1BN+2>*V:U> "62:0';&HSR>#SP.^2*R_$OC:5K8:<+/4=&U(3VTBK/M'F1&
M=$;:R,0>N"/>@#T"BJNHZA;:3IUQJ%[)Y=O;1F21L9P![=ZYX^/[2UE@.KZ3
MJ6DVUR&,-U=QH(SA2V#M8E3@' (H ZNBO/M;\;SW::']DT[5M/CO=5M1%-*B
MHMS$7&5X8XW#G#8R*Z(>,=,/A%O$Q2X6U0',10><&#[-FW.-V[C&: -^BL#3
M=5M3K'B R7-XGV,PO<)=%?*MP80WR8)P,<MGOFJEOX_L)6M9KC3M1L]/O7"6
MVH7$2K#(3]W^+<H;L2!F@#JJ*Y6'Q_8R+#=/IFI0Z7<2".+4I85$+$G"D_-N
M52<88J!S6R-;MO\ A(7T1DE2X6U%T'8#8Z;MIP<YR#UX[B@#1HKF+3Q]H]]X
M7E\0V\=T]M%.+?RMB^:[EE50!NQSN4CGH:KW>O-9>'_%=]I[W]U<6$\RA90C
M"%Q$I^0$_P"K7(8YY^]P>* .OHKSI_%U_'=>#;F:VU(F]M+CS;1$4O=2!(MK
M;5;;CEF!)& 3G%=;H/B.#77O+<6ES97=BZI<6UTH#IN&5/!(((Z$&@#8HKFK
M7QO9WNLW&FV^G:@ZVD\D%U=>4HA@9,\LV[H<'],@9J!?B%IWDQWTVG:E!I,K
MA$U.2$" Y. Q^;<%)Z,5 YH ZRBN-G^)5A:Z:NJW&BZO'ILJEH+OR4*RX!(P
M-^1D#@L!^%7+/QQ9W-Q9"73=1L[746"6=Y<1*L4S$94<,67=VW 9H Z:BN7N
M?'=G#)=O!I>I7EC8R-'<WUO"K11E?O8RP9@O<J#BF2_$'3B+F>PT_4-2L+/_
M (^;ZTC5HH^,GJP+8!R=H.* .KHKD/"?BJZU_P 1ZU UM=?8HFC-K(R1A$0Q
MJ>2&R2V[<.O'ITIT'B2^?XD7FC26ET+&&S1E;;&$1B6)D)W9VG  ]QT'6@#K
M:AN+2VNU1;FWBG$;B1!(@;:XZ,,]".QKF1\0]/,(OCINI#2#)L&J&%?(ZXW?
M>W;,\;MN*V=;UZST*SCN+A99FGD6*""!-\DSGHJC\"?2@"]/:V]T(Q<013>5
M()(_,0-L<=&&>A'8TC6MN]RETUO$TZ*464H"ZJ>H!Z@' XKEKKXCZ9IK>3JN
MG:E876]%^S2Q*SLKD@.NUB&7(P<$G/:H]2\>M%8:I"NCZE8ZG;V#W5O%<11_
MO%'&\88@A206!.< \'I0!T5GX>T33[QKVRTBRMKELYFBMU5SGKR!FK=S:VUY
M%Y-U;Q3Q[@VR5 PR#D'![@\US-AXR$'AC1KB^LKZ74=0C5(;5(T,MRP0%G4!
MMH7ODD8!YQTIEQ\2-,LV6WO-.U."_,RP_83"IEW,K,A&&PP;:0"">>N* .J-
MM;FZ%T8(S<*AC$NP;PI.2N>N,@''M4,FEZ?-'<QRV%LZ79!N%:)2)B!@;N/F
MX Z^E8NCZU'J7B=T>/5;.X;3DE:QN@HCC'F.N[ ).\X^F,527XF:<^G_ -J)
MI.K-IJ/LGO/(79"=VTY^;) [E00/KQ0!T=CH>DZ8!]@TRSM<(4S# J':3DC@
M=">:BM_#'A^U:9K?1-/B-PI24I:H-ZGJ#QR#Z5G7?C:T@O;J"UTW4-0AL2!>
M7-I$K1P'&<<L"Q Y(4'%/N/$-EJG@"XU^)[VVM)+.24/$%6=% .2O.-W''-
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MY!(H ;+X;T*:YAN9=&L'F@55BD:V0L@7[H!QP!V]*MK8V:+.JVL*K<DM.!&
M)21@EO[V1QS7 2>(]37Q:VO?:Y/^$?CU$:0T.?DZ8,WIQ*0N?2NSUW7[70+>
M%YXI[B:YE$-O;6Z;I)G/. ,@= 222 * +=OIMA:2+);65O Z1"%6CB52L8.0
M@('"Y)..E,ETC3)[>>WFTZUDAN7,DT;0J5E?CYF&.3P.3Z"N<F^)&FVC7L5_
MIFIV<]C;"XGBEB3(0NJ#!#8;E@>#C /?BK/_  G%JNG+>3:5JD+33B&TMW@
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M242A6=OFR N"I]\\$<U=\6:[<:-XP\-I&+N:&Y2[#VEJ-S3L%3:,9 XR3DD
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MRVL:;8SM#%?F8;F (R%S4/@[7O[?UWQ!<074DUCNM7M5<G$:M K$ =N2<^]
M&[J.@Z/J[H^IZ79WK1_<:X@5ROL"15FWL;.TD>2VM887D55=HXPI8*,*"1U
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MF;!'' ]:Z2ZU.Z\0^*?#4MKH6J06]G<R/<S75JT7E$Q, O/7GJ1QTYYKNJ*
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MU:TT?6C:P700WNIS2O(ZB.0_<?E$#$8)QDFO4!=6[7;6@N(C<*@D:$.-X4G
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MM(N[KQ/XR1HI(8M0L[:&"=E(5CY<BG![X+#.*["HGNK>*YBMI)XDGF#&*)G
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M1VUM&YPK2.P5=Q]!U_"MJLGQ+H8\0Z.UD+@VTRR)-;SA=WE2HP96QWY'3T-
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MLT @);RBCL$#;N"#DDXYZ8'6JP^)EU%I<6O2ZYHDBL5>318Q^^2,D<"3=S(
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M%E+ *@X!ZG)H ]DHKQ[3]-U6_P#'L7A[4Y=2LM)\B:2*T;45DE"80^6SHY.
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M7$(MG51+*F$FRH.4/<#./K7E.GZ''#\))?$4=[?1ZC:B>:VDCNG58-LS_*J
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MZAJCQ8M)K"&%)-PY=7<D8SGH17/>$_"^L:9XALKN\M!'#%%>J[>8AP9)PZ<
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MS[(8(_X=TFT_,00=H&>OIFL.#Q+<:S\1]#L[JS:PN[ WL5S LWF(3Y<3*P8
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MUMT51M<J'+ 9S\IX''(]*TM9U*[MO&GANPAE"V]X+KSTV*=VR,%>2,C!/;%
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M_P ,Z/9Q3"'7KR^^P7+!%)B:(GSWVD8^ZI/3^,4 =[5;4=1M-)L)K^^F$%M
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M;2T>:5S9Z>\"&#RU<J%D;!<D[>2",9X%9&C6_B!= \2:G9:X; 6>HWLL5O'
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M9F49,8<;@/IUH RM6\.IJL&D1-<;!IEY'<_ZO=YNQ67;UXSNZ\UD1^"-4M;
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M$\6D7;2,T?V4-< /]Y?-+<YSU*Y]ZJZ)\.=6\/Z++I&G>+'CM;DDS9LE+#(
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MV_RVV[N@QGT[>M:M !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M1K8RD '"D*<# RH^4D#H<<4^\\'^'[^WM8+G3(G2SB$,!!961 ,;0P(./;-
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M5-VD1A67N$)!(_,"@#RE[&'1M(?5[K2]/US2DO#<C6K.;RKY#YO5B1EB#\N
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MB\"FZAC:-)><JK$$C\<"@#DO#4\5M'XU>:14$6JSR/N.-J^4G)]N#65\./\
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MZC%UY#EI]\(59&4+N4,V0,]AGBN\M-2@O+R\M(EE$EFZI(7C*J21D;2>OX4
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M*N3.($C=VV$##@E>O?Y3D=B*YNY\?6Z^*]/$$]S+IT]M<)]GBMB\DLZ2!<*
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MC<S7BE-T<%NTFU7'#' ^[R,GWJ*\\>:)9W-Q$QNY8K1_+NKJ"TDD@@;N&<#
MQW].]9O@S3;C3O%>MQ7*,SQ6&G0^<1PY6)@V#WY K,T?6+;PSX4O?#>I6ETV
MJQO<JD"VSO\ ;=[L592!@@A@.O&.: .YTW7-/U:6[CM)M[6;JLN1@?,H96![
MJ000:R[/Q%::OK&DR66I3+;WEO.\=L;?B<(P&_<>5QV]<UQ5UHVN^&=+TRWL
MX)&NM:TN/2KG8,B"8$!'8C^ZC2#/^R*ZA],73O'7AJUM86%K::9<0J0O"@>6
M "?7B@"[-X]T.">17-W]FBF\B2]6U<VZ29P5,F,=>,]/>ETGQ#8VW@Y=9O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M\O>.G1<<9]>*T(M2M)]2N-.CF#75LB/-& ?D#YV\].=IH XA_!VIV%A'H_\
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MJ[N[T6VO-;T[5I'E$^G+*L2J1M82!0VX8S_",8(K,N_ ^FWMYJDTUQ>&#5D
MN;42 1;QMVR+QD,-HYS^% &'X6OHX/$UO9S7/B'3[F>%PUAK#-,ERP .Z.0D
MC(&<XZCL,5?OM=D\+^*=6;4;B233[G3S?6JR.2$>(;9(USZ@HV/<UHZ?X2CM
M=4M]1O=6U#5)[-66U^UNA$.X8) 55RQ'&3FI_$7A;3?$ZV:ZB),6=P)T\M@-
MV.J-D'*GN/;K0!R<\EW:Z'H-IK.M:L;V\$EQ<66GJ[7-P6^;:'!S&B;L8X!Q
MUXK#L;V\;QW9Z7*=36UM=4MY+>'4Y1)/%O@FW MDG!V@@$\5Z/K7AJ+5[^UU
M&*^N]/OK162.XM2N2C8RI#*01QZ5G6WP\TNVUV/6C?:C->+*DSM-,K"5U5U!
M;Y?1R,# X& * *2:[?6$/CF]\UYSILI:VCD8LJ8@5@ .PSR:R-;T*XM_#6B:
MI+KNH7<\]]9/=+/<%XI2TBGY4/"8)&-N.!CFN[M?#]C:S:K)\\PU:3?<1RD%
M?N!" ,="!WS6+_PKNR:.UMY=8U::SL9DFM+5YU*0E&! ^[E@,8&XG )QZT <
MMJC7&K?!-[J]O;J29+QOG\YLN/M90!O4 = >F!Z5T\UU)X5\76J75_<R:3?6
M#H#<S-)Y<T(+DY/]Y,_4K6A_PAFF_P#"(R^&3+<FSD9FWEQYBEI#)D$#'#'C
MCMWK$\7Z/+K%GIOA'[/J5\QECEEU251LCC!8.6<8&\KE=N/XA0!M^"7OKKP\
MNIZA+*TVI2O=K'(Q(AC<YC1?0!=O'J3704U$2*-8XU"HH 50. !VIU !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %-=TCC:21@B*,LS'  ]2:=7)?$L$^$QYF[[%]LM_MVW/\ Q[^8
M-^<=NF?:@#<LO$.BZD)C8ZO97(@!:7R;A6V =S@\#WJ2SUC2]0N'M[+4;6YF
MC4.Z0S*[*IY!(!Z'(K@O';:6;K1O[#^RF]V3Y-KM_P"/7R'W9V_P_=QGOTKI
M?A_IME9>"]'EMK6**6>QB>614 9RRACD]3R30!L:EK6EZ.J-J>HVMD)#A#<3
M*F[Z9/-1W'B#1;2+S;G5[&&,QK(&>X0 HQ(5NO0D'![XKA[M=0;XH:UBYT>&
M3[+!]E&JP-)F':=_EX=<#?NW=>U9/P^TNQE^(MZS3VFHPQ6+O;F&W9((29V#
M+$&SE0=V""1\Q - '8>*?'-MIEKIHTC4-)EFU*<(DUQ<#R8X\-F0[3DC*XZ]
M:W9]:L=)T^VFUO4[&U>1%R[2B.-WP,[-QR1_2O-K:SMHM<A@2",1)XQF1$VC
M"K]G!V@=ADDXKI818K\4M5_MCR0_V" :=Y^,>7\WF[<\9W8SB@#J)=;TF"UC
MNIM3LXX)4+QRM.H5U')(.>0/:HKGQ)H5G:P75SK%C#!<C,,CW"!9!ZJ<\_A7
ME^F6=AJ'CRPMXH(IM$.LWK6L>T&)BL"EMHZ%?,&1CC(KJM-BTNV^(OB"/4DM
M8BEK;+8),%55M]AWA >,;\YQ[4 =5>:YI&G6L5U>ZI:6\$W^JEEG55D_W23S
M^%)<Z]H]G8QWUSJMG#:S?ZN9YU"2?[IS@_A7E^D-;R^,Y/[ ?3;2Q%EMTT:M
M"\B.GF/YIA^<8^?/X8Q@5'X>=5\77=GIC:'=W:^;.MU,LL=K; L \<,98[OF
M&2P..2,]J .\N/&VG1:]90)?V#:7<6DL[WOGC:I1E &[./XJT;C6HYK6QNM*
MOM-G@N;M(FEDN!M=3G(0CJ_H/K7D?A232I/BY,-2N-/G199VA>*,);M,5CY5
M22.S8.3DC/I6M?\ V<^,9VTS9_9I\1Z:,Q8\LW&U_,VXXS]W/O0!Z#;:Y//X
MHU?2#'$L=A;0RI(206+[L[O8;15*^\9PZ-HVC76I3:>TVI7$<+-!=#R54GYY
M%8]548R?<=*K6O\ R4#Q3_V#K7^4E<ZH@7X;^!)KCRQ''J5IO>3&%7+9R3VZ
M4 >G6]W;788VUQ%.%.&,;AL'&><>Q%.AGAN8_,@E25,E=R,&&0<$9'O7G_B3
M4W\&^(+Z_LUW1Z]8 6RIR#>)A$Q_O*Z_7;79>'=(30?#UCI:'=]FB"NW]]^K
M-^+$G\: &Z;JF_2VO-1NM/0"9H_-MYP8A\^U1N/\70$>O%2V.NZ1J=S);6&J
M6=U-%_K(X9U=E^H!KSB6)9_@SJ$+_=DU4J<>AOE%='J]A9V'C_PA]CM8K?(N
MXCY2!<H(<A3CL#0!U5_J5CI5L;G4+R"TA!QYD\@1<^F3WJM#XCT.>V6YBUBP
M>%BP607*;25&6&<]AR?05S_BVZ4^*M%L;>QL9=1\N:6"YU&5A#"!@-A1]YSQ
M] *X*P@AU'XM?9;N33[U#?1/(+.+; 76WE)PI)S@J,G/)% 'K]IKVCW\(FL]
M5L[B-I!$'CG5@7/1>#U/I5QYX8Y8X7E19)<^6C, 7P,G [X%><:[H"ZAXK\2
M66G1+!<-I=M=0>6H7_2(Y'*-]?E SZ&M+PGJ2^,_$;>(PN+:PLH[:!3T$\@#
MS?BHV+^= '97E]::=;-<WUU#:P)]Z69PBC\36%K?CC1]+\/'6+:]L[Z-I4BC
M$=RN&8L >>?N@[B/050\6?9AXW\,'52@TT&XV^=CROM&T;-V>,XW;<]^E<AX
MX%@=>UA]-6'['':V1OFBQY:S_:EVDXXW;,Y]J .]F\96-MXE:SN;RRATW^S8
M[Q+QY@%<M(R@!LX(PN1BMAM9TM=-&IMJ5H+$C(N3,OEG_@6<5RZV>GWWQ8$Q
M@@N$BT&,P':&5<SN,KVZ=ZXD130^*TMH7L+:QAU^_6 7T1:V2;RXBH*AEP>7
MV\]<XH ]:C\1:)+9K>)K%BUNY8+*+A-I(&2,YZ@ D^@%6;:]MK^R6\LKF&X@
MD4E)8W#(WXCW%>07FFPWGQ+TV*]O-+NS)=Q?:[73[5TAW+'(RL^YF!8@8(ST
M XKV#R(;:R:&")(HU4[4C4*H^@% %32=3-QH]E=7]S8B:YPH:VF#1.YS@(Q^
M]T_0U:N-0LK/?]JO((-D9E;S9 NU <%CD\#)'->96;I#\// $TC!(X]6MR[L
M<!1B49)[<D4OQ$N[>?7]9AAF21X?"\HD"MG:3/&0#Z''/XT =W+K]M/=V\&F
M:CIDY%WY%TK7(WK\K':H!Y?(Z'L#Z59U#7]&TF9(=1U6SLY).42>=4+#UP3T
MKE=6TVRTR3P;%96L5NO]I1@^6@4MB"3DD=3[FJNL6I'BW6[C2=2TF2X>&)=0
MT_6(2J[0G!23KM*]>",YS0!V5[XATBQE2WGU2RBN94W0Q23J&D],#.3FLOPE
MXCO?$%O:7-Q]@C2XL$N##%*3,KEV!)4_P8 P?7-<7\/+CPS<^$M=FU6WM+8R
M3.TL$[!FCMM@\I5+<E0O"G\JF^&>_P#M*T\O&_\ X1J';GU\Z3% 'H<GB'18
MM1_LV35[)+W./L[7"B3/IMSG-8MEXV@UG3=3GTRXTU)K*]^SK]HNQL>,2*OF
M$CH&R=O8G S7.: _A6/X7I_;L<<LHE/VV,'_ $EKGS#D<$/OSC'.<>U4Y#;+
MX(\511^6LR^(SNC&-ZK]KCQD=<4 >GZAJNGZ3 )]2OK>SB)P'GE" GT&::-9
MTHVD5V-2M#;S9$4WGKL? ).#G!X!/X&N7O?L@^+$)U<Q>5_97_$O\_&SS/,/
MF;<\;\;??%<E<6MA?^-VMK6**71'\06VQ$ ,+3"WD,H Z'D+F@#U73M8TS6$
M=],U&UO5C.'-O,K[3[X/%6%N8'DEC6:-GAQYJA@2F1D9';CGFN4MK:"T^+DR
MVT*0K-H:O(L:A0S"8@$X[XXK)\<3S:#KMX]KE6\2:<+*+'>Y5PB'_OB4_P#?
M- '?"^LS;)<BZA,$A 242#:Q)P #T//%<_HGC?3KRV8ZK?V%C<F[F@BA><(7
M5)"H.&.><?G7*Z':[/$%EX&&XP:'J4U\0?\ G@ '@R>_SS?^.4_3-)T^3X9^
M*[B2SA>:674':1D!8E2^WGVP,4 >@:CKND:0\::EJEI9M+]Q;B=4+?3)I+C7
M]&M&5;G5K*%F* ![A 3NR5[]\''KBO,/#!U&?4]2>6\T2.Y>VMB1JT#2,UOY
M*X*G>HV9SGWZU)\+=(T^X\1:M)*]OJ<<$$/V24V[*D:,\A(0/DX!7 /H.M '
MI5UX@T:RODL;O5K*"Z?&V"6X57.>G!.>:=K5W/8Z7)<6TEI'*K( UY)Y<0!<
M Y;UP3CU.!7EVF1W4N@Z^NH7WAZ'-U<_VBNH6KO<*=QP21(,\8VX'ICFNA\1
M(\?P<MTDN6NBJ60\]D9#(/.BP2&Y!QCKS0!T4_BRPM_&$/AR2:W666V,I9IU
M!#[E"Q[?[Q#$CV'2KNK7D]FMF8)+-/.NXXG^U2;,JQY">K^@[US]X;6+XM6#
M3^2C2Z1*J%\#<_G)@#/4XJ7Q]_J_#W_8?L__ $(T ;>HZ]H^D2)'J6JV=F\G
M*+/.J%AZ@$]*M/=VT4"SR7$20OC;(S@*<],'W[5PNLVS#QEJMQI&I:4UXUM$
MM[8:O"=C( <%'ZXQG.,C/6KVDVEIXO\ A6EG!9#3X;FV>.&(.7$3*Q"LK'DC
M<H8'TQ0!UTD\,+1K+,D;2MM0,P!<^@]35#_A)=!_M'^SO[9L/MF[9Y'VE-^[
MTQG.?:N,T+6'\5:I;:K=Q2%/#NG,;B-1AOMC@JX'N%1L?[]<SKER6^&,=S"F
M@Z;ITICDM+6(M-=9\P'_ %A(PPY+'!/!% 'H>E^)KW5/!MMK0%A;3S7+1$7$
MI2(*)VCX/]X@<#N36YJ.L:7I"HVIZC:V2R'"&XF5-Q]LGFO-H?\ DC&G_P#8
M4'_I<U="OV)?BEJ9UGR0S:="-/\ M&-ICRWF[<\9W8S[4 ;7AG7GUY-4=DB"
M6>HRVL31G(=%"D-]3GM5J]\0:+IMTEI?:M96MP_W8IKA48^G!-<W\,?L/]G:
MY_9FS[%_;=QY'E_=VX3&WV]/:J7ALZ"MIXG'B$VGVO\ M&X-_P#:MN[RL_)U
MYV;,;<<>E '9WFNZ1IS[+[5+.V8;<K-.J$;L[>">^#CZ&KDLL<,32RNL<: L
MSL<!0.Y->4?#734O]9BDUBT6XFAT2#RA<H&*H99-AP>^P+S73_%+SSX8M@C1
MI;?VC;_;&F4M$(MW.\ @E-VW/(XH Z"V\2:%>02SVVLV$T4) D=+E"J$G R<
M\9)P/6DC\3:#*\Z1ZWI[-; M,!<I^[ X);G@9KR3XBVLDL-N;G5=%\\Q!1#I
M-I(K2PF2,8=M[ *#M(SCD<5W6O:9867C'P>MK900KYMQ#A(P 4\AOE/J.* +
M7@?Q1>>)],FU6[ETV.V/,<%NY,L RW^M). < 'H*V;/Q%HFH^=]BUBQN?(4M
M+Y5PC;%'4G!X'O7G$$>WX#Z<P0K;LT1O3&.3!Y_SYQSC'7VS5SXA-I)BT?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M/6K=% $7V6W^U_:_(B^T^7Y?G;!OV9SMW=<9YQ3+JPL[UX'NK6*=K:02PF1
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M&1Q[T 34444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0V^H:N1/(D:!1#&?]7$ .@"XSZDG-=92    # '0"EH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "O,H;DP>/\ Q6!X6FUO,UO\
MT:Q'ROW(X^<CK[>E>FUQS^'_ !38>)=7U/1;W25AU-XW9+N&1V78@7^%A[T
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M>#_B"UU?0SQB]F5D2WV%I-L7SYW' Q@;<>^>U>B>%M$ET#1VL9IDE8W$TVY
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M)EE0OLB8$&&0=Q@XR#G&/2MK1]/UY=4EU#6K^V*^4(HK.R1A$O.2Y+<ENW8
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MMJ%L7U(3-&6D(8JH;*JP'YKP: /2;OQ5=6U[IVFIH5Q-J5["T\ELLT8%NBD
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M,J92)1L_VB2 /<UR_BK3%LK:P:+P[=Z/'<L\4CW&H;Y+E?*9L.BL>Z@Y)X-
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M;O*S1,Q.2P7.%)/.13=,\':3I=]'?)]JN;B!"D#W=T\_D*>H3<3MXX]:W:*
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MQD 8!ZUH:?8P:980V5L&$,"!$WN6.!ZD\FK-% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M /OBNWKE] T_4Y_%&H>(M1L1IJW%O';16ID5W8*2=[E<C/.  3Q744 %%%%
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M)7"2SI))/*Z[.-A("@9.2<GTJ]XWTR^U7P^(].@%Q<P74-PD)<)YFR0,5R>
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M,C< :U/%^B2^(?#%YIEO(L<\@5XF?[H=&#KGVRH!^M8EY!XB\57.DVU]H?\
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MSJ6K>"-5M)I]9N=6M[NTNY)H;E$ $D,1D!3:HV@X(QSUK''B;7(=)MM8@O\
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M??VNJ:?!?V4OFVUP@DB?:5W*>AP<$?C7#I8S#XB^)IO[1NBJ:=&YB.S8X99
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MD&BQ7/DH%PSF9E.<@G! '3T%;#G5;OQ%:^%8-;O+>WMM.%W<WBB/[1.6<JJ
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MDK G,DJLA9<C:=N .M2V/BV^UVYN(Y]?U/[/9)'%%<:)IS2+<R;06D<[&QU
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MY]6\276H16+;X81"L(9L8#2%?OD#Z"M%]$1O%,>O>>V^.R:T\K;P07#;L_\
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MWGAZUTG49M0M)-^G39MIXUD(SLP-K MU(SC/-=7:Z=IFM^/O$J:_;6]V]M'
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M.IZ<MW(GS122*6\S&.#A2 V* /19_%VEW.A:K?:+J-I>S6%K)-L5]P!521D
MYP2/_KTMGK-W=1>'96FL(O[2@\RXBD+"1SY6_$(SV/)SGY:Y'QI=V6I:TCZ-
M-!<-;Z'?F^DMF#*(6B_=JQ''W^0*O0_\?OPW_P"O>3_TC- '4ZGXGT+1;E+;
M4]6M+29QD1RR@''J1V'N:34_%6@:.T:ZCJ]I;M*H=%>4993T;'I[]*YC1+W1
M]-UCQ<GB"XMH+J6]9W^U, 9+4QKY>,_>7&X8%9&B:U:2W=__ &&-,\,V<-O
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M,J^9:^4NS!;JHPP.*P]*N?\ A%=*T_QBL,BZ:)KNU\O!!^R.[/!QV <<>ST
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M8,WC"7[3%86>@WMWJ1MUN+BT5XU^S*>@=V8+N/8"ETKQQI^K:G:V"6US;S7
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MB6]U!,;7[)+=0+(#B+#[<@]P,U9U#0A;^+O"\FF:;'#96;79E\B((D6Z( 9
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MDL>_05QGBN]UVYOK?P[J&HP-+9ZI9,EPEJ,7"2OA&9<X!0JV0.&R.F*[O6]
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MD;<0 >^!S0!U-%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M*** "BBB@ HHHH **** "BBB@ II1"X<J"PX#8Y%.HH **** "BBB@ HHHH
M**** "BBB@!&574JRAE/!!&0:    !@#H*6B@ HHHH **** "BBB@ HHHH *
M*** "BBB@!NQ-_F;%WXQNQSCTIU%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M*%V2KC*[P"",$$$#D&N8UCPQ)/XE?7[OPJNL0ZA:Q"6U,T8FLY5&,#+!6!!
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M-SX3\.V$-N&N+&YL7G3>HV+&5WG.<'&.W7M77T %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%8_B?0%\1Z2+/[2UM+'-'/#,$#A70Y&5/##VK8HH X+Q'\.-0\6&VEU?Q,3+
M;[@H@LPD84XS@;B=QP.23T'%:L7A*]N]2M;G7]9_M2&Q#?9H!;"(%F4J7DP3
MN;:2.,#G.*ZBB@#B_P#A [\Z5_PC[>(Y#H(.W[-]F'G^5G/E>;G[O;.W..*T
M-2\%V>H^)M,UKSFB6P4!K95^6;9DQ9.>-A8D=:Z2B@#GM4\-W<NN?VWHNJC3
MKV2$07 DMQ-%,H)*Y7((89/(-.TC0-3TRXAEE\17%VK/++>)+$I$[L!MV\_N
MU7'"KZUOT4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
J%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>formofindemnificationagr006.jpg
<TEXT>
begin 644 formofindemnificationagr006.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  H'!P@'!@H(" @+"@H+#A@0#@T-
M#AT5%A$8(Q\E)"(?(B$F*S<O)BDT*2$B,$$Q-#D[/CX^)2Y$24,\2#<]/CO_
MVP!# 0H+"PX-#AP0$!P[*"(H.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[
M.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SO_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MT:?"?Q+#)&UM?+J@DO+,J%6V=IXSL3!(*8Q@CKS7H?C;CP-KO_8.G_\ 1;4
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M$,ZO<V>SSXP#F/>,KGZ@5P6NZAJUSKWAZ?Q%H T>RMM05ENX;E;EO,(*HC$
M%$8GDX/05L>'?^2D>,OI8_\ HIJ -C6/%.AZ!+'#J>HQP32#*1 %W(]=J@G'
MOBK&DZWIFNVINM+O8KJ(':Q0\J?0CJ#[&N<\ 1I=7'B#5YU#7\VK3P2.WWDC
MC(5(_8 ?SI+J*/3OBSISV2A&U.PF%ZJ# ?RR"CD>N21G\* +7_"R_!H<J=>@
M!!P<HX _'%;4>N:7-/9P0WT4KW\;26WEG<)57&X@CCC(K@/ ?B*_M/!-I96_
MA34M053,%EC\H129E<]6;..<'([&J%GIFN>&-;\+P1:=!<Z@R7\WV(7(CCA#
ME3L#X(X!].M 'J=WJ-G8RVT5U.L3W<OE0 @_.^"<#\ :34]4L=&T^2_U&Y2W
MMHL;Y'S@9( Z>Y%<)K=_X@N_$7A=-7T*#3HAJ@*21WPG+-Y;\8VC'&>:L>.M
M9TH^*=$T35;E(K*(F_NPP)#;<K$O /5LG_@- '=0S1W,$<\+B2*50Z.O1@1D
M$5SK?$;PBC,K:U$"A*M^[? (Z\[:S_AAK%O=Z-=:-#<_:/['N&@BDYR\!),3
M<^V1_P !K \*>)]9T#P3)/%X6FOK&WGN':YCND''FL2=G+8'.>.V: /0)/$^
MB1:$=<;4H#IHQFY0[EY.W''?)Q6A;7,-Y:Q75O(LD,R"2-UZ,I&0?RKRR_TQ
MK?X6ZE>S/:NNLZI#>B&U;=#&KS1@*#@9X'/ YK3M;^XT?P7JGAJ%R-0LKPZ7
M9Y/S%9B/);\$?/\ P T =MI&MZ;KUJ]UI=VEU"DAB9TS@,,$CGZBEEUK38=9
MAT:2\C6_GC,L=N?O,HSD_H?R-<Q\,;*'3--URQ@&V&UUJXB0'LJA /Y5Q.H>
M)-*O!JOBF._3^UX=2CFT^':WS6\/R!<XP ZM(2/<4 >UUFZQXBTC0(XWU2_B
MMO-.(T.6=_HHR3^ JU8WL&HV%O?6S[X+B-98V]589'\ZY7PW&E[\0O%%]=*'
MNK1X+:#=R88C'N^7TW$DF@#H-&\0Z1X@BDETJ^CN1$=LBKD,A_VE."/Q%4]2
M\;^&M(O'L[W58DGC_P!8B*TAC_WMH.W\<4FK6>GV%[>:[;JBZR-/D5 'P954
M;AE/XL$#GM5?X=6=O;>!M,EA :2\A%Q<2GEI97Y8L>YR<?A0!LG6],_L=M86
M]A?3UC,AN$;<NT=3Q6.OQ'\(,5!UR%0QP&='4?F1BN1U6--/B^(VE6:A+%+2
M*X$2\+%+)&=^!VS@&K6H>+-9M/#%I8WOA1+>WOH$M8[NZO4:W!9, OM!*@^^
M/K0!VFK^*-$T*"WGU/48K>*ZSY+X+"3@'C /8BHM(\8^'==NOLNF:M;W$^,^
M4"58CO@'!/X5QVJVD_A.?P%:"&?5)K$SQE+<#?(?)P=NX@8&>YZ"K6LG6_$>
MIZ;J,7ARXTM-':2Z:YNVC\Q\(<1*JDDACUSQ0!TNI^-O#>CWC6=]JL27"#+Q
MHK2&/_>V@[?QQ5X:WI;:,VL)?0R:>D9D:X1MRA1U/'I6)\-K6"'P/I]S'AY[
MU/M%S,>6EE8DL6/<YX_"N6U>./3I/B%IEDH2R.G)=&).%BE=&W8';< #0!U@
M^(_A D9UR%0W1G1U'YD8KI$FBDA6=)$:)EW*X8%2O7.?2O.+SQ;K-CX5LK2]
M\*+#;7ENELEW=7J-;@L@ ,FT$J#[X],U9\1,W@OX66FAO?+]JG1-/6?G"[_O
ML.^%7=CZ"@#L])UG3M=L1>Z7=I=6Y8KYB9QD=1S61=_$/PE87<UI=:U%%/!(
M8Y$*/\K X(Z>M<[X-UC1+#QO<Z'HMVLNG:A:QS6Z@$".:-0CKR!R456_ UL_
M$K_D7;3_ +"=K_Z,% &II_B_0-5LKR]L=2CFM[!/,N9 K 1K@G)R/13T]*U;
M>YANK2*ZAD#P2H)$?H"I&0?RK*\9_P#(CZ]_V#;C_P!%M7,>))Y8?@YI\<<C
M1)<VUE!-(IP4C?8K?F#C\: -T_$+PD+K[.=<M]V_9YF&\K/IYF-OZUK:EK6F
MZ/!!/J%Y';Q7$JPQ.Y^5G8$@9^@//2GC2M/72AI0LX?L(C\K[/L&S9Z8KR<V
ML>K^!?#VCWA>>R7Q,;*-BW+0CS57GV' ^E 'K.HZC9Z38O>W\ZP6\94-(P)
M+,%'3W(%6J\H\0:G=V_@76/"NL2E]1TQ[8Q3-_R]VQN(PD@]Q]UO<>]>KT %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !7.^/M4OM&\%:AJ&G3^1=1>7Y<FQ
M6VYD53PP(/!-=%7*?$Z%[CX>ZI%'&TC-Y0"H"2?WJ>E &=XC7Q5X6T.XUP>+
MOMRV8#O;75C"B2C(&W<@!!.>*U!\0M"'S.UT(48)/=+:R-! YQ\K2 ;003@]
MAWI8?AUX6AG2;^SGF>-MR"XNI9E!]=KL0?RK@-/ABTOPK-H&JZQX@BU"/S8'
MTFV@0BYW,W^K)B.5;.<Y[F@#T:S\;:)J&JG3;.2>>9'D21DMW,<;)G(9L8!^
M4X]>/45K:9J-OJVG0W]H7,$PRF]"C8SCD'D=*Y/X6V)TKPO>020S1&/4;C(E
MY<@$ $D<$X'4<&NLTS48-6TZ&_M?,\F897S$*-UQR#R.E %JBBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH *:P)0A6VDC@^E.HH P/[$U[_H;
M;K_P#M__ (BFC1==7[WC"ZY/&;.W'X?<KH:\W\86]WXF\07XT^4J_ABU6>W(
M/WKPL) /?Y$ _P"!T =1_8>O[B?^$ONL8Z?8K?\ ^(H.AZ_N!'B^Z '4?8K?
MG_QRH=0\81P?#UO%EE"LZ_9DF6)FP,D@%2?8DC\*M>(=<NM*N]+M+.WAFFU&
M9X4,SE55A&S#. 3C( - $;Z)KV!_Q6%TN3_SYV__ ,12G1->(./%UT#Z_8[?
M_P"(K@(;_6'^'GAN\NHDNYAKL+0!9V,DY\V3ARPX);C//%=3=>.+_P .W-U!
MXGT^VC\NR:\@>QF:02894\L[E!W99>>G- &L-$UX  ^+KHGU^QV__P 131HF
MO(I+^,+H^YL[<?\ LE4QXEU_3+C3Y/$&DVEO9:C,D"M;7#.]M(_W!("H!!/&
M1T-8%WXMU/7/ -YK6I^';-M&> $1-=,'E<2JO0#A<YQSGY?>@#K!H>O[B3XO
MNB#T'V*WX_\ '*/[#U_<#_PE]UC'3[%;_P#Q%2Z_>ZY8!KFPCTG[%%$7FEOK
MF2(H1G/W488QCO7.VOCW6+BQT])-*M(-0U1Y&M5EN&2);= /WKDKN )/ QD^
MU &Z=#U\XQXONASS_H5OS_XY0VBZZ<JOB^Z#8_Y\[?C_ ,<K$'C_ %'^U%\.
M+IEI+KTK@1>5<EK5XRI8R[\;@!M(*XSFGZ!/J4WQ-U(:M:0V]S'I4*'R)"\<
M@\QR&4D XYQ@CJ#0!KOH^MQ(7D\87*J.K-:6X'_H-)'H^MF-6_X3*X<-T86E
MO@_^.UB^-;)CXGL]0U71+O6]"BM2GV>V3S?)GW9\QH\C<-O&><8-8EM<>$X=
M5LI] <2VT^IVL3Z3('B^R3[FQ.%."#CC&-IH [<:'KX)SXONCD\?Z%;\?^.4
M?V'K^[/_  E]UC'3[%;_ /Q%0WOB#5[GQ!=Z/X?L+2=]/C1[N:\F:-0SC*QK
MM4DG'.>@K'MOB#JU]-86EMH40O;ZZN[80RW! A,.WEF /')S@=N.M &\=#U\
MD$>+[H =1]BM^?\ QRAM#U\C \7W0/K]BM__ (BL^W\6:X7U+3)="CGUBQE@
M0);3DP.LN2LA8C*J-ISQ_.N9\;^+_$-O876B3QZ:EQ)$DPN+&\<[4$J*RD;<
M@DL/8J3]* .W.B:]CCQ==?\ @';_ /Q% T/7@H!\771/K]CM^?\ QRJUWXAU
MH:I;Z#86%E+JQM?M-V\D[BW@7=M&#MW,20<# K+N?B!J5O)'IIT6,ZRM^ME-
M;"?]WEXR\<BOC[IQGD9 S0!N+H>OC.?%]T>?^?*W_P#B*!H>O[B3XONB#T'V
M*WX_\<IFC>(-3DUZ71-=L[:UNQ:+=1-;RETD7<5;D@=#M_[ZJYX9UJ3Q!I1U
M(P+%!+/(+;!R7B5BJN?3."?IB@"L=#U_<#_PE]UCN/L5OS_XY0VAZ^<8\7W0
MY_Y\K?\ ^(KH** , Z'KQ4@>+KH'U^QV_'_CE T37L<^+KH_]N=O_P#$5OT4
M <^NAZ^!@^+[HGU^Q6__ ,10-#U\$D^+[H@]!]BM^/\ QRN@HH Y_P#L/7]V
M?^$ONL8Z?8K?_P"(H.AZ^<8\7W0P>?\ 0K?G_P <KH** ,!M#UXJ0/%UT#Z_
M8[?_ .(H_L37O^AMNO\ P#M__B*WZ* .?70]?"@-XONF/K]BMQ_[)0-#U\9S
MXONCSQ_H5OQ_XY7044 <_P#V'K^XG_A+[K&.GV*W_P#B*#H>O[@1XON@!U'V
M*WY_\<KH** .?;0]?(X\7W0/K]BM_P#XBE.B:]@X\770_P"W.W_^(K?HH P!
MHFO  'Q==$^OV.W_ /B*1=#U\#GQ?='G_GRM_P#XBN@HH Y\:'K^XD^+[H@]
M!]BM^/\ QRC^P]?W _\ "7W6,=/L5O\ _$5T%% '/MH>OG&/%]T.>?\ 0K?G
M_P <I6T/7BI \770/K]CM_\ XBM^B@# _L37O^ANNO\ P#M__B*1=#U\+AO%
M]TQ]?L5O_P#$5T%% '/C0]?!.?%]T<GC_0K?C_QRC^P]?W9_X2^ZQCI]BM__
M (BN@HH Y\Z'KY8$>+[H =1]BM^?_'*&T/7R./%]T#Z_8K?_ .(KH** ,#^Q
M->_Z&VZ_\ [?_P"(K;@22*WCCEF,TB( TK* 7(')P.!GKQ4E% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 URP1BJ[F X7.,FN,T+X>Z9)I[77B;2[2]U>[
MFDGN9&&\!F8D*#Z 8%=K10!P2^"=17PIXD\+1-%'8W$K2:6Y;A%8AS&1U ##
M'XU8ELO%.N:WH-[J&EVMA!IMP9)E6Z\UI"8V7<,   $].O/;'/:T4 >?:=X8
MUZ+0-(T>XM($_LC6(K@3K<;A-")'8MC&5(W 8[U>\9^#KOQ1J:F.1(8/[.EA
M$I/*R^9&Z<=QE.:[.B@#B[JP\3^)I--L]6TZUTZUL[J.ZN9H[GS?M#1G(5%P
M"H)Y.>0*A;PEJI^$/_",A(O[0\H)MW_+GS=W7Z5W5% '&>,=-\0:MJ]G##ID
M-_HD $LMLUV(?M$H/ ?*G*#@X[GKTJIK&A:SKNH6.M7GAG39);$/"VG7-RLR
M7$38.58IA64CC(Y!/(KOJ* /.(O">MV^LP>)=/T/1],ELG*PZ7;A$,T3*5??
M*J@;NA7@@<^M;NAZ?KLOC*\UW5K2"TAGL8[>&&.;S&3:['#' !/)/''..U=5
M10!S.L6_B:PU[^UM%\O4;66$13Z;<7!B"L"2'C." 2#@Y';\N=U#PIXC\1>*
M]+\27MA9Z<UE<P#[+'/YCF)7W,SO@ D8  'J:](HH XN1=0TSQKK$^A"QU![
MR*%[RTGN3 ]NZKM5P=IRA4<^XK%\#Z3J5_>Z7K;M#+%;ZCJ;SS(<+(9"%#(.
MX+*U=SJOAG0]<F2;5-+MKN6,;5>1,L!Z9]/:M"WMX+2W2WMH4AAC4*D<:A54
M>@ Z4 <%XF\'ZUJ.N:G?6T44]I<2V3O:-.8_M<<2R!XR1TY93SP<5E:UX!UG
M4Y?.TW0M+T>'[(T26T,B[MX='!<JH!W;,<9QW//'J]% ''S67B&WUV'Q-::5
M!)/<V8MK[3C= %"K%E9),8/4@@XJA!X1UJX\16_B*^2WCNI]32XG@CDW+!"D
M+QHH; W-\W./6N_HH X7XF6LTJ:5+IEPD.JR7#6,0[M'.A1^/;AL]MM=E864
M&FZ?;V-LNV&VB6*,>BJ,#^50MHVF/JZZN]C"U^D?EK<%<NJ\\ ]NI_.KU !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M[[27A,L/]HP:? Z0E-Q\MYR6*_>P.3T/I771#2!\7[<Z=]G\\Z1+]H\C&/\
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M S[BG6.H66IVPN=/NX+N G D@D#KGTR*Y77+&VOOBAX?6ZA298K*YD577(W
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MF.(-"S_UVF_^)KH:* .?#^-,<P:%G_KM-_\ $T@?QKCF#0A])IO_ (FNAHH
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MLD(>,,(W7[K+GH1V(J>BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M)%:PQN.C+& 14]%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !2=>#2T4 9?A_P[
MIOAC3FL-+B:.!I6E(9MQW''?Z #\*31?#FF^'[:ZM].B,<=U.\\@+9^9L X]
M!@# K5HH PI?!^E2^&K?0")TM+4HT#I*5DC93E6##G(/>KEAHEKIU[/>Q--)
M<7$,4,LDLA8N(P0I/O\ ,<GO6C10!SLO@?1I+9(E%S#+%<R7,-S#.4EB>0Y?
M:P['TZ5!_P *]T3/GB2^&H>9YG]I"Z;[23C;C?Z8XVXQ[5U-% '+?\*]T99!
M=1SZA'J&\LVHI=M]H?( (9NZX XQ@8XK8T;0[+0K:2&T$C--(99III#))*YZ
MLS'J>!6C10!S/A_0OL>F:CX:O[03::DK_9BXRDD$A+;?JI++] IJ%/AQHRA(
M);O5;BQC(*V$]\[VXQT&PGD#T)KK** .9U/P[!8>#KK2M,TI-1B=VD:SFEV^
M8&?<X5N,'DE?0@5SNF>%FU+Q187W]EZO:6EE#.DLVK77F2R;T*"-!O;"@,QS
MQ7I%% &1+X9TV;P];:$ZR?8[81",!_F_=D%<GZJ*H/X!T=_M,1EOQ974C226
M"W;+ 68Y)VCMGG&<>U=-10!S>G^ ]$TU+F*$736UW:BVGMI)V,4BA0H8K_>V
MJ!N'-,MO &D036DLEQJ%T]BX:U-S=M((0 1M4'@#GZ\#GBNGHH RK;PYI=OX
M;7P]]G\W3EB,7E2G=E3ZG^M9T/A#3M(D34B^I:G+I\;-:07%RTPB..B*>Y'
M)S7344 8OA/2)](T0+>;3?74KW5V5.1YLAW,![#A?PK:HHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M1EE,D8<*_&W:OL 3GK0!O?\ ""^'02?L<W/_ $^3_P#Q='_""^'<@_8YN/\
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MD48#MD;G.U1RW<=/04 :Z^!_#;A76UE8$9!%[-@C_ONE/@7PZ>MG-^%Y/_\
M%U!\/9Y'\,&RE<NVFW4]D')Y*QN57\EP/PKJ* .>/@7PZ1C['-_X&3?_ !=
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MV.?G_I]G_P#BZ/\ A!?#N<_8YN/^GR?_ .+KH:* .>/@7PZ<?Z'-Q_T^3_\
MQ=!\"^'2,?8YO_ R;_XNNAHH Y__ (07P[_SYS?^!DW_ ,72#P+X= P+.;\;
MR<_^SUT-% '/#P+X=!)^QS<_]/D__P 71_P@OAW=G['-G&/^/R?_ .+KH:*
M.>/@7PZ2#]CFX_Z?)_\ XN@^!?#I&#9S?A>3C_V>NAHH Y__ (0;P[_SYS?^
M!DW_ ,72#P+X= Q]CF_&\F_^+KH:* .>'@7PZ,_Z'-S_ -/D_P#\71_P@OAW
M.?L<W_@9/_\ %UT-% &18>%='TR\2[M+:1)D!"LUS*XY&#PS$5KT44 %%%%
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MC &.]=-10!A>#-*GTCPU;PW@ O)V>YN0.TDC%V'X9Q^%;M%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "L#QAHU[X@TF+2K9D2
MWN+F/[:S,0?(#;F"^YP!^=;]% '(^(/AYH=]H=U!I.DV%AJ&W=:W,4"QM'(I
M#+\P&0,C!]C3KO2]?@UBP\26<%I<7_V 6=_9O,8T<9W[D?:<$,6ZCD&NLHH
M\\7P=XD?4+K7I9+%=5&H1WMO$LC&)E$7EM$QQD?+P&QVS@9I-9\,>*?$EYJ-
M[=P6-F+G1Y+&"W2X,FQS(C99MHSG:>@XP*]$HH YCQ7X9GUFRTV6U2UEO-,F
M$J0W:[H9AMVLC<'&1T.#@@5CMX>\2RW!OK31_#^EI&JK_9PB27[4,_.'E\L%
M01TP#[UW]% 'FT/@_7+?5YM7L=#T6RM9D6*XT/S=\5T!DERVS:K D8PO8Y]]
M[P9X:N=$O-4O9;2VTV&_:,Q:=:REXX=H(+9P!N;/8 <"NKHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MT81>0W36\?F!8941E&]U[D]5]B?6@"\&\99.8M#QV_>S?_$T;O&6?]5H>/\
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MO^]F_P#B:"WC+M%H9^LLW_Q-;]% & 6\98XBT//_ %TF_P#B: WC+',6A_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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ME;%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !7-^/M*N]6\*3QV$?FW5O)'<Q1
M?\]#&X;;^(!Q[XKI** .5'Q)\+?V=]J;456;&#9%3]I#_P!SR^N[/'I[UR'A
MBV;PIXEL-4\3[+"/4;*X=&G.([>>2;>4+'A6,>WKCH17JOV>#S_/\F/S<8\S
M:-WYTLD<<R%)45T/56&0: /,QK&B?\)]9^(%MUMM&W7$ U%@%@EN2$S)N]"
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_
!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>formofindemnificationagr007.jpg
<TEXT>
begin 644 formofindemnificationagr007.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  H'!P@'!@H(" @+"@H+#A@0#@T-
M#AT5%A$8(Q\E)"(?(B$F*S<O)BDT*2$B,$$Q-#D[/CX^)2Y$24,\2#<]/CO_
MVP!# 0H+"PX-#AP0$!P[*"(H.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[
M.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SO_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MMU%):RV5]8R^5=6LI!:-B,@@C@J1R".M8]_'J6E^+H_$MOI-S?6MYIZVUQ!
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M6ER6%EIOF0V[2OLB4/&KLJ[,;P<A1T( )(/%;&G>(=.T?1?$^K&Q^SQ6.J7
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M=W9'"Q_(H*CY .AXY[=ZZJ/Q3K&FWNF+KFE6MI8:D3'%)%<EY(&"%@) 5 Y
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M=ZVKNZBLK.:[G)6*"-I'(&<*HR?T%)8WD.HV%O?6S%H+F)98R1@E6 (X^AH
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M .:;PWJ)T[QI!L3?K)E^R?./FW0!!GTY%2ZIX>OKSP]X<L8T0RZ?>64MP"^
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M^MW-P)&ER205!!96(PO8#K[5ZM10!QGA[PWJ=CX'UC2[J)$N[V2Z>-0X(_>
M[<G\:W-)TZXL_!]EIDP47$.GQP. <C>(PIY^M7H;^TN+VYLH9U>XM=GGQCK'
MN&5S]1S5F@#AX?"VJ)X$\/:08X_M6GW=M+.-XP%23<V#WXJ?QEX0N?%&JP ,
ML=K_ &?<V[RYY1W*%#CN,KS7427]I%?Q6#SJ+J9&DCB[LJXR?IR*LT <+>V7
MB_6SHMM>Z5:6L>GW\$]U,MT'\\(>2BXX'4\\]!65;>![[2=.DT:#PCH6H2*S
M+;:M<B,X0DD&1"I8LH..,@X%>ESSQ6MO)<3R+'%$A=W8X"J!DD_A5(Z[I_VG
M3;<3%GU1&>U(4X=54,3[<$=: .4L_"&IVOPTU?P_Y<'VNY>X\E4(5"';*].%
M&.W:M/Q!H%_J-YH,MNB%;$3>=E\8W0,@QZ\FNIHH XFY\+ZG)\+++P^J1_;H
M4M@Z[QMRDB,W/T4T_P#X1;49/!_B?2CY:7&IWEW-;Y?*E9&RF3V_I79T4 <#
MXP;4$\$6&J2V\=AKFFW$3VT E$NYRWE[ 1UW*W3_  S75^'-(70?#UCI:G<;
M>(!V_ON>6;\6)/XU+=:+IE[J-MJ-U8PS7=I_J)77)C^E7J .-MO ]KJ^M:OJ
MWBC3K>ZEN+@):(YWB*!!A?H2<DBHH/!Z:-?Z]:6\4=MX;U73SY@1O^/>4*4;
M"^A4YSZBNWI* /*=>N?$#> -/TV1-.DLVEM(8KV"Y+F^42)L"1[>"< G)_A/
MX=7IGA:X;PQKVCWY$7]IW=VZ,AW;4E8[6^O.<5IV?A#PY87XO[31K2&Y4EED
M2,#83U*CH/PK9H \Q7P3?W6FP:-)X0T&SE $5QJZI&^Y ,%D3:&#D>N,&BU\
M%ZC!IMOHW_"(>'C<1;8VUB2.-U= ?OF,KN+D#H3C/.:]%^WVG]I#3?/7[683
M/Y/?R\[=WTR<59H X./PEJR_"JQ\/&./[? \1=?,&W"SASS]!5GQKX.N?%6H
MQ*CI';_V?<0-(3]V1F1DX[C*<UT$OB#38["2]2<SP17'V=VA0OB3<%(P/0GD
MUIT >8WG@_4]2T_[%%X+\/Z7.(V$UXJQ/YAVD 1 *"I+8.3C;[UT.I>'M0N?
M"&@Z;$B&XL9K)Y@7  $17?@]^AKK:* .:\*Z=JFD7VLVMY:QBTN-0FO+>Y28
M'>)&SM*8R"/6J?B_PK?:UKVF75D4%N^VWU(,V"\"RI* /?*D?\"-=';:O9W>
MK7NEPNQNK%8VG4J0%#@E<'OP#5Z@#C=&\)WUEX]U#4YV0Z8K236*@_,LLP3S
M21VY0_\ ?1JJ_A+5C\-+K1%2+[>;MKB-#)\K#[3YH&>V5'YFNZD=8XVD;A5!
M)^E5M+U*UUC3+?4;)R]O<H'C8J02/H: ,73].U.;QH->O+1+6.32$MGB$PD*
M2B5F(R.HP1S4_AC2;O2[C77NE4"^U22YAVMG*%$ SZ'*FMZB@#S^^\,Z])I_
MB_2(K.%X=7E>ZM;G[0!EF"#85QD?=)S6WXHT"YUHZ)'&H,5K>"2X^;!">6ZG
M'J?F%=+56348(M3ATYO,\^>-I$PA*X7&<MT!Y'% 'G5KX)U&STN/15\(^'Y[
MB(B-=9FCC960'[[1E=Q?'&,XSWKLO$WAUM:T**TM)DMKNRECN+*4K\L<L?W<
M@=NH^AK5M+^UOC.+6=9?LTQ@EV_PN "5^HR*L4 <9?2>.M:L&TH:7:Z.\PV3
M:E'?>8$7^(QH &R1TR1CU[T6NF>(/"FI:C_9.GIK%EJ$BSJ9;L1RQ2[ K;RP
M.X':#D<]>*[.B@#A?"/@W4]!\3'4KV2*4W%A(+F2,\>>\YD(4'G: 0,^U6(O
M#6I+X1\5::4C^T:I=7LML-XP5ESLR>U=E10!YGX3F\2Z9<:_:Z;I5O?*M\$R
M]R(_)E$,8);(^9>G3G@^M*? FH::=(BGT^+Q%8VMHZ2VDDXC5;EY"[2@-PP.
MXKSR *]#MK&ULY)Y+:!(FN9/-F*C&]\ 9/O@"K% 'FOAGP3K6F?$-M:N+&QM
M+%ED*Q6CC9%N1 % P.FWDX&>M;&H^&_M$_C"34WB@L=5@A$4S./D,<9!8^FU
ML'\*[*J6JZ/IVMVJVNJ6<5W KB01RC(W#H?U- ',>!$OH?!UQXAO]CZGJBF\
M<RML4J$Q&"QZ+M4'/;<:Z;1;Z74]#L;^>#[/+<P)*T6<["P!Q^M7%150(J@*
M!@*!P!Z4Z@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ KFO'VMWFA^&_-T_<MU<W$5M$Z1[V0
MNV"P7N<9P/7%=+5#6]&M-?TJ73KT/Y4F"&C;:Z,#E64]B" : /.;[6-8T4K+
M97WB"VLY8VCO+K7+0R);''RRKQUSQMZ'(XJAX@\67_A5;74=)N_$-Q',LD<G
M]L1$0RGRR590P!!!P> !BNRO_AXNM1A==\0:EJ!B3;;$^7%Y!R#OPJC<W Y;
M-/O_ (?QZV]L^O:U>ZFUNQVJZQQH492K+M11R<_>ZC QB@"GJWA_5M.\/3WG
M_"37=R[64PO8KM@T4P,39\M0!L(/3':LNU@U30?!_AG7(M>OI)'-E'):NR_9
MS#)M78$QP0"/FSG(S70/X 6[@CM=3UW4-0M+9&6U@F$8$1*E0Y*J"[*"<$UI
MW/A:VN?#FGZ(UQ*(; VY208W-Y.-N?KMYH @\;:G?6&FV5MITWV>XU._ALEN
M-H8PAR<L >"< X^M<OXNM+[0!%8)K^IW-EJMO<1RK<3!Y$=(BX96QD [2K#I
M@UW6N:):>(-,:QNS(B[EDCEB;;)$ZG*NI[$&LA?!7VF=KK6-9O-4N%MY+>W>
M5(T$"NNUF554 L1QDT 3^!+0VG@K20;F>?S;.&3]\P;9F-?E7@84=A7/:IK.
MKV?_  D&@Q7T@U&?4($TV9CRD=QCI[)ME_*NXTNP32])L].B=GCM($A5FZL%
M4*"??BLZ^\*V-_XJT_Q%*\@N+%&18P1L?(8 M[KO;'UH Y?3/$%_K\>BVXN)
M$:#2Y[C4P#_K)%S"%/\ P,.V/]FLC3X-3T/X7Z7XE@UZ^\ZW6 BUW+]G,32*
MFPICT;KG.:[O2/!]AHUWK-S;22E]7D+R;L8CSN.%]!EV/XTV7P?:2^"HO"QN
M9A;1I&@E&-Y".&';'5: .>E\3:K8>%/%5_'.9;FVUF2TM6EY$2L\:+^"[R:7
MQ7H&I:3X6U*=/$=Y>0MI]PMW#?.'$I\LX:/ &P@]AQBNC3PAIQTO5]-N#)/;
MZO=27,P8@%6?'W2/0J"*S;KX?C5(3%K.O7^I+'!)#;"58U\G>NTN=JC>^#C+
M>] &6(-4\/6WA?45UZ^N7OKJVM;FWE93 4D4_=0#Y=N!@]?7-='XTOOL6DPY
MU=]+$URD;/#$9)I5.<I$ "=Y]<''-6K_ ,.V]_9Z5;232*NF7,-Q&5QES&,
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MA6QF_MQ9WEDCUS'GID#8!&$^4_09^M 'FVMZU=6>BVU_8:OXBOGGD2*XN+J
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ME=N!^%9&G>$%L9-'DFU2YNWT<2K;F54&4= @4X Z <'\Z ..UG7=:\,:A?\
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M/A\IKC2+<2@&4?OFV,Q4 <_+M /UJYH?B.RU;3].=[JUCOKRTBN&M%F4NNY
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M]I.PV>!:W"1>9F'ON4YQC]: .OTJ^UA-X\1QZ;9&1U2V%O<EO,8YR/F YZ8
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M=8WI;!1Y6W/(7;R".]87P]TVRU+6="^VV\=RD/AYI$290RAOM+@-@\9P3^=
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MP\VJ?VH=%LC>[M_G>2N[=_>^OOUK.T#Q/;Q^%M&O==U2-;K4XE<&0*N6*Y(
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M^E:FFEZ1I]KJ%Y:RQ1S^4%VLZD9R <=><"KI\9>'0VW^U83_ *1]G) )"R9
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M:5XRPRK9.-[#@8_,=:ZG2O$%MJEU?6@@GM;BP\OSXKA54J'7<IX)&,9'U!H
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M6KS/;P1Q-<2>9*44 N^ -Q]3@#\JGHHH **** "BBB@ HHHH **** "BBB@
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MIXBDN+B)[+4X)(;2,9S#YIW2YXP/GP1C/2@#=T[6+G4/$VK6*)$+'3EBC\P
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M)WAQ<)M\S:<;UYY4]CWKQ_P[9?:_B;:6=ZE]&MK<72Q037[R- JQQ.J;E;D
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MK>V@M(%@MH8X(D^['&H51] *EHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** (X8(K>/RX(DB3).U%"C).2<#WJ2BB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M:+J&MWLDHU?0DTQ5 ,;+>K/O/<8"C&* ->BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M!KT"B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M @D&0%0/8@'(]Z[*@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "N2\1:=KB^+],US2-/@OEM;66&2.6Y\GER,'.#Z>E:NJ
M^*=)T75]/TN^G:.YU%MEN-A(8Y P3VY(J?7=<L/#FDRZIJ<IBMHBH8A2Q))
M  '7K0!@QZ1X@\0:]I^H>(+>TL+/3',T%G!,9FDEQ@,[8  4$X [UA/X,U5_
M[6@N- T[4+^\EF,6LW<X?8CYVX0@LI4'  P..M=X-:M#_9VWS6&IC,!$9(QL
MW_-_=X]:T* /.9/ >JSQ:#!F*. V-O9ZU'O^^L!5EVXZY(9?H:Z?^QKD^/IM
M794-E)I*VF=WS;Q*S$8],$<UI6VK6EWJM[ID3L;FQ6-IU*D "0$K@]_NFKM
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MM;S%"G/TQ0!HT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MA&N<X&1P,D\"K5EIMAID1BL+*WM(R<E((EC!/T JS10 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!QVFZ#%<^/O%%
MWJ6E)-!*+/[-+<6X96Q&0VTD=CC.*FUC2?+\5>%#8:>$M+6XN6E\B+"1;H6
M)P,#)_6NKHH X37Y=2?Q;<0ZBVOQZ4((S9#1XWQ*YSO$CH-P.<8R0,5C_#C1
M=3L/&U_<WFDWEE"8;D(UP&;&Z9& \PYW''?)S@UZ;:W=M?0"XL[B*XA)($D3
MAU)!P1D<<$$5-0!Y7J?A>[U;79[>ZT^\^Q7'B/S9&164-#]GP6W#^$GY<^^*
MZWP;'J.DI<>&[^&9XM-(%E>E#LG@/W03TWK]TCV!KIZ* ,+QO;3WG@G6+:UA
M>::6T=4CC4LS$CH .M5/$&B7>M?#:72+==MW)91A4?Y<NNUMI],E<?C745%<
MW,%G;O<W4\<$,8W/)*X55'J2>!0!PNNWU[XQM-/TJTT+4K25;N*>[DNK8Q);
MK&=Q 8\.Q(P-N<^U%GHVH-\$#I(LI4OCISI]G92K[LDXP>]=U;7,%Y;I<VL\
M<\,@W))$X96'J".#4=KJ-C?/,EG>6]P]N_ES+%*KF-O[K8/!]C0!RFF&YU'Q
MEH^JC3KVVMQH\L+_ &FW:,QOYB?*P/0G!(]1S72Z;J\6IW%_!'!<0O87!MY/
M.0+N.T,&7DY4A@03BK]106L%L93!$L9FD,DA4??8]2?4\#\A0!PVI>'+S5M9
M\9Q^1+&+NUM#9SE2%:6-79=I[X8+FJ$VFZSJOAK^V+S3+B/4M2UBUFDMO+.^
M&&)U501V  9O^!5Z;10!Q&O7-SI'Q'M-7_LC4KZU_LI[<M96QEVN90P!Q["E
M']H>,/%&E7CZ1>:;I>DN\Y:^01R3RE=JA4R2 ,DY/6NVHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M%U"N%)9"06QC//7-5-&M_'5]X-L+. Z#;6L^GQ1I.6F>58S& #MVA=V/?&:
M.ZL[NVU&QAO+619K>XC$D;CHRD9%5HK[3K75H]!@58KC[,URL4<>U5C#!<\<
M=3T^M<)X-\)6VIV&HV^HWU])_95Y)IUIY5T\/D)$  X52!N8G<2<]1VK-\&P
MIXD\665WJDD]Q.^BS;YDN)$\TQW/E!_E88RJC('!//7F@#U'2M5M-9L1>V3E
MX&=T#%2,E&*G@^ZFKE>069GT?X;:>FD_:A-J^LM9S&*Y(D*>=+PC.VU&(4+G
MCDY/-5_$]OKFDFT32['4] M+N:.*<3ZI'/EO,3:Z#S&;/.#C@@C- 'L]%9^C
M:+:Z%9&TM'N'C9S(3/.TK%B!GEB3VZ?6M"@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M^4VX8'&<$$"M?1=)MM"T:TTJTW>3:QB-2QR3CN?<GF@"]1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
+!1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>hbvpipeline002.jpg
<TEXT>
begin 644 hbvpipeline002.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_X1#T17AI9@  34T *@    @ ! $[  (
M   .   (2H=I  0    !   (6)R=  $    <   0T.H<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $=L;W)I82!0
M:6-H:6D   60 P "    %   $*:0!  "    %   $+J2D0 "     S<R  "2
MD@ "     S<R  #J'  '   (#   ")H     '.H    (
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MUM?8V=KAXN/DY>;GZ.GJ\?+S]/7V]_CY^O_$ !\!  ,! 0$! 0$! 0$
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MG:?$+4PW[RVM&'HJL/\ V:NI\/\ B:VUU6C"&&Y09:,G.1Z@]Z=3"U::YFM
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M]@0SI]D^T><P.?-VXQ^!J#5M7OO$U_$/*SM^6*&($XSU^IZ5Z*HU%B74V7_
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M4X,LA.TGV ZCWJC!\0[Y9!]JM+=TSR(]RG]2:Q_#E_INFW[7&J6\EP N(U5
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@W-U!9P--=2I%&HR68XKQS:;K4]MHI'FS8C4#ID\5T:_#W4RWSW-H!ZAF/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110!POCK3;V[U6WDM+2>=!!M+11EL'<?2NB\*6\UKX8M(;F)HI
M%W[D<8(R['I]#6Q171*NY4E3ML<\*"C5=6^X4445SG0%%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 45137-)DN!!'J=F\S-L$:W"%BW
MIC.<U*^H6L>I16#RXNI4,B1[2<J.ISC _&@"S1110 4444 %%%117,$\DB03
MQR/$VV14<$H?0XZ&@"6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MW_GLW_?!I_\ 8&F?\^H_[[;_ !H_L#3/^?4?]]M_C0 S_A(]-_Y[-_WP:/\
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M_P :/[ TS_GU'_?;?XT ,_X2/3?^>S?]\&C_ (2/3?\ GLW_ 'P:?_8&F?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BLG6M=
M_L>[TR#[/YWV^Y6WW;]NS) ST.>O3BM"YN[:RA\Z\N(K>+.-\KA5S]30!-15
M4ZG8+9"\:]MQ:L<"<RKL/./O9QUIUOJ%G=V[W%K=P30H2'DCD#*N!DY(.!Q0
M!8HKG7\3K-XLT[3M.FM+JTN4D,DL;;RK*I. 0<#M^=6]?\01Z'';HMO)=W=T
M_EV]O&<%SQGGL!D?G0!KT5SMAXIF?6X]*UK2GTRYG7=!F995DZY&X8P>/?\
M#C.JNLZ6\D<:ZE9L\IVQJ)URYSC &>>>* +M%%% !1110 4444 8/C+6;C0_
M#<MU9X$[.L<;D A">^#UX!INF>'[[2I([IM:O[Z18V$UO/+O24X_AS]SGO\
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M,]Q]G^S^3<-!MW[LX .<X'KTK7H **** "BBB@ HHHH **** "BBB@ HHHH
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M7U^]Y<Z<CSR-N=@[J&/J5!Q]>.:VD18XU2-0B* %51@ >@%(!:*** "BBB@
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M:"\7]F-J%OA8WM8A\WEY )4=R!R![=1UJPVE63ZNFIO"6O$C\M9"[':OH!G
MZ^E7* /.+#2+^>'6K;2K34+/2I;1A#:WX*GSB<X0$\#J,_G3[9M0O[WPK&=&
MU"W33<1S2S0%5SM49'M\O4XZUZ)13 \E.D7#Z1?V#>&KN34+N\+6]X8,*B[A
MU8_='!]CG/:MJ:RO)_%6M64,F^[;1EC#[L;VPH/)]?ZUZ!5&RT73].O;J[L[
M81W%VQ>:3<6+$DD]3QR>@Q0!YYX;T>^&L:?OBU"SG@# .VDK%&#M.0TH;+#C
M&6!SGWK1\,:;%#]GTW5/"\SWL<TAFOI8OW;*0W.\_>&#C;T/6O0** /+['2F
M3PE=Z=>:!J N4G#23PVX#,N[C:3_ *S!_AZ8[CK74^!H[R+3;I;RQ^RH9RT9
M:V%NTO &YHP<+P ....YR3T]%( KD?&.D-J^O>'XI+26XM!)*+@HK;54[.I'
M3I7744 <#!X>_LKQ/K4>FZ?-'9OI3I$0KLK.0ORACG)]LUCZ3I%R@TE=)T;4
M['5XY@;F\F1DB*9.>IQTQQ@9YZUZM13 \_\ %6FZI;Z_=G1[6:6'6;989FBC
M)6-MP!+8Z?+GK_>-=M;VPTW28[:SCWBWA"1ID+O(' SVSZU:HI >>:=;3'Q/
M93^'M'U31U=]VH1SH4MV7OC/!/S$#ICC '-9]S;:G!X6U/0AHVH23M>F831P
MDQE,KR#W/'05ZG13 \[U*S:'Q7?W5[X?NM2MY+)(H_+MO,"R;5Y&?H1D<C\:
MBM]/NM-C\&V]^&6;[5*QC;J@)! _K^->DU0DT/3I=9359+8->QKM64LW ^F<
M=_2@#S*YT#4DO+RWOH-0WO=-()[;2UN-V2"&$VX,/IV^N16W<Z>]KXEU4ZQH
M%SK7VT+]EGBCW*HQC!;_ )9]N>HQZ5Z#10!P4NF"T\;:OG09IX;N ?99(( $
M1O+^;Y^B$G(SUR:/ ]E<VFMRA--N(+-;8@37EH()5)8'9D?ZSI]XC/';H>]H
MI %%%% !1110 4444 %<3J^A7&J_$16+7]K:FRP;JU)3G)^7?@C\*[:B@#B=
M;\,06\OAS3[&PDFLH;HF?Y"XP=N6<^_OQVZ51;3M0T^+Q2FFZ1NCEGB\F)K;
M<A7+9*(1AL<<<]J]$HH \MTK2KTW.K-/IE\]O-IQ4*+);-G.]>%5<KNP"0.I
M]*?:Z3JT_AS6K.STZ:*-HXA&\UH+::8*V=A4'!P"WS=3T)Z >GT4[@>>>#=-
MN(O$<=Q+%J%N4MV1A)I2VL;#C@LK<G//(R<5MZE:7,GQ(T>Y2WE:WCMY \H0
ME%)5L GH.M=112 Y?P%:7-GH]XEW;RP.U](ZK*A4E2%P>>U=1110 4444 %%
M%% !1110 4444 %%%% !114%]#)<64L4#^7(PPK9(Q^5 $]%<W_8.J_]!'_R
M(U']@ZK_ -!'_P B-0!TE%<W_8.J_P#01_\ (C4?V#JO_01_\B-0!TE%<W_8
M.J_]!'_R(U']@ZK_ -!'_P B-0!TE%<W_8.J_P#01_\ (C4?V#JO_01_\B-0
M!TE%<W_8.J_]!'_R(U']@ZK_ -!'_P B-0!TE%<W_8.J_P#01_\ (C4?V#JO
M_01_\B-0!TE%<W_8.J_]!'_R(U']@ZK_ -!'_P B-0!TE%<W_8.J_P#01_\
M(C4?V#JO_01_\B-0!TE%<W_8.J_]!'_R(U']@ZK_ -!'_P B-0!TE%<W_8.J
M_P#01_\ (C4?V#JO_01_\B-0!TE%<W_8.J_]!'_R(U']@ZK_ -!'_P B-0!T
ME%<W_8.J_P#01_\ (C4?V#JO_01_\B-0!TE%<W_8.J_]!'_R(U']@ZK_ -!'
M_P B-0!TE%<W_8.J_P#01_\ (C4?V#JO_01_\B-0!TE%<W_8.J_]!'_R(U']
M@ZK_ -!'_P B-0!TE%<W_8.J_P#01_\ (C4?V#JO_01_\B-0!TE%<W_8.J_]
M!'_R(U']@ZK_ -!'_P B-0!TE%<W_8.J_P#01_\ (C4?V#JO_01_\B-0!TE%
M<W_8.J_]!'_R(U']@ZK_ -!'_P B-0!TE%<W_8.J_P#01_\ (C4?V#JO_01_
M\B-0!TE%<W_8.J_]!'_R(U']@ZK_ -!'_P B-0!TE%<W_8.J_P#01_\ (C4?
MV#JO_01_\B-0!TE%<W_8.J_]!'_R(U']@ZK_ -!'_P B-0!TE%<W_8.J_P#0
M1_\ (C4?V#JO_01_\B-0!TE%<W_8.J_]!'_R(U']@ZK_ -!'_P B-0!TE%<W
M_8.J_P#01_\ (C4?V#JO_01_\B-0!TE%<W_8.J_]!'_R(U']@ZK_ -!'_P B
M-0!TE%<W_8.J_P#01_\ (C4?V#JO_01_\B-0!TE%<W_8.J_]!'_R(U']@ZK_
M -!'_P B-0!TE%<W_8.J_P#01_\ (C4?V#JO_01_\B-0!TE%<W_8.J_]!'_R
M(U']@ZK_ -!'_P B-0!TE8C>#M ?43?/IL;7#/YA)=MI;UVYV_I5;^P=5_Z"
M/_D1J/[!U7_H(_\ D1J +FI^%-$UB[^U:C8++.0%+AV0D#IG:1GZFK":%IT=
MU!<K;#S;>W%M$2['$?\ =P3@]>_-9?\ 8.J_]!'_ ,B-1_8.J_\ 01_\B-0!
M8M_!N@6FH)>VVGK'.C^8K+*^%/LN<?AC%2IX6T6/5_[32PC6[W[]X9L;O7;G
M;G\.O/6J7]@ZK_T$?_(C4?V#JO\ T$?_ "(U %O_ (1+1/,NY!8J&O%*S[9'
M 8$AB,9XY Z8IU_X6T;4X;>.]L5D6V01Q'>RE5'09!!(^M4O[!U7_H(_^1&H
M_L'5?^@C_P"1&H T3X<TG[':VHLU6&TD$L**S#:X_BX/)^N:L1:79P:I/J,4
M.VZN%"RR;B=P P.,X'3M6-_8.J_]!'_R(U']@ZK_ -!'_P B-0!TE%<W_8.J
M_P#01_\ (C4?V#JO_01_\B-0!TE%<W_8.J_]!'_R(U']@ZK_ -!'_P B-0!T
ME%<W_8.J_P#01_\ (C4?V#JO_01_\B-0!TE%<W_8.J_]!'_R(U']@ZK_ -!'
M_P B-0!TE%<W_8.J_P#01_\ (C4?V#JO_01_\B-0!TE%<W_8.J_]!'_R(U']
M@ZK_ -!'_P B-0!TE%<W_8.J_P#01_\ (C4?V#JO_01_\B-0!TE%<W_8.J_]
M!'_R(U']@ZK_ -!'_P B-0!TE%<W_8.J_P#01_\ (C4?V#JO_01_\B-0!TE%
M<W_8.J_]!'_R(U']@ZK_ -!'_P B-0!TE%<W_8.J_P#01_\ (C4?V#JO_01_
M\B-0!TE%<W_8.J_]!'_R(U']@ZK_ -!'_P B-0!TE%<W_8.J_P#01_\ (C4?
MV#JO_01_\B-0!TE%<W_8.J_]!'_R(U']@ZK_ -!'_P B-0!TE%<W_8.J_P#0
M1_\ (C4?V#JO_01_\B-0!TE%<W_8.J_]!'_R(U']@ZK_ -!'_P B-0!TE%<W
M_8.J_P#01_\ (C4?V#JO_01_\B-0!TE%<W_8.J_]!'_R(U']@ZK_ -!'_P B
M-0!TE%<W_8.J_P#01_\ (C4?V#JO_01_\B-0!TE%<W_8.J_]!'_R(U']@ZK_
M -!'_P B-0!TE%<W_8.J_P#01_\ (C4?V#JO_01_\B-0!TE%<W_8.J_]!'_R
M(U']@ZK_ -!'_P B-0!TE%<W_8.J_P#01_\ (C4?V#JO_01_\B-0!TE%<W_8
M.J_]!'_R(U']@ZK_ -!'_P B-0!TE%<W_8.J_P#01_\ (C4?V#JO_01_\B-0
M!TE%<W_8.J_]!'_R(U']@ZK_ -!'_P B-0!TE%<W_8.J_P#01_\ (C4?V#JO
M_01_\B-0!TE%<W_8.J_]!'_R(U']@ZK_ -!'_P B-0!TE%<W_8.J_P#01_\
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M)UA\J(XQDD$9YZ>XZYJ/JM:R=M_-?CV^9?URA=KFV\G^'?Y'945Y+X.\4?\
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MNR20FUO8(XXT5CO!55!R,8_A/<UTM%%83FYM-^2^XZ(4XTTU'JV_O"BBBH-
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M4 5O[.L_^?:/_OFC^SK/_GVC_P"^:LT4 5O[.L_^?:/_ +YH_LZS_P"?:/\
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M_OFK-% %;^SK/_GVC_[YH_LZS_Y]H_\ OFK-% %;^SK/_GVC_P"^:/[.L_\
MGVC_ .^:LT4 5O[.L_\ GVC_ .^:/[.L_P#GVC_[YJS10!6_LZS_ .?:/_OF
MC^SK/_GVC_[YJS10!6_LZS_Y]H_^^:/[.L_^?:/_ +YJS10!6_LZS_Y]H_\
MOFC^SK/_ )]H_P#OFK-% %;^SK/_ )]H_P#OFC^SK/\ Y]H_^^:LT4 5O[.L
M_P#GVC_[YH_LZS_Y]H_^^:LT4 5O[.L_^?:/_OFC^SK/_GVC_P"^:LT4 5O[
M.L_^?:/_ +YH_LZS_P"?:/\ [YJS10!6_LZS_P"?:/\ [YH_LZS_ .?:/_OF
MK-% %;^SK/\ Y]H_^^:/[.L_^?:/_OFK-% %;^SK/_GVC_[YH_LZS_Y]H_\
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MV4?\,]_]3/\ ^4__ .V4<TNP?5\'_P __P#R5GM%%>+_ /#/?_4S_P#E/_\
MME'_  SW_P!3/_Y3_P#[91S2[!]7P?\ S_\ _)6>T45XO_PSW_U,_P#Y3_\
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MW_U,_P#Y3_\ [91_PSW_ -3/_P"4_P#^V4<TNP?5\'_S_P#_ "5GM%%>+_\
M#/?_ %,__E/_ /ME'_#/?_4S_P#E/_\ ME'-+L'U?!_\_P#_ ,E9[117B_\
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M5GM%%>+_ /#/?_4S_P#E/_\ ME'_  SW_P!3/_Y3_P#[91S2[!]7P?\ S_\
M_)6>T45XO_PSW_U,_P#Y3_\ [91_PSW_ -3/_P"4_P#^V4<TNP?5\'_S_P#_
M "5GM%%>+_\ #/?_ %,__E/_ /ME'_#/?_4S_P#E/_\ ME'-+L'U?!_\_P#_
M ,E9[117B_\ PSW_ -3/_P"4_P#^V4?\,]_]3/\ ^4__ .V4<TNP?5\'_P _
M_P#R5GM%%>+_ /#/?_4S_P#E/_\ ME'_  SW_P!3/_Y3_P#[91S2[!]7P?\
MS_\ _)6>T5D^*=2O](\,WM_H]C]OO(4#1V_)W<@$X')P,G ZXKRW_AGO_J9_
M_*?_ /;*S?$7P8M?#6@7.K7_ (E=H+=02L>G99B2% '[WN2*3E*VQI3PV$<T
ME6OKMRO7R.V\&?%_2O$+)9:R%TO42=H#M^ZD/LQZ'V/YFO1*^5/"G@/6O&%S
MC3("EHK8>\F&V-?\3[#-?27A7P^?#.@PZ:VH7-^8_P#EK<-G'LH[+Z#)Q1"4
MFM1YEAL/0E^ZEKV[?UV-FBBBM#R HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ J.XMX;NW>"ZACGAD&'CD4,K#T(/!J2B@-AD$$5M D-M$D,2#"1QJ
M%51Z #I3Z** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "FN@D0J2P![JQ!_,4ZB@"M]AC_YZ
M7'_@0_\ C1]AC_YZ7'_@0_\ C5FB@"M]AC_YZ7'_ ($/_C1]AC_YZ7'_ ($/
M_C5FB@"M]AC_ .>EQ_X$/_C1]AC_ .>EQ_X$/_C5FB@"M]AC_P">EQ_X$/\
MXT?88_\ GI<?^!#_ .-6:* *WV&/_GI<?^!#_P"-'V&/_GI<?^!#_P"-6:*
M*WV&/_GI<?\ @0_^-'V&/_GI<?\ @0_^-6:* *WV&/\ YZ7'_@0_^-'V&/\
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M_GI<?^!#_P"-'V&/_GI<?^!#_P"-6:* *WV&/_GI<?\ @0_^-'V&/_GI<?\
M@0_^-6:* *WV&/\ YZ7'_@0_^-'V&/\ YZ7'_@0_^-6:* *WV&/_ )Z7'_@0
M_P#C1]AC_P">EQ_X$/\ XU9HH K?88_^>EQ_X$/_ (T?88_^>EQ_X$/_ (U9
MHH K?88_^>EQ_P"!#_XT?88_^>EQ_P"!#_XU9HH K?88_P#GI<?^!#_XT?88
M_P#GI<?^!#_XU9HH K?88_\ GI<?^!#_ .-'V&/_ )Z7'_@0_P#C5FB@"M]A
MC_YZ7'_@0_\ C1]AC_YZ7'_@0_\ C5FB@"M]AC_YZ7'_ ($/_C1]AC_YZ7'_
M ($/_C5FB@"M]AC_ .>EQ_X$/_C1]AC_ .>EQ_X$/_C5FB@"M]AC_P">EQ_X
M$/\ XT?88_\ GI<?^!#_ .-6:* *WV&/_GI<?^!#_P"-'V&/_GI<?^!#_P"-
M6:* *WV&/_GI<?\ @0_^-'V&/_GI<?\ @0_^-6:* *WV&/\ YZ7'_@0_^-'V
M&/\ YZ7'_@0_^-6:* *WV&/_ )Z7'_@0_P#C1]AC_P">EQ_X$/\ XU9HH K?
M88_^>EQ_X$/_ (T?88_^>EQ_X$/_ (U9HH K?88_^>EQ_P"!#_XT?88_^>EQ
M_P"!#_XU9HH K?88_P#GI<?^!#_XT?88_P#GI<?^!#_XU9HH K?88_\ GI<?
M^!#_ .-'V&/_ )Z7'_@0_P#C5FB@"M]AC_YZ7'_@0_\ C1]AC_YZ7'_@0_\
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M^>EQ_P"!#_XU9HH K?88_P#GI<?^!#_XT?88_P#GI<?^!#_XU9HH K?88_\
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M 4444 %%%% !1110 4444 %,GFCMK>2>=MD<2EW8]@!DFGUSOC*Y_P! MM-
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MBO%_^+X?Y^Q4?\7P_P _8JOG\F<7]G_]/8?^!?\  /:**\7_ .+X?Y^Q4?\
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MA^']+\.:>+/1K..VB'WMHRSGU9NI/UK2HHH"4G)\TG=A11102%%%% !1110
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MY_\ D44>?=?\^?\ Y%%6:* *WGW7_/G_ .111Y]U_P ^?_D459HH K>?=?\
M/G_Y%%'GW7_/G_Y%%6:* *WGW7_/G_Y%%'GW7_/G_P"115FB@"MY]U_SY_\
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MG_Y%%6:* *WGW7_/G_Y%%'GW7_/G_P"115FB@"MY]U_SY_\ D44>?=?\^?\
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M"&16.LE"1DJ;2;(]N$J5.+.ZMEN)HM>[>_;4[6BN+_X6[X'_ .@W_P"2D_\
M\11_PMWP/_T&_P#R4G_^(I\T>YS_ %3$?\^Y?<SM**XO_A;O@?\ Z#?_ )*3
M_P#Q%'_"W? __0;_ /)2?_XBCFCW#ZIB/^?<ON9VE%<7_P +=\#_ /0;_P#)
M2?\ ^(H_X6[X'_Z#?_DI/_\ $4<T>X?5,1_S[E]S.THKB_\ A;O@?_H-_P#D
MI/\ _$4?\+=\#_\ 0;_\E)__ (BCFCW#ZIB/^?<ON9VE%<7_ ,+=\#_]!O\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %'3K
M12.BR(4D4,IZJPR#0 ;E]1^=&Y?4?G4'V"S_ .?2#_OV*/L%G_SZ0?\ ?L4
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M5O[/M?\ GE_X\?\ &C^S[7_GE_X\?\: +-%5O[/M?^>7_CQ_QH_L^U_YY?\
MCQ_QH LT56_L^U_YY?\ CQ_QH_L^U_YY?^/'_&@"S15;^S[7_GE_X\?\:/[/
MM?\ GE_X\?\ &@"S15;^S[7_ )Y?^/'_ !H_L^U_YY?^/'_&@"S15;^S[7_G
ME_X\?\:/[/M?^>7_ (\?\: +-%5O[/M?^>7_ (\?\:/[/M?^>7_CQ_QH LT5
M6_L^U_YY?^/'_&C^S[7_ )Y?^/'_ !H LT56_L^U_P">7_CQ_P :/[/M?^>7
M_CQ_QH LT56_L^U_YY?^/'_&C^S[7_GE_P"/'_&@"S15;^S[7_GE_P"/'_&C
M^S[7_GE_X\?\: +-%5O[/M?^>7_CQ_QH_L^U_P">7_CQ_P : +-%5O[/M?\
MGE_X\?\ &C^S[7_GE_X\?\: +-%5O[/M?^>7_CQ_QH_L^U_YY?\ CQ_QH LT
M56_L^U_YY?\ CQ_QH_L^U_YY?^/'_&@"S15;^S[7_GE_X\?\:/[/M?\ GE_X
M\?\ &@"S15;^S[7_ )Y?^/'_ !H_L^U_YY?^/'_&@"S15;^S[7_GE_X\?\:/
M[/M?^>7_ (\?\: +-%5O[/M?^>7_ (\?\:/[/M?^>7_CQ_QH LT56_L^U_YY
M?^/'_&C^S[7_ )Y?^/'_ !H LT56_L^U_P">7_CQ_P :/[/M?^>7_CQ_QH L
MT56_L^U_YY?^/'_&C^S[7_GE_P"/'_&@"S15;^S[7_GE_P"/'_&C^S[7_GE_
MX\?\: +-%5O[/M?^>7_CQ_QH_L^U_P">7_CQ_P : +-%5O[/M?\ GE_X\?\
M&C^S[7_GE_X\?\: +-%5O[/M?^>7_CQ_QH_L^U_YY?\ CQ_QH LT56_L^U_Y
MY?\ CQ_QH_L^U_YY?^/'_&@"S15;^S[7_GE_X\?\:/[/M?\ GE_X\?\ &@"S
M15;^S[7_ )Y?^/'_ !H_L^U_YY?^/'_&@"S15;^S[7_GE_X\?\:/[/M?^>7_
M (\?\: +-%5O[/M?^>7_ (\?\:/[/M?^>7_CQ_QH LT56_L^U_YY?^/'_&C^
MS[7_ )Y?^/'_ !H LT56_L^U_P">7_CQ_P :/[/M?^>7_CQ_QH LT56_L^U_
MYY?^/'_&C^S[7_GE_P"/'_&@"S15;^S[7_GE_P"/'_&C^S[7_GE_X\?\: +-
M%5O[/M?^>7_CQ_QH_L^U_P">7_CQ_P : +-%5O[/M?\ GE_X\?\ &C^S[7_G
ME_X\?\: +-%5O[/M?^>7_CQ_QH_L^U_YY?\ CQ_QH LT56_L^U_YY?\ CQ_Q
MH_L^U_YY?^/'_&@"S15;^S[7_GE_X\?\:/[/M?\ GE_X\?\ &@"S15;^S[7_
M )Y?^/'_ !H_L^U_YY?^/'_&@"S15;^S[7_GE_X\?\:/[/M?^>7_ (\?\: +
M-%5O[/M?^>7_ (\?\:/[/M?^>7_CQ_QH LT56_L^U_YY?^/'_&C^S[7_ )Y?
M^/'_ !H LT56_L^U_P">7_CQ_P :/[/M?^>7_CQ_QH LT56_L^U_YY?^/'_&
MC^S[7_GE_P"/'_&@"S15;^S[7_GE_P"/'_&C^S[7_GE_X\?\: +-%5O[/M?^
M>7_CQ_QH_L^U_P">7_CQ_P : +-%5O[/M?\ GE_X\?\ &C^S[7_GE_X\?\:
M+-%5O[/M?^>7_CQ_QH_L^U_YY?\ CQ_QH LT56_L^U_YY?\ CQ_QH_L^U_YY
M?^/'_&@"S15;^S[7_GE_X\?\:/[/M?\ GE_X\?\ &@"S15;^S[7_ )Y?^/'_
M !H_L^U_YY?^/'_&@"S15;^S[7_GE_X\?\:/[/M?^>7_ (\?\: +-%5O[/M?
M^>7_ (\?\:/[/M?^>7_CQ_QH LT56_L^U_YY?^/'_&C^S[7_ )Y?^/'_ !H
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MG_Q5 %BBJ_VF7_GRG_[Z3_XJC[3+_P ^4_\ WTG_ ,50!8HJO]IE_P"?*?\
M[Z3_ .*H^TR_\^4__?2?_%4 6**K_:9?^?*?_OI/_BJ/M,O_ #Y3_P#?2?\
MQ5 %BBJ_VF7_ )\I_P#OI/\ XJC[3+_SY3_]])_\50!8HJO]IE_Y\I_^^D_^
M*H^TR_\ /E/_ -])_P#%4 6**K_:9?\ GRG_ .^D_P#BJ/M,O_/E/_WTG_Q5
M %BBJ_VF7_GRG_[Z3_XJC[3+_P ^4_\ WTG_ ,50!8HJO]IE_P"?*?\ [Z3_
M .*H^TR_\^4__?2?_%4 6**K_:9?^?*?_OI/_BJ/M,O_ #Y3_P#?2?\ Q5 %
MBBJ_VF7_ )\I_P#OI/\ XJC[3+_SY3_]])_\50!8HJO]IE_Y\I_^^D_^*H^T
MR_\ /E/_ -])_P#%4 6**K_:9?\ GRG_ .^D_P#BJ/M,O_/E/_WTG_Q5 %BB
MJ_VF7_GRG_[Z3_XJC[3+_P ^4_\ WTG_ ,50!8HJO]IE_P"?*?\ [Z3_ .*H
M^TR_\^4__?2?_%4 6**K_:9?^?*?_OI/_BJ/M,O_ #Y3_P#?2?\ Q5 %BBJ_
MVF7_ )\I_P#OI/\ XJC[3+_SY3_]])_\50!8HJO]IE_Y\I_^^D_^*H^TR_\
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MC[3+_P ^4_\ WTG_ ,50!8HJO]IE_P"?*?\ [Z3_ .*H^TR_\^4__?2?_%4
M6**K_:9?^?*?_OI/_BJ/M,O_ #Y3_P#?2?\ Q5 %BBJ_VF7_ )\I_P#OI/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "L
MS5H+OR9VTVPLYYIH6C=YI-C'@[5X4[AR>"1^M:=4+O3)+F=Y(=3O;3S$"LD+
M(5XSR-RMM//;':@#E[:_GAT7PW9Z%>211W$CV\CS1*7&T$'CD @@D#)[9R*U
M5FU"[U^XTJ#4I84LK97:?RXV>61SD;LKMV@#H "?6KJ^'+&-=.2'S(TTYS)"
MJMG<3G.[.2<Y)I]YHD5U?F]AN;BSN&B\F1[=E!D3.0#N!P1V(P>>M &;X$W?
M\(XWF8+?:IMVT<9WFLJ37K^]D(M-5,=ZVI?9AI\"Q,1$#@GE2<X!8M]WVKJ]
M(TBWT2P^R6;2-%O9QYC;B"3G&:YB+1]7M].DM[>WO8=1-PSI=1WH%JF9-V1'
MO^[@GY=AS3 FGUJ^N;C5!;75Y";*0P6\=O8&9975<DR,$(Y) P"N!5E+[5-0
M\065I]I?3XY=+6ZGC6%2ZN6P0-X..N#D'ITSR-)]#7[5//:WMU9-<X,ZVY0+
M(P&-WS*2IQW4CH._-3II4":NNHJ\IE6V^S ,V1MW;LG/).>^:0%;PY>W-[I\
MRWSB6>UNI;9I0H7S-C8W8' K6JII^G1::MPL#.PN+A[AMY!PSG) P.E6Z "N
M4^(_BB?PEX.EO[)5-U)(L$)89",V3N([X /XXKJZQ_%7AJU\6>'I]*O6:-9,
M,DJC)C<=& [_ $]":3O;0VH."JQ=3X;ZGSGI_P 3?%EAJBWK:Q<7/S9>"=]T
M;CN-O0?ABO54^/7ADHN_3]6#8Y BC(!^OF5SNG? .^&J+_:NK6QL5;+?9PWF
M./3!&%^N37JR>"O"Z1J@\.:20HP-UE&3^9'-914SW,;7R^35HW]-#C/^%]>%
M_P#GPU?_ +\Q?_'*/^%]>%_^?#5_^_,7_P <KM/^$-\+_P#0MZ1_X Q?_$T?
M\(;X7_Z%O2/_  !B_P#B:NT^YY_M,#_)+[SB_P#A?7A?_GPU?_OS%_\ '*/^
M%]>%_P#GPU?_ +\Q?_'*[3_A#?"__0MZ1_X Q?\ Q-'_  AOA?\ Z%O2/_ &
M+_XFBT^X>TP/\DOO.+_X7UX7_P"?#5_^_,7_ ,<H_P"%]>%_^?#5_P#OS%_\
M<KM/^$-\+_\ 0MZ1_P" ,7_Q-'_"&^%_^A;TC_P!B_\ B:+3[A[3 _R2^\XO
M_A?7A?\ Y\-7_P"_,7_QRC_A?7A?_GPU?_OS%_\ '*[3_A#?"_\ T+>D?^ ,
M7_Q-'_"&^%_^A;TC_P  8O\ XFBT^X>TP/\ )+[SB_\ A?7A?_GPU?\ [\Q?
M_'*/^%]>%_\ GPU?_OS%_P#'*[3_ (0WPO\ ]"WI'_@#%_\ $T?\(;X7_P"A
M;TC_ , 8O_B:+3[A[3 _R2^\XO\ X7UX7_Y\-7_[\Q?_ !RC_A?7A?\ Y\-7
M_P"_,7_QRNT_X0WPO_T+>D?^ ,7_ ,31_P (;X7_ .A;TC_P!B_^)HM/N'M,
M#_)+[SB_^%]>%_\ GPU?_OS%_P#'*/\ A?7A?_GPU?\ [\Q?_'*[3_A#?"__
M $+>D?\ @#%_\31_PAOA?_H6](_\ 8O_ (FBT^X>TP/\DOO.+_X7UX7_ .?#
M5_\ OS%_\<H_X7UX7_Y\-7_[\Q?_ !RNT_X0WPO_ -"WI'_@#%_\31_PAOA?
M_H6](_\  &+_ .)HM/N'M,#_ "2^\XO_ (7UX7_Y\-7_ ._,7_QRC_A?7A?_
M )\-7_[\Q?\ QRNT_P"$-\+_ /0MZ1_X Q?_ !-'_"&^%_\ H6](_P# &+_X
MFBT^X>TP/\DOO.+_ .%]>%_^?#5_^_,7_P <H_X7UX7_ .?#5_\ OS%_\<KM
M/^$-\+_]"WI'_@#%_P#$T?\ "&^%_P#H6](_\ 8O_B:+3[A[3 _R2^\XO_A?
M7A?_ )\-7_[\Q?\ QRC_ (7UX7_Y\-7_ ._,7_QRNT_X0WPO_P!"WI'_ ( Q
M?_$T?\(;X7_Z%O2/_ &+_P")HM/N'M,#_)+[SB_^%]>%_P#GPU?_ +\Q?_'*
M/^%]>%_^?#5_^_,7_P <KM/^$-\+_P#0MZ1_X Q?_$T?\(;X7_Z%O2/_  !B
M_P#B:+3[A[3 _P DOO.+_P"%]>%_^?#5_P#OS%_\<H_X7UX7_P"?#5_^_,7_
M ,<KM/\ A#?"_P#T+>D?^ ,7_P 31_PAOA?_ *%O2/\ P!B_^)HM/N'M,#_)
M+[SB_P#A?7A?_GPU?_OS%_\ '*/^%]>%_P#GPU?_ +\Q?_'*[3_A#?"__0MZ
M1_X Q?\ Q-'_  AOA?\ Z%O2/_ &+_XFBT^X>TP/\DOO.+_X7UX7_P"?#5_^
M_,7_ ,<K-\1?&/PSKWAV]TM(];M&N8R@FCABRG?_ )Z<CL1W!->C?\(;X7_Z
M%O2/_ &+_P")K,\1^#--/AR]'AWPYHO]I^6?L_F6,.-WXKC.,XSQG&:34[&E
M.K@E-6@T[]SQ;P?\4]8\*2+;2NVI:8&_U$[89!ZHW.WZ<C^=>_>&?%&F^+-)
M%_I+N8\[721-K1MZ'M^617F?@_X(_O1?>,G5FW;A80, O_ V'\E_/M7K]K:V
M]C:QVUG!'!!&-J1QJ%51Z "E34EN7F=7"3E^Z7O=6MO^"2T445J>,%%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1139%+QE5=D)_B7&1^= #J*J_8Y?^?^Y_
M)/\ XFC['+_S_P!S^2?_ !- %JBJOV.7_G_N?R3_ .)H^QR_\_\ <_DG_P 3
M0!:HJK]CE_Y_[G\D_P#B:/L<O_/_ '/Y)_\ $T 6J*J_8Y?^?^Y_)/\ XFC[
M'+_S_P!S^2?_ !- %JBJOV.7_G_N?R3_ .)H^QR_\_\ <_DG_P 30!:HJK]C
ME_Y_[G\D_P#B:/L<O_/_ '/Y)_\ $T 6J*J_8Y?^?^Y_)/\ XFC['+_S_P!S
M^2?_ !- %JBJOV.7_G_N?R3_ .)H^QR_\_\ <_DG_P 30!:HJK]CE_Y_[G\D
M_P#B:/L<O_/_ '/Y)_\ $T 6J*J_8Y?^?^Y_)/\ XFC['+_S_P!S^2?_ !-
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M_P 30!:HJK]CE_Y_[G\D_P#B:/L<O_/_ '/Y)_\ $T 6J*J_8Y?^?^Y_)/\
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M?R3_ .)H^QR_\_\ <_DG_P 30!:HJK]CE_Y_[G\D_P#B:/L<O_/_ '/Y)_\
M$T 6J*J_8Y?^?^Y_)/\ XFC['+_S_P!S^2?_ !- %JBJOV.7_G_N?R3_ .)H
M^QR_\_\ <_DG_P 30!:HJK]CE_Y_[G\D_P#B:/L<O_/_ '/Y)_\ $T 6J*J_
M8Y?^?^Y_)/\ XFC['+_S_P!S^2?_ !- %JBJOV.7_G_N?R3_ .)H^QR_\_\
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M_P#B:/L<O_/_ '/Y)_\ $T 6J*J_8Y?^?^Y_)/\ XFC['+_S_P!S^2?_ !-
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M_P 30!:HJK]CE_Y_[G\D_P#B:/L<O_/_ '/Y)_\ $T 6J*J_8Y?^?^Y_)/\
MXFC['+_S_P!S^2?_ !- %JBJOV.7_G_N?R3_ .)H^QR_\_\ <_DG_P 30!:H
MJK]CE_Y_[G\D_P#B:/L<O_/_ '/Y)_\ $T 6J*J_8Y?^?^Y_)/\ XFC['+_S
M_P!S^2?_ !- %JBJOV.7_G_N?R3_ .)H^QR_\_\ <_DG_P 30!:HJK]CE_Y_
M[G\D_P#B:GBC:*/:TKRG/WGQG] * 'T444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MZ2T6X?9YNU0&/.3C<2,GOZ<5ZB-"T@0K"-*LA$DOG*@MTVK)_? Q][WZU/\
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M72[):XNKN=;P," %"+D%>@&%/ QVJ_XZ>VO]>\0W*1:?!-92HF^\O)?M4C#
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M),VMV L;.X.ID+_IDKW^<D[F7=M"^^!V'UUO%3W*>-O$N?-_LIKBU74_L_\
MK?)P.AZ8S^N.V:]BD\.Z)-<2SS:/8233',DC6J%G.<\G'/(!_"IFTG3FDN9&
ML+4O=KMN&,*YF'3#G'S#ZUI_:$+I\O2WXI_A8S_LR=FN9:N_X-?C?4\<\200
MZIXQ.FQ7&CPZ3;:?$VFKJ=S+! L;*IW1E",L2?XLY [XJS/927T/@&PO]2^V
MI+)=P-<VLKCS8MRJ5W$!L;<J>.1^=>J3>']&N+:"WN-(L)8;<$0Q/;(RQ9Z[
M01@9QVJ=M,L'>U9[*W9K,8MB8E)@X ^3CY>@Z>@K/Z\K123T_P FK_C=FO\
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M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %-<LJ$HN]NRYQFG44
M5O/NO^?/_P BBCS[K_GS_P#(HJS10!6\^Z_Y\_\ R**//NO^?/\ \BBK-% %
M;S[K_GS_ /(HH\^Z_P"?/_R**LT4 5O/NO\ GS_\BBCS[K_GS_\ (HJS10!6
M\^Z_Y\__ "**//NO^?/_ ,BBK-% %;S[K_GS_P#(HH\^Z_Y\_P#R**LT4 5O
M/NO^?/\ \BBCS[K_ )\__(HJS10!6\^Z_P"?/_R**//NO^?/_P BBK-% %;S
M[K_GS_\ (HH\^Z_Y\_\ R**LT4 5O/NO^?/_ ,BBCS[K_GS_ /(HJS10!6\^
MZ_Y\_P#R**//NO\ GS_\BBK-% %;S[K_ )\__(HH\^Z_Y\__ "**LT4 5O/N
MO^?/_P BBCS[K_GS_P#(HJS10!6\^Z_Y\_\ R**//NO^?/\ \BBK-% %;S[K
M_GS_ /(HH\^Z_P"?/_R**LT4 5O/NO\ GS_\BBCS[K_GS_\ (HJS10!6\^Z_
MY\__ "**//NO^?/_ ,BBK-% %;S[K_GS_P#(HH\^Z_Y\_P#R**LT4 5O/NO^
M?/\ \BBCS[K_ )\__(HJS10!6\^Z_P"?/_R**//NO^?/_P BBK-% %;S[K_G
MS_\ (HH\^Z_Y\_\ R**LT4 5O/NO^?/_ ,BBCS[K_GS_ /(HJS10!6\^Z_Y\
M_P#R**//NO\ GS_\BBK-% %;S[K_ )\__(HH\^Z_Y\__ "**LT4 5O/NO^?/
M_P BBCS[K_GS_P#(HJS10!6\^Z_Y\_\ R**//NO^?/\ \BBK-% %;S[K_GS_
M /(HH\^Z_P"?/_R**LT4 5O/NO\ GS_\BBCS[K_GS_\ (HJS10!6\^Z_Y\__
M "**//NO^?/_ ,BBK-% %;S[K_GS_P#(HH\^Z_Y\_P#R**LT4 5O/NO^?/\
M\BBCS[K_ )\__(HJS10!6\^Z_P"?/_R**//NO^?/_P BBK-% %;S[K_GS_\
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M\_\ R**LT4 5O/NO^?/_ ,BBCS[K_GS_ /(HJS10!6\^Z_Y\_P#R**//NO\
MGS_\BBK-% %;S[K_ )\__(HH\^Z_Y\__ "**LT4 5O/NO^?/_P BBCS[K_GS
M_P#(HJS10!6\^Z_Y\_\ R**//NO^?/\ \BBK-% %;S[K_GS_ /(HH\^Z_P"?
M/_R**LT4 5O/NO\ GS_\BBCS[K_GS_\ (HJS10!6\^Z_Y\__ "**//NO^?/_
M ,BBK-% %;S[K_GS_P#(HH\^Z_Y\_P#R**LT4 5O/NO^?/\ \BBCS[K_ )\_
M_(HJS10!6\^Z_P"?/_R**//NO^?/_P BBK-% %;S[K_GS_\ (HH\^Z_Y\_\
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MT7_Q5'_"9^%_^ADTC_P.B_\ BJ+H/8U/Y7]QM45B_P#"9^%_^ADTC_P.B_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !6#XOT.X\0:/%:6CPHZW"R'SB0" "". ?6MZB@#/DTBUCTN[M=-M;>T-
MQ$R?NHP@)*D G ]ZY:W\+^)QX?CT&2]TV"PY626$2-*5))(Y '4^U=S10!FP
M>'M)@AMT_L^VE:W14266%6?"C@YQUK"LM#\2:3J^I3Z<^E/!?733D3F0L 6)
M X &<'WKKZ* .-U30O$U[XF@U6%]) LV<6RN9>4.<;QCK@]C781>9Y*>=M\S
M:-^SIGOCVIU% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !5/5$O);&2&QB@D:561C-,8PH(QD85L_3BKE% &#IFG:I9>&HM-F@L)6A18
M]K2LR3IT8'Y!MX]F^E4#X3NSH]W#&UM!))>)=06T;,88=I!V@X!YYZ*/I76T
M4 4;Q[G^P;II(<7'D.?+MW+DG!P%) R?PZUQV@R06,FB_9+FSU*>0+$UO$TC
M26JLN78;I&"X(&?E7/3CI7?T4 <K9>%/L$8M5TS1[F-9"4O+B/,NPG.&3;\Q
M&2 =X['VK4MM*GAUC6;MFC,=\(A$ 3D;4VG/'KZ9K6HH SO#^GRZ5H%I8W#(
MTL$>UC&25)SVR!6C110 5RGQ(\+W'BWP;-86)474<BSPJQP'9<C;GMD$_CBN
MKHI-75C2G4E2FIQW1\M:=\-/%FH:HMD=&NK;YL/-<1E(T'<[CP?PS7JR? 7P
MT(U\S4-6+X^8K+& 3]/+KT^BH5.*/2K9MB*K7*^7T/,?^%"^%_\ G_U?_O\
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M\+:=X2T@:?I0D\O.YWE<LSMZGL/P %;-%$8*(\7CZN*T>D>P44459YX4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4UWV(6VLV.RC)-.HH K?;?^G:X_[]T?;?
M^G:X_P"_=6:* *WVW_IVN/\ OW1]M_Z=KC_OW5FB@"M]M_Z=KC_OW1]M_P"G
M:X_[]U9HH K?;?\ IVN/^_='VW_IVN/^_=6:* *WVW_IVN/^_='VW_IVN/\
MOW5FB@"M]M_Z=KC_ +]T?;?^G:X_[]U9HH K?;?^G:X_[]T?;?\ IVN/^_=6
M:* *WVW_ *=KC_OW1]M_Z=KC_OW5FB@"M]M_Z=KC_OW1]M_Z=KC_ +]U9HH
MK?;?^G:X_P"_='VW_IVN/^_=6:* *WVW_IVN/^_='VW_ *=KC_OW5FB@"M]M
M_P"G:X_[]T?;?^G:X_[]U9HH K?;?^G:X_[]T?;?^G:X_P"_=6:* *WVW_IV
MN/\ OW1]M_Z=KC_OW5FB@"M]M_Z=KC_OW1]M_P"G:X_[]U9HH K?;?\ IVN/
M^_='VW_IVN/^_=6:* *WVW_IVN/^_='VW_IVN/\ OW5FB@"M]M_Z=KC_ +]T
M?;?^G:X_[]U9HH K?;?^G:X_[]T?;?\ IVN/^_=6:* *WVW_ *=KC_OW1]M_
MZ=KC_OW5FB@"M]M_Z=KC_OW1]M_Z=KC_ +]U9HH K?;?^G:X_P"_='VW_IVN
M/^_=6:* *WVW_IVN/^_='VW_ *=KC_OW5FB@"M]M_P"G:X_[]T?;?^G:X_[]
MU9HH K?;?^G:X_[]T?;?^G:X_P"_=6:* *WVW_IVN/\ OW1]M_Z=KC_OW5FB
M@"M]M_Z=KC_OW1]M_P"G:X_[]U9HH K?;?\ IVN/^_='VW_IVN/^_=6:* *W
MVW_IVN/^_='VW_IVN/\ OW5FB@"M]M_Z=KC_ +]T?;?^G:X_[]U9HH K?;?^
MG:X_[]T?;?\ IVN/^_=6:* *WVW_ *=KC_OW1]M_Z=KC_OW5FB@"M]M_Z=KC
M_OW1]M_Z=KC_ +]U9HH K?;?^G:X_P"_='VW_IVN/^_=6:* *WVW_IVN/^_=
M'VW_ *=KC_OW5FB@"M]M_P"G:X_[]T?;?^G:X_[]U9HH K?;?^G:X_[]T?;?
M^G:X_P"_=6:* *WVW_IVN/\ OW1]M_Z=KC_OW5FB@"M]M_Z=KC_OW1]M_P"G
M:X_[]U9HH K?;?\ IVN/^_='VW_IVN/^_=6:* *WVW_IVN/^_='VW_IVN/\
MOW5FB@"M]M_Z=KC_ +]T?;?^G:X_[]U9HH K?;?^G:X_[]T?;?\ IVN/^_=6
M:* *WVW_ *=KC_OW1]M_Z=KC_OW5FB@"M]M_Z=KC_OW1]M_Z=KC_ +]U9HH
MK?;?^G:X_P"_='VW_IVN/^_=6:* *WVW_IVN/^_='VW_ *=KC_OW5FB@"M]M
M_P"G:X_[]T?;?^G:X_[]U9HH K?;?^G:X_[]T?;?^G:X_P"_=6:* *WVW_IV
MN/\ OW1]M_Z=KC_OW5FB@"M]M_Z=KC_OW1]M_P"G:X_[]U9HH K?;?\ IVN/
M^_='VW_IVN/^_=6:* *WVW_IVN/^_='VW_IVN/\ OW5FB@"M]M_Z=KC_ +]T
M?;?^G:X_[]U9HH K?;?^G:X_[]T?;?\ IVN/^_=6:* *WVW_ *=KC_OW1]M_
MZ=KC_OW5FB@"M]M_Z=KC_OW1]M_Z=KC_ +]U9HH K?;?^G:X_P"_='VW_IVN
M/^_=6:* *WVW_IVN/^_='VW_ *=KC_OW5FB@"M]M_P"G:X_[]T?;?^G:X_[]
MU9HH K?;?^G:X_[]T?;?^G:X_P"_=6:* *WVW_IVN/\ OW1]M_Z=KC_OW5FB
M@"M]M_Z=KC_OW1]M_P"G:X_[]U9HH K?;?\ IVN/^_='VW_IVN/^_=6:* *W
MVW_IVN/^_='VW_IVN/\ OW5FB@"M]M_Z=KC_ +]T?;?^G:X_[]U9HH K?;?^
MG:X_[]T?;?\ IVN/^_=6:* *WVW_ *=KC_OW1]M_Z=KC_OW5FB@"M]M_Z=KC
M_OW1]M_Z=KC_ +]U9HH K?;?^G:X_P"_='VW_IVN/^_=6:* *WVW_IVN/^_=
M'VW_ *=KC_OW5FB@"M]M_P"G:X_[]T?;?^G:X_[]U9HH K?;?^G:X_[]T?;?
M^G:X_P"_=6:* *WVW_IVN/\ OW1]M_Z=KC_OW5FB@"M]M_Z=KC_OW4T4GFIN
MV.G/1Q@T^B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
,* "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6655662272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborations, Contracts and Licensing Agreements (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">$ 3,061<span></span>
</td>
<td class="nump">$ 1,587<span></span>
</td>
<td class="nump">$ 4,393<span></span>
</td>
<td class="nump">$ 4,267<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember', window );">Royalties | Gritstone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember', window );">License | Gritstone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_RoyaltyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=abus_GritstoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=abus_GritstoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6815484688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statement of Stockholders' Equity (Parenthetical)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2018 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>Statement of Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Issuance costs on preferred stock issued</a></td>
<td class="nump">$ 135<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6824399824">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated of property, plant, and equipment</a></td>
<td class="nump">$ 8,612<span></span>
</td>
<td class="nump">$ 7,090<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockNoParValue', window );">Preferred stock, no par value (in USD per share)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">1,164,000<span></span>
</td>
<td class="nump">1,164,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">1,164,000<span></span>
</td>
<td class="nump">1,164,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">1,164,000<span></span>
</td>
<td class="nump">1,164,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockNoParValue', window );">Common shares, no par value (in USD per share)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common shares, shares issued (in shares)</a></td>
<td class="nump">56,850,172<span></span>
</td>
<td class="nump">55,518,800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common shares, shares outstanding (in shares)</a></td>
<td class="nump">56,850,172<span></span>
</td>
<td class="nump">55,518,800<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockNoParValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount per share of no-par value common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockNoParValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockNoParValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount per share of no-par value preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockNoParValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6813592848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Site Consolidation - Reserve Activity (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">21 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Site consolidation accrual as of December 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,331<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Additional accruals and other adjustments</a></td>
<td class="nump">$ 182<span></span>
</td>
<td class="num">$ (492)<span></span>
</td>
<td class="nump">33<span></span>
</td>
<td class="nump">$ 3,710<span></span>
</td>
<td class="nump">$ 4,800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,161)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Site consolidation accrual as of September 30, 2019</a></td>
<td class="nump">203<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">203<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">203<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=abus_EmployeeSeveranceandRelocationMember', window );">Employee severance and relocation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Site consolidation accrual as of December 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">697<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Additional accruals and other adjustments</a></td>
<td class="nump">231<span></span>
</td>
<td class="nump">198<span></span>
</td>
<td class="nump">429<span></span>
</td>
<td class="nump">3,399<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(923)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Site consolidation accrual as of September 30, 2019</a></td>
<td class="nump">203<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">203<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">203<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_FacilityClosingMember', window );">Facility and other expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Site consolidation accrual as of December 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">634<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Additional accruals and other adjustments</a></td>
<td class="num">(49)<span></span>
</td>
<td class="num">$ (690)<span></span>
</td>
<td class="num">(396)<span></span>
</td>
<td class="nump">$ 311<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(238)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Site consolidation accrual as of September 30, 2019</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRestructuring">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3367-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRestructuring</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserveRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserveRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=abus_EmployeeSeveranceandRelocationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=abus_EmployeeSeveranceandRelocationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_FacilityClosingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_FacilityClosingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6634181664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of presentation</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Basis of presentation</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (&#8220;U.S. GAAP&#8221;) for interim financial statements and accordingly, do not include all disclosures required for annual financial statements. These statements should be read in conjunction with the Company&#8217;s audited consolidated financial statements and notes thereto for the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;"> included in the Company&#8217;s Annual Report on Form 10-K for the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;"> (the &#8220;2018 Form 10-K&#8221;). These unaudited condensed consolidated financial statements reflect, in the opinion of management, all adjustments and reclassifications necessary to fairly present the Company's financial position as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;"> and the Company's results of operations and cash flows for the </font><font style="font-family:inherit;font-size:10pt;">three and nine months ended September 30, 2019 and 2018</font><font style="font-family:inherit;font-size:10pt;">. The results of operations for the </font><font style="font-family:inherit;font-size:10pt;">three and nine months ended September 30, 2019 and 2018</font><font style="font-family:inherit;font-size:10pt;">, respectively, are not necessarily indicative of the results for the full year. These unaudited condensed consolidated financial statements follow the same significant accounting policies as those described in the notes to the audited consolidated financial statements of the Company for the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">, except as described below under Recent Accounting Pronouncements.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of consolidation</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Principles of consolidation</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These unaudited condensed consolidated financial statements include the accounts of the Company and its </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;"> wholly-owned subsidiaries, Arbutus Biopharma Inc. ("Arbutus Inc.") and Arbutus Biopharma US Holdings, Inc. All intercompany transactions and balances have been eliminated in consolidation.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Income or loss per share</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Income or loss per share</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company follows the two-class method when computing net loss attributable to common shareholders per share as the Company has issued Series A participating convertible preferred shares (the "Preferred Shares"), as further described in note 12, that meet the definition of participating securities. The Preferred Shares entitle the holders to participate in dividends but do not require the holders to participate in losses of the Company. Accordingly, if the Company reports a net loss attributable to holders of the Company's common shares, net losses are not allocated to holders of the Preferred Shares. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss attributable to common shareholders per share is calculated based on the weighted average number of common shares outstanding. The calculation of diluted net loss attributable to common shareholders per share does not differ from the calculation of basic net loss attributable to common shareholders per share, as the effect of the Company&#8217;s dilutive potential common shares was anti-dilutive. During the </font><font style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2019 and 2018</font><font style="font-family:inherit;font-size:10pt;">, potential common shares of approximately </font><font style="font-family:inherit;font-size:10pt;">28.2 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">24.2 million</font><font style="font-family:inherit;font-size:10pt;">, respectively, consisting of the "if-converted" number of Preferred Shares and outstanding stock options, were excluded from the calculation of net loss per common share because their inclusion would be anti-dilutive.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsPolicy', window );">Equity method investment</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Equity method investment</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company accounts for its investment in associated companies in accordance with the Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC") 323, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Investments - Equity Method and Joint Ventures </font><font style="font-family:inherit;font-size:10pt;">("ASC</font><font style="font-family:inherit;font-size:10pt;font-style:italic;"> </font><font style="font-family:inherit;font-size:10pt;">323").  In accordance with ASC 323, associated companies are accounted for as equity method investments. Results of associated companies are presented on a one-line basis. Investments in, and advances to, associated companies are presented on a one-line basis in the caption &#8220;Investment in Genevant&#8221; in the Company's Condensed Consolidated Balance Sheets, net of allowance for losses, which represents the Company's best estimate of probable losses inherent in such assets.  The Company's proportionate share of any associated companies' net income or loss is presented on a one-line basis in the caption "Equity investment (loss)" in the Company's Condensed Consolidated Statement of Operations.  Transactions between the Company and any associated companies are eliminated on a basis proportional to the Company's ownership interest.  Financial results of Genevant Sciences Ltd. ("Genevant") are recorded on a one-quarter lag basis. </font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue recognition</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Revenue recognition </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company recognizes the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers under a five-step model: (i) identify contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when or as a performance obligation is satisfied. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company generates revenue primarily through collaboration agreements and license agreements. Such agreements may require the Company to deliver various rights and/or services, including intellectual property rights or licenses and research and development services. Under such agreements, the Company is generally eligible to receive non-refundable upfront payments, funding for research and development services, milestone payments, and royalties.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In contracts where the Company has more than one performance obligation to provide its customer with goods or services, each performance obligation is evaluated to determine whether it is distinct based on whether (i) the customer can benefit from the good or service either on its own or together with other resources that are readily available and (ii) the good or service is separately identifiable from other promises in the contract. The consideration under the contract is then allocated between the distinct performance obligations based on their respective relative stand-alone selling prices. The estimated stand-alone selling price of each deliverable reflects the Company's best estimate of what the selling price would be if the deliverable was regularly sold on a stand-alone basis and is determined by reference to market rates for the good or service when sold to others or by using an adjusted market assessment approach if the selling price on a stand-alone basis is not available. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The consideration allocated to each distinct performance obligation is recognized as revenue when control is transferred to the customer for the related goods or services. Consideration associated with at-risk substantive performance milestones, including sales-based milestones, is recognized as revenue when it is probable that a significant reversal of the cumulative revenue recognized will not occur. Sales-based royalties received in connection with licenses of intellectual property are subject to a specific exception in the revenue standards, whereby the consideration is not included in the transaction price and recognized in revenue until the customer&#8217;s subsequent sales or usages occur.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment information</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Segment information</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company operates as a single segment. </font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent accounting pronouncements</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Recent accounting pronouncements</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies that are adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on the Company's financial position or results of operations upon adoption.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company adopted Accounting Standard Update (&#8220;ASU&#8221;) No. 2016-02, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Leases</font><font style="font-family:inherit;font-size:10pt;"> (Topic 842), as of January 1, 2019, using the modified retrospective approach with the effective date transition method (note 5). Accordingly, all periods prior to adoption are presented in accordance with legacy accounting and the Company recorded no retrospective adjustments to the comparative periods presented. In addition, the Company elected the package of practical expedients permitted under the transition guidance within ASC 842, which among other things, allowed the Company to carry forward its historical lease classification. In addition, the Company elected the short term exemption, which allows entities to not capitalize their leases with a term of 12 months or less. Adoption of the new standard resulted in the recording of operating lease right-of-use assets (&#8220;ROU assets&#8221;) and lease liabilities of approximately </font><font style="font-family:inherit;font-size:10pt;">$3.2 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$4.1 million</font><font style="font-family:inherit;font-size:10pt;">, respectively, as of January 1, 2019.  The standard did not materially impact the Company&#8217;s consolidated statements of operations and statements of cash flow.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In November 2018, the FASB issued targeted amendments to ASU No. 2018-18, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Collaborative Arrangements </font><font style="font-family:inherit;font-size:10pt;">(Topic 808), and ASU No. 2016-10, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers </font><font style="font-family:inherit;font-size:10pt;">(Topic 606), to clarify that certain transactions between parties to collaborative arrangements should be accounted for in accordance with FASB revenue guidance when the counterparty is a customer. This guidance also prohibits the presentation of collaborative arrangements as revenues from contracts with customers if the counterparty is not a customer. This guidance, which is required to be applied retrospectively&#160;and is effective for interim and annual periods beginning after December 15, 2019, with early adoption permitted, is not expected to have a material impact on the Company&#8217;s consolidated financial statements.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair value of financial instruments</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair value of financial instruments</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company measures certain financial instruments and other items at fair value.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">To determine the fair value, the Company uses the fair value hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs market participants would use to value an asset or liability and are developed based on market data obtained from independent sources. Unobservable inputs are inputs based on assumptions about the factors market participants would use to value an asset or liability. The three levels of inputs that may be used to measure fair value are as follows:</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level 1 inputs are quoted market prices for identical instruments available in active markets.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level 2 inputs are inputs other than quoted prices included within Level 1 that are observable for the asset or liability either directly or indirectly. If the asset or liability has a contractual term, the input must be observable for substantially the full term. An example includes quoted market prices for similar assets or liabilities in active markets.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level 3 inputs are unobservable inputs for the asset or liability and will reflect management&#8217;s assumptions about market assumptions that would be used to price the asset or liability.</font></div></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.3A-02)<br> -URI http://asc.fasb.org/extlink&amp;oid=27015204&amp;loc=d3e355033-122828<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.3A-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=27015204&amp;loc=d3e355100-122828<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21D<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=SL94080555-108585<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6607719696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Payable and Accrued Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Schedule of accounts payable and accrued liabilities</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts payable and accrued liabilities are comprised of the following:</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:63%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">September&#160;30, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">December&#160;31, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Trade accounts payable</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,400</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,192</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development accruals</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,112</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,716</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Professional fee accruals</font></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,177</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">871</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Payroll accruals</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,509</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,341</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other accrued liabilities</font></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">309</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,199</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,429</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6815489872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contingencies and Commitments<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Contingencies and commitments</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Contingencies and commitments</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Arbitration with the University of British Columbia </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certain early work on LNP delivery systems and related inventions was undertaken by the Company and assigned to the University of British Columbia ("UBC"). These inventions were subsequently licensed back to the Company by UBC under a license agreement, initially entered into in 1998 and subsequently amended in 2001, 2006 and 2007. The Company has granted sublicenses under the UBC license to Alnylam. Alnylam has in turn sublicensed back to the Company under the licensed UBC patents for discovery, development and commercialization of siRNA products. Certain sublicenses were also granted to other parties.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On November 10, 2014, UBC filed a notice of arbitration against the Company and on January 16, 2015, filed a Statement of Claim, which alleged entitlement to </font><font style="font-family:inherit;font-size:10pt;">$3.5</font><font style="font-family:inherit;font-size:10pt;"> million in allegedly unpaid royalties based on publicly available information, and an unspecified amount based on non-public information. UBC also sought interest and costs, including legal fees. The Company filed its Statement of Defense to UBC's Statement of Claims, as well as a Counterclaim involving a patent application that the Company alleged UBC wrongly licensed to a third party.  The proceedings were divided into </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> phases, with the first hearing taking place in June 2017. In the first phase, the arbitrator determined which agreements are sublicense agreements within UBC's claim. Also in the first phase, UBC updated its alleged entitlement from </font><font style="font-family:inherit;font-size:10pt;">$3.5</font><font style="font-family:inherit;font-size:10pt;"> million originally claimed to seek </font><font style="font-family:inherit;font-size:10pt;">$10.9</font><font style="font-family:inherit;font-size:10pt;"> million in alleged unpaid royalties, plus interest arising from payments as early as 2008. The arbitrator also held in the first phase of the arbitration that the patent application that is the subject of the Counterclaim was not required to be licensed to Arbutus.&#160;The second phase of arbitration took place in April 2019. On&#160;August&#160;20, 2019, the arbitrator issued his decision for the second phase of the arbitration, awarding UBC </font><font style="font-family:inherit;font-size:10pt;">$5.9 million</font><font style="font-family:inherit;font-size:10pt;">, which includes interest of approximately </font><font style="font-family:inherit;font-size:10pt;">$2.6 million</font><font style="font-family:inherit;font-size:10pt;">. The Company paid the </font><font style="font-family:inherit;font-size:10pt;">$5.9 million</font><font style="font-family:inherit;font-size:10pt;"> award to UBC in September 2019. The arbitrator also held that the third phase of the arbitration, which would address patent validity, should the Company choose to pursue a third phase, would not provide a defense to the award. An award for costs and attorneys&#8217; fees is still to be determined. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company recorded a charge of </font><font style="font-family:inherit;font-size:10pt;">$6.5 million</font><font style="font-family:inherit;font-size:10pt;"> in the third quarter of 2019, consisting of </font><font style="font-family:inherit;font-size:10pt;">$5.9 million</font><font style="font-family:inherit;font-size:10pt;"> for the award (including interest) and </font><font style="font-family:inherit;font-size:10pt;">$0.6 million</font><font style="font-family:inherit;font-size:10pt;"> for an estimate of a potential award for costs and attorney's fees. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">License Agreements between Enantigen and Blumberg and Drexel</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In October 2014, Arbutus Inc. acquired all of the outstanding shares of Enantigen Therapeutics, Inc. (&#8220;Enantigen&#8221;) pursuant to a stock purchase agreement. Through this transaction, Arbutus Inc. acquired a HBV surface antigen secretion inhibitor program and a capsid assembly inhibitor program. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the stock purchase agreement, Arbutus Inc. agreed to pay up to a total of </font><font style="font-family:inherit;font-size:10pt;">$21.0</font><font style="font-family:inherit;font-size:10pt;"> million to Enantigen&#8217;s selling shareholders upon the achievement of specified development and regulatory milestones for (a) the first </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;"> products that contain either a capsid compound or an HBV surface antigen compound that is covered by a patent acquired under this agreement, or (b) a capsid compound from an agreed upon list of compounds. The amount paid could be up to an additional </font><font style="font-family:inherit;font-size:10pt;">$102.5 million</font><font style="font-family:inherit;font-size:10pt;"> in sales performance milestones in connection with the sale of the first commercialized product by Arbutus Inc. for the treatment of HBV, regardless of whether such product is based upon assets acquired under this agreement, and a low single-digit royalty on net sales of such first commercialized HBV product, up to a maximum royalty payment of </font><font style="font-family:inherit;font-size:10pt;">$1.0 million</font><font style="font-family:inherit;font-size:10pt;"> that, if paid, would be offset against Arbutus Inc.'s milestone payment obligations.  The contingent consideration for this acquisition is a financial liability and measured at its fair value at each reporting period, with any changes in fair value from the previous reporting period recorded in the statement of operations and comprehensive loss (see note 3).  The fair value of the contingent consideration was </font><font style="font-family:inherit;font-size:10pt;">$3.0 million</font><font style="font-family:inherit;font-size:10pt;"> as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the stock purchase agreement, Enantigen must also fulfill its obligations as they relate to the </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> patent license agreements with The Baruch S. Blumberg Institute ("Blumberg") and Drexel University ("Drexel"). Pursuant to each patent license agreement, Enantigen is obligated to pay Blumberg and Drexel up to approximately </font><font style="font-family:inherit;font-size:10pt;">$0.5</font><font style="font-family:inherit;font-size:10pt;"> million in development and regulatory milestones per licensed product, royalties in the low single-digits, and a percentage of revenue it receives from its sub-licensees.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Research Collaboration and Funding Agreement with Blumberg</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In November 2018, the Company entered into a new </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;">-year master services agreement with Blumberg that expires in November 2020.&#160; The new agreement replaces all rights and obligations of the prior research collaboration and funding agreements, as amended. Under the new agreement, Blumberg will perform specific research activities based upon statements of work and the Company will no longer provide a fixed amount of funding to Blumberg.&#160; As of September 30, 2019, the Company has executed statements of work with Blumberg for an aggregate cost of </font><font style="font-family:inherit;font-size:10pt;">$0.8</font><font style="font-family:inherit;font-size:10pt;"> million under this new agreement.  Intellectual property that is generated during the research activities is the Company's exclusive property and all financial obligations for it to utilize the intellectual property are satisfied in the upfront cost of the research activities.  Under the terms of the new agreement, the Company retains all rights to any inventions arising from performance of the agreement and no license is granted to Blumberg, nor are milestones for said inventions due to Blumberg.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6637995808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Significant accounting policies</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Significant accounting policies</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Basis of presentation</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (&#8220;U.S. GAAP&#8221;) for interim financial statements and accordingly, do not include all disclosures required for annual financial statements. These statements should be read in conjunction with the Company&#8217;s audited consolidated financial statements and notes thereto for the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;"> included in the Company&#8217;s Annual Report on Form 10-K for the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;"> (the &#8220;2018 Form 10-K&#8221;). These unaudited condensed consolidated financial statements reflect, in the opinion of management, all adjustments and reclassifications necessary to fairly present the Company's financial position as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;"> and the Company's results of operations and cash flows for the </font><font style="font-family:inherit;font-size:10pt;">three and nine months ended September 30, 2019 and 2018</font><font style="font-family:inherit;font-size:10pt;">. The results of operations for the </font><font style="font-family:inherit;font-size:10pt;">three and nine months ended September 30, 2019 and 2018</font><font style="font-family:inherit;font-size:10pt;">, respectively, are not necessarily indicative of the results for the full year. These unaudited condensed consolidated financial statements follow the same significant accounting policies as those described in the notes to the audited consolidated financial statements of the Company for the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">, except as described below under Recent Accounting Pronouncements.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Principles of consolidation</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These unaudited condensed consolidated financial statements include the accounts of the Company and its </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;"> wholly-owned subsidiaries, Arbutus Biopharma Inc. ("Arbutus Inc.") and Arbutus Biopharma US Holdings, Inc. All intercompany transactions and balances have been eliminated in consolidation.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Income or loss per share</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company follows the two-class method when computing net loss attributable to common shareholders per share as the Company has issued Series A participating convertible preferred shares (the "Preferred Shares"), as further described in note 12, that meet the definition of participating securities. The Preferred Shares entitle the holders to participate in dividends but do not require the holders to participate in losses of the Company. Accordingly, if the Company reports a net loss attributable to holders of the Company's common shares, net losses are not allocated to holders of the Preferred Shares. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss attributable to common shareholders per share is calculated based on the weighted average number of common shares outstanding. The calculation of diluted net loss attributable to common shareholders per share does not differ from the calculation of basic net loss attributable to common shareholders per share, as the effect of the Company&#8217;s dilutive potential common shares was anti-dilutive. During the </font><font style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2019 and 2018</font><font style="font-family:inherit;font-size:10pt;">, potential common shares of approximately </font><font style="font-family:inherit;font-size:10pt;">28.2 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">24.2 million</font><font style="font-family:inherit;font-size:10pt;">, respectively, consisting of the "if-converted" number of Preferred Shares and outstanding stock options, were excluded from the calculation of net loss per common share because their inclusion would be anti-dilutive. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table sets out the computation of basic and diluted net loss attributable to common shareholders per share:</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands, except share and per share amounts)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Numerator:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Allocation of distributable earnings</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Allocation of undistributable loss</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(85,295</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(27,040</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(137,338</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(46,255</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Allocation of loss attributed to common shareholders</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(85,295</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(27,040</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(137,338</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(46,255</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Denominator:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted average number of common shares - basic and diluted</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">56,850,172</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">55,421,504</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">56,469,358</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">55,241,284</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic and diluted net loss attributable to common shareholders per share</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.50</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.49</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2.43</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.84</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Equity method investment</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company accounts for its investment in associated companies in accordance with the Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC") 323, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Investments - Equity Method and Joint Ventures </font><font style="font-family:inherit;font-size:10pt;">("ASC</font><font style="font-family:inherit;font-size:10pt;font-style:italic;"> </font><font style="font-family:inherit;font-size:10pt;">323").  In accordance with ASC 323, associated companies are accounted for as equity method investments. Results of associated companies are presented on a one-line basis. Investments in, and advances to, associated companies are presented on a one-line basis in the caption &#8220;Investment in Genevant&#8221; in the Company's Condensed Consolidated Balance Sheets, net of allowance for losses, which represents the Company's best estimate of probable losses inherent in such assets.  The Company's proportionate share of any associated companies' net income or loss is presented on a one-line basis in the caption "Equity investment (loss)" in the Company's Condensed Consolidated Statement of Operations.  Transactions between the Company and any associated companies are eliminated on a basis proportional to the Company's ownership interest.  Financial results of Genevant Sciences Ltd. ("Genevant") are recorded on a one-quarter lag basis.    </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Revenue recognition </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company recognizes the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers under a five-step model: (i) identify contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when or as a performance obligation is satisfied. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company generates revenue primarily through collaboration agreements and license agreements. Such agreements may require the Company to deliver various rights and/or services, including intellectual property rights or licenses and research and development services. Under such agreements, the Company is generally eligible to receive non-refundable upfront payments, funding for research and development services, milestone payments, and royalties.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In contracts where the Company has more than one performance obligation to provide its customer with goods or services, each performance obligation is evaluated to determine whether it is distinct based on whether (i) the customer can benefit from the good or service either on its own or together with other resources that are readily available and (ii) the good or service is separately identifiable from other promises in the contract. The consideration under the contract is then allocated between the distinct performance obligations based on their respective relative stand-alone selling prices. The estimated stand-alone selling price of each deliverable reflects the Company's best estimate of what the selling price would be if the deliverable was regularly sold on a stand-alone basis and is determined by reference to market rates for the good or service when sold to others or by using an adjusted market assessment approach if the selling price on a stand-alone basis is not available. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The consideration allocated to each distinct performance obligation is recognized as revenue when control is transferred to the customer for the related goods or services. Consideration associated with at-risk substantive performance milestones, including sales-based milestones, is recognized as revenue when it is probable that a significant reversal of the cumulative revenue recognized will not occur. Sales-based royalties received in connection with licenses of intellectual property are subject to a specific exception in the revenue standards, whereby the consideration is not included in the transaction price and recognized in revenue until the customer&#8217;s subsequent sales or usages occur.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Segment information</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company operates as a single segment. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Recent accounting pronouncements</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies that are adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on the Company's financial position or results of operations upon adoption.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company adopted Accounting Standard Update (&#8220;ASU&#8221;) No. 2016-02, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Leases</font><font style="font-family:inherit;font-size:10pt;"> (Topic 842), as of January 1, 2019, using the modified retrospective approach with the effective date transition method (note 5). Accordingly, all periods prior to adoption are presented in accordance with legacy accounting and the Company recorded no retrospective adjustments to the comparative periods presented. In addition, the Company elected the package of practical expedients permitted under the transition guidance within ASC 842, which among other things, allowed the Company to carry forward its historical lease classification. In addition, the Company elected the short term exemption, which allows entities to not capitalize their leases with a term of 12 months or less. Adoption of the new standard resulted in the recording of operating lease right-of-use assets (&#8220;ROU assets&#8221;) and lease liabilities of approximately </font><font style="font-family:inherit;font-size:10pt;">$3.2 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$4.1 million</font><font style="font-family:inherit;font-size:10pt;">, respectively, as of January 1, 2019.  The standard did not materially impact the Company&#8217;s consolidated statements of operations and statements of cash flow.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In November 2018, the FASB issued targeted amendments to ASU No. 2018-18, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Collaborative Arrangements </font><font style="font-family:inherit;font-size:10pt;">(Topic 808), and ASU No. 2016-10, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers </font><font style="font-family:inherit;font-size:10pt;">(Topic 606), to clarify that certain transactions between parties to collaborative arrangements should be accounted for in accordance with FASB revenue guidance when the counterparty is a customer. This guidance also prohibits the presentation of collaborative arrangements as revenues from contracts with customers if the counterparty is not a customer. This guidance, which is required to be applied retrospectively&#160;and is effective for interim and annual periods beginning after December 15, 2019, with early adoption permitted, is not expected to have a material impact on the Company&#8217;s consolidated financial statements.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6640608976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets and Goodwill<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">Intangible assets and goodwill</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;"> Intangible assets and goodwill</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Acquired IPR&amp;D intangible assets relate to the Company's covalently closed circular DNA ("cccDNA") program.  During the </font><font style="font-family:inherit;font-size:10pt;">three months ended September 30, 2019</font><font style="font-family:inherit;font-size:10pt;">, the Company recorded a </font><font style="font-family:inherit;font-size:10pt;">$43.8 million</font><font style="font-family:inherit;font-size:10pt;"> non-cash impairment expense to reduce the carrying value of its IPR&amp;D intangible assets to </font><font style="font-family:inherit;font-size:10pt;">zero</font><font style="font-family:inherit;font-size:10pt;"> as of September 30, 2019.  The Company also recognized a corresponding income tax benefit of </font><font style="font-family:inherit;font-size:10pt;">$12.7 million</font><font style="font-family:inherit;font-size:10pt;"> related to the decrease in its deferred tax liability related to the IPR&amp;D intangible assets.  The impairment was due to a decision to delay indefinitely the further development of the Company's cccDNA program while the Company focuses on its other development programs. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Goodwill represents the excess of purchase price over the value assigned to the net tangible and identifiable intangible assets in connection with the business combination that formed Arbutus.  In the third quarter of 2019, the Company assessed the changes in circumstances that occurred during the quarter to determine if it was more likely than not that the fair value of its single reporting unit was below its carrying amount.  Although the Company's annual impairment test is performed during the fourth quarter, the Company performs this qualitative assessment each interim reporting period.  Due to a sustained decrease in the Company's share price in recent months, the Company's market capitalization was reduced below the book value of its net assets and the Company concluded that the fair value of its single reporting unit was below its carrying amount by an amount in excess of the carrying value of the goodwill.  As a result, the Company recorded a </font><font style="font-family:inherit;font-size:10pt;">$22.5 million</font><font style="font-family:inherit;font-size:10pt;"> non-cash impairment expense to reduce the carrying value of its goodwill asset to </font><font style="font-family:inherit;font-size:10pt;">zero</font><font style="font-family:inherit;font-size:10pt;"> as of September 30, 2019.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI http://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>33
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
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M'WXW8=<;N[?_V/@JV#;PZR[:+U!+ P04    " !U8V9/F5R<(Q &  "<)P
M$P   'AL+W1H96UE+W1H96UE,2YX;6SM6EMSVC@4?N^OT'AG]FT+QC:!MK03
M<VEVV[29A.U.'X416(UL>621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS
M[BYBZ(:(E/)X8-DOV]:[MR_>X%<R)!%!,!FGK_# "J5,7K5::0##.'W)$Q+#
MW(*+"$MX%,O67.!;&B\CUNJTV]U6A&ELH1A'9&!]7BQH0-!445IO7R"TY1\S
M^!7+5(UEHP$35T$FN8BT\OELQ?S:WCYES^DZ'3*!;C ;6"!_SF^GY$Y:B.%4
MPL3 :F<_5FO'T=)(@(+)?90%NDGVH],5"#(-.SJ=6,YV?/;$[9^,RMIT-&T:
MX./Q>#BVR]*+<!P$X%&[GL*=]&R_I$$)M*-IT&38]MJND::JC5-/T_=]W^N;
M:)P*C5M/TVMWW=..B<:MT'@-OO%/A\.NB<:KT'3K:28G_:YKI.D6:$)&X^MZ
M$A6UY4#3( !8<';6S-(#EEXI^G64&MD=N]U!7/!8[CF)$?[&Q036:=(9EC1&
M<IV0!0X -\313%!\KT&VBN#"DM)<D-;/*;50&@B:R('U1X(AQ=RO_?67N\FD
M,WJ=?3K.:Y1_::L!I^V[F\^3_'/HY)^GD]=-0LYPO"P)\?LC6V&')VX[$W(Z
M'&="?,_V]I&E)3+/[_D*ZTX\9Q]6EK!=S\_DGHQR([O=]EA]]D]';B/7J<"S
M(M>41B1%G\@MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(
MWXV(]ZMOFCU7H5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU
M+,76>)7 \:V</!T3$LV4"P9!AI<D)A*I.7Y-2!/^*Z7:_IS30/"4+R3Z2I&/
M:;,CIW0FS>@S&L%&KQMUAVC2/'K^!?F<-0H<D1L= F<;LT8AA&F[\!ZO)(Z:
MK<(1*T(^8ADV&G*U%H&V<:F$8%H2QM%X3M*T$?Q9K#63/F#([,V1=<[6D0X1
MDEXW0CYBSHN0$;\>ACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*
MY \FIS_I,C0'HYI9";V$5FJ?JH<T/J@>,@H%\;D>/N5Z> HWEL:\4*Z">P'_
MT=HWPJOX@L Y?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=R
MS<C'5*^3*=@YG\#L_6@^GO'M^MDDA*^:62TC%I!+@;-!)+C\B\KP*L0)Z&1;
M)0G+5--E-XH2GD(;;NE3]4J5U^6ON2BX/%ODZ:^A=#XLS_D\7^>TS0LS0[=R
M2^JVE+ZU)CA*]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZ
MG=PZ.)Z8D;D*TU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCR
MHB'NH8:8S\-#AWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)2
M56 Q6\8#*Y"B?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYE
ML<%5'<]56_*POFH]M!5.S_Y9K<B?#!%.%@L22&.4%Z9*HO,94[[G*TG$53B_
M13.V$I<8O./FQW%.4[@2=K8/ C*YNSFI>F4Q9Z;RWRT,"2Q;B%D2XDU=[=7G
MFYRN>B)V^I=WP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5
M' 86%S+D4.Z2D 83 <V4R43P H)DIAR F/H+O?(,N2D5SJT^.7]%+(.&3E[2
M)1(4BK ,!2$7<N/O[Y-J=XS7^BR!;814,F35%\I#B<$],W)#V%0E\Z[:)@N%
MV^)4S;L:OB9@2\-Z;ITM)__;7M0]M!<]1O.CF> >LX=SFWJXPD6L_UC6'ODR
MWSEPVSK> U[F$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\
MU*M:I60K$3]+!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHS
MU8NL.8T*;T'50.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!
M4$L#!!0    ( '5C9D^<W4 #?0(  #X)   8    >&PO=V]R:W-H965T<R]S
M:&5E=#$N>&ULC59_KYL@%/TJQ@_P%/S9QC9INRQ;LB7-6_;V-[6T-4_% :UO
MWWZ /N?@NNP?!3SG'B[7 Q0]XZ_B1JGTWIJZ%1O_)F6W#@)1WFA#Q!/K:*N^
M7!AOB%1=?@U$QRDY&U)3!S@,TZ A5>MO"S-VY-N"W65=M?3(/7%O&L)_[6G-
M^HV/_/>!Y^IZDWH@V!8=N=)O5'[OCESU@BG*N6IH*RK6>IQ>-OX.K0\HTP2#
M>*EH+V9M3Z=R8NQ5=SZ?-WZH9T1K6DH=@JC7@QYH7>M(:AX_QZ#^I*F)\_9[
M](\F>97,B0AZ8/6/ZBQO&S_WO3.]D'LMGUG_B8X));XW9O^%/FBMX'HF2J-D
MM3!/K[P+R9HQBII*0]Z&=]6:=S]\B:.1!A/P2, 3 ?^;$(V$:"*@V"0_S,RD
M^H%(LBTXZST^5*LC^J= ZT@M9JD'S=J9;RI;H48?V[ ('CK,B-@/"#Q#H D1
MJ-B3 (8$]MBAX[\%#BXB@@4B,(/(T*,9/8;I,4B/#3V>T1-K 5Q$"@LDH$#B
MT#-+P$7DL$ *"J0.?64)N @4P@H9J)"Y?&1) ! ,2^2@1.[R(TL"@"Q4>@5*
MK%R^76H LE!K%,)V"MT(=KDAS$+!T8)ID1O!JOEAQ"0&TPX_=IHG(<H6ZH)
M_^X0=K2PLT4 F(5- L$F1I$; =LJ &9AIT"PUY%K91S;*@ F65"!#8]</^/4
M5OEOSR/8],CU-'9^-!>S) +['KFNQKDM F!6EDHP.XT:RJ_FX!9>R>ZMN37,
M1J?+P0Z;T^P/?+A9?"7\6K7".S&ISD1S<ET8DU1-)7Q2BWI3EYFI4].+U,U,
MM?EPH@\=R;KQMA),5Z;M;U!+ P04    " !U8V9/_4[8ZB@$  !E%   &
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M1DI?(;1D*AA&B:XP7W'%@QHUV7Z4#F3@N8J4J\KG*C)%J9"278I<_:IAI?Y
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MRS4;9L.P$;0;QQZ89F_V!U!+ P04    " !U8V9/0^?&SND(  "/-@  &
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M(ZHT&HQ# CBTL@2A:W$(A,ZU *!< 448AX1P*(T= 1QV%8K$(2$<%J5\0)9
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MMHZ;%AVK^ND1D?DEE_\ 4$L#!!0    ( '5C9D_@&GE@N@8  /LF   8
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MP-BQ(.<4ZQZ &0KL?BBN"U9.!1M)\U":%])X8S(O:K$)N\5SR9B43P/)=,/
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M R3LZR1]7?-LA8 9I]PE<T#YP'JX0*%4PF.5$-.198>PM1.P=L<S%I(^JY+
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M'VPQ%-0^'#_@V4YC-AG>]/,/8LLW+OX"4$L#!!0    ( '5C9D]RYMS7M $
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M AH7CC?^;*8QFPRG^_2#R/R-R[]02P,$%     @ =6-F3\EXU0*V 0  T@,
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M/AP_X-E.8S89WO3S#V++-R[^ E!+ P04    " !U8V9/HF@&X[@!  #2 P
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M%XXW_FRF,9L,I_OY!Y'E&Y=_ 5!+ P04    " !U8V9/7BIJ]K4!  #2 P
M&0   'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6QU4V%OVR 0_2N('U 2XFY5
M9%MJ.E6KM$I1IVV?B7VV4<&X@./VW^_ CNMVWA?@CGOOWAU'.AC[[!H 3UZU
M:EU&&^^[/6.N:$ +=V4Z:/&F,E8+CZ:MF>LLB#*"M&)\L_G"M) MS=/H.]H\
M-;U7LH6C):[76MBW R@S9'1++XXG63<^.%B>=J*&G^!_=4>+%IM92JFA==*T
MQ$*5T=OM_I"$^!CP6\+@%F<2*CD9\QR,AS*CFR (%!0^, C<SG '2@4BE/$R
M<=(Y90 NSQ?V^U@[UG(2#NZ,^B-+WV3TAI(2*M$K_V2&[S#5<TW)5/P/.(/"
M\* $<Q1&N;B2HG?>Z(D%I6CQ.NZRC?LPWB07V#J 3P ^ VXB@(V)HO)OPHL\
MM68@=NQ])\(3;_<<>U,$9VQ%O$/Q#KWGG/-MRLZ!:(HYC#%\$?,>P9!]3L'7
M4ASX/W"^#M^M*MQ%^.Z#PO\0)*L$221(/A#L/I6X%I-\2L(6/=5@ZSA-CA2F
M;^,D+[SSP-[R^";OX>.T/PI;R]:1D_'XLK'_E3$>4,KF"D>HP0\V&PHJ'XY?
M\6S',1L-;[KI!['Y&^=_ 5!+ P04    " !U8V9/?K \O[8!  #2 P  &0
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MI9VKOE_VAI'M\!:0\4$J_@%02P,$%     @ =6-F3W<Y-*.X 0  T@,  !D
M  !X;"]W;W)K<VAE971S+W-H965T,C,N>&UL;5/;;MP@$/T5Q >$7?:2[<JV
ME$U5I5(KK5(U>6;ML8T"Q@&\3O^^ W8<-_4+,,,Y9RX,26_LBZL!/'G3JG$I
MK;UOCXRYO 8MW(UIH<&;TE@M/)JV8JZU((I(THKQU6K/M) -S9+H.]LL,9U7
MLH&S):[36M@_)U"F3^F:OCL>957[X&!9THH*?H'_W9XM6FQ2*:2&QDG3$ ME
M2N_6Q],VX"/@24+O9F<2*KD8\Q*,[T5*5R$A4)#[H"!PN\(]*!6$,(W749-.
M(0-Q?GY7_Q9KQUHNPL&]4<^R\'5*#Y044(I.^4?3/\!8SXZ2L?@?< 6%\) )
MQLB-<G$E>>>\T:,*IJ+%V[#+)N[]<+/?C;1E A\)?"(<8APV!(J9?Q5>9(DU
M/;%#[UL1GGA]Y-B;/#AC*^(=)N_0>\WX;I^P:Q :,:<!PV>8]81@J#Z%X$LA
M3OP_.E^F;Q8SW$3Z9A[]RWY98+LHL(T"VW]*O/U4XA+F\"D(F_54@ZWB-#F2
MFZZ)DSSS3@-[Q^.;?,"':?\I;"4;1R[&X\O&_I?&>,!45C<X0C5^L,E04/IP
MO,6S'<9L,+QIQQ_$IF^<_0502P,$%     @ =6-F3V@D_'/1 0  G 0  !D
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M'D"9/J5K>@D\R:KV(<"RI!45_ 3_JSU:]-BD4D@-C9.F(1;*E-ZO]X=MP$?
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MHL3=,0"0$HQH2)P208PD'D?4K1'$B G"*8%%)J#(!! 9.2(;3'+QU$;N#@!
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MD,N=;FYC<U]U)TS=@U:'_O3,.QWAK?\!4$L#!!0    ( '5C9D_L;KR'(0(
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M2C]I^_!.G"O0'H,'W:=*C^+Q0.&DS#;5>]$/I/Z@>#O,6C0._/P?4$L#!!0
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MUQ]1VKRC9(L"@S^V)OQDVJ<(]NS<2'WF!M&^0S\A_<>/XDLX7T%/?*TZNFW
M;_+V.OB!^:EJ1+!C4O49TPV.C$FBO$</:C-*=0/U$TJ.4@]G:LQM'[83R5IW
MQ8#^GBO^ U!+ P04    " !U8V9/B4\;?+0"   9"@  &0   'AL+W=O<FMS
M:&5E=',O<VAE970S-"YX;6R-5EUOFS 4_2N(]Q5L/A,ED9JT-),VJ6JU[=E-
MG 05,+.=I/OWLPVEP=RFY"'8EW/./=<V<&=GQE_%@5+IO)5%)>;N0<IZZGEB
M<Z E$3>LII6ZLV.\)%)-^=X3-:=D:TAEX6'?C[V2Y)6[F)G8(U_,V%$6>44?
MN2..94GXOR4MV'GN(O<]\)3O#U('O,6L)GOZ3.6O^I&KF=>I;/.25B)GE</I
M;N[>HND:84TPB-\Y/8N+L:-+>6'L54^^;^>NKQW1@FZDEB#J<J(K6A1:2?GX
MVXJZ74Y-O!R_JV>F>%7,"Q%TQ8H_^58>YF[J.ENZ(\="/K'SFK8%1:[35O^#
MGFBAX-J)RK%AA3#_SN8H)"M;%66E)&_--:_,]=S<B=]I, &W!-P15.YKA* E
M!&,)84L(/PCA54+4$J*QA+@EQ&,M)2TA&9LA;0FI1?":[3#[>T<D6<PX.SN\
M.:(UT4\"FJ;J!&UTT!P8<T]ML5#1TR) X<P[::$6LVPPN(>)^IC5$)/$?4@V
MA* .X2F3G5,,.5UBP(658C7$X#[B;HA(DC[D'DID8;(O$SU\G6@-)8)7) #W
M+C#\H,=/88$0% B-0-@3F%A+VF!B@ZD,YEL0(7M9 11.@]1:-0"%4#BQUN7A
M*[%>91%8632LS#*S:B#111;D3V*K_&P4:AT-'&/U"V'',>@X'CK&/BR0@ +)
M^-.0@@+IB-.00J?!]ZTG:(C"X<1&98 60I=B/<\3T/,$6#5D>88PUOG-KF-Z
M1I /OTA]0"+X1.*3=S$:OX4(?$G>(@RX&+S/\6#E@V2X\-[%-Z2D?&]Z#.%L
MV+&2VN5%M.MC;DT;8\57:'J/@'B&I@]-E_(AWS1-/PG?YY5P7IA47S[S?=HQ
M)JER[]^HA^V@^K1N4M"=U,-$C7G3K#03R>JV$?.Z;G#Q'U!+ P04    " !U
M8V9/+;UM.9P"  #U"0  &0   'AL+W=O<FMS:&5E=',O<VAE970S-2YX;6R5
M5FW/FC 4_2N$'R"T15Z,DJC+LB5;8IYEV^>J5<D#E+55GOW[]86'(5X6]T7:
M<NXY][8<>Y<M%Z_RPICRWJJREBO_HE2S" )YN+"*RAEO6*W?G+BHJ-)3<0YD
M(Q@]VJ"J#' 8QD%%B]K/EW9M)_(EOZJRJ-E.>/):553\WK"2MRL?^>\++\7Y
MHLQ"D"\;>F;?F/K>[(2>!3W+L:A8+0M>>X*=5OX:+;8X- $6\:-@K1R,/5/*
MGO-7,_E\7/FAR8B5[* ,!=6/&]NRLC1,.H]?':G?:YK X?B=_:,M7A>SIY)M
M>?FS.*K+RD]][\A.]%JJ%]Y^8EU!<]_KJO_";JS4<).)UCCP4MI?[W"5BE<=
MBTZEHF_N6=3VV;HW2=*%P0&X"\!]0!3^,X!T :0/P*YXEYDM]0-5-%\*WGK"
MG59#S4>!%D1OYL$LVKVS[W2U4J_><H+GR^!FB#K,QF'P (-Z1*#9>PD,26SP
M0SC!\;W$%L(DL @!ZR"6@-P1I#!!!!)$EB"Z(\A&&^$P<XNI+0;#$G-08OXH
M0<*1A,-D PDTF]CM&!2) 1$T$G&8=" 2SC)8) %%$D $CT020&1BNU)0) 5$
MR$@D?;Z2#!3) )%H))(]G,FP$O<!0YB)<T,A[,002&4^03%A9O2\"Q!HUC7"
M0!;Q^ \!/VL$!+L5$4 E&:M H*EJ8%,CP-5D[&H(%(43.K"S$6#M:.KX8=^B
M^#_.#G8E@FSY4"T BJ9.#S8F IP9D0D*V'8H>[Y:#/L%0WX95PN!HFBD$PPN
MRXJ)L^TKI'?@UUJ92VFPVO<N:VPNV]'Z1O<T[A+^2^,:HJ]4G(M:>GNN]%5N
M+]P3YXKI',.9_G@NN@?K)R4[*3-,]%BX1L1-%&^Z)BOH.[W\#U!+ P04
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M4$/+U(/HH3,[)R%;IHTISTCU$MC1!;4<D2BBJ&5-%U:E6WN252DNFC<=/,E
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M838XG+2=9F8NQPXY&EKT4_='\Q-4_0=02P,$%     @ =6-F3\:KSU.L @
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MLF[.HE Z_#:-;6_&<7J39W.8/R"> ^(E ";_#4!S +("P$1FK'[&$E<E9V/
MIX\U8'TGX!:I8I[TIJF=>:?<"K5[KU"6E^"N$\V:_:2)5YKX45&["@07"5
M"T7LI8A-/%J? %-_ N1-@$R"Y,%&8=F8-)G1]$8#DRBRG+@B!#>Q'R7QHB0>
ME(V%,FG2U2D)A'9175&<P\R/DGI14A<EMPSO4^<4"'/K!M2NJ,@_^,"9ER3S
MD$"+)'-)TLBJ7.V*8I1\@))[47(/BE7Z?>ZB6!RN JU8'S *+T;A8$#GQA;.
M92S@QJZ(*]HDL8T"5OU ]^<?F%_;7@1')E5K,0W@PI@D*F'TI%PUZI>P+"BY
M2#W-U9Q/C7%:2#;,/1\L/Y[J'U!+ P04    " !U8V9/%<$0/'0"   L"
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M3+IFVTT8;M6'A--_S>3_ %!+ P04    " !U8V9/P;B.4RP#  !=#0  &0
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MJLT&]#I-A=E1MWWNY/14"U5)+]J-EN= =:I1?.4OUKXEOE&C2'>V3_EVCOU
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MU^L"0$:^WT?V\[(T&P1T&Q):-"Q5C\@G9MQ2: BJM$AW30W7:IE;;5NJ$L6
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MDF/6MMMV(FC=?4J _GLF_0=02P,$%     @ =6-F3UL!AO1940  P#H! !0
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M7_XEM$G9UVUVG^-F8+R/R=(;Y+*>;M:;)GJ=5RLX@V42757UJF.L*UA5G10
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M!;KN,T1\8#QP.1!VS08N!+$+NMSIHJ[*/(T6&;ZQAK6\!JS&*T,'E."$A.H
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MV@MOP8)3H91/LTK4JNIFD:]TP$'?NMZ6>J]0)[H#+9=P]?UZAJJ6>H!J%ME
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MSO?C?5**#5\21P;Z.VV@*.ADJC3=U'U*.%&K,C4FA!LH:W.964X^S94X:#;
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M\RL9BDI>DIC%!K/G#'#0J&2 @HS"3H7U<:##MJLK3MNE8LE&@?PAT\7AR);
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M; +0:AQE"OM=4^&W%)_A5:P*82J,67::I?&3F'@2!CENZK&NL'JG8QI*)*:
MRLI)20)6 ZD'#R$7MRJ3B\E"VPI->[9%9)[7 *$%T#!. O]*(GN1L+^;7 J
M)6<ZDH'?IV%$1Q*TPUMB2E<+WEA%]YG\^'7WE=C)4"5@X35N*J44.3,245JQ
MF8L: 0<PDUB>@YO"ALG-AA.(Q)%E7T&L'+B9?FK$-@K' )6-I>LZ4=I6M*HJ
MG-<@71-OB 4C0E#*U_.WI]-1K9NL$:,+:;CJNJ[!K,-Q+-Q3'+U54="Q-*J
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M^L.J;8?+AMHV4"%*KM2:JPX0U-S+X<^*!.OP,/M=K%&#U0;)_X*6$S;+FQH
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M@N!+<A1BPC6\S5I6E00T=>JQK6" 'QM1WIM05)&J--N\E/9Q/@U5^OW,GNS
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M/+@PDMB[%J<#K:W0(+:'45YRFS,43TI[,0S!CE%BZR3%VRCZ:FH[<T,+'4B
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MDW>6VWTB[;?/^Q=;(+#;2_0"?O;[.",ZU[S#\]"IF.]#8SW$W^9=:+^,;H;
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MR*I09%4HLBH4616*K.J*LG;'M-9E\U>23V,6^_FL^]]W\@U02P$"% ,4
M" !U8V9/'R// \     3 @  "P              @ $     7W)E;',O+G)E
M;'-02P$"% ,4    " !U8V9/)^B'#H(   "Q    $               @ 'I
M    9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( '5C9D]SVZ]I[@   "L"
M   1              "  9D!  !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0
M   ( '5C9D^97)PC$ 8  )PG   3              "  ;8"  !X;"]T:&5M
M92]T:&5M93$N>&UL4$L! A0#%     @ =6-F3YS=0 -] @  /@D  !@
M         ( !]P@  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0
M   ( '5C9D_]3MCJ* 0  &44   8              "  :H+  !X;"]W;W)K
M<VAE971S+W-H965T,BYX;6Q02P$"% ,4    " !U8V9/3FF#3#P"  "T!P
M&               @ $($   >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L!
M A0#%     @ =6-F3X*RML5-!0  D!H  !@              ( !>A(  'AL
M+W=O<FMS:&5E=',O<VAE970T+GAM;%!+ 0(4 Q0    ( '5C9D]6\&T8: (
M (<'   8              "  ?T7  !X;"]W;W)K<VAE971S+W-H965T-2YX
M;6Q02P$"% ,4    " !U8V9/0^?&SND(  "/-@  &               @ &;
M&@  >&PO=V]R:W-H965T<R]S:&5E=#8N>&UL4$L! A0#%     @ =6-F3\)Z
M=WV] 0  U0,  !@              ( !NB,  'AL+W=O<FMS:&5E=',O<VAE
M970W+GAM;%!+ 0(4 Q0    ( '5C9D_@&GE@N@8  /LF   8
M  "  :TE  !X;"]W;W)K<VAE971S+W-H965T."YX;6Q02P$"% ,4    " !U
M8V9/7-<O"+(!  #2 P  &               @ &=+   >&PO=V]R:W-H965T
M<R]S:&5E=#DN>&UL4$L! A0#%     @ =6-F3[3R.HJV 0  T@,  !D
M         ( !A2X  'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q02P$"% ,4
M    " !U8V9/9%7MHK8!  #2 P  &0              @ %R,   >&PO=V]R
M:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0    ( '5C9D^T-(1:MP$  -(#
M   9              "  5\R  !X;"]W;W)K<VAE971S+W-H965T,3(N>&UL
M4$L! A0#%     @ =6-F3W+FW->T 0  T@,  !D              ( !330
M 'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6Q02P$"% ,4    " !U8V9/R7C5
M K8!  #2 P  &0              @ $X-@  >&PO=V]R:W-H965T<R]S:&5E
M=#$T+GAM;%!+ 0(4 Q0    ( '5C9D]%X1JRN0$  -(#   9
M  "  24X  !X;"]W;W)K<VAE971S+W-H965T,34N>&UL4$L! A0#%     @
M=6-F3Z)H!N.X 0  T@,  !D              ( !%3H  'AL+W=O<FMS:&5E
M=',O<VAE970Q-BYX;6Q02P$"% ,4    " !U8V9/7BIJ]K4!  #2 P  &0
M            @ $$/   >&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4
M Q0    ( '5C9D]^L#R_M@$  -(#   9              "  ? ]  !X;"]W
M;W)K<VAE971S+W-H965T,3@N>&UL4$L! A0#%     @ =6-F3Z\ZK;^V 0
MT@,  !D              ( !W3\  'AL+W=O<FMS:&5E=',O<VAE970Q.2YX
M;6Q02P$"% ,4    " !U8V9/8[$D_K8!  #2 P  &0              @ '*
M00  >&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4 Q0    ( '5C9D^@
MK(&HN $  -(#   9              "  ;=#  !X;"]W;W)K<VAE971S+W-H
M965T,C$N>&UL4$L! A0#%     @ =6-F3R0?^]H9 @  G 8  !D
M     ( !ID4  'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( '5C9D]4="02MP$  -(#   9              "
M =9/  !X;"]W;W)K<VAE971S+W-H965T,C<N>&UL4$L! A0#%     @ =6-F
M3W59!,JS 0  T@,  !D              ( !Q%$  'AL+W=O<FMS:&5E=',O
M<VAE970R."YX;6Q02P$"% ,4    " !U8V9/K^AJ63X"  #.!@  &0
M        @ &N4P  >&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0
M   ( '5C9D]&P0:R#P,  +T,   9              "  2-6  !X;"]W;W)K
M<VAE971S+W-H965T,S N>&UL4$L! A0#%     @ =6-F3WXZ!&C/ P  SA,
M !D              ( !:5D  'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6Q0
M2P$"% ,4    " !U8V9/[&Z\AR$"  #\!0  &0              @ %O70
M>&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+ 0(4 Q0    ( '5C9D\+;7$Z
M3 (  /,&   9              "  <=?  !X;"]W;W)K<VAE971S+W-H965T
M,S,N>&UL4$L! A0#%     @ =6-F3XE/&WRT @  &0H  !D
M ( !2F(  'AL+W=O<FMS:&5E=',O<VAE970S-"YX;6Q02P$"% ,4    " !U
M8V9/+;UM.9P"  #U"0  &0              @ $U90  >&PO=V]R:W-H965T
M<R]S:&5E=#,U+GAM;%!+ 0(4 Q0    ( '5C9D\]B\S7I0$  +T#   9
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M970T,"YX;6Q02P$"% ,4    " !U8V9/%<$0/'0"   L"   &0
M    @ &0<P  >&PO=V]R:W-H965T<R]S:&5E=#0Q+GAM;%!+ 0(4 Q0    (
M '5C9D_=3O)VC@(  -D(   9              "  3MV  !X;"]W;W)K<VAE
M971S+W-H965T-#(N>&UL4$L! A0#%     @ =6-F3\&XCE,L P  70T  !D
M             ( ! 'D  'AL+W=O<FMS:&5E=',O<VAE970T,RYX;6Q02P$"
M% ,4    " !U8V9/FMHWU=<"   ^#   &0              @ %C?   >&PO
M=V]R:W-H965T<R]S:&5E=#0T+GAM;%!+ 0(4 Q0    ( '5C9D\^Y](K%@(
M -4%   9              "  7%_  !X;"]W;W)K<VAE971S+W-H965T-#4N
M>&UL4$L! A0#%     @ =6-F3XTKT7KF P  (10  !D              ( !
MOH$  'AL+W=O<FMS:&5E=',O<VAE970T-BYX;6Q02P$"% ,4    " !U8V9/
MXR"MNU<"  "L!P  &0              @ ';A0  >&PO=V]R:W-H965T<R]S
M:&5E=#0W+GAM;%!+ 0(4 Q0    ( '5C9D_%?+1!I0,  .H0   9
M      "  6F(  !X;"]W;W)K<VAE971S+W-H965T-#@N>&UL4$L! A0#%
M  @ =6-F3Q_8T@A^ @  VP@  !D              ( !18P  'AL+W=O<FMS
M:&5E=',O<VAE970T.2YX;6Q02P$"% ,4    " !U8V9/6P&&]%E1  # .@$
M%               @ 'ZC@  >&PO<VAA<F5D4W1R:6YG<RYX;6Q02P$"% ,4
M    " !U8V9/9\KK34<"  "V"@  #0              @ &%X   >&PO<W1Y
M;&5S+GAM;%!+ 0(4 Q0    ( '5C9D]=SV/I700  "@A   /
M  "  ??B  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " !U8V9/G.$P>-0!
M   ('@  &@              @ &!YP  >&PO7W)E;',O=V]R:V)O;VLN>&UL
M+G)E;'-02P$"% ,4    " !U8V9/8H^-M<0!  #_'0  $P
M@ &-Z0  6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     .@ Z ,@/  ""ZP
"   !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6607845520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Supplemental Cash Flow Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash paid for amounts included in the measurement of lease liabilities</a></td>
<td class="nump">$ 921<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6765698496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Instruments - Changes in Fair Value of Contingent Consideration (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_FairValueLiabilitiesMeasuredonRecurringBasisRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Liability at beginning of the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,126<span></span>
</td>
<td class="nump">$ 10,424<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Increase (decrease) in fair value of liability</a></td>
<td class="num">$ (376)<span></span>
</td>
<td class="num">$ (5,608)<span></span>
</td>
<td class="num">(121)<span></span>
</td>
<td class="num">(6,263)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Liability at end of the period</a></td>
<td class="nump">$ 3,005<span></span>
</td>
<td class="nump">$ 4,161<span></span>
</td>
<td class="nump">$ 3,005<span></span>
</td>
<td class="nump">$ 4,161<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_FairValueLiabilitiesMeasuredonRecurringBasisRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair Value, Liabilities Measured on Recurring Basis [Roll Forward]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_FairValueLiabilitiesMeasuredonRecurringBasisRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI http://asc.fasb.org/extlink&amp;oid=6911338&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6816171184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Instruments<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair value of financial instruments</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair value of financial instruments</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company measures certain financial instruments and other items at fair value.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">To determine the fair value, the Company uses the fair value hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs market participants would use to value an asset or liability and are developed based on market data obtained from independent sources. Unobservable inputs are inputs based on assumptions about the factors market participants would use to value an asset or liability. The three levels of inputs that may be used to measure fair value are as follows:</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level 1 inputs are quoted market prices for identical instruments available in active markets.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level 2 inputs are inputs other than quoted prices included within Level 1 that are observable for the asset or liability either directly or indirectly. If the asset or liability has a contractual term, the input must be observable for substantially the full term. An example includes quoted market prices for similar assets or liabilities in active markets.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level 3 inputs are unobservable inputs for the asset or liability and will reflect management&#8217;s assumptions about market assumptions that would be used to price the asset or liability.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table presents information about the Company&#8217;s assets and liabilities that are measured at fair value on a recurring basis, and indicates the fair value hierarchy of the valuation techniques used to determine such fair value:</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Level 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Level 2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Level 3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">As of September 30, 2019</font></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Assets</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">90,082</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">90,082</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Liabilities</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Liability-classified options</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">86</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">86</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contingent consideration</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,005</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,005</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,091</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,091</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.8046875%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Level 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Level 2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Level 3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">As of December 31, 2018</font></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Assets</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36,942</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36,942</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Short-term investments</font></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">87,675</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">87,675</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">124,617</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">124,617</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Liabilities</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Liability-classified stock option awards</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">479</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">479</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contingent consideration</font></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,126</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,126</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,605</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,605</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company's liability-classified options are measured at fair value using the Black-Scholes valuation model. Assumptions about the Company's expected stock-price volatility are based on the historical volatility of the Company's publicly-traded stock. The risk-free interest rate used for each grant is equal to the zero coupon rate for instruments with a similar expected life. The assumptions around the expected life are based on the Company's historical data. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">To determine the fair value of the contingent consideration, the Company uses a probability-weighted assessment of the likelihood the milestones would be met and the estimated timing of such payments (see note 10). The potential contingent payments are then discounted to their present value using a probability-adjusted discount rate that reflects the early-stage nature of the development program, time to complete the program development, and overall biotech indices. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table presents the changes in fair value of the Company&#8217;s liability-classified stock option awards:</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:38%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Liability at beginning of the period</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Fair value of liability-classified options exercised in the period</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Increase (decrease) in fair value of liability</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Liability at end of the period</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nine months ended September 30, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,239</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,499</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,738</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nine months ended September 30, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">479</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(393</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">86</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table presents the changes in fair value of the Company&#8217;s contingent consideration: </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:38%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Liability at beginning of the period</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Increase (decrease) in fair value of liability</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Liability at end of the period</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nine months ended September 30, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,424</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6,263</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,161</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nine months ended September 30, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,126</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(121</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,005</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -URI http://asc.fasb.org/topic&amp;trid=2155941<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6631344768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Payable and Accrued Liabilities<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accounts payable and accrued liabilities</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Accounts payable and accrued liabilities</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts payable and accrued liabilities are comprised of the following:</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:63%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">September&#160;30, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">December&#160;31, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Trade accounts payable</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,400</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,192</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development accruals</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,112</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,716</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Professional fee accruals</font></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,177</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">871</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Payroll accruals</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,509</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,341</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other accrued liabilities</font></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">309</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,199</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,429</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6632729904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborations, Contracts and Licensing Agreements<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaborations, contracts and licensing agreements</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Collaborations, contracts and licensing agreements</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue contracts are described in detail in the Overview section of Part I, Item 2, "Management's Discussion and Analysis of Financial Condition and Results of Operations" in the Company's 2018 Form 10-K. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In 2012, the Company entered into a license agreement with Alnylam that entitles Alnylam to develop and commercialize products with the Company's LNP technology. Alnylam's ONPATTRO program, which represents the first approved application of LNP technology, was approved by the U.S. Food and Drug Administration ("FDA") and the European Medicines Agency ("EMA") during the third quarter of 2018 and was launched immediately upon approval in the US. The Company is entitled to tiered low to mid single-digit royalty payments on global net sales of ONPATTRO and received its first royalty payment in the fourth quarter of 2018. In July 2019, the Company sold a portion of its royalty entitlement for Alnylam's ONPATTRO to OMERS.  See note 9 - Sale of future royalties for further details.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue for the </font><font style="font-family:inherit;font-size:10pt;">three and nine months ended September 30, 2019</font><font style="font-family:inherit;font-size:10pt;"> consists primarily of a net </font><font style="font-family:inherit;font-size:10pt;">$1.5 million</font><font style="font-family:inherit;font-size:10pt;"> development milestone earned under our license agreement with Gritstone, royalties on net global sales of Alnylam's ONPATTRO, a milestone and royalties on net sales of Spectrum Pharmaceuticals, Inc.'s ("Spectrum") Marqibo</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174; </sup></font><font style="font-family:inherit;font-size:10pt;">and services provided to Gritstone Oncology, Inc. ("Gritstone").  Revenue for the three and nine months ended September 30, 2018 consisted primarily of revenue earned under our license agreement with Gritstone, including a net </font><font style="font-family:inherit;font-size:10pt;">$1.3 million</font><font style="font-family:inherit;font-size:10pt;"> development milestone payment, the earned portion of an upfront license fee and services provided to Gritstone.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI http://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6638486320">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Weighted Average Remaining Lease Term and Discount Rate (Details)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term (years)</a></td>
<td class="text">7 years 3 months 18 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate</a></td>
<td class="nump">8.90%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6798440944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Instruments - Changes in Fair Value of Liabilities-Classified as Stock Option (Details) - Liability classified stock options - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_FairValueLiabilitiesMeasuredonRecurringBasisRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_EmployeeStockOptionsLiabilityClassifiedOutstandingFairValueDisclosure', window );">Liability at beginning of the period</a></td>
<td class="nump">$ 479<span></span>
</td>
<td class="nump">$ 1,239<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisesinPeriodFairValue', window );">Fair value of liability-classified options exercised in the period</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_IncreaseDecreaseinFairValueofLiabilityClassifiedOptions', window );">Increase (decrease) in fair value of liability</a></td>
<td class="num">(393)<span></span>
</td>
<td class="nump">1,499<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_EmployeeStockOptionsLiabilityClassifiedOutstandingFairValueDisclosure', window );">Liability at end of the period</a></td>
<td class="nump">$ 86<span></span>
</td>
<td class="nump">$ 2,738<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_EmployeeStockOptionsLiabilityClassifiedOutstandingFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Employee Stock Options, Liability Classified, Outstanding, Fair Value Disclosure</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_EmployeeStockOptionsLiabilityClassifiedOutstandingFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_FairValueLiabilitiesMeasuredonRecurringBasisRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair Value, Liabilities Measured on Recurring Basis [Roll Forward]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_FairValueLiabilitiesMeasuredonRecurringBasisRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_IncreaseDecreaseinFairValueofLiabilityClassifiedOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) in Fair Value of Liability Classified Options</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_IncreaseDecreaseinFairValueofLiabilityClassifiedOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisesinPeriodFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Fair Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisesinPeriodFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=abus_EmployeeStockOptionLiabilityClassifiedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=abus_EmployeeStockOptionLiabilityClassifiedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6827130144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contingencies and Commitments (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Aug. 20, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 16, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2017 </div>
<div>USD ($) </div>
<div>Legal_proceedings</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 31, 2014 </div>
<div>USD ($) </div>
<div>patent </div>
<div>product</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_ContingenciesandCommitmentsLineItems', window );"><strong>Contingencies and Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyLossInPeriod', window );">Arbitration settlement charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,486,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 6,486,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Fair value of contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,005,000<span></span>
</td>
<td class="nump">$ 4,161,000<span></span>
</td>
<td class="nump">3,005,000<span></span>
</td>
<td class="nump">$ 4,161,000<span></span>
</td>
<td class="nump">$ 3,126,000<span></span>
</td>
<td class="nump">$ 10,424,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=abus_ArbutusInc.Member', window );">Arbutus Inc. | Enantigen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_ContingenciesandCommitmentsLineItems', window );"><strong>Contingencies and Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh', window );">Business combination, high end of payment upon achievement of certain triggering events</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_NumberOfProductsCoveredByPatentAcquiredUnderAgreement', window );">Number of products covered by patent acquired under the agreement | product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_LicenseAgreementMaximumDevelopmentAndRegulatoryMilestonePaymentsPerLicense', window );">Development and regulatory milestones payment per licensed compound series, maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=abus_BlumbergandDrexelMember', window );">Blumberg and Drexel | Arbutus Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_ContingenciesandCommitmentsLineItems', window );"><strong>Contingencies and Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_LicenseAgreementMaximumDevelopmentAndRegulatoryMilestonePaymentsPerLicense', window );">Development and regulatory milestones payment per licensed compound series, maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">102,500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_LicenseAgreementMaximumDevelopmentAndRegulatoryMilestonePaymentsPerRoyalty', window );">Development and regulatory milestones payment per royalty, maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_NumberofPatentLicenses', window );">Number of patent license agreements | patent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=abus_BlumbergMember', window );">Blumberg | Arbutus Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_ContingenciesandCommitmentsLineItems', window );"><strong>Contingencies and Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_ResearchFundingPeriod', window );">Research funding period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_ContractualObligationAmountOfResearchFundingPerYear', window );">Research funding per year under research collaboration and funding agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_ContingenciesandCommitmentsLineItems', window );"><strong>Contingencies and Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Fair value of contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,005,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,005,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,126,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Blumberg and Drexel | Enantigen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_ContingenciesandCommitmentsLineItems', window );"><strong>Contingencies and Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Fair value of contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=abus_ArbitrationWithTheUniversityOfBritishColumbiaMember', window );">Arbitration with the University of British Columbia</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_ContingenciesandCommitmentsLineItems', window );"><strong>Contingencies and Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesSoughtValue', window );">Loss contingency, damages sought for allegedly unpaid royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_Numberoflegalproceedings', window );">Number of legal proceedings | Legal_proceedings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty', window );">Arbitration settlement, amount awarded to other party</a></td>
<td class="nump">$ 5,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementInterest', window );">Arbitration settlement interest</a></td>
<td class="nump">2,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyLossInPeriod', window );">Arbitration settlement charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForLegalSettlements', window );">Arbitration settlement payment</a></td>
<td class="nump">$ 5,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=abus_ArbitrationWithTheUniversityOfBritishColumbiaMember', window );">Arbitration with the University of British Columbia | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_ContingenciesandCommitmentsLineItems', window );"><strong>Contingencies and Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyEstimateOfPossibleLoss', window );">Estimate of potential arbitration award for costs and attorney's fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_ContingenciesandCommitmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_ContingenciesandCommitmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_ContractualObligationAmountOfResearchFundingPerYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual Obligation, Amount of Research Funding Per Year</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_ContractualObligationAmountOfResearchFundingPerYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_LicenseAgreementMaximumDevelopmentAndRegulatoryMilestonePaymentsPerLicense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Agreement, Maximum Development and Regulatory Milestone Payments Per License</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_LicenseAgreementMaximumDevelopmentAndRegulatoryMilestonePaymentsPerLicense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_LicenseAgreementMaximumDevelopmentAndRegulatoryMilestonePaymentsPerRoyalty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Agreement Maximum Development And Regulatory Royalty Payment per Royalty</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_LicenseAgreementMaximumDevelopmentAndRegulatoryMilestonePaymentsPerRoyalty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_NumberOfProductsCoveredByPatentAcquiredUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Products Covered By Patent Acquired Under Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_NumberOfProductsCoveredByPatentAcquiredUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_NumberofPatentLicenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of Patent Licenses</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_NumberofPatentLicenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_Numberoflegalproceedings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of legal proceedings</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_Numberoflegalproceedings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_ResearchFundingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research Funding Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_ResearchFundingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For contingent consideration arrangements recognized in connection with a business combination, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI http://asc.fasb.org/extlink&amp;oid=6911338&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount awarded to other party in judgment or settlement of litigation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementAmountAwardedToOtherParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest expense (income) directly attributable to an award in settlement of litigation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyDamagesSoughtValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value (monetary amount) of the award the plaintiff seeks in the legal matter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82911808&amp;loc=d3e14557-108349<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82911808&amp;loc=d3e14435-108349<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82911808&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyDamagesSoughtValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyEstimateOfPossibleLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reflects the estimated amount of loss from the specified contingency as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=82911808&amp;loc=d3e14435-108349<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=82911808&amp;loc=d3e14557-108349<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=115931803&amp;loc=d3e12021-110248<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyEstimateOfPossibleLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyLossInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of loss pertaining to the specified contingency that was charged against earnings in the period, including the effects of revisions in previously reported estimates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82911808&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyLossInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForLegalSettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for the settlement of litigation or for other legal issues during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForLegalSettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=abus_ArbutusInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=abus_ArbutusInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=abus_EnantigenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=abus_EnantigenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=abus_BlumbergandDrexelMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=abus_BlumbergandDrexelMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=abus_BlumbergMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=abus_BlumbergMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=abus_ArbitrationWithTheUniversityOfBritishColumbiaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=abus_ArbitrationWithTheUniversityOfBritishColumbiaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6827516848">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statement of Stockholders' Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Convertible Preferred Shares</div></th>
<th class="th"><div>Common Shares</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Deficit</div></th>
<th class="th"><div>Accumulated Other Comprehensive Loss</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning balance (in shares) at Dec. 31, 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="nump">55,060,650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2017</a></td>
<td class="nump">$ 182,473<span></span>
</td>
<td class="nump">$ 49,780<span></span>
</td>
<td class="nump">$ 876,108<span></span>
</td>
<td class="nump">$ 42,840<span></span>
</td>
<td class="num">$ (738,070)<span></span>
</td>
<td class="num">$ (48,185)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockAccretionOfRedemptionDiscount', window );">Accretion of accumulated dividends on Preferred Shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 2,336<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,336)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">1,510<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,510<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_AdjustmentstoAdditionalPaidinCapitalCertainFairValueAdjustmentstoLiabilityStockOptionAwards', window );">Certain fair value adjustments to liability-classified</a></td>
<td class="num">(504)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(504)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common shares pursuant to the Sale Agreement (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">664,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common shares pursuant to the Sale Agreement</a></td>
<td class="nump">66,265<span></span>
</td>
<td class="nump">$ 66,265<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common shares pursuant to exercise of options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,541<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common shares pursuant to exercise of options</a></td>
<td class="nump">103<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 180<span></span>
</td>
<td class="num">(77)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(17,429)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(17,429)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Mar. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,164,000<span></span>
</td>
<td class="nump">55,087,191<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2018</a></td>
<td class="nump">232,418<span></span>
</td>
<td class="nump">$ 118,381<span></span>
</td>
<td class="nump">$ 876,288<span></span>
</td>
<td class="nump">43,769<span></span>
</td>
<td class="num">(757,835)<span></span>
</td>
<td class="num">(48,185)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning balance (in shares) at Dec. 31, 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="nump">55,060,650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2017</a></td>
<td class="nump">182,473<span></span>
</td>
<td class="nump">$ 49,780<span></span>
</td>
<td class="nump">$ 876,108<span></span>
</td>
<td class="nump">42,840<span></span>
</td>
<td class="num">(738,070)<span></span>
</td>
<td class="num">(48,185)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(38,811)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Sep. 30, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,164,000<span></span>
</td>
<td class="nump">55,472,319<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2018</a></td>
<td class="nump">215,272<span></span>
</td>
<td class="nump">$ 123,489<span></span>
</td>
<td class="nump">$ 878,805<span></span>
</td>
<td class="nump">45,500<span></span>
</td>
<td class="num">(784,325)<span></span>
</td>
<td class="num">(48,197)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning balance (in shares) at Mar. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,164,000<span></span>
</td>
<td class="nump">55,087,191<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Mar. 31, 2018</a></td>
<td class="nump">232,418<span></span>
</td>
<td class="nump">$ 118,381<span></span>
</td>
<td class="nump">$ 876,288<span></span>
</td>
<td class="nump">43,769<span></span>
</td>
<td class="num">(757,835)<span></span>
</td>
<td class="num">(48,185)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockAccretionOfRedemptionDiscount', window );">Accretion of accumulated dividends on Preferred Shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 2,541<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,541)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">1,862<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,862<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_AdjustmentstoAdditionalPaidinCapitalCertainFairValueAdjustmentstoLiabilityStockOptionAwards', window );">Certain fair value adjustments to liability-classified</a></td>
<td class="num">(34)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(34)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common shares pursuant to exercise of options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">238,059<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common shares pursuant to exercise of options</a></td>
<td class="nump">735<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,903<span></span>
</td>
<td class="num">(1,168)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="nump">3,091<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,091<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Jun. 30, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,164,000<span></span>
</td>
<td class="nump">55,325,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2018</a></td>
<td class="nump">238,072<span></span>
</td>
<td class="nump">$ 120,922<span></span>
</td>
<td class="nump">$ 878,191<span></span>
</td>
<td class="nump">44,429<span></span>
</td>
<td class="num">(757,285)<span></span>
</td>
<td class="num">(48,185)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockAccretionOfRedemptionDiscount', window );">Accretion of accumulated dividends on Preferred Shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 2,567<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,567)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">1,658<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,658<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_AdjustmentstoAdditionalPaidinCapitalCertainFairValueAdjustmentstoLiabilityStockOptionAwards', window );">Certain fair value adjustments to liability-classified</a></td>
<td class="num">(407)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(407)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common shares pursuant to exercise of options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">147,069<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common shares pursuant to exercise of options</a></td>
<td class="nump">434<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 614<span></span>
</td>
<td class="num">(180)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Currency translation adjustment</a></td>
<td class="num">(12)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(24,473)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(24,473)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Sep. 30, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,164,000<span></span>
</td>
<td class="nump">55,472,319<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2018</a></td>
<td class="nump">215,272<span></span>
</td>
<td class="nump">$ 123,489<span></span>
</td>
<td class="nump">$ 878,805<span></span>
</td>
<td class="nump">45,500<span></span>
</td>
<td class="num">(784,325)<span></span>
</td>
<td class="num">(48,197)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning balance (in shares) at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,164,000<span></span>
</td>
<td class="nump">55,518,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2018</a></td>
<td class="nump">200,234<span></span>
</td>
<td class="nump">$ 126,136<span></span>
</td>
<td class="nump">$ 879,405<span></span>
</td>
<td class="nump">48,084<span></span>
</td>
<td class="num">(805,221)<span></span>
</td>
<td class="num">(48,170)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockAccretionOfRedemptionDiscount', window );">Accretion of accumulated dividends on Preferred Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,715<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,715)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">1,665<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,665<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_AdjustmentstoAdditionalPaidinCapitalCertainFairValueAdjustmentstoLiabilityStockOptionAwards', window );">Certain fair value adjustments to liability-classified</a></td>
<td class="nump">47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common shares pursuant to the Sale Agreement (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">614,401<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common shares pursuant to the Sale Agreement</a></td>
<td class="nump">2,248<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,248<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common shares pursuant to exercise of options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">122,603<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common shares pursuant to exercise of options</a></td>
<td class="nump">288<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 490<span></span>
</td>
<td class="num">(202)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Currency translation adjustment</a></td>
<td class="num">(22)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(22)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(23,251)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23,251)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Mar. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,164,000<span></span>
</td>
<td class="nump">56,255,804<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2019</a></td>
<td class="nump">181,209<span></span>
</td>
<td class="nump">$ 128,851<span></span>
</td>
<td class="nump">$ 882,143<span></span>
</td>
<td class="nump">49,594<span></span>
</td>
<td class="num">(831,187)<span></span>
</td>
<td class="num">(48,192)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning balance (in shares) at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,164,000<span></span>
</td>
<td class="nump">55,518,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2018</a></td>
<td class="nump">200,234<span></span>
</td>
<td class="nump">$ 126,136<span></span>
</td>
<td class="nump">$ 879,405<span></span>
</td>
<td class="nump">48,084<span></span>
</td>
<td class="num">(805,221)<span></span>
</td>
<td class="num">(48,170)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(129,069)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Sep. 30, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,164,000<span></span>
</td>
<td class="nump">56,850,172<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2019</a></td>
<td class="nump">83,637<span></span>
</td>
<td class="nump">$ 134,405<span></span>
</td>
<td class="nump">$ 884,623<span></span>
</td>
<td class="nump">55,385<span></span>
</td>
<td class="num">(942,559)<span></span>
</td>
<td class="num">(48,217)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning balance (in shares) at Mar. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,164,000<span></span>
</td>
<td class="nump">56,255,804<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Mar. 31, 2019</a></td>
<td class="nump">181,209<span></span>
</td>
<td class="nump">$ 128,851<span></span>
</td>
<td class="nump">$ 882,143<span></span>
</td>
<td class="nump">49,594<span></span>
</td>
<td class="num">(831,187)<span></span>
</td>
<td class="num">(48,192)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockAccretionOfRedemptionDiscount', window );">Accretion of accumulated dividends on Preferred Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,762<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,762)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">3,915<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,915<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_AdjustmentstoAdditionalPaidinCapitalCertainFairValueAdjustmentstoLiabilityStockOptionAwards', window );">Certain fair value adjustments to liability-classified</a></td>
<td class="nump">230<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">230<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common shares pursuant to the Sale Agreement (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">593,689<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common shares pursuant to the Sale Agreement</a></td>
<td class="nump">2,477<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,477<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common shares pursuant to exercise of options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">679<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common shares pursuant to exercise of options</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Currency translation adjustment</a></td>
<td class="num">(52)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(52)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(23,315)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23,315)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Jun. 30, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,164,000<span></span>
</td>
<td class="nump">56,850,172<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2019</a></td>
<td class="nump">164,466<span></span>
</td>
<td class="nump">$ 131,613<span></span>
</td>
<td class="nump">$ 884,623<span></span>
</td>
<td class="nump">53,738<span></span>
</td>
<td class="num">(857,264)<span></span>
</td>
<td class="num">(48,244)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockAccretionOfRedemptionDiscount', window );">Accretion of accumulated dividends on Preferred Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,792<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,792)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">1,592<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,592<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_AdjustmentstoAdditionalPaidinCapitalCertainFairValueAdjustmentstoLiabilityStockOptionAwards', window );">Certain fair value adjustments to liability-classified</a></td>
<td class="nump">55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Currency translation adjustment</a></td>
<td class="nump">27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(82,503)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(82,503)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Sep. 30, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,164,000<span></span>
</td>
<td class="nump">56,850,172<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2019</a></td>
<td class="nump">$ 83,637<span></span>
</td>
<td class="nump">$ 134,405<span></span>
</td>
<td class="nump">$ 884,623<span></span>
</td>
<td class="nump">$ 55,385<span></span>
</td>
<td class="num">$ (942,559)<span></span>
</td>
<td class="num">$ (48,217)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_AdjustmentstoAdditionalPaidinCapitalCertainFairValueAdjustmentstoLiabilityStockOptionAwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments to Additional Paid in Capital, Certain Fair Value Adjustments to Liability Stock Option Awards</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_AdjustmentstoAdditionalPaidinCapitalCertainFairValueAdjustmentstoLiabilityStockOptionAwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) from recognition of equity-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=109196918&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109196918&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=79507207&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=109228884&amp;loc=d3e1436-108581<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockAccretionOfRedemptionDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of accretion of the preferred stock redemption discount during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockAccretionOfRedemptionDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6824523536">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 90,082,000<span></span>
</td>
<td class="nump">$ 36,942,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">87,675,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">2,488,000<span></span>
</td>
<td class="nump">1,431,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">1,771,000<span></span>
</td>
<td class="nump">3,181,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">94,341,000<span></span>
</td>
<td class="nump">129,229,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investment in Genevant</a></td>
<td class="nump">10,969,000<span></span>
</td>
<td class="nump">22,224,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net accumulated depreciation $8,612 (December 31, 2018: $7,090)</a></td>
<td class="nump">9,150,000<span></span>
</td>
<td class="nump">10,145,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right of use asset (note 5)</a></td>
<td class="nump">2,817,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">43,836,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">22,471,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">117,277,000<span></span>
</td>
<td class="nump">227,905,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued liabilities (note 7)</a></td>
<td class="nump">8,199,000<span></span>
</td>
<td class="nump">9,429,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveCurrent', window );">Site consolidation accrual (note 8)</a></td>
<td class="nump">203,000<span></span>
</td>
<td class="nump">1,331,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_EmployeeStockOptionsLiabilityClassifiedOutstanding', window );">Liability-classified options (note 3)</a></td>
<td class="nump">86,000<span></span>
</td>
<td class="nump">479,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Lease liability, current (note 5)</a></td>
<td class="nump">329,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">8,817,000<span></span>
</td>
<td class="nump">11,239,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent', window );">Liability related to sale of future royalties (note 9)</a></td>
<td class="nump">18,675,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRentCreditNoncurrent', window );">Deferred rent and inducements, non-current</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">645,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent consideration (notes 3 and 10)</a></td>
<td class="nump">3,005,000<span></span>
</td>
<td class="nump">3,126,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease liability, non-current (note 5)</a></td>
<td class="nump">3,143,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred tax liability (note 6)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">12,661,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">33,640,000<span></span>
</td>
<td class="nump">27,671,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockIncludingAdditionalPaidInCapitalNetOfDiscount', window );">Preferred shares, Authorized - 1,164,000 with no par value, Issued and outstanding: 1,164,000 (December 31, 2018 - 1,164,000)</a></td>
<td class="nump">134,405,000<span></span>
</td>
<td class="nump">126,136,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common shares, Authorized - unlimited number with no par value, Issued and outstanding: 56,850,172 (December 31, 2018 - 55,518,800)</a></td>
<td class="nump">884,623,000<span></span>
</td>
<td class="nump">879,405,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">55,385,000<span></span>
</td>
<td class="nump">48,084,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Deficit</a></td>
<td class="num">(942,559,000)<span></span>
</td>
<td class="num">(805,221,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(48,217,000)<span></span>
</td>
<td class="num">(48,170,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">83,637,000<span></span>
</td>
<td class="nump">200,234,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 117,277,000<span></span>
</td>
<td class="nump">$ 227,905,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_EmployeeStockOptionsLiabilityClassifiedOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Employee Stock Options, Liability Classified, Outstanding</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_EmployeeStockOptionsLiabilityClassifiedOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Liability Related To Sale Of Future Royalties, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130549-203045<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=d3e637-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669686-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6801-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI http://asc.fasb.org/extlink&amp;oid=6911338&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e31931-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRentCreditNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For a classified balance sheet, the cumulative difference between the rental income or payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense, by the lessor or lessee, respectively, more than one year after the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.26(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902458&amp;loc=d3e39927-112707<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRentCreditNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=77989000&amp;loc=SL49117168-202975<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockIncludingAdditionalPaidInCapitalNetOfDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par value plus amounts in excess of par or issuance value (in cases of no-par value stock) for nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) issued and outstanding, net of discount on shares. Aggregate for preferred stock issued and outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.4-07)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187103-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockIncludingAdditionalPaidInCapitalNetOfDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserveCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of known and estimated obligations associated with exit from or disposal of business activities or restructurings pursuant to a duly authorized plan, which are expected to be paid in the next twelve months or in the normal operating cycle if longer. Costs of such activities include those for one-time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, relocating employees, and costs associated with an ongoing benefit arrangement, but excludes costs associated with the retirement of a long-lived asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserveCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(g))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6813111264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Site Consolidation - Consolidation Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">21 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Total site consolidation expense</a></td>
<td class="nump">$ 182<span></span>
</td>
<td class="num">$ (492)<span></span>
</td>
<td class="nump">$ 33<span></span>
</td>
<td class="nump">$ 3,710<span></span>
</td>
<td class="nump">$ 4,800<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=abus_EmployeeSeveranceandRelocationMember', window );">Employee severance and relocation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Total site consolidation expense</a></td>
<td class="nump">231<span></span>
</td>
<td class="nump">198<span></span>
</td>
<td class="nump">429<span></span>
</td>
<td class="nump">3,399<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_FacilityClosingMember', window );">Facility and other expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Total site consolidation expense</a></td>
<td class="num">$ (49)<span></span>
</td>
<td class="num">$ (690)<span></span>
</td>
<td class="num">$ (396)<span></span>
</td>
<td class="nump">$ 311<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=abus_EmployeeSeveranceandRelocationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=abus_EmployeeSeveranceandRelocationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_FacilityClosingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_FacilityClosingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6813449936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of basic and diluted net income (loss) per common share</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table sets out the computation of basic and diluted net loss attributable to common shareholders per share:</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands, except share and per share amounts)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Numerator:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Allocation of distributable earnings</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Allocation of undistributable loss</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(85,295</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(27,040</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(137,338</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(46,255</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Allocation of loss attributed to common shareholders</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(85,295</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(27,040</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(137,338</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(46,255</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Denominator:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted average number of common shares - basic and diluted</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">56,850,172</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">55,421,504</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">56,469,358</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">55,241,284</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic and diluted net loss attributable to common shareholders per share</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.50</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.49</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2.43</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.84</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6633660320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Site Consolidation (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock', window );">Schedule of expenses and reserve recorded for site consolidation</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Site consolidation expenses were as follows: </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Employee severance and relocation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">231</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">198</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">429</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,399</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Facility and other expenses</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(49</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(690</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(396</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">311</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total site consolidation expense</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">182</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(492</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,710</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Site consolidation activity was as follows:</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:58%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Employee severance and relocation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Facility and other expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Site consolidation accrual as of December 31, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">697</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">634</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,331</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Additional accruals and other adjustments</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">429</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(396</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Payments</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(923</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(238</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,161</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Site consolidation accrual as of September 30, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">203</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">203</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6825011552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Method Investment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Gains (losses) on equity method investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (3,512)<span></span>
</td>
<td class="num">$ (2,838)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (11,497)<span></span>
</td>
<td class="num">$ (2,838)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investment in Genevant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,969<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,969<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,224<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=abus_GenevantSciencesCorporationMember', window );">Genevant Sciences Corporation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Gains (losses) on equity method investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (3,500)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,900<span></span>
</td>
<td class="num">$ (11,500)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership interest in equity method investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=abus_RoivantSciencesLtdMember', window );">Roivant Sciences Ltd | Genevant Sciences Corporation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_EquityMethodInvestmentPropertyContribution', window );">Property contribution to investment in Genevant</a></td>
<td class="nump">$ 37,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_EquityMethodInvestmentPropertyContribution">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investment, Property Contribution</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_EquityMethodInvestmentPropertyContribution</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the entity's proportionate share for the period of the net income (loss) of its investee (such as unconsolidated subsidiaries and joint ventures) to which the equity method of accounting is applied. This item includes income or expense related to stock-based compensation based on the investor's grant of stock to employees of an equity method investee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEquityMethodInvestmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=abus_GenevantSciencesCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=abus_GenevantSciencesCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=abus_RoivantSciencesLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=abus_RoivantSciencesLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6827519600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies - Schedule of Computation of Basic and Diluted Income (Loss) (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss attributable to common shareholders (note 2)</a></td>
<td class="num">$ (85,295)<span></span>
</td>
<td class="num">$ (27,040)<span></span>
</td>
<td class="num">$ (137,338)<span></span>
</td>
<td class="num">$ (46,255)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average number of common shares - basic and diluted</a></td>
<td class="nump">56,850,172<span></span>
</td>
<td class="nump">55,421,504<span></span>
</td>
<td class="nump">56,469,358<span></span>
</td>
<td class="nump">55,241,284<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and diluted net loss attributable to common shareholders per share</a></td>
<td class="num">$ (1.50)<span></span>
</td>
<td class="num">$ (0.49)<span></span>
</td>
<td class="num">$ (2.43)<span></span>
</td>
<td class="num">$ (0.84)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_DistributableEarningsLossAvailabletoCommonShareholdersBasic', window );">Allocation of distributable earnings</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UndistributedEarningsLossAvailableToCommonShareholdersBasic', window );">Allocation of undistributable loss</a></td>
<td class="num">(85,295)<span></span>
</td>
<td class="num">(27,040)<span></span>
</td>
<td class="num">(137,338)<span></span>
</td>
<td class="num">(46,255)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss attributable to common shareholders (note 2)</a></td>
<td class="num">$ (85,295)<span></span>
</td>
<td class="num">$ (27,040)<span></span>
</td>
<td class="num">$ (137,338)<span></span>
</td>
<td class="num">$ (46,255)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average number of common shares - basic and diluted</a></td>
<td class="nump">56,850,172<span></span>
</td>
<td class="nump">55,421,504<span></span>
</td>
<td class="nump">56,469,358<span></span>
</td>
<td class="nump">55,241,284<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and diluted net loss attributable to common shareholders per share</a></td>
<td class="num">$ (1.50)<span></span>
</td>
<td class="num">$ (0.49)<span></span>
</td>
<td class="num">$ (2.43)<span></span>
</td>
<td class="num">$ (0.84)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_DistributableEarningsLossAvailabletoCommonShareholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Distributable Earnings (Loss) Available to Common Shareholders, Basic</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_DistributableEarningsLossAvailabletoCommonShareholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1377-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UndistributedEarningsLossAvailableToCommonShareholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of undistributed earnings (loss) allocated to common stock as if earnings had been distributed. Excludes distributed earnings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=SL5780133-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 66<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e2814-109256<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 65<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e2793-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UndistributedEarningsLossAvailableToCommonShareholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6815501440">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Maturities of Lease Liabilities (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">October through December 2019</a></td>
<td class="nump">$ 188<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2020</a></td>
<td class="nump">657<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2021</a></td>
<td class="nump">677<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2022</a></td>
<td class="nump">581<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2023</a></td>
<td class="nump">598<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">2,039<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total Lease Payments</a></td>
<td class="nump">4,740<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: interest</a></td>
<td class="num">(1,268)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of lease payments</a></td>
<td class="nump">$ 3,472<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due after fifth fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fifth fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fourth fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease having an initial or remaining lease term in excess of one year due in remainder of fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6638244720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Leases</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;"> operating leases for office and laboratory space.  The Company's corporate headquarters is located at 701 Veterans Circle, Warminster, Pennsylvania.  The lease expires on April 30, 2027, and the Company has the option of extending the lease for </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;"> further </font><font style="font-family:inherit;font-size:10pt;">five</font><font style="font-family:inherit;font-size:10pt;">-year terms.  The Company also leases office space located at 626 Jacksonville Rd, Warminster, Pennsylvania under a lease that expires on December 31, 2021, and the Company has an option to extend the lease term to April 30, 2027.  In connection with the Company's site consolidation in 2018, the Company ceased using its office and laboratory space located in Burnaby, British Columbia, Canada on June 30, 2018. The Company subleased a portion of the Burnaby facility to various tenants, including Genevant, until the lease expired on July 31, 2019.  The Company recognized the remaining lease payments for the Burnaby facility, less sublease income under contract, in site consolidation expenses in 2018. The Company&#8217;s lease agreements do not contain any material residual value guarantees or material restrictive covenants.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company adopted ASU No. 2016-02, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Leases</font><font style="font-family:inherit;font-size:10pt;"> (Topic 842) on January 1, 2019 using the modified retrospective basis applied at the effective date of the new standard and elected to utilize a package of practical expedients.  Leases with an initial term of 12 months or less are not recorded on the balance sheet. The Company determines if an arrangement is a lease at inception. Right-of-use assets represent the Company's right to use an underlying asset for the lease term and lease liabilities represent the Company's obligation to make lease payments arising from the lease. Operating lease right-of-use assets and lease liabilities are recognized based on the present value of lease payments over the lease term. The leases do not provide an implicit rate so, in determining the present value of lease payments, the Company utilized its incremental borrowing rate for the applicable lease, which was </font><font style="font-family:inherit;font-size:10pt;">9.0%</font><font style="font-family:inherit;font-size:10pt;"> for the 701 Veterans Circle lease, </font><font style="font-family:inherit;font-size:10pt;">7.6%</font><font style="font-family:inherit;font-size:10pt;"> for the 626 Jacksonville Rd. lease and </font><font style="font-family:inherit;font-size:10pt;">5.0%</font><font style="font-family:inherit;font-size:10pt;"> for the Burnaby lease. The Company recognizes lease expense on a straight-line basis over the remaining lease term.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the </font><font style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2019</font><font style="font-family:inherit;font-size:10pt;">, the Company incurred total operating lease expenses of </font><font style="font-family:inherit;font-size:10pt;">$1.1 million</font><font style="font-family:inherit;font-size:10pt;">, which included lease expenses associated with fixed lease payments of </font><font style="font-family:inherit;font-size:10pt;">$0.9 million</font><font style="font-family:inherit;font-size:10pt;">, and variable payments associated with common area maintenance and similar expenses of </font><font style="font-family:inherit;font-size:10pt;">$0.2 million</font><font style="font-family:inherit;font-size:10pt;">. For the </font><font style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2018</font><font style="font-family:inherit;font-size:10pt;">, the straight-line fixed expense for leases was </font><font style="font-family:inherit;font-size:10pt;">$0.9 million</font><font style="font-family:inherit;font-size:10pt;">. Sublease income for the </font><font style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2019</font><font style="font-family:inherit;font-size:10pt;"> was </font><font style="font-family:inherit;font-size:10pt;">$0.2 million</font><font style="font-family:inherit;font-size:10pt;">, versus </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;"> for the </font><font style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2018</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted average remaining lease term and discount rate were as follows:</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:8px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2" rowspan="1"></td></tr><tr><td style="width:76%;" rowspan="1" colspan="1"></td><td style="width:24%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">As of September 30, 2019</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted-average remaining lease term (years)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.3</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted average discount rate</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.9%</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company did not include options to extend its lease terms as part of its ROU asset and lease liabilities. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:20px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Supplemental cash flow information related to the Company's operating leases was as follows:</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:68%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash paid for amounts included in the measurement of lease liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">921</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Maturities of lease liabilities were as follows:</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:78%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:20%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">As of September 30, 2019</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">October through December 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">188</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2020</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">657</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2021</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">677</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2022</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">581</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2023</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">598</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Thereafter</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,039</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total Lease Payments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,740</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less: interest</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,268</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Present value of lease payments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,472</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6815477728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Sale of Future Royalties<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureAbstract', window );"><strong>Other Liabilities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_LiabilitiesRelatedToSaleOfFutureRoyaltiesTextBlock', window );">Sale of future royalties</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Sale of future royalties </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On July 2, 2019, the Company entered into a Purchase and Sale Agreement (the "Agreement") with the Ontario Municipal Employees Retirement System (or "OMERS"), pursuant to which the Company sold to OMERS part of its royalty interest on future global net sales of ONPATTRO&#8482; (Patisiran) ("ONPATTRO"), an RNA interference therapeutic currently being sold by Alnylam.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ONPATTRO utilizes Arbutus&#8217; LNP technology, which was licensed to Alnylam pursuant to the Cross-License Agreement, dated November 12, 2012, by and between the Company and Alnylam (the &#8220;LNP License Agreement&#8221;).&#160;Under the terms of the LNP License Agreement, the Company is entitled to tiered royalty payments on global net sales of ONPATTRO ranging from </font><font style="font-family:inherit;font-size:10pt;">1.00%</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">2.33%</font><font style="font-family:inherit;font-size:10pt;"> after offsets, with the highest tier applicable to annual net sales above </font><font style="font-family:inherit;font-size:10pt;">$500 million</font><font style="font-family:inherit;font-size:10pt;">. This royalty interest was sold to OMERS, effective as of January 1, 2019, for </font><font style="font-family:inherit;font-size:10pt;">$20 million</font><font style="font-family:inherit;font-size:10pt;"> in gross proceeds before advisory fees. OMERS will retain this entitlement until it has received </font><font style="font-family:inherit;font-size:10pt;">$30 million</font><font style="font-family:inherit;font-size:10pt;"> in royalties, at which point </font><font style="font-family:inherit;font-size:10pt;">100%</font><font style="font-family:inherit;font-size:10pt;"> of such royalty interest on future global net sales of ONPATTRO will revert to the Company. OMERS has assumed the risk of collecting up to </font><font style="font-family:inherit;font-size:10pt;">$30 million</font><font style="font-family:inherit;font-size:10pt;"> of future royalty payments from Alnylam and Arbutus is not obligated to reimburse OMERS if they fail to collect any such future royalties.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The </font><font style="font-family:inherit;font-size:10pt;">$30 million</font><font style="font-family:inherit;font-size:10pt;"> in royalties to be paid to OMERS is accounted for as a liability, with the difference between the liability and the gross proceeds received accounted for as a discount. The discount, as well as </font><font style="font-family:inherit;font-size:10pt;">$1.5 million</font><font style="font-family:inherit;font-size:10pt;"> of transaction costs, will be amortized as interest expense based on the projected balance of the liability as of the beginning of each period. Management estimated an effective annual interest rate of approximately </font><font style="font-family:inherit;font-size:10pt;">25%</font><font style="font-family:inherit;font-size:10pt;">. Over the course of the Agreement, the actual interest rate will be affected by the amount and timing of royalty revenue recognized and changes in the timing of forecasted royalty revenue. On a quarterly basis, the Company will reassess the expected timing of the royalty revenue, recalculate the amortization and effective interest rate and adjust the accounting prospectively as needed. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company will recognize non-cash royalty revenue related to the sales of ONPATTRO during the term of the Agreement. As royalties are remitted to OMERS from Alnylam, the balance of the recognized liability will be effectively repaid over the life of the Agreement. There are a number of factors that could materially affect the amount and timing of royalty payments from Alnylam, none of which are within the Company's control. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the </font><font style="font-family:inherit;font-size:10pt;">three and nine months ended September 30, 2019</font><font style="font-family:inherit;font-size:10pt;">, the Company recognized non-cash royalty revenue of </font><font style="font-family:inherit;font-size:10pt;">$1.0 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$1.1 million</font><font style="font-family:inherit;font-size:10pt;"> of related non-cash interest expense. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The table below shows the activity related to the net liability from inception of the Agreement through </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:68%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:30%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Nine Months Ended September 30, 2019</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net liability related to sale of future royalties - beginning balance</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Initial recognition of liability</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Debt discount and issuance costs</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(11,451</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-cash royalty revenue</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(979</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-cash interest expense</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,106</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net liability related to sale of future royalties - ending balance</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,675</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition to the royalty from the Alnylam LNP License Agreement, the Company is also receiving a second, lower royalty interest on global net sales of ONPATTRO originating from a settlement agreement and subsequent license agreement with Acuitas Therapeutics, Inc. ("Acuitas"). The royalty from Acuitas has been retained by the Company and was not part of the royalty sale to OMERS.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_LiabilitiesRelatedToSaleOfFutureRoyaltiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Liabilities Related To Sale Of Future Royalties</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_LiabilitiesRelatedToSaleOfFutureRoyaltiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6812970352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Sale of Future Royalties - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 02, 2019</div></th>
<th class="th"><div>Jan. 01, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_OtherLiabilitiesDisclosureLineItems', window );"><strong>Other Liabilities Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties', window );">Non-cash royalty revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 979<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 979<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_NonCashRoyaltyExpenseRelatedToSaleOfFutureRoyalties', window );">Non-cash interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,106<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,106<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=abus_OMERSMember', window );">OMERS</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_OtherLiabilitiesDisclosureLineItems', window );"><strong>Other Liabilities Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_RoyaltyInterestSoldPercentageOfSalesAnnualRevenueThresholdOfHighestTier', window );">Annual royalty revenue</a></td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_GrossProceedsFromRoyaltyInterestSold', window );">Gross proceeds from sale of royalty interest. before advisory fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_RoyaltyInterestSoldMaximumRoyaltiesForBuyer', window );">Entitlement of royalties to be received</a></td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_RoyaltyGuaranteesCommitmentsPercentage', window );">Royalty guarantees commitments percentage</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_RoyaltyPayable', window );">Future royalty payments</a></td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_TransactionCostsRelatedToSaleOfFutureRoyalties', window );">Transaction costs on sale of royalties</a></td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_EffectiveAnnualInterestRateOfRoyaltyLiability', window );">Effective annual interest rate on royalty liability</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties', window );">Non-cash royalty revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_NonCashRoyaltyExpenseRelatedToSaleOfFutureRoyalties', window );">Non-cash interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=abus_OMERSMember', window );">OMERS | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_OtherLiabilitiesDisclosureLineItems', window );"><strong>Other Liabilities Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_RoyaltyPercentageofInterestSold', window );">Royalty interest sold percentage</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=abus_OMERSMember', window );">OMERS | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_OtherLiabilitiesDisclosureLineItems', window );"><strong>Other Liabilities Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_RoyaltyPercentageofInterestSold', window );">Royalty interest sold percentage</a></td>
<td class="nump">2.33%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_EffectiveAnnualInterestRateOfRoyaltyLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Annual Interest Rate Of Royalty Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_EffectiveAnnualInterestRateOfRoyaltyLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_GrossProceedsFromRoyaltyInterestSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross Proceeds From Royalty Interest Sold</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_GrossProceedsFromRoyaltyInterestSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_NonCashRoyaltyExpenseRelatedToSaleOfFutureRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non Cash Royalty Expense Related To Sale Of Future Royalties</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_NonCashRoyaltyExpenseRelatedToSaleOfFutureRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non Cash Royalty Revenue Related To Sale Of Future Royalties</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_OtherLiabilitiesDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Liabilities Disclosure [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_OtherLiabilitiesDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_RoyaltyGuaranteesCommitmentsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the royalty guarantees commitments percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_RoyaltyGuaranteesCommitmentsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_RoyaltyInterestSoldMaximumRoyaltiesForBuyer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalty Interest Sold, Maximum Royalties For Buyer</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_RoyaltyInterestSoldMaximumRoyaltiesForBuyer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_RoyaltyInterestSoldPercentageOfSalesAnnualRevenueThresholdOfHighestTier">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalty Interest Sold, Percentage Of Sales, Annual Revenue Threshold Of Highest Tier</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_RoyaltyInterestSoldPercentageOfSalesAnnualRevenueThresholdOfHighestTier</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_RoyaltyPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the royalty payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_RoyaltyPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_RoyaltyPercentageofInterestSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalty, Percentage of Interest Sold</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_RoyaltyPercentageofInterestSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_TransactionCostsRelatedToSaleOfFutureRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Transaction Costs Related To Sale Of Future Royalties</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_TransactionCostsRelatedToSaleOfFutureRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=abus_OMERSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=abus_OMERSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6825093264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">$ 3,061<span></span>
</td>
<td class="nump">$ 1,587<span></span>
</td>
<td class="nump">$ 4,393<span></span>
</td>
<td class="nump">$ 4,267<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">17,731<span></span>
</td>
<td class="nump">16,566<span></span>
</td>
<td class="nump">45,183<span></span>
</td>
<td class="nump">46,871<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">3,249<span></span>
</td>
<td class="nump">2,631<span></span>
</td>
<td class="nump">15,850<span></span>
</td>
<td class="nump">10,075<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">507<span></span>
</td>
<td class="nump">497<span></span>
</td>
<td class="nump">1,521<span></span>
</td>
<td class="nump">1,677<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Site consolidation (note 8)</a></td>
<td class="nump">182<span></span>
</td>
<td class="num">(492)<span></span>
</td>
<td class="nump">33<span></span>
</td>
<td class="nump">3,710<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Impairment of intangible assets (note 6)</a></td>
<td class="nump">43,836<span></span>
</td>
<td class="nump">14,811<span></span>
</td>
<td class="nump">43,836<span></span>
</td>
<td class="nump">14,811<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairment of goodwill (note 6)</a></td>
<td class="nump">22,471<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">22,471<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyLossInPeriod', window );">Arbitration (note 10)</a></td>
<td class="nump">6,486<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">6,486<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">94,462<span></span>
</td>
<td class="nump">34,013<span></span>
</td>
<td class="nump">135,380<span></span>
</td>
<td class="nump">77,144<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(91,401)<span></span>
</td>
<td class="num">(32,426)<span></span>
</td>
<td class="num">(130,987)<span></span>
</td>
<td class="num">(72,877)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (loss)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">503<span></span>
</td>
<td class="nump">756<span></span>
</td>
<td class="nump">1,709<span></span>
</td>
<td class="nump">2,319<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense (note 9)</a></td>
<td class="num">(1,100)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,114)<span></span>
</td>
<td class="num">(104)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign exchange gain (loss)</a></td>
<td class="num">(25)<span></span>
</td>
<td class="nump">145<span></span>
</td>
<td class="nump">43<span></span>
</td>
<td class="num">(740)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnInvestments', window );">Gain on investment (note 4)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">24,884<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Equity investment loss (note 4)</a></td>
<td class="num">(3,512)<span></span>
</td>
<td class="num">(2,838)<span></span>
</td>
<td class="num">(11,497)<span></span>
</td>
<td class="num">(2,838)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_IncreaseDecreaseInFairValueOfContingentConsiderationLiability', window );">Change in fair value of contingent consideration (notes 3 and 10)</a></td>
<td class="nump">376<span></span>
</td>
<td class="nump">5,608<span></span>
</td>
<td class="nump">121<span></span>
</td>
<td class="nump">6,263<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income (loss)</a></td>
<td class="num">(3,758)<span></span>
</td>
<td class="nump">3,671<span></span>
</td>
<td class="num">(10,738)<span></span>
</td>
<td class="nump">29,784<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="num">(95,159)<span></span>
</td>
<td class="num">(28,755)<span></span>
</td>
<td class="num">(141,725)<span></span>
</td>
<td class="num">(43,093)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit (note 6)</a></td>
<td class="nump">12,656<span></span>
</td>
<td class="nump">4,282<span></span>
</td>
<td class="nump">12,656<span></span>
</td>
<td class="nump">4,282<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(82,503)<span></span>
</td>
<td class="num">(24,473)<span></span>
</td>
<td class="num">(129,069)<span></span>
</td>
<td class="num">(38,811)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockDividendsAndOtherAdjustmentsAbstract', window );"><strong>Items applicable to preferred shares:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockDividendsAndOtherAdjustments', window );">Accrual of coupon on convertible preferred shares</a></td>
<td class="num">(2,792)<span></span>
</td>
<td class="num">(2,567)<span></span>
</td>
<td class="num">(8,269)<span></span>
</td>
<td class="num">(7,444)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss attributable to common shareholders (note 2)</a></td>
<td class="num">$ (85,295)<span></span>
</td>
<td class="num">$ (27,040)<span></span>
</td>
<td class="num">$ (137,338)<span></span>
</td>
<td class="num">$ (46,255)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net loss attributable to common shareholders, per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and dilutive (in USD per share)</a></td>
<td class="num">$ (1.50)<span></span>
</td>
<td class="num">$ (0.49)<span></span>
</td>
<td class="num">$ (2.43)<span></span>
</td>
<td class="num">$ (0.84)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_WeightedAverageNumberOfCommonSharesAbstract', window );"><strong>Weighted average number of common shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Basic and diluted (in shares)</a></td>
<td class="nump">56,850,172<span></span>
</td>
<td class="nump">55,421,504<span></span>
</td>
<td class="nump">56,469,358<span></span>
</td>
<td class="nump">55,241,284<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_IncreaseDecreaseInFairValueOfContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Fair Value Of Contingent Consideration Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_IncreaseDecreaseInFairValueOfContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_WeightedAverageNumberOfCommonSharesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average number of common shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_WeightedAverageNumberOfCommonSharesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450222&amp;loc=d3e30840-110895<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109240200&amp;loc=d3e30700-110894<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109240200&amp;loc=d3e30690-110894<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized and unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27405-111563<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(c),9(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=108376223&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=108376223&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68072869&amp;loc=d3e41242-110953<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the entity's proportionate share for the period of the net income (loss) of its investee (such as unconsolidated subsidiaries and joint ventures) to which the equity method of accounting is applied. This item includes income or expense related to stock-based compensation based on the investor's grant of stock to employees of an equity method investee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109238882&amp;loc=d3e38679-109324<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyLossInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of loss pertaining to the specified contingency that was charged against earnings in the period, including the effects of revisions in previously reported estimates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82911808&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyLossInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1377-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendsAndOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate value of preferred stock dividends and other adjustments necessary to derive net income apportioned to common stockholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1377-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendsAndOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendsAndOtherAdjustmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendsAndOtherAdjustmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6807089552">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accounts Payable and Accrued Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableTradeCurrent', window );">Trade accounts payable</a></td>
<td class="nump">$ 1,400<span></span>
</td>
<td class="nump">$ 3,192<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_AccruedResearchAndDevelopment', window );">Research and development accruals</a></td>
<td class="nump">4,112<span></span>
</td>
<td class="nump">2,716<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Professional fee accruals</a></td>
<td class="nump">1,177<span></span>
</td>
<td class="nump">871<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_AccruedPayrollCurrent', window );">Payroll accruals</a></td>
<td class="nump">1,509<span></span>
</td>
<td class="nump">2,341<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other accrued liabilities</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">309<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued liabilities</a></td>
<td class="nump">$ 8,199<span></span>
</td>
<td class="nump">$ 9,429<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_AccruedPayrollCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Payroll Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_AccruedPayrollCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_AccruedResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research and development accruals</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_AccruedResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableTradeCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableTradeCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6812912208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flow - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>OPERATING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (82,503)<span></span>
</td>
<td class="num">$ (24,473)<span></span>
</td>
<td class="num">$ (129,069)<span></span>
</td>
<td class="num">$ (38,811)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Items not involving cash:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income tax benefit</a></td>
<td class="num">(12,661)<span></span>
</td>
<td class="num">(4,282)<span></span>
</td>
<td class="num">(12,661)<span></span>
</td>
<td class="num">(4,282)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation</a></td>
<td class="nump">507<span></span>
</td>
<td class="nump">497<span></span>
</td>
<td class="nump">1,521<span></span>
</td>
<td class="nump">1,677<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Loss (gain) on sale of property and equipment</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(26)<span></span>
</td>
<td class="num">(11)<span></span>
</td>
<td class="num">(26)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">1,516<span></span>
</td>
<td class="nump">1,828<span></span>
</td>
<td class="nump">6,822<span></span>
</td>
<td class="nump">5,445<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossUnrealized', window );">Unrealized foreign exchange losses (gains)</a></td>
<td class="nump">24<span></span>
</td>
<td class="num">(131)<span></span>
</td>
<td class="num">(71)<span></span>
</td>
<td class="nump">795<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Change in fair value of contingent consideration</a></td>
<td class="num">(376)<span></span>
</td>
<td class="num">(5,608)<span></span>
</td>
<td class="num">(121)<span></span>
</td>
<td class="num">(6,263)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment of intangible assets</a></td>
<td class="nump">43,836<span></span>
</td>
<td class="nump">14,811<span></span>
</td>
<td class="nump">43,836<span></span>
</td>
<td class="nump">14,811<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairment of goodwill</a></td>
<td class="nump">22,471<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">22,471<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCosts', window );">Site consolidation non-cash portion</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">396<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnInvestments', window );">Gain on investment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(24,884)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfEquityInvestments', window );">Equity investment loss</a></td>
<td class="nump">3,512<span></span>
</td>
<td class="nump">2,838<span></span>
</td>
<td class="nump">11,497<span></span>
</td>
<td class="nump">2,838<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties', window );">Non-cash royalty revenue</a></td>
<td class="num">(979)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(979)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_NonCashRoyaltyExpenseRelatedToSaleOfFutureRoyalties', window );">Non-cash interest expense</a></td>
<td class="nump">1,106<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,106<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Net change in non-cash operating items:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(957)<span></span>
</td>
<td class="nump">784<span></span>
</td>
<td class="num">(1,057)<span></span>
</td>
<td class="num">(136)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="nump">1,080<span></span>
</td>
<td class="nump">109<span></span>
</td>
<td class="nump">1,839<span></span>
</td>
<td class="nump">1,017<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerAsset', window );">Accrued revenue</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">128<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued liabilities</a></td>
<td class="nump">538<span></span>
</td>
<td class="nump">1,094<span></span>
</td>
<td class="num">(1,320)<span></span>
</td>
<td class="num">(2,171)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(325)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,093)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInRestructuringReserve', window );">Restructuring accrual</a></td>
<td class="num">(138)<span></span>
</td>
<td class="num">(320)<span></span>
</td>
<td class="num">(917)<span></span>
</td>
<td class="nump">770<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities', window );">Other liabilities</a></td>
<td class="num">(446)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(541)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(23,470)<span></span>
</td>
<td class="num">(13,204)<span></span>
</td>
<td class="num">(57,655)<span></span>
</td>
<td class="num">(50,791)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>INVESTING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromInvestments', window );">Acquisition of short and long-term investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(48,025)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfRestrictedInvestments', window );">Disposition of short and long-term investments</a></td>
<td class="nump">16,410<span></span>
</td>
<td class="nump">24,590<span></span>
</td>
<td class="nump">87,675<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds from sale of property and equipment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">25<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="nump">25<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Acquisition of property and equipment</a></td>
<td class="num">(255)<span></span>
</td>
<td class="num">(237)<span></span>
</td>
<td class="num">(526)<span></span>
</td>
<td class="num">(911)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used) in investing activities</a></td>
<td class="nump">16,155<span></span>
</td>
<td class="nump">24,378<span></span>
</td>
<td class="nump">87,160<span></span>
</td>
<td class="num">(48,911)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>FINANCING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_ProceedsFromSaleOfFutureRoyaltiesNet', window );">Proceeds from sale of future royalties, net</a></td>
<td class="nump">18,549<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">18,549<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Promissory note repayment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(12,001)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Proceeds from sale of Series A Preferred Shares, net of issuance costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">66,265<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Issuance of common shares pursuant to the ATM</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,725<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Issuance of common shares pursuant to exercise of options</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">435<span></span>
</td>
<td class="nump">290<span></span>
</td>
<td class="nump">1,273<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">18,549<span></span>
</td>
<td class="nump">435<span></span>
</td>
<td class="nump">23,564<span></span>
</td>
<td class="nump">55,537<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of foreign exchange rate changes on cash and cash equivalents</a></td>
<td class="num">(24)<span></span>
</td>
<td class="nump">131<span></span>
</td>
<td class="nump">71<span></span>
</td>
<td class="num">(795)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Increase in cash and cash equivalents</a></td>
<td class="nump">11,210<span></span>
</td>
<td class="nump">11,740<span></span>
</td>
<td class="nump">53,140<span></span>
</td>
<td class="num">(44,960)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, beginning of period</a></td>
<td class="nump">78,872<span></span>
</td>
<td class="nump">10,193<span></span>
</td>
<td class="nump">36,942<span></span>
</td>
<td class="nump">66,893<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, end of period</a></td>
<td class="nump">90,082<span></span>
</td>
<td class="nump">21,933<span></span>
</td>
<td class="nump">90,082<span></span>
</td>
<td class="nump">21,933<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Non-cash transactions:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsPreferredStockCash', window );">Preferred shares dividends accrued</a></td>
<td class="num">(2,792)<span></span>
</td>
<td class="num">(2,567)<span></span>
</td>
<td class="num">(8,269)<span></span>
</td>
<td class="num">(7,444)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContributionOfProperty', window );">Investment in Genevant</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 24,665<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_NonCashRoyaltyExpenseRelatedToSaleOfFutureRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non Cash Royalty Expense Related To Sale Of Future Royalties</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_NonCashRoyaltyExpenseRelatedToSaleOfFutureRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non Cash Royalty Revenue Related To Sale Of Future Royalties</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_ProceedsFromSaleOfFutureRoyaltiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Sale Of Future Royalties, Net</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_ProceedsFromSaleOfFutureRoyaltiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContributionOfProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of property contributed in noncash investing and financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContributionOfProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPreferredStockCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid preferred stock dividends declared with the form of settlement in cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 405<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6957935&amp;loc=d3e64057-112817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPreferredStockCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossUnrealized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109240200&amp;loc=d3e30690-110894<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109240200&amp;loc=d3e30700-110894<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450222&amp;loc=d3e30840-110895<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossUnrealized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized and unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27405-111563<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(c),9(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfEquityInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the carrying value and the sale price of equity securities, not separately or otherwise categorized as trading or available-for-sale. This element includes investments in which the entity holds a small ownership stake (generally, less than 20% of the shares outstanding) and cannot exert significant influence.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfEquityInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=108376223&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=108376223&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInRestructuringReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the carrying amount (including both current and noncurrent portions of the accrual) of the liability pertaining to the exit from or disposal of business activities or restructuring pursuant to a duly authorized plan, excluding costs or losses pertaining to an entity newly acquired in a business combination and to asset retirement obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInRestructuringReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net cash paid (received) associated with the acquisition or disposal of all investments, including securities and other assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfRestrictedInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale of investments that are pledged or subject to withdrawal restrictions during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfRestrictedInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of stock options granted under share-based compensation arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after cash payment, of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6814063200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity and Stock-based Compensation (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="5">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2018</div></th>
<th class="th"><div>Oct. 31, 2017</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of shares under the agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,725,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common shares pursuant to the agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,477,000<span></span>
</td>
<td class="nump">$ 2,248,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 66,265,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Proceeds from sale of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 66,265,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_PreferredStockMember', window );">Preferred Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,164,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=abus_RoivantSciencesLtdMember', window );">Roivant Sciences Ltd</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_NoncontrollingInterestOwnershipPercentageByNoncontrollingOwnersAfterConversion', window );">Ownership percentage by noncontrolling owners after conversion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_NoncontrollingInterestMaximumOwnershipPercentagebyNoncontrollingOwners', window );">Maximum ownership percentage by noncontrolling owners</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Proceeds from sale of stock</a></td>
<td class="nump">$ 66,400,000<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=abus_RoivantSciencesLtdMember', window );">Roivant Sciences Ltd | Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common shares pursuant to the agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 116,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockDividendRatePercentage', window );">Preferred stock dividend rate as a percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stated value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_ConvertiblePreferredStockSharesOfCommonStockIssueduponConversion', window );">Number of common shares to be issued upon conversion of convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_NoncontrollingInterestInvestmentCommitmentPeriod', window );">Investment commitment period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=abus_OpenMarketSaleAgreementMember', window );">Open Market Sale Agreement | Jefferies LLC | Common Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesSubscriptions', window );">Aggregate sale price of common shares under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued under agreement (in sales)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,208,090<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of shares under the agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_ConvertiblePreferredStockSharesOfCommonStockIssueduponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Convertible Preferred Stock, Shares Of Common Stock Issued upon Conversion</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_ConvertiblePreferredStockSharesOfCommonStockIssueduponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_NoncontrollingInterestInvestmentCommitmentPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Noncontrolling Interest, Investment Commitment Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_NoncontrollingInterestInvestmentCommitmentPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_NoncontrollingInterestMaximumOwnershipPercentagebyNoncontrollingOwners">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Noncontrolling Interest, Maximum Ownership Percentage by Noncontrolling Owners</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_NoncontrollingInterestMaximumOwnershipPercentagebyNoncontrollingOwners</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_NoncontrollingInterestOwnershipPercentageByNoncontrollingOwnersAfterConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Noncontrolling Interest, Ownership Percentage By Noncontrolling Owners After Conversion</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_NoncontrollingInterestOwnershipPercentageByNoncontrollingOwnersAfterConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesSubscriptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Monetary value of common stock allocated to investors to buy shares of a new issue of common stock before they are offered to the public. When stock is sold on a subscription basis, the issuer does not initially receive the total proceeds. In general, the issuer does not issue the shares to the investor until it receives the entire proceeds.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=65888546&amp;loc=d3e21300-112643<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesSubscriptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendRatePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage rate used to calculate dividend payments on preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendRatePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=abus_RoivantSciencesLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=abus_RoivantSciencesLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=abus_OpenMarketSaleAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=abus_OpenMarketSaleAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=abus_JefferiesLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=abus_JefferiesLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6811056080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies - Narrative (Details)<br> $ in Thousands, shares in Millions</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($) </div>
<div>subsidiary </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2018 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 01, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_WhollyOwnedSubsidiariesIncludedinFinancialStatements', window );">Wholly-owed subsidiaries | subsidiary</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive common shares excluded from calculation of loss per common share (in shares) | shares</a></td>
<td class="nump">28.2<span></span>
</td>
<td class="nump">24.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">ROU assets</a></td>
<td class="nump">$ 2,817<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,200<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease liabilities</a></td>
<td class="nump">$ 3,143<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,100<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_WhollyOwnedSubsidiariesIncludedinFinancialStatements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the number of wholly owned subsidiaries included in the reporting of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_WhollyOwnedSubsidiariesIncludedinFinancialStatements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6632406032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transaction<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related party transactions</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Related Party Transactions</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Through the first quarter of 2019, the Company purchased certain research and development services from Genevant.  These services were billed at agreed hourly rates and were reflective of market rates for such services.&#160; The total cost of these services for the </font><font style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2019</font><font style="font-family:inherit;font-size:10pt;"> was </font><font style="font-family:inherit;font-size:10pt;">$33 thousand</font><font style="font-family:inherit;font-size:10pt;">.  There were </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> such costs incurred during the second and third quarter of 2019. The total cost of these services was </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$0.2 million</font><font style="font-family:inherit;font-size:10pt;"> for the </font><font style="font-family:inherit;font-size:10pt;">three and nine months ended September 30, 2018</font><font style="font-family:inherit;font-size:10pt;">, respectively, and are included in the Condensed Consolidated Statements of Operations under research and development. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Conversely, Genevant purchased certain administrative and transitional services from the Company totaling </font><font style="font-family:inherit;font-size:10pt;">$40 thousand</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$284 thousand</font><font style="font-family:inherit;font-size:10pt;"> for the </font><font style="font-family:inherit;font-size:10pt;">three and nine months ended September 30, 2019</font><font style="font-family:inherit;font-size:10pt;">, respectively. The total income from these services was </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$0.3 million</font><font style="font-family:inherit;font-size:10pt;"> for the </font><font style="font-family:inherit;font-size:10pt;">three and nine months ended September 30, 2018</font><font style="font-family:inherit;font-size:10pt;">, which were netted against research and development expenses in the Condensed Consolidated Statements of Operations. In addition, Genevant had a sublease for </font><font style="font-family:inherit;font-size:10pt;">17,900</font><font style="font-family:inherit;font-size:10pt;"> square feet in the Company's Burnaby facility. Sublease income from Genevant was </font><font style="font-family:inherit;font-size:10pt;">$21 thousand</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;"> for the </font><font style="font-family:inherit;font-size:10pt;">three and nine months ended September 30, 2019</font><font style="font-family:inherit;font-size:10pt;">, respectively, and was netted against site consolidation costs and lease liability (see notes 7 and 8).  The Company&#8217;s Burnaby facility lease and the corresponding sublease to Genevant expired on July 31, 2019.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6786238800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of Lease Terms, Discount Rate and Supplemental Cash Flow Information</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted average remaining lease term and discount rate were as follows:</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:8px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2" rowspan="1"></td></tr><tr><td style="width:76%;" rowspan="1" colspan="1"></td><td style="width:24%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">As of September 30, 2019</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted-average remaining lease term (years)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.3</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted average discount rate</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.9%</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company did not include options to extend its lease terms as part of its ROU asset and lease liabilities. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:20px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Supplemental cash flow information related to the Company's operating leases was as follows:</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:68%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash paid for amounts included in the measurement of lease liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">921</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Maturities of Lease Liabilities</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Maturities of lease liabilities were as follows:</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:78%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:20%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">As of September 30, 2019</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">October through December 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">188</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2020</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">657</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2021</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">677</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2022</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">581</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2023</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">598</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Thereafter</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,039</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total Lease Payments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,740</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less: interest</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,268</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Present value of lease payments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,472</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.19.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>169</ContextCount>
  <ElementCount>301</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>40</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>11</UnitCount>
  <MyReports>
    <Report instance="abus-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arbutusbio.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="abus-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001000 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arbutusbio.com/role/CondensedConsolidatedBalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="abus-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1001501 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arbutusbio.com/role/CondensedConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="abus-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1002000 - Statement - Condensed Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arbutusbio.com/role/CondensedConsolidatedStatementsOfOperations</Role>
      <ShortName>Condensed Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="abus-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1003000 - Statement - Condensed Consolidated Statements of Comprehensive Income (Loss) Condensed Consolidated Statements of Comprehensive Income (Loss)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arbutusbio.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLossCondensedConsolidatedStatementsOfComprehensiveIncomeLoss</Role>
      <ShortName>Condensed Consolidated Statements of Comprehensive Income (Loss) Condensed Consolidated Statements of Comprehensive Income (Loss)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="abus-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1004000 - Statement - Condensed Consolidated Statement of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arbutusbio.com/role/CondensedConsolidatedStatementOfStockholdersEquity</Role>
      <ShortName>Condensed Consolidated Statement of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="abus-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1004501 - Statement - Condensed Consolidated Statement of Stockholders' Equity (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arbutusbio.com/role/CondensedConsolidatedStatementOfStockholdersEquityParenthetical</Role>
      <ShortName>Condensed Consolidated Statement of Stockholders' Equity (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="abus-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>1005000 - Statement - Condensed Consolidated Statements of Cash Flow</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arbutusbio.com/role/CondensedConsolidatedStatementsOfCashFlow</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flow</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="abus-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2101100 - Disclosure - Nature of Business and Future Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arbutusbio.com/role/NatureOfBusinessAndFutureOperations</Role>
      <ShortName>Nature of Business and Future Operations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="abus-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2102100 - Disclosure - Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arbutusbio.com/role/SignificantAccountingPolicies</Role>
      <ShortName>Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="abus-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2103100 - Disclosure - Fair Value of Financial Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arbutusbio.com/role/FairValueOfFinancialInstruments</Role>
      <ShortName>Fair Value of Financial Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="abus-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2104100 - Disclosure - Equity Method Investment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arbutusbio.com/role/EquityMethodInvestment</Role>
      <ShortName>Equity Method Investment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="abus-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2105100 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arbutusbio.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="abus-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2106100 - Disclosure - Intangible Assets and Goodwill</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arbutusbio.com/role/IntangibleAssetsAndGoodwill</Role>
      <ShortName>Intangible Assets and Goodwill</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="abus-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2107100 - Disclosure - Accounts Payable and Accrued Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arbutusbio.com/role/AccountsPayableAndAccruedLiabilities</Role>
      <ShortName>Accounts Payable and Accrued Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="abus-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2108100 - Disclosure - Site Consolidation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arbutusbio.com/role/SiteConsolidation</Role>
      <ShortName>Site Consolidation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="abus-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2109100 - Disclosure - Sale of Future Royalties</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arbutusbio.com/role/SaleOfFutureRoyalties</Role>
      <ShortName>Sale of Future Royalties</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="abus-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2110100 - Disclosure - Contingencies and Commitments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arbutusbio.com/role/ContingenciesAndCommitments</Role>
      <ShortName>Contingencies and Commitments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="abus-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2111100 - Disclosure - Collaborations, Contracts and Licensing Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arbutusbio.com/role/CollaborationsContractsAndLicensingAgreements</Role>
      <ShortName>Collaborations, Contracts and Licensing Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="abus-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2112100 - Disclosure - Stockholders' Equity and Stock-based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arbutusbio.com/role/StockholdersEquityAndStockBasedCompensation</Role>
      <ShortName>Stockholders' Equity and Stock-based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="abus-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2113100 - Disclosure - Related Party Transaction</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arbutusbio.com/role/RelatedPartyTransaction</Role>
      <ShortName>Related Party Transaction</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="abus-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2202201 - Disclosure - Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arbutusbio.com/role/SignificantAccountingPoliciesPolicies</Role>
      <ShortName>Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://arbutusbio.com/role/SignificantAccountingPolicies</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="abus-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2302302 - Disclosure - Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arbutusbio.com/role/SignificantAccountingPoliciesTables</Role>
      <ShortName>Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://arbutusbio.com/role/SignificantAccountingPolicies</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="abus-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2303301 - Disclosure - Fair Value of Financial Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arbutusbio.com/role/FairValueOfFinancialInstrumentsTables</Role>
      <ShortName>Fair Value of Financial Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://arbutusbio.com/role/FairValueOfFinancialInstruments</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="abus-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2305301 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arbutusbio.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://arbutusbio.com/role/Leases</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="abus-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2307301 - Disclosure - Accounts Payable and Accrued Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arbutusbio.com/role/AccountsPayableAndAccruedLiabilitiesTables</Role>
      <ShortName>Accounts Payable and Accrued Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://arbutusbio.com/role/AccountsPayableAndAccruedLiabilities</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="abus-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2308301 - Disclosure - Site Consolidation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arbutusbio.com/role/SiteConsolidationTables</Role>
      <ShortName>Site Consolidation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://arbutusbio.com/role/SiteConsolidation</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="abus-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2309301 - Disclosure - Sale of Future Royalties (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arbutusbio.com/role/SaleOfFutureRoyaltiesTables</Role>
      <ShortName>Sale of Future Royalties (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://arbutusbio.com/role/SaleOfFutureRoyalties</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="abus-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2402403 - Disclosure - Significant Accounting Policies - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arbutusbio.com/role/SignificantAccountingPoliciesNarrativeDetails</Role>
      <ShortName>Significant Accounting Policies - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="abus-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2402404 - Disclosure - Significant Accounting Policies - Schedule of Computation of Basic and Diluted Income (Loss) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arbutusbio.com/role/SignificantAccountingPoliciesScheduleOfComputationOfBasicAndDilutedIncomeLossDetails</Role>
      <ShortName>Significant Accounting Policies - Schedule of Computation of Basic and Diluted Income (Loss) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="abus-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2403402 - Disclosure - Fair Value of Financial Instruments - Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arbutusbio.com/role/FairValueOfFinancialInstrumentsAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails</Role>
      <ShortName>Fair Value of Financial Instruments - Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="abus-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2403403 - Disclosure - Fair Value of Financial Instruments - Changes in Fair Value of Liabilities-Classified as Stock Option (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arbutusbio.com/role/FairValueOfFinancialInstrumentsChangesInFairValueOfLiabilitiesClassifiedAsStockOptionDetails</Role>
      <ShortName>Fair Value of Financial Instruments - Changes in Fair Value of Liabilities-Classified as Stock Option (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="abus-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2403404 - Disclosure - Fair Value of Financial Instruments - Changes in Fair Value of Contingent Consideration (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arbutusbio.com/role/FairValueOfFinancialInstrumentsChangesInFairValueOfContingentConsiderationDetails</Role>
      <ShortName>Fair Value of Financial Instruments - Changes in Fair Value of Contingent Consideration (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="abus-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2404401 - Disclosure - Equity Method Investment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arbutusbio.com/role/EquityMethodInvestmentDetails</Role>
      <ShortName>Equity Method Investment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://arbutusbio.com/role/EquityMethodInvestment</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="abus-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2405402 - Disclosure - Leases - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arbutusbio.com/role/LeasesNarrativeDetails</Role>
      <ShortName>Leases - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="abus-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2405403 - Disclosure - Leases - Weighted Average Remaining Lease Term and Discount Rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arbutusbio.com/role/LeasesWeightedAverageRemainingLeaseTermAndDiscountRateDetails</Role>
      <ShortName>Leases - Weighted Average Remaining Lease Term and Discount Rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="abus-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2405404 - Disclosure - Leases - Supplemental Cash Flow Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arbutusbio.com/role/LeasesSupplementalCashFlowInformationDetails</Role>
      <ShortName>Leases - Supplemental Cash Flow Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="abus-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2405405 - Disclosure - Leases - Maturities of Lease Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arbutusbio.com/role/LeasesMaturitiesOfLeaseLiabilitiesDetails</Role>
      <ShortName>Leases - Maturities of Lease Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="abus-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2406401 - Disclosure - Intangible Assets and Goodwill (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arbutusbio.com/role/IntangibleAssetsAndGoodwillDetails</Role>
      <ShortName>Intangible Assets and Goodwill (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://arbutusbio.com/role/IntangibleAssetsAndGoodwill</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="abus-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2407402 - Disclosure - Accounts Payable and Accrued Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arbutusbio.com/role/AccountsPayableAndAccruedLiabilitiesDetails</Role>
      <ShortName>Accounts Payable and Accrued Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://arbutusbio.com/role/AccountsPayableAndAccruedLiabilitiesTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="abus-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2408402 - Disclosure - Site Consolidation - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arbutusbio.com/role/SiteConsolidationNarrativeDetails</Role>
      <ShortName>Site Consolidation - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="abus-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2408403 - Disclosure - Site Consolidation - Consolidation Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arbutusbio.com/role/SiteConsolidationConsolidationExpensesDetails</Role>
      <ShortName>Site Consolidation - Consolidation Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="abus-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2408404 - Disclosure - Site Consolidation - Reserve Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arbutusbio.com/role/SiteConsolidationReserveActivityDetails</Role>
      <ShortName>Site Consolidation - Reserve Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="abus-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2409402 - Disclosure - Sale of Future Royalties - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arbutusbio.com/role/SaleOfFutureRoyaltiesNarrativeDetails</Role>
      <ShortName>Sale of Future Royalties - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="abus-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2409403 - Disclosure - Sale of Future Royalties - Liability Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arbutusbio.com/role/SaleOfFutureRoyaltiesLiabilityActivityDetails</Role>
      <ShortName>Sale of Future Royalties - Liability Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="abus-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2410401 - Disclosure - Contingencies and Commitments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arbutusbio.com/role/ContingenciesAndCommitmentsDetails</Role>
      <ShortName>Contingencies and Commitments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://arbutusbio.com/role/ContingenciesAndCommitments</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="abus-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2411401 - Disclosure - Collaborations, Contracts and Licensing Agreements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arbutusbio.com/role/CollaborationsContractsAndLicensingAgreementsDetails</Role>
      <ShortName>Collaborations, Contracts and Licensing Agreements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://arbutusbio.com/role/CollaborationsContractsAndLicensingAgreements</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="abus-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2412401 - Disclosure - Stockholders' Equity and Stock-based Compensation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arbutusbio.com/role/StockholdersEquityAndStockBasedCompensationDetails</Role>
      <ShortName>Stockholders' Equity and Stock-based Compensation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://arbutusbio.com/role/StockholdersEquityAndStockBasedCompensation</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="abus-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2413401 - Disclosure - Related Party Transaction (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arbutusbio.com/role/RelatedPartyTransactionDetails</Role>
      <ShortName>Related Party Transaction (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://arbutusbio.com/role/RelatedPartyTransaction</ParentRole>
      <Position>49</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>abus-20190930.xml</File>
    <File>abus-20190930.xsd</File>
    <File>abus-20190930_cal.xml</File>
    <File>abus-20190930_def.xml</File>
    <File>abus-20190930_lab.xml</File>
    <File>abus-20190930_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/srt/2018-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2018-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2018-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6641226384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Business and Future Operations<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Nature of business and future operations</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Nature of business and future operations</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Arbutus Biopharma Corporation (the &#8220;Company&#8221; or &#8220;Arbutus&#8221;) is a biopharmaceutical business dedicated to discovering, developing, and commercializing a cure for patients suffering from chronic hepatitis B infection, a disease of the liver caused by the hepatitis B virus (&#8220;HBV&#8221;). To pursue its strategy of developing a curative combination regimen, the Company has assembled a pipeline of multiple drug candidates with differing and complementary mechanisms of action targeting HBV.  These include  AB-729, the Company's subcutaneously-delivered RNA interference ("RNAi") therapeutic candidate currently in a Phase 1a/1b clinical trial, AB-452, the Company's lead oral HBV RNA destabilizer candidate currently in pre-clinical testing, next-generation oral capsid inhibitor compounds, and compounds that inhibit PD-L1. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The success of the Company is dependent on obtaining the necessary regulatory approvals to bring its products to market and achieving profitable operations. The Company's research and development activities and commercialization of its products are dependent on its ability to successfully complete these activities and to obtain adequate financing through a combination of financing activities and operations. It is not possible to predict either the outcome of the Company's existing or future research and development programs or the Company&#8217;s ability to continue to fund these programs in the future.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6813952496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transaction (Details) - Genevant Sciences Corporation - Equity Method Investee<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Sep. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Sep. 30, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=abus_GenevantSciencesCorporationMember', window );">Research and development services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty', window );">Expenses from transactions with related party</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">$ 33,000<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=abus_GenevantSciencesCorporationMember', window );">Administrative And Transitional Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromRelatedParties', window );">Income from related party</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">284,000<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=abus_GenevantSciencesCorporationMember', window );">Sublease, Burnaby Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromRelatedParties', window );">Income from related party</a></td>
<td class="nump">$ 21,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_NetRentableAreaSublease', window );">Area of sublease facility | ft&#178;</a></td>
<td class="nump">17,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_NetRentableAreaSublease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net Rentable Area, Sublease</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_NetRentableAreaSublease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue, fees and commissions earned from transactions between (a) a parent company and its subsidiaries; (b) subsidiaries of a common parent; (c) an entity and trusts for the benefit of employees, for example, but not limited to, pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management; (d) an entity and its principal, owners, management, or members of their immediate families; and (e) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07.1(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873854&amp;loc=SL114874292-224272<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=abus_GenevantSciencesCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=abus_GenevantSciencesCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_EquityMethodInvesteeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_EquityMethodInvesteeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abus_ResearchAndDevelopmentServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abus_ResearchAndDevelopmentServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abus_AdministrativeAndTransitionalServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abus_AdministrativeAndTransitionalServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abus_SubleaseBurnabyFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abus_SubleaseBurnabyFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6764981152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Sale of Future Royalties - Liability Activity (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_LiabilityRelatedToSaleOfFutureRoyaltiesRollForward', window );"><strong>Liability Related To Sale Of Future Royalties [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_LiabilityRelatedToSaleOfFutureRoyalties', window );">Net liability related to sale of future royalties - beginning balance</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_LiabilityFromSaleOfFutureRoyaltiesAdditions', window );">Initial recognition of liability</a></td>
<td class="nump">30,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_LiabilityFromSaleOfFutureRoyaltiesDiscountsAndIssuanceCosts', window );">Debt discount and issuance costs</a></td>
<td class="num">(11,451)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_LiabilityFromSaleOfFutureRoyaltiesNonCashRoyaltyIncome', window );">Non-cash royalty revenue</a></td>
<td class="num">(979)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_LiabilityFromSaleOfFutureRoyaltiesNonCashExpense', window );">Non-cash interest expense</a></td>
<td class="nump">1,106<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_LiabilityRelatedToSaleOfFutureRoyalties', window );">Net liability related to sale of future royalties - ending balance</a></td>
<td class="nump">$ 18,675<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_LiabilityFromSaleOfFutureRoyaltiesAdditions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Liability From Sale Of Future Royalties, Additions</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_LiabilityFromSaleOfFutureRoyaltiesAdditions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_LiabilityFromSaleOfFutureRoyaltiesDiscountsAndIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Liability From Sale Of Future Royalties, Discounts And Issuance Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_LiabilityFromSaleOfFutureRoyaltiesDiscountsAndIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_LiabilityFromSaleOfFutureRoyaltiesNonCashExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Liability From Sale Of Future Royalties, Non Cash Expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_LiabilityFromSaleOfFutureRoyaltiesNonCashExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_LiabilityFromSaleOfFutureRoyaltiesNonCashRoyaltyIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Liability From Sale Of Future Royalties, Non Cash Royalty Income</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_LiabilityFromSaleOfFutureRoyaltiesNonCashRoyaltyIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_LiabilityRelatedToSaleOfFutureRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Liability Related To Sale Of Future Royalties</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_LiabilityRelatedToSaleOfFutureRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_LiabilityRelatedToSaleOfFutureRoyaltiesRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Liability Related To Sale Of Future Royalties [Roll Forward]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_LiabilityRelatedToSaleOfFutureRoyaltiesRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6825243008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Comprehensive Income (Loss) Condensed Consolidated Statements of Comprehensive Income (Loss) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (82,503)<span></span>
</td>
<td class="num">$ (24,473)<span></span>
</td>
<td class="num">$ (129,069)<span></span>
</td>
<td class="num">$ (38,811)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive income (loss):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Share of other comprehensive income (loss) of equity method investment (note 4)</a></td>
<td class="nump">27<span></span>
</td>
<td class="num">(12)<span></span>
</td>
<td class="num">(47)<span></span>
</td>
<td class="num">(12)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (82,476)<span></span>
</td>
<td class="num">$ (24,485)<span></span>
</td>
<td class="num">$ (129,116)<span></span>
</td>
<td class="num">$ (38,823)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=d3e557-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6824312176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Oct. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_DocumentAndEntityInformationAbstract', window );"><strong>Document and Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Arbutus Biopharma Corp<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001447028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56,850,172<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_DocumentAndEntityInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Document and Entity Information [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_DocumentAndEntityInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated), (5) Smaller Reporting Accelerated Filer or (6) Smaller Reporting Company and Large Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if company meets the shell company criteria: a company with no or nominal operations, and with no or nominal assets or assets consisting solely of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a smaller reporting company with both a public float and revenues of less than $75 million.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6655755936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Site Consolidation - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">21 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Site consolidation (note 8)</a></td>
<td class="nump">$ 182<span></span>
</td>
<td class="num">$ (492)<span></span>
</td>
<td class="nump">$ 33<span></span>
</td>
<td class="nump">$ 3,710<span></span>
</td>
<td class="nump">$ 4,800<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_FacilityClosingMember', window );">Facility closing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostExpectedCost1', window );">Expected total cost of site consolidation</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Site consolidation (note 8)</a></td>
<td class="num">$ (49)<span></span>
</td>
<td class="num">$ (690)<span></span>
</td>
<td class="num">$ (396)<span></span>
</td>
<td class="nump">$ 311<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostExpectedCost1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount expected to be recognized in earnings for the specified restructuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostExpectedCost1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_FacilityClosingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_FacilityClosingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6654823296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity and Stock-based Compensation<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' equity and stock-based compensation</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">  Stockholders' equity and stock-based compensation</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Open Market Sale Agreement</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In December&#160;2018, the Company entered into an Open Market Sale Agreement&#160;(&#8220;Sale Agreement&#8221;) with Jefferies LLC, under which it may issue and sell common shares, from time to time, for an aggregate sales price of up to </font><font style="font-family:inherit;font-size:10pt;">$50.0 million</font><font style="font-family:inherit;font-size:10pt;">. For the </font><font style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2019</font><font style="font-family:inherit;font-size:10pt;">, the Company issued </font><font style="font-family:inherit;font-size:10pt;">1,208,090</font><font style="font-family:inherit;font-size:10pt;"> common shares pursuant to the Sale Agreement, resulting in gross proceeds of approximately </font><font style="font-family:inherit;font-size:10pt;">$5.2 million</font><font style="font-family:inherit;font-size:10pt;">. There were </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> shares issued during the </font><font style="font-family:inherit;font-size:10pt;">three months ended September 30, 2019</font><font style="font-family:inherit;font-size:10pt;"> under the Sale Agreement.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Series A participating convertible preferred shares </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In October 2017, the Company entered into a subscription agreement with Roivant for the sale of </font><font style="font-family:inherit;font-size:10pt;">1,164,000</font><font style="font-family:inherit;font-size:10pt;"> Preferred Shares for gross proceeds of </font><font style="font-family:inherit;font-size:10pt;">$116.4</font><font style="font-family:inherit;font-size:10pt;">&#160;million. These Preferred Shares are non-voting and accrue an </font><font style="font-family:inherit;font-size:10pt;">8.75%</font><font style="font-family:inherit;font-size:10pt;"> per annum coupon in the form of additional Preferred Shares, compounded annually, until October 16, 2021, at which time all the Preferred Shares will be subject to mandatory conversion into common shares (subject to limited exceptions in the event of certain fundamental corporate transactions relating to Arbutus&#8217; capital structure or assets, which would permit earlier conversion at Roivant&#8217;s option). The conversion price is </font><font style="font-family:inherit;font-size:10pt;">$7.13</font><font style="font-family:inherit;font-size:10pt;">&#160;per share, which will result in the Preferred Shares being converted into approximately </font><font style="font-family:inherit;font-size:10pt;">23</font><font style="font-family:inherit;font-size:10pt;"> million common shares. After conversion of the Preferred Shares into common shares, based on the number of common shares outstanding </font><font style="font-family:inherit;font-size:10pt;">as of September 30, 2019</font><font style="font-family:inherit;font-size:10pt;">, Roivant would hold&#160;approximately </font><font style="font-family:inherit;font-size:10pt;">49%</font><font style="font-family:inherit;font-size:10pt;"> of the Company's common shares. Roivant agreed to a </font><font style="font-family:inherit;font-size:10pt;">four</font><font style="font-family:inherit;font-size:10pt;"> year lock-up period for this investment and its existing holdings in the Company. Roivant also agreed to a </font><font style="font-family:inherit;font-size:10pt;">four</font><font style="font-family:inherit;font-size:10pt;"> year standstill whereby Roivant will not acquire greater than&#160;</font><font style="font-family:inherit;font-size:10pt;">49.99%</font><font style="font-family:inherit;font-size:10pt;">&#160;of the Company's common shares or securities convertible into common shares. The initial investment of&#160;</font><font style="font-family:inherit;font-size:10pt;">$50.0</font><font style="font-family:inherit;font-size:10pt;">&#160;million closed in October 2017, and the remaining amount of&#160;</font><font style="font-family:inherit;font-size:10pt;">$66.4</font><font style="font-family:inherit;font-size:10pt;"> million closed in January 2018 following regulatory and shareholder approvals.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company records the Preferred Shares wholly as equity under ASC 480, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Distinguishing Liabilities From Equity,</font><font style="font-family:inherit;font-size:10pt;"> with no bifurcation of conversion feature from the host contract, given that the Preferred Shares cannot be cash settled and the redemption features are within the Company's control, which include a fixed conversion ratio with predetermined timing and proceeds. The Company accrues for the </font><font style="font-family:inherit;font-size:10pt;">8.75%</font><font style="font-family:inherit;font-size:10pt;"> per annum compounding coupon at each reporting period end date as an increase to preferred share capital, and an increase to deficit (see Condensed Consolidated Statement of Stockholders' Equity).</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6789213728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Assets and liabilities measured at fair value on a recurring basis</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table presents information about the Company&#8217;s assets and liabilities that are measured at fair value on a recurring basis, and indicates the fair value hierarchy of the valuation techniques used to determine such fair value:</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Level 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Level 2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Level 3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">As of September 30, 2019</font></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Assets</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">90,082</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">90,082</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Liabilities</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Liability-classified options</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">86</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">86</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contingent consideration</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,005</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,005</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,091</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,091</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_ChangesInFairValueofLiabilityOptionTableTextBlock', window );">Changes in fair value of liability option</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table presents the changes in fair value of the Company&#8217;s liability-classified stock option awards:</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:38%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Liability at beginning of the period</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Fair value of liability-classified options exercised in the period</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Increase (decrease) in fair value of liability</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Liability at end of the period</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nine months ended September 30, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,239</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,499</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,738</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nine months ended September 30, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">479</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(393</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">86</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock', window );">Schedule of changes in fair value of contingent consideration</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table presents the changes in fair value of the Company&#8217;s contingent consideration: </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:38%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Liability at beginning of the period</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Increase (decrease) in fair value of liability</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Liability at end of the period</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nine months ended September 30, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,424</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6,263</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,161</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nine months ended September 30, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,126</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(121</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,005</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_ChangesInFairValueofLiabilityOptionTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Changes In Fair Value of Liability Option [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_ChangesInFairValueofLiabilityOptionTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of contingent payment arrangements including the terms that will result in payment and the accounting treatment that will be followed if such contingencies occur, including the potential impact on earnings per share if contingencies are to be settled in common stock of the entity. The description also may include the period over which amounts are expected to be paid, and changes in the amount since the previous reporting period. This also includes contingent options and commitments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19190-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6610803392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Sale of Future Royalties (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureAbstract', window );"><strong>Other Liabilities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_LiabilitiesRelatedToSaleOfFutureRoyaltiesRollForwardTableTextBlock', window );">Schedule of activity related to the net liability from inception of the Agreement</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The table below shows the activity related to the net liability from inception of the Agreement through </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:68%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:30%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Nine Months Ended September 30, 2019</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net liability related to sale of future royalties - beginning balance</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Initial recognition of liability</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Debt discount and issuance costs</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(11,451</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-cash royalty revenue</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(979</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-cash interest expense</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,106</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net liability related to sale of future royalties - ending balance</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,675</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_LiabilitiesRelatedToSaleOfFutureRoyaltiesRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Liabilities Related To Sale Of Future Royalties Roll Forward</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_LiabilitiesRelatedToSaleOfFutureRoyaltiesRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6813257232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets and Goodwill (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems', window );"><strong>Indefinite-lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Impairment of intangible assets</a></td>
<td class="nump">$ 43,836,000<span></span>
</td>
<td class="nump">$ 14,811,000<span></span>
</td>
<td class="nump">$ 43,836,000<span></span>
</td>
<td class="nump">$ 14,811,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 43,836,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairment of goodwill</a></td>
<td class="nump">22,471,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">22,471,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,471,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=abus_InProcessResearchandDevelopmentcccDNASterilizersMember', window );">IPR&amp;D &#8211; cccDNA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems', window );"><strong>Indefinite-lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Impairment of intangible assets</a></td>
<td class="nump">43,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability', window );">Tax benefit related to decrease in deferred tax liability for indefinite delay of further development) Liability</a></td>
<td class="nump">$ 12,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=77989000&amp;loc=SL49117168-202975<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=108376223&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=108376223&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income tax expense (benefit) from continuing operations attributable to an adjustment of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=abus_InProcessResearchandDevelopmentcccDNASterilizersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=abus_InProcessResearchandDevelopmentcccDNASterilizersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6814172960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Narrative (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($) </div>
<div>lease </div>
<div>renewal_option</div>
</th>
<th class="th">
<div>Sep. 30, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_LesseeOperatingLeaseNumberofLeases', window );">Number of leases | lease</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Total operating lease expense</a></td>
<td class="nump">$ 1.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_FixedLeaseCost', window );">Fixed lease payments</a></td>
<td class="nump">0.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease costs</a></td>
<td class="nump">0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_StrightlineFixedLeaseCost', window );">Straight-line fixed expenses leases</a></td>
<td class="nump">0.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubleaseIncome', window );">Sublease income</a></td>
<td class="nump">$ 0.2<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseArrangementTypeAxis=abus_CorporateHeadquartersLocated701VeteransCircleWarminsterPennsylvaniaMember', window );">Corporate Headquarters Located 701 Veterans Circle, Warminster, Pennsylvania</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_LesseeOperatingLeaseNumberOfRenewalOptions', window );">Number of renewal options | renewal_option</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LessorOperatingLeaseRenewalTerm', window );">Lease renewal term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDiscountRate', window );">Incremental borrowing rate</a></td>
<td class="nump">9.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseArrangementTypeAxis=abus_OfficesLocatedat626JacksonvilleRd.WarminsterPennsylvaniaMember', window );">Offices Located at 626 Jacksonville Rd., Warminster, Pennsylvania [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDiscountRate', window );">Incremental borrowing rate</a></td>
<td class="nump">7.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseArrangementTypeAxis=abus_SubleaseBurnabyFacilityMember', window );">Sublease, Burnaby Facility | Genevant Sciences Corporation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDiscountRate', window );">Incremental borrowing rate</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_FixedLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fixed Lease, Cost</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_FixedLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_LesseeOperatingLeaseNumberOfRenewalOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Number Of Renewal Options</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_LesseeOperatingLeaseNumberOfRenewalOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_LesseeOperatingLeaseNumberofLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Number of Leases</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_LesseeOperatingLeaseNumberofLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_StrightlineFixedLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stright-line Fixed Lease, Cost</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_StrightlineFixedLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Discount rate used by lessee to determine present value of operating lease payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessor's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888428&amp;loc=SL77919359-209981<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubleaseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of sublease income excluding finance and operating lease expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubleaseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseArrangementTypeAxis=abus_CorporateHeadquartersLocated701VeteransCircleWarminsterPennsylvaniaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseArrangementTypeAxis=abus_CorporateHeadquartersLocated701VeteransCircleWarminsterPennsylvaniaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseArrangementTypeAxis=abus_OfficesLocatedat626JacksonvilleRd.WarminsterPennsylvaniaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseArrangementTypeAxis=abus_OfficesLocatedat626JacksonvilleRd.WarminsterPennsylvaniaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseArrangementTypeAxis=abus_SubleaseBurnabyFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseArrangementTypeAxis=abus_SubleaseBurnabyFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=abus_GenevantSciencesCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=abus_GenevantSciencesCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6826233232">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value of Financial Instruments - Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent consideration (notes 3 and 10)</a></td>
<td class="nump">$ 3,005<span></span>
</td>
<td class="nump">$ 3,126<span></span>
</td>
<td class="nump">$ 4,161<span></span>
</td>
<td class="nump">$ 10,424<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">90,082<span></span>
</td>
<td class="nump">36,942<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87,675<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">124,617<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_EmployeeStockOptionsLiabilityClassifiedOutstandingFairValueDisclosure', window );">Liability-classified options</a></td>
<td class="nump">86<span></span>
</td>
<td class="nump">479<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent consideration (notes 3 and 10)</a></td>
<td class="nump">3,005<span></span>
</td>
<td class="nump">3,126<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total Liabilities</a></td>
<td class="nump">3,091<span></span>
</td>
<td class="nump">3,605<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">90,082<span></span>
</td>
<td class="nump">36,942<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87,675<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">124,617<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_EmployeeStockOptionsLiabilityClassifiedOutstandingFairValueDisclosure', window );">Liability-classified options</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent consideration (notes 3 and 10)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total Liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_EmployeeStockOptionsLiabilityClassifiedOutstandingFairValueDisclosure', window );">Liability-classified options</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent consideration (notes 3 and 10)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total Liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_EmployeeStockOptionsLiabilityClassifiedOutstandingFairValueDisclosure', window );">Liability-classified options</a></td>
<td class="nump">86<span></span>
</td>
<td class="nump">479<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent consideration (notes 3 and 10)</a></td>
<td class="nump">3,005<span></span>
</td>
<td class="nump">3,126<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total Liabilities</a></td>
<td class="nump">$ 3,091<span></span>
</td>
<td class="nump">$ 3,605<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_EmployeeStockOptionsLiabilityClassifiedOutstandingFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Employee Stock Options, Liability Classified, Outstanding, Fair Value Disclosure</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_EmployeeStockOptionsLiabilityClassifiedOutstandingFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI http://asc.fasb.org/extlink&amp;oid=6911338&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6620431936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Method Investment<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract', window );"><strong>Equity Method Investments and Joint Ventures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsDisclosureTextBlock', window );">Equity method investment</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;"> Equity method investment</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In April 2018, the Company entered into an agreement with Roivant Sciences Ltd. (&#8220;Roivant&#8221;), its largest shareholder, to launch Genevant, a company focused on the discovery, development, and commercialization of a broad range of RNA-based therapeutics enabled by the Company's lipid nanoparticle ("LNP") and ligand conjugate delivery technologies. The Company licensed exclusive rights to its LNP and ligand conjugate delivery platforms to Genevant for RNA-based applications outside of HBV. Genevant plans to develop products in-house and pursue industry partnerships to build a diverse pipeline of therapeutics across multiple modalities, including RNAi, mRNA, and gene editing. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the terms of the agreement, Roivant contributed $</font><font style="font-family:inherit;font-size:10pt;">37.5</font><font style="font-family:inherit;font-size:10pt;"> million in seed capital to Genevant.  The Company retained all rights to its LNP and conjugate delivery platforms for HBV, and is entitled to a tiered low single-digit royalty from Genevant on future sales of products enabled by the delivery platforms licensed to Genevant. The Company also retained the entirety of its royalty entitlement on the commercialization of Alnylam Pharmaceuticals Inc.'s ("Alnylam") ONPATTRO&#8482; (Patisiran/ALN-TTR02).  The Company recognized a non-cash gain of&#160;</font><font style="font-family:inherit;font-size:10pt;">$24.9 million</font><font style="font-family:inherit;font-size:10pt;"> in the second quarter of 2018 in connection with the equity interest received by Arbutus upon Genevant&#8217;s formation.  </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;">, the Company held an equity interest of approximately </font><font style="font-family:inherit;font-size:10pt;">40%</font><font style="font-family:inherit;font-size:10pt;"> of the common equity of Genevant and accounts for its interest in Genevant using the equity method.  The carrying value of the Company's interest in Genevant as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;"> was </font><font style="font-family:inherit;font-size:10pt;">$11.0 million</font><font style="font-family:inherit;font-size:10pt;">.  The basis difference between the Company&#8217;s carrying value in Genevant and the Company&#8217;s share of Genevant's net assets is attributed primarily to indefinite-lived in-process research and development ("IPR&amp;D") (the delivery technology transferred to Genevant).  For the </font><font style="font-family:inherit;font-size:10pt;">three and nine months ended September 30, 2019</font><font style="font-family:inherit;font-size:10pt;">, the Company recorded equity investment losses of </font><font style="font-family:inherit;font-size:10pt;">$3.5 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$11.5 million</font><font style="font-family:inherit;font-size:10pt;">, respectively, for its proportionate share of Genevant&#8217;s net loss, recorded on a one-quarter lag basis.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity method investments and joint ventures. Equity method investments are investments that give the investor the ability to exercise significant influence over the operating and financial policies of an investee. Joint ventures are entities owned and operated by a small group of businesses as a separate and specific business or project for the mutual benefit of the members of the group.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -URI http://asc.fasb.org/topic&amp;trid=2196965<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6638873808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Site Consolidation<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock', window );">Site consolidation</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Site consolidation </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In 2018, the Company substantially completed a site consolidation and organizational restructuring to align its HBV business in Warminster, PA, including a reduction of its global workforce and closure of its Burnaby facility. The Company estimates that the total expenses to complete the site consolidation will be approximately </font><font style="font-family:inherit;font-size:10pt;">$5.0</font><font style="font-family:inherit;font-size:10pt;"> million, of which </font><font style="font-family:inherit;font-size:10pt;">$4.8 million</font><font style="font-family:inherit;font-size:10pt;"> has been incurred as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;">.  Included in the site consolidation plan was the payment of one-time employee termination benefits, employee relocation costs, and site closure costs.  The Company ceased using its Burnaby facility as of June 30, 2018 and recognized the remaining committed cost, less sublease income under contract, in site consolidation expenses in 2018.  The lease for the Burnaby facility expired on July 31, 2019.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Site consolidation expenses were as follows: </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Employee severance and relocation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">231</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">198</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">429</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,399</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Facility and other expenses</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(49</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(690</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(396</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">311</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total site consolidation expense</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">182</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(492</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,710</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Site consolidation activity was as follows:</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:58%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Employee severance and relocation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Facility and other expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Site consolidation accrual as of December 31, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">697</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">634</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,331</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Additional accruals and other adjustments</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">429</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(396</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Payments</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(923</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(238</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,161</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Site consolidation accrual as of September 30, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">203</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">203</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -URI http://asc.fasb.org/topic&amp;trid=2175745<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>77
<FILENAME>0001447028-19-000071-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001447028-19-000071-xbrl.zip
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M"\4;MNWMD[I)DU%Q[^E70PKP_'8H/NBM'%O?12IF#Y>&3FJ'RMG0R>+0?B,
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ML!O:*"?F.-DB)W5SS.KFH#;*ZFW&DS@YCH#9WJL2G43#$8J&I[S*>F* XV:
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MG([WH_JS@_6R"F<E@*5+PYW0LV.YW+I@'7II'$E$L2R]8XXZBT7%M+)!8_&
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M=9$4_<DLSO"/_N3RM\OB[X-^R;J3;^_/_0BFC2_#$ FP_B!5:Y,X)S$X8F4
M1U+YJ/ TSX?L&5]DC9IRO*L46$7QC@:+:4SU0=^B)G-LC=%- ZP9#4YEKK@A
M,9*<"<>S1P7 J\9C@H< \WC(VRP3SL&'#]1F )EC>0/+-$*N<@P^L,:K54\
M^1K#V06EDR/:,.*X,3Y83]&-"^BD*E.]3 I>T8)5]30(M)'>$DVU!4.7:\4]
MT%UA% 5(+YW1S%6C[8] H%H-I<[8FY6! 6-OS\5@[M.?@<>HR :,8<Q$"<[Z
M+"GUD@4"4D" #<=N;;A:%.X1G%G'?YEV1J"*"HR!WIITXWNE^P0W^"DQW%(+
M0@ 0TIH%93FF6B:62(1EKC$?Z"V&#\)A%>7%),RYJ7;' GDX\M-OQ6@O>"]E
MF&HJK+0IA002&^_2,FH1[1!,RDE6\C!7\BXVP*4-_WLJ@6\!>V(\*X0P]YE^
MNX1Q6 ;B_?E?^Q>7,.>W_E/0Q@O@<X)Y_2XSF;G)@B)MM*)):UVM($76$F<;
M1%<)]Z'S#:/CC8?B.\ <]*(.()V%%]*"KR9T!FF7HX\>E'VH!#?JN6(.: 7^
M.QH,S]>D4V^WH.7(CYA95C[&W^9,N58(6*M!7%L3I0&<;.9.X(H+H$7D3-7Z
M$(1QOH)X X9'08G^X"&42"9$S7.403!%*=C]SB E. ^*^*50\@(EZ(9T* N\
M? ;;M(>EW\#HG94"NT\+_/SM?LC\3*[,JYSGU:6O\(4^F,K]P4ROW"4S'BR9
MU40K'>4QI*@<\$QB6-J^K$Z0#%AG38;9_DAQ$&H_43*L 5.2:J*(,=%;'XRG
M=DYMS60UW?HIJ3T9@0R?7('W_<C[+02,36X=4T%+:;(68)!$$303WOB8JZ'F
M15G<",8=H L'P66JX 8QU)VIW:7T"LNSBPZDC\!<EHCIS01K$DCE@G85UX8N
MY5=LALT=$?X!:O?J&P9S>I]N&_S <S"5KZ8]=$5S?] 9=/N=J[M8Z*:INH3E
MS,".2(E[";:FTRKGC"?B5*3H%T\I%]L0W891MH$0T0-OX$<'O_7*2WM7G8MF
M_KM/CBYKJ@AXQ*S4Y06D1*3T3"J&51_?_'0."!9_^J'R\MLOSON%Y/ZXV[G"
M"HYIUD#J 1_W)A.:D\4 BL2S+RV=\TQD)Y2-6K_YZ>R,LC-.9Y]O^M(M)''8
MG5[?#9CO5OA;RVG O:OG2'#".4&,DDQI[T.('CQM@7FY'$#YE<^@:/Q*/1@(
MYT.!X!P;MN#E*&5E @F@G8J& 3Q<!TW<F[)=5QT8=U]9!6(&W\.7A 7JB0?O
MW&.RO*+@L;/@X0?PFCSSZLU2Q[#&+ZV"@0KA 5]/L @$_!*5!)$T6"LC=XY9
MIXT#=HQXJG3VZ_)W\=6WGYNYP:' JJ-7;P>]XNO_+5IN]BRD,">C0PY9:UC]
M+%W2X!,"!$JIE&Q<;KW7^*45,.[KZ\V+<#;4,9O)DUE4<U&HD,4C<>T%!3,#
M+'/CN3"">L98XLI[HN52(>;;TJ!2&4FH9DL M\"T OULLWTL;H8CO#6 HN9!
M3*PX$E Y36#YE(C 3DJ .\%(% P>O/GIG]C?:]V7EJ%)U\7H I[]933\8W*)
MFKPS>,C"@E5K&169:RXEU<D[G9*"OX&TH5XOB[>63RU#D_M7Q2@ FU\,1P^!
M@IB8\.)&-M));8REL&2)1.*]3 J<C9]<MUM<X?V,HO==^?9%B)8^MPS)Q^*B
M[(<XF*#V?<CJ2$LRYRYJL%XYEUXI!S(.G%_J4W8$0)F%CK[S_>$-L,AUYSM,
M5EN$9_FCRP!]NBRNKAZ^/J >77D.YF.0 :_5IR!!TD0.?CBAOF9]%K^P\FW8
M-E>WIR /V?74"V!5YAW)$MC!!)4Y"^ +T@"6/<C\R6BZ_.W%+^#';WL^POJ5
MES'FCK ;].;MGVX-7=#?6S4>4[!E)#AB*<8DP5'W5&H0CA3X* I2K1%A!9M%
M(+> ;&<(M>6%@WT'NBPQ3-@!Z<Y\SCRB$< D"-]4"4-AE84]( 3&8Z_8:D5R
MTHXG<)317&$<=(55-IF,341 0U0C)M2R-@06(=D:X%:*8\^3S$+.(B'7.(O7
MK[S--&I*??6FAYA;V5L"_+'H%OTO./*78K(5B3DA>+.-8!<LR1S%'G$N\:P)
MZ#M#*SQ"!:>U$->!LCW(;43&DIF9V9P$C>"Y&4P9<AA@XH2+5"U5R(0QVX)<
M-NL;#<]!!I7%ZG.QI7!Q8#T8K.MK7)(I&+"[-/S)!Y#",5:/EHRND+D%EL=
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MX"^*97LU\0DS&E6-$-PI>JVFO 2OT3EJI?-2:.D".%L<5D)IE6UM.70T![8
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MS!^H",V6 O.**6RN5"Q#3?T0!T5JV4W0#V1]T&(\C<XMBT$I@B\N#*Z<9%C
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M-CCCRF@2:=^W$]J,, :,4G>D]CG>SKQ,NNP[9XB:F'J202SB1R%AL5=3)HK
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M*.9&H*?]CB9XD/K;T,:U%\"[!(921G%Z-F$^*&@6ZUB&'@ :N!HB]PTSC![
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MLE$(!%"N1R@->>03I8)-0[8VG\3#4=V58>,2_E>Y5&J<4"5=J6.(K%6( XS
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MI)VR$\D\UK]&?_HT)OC6!.=K:,R2@$]B)W'C9"&AP] /-J4Q*3D!Q ]2F,+
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MA6L]D>P_DR+##_^$>@YWZNZM9,'P"EREQ+F1U/-#X:D(E*P@Q&-8:'&?DNU
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MM?PD/1]G5]FLN\/YOMF+=2259DBI##T]2^BUYS3 7>;S LYV#<L/#C#<W^>
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M4[4RIG=U54B3(SRYR[C* =ER)V85@TD*M#1?/RQC[T^@=[/9'-!Z_Z[Y9=T
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M6GC]HWG+0=D\0N%L^PR%Q+DH\F3LV(E#^(M??]'GE<\S:Y5\ ]+H-(S7IF>
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M9D9C;5"XI#\Z[[_@K60&:OVO^J=?SN'/+OVA<T"C_&IJJY43.]C#[IO BEX
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MQPT<-W#<P'%O@^->=LS10U_QT99C'$JK4Z',X\LSVA1X"7-OF7>F^##W=LB
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M[=DU9!GJ]JQSCUZG<@UHV[&E&W1Y%Q) "!.\S;9\X?!(FIPP7V5!4_>!]1C
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MI73?L&:Q"]91,(!%@V;7>FJO.<^Y_5SH-18'4%J/G-\33U.I+WV]+'S"$Z?
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M0AWKES0J:0]NA[>=QFAXV_C0'?::P^:@T^PW;UJ]N^;M[6W[#!J5W'NQH@P
M9&?3[T-]6:A P]P>5:2$U&DC$_U>?)6+WFZ>A3>5P)R;>[R\N<>!NQRTCKI'
M T^>)W\$DS^239;*N1'Y</L'*$E>J9K0GV>14N(G^&VFQ0?0KFZYG#;[KLQT
MUIGN9^PO]WJ>8_3CA@RV6?.%W0.8U9C57L%J \LAK+<D'[/B2;$BHQZS6M50
MCPV\5_(?]S3B\X,OY;@/\X4?+I426@$=9. H*HD?*3]T7GJ0T/YV;=73IJUM
MU7Z3VXZA/F:K;6^3MNHKC_?Q:91320NI.K<QSA3O:P[M>=)57WG&&<89QIG#
MX$RG92U,4OF59YQAG&&<.51Z:WO(2+.?:,X<9-Q7)Q:TN9,.5:"E4$T8PX5Y
MLN<N<<.3*Z%VV;&^O[%B@OTABW4^>7:$E*/LYRPMO6&#Q87%A<7E>>+2'EJK
MT,GBPN)RXN+2;EK;%*H*X[^M!U.] ,K>JR@)_>1IMDJ&58[B2&DE8B['<=ZX
M::_+XW'S#$>%SR$J?!2LR/#UDO#7_O%K)]?E*#C-FE_#Z,;HQNAFW:%LLVW&
MMAFC5X58D='K!7O]_::UW9;CYAJ+8;3GU;BJ=@6GG<A1[2EM*4HEG=A[P-2%
M1ZF+-:DJ,DLN205 T+)2DJH[.*?:/!6[_:PGW^"J3$=@0_.QZ:?/N5;Z5";S
MX=GPH9U$4^9 YL!=.?!%7958%;^V@D23*TAPQHX%)]^)$NFC?Q].Q*URTF)_
MS9JP60:+CT;M*Y9:F7!I;]C?.SVJLO*OC8<>$1Y53@,RSIPYSK0[C#.,,XPS
MC#/[S2RNM;E(UK,%YDC\^7V2< 0#0Y\*O2GC5>E",$ZZN*$Y!Z^9#W[C?18K
MME2% ?:MK5DIG[ \\%E5/JO*XG* U.*J\/U!++ *.8#[I.U'N=R;Y?6MG3ZK
M)#ZLBAJV["7TOY9JYZW;*B2WQZOTSDAR6^TWZVC#DLN2RY)K37*;M6;/=D-U
MEET.8NZ:(E)J""D.W9^J*F2SMG5R3#LDK08[X1R3.OB^:E5XYRPQP+# H-5L
M6>.!JJPG8P%C 6,!VP-O>O ]^_NOWR7Z:BKEXOV],U-NXJM?)I^4CJ/$B9,(
M.& 4N)^4+V/EWH0ZUI^!"-=^Z/SVPY_^XZ_YK6J*8>]/:A$"D8/I1S#JG:7Y
M-[\!K7TDX2<U^=O%W2U:]/_=_I_/MQ?"<^$+Z<17MS?=Z\;@IMF^:=Q=W_1N
M.]?]VU:K.VBW.]>MNU[_XH>U)2F2]QNGHK>M:+7.QYN/>/E[+X8W..:;C?,*
M*;6%%TSPB/DWS_Y5=L*[<WZUI_1YIL1-. <D68IPH2(0'BIL((6&4?AXA)-6
ML"Z^+MZ;(OH<.2L))DS1FP#L!?'(<<(DR._RE'Z)9 [N^C>-3J-]=S-L=3NC
MUJ@_''UHWM[U^[U>I]FY.6W)O-C*D+N(]Z8PKU8( R#I$HE%ND9'+ 6G)=C/
M!>=KJ3V*7RTBI4%6&9XK-R6 9ZU$$LC$]<"L0?1S\?RR6XA'PH>)%\C \;#T
M-*RBHGU],9,/2HR5"G!]%S*"ZSR*7(:12V?R'[UX)GZMW]?%5 4 _;Z_Q)\Q
MF.F6!!QL*\=;^ ",EYEOVVI\3W?^?33ZF'_7_/Z= #T/KXEA1O/MP\+T3S,(
M5##+FG!#$81H(CA^XBH!PQ"NIQT_U GPI8C4[XF'@\<GRR# L.NV!]>%(5;A
M57H6)KX+-("'2)H]4.U_D\"A&"Y-/U[IO]QM[W\/HUP1_!MDQOG ^&&DF-.J
MXI &BL]= A\*!0OF;BK/79@A.XFX<BN?/)*XR^.S%2!"/467D5D H]8%4/$.
M[#K1;%S]_Z.=]B4.NL#7^.35M(K,G;'8;O(8J8FOG+B6D3=<> 'R(0 P6!IR
M2I?5B/\+B=%IY0S'EUJ3\D7>U2( HF@MHZ5 AI->!+*;PGAQ[?ZB"V-9A-HS
MNQ>$^E:HEV]]%%;GJ3V0G58'IU^>$,PR\6.:@K%8B2!XG2/U3& P1^?,:&40
M\2Q2IH1) "I"S.&2F4Y9?'/OARZTQI[$<T_,^60F6<,)+A065U.H$D!9D4[(
MN!SN!ZEQB?M!J0$5X@)1,C),$A =1)_7R:FIZ49/U'(._WS=[$5IBF<AO,Y5
MVHF\\0I 4[40TH?G:Y1T>IE;=J2X6A/J"]H22)\59<8*:9O +")0(E@P0:R\
M/?$Q"@/XVTDU^A$;;J=EBS[7H_BXLA2!B4M;YL<Y\1-<RU?[%9FA3J!F9'<#
MLU [>/"U'<WT&-JQ)1YG .W+J_ Q@+GI9*P]UP/EHG1-C*)Q$B=:7'OA8B:C
MN13_")RZN+S(?L"/%^]H8IO7_GHO_@N$ !80'D4WCD 5D1ODI!2)(QEHZ:R,
ME;'TT0LK^FG*]^9 \5AEOLI*?!@+JS*EYV(AL$$(U@,H;_!DM0"K#?Q1,&R.
M<]8GN) ;\>^TF"\!&6#.%?E<8J[ NG,!.Q2*Y'R1D*42J-BLJXQCL&P24R 7
M3#VX!$QGL]0 -V#G%-;>V(JK-\[@LZ=U0B8V I$8B87$S3]O(>D]  *T&XA/
M!_]NHB(,A=##M/%<+S[F7]_3UQ?O:E2:.(GHD&W)*D6+5#1;-1B%C&%JRGB+
MK@*D-[XAA@-+(]#*28!Z,#CCBJR_#DS2V(M]HP^R&0,A5D]1^&9@ P]4C*L%
M$"N+^:2QG6_<BG16ZRJF3G9C'D3RROHGHO@$;F,\N5#9^\J/!?^RN(( Y]D#
MT-)/W1)PT;&0)9!@\SGKY/G&QLDKI&.P?^GX>3<N]X"(TG<2VHH%18=V16A<
M(@.3&%_$RJ!3H&="?B69BP6ZBS")P>8(<+:&[[(GIDSJ>GZ"S]E1$-T0WH%K
MZ7H36"\QB<(Y#7#M-3!XS]GQ);5,W!6\PHG7.*T45J/9H&N[  $%>0*+JTP.
MJC<./UQE5];%+>UYVPL ',+M?VJZ0"JY6$3A%V\./ 3>OY7WM0;UEH"K_&W^
MR,[1*3M#ZU@>VGI(!:U)3Q.BIWQXX4VN4O6BW(N"(&X@/%5L6,DC# 5W8L,%
M&;,UD&D0*'#V3?#X*4G*90CEH[C:8/LZ,M&D!;S(N!>: O19]'Z-\8_8W#A1
M"\I83H1&A(Q:Q83@A@_(:%I#5&2IUT%X57HNG" ;%-Y42C@\JS82/2MM)#K<
M28$GSY,_[<D?R1FYRJ6ZY\/M'Z!R?*7J>G^FS=>?C//U8=/Y>@%1F>F8Z9['
M=#^CP_]ZGCL2]-OKD0CNFV&7-0]]AOI4,8]9;1NK';2E [/:.;$:HQJS6M50
M[4@,N.KR7[-[5GVG\LS.-*<A<(L9#G-*"./>5'OPUY(YIG[#=/<"DF](TV.0
M[LH0ZVAAD3F..8XYKLJ$JPRQF./.@>..Q-'8:T,</^N!;I(8=2'C1<DHP",$
MAPP15(5.9UDLB@O'<3AL3\J<L8"QH"KKR5C 6,!8P%C 6,!8P%C 6& +"TYW
M*\EVW %F6XH\X.F;7:)?W),FN^]RT*VUAEUKL5=N2L.A:VXH]6:MX/JU1J?!
MPEL-X7U+OF/A/GGA;K;[M3;W>F3I9ND^0>GN]&JM+MO=;R/<O(&_YDB7RE:8
M>E!;BE9PL.Y,@W66HP+G 3+5PY/*&0*,$B>%$G;##XP2C!*,$J>'$I;C& P3
M#!,,$Z<'$W8#(N>!$J>;.6#]$.JM"D)J4L#'4 ^/SA5BP<H1CCF..8XY[B@(
M5QEB,<>= \?Q+M;W_WYN&XZKS7KMN_#GMS:LCV[?N=NK#;J-6K/?LH5S56$-
MO(]/9+P-;)^>6'1KG5:SUFUT6"Q8+%@L5MJBTQO6VEUKT7L6"Q:+XQ>+;JW5
M:=9: ]869Q.0?CUMKRTUD#HD1#VY5%4ALK6]LV\RY5%LJC7K77O'@\X[A_B(
M4*QRI@#CT)GC4*/>L59!GG&(<8AQB'%H%QQJU3MMQB'&(<8AQJ'#VD/V8D=G
MCD.%D--W%$#9=OV;Q<(*U.'^W7N>DOF(E[_W8GB#\T3JYX??$R]>BKF*9Z$K
MO.!!Z7BN8+)'.>L37$BZ[_-,B9MP#FBS%-)QJ!N/F(21\."_JT6#/X74.G0\
MB2%4A^[PE*;OX;;(E8&CQ*,7ST0,C[SS OC"D[X8F8?"E,1]+ -71JX6UR'\
M1UQ>W(WNKR_>;;_F)G2]B9<>GKZ\&-W?P)7M5KLF-LC]:@XF4OPCGRTFLJ3L
M^Y-A7XP?_S/TX#7_@M\3S'5Y[2B,2L)Y[6D^=D8(%+]X5Q?B'YL+#4,W"[*5
M,ZB]DUE8^!Y92FJAG@ %71>?E$Y\('TX>?IY"R"\HN<!3TCX1UVA3%'6$3RB
MN()>4*-5D^X#CEB+./S*0+_Z8$'MK)1PY(*8,2NJV&H4> 8O^KL*%+PMSB]H
M?I_=F\K87Y"O ["&-;P*_J)Z$32>:^D39>]G2L6Z1KL42 H?+&CZ 2F(VQ8*
M?GR<><Y,1"H=MEY[Q1C&).#_O3D\&I^RB,)Q7KJ/I!86/!VT3N!10!B%BR ^
MEQX$]RW""">-#S(MNW!0"!9;2/D7&K47P!=PG1FN\/3+J'N12EX!?"[Q0>\N
MGDU+ )%8T9TPV%\6V 8+GDS3BV2@I4,?@4SQHU*E9QJ6>6)ZQ"G*]^A 0S89
M,X<"H7S<2BH/,WP,5*1GW@)F$ /A=0Q#64%DM.+\C(/$O>,I8ML?8[<.\)?]
M !B(HX@4BF*1H+\G,H)G"U].,W& _SMBS51P\9[G[%5V.L^UF#ZI!Q4D9G&G
M@6>PYBAG? [64KI*?RB#OJ:3(<IPE"XCP(#!:0_ ^,M".8C3(:". &3R8C_5
MBGASC+ T,1FU "5S#R%M&H9@!L$56D4/GE%APH%9 ;I&&JNRP@U23+P'!=RE
M%F(>NLI_+RZ]=\)S\1V3)8!7  ]WXDO]SBAMF3_B>[BR>"D.!+ 2QC0GA1..
M@8X&.7.,3I]&M\*]K@+(F2.4Y[,PX JS@!'C90_O2(<YJ$"V7I3!Y;-?C1!]
M"8_-%R"G^.,,T-P8&O*)YZ$ZTO"7GG@*@/6(>?'$Q6L*"@_T-G!]MKK +7,9
MP3. 'Z(PF<XP3N++<6C4NY#32"EC_"&+ ,ZB:5#XNB[NR=9973>7*,=@;T2J
M9 4 2X(H@6!%X@%>&28P"B04/?F[@DC6T-KQ$R02Z7;?!S%/0*>C0: B,&/2
M^] :,@,RHT.+2$8X&LQ,@1GZX8(LENS)=?$K";@N#[E6&B<PLZ&3#U2! 4^]
M-)4%9$/!\ 6PQ56D)H 59/XEBTF$Z[*0R_1I^!,.'I'HFV.J"5A"L%Z UPJ/
MH.F$2^G'8"/5CYC]3E"BP&O+@%,C/*[Q^0R0<A[2ES(0M*S;41-8"CCZ 70%
M!08R%6)4RH:BJ@DE@8V>1F P9?U$IB705DH$!@BCP]@#7H1%QT&Z8C1GC:6;
M_8X:CG1"-@P'1C\&09C G<#A<_H5AU48E5 >W8PCB,DFQQ_C<&J>23,)Z4^0
M@S")2.'.9)S:V])%Y)$/TO-)E$@+>>E UE^%2D8M).(7W)1J6(_NH^&9]Z2:
M?D/%U<D+@T\:[DS!S6C[XE7XDA@57J9>W9)#DU/O*;V:4Q6N]FC2:*(@:$3*
ME_2'QF ,<"<RA@9L0Z @G:W-$#,7TWWZ2K1HB!E2/"4: "+YQASZNMOZB.3'
M:\J/? P3'R<KO(F9:N'1CQ(5QC3Q9024!Y<P=9&* S0N&RX@<EG&??!$5 83
M=(R-50+:YC?P9XT6RDRU]:4FFX/> W?0NI(HP+,2C4,&SI0NBC:\('T@.MM:
M$[+*!3 !DB>=RAKMMH\<_A>$\8H7V8RIUI0VI7<EHL D1AR^+IZXQKE]ZPJI
MRS8N84#H$P2DKD-D'EZ"Q8QG2:"W>11UBIL4QKF*>AAG(;Z*//T;&"%C9$,"
MA>* <W.@9 AI"=]>&7PI7?'5.1G0SR-5!GJ%AD6B,# L UX>P<,1&LP\YTF*
M5%'9=?Z#)N#[)">AXR01V'Z%4>7F2F8H82P2J1HHXYG0['.##=ZWW;A#U0"T
M^5_X'HD/PP4,Q>&F/>]I)8-T#<P(=1;@KAE]/%YFJ%Y8AU3"#4G-X+;[3L:4
MS.<,UV7OP7BZ7V*'O!=,_WM-*PJ&+UEW2!CDBD3+*?Y%]#IB^3LM2'EN].A>
M3=,X-(DG,LEQ3O@$UW##NPT7J7-+H0HT%'Q4_K2"K,XK,Z7G1VX=LN96^YB@
M(@+XVS%>^W'._@07E.Z[(P_1FYO0(_P7=]L>GUX]4O.>UHGQ$6A_>W1_C2K3
M.'*93@<)CNG^<>AZ1?=1NN$B7MV=;S;IS)1)[0:X1$TFJ1N&>UD8!0+MK,V+
M'L%;1,L1-#I8,>50T!B<(%#]Z4OQ%P]^<-*(-+(G>J)F$KD-LAHAFAM+\$U6
MK\_MIYF$3U*@4Q;A=E7VW/7-N$F^H;4(M=F],$&E;',KS'?B1+) :Q.I A_9
MUJC4E$HI(2GC;LG0$+\ND$/%96$[?'3_:V'O^YWX.:R+5J/9NVJT]I:V\:,"
MDWX387>9N;C\'"[ >!]T6N]JJ73^4P:)C):B6<.9#&NI6X^L/Z<,%70G%'AC
M>?@D]^GS;)BR3!LSW@A(F@AQ"7*F1/==G0@=X6K[RQJZC>AN>>BU@;U/X:I<
M:M;R%K8DXOAJ*IUE$=?072B"1KZ-'(3KDZ"8A8&_S*W$FR*9.8'IJ-+WURE!
M!/@4AU9&)H5NDS(O!N3X#0O(T#X7>C(.P 5NC@%>XJL6&(N)\>I5P*M KFGB
MK>8',\8,%%BL+"%"SD.8I,%D_'VJ:R:!0I6GC?MH,H)%!4OY$5D9 X(S\,C#
MB ;D(TN!3(,[G*<@/7.">A9& +\P#9B6FB_,U>GP<"C:[/YY9CL/\=61"^+G
M/U0:BJ/7ZVR[CIX%]&JV@.&">&;V$D G +-DK)!J$=1BN2XRP+MR'LU:(Q>L
MH!@^F+G2+L55.+E*<,>$DD%*@OWIEU_3KTOR3?LL] #?DV//-_/"#!&4@2\4
MR .U8T4X_]RNMS"<X&]S;':2=AR]G:%UZDVK0ZL5PK$$!-N@*,W6R1?<]5SB
MITQ1H[XWJKK K*4@@%-,FM%9TLRZKD8RE7]TI)X)3.UGS5VI*0%"_1P^**K-
M!1PRJ*ULU=3RBV4T553)"Q;3S>$=]':FJP=7>-^>=/7-:L,6E,@H F2?IFQE
M)YTRU=^-P3NS+UF86.^JV=C;Q++4'=K=N5GMN"&$W^0I&S;GV&OT8(ZHR7P9
MF?0-,.4=%<42 7];GAMH[TSO.*6%D,6%  V6;J^4LS>W&!C$65G <:6;9RK;
MS\*[(WPM;56O4D]P^PCWKK-;I*]I@W'FC;UT6RBU+/+>25\9\2J2K,T"..4%
M6.7,I+LLZP.CW92G!I=I;XI>4ZJ FZ;Q@)+S-\P_?[E*5TNWF%;FGZ$CPO,\
MS30,*)Z<6E-C-?6"@ RU">;RW8+?1L+<[&;6)TU(T>96;@CF1E,MFXQ)-S(#
M?9;[]K1:6'EU*QWP==C/_O[K=XF^FDJY>'^_"N*O'(F/\ H'V/$S8.*U'SJ_
M_?"G__AK?D<,7Z0U.$P^Z,]@(=^"Z^N'.HE4?A.M-7SXI"9_N[B[12+]=_M_
M/M]>",^%+V"F5Z/;F^'MA\%UMWESUVVU>L.[_J Q:HR:O?[HMO^A??'#&K(7
M)?&S-P>N^AD,JT_A7#Y]B*VRBF%[P$J((H7_DN5E&U4//Z3[)&CRJT ??3!Y
M[PFD@P.LX2^P-.(GLZ6,FUMBE&4)'?-2G:15E@'YBA%7YEGN15)J.+IKZ.0'
MXBO+FS^EZ*)MNR9UTTAI_!/54(3Z_\<?;VJI?YTGJ&(F'-F(!@.4[Y=+N];2
MO)I2U)0.=6#B';QU2B<$:"LQ3_Q(%GBM'1>KVZ@WK/I8=7&7;H];>5R "4RI
M@PZF-9Y"4(O8J.]VPZAO2[YA.0.0['HK3V[66HU!K3'<K%VTDWM=+@V\2"*=
MX"Y^&DTJLVLM#5>8/$HQC?#D"!B$CE+NW@(*7<L!!4J*BL  QG_L,%5H9RG2
M-4B9Q4VB+(1IY?'Q#%;Q37B_$!4L\P\'(JHRI>VVRKW1/"/C@SK>P@0?P7BG
MT_68\+.@W#O4@"FW'N?\3W!),ROF%R<.T]!2_VNV"R47.9&W**?E&S/D4^C1
M ;<L-PU-!@1X2QJLV>O4&@U+&NQCSI+WAB5QT)NZR8XV:C9[]<WJ%*]S=U+M
M1HI)J\WYF)W?X.HAS+>'I.-$9 7:F=:@WN_^IYW5P%*<&##!^ [M'Z<;&YCN
M1"9"NCDC_8V)ULB3Q6(=*@NZ8%C=Y,AE;-WLH:9J-6M"QJEA3.8N[L+A>S:H
M1SODXU(&X!QC\7$8+5-HTR8#<*VXJ!:7A7OP0"E&6O*4P3PA'(-:M(&?A?7H
M( ?*DD3S/%I@.$R5@WTF>1O5>RA&T3B)DWS+IMG_/MML N)'B8,'V<UY*4UG
MCLVD37JU"2I1J,G##/O5=( ZJ1"7HD8F&/4N3U[/+C?>@&<I^OGG?KVY64OJ
M=5*2UWC-*8 +:PS2;"DV%G^L"@HLAS[[5FK+SFPS0[?,AW4QHD!C8;G2K<2-
M^6XR<:UTA.#)GB!A$M,6%9++RE3,9MC>O*M,01DQP A9(:!K?WT[0TOPF"[<
M*A]G;:6S>9$^=DVZLI4W3\(DLC.%):"-P*CN5;)(@^*IG>"5BI%07#T&7^,+
M9=%/:95PNW^M0D!ATKC!4/69DYC A !\LM3PG!FS9"SIF-.*,!4,Z-/!K:^$
M-W?CR/K0$E.N1O9U[C1G$ASP2VF#JN@6;.*.T3 >'I#'[8P56X03RY2@H--^
M3#*!&QDF.:-L5F<I.I&:@\8GJRP[66Y[=CU;!J?8G%26JX!Q3I!AS'S!N9BC
M660@49QQ56K=Z,X'$%3VY2LUI?6:!R9M=)LY# OI+PM5?DRP!G.T.H/];;W?
M&AV0>!HSOL2/A40D2O0UVX<U.XQ.+FP0BK$W22*GL#F=VT\3P&4TJ_-CJ+-0
MQ_F.=$U,O0?:'D^3=#>HZ(![ C@_5B;+!C.*?>468,%-L\JR-QDO+DV(6\=8
M.B:6[V";XT14,^(+[>[EHZ9<'S.[!;XB/Q,98[4;XQEF+F^]6"0H]1=7YR.K
M[#4:%]#8[28#.3:G\2)%U7LP\]M8'0I/P*-OA><ST(-S(DISHW/0I3A5YE&E
MU:;*U[IJXCG@15UJI9Y5K*B\*VM8]]V+M]N?NWF..^Z .+^]GX1AC"FH/\('
M\86^ KX!,L_B>/'^N^\>'Q_K7\:17P^CZ7>M1J/]'?[\'5YXD5X?+Q=P/3R9
M L 7^.CO-I[]PY_^^AT^QWN/__[P?U!+ P04    " !U8V9/GP,;[\\0  ",
MK@  $0   &%B=7,M,C Q.3 Y,S N>'-D[5UM<QHY$OZ^OV*.+Y>M.FQLYV6=
M2K*%'3OK+2=0QMGL?=H2,P)T&32LI+'-_?KKUKPS0LP,))"#E*L",^I6=S]2
MJUMOO/GU:>H[#U1(%O"WK9.C3LNAW T\QL=O6Y\'[>[@\N:F]>N[G][\H]W^
M\^+NUGD?N.&4<N5<"DH4]9Q'IB;.%X_*K\Y(!%/G2R"^L@?2;D=$CO[P)+W7
MTIW0*7&(4H(-0T6O S%]3T<D]-7;5LC_#HG/1HQZ(()/L8I"@=QK1<28JD]D
M2N6,N/1M:Z+4[/7Q,1' -I1#%ARYP?3XM'-RWCD_ Y5 22Y?DV$HJY;U&?^:
MEGU\?#QZ&@K_*!!C*-DY.\;70R)I4IP'G(=3,X&GQ+&:S^@Q%&I#*2J8F]*M
M)BH28 %/I31YJ5X<1R_S19E%!\:E(MQ-=7@JZ?QXIDN?G)^?'^NW:5'IF0H"
MVY/C/S_>#C30K7<_.8X&GDUG@5 .+P$V(G*H*:50",$O[<Y)^^RDY41-Y39P
MB=(-,Z]NB>B8^DKBMW;&X@CJ;3G'-40(97M,R*R^&'G"2)3XR;KBB,"G<D/R
M:%[K"H0-<E,":5Y-!+(UY"7BE$GP6SNA:^.C]LGI>E)D+J&>% G=)J0X![?F
M(M0 FZO:]&GF$TY4(.;7\+V:9+X0!2Y7&1,4\1Q%/'FYAHB:,Z=C'#RJBY2G
MVJ@<-<R24*Q=OWE(J")&GO)31+A!:9I)TEP,\_!5L?\D!%CQBWI52NH>C8.'
M8S<(N1)S]$ROJK@T$UWRI9TQ:2A,* 3$7@VDR1.FW]:6QZ-LI:^7RXCP0Q/O
M7F!&G]Q)?1%2*OUI;2$8?Z!2!QIG=4#)D<6?VQF+9I)PPEQ9NW5D5-''M=N%
M9"ZR.ZDC1$*#']H9<4,!U$S4;Q8IE?YD:1:$\T!I3O@H>3B;,3X*HB?P#$?M
MU\G0?4='CHZ/7\<#ISV*/IZ)8$:%8A!,Y1()S6 BZ.AM"S.5=I*2_.42_PCB
M[J1(J8)B4*$'*2!Q0U\K<9L)F7! M_VV)<':/HTU_^Y*>7145RD@89SML$X^
M&=;5"4BHOZ/JS 2MJPZ02$C<&S4\9' /!1P&R677U<.J[),Y&?JTRSUX(D+J
MW3(R9#Y#)5H.DGR^NUF6U&N1*G%*)$EDR9K:N].3SJN33L=I.^^9=/U AH+"
MEX2M$_-U"/><F+.38_WF>)'A0E6AI%Z/O].?%\T7$\=%+(0+_;TR7;%+&<GB
MAPDZ:V+VGBK"_ U"ES"T(?B\\^IYY[0I@LZSN(Z?#U@63'^/;S8(9<S/AN19
MY]59YZ0YDE$5^P3D9>##&!,(+8:\#"!5@:1> @"WS*5<,C[NC@75\ZT5L:S'
MTNI:X5_9M1;Y_\M):]"XIG4X624'/,W&K^5M&W&VNMV3D^?ESEH?W;UTP& 6
M#RQ!/?@@ Y]Y./%U07R<L!Q,**W>65?RL6 (O1/^L(<.P) :#@UAS-/),W5B
MKD[$]H!5SL9](D"]"54,!-X4<$6F*U!\H7MB;12=9X5:]KX'I@;LC08J<+].
M M^C0E[]'3(U7P-8.U\[ML\K]]"L2#!R\O7\TXEJ.L!K@6%3G;A&)2N K]RI
M5P)_Z.=+,)*]T261DVL_>-P$Y'EV=G!?U._5$M%%]@[R/T"8LWDP!0TG&%H^
MT!L.8-';0,JF=)MJ"1N6RMZ@SIHVJ'QM3E2=\PPK_'EM!H<VFJ':F]$X*=I0
M\\HQM+>,TX8M(ZM@OW!4D)]2[C**R3&T[BE3M:9/EC.P3Y9TC),E.6XZA<[Q
M.\#28!9D)1_[G$?'..=A 6DOIS>27:1@X2NPC9K?\%$@IEJJ:D!9.5@@ZJ13
M&NE.UMQ'Q"9BY^3X[1$P43KPD:I)X-WH?0MHEVJ0+*&U+ZX]-SBU.">).#D9
MJ[W'H98KL[.P+Y@]-WBQ9:CLI0.[)DS\0?R0]D;7C!/P[,2_X5*)L$8HL(J)
MO>><&7H.<G0T2PS04J9.CNL!I,0272EIO,"1KA%^I 1-Z7551LSO*.ZJ@Q'\
M@DA6+Y[XMB+8._&98=6[0@/!%54M5KPBDZV?)I(Y1!48<2<5S]'R'5Q"&>K+
M"8$04-[P7+DT,%289C$OSJ<VV<(:5+NR53UOUJIB41S&%P@R>9R"0(=F5 W/
M7!^]](F4^IQ45^J)WM[L>[2HZA*L;%QG&VY<.=':F6P.D=%$N!.)=VAJ9:#K
M;/"IQLJ^M^?,L+>G"OA[N*WG!B3G8X9;J9((XD,0>(_,K[@R96-@#SM?&L+.
MC%L^=$@8'G!!*]1RP17XV!WI2T,"9T=I+SW@+42T55U<7-;>.UX8>D=$N'=6
M_4A4*/2X"_$!/FFZ#[@Z.WN?> %_9FS@0\9>!PWX>.]W 5<V_"5(>[IA,".>
M!T2_ :*?B, $ZX$VZ(8EVI4(E>8@4H127GN,Q2"<S:+K+HB?; W)+3TT0*@B
MQY6XE;+\%+=\#=F&D_R*R1X#6B=K*E#8DZ,7AN0H!F0/\Y](\R^4C2>*>MT'
M*LB8WM$I@2KX6+^]IV(*83,:#$^'W!'5Q-TUK6)E[RI-<Z2]*ZG2B>MTTDKC
M00RKU:%[4K&#->]EE_N$8SSMC2Y"R3B5F"==A_I1S=TT51C9(W_349:(*X8?
M"5^-6\1Y/_?/W%$?MQ+UB5#S>T&X)&[U1?]EQ/9],Z:%LIB3HUDY.5X'*&IY
MR14\['MES@R3%$N!V4O_-B ^SJAJ?W$7S(E?_>"SF=3NP\X-/07YZ+G7R&FE
MK/8=A225G'>A>3[ _[7Z33V6]FCBW!!-+$,- XVD%B>IYM"U$O,TRXRKL5H)
M8BE1MH"XWZFST>!U$B\; WL>=F[(PY;BM(>9V8"-.1LQEW 5G\N'Q*4?^,RM
M/G)96=A'L%/3");Q<S*&3L+Q $YDAX:^KQ9+NP\\-0UD=O .KM!F_PWVNTK]
M[[0#?V7WN +"9\FG VZQ(? &72_T:736*XQT[(UP;YVK)YS\$'*D[.C7YGIL
MTYI7=NS2;/+JCIW(DAPBBZ71TRDH3SP'IB5:.)AV\ 0+N-8*CBHPL@=)^%?;
M"^QCK*1H=KZN\BQ8F<P>$_UBC(D4=0I,]MGNA2]73S,\^EC7J=9A:?>6OQC#
MH$6\HG-EN>]))7OJ_!;LWS2:7<5F)70&QV> ;M^#U@4SWX$VXH$VFTJKR&PE
M<H80Q8!<S'W/)\\6;5XOOC 3VV.*7TP3+V6 ]C&,*-TB Y&Z?@AA,MX/,,6!
MH4Z 48.A?>G-.!UCNG\&0WG]HHUWQNH#TFD=!RA-EJ_G(^OSM2_=G1J6[FH#
M^__N.M\<+]P='C\HW#"N[Q>/?_%(MP&\A?FO^/K2/ID#2_]27^JO6OIJ='T[
MJ_$EPZL5\99F!:];C@R'4C$58DT?1!#.WK;TCP*]!J\Y;3G1;<S1DVG  0DQ
MOX$W*'_+B9X/H]O@WK9<03VFDL<S*EC@W6L&T<^HJ/P5ZLNTP:&3"'>"$PGT
M@?K!;%K6:FFAW=7.^T\8'866*NAZGFXIQ.\3YC%^268,-^)1 2T].S)5H$E7
MY'+GI;J/1'@RM<TWK6(KEO5"$0])9=,2$  O!4TDRIEZ"CT17V+L#$U$;Q"(
MK3& N(RY>(!V.J0B,UT=DB:FB'[]Z[47X#:M14M453E340R9BLI]86IR/Z&?
M.=,_T:;FO=$%[FB6D\O #Z=#1A94;42Z-967HQR-8#?</2HI6'JQ?<0NT*!4
MC(NREI[NGIT3$6&,?B_H$_7-&I1?;]_FY4.H07H(=1ZY-YT(W-,G=>&#RTN4
M:D*XAKHJ8;-Q\ J7"I'"3440I5"L+QT^*I9M/@Z C,#_>^JH0:J@7U*NFFZ>
M>CT!<84;#K55-JEE02M4-R1^;^BSL:;H3G%&O#=*PI_KD..O</:I^#=\SRM:
MGW1G(R=0YP%_D02$ZPLZHA#(1EG)8$($C:XZ!!'THQLI(3H,9WIJ-?[)TIQ9
MUN6S1MO7==A:A<44EJ8O9GA+.OV-$N_OD @%HNK?.*+>J\[)'Q2^0QQSR83K
MTR]$3+$2*OJ4<SGW'PA?# XVR7#[_O\]1G3X,[(HQQ41N#U>XMI?]P$22GRH
M@AATA"?.2O6R86*0]5C\.#&S[::T;DR4VJ1:V6T-%*E.5Z,1=:-XGH=XTP"T
M5"KU"0SP@WK_U3P=U1/EZA(U:N70Q''\ &DW/AI>36=^,*=T0/%@"#05&.GN
M($&.?O>LV-LKEMV]F#05/,M34TRRZSN6*%N-9OO>RR"P-$C<"Q4.'#B86U1=
M3;FSXW]];=*H/9MY;&X:,[/=M1:'$@RBW(767WJ\ PW<>/=@/_H!NKF.8G'D
MS85PM2B^(40>'6YP[$U;F.%^MV#A4K>[P/>O X&3<HE1FI-O?82^9D_4T^<5
M+P.9QA>EIS\,DA\HIQ $JP&DF,!>)N%T:>2M4G#WAMT/@N$T,:<+RI0>;]^W
M0#52@F-P*?7DM0BF<>B6Q',#"-0S^2N5_6%:X0W7RDB9Y/JDL$KBNN[[3]T!
MZ ;.XK^0K131;$R]?=!O.(R=X#;>T^C_*O<9EA* =9GL6C-9:AUFG-W,Q4!1
M=+3,+M7)?YPL^'<*V9_ 0W:WE\5>87RS_19_"_V4)L?/XPL'/ND)>9SIX_21
M^ LPUJ)HCAP#WSFFHN&$5P7]@E%R+=<JO7(EMZ]/%J+%9YCO ^,QLUR@9EZB
MV BG;:Y9U+=)<QOLK,YS##>,(B?K]W)1V6HD.^=S:ZB>W%B"]VO@1#Q6BYE
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MV6CR-"Q>HJF#^3QN-,]K8^"W:.?+60R#Q4WAR<?HE[,93*2AG==-YUZ1EY>
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MO6Z=4EL?YX$IMOH2YEN^ .4\CWK?Q&O>B/TCL%&Y\X>#TG__R_\!4$L#!!0
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MR+U%L7XS.Z$R8^M5]+J7A_9P.M/^X,KYY"Z=9U?7[\,O)I^GAXK3U.J?*$0
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MUT\]BN9'EG9DA#@  $)"& XI)&D*."&$RC1)4AC]P8:1YUQ7>5W>5ZNVHU(
M=3_=8OZ?';2@P18<@PM^Z^']O__RYX-GCU@M5R^])@VHFV7]I4'6D: 0AN3/
M^697]S]YHW_R!H1=I_M/IFP]);I<N2>ZY6VC$XVRZE[21^\2K59!6:WS2B5
M_1\MJ]4K >H^\>=5J7KUN]V;1['2B9 O=TI/+V3+DW+K)8Z,VYLHZM6FK.^K
M_+-JO4Q1\(^%9'&8 0&)1)@G,*0T)'W3$QPGB]V^RQG<_EZR*\*4)P@G*8DH
MSN*$$HP8( Q1()D Q*8I[D[TB@;M\:YIC[LCL"<;H7^JQZF<;Y:="=X!:/";
MAAHT6&>B?B^P.$ (Q\1BWIHXRC-#>1S/GJE2OLO5N/(@QTIQD8A(R($D'-$H
M@TD$H)  9UQ9!X8MU/*I_AIA"^1B&<9C'LXTHX&$S:.E# 5?.GEI;-_WNL[S
MZ[N\6NZ*[=?6YJ&1,0@H2VB$,RD E"H%4>E)9U0D*;!)!D::\MS_MW#L^OJQ
MY)F*QV2\V8J)!G85[*$%O;Q<K!,_S]59P7%"\EP$R(TSSP3)(4>F J5G9-?W
MF_SZYE1RP!X>_6;Y99,O>$@1DK&R3B6.8880PQ!3&3$1A9);Z98?!)[EK <=
ME#?!Z<S[*OCR\.37OS7P3S?;*8-DIH^7CX^=;'H+C1=%'<3N&:'U&ZUYZ*]G
M'\LIWW\SM:ZKW8*7]UNE5,T$ROOE;4Y_%O5"\(1F(J$LC&4$)  <)+T9BD%L
M(L2#'^Y98X\Q!1J4&E<I6(;:.9RR\[(X"5MVBF=-E(F2*3^/5$Q]]U3!3A'Q
M@CB-YNRRNC,>?NGHW3%7BX_YG7I;OJD4DGZM\EQO4GAJ692WRV*[""4*69C*
M+(I8)$@2AW&O5"BCG)M*B#N+T^M*"\Q"61S2^[K<7(;9T1KT&JG.5,B8GQ/2
MY)[?R^N5!Y]*GV^DF;(MO]S7B[_DV_S[<KO[M"IRQ4/-R^JNK)J=4[_FMU_R
M:H%#R 66*6$I!3!F(12P-YJ*U$C2')GRK&4]P*!'&!Q!-),S5YR>U[$+T&DG
M8&>9#'YK\1GV$*XH77?;"YL_FA.UCX!-1?&3_D*[K7N#%*01:/H",R)>Z 0<
M,WA9]7?M3.GE+7.SP>+QR+M)I3-&**2)B$0H"  R@2G: X@8<[&_8H#9B;97
M=#-9%N-D'Q2/VU?AF=TQVRH<C*N=;9QX3M. ?1,CN)['7* /QPQW38SF;HCZ
M=6DUPB))""00<A!Q+E*,26^()3P;JG*&CY]6S:Q&YV-(L]<M#WR-TB<78^Y1
M"G5RH.V O?DICJT#9Y1E$!>F"B+_X[[8/?R:[[Z5Z[?;[WF]R_,N88M"-42G
M0@"A-T6J43H4HC.(DR@R&BL[,.-945ID00LMZ+'9*<H8$LV492+^[!3F9>JL
MAVMNI.8T0V<DQP&M\Y >%XZ4SE\Y)T.Y)GVBG&:,90!2'A$<<LYP/UF(,T:%
M@[&;D9U)TYLC<"X';F:$CAJI.>=R3.IC0>.4P[1AXS(K9N>A34X\,1MY#6!G
MI#IUR1EC,@U%Q'&2)!F$)&8)[6WR4+HXNV-HZ7(*-7HP-H#642KE@5%G.G7Q
MX=HSGNRURI+?6:N5K2]F>C6((:.ET(]YG:L/?J/;M<B_YYOR3J_*?,JK[\4J
MK[L\3F1IHL:1),X81*F0823[*?E8TMAH1MR=->_*U6(,EMMUL#Z@#.H.IL4*
MGAMV#=9%)R?65L Z3A6^X A@T",<LCSJAER+%=+)21ZV2.J ;+.%4A,^3JV5
M.N5R!LNE;OTI?;UU%CT#7=\6VT*?;=L5WW-EO>F/"OTJ+C=/S%. 0@AX K'@
M%/-8)/N.*<88(>,.PJ51S_W$8ZA-8SL&NV]M%HKFE'*#7N-2;-MU'J9$#^E#
MG#)NT95<BOEA/8J[")AU+!;LG.I??! \@V[&BUNEYQ?3HM/Y=/]EHT\MLOMJ
MN_SRD"U7Q::976Y[.4P%H!PS*-482)!(<K$W&$)HW,V,,^.Y8^G!704=O*#'
M9R%L(XDTZ#RFX]"NNSA-WY .8B2/%EW"='P.ZP3&\&HF^V<9."7T;FB;@;0[
M<J1T_DHYF?]^5VSSM[O\MEY  #D& #$N$X%#R022O=F81$9C!6?&+C<+KC$&
M#4@W,^$6!(^:#/?#K;/Y<!-:IYP3W]-E/RUNS_2L9\8'N&,V.3Z4IY&*)G_>
MY=LZKS-%P/&FSK\7NV_'?[((HS0E+),HPD)F.$5)RCM421I"[$#PG&'QO8FJ
MP]F6MCZNX=?6O:Z.:_PYD45W41JEFA<)D"-1O0H>A^WSL[ ]^M-9R*XIW_:J
M[#R2LQ9M]]Z::;HGELTE_WN^O<^U]2-K15XO$C5D05B&DB#,>"8YXOWNVB2+
MB.7AH*%6/,OTV^VJO,W;UCY*D@>S:"JV4Q!H*Z,-II:\8V$LSBP%>)+&$^R<
M%;VQC,Y%SD;[\4RHW#!C- WZ/M]]U!,T:OA.JWS9C^,7"$8DE(!$/$4L8PP!
MVE?Y2"B&D?$$Z% #OM?4%!9==:ON\ 0W]C.?@[DSF/.<@C8[N5&(@AY2H#%=
M!3VJ*3BSF-^<@KMA,YM#.#2;T3SA\ZFYS+$4S6 6<[0+I<-7QB[I^TM9KG\4
MFPW=KM\JH]NOA;9;U_GNJ+SUOMJOX"S!6,0TR@B4$B*$TZ:89@RAQF&8PK@U
MZD]G>IS-KK@#TJ"%^JA _(5*5ULQ>28%\A.1>:1%GGPKIWBG/33FH]*X!&0(
M1R*$%% D&$P2W(/(4&RTLNS)M/>QWKXM+]NVK%OXU\X'NP&?:](=2J@?OKUI
MZ,7J<]N1.59&[:/R.]+1 <X-$=*A'%I=N,'+>M>4I3VZW@.D$F*B1KL\%$Q$
M<2QI(J4 44SC."%V-P^<L$&2+(L10@ "G*D.(D88IF&L3$H04N\[<8X*03<0
M@\]Y=5M?-4U55ZL+/BYW>=.</]W?W6V:,G;+3<"7];<@VY0_5"N_*:M;BUIJ
MHUDWT\PI"+<3QW?MWA*-J:NC'5SPDH(7V3FC=F/YG(>LC?;BI0M21K,RYJ:4
M=\7R2[OG9;F[KXJNMO8!241(!"*((\ RBE).HBSNFQ,&L1Q[?<JK]J$^&9^"
MC B"!6"IWL3/,2*"\4@0.:' =0B+O#[(70__W-SU=+$PE;;+AL%6]EZ\HN5J
M3_W#51^9AQGHHC6U9S737Z#FHJ<>/32X^\4MFZ8Z3%=-;J1 ?"@WQ:HXNB(K
MHG$2TB1A<:*24P0%0TR-\D64J=%_QDU'?",L^&O)!U!!C^IB<V&G"3K3'AVP
M.H]FY\*1TOD;9]>(V+(NZNN;)W8?VG\?6C#D$B>,($S#"$,F0*Q&?[UQDEAM
MIG5DTG/*TJ#4&<J=^E"_U&.7G+CBUDRL+D"KG7#M&3U O&HE3&4<W7\OEG*8
ML7=&U1S3/P^%<^U4Z?65M5,^7FYK96C=-.RG)C-",(JAP"%*$41" $0[DX@2
M;J5WHPQY5KD/5;%=%7>;=C"V.D9JIW7CV#13N,F(M-.U1[#FHVCGV#JC8TY(
MGH=ZN7&E]/ 26M9$759;)8[UA[SZ]&U9Y4^M)A@G5.DB9,H4%QA2)8^=U90R
MJSLNQ]J:9L=H606;LJX#-0H-:@W3LC[J6$+-]&I*+NTDJT<6*&A!@VT^NO4*
M:V>DRQ7?\U O9]X\K:/JE*7A=9WU&E;=&E\PS&2<\0A SC/ 6 )YW-M,!+8J
M5SC.DF?]ZDH4W[8EBHL]O+'UG:W(-%2OR7BTU*X7JCPWR&8@7><H.R=<3JB>
MB6RY\>75XL_#&1IP.$<E?<TDG#X6Q._KG<I!JF>Y'V>80RI%@DE,:$AC&?4@
MP@A8E:=W;-JSJ/5'4:I\57[=%O:#1]=,FPG<!4FV4[Q'1WUZJ.V)R![LY;7/
MCLTS8N@I+/-01U_.G3Y$Y)Y#4_W\E'_5(OTQORNK,Y-[(6$1!IQS?9T(QI"$
M'$),HBCB*"9&1XW<6O2]%Z(%J9*_@5NV'/%J)I+34VJGC3V;>X#S&<@:47=&
M"-U2/P_]<^Q3Z?-EM5.[]_F/HW6,JMRJ+U?Y49;Z%$:8<<5@3+(D(IAF@B*.
M]TDKHK&-\#DW[CUC7.E&NSQL9;A[!-I.$-U3;Z:-%V7=3B85U.!XX\@CL/.1
M3%M&SZBGM^#,0TC]N5=.])+;R6NV+*J_+3?W^:_Y4I]&T !.V(>04B!$FL0P
MBXB,XS3M[>,46BW=NK/J65 UT."[1JK7<6^*[7*[*I:*QFV]J^X':*I#OLW$
M]#)4VZEHPW(#,CA".1_Y-.;PC&ZZC\,\!-.#7Z7O-]AVOE*W]97>@;O]2K?K
MKGP(7>V*[\W6^OU60B1"+)3M2' D,5))+T!10E@L8!3SU/P:(W.#DB0DDW$4
M"1P2I#H&P D!$J<D#G'J<^[L"&-S@JJOE7. >;'ML\8$GITN<QV$>;17#WX]
MFR3SPYSQ_%AW*.;ZY@02?:*I/EJ8#8&4A*64<QJ&/)-1FNU;;0A3JYDR2]M<
M )2%""G)@)B'"0NS.,T(E5B2-!.^QXO'YX?RODB@;LQZ;V[UO5UZ4&_D.K@I
MJZ N=OF8O6S. V,XU7;!F+@2U0;BQ<\/63)Y;@[.4TSFH;'>O'LZ+^>515.]
MO=Y]RZNCDX8OU AA$44@#@$,(25$*)N1 %"*4!  0FAZ"ZT#2_X:;P/N^,3E
M'(KJO,[8F4;JD.YYM$N7#I7>7DV+.H-'!KL6_[G\M-2"D-TK+<@_E@_+C?[M
M49$))B2/4$)D!.*4B# "N$>1)LAH2Y@OV[ZSG66;Z=PT^(*J!VA1:,\'X>>U
M;PY<VPGAL03V^<OG,FC8O[X)6L3!'K)9L9QI0F%1#O'"(1E6*=$R-".K)]I3
M]$)GY)OL&=1<].E=.<TK:YDQ/CKE_O>\^/I-3Q!\5S_]FG_,]5W)_2]UP9YP
M$0$4@83$.&,J506Q)!2"F+$4$4AP8C5$=V[<<Z_5(WRS;"&J,7F',6AK[*IG
MW@:_/.3+JOZCW8#<?1P,\_A+AL RJW]:UZ-'&W1P@SW>HQ)3$R?YEG2>2_E]
M168F P!O[CT=#OCET8G0]D70= VT#WFE=XXLPC@BE(=1F(0B!()&%,0]#,%3
MJWI*SHU/)+1!+[3KODJ<<L/R))Q[XATHJV_.72OKHRI]5T$'>4;:^@*A0[5U
M3&Q^!]HZRCT;;1W/H_TRT].3?[K\PHH]\/+VMMSRS;*NFWG[!:24(TI"K,LU
M4<Y2FB80AK$0(HH28E5QT[WU"9>:7CHFV\"^"KX\!"WRH(%^%;S=KC;W:RT3
MGW^4[0_[,VKM<HCE]8L>PF:[#'6)B-EI\P6"Y7G!RI!SHR4KU_&;AWY[]._D
MLI4?)HT5?*<Z"3V)UEBZOOFT*U?_H#^+>I%FJ4@S(&.!PP0!E,9IUMM+ ;:J
M_##<BF=%;ING:N$-HN WC<E63(<S:"B:DY!G)XYVO/G1M5.TG-.OT53.1*?&
M^_%4CQPQ8UPAZ\B,*/5<P"+"),,I#''$$PD(#:' O2&*[$[K#7C\Q$K3HK+4
MFB&LF8F,9\+&J<MK7/FI<?6,D3/",H*^>2C*& >>5K$:RX5YE3V=(C5V?LUO
MO^35@HD0<Y1(7<P4*GG2%_%T=A  H56M%_NG^U:0=IC1)(F6)RX&,&4H&UY)
MLE2-CI]6,UHXD]?%>T+'.<D83-U,%&,X_F=E[\8Q,;3673/2>E=L\[<J]:D7
M"!,N*0*$R2BD)(LRRO9&49J-*75G:<JSDKB:SM .!8U'EGG,V$B8B=.$0;!3
MJBGYGZ2.WF-FSXB>HY#,0P%=.?-*$;U1'(W2QOVVS1C3."(L#9,8$:Z,1U#T
M-B$+Q6AI-+;D61G?W]_JA96R^F<'@F9.WP@]\\*<(SF[V);OLTS9RI,UPS-6
M)WM?3,1I($-&V[M%H9Y=?+EO;E#NK;\KZYI^7Q8;_<-=V260&L^W<J-XK1M8
M^EI6$$94,IY%ZC\1Y^D^C8R)-"J#XAV$9T6CF^9%+%1&4=[H[1P'1X*\\\1B
MQ['7<)R7P5E%PDXA'Z$^K";^HH'_,=A##W9E<#S*[]!W:CJ7*%EL$)]+M(;M
M%/<;-;/]XR,8?*&?FRPH,]A1/HF;Y<0ONUU2_]?M7N_S]8N(/I]$I,N8890Q
M$B&49$DJ2!1UB##!F=5&'9\X)NT^[[>/.U!]48#=0,%K2,R&$7.)AET7^@BU
M;S%V,PH90?29,<H4X9O'"&823\OI&X=M\<==>S/)RRCTK/DC%)(3K$RG "$@
M*1=9#),]"HJRQ:[<+3=FPNW:MI58[V&:S][DN_;NEN7N2*25(JQ:1:B/0A;\
MLBUW>0 MCPLYCX:99E\R$'8ZK6/0W:1S3IN/$%]$FRT)/:/'OD(S#PWVYMVS
M4I ^61PZ"RZ*C>X']O-;H> I)Q(F-")"9B$C*DOOK*(0C+H-R]:6Y\17Y-OR
MMM@ZF NW)G'8;+A/_L;/AW?H9C,C_H0MBSGQH3S/0\^<>?/*O/@XEDSUZLG!
MG_?W>O?$]4V#X/I^5^^66[UTW$[2;]<=J$4*8"QP#%G(82C#A M,>S <HM!&
MQCQ!\*QNS\XY;AO<[46EAURQ#MX$7YJ5+%V(;-UBMU-#7R$R$\D91,=..Y\=
M@'R_#TR[\2TX@MTO,^K@B%>"XT55A]%[1FP]QVL>&NS;R7+2-N!BG\7!:L;"
M2,;*I P!DC@-HPAT5A442A?*B2_EN+T6YM9LVODQ,./FSIZ*:["U&<,[NJ/5
M.@C#,E2?[(_/4"\LI:^09;UIPY[F>8BC,V^,-FX,96E8\8T/RX?FNH!%PE(J
M*0QY%,<H3B'%$F.5&!.>QDDHK>Y1.&&",$@9E"KM%BGF-&$040004H8E#ZGW
M@X7+^EMPMRS:JL'+6WT>OPZ*9C-GKF]G#7;?\N#V4,U=9SAM+:/-H435F((;
MYF2;J=D$/-N)V+/B&3VF2U;'Z#&<T:N11,Y#IL8Z<;:>Q4!.'!=';TY=)Q$#
M408(SM*884@SRM.V_G8HP@Q:G2BRL4M$DB$$LH03@8%JKAP)B3!"+ 8DBKU?
M)'A4_,"L(O?@$A0.8F F8)>BWT[57#)_R0+HQI4DW 5C'LKHQ;-A1<\'L#?H
M0AAMK;'=7)C0G!I'$$5<$L&%3$.508J8)'V;)1(SNQNKS]N*!.4Q5SE.C$*<
MIC&)HC!$)$F4G911WW.)CUOI9_7Q074D1C-JIH)3DFFG?/8\^K\XYSE!9S3-
M%;7ST#%GWIR[&F<T2Z9ZI5^G)VK9G4U7;8I0FM 4A)PEE$,:T[Y=10AP&Z4Z
M;87AD$M.8AYE F<RHS0FC&*>J+&V(-XON6E:T[.,8E@1BA%4FDG4-"S:B=-
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MSY$^/+O1>3PC#B;KWNWKB@A&8(2C*,6$)E(0#%7BVS48Q(6K&;N#P2ADF(:
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M8Y1E4B9(R9K4IZ@@[QM)&L5#K^5]9 -(R2&D "0081AC0C"32 K&$T(3[X?
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M>^2:7IQKG&O+*%QIW=T[&#S7:'T%Y^\D^?0=P#.]PVS>G7ET./.AX^EAHMD
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M%G9V:=>S +:K&0X'ZR,8'KPI:1)RW>Q*:N@^[$V:T4C\)(MVNY)&QV*NLNC
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MC&#2(,F:AD0[8>DPM?2-2;Y&4&>1ATU#X;"4;""59OG92<=/I6KCF9I!UN;
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M8="?=E3#_3=^ZW6+:BV(^TI?D)971;EN!I#O\Q_-;^J%OAR2(8P98I G"<2
M]/M:")%99M<9N;'IO4-Z>]0%/9ZHN+NO]*]VNNS*!?LC(Q[/-2^G<9A)NW/K
MT],&Z8&Q85L11/&]6.?;]<?E+E<@5GJ;R]=\@<.40 !Q3/0%V#1!(NJS54(C
M&@_?FC#0X&1;%>IF9G[=H0PJ/=FXK(-E<->"M1MGNR';;'P].<]VX^HGB[!7
M08\PT!"O@@/(2^X3>9DVXWTC(UF?A_:Y=>GLOA(G? U3O@_+ZKKZM--ESQK=
M5>:;/&DA:2)P&J.48!A3*E/.66=<%[[+AFO?8),3JE]3!NZ[1M>D]>MRLUE6
MM5:_-FNQG&ATQ?D0"9R$[I$BJ#"J!AVT*-OU%JV$[63C)87P%'G&4CB:_3F*
MX7BGSLJA(\Z,#@2<W"[3CA8?396TJ>K]7;EM_ZK6,YJ9$N8LB<*0AYAF*C6-
M<9^>BA0Q9GQPP#N2R19K'@_OU*CN2[Y?N5&0U>][S.VG#UO4[AXGH!;[[/W'
M\;SVSB^$MBO>)S<*7O5K/M<WP?'">+\&U,3TX,2L@F9QB&)6P1MVV&*"()J=
MS!C+Y0O=Z[0QFL%)C^E\+2_1"BSZZ/>*K7*[4\RI3WQ]NU6=4U[OKG]LE<EO
MQ=UAQ,0>'G^T_0B]47]PA##F@ @"T@1&.-('6XB@'4(I.3<Z<'()7)[[[SWN
M?HY' =?U][:/H =E\[%@J<$?]>06JC]U. TZ[AE'TJX;?XPNZ#VY"@[1/3@3
ML(?@R1^T'PL:AX;UZ5-'UZ*'GW&4A_7W4T?;K/-W2_.I5.!"P9Q!8G IS\O+
M-Z712<-;9;*M?Z[SF*+YJEUU6L@09F$:T0A$,@UCP476;UJ7C$BC:X/\6/;<
M\1^0-2/W%II. A2VT<(_AO#!'?=$7#OJFH_X/\ -/ER>_]%=ZT1Q<-QY#HK'
MF*[Q-$UVG9\#NF?;O;GP[?4.S!F#([JH7Y<_B]O[VQ?ZTB\O]J6+C-"(I)&$
M1$@<JTZ4DOXXNH29V2G+*?%X[LXZO-U U7 \.UIGW4=M<.]WT8 YZA/[(+XX
MD/ER8B SPR".[D(O&DS'':O;H([I<6U9M>N'O<5LMKVS/X]?[[,]LSWV#,J)
MZ?0%QEF"]/7B(0TSDJ08)4F/@I ,N3F1,M2Z]^W C\^GU-UIL_.KOI,>0SG!
MW-F-'WYB,)<=()Z\,SRPXH9%H[Q<=-T>W:[E=E?L'MYN;\KJMND%_[_VOK5'
M;AS+\OO\"@$[V*D"LF8E4M2C%QB SQYC767#=O=@X ^!<(0R4]N1H>QXN)W[
MZY?4(R(R,T))4J1"GEV@NRKMLG7//20/[^7C$G_;[C;SQ6X6$<%R]3Z> 'D<
MYTQ$'*G7M C+\AB'7"=^<V+(7W36P0OFZV70  Q.$ 9?.XPF!1'=D&L05XU.
MLEW4Y(!LO8A(AX]+\8Y3+B<0S;CUI_+5Z_2T:UF4![-?Y-^804'CG"#&!$HS
M%C(L$.P^GV9Z&]W&'_6<W1^&B0*C)SOFO/1+MU=*+!6ZEXTS<=.V"YRVQ>)?
M[ZKO_T,ZU<1,\H>7H=)+A\^H@S4GUQ4!>]C5P+Z@/Z2Q_/92?5^LYG>SB,>
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M#QE?9DA/LFQIG9Q(63MR69:&<6-Z9N;C_$GMA$LMQ.J:7+%\C60&4\Z8@#F
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M,Y9A'&.>1SD+(>W6[2!+N%7(8&MKK*AA-_]Q'(+MJ$L,U_X'\VH6+8Q!J67
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MNOQ1*<S!HP)M6L36:4MHQJ)7:P3#N/1XO_/S"?T-U  ?Z:_1!A][Z?=4*->
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M>W-G"'6R%3>DH7ZVG;=!OEIOM UGV.A.?[.*V8K:=D9YFO%,D"A!(1(HIQ"
MSI+(#4)_R^^/MS/6K.:W"WC'K2^;&^JF'&IO;GFESVKW2IU1:YCK,(W E\5]
M?H^\#;W-K\N?V5W^YP[W;PQ9TS.!\&^H!^=N\0]B0TMM/Q7;0O[!>[%?JSH!
M[96,)!44DHPAFE.09#CB25<L(.,PQ ;;,'8&O.^H=+""VP:7RJ_Z;AHY8TY#
M8OU39J:P!ZY:0&_=RG+&E8&\^N?,3EU-N=/3UK/>7I+68=1,0%D'.E YZR:&
MM5<W\\5N/U]]^+9J+^<V900^W+Y&\9_RU[-(I'D40P["G(<\9R$..QAY'@F3
MS6\?YJ^BR<&3_*WV)-BF^^^+:B4]K;IK(>OEX6_8'!3STE0:,G_M-C*;!$[0
M!D>X70F5#[?!.:4+%.AK-X5A\==K-HG=''.^:0[E;2J;MM&O*&O(UZ59RB?U
M$YC#O+KWLORL7QYUEWOQ8J&L;C_.G^;?5L67S7Q9T';=*$XA"J6=),_D/W@(
M:(9@RD1(>0P$-'K&JL].2'$",I)G>280ES_%%.(\8Q!&+(K- D"+59T:2S!O
M :I=6(70['K,(!K[IZ&Q&32;<3I400OK)JB!W00MM'%7N'LXZEF_=L'L-%:G
MG7A2N>]W)F^.+A:;?;'L1!"OER=[8S,!J32144%)$N<X82E(V[&$L$P0]-\?
M[37#A<@1@#RB J%49APBIW$4IB3+$(]Q[%F1#I& BIJ7IV='%.KYRF35=""?
M&B'R>%0:2Y/"=8RKU.;]";3Q2#1YSW0T,@<NE1AW3<UW3OO\OQ26NB%M @&H
M(T<JYQW*.*A4-C]NJMMBNY7=:[X21;$]!$09#4/&H&SX3,:QC (9U[;CA1*J
M];*7IJDPY S&.8A !E#"228$X5&6ATD.<N;]K:]36*KTA:& N^)3.\ <BTH[
M(7_&IH)VO2BSAZC^0-,%PY.)-9TX\SK<=,>12<0IXUOI_JHS!,-4Y!'@(4Q1
M%L,(,YQW@RK'(C.--%]\7C!,LX1!DH,$41P1)+(X#I,HA;&0__,M3 V: 0&E
M*5WZ@:1'IBQUIR7K+;%QQI5YO.B1,[LXT90[H^CPN;=O1(66U$PG&K1UX$P4
M.(@+W>BO+KS=&NR.HY5'!0=(A F'.(.$YAG+<)*2KO>C-#4Z(OJ&*2I"P)AT
M*,\HHI 2GH*$1!'&>2XS--_/OS1UZN?M2%@=\9E%?T/YU(O^1J323(4;%CL]
M.8%VI>BOGZB>Z,\1P].(_EPY4WGIA8/V0&2*W#/:! 4<1"SD,,JR*$,8=KE6
M$N.$S';5;KZRVA/IM8LX)"F3Z3JD(9+_R%@,&:5)(M%D66*V1W* :+[,W^Z.
M-&4=#91MC.7^/@+UE_^=-,,T!JD7S_JW!QRRIWEO]6#E4[&:[]3+'Y_GJ^+#
MK=CO]IOB4_=0Y"<9]XAJHZJ3?JGW,8H?.R+)^ML,XEA=HXT!"Q,BP\T0 U5Z
M/T]Q(@1"D<%]5>]8/$<LGQ?WQ7*_JN^LS!>[\GNY>PHVC2_JY1U5YFE=[ XC
M_BE0G2XHZ]ZH3IK(OZ?^C$WAH3%:4B,)G5@CFL5*)^"#%GWPI0H4?G7ZI_$@
M.+@0*!^"UHG@:^U&H/P(:D=,GH >H_6,KJ9.JA5MKZ3:M^;@ZZ=#^;N4E8_8
M,A-(X<?TMKI._S>+M=^M5=''SW(D-&]V?=O6!Z%F/,S42S<,\3P+$49)C,(X
M(C&-XS!+@.Y;=[:?]R?)#:+@ "GXVH&Z+*]>@N4+U/0$QD/)G$80/-B+RFT7
M,QLOGU2QYGVQ/9C!$1)9DB41R5F$6<J3,.[," 2,GD4Q_KCW<R\U'K/E,7.&
M]*3$*SEF&M)!N9IVO.2B1S2L:9N&6MC#KQQU'\/%]L?ZXO?ZCO]XK.\?'NQ1
MA'@*!$H!8RE"3 !(6WL1R8!66CO<BN\E]@Y84+3(#-?6[>G37%8?A3G#%?4#
M:1VHJPG+17KZUM$'4SH-J7'@Q\O5<T?,Z <GYPZ5M<9GC&,>0H%"D7)&(L0@
MZ00ORD$.S2*5(9:\ARWGST2:QC&#R-0-:L;BT33".:'PM.!6"VWL<*>'I=[8
MQP6[TU G1[Z\BHK<,:2K4G\NUE(65VIG8OE0KLMM_539]Z*SB@7!"<\@2H",
MSJ(HY 1T5EE*C#*JH;8\*U4+K]F]>P;03*L&4ZJG5F.R::97IT0^QW8=Q7J#
MJ1[-<L7Q-%3+F3>5GYYHIERL>-P4B[+9[TB2&(<187$:PS1E@-"X6U^*8BQB
M$YDR^K!G33K%8J9"9O3H28XW9LST18L4+TIR:KE'-JQXFH9&V$&O'/03X^QJ
MM]DO=GOU:!]MWJI79X<192&+"0@QC#%(PX,I &)A]E2BE0F37F]58N1SN2OJ
M.IG5JEPV%2Q^65?R][)?1\\#7M'3'_[;LSF-L3',A=?!_E ^M+<5'Q[GY4;E
M$A]NWZUWLC>I%U#Q=EOLMOS'8K57E13^7%7+?Y2KU0P"$64X1Y'\7T@XRK,T
MZ3#P/"<F4ZE;RY[GVB-8=5*G/, -YC7>=I@E(P\S(PK[]BN]-,4T!J8GWU[N
M;7ID4#M=;S]_Q%(_9(R@5 R<YCQ/4 (CDF84ML9 3@0PRM+M3(PZ..]:C%<:
MD^<IZLLCAW$ZC5$VU(F76:,+3G3'S8OWP-4OWZW;VGF8(0!3J,H&Q3F&D+$4
M=Q93BK0N,[JPXWD$X<VW<K<YC1BC<.1QT\-.S^!QP>DT1I 33_I?NA_ CO6N
M^HSB-..1#%V3',> DT@0TMG)>!Z:W/LP_[K1N#&_W?%%_96@<KV7_C9IEGOH
M3OD:NG=^Y0USDXUR;=ZFH24#\+^U,6[(A+%N-(<$Z]D>)K& @G"&:0H@IBB*
MNB@9$*2JZ%DHA\'W/6N'PM#< FGUHUK;ZH8):8;*X8DO6^UH#P7_H@"-'*"<
MH41'0BP(G)B(V'AP24:LV= 5DC^J=?7<6*M<Q^/&" B2)1P0D:<IS4.*>6=7
M2%TS">F'6_-]S*^^ UZVHV;5.VI\\:FG..-2::8_I]@.$M3"^_5J1P#?9*Q'
MGMRQ/0VQ<NA/Y:M?FM[W^5YL=VKIH['Z;BV'O_P=J9NAH!2Q*$M2#K%(^=%<
M3EABM 9O:\3WBEZ+HU4N,\FR9TY/J48AS4R@CI!:>;H).E1CWY4ZSTW?YL-0
M.J>A0,/=>'5=R@DO^GK3?+X[F -R@(' "%(,.6$TE.K66H$9)N%L7=S5UR--
MU,;,A-9XR9OQ\@J-N=:TBS?M FAN&"@9\Z<K-AXXL]28EJ>KG--[P4.OGM@Q
M-A49L43_2CV&L* K&J+:%.7=NBE3LGCZLIFOMZK\1;7^\[Q<JS2/%+?RSWR9
M_YB%*&)2L_*<0@0S1A$!G6Q!&&=&CR*XM.LYE&FA2G59W,O?+X([B= J%7-*
MMI[Z7(MG,V7J*.Y@!B<X@S_7=-?K13?!MQIM(.&.JUX&//8HFX_6F(;J>?&L
M\M^7#0]HM'8^K(^QW7:6J +XD&5YB,(D3R@4$>ILT8@;'4^VL^!9 >L1*$=B
M>4Q2FA K'OMHQCEV^DYF#&)S&B-KH \OSV4X8,2LX(FR)J17_._[<O?T>[&[
MKY:GMA%,$>),O1<A;49AFB>'N"9!.#1;#7%AT?-H:F"=#B852EQI1&DQUANK
MNV1\&B/.L4]GBZBX94RK7J TO"GFVX(5S;_?K<6\W/QUOMH7'VX/ATQV\J=M
MN6SW,[MB2D\SB%/,< A GH T3+(4@6ZS!Z:,48/5A!'0C+/P0)M\0$Z.MQ)[
M\%V!5P<8%P?X]5G^ _YFC&\#6%^>ZSN@-7KK]6<34VDQVS)4-=[@EP[YK\&[
M=:# !S5Z55'NB#]XYL"AZO+3=-K*H!C@=-K,K@Z@[[;3*PDXB,4SD^>(33.!
M0H C.5J-WNT=G6N849RPF.>92 7+PB1"A'8'LF 4"FYR3,K>RC@'+;V=9GB;
MQ8&G&)P2Z/#TPD2.+-@<5="F=!IY@0,_=(\F&#)CEY$W0KB7MC\<SB\V*VC-
MG_LR_U%L^8_=9BZI+=?SS=.[7?&PE:!5@"N96]6PNTW-#/)$O>Y#,,Y0!%&.
M.M64_T?01,6NB7.,0Z/M*G:K@SN%WW2O\HH-J;OO^7.TH7$R<3R^VAS^/;H6
M''WKFKC]\[5[-\%S=ZYVPL-;PV@O%%VG.TQC&ID$$[V+4M=L';.I3")I9TQ2
MK(O;<C?+,*1AG)$X@X0(F<JQM%LXBQ. A-6I%SM38YU^Z281J3DUL+?OS;IE
MU&0^\,3B$"V7D+H3,<$O+:JKK,*_XN9-.;5G<TI2.,"+LS(VE!7MC+[8G=R&
M8(!S$<49)2S.24;2"'5[:#&!'!ME\49?]ARQ_E$T.U0C)YJG%/0EEU943:/[
M6V)_F40.8$"WJW^4+5ML-L7R\ZY:_(V5W\MEL5YN\7K9/%NW_-_[=N?J<*@>
M0@Y# @7.,I[%,0+1X;Q:3# TNGCOP;SG3=XZ( KFCX^K<E&_+;2K@L?.BV![
M/Y=_]T]F\[./-M";NJ],O]FL?@ ;U&B# ]QZTZU]4O.(^&J7?\Q)[5%!CRTT
M#:GTZ6 U6F_W);JSG$$0LDQ@$,9<)"G%QP G3C&QR'H<6A\G$<+-@^[-!OS^
ML:J/K,GN];W8[.I*7R_UUY?\OMT:KF7730N,(;=3U5@GVJK=##^;INH[9JVE
MAMSI:BB?;];E^F[[L=A\5H/^(-E)S"/"*>54@)C'G$#<5<]!*8^$27AJ;<1S
M$-IE;L%\M]N4W_:[+A*5V<*#%,=:!N^KE>QGVYO@48[4^G?,=-&>83T5'(5<
M,\WK( 424U"#NEH4>8F='CT;3.@TU&NX&Y7CCC9,F<A\6R[4XQ#E:B\#H)F(
M&1(1C-((<"IS^#A,NG=K5*EUHT>LAMKRK%,UG.8)&05(/27P2[D._O*9'45I
MY!79-Q@S&%ZV7$]SE%E[\\9@&\:2UOGG_RC*NWOY;2P3@OE=\<?^X5NQ4<?!
MU%Q8@S@F=  B)C,YAG,4<D0C!%+6F<\1U2JYZMRHYU'800WF#=9@78-M\JEC
MO*"9-KFGO#]<N"K;9N'#@>@69M#@;(ZRUD0W4'6""L^<&QPUOA;W=@>+!W=V
MO9/#!J1<.B?L@]<)G KVXE;EN3^:17@7$-2V/^QWVYV,>.0<^'+J0U',8)J'
M(F%1@BG,HR0Z3GV F+USX0F$R0BU>@GC14PH1ZH*"9M!.7(L:$=A3XCHN4VF
M$3GZ=K(:M9\;5M7H;ANP<KM85=N][+1?BA\[(@GZVPQ& LMI H&$ XC#6/Y$
M(4 93I*($F[T.FB_)<*D":E?'$8Q(F&209[3+(,P)0"*R/<FJ'AV*^ZV7,_7
MBW(NZ5JKUU'ZUX-]\*JWX#0>I69AX\FEIQ-DP5>%+:C!C;SVU$M4C_RY(7@:
M*N?(EY>5+APRI)4;'RX_?2I6]?9;]7F^*C[<BOU.VOY4/<U7N[+8?JI6*U%M
M_C'?+&<I1XQDC!) 8)8G*4M0#@!&A%*!8[TJK+YL>]:U ^*@A1Q\J0(%6J5P
M#>S@@#OXJI '+7233,Y'HV@DT5=N#S-1_(F;PB"WOG*3V*787II&+^TVY^M2
M]NV1^0DDX3Z]J\;IO^XGN1F/\Y22'(<8Q!&@6(0I[TS'*$]GC_4#+)]W\\W.
MW?SVIEF3$?L2H=F6\6'@;MJ!NZN"K1JX*HIO!N[F,'!_"[X5=^5:K>8'W^;R
M8PO-#62W;>)N8G/:$!YGLVNP['[.<LKV"!/5.#/3P.E(F]2?9P[2=\EBXC'D
MRVRV43?JSEK%RV59WZV;H9QPRE1UUS!G(H99A&!CGH5J)=H\EW)@U',2]6XM
M<<Q7<HY95'?K&I.:7PZ3CXV\N:#:9"(9F67;R43!O"AH-\$![+4HMYE51J9^
MZ,PRN D,IY>WZ7ESBG'(\)2F&9=NG9UJG//F:+I1:XG57EU;6"_?;;=[%:G3
M:JN*#=*(I%&"1)(2$.54())W<%">QZ:U_7QBT1JT@^\2L.+;+EBV(.M=R+)%
M&2P43*=*.:!AG$Q6GAO#[^1U !](]$$'/Z!3:B6G\]LXK>5YOK-J-5=3X$4&
M[:?$X8WR4TR1#MPTFS)=\>IH"OVC6M/Y]K[Y]5-SZWJ6P!C&(D6<IQ#E@D09
M.4SF!*30_>QI!6.<B5-"^VTAL;4+A&H)\7NQWELM"3IN!B=SI3_J_4Z3$G>@
M@+>_]]06III LSB='+TWC^=YT;297$V)YWBSGPT'M<)/,1$.\]!L#G3 IMOI
MKZM1F48B5R>L!$T(3'*1 (@[#%$6<X>KEH:6/2]='B:Y\L7+<S[D5)MME_.;
M#Z)]SVQOO6HW1AOXF,Q\M,58TYCA2X-#YZ_+M8C]4OXSS5G&OEG-5G8,.CW&
M$85A&.<(1'$6HS0#D$;989$U1:(]QL'72X>'.-XR:GZ(H\/G]0A'41^.?_/\
MQJ3VN'6IGM+@=.62S1ZW&5^Z5QT^RSFD4%/)A]LF-,7K):T>'C?%O12 \GM;
M,O9PU2J#D2 I"@D..8J21(@4   9% )G(M*MC>/:K+] YH!4#;UG$+OBT->J
M'6'(8<^)?E^M,8TS_MZ\J\;ITV8#NB[,<\:LJBXIIY8/MU_F/S[6,]/+5U8.
MP!#/&0=I&J=R8LBC$#"5G#; 0,:TK@:,",=SMMC4P%H\&_G/7D QK ,Y1@/I
MB?#$VL9,EYMF.2O(W6/#*I*2HJT*1%]+HX=3W"/;([;?-)1\3(>KJXT5-WI_
M^;5E.2W5OUK5JP?'&FX'-ZI-_1].BHY]J3[.Y6=V,Q[A!&8A11&),T1)+@CM
M?,@92UU,#==![GD6:<J,236JWII.U!\JFC=F'^IW18W>;?X9^LBPV6GZW</Y
M1-:Z''0^!R=.UZ>;3MP^J=9Y.@/>!*WW 7Y13+ A8!K3HI>VM9A!K]O'ICW9
M7ID;S7EY"BVH.X6?@=^!F>5"O78!(O6ZNP@SH4[,M!9)!&EJ\BS%$#M&TZ/Y
M(Q7/Y:_WN0KW%.K-1V.Q9S9[:"9 -Y.0_1X*>T3:!?'3D%0GGE3NNZ697'TJ
M5/F7Q6Z_*==W4DW;=6LLU?5[V9WZ:ZI>'(M>)"2)4Y;'819F$"81ISB1&1 /
MDY"'662TIN0%@._XO]P5]6ORU:I<UC./F<#Y(5U/^:[.MYDD/H-;A\?=O= C
MXI,2/%>LP&-#;(]0>FVG:2BH7Q>K$?N]X3;=XKY8[M6V(%XT)ZH_SI_45"YA
MU0]G%,MN'U'B^E('K0=(/.%Y2B,2)3'$29JQD, DI")':1PBQ$RT=Q 0BB '
M%$8HPC%*!<H(A0D0.2!1A-,X\:W!+785$\U;],%C [_6B7GCP&'[7?N6_CC-
MI+FU.I46,MQG/6F<#GCP\:1Q6NS!"7@IW?5_OIJ #^&Z;S]VC":<AJ"/X^K+
MG=KQ^-45>*RJYGR1?P7_*+<SQG&*,(8QY!1AF@*<A0"D$258Q-Q,L<V^[%F"
M:S"!0A-\57@TBWA9LJ0GF/X(,E- ?6Z\:-DS&GK$R8ZN::B-)?;*18<Q#/C:
M5Q6*^@B)S.Z;U<K-1O:8^I#)ECP=_XR4+_5[-; CNO7RH^Q@?\P?"E8]S,OU
MC$808,91R-,\!RQ&!*<-5!)F,3=*PJ\"T+,Z\6;;K1F(7QM,A@IUG7;3C RG
MWF1F>FG66G[B/P^,]L6%UVS :2CX=2EX&4=>OSVTCMSSA\=5]504]2M^'QX5
MR,.I8[J:;[?E;5DL?R]4S?49%A"!#,2"QSG/4<X3(3K[+./Z;^<XM>I9^8]7
M8Q8'9,&V?A&S>C0MKN26[GYMOR[3AH+=PFR?&FV W@1'[H]8@Z\-6I,BOVYI
M-[@*=C7Z[:Z!.6T&O2LE)@Q=NE?BA>4)7"[QXU?ENW\.FWZV9P"<//-QIH#^
M#*0LX5SPG %5ZC$G4, 6F%HQ-2WK.PXHD]%L7?3W.'+GNY-JOM5ML+LO@N:S
M[@>P.5L&(]MC4TQSR/MT^ TM\,ZUEDC4<?*WGECZV]/QCYR&TJT3_$>Q693;
M8ENNFW/8!]PS@EE$!,192+,PA2%F G=H(YQ0TPH_5X2JI2>#JP ]?_CG<!GU
MMY/8N(V*@Z+U19U2UI&;:36\1FP]]<:VVVQ3B'^K(0>G;@4G?@7?GH+3/]?Z
MUJRWW+1AX_8F.#BH>D#CXDUP?.SH)^D)!N'^3](C[)*#*?0,O9#$7S-<BE,F
MT/ 3"%ZFP$(UK>%H$.:\O!U6K@_FJMMS@5@#<L:2+**I!$-5;A8+ A/40>$0
M:3TZZ!6 YP6Z#G;PR[(%_JM2E=OSD8K!I..M031BBRFTA5G@<&P&=MH,)V\;
MRF8XNY+TP7@9U5O+&,SU4V@ANXG<7TOI3<^6S%V:>WTWQ 0F5N\N5B-V[-&7
M!XF@)&<H0AS'&(<HC\EA22*6OVU4+FH<2.:+@\;%I)XM#1;KY?]KBX*Z33"!
MX3^RP^X7!<VXUG^+>]'"J&2$?M?N4B0@5T8PC2D'(((@CY.F&!8G*"9L=OIH
MO<:3T38V3(;O*1R#9;A%MR==XQK[>>@SI/0<3AE&XC1.EPSTX=4ST,,9&7@I
M3Q7;5[4<%^W/T8Q&'"/ B$QGLT0.TC"-V\K#G*98SI/#+^*9&_5]KJ\%$]0W
MD^LG8-1$N/5S)\^"<[WS>U>AVRP_O'SW3B&["0XMH7XYB<MVK]CKD3CG#3 -
MU7/OEMY%NJ&\';7QM">]ES_]VS]UOR/_H1;^_NV?_B]02P,$%     @ =6-F
M3X'_A1+&7@  )H$$ !4   !A8G5S+3(P,3DP.3,P7W!R92YX;6SLO=EV(SF2
M)GP_3Y%_SG568E_Z3,T<K-4Q$QF*HXBJG+G"85 NR;LHNHJ+(M1/_P,DG=JX
M..D+78SN4YT9H71 L,\^&,P @^%__*\?=Z-?'K+)-"_&?_T5_@7\^DLV'A97
M^?CFK[_^_<MOZHOY\.'7__4__]O_^/]^^^W_ZLN/O]AB.+_+QK-?S"0;S+*K
M7[[GL]M?_KS*IO_\Y7I2W/WR9S'Y9_XP^.VW9:-?%G\8Y>-__EOZQ[?!-/OE
MQS3_M^GP-KL;?"R&@]GB=]_.9O?_]OOOW[]__\N/;Y/17XK)S>\( /S[NM76
M+]+??BL_^RW]Z#>(?L/P+S^F5[_^$B4<3Q>_N\(O*3__\>;[[WCQ-912_K[X
MK^M/I_FF#V.W\/?_^\?'+PLY?\O'T]E@/,Q^_9__[9=?EG!,BE%VF5W_DO[]
M]\L/ZTX&DV_SV7SZ+2_^,BSN?D__^7<U'!;S\6SZ>? X^#;*U/@J_F0RSZX^
MYH-O^2B?Y=DT#FC1[^TDN_[KKX-O\VG$ DH@,4A(_/=#^I@]WF=__76:W]V/
M(B:_MS=HF\T&^:B1L;_JJC,1OJ;_TH@$+WMJ1 !3C$:#;\5D,<NFIAC/)H/A
M;!I__<=\F(VG<:*KFTF6I2F]5X:C.NM>C(J<JM-G0T*-K^+OR:[B'Z;%*+]*
M]E0/1LE.?+G-LBH*J=I#1P/^/)A$M&ZS63X<C.J/?F-W[8GR91;_F=1]<?UE
M5@S_>5N,KN+:Z/XUSV>/1TE3J<<3"51?5X=WWX&HTXMK,YC>^E'QO9Y0&SKJ
M:/C%W?TDNTTFZ"'[$-VQN^QC,9T>VZX^"NV,IQLP+^ZSE86OC</;KIH281;7
MFNAW1Q<@KCX1MKM\5G%!WMNT[2%67FRK]M#(@,LH)?XF%W_Q[/'#^+J8W"VT
MMV^H5=HV,LBEG?PCF]T65Q_&#]ET@<>^X>UNU>+ *FJZ4N-&AND'^>0?@]$\
MN[CV^3AZ#?E@]"'&69-YI<E3L7D70U73:;;R/-?!P!_98#J?9%=J]M1X?)D-
MYY-)G$AZ,,VKSKU.?GD7,)G;030ATP_C9]^M#<LLF>W\:F6BFX'F^%]X*CB>
MZ=",!M-I?IU'+4X7[MG%?;O('/R[NP"I6G1^4">-#/O#>!81S--60#G__E84
M5]_ST5Y?O$+3MH=8D435>VADP!^CU=JOZY=?-?B+_QC,YI,%_>-<2#\Y?)_K
MX(X:'/ZGP229LH?LH+%N:]7@P+[,[V,G:2(.1F5$]LPG.VBXA_75H!#5[-"F
M;QL<Q)]9?G,;HQKU$%>MF]CX;I"/XV*V^*]?L\E=G* VGRYV*B]CX',0M#4[
M;T3,3VGF1".NY]-\G$V3P?'SQ8\JAX$'=-'(D"^S40HT/P\FL\>OD\%X.AA6
MB5+V-&MS:!594:UU(P/],ABEE7NAILOB<3"J<AZRLU%[PRIM^:.*<#S$?U>$
M\ZC.VA/CT-7BH$[:&W8U,URA:3-#S&_&T4L>#L:SU?E0M)>?BU$^K,+?*HW;
M'^;!1#BFL_;%: 3U[M%/Q\M7\U&VW&V=SQ8+5%R\8H0^7*RWHWFTP4^;KTTH
MJ>;O;!^4BI.\>A<-#7F6/6TM5UCBMS9H9S@O_N)^W*>]\.I\.:*S=L0XW!Y5
M[*"=X5YFTVSRD!WJ#!S633M#KSK-=C9K9FAO3A^C'5K\,!JE=*!SEPA8;=(=
MWE77(E3ER-$]'BS0ZX0JN91IG-VD".#CX%OV:E-K4[O19/*B6<KDDBF3"[*%
M/)MZ:WBDG[)9LX-]W6'#X_V<3?+BRHT;AGASMZV,_<LLAH=MC/YMQPV/_VN<
M5EFS(W_;9=-C+F:#4<-C?M-E<V,^@ABSM\.LR(+[25Q"QTMG]F/\P>K[U&]C
MJ9G+7Y[]F&7CJ^QJD0M:_OI1,=PDYT+&Z\'TVT+0:.)O!H/["!(4OV>CV;3\
M2;+\XC< 5UFO_WWUX[ :U+0<U6 T5=^FBT2W<DRCA,Y??XV_/U1H%825(JXQ
M5%.GI?2,&J$!L@XPR!7B]*6HHY3?6TQ60+<K:Z4<T7PZ'!7I:/-KU(*. _GG
M#AR.[#%H[:U3Q"N$)>-2.,!!B1$6RE?!Z#D=U63X2S&)Z_A??X6__A+_RW4V
MF:Q6PAU)S0MZSM[8E,%D^(+4;QNNOOC]?I'"]=OP-A]=E:U3CG<+;"E.@7R4
MLS0!OV^T =U8AXW>U[LV$AA*2)V2'C)"+0126\B1,50PJQQDO3$27R>#J\S,
M)Y-G*33[#<'S5@$8Q9#0D>?"4Q?_1 Q64EB,H84$J)]GLE?6^N[)7@/=IPF]
MC45OPZ3TD[":E"F*CGW<IEVL["$;%?=WFXFQOU%PWDN*L(/&4\JID5X: @'7
M0E!'%*G!"W3>O&@<W/VT:,RXI#%_GA37V31=J1J,?)9-*]F7'0T# ,YB(A%$
M E'FM/!>.Q@75B:1M+*2S[6%2OB\J=0*P'6M3!0PPC':3HOM'P=OE8FR8BU1
M=*84U-0+0A;N#?'Q?S6H0,Z;"HV!VI4UN9C=9I.WWN)^:[*[83 ^>L0VBB>%
MH08;[3AB&D*EI.28ZQH4HN=-H58 [G!QVAN)'.P)[^HE4(<UMW&IQ@;0^ ]A
M";;&,(:B(R=8'<^8'4RT-]M4[X%H[:'=D]!WTUG0NXY\/3= $..,9(PR;"0V
M4&#K"8(JJ@&<+O)].K6OK)@J>V1UN@V&8H<,AA0J0KFG0AO,D)<H64M.*NT3
MG$?L7)DWQ<G@[\!DU+A@WJ'5N(R!Z'B>^:C@<HA_YK-;,Y_.BKOH&.RW(!5[
M"#9:<>@0M )RZJ543D/+).02*([!"??1GFGJ(5.32;H-LKCG== &^P&]!*04
M(H)"!"FFC@/%!"-,$F.II,CQ\[(5C3.DZ KYOIF)4^^N=V<M!'4NZHH"X('@
M%$B% $**:J.9\E[TP??8O)_WC("EA%^+S]DDW<OPQ601;RT7KTJ>2-U?$ICC
M,'K3@G'## ;1E=:D1))2>F8'>(WS:ZN/TK%BC@RMIY/9,VK'O[VF=?Q1^#PI
MKN;#V<7D2S9YB%9'_<BG&\BY[=, /8]FFR,K(30T_E,RL9)$,"#J[.GVD&*G
MH$#1J 8ZX%):P%8#G-HBW9[:3:BWWP> F=90$V(32D0:P/A:)@7L>;"JODK?
M<J,VF%WMXRWOHSS^D=U]RR:[O(;GWP7(#8_!I=3*4",41X1$9"P"A"#A:IT;
M]),8=?19-(=D5ZQ8.K[97E:\^"Y$- 2.48+T'$F/@$ PR8*ECPL]%G5BJAZ=
M4;?#BCI(MKF8F+0+E$WNT[7+3X.[78[)ID^#H\H:"A4S$B"K*>5:EW@X3N5Y
M<*(GCDD#&FB32Y?9_3Q",IAFZWCZ]8AW.BJ5VP<9UVIG#(LFU$E,N>.2KF>A
MQ^9\UJ=Z*B_:!_?H](:_3?)9#!G'VU>A39\%E;:69+22'A"I)/(&^]7HI&/H
MC'S6%C16- 9L9_[K\7;V8S[./LRRNTWK69/=!TPH\Q1(1#U&0!M.<;G3(6GT
M\\XKX>J$:^ )M=8=WQ>[:[LYN_PD6"HMU!PC;UWT(ADR$J\D4)3+,SL/[5;I
M;QAW%.:=G&X<5M2YP[.,9P5_UV72/A?3?,&U_0<959H'A!TE3ED=_Q\[R0QU
M"J=T&>*=PQJ>\.[ LH;9?CE??ABT50@XY80A!!".)3&HE,AH<"9[+^TH^75"
M5!UD.\NT6PQRE9=5F2ZOO@]" .&\H]QS:F5TM9U;R^:A/9.(J*YB-_*C'I1=
MT225GTN5D.._TO7\A\%H48UU9@:3R6,^OEG4H]R5/%&E?3# .*RD\XI:KYQ4
M_&FF26;/)+IJ2/^ODR1:0+@K=GVY+2:S5'7OJ0;S+A=TT^=!<L(A,$ +@22%
M4;QHG%>2 5[MKN_[V0ILECL- -IU9OAE-LPBR6,<]RF;54\%W]0L (6<LY0!
M8@UF#DDF02FIH*!2'NS[B:";I4Z#P'9%H<^3['Z07ZT*/46;N;PB\1R670G5
M^UL'IJ$GBJ1]L.@U&DD07$Z=*#/4O@ZA>GCQJ5E"-8_O25SIJBYT@ !C;0SB
M4!B,B"0PW858RD(DK.,Z'[YNM7[QI W7^4 (NZ+#YK<E=ODU6UH$[!F0U# I
MH>5:0:X8*N7SUM:)R7N[/M6F2#-@=K<F%??99/;X>318/N821[_888RKZ<[%
M:'NSD&Z:*R0MYEYQQAP'1J^G!3%U+O7W=A6J39L&$>WL[NVRUO>J>/EE*FQ^
M<?WWZ?(9@QWDV=DN1#DQ8(YBXKECADME>"FK K12@O;[N7G;$'N:A+0K^KQ^
M]R(2W?T8CN;I7=W73W5L8%&5YD%(01#%QJ<KQA)3R?!:<@1%G17L\-NU[X5,
M+2#;%:<J\&8M@8O#9##5RHG++X]_ !2L)(!:H3KGU_QLN7$D>MV&0GMCH! =
M=Q@'*@B45 OKJ5!J/7J#Z@3*/0Q^.CAM.A#1[C)^U]=ZR[J^+XO][C]XJMI%
M<!(*"P77#"! M<0H8K)" #)6QW'I8;34*J=:POP$K*M^P+F]4="<8HH8AD9)
M#00S,8XLI>0,UK%6/3R>:E[YV]E5#^GSK4J#N;/68XDP1DI3Y@$N-RL@LJB.
M+>LWXXXF1(VB-(>!W6$*ZFPR'Z9']L8WJY<3]I-L1ZN@'5?02JN$MHA*0"B0
M*SD15JY.,-;#D](62-4<N$>GK[N[^U'QF&7/WBM]>E_KZ4'3B_EL&H/(%#%N
MRW _O*> -.<Z59M31'NA$3&D-/C1HS!UCBQZZ&$U2*!N #_-ON.3"/MK_NUL
M&"P%UD 'J <@1;3$65A*B[2J4_.OA_O6+=BG1O$]G;-^D),>O "8&$P(%P(K
M@0B$>BT5!&=VCGH"Y_Q A(]>VM9\7;W)^;78_!QC,1[N+DI[<$>!"**!PI+'
M/W!A-(.\S"M T+ S.VAMC4.=H-^57;(KI5VF.Q[QW_EL)_.J- M22N!UNH O
M'$8LVF+'US-)^/-=X=JQ50UBW16KR@>;37'W+1^7KQ"F-7MYE6B:7ZT><%[/
MHTJTJ]5O$(! #-*U(@.]4EPY6EIX3(&H<Q1S\)GO0S;Y5KQW9G:ICA.[_97H
MN;=M7 0P9AXZS#BEPF,D?7E^@1FN5=&AAR?%K1.P:<"[7G67#_-^'?QXAM3N
ME*@]+0.&2 HKE"(J@BHMP*:,?K!EKL[:V\/CYL[6WF;@/D&P62W*#,9#X8&0
M.KD-G%AED2WE0*36GM?A+MO[/JD^'M;.[B,=<T"]:W(1I)'7*J[CSDH*B)-K
M&ZLEJG,WJ8>Y=*V2IS&4.[QMLM3.8N313"X3N-35U0*0",T@C];3#.[S.*NC
MR;RX3G6-TZG5SL3?HWL-S@ /F:#,"X&4<=;I\IP+8R/=>1TJ-D&8MU=4.@*_
ML^N]Q=U=,5Z(L_<F[ZM/0_0<$5!,,H4U( JY&*BL)"+$5GL_\?T<)[9 IYJ(
M=I;]L)G>NS(=-K<(T!*@*$1*"X*]=9R9,F>1  GK7$SHX39K"XQI!MCN,AAF
M@WR<7;G!9!S-Y%0-A_.[^6)3.$8/^3#?G<BPKW&P0F*HC!68.\T%<M26/B2!
M%9^Q>3^[J2W0J7&,.TS(*@>ZN"4:+6E4UVUZ5>$A6T:D'XOI=+$"Q]!T=U+6
M(3T%IZ4FC%I-O=%,<T8E7^.A69UBM+WTZ)LW8:T"?KI \:  ,=U<=48"0Q"0
M*B[ZGJTOE*7@J([OU,-7YUJ@46U,^Y(!7R/S/3A*K7&"(&$XIIYRI,N<LSAE
M9*4J9.^)12?,>#\0ZR=VG; "W^<%K+?9+!\^N>MG68Y/,>NP]\QA3E.JE%84
M.&NY=FGAJ/9P0.N>BLVBJN/PT\CCGT?90H3QE;HK)K/\/Q<_WWH+N9H+4^M7
M!!@]/,P)T!Q8"@"0B' CH,,$.0,E/K?]H2:)M=W+Z5(GI]G;_%1$2[-O^VA;
MDP XT$PQ(2Q3%"&NE%0IR<Q[(0'F=:XZ]'(;J476-83Q:5CTY38".%7SV6TQ
MR?\SNZK,I=<- TD1JM< 4P4I1$0A+ SU#  E#*!U3GI[N<W4&:-J(GU*7GV8
M3N<'<VK9*!#L@8<"0"8-18)K8P1EV$L</4I!Z\3\O=QGZIA/1Z%\2B[MOEQ3
ML64@VBL+$4="2\H4D)H8;H&&!!DK:A5WZN5.4L>L.A[J$YR]5?*@-GX?!"/1
M&Z1Q$0>(TKBPQRB5.:,AU!!94>=,I8=Y<ZW2J F 3T">B@O<EA8!.&<04@!P
M1"AB5 BJ'7%6&RX45W4VD7J8%]<5@6I ?#(*55O7=C4+W@*C',+&4$6A0-KK
M&'A(2F#\BS%UR"1^=C(=C_.I=B.?X;-]X_N4&Y)'YOM5:!^PDX++M'NC=71?
M652W0@A;[)UQ!%=:EUN6?^];Y2\^#-9!PJV%0&.G,8A_%:R4*)FUL]T>;$++
M;XZO:D#;W2'G:I!+H=-);3'.TN,"FU_KK-0NO1H'I;%2"&XIQT0*"$I9&1%U
MEH@^T^A 16_C2P.0=D6?5T/=^@;GSN^#!\@KZ9E1J8*F%T097,I&0;67EMXA
M7>KI>6-)Y'K(GF;#9>]3T9L^#XYH(['12K@8]S,CA2VMLH4<U-D /I@S75QG
MK*G?G;LI1T%Z@A!F+U/>?!L<9<AZ"XVE0FNH/(.PE,DQK,[KY*E9DM1%\\3)
MRWO9LK-=@"A:7QUG!%&."JR0A.O9X D_LT)(S3*G261/E<F\ESZ;&P3'K*46
M,2 9]31:3@!E*1TPM>Z@]O DJ5G>- )ICQ*4]YN@JGT$HC"3RGM'&('6&:0@
M+S&@R)S945+#YJ@EE#L/TC]6>'?\[<<!(4[34RAQ[L3_LXX"5T:DCNES*PK9
M=#A^+(Z=L:/:V="+TPI' )<$1V]?&8V$<QR5,\GIB$J7T=-]-LF+M(\\F77#
MBR,4^N9-Q:.Q?"^W%Y@QBFM"H'9 "VV%\K242@A9)R'F8)OQ'AE2%]'3[,6D
M LJ+Y-6+Z\OL*KM;5# ]^,KZSEZ"QQ80Z+B)$:11@EL!;(D#D*B;P$HNF37.
M;A;UZ[I;E.I3JSVLNPO8_V.^>K+M:[$E5ER8V&^#Q6GC77HN<J'KRRS.I6D^
MR[YDDX=\F'U>6(;+;%C<C!>][$NP:?M7!^>0MXK)='&2(V\P-^M9S@SNMI;,
M>Z)USS2S?RYL*7'Z3([9*SGR4@Z335*@ZP?Y,@'I19MU(:]G1:35]\'D:I/7
MW_:O#%8JG X>A!4T1EE:4/6D3L3J/-O>P[BS 3[W3".=^IM+C]@N:N<O9^'2
M4_Z4?5_\I]UQ:Y4.@H'8(0>M1:FTE+<&HG(OR&-!Z_"QS[F0#7FD3>-[8G8M
MYDT-<KUL'WC2D)98$:"XLO%/OO26/*2D3K&)/J=)ML:M6O#VPG ]?\?!_<@F
MPWRZ>Y/EX,Z" $9[ B6TC E.',!4EZ@((NN<%_0YG;)E@]8$UGTP;@T1<'M?
M01!CN&#04Y*.XAR5F*P-/H9U^"=_1OXU!G57]*M97:=2A1<?Y6-&,:8-AU#!
M&(BY4G)*:U5^3D^EG#'+6H"W*V+%X3V-=0>#7GP7$ ?<6IJN"L8)8@@@9BT+
M(;;.92?8R\RN!LE2!\D^'U=9Y(R02FL@!446\2C%4A(/+*OU7CT\\C3"C:_>
M"RMJ0/E>3JN@] @*(ZVW%CH%N?!R+16L524)'IRM]?X(4A?07EX^ZEUII!9O
M(FF%$54<, NQQRI=?V: .825$9CK2N?Y)SSK>?*DTS]3=2M33'>_,5^CV^B'
M*VSLPE\2TD/I&+4E6HCX.GN(?;YOT R#CCFV:481)[<RTXMK,YC>^E'QO0_V
MI!S+]# S\J990!1)")##V@(/&*0*K!Q%(QG4E7(]6@LATG _3XJ'/.*K'_\^
M3<^1K%^^4<-9_K"LZ+<?@\,["UP!JPQR@$O*"3>I[,T:&>7.MUQ:#9*\C4G:
M1;W?X2QFTFOJI&!,6.ZU%V:UYV,4(>K,UIHVE;TSUCT,YA,DNJ17N2(R"T?]
M:Y&2$\;#?)2]D.)KT9RQ:_M7!Y<2*!#!0D@F/!=8$5@BSDTMT]C#I.(.B=TS
MS74U5]X\-N9^I R?3&?C['KG,P)[6@8J)23 $XNQ<(1;('VI""4<K7,'L(<F
MN#_TV?>:7"TU=4?+_:5==W)S?_,@+%+(2\D%))P[B*FQI>0(L#,SI3TF:..Z
MZHJE?QODXP36Q7CY$/>+8L-5"DQ7ZR P 8!"2E%EG?"($,]7=QV,QA1U\[I/
MU[G;O25L*TKK]!Q(O\[EW7<B]*9! !Y[[H!(UXF5@E1PMI:.6U;G:+F'"=>]
MY6(CVNF*>[Z89/G-V"R>21X^?IT,XGB':<#EE/K[>)(-1GMJ5!_23: <J3CY
MG/7*8Q@7$$?62$A7BZ?5$ZE?FLZ?DZDM:JTK_E9_>EY-HG@WR]UK<YO^^&$<
M_9GY8H]OSVOU< ?U.QI!P!@!320A0G-(/</.EKN.VE!?Y^KRP>G>722#]';6
M]%/AG6WD3:<1]KO[03Y)<D6Q)C<[$\XW-PCI[:ITO&9BJ, !(=2:M3FQ,0 ^
MKPSSWI*Y$>UT%ML5Q=7W?#1Z&N^> XC-#0*@-CUMQ9&%!@"3\E!3V1U/J8:4
MV3JW&PY.-/^I36DC^NFN+%*4=CZ<+3*<]V5EO/TX2*J]A%)I( 0R&!"E33FG
M!#!UZ@CT,+V\MYRKK9GN=[(^C!^R%9:5-JZ>?1^0((9J33FAT CAY/JN;Y0-
M4EJ#=0?DF_]7M-6,?DZUB[I,D3J4AUO:!BV1L40JQ2&)_S! E^4UC=$1S6X2
MV_]K\[0EA1U=,"#"DF2^+!X'H]GC9?:0C>?99;8H5_:U6 [.SZ/ESI:?Y!L#
MCV.["@PA)P%RACA/H)<4.UE*:1&J=3I:_?3IIZ=E1_IKB*6KH]LF6%JIJ^"U
M]P)Q[K%6D'*#&=#KN2CKW0KJ83G6]T#/-A37U4H?H9MD@VEFL^6_GX&UREFN
MD&)5O9, %+)Q"9%.>N(D1IB710@C"EK4,;(]9&^'R5*MZ>!T3%3#1>VN:9SJ
M6?ZPY_V6*LT#B5$>9AP@Y3BG&J1HKY2<(>$Z28#J,!AJ@Q1[>5<;]],Q[O,D
MNQ_D5V6"ULJPJ_&R6NYBLW17Z'-<AP%*;3RGB#.%-1(4(ULN05;&_^\DZ^G<
M6=F")D['TW1ZE/#Y,Y_=FN@?1>]G*<)!Y-S:2P 4>^6$)3#&>IHKJ=@:!^M4
MG=.98[.;SH^13<%_^@7Z\^ QF?F4(3@<3N916:MCS,VQ3[T.XV("(;8*:D<Q
MI=0CYGF)3BHH>UYY3B==PAO40[^,Y?J<O;;!7/<4K$$FP0 E=3'&HPHKOYZU
M6-1Y,K"'!2)[8S*/5<#I"/GB""K^)9L\'!;9;.H@>*9M1%8[ Y'%A!)$RE,L
M"P6K$UGWL![D2>C7 .XGW-=)?NX:I&-7Z*V]!*8$-MXR8@CAZ7T)5+Y-8RRK
MEW[<PXR>D_"O*? [O"A<<?MK!P>K=Q(X4 )01R0FB@O*D"ZK?QGKA:RSO7.X
M9UA$#IS+YF)K.C@Q$Y>'G V53]C16?# >64%=$08)+4T3J\B.HLIJG5JT\.+
M;5V63V@.]:ZX&(.JQ7F6+R91F&&674U]A+!:=L7^QL'%F P PQDVT$&N(?>^
ME-I:7R?1K)>;W&T2X_6+(TVCWQGGGHUV>3RY\&7SX2Q!58EXU7H(T% ,+54,
M:"B(TIY27,KO8CQV7I:N2^ZUHH#3$?#%'4TUOJIR.?> 7J+;#2&4%%IC".0"
M<XM,B0-FL,Y=\O=STMP-$9M20M<K\-="#>-0)]E17*S<27!&<"MY]&Z$,%!9
M)5PY)8F N$X2;O6XY+Q7Y,:UT+_(I)&()% E :%>* PHB'.34V=+%#3@W3Z?
M>ZH8N0TFMJ:#$S/1Y^/!>-A0C+RCLZ"!,<Q8!RF+. L  4<E*I;K;DIJG&6,
MW!SJ1V?-OG4:7N5'?MJ8O%"Y;8 ,.FPL\E(IP(&*2.FU',;5>EBA?^QI4]%%
MN]!W=U_O?N4;7%Q_*F99>9B]PVAM:Q*46A0_( AX!)FFRCT9; %)G;.U_MX,
MZ(!C#0-_BF"VK..\N-+_$#W//([[Y<NT%0/:"CT%HD@$A#"CA!)026F9*_%
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M&^>,E 93+*RA&I5X8DQ$M_[1.^97>YAWMA6T&N?%N-I3%AN_#PP+XU.&&*"
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MG^,)0HIJ$Q<3)RIM551T7%\,9? "^Z];GMRNU"X0)EWTR031V'I.!?2.KF1
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M[,;+#P..JYR+7A(GGJ$$$$X>^&K9D[B.4]'+I.%VC$8M4#M+'OXRO[\?+0Z
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MA,#,<B@XP=27,A, SZ1";'V5'W79^#!PCW95+_YPEU_V/%7_]$G@G'A(C:,
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M4$L! A0#%     @ =6-F3Q[TJ5%?\   Q3T+ !$              ( !
M &%B=7,M,C Q.3 Y,S N>&UL4$L! A0#%     @ =6-F3Y\#&^_/$   C*X
M !$              ( !CO   &%B=7,M,C Q.3 Y,S N>'-D4$L! A0#%
M  @ =6-F3[E3X9)('0  VC$! !4              ( !C $! &%B=7,M,C Q
M.3 Y,S!?8V%L+GAM;%!+ 0(4 Q0    ( '5C9D__:0Z0QS,  #I8 @ 5
M          "  0<? 0!A8G5S+3(P,3DP.3,P7V1E9BYX;6Q02P$"% ,4
M" !U8V9/$LRQ+KFA   <^@< %0              @ $!4P$ 86)U<RTR,#$Y
M,#DS,%]L86(N>&UL4$L! A0#%     @ =6-F3X'_A1+&7@  )H$$ !4
M         ( ![?0! &%B=7,M,C Q.3 Y,S!?<')E+GAM;%!+!08     !@ &
+ (H!  #F4P(    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
